data_2lq8_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lq8 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 56.5 mttt . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.594 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.2 mttp -125.82 174.51 8.3 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.222 -0.924 . . . . 0.0 109.126 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.628 ' CG ' ' CE ' ' A' ' 98' ' ' MET . 60.0 m95 -109.9 126.66 54.11 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.132 -0.98 . . . . 0.0 109.346 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -118.74 167.39 11.72 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.211 -0.931 . . . . 0.0 109.415 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.51 HD12 ' CE1' ' A' ' 160' ' ' PHE . 95.1 mt -103.25 118.77 50.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.195 -0.94 . . . . 0.0 109.314 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.453 HG23 HG13 ' A' ' 62' ' ' VAL . 85.3 t -90.46 137.32 21.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.466 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.486 ' CD2' ' CG2' ' A' ' 84' ' ' VAL . 0.1 OUTLIER -89.62 141.75 28.31 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.276 -0.89 . . . . 0.0 109.245 179.875 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 58' ' ' GLY . 11.2 t -157.15 -172.48 4.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.23 -0.918 . . . . 0.0 109.358 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.473 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 90.9 mtp -105.56 123.62 48.2 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.2 -0.937 . . . . 0.0 109.516 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.422 ' C ' ' O ' ' A' ' 13' ' ' MET . 9.2 t -43.07 127.07 4.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.299 -0.875 . . . . 0.0 109.397 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.74 -19.85 40.5 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.473 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.2 m-85 -108.47 3.54 23.28 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.239 -1.153 . . . . 0.0 109.64 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.42 ' HG2' HG21 ' A' ' 12' ' ' THR . 98.4 mt-10 -57.92 -59.33 5.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -47.71 -38.11 14.53 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.218 -0.926 . . . . 0.0 109.403 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 24.7 mttt -68.8 -43.66 75.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.282 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.442 ' O ' HG13 ' A' ' 24' ' ' ILE . 89.6 t -58.96 -46.53 91.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 109.566 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.411 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.4 tttm -56.94 -49.8 74.55 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.219 -0.925 . . . . 0.0 109.548 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -64.83 -43.19 93.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.196 -0.94 . . . . 0.0 109.407 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.476 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 89.3 m-20 -54.92 -39.77 69.18 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.222 -0.924 . . . . 0.0 109.391 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.526 ' CG2' HD12 ' A' ' 40' ' ' ILE . 95.1 mt -65.62 -44.04 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.3 -0.875 . . . . 0.0 109.624 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -55.84 -48.22 75.86 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.07 -1.019 . . . . 0.0 109.947 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 42.9 mttm -78.41 -35.34 47.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.093 -1.004 . . . . 0.0 109.612 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.555 ' HG3' ' CE1' ' A' ' 73' ' ' PHE . 10.7 tptt -53.25 -33.0 51.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.247 -0.908 . . . . 0.0 109.13 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.48 HG13 ' O ' ' A' ' 33' ' ' ILE . 22.3 t -89.52 -19.89 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.342 -0.849 . . . . 0.0 109.287 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -72.64 -57.64 3.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.564 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.69 -29.9 66.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.895 . . . . 0.0 109.437 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.408 ' HB ' HG13 ' A' ' 33' ' ' ILE . 80.7 p -96.6 -3.02 43.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.237 -0.915 . . . . 0.0 109.477 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 50.02 30.17 15.82 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.528 ' CG2' HD13 ' A' ' 36' ' ' LEU . 21.6 mt -98.3 72.04 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.248 -1.148 . . . . 0.0 109.519 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.472 ' HA ' HG13 ' A' ' 28' ' ' VAL . 37.9 mttp -90.49 20.36 4.62 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.266 -0.896 . . . . 0.0 109.505 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.486 ' O ' HG23 ' A' ' 65' ' ' ILE . 81.4 m-20 -111.27 -23.04 11.06 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.189 -0.944 . . . . 0.0 109.525 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.535 HD22 ' CA ' ' A' ' 70' ' ' ALA . 18.9 mt -88.36 -31.23 19.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.29 -0.882 . . . . 0.0 109.76 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 93.4 t -108.19 142.87 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.179 -0.951 . . . . 0.0 109.376 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.86 -121.88 3.17 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -92.91 140.92 28.99 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.28 -1.13 . . . . 0.0 109.838 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.526 HD12 ' CG2' ' A' ' 24' ' ' ILE . 85.2 mt -108.91 134.64 50.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.336 -0.853 . . . . 0.0 109.084 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.57 HG21 ' CH2' ' A' ' 7' ' ' TRP . 28.7 t -121.68 159.34 24.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.074 -1.016 . . . . 0.0 109.412 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.491 ' CG2' HG21 ' A' ' 44' ' ' ILE . 2.9 mt -140.44 127.62 12.28 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.292 -0.88 . . . . 0.0 109.479 -179.852 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.599 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 45.2 Cg_endo -66.72 -5.93 14.32 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.799 2.333 . . . . 0.0 111.391 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.553 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 6.1 pt . . . . . 0 N--CA 1.49 1.557 0 O-C-N 121.398 -0.814 . . . . 0.0 109.374 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.553 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 5.3 mttp . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.599 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 0.6 OUTLIER -56.88 -45.82 82.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -0.962 . . . . 0.0 109.235 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.548 ' CD2' HD12 ' A' ' 55' ' ' LEU . 85.2 m-85 -125.25 111.94 26.29 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.937 . . . . 0.0 109.08 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -66.28 133.77 33.92 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.573 2.182 . . . . 0.0 111.985 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.459 ' O ' HG23 ' A' ' 12' ' ' THR . . . 74.46 -11.97 6.31 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.2 m-30 -99.82 131.29 45.89 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.649 -1.501 . . . . 0.0 110.258 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 42.5 t -134.25 148.77 29.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.671 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 17.0 m-85 -108.38 124.44 50.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.887 -1.133 . . . . 0.0 109.733 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.508 ' CG2' HG12 ' A' ' 40' ' ' ILE . 14.3 p -134.13 145.54 32.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.353 -0.842 . . . . 0.0 109.804 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.599 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 18.4 tt0 -108.51 127.3 53.81 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.47 ' SD ' HG13 ' A' ' 74' ' ' VAL . 58.7 mtm -151.93 163.68 38.73 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 118.954 -1.098 . . . . 0.0 111.022 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.525 HG12 ' HA ' ' A' ' 36' ' ' LEU . 3.3 pt -85.87 126.9 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.487 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 47.7 ttm -75.34 141.48 43.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.83 -178.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.487 ' HB2' ' O ' ' A' ' 66' ' ' MET . 47.0 t30 176.4 175.36 0.32 Allowed 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 -179.708 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -72.12 -40.85 67.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.168 -0.957 . . . . 0.0 109.593 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -72.46 -32.06 65.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.234 -0.916 . . . . 0.0 109.75 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.535 ' CA ' HD22 ' A' ' 36' ' ' LEU . . . -71.71 -47.3 54.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.193 -0.942 . . . . 0.0 109.818 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.519 ' O ' HG23 ' A' ' 74' ' ' VAL . 67.9 t80 -60.36 -49.33 78.01 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.154 -0.966 . . . . 0.0 109.682 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -63.14 -28.89 70.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.088 -1.007 . . . . 0.0 110.314 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.555 ' CE1' ' HG3' ' A' ' 27' ' ' LYS . 46.3 t80 -80.72 -41.42 23.62 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.007 -1.058 . . . . 0.0 109.819 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 71' ' ' TYR . 20.1 m -70.68 -53.24 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.242 -0.911 . . . . 0.0 109.405 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 33.0 tpt85 -52.14 -32.46 35.71 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.208 -0.932 . . . . 0.0 109.577 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 51.7 p -79.64 7.05 9.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.366 -0.834 . . . . 0.0 109.917 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.603 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 47.0 t -64.25 133.82 95.76 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.103 -0.998 . . . . 0.0 109.484 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.566 ' HB2' ' CD2' ' A' ' 79' ' ' TYR . 46.9 Cg_endo -68.2 136.9 38.88 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.68 2.253 . . . . 0.0 111.845 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.566 ' CD2' ' HB2' ' A' ' 78' ' ' PRO . 47.2 m-85 76.05 -1.94 2.85 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.418 -0.801 . . . . 0.0 109.623 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.603 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 2.8 t -87.86 127.76 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.129 -0.982 . . . . 0.0 109.273 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.1 mmm -89.02 -5.8 57.66 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.643 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 135.09 -152.8 20.9 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -143.14 141.7 31.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -1.213 . . . . 0.0 109.48 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.486 ' CG2' ' CD2' ' A' ' 11' ' ' LEU . 38.8 t -63.55 128.5 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.504 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 6.9 p -162.84 161.77 26.14 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.257 -0.902 . . . . 0.0 109.507 -179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 m -88.74 -35.61 16.61 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -123.58 -87.71 0.81 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.524 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -105.32 -128.38 6.17 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.524 ' O ' ' O ' ' A' ' 88' ' ' GLY . 6.8 pm0 -34.26 155.98 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.586 -0.949 . . . . 0.0 110.115 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.504 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.4 Cg_endo -69.62 160.12 50.92 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.578 2.185 . . . . 0.0 112.081 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 20.6 m -98.84 154.0 37.59 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.349 -0.844 . . . . 0.0 109.455 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.431 ' CB ' ' HD3' ' A' ' 6' ' ' LYS . 49.6 Cg_endo -70.35 147.64 59.53 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.693 2.262 . . . . 0.0 111.809 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 7' ' ' TRP . 21.3 t -85.4 142.44 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.219 -0.926 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . 0.469 ' O ' ' N ' ' A' ' 97' ' ' GLU . 81.1 tttt -67.66 126.24 28.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -0.9 . . . . 0.0 109.453 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 94' ' ' LYS . 47.3 t0 -43.67 -45.35 6.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.408 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.432 ' HD2' ' NZ ' ' A' ' 94' ' ' LYS . 57.4 mtt180 -55.42 -31.28 61.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.237 -0.914 . . . . 0.0 109.51 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.469 ' N ' ' O ' ' A' ' 94' ' ' LYS . 57.3 mt-10 -79.22 -24.45 43.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.262 -0.899 . . . . 0.0 109.662 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.628 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 75.7 mtp -84.53 -23.71 29.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.157 -0.964 . . . . 0.0 109.352 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.591 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 57.3 mtt180 -37.53 -52.55 2.52 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.351 -0.843 . . . . 0.0 109.919 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -69.39 -28.25 27.27 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.546 2.164 . . . . 0.0 111.989 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.524 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 24.4 mm -81.95 -41.18 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 109.361 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.596 ' N ' HD11 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -68.95 -41.44 78.0 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.198 -0.938 . . . . 0.0 109.136 179.816 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.47 ' HG2' ' HA ' ' A' ' 135' ' ' PRO . 21.4 tpt85 -63.25 -49.49 73.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.861 . . . . 0.0 108.989 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -72.66 -36.29 67.92 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.369 -0.832 . . . . 0.0 109.208 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.524 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.85 -0.47 9.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.436 -0.79 . . . . 0.0 109.94 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.34 7.79 85.21 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.543 ' CD1' ' CG2' ' A' ' 41' ' ' VAL . 53.5 mt -77.28 -19.97 55.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.28 -1.13 . . . . 0.0 109.446 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 36.1 tp10 . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.217 -0.927 . . . . 0.0 109.557 -179.94 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.56 ' HB3' ' CD ' ' A' ' 175' ' ' LYS . 45.6 p90 . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.443 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 37.6 mttt -150.64 156.98 42.43 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.072 -1.018 . . . . 0.0 109.972 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.483 ' HA ' HG23 ' A' ' 143' ' ' ILE . 14.1 p -62.93 143.99 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.389 -0.819 . . . . 0.0 109.556 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.49 -32.21 3.41 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.443 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 7.5 m-20 -48.67 163.82 0.07 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.359 -1.083 . . . . 0.0 109.144 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.0 ttm -95.57 126.4 40.83 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.182 -0.949 . . . . 0.0 109.066 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.568 ' CG2' ' O ' ' A' ' 174' ' ' GLU . 5.1 p -124.21 141.93 42.71 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.192 -0.943 . . . . 0.0 109.215 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.408 ' N ' ' O ' ' A' ' 174' ' ' GLU . 12.6 ttpp -107.57 143.34 36.13 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.113 -0.992 . . . . 0.0 109.049 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.537 ' CD1' ' HB3' ' A' ' 139' ' ' PHE . 96.5 mt -83.96 152.46 3.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.127 -0.983 . . . . 0.0 108.798 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.456 ' C ' ' HG2' ' A' ' 137' ' ' GLU . 27.4 pt -150.8 2.26 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.056 -1.028 . . . . 0.0 109.606 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.494 ' HB2' ' CB ' ' A' ' 172' ' ' GLU . 2.5 m -145.42 141.35 28.33 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.146 -0.972 . . . . 0.0 109.665 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.43 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 107.5 -170.75 15.77 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.47 ' HA ' ' HG2' ' A' ' 103' ' ' ARG . 49.7 Cg_endo -69.03 -18.66 40.31 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 123.338 2.692 . . . . 0.0 112.57 -179.606 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.58 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 97.8 m-85 -107.53 15.31 24.93 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.969 -1.082 . . . . 0.0 109.561 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.507 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 35.1 mt-10 -38.45 142.24 0.2 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.417 -0.802 . . . . 0.0 110.148 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 138' ' ' ASP . 0.3 OUTLIER 76.53 20.34 1.47 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.333 -0.854 . . . . 0.0 110.743 178.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.62 ' CE1' ' CG1' ' A' ' 157' ' ' VAL . 1.0 OUTLIER -108.37 131.17 55.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.831 -1.168 . . . . 0.0 109.623 179.901 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -84.97 134.3 34.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.155 -0.966 . . . . 0.0 109.508 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.59 167.89 26.48 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.8 -1.19 . . . . 0.0 110.269 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.438 ' C ' HG13 ' A' ' 155' ' ' VAL . 40.9 t -108.89 136.3 45.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.452 -1.028 . . . . 0.0 109.226 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.534 ' CD1' HG13 ' A' ' 129' ' ' VAL . 18.4 mm -67.38 114.85 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.259 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -97.25 -34.37 11.12 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.088 -1.007 . . . . 0.0 109.482 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -151.75 146.75 25.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.14 -0.975 . . . . 0.0 109.613 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.51 HG22 ' CD2' ' A' ' 153' ' ' LEU . 1.5 mt -120.06 123.7 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.333 -0.854 . . . . 0.0 109.304 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -107.3 98.14 21.78 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.655 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.553 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.8 Cg_endo -71.66 173.86 11.93 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.721 2.281 . . . . 0.0 111.779 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.553 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.0 tt0 80.53 -21.07 0.34 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.345 -0.847 . . . . 0.0 109.879 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.442 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 47.5 mtt85 -128.75 -11.88 4.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.111 -0.993 . . . . 0.0 109.45 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.485 ' C ' ' CG2' ' A' ' 170' ' ' VAL . 31.9 mt-30 69.26 48.25 0.67 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.277 -0.89 . . . . 0.0 109.774 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -122.34 146.08 47.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.132 -0.98 . . . . 0.0 108.87 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.51 ' CD2' HG22 ' A' ' 146' ' ' ILE . 0.4 OUTLIER -135.62 122.47 21.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.101 -1.0 . . . . 0.0 110.565 -179.398 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 5.8 mtmm -81.91 130.97 35.24 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.5 ' CG1' ' CG1' ' A' ' 129' ' ' VAL . 4.2 t -128.46 147.93 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.961 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.522 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 4.4 t30 -97.14 113.02 24.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.392 -0.817 . . . . 0.0 109.26 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.62 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 67.7 t -94.39 141.62 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.241 -0.912 . . . . 0.0 109.642 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' THR . . . . . 0.449 ' N ' HG13 ' A' ' 157' ' ' VAL . 60.1 m -94.2 95.71 9.13 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.383 -0.823 . . . . 0.0 109.63 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.435 ' O ' ' HB2' ' A' ' 160' ' ' PHE . 5.4 mt -121.72 141.37 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.253 -0.905 . . . . 0.0 109.581 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.671 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 96.6 m-85 61.26 41.26 13.5 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.847 . . . . 0.0 109.523 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.33 16.81 22.31 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 18.5 mtp85 -129.71 151.71 50.0 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.154 -1.203 . . . . 0.0 109.575 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . 0.467 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 73.4 mt-10 -95.97 136.73 36.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.249 -0.907 . . . . 0.0 109.506 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 16.3 m -145.44 128.33 8.22 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.618 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.2 Cg_endo -70.24 136.67 32.28 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.757 2.304 . . . . 0.0 111.618 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.537 HG13 ' CG2' ' A' ' 157' ' ' VAL . 3.7 p -123.23 142.86 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.14 -0.975 . . . . 0.0 109.559 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.45 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 6.3 m -92.83 119.19 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.413 -0.805 . . . . 0.0 109.485 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.482 HD11 ' O ' ' A' ' 166' ' ' VAL . 0.0 OUTLIER -142.12 167.9 21.02 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.238 -0.914 . . . . 0.0 110.384 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.502 ' ND1' ' OE2' ' A' ' 172' ' ' GLU . 47.8 m170 -82.27 141.01 33.3 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.485 ' CG2' ' C ' ' A' ' 151' ' ' GLN . 59.5 t -53.94 -36.78 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.185 -0.947 . . . . 0.0 108.893 179.697 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 7.1 p -75.16 -6.77 51.36 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.561 -0.712 . . . . 0.0 109.812 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.502 ' OE2' ' ND1' ' A' ' 169' ' ' HIS . 92.7 mt-10 -96.17 -3.39 44.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.083 -1.011 . . . . 0.0 109.866 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.454 HG22 HG21 ' A' ' 129' ' ' VAL . 3.7 m -133.45 170.68 19.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.106 -0.997 . . . . 0.0 109.993 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.568 ' O ' ' CG2' ' A' ' 129' ' ' VAL . 25.6 tp10 -127.56 144.01 51.11 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.56 ' CD ' ' HB3' ' A' ' 123' ' ' PHE . 9.7 mttp . . . . . 0 N--CA 1.489 1.51 0 O-C-N 121.069 -1.019 . . . . 0.0 109.567 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.7 mttt . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.579 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 41.7 mmtt -130.65 171.11 13.43 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.356 -0.84 . . . . 0.0 109.126 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.591 ' CZ3' ' CG2' ' A' ' 41' ' ' VAL . 60.1 m95 -104.55 126.5 51.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.202 -0.936 . . . . 0.0 109.329 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -116.94 168.03 10.6 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.154 -0.966 . . . . 0.0 109.145 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.527 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 65.1 mt -104.37 115.94 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.156 -0.965 . . . . 0.0 109.379 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.527 HG21 ' CE2' ' A' ' 83' ' ' PHE . 65.5 t -92.09 138.21 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.216 -0.927 . . . . 0.0 109.248 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.535 ' CD2' ' N ' ' A' ' 11' ' ' LEU . 3.5 mm? -88.12 141.9 28.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.312 -0.867 . . . . 0.0 109.338 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 1.3 p -153.44 174.85 13.84 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.235 -0.916 . . . . 0.0 109.375 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.436 ' O ' ' C ' ' A' ' 14' ' ' SER . 98.1 mtp -95.63 121.02 36.9 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.165 -0.959 . . . . 0.0 109.439 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 13' ' ' MET . 22.4 t -42.03 126.76 3.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.291 -0.88 . . . . 0.0 109.51 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.23 -19.98 33.69 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.435 ' O ' ' C ' ' A' ' 17' ' ' GLU . 89.0 m-85 -108.77 -18.79 13.62 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.233 -1.157 . . . . 0.0 109.629 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.485 ' OE1' HD11 ' A' ' 44' ' ' ILE . 43.4 mt-10 -41.48 -67.09 0.28 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.311 -0.868 . . . . 0.0 109.596 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -46.76 -38.59 10.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.193 -0.942 . . . . 0.0 109.415 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.444 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 24.0 tttp -69.22 -34.87 75.52 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.242 -0.911 . . . . 0.0 109.179 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.455 ' O ' HG13 ' A' ' 24' ' ' ILE . 43.8 t -68.78 -41.35 82.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.333 -0.854 . . . . 0.0 109.279 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.486 ' HD2' HD11 ' A' ' 42' ' ' ILE . 16.7 tttm -57.06 -50.82 71.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.277 -0.89 . . . . 0.0 109.487 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -62.31 -33.82 75.42 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.177 -0.952 . . . . 0.0 109.151 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.495 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 23.4 m120 -65.62 -33.65 76.4 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.302 -0.874 . . . . 0.0 109.284 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.572 ' CG2' HD11 ' A' ' 40' ' ' ILE . 79.2 mt -67.66 -45.37 84.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.271 -0.893 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -55.6 -46.19 77.35 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.895 . . . . 0.0 109.576 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.9 mttt -75.41 -36.04 60.9 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.605 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.572 ' HE3' ' CE1' ' A' ' 73' ' ' PHE . 28.6 tttp -54.72 -32.42 59.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.21 -0.931 . . . . 0.0 109.27 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.506 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 99.2 t -88.5 -22.89 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.878 . . . . 0.0 109.504 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -72.24 -57.0 4.59 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.237 -0.914 . . . . 0.0 109.609 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.22 -24.17 66.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.536 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 48.1 p -98.43 -17.37 18.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.418 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 62.74 26.14 68.28 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.53 ' CG2' ' CD1' ' A' ' 36' ' ' LEU . 76.7 mt -97.38 77.48 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.176 -1.191 . . . . 0.0 109.438 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.416 ' HG2' ' O ' ' A' ' 34' ' ' LYS . 17.8 tttp -89.72 22.85 2.89 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.29 -0.881 . . . . 0.0 109.129 179.822 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.536 ' O ' ' CD1' ' A' ' 65' ' ' ILE . 92.0 m-20 -118.27 -9.46 10.42 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.37 -0.831 . . . . 0.0 109.572 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.534 ' CD2' HD13 ' A' ' 65' ' ' ILE . 96.9 mt -97.47 -51.74 4.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.905 . . . . 0.0 109.387 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.519 HG11 ' CG2' ' A' ' 24' ' ' ILE . 59.3 t -94.73 136.12 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.258 -0.902 . . . . 0.0 109.245 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.89 -119.99 3.84 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 86.4 mtt180 -91.76 139.97 30.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.295 -1.12 . . . . 0.0 109.825 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.572 HD11 ' CG2' ' A' ' 24' ' ' ILE . 29.4 mt -107.91 133.39 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.397 -0.815 . . . . 0.0 109.115 179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.591 ' CG2' ' CZ3' ' A' ' 7' ' ' TRP . 25.8 t -121.99 132.56 70.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.175 -0.953 . . . . 0.0 109.25 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.486 HD11 ' HD2' ' A' ' 21' ' ' LYS . 4.5 mt -124.67 125.81 25.46 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.267 -0.896 . . . . 0.0 109.577 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.596 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 49.1 Cg_endo -68.4 -2.75 9.66 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.858 2.372 . . . . 0.0 111.422 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.671 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 87.7 mt . . . . . 0 N--CA 1.49 1.53 0 O-C-N 121.35 -0.843 . . . . 0.0 109.602 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.671 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 1.3 mttp . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.596 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 35.0 mt -59.7 -41.83 91.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.112 -0.993 . . . . 0.0 108.654 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -129.19 105.1 17.93 Favored Pre-proline 0 N--CA 1.489 1.48 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.7 136.13 48.22 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.484 2.122 . . . . 0.0 112.093 -179.046 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.34 -18.47 4.36 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.482 ' CE1' HD13 ' A' ' 11' ' ' LEU . 3.6 m-30 -95.77 129.24 43.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.666 -1.49 . . . . 0.0 110.51 -178.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 36.1 t -133.23 147.07 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.683 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 9.6 m-85 -108.79 124.67 50.95 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.856 -1.153 . . . . 0.0 109.861 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.502 HG12 ' N ' ' A' ' 63' ' ' GLU . 61.9 t -135.62 146.76 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.904 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.579 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 26.4 tt0 -110.88 127.41 55.43 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.519 ' CE ' HG11 ' A' ' 74' ' ' VAL . 40.4 mtm -152.16 163.65 38.95 Favored 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 118.757 -1.177 . . . . 0.0 111.304 -178.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.536 ' CD1' ' O ' ' A' ' 35' ' ' ASN . 2.3 pt -82.64 124.81 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.472 ' CE ' ' HG2' ' A' ' 89' ' ' GLN . 94.9 mmm -76.23 142.72 41.35 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.146 -0.971 . . . . 0.0 109.885 -178.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 m-20 177.31 170.18 0.58 Allowed 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -68.79 -41.6 78.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.128 -0.982 . . . . 0.0 109.454 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -78.08 -29.61 49.22 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.173 -0.954 . . . . 0.0 109.85 -179.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.48 ' O ' ' CG2' ' A' ' 74' ' ' VAL . . . -72.86 -48.92 33.45 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.12 -0.987 . . . . 0.0 109.479 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.441 ' CE1' ' HG3' ' A' ' 89' ' ' GLN . 75.1 t80 -61.22 -48.1 83.06 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.258 -0.901 . . . . 0.0 109.564 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -61.46 -29.32 69.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.209 -0.932 . . . . 0.0 109.777 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.572 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 48.7 t80 -80.78 -41.74 22.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.121 -0.987 . . . . 0.0 109.472 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.519 HG11 ' CE ' ' A' ' 64' ' ' MET . 4.2 t -68.76 -56.23 12.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.33 -0.856 . . . . 0.0 109.511 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.1 tpt85 -54.59 -17.34 3.18 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.358 -0.838 . . . . 0.0 109.735 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 26.2 p -91.3 6.91 43.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.26 -0.9 . . . . 0.0 109.872 -179.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.598 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 25.1 t -64.43 137.85 97.26 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.052 -1.03 . . . . 0.0 109.542 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.576 ' HB2' ' CE2' ' A' ' 79' ' ' TYR . 47.7 Cg_endo -68.47 137.63 40.01 Favored 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 122.718 2.278 . . . . 0.0 111.778 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.576 ' CE2' ' HB2' ' A' ' 78' ' ' PRO . 17.5 m-85 76.17 -4.64 2.32 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.388 -0.82 . . . . 0.0 109.712 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.598 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 5.4 t -87.02 129.66 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.055 -1.028 . . . . 0.0 109.101 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 98.9 mmm -88.14 -7.17 57.31 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.517 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.07 -145.23 15.84 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.591 ' CB ' ' HG3' ' A' ' 90' ' ' PRO . 1.4 m-85 -140.49 148.6 41.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -1.183 . . . . 0.0 109.708 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.527 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 3.4 p -75.78 134.61 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.246 -0.909 . . . . 0.0 109.344 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 88' ' ' GLY . 4.3 p -162.94 163.74 26.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.204 -0.935 . . . . 0.0 109.664 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.0 m -91.43 -33.34 15.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.37 -0.831 . . . . 0.0 109.421 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -124.98 -84.32 0.58 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.554 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -110.31 -135.24 6.97 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.554 ' C ' ' O ' ' A' ' 88' ' ' GLY . 1.0 OUTLIER -29.49 150.45 0.03 OUTLIER Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.584 -0.951 . . . . 0.0 110.302 -179.484 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.591 ' HG3' ' CB ' ' A' ' 83' ' ' PHE . 50.1 Cg_endo -68.22 142.05 54.14 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.899 2.399 . . . . 0.0 112.153 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . 0.553 ' CG2' ' HD2' ' A' ' 92' ' ' PRO . 3.7 p -75.69 144.67 77.28 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 109.26 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.553 ' HD2' ' CG2' ' A' ' 91' ' ' VAL . 46.0 Cg_endo -68.34 150.28 76.0 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.61 2.207 . . . . 0.0 111.806 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.453 ' HB ' ' SD ' ' A' ' 98' ' ' MET . 2.4 t -76.53 137.95 21.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.291 -0.881 . . . . 0.0 109.533 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.1 tttp -74.19 132.99 42.71 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.313 -0.867 . . . . 0.0 109.415 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.405 ' C ' ' O ' ' A' ' 94' ' ' LYS . 79.3 m-20 -44.11 -41.7 5.79 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.448 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.422 ' HB2' ' HD3' ' A' ' 94' ' ' LYS . 53.1 mtp180 -60.85 -27.03 67.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.278 -0.889 . . . . 0.0 109.497 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.516 ' N ' ' O ' ' A' ' 94' ' ' LYS . 45.1 mt-10 -86.6 -26.06 24.62 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.241 -0.912 . . . . 0.0 109.398 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.536 ' CB ' HD12 ' A' ' 102' ' ' LEU . 27.9 mmm -85.59 -22.97 27.79 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.219 -0.926 . . . . 0.0 109.5 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.591 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.1 OUTLIER -42.61 -49.09 13.23 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.29 -0.881 . . . . 0.0 109.887 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 51.9 Cg_endo -74.2 -27.32 11.75 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.435 2.09 . . . . 0.0 111.672 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.539 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 33.8 mm -80.87 -38.75 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.333 -0.855 . . . . 0.0 109.344 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.536 HD12 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -69.27 -40.07 78.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.313 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.54 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 19.5 ttm180 -64.36 -50.42 67.78 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.904 . . . . 0.0 109.308 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 6.8 tt -72.29 -36.19 68.88 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.296 -0.877 . . . . 0.0 109.216 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -69.76 -2.93 13.36 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.308 -0.87 . . . . 0.0 109.908 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.86 8.98 86.74 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.417 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 1.0 OUTLIER -72.53 -17.05 61.77 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -1.17 . . . . 0.0 109.416 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.241 -0.912 . . . . 0.0 109.517 179.897 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 8.9 p90 . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.434 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 13.9 mmtt -137.77 165.22 26.97 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -0.925 . . . . 0.0 109.758 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 14.2 p -62.42 143.13 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.316 -0.865 . . . . 0.0 109.536 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 85.68 -33.11 3.54 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.434 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 31.8 m-20 -49.67 159.19 0.39 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.532 -0.981 . . . . 0.0 109.247 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 2.0 ttp -94.19 127.62 40.14 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.136 -0.978 . . . . 0.0 109.008 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.548 ' CG2' ' CG1' ' A' ' 143' ' ' ILE . 5.9 t -125.99 142.49 42.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.361 -0.837 . . . . 0.0 109.28 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.484 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 22.2 tttp -105.41 142.13 35.7 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.405 -0.809 . . . . 0.0 108.875 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.522 ' CD1' ' HB3' ' A' ' 139' ' ' PHE . 66.9 mt -83.3 155.1 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.186 -0.946 . . . . 0.0 108.618 179.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.522 ' N ' HG21 ' A' ' 131' ' ' ILE . 29.1 pt -150.62 2.8 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.076 -1.015 . . . . 0.0 109.549 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 72.3 m -148.19 144.44 27.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.071 -1.018 . . . . 0.0 109.992 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 104.29 -167.99 16.23 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.54 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 48.3 Cg_endo -68.97 -20.74 38.21 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 123.124 2.549 . . . . 0.0 112.408 -179.544 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.515 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.3 m-85 -110.31 15.95 21.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.829 -1.169 . . . . 0.0 109.435 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.537 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 1.7 tt0 -43.8 143.26 1.09 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.486 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.537 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 16.4 m-20 75.85 27.65 0.94 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.374 -0.829 . . . . 0.0 110.258 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.522 ' HB3' ' CD1' ' A' ' 131' ' ' ILE . 1.3 t80 -117.68 133.58 55.8 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.021 -1.049 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -82.96 133.75 35.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.127 -0.983 . . . . 0.0 109.653 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.449 ' HA3' HG23 ' A' ' 155' ' ' VAL . . . -145.15 167.34 27.36 Favored Glycine 0 N--CA 1.49 2.279 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.098 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.438 ' O ' HG22 ' A' ' 155' ' ' VAL . 58.4 t -110.38 136.92 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.442 -1.034 . . . . 0.0 109.404 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.593 ' CG2' ' CD1' ' A' ' 146' ' ' ILE . 43.2 mm -69.36 118.69 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . 0.518 ' O ' ' CG ' ' A' ' 145' ' ' GLU . 47.3 tttp -98.17 -32.35 11.63 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.041 -1.037 . . . . 0.0 109.557 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 144' ' ' LYS . 85.7 mt-10 -157.68 153.33 26.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.058 -1.026 . . . . 0.0 110.073 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.593 ' CD1' ' CG2' ' A' ' 143' ' ' ILE . 6.1 mm -123.65 126.49 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.406 -0.809 . . . . 0.0 109.591 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -108.85 99.37 34.37 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.349 -0.845 . . . . 0.0 109.476 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.549 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.2 Cg_endo -71.21 173.77 11.74 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.739 2.293 . . . . 0.0 111.764 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.549 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.5 mt-10 79.97 -20.98 0.35 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.358 -0.839 . . . . 0.0 109.865 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.423 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 32.6 mtp180 -128.78 -13.4 4.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.079 -1.013 . . . . 0.0 109.476 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.423 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 37.8 mt-30 69.58 48.22 0.62 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.283 -0.886 . . . . 0.0 109.685 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . 0.522 ' OE2' ' CG1' ' A' ' 167' ' ' VAL . 59.5 tt0 -120.41 144.25 48.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.964 . . . . 0.0 108.936 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.568 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 29.4 mt -130.12 131.01 45.53 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.078 -1.014 . . . . 0.0 110.083 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 13.6 mttt -93.07 130.9 38.53 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.52 HG13 HD11 ' A' ' 168' ' ' LEU . 13.9 p -132.7 147.48 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.096 -1.003 . . . . 0.0 110.057 -179.521 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.542 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.6 m-20 -96.7 117.0 30.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.464 -0.773 . . . . 0.0 109.265 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . . . . . . . . . 44.9 t -96.79 141.38 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 109.501 -179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' THR . . . . . 0.402 ' HA ' ' O ' ' A' ' 162' ' ' ARG . 73.5 m -96.07 94.91 7.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.273 -0.892 . . . . 0.0 109.929 -179.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.455 ' O ' ' HB2' ' A' ' 160' ' ' PHE . 6.2 mt -118.22 140.78 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.25 -0.906 . . . . 0.0 109.422 179.483 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.683 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 97.3 m-85 62.25 40.16 11.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.331 -0.855 . . . . 0.0 109.337 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.48 17.9 34.87 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.411 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 36.9 mtt-85 -128.29 156.12 43.52 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.179 -1.189 . . . . 0.0 109.618 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -99.84 134.23 43.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.886 . . . . 0.0 109.558 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 37.3 m -143.11 127.44 9.59 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.303 -0.873 . . . . 0.0 109.554 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.542 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.3 Cg_endo -69.63 135.18 30.09 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.76 2.307 . . . . 0.0 111.544 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.459 ' O ' HD11 ' A' ' 168' ' ' LEU . 34.5 t -123.49 142.59 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.986 . . . . 0.0 109.861 -179.729 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.522 ' CG1' ' OE2' ' A' ' 152' ' ' GLU . 29.4 t -93.78 119.35 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.403 -0.81 . . . . 0.0 109.485 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.52 HD11 HG13 ' A' ' 155' ' ' VAL . 0.0 OUTLIER -141.91 168.65 19.25 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.209 -0.932 . . . . 0.0 110.413 -179.651 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.5 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 42.3 m170 -83.51 140.6 32.2 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.472 ' HB ' ' HG ' ' A' ' 153' ' ' LEU . 7.5 p -54.91 -36.33 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.26 -0.9 . . . . 0.0 109.183 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 84.4 p -75.84 -7.26 54.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -0.868 . . . . 0.0 109.707 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.5 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 84.3 mt-10 -87.61 -2.44 58.61 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.069 -1.019 . . . . 0.0 109.647 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.486 ' HA ' HG12 ' A' ' 132' ' ' ILE . 3.7 m -142.05 175.91 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.191 -0.943 . . . . 0.0 109.446 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.532 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 76.2 tt0 -140.57 167.26 22.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.281 -0.887 . . . . 0.0 108.932 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.532 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.1 tttp . . . . . 0 N--CA 1.49 1.557 0 O-C-N 121.03 -1.044 . . . . 0.0 109.6 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.467 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 74.8 mttt . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 121.23 0.538 . . . . 0.0 109.658 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.552 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 10.9 mttp -129.17 175.63 8.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.291 -0.881 . . . . 0.0 109.259 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.594 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 56.7 m95 -112.38 124.69 53.05 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.262 -0.899 . . . . 0.0 109.233 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.485 ' CD1' ' HA ' ' A' ' 92' ' ' PRO . 62.6 m-85 -117.36 171.81 7.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.189 -0.944 . . . . 0.0 109.335 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.557 HG12 ' CZ ' ' A' ' 61' ' ' PHE . 40.9 mt -112.49 107.83 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.174 -0.954 . . . . 0.0 108.995 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.606 ' CG1' ' CG1' ' A' ' 60' ' ' VAL . 10.8 p -83.5 146.05 7.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.208 -0.932 . . . . 0.0 109.465 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.564 HD22 ' CE1' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -90.77 142.25 27.95 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.525 -0.734 . . . . 0.0 109.67 -179.667 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.477 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.1 t -154.97 -176.07 5.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.299 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.456 ' HE3' ' CE2' ' A' ' 16' ' ' TYR . 58.2 mtm -102.23 125.66 48.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.187 -0.946 . . . . 0.0 109.445 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.4 m -45.59 128.02 8.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -0.936 . . . . 0.0 109.536 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.21 -19.46 37.38 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.456 ' CE2' ' HE3' ' A' ' 13' ' ' MET . 94.1 m-85 -108.19 -7.91 15.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.313 -1.11 . . . . 0.0 109.436 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.505 ' OE1' ' CD1' ' A' ' 44' ' ' ILE . 47.9 mt-10 -47.93 -53.91 14.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.474 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -55.62 -37.05 67.66 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.239 -0.913 . . . . 0.0 109.346 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.516 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 88.5 mttt -73.25 -34.86 66.07 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 109.372 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.4 t -66.69 -46.6 85.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.211 -0.931 . . . . 0.0 109.414 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 23.2 tttt -58.92 -48.44 81.48 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.278 -0.889 . . . . 0.0 109.666 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.9 mt-10 -65.71 -40.26 92.06 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.219 -0.926 . . . . 0.0 109.507 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.53 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 92.7 m-20 -60.45 -42.06 95.35 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.218 -0.926 . . . . 0.0 109.379 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.432 HG21 HD11 ' A' ' 40' ' ' ILE . 96.7 mt -64.38 -44.64 97.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.307 -0.871 . . . . 0.0 109.552 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.456 ' O ' ' HG3' ' A' ' 29' ' ' GLU . 87.9 mt-10 -59.23 -47.02 86.91 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.172 -0.955 . . . . 0.0 110.036 -179.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.2 ttpt -80.19 -38.39 31.36 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.049 -1.032 . . . . 0.0 109.731 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.584 ' HG2' ' CE1' ' A' ' 73' ' ' PHE . 19.3 tttt -57.16 -25.64 59.26 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.331 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.544 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 89.4 t -88.07 -26.98 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.301 -0.875 . . . . 0.0 109.482 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.456 ' HG3' ' O ' ' A' ' 25' ' ' GLU . 93.1 mt-10 -66.92 -47.65 71.07 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.504 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.12 -28.91 69.96 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -0.888 . . . . 0.0 109.365 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 71.9 p -89.03 -12.02 42.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.286 -0.884 . . . . 0.0 109.322 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 61.07 24.04 62.53 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.544 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 54.7 mt -101.35 74.43 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -1.139 . . . . 0.0 109.552 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.6 mttp -85.26 -3.8 58.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.336 -0.853 . . . . 0.0 109.597 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 90.5 m-20 -93.12 -7.01 46.68 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.209 -0.932 . . . . 0.0 109.4 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.532 ' N ' HD23 ' A' ' 36' ' ' LEU . 4.4 mm? -95.66 -50.83 4.77 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.267 -0.895 . . . . 0.0 109.34 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.462 HG11 HG22 ' A' ' 28' ' ' VAL . 8.7 p -95.35 139.16 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.381 -0.824 . . . . 0.0 109.554 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.1 -122.16 4.07 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 88.6 mtt-85 -95.34 142.7 27.43 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.223 -1.163 . . . . 0.0 109.706 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.49 HG12 HG11 ' A' ' 62' ' ' VAL . 75.4 mt -109.73 137.5 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.196 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.568 ' CG1' ' HB2' ' A' ' 61' ' ' PHE . 7.7 p -127.93 162.08 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.169 -0.957 . . . . 0.0 109.36 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.53 ' CG2' HD11 ' A' ' 44' ' ' ILE . 5.9 mt -144.2 130.13 9.87 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.167 -0.958 . . . . 0.0 109.902 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.49 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.1 Cg_endo -66.36 -3.71 9.33 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.861 2.374 . . . . 0.0 111.478 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.654 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 61.0 mt . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.89 . . . . 0.0 109.508 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 3.6 mttp . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.583 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 16.9 tp -65.25 -22.3 66.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.863 -1.148 . . . . 0.0 109.775 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.583 ' CE2' ' HG ' ' A' ' 55' ' ' LEU . 95.8 m-85 -148.37 98.17 3.73 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.21 -0.931 . . . . 0.0 108.818 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -65.86 140.56 61.53 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.723 2.282 . . . . 0.0 112.205 -179.243 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.4 -10.89 10.21 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.564 ' CE1' HD22 ' A' ' 11' ' ' LEU . 3.0 m-30 -107.25 132.6 52.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.749 -1.442 . . . . 0.0 110.291 -179.244 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.606 ' CG1' ' CG1' ' A' ' 10' ' ' VAL . 0.2 OUTLIER -135.22 151.4 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 179.001 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.568 ' HB2' ' CG1' ' A' ' 41' ' ' VAL . 14.0 m-85 -111.73 126.56 55.18 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.948 -1.095 . . . . 0.0 110.258 -179.14 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.534 HG12 ' CG ' ' A' ' 64' ' ' MET . 67.1 t -130.22 141.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.547 -0.721 . . . . 0.0 109.66 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.594 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 10.8 tt0 -104.16 125.92 50.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 108.766 179.538 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.534 ' CG ' HG12 ' A' ' 62' ' ' VAL . 30.7 mtm -156.18 172.92 17.61 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.019 -1.051 . . . . 0.0 110.783 -179.073 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.494 HD12 HD21 ' A' ' 36' ' ' LEU . 4.8 pt -95.17 130.48 43.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.477 ' SD ' ' NE2' ' A' ' 89' ' ' GLN . 4.1 tpp -76.04 143.34 41.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.3 -0.875 . . . . 0.0 110.037 -178.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.473 ' HB2' ' O ' ' A' ' 66' ' ' MET . 42.6 t30 176.69 175.78 0.33 Allowed 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 69' ' ' GLU . 28.6 p-10 -71.6 -40.45 69.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.145 -0.972 . . . . 0.0 109.406 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.473 ' N ' ' OD1' ' A' ' 68' ' ' ASP . 71.0 mm-40 -73.23 -35.5 66.28 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.362 -0.836 . . . . 0.0 109.716 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.5 ' HB3' ' CD1' ' A' ' 36' ' ' LEU . . . -67.63 -47.87 68.37 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 109.589 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.528 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 84.0 t80 -59.77 -51.57 69.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.676 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -57.48 -29.03 63.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.239 -0.913 . . . . 0.0 109.876 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.584 ' CE1' ' HG2' ' A' ' 27' ' ' LYS . 65.9 t80 -80.4 -40.79 25.78 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.113 -0.992 . . . . 0.0 109.929 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.488 ' CG2' ' O ' ' A' ' 70' ' ' ALA . 2.6 t -64.63 -60.33 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.185 -0.947 . . . . 0.0 109.92 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.474 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 10.8 tpt180 -51.58 -42.92 62.26 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.097 -1.002 . . . . 0.0 109.736 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.8 t -67.58 1.24 2.5 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.11 -0.994 . . . . 0.0 110.244 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.616 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 30.7 t -62.29 133.98 94.59 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 120.928 -1.107 . . . . 0.0 109.317 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.584 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 46.0 Cg_endo -68.0 136.08 36.95 Favored 'Trans proline' 0 C--O 1.213 -0.738 0 C-N-CA 122.727 2.285 . . . . 0.0 111.866 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.584 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 54.3 m-85 77.61 -2.26 2.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.528 -0.733 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.616 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.0 t -87.45 126.96 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.102 -0.999 . . . . 0.0 109.162 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 66.1 mtp -90.02 -24.65 21.15 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 109.73 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.486 ' O ' ' N ' ' A' ' 11' ' ' LEU . . . 158.25 -158.04 28.85 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.586 ' CD1' ' HD3' ' A' ' 90' ' ' PRO . 15.3 p90 -140.56 154.13 46.4 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.243 -1.151 . . . . 0.0 109.506 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.493 ' CG2' ' CD2' ' A' ' 11' ' ' LEU . 47.5 t -81.73 113.45 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.137 -0.977 . . . . 0.0 109.466 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.512 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 5.3 p -145.2 164.66 30.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.226 -0.921 . . . . 0.0 109.498 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 23.9 m -86.47 -33.17 20.46 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.287 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -135.58 -76.91 0.09 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.55 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -109.61 -133.56 6.7 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.55 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.4 OUTLIER -29.49 150.31 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.63 -0.924 . . . . 0.0 110.315 -179.636 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.586 ' HD3' ' CD1' ' A' ' 83' ' ' PHE . 44.5 Cg_endo -67.81 147.45 75.1 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.833 2.355 . . . . 0.0 111.973 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . 0.544 ' CG2' ' HD2' ' A' ' 92' ' ' PRO . 3.4 p -80.81 144.69 56.22 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.317 -0.864 . . . . 0.0 109.369 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.544 ' HD2' ' CG2' ' A' ' 91' ' ' VAL . 47.3 Cg_endo -68.6 151.39 75.16 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.66 2.24 . . . . 0.0 111.715 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.463 ' N ' ' O ' ' A' ' 7' ' ' TRP . 11.9 t -83.64 131.76 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.232 -0.918 . . . . 0.0 109.583 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 54.9 mttm -69.87 143.17 52.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.31 -0.868 . . . . 0.0 109.446 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -53.3 -39.97 64.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.25 -0.907 . . . . 0.0 109.596 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -57.98 -34.34 69.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.274 -0.891 . . . . 0.0 109.558 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.7 mt-10 -81.34 -25.41 36.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.266 -0.896 . . . . 0.0 109.525 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.576 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 98.6 mtp -84.1 -26.42 28.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.899 . . . . 0.0 109.58 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.563 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.4 OUTLIER -36.24 -54.24 1.53 Allowed Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.448 -0.783 . . . . 0.0 109.927 -179.838 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.563 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.5 Cg_endo -70.1 -28.2 23.93 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.481 2.121 . . . . 0.0 111.748 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.495 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 33.1 mm -80.57 -41.12 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.567 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.552 ' CB ' ' HB2' ' A' ' 108' ' ' GLU . 1.0 OUTLIER -67.85 -40.65 83.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.226 -0.921 . . . . 0.0 109.505 179.995 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.551 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 1.3 ttt85 -63.91 -49.52 72.33 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 109.212 179.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.21 -36.42 69.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.264 -0.898 . . . . 0.0 108.961 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.518 ' HB3' ' CG2' ' A' ' 41' ' ' VAL . . . -75.62 -4.11 38.23 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.436 -0.79 . . . . 0.0 109.641 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.66 11.47 83.06 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.484 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 7.1 mt -87.3 -28.09 22.48 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.158 -1.201 . . . . 0.0 109.724 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . 0.552 ' HB2' ' CB ' ' A' ' 102' ' ' LEU . 87.9 tt0 . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.247 -0.908 . . . . 0.0 109.469 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.462 ' HB3' ' HE2' ' A' ' 175' ' ' LYS . 50.7 p90 . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.454 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 20.8 mttm -146.48 155.65 42.69 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.131 -0.98 . . . . 0.0 109.869 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.416 ' HA ' HG22 ' A' ' 143' ' ' ILE . 14.2 p -60.98 143.96 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -0.875 . . . . 0.0 109.584 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.09 -33.45 3.13 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.454 ' OD2' ' HB2' ' A' ' 124' ' ' LYS . 32.7 m-20 -48.78 163.13 0.08 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.38 -1.07 . . . . 0.0 109.207 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.8 ttm -96.3 126.72 41.7 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.051 -1.031 . . . . 0.0 108.807 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.607 ' CG2' ' O ' ' A' ' 174' ' ' GLU . 5.6 p -124.3 141.28 45.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.108 -0.995 . . . . 0.0 109.262 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.522 ' N ' ' O ' ' A' ' 174' ' ' GLU . 35.9 tttp -104.34 144.21 31.94 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.206 -0.934 . . . . 0.0 108.956 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.512 HG22 ' HA ' ' A' ' 137' ' ' GLU . 95.7 mt -85.69 152.01 3.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.116 -0.99 . . . . 0.0 108.623 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.428 HG22 ' O ' ' A' ' 131' ' ' ILE . 42.1 pt -150.32 2.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.162 -0.961 . . . . 0.0 109.434 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.46 ' HB2' ' CB ' ' A' ' 172' ' ' GLU . 75.4 m -148.26 144.48 27.66 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.145 -0.972 . . . . 0.0 109.912 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.75 -165.28 18.89 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.551 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 46.9 Cg_endo -68.03 -21.82 42.51 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 123.202 2.602 . . . . 0.0 112.811 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.522 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.5 m-85 -108.29 15.78 23.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.834 -1.166 . . . . 0.0 109.604 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.536 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 2.4 tt0 -42.96 139.94 1.56 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.176 -0.953 . . . . 0.0 109.384 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.536 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 18.6 m-20 75.21 24.95 1.37 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.368 -0.832 . . . . 0.0 110.335 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.568 ' CE1' HG12 ' A' ' 157' ' ' VAL . 1.5 t80 -115.71 135.8 53.68 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.961 -1.087 . . . . 0.0 109.421 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.34 133.5 34.14 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.177 -0.952 . . . . 0.0 109.692 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.495 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.02 170.89 25.74 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.294 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.457 ' N ' ' CG1' ' A' ' 155' ' ' VAL . 40.8 t -116.12 135.72 55.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.447 -1.031 . . . . 0.0 109.357 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.48 ' CD1' ' HD2' ' A' ' 175' ' ' LYS . 70.8 mt -67.56 115.87 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.257 -0.902 . . . . 0.0 109.192 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . 0.429 ' C ' ' HG2' ' A' ' 145' ' ' GLU . 2.0 tttp -98.08 -33.74 11.04 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.036 -1.04 . . . . 0.0 109.502 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.429 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 75.3 mm-40 -151.01 146.03 25.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.114 -0.991 . . . . 0.0 109.536 179.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.586 ' CG2' ' CD2' ' A' ' 153' ' ' LEU . 23.8 pt -122.25 125.88 73.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.135 -0.978 . . . . 0.0 109.488 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.37 100.6 34.53 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.268 -0.895 . . . . 0.0 109.5 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.56 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.2 Cg_endo -71.18 171.12 16.61 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.704 2.269 . . . . 0.0 111.779 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.56 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.8 mt-10 80.95 -20.48 0.37 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.399 -0.813 . . . . 0.0 109.899 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.429 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 88.6 mtt180 -127.75 -12.01 5.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.086 -1.009 . . . . 0.0 109.526 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.429 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 31.5 mt-30 69.23 48.91 0.64 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.665 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -122.22 145.81 47.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.09 -1.006 . . . . 0.0 109.097 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.586 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 60.6 mt -138.42 115.29 10.78 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.075 -1.016 . . . . 0.0 110.147 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 27.3 mttm -78.85 133.56 37.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.3 -0.875 . . . . 0.0 108.643 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.546 HG12 ' N ' ' A' ' 156' ' ' ASN . 53.9 t -127.44 151.17 33.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.182 -0.949 . . . . 0.0 109.762 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.546 ' N ' HG12 ' A' ' 155' ' ' VAL . 26.2 t-20 -98.0 117.6 32.7 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.237 -0.914 . . . . 0.0 109.352 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.568 HG12 ' CE1' ' A' ' 139' ' ' PHE . 39.7 t -101.03 143.41 14.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.252 -0.905 . . . . 0.0 109.708 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 93.1 m -94.74 91.26 6.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.383 -0.823 . . . . 0.0 109.724 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.492 HG23 ' CE2' ' A' ' 160' ' ' PHE . 8.6 mt -115.78 140.54 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.424 179.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.492 ' CE2' HG23 ' A' ' 159' ' ' ILE . 8.4 m-85 60.54 41.21 15.93 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.376 -0.827 . . . . 0.0 109.334 -179.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.05 16.28 12.9 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 92.4 mtt-85 -126.26 148.3 49.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.201 -1.176 . . . . 0.0 109.39 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . 0.484 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 94.3 mt-10 -94.81 135.77 35.91 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.278 -0.889 . . . . 0.0 109.679 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' THR . . . . . 0.51 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 49.7 m -147.2 128.18 7.1 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.274 -0.891 . . . . 0.0 109.735 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.49 139.69 38.26 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.746 2.297 . . . . 0.0 111.46 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.4 p -126.61 145.79 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.089 -1.007 . . . . 0.0 109.869 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.429 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 5.3 t -92.54 118.86 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.459 -0.775 . . . . 0.0 109.505 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.429 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 19.3 mt -141.52 167.23 22.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.184 -0.947 . . . . 0.0 110.495 -179.302 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -83.97 141.34 31.29 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.71 -0.619 . . . . 0.0 109.5 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 4.1 p -56.42 -36.28 46.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.287 -0.883 . . . . 0.0 109.319 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 53.8 p -75.96 -7.18 54.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -0.883 . . . . 0.0 109.828 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.46 ' CB ' ' HB2' ' A' ' 133' ' ' SER . 64.5 mt-10 -99.75 -2.23 35.73 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.086 -1.009 . . . . 0.0 109.404 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 12.7 m -132.48 170.1 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.23 -0.919 . . . . 0.0 109.627 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.607 ' O ' ' CG2' ' A' ' 129' ' ' VAL . 53.5 tt0 -129.87 145.14 51.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.293 -0.88 . . . . 0.0 109.343 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.48 ' HD2' ' CD1' ' A' ' 143' ' ' ILE . 34.4 mmtm . . . . . 0 N--CA 1.489 1.52 0 O-C-N 121.024 -1.048 . . . . 0.0 109.514 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.459 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 20.0 mttm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.284 0.564 . . . . 0.0 109.625 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 16.8 mmtp -127.47 172.07 11.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.329 -0.857 . . . . 0.0 109.39 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.62 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 46.3 m95 -106.34 128.24 53.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.335 -0.853 . . . . 0.0 109.142 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.541 ' CE1' ' CE ' ' A' ' 66' ' ' MET . 74.8 m-85 -120.35 160.96 22.0 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.214 -0.929 . . . . 0.0 109.359 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.43 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 97.1 mt -102.66 115.35 44.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.233 -0.917 . . . . 0.0 109.252 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.2 t -91.35 141.28 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.224 -0.923 . . . . 0.0 109.452 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.452 ' HB3' ' HB2' ' A' ' 81' ' ' MET . 3.2 mm? -84.74 144.23 28.64 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.28 -0.888 . . . . 0.0 109.308 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.498 ' CG2' ' HG2' ' A' ' 17' ' ' GLU . 11.9 t -155.86 -176.56 6.02 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.167 -0.958 . . . . 0.0 109.271 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 56.8 mtm -104.71 123.73 48.13 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.25 -0.906 . . . . 0.0 109.568 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.441 ' OG ' ' HB2' ' A' ' 57' ' ' PRO . 2.6 m -45.32 128.32 7.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.408 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.3 -19.98 33.52 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.501 ' O ' ' N ' ' A' ' 19' ' ' LYS . 77.1 m-85 -111.64 -9.3 14.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.297 -1.119 . . . . 0.0 109.441 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.559 ' HA ' ' CG1' ' A' ' 20' ' ' VAL . 92.6 mt-10 -43.3 -41.54 4.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.23 -0.919 . . . . 0.0 109.543 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -63.57 -31.3 72.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 109.302 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.501 ' N ' ' O ' ' A' ' 16' ' ' TYR . 27.7 mttm -76.94 -56.43 4.6 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.276 -0.89 . . . . 0.0 109.352 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.559 ' CG1' ' HA ' ' A' ' 17' ' ' GLU . 2.0 p -44.72 -49.73 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.415 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.441 ' HD2' HD12 ' A' ' 42' ' ' ILE . 10.5 tttm -61.03 -48.32 82.32 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.207 -0.933 . . . . 0.0 109.874 -179.711 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -62.96 -35.48 80.29 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.07 -1.019 . . . . 0.0 109.504 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.484 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 33.9 m120 -64.92 -37.54 87.99 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.308 -0.87 . . . . 0.0 109.22 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.525 ' CG2' HG11 ' A' ' 37' ' ' VAL . 89.0 mt -63.19 -45.62 98.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.3 -0.875 . . . . 0.0 109.478 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -55.41 -46.77 76.6 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.214 -0.929 . . . . 0.0 109.715 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 27.7 ttmt -76.06 -35.63 59.34 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.261 -0.899 . . . . 0.0 109.456 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.418 ' O ' ' CG2' ' A' ' 31' ' ' THR . 44.2 tptt -54.93 -32.33 61.16 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.918 . . . . 0.0 109.242 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.524 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 77.5 t -87.13 -22.91 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.329 -0.857 . . . . 0.0 109.406 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -71.32 -55.4 8.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.669 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.39 -31.16 71.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.186 -0.946 . . . . 0.0 109.684 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' A' ' 27' ' ' LYS . 29.5 p -87.32 -20.92 26.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.118 -0.989 . . . . 0.0 109.491 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 68.21 22.07 74.26 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.555 ' CG2' ' CB ' ' A' ' 36' ' ' LEU . 63.4 mt -98.89 79.45 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -1.142 . . . . 0.0 109.449 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -85.09 -17.23 38.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.236 -0.915 . . . . 0.0 109.24 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -84.24 5.01 28.25 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.317 -0.865 . . . . 0.0 109.482 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.583 ' CD1' ' CB ' ' A' ' 70' ' ' ALA . 12.5 tp -105.98 -54.26 2.51 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.176 -0.953 . . . . 0.0 109.37 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.525 HG11 ' CG2' ' A' ' 24' ' ' ILE . 86.4 t -96.5 133.32 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.403 -0.81 . . . . 0.0 109.297 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.85 -123.4 5.26 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 89.7 mtt180 -93.52 147.49 22.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -1.125 . . . . 0.0 109.845 -179.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.528 ' CG2' HG21 ' A' ' 62' ' ' VAL . 70.2 mt -110.32 135.55 49.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.291 -0.88 . . . . 0.0 109.344 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.597 ' CG2' ' CZ3' ' A' ' 7' ' ' TRP . 32.8 t -119.72 151.7 22.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.951 . . . . 0.0 109.39 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.464 HG22 HG12 ' A' ' 44' ' ' ILE . 10.5 mt -131.9 127.53 21.23 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.897 . . . . 0.0 109.442 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.509 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 46.2 Cg_endo -66.78 -4.46 11.21 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.862 2.375 . . . . 0.0 111.867 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.586 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 8.4 pt . . . . . 0 N--CA 1.489 1.497 0 O-C-N 121.12 -0.987 . . . . 0.0 109.387 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.586 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 7.6 mttp . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.509 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 24.7 mt -55.61 -45.43 77.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.105 -0.997 . . . . 0.0 109.269 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.419 ' CE2' ' CE2' ' A' ' 160' ' ' PHE . 89.3 m-85 -131.7 110.34 14.65 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.125 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.441 ' HB2' ' OG ' ' A' ' 14' ' ' SER . 43.1 Cg_endo -66.22 139.35 54.85 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.746 2.297 . . . . 0.0 112.184 -179.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.483 ' O ' HG22 ' A' ' 12' ' ' THR . . . 73.96 -9.83 8.43 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.5 m-30 -94.17 129.07 40.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.669 -1.489 . . . . 0.0 110.395 -179.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.457 ' CG2' HG23 ' A' ' 12' ' ' THR . 44.8 t -130.22 137.75 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.419 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.503 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 8.0 m-85 -110.15 125.95 53.57 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.902 -1.124 . . . . 0.0 110.051 -179.462 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.528 HG21 ' CG2' ' A' ' 40' ' ' ILE . 55.8 t -138.51 149.92 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.418 -0.801 . . . . 0.0 109.805 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.62 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 61.6 tt0 -110.66 129.04 55.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 108.888 179.536 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.556 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 9.2 mtm -161.79 -176.06 5.04 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.137 -0.977 . . . . 0.0 109.804 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.545 ' CD1' HD11 ' A' ' 36' ' ' LEU . 18.9 pt -94.94 119.76 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.541 ' CE ' ' CE1' ' A' ' 8' ' ' TYR . 16.2 ttm -87.36 101.04 13.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.382 -0.824 . . . . 0.0 109.676 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' A' ' 66' ' ' MET . 84.8 m-20 -138.7 -166.54 2.03 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.303 -0.873 . . . . 0.0 108.895 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -71.17 -47.34 58.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.098 -1.001 . . . . 0.0 109.799 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 70' ' ' ALA . 93.7 mt-10 -70.84 -57.14 4.92 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.055 -1.028 . . . . 0.0 109.612 -179.736 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.583 ' CB ' ' CD1' ' A' ' 36' ' ' LEU . . . -44.51 -42.99 7.62 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.551 ' CD1' ' OE1' ' A' ' 89' ' ' GLN . 71.1 t80 -61.39 -54.84 38.4 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.267 -0.896 . . . . 0.0 109.696 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -51.58 -31.0 23.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.18 -0.95 . . . . 0.0 110.049 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -81.01 -41.95 21.9 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.144 -0.972 . . . . 0.0 109.766 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.654 ' CG1' ' CZ ' ' A' ' 83' ' ' PHE . 47.4 t -70.96 -54.58 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.249 -0.907 . . . . 0.0 109.443 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.443 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 25.0 tpt85 -51.45 -18.62 1.11 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.182 -0.949 . . . . 0.0 109.211 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 66.3 p -101.65 5.89 41.73 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.41 -0.806 . . . . 0.0 109.925 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.593 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 17.2 t -60.86 135.57 92.89 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.013 -1.055 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.606 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 48.4 Cg_endo -69.14 129.39 18.16 Favored 'Trans proline' 0 C--O 1.213 -0.74 0 C-N-CA 122.776 2.318 . . . . 0.0 112.002 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.606 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 40.7 m-85 84.45 -10.13 0.88 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.665 -0.647 . . . . 0.0 109.56 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.593 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 4.9 t -84.92 127.3 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.177 -0.952 . . . . 0.0 109.257 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.452 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 78.4 mtp -87.0 -23.99 24.82 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.296 -0.877 . . . . 0.0 109.379 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.544 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 153.07 -155.58 26.21 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.654 ' CZ ' ' CG1' ' A' ' 74' ' ' VAL . 1.6 m-85 -137.42 140.13 41.11 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.322 -1.105 . . . . 0.0 109.402 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.5 p -64.85 125.41 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 109.519 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.529 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.7 p -159.35 161.69 35.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.241 -0.912 . . . . 0.0 109.516 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 85.8 p -92.01 -36.66 13.27 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.249 -0.907 . . . . 0.0 109.391 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -120.47 -88.19 1.04 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.515 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -104.25 -133.93 7.98 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.551 ' OE1' ' CD1' ' A' ' 71' ' ' TYR . 0.9 OUTLIER -34.25 155.06 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.547 -0.972 . . . . 0.0 110.134 -179.599 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.529 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.3 Cg_endo -68.47 163.72 35.55 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.824 2.349 . . . . 0.0 111.855 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.7 m -93.97 154.08 40.78 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.294 -0.879 . . . . 0.0 109.31 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.38 142.45 45.23 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.605 2.203 . . . . 0.0 111.796 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.447 ' CG2' ' O ' ' A' ' 7' ' ' TRP . 2.3 t -73.04 131.49 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -0.899 . . . . 0.0 109.306 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . 0.484 ' O ' ' N ' ' A' ' 97' ' ' GLU . 42.2 mttm -71.6 132.75 45.09 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.193 -0.942 . . . . 0.0 109.264 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 94' ' ' LYS . 82.1 m-20 -44.46 -41.28 6.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.226 -0.921 . . . . 0.0 109.459 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -61.04 -24.91 66.55 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.265 -0.897 . . . . 0.0 109.502 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.484 ' N ' ' O ' ' A' ' 94' ' ' LYS . 54.2 mt-10 -87.14 -27.0 23.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.162 -0.961 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.526 ' CB ' HD11 ' A' ' 102' ' ' LEU . 37.4 mmm -84.63 -26.87 27.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.166 -0.959 . . . . 0.0 109.42 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.557 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 5.1 ttp180 -37.06 -54.98 1.75 Allowed Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.47 -0.769 . . . . 0.0 109.994 -179.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.557 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.1 Cg_endo -69.05 -27.21 30.13 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.535 2.157 . . . . 0.0 111.79 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.546 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 51.1 mm -81.44 -41.94 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.226 -0.921 . . . . 0.0 109.284 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.526 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -68.27 -40.13 81.95 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.219 -0.926 . . . . 0.0 109.231 179.754 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 21.2 mtt180 -62.77 -50.57 70.53 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.333 -0.854 . . . . 0.0 108.978 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -73.35 -35.34 65.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.459 -0.776 . . . . 0.0 109.11 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -71.99 -2.73 19.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.385 -0.822 . . . . 0.0 109.633 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.48 9.68 84.56 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.58 ' CD2' ' CG2' ' A' ' 41' ' ' VAL . 8.0 mp -80.9 -21.95 40.16 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.164 -1.198 . . . . 0.0 109.429 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.381 -0.824 . . . . 0.0 109.501 179.914 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.528 ' CG ' ' HE2' ' A' ' 175' ' ' LYS . 31.4 p90 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.506 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 14.1 mttt -140.35 -174.52 3.97 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.034 -1.041 . . . . 0.0 110.076 -179.615 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 13.8 p -61.78 141.94 16.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.451 -0.781 . . . . 0.0 109.677 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 86.72 -34.31 3.55 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.506 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 24.0 m-20 -49.29 158.73 0.36 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.316 -1.108 . . . . 0.0 109.633 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' MET . . . . . 0.454 ' SD ' ' O ' ' A' ' 141' ' ' GLY . 2.7 tpp -95.53 127.91 41.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.336 -0.853 . . . . 0.0 108.871 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.542 ' CG2' ' CG1' ' A' ' 173' ' ' VAL . 2.0 p -127.72 143.83 39.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.264 -0.898 . . . . 0.0 109.816 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.451 ' O ' HG13 ' A' ' 173' ' ' VAL . 21.0 tttt -108.55 142.29 39.21 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.266 -0.896 . . . . 0.0 109.319 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.548 ' O ' ' CD1' ' A' ' 132' ' ' ILE . 96.6 mt -80.14 152.22 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.139 -0.976 . . . . 0.0 108.971 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.548 ' CD1' ' O ' ' A' ' 131' ' ' ILE . 1.1 mm -146.67 2.27 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.088 -1.007 . . . . 0.0 109.391 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.553 ' CA ' ' HG2' ' A' ' 137' ' ' GLU . 50.6 m -148.64 143.12 26.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.259 -0.9 . . . . 0.0 109.758 -179.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.447 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 105.77 -169.23 15.8 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.56 -19.98 41.73 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 123.317 2.678 . . . . 0.0 112.679 -179.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.503 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.6 m-85 -106.77 16.71 24.11 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.933 -1.104 . . . . 0.0 109.605 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.568 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 62.9 mt-10 -41.58 139.01 1.22 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.163 -0.961 . . . . 0.0 110.073 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.568 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.8 OUTLIER 80.37 19.41 0.56 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.277 -0.89 . . . . 0.0 110.788 178.775 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.595 ' CD1' HG11 ' A' ' 157' ' ' VAL . 1.0 OUTLIER -108.18 141.67 39.57 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.794 -1.191 . . . . 0.0 109.565 179.798 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -94.53 135.95 35.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.225 -0.922 . . . . 0.0 109.22 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.494 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.83 168.99 27.38 Favored Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.571 -1.299 . . . . 0.0 110.5 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 155' ' ' VAL . 39.5 t -111.14 137.49 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.593 -0.945 . . . . 0.0 109.369 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.43 ' O ' ' N ' ' A' ' 126' ' ' GLY . 69.8 mt -68.71 118.26 12.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 109.303 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . 0.414 ' O ' ' HG2' ' A' ' 145' ' ' GLU . 47.7 tttp -100.39 -33.29 10.43 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.975 -1.078 . . . . 0.0 109.561 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.414 ' HG2' ' O ' ' A' ' 144' ' ' LYS . 64.2 mt-10 -153.85 149.12 27.02 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.132 -0.98 . . . . 0.0 109.812 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.478 HG22 HD22 ' A' ' 153' ' ' LEU . 1.7 mt -124.33 127.59 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.354 -0.841 . . . . 0.0 109.379 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.13 104.1 55.77 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.628 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' HB2' ' A' ' 149' ' ' GLU . 52.4 Cg_endo -72.35 173.21 13.47 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.72 2.28 . . . . 0.0 111.661 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.544 ' HB2' ' O ' ' A' ' 148' ' ' PRO . 39.5 mm-40 78.25 -22.0 0.31 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.397 -0.814 . . . . 0.0 110.062 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.42 ' NH1' ' HG3' ' A' ' 150' ' ' ARG . 0.6 OUTLIER -124.15 -15.5 6.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.1 -1.0 . . . . 0.0 109.119 179.776 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.421 ' HB3' HG13 ' A' ' 170' ' ' VAL . 30.9 mt-30 69.58 47.98 0.63 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.461 -0.774 . . . . 0.0 109.439 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . 0.447 ' O ' HD21 ' A' ' 153' ' ' LEU . 97.8 mt-10 -119.76 143.56 47.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.215 -0.928 . . . . 0.0 109.081 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.478 HD22 HG22 ' A' ' 146' ' ' ILE . 14.4 mt -130.95 122.85 27.64 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.16 -0.963 . . . . 0.0 110.231 -179.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 13.9 mttt -85.57 129.78 34.74 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 142' ' ' VAL . 10.9 p -129.36 146.94 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.222 -0.923 . . . . 0.0 109.951 -179.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.523 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 3.7 m-20 -98.02 108.89 21.71 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.218 -0.926 . . . . 0.0 109.537 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.595 HG11 ' CD1' ' A' ' 139' ' ' PHE . 82.2 t -88.14 140.72 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.18 -0.95 . . . . 0.0 109.376 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' THR . . . . . 0.454 ' N ' HG12 ' A' ' 157' ' ' VAL . 47.7 m -96.62 89.23 4.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.332 -0.855 . . . . 0.0 109.617 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.483 ' CG1' HG13 ' A' ' 157' ' ' VAL . 2.6 mt -115.74 144.87 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.192 -0.942 . . . . 0.0 109.395 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.503 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 18.7 m-85 61.93 37.41 15.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.276 -0.89 . . . . 0.0 109.226 -179.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.03 17.95 31.85 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.426 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 89.5 mtt-85 -127.66 157.49 40.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.216 -1.167 . . . . 0.0 109.481 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . 0.44 ' OE2' ' ND2' ' A' ' 156' ' ' ASN . 83.6 tt0 -100.82 133.35 45.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.327 -0.858 . . . . 0.0 109.591 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 79.7 m -144.04 127.3 8.83 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.905 . . . . 0.0 109.684 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.4 Cg_endo -70.98 137.16 31.33 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.723 2.282 . . . . 0.0 111.598 179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 46.1 t -125.66 144.48 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.229 -0.92 . . . . 0.0 109.862 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.406 ' O ' ' HG ' ' A' ' 168' ' ' LEU . 44.4 t -92.68 119.35 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.438 -0.789 . . . . 0.0 109.485 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.406 ' HG ' ' O ' ' A' ' 167' ' ' VAL . 1.4 mt -138.71 164.69 28.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.229 -0.92 . . . . 0.0 110.48 -179.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.504 ' HB2' ' HB2' ' A' ' 172' ' ' GLU . 88.6 m-70 -81.57 145.64 30.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.632 -0.668 . . . . 0.0 109.291 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.421 HG13 ' HB3' ' A' ' 151' ' ' GLN . 6.2 p -62.11 -35.73 70.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.305 -0.872 . . . . 0.0 108.982 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.408 ' N ' HG11 ' A' ' 170' ' ' VAL . 82.9 p -78.59 -9.66 59.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.254 -0.904 . . . . 0.0 109.362 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.504 ' HB2' ' HB2' ' A' ' 169' ' ' HIS . 46.8 mt-10 -97.69 -1.14 44.19 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.405 -0.809 . . . . 0.0 109.022 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.542 ' CG1' ' CG2' ' A' ' 129' ' ' VAL . 97.9 t -126.14 163.25 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.297 -0.877 . . . . 0.0 109.412 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.531 ' N ' HG11 ' A' ' 173' ' ' VAL . 55.8 tt0 -137.26 154.95 50.02 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.314 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.528 ' HE2' ' CG ' ' A' ' 123' ' ' PHE . 19.8 mttt . . . . . 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.395 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.462 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 21.8 mttm . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 121.299 0.571 . . . . 0.0 109.575 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.59 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.6 mttt -131.53 173.1 11.45 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.16 -0.962 . . . . 0.0 109.407 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.625 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 51.9 m95 -108.82 126.74 53.36 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.415 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.502 ' CZ ' ' SD ' ' A' ' 66' ' ' MET . 91.3 m-85 -116.2 168.55 10.01 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.329 -0.857 . . . . 0.0 109.492 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.502 HG12 ' CE1' ' A' ' 61' ' ' PHE . 36.5 mt -106.49 116.51 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.282 -0.886 . . . . 0.0 109.197 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.508 ' CG1' HG22 ' A' ' 80' ' ' VAL . 72.5 t -91.56 136.52 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.282 -0.886 . . . . 0.0 109.294 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.493 ' CD2' HG21 ' A' ' 84' ' ' VAL . 3.8 mm? -89.18 146.89 24.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.374 -0.829 . . . . 0.0 109.496 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.6 t -161.83 -168.03 1.84 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.302 -0.874 . . . . 0.0 109.362 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 67.3 mtp -107.38 134.5 50.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.242 -0.911 . . . . 0.0 109.492 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 11.0 t -54.74 130.25 39.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.291 -0.881 . . . . 0.0 109.393 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.46 -20.22 37.75 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -109.87 -3.23 16.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.285 -1.127 . . . . 0.0 109.717 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -47.48 -64.56 0.75 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.254 -0.903 . . . . 0.0 109.594 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 75.8 mm-40 -48.73 -38.87 22.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.183 -0.948 . . . . 0.0 109.435 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.466 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 54.1 tttp -66.77 -45.9 77.03 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.304 -0.872 . . . . 0.0 109.278 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.474 HG21 ' HB3' ' A' ' 79' ' ' TYR . 50.7 t -61.65 -44.5 98.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -0.91 . . . . 0.0 109.501 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.1 tttt -60.51 -45.62 93.13 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -0.957 . . . . 0.0 109.219 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -65.72 -40.42 92.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.315 -0.866 . . . . 0.0 109.347 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.575 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 31.2 m120 -60.59 -46.15 91.3 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.337 -0.852 . . . . 0.0 109.431 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.405 HG13 ' O ' ' A' ' 20' ' ' VAL . 95.0 mt -56.01 -42.87 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.215 -0.928 . . . . 0.0 109.268 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -56.17 -43.56 78.5 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.193 -0.942 . . . . 0.0 109.594 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.418 ' HB3' ' HE2' ' A' ' 26' ' ' LYS . 47.9 mtpt -80.14 -35.62 36.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.208 -0.933 . . . . 0.0 109.434 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 11.5 tptt -54.69 -31.52 58.05 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.286 -0.883 . . . . 0.0 109.334 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.517 ' CG2' HG21 ' A' ' 37' ' ' VAL . 39.2 t -89.75 -23.3 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.301 -0.874 . . . . 0.0 109.392 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 46.3 tp10 -69.2 -52.63 25.94 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.288 -0.883 . . . . 0.0 109.543 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.37 -32.48 73.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 59.4 p -84.87 -25.29 28.1 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 79.48 -3.42 67.93 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.543 ' CG2' HD22 ' A' ' 36' ' ' LEU . 84.8 mt -76.16 74.38 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.193 -1.18 . . . . 0.0 109.553 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.454 ' HA ' HG11 ' A' ' 28' ' ' VAL . 23.6 mttt -88.49 1.12 55.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.192 -0.942 . . . . 0.0 109.657 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.408 ' O ' HG23 ' A' ' 65' ' ' ILE . 93.2 m-20 -97.06 -13.09 22.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.181 -0.949 . . . . 0.0 109.492 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.579 ' N ' ' CD2' ' A' ' 36' ' ' LEU . 2.5 mm? -88.32 -49.05 7.21 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.291 -0.881 . . . . 0.0 109.467 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.517 HG21 ' CG2' ' A' ' 28' ' ' VAL . 78.5 t -91.12 139.49 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.244 -0.91 . . . . 0.0 109.256 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.467 ' N ' HG11 ' A' ' 37' ' ' VAL . . . -109.04 -127.09 5.44 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 88.2 mtt180 -92.16 146.97 23.3 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.255 -1.144 . . . . 0.0 109.755 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.493 HD13 HG21 ' A' ' 40' ' ' ILE . 67.1 mt -112.55 134.16 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.913 . . . . 0.0 109.336 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.578 HG22 ' CZ3' ' A' ' 7' ' ' TRP . 33.3 m -128.08 155.77 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.235 -0.916 . . . . 0.0 109.45 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.453 HG22 HG12 ' A' ' 44' ' ' ILE . 11.5 mt -133.63 128.63 20.09 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.268 -0.895 . . . . 0.0 109.63 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.498 ' O ' HD13 ' A' ' 55' ' ' LEU . 43.8 Cg_endo -66.45 -3.89 9.77 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.928 2.418 . . . . 0.0 111.744 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.594 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 11.4 pt . . . . . 0 N--CA 1.488 1.469 0 O-C-N 121.145 -0.972 . . . . 0.0 109.464 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.594 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 4.7 mttp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.425 -0.584 . . . . 0.0 109.425 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.545 ' CD1' ' N ' ' A' ' 55' ' ' LEU . 5.2 mp -62.29 -24.68 67.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.171 -0.956 . . . . 0.0 109.465 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.648 ' CZ ' ' CD1' ' A' ' 159' ' ' ILE . 97.4 m-85 -148.79 100.59 3.47 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.316 -0.865 . . . . 0.0 109.056 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -66.08 139.75 57.13 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.733 2.288 . . . . 0.0 111.855 -179.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.17 -12.5 6.88 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.44 ' CE1' HD12 ' A' ' 11' ' ' LEU . 2.5 m-30 -100.03 131.3 46.07 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.704 -1.468 . . . . 0.0 110.128 -179.317 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.424 HG11 ' N ' ' A' ' 61' ' ' PHE . 45.6 t -134.62 144.77 33.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.361 -0.837 . . . . 0.0 108.887 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.534 ' HB2' ' CG2' ' A' ' 41' ' ' VAL . 74.2 m-85 -106.55 122.98 47.4 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.978 -1.077 . . . . 0.0 109.779 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 59.7 t -131.37 143.78 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.796 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.625 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 18.0 tt0 -108.2 127.29 53.7 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.328 -0.857 . . . . 0.0 109.166 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.496 ' HE1' ' CG1' ' A' ' 74' ' ' VAL . 32.8 mtm -153.98 170.88 20.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.072 -1.018 . . . . 0.0 110.653 -179.261 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.515 HG12 ' HA ' ' A' ' 36' ' ' LEU . 5.3 pt -95.14 131.34 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.536 ' CE ' ' NE2' ' A' ' 89' ' ' GLN . 59.3 mmm -75.95 143.26 41.7 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.893 . . . . 0.0 109.897 -178.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.438 ' HB2' ' O ' ' A' ' 66' ' ' MET . 37.6 t30 178.23 158.06 0.46 Allowed 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -59.61 -42.06 91.79 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -0.927 . . . . 0.0 109.594 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.573 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 69.3 mm-40 -74.85 -34.1 62.22 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.891 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.518 ' CB ' HD12 ' A' ' 36' ' ' LEU . . . -69.13 -46.36 67.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.149 -0.97 . . . . 0.0 109.756 -179.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.527 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 91.1 t80 -61.06 -47.03 88.25 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.156 -0.965 . . . . 0.0 109.782 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.457 ' O ' ' HB2' ' A' ' 76' ' ' SER . 27.5 m120 -62.07 -28.36 69.55 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 109.861 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.573 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 13.7 m-85 -84.54 -42.55 15.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.15 -0.969 . . . . 0.0 109.756 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.496 ' CG1' ' HE1' ' A' ' 64' ' ' MET . 25.9 t -69.76 -57.58 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.161 -0.962 . . . . 0.0 109.697 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.45 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 0.6 OUTLIER -59.26 -13.89 9.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.189 -0.944 . . . . 0.0 109.311 179.823 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 15.4 m -95.86 5.38 51.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.304 -0.873 . . . . 0.0 109.93 -179.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.604 ' CG1' ' HB ' ' A' ' 80' ' ' VAL . 2.3 p -75.46 134.29 73.31 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 120.965 -1.085 . . . . 0.0 109.457 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.627 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 43.8 Cg_endo -65.17 138.82 57.9 Favored 'Trans proline' 0 C--O 1.214 -0.72 0 C-N-CA 122.88 2.387 . . . . 0.0 112.287 -179.277 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.627 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 24.3 m-85 90.79 -9.32 0.3 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.857 -0.527 . . . . 0.0 109.662 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.604 ' HB ' ' CG1' ' A' ' 77' ' ' VAL . 5.7 p -90.88 127.08 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.979 -1.076 . . . . 0.0 109.332 179.506 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 82.8 mtp -86.24 -29.5 23.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.249 -0.907 . . . . 0.0 109.375 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.524 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 167.4 -164.22 37.74 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.524 ' CD1' ' O ' ' A' ' 82' ' ' GLY . 21.3 m-85 -134.33 141.39 46.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.207 -1.173 . . . . 0.0 109.499 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.493 HG21 ' CD2' ' A' ' 11' ' ' LEU . 19.9 t -64.29 123.82 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.25 -0.906 . . . . 0.0 109.409 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.533 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.6 p -162.76 162.26 26.61 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.28 -0.887 . . . . 0.0 109.522 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.1 t -91.55 -33.33 15.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.276 -0.89 . . . . 0.0 109.343 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -129.66 -82.32 0.29 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.519 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -106.66 -131.57 6.82 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.536 ' NE2' ' CE ' ' A' ' 66' ' ' MET . 1.4 mt-30 -33.31 152.08 0.05 OUTLIER Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.522 -0.987 . . . . 0.0 110.109 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.533 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.7 Cg_endo -69.1 159.25 54.64 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.841 2.361 . . . . 0.0 111.803 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 3.7 m -98.1 154.19 37.81 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.167 -0.958 . . . . 0.0 109.378 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.421 ' CB ' ' HD2' ' A' ' 6' ' ' LYS . 49.0 Cg_endo -70.19 150.99 66.41 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.612 2.208 . . . . 0.0 111.701 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.474 ' HB ' ' SD ' ' A' ' 98' ' ' MET . 31.2 t -85.46 142.38 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.249 -0.907 . . . . 0.0 109.33 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -78.37 139.2 38.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.936 . . . . 0.0 109.446 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.421 ' O ' ' N ' ' A' ' 99' ' ' ARG . 52.9 t0 -50.36 -39.14 45.62 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.497 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.5 mtm180 -52.06 -41.26 62.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.219 -0.926 . . . . 0.0 109.475 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.427 ' C ' ' HD2' ' A' ' 100' ' ' PRO . 63.0 mt-10 -85.38 -23.61 27.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.244 -0.91 . . . . 0.0 109.458 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.567 ' HE3' ' CD1' ' A' ' 7' ' ' TRP . 97.7 mtp -84.24 -23.64 30.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -0.927 . . . . 0.0 109.644 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.623 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 6.0 mmm180 -46.54 -48.04 48.13 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.256 -0.902 . . . . 0.0 109.788 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.623 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 50.6 Cg_endo -72.14 -27.3 17.03 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.394 2.063 . . . . 0.0 111.822 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.537 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 27.3 mm -81.49 -42.27 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.185 -0.947 . . . . 0.0 109.435 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.475 ' HA ' ' HB2' ' A' ' 107' ' ' LEU . 1.2 mt -69.15 -39.9 78.54 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.237 -0.915 . . . . 0.0 109.339 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.557 ' CZ ' ' NH1' ' A' ' 99' ' ' ARG . 23.5 mtt180 -64.27 -51.17 64.86 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.3 -0.875 . . . . 0.0 109.148 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.5 tt -71.44 -36.17 71.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.346 -0.846 . . . . 0.0 109.247 179.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.86 -0.26 8.72 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.328 -0.857 . . . . 0.0 109.989 -179.729 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.19 9.12 84.1 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.51 ' CD2' HG13 ' A' ' 41' ' ' VAL . 10.1 mp -80.72 -22.67 40.1 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.194 -1.18 . . . . 0.0 109.456 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . 0.424 ' HG3' ' CB ' ' A' ' 102' ' ' LEU . 53.7 mt-10 . . . . . 0 N--CA 1.491 1.581 0 O-C-N 121.302 -0.874 . . . . 0.0 109.497 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.492 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 77.1 mttt -134.51 151.84 51.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.122 -0.986 . . . . 0.0 109.95 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.456 ' HA ' HG22 ' A' ' 143' ' ' ILE . 22.5 t -65.32 141.58 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.451 -0.781 . . . . 0.0 109.23 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 89.19 -30.63 5.46 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.498 ' OD2' ' HE2' ' A' ' 175' ' ' LYS . 63.4 m-20 -47.8 161.89 0.09 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.309 -1.112 . . . . 0.0 108.989 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 6.1 ttm -102.09 128.23 48.65 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.025 -1.047 . . . . 0.0 109.096 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.559 HG12 ' CD1' ' A' ' 143' ' ' ILE . 11.6 m -128.67 143.88 39.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.387 -0.821 . . . . 0.0 109.715 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.51 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 44.4 tttt -100.84 140.56 34.96 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.539 HG22 ' N ' ' A' ' 132' ' ' ILE . 86.1 mt -79.39 154.62 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.024 -1.048 . . . . 0.0 108.371 179.375 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.594 ' CD1' ' CG ' ' A' ' 174' ' ' GLU . 1.1 pt -149.12 0.46 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.015 -1.053 . . . . 0.0 109.505 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.579 ' CB ' ' HG2' ' A' ' 172' ' ' GLU . 3.1 m -148.68 147.54 29.03 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.058 -1.027 . . . . 0.0 110.372 -179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.77 -170.29 19.92 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.463 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 45.9 Cg_endo -68.24 -21.46 41.76 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.199 2.599 . . . . 0.0 112.487 -179.753 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.469 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 91.5 m-85 -108.81 16.33 22.84 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.002 -1.061 . . . . 0.0 109.284 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.575 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 2.5 tt0 -48.09 142.69 4.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.316 -0.865 . . . . 0.0 109.788 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.575 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 14.5 t0 81.44 23.17 0.29 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.424 -0.797 . . . . 0.0 110.242 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.621 ' CE1' ' CG1' ' A' ' 157' ' ' VAL . 1.0 OUTLIER -116.13 141.75 47.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.984 -1.073 . . . . 0.0 109.463 179.813 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -90.12 136.18 33.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.191 -0.943 . . . . 0.0 109.516 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.491 ' HA3' HG12 ' A' ' 155' ' ' VAL . . . -148.02 171.18 28.56 Favored Glycine 0 N--CA 1.49 2.268 0 C-N-CA 119.636 -1.269 . . . . 0.0 110.538 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.589 ' N ' ' CG1' ' A' ' 155' ' ' VAL . 89.4 t -118.05 136.41 55.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.678 -0.895 . . . . 0.0 109.237 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.559 ' CD1' HG12 ' A' ' 129' ' ' VAL . 79.4 mt -66.78 115.8 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.43 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 33.2 tttt -97.63 -34.56 10.9 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.03 -1.044 . . . . 0.0 109.231 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -149.78 144.62 26.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.201 -0.937 . . . . 0.0 109.329 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.503 ' CG2' ' CD2' ' A' ' 153' ' ' LEU . 31.9 pt -123.98 127.66 73.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.573 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 28.5 t0 -111.81 100.19 47.72 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.484 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.568 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.3 Cg_endo -71.27 176.01 8.5 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.778 2.319 . . . . 0.0 111.71 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.568 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.4 mt-10 81.48 -21.05 0.33 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.434 -0.791 . . . . 0.0 109.84 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.45 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 82.1 mtt180 -131.15 -10.46 3.74 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.15 -0.969 . . . . 0.0 109.495 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.45 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 43.3 mt-30 69.97 48.54 0.54 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.252 -0.905 . . . . 0.0 109.967 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . 0.456 ' O ' HD23 ' A' ' 153' ' ' LEU . 81.3 tt0 -120.44 144.99 47.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.981 -1.075 . . . . 0.0 108.852 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.503 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 70.6 mt -139.91 127.69 21.9 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.102 -0.999 . . . . 0.0 110.441 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -91.74 132.77 36.16 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.589 ' CG1' ' N ' ' A' ' 142' ' ' VAL . 92.9 t -133.99 126.96 51.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.116 -0.99 . . . . 0.0 109.914 -179.358 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.536 ' OD1' ' N ' ' A' ' 164' ' ' THR . 51.9 t-20 -76.1 137.12 39.93 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.341 -0.85 . . . . 0.0 109.862 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.621 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 59.8 t -114.46 147.53 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.329 -0.857 . . . . 0.0 109.069 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 18.2 m -99.41 91.88 5.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.999 -1.063 . . . . 0.0 109.913 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.648 ' CD1' ' CZ ' ' A' ' 56' ' ' PHE . 2.5 pt -124.58 151.53 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.235 -0.916 . . . . 0.0 108.991 179.311 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.576 ' CD2' HD13 ' A' ' 159' ' ' ILE . 16.7 m-30 60.53 35.45 20.16 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -0.926 . . . . 0.0 108.969 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.03 15.37 9.99 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 21.0 mtp180 -128.22 158.22 38.71 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.179 -1.189 . . . . 0.0 109.595 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . 0.434 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 90.7 mt-10 -100.97 132.76 46.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.268 -0.895 . . . . 0.0 109.551 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' THR . . . . . 0.536 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 47.4 m -139.78 127.31 12.85 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.943 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.59 134.1 25.49 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.741 2.294 . . . . 0.0 111.175 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.429 HG12 HD12 ' A' ' 168' ' ' LEU . 2.2 t -120.03 164.09 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 120.962 -1.086 . . . . 0.0 110.153 -179.527 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.626 ' O ' ' CD1' ' A' ' 168' ' ' LEU . 43.0 t -117.03 115.94 50.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 N-CA-C 109.119 -0.696 . . . . 0.0 109.119 179.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.656 ' N ' ' CD2' ' A' ' 168' ' ' LEU . 0.3 OUTLIER -139.49 167.55 21.84 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 121.878 0.847 . . . . 0.0 110.249 -179.52 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.401 ' O ' ' HB2' ' A' ' 172' ' ' GLU . 96.1 m-70 -78.94 141.01 37.92 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.432 ' CG2' HD13 ' A' ' 153' ' ' LEU . 7.2 p -55.01 -36.43 38.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.056 -1.028 . . . . 0.0 108.88 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 33.6 p -75.07 -5.23 43.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.455 -0.778 . . . . 0.0 109.553 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.579 ' HG2' ' CB ' ' A' ' 133' ' ' SER . 2.4 mt-10 -87.17 -1.82 58.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.225 -0.922 . . . . 0.0 109.707 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.51 ' HB ' ' O ' ' A' ' 130' ' ' LYS . 1.3 m -150.91 -178.31 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.138 -0.976 . . . . 0.0 109.465 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.594 ' CG ' ' CD1' ' A' ' 132' ' ' ILE . 3.5 mt-10 -138.01 170.2 16.45 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.082 -1.011 . . . . 0.0 109.1 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.498 ' HE2' ' OD2' ' A' ' 127' ' ' ASP . 52.0 tttm . . . . . 0 N--CA 1.489 1.513 0 O-C-N 121.0 -1.062 . . . . 0.0 109.553 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.479 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 27.4 mttm . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.533 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 1.3 mtpp -125.93 -179.78 4.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.196 -0.94 . . . . 0.0 109.321 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.586 ' CG ' ' CE ' ' A' ' 98' ' ' MET . 69.2 m95 -117.72 122.21 42.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.135 -0.978 . . . . 0.0 109.178 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -115.33 170.94 8.01 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.18 -0.95 . . . . 0.0 109.376 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.43 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 33.0 mt -112.89 110.74 33.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.296 -0.877 . . . . 0.0 109.065 179.681 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.532 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 10.3 p -88.66 142.48 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.215 -0.928 . . . . 0.0 109.512 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.533 HD23 ' CE1' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -89.04 145.68 25.32 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.294 -0.879 . . . . 0.0 109.625 -179.893 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.458 HG23 ' N ' ' A' ' 13' ' ' MET . 96.0 m -156.84 160.78 39.51 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.285 -0.884 . . . . 0.0 109.52 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.568 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 94.9 mmm -76.98 124.19 27.42 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.216 -0.928 . . . . 0.0 109.469 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 13' ' ' MET . 70.2 m -44.59 125.44 4.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.95 . . . . 0.0 109.301 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.0 -19.98 34.26 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.568 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 92.0 m-85 -107.14 -5.64 17.86 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.22 -1.165 . . . . 0.0 109.505 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.45 ' OE1' HD11 ' A' ' 44' ' ' ILE . 68.2 mt-10 -51.52 -54.62 25.37 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 109.486 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -51.48 -34.49 35.95 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.219 -0.926 . . . . 0.0 109.368 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.46 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 64.1 mttm -76.35 -49.54 16.6 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.178 179.783 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.484 HG22 ' CB ' ' A' ' 79' ' ' TYR . 42.0 t -52.22 -49.92 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.337 -0.852 . . . . 0.0 109.365 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.405 ' HG3' ' CG2' ' A' ' 40' ' ' ILE . 29.9 tttt -56.83 -50.33 72.72 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.65 -34.55 77.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.332 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.527 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 32.8 m120 -65.32 -48.14 74.07 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.404 -0.81 . . . . 0.0 109.586 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 77.4 mt -54.02 -44.52 62.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.133 -0.98 . . . . 0.0 109.437 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 75.1 tt0 -56.21 -46.14 79.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.246 -0.909 . . . . 0.0 109.721 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 7.7 mmtp -78.35 -36.13 46.58 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.16 -0.962 . . . . 0.0 109.509 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 8.9 tptt -53.9 -30.72 47.31 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.282 -0.886 . . . . 0.0 109.358 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.435 ' CG1' ' CG1' ' A' ' 37' ' ' VAL . 35.5 m -89.3 -22.04 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.3 -0.875 . . . . 0.0 109.41 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.421 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 44.6 mm-40 -70.71 -54.52 11.49 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.611 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.72 -31.09 71.95 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.185 -0.947 . . . . 0.0 109.451 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 37.8 p -87.54 -8.23 56.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.413 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 60.58 28.54 67.89 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.543 ' CG2' ' CG ' ' A' ' 36' ' ' LEU . 46.7 mt -107.48 73.22 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -1.149 . . . . 0.0 109.515 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.6 mtmt -87.68 -2.36 58.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.225 -0.922 . . . . 0.0 109.573 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -94.08 -12.8 27.73 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -0.929 . . . . 0.0 109.473 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.573 ' N ' ' CD2' ' A' ' 36' ' ' LEU . 1.8 mm? -86.92 -47.82 8.67 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.311 179.835 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.435 ' CG1' ' CG1' ' A' ' 28' ' ' VAL . 11.6 p -94.16 142.65 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.388 -0.82 . . . . 0.0 109.518 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -113.45 -123.97 4.08 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 82.0 mtt180 -94.43 140.07 30.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.253 -1.145 . . . . 0.0 109.619 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.427 HG12 HG11 ' A' ' 62' ' ' VAL . 58.8 mt -106.33 136.06 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 109.361 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.57 HG23 ' CZ3' ' A' ' 7' ' ' TRP . 31.5 m -127.16 161.98 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.223 -0.923 . . . . 0.0 109.06 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.489 HG23 ' CD1' ' A' ' 44' ' ' ILE . 9.7 mt -144.02 126.99 8.72 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.142 -0.974 . . . . 0.0 110.034 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.69 -2.28 9.08 Favored 'Trans proline' 0 C--O 1.217 -0.533 0 C-N-CA 122.917 2.411 . . . . 0.0 111.381 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.816 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 76.8 mt . . . . . 0 C--N 1.303 -1.429 0 O-C-N 121.185 -0.947 . . . . 0.0 109.491 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.816 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 8.4 mttt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.573 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 61.3 tp -67.04 -23.13 65.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.8 -1.188 . . . . 0.0 109.666 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.573 ' CE2' ' HG ' ' A' ' 55' ' ' LEU . 57.1 m-85 -145.46 97.13 4.73 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 108.836 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -66.01 136.48 44.89 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.59 2.193 . . . . 0.0 112.247 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.74 -13.17 8.91 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.533 ' CE1' HD23 ' A' ' 11' ' ' LEU . 2.4 m-30 -100.84 130.47 46.86 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.688 -1.478 . . . . 0.0 110.23 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.532 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 79.2 t -134.38 147.44 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.373 -0.829 . . . . 0.0 108.809 179.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.529 ' HB2' ' CG2' ' A' ' 41' ' ' VAL . 15.7 m-85 -107.58 122.12 46.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.005 -1.06 . . . . 0.0 109.956 -179.532 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.427 HG11 HG12 ' A' ' 40' ' ' ILE . 7.9 m -125.81 136.77 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.405 -0.809 . . . . 0.0 109.642 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.564 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 7.8 tt0 -101.01 123.96 45.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.228 -0.92 . . . . 0.0 108.974 179.553 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.53 ' HB3' ' O ' ' A' ' 36' ' ' LEU . 14.0 mtm -156.06 176.45 12.65 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.999 -1.063 . . . . 0.0 110.36 -179.266 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.543 ' CD1' HD11 ' A' ' 36' ' ' LEU . 7.9 pt -99.38 132.28 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.482 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 47.4 ttm -76.66 144.17 39.63 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.347 -0.846 . . . . 0.0 109.992 -178.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.482 ' HB2' ' O ' ' A' ' 66' ' ' MET . 50.6 t30 176.2 171.53 0.4 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -67.25 -41.64 85.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.1 -1.0 . . . . 0.0 109.446 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.579 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 97.4 mt-10 -71.72 -38.1 70.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.295 -0.878 . . . . 0.0 109.872 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -64.93 -44.9 87.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.19 -0.944 . . . . 0.0 109.466 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.493 ' CD2' ' OE1' ' A' ' 89' ' ' GLN . 27.9 t80 -60.0 -52.02 67.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.284 -0.885 . . . . 0.0 109.641 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.53 ' O ' ' HB3' ' A' ' 76' ' ' SER . 96.1 m-20 -59.34 -28.32 66.72 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.204 -0.935 . . . . 0.0 110.164 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 21.9 m-85 -85.45 -43.53 13.52 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.957 -1.089 . . . . 0.0 109.95 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 71.6 t -70.06 -57.84 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.288 -0.883 . . . . 0.0 110.025 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.521 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 29.3 tpt85 -60.83 -22.58 64.34 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.171 -0.956 . . . . 0.0 109.826 -179.669 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.53 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 35.4 p -93.71 5.89 50.13 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.127 -0.983 . . . . 0.0 109.88 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.642 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 5.1 p -70.15 129.42 90.66 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.125 -0.985 . . . . 0.0 109.331 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.678 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 43.5 Cg_endo -65.48 138.92 56.81 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 122.782 2.322 . . . . 0.0 112.177 -179.382 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.678 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 59.9 m-85 91.54 -11.98 0.23 Allowed 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.642 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 4.7 t -93.96 134.12 32.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.994 -1.066 . . . . 0.0 109.171 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 85.6 mmm -87.95 -27.4 22.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.205 -0.934 . . . . 0.0 109.492 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.457 ' O ' ' N ' ' A' ' 11' ' ' LEU . . . 161.9 -160.24 32.24 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.617 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 1.6 p90 -139.61 153.92 47.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -1.094 . . . . 0.0 109.314 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.488 ' CG1' ' O ' ' A' ' 84' ' ' VAL . 10.6 p -84.71 113.7 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.188 -0.945 . . . . 0.0 109.615 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.526 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.4 p -148.47 163.24 37.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.895 . . . . 0.0 109.438 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 80.6 p -86.5 -34.55 19.98 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.419 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -127.32 -91.11 0.74 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.557 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -102.59 -126.95 5.97 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.557 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -30.27 152.39 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.61 -0.935 . . . . 0.0 110.375 -179.606 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.571 ' HD3' ' CD2' ' A' ' 83' ' ' PHE . 47.1 Cg_endo -68.13 137.69 41.39 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.917 2.411 . . . . 0.0 112.014 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 18.8 m -73.54 144.92 84.25 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.351 -0.843 . . . . 0.0 109.336 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.31 153.81 66.08 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.645 2.23 . . . . 0.0 111.702 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 7' ' ' TRP . 18.6 t -93.9 129.45 44.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.379 -0.826 . . . . 0.0 109.36 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 25.4 mttm -64.29 141.38 58.79 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.227 -0.921 . . . . 0.0 109.512 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -51.37 -38.64 54.36 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.228 -0.92 . . . . 0.0 109.415 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 62.3 mtt85 -58.2 -38.26 76.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.347 -0.846 . . . . 0.0 109.557 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -77.61 -25.93 50.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.196 -0.94 . . . . 0.0 109.454 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.586 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 95.4 mtp -86.03 -22.27 27.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.388 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.586 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 1.1 mtm180 -36.27 -52.8 1.7 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.525 -0.734 . . . . 0.0 109.861 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.586 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 49.7 Cg_endo -70.01 -27.98 24.62 Favored 'Trans proline' 0 C--O 1.214 -0.718 0 C-N-CA 122.469 2.113 . . . . 0.0 111.908 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.526 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 29.8 mm -81.98 -43.41 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.176 -0.952 . . . . 0.0 109.451 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.533 HD13 ' CB ' ' A' ' 98' ' ' MET . 1.2 mt -68.94 -40.0 79.26 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.23 -0.919 . . . . 0.0 109.445 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.547 ' NH2' ' NH1' ' A' ' 99' ' ' ARG . 24.1 mtt180 -64.36 -50.59 67.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.124 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.62 -36.07 70.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.382 -0.824 . . . . 0.0 109.3 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.526 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -71.27 1.47 6.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.323 -0.861 . . . . 0.0 110.035 -179.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.07 8.25 82.88 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.523 ' N ' HD13 ' A' ' 107' ' ' LEU . 9.4 mp -80.91 -22.07 40.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -1.148 . . . . 0.0 109.368 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . 0.469 ' HB3' ' HA ' ' A' ' 103' ' ' ARG . 47.6 tp10 . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.333 -0.854 . . . . 0.0 109.487 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.494 ' CE1' HG21 ' A' ' 146' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.439 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 7.1 mttp -141.13 145.42 35.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.076 -1.015 . . . . 0.0 109.868 -179.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 22.4 m -63.98 141.99 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.38 -0.825 . . . . 0.0 109.397 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 87.44 -31.69 4.42 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.017 -1.633 . . . . 0.0 109.017 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.496 ' CG ' ' CE ' ' A' ' 175' ' ' LYS . 13.0 t70 -48.5 164.04 0.06 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.513 -0.992 . . . . 0.0 109.055 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.2 ttm -100.29 127.47 46.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.086 -1.009 . . . . 0.0 109.241 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.562 ' CG1' HG12 ' A' ' 143' ' ' ILE . 35.0 m -125.89 142.35 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.34 -0.85 . . . . 0.0 109.26 179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.47 ' O ' HG21 ' A' ' 173' ' ' VAL . 7.8 tttt -102.79 141.83 34.94 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.357 -0.839 . . . . 0.0 108.858 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.534 HG21 ' N ' ' A' ' 132' ' ' ILE . 89.8 mt -81.73 152.35 4.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.102 -0.999 . . . . 0.0 108.557 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.537 HD12 ' CA ' ' A' ' 173' ' ' VAL . 0.5 OUTLIER -150.45 1.64 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.024 -1.048 . . . . 0.0 109.382 179.647 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.512 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 2.9 m -147.27 143.49 28.15 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.128 -0.982 . . . . 0.0 109.896 -179.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.17 -166.92 17.76 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.6 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 45.7 Cg_endo -68.49 -22.51 38.65 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 123.179 2.586 . . . . 0.0 112.594 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.6 ' CD1' ' HG2' ' A' ' 135' ' ' PRO . 70.7 m-85 -106.46 17.3 23.54 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.786 -1.196 . . . . 0.0 109.533 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.56 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 1.5 tt0 -48.18 137.57 10.56 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.168 -0.957 . . . . 0.0 109.599 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.56 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 10.8 m-20 81.62 22.34 0.3 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.479 -0.763 . . . . 0.0 110.323 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.621 ' CE1' ' CG1' ' A' ' 157' ' ' VAL . 1.5 t80 -115.03 143.04 45.81 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.966 -1.084 . . . . 0.0 109.566 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -92.0 134.7 34.57 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.146 -0.971 . . . . 0.0 109.493 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.41 167.24 27.52 Favored Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.739 -1.22 . . . . 0.0 110.212 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.502 ' N ' HG13 ' A' ' 155' ' ' VAL . 37.6 t -115.07 137.14 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.54 -0.976 . . . . 0.0 109.139 179.651 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.619 ' CG2' ' CD1' ' A' ' 146' ' ' ILE . 28.1 mm -69.13 122.4 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.262 -0.899 . . . . 0.0 109.423 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . 0.468 ' C ' ' HG2' ' A' ' 145' ' ' GLU . 0.2 OUTLIER -106.53 -33.3 7.73 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.04 -1.038 . . . . 0.0 109.627 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.468 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 70.0 mm-40 -151.38 146.58 26.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.014 -1.054 . . . . 0.0 109.874 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.619 ' CD1' ' CG2' ' A' ' 143' ' ' ILE . 6.0 mm -120.86 122.76 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.091 -1.006 . . . . 0.0 109.491 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 14.7 t0 -107.08 99.21 25.38 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.307 -0.87 . . . . 0.0 109.349 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.565 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.6 Cg_endo -71.45 172.26 14.57 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.801 2.334 . . . . 0.0 111.841 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.565 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 4.6 mt-10 80.62 -20.16 0.39 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.377 -0.827 . . . . 0.0 109.786 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 94.8 mtt-85 -128.04 -13.66 5.08 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.142 -0.974 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.432 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 35.9 mt-30 70.33 48.47 0.49 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.245 -0.909 . . . . 0.0 109.38 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -120.01 143.13 48.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.085 -1.01 . . . . 0.0 109.245 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.589 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 98.8 mt -128.64 130.73 47.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.219 -0.926 . . . . 0.0 110.103 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . 0.456 ' HD3' ' HB2' ' A' ' 145' ' ' GLU . 22.7 mtpp -92.93 126.17 37.89 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.502 HG13 ' N ' ' A' ' 142' ' ' VAL . 4.0 t -126.31 145.86 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.252 -0.905 . . . . 0.0 110.086 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.526 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 27.7 t-20 -98.87 114.9 27.7 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.451 -0.781 . . . . 0.0 109.326 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.621 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 41.7 t -97.54 142.59 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.373 -0.829 . . . . 0.0 109.665 -179.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 13.3 m -96.57 95.61 8.1 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.784 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.553 HD13 ' CE2' ' A' ' 160' ' ' PHE . 19.0 pt -125.94 146.72 31.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.319 -0.863 . . . . 0.0 109.301 179.76 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.553 ' CE2' HD13 ' A' ' 159' ' ' ILE . 11.5 m-85 63.24 36.26 12.0 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.219 -0.926 . . . . 0.0 109.321 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.05 16.64 19.53 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.411 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 17.8 mtt-85 -130.15 158.69 38.98 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.291 -1.123 . . . . 0.0 109.548 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -99.42 132.99 44.37 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.202 -0.936 . . . . 0.0 109.375 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' THR . . . . . 0.418 HG22 ' CZ ' ' A' ' 56' ' ' PHE . 27.9 m -144.13 124.84 7.74 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.188 -0.945 . . . . 0.0 109.647 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -70.81 139.47 36.67 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.738 2.292 . . . . 0.0 111.763 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.476 HG12 HG21 ' A' ' 157' ' ' VAL . 5.6 p -124.48 143.58 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.155 -0.965 . . . . 0.0 109.646 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.429 ' O ' ' CG1' ' A' ' 167' ' ' VAL . 10.7 p -92.31 119.36 39.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.414 -0.804 . . . . 0.0 109.33 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.565 ' CD1' ' CG1' ' A' ' 173' ' ' VAL . 0.7 OUTLIER -140.48 165.91 26.14 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.22 -0.925 . . . . 0.0 110.621 -179.054 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.452 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 98.2 m-70 -80.32 145.54 32.05 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.487 HG21 ' CD1' ' A' ' 153' ' ' LEU . 11.0 p -60.14 -34.58 57.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.19 -0.944 . . . . 0.0 108.975 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 54.3 p -76.82 -6.73 53.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.322 -0.861 . . . . 0.0 109.321 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.512 ' HA ' ' HB2' ' A' ' 133' ' ' SER . 74.4 mt-10 -96.33 5.94 49.85 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.299 -0.876 . . . . 0.0 109.25 179.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.565 ' CG1' ' CD1' ' A' ' 168' ' ' LEU . 1.5 p -148.07 169.01 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.279 -0.888 . . . . 0.0 108.723 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.565 ' N ' ' CG2' ' A' ' 173' ' ' VAL . 57.0 mt-10 -138.51 167.79 21.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.011 -1.056 . . . . 0.0 109.202 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.496 ' CE ' ' CG ' ' A' ' 127' ' ' ASP . 63.0 tttt . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.077 -1.015 . . . . 0.0 109.485 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.6 mttt . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 121.296 0.57 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.532 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 24.6 mmtp -128.75 175.5 8.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -0.93 . . . . 0.0 109.307 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.609 ' CD1' ' HG3' ' A' ' 63' ' ' GLU . 64.6 m95 -112.17 124.59 52.77 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.247 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 66' ' ' MET . 81.3 m-85 -117.0 170.98 8.21 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.212 -0.93 . . . . 0.0 109.422 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.601 HG12 ' CE1' ' A' ' 61' ' ' PHE . 42.1 mt -107.45 116.33 50.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.251 -0.905 . . . . 0.0 109.379 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.469 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 50.0 t -93.43 139.14 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.241 -0.912 . . . . 0.0 109.362 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.59 HD12 ' CE1' ' A' ' 59' ' ' TYR . 4.2 mm? -86.78 146.28 26.3 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.316 -0.865 . . . . 0.0 109.33 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.471 HG22 ' HA2' ' A' ' 58' ' ' GLY . 11.2 t -158.24 -176.21 5.78 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.263 -0.898 . . . . 0.0 109.501 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.483 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 64.0 mtm -101.2 120.01 39.6 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.175 -0.953 . . . . 0.0 109.533 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.426 ' OG ' ' HB2' ' A' ' 57' ' ' PRO . 43.0 m -43.39 128.3 4.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 109.385 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.08 -19.88 47.43 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.483 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 87.2 m-85 -109.54 9.59 25.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.346 -1.091 . . . . 0.0 109.511 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -60.03 -45.1 93.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.203 -0.936 . . . . 0.0 109.493 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -58.82 -35.31 72.67 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.183 -0.948 . . . . 0.0 109.329 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -72.73 -34.0 66.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -0.929 . . . . 0.0 109.355 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 87.0 t -72.39 -53.05 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.912 . . . . 0.0 109.461 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 46.2 tttm -57.62 -49.91 74.9 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.301 -0.874 . . . . 0.0 109.372 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -63.4 -35.86 81.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.196 -0.94 . . . . 0.0 109.165 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.471 ' OD1' ' HD2' ' A' ' 78' ' ' PRO . 13.8 t-20 -62.72 -47.59 82.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.345 -0.847 . . . . 0.0 109.48 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.49 ' CG2' HG11 ' A' ' 37' ' ' VAL . 89.7 mt -55.75 -43.58 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.278 -0.889 . . . . 0.0 109.501 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -57.64 -46.87 83.62 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.943 . . . . 0.0 110.11 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 76.4 mttt -75.63 -37.31 59.83 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.984 -1.073 . . . . 0.0 109.824 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.602 ' HE3' ' CE1' ' A' ' 73' ' ' PHE . 42.2 tttp -55.95 -29.68 60.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.133 -0.98 . . . . 0.0 109.204 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.53 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 37.8 t -82.98 -26.42 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.866 . . . . 0.0 109.508 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.41 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 66.8 mm-40 -67.68 -51.65 47.16 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.247 -0.908 . . . . 0.0 109.474 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.07 -43.91 51.54 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.246 -0.909 . . . . 0.0 109.444 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 62.6 p -88.88 -7.95 55.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.187 -0.946 . . . . 0.0 109.624 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 54.95 22.58 28.12 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.561 ' CG2' ' CD1' ' A' ' 36' ' ' LEU . 74.8 mt -84.69 100.91 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.252 -1.146 . . . . 0.0 109.512 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.5 mttt -103.54 35.33 2.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.264 -0.897 . . . . 0.0 109.357 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.451 ' OD1' HG21 ' A' ' 33' ' ' ILE . 18.6 p-10 -136.41 8.45 3.13 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.204 -0.935 . . . . 0.0 109.784 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.592 ' CD2' ' CD1' ' A' ' 65' ' ' ILE . 82.1 mt -113.09 -42.88 3.46 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.22 -0.925 . . . . 0.0 109.34 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.49 HG11 ' CG2' ' A' ' 24' ' ' ILE . 52.5 t -106.93 138.68 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.226 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -109.37 -124.65 4.93 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.409 ' O ' ' CH2' ' A' ' 7' ' ' TRP . 64.8 mtt85 -95.13 140.12 30.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.243 -1.151 . . . . 0.0 109.789 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.402 HD11 HG23 ' A' ' 40' ' ' ILE . 67.9 mt -102.13 135.94 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.307 -0.87 . . . . 0.0 109.032 179.586 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.531 ' CG2' ' CH2' ' A' ' 7' ' ' TRP . 53.5 t -118.51 147.21 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.066 -1.021 . . . . 0.0 109.678 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.526 ' CG2' HG21 ' A' ' 44' ' ' ILE . 2.5 mt -119.74 125.72 27.28 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.254 -0.904 . . . . 0.0 109.411 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.501 ' CB ' ' CD2' ' A' ' 56' ' ' PHE . 49.6 Cg_endo -70.33 -5.33 16.3 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.735 2.29 . . . . 0.0 111.814 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.559 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 14.6 pt . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.258 -0.901 . . . . 0.0 109.569 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.559 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 37.8 mttt . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.618 ' O ' ' CD1' ' A' ' 56' ' ' PHE . 49.4 mt -60.72 -24.77 65.93 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.091 -1.006 . . . . 0.0 109.462 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.618 ' CD1' ' O ' ' A' ' 55' ' ' LEU . 1.0 OUTLIER -151.59 104.58 2.89 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.298 -0.876 . . . . 0.0 108.78 179.655 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.426 ' HB2' ' OG ' ' A' ' 14' ' ' SER . 43.7 Cg_endo -66.93 142.17 61.39 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.541 2.161 . . . . 0.0 111.845 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.471 ' HA2' HG22 ' A' ' 12' ' ' THR . . . 74.48 -9.48 10.31 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.59 ' CE1' HD12 ' A' ' 11' ' ' LEU . 2.9 m-30 -102.52 132.08 48.81 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.8 -1.412 . . . . 0.0 110.046 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.419 HG23 HG23 ' A' ' 12' ' ' THR . 45.8 t -134.74 147.75 29.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.859 . . . . 0.0 108.818 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.601 ' CE1' HG12 ' A' ' 9' ' ' ILE . 93.2 m-85 -110.34 123.19 49.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.937 -1.102 . . . . 0.0 109.902 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.474 HG22 ' O ' ' A' ' 62' ' ' VAL . 4.9 m -130.66 143.34 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.302 -0.874 . . . . 0.0 109.767 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.609 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 8.1 tt0 -101.46 125.35 48.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 109.04 179.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.475 ' CB ' ' O ' ' A' ' 36' ' ' LEU . 14.6 ptt? -163.38 -177.37 5.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.984 -1.072 . . . . 0.0 110.457 -179.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.592 ' CD1' ' CD2' ' A' ' 36' ' ' LEU . 7.5 pt -100.9 125.04 54.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.539 -0.726 . . . . 0.0 109.578 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 8' ' ' TYR . 73.5 mmm -89.56 99.64 12.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 109.398 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.461 ' OD1' HG13 ' A' ' 65' ' ' ILE . 21.3 m120 -139.04 -164.29 1.63 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.062 -1.024 . . . . 0.0 109.174 179.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -73.04 -51.92 16.34 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.249 -0.907 . . . . 0.0 110.005 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -72.82 -58.34 3.41 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.096 -1.003 . . . . 0.0 109.743 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.491 ' O ' ' CG2' ' A' ' 74' ' ' VAL . . . -47.3 -44.19 23.13 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.456 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.577 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 88.0 t80 -61.65 -51.6 67.79 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.164 -0.96 . . . . 0.0 109.586 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.495 ' O ' ' HB3' ' A' ' 76' ' ' SER . 83.6 m-20 -59.16 -29.28 67.32 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.228 -0.92 . . . . 0.0 109.888 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.602 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 15.8 t80 -82.61 -43.21 17.28 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.091 -1.006 . . . . 0.0 109.636 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.491 ' CG2' ' O ' ' A' ' 70' ' ' ALA . 16.4 t -65.22 -58.1 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.41 -0.806 . . . . 0.0 109.505 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.503 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 15.1 tpt180 -58.23 -11.02 2.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.324 -0.86 . . . . 0.0 110.095 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 29.0 p -95.41 5.38 51.79 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.927 -1.108 . . . . 0.0 109.898 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.577 ' CG1' ' HB ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -71.85 128.72 89.11 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.094 -1.004 . . . . 0.0 109.086 179.871 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.644 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 42.0 Cg_endo -64.97 140.45 66.26 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.566 2.177 . . . . 0.0 111.891 -179.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.644 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 8.2 m-85 91.7 -10.02 0.24 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.89 -0.506 . . . . 0.0 109.817 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.577 ' HB ' ' CG1' ' A' ' 77' ' ' VAL . 4.3 p -93.57 134.47 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.879 -1.138 . . . . 0.0 109.85 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 88.6 mtp -86.91 -23.98 24.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.379 -0.825 . . . . 0.0 109.258 179.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.572 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 155.19 -156.38 26.91 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.572 ' CD1' ' O ' ' A' ' 82' ' ' GLY . 15.3 m-85 -135.19 143.22 46.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.266 -1.137 . . . . 0.0 109.474 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 90' ' ' PRO . 9.5 p -69.46 131.81 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.286 -0.884 . . . . 0.0 109.512 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.549 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.3 p -166.92 158.65 12.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.271 -0.893 . . . . 0.0 109.616 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.2 m -86.05 -31.79 21.78 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.282 -0.886 . . . . 0.0 109.269 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -131.03 -85.37 0.34 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.542 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -104.17 -134.24 8.09 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.577 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.6 OUTLIER -30.91 150.79 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.819 0 O-C-N 121.557 -0.967 . . . . 0.0 110.317 -179.622 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.549 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.5 Cg_endo -68.38 141.3 50.92 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.819 2.346 . . . . 0.0 112.087 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . 0.549 ' CG2' ' HD2' ' A' ' 92' ' ' PRO . 4.0 p -77.14 144.35 71.4 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.344 -0.847 . . . . 0.0 109.364 179.801 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.549 ' HD2' ' CG2' ' A' ' 91' ' ' VAL . 47.4 Cg_endo -68.39 153.52 73.92 Favored 'Trans proline' 0 C--O 1.216 -0.575 0 C-N-CA 122.66 2.24 . . . . 0.0 111.743 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.496 ' CG1' ' HB2' ' A' ' 97' ' ' GLU . 86.2 t -89.38 133.66 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.268 -0.895 . . . . 0.0 109.649 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 26.4 mtmt -61.49 138.4 58.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.331 -0.856 . . . . 0.0 109.449 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -49.4 -35.81 20.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.928 . . . . 0.0 109.464 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 76.5 mtt180 -61.57 -28.95 69.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.504 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.496 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . 77.1 mt-10 -82.41 -25.22 33.9 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.92 . . . . 0.0 109.599 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.503 ' O ' ' C ' ' A' ' 99' ' ' ARG . 30.9 mmm -85.37 -28.92 24.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.208 -0.932 . . . . 0.0 109.385 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.577 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -36.33 -54.26 1.56 Allowed Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.413 -0.804 . . . . 0.0 109.844 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.607 ' HB2' ' CE1' ' A' ' 136' ' ' PHE . 48.6 Cg_endo -69.28 -26.91 29.39 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.581 2.188 . . . . 0.0 111.938 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.456 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 22.3 mm -82.67 -39.42 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.255 -0.903 . . . . 0.0 109.352 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.583 ' N ' ' CD1' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -72.05 -40.53 68.27 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.097 179.823 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.486 ' HA ' ' HB2' ' A' ' 108' ' ' GLU . 9.3 ttt180 -64.54 -48.5 74.84 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.869 . . . . 0.0 109.158 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.2 tt -71.72 -35.12 70.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.271 -0.893 . . . . 0.0 109.184 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -71.83 2.15 5.92 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.335 -0.853 . . . . 0.0 110.178 -179.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.0 9.4 83.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.451 ' HB3' ' HB3' ' A' ' 102' ' ' LEU . 0.4 OUTLIER -76.56 -18.68 58.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.073 -1.251 . . . . 0.0 109.314 179.85 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . 0.486 ' HB2' ' HA ' ' A' ' 103' ' ' ARG . 91.2 mt-10 . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.278 -0.889 . . . . 0.0 109.555 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.446 ' HA ' ' HD2' ' A' ' 175' ' ' LYS . 45.7 p90 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.417 ' HG2' ' C ' ' A' ' 123' ' ' PHE . 12.5 mmtt -138.12 163.75 30.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.094 -1.004 . . . . 0.0 110.063 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 11.0 p -62.9 141.95 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.443 -0.785 . . . . 0.0 109.548 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 86.98 -33.21 3.83 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.467 ' O ' HG23 ' A' ' 142' ' ' VAL . 71.4 m-20 -46.51 161.76 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.378 -1.072 . . . . 0.0 109.102 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 15.4 ttm -99.82 127.88 45.96 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.138 -0.976 . . . . 0.0 108.959 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.536 ' CG1' HG13 ' A' ' 143' ' ' ILE . 33.4 m -127.78 143.21 41.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.193 -0.942 . . . . 0.0 109.612 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.479 ' HG3' ' O ' ' A' ' 139' ' ' PHE . 12.1 ttpt -101.69 143.02 32.16 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.45 -0.781 . . . . 0.0 109.046 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.53 ' C ' HG13 ' A' ' 132' ' ' ILE . 93.1 mt -80.39 147.0 6.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.132 -0.98 . . . . 0.0 108.421 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.53 HG13 ' C ' ' A' ' 131' ' ' ILE . 18.7 mt -145.03 1.22 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.018 -1.051 . . . . 0.0 109.337 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.485 ' HA ' ' HG2' ' A' ' 137' ' ' GLU . 16.7 t -148.48 142.37 25.77 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.188 -0.945 . . . . 0.0 109.689 -179.608 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.436 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 105.38 -166.5 14.44 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.45 ' HA ' ' HD3' ' A' ' 103' ' ' ARG . 47.7 Cg_endo -68.09 -19.88 44.7 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 123.23 2.62 . . . . 0.0 112.714 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.607 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 96.4 m-85 -107.28 19.74 19.92 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.816 -1.177 . . . . 0.0 109.626 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.525 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 36.7 mt-10 -43.85 137.51 3.13 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.206 -0.934 . . . . 0.0 109.991 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.525 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.6 OUTLIER 77.87 26.47 0.62 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.259 -0.901 . . . . 0.0 110.675 178.87 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.635 ' CE1' ' CG1' ' A' ' 157' ' ' VAL . 2.0 t80 -114.62 159.79 20.05 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.774 -1.204 . . . . 0.0 109.556 179.696 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -108.63 135.22 50.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.245 -0.909 . . . . 0.0 109.399 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.475 ' HA3' HG23 ' A' ' 155' ' ' VAL . . . -146.86 170.23 27.84 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.52 -179.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.542 ' N ' ' CG2' ' A' ' 155' ' ' VAL . 8.5 p -119.19 136.94 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.627 -0.926 . . . . 0.0 109.222 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.536 HG13 ' CG1' ' A' ' 129' ' ' VAL . 88.7 mt -67.22 115.14 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.302 -0.874 . . . . 0.0 109.445 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 68.9 tttt -98.33 -34.77 10.55 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.099 -1.001 . . . . 0.0 109.223 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -149.39 144.47 26.41 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.105 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.579 ' CG2' ' CD2' ' A' ' 153' ' ' LEU . 26.7 pt -126.27 129.32 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.101 -0.999 . . . . 0.0 109.695 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.85 103.13 48.5 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.345 -0.847 . . . . 0.0 109.38 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.549 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.3 Cg_endo -71.08 169.37 20.73 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.711 2.274 . . . . 0.0 111.898 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.549 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.2 tt0 80.81 -21.23 0.33 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.433 -0.792 . . . . 0.0 110.044 179.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.461 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 24.0 mtp85 -124.91 -11.73 7.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.063 -1.023 . . . . 0.0 109.515 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.461 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 42.8 mt-30 69.07 48.13 0.7 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.316 -0.865 . . . . 0.0 109.499 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 -121.13 144.93 48.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.104 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.579 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 58.1 mt -139.54 121.89 16.02 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.16 -0.963 . . . . 0.0 110.226 -179.701 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . 0.445 ' HE3' ' CB ' ' A' ' 165' ' ' PRO . 18.5 ttpt -83.18 132.04 35.09 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.242 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.542 ' CG2' ' N ' ' A' ' 142' ' ' VAL . 9.0 p -125.92 149.76 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.781 -179.612 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.518 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 3.5 t30 -99.19 116.21 30.87 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.396 -0.815 . . . . 0.0 109.205 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.635 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 65.7 t -102.59 146.09 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.212 -0.93 . . . . 0.0 109.581 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' THR . . . . . 0.505 ' N ' HG13 ' A' ' 157' ' ' VAL . 25.8 m -93.75 113.02 24.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.356 -0.84 . . . . 0.0 109.533 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.584 HD11 ' CE1' ' A' ' 56' ' ' PHE . 15.0 pt -145.35 144.6 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.256 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.56 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 46.5 m-85 60.18 35.78 21.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.133 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.91 15.41 13.09 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 67.7 mtp180 -127.37 154.28 45.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.063 -1.257 . . . . 0.0 109.637 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . 0.436 ' OE1' ' N ' ' A' ' 163' ' ' GLU . 58.0 mp0 -97.73 134.9 40.28 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.151 -0.968 . . . . 0.0 109.427 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 24.5 m -147.9 126.12 5.99 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.257 -0.902 . . . . 0.0 109.764 -179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.518 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.8 Cg_endo -70.83 142.8 44.06 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.702 2.268 . . . . 0.0 111.545 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 41.8 t -125.72 144.08 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.058 -1.026 . . . . 0.0 109.788 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.402 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 55.4 t -91.48 118.4 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.414 -0.804 . . . . 0.0 109.194 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.402 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 27.0 mt -140.71 166.31 25.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.12 -0.987 . . . . 0.0 110.543 -179.014 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.434 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 79.7 m80 -81.54 144.44 31.3 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.503 ' CG2' HD11 ' A' ' 153' ' ' LEU . 11.6 p -59.22 -35.39 57.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.346 -0.846 . . . . 0.0 109.025 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 19.4 m -76.96 -8.16 56.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.249 -0.907 . . . . 0.0 109.508 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.483 ' HG2' ' HB3' ' A' ' 133' ' ' SER . 18.6 mt-10 -92.22 2.22 56.74 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.301 -0.874 . . . . 0.0 109.195 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.438 HG13 ' C ' ' A' ' 172' ' ' GLU . 4.1 m -145.06 173.07 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.313 -0.867 . . . . 0.0 109.242 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.518 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 84.2 tt0 -136.94 164.0 29.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.165 -0.959 . . . . 0.0 108.985 179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.518 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 36.7 tttm . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.084 -1.01 . . . . 0.0 109.521 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.469 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 20.5 mttt . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.583 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.4 mmtp -129.99 172.11 12.07 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.277 -0.89 . . . . 0.0 109.419 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.606 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 61.3 m95 -107.44 127.17 53.36 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.286 -0.884 . . . . 0.0 109.215 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.423 ' OH ' ' SD ' ' A' ' 66' ' ' MET . 54.0 m-85 -117.86 167.88 11.0 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.179 -0.951 . . . . 0.0 109.288 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.54 HG12 ' CE1' ' A' ' 61' ' ' PHE . 22.7 mt -101.98 118.32 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.903 . . . . 0.0 109.29 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.424 HG22 HG23 ' A' ' 62' ' ' VAL . 84.3 t -93.88 136.79 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.273 -0.892 . . . . 0.0 109.337 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.403 ' HB3' ' HB2' ' A' ' 81' ' ' MET . 0.2 OUTLIER -89.2 141.13 28.78 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.202 -0.936 . . . . 0.0 109.419 -179.901 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 11.3 t -154.48 -170.91 3.68 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.282 -0.886 . . . . 0.0 109.442 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.542 ' HE2' ' CD2' ' A' ' 16' ' ' TYR . 59.2 mtm -105.07 122.93 46.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.203 -0.935 . . . . 0.0 109.496 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 21.0 m -45.75 128.87 8.99 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.223 -0.923 . . . . 0.0 109.278 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.74 -20.18 44.8 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.542 ' CD2' ' HE2' ' A' ' 13' ' ' MET . 98.8 m-85 -111.01 10.23 22.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.278 -1.131 . . . . 0.0 109.57 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -61.8 -46.59 88.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.204 -0.935 . . . . 0.0 109.456 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -56.73 -34.02 67.11 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.19 -0.943 . . . . 0.0 109.524 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -75.31 -44.72 43.95 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.241 -0.912 . . . . 0.0 109.456 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.442 HG23 ' HB2' ' A' ' 79' ' ' TYR . 48.4 t -59.0 -50.98 77.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.318 -0.863 . . . . 0.0 109.385 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 49.5 tttm -59.79 -47.83 84.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.305 -0.872 . . . . 0.0 109.437 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -62.38 -34.81 77.43 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.259 -0.9 . . . . 0.0 109.245 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.459 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 5.7 m120 -64.77 -38.03 89.6 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.251 -0.906 . . . . 0.0 109.517 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.503 ' CD1' HD12 ' A' ' 40' ' ' ILE . 92.6 mt -63.52 -45.26 98.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.226 -0.921 . . . . 0.0 109.755 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -57.32 -46.04 83.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.146 -0.971 . . . . 0.0 109.992 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -81.6 -37.11 28.14 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.03 -1.044 . . . . 0.0 109.825 -179.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.547 ' HG3' ' CZ ' ' A' ' 73' ' ' PHE . 13.3 tptp -55.86 -29.63 60.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.114 -0.991 . . . . 0.0 109.283 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.529 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 70.4 t -87.56 -25.21 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.296 -0.877 . . . . 0.0 109.43 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 48.2 tp10 -66.47 -49.09 67.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.324 -0.86 . . . . 0.0 109.32 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.02 -27.49 65.5 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.379 -0.826 . . . . 0.0 109.313 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 73.0 p -94.25 -25.55 17.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -0.916 . . . . 0.0 109.388 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 73.26 25.49 72.96 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.529 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 76.4 mt -98.09 82.27 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -1.109 . . . . 0.0 109.447 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.431 ' O ' ' HG3' ' A' ' 34' ' ' LYS . 14.8 tptm -89.63 -6.07 56.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.227 -0.921 . . . . 0.0 109.714 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.491 ' O ' HG23 ' A' ' 65' ' ' ILE . 33.1 m120 -94.34 -4.58 48.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.249 -0.907 . . . . 0.0 109.561 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.603 ' CD1' ' CB ' ' A' ' 70' ' ' ALA . 8.3 tp -97.85 -54.39 3.11 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.305 -0.872 . . . . 0.0 109.664 -179.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.508 HG13 ' CG2' ' A' ' 28' ' ' VAL . 3.7 p -92.65 135.2 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.228 -0.92 . . . . 0.0 109.104 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -106.8 -123.14 5.04 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 59.6 mtt85 -94.11 139.7 30.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.34 -1.094 . . . . 0.0 110.006 -179.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.535 ' CG2' HG11 ' A' ' 62' ' ' VAL . 91.8 mt -108.39 136.56 43.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.558 HG23 ' CZ3' ' A' ' 7' ' ' TRP . 33.9 m -130.59 155.09 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.071 -1.018 . . . . 0.0 109.616 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.457 HG21 HG12 ' A' ' 44' ' ' ILE . 11.8 mt -128.48 133.91 25.69 Favored Pre-proline 0 N--CA 1.489 1.482 0 O-C-N 121.371 -0.831 . . . . 0.0 109.353 -179.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.542 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 40.9 Cg_endo -63.33 -6.57 10.32 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.715 2.276 . . . . 0.0 111.502 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.587 ' CB ' ' HA ' ' A' ' 54' ' ' LYS . 3.7 pt . . . . . 0 N--CA 1.489 1.482 0 O-C-N 121.329 -0.857 . . . . 0.0 109.09 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.587 ' HA ' ' CB ' ' A' ' 44' ' ' ILE . 11.3 mttp . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.542 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 9.9 tp -53.64 -47.93 69.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.1 -1.0 . . . . 0.0 109.423 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.58 ' CZ ' HD13 ' A' ' 159' ' ' ILE . 95.9 m-85 -135.57 111.95 10.7 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.121 -0.987 . . . . 0.0 109.121 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -66.7 142.48 64.05 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.584 2.189 . . . . 0.0 111.879 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.37 -8.18 7.34 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.4 m-30 -100.27 131.94 45.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.793 -1.416 . . . . 0.0 110.122 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.431 HG12 ' N ' ' A' ' 61' ' ' PHE . 46.5 t -134.28 144.69 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.325 -0.859 . . . . 0.0 109.03 179.564 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.54 ' CE1' HG12 ' A' ' 9' ' ' ILE . 59.6 m-85 -107.03 123.38 48.13 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.114 -0.991 . . . . 0.0 109.821 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.535 HG11 ' CG2' ' A' ' 40' ' ' ILE . 29.6 m -132.94 144.46 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.344 -0.848 . . . . 0.0 109.653 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.606 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 37.3 tt0 -110.62 128.95 55.9 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -0.92 . . . . 0.0 109.051 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.529 ' HE2' ' CG1' ' A' ' 74' ' ' VAL . 35.1 mtm -156.01 174.3 15.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.011 -1.056 . . . . 0.0 110.66 -179.35 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.544 ' CG1' HD11 ' A' ' 36' ' ' LEU . 10.2 pt -93.92 128.23 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-O 121.323 0.583 . . . . 0.0 109.577 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.487 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 91.3 mtp -76.82 145.29 38.53 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.372 -0.83 . . . . 0.0 110.046 -178.834 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.487 ' HB2' ' O ' ' A' ' 66' ' ' MET . 45.1 t-20 176.48 173.63 0.38 Allowed 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -70.44 -42.06 72.03 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.056 -1.028 . . . . 0.0 109.292 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -75.92 -30.86 58.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -0.894 . . . . 0.0 109.59 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.603 ' CB ' ' CD1' ' A' ' 36' ' ' LEU . . . -69.58 -48.08 61.39 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.192 -0.942 . . . . 0.0 109.37 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -60.21 -48.55 81.24 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.237 -0.914 . . . . 0.0 109.555 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -59.66 -29.4 68.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.193 -0.942 . . . . 0.0 109.987 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.547 ' CZ ' ' HG3' ' A' ' 27' ' ' LYS . 72.4 t80 -82.0 -43.43 18.0 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.112 -0.992 . . . . 0.0 109.578 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.529 ' CG1' ' HE2' ' A' ' 64' ' ' MET . 2.7 t -66.26 -57.01 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.321 -0.862 . . . . 0.0 109.247 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 13.2 tpt180 -50.34 -32.75 18.08 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.427 -0.796 . . . . 0.0 109.612 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 9.4 t -78.33 6.25 8.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.331 -0.856 . . . . 0.0 110.199 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.593 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 54.8 t -63.27 131.48 94.79 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 120.957 -1.09 . . . . 0.0 109.408 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.584 ' HB2' ' CD2' ' A' ' 79' ' ' TYR . 47.2 Cg_endo -67.89 137.73 42.37 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.66 2.24 . . . . 0.0 111.983 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.584 ' CD2' ' HB2' ' A' ' 78' ' ' PRO . 58.9 m-85 76.15 -4.41 2.37 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.503 -0.748 . . . . 0.0 109.797 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.593 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.8 t -87.57 129.94 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.108 -0.995 . . . . 0.0 109.162 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.403 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 95.5 mmm -88.31 -7.2 57.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.153 -0.967 . . . . 0.0 109.49 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 132.44 -150.83 19.75 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.512 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 4.6 m-85 -140.01 145.79 38.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.228 -1.16 . . . . 0.0 109.542 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.505 ' CG1' ' O ' ' A' ' 84' ' ' VAL . 10.0 p -68.06 119.1 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.385 -0.822 . . . . 0.0 109.469 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.528 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 6.1 p -153.81 165.65 35.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.195 -0.941 . . . . 0.0 109.452 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 t -91.11 -30.43 16.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.399 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -134.57 -73.9 0.08 OUTLIER Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -115.4 -133.05 5.3 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.545 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.5 OUTLIER -31.07 146.48 0.06 OUTLIER Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.588 -0.948 . . . . 0.0 110.135 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.528 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.3 Cg_endo -69.12 141.35 47.59 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.957 2.438 . . . . 0.0 112.096 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . 0.539 ' CG1' ' HD2' ' A' ' 92' ' ' PRO . 68.9 t -67.48 143.9 97.45 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.323 -0.861 . . . . 0.0 109.434 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.539 ' HD2' ' CG1' ' A' ' 91' ' ' VAL . 48.0 Cg_endo -69.43 148.14 66.55 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.622 2.215 . . . . 0.0 111.701 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.418 ' CG2' ' O ' ' A' ' 7' ' ' TRP . 3.0 t -81.87 127.49 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.19 -0.944 . . . . 0.0 109.54 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -69.99 139.87 52.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.317 -0.864 . . . . 0.0 109.47 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -48.83 -40.41 29.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.212 -0.93 . . . . 0.0 109.37 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 59.9 mtt180 -59.01 -34.48 71.92 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.235 -0.916 . . . . 0.0 109.418 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -80.2 -25.96 39.42 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.276 -0.89 . . . . 0.0 109.417 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.571 ' HE2' ' CG ' ' A' ' 7' ' ' TRP . 93.2 mtp -84.26 -24.73 29.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.261 -0.9 . . . . 0.0 109.556 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.578 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 3.2 tpt85 -36.43 -53.15 1.74 Allowed Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.39 -0.819 . . . . 0.0 109.829 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 50.2 Cg_endo -70.49 -28.07 22.23 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.574 2.183 . . . . 0.0 111.724 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.495 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 35.8 mm -80.62 -42.26 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 109.486 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.531 HD12 ' CB ' ' A' ' 98' ' ' MET . 0.7 OUTLIER -67.06 -40.03 87.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.184 -0.948 . . . . 0.0 109.236 179.772 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.577 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 39.8 ttt-85 -63.06 -50.57 70.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.155 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.402 ' CD2' ' C ' ' A' ' 104' ' ' LEU . 5.5 tt -72.58 -35.26 67.89 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.267 -0.896 . . . . 0.0 109.078 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.495 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -71.18 -3.12 18.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.425 -0.797 . . . . 0.0 109.778 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.46 11.63 82.5 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.536 ' CD2' HG12 ' A' ' 41' ' ' VAL . 9.9 mp -79.46 -19.38 49.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.308 -1.113 . . . . 0.0 109.698 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . 0.428 ' OE2' HD13 ' A' ' 102' ' ' LEU . 96.5 mt-10 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.236 -0.915 . . . . 0.0 109.608 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 13.3 p90 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.337 0.589 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.405 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 14.7 mttp -150.95 161.43 42.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.238 -0.913 . . . . 0.0 109.397 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.411 ' HA ' HG21 ' A' ' 143' ' ' ILE . 40.2 t -60.15 141.33 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.258 -0.901 . . . . 0.0 109.525 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 86.06 -33.29 3.6 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.405 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 70.3 m-20 -47.74 162.22 0.08 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.374 -1.074 . . . . 0.0 109.132 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 9.4 ttm -96.67 126.66 42.0 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.157 -0.964 . . . . 0.0 109.082 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.525 ' O ' ' O ' ' A' ' 141' ' ' GLY . 2.7 t -125.37 141.27 45.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.23 -0.919 . . . . 0.0 109.214 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 15.8 tttt -102.55 143.02 32.78 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.245 -0.909 . . . . 0.0 108.98 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.511 ' CD1' ' HB3' ' A' ' 139' ' ' PHE . 66.8 mt -83.71 151.78 3.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.448 HD13 HG22 ' A' ' 132' ' ' ILE . 2.2 pt -149.67 2.69 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.038 -1.038 . . . . 0.0 109.382 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.558 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 71.9 m -148.7 143.33 26.38 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.185 -0.947 . . . . 0.0 109.884 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.475 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 101.57 -164.07 17.69 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.577 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 47.4 Cg_endo -68.16 -22.01 41.47 Favored 'Trans proline' 0 C--O 1.216 -0.587 0 C-N-CA 123.215 2.61 . . . . 0.0 112.913 -179.187 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.497 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 94.0 m-85 -106.21 19.59 20.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.743 -1.223 . . . . 0.0 109.418 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.508 ' HG2' ' HA ' ' A' ' 133' ' ' SER . 44.4 mt-10 -40.75 137.04 1.26 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.871 . . . . 0.0 109.988 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.462 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 4.4 m-20 71.08 29.77 2.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.389 -0.82 . . . . 0.0 110.656 179.05 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.579 ' CE1' HG13 ' A' ' 157' ' ' VAL . 1.9 t80 -116.7 128.06 54.98 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.912 -1.117 . . . . 0.0 109.579 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.34 133.3 40.01 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.285 -0.884 . . . . 0.0 109.797 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.525 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -142.66 169.66 25.46 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 41.1 t -115.31 136.61 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.314 -1.109 . . . . 0.0 109.506 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.514 HG22 ' CD2' ' A' ' 153' ' ' LEU . 49.6 mt -67.28 113.82 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.221 -0.924 . . . . 0.0 108.898 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . 0.404 ' HD3' ' ND2' ' A' ' 156' ' ' ASN . 18.1 tptm -98.56 -35.45 10.22 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.926 -1.109 . . . . 0.0 109.768 -179.506 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.441 ' HB2' ' HB2' ' A' ' 154' ' ' LYS . 38.6 mt-10 -153.29 148.31 26.65 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.133 -0.979 . . . . 0.0 109.754 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.439 HG23 HD11 ' A' ' 146' ' ' ILE . 3.4 mt -125.15 127.85 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.277 -0.889 . . . . 0.0 109.434 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -110.61 102.3 51.54 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.192 -0.942 . . . . 0.0 109.525 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.55 ' O ' ' HB2' ' A' ' 149' ' ' GLU . 51.9 Cg_endo -71.54 173.07 13.05 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.607 2.204 . . . . 0.0 111.881 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.55 ' HB2' ' O ' ' A' ' 148' ' ' PRO . 45.2 mm-40 79.86 -21.1 0.35 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.473 -0.767 . . . . 0.0 109.906 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.461 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 46.6 mtt180 -127.63 -13.98 5.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.058 -1.026 . . . . 0.0 109.509 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.461 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 66.9 mm-40 70.82 47.99 0.43 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.32 -0.863 . . . . 0.0 109.802 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -118.43 142.21 47.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.116 -0.99 . . . . 0.0 108.852 179.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.514 ' CD2' HG22 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -129.76 113.06 14.25 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.137 -0.977 . . . . 0.0 110.16 -179.535 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . 0.441 ' HB2' ' HB2' ' A' ' 145' ' ' GLU . 13.7 mttm -78.18 127.66 32.61 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.083 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.455 HG12 ' N ' ' A' ' 156' ' ' ASN . 40.4 t -126.17 147.05 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.088 -1.007 . . . . 0.0 109.908 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.513 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 70.1 m-20 -95.81 113.72 25.38 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.431 -0.793 . . . . 0.0 109.035 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.579 HG13 ' CE1' ' A' ' 139' ' ' PHE . 89.3 t -97.72 142.8 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.205 -0.935 . . . . 0.0 109.613 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 28.2 m -100.32 94.25 6.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.341 -0.85 . . . . 0.0 109.876 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.58 HD13 ' CZ ' ' A' ' 56' ' ' PHE . 2.2 pt -125.85 152.3 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.281 -0.887 . . . . 0.0 109.143 179.586 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.428 ' O ' ' HG3' ' A' ' 162' ' ' ARG . 18.8 m-30 60.47 38.68 19.02 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.143 -0.973 . . . . 0.0 109.111 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 55.05 14.47 5.75 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.428 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 52.3 mtt85 -128.99 156.32 43.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.129 -1.218 . . . . 0.0 109.668 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -99.39 134.52 42.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.32 -0.862 . . . . 0.0 109.255 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 21.7 m -147.51 127.45 6.66 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.271 -0.893 . . . . 0.0 109.674 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.513 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.8 Cg_endo -70.5 139.94 38.8 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.725 2.283 . . . . 0.0 111.701 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.44 ' O ' HD13 ' A' ' 168' ' ' LEU . 5.3 p -125.13 144.35 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.18 -0.95 . . . . 0.0 109.515 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.43 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 14.1 m -93.76 119.23 41.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.386 -0.821 . . . . 0.0 109.534 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.474 ' CD1' ' N ' ' A' ' 168' ' ' LEU . 0.0 OUTLIER -142.07 168.78 18.93 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -0.909 . . . . 0.0 110.576 -179.492 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.429 ' HB2' ' OE1' ' A' ' 172' ' ' GLU . 99.1 m-70 -83.98 142.39 30.53 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.429 HG11 ' C ' ' A' ' 151' ' ' GLN . 3.1 m -53.58 -34.85 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.295 -0.878 . . . . 0.0 109.151 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 60.2 p -73.81 -6.05 44.65 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.335 -0.853 . . . . 0.0 109.982 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.558 ' CG ' ' HB2' ' A' ' 133' ' ' SER . 2.4 mt-10 -95.6 3.88 53.63 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.015 -1.053 . . . . 0.0 110.02 -179.54 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.455 HG13 ' O ' ' A' ' 172' ' ' GLU . 11.2 m -144.0 169.36 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.057 -1.027 . . . . 0.0 109.601 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.522 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 80.3 tt0 -140.56 166.15 25.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.223 -0.923 . . . . 0.0 108.893 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.522 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 38.9 tttm . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.019 -1.05 . . . . 0.0 109.51 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 55.4 mttt . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 121.263 0.554 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.492 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.9 mmtp -128.0 175.26 8.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.289 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.603 ' CZ3' ' CG2' ' A' ' 41' ' ' VAL . 80.9 m95 -110.33 127.0 54.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.137 -0.977 . . . . 0.0 109.576 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.432 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 60.7 m-85 -121.78 167.07 13.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.229 -0.919 . . . . 0.0 109.488 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.559 ' CD1' ' CD1' ' A' ' 160' ' ' PHE . 76.2 mt -106.61 117.1 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.158 -0.964 . . . . 0.0 109.301 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.434 ' CG1' HG21 ' A' ' 80' ' ' VAL . 85.3 t -88.56 141.98 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.28 -0.888 . . . . 0.0 109.569 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.419 HD11 ' HA ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -93.74 138.84 31.51 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.325 -0.86 . . . . 0.0 109.387 179.905 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 14.9 t -155.58 -169.54 3.15 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.457 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.47 ' CG ' ' HE2' ' A' ' 81' ' ' MET . 90.8 mmm -104.01 119.55 39.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.233 -0.917 . . . . 0.0 109.387 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 13' ' ' MET . 17.8 p -42.46 128.52 3.92 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.232 -0.918 . . . . 0.0 109.475 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.34 -20.31 35.35 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.405 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 90.3 m-85 -110.67 -1.4 16.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -1.133 . . . . 0.0 109.557 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -53.34 -55.24 26.39 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.241 -0.912 . . . . 0.0 109.404 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -49.13 -32.22 9.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.166 -0.958 . . . . 0.0 109.418 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 23' ' ' ASN . 62.3 mttm -76.83 -36.75 56.66 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.286 -0.883 . . . . 0.0 109.311 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 98.4 t -66.73 -52.01 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.33 -0.856 . . . . 0.0 109.523 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -56.89 -50.87 71.19 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.231 -0.918 . . . . 0.0 109.484 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -64.68 -34.82 79.19 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.153 -0.967 . . . . 0.0 109.38 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.452 ' CG ' ' HG2' ' A' ' 78' ' ' PRO . 2.1 t30 -66.0 -44.32 85.14 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.408 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 81.7 mt -57.39 -43.37 82.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.272 -0.892 . . . . 0.0 109.443 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -58.38 -44.44 88.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.205 -0.934 . . . . 0.0 109.789 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 31.9 mtmt -77.88 -37.48 48.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.112 -0.992 . . . . 0.0 109.798 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.585 ' HE3' ' CE1' ' A' ' 73' ' ' PHE . 42.1 tttp -57.04 -28.94 62.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.908 . . . . 0.0 109.313 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.538 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 42.4 t -83.86 -27.43 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.314 -0.866 . . . . 0.0 109.464 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.448 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 54.9 mm-40 -66.8 -49.25 66.45 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.271 -0.893 . . . . 0.0 109.444 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.2 -35.12 66.91 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.241 -0.912 . . . . 0.0 109.482 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.3 p -92.86 -22.71 19.12 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.271 -0.893 . . . . 0.0 109.591 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 74.3 1.59 60.87 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.555 HG22 ' CD1' ' A' ' 36' ' ' LEU . 48.1 mm -69.39 80.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.318 -1.107 . . . . 0.0 109.429 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -90.89 14.54 13.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 109.458 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.476 ' O ' HG22 ' A' ' 65' ' ' ILE . 24.7 m120 -113.39 -3.07 13.81 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.235 -0.916 . . . . 0.0 109.601 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.555 ' CD1' HG22 ' A' ' 33' ' ' ILE . 11.8 mt -98.59 -51.2 4.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.946 . . . . 0.0 109.599 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 99.1 t -95.55 144.58 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.313 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -114.87 -124.75 3.92 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 18.6 mtt85 -91.56 142.18 27.91 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.309 -1.112 . . . . 0.0 109.885 -179.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.483 HG12 ' CG1' ' A' ' 62' ' ' VAL . 65.4 mt -109.94 134.42 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.152 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.603 ' CG2' ' CZ3' ' A' ' 7' ' ' TRP . 30.4 m -127.5 144.54 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.208 -0.932 . . . . 0.0 109.263 179.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.503 HG21 ' CD1' ' A' ' 44' ' ' ILE . 67.6 mt -129.94 129.14 22.98 Favored Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.294 -0.879 . . . . 0.0 109.623 -179.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.541 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.3 Cg_endo -66.71 -2.65 7.93 Favored 'Trans proline' 0 C--O 1.217 -0.544 0 C-N-CA 122.879 2.386 . . . . 0.0 111.348 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.729 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 85.6 mt . . . . . 0 N--CA 1.488 1.462 0 O-C-N 121.144 -0.972 . . . . 0.0 109.554 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.729 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 1.9 mttp . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.541 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 9.2 tp -59.71 -42.14 92.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.904 -1.123 . . . . 0.0 108.909 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.58 ' CZ ' HD12 ' A' ' 159' ' ' ILE . 19.4 m-85 -126.3 101.15 28.51 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.217 -0.927 . . . . 0.0 108.789 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 41.7 Cg_endo -65.63 137.09 48.75 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.681 2.254 . . . . 0.0 112.26 -179.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.36 -12.61 5.5 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.534 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 1.7 m-30 -100.47 132.15 46.01 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.748 -1.442 . . . . 0.0 110.32 -179.199 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.413 HG11 HG12 ' A' ' 42' ' ' ILE . 40.0 t -132.99 143.07 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.349 -0.844 . . . . 0.0 108.926 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.526 ' CE1' HG12 ' A' ' 9' ' ' ILE . 18.8 m-30 -106.68 123.86 48.75 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.003 -1.061 . . . . 0.0 109.805 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.483 ' CG1' HG12 ' A' ' 40' ' ' ILE . 93.0 t -131.16 142.13 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.339 -0.851 . . . . 0.0 109.653 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.584 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 39.1 tt0 -105.9 128.77 53.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.262 -0.899 . . . . 0.0 108.981 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.494 ' CG ' ' C ' ' A' ' 63' ' ' GLU . 16.5 mtm -155.96 178.65 10.03 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.169 -0.957 . . . . 0.0 110.05 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.537 ' CD1' HD21 ' A' ' 36' ' ' LEU . 6.1 pt -101.01 133.89 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.59 -0.694 . . . . 0.0 109.321 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.478 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 53.9 ttm -77.24 144.33 38.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.224 -0.922 . . . . 0.0 110.1 -178.654 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.478 ' HB2' ' O ' ' A' ' 66' ' ' MET . 29.0 t-20 176.46 175.56 0.32 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -72.6 -43.06 63.83 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.249 -0.907 . . . . 0.0 109.323 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -75.64 -28.01 58.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.686 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.539 ' CB ' HD23 ' A' ' 36' ' ' LEU . . . -70.58 -47.56 59.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.131 -0.981 . . . . 0.0 109.302 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.526 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 89.0 t80 -60.88 -54.94 38.9 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.289 -0.882 . . . . 0.0 109.275 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.447 ' O ' ' OG ' ' A' ' 76' ' ' SER . 42.2 t-20 -52.85 -31.81 41.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.221 -0.924 . . . . 0.0 109.975 -179.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.585 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 81.9 t80 -80.08 -43.27 22.09 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.035 -1.04 . . . . 0.0 109.567 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.522 ' CG2' ' O ' ' A' ' 70' ' ' ALA . 3.2 t -68.26 -55.48 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.295 -0.878 . . . . 0.0 109.414 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.486 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 16.5 tpt180 -61.56 -9.58 6.23 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.338 -0.851 . . . . 0.0 109.837 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 72' ' ' ASN . 42.7 p -101.67 2.09 38.32 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.148 -0.97 . . . . 0.0 109.983 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.625 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -68.75 135.29 90.15 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.057 -1.027 . . . . 0.0 108.954 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.629 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 43.9 Cg_endo -66.21 138.96 53.43 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.394 2.063 . . . . 0.0 111.99 -179.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.629 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 5.5 m-85 89.09 -8.08 0.44 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.801 -0.562 . . . . 0.0 109.829 -179.838 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.625 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 2.4 t -89.34 129.5 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.966 -1.084 . . . . 0.0 109.661 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.47 ' HE2' ' CG ' ' A' ' 13' ' ' MET . 18.7 mtt -93.53 -25.06 17.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.459 -0.776 . . . . 0.0 109.246 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 164.54 -162.61 35.59 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.477 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 48.6 m-85 -136.21 151.74 50.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.187 -1.184 . . . . 0.0 109.559 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.8 t -67.01 101.42 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.282 -0.886 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.543 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.0 OUTLIER -143.98 162.85 35.12 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -0.918 . . . . 0.0 109.505 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.0 m -95.18 -34.52 12.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.349 -0.845 . . . . 0.0 109.278 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -129.39 -72.78 0.14 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.541 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -113.91 -137.89 6.75 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.541 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.3 OUTLIER -31.03 148.45 0.04 OUTLIER Pre-proline 0 N--CA 1.493 1.704 0 O-C-N 121.506 -0.997 . . . . 0.0 110.274 -179.718 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.543 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.3 Cg_endo -69.54 149.61 68.53 Favored 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.82 2.347 . . . . 0.0 111.887 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 36.0 m -80.73 152.31 72.13 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.323 -0.861 . . . . 0.0 109.403 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.07 143.36 49.12 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.693 2.262 . . . . 0.0 111.81 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.437 ' CG1' ' SD ' ' A' ' 98' ' ' MET . 29.3 t -69.48 142.16 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.192 -0.942 . . . . 0.0 109.414 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . 0.429 ' HB2' ' HG3' ' A' ' 97' ' ' GLU . 32.0 mttt -70.67 134.12 47.25 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.537 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -50.27 -41.46 50.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.863 . . . . 0.0 109.419 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -63.14 -24.07 67.72 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.438 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.429 ' HG3' ' HB2' ' A' ' 94' ' ' LYS . 40.9 mt-10 -84.95 -23.66 28.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -0.913 . . . . 0.0 109.456 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.509 ' O ' ' C ' ' A' ' 99' ' ' ARG . 52.5 mmm -85.19 -33.18 22.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.265 -0.897 . . . . 0.0 109.384 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.579 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -36.1 -53.41 1.57 Allowed Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.459 -0.776 . . . . 0.0 109.795 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.584 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 47.4 Cg_endo -69.79 -26.57 27.3 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.494 2.129 . . . . 0.0 111.616 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.531 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 32.3 mm -81.09 -38.51 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.236 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.578 ' N ' HD11 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -71.36 -40.35 70.69 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.328 -0.858 . . . . 0.0 109.16 179.733 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 58.0 mtt-85 -63.15 -50.06 71.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.403 -0.81 . . . . 0.0 109.028 179.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.4 tt -72.35 -35.55 68.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.385 -0.822 . . . . 0.0 109.079 179.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -69.33 -1.62 8.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.393 -0.817 . . . . 0.0 110.023 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.12 8.25 82.97 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.409 ' HB3' ' HB3' ' A' ' 102' ' ' LEU . 0.7 OUTLIER -74.37 -17.55 60.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.16 -1.2 . . . . 0.0 109.431 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . 0.418 ' HG3' ' HB3' ' A' ' 102' ' ' LEU . 88.9 mt-10 . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.898 . . . . 0.0 109.479 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.603 ' CB ' ' HD3' ' A' ' 175' ' ' LYS . 38.3 p90 . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 17.4 mttt -144.27 162.75 35.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.135 -0.978 . . . . 0.0 109.922 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 12.1 t -64.04 141.79 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.472 -0.768 . . . . 0.0 109.297 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 87.47 -31.23 4.58 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.463 ' O ' HG12 ' A' ' 142' ' ' VAL . 22.6 t70 -49.71 162.92 0.14 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.299 -1.118 . . . . 0.0 109.27 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.9 ttp -94.72 125.35 39.31 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.13 -0.982 . . . . 0.0 109.073 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.543 ' CG2' ' O ' ' A' ' 174' ' ' GLU . 2.0 p -124.31 140.77 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.173 -0.954 . . . . 0.0 109.02 179.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 174' ' ' GLU . 59.9 tttt -106.2 142.72 35.41 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.153 -0.967 . . . . 0.0 109.361 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.557 ' O ' ' CD1' ' A' ' 132' ' ' ILE . 88.2 mt -82.75 152.91 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.161 -0.962 . . . . 0.0 108.581 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.557 ' CD1' ' O ' ' A' ' 131' ' ' ILE . 2.6 mm -148.94 1.66 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.103 -0.998 . . . . 0.0 109.463 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.539 ' CB ' ' HG2' ' A' ' 172' ' ' GLU . 28.3 m -150.82 147.64 27.51 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.13 -0.981 . . . . 0.0 110.331 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.84 -164.12 18.56 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 179.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.482 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 46.2 Cg_endo -67.93 -23.52 40.79 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 123.026 2.484 . . . . 0.0 112.535 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.584 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 93.4 m-85 -108.86 18.76 20.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.962 -1.086 . . . . 0.0 109.456 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.532 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 1.8 tt0 -48.35 140.69 7.39 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.289 -0.882 . . . . 0.0 109.687 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.532 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 12.8 m-20 76.93 28.73 0.64 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.468 -0.77 . . . . 0.0 110.243 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.482 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 1.9 t80 -118.42 153.52 33.95 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.08 -1.012 . . . . 0.0 109.485 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -101.2 133.34 45.91 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.246 -0.909 . . . . 0.0 109.197 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.499 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.25 170.38 26.65 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 119.535 -1.317 . . . . 0.0 110.604 -179.413 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 127' ' ' ASP . 44.9 t -115.11 137.71 47.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.602 -0.94 . . . . 0.0 109.348 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.556 ' CG2' HD23 ' A' ' 153' ' ' LEU . 14.9 mm -68.74 115.27 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.226 -0.921 . . . . 0.0 109.502 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . 0.418 ' HG2' ' HG3' ' A' ' 145' ' ' GLU . 21.2 tttp -99.0 -34.46 10.41 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.039 -1.038 . . . . 0.0 109.321 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.418 ' HG3' ' HG2' ' A' ' 144' ' ' LYS . 89.5 mt-10 -152.57 147.6 26.37 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.133 -0.98 . . . . 0.0 109.444 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.42 HG23 ' HG ' ' A' ' 153' ' ' LEU . 6.6 mt -126.56 130.05 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.216 -0.928 . . . . 0.0 109.622 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -110.33 103.39 53.87 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.286 -0.884 . . . . 0.0 109.528 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.557 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.55 171.83 15.52 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.747 2.298 . . . . 0.0 111.631 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.557 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.3 mt-10 80.68 -20.34 0.38 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.319 -0.863 . . . . 0.0 109.876 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.454 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 43.3 mtt85 -128.21 -12.18 5.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.05 -1.031 . . . . 0.0 109.582 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.454 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 37.1 mt-30 69.68 48.97 0.56 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.907 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -120.12 144.54 47.58 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.081 -1.012 . . . . 0.0 109.116 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.556 HD23 ' CG2' ' A' ' 143' ' ' ILE . 0.0 OUTLIER -133.92 115.73 14.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.097 -1.002 . . . . 0.0 110.115 -179.381 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 7.1 mttt -78.04 132.42 37.76 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.328 -0.857 . . . . 0.0 108.786 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.531 HG11 ' CG2' ' A' ' 166' ' ' VAL . 13.2 p -130.21 147.01 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.119 -0.988 . . . . 0.0 110.008 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.488 ' OD1' ' CA ' ' A' ' 165' ' ' PRO . 0.9 OUTLIER -97.53 115.96 28.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.435 -0.791 . . . . 0.0 109.183 179.66 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.479 HG12 HG22 ' A' ' 159' ' ' ILE . 87.1 t -97.64 143.22 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.163 -0.961 . . . . 0.0 109.747 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.3 m -91.88 111.88 23.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.314 -0.867 . . . . 0.0 109.643 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.58 HD12 ' CZ ' ' A' ' 56' ' ' PHE . 13.6 pt -144.56 143.92 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.295 -0.878 . . . . 0.0 109.486 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.559 ' CD1' ' CD1' ' A' ' 9' ' ' ILE . 78.2 m-85 62.1 34.36 16.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.282 -0.886 . . . . 0.0 109.396 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.28 16.47 20.42 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 73.6 mtt-85 -128.91 151.14 49.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -93.7 135.05 35.38 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.233 -0.917 . . . . 0.0 109.392 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 60.8 m -144.64 126.31 7.96 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.242 -0.911 . . . . 0.0 109.67 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.488 ' CA ' ' OD1' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.8 139.58 36.93 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 122.624 2.216 . . . . 0.0 111.39 179.676 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.531 ' CG2' HG11 ' A' ' 155' ' ' VAL . 1.9 m -125.75 144.54 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.059 -1.026 . . . . 0.0 109.988 -179.682 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.526 ' C ' ' CD2' ' A' ' 168' ' ' LEU . 14.7 m -92.05 117.48 35.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.526 ' CD2' ' C ' ' A' ' 167' ' ' VAL . 3.2 mm? -139.78 166.24 25.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.156 -0.965 . . . . 0.0 110.289 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.5 ' HB2' ' HB2' ' A' ' 172' ' ' GLU . 82.2 m-70 -83.95 141.15 31.45 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 9.1 p -56.78 -36.58 49.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.293 -0.879 . . . . 0.0 109.296 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 32.1 p -77.29 -8.47 57.67 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.094 -1.004 . . . . 0.0 109.722 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.539 ' HG2' ' CB ' ' A' ' 133' ' ' SER . 1.3 mt-10 -88.67 -4.79 58.47 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.194 -0.941 . . . . 0.0 109.275 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.9 m -137.22 176.51 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.192 -0.942 . . . . 0.0 109.799 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.543 ' O ' ' CG2' ' A' ' 129' ' ' VAL . 72.9 tt0 -132.15 155.43 48.18 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.603 ' HD3' ' CB ' ' A' ' 123' ' ' PHE . 16.2 mttm . . . . . 0 N--CA 1.489 1.523 0 O-C-N 120.965 -1.084 . . . . 0.0 109.712 -179.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 33.4 mttm . . . . . 0 N--CA 1.488 1.464 0 CA-C-O 121.342 0.591 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.58 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 11.6 mttt -130.47 173.76 10.54 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.905 . . . . 0.0 109.192 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.605 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 61.5 m95 -108.59 127.51 54.01 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -0.901 . . . . 0.0 109.3 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.447 ' OH ' ' SD ' ' A' ' 66' ' ' MET . 91.6 m-85 -115.61 169.15 9.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.211 -0.93 . . . . 0.0 109.33 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.569 HG12 ' CE1' ' A' ' 61' ' ' PHE . 27.3 mt -109.89 113.57 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 109.192 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.453 HG23 ' CG2' ' A' ' 62' ' ' VAL . 82.4 t -88.51 140.58 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.221 -0.925 . . . . 0.0 109.369 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.628 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 2.9 mm? -95.36 146.36 24.45 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.357 -0.839 . . . . 0.0 109.414 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.5 t -161.17 -164.26 1.14 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.265 -0.897 . . . . 0.0 109.114 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.496 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 94.0 mtp -105.32 124.71 50.0 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.186 -0.946 . . . . 0.0 109.516 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.0 t -45.78 131.1 9.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.294 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.94 -19.33 47.08 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.496 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 95.6 m-85 -108.96 6.34 25.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.284 -1.127 . . . . 0.0 109.564 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -62.79 -52.82 61.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.261 -0.899 . . . . 0.0 109.507 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -50.7 -35.78 32.84 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.187 -0.945 . . . . 0.0 109.61 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.48 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 58.4 mttt -73.9 -47.81 35.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.247 -0.908 . . . . 0.0 109.556 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.534 ' CG2' ' HB2' ' A' ' 79' ' ' TYR . 74.8 t -54.32 -48.41 67.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.226 -0.922 . . . . 0.0 109.579 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 40.8 tttm -57.56 -49.66 75.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -0.923 . . . . 0.0 109.615 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -65.42 -39.18 91.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.244 -0.91 . . . . 0.0 109.497 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 19' ' ' LYS . 70.2 m-20 -62.16 -44.62 96.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.869 . . . . 0.0 109.622 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.405 HD13 HG23 ' A' ' 24' ' ' ILE . 96.7 mt -57.76 -43.83 84.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.522 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -56.42 -44.55 80.48 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.206 -0.934 . . . . 0.0 109.823 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -75.55 -35.33 60.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.06 -1.025 . . . . 0.0 109.437 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.468 ' CD ' HG23 ' A' ' 77' ' ' VAL . 10.1 tttm -56.44 -34.16 66.57 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.229 -0.92 . . . . 0.0 109.331 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.529 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 43.4 t -83.99 -25.42 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.334 -0.854 . . . . 0.0 109.593 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 46.7 tp10 -70.32 -53.95 14.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.264 -0.897 . . . . 0.0 109.656 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.92 -33.6 72.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -0.92 . . . . 0.0 109.693 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 50.7 p -83.35 -35.91 24.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.182 -0.949 . . . . 0.0 109.488 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 84.75 17.8 62.91 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.529 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 78.8 mt -95.74 78.31 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.218 -1.166 . . . . 0.0 109.414 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 45.0 mttm -85.68 6.1 29.12 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.486 ' O ' HG22 ' A' ' 65' ' ' ILE . 24.5 m120 -102.3 -6.94 22.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.224 -0.923 . . . . 0.0 109.547 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.575 ' CD1' ' CB ' ' A' ' 70' ' ' ALA . 10.5 tp -97.68 -54.05 3.24 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.302 -0.874 . . . . 0.0 109.681 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.534 HG23 ' CE ' ' A' ' 64' ' ' MET . 87.4 t -90.38 133.66 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.284 -0.885 . . . . 0.0 109.324 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.65 -126.87 5.88 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 44.5 mtt180 -93.58 140.65 29.37 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -1.155 . . . . 0.0 109.887 -179.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 63.2 mt -103.76 134.0 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.308 -0.87 . . . . 0.0 109.09 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.585 HG21 ' CZ3' ' A' ' 7' ' ' TRP . 34.7 m -124.7 146.7 29.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.132 -0.98 . . . . 0.0 109.692 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.522 ' CG2' HG22 ' A' ' 44' ' ' ILE . 1.2 mt -117.75 128.9 25.7 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.423 -0.798 . . . . 0.0 109.465 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.65 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.6 Cg_endo -66.43 -6.22 14.59 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.903 2.402 . . . . 0.0 111.857 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.551 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 13.1 pt . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.178 -0.951 . . . . 0.0 109.413 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.551 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 1.9 mttt . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.65 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 0.7 OUTLIER -54.16 -45.84 72.15 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.036 -1.04 . . . . 0.0 108.85 179.756 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.491 ' CZ ' ' CD1' ' A' ' 55' ' ' LEU . 16.5 m-85 -123.97 110.32 29.41 Favored Pre-proline 0 N--CA 1.487 1.422 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.368 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -66.92 137.89 46.37 Favored 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.645 2.23 . . . . 0.0 111.942 -179.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.19 -7.71 10.28 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.628 ' CE1' ' CD1' ' A' ' 11' ' ' LEU . 3.7 m-85 -107.54 134.37 50.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.896 -1.355 . . . . 0.0 110.082 -179.351 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 43.3 t -134.52 150.42 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.569 ' CE1' HG12 ' A' ' 9' ' ' ILE . 72.9 m-85 -108.67 123.64 49.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.988 -1.07 . . . . 0.0 109.711 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.453 ' CG2' HG23 ' A' ' 10' ' ' VAL . 19.0 m -131.86 144.24 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.382 -0.824 . . . . 0.0 109.569 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.605 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 22.7 tt0 -105.27 126.7 52.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.364 -0.835 . . . . 0.0 109.038 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.534 ' CE ' HG23 ' A' ' 37' ' ' VAL . 4.9 mtp -156.47 175.0 14.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.107 -0.996 . . . . 0.0 110.293 -179.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.486 HG22 ' O ' ' A' ' 35' ' ' ASN . 10.6 pt -97.39 129.13 47.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.608 -0.683 . . . . 0.0 109.236 179.7 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.486 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 0.0 OUTLIER -76.36 145.87 39.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.919 . . . . 0.0 109.621 -179.026 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.582 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 44.1 t30 175.78 163.61 0.34 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -59.56 -40.47 87.39 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.058 -1.027 . . . . 0.0 109.581 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.544 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 99.1 mt-10 -72.19 -43.74 64.07 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.217 -0.927 . . . . 0.0 109.895 -179.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.575 ' CB ' ' CD1' ' A' ' 36' ' ' LEU . . . -56.4 -44.88 80.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.087 -1.008 . . . . 0.0 109.572 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.582 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 36.2 m-85 -60.32 -62.39 1.9 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.22 -0.925 . . . . 0.0 109.269 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.483 ' O ' ' HB2' ' A' ' 76' ' ' SER . 95.8 m-20 -43.52 -30.86 0.62 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.388 -0.82 . . . . 0.0 109.82 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.544 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 24.4 m-85 -82.94 -42.41 17.69 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.167 -0.958 . . . . 0.0 109.898 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.641 ' CG1' ' CZ ' ' A' ' 83' ' ' PHE . 61.2 t -69.99 -55.33 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.217 -0.927 . . . . 0.0 109.498 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.507 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 6.1 tpt180 -57.77 -14.32 5.65 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.292 -0.88 . . . . 0.0 109.307 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.483 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 3.8 m -105.61 2.5 28.28 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.208 -0.933 . . . . 0.0 109.691 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.608 HG13 ' HB ' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -68.37 150.65 97.63 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.048 -1.033 . . . . 0.0 109.087 179.911 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.672 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 47.7 Cg_endo -68.83 124.75 11.79 Favored 'Trans proline' 0 C--O 1.214 -0.714 0 C-N-CA 122.569 2.179 . . . . 0.0 112.429 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.672 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 53.5 m-85 88.59 0.02 0.38 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.776 -0.577 . . . . 0.0 110.773 179.164 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.608 ' HB ' HG13 ' A' ' 77' ' ' VAL . 7.4 p -84.16 112.9 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.738 -1.226 . . . . 0.0 109.523 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 86.0 mmm -87.43 -30.1 20.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.274 -0.891 . . . . 0.0 109.232 179.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.454 ' O ' ' HB2' ' A' ' 11' ' ' LEU . . . 174.26 -169.03 41.99 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.641 ' CZ ' ' CG1' ' A' ' 74' ' ' VAL . 15.7 m-85 -127.66 147.62 50.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.248 -1.148 . . . . 0.0 109.514 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.481 ' CG2' HD23 ' A' ' 11' ' ' LEU . 59.2 t -67.3 77.1 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.32 -0.862 . . . . 0.0 109.254 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.536 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 3.1 p -127.71 162.78 25.76 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.332 -0.855 . . . . 0.0 109.634 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 87.8 p -95.91 -33.33 12.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.42 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.98 -77.09 0.19 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.508 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -106.58 -145.19 12.41 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.508 ' C ' ' O ' ' A' ' 88' ' ' GLY . 2.5 pm0 -33.31 154.01 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.582 -0.952 . . . . 0.0 110.188 -179.458 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.536 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 51.7 Cg_endo -70.68 168.55 22.42 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.513 2.142 . . . . 0.0 112.032 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . 0.524 ' CG1' ' HD2' ' A' ' 92' ' ' PRO . 0.1 OUTLIER -98.7 148.98 35.29 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.33 -0.856 . . . . 0.0 109.199 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.524 ' HD2' ' CG1' ' A' ' 91' ' ' VAL . 48.7 Cg_endo -69.31 150.8 71.4 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.616 2.21 . . . . 0.0 111.705 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.525 ' CG2' ' O ' ' A' ' 7' ' ' TRP . 2.5 t -80.06 126.65 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.912 . . . . 0.0 109.528 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . 0.487 ' O ' ' N ' ' A' ' 97' ' ' GLU . 51.0 mttt -71.9 136.62 46.96 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.267 -0.895 . . . . 0.0 109.271 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.481 ' O ' ' HG3' ' A' ' 99' ' ' ARG . 82.8 m-20 -43.25 -41.65 3.99 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.918 . . . . 0.0 109.346 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 21.8 mtm180 -56.75 -30.38 63.53 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.336 -0.852 . . . . 0.0 109.692 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.487 ' N ' ' O ' ' A' ' 94' ' ' LYS . 53.6 mt-10 -87.01 -27.75 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.599 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.543 ' CB ' HD13 ' A' ' 102' ' ' LEU . 75.2 mmm -80.08 -24.72 40.43 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.359 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.585 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 25.6 mtp85 -37.37 -53.71 2.2 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.482 -0.761 . . . . 0.0 109.786 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.9 Cg_endo -69.28 -30.74 24.02 Favored 'Trans proline' 0 C--O 1.216 -0.577 0 C-N-CA 122.587 2.191 . . . . 0.0 111.749 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 16.3 mm -77.52 -43.69 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.139 -0.976 . . . . 0.0 109.238 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.543 HD13 ' CB ' ' A' ' 98' ' ' MET . 1.1 mt -63.19 -40.77 98.46 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.275 -0.891 . . . . 0.0 109.031 179.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.542 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 24.7 ttt-85 -60.11 -45.85 91.59 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 108.783 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.512 ' CD2' ' O ' ' A' ' 44' ' ' ILE . 0.6 OUTLIER -68.45 -34.31 75.74 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.391 -0.818 . . . . 0.0 108.912 179.397 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.506 ' O ' ' HG ' ' A' ' 107' ' ' LEU . . . -90.47 17.88 6.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.32 -0.863 . . . . 0.0 109.033 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 43.76 28.89 1.22 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.54 ' CD1' HG13 ' A' ' 41' ' ' VAL . 88.3 mt -90.12 -26.64 20.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -1.158 . . . . 0.0 109.535 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . 0.505 ' HB2' ' CB ' ' A' ' 102' ' ' LEU . 87.2 tt0 . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.238 -0.914 . . . . 0.0 109.63 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.625 ' CZ ' ' HB2' ' A' ' 175' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.481 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 12.2 mttt -113.91 157.22 22.67 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.11 -0.994 . . . . 0.0 110.146 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.444 ' HA ' HG23 ' A' ' 143' ' ' ILE . 22.0 t -64.43 144.99 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.512 -0.742 . . . . 0.0 109.469 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.68 -28.23 4.5 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.625 ' HB3' ' CE2' ' A' ' 123' ' ' PHE . 8.3 m-20 -50.48 167.52 0.06 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.466 -1.02 . . . . 0.0 108.898 179.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -99.05 126.36 44.75 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.026 -1.047 . . . . 0.0 109.112 179.838 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.465 HG21 ' O ' ' A' ' 174' ' ' GLU . 2.3 p -124.93 142.8 40.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.373 -0.829 . . . . 0.0 109.08 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 21.1 tttt -104.9 142.91 33.92 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.293 -0.879 . . . . 0.0 109.236 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.458 HD12 ' HB3' ' A' ' 136' ' ' PHE . 74.3 mt -83.01 152.99 3.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.152 -0.967 . . . . 0.0 108.629 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.468 ' C ' ' HG2' ' A' ' 137' ' ' GLU . 34.2 pt -150.1 2.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.926 -1.109 . . . . 0.0 109.494 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.553 ' CA ' ' HG2' ' A' ' 137' ' ' GLU . 5.9 t -147.11 142.09 26.99 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.048 -1.032 . . . . 0.0 109.634 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.451 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 102.22 -166.0 17.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 179.266 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.542 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 48.4 Cg_endo -68.28 -20.61 42.69 Favored 'Trans proline' 0 C--O 1.214 -0.701 0 C-N-CA 123.382 2.721 . . . . 0.0 113.104 -179.157 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.505 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.1 m-85 -105.77 15.86 26.13 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.836 -1.165 . . . . 0.0 109.54 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.553 ' HG2' ' CA ' ' A' ' 133' ' ' SER . 73.0 mt-10 -41.5 137.35 1.56 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.196 -0.94 . . . . 0.0 109.95 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.491 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.6 OUTLIER 75.48 25.18 1.26 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.303 -0.873 . . . . 0.0 110.656 178.954 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.574 ' CE1' HG22 ' A' ' 157' ' ' VAL . 1.1 t80 -115.96 134.25 55.17 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.876 -1.14 . . . . 0.0 109.579 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -83.79 134.29 34.73 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.196 -0.94 . . . . 0.0 109.551 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.17 169.38 25.78 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.409 HG11 ' N ' ' A' ' 143' ' ' ILE . 71.2 t -115.25 136.3 52.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.404 -1.057 . . . . 0.0 109.42 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.556 HG12 ' CD2' ' A' ' 153' ' ' LEU . 39.4 mt -67.61 117.92 10.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.162 -0.961 . . . . 0.0 109.505 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 24.5 tttm -99.79 -34.5 10.13 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.152 -0.967 . . . . 0.0 109.407 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.462 ' HB3' ' HD2' ' A' ' 154' ' ' LYS . 85.1 tt0 -153.85 148.99 26.89 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.11 -0.994 . . . . 0.0 109.66 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.508 HG22 ' CD1' ' A' ' 153' ' ' LEU . 3.3 mt -124.07 126.79 72.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.287 -0.883 . . . . 0.0 109.425 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.55 101.75 41.14 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.219 -0.925 . . . . 0.0 109.495 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.563 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 49.9 Cg_endo -71.6 170.54 18.34 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.653 2.235 . . . . 0.0 111.665 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.563 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.1 mt-10 80.48 -20.39 0.38 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.441 -0.787 . . . . 0.0 109.952 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.407 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 70.8 mtp180 -127.55 -13.58 5.38 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.12 -0.987 . . . . 0.0 109.67 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.407 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 29.0 mt-30 69.44 48.16 0.64 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.887 . . . . 0.0 109.499 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . 0.415 ' OE2' HG12 ' A' ' 167' ' ' VAL . 82.9 tt0 -118.75 143.05 47.14 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.099 -1.001 . . . . 0.0 108.803 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.556 ' CD2' HG12 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -130.77 117.67 19.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.048 -1.032 . . . . 0.0 110.321 -179.174 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . 0.462 ' HD2' ' HB3' ' A' ' 145' ' ' GLU . 11.2 mttt -79.82 129.65 34.66 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.522 HG21 ' CG2' ' A' ' 166' ' ' VAL . 14.3 m -131.19 148.02 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.157 -0.965 . . . . 0.0 109.724 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.518 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.7 m-20 -100.48 119.04 37.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.37 -0.832 . . . . 0.0 109.437 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.574 HG22 ' CE1' ' A' ' 139' ' ' PHE . 3.4 p -100.35 144.05 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.309 -0.869 . . . . 0.0 109.501 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 28.0 m -96.89 97.05 8.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.391 -0.818 . . . . 0.0 109.984 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.494 HG13 HG23 ' A' ' 157' ' ' VAL . 13.0 mt -118.21 139.27 46.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.914 . . . . 0.0 109.332 179.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.493 ' CE2' HG23 ' A' ' 159' ' ' ILE . 40.0 m-85 59.67 41.74 18.14 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.402 -0.811 . . . . 0.0 109.32 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 54.14 16.61 6.55 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 4.3 mtp-105 -119.21 147.07 44.64 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.089 -1.242 . . . . 0.0 109.628 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -95.66 129.73 42.77 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.28 -0.887 . . . . 0.0 109.573 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.2 m -145.94 128.22 7.87 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.908 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.518 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.5 Cg_endo -70.52 138.72 36.0 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.686 2.257 . . . . 0.0 111.369 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.522 ' CG2' HG21 ' A' ' 155' ' ' VAL . 2.9 m -122.4 168.09 15.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.005 -1.059 . . . . 0.0 110.01 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.415 HG12 ' OE2' ' A' ' 152' ' ' GLU . 42.8 t -116.44 117.95 57.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.541 -0.724 . . . . 0.0 109.309 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.486 ' CD1' ' N ' ' A' ' 168' ' ' LEU . 2.4 mp -141.21 165.75 26.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.258 -0.901 . . . . 0.0 110.519 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -80.2 143.38 33.83 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.431 ' CG1' ' N ' ' A' ' 171' ' ' SER . 4.3 p -57.96 -36.86 57.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.269 -0.895 . . . . 0.0 108.789 179.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.431 ' N ' ' CG1' ' A' ' 170' ' ' VAL . 49.8 m -77.17 -7.47 55.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.482 -0.761 . . . . 0.0 109.417 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.428 ' CG ' ' HB3' ' A' ' 133' ' ' SER . 5.5 mt-10 -95.8 -2.66 47.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.291 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 11.3 m -127.51 164.72 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.225 -0.922 . . . . 0.0 109.392 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.465 ' O ' HG21 ' A' ' 129' ' ' VAL . 58.3 tt0 -134.64 153.81 51.81 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.259 -0.901 . . . . 0.0 109.07 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.625 ' HB2' ' CZ ' ' A' ' 123' ' ' PHE . 33.1 pttt . . . . . 0 N--CA 1.489 1.478 0 O-C-N 121.182 -0.949 . . . . 0.0 109.493 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.462 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 82.9 mttt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.304 0.573 . . . . 0.0 109.496 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 18.7 mttp -130.65 176.45 8.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.294 -0.879 . . . . 0.0 109.579 -179.69 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.652 ' CZ3' ' CG2' ' A' ' 41' ' ' VAL . 76.1 m95 -113.16 125.06 53.93 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.279 -0.888 . . . . 0.0 109.179 179.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -115.37 170.4 8.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.164 -0.96 . . . . 0.0 109.139 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.56 HG12 ' CE1' ' A' ' 61' ' ' PHE . 21.5 mt -113.88 97.77 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.101 -1.0 . . . . 0.0 108.818 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.661 ' CG1' ' CG1' ' A' ' 60' ' ' VAL . 3.9 p -81.83 151.09 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.254 -0.903 . . . . 0.0 109.264 -179.771 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.534 ' CD2' ' CE1' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -94.34 142.96 26.82 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.388 -0.82 . . . . 0.0 110.013 -179.312 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.4 p -144.59 -171.59 3.64 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.372 -0.83 . . . . 0.0 109.01 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.504 ' CG ' ' SD ' ' A' ' 81' ' ' MET . 44.4 mtm -102.38 118.98 38.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.165 -0.959 . . . . 0.0 109.596 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 13' ' ' MET . 43.7 m -42.14 121.74 1.94 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.22 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.53 -18.3 32.69 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.069 -1.613 . . . . 0.0 109.069 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.43 ' O ' ' C ' ' A' ' 17' ' ' GLU . 92.9 m-85 -108.91 -13.25 14.78 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.397 -1.061 . . . . 0.0 109.61 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.43 ' C ' ' O ' ' A' ' 16' ' ' TYR . 95.1 mt-10 -42.71 -55.27 3.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.279 -0.888 . . . . 0.0 109.372 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -54.16 -36.46 63.36 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.215 -0.928 . . . . 0.0 109.141 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.421 ' N ' ' O ' ' A' ' 16' ' ' TYR . 28.0 mttp -70.3 -37.41 74.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.275 -0.891 . . . . 0.0 109.131 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 61.2 t -64.07 -47.13 91.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.431 -0.793 . . . . 0.0 109.411 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.6 tttm -55.1 -50.93 67.96 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.224 -0.923 . . . . 0.0 109.331 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -64.55 -41.92 96.01 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.281 -0.887 . . . . 0.0 109.311 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.459 ' ND2' ' HG2' ' A' ' 78' ' ' PRO . 24.1 t-20 -57.62 -39.75 77.62 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.186 -0.946 . . . . 0.0 109.452 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.517 ' CG2' HD12 ' A' ' 40' ' ' ILE . 96.4 mt -62.89 -44.73 99.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -0.927 . . . . 0.0 109.648 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -53.81 -45.29 70.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.15 -0.969 . . . . 0.0 109.64 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.9 mttt -79.99 -32.37 39.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.485 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.413 ' HG2' HG22 ' A' ' 77' ' ' VAL . 48.7 tptt -56.77 -38.3 72.3 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.308 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 40.7 t -83.81 -22.93 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.338 -0.851 . . . . 0.0 109.399 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -69.16 -53.27 20.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.571 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.77 -33.47 64.36 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.619 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 23.1 p -91.42 -19.92 22.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.229 -0.92 . . . . 0.0 109.612 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 68.83 9.97 60.37 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.527 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 54.3 mt -80.16 88.5 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.292 -1.122 . . . . 0.0 109.414 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.3 mttt -91.74 9.18 33.6 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.155 -0.966 . . . . 0.0 109.438 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 38.0 p30 -110.93 9.13 22.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.289 -0.882 . . . . 0.0 109.59 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.541 HD23 ' CG1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -109.71 -55.22 2.46 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.182 -0.948 . . . . 0.0 109.172 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.455 ' CG2' ' HE3' ' A' ' 64' ' ' MET . 68.9 t -94.15 130.98 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.317 -0.864 . . . . 0.0 109.31 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.75 -122.84 5.16 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -89.74 148.56 23.19 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.275 -1.132 . . . . 0.0 109.822 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.517 HD12 ' CG2' ' A' ' 24' ' ' ILE . 72.2 mt -116.21 132.93 64.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.4 -0.812 . . . . 0.0 108.909 179.641 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.652 ' CG2' ' CZ3' ' A' ' 7' ' ' TRP . 34.3 t -125.87 161.81 30.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 O-C-N 121.049 -1.032 . . . . 0.0 109.346 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.457 HG22 HD12 ' A' ' 44' ' ' ILE . 2.3 mt -140.92 127.61 11.74 Favored Pre-proline 0 N--CA 1.487 1.402 0 O-C-N 121.208 -0.933 . . . . 0.0 109.83 -179.709 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.543 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 45.8 Cg_endo -67.16 -2.64 8.39 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.841 2.36 . . . . 0.0 111.305 179.569 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.706 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 19.0 pt . . . . . 0 N--CA 1.489 1.48 0 O-C-N 121.312 -0.868 . . . . 0.0 109.615 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.706 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 13.6 mttp . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.607 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 18.2 tp -57.48 -45.85 84.38 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.039 -1.038 . . . . 0.0 109.291 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.607 ' CE2' ' HG ' ' A' ' 55' ' ' LEU . 57.9 m-85 -131.44 109.4 14.83 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.141 -0.974 . . . . 0.0 108.864 179.482 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -65.45 138.9 56.89 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.579 2.186 . . . . 0.0 111.974 -179.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.84 -16.7 5.11 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 179.605 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.534 ' CE1' ' CD2' ' A' ' 11' ' ' LEU . 3.3 m-30 -98.63 129.08 45.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.788 -1.419 . . . . 0.0 110.406 -179.207 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.661 ' CG1' ' CG1' ' A' ' 10' ' ' VAL . 7.7 p -136.92 151.58 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.56 ' CE1' HG12 ' A' ' 9' ' ' ILE . 7.7 m-85 -110.0 127.07 54.58 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.914 -1.116 . . . . 0.0 110.756 -178.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.551 HG12 ' CG ' ' A' ' 64' ' ' MET . 90.3 t -129.51 139.82 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.649 -0.657 . . . . 0.0 109.318 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.603 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 9.7 tt0 -101.83 126.94 48.81 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.114 -0.991 . . . . 0.0 109.104 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.551 ' CG ' HG12 ' A' ' 62' ' ' VAL . 1.8 mtp -157.28 178.02 10.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.043 -1.036 . . . . 0.0 110.071 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.541 ' CG1' HD23 ' A' ' 36' ' ' LEU . 12.2 pt -99.95 131.92 46.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.593 -0.692 . . . . 0.0 109.286 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.474 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 42.1 ttm -77.65 145.76 36.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 110.086 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.474 ' HB2' ' O ' ' A' ' 66' ' ' MET . 49.8 t-20 176.74 172.37 0.45 Allowed 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 67' ' ' ASN . 90.2 m-20 -69.47 -42.81 74.35 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.163 -0.961 . . . . 0.0 109.275 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.49 ' HG2' ' CD2' ' A' ' 73' ' ' PHE . 69.7 tt0 -73.82 -31.54 63.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.327 -0.858 . . . . 0.0 109.55 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.521 ' HB1' ' CD2' ' A' ' 36' ' ' LEU . . . -70.92 -45.07 64.92 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.146 -0.971 . . . . 0.0 109.356 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.486 ' HA ' ' CG1' ' A' ' 74' ' ' VAL . 71.8 t80 -60.99 -47.0 88.48 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.265 -0.897 . . . . 0.0 109.72 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.492 ' O ' ' HB2' ' A' ' 76' ' ' SER . 96.4 m-20 -64.72 -27.65 69.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.106 -0.996 . . . . 0.0 110.035 -179.518 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.49 ' CD2' ' HG2' ' A' ' 69' ' ' GLU . 3.6 m-85 -84.19 -42.98 15.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.045 -1.034 . . . . 0.0 109.917 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.486 ' CG1' ' HA ' ' A' ' 71' ' ' TYR . 2.9 p -67.12 -57.87 8.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.264 -0.898 . . . . 0.0 109.803 -179.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.463 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 28.5 tpt85 -62.84 -10.27 12.58 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.103 -0.998 . . . . 0.0 109.676 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.492 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 19.4 m -99.25 1.49 44.74 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.147 -0.971 . . . . 0.0 109.953 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.604 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -70.43 140.71 87.57 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.023 -1.048 . . . . 0.0 109.229 -179.976 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.648 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 45.6 Cg_endo -66.73 134.9 36.58 Favored 'Trans proline' 0 C--O 1.213 -0.765 0 C-N-CA 122.706 2.271 . . . . 0.0 111.849 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.648 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 10.0 m-85 92.62 -10.77 0.18 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.816 -0.552 . . . . 0.0 109.52 -179.708 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.604 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 2.3 t -85.7 121.06 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.116 -0.99 . . . . 0.0 109.144 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.504 ' SD ' ' CG ' ' A' ' 13' ' ' MET . 82.8 mtp -88.4 -33.69 17.82 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.241 -0.912 . . . . 0.0 109.565 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' A' ' 11' ' ' LEU . . . 172.01 -168.98 42.12 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.631 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 0.8 OUTLIER -134.21 146.65 50.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.189 -1.183 . . . . 0.0 109.524 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.484 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 14.2 p -81.23 114.38 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.212 -0.93 . . . . 0.0 109.368 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.57 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.9 OUTLIER -154.04 164.88 37.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.256 -0.902 . . . . 0.0 109.639 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 77.0 p -84.5 -30.63 25.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.167 -0.958 . . . . 0.0 109.267 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -130.96 -102.54 0.93 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.548 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -93.16 -129.15 5.08 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.548 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -29.5 150.47 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.675 -0.897 . . . . 0.0 110.315 -179.56 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.57 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 46.2 Cg_endo -67.66 143.03 60.52 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.753 2.302 . . . . 0.0 112.002 -179.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 6.2 m -74.07 147.56 85.96 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.325 -0.86 . . . . 0.0 109.293 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.484 ' CB ' ' HD3' ' A' ' 6' ' ' LYS . 49.2 Cg_endo -69.82 145.39 56.63 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.708 2.272 . . . . 0.0 111.7 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.526 ' CG1' ' HG2' ' A' ' 98' ' ' MET . 9.9 p -70.11 135.16 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.932 . . . . 0.0 109.231 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . 0.468 ' HE2' ' HD2' ' A' ' 96' ' ' ARG . 15.4 tttp -70.95 136.48 48.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.179 -0.95 . . . . 0.0 109.592 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -46.58 -52.05 14.34 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.221 -0.924 . . . . 0.0 109.355 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.468 ' HD2' ' HE2' ' A' ' 94' ' ' LYS . 72.0 mtt85 -60.84 -16.47 41.63 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.292 -0.88 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.504 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 6.7 mt-10 -88.59 -28.5 20.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.274 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.612 ' HE3' ' CD1' ' A' ' 7' ' ' TRP . 31.4 mtp -75.85 -28.69 58.3 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -0.874 . . . . 0.0 109.61 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.576 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.46 -53.37 1.3 Allowed Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.485 -0.76 . . . . 0.0 109.979 -179.609 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.7 Cg_endo -69.01 -34.96 15.85 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.538 2.158 . . . . 0.0 112.111 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.418 HG22 ' CD2' ' A' ' 61' ' ' PHE . 8.7 mm -78.57 -44.51 26.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.118 -0.989 . . . . 0.0 109.444 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.601 ' CD1' ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -62.19 -41.35 98.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.106 -0.996 . . . . 0.0 108.873 179.725 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.465 ' HD2' ' O ' ' A' ' 135' ' ' PRO . 36.3 mtt180 -61.03 -43.21 99.23 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -70.01 -35.76 74.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 109.134 179.667 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.519 ' HB3' ' CG1' ' A' ' 41' ' ' VAL . . . -88.13 20.96 2.94 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.21 179.681 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 46.92 28.4 3.88 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.538 ' CD1' HD12 ' A' ' 102' ' ' LEU . 35.9 mt -80.04 -22.84 41.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.196 -1.179 . . . . 0.0 109.146 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.345 -0.847 . . . . 0.0 109.314 179.959 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.525 ' CD2' ' O ' ' A' ' 123' ' ' PHE . 51.7 p90 . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.463 ' N ' ' OD2' ' A' ' 127' ' ' ASP . 27.5 mttp -141.81 164.48 30.07 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.247 -0.908 . . . . 0.0 109.558 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.511 ' HA ' HG23 ' A' ' 143' ' ' ILE . 7.9 p -66.5 126.11 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.318 -0.864 . . . . 0.0 109.659 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 103.68 -33.32 6.67 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.49 ' HB2' HD11 ' A' ' 143' ' ' ILE . 73.2 m-20 -48.15 165.33 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.385 -1.068 . . . . 0.0 108.922 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.4 ttm -97.26 126.91 42.78 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.044 -1.035 . . . . 0.0 108.97 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.585 ' CG2' ' CG1' ' A' ' 143' ' ' ILE . 12.7 t -125.36 141.91 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.248 -0.908 . . . . 0.0 109.535 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.476 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 42.8 tttp -106.61 143.91 34.04 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.357 -0.839 . . . . 0.0 108.946 179.495 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.541 HG22 ' N ' ' A' ' 132' ' ' ILE . 65.8 mt -84.76 155.31 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.129 -0.982 . . . . 0.0 108.817 179.636 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.541 ' N ' HG22 ' A' ' 131' ' ' ILE . 27.2 pt -150.59 2.95 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.126 -0.984 . . . . 0.0 109.488 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 72.7 m -148.66 145.08 27.57 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.151 -0.968 . . . . 0.0 110.107 -179.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.15 -170.55 16.8 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.465 ' O ' ' HD2' ' A' ' 103' ' ' ARG . 48.2 Cg_endo -68.66 -19.8 41.31 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 123.275 2.65 . . . . 0.0 112.467 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.515 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 98.1 m-85 -112.96 13.22 19.48 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.05 -1.031 . . . . 0.0 109.487 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.527 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 1.6 tt0 -42.73 151.74 0.12 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 109.663 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.527 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 25.3 m-20 72.99 28.1 1.98 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.455 -0.778 . . . . 0.0 110.091 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.553 ' CE1' ' CG1' ' A' ' 157' ' ' VAL . 0.9 OUTLIER -120.43 136.99 54.57 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.99 -1.069 . . . . 0.0 109.539 179.877 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.08 133.94 34.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.225 -0.922 . . . . 0.0 109.579 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.92 170.05 25.95 Favored Glycine 0 N--CA 1.492 2.374 0 C-N-CA 119.836 -1.173 . . . . 0.0 110.171 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.537 ' N ' ' CG2' ' A' ' 155' ' ' VAL . 47.9 t -115.76 136.03 53.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.387 -1.066 . . . . 0.0 109.439 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.585 ' CG1' ' CG2' ' A' ' 129' ' ' VAL . 87.7 mt -65.12 115.22 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.89 . . . . 0.0 109.386 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . 0.453 ' C ' ' HG2' ' A' ' 145' ' ' GLU . 36.6 tttp -100.26 -36.38 9.3 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.062 -1.024 . . . . 0.0 109.377 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.453 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 67.2 mm-40 -149.57 144.26 26.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.967 . . . . 0.0 109.351 -179.9 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.545 ' CG2' ' HG ' ' A' ' 153' ' ' LEU . 2.4 mt -123.04 125.85 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.183 -0.948 . . . . 0.0 109.406 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -108.18 101.46 41.9 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.236 -0.915 . . . . 0.0 109.63 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.552 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.7 171.4 16.49 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.72 2.28 . . . . 0.0 111.781 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.552 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 10.8 tt0 80.55 -20.97 0.35 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.3 -0.875 . . . . 0.0 109.791 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.449 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 93.1 mtt-85 -126.59 -12.99 6.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.916 . . . . 0.0 109.437 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.449 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 29.9 mt-30 69.83 48.6 0.56 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.204 -0.935 . . . . 0.0 109.61 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -120.06 143.62 48.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.138 -0.976 . . . . 0.0 109.08 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.545 ' HG ' ' CG2' ' A' ' 146' ' ' ILE . 0.1 OUTLIER -136.99 112.38 9.24 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.15 -0.969 . . . . 0.0 110.12 -179.599 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . 0.419 ' HD2' ' HB2' ' A' ' 145' ' ' GLU . 30.8 mttm -79.85 130.94 35.72 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.06 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.537 ' CG2' ' N ' ' A' ' 142' ' ' VAL . 7.3 p -133.39 127.48 53.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.121 -0.987 . . . . 0.0 109.752 -179.469 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.532 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 50.2 m-20 -73.18 135.4 44.61 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.362 -0.836 . . . . 0.0 109.709 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.553 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 53.9 t -116.8 149.96 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.466 -0.772 . . . . 0.0 109.195 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 57.2 m -96.34 103.01 14.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.107 -0.996 . . . . 0.0 109.711 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.412 ' O ' ' HB2' ' A' ' 160' ' ' PHE . 20.5 mt -129.98 140.77 48.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.285 -0.884 . . . . 0.0 109.311 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.435 ' O ' ' HG3' ' A' ' 162' ' ' ARG . 52.8 m-85 60.3 40.4 17.76 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.186 -0.946 . . . . 0.0 108.97 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.64 16.31 15.88 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.435 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 46.1 mtp180 -128.43 156.13 43.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.111 -1.229 . . . . 0.0 109.57 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -100.24 133.75 44.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.289 -0.882 . . . . 0.0 109.443 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.7 m -141.33 127.77 11.41 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.342 -0.849 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.532 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.9 Cg_endo -70.35 133.68 25.03 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.658 2.238 . . . . 0.0 111.44 179.697 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.463 ' O ' HD11 ' A' ' 168' ' ' LEU . 2.8 p -122.67 141.87 41.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.204 -0.935 . . . . 0.0 109.675 -179.837 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.463 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 18.0 m -93.17 120.11 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.458 -0.776 . . . . 0.0 109.458 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.463 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 0.0 OUTLIER -142.3 167.81 21.22 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.33 -0.857 . . . . 0.0 110.487 -179.471 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.481 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 98.0 m-70 -81.6 142.0 33.19 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.622 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 10.8 p -55.92 -35.98 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.177 -0.952 . . . . 0.0 109.025 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 74.6 p -75.71 -6.61 51.39 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.403 -0.811 . . . . 0.0 109.626 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.481 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 41.8 mt-10 -90.99 -0.68 57.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.135 -0.978 . . . . 0.0 109.572 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.476 ' HB ' ' O ' ' A' ' 130' ' ' LYS . 2.8 m -147.13 177.74 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.176 -0.953 . . . . 0.0 109.452 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.525 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 83.5 tt0 -136.55 163.75 29.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.149 -0.969 . . . . 0.0 109.263 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.525 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.3 mmtt . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.47 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 47.0 mttt . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.544 ' HB2' ' CZ ' ' A' ' 8' ' ' TYR . 26.5 mmtp -128.6 175.47 8.54 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.354 -0.841 . . . . 0.0 109.613 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.628 ' CG ' ' CE ' ' A' ' 98' ' ' MET . 47.2 m95 -111.65 124.26 51.94 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.39 -0.819 . . . . 0.0 108.968 179.657 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.544 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 59.3 m-85 -117.94 168.65 10.31 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.141 -0.975 . . . . 0.0 109.478 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.538 HG12 ' CE1' ' A' ' 61' ' ' PHE . 33.9 mt -107.5 114.63 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.208 -0.932 . . . . 0.0 109.367 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.547 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 8.5 p -92.65 141.17 15.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.234 -0.916 . . . . 0.0 109.222 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.561 HD13 ' CE1' ' A' ' 59' ' ' TYR . 3.7 mm? -89.62 143.28 26.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.408 -0.807 . . . . 0.0 109.739 -179.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.437 HG23 ' HA2' ' A' ' 58' ' ' GLY . 9.0 t -152.99 -166.03 2.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.325 -0.859 . . . . 0.0 109.408 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.416 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 46.2 mtt -108.14 130.83 55.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.532 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.0 t -54.26 128.27 30.54 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.196 -0.94 . . . . 0.0 109.391 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.55 -20.31 44.8 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 -179.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.416 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 79.4 m-85 -104.47 5.94 34.48 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.38 -1.071 . . . . 0.0 109.557 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.543 ' OE1' ' CG2' ' A' ' 60' ' ' VAL . 41.1 mm-40 -53.36 -62.32 1.73 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.62 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 17' ' ' GLU . 60.7 mt-10 -42.68 -35.64 1.18 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -0.889 . . . . 0.0 109.583 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.528 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 27.3 mttt -74.18 -44.61 52.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.472 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.411 ' O ' HG13 ' A' ' 24' ' ' ILE . 70.6 t -58.44 -53.11 51.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.48 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.448 ' HD2' HD13 ' A' ' 42' ' ' ILE . 21.5 tttm -58.4 -47.07 85.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.348 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -63.13 -41.17 99.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.329 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.54 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 87.7 m-20 -59.29 -42.78 92.09 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.904 . . . . 0.0 109.503 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.526 ' CD1' HD12 ' A' ' 40' ' ' ILE . 69.7 mt -61.5 -46.46 96.53 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.229 -0.919 . . . . 0.0 109.715 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -54.83 -46.22 74.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.145 -0.972 . . . . 0.0 109.56 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -75.78 -35.57 60.07 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.132 -0.98 . . . . 0.0 109.459 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.428 ' O ' ' CG2' ' A' ' 31' ' ' THR . 7.8 ttpt -56.14 -34.26 65.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.253 -0.905 . . . . 0.0 109.314 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 44.2 t -85.52 -25.15 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -0.873 . . . . 0.0 109.377 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -69.77 -54.17 14.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.186 -0.946 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.22 -24.76 67.79 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.197 -0.94 . . . . 0.0 109.526 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.428 ' CG2' ' O ' ' A' ' 27' ' ' LYS . 40.2 p -94.96 -21.75 18.41 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.165 -0.959 . . . . 0.0 109.531 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 63.68 22.01 65.66 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.592 ' CG2' ' CD1' ' A' ' 36' ' ' LEU . 42.7 mm -95.07 91.79 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.271 -1.134 . . . . 0.0 109.465 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.9 mtpt -98.81 10.03 42.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.27 -0.894 . . . . 0.0 109.52 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -108.24 5.44 25.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.19 -0.944 . . . . 0.0 109.492 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.592 ' CD1' ' CG2' ' A' ' 33' ' ' ILE . 88.3 mt -117.78 -30.94 5.29 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.276 -0.89 . . . . 0.0 109.39 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.496 ' HA ' ' HG2' ' A' ' 64' ' ' MET . 73.0 t -114.68 129.35 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.309 -0.869 . . . . 0.0 109.305 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.73 -129.89 6.84 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 23.4 mtt-85 -90.44 147.89 23.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.274 -1.133 . . . . 0.0 109.777 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.55 HG23 ' CG2' ' A' ' 62' ' ' VAL . 59.9 mt -113.32 136.61 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.337 -0.852 . . . . 0.0 109.383 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.554 ' CG1' ' HB2' ' A' ' 61' ' ' PHE . 9.3 p -130.4 158.29 42.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.199 -0.938 . . . . 0.0 109.54 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.461 ' CG2' HG21 ' A' ' 44' ' ' ILE . 3.3 mt -131.78 129.05 21.86 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.559 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.515 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 46.1 Cg_endo -67.2 -4.73 12.19 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.788 2.325 . . . . 0.0 111.587 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.571 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 12.7 pt . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.299 -0.876 . . . . 0.0 109.451 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.571 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 47.6 mttt . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.515 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 6.7 mp -61.55 -26.8 68.18 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.097 -1.002 . . . . 0.0 109.527 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.444 ' HB3' ' HB2' ' A' ' 59' ' ' TYR . 97.2 m-85 -145.83 103.8 4.2 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.893 . . . . 0.0 109.31 179.778 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.405 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 43.5 Cg_endo -67.17 137.75 44.96 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.666 2.244 . . . . 0.0 111.865 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.437 ' HA2' HG23 ' A' ' 12' ' ' THR . . . 72.91 -9.28 6.68 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.561 ' CE1' HD13 ' A' ' 11' ' ' LEU . 3.2 m-85 -103.49 132.65 49.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.795 -1.415 . . . . 0.0 109.82 -179.511 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.547 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 4.9 t -135.58 148.65 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.354 -0.841 . . . . 0.0 108.923 179.41 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.554 ' HB2' ' CG1' ' A' ' 41' ' ' VAL . 63.3 m-85 -107.87 121.65 45.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.073 -1.017 . . . . 0.0 109.764 -179.64 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.55 ' CG2' HG23 ' A' ' 40' ' ' ILE . 57.6 t -129.06 141.14 47.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.357 -0.839 . . . . 0.0 109.699 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.602 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 52.4 tt0 -97.03 124.73 41.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.339 -0.851 . . . . 0.0 108.862 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.507 ' CG ' ' O ' ' A' ' 63' ' ' GLU . 37.3 mtm -158.4 -179.82 8.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.147 -0.971 . . . . 0.0 109.777 -179.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.576 ' CD1' ' CD2' ' A' ' 36' ' ' LEU . 8.5 pt -102.64 129.0 54.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.2 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.511 ' O ' ' HG3' ' A' ' 66' ' ' MET . 5.2 ptp -85.58 96.2 9.57 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.129 -0.982 . . . . 0.0 109.668 -179.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.598 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 23.0 t-20 -140.04 170.48 15.78 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -52.81 -47.58 67.53 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.038 -1.039 . . . . 0.0 109.987 -179.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.458 ' O ' ' C ' ' A' ' 70' ' ' ALA . 64.6 mm-40 -64.87 -64.34 0.89 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.095 -1.003 . . . . 0.0 110.132 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.458 ' C ' ' O ' ' A' ' 69' ' ' GLU . . . -39.77 -38.8 0.69 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.263 -0.898 . . . . 0.0 109.926 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.598 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 15.4 m-85 -61.11 -62.16 2.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.226 -0.921 . . . . 0.0 109.362 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -45.76 -34.9 3.93 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.503 -0.748 . . . . 0.0 110.412 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -81.39 -43.85 18.39 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.888 -1.133 . . . . 0.0 110.136 -179.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.642 ' CG1' ' CZ ' ' A' ' 83' ' ' PHE . 45.4 t -64.43 -58.67 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.25 -0.906 . . . . 0.0 109.643 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -35.05 19.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.366 -0.834 . . . . 0.0 110.034 -179.589 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 53.6 p -78.16 4.89 11.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.083 -1.01 . . . . 0.0 110.37 -179.279 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.611 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 41.1 t -64.32 133.62 95.71 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 120.872 -1.143 . . . . 0.0 109.286 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.58 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 46.1 Cg_endo -68.27 134.83 32.43 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.702 2.268 . . . . 0.0 112.02 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.58 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 60.2 m-85 77.61 -1.54 2.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.525 -0.734 . . . . 0.0 109.855 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.611 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.4 t -88.6 127.32 41.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.173 -0.955 . . . . 0.0 109.147 179.609 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 82.5 mmm -90.77 -17.97 25.74 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.21 -0.931 . . . . 0.0 109.645 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.592 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 151.71 -155.61 26.23 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.642 ' CZ ' ' CG1' ' A' ' 74' ' ' VAL . 3.6 m-85 -140.04 152.67 46.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -1.16 . . . . 0.0 109.5 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.465 HG22 ' CD2' ' A' ' 11' ' ' LEU . 4.6 t -77.27 119.58 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.291 -0.881 . . . . 0.0 109.275 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.541 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.9 p -156.49 162.17 39.98 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.227 -0.92 . . . . 0.0 109.596 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.78 -34.8 14.45 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.887 . . . . 0.0 109.393 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -122.09 -86.33 0.83 Allowed Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -107.04 -130.37 6.43 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.545 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.1 OUTLIER -33.82 156.4 0.04 OUTLIER Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.43 -1.041 . . . . 0.0 110.056 -179.693 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.541 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.9 Cg_endo -69.71 157.74 59.44 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 122.492 2.128 . . . . 0.0 112.109 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.9 m -90.15 153.64 46.83 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.351 -0.843 . . . . 0.0 109.452 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.442 ' HB3' ' HB3' ' A' ' 6' ' ' LYS . 49.1 Cg_endo -69.81 145.48 56.99 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.658 2.239 . . . . 0.0 111.812 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.464 ' HB ' ' SD ' ' A' ' 98' ' ' MET . 7.6 t -84.22 129.69 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.235 -0.915 . . . . 0.0 109.194 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . 0.414 ' O ' ' C ' ' A' ' 95' ' ' ASP . 23.6 tttt -70.56 132.77 46.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.191 -0.943 . . . . 0.0 109.578 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 94' ' ' LYS . 80.5 m-20 -44.48 -39.86 5.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.205 -0.934 . . . . 0.0 109.356 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.492 ' CZ ' ' HB3' ' A' ' 96' ' ' ARG . 13.4 mtp-105 -53.79 -35.51 61.44 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.272 -0.893 . . . . 0.0 109.374 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.458 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 65.2 mt-10 -84.73 -27.48 26.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.269 -0.894 . . . . 0.0 109.372 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.628 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 94.4 mtp -84.98 -12.31 53.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.295 -0.878 . . . . 0.0 109.505 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.64 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -51.18 -48.42 85.46 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.171 -0.956 . . . . 0.0 109.853 179.864 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.64 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.5 Cg_endo -70.82 -27.6 21.22 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.485 2.123 . . . . 0.0 111.861 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.454 ' O ' ' HB3' ' A' ' 105' ' ' ALA . 35.8 mm -81.52 -44.4 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 109.565 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.551 HD12 ' CB ' ' A' ' 98' ' ' MET . 0.7 OUTLIER -66.46 -38.76 88.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.232 -0.917 . . . . 0.0 109.256 -179.926 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.524 ' CZ ' ' NH1' ' A' ' 99' ' ' ARG . 67.7 mtt180 -65.47 -50.16 66.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.429 -0.794 . . . . 0.0 109.322 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -72.64 -36.24 67.96 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.273 -0.892 . . . . 0.0 109.364 179.762 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.48 ' HB2' ' CG2' ' A' ' 41' ' ' VAL . . . -73.44 -0.99 16.52 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.371 -0.831 . . . . 0.0 109.687 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.03 11.6 81.44 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.512 ' CD1' HG23 ' A' ' 41' ' ' VAL . 61.3 mt -85.51 -24.11 27.45 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.128 -1.219 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . 0.411 ' HB2' ' HB2' ' A' ' 102' ' ' LEU . 73.5 tt0 . . . . . 0 N--CA 1.49 1.553 0 O-C-N 121.283 -0.886 . . . . 0.0 109.591 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 3.6 p90 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 22.4 mttt -149.02 157.29 43.3 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.221 -0.925 . . . . 0.0 109.52 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.453 ' HA ' HG21 ' A' ' 143' ' ' ILE . 44.7 t -60.33 140.04 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.488 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 87.85 -34.12 3.81 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.498 ' OD2' ' CE ' ' A' ' 175' ' ' LYS . 43.0 t0 -48.51 157.68 0.34 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.431 -1.041 . . . . 0.0 109.465 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.8 ttm -96.07 127.5 42.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.244 -0.91 . . . . 0.0 108.861 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.563 ' CG2' ' CD1' ' A' ' 143' ' ' ILE . 51.3 t -126.44 142.08 44.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.256 -0.903 . . . . 0.0 109.42 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.541 ' N ' HG11 ' A' ' 129' ' ' VAL . 5.8 ttpp -101.95 142.85 32.6 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.376 -0.828 . . . . 0.0 109.065 179.738 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.458 HG21 ' HA ' ' A' ' 137' ' ' GLU . 70.8 mt -82.9 151.35 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.042 -1.036 . . . . 0.0 108.761 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.546 HD13 ' CG ' ' A' ' 174' ' ' GLU . 33.2 pt -148.99 2.95 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.95 -1.093 . . . . 0.0 109.503 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.533 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 68.8 m -146.35 141.76 27.57 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.11 -0.994 . . . . 0.0 109.712 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.409 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 107.04 -170.85 16.16 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.581 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.52 -18.91 43.23 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 123.213 2.609 . . . . 0.0 112.797 -179.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.509 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.9 m-85 -108.94 19.11 19.97 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.964 -1.085 . . . . 0.0 109.487 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.529 ' HG2' ' CA ' ' A' ' 133' ' ' SER . 43.8 mt-10 -41.31 141.85 0.64 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 110.22 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 138' ' ' ASP . 0.5 OUTLIER 76.03 24.39 1.19 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.299 -0.875 . . . . 0.0 110.757 179.002 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.587 ' CE1' HG12 ' A' ' 157' ' ' VAL . 0.5 OUTLIER -111.73 129.32 56.15 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.828 -1.17 . . . . 0.0 109.729 179.912 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.4 ' N ' ' HD1' ' A' ' 139' ' ' PHE . . . -76.46 134.8 39.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.905 . . . . 0.0 109.392 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.468 ' HA3' HG22 ' A' ' 155' ' ' VAL . . . -143.79 166.62 26.94 Favored Glycine 0 N--CA 1.489 2.221 0 C-N-CA 119.718 -1.23 . . . . 0.0 110.164 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.496 ' N ' ' CG2' ' A' ' 155' ' ' VAL . 47.0 t -116.16 137.34 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.591 -0.946 . . . . 0.0 109.256 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.604 ' CG2' ' CD1' ' A' ' 146' ' ' ILE . 88.6 mt -70.39 120.49 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.305 -0.872 . . . . 0.0 109.268 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . 0.502 ' O ' ' HG2' ' A' ' 145' ' ' GLU . 75.0 tttt -103.65 -33.07 9.1 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.964 -1.085 . . . . 0.0 109.711 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.502 ' HG2' ' O ' ' A' ' 144' ' ' LYS . 15.5 mt-10 -150.5 145.66 26.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.058 -1.027 . . . . 0.0 109.845 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.604 ' CD1' ' CG2' ' A' ' 143' ' ' ILE . 0.9 OUTLIER -115.44 117.91 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.218 -0.926 . . . . 0.0 108.973 179.542 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -106.64 98.13 19.46 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.156 -0.965 . . . . 0.0 109.785 -179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.55 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.5 Cg_endo -72.33 173.65 12.76 Favored 'Trans proline' 0 C--O 1.216 -0.588 0 C-N-CA 122.675 2.25 . . . . 0.0 111.734 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.55 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 4.5 mt-10 78.98 -22.06 0.3 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.26 -0.9 . . . . 0.0 109.876 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.429 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 40.8 mtm180 -126.33 -16.78 5.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.039 -1.038 . . . . 0.0 109.3 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.429 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 6.0 mt-30 71.04 47.54 0.41 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.3 -0.875 . . . . 0.0 109.511 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 64.9 tt0 -116.44 139.83 50.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.124 -0.985 . . . . 0.0 108.885 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.526 HD11 ' CG2' ' A' ' 146' ' ' ILE . 2.7 mm? -124.88 111.79 15.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.153 -0.967 . . . . 0.0 110.108 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . 0.433 ' HD3' ' HB2' ' A' ' 145' ' ' GLU . 17.2 mtpp -78.02 122.68 25.88 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.506 HG13 HG13 ' A' ' 166' ' ' VAL . 10.4 p -126.92 149.27 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.039 -1.038 . . . . 0.0 109.904 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.526 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 1.9 t-20 -97.99 110.54 23.09 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.439 -0.788 . . . . 0.0 109.488 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.587 HG12 ' CE1' ' A' ' 139' ' ' PHE . 87.1 t -96.38 144.64 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.2 -0.938 . . . . 0.0 109.268 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 96.1 m -102.92 111.93 24.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -0.965 . . . . 0.0 109.995 -179.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.494 HG12 ' CZ ' ' A' ' 139' ' ' PHE . 2.9 mt -133.22 143.24 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.276 -0.89 . . . . 0.0 109.036 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.435 ' O ' ' HG3' ' A' ' 162' ' ' ARG . 11.9 m-85 62.18 43.37 8.65 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.152 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 54.35 16.15 6.45 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 179.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.435 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 15.8 mtt-85 -126.59 160.05 31.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.036 -1.273 . . . . 0.0 109.54 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -100.93 127.88 47.22 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.25 -0.907 . . . . 0.0 109.687 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 43.3 m -136.91 121.22 12.39 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 0.0 109.606 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -70.34 136.57 31.75 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.755 2.304 . . . . 0.0 111.541 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.506 HG13 HG13 ' A' ' 155' ' ' VAL . 3.6 p -125.74 144.24 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.035 -1.041 . . . . 0.0 110.165 -179.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.501 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 51.1 t -95.51 120.15 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.554 -0.716 . . . . 0.0 109.465 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.501 HD11 ' CG1' ' A' ' 155' ' ' VAL . 0.1 OUTLIER -141.01 168.38 19.93 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.204 -0.935 . . . . 0.0 110.518 -179.44 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.442 ' CD2' ' OE1' ' A' ' 172' ' ' GLU . 90.7 m-70 -79.45 144.59 33.9 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.486 ' CG2' HD22 ' A' ' 153' ' ' LEU . 9.6 p -58.68 -35.49 55.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.121 -0.987 . . . . 0.0 108.822 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 53.0 p -75.69 -6.67 51.64 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.43 -0.794 . . . . 0.0 109.115 179.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.533 ' CG ' ' HB2' ' A' ' 133' ' ' SER . 1.2 mt-10 -88.65 2.85 52.48 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.289 -0.882 . . . . 0.0 109.44 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.512 HG22 ' CG1' ' A' ' 129' ' ' VAL . 2.9 m -152.03 176.54 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.218 -0.926 . . . . 0.0 109.293 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.546 ' CG ' HD13 ' A' ' 132' ' ' ILE . 5.5 mt-10 -141.54 172.73 12.28 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.141 -0.974 . . . . 0.0 109.01 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.498 ' CE ' ' OD2' ' A' ' 127' ' ' ASP . 24.4 tttt . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.091 -1.006 . . . . 0.0 109.37 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 33.0 mttt . . . . . 0 N--CA 1.489 1.477 0 CA-C-O 121.261 0.553 . . . . 0.0 109.546 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.574 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 15.7 mtpp -126.41 175.82 7.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.361 -0.837 . . . . 0.0 109.52 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.605 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 46.6 m95 -110.47 126.72 54.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.278 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -115.53 164.46 14.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.918 . . . . 0.0 109.472 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.538 HG12 ' CE1' ' A' ' 61' ' ' PHE . 62.0 mt -106.03 115.29 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.16 -0.962 . . . . 0.0 109.021 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 92.2 t -92.09 138.25 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.237 -0.914 . . . . 0.0 109.626 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.491 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.0 mm? -92.78 146.5 23.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.321 -0.862 . . . . 0.0 109.209 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.487 HG22 ' HA2' ' A' ' 58' ' ' GLY . 12.6 t -157.22 -177.97 7.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.187 -0.945 . . . . 0.0 109.376 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.568 ' HE1' ' CE2' ' A' ' 16' ' ' TYR . 49.0 mtm -96.72 130.39 43.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.182 -0.949 . . . . 0.0 109.504 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.5 p -50.87 129.37 23.17 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.912 . . . . 0.0 109.544 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.84 -20.27 36.67 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.568 ' CE2' ' HE1' ' A' ' 13' ' ' MET . 80.3 m-85 -108.83 -5.2 16.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.214 -1.168 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.509 ' OE1' ' CD1' ' A' ' 44' ' ' ILE . 88.9 mt-10 -46.72 -52.48 13.82 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.253 -0.904 . . . . 0.0 109.554 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.8 mt-10 -55.11 -36.19 65.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.221 -0.925 . . . . 0.0 109.465 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 60.7 mttp -74.55 -31.37 62.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.256 -0.903 . . . . 0.0 109.291 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.446 ' O ' HG13 ' A' ' 24' ' ' ILE . 51.6 t -67.64 -48.78 75.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.34 -0.85 . . . . 0.0 109.353 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 29.9 tttm -59.05 -44.48 91.82 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.273 -0.892 . . . . 0.0 109.302 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -65.13 -45.08 86.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.906 . . . . 0.0 109.275 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 23' ' ' ASN . 1.1 t-20 -51.78 -38.82 57.11 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -0.866 . . . . 0.0 109.402 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.521 ' CG2' HD12 ' A' ' 40' ' ' ILE . 65.9 mt -68.89 -44.29 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.764 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 41.9 tp10 -55.18 -49.13 72.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.047 -1.033 . . . . 0.0 109.858 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 23.6 mttm -75.22 -34.42 61.47 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.105 -0.997 . . . . 0.0 109.456 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.482 ' HD2' HG21 ' A' ' 77' ' ' VAL . 33.1 tttm -55.62 -36.2 66.72 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.325 -0.86 . . . . 0.0 109.205 179.774 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.493 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 84.0 t -83.07 -24.0 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.294 -0.879 . . . . 0.0 109.601 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 -69.9 -55.12 10.53 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.279 -0.888 . . . . 0.0 109.485 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.74 -38.92 50.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.291 -0.881 . . . . 0.0 109.412 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.405 ' CB ' HG13 ' A' ' 33' ' ' ILE . 82.6 p -98.54 0.1 44.34 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.271 -0.893 . . . . 0.0 109.513 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 46.82 34.42 7.13 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.512 HG23 ' CD1' ' A' ' 36' ' ' LEU . 37.4 mt -92.6 75.34 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.331 -1.099 . . . . 0.0 109.498 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -90.19 24.92 2.34 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.211 -0.931 . . . . 0.0 109.049 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.444 ' O ' HG23 ' A' ' 65' ' ' ILE . 85.9 m-20 -117.25 -24.29 7.52 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.346 -0.846 . . . . 0.0 109.456 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.535 HD21 ' CG1' ' A' ' 65' ' ' ILE . 22.9 mt -92.11 -29.29 16.6 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.282 -0.886 . . . . 0.0 109.419 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.43 ' HA ' ' HG2' ' A' ' 64' ' ' MET . 38.9 t -110.43 129.35 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.368 -0.833 . . . . 0.0 109.04 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.51 -124.37 5.42 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 77.5 mtt180 -92.23 146.85 23.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.273 -1.133 . . . . 0.0 109.859 -179.431 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.525 HG12 ' CG2' ' A' ' 62' ' ' VAL . 55.7 mt -113.64 135.27 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.397 -0.815 . . . . 0.0 109.15 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.585 ' CG2' ' CH2' ' A' ' 7' ' ' TRP . 17.3 t -128.76 159.31 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.116 -0.99 . . . . 0.0 109.643 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.459 HG21 HD11 ' A' ' 42' ' ' ILE . 12.3 mt -144.36 128.67 9.13 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.471 -0.768 . . . . 0.0 109.359 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.516 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 44.0 Cg_endo -66.32 -6.19 14.34 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.713 2.275 . . . . 0.0 111.43 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.56 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 14.5 mt . . . . . 0 N--CA 1.489 1.477 0 O-C-N 121.406 -0.808 . . . . 0.0 109.397 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.56 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 69.2 mttt . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.525 ' HB3' ' CE2' ' A' ' 56' ' ' PHE . 6.7 mp -52.7 -47.3 67.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.379 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.525 ' CE2' ' HB3' ' A' ' 55' ' ' LEU . 3.2 m-85 -139.23 113.0 8.08 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.14 -0.975 . . . . 0.0 109.374 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.413 ' C ' ' H ' ' A' ' 59' ' ' TYR . 41.8 Cg_endo -65.67 146.26 83.66 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.546 2.164 . . . . 0.0 111.471 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.487 ' HA2' HG22 ' A' ' 12' ' ' THR . . . 73.04 -13.56 3.26 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.531 ' OH ' ' CZ ' ' A' ' 162' ' ' ARG . 1.9 m-85 -93.69 129.28 40.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.883 -1.363 . . . . 0.0 110.044 -179.422 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 41.9 t -134.69 142.82 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.202 179.703 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.688 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 76.7 m-85 -108.05 124.97 51.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.127 -0.983 . . . . 0.0 109.826 -179.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.525 ' CG2' HG12 ' A' ' 40' ' ' ILE . 3.6 p -130.33 142.2 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.345 -0.847 . . . . 0.0 109.868 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.605 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 37.7 tt0 -103.4 124.62 49.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.215 -0.928 . . . . 0.0 108.844 179.434 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.456 ' HB3' ' O ' ' A' ' 36' ' ' LEU . 41.8 mtm -153.47 169.09 24.03 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.92 -1.113 . . . . 0.0 110.648 -179.259 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.535 ' CG1' HD21 ' A' ' 36' ' ' LEU . 5.4 pt -94.49 130.07 43.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.478 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 36.8 ttm -77.15 144.54 38.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.318 -0.864 . . . . 0.0 109.973 -178.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.478 ' HB2' ' O ' ' A' ' 66' ' ' MET . 35.3 t30 176.81 171.6 0.47 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.677 -0.639 . . . . 0.0 109.289 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -69.27 -42.53 75.41 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.228 -0.92 . . . . 0.0 109.402 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -75.85 -29.17 58.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.309 -0.869 . . . . 0.0 109.71 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -75.27 -47.54 27.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.121 -0.987 . . . . 0.0 109.418 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.412 ' O ' HG12 ' A' ' 74' ' ' VAL . 56.3 t80 -59.97 -46.49 89.26 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.291 -0.88 . . . . 0.0 109.504 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.451 ' O ' ' HB3' ' A' ' 76' ' ' SER . 23.4 m120 -68.18 -26.22 65.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.327 -0.858 . . . . 0.0 109.962 -179.671 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.478 ' CE1' ' NZ ' ' A' ' 27' ' ' LYS . 22.6 t80 -83.42 -42.76 16.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.03 -1.044 . . . . 0.0 109.915 -179.675 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.492 ' CG1' ' H ' ' A' ' 75' ' ' ARG . 7.4 p -67.89 -55.71 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.405 -0.81 . . . . 0.0 109.605 -179.503 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.564 ' HG2' ' CE2' ' A' ' 83' ' ' PHE . 0.2 OUTLIER -57.99 -10.72 1.95 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.145 -0.972 . . . . 0.0 109.747 -179.934 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.451 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 25.6 p -93.24 4.89 53.23 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.073 -1.017 . . . . 0.0 109.98 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.63 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -73.81 126.8 89.25 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.085 -1.009 . . . . 0.0 109.327 -179.978 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.629 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 42.7 Cg_endo -65.1 142.86 76.09 Favored 'Trans proline' 0 C--O 1.213 -0.752 0 C-N-CA 122.65 2.234 . . . . 0.0 111.898 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.629 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 17.9 m-85 89.37 -12.79 0.37 Allowed 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.63 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 1.7 t -89.51 130.12 39.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.077 -1.014 . . . . 0.0 109.361 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 90.9 mmm -84.38 -27.33 27.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.32 -0.862 . . . . 0.0 109.311 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 161.35 -160.58 32.31 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 82' ' ' GLY . 14.9 m-85 -136.23 140.24 43.35 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.272 -1.134 . . . . 0.0 109.341 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.45 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 7.7 p -66.35 125.09 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.122 -0.986 . . . . 0.0 109.405 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.541 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.6 p -163.72 159.08 21.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.211 -0.931 . . . . 0.0 109.573 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -86.23 -33.85 20.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.272 -0.893 . . . . 0.0 109.314 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.23 -87.59 0.71 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.547 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -108.85 -125.86 5.24 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.547 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.1 OUTLIER -31.17 147.27 0.05 OUTLIER Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 121.614 -0.933 . . . . 0.0 110.015 -179.819 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.541 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.3 Cg_endo -69.2 154.29 70.19 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.8 2.334 . . . . 0.0 112.081 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . 0.573 ' CG1' ' HD2' ' A' ' 92' ' ' PRO . 0.2 OUTLIER -86.97 147.7 43.6 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.308 -0.87 . . . . 0.0 109.25 179.849 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.573 ' HD2' ' CG1' ' A' ' 91' ' ' VAL . 48.7 Cg_endo -69.24 150.6 71.58 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.626 2.217 . . . . 0.0 111.82 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 5.3 t -83.57 135.66 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.911 . . . . 0.0 109.621 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -72.86 136.05 45.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.346 -0.846 . . . . 0.0 109.393 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -47.94 -36.91 13.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.21 -0.931 . . . . 0.0 109.578 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 73.4 mtt85 -56.59 -37.14 70.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.571 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.7 mt-10 -83.36 -24.24 32.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.25 -0.906 . . . . 0.0 109.608 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.54 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 56.5 mtp -84.39 -29.6 26.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.142 -0.974 . . . . 0.0 109.495 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.576 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 31.6 ttt85 -37.01 -53.81 1.9 Allowed Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.344 -0.848 . . . . 0.0 109.931 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -68.82 -27.8 30.82 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.497 2.132 . . . . 0.0 111.777 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.509 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 19.5 mm -80.66 -41.7 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.24 -0.912 . . . . 0.0 109.248 179.71 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.59 ' CD1' ' N ' ' A' ' 102' ' ' LEU . 3.7 mp -68.52 -40.71 80.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.304 -0.872 . . . . 0.0 109.193 179.775 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.532 ' NE ' ' HA ' ' A' ' 135' ' ' PRO . 34.0 ttt180 -64.25 -50.34 68.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.347 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.422 HD22 HD11 ' A' ' 55' ' ' LEU . 0.5 OUTLIER -71.86 -36.88 70.25 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.35 -0.844 . . . . 0.0 109.272 179.736 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.509 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -72.21 0.6 9.39 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.854 -179.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 77.26 8.32 86.98 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.505 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 19.2 mt -79.88 -22.53 42.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.134 -1.215 . . . . 0.0 109.511 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . 0.463 ' HB2' ' HA ' ' A' ' 103' ' ' ARG . 10.3 mt-10 . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.228 -0.92 . . . . 0.0 109.459 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 22.8 m-30 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 50.9 mttt -130.89 153.83 48.72 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.155 -0.966 . . . . 0.0 109.863 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.449 HG22 ' O ' ' A' ' 144' ' ' LYS . 7.1 p -61.51 144.43 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.359 -0.838 . . . . 0.0 109.501 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.32 -33.38 3.19 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -50.16 161.27 0.29 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.368 -1.078 . . . . 0.0 109.397 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' MET . . . . . 0.403 ' HA ' ' HA ' ' A' ' 142' ' ' VAL . 4.6 ttm -95.76 126.88 41.33 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.28 -0.887 . . . . 0.0 108.669 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.571 ' CG2' ' O ' ' A' ' 174' ' ' GLU . 6.7 p -125.64 141.58 45.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.193 -0.942 . . . . 0.0 109.388 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.524 ' N ' ' O ' ' A' ' 174' ' ' GLU . 24.1 tttt -104.41 142.78 33.98 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 108.988 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.51 HG23 ' HA ' ' A' ' 137' ' ' GLU . 81.5 mt -82.3 153.62 4.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.448 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.535 ' CG2' ' HG3' ' A' ' 174' ' ' GLU . 17.9 pt -149.08 1.25 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.967 -1.083 . . . . 0.0 109.499 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.508 ' HB3' ' CB ' ' A' ' 172' ' ' GLU . 31.2 t -145.85 143.23 29.49 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.124 -0.985 . . . . 0.0 110.039 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.03 -168.91 15.3 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.318 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.578 ' HG2' ' CD2' ' A' ' 136' ' ' PHE . 47.5 Cg_endo -68.63 -18.15 42.77 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 123.365 2.71 . . . . 0.0 112.563 -179.565 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.578 ' CD2' ' HG2' ' A' ' 135' ' ' PRO . 73.1 m-85 -111.84 13.92 20.98 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.878 -1.139 . . . . 0.0 109.636 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.51 ' HA ' HG23 ' A' ' 131' ' ' ILE . 1.2 tt0 -41.56 148.09 0.16 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.277 -0.889 . . . . 0.0 109.55 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.5 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 17.0 m-20 72.54 28.14 2.26 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -0.85 . . . . 0.0 110.268 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.534 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 1.1 t80 -117.74 131.51 56.59 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.029 -1.044 . . . . 0.0 109.414 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -82.24 134.15 35.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.123 -0.986 . . . . 0.0 109.6 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.513 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.9 172.93 25.59 Favored Glycine 0 N--CA 1.49 2.269 0 C-N-CA 119.78 -1.2 . . . . 0.0 110.305 -179.567 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.403 ' HA ' ' HA ' ' A' ' 128' ' ' MET . 23.2 t -117.56 136.24 55.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.469 -1.018 . . . . 0.0 109.363 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.516 ' CG2' HD23 ' A' ' 153' ' ' LEU . 67.3 mt -66.33 115.25 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.299 -0.876 . . . . 0.0 109.184 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . 0.449 ' O ' HG22 ' A' ' 125' ' ' VAL . 2.4 tttt -100.02 -35.53 9.67 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.04 -1.037 . . . . 0.0 109.615 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -152.8 147.66 26.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.142 -0.974 . . . . 0.0 109.622 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.501 HG21 ' CD1' ' A' ' 153' ' ' LEU . 3.1 mt -124.96 126.83 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.304 -0.872 . . . . 0.0 109.352 179.792 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.94 99.43 30.53 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.217 -0.927 . . . . 0.0 109.647 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.562 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 50.1 Cg_endo -70.3 171.93 14.12 Favored 'Trans proline' 0 C--O 1.216 -0.59 0 C-N-CA 122.681 2.254 . . . . 0.0 111.747 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.562 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.8 mt-10 81.06 -20.87 0.35 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.35 -0.844 . . . . 0.0 109.887 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.424 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 16.1 mtt-85 -128.83 -12.96 4.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.619 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.541 ' C ' HG23 ' A' ' 170' ' ' VAL . 29.4 mt-30 70.72 48.49 0.42 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.271 -0.893 . . . . 0.0 109.636 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -118.6 141.66 48.38 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.138 -0.976 . . . . 0.0 108.745 179.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.516 HD23 ' CG2' ' A' ' 143' ' ' ILE . 0.1 OUTLIER -133.4 111.82 11.07 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.101 -0.999 . . . . 0.0 109.937 -179.537 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 21.1 mttt -80.61 129.5 34.55 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.532 ' CG1' HG11 ' A' ' 129' ' ' VAL . 35.4 m -123.61 152.54 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.059 -1.026 . . . . 0.0 109.715 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.485 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 47.2 t-20 -96.53 108.56 21.16 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.385 -0.822 . . . . 0.0 109.431 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.547 HG23 ' CG1' ' A' ' 159' ' ' ILE . 2.2 p -92.02 140.19 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.162 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' THR . . . . . 0.521 ' N ' HG22 ' A' ' 157' ' ' VAL . 84.9 m -99.79 99.16 9.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.271 -0.893 . . . . 0.0 109.952 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.547 ' CG1' HG23 ' A' ' 157' ' ' VAL . 2.0 mt -122.45 143.66 34.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.296 -0.878 . . . . 0.0 109.092 179.548 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.688 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 85.0 m-85 61.72 39.38 14.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.241 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.77 17.89 29.81 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.531 ' CZ ' ' OH ' ' A' ' 59' ' ' TYR . 25.2 mtt85 -127.26 156.72 41.45 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.106 -1.232 . . . . 0.0 109.568 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . 0.431 ' HB3' ' OD1' ' A' ' 156' ' ' ASN . 91.3 mt-10 -99.92 130.72 46.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.925 . . . . 0.0 109.471 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' THR . . . . . 0.524 ' O ' ' CG1' ' A' ' 157' ' ' VAL . 16.1 m -140.52 121.64 9.21 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.285 -0.884 . . . . 0.0 109.732 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.485 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.8 Cg_endo -70.02 138.21 36.48 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.697 2.264 . . . . 0.0 111.536 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.4 p -126.89 145.65 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.117 -0.989 . . . . 0.0 109.815 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.429 ' O ' ' CG1' ' A' ' 167' ' ' VAL . 11.4 p -91.87 119.73 39.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.416 -0.802 . . . . 0.0 109.326 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.42 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 12.3 mt -140.28 165.29 27.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 110.582 -179.16 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.419 ' O ' HG12 ' A' ' 173' ' ' VAL . 91.6 m-70 -79.07 147.0 32.95 Favored 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 121.345 0.593 . . . . 0.0 109.576 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.541 HG23 ' C ' ' A' ' 151' ' ' GLN . 4.4 t -63.16 -35.17 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 37.7 m -77.05 -7.12 55.13 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.467 -0.77 . . . . 0.0 109.295 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.508 ' CB ' ' HB3' ' A' ' 133' ' ' SER . 91.6 mt-10 -103.05 5.41 38.09 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.284 -0.885 . . . . 0.0 109.385 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.419 HG12 ' O ' ' A' ' 169' ' ' HIS . 2.7 m -129.69 160.29 40.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.19 -0.944 . . . . 0.0 109.58 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.571 ' O ' ' CG2' ' A' ' 129' ' ' VAL . 28.8 mt-10 -133.16 150.8 52.0 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.295 -0.878 . . . . 0.0 109.048 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.417 ' HA ' ' HA ' ' A' ' 129' ' ' VAL . 4.2 pttm . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.094 -1.004 . . . . 0.0 109.514 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.469 ' HG2' HG23 ' A' ' 65' ' ' ILE . 83.5 mttt . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 121.343 0.592 . . . . 0.0 109.495 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.562 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 41.2 mmtm -130.24 174.52 9.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.399 -0.813 . . . . 0.0 109.539 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.64 ' CG ' ' CE ' ' A' ' 98' ' ' MET . 40.3 m95 -105.56 125.4 50.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.293 -0.879 . . . . 0.0 109.011 179.664 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -115.48 166.35 11.99 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.11 -0.994 . . . . 0.0 109.343 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.551 HG12 ' CD1' ' A' ' 61' ' ' PHE . 55.8 mt -110.87 112.15 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.194 -0.941 . . . . 0.0 109.087 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.536 ' CG2' ' HB ' ' A' ' 60' ' ' VAL . 20.3 m -90.51 141.1 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.171 -0.956 . . . . 0.0 109.496 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.407 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -85.98 145.07 27.28 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.424 -0.797 . . . . 0.0 109.401 -179.926 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.7 p -149.63 -173.74 4.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.182 -0.949 . . . . 0.0 109.507 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.467 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 70.9 mtp -107.81 128.89 55.0 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.21 -0.931 . . . . 0.0 109.738 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.5 m -47.65 119.82 2.98 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.261 -0.899 . . . . 0.0 109.279 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.59 -20.26 27.63 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.467 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 94.5 m-85 -105.58 -16.36 14.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.198 -1.177 . . . . 0.0 109.496 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 16' ' ' TYR . 49.7 mt-10 -44.0 -62.04 1.26 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.193 -0.942 . . . . 0.0 109.345 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -49.54 -38.83 32.37 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.215 -0.928 . . . . 0.0 109.206 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -66.73 -33.0 74.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.346 -0.846 . . . . 0.0 109.076 179.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 24' ' ' ILE . 91.8 t -72.01 -45.94 61.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.323 -0.861 . . . . 0.0 109.369 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.511 ' HG3' ' CD1' ' A' ' 40' ' ' ILE . 19.0 tttm -51.85 -56.09 16.09 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.23 -0.919 . . . . 0.0 109.246 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -62.04 -34.93 77.16 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.319 -0.863 . . . . 0.0 109.256 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.482 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 23.2 t-20 -65.28 -36.67 84.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.411 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.404 HG13 ' O ' ' A' ' 20' ' ' VAL . 90.4 mt -66.3 -46.47 87.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.145 -0.972 . . . . 0.0 109.782 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.451 ' O ' ' HG2' ' A' ' 29' ' ' GLU . 65.8 mm-40 -56.88 -46.68 81.72 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.099 -1.0 . . . . 0.0 109.874 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 29.0 mttt -77.3 -36.72 53.91 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.104 -0.998 . . . . 0.0 109.576 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.538 ' HG3' ' CZ ' ' A' ' 73' ' ' PHE . 5.3 tptt -56.12 -31.05 62.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 109.095 179.774 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.53 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 11.6 t -84.76 -26.31 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.347 -0.845 . . . . 0.0 109.264 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.451 ' HG2' ' O ' ' A' ' 25' ' ' GLU . 61.7 mm-40 -67.87 -51.48 47.72 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.298 -0.876 . . . . 0.0 109.375 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.42 -32.3 66.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.921 . . . . 0.0 109.386 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 63.1 p -94.71 -11.31 29.36 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.354 -0.842 . . . . 0.0 109.447 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 54.83 24.51 33.84 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.541 ' CG2' HD13 ' A' ' 36' ' ' LEU . 69.8 mt -85.96 116.62 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.198 -1.178 . . . . 0.0 109.352 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.449 ' HG2' ' O ' ' A' ' 34' ' ' LYS . 86.0 tttt -121.98 -10.44 8.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.179 -0.95 . . . . 0.0 109.395 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.554 ' O ' ' CD1' ' A' ' 65' ' ' ILE . 87.5 m-20 -98.67 13.81 30.8 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.207 -0.933 . . . . 0.0 109.426 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.606 ' CD1' ' N ' ' A' ' 36' ' ' LEU . 6.0 mp -120.69 -53.38 2.09 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.336 -0.853 . . . . 0.0 109.111 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 90.3 t -100.66 129.55 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.426 -0.796 . . . . 0.0 109.034 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.25 -121.76 4.62 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -98.03 148.4 23.54 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.277 -1.131 . . . . 0.0 109.991 -179.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.511 ' CD1' ' HG3' ' A' ' 21' ' ' LYS . 44.5 pt -119.8 143.21 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.42 -0.8 . . . . 0.0 108.857 179.495 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.565 HG23 ' CH2' ' A' ' 7' ' ' TRP . 25.1 t -129.52 154.6 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.127 -0.983 . . . . 0.0 109.871 -179.527 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.512 ' CG2' HG13 ' A' ' 44' ' ' ILE . 18.4 mt -127.86 128.62 23.83 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.366 -0.834 . . . . 0.0 109.212 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.471 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 45.1 Cg_endo -66.82 -4.27 10.92 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.836 2.357 . . . . 0.0 111.692 -179.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.539 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 54.8 mt . . . . . 0 N--CA 1.491 1.584 0 O-C-N 121.336 -0.853 . . . . 0.0 109.551 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.539 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 63.6 mttt . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.5 ' O ' ' CD1' ' A' ' 56' ' ' PHE . 44.2 mt -64.13 -21.54 66.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -1.0 . . . . 0.0 109.181 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.645 ' CZ ' ' CD1' ' A' ' 159' ' ' ILE . 8.8 m-85 -148.97 101.88 3.39 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.323 -0.861 . . . . 0.0 108.986 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -65.47 136.31 46.12 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.7 2.267 . . . . 0.0 112.176 -179.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.44 -15.22 7.55 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -99.31 129.53 45.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.799 -1.412 . . . . 0.0 110.292 -179.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.536 ' HB ' ' CG2' ' A' ' 10' ' ' VAL . 88.2 t -133.23 148.88 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.599 ' CE1' ' CZ ' ' A' ' 160' ' ' PHE . 84.2 m-85 -109.71 124.62 51.55 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.773 -1.205 . . . . 0.0 110.248 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.428 HG11 HG22 ' A' ' 40' ' ' ILE . 91.8 t -133.58 145.16 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.382 -0.824 . . . . 0.0 109.635 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.612 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 28.2 tt0 -112.08 128.01 56.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.24 -0.913 . . . . 0.0 108.976 179.575 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.513 ' CE ' HG21 ' A' ' 74' ' ' VAL . 15.4 mtm -153.9 168.69 25.51 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.867 -1.146 . . . . 0.0 110.805 -179.113 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.554 ' CD1' ' O ' ' A' ' 35' ' ' ASN . 0.5 OUTLIER -89.11 130.39 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.653 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.423 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 56.6 ttm -75.85 141.8 42.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.89 . . . . 0.0 110.191 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.423 ' HB2' ' O ' ' A' ' 66' ' ' MET . 46.0 t30 179.11 166.15 0.96 Allowed 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -66.14 -41.13 90.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.966 . . . . 0.0 109.505 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 64.2 tt0 -76.46 -31.5 57.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.844 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.465 ' O ' ' CG2' ' A' ' 74' ' ' VAL . . . -68.78 -49.36 59.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.972 -1.08 . . . . 0.0 109.621 -179.763 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.568 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 71.8 t80 -60.62 -50.98 71.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.215 -0.928 . . . . 0.0 109.751 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -57.09 -29.69 63.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -0.937 . . . . 0.0 110.059 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.538 ' CZ ' ' HG3' ' A' ' 27' ' ' LYS . 77.4 t80 -80.51 -41.88 23.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.098 -1.001 . . . . 0.0 109.776 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.513 HG21 ' CE ' ' A' ' 64' ' ' MET . 2.8 t -70.08 -55.07 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.466 -0.771 . . . . 0.0 109.602 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.455 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 32.0 tpt85 -61.43 -13.33 19.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.329 -0.857 . . . . 0.0 110.013 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 78.1 p -97.31 4.57 50.79 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.115 -0.99 . . . . 0.0 109.923 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.597 HG11 ' HB ' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -74.85 137.21 73.32 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 120.965 -1.084 . . . . 0.0 109.315 -179.992 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.63 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 44.2 Cg_endo -66.34 137.36 46.95 Favored 'Trans proline' 0 C--O 1.213 -0.75 0 C-N-CA 122.676 2.251 . . . . 0.0 111.893 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.63 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 19.1 m-85 92.45 -13.54 0.18 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.934 -0.479 . . . . 0.0 109.759 -179.773 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.597 ' HB ' HG11 ' A' ' 77' ' ' VAL . 8.6 p -82.43 122.91 37.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.891 -1.131 . . . . 0.0 109.365 179.765 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 95.5 mmm -87.94 -30.71 19.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.294 -0.879 . . . . 0.0 109.362 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.545 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 168.05 -165.85 39.04 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.57 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 4.6 m-85 -137.52 139.61 40.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.332 -1.099 . . . . 0.0 109.46 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.0 t -66.08 125.01 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.258 -0.901 . . . . 0.0 109.331 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.553 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.8 p -160.18 158.97 31.06 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.15 -0.969 . . . . 0.0 109.667 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 59.5 p -82.84 -36.47 25.45 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.329 -0.857 . . . . 0.0 109.234 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.07 -86.56 0.52 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -103.13 -127.87 6.21 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.568 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -33.98 151.93 0.05 OUTLIER Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.512 -0.993 . . . . 0.0 110.046 -179.668 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.553 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.1 Cg_endo -69.38 158.66 56.64 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.807 2.338 . . . . 0.0 112.01 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.8 m -93.38 154.14 41.38 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.423 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -70.06 146.96 59.86 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.654 2.236 . . . . 0.0 111.735 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 45.1 t -83.62 140.18 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.297 -0.877 . . . . 0.0 109.417 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . 0.471 ' HE2' ' NH2' ' A' ' 96' ' ' ARG . 79.8 tttt -73.21 130.69 40.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.491 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -46.53 -39.07 10.26 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.278 -0.889 . . . . 0.0 109.425 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.471 ' NH2' ' HE2' ' A' ' 94' ' ' LYS . 15.5 mtt85 -60.56 -30.77 70.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.344 -0.847 . . . . 0.0 109.417 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.427 ' N ' ' O ' ' A' ' 94' ' ' LYS . 52.7 mt-10 -80.08 -26.8 39.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.892 . . . . 0.0 109.528 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.64 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 55.3 mtp -86.12 -21.77 27.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.226 179.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.557 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.47 -53.23 1.31 Allowed Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.482 -0.761 . . . . 0.0 109.807 179.981 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.591 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 50.4 Cg_endo -71.41 -26.69 20.11 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.463 2.109 . . . . 0.0 111.878 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.479 ' N ' ' O ' ' A' ' 98' ' ' MET . 35.2 mm -82.42 -42.96 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -0.934 . . . . 0.0 109.607 -179.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.59 ' N ' HD11 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -67.83 -40.82 83.74 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.183 -0.948 . . . . 0.0 109.417 179.923 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.47 ' HG2' ' HA ' ' A' ' 135' ' ' PRO . 19.7 tpt180 -65.86 -49.1 69.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.253 -0.904 . . . . 0.0 109.315 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.71 -37.03 70.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.358 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.522 ' CB ' HG13 ' A' ' 41' ' ' VAL . . . -74.35 1.3 11.95 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.315 -0.866 . . . . 0.0 109.773 -179.811 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.47 11.07 85.44 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.528 ' N ' ' O ' ' A' ' 102' ' ' LEU . 3.2 tp -82.05 -24.86 35.07 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.219 -1.166 . . . . 0.0 109.525 179.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 . . . . . 0 N--CA 1.49 1.559 0 O-C-N 121.214 -0.929 . . . . 0.0 109.584 -179.871 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.576 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 14.1 m-85 . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.429 ' HD3' ' O ' ' A' ' 123' ' ' PHE . 62.1 mmtt -139.35 156.37 47.05 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.25 -0.906 . . . . 0.0 109.536 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.507 ' HA ' HG22 ' A' ' 143' ' ' ILE . 10.1 t -57.37 137.46 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.258 -0.901 . . . . 0.0 109.606 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.81 -34.55 3.86 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 37.2 m-20 -47.8 160.8 0.12 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.341 -1.094 . . . . 0.0 109.405 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.4 ttm -100.87 127.93 47.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.193 -0.942 . . . . 0.0 109.059 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.552 ' CG1' HG13 ' A' ' 143' ' ' ILE . 25.7 m -128.72 145.31 35.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.358 -0.839 . . . . 0.0 109.667 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.471 ' O ' HG22 ' A' ' 173' ' ' VAL . 57.7 tttt -103.22 139.39 38.76 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.787 -0.819 . . . . 0.0 108.787 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.513 ' CD1' ' HB3' ' A' ' 139' ' ' PHE . 80.9 mt -78.41 153.71 5.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -149.17 1.26 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.946 -1.096 . . . . 0.0 109.465 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.492 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 70.1 m -148.27 144.3 27.53 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.114 -0.991 . . . . 0.0 110.06 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.59 -164.88 17.73 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.506 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 46.2 Cg_endo -68.35 -21.84 40.53 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 123.071 2.514 . . . . 0.0 112.643 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.591 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 86.9 m-85 -107.67 18.21 21.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.84 -1.163 . . . . 0.0 109.442 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.531 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 3.1 tt0 -45.53 139.05 4.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.255 -0.903 . . . . 0.0 109.617 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.531 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 28.9 m-20 73.74 28.54 1.6 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.385 -0.822 . . . . 0.0 110.423 179.526 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.52 ' CE1' ' CG1' ' A' ' 157' ' ' VAL . 1.7 t80 -117.4 131.87 56.68 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.041 -1.037 . . . . 0.0 109.445 179.668 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.53 132.26 37.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.19 -0.944 . . . . 0.0 109.647 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -142.98 167.46 26.33 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.529 ' CG1' ' HB2' ' A' ' 156' ' ' ASN . 11.1 p -117.42 138.33 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.353 -1.086 . . . . 0.0 109.393 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.552 HG13 ' CG1' ' A' ' 129' ' ' VAL . 60.6 mt -68.81 117.11 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.152 -0.968 . . . . 0.0 109.676 -179.832 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -102.43 -35.52 8.75 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.142 -0.973 . . . . 0.0 109.253 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.445 ' HB2' ' HB2' ' A' ' 154' ' ' LYS . 62.8 mt-10 -152.95 148.19 26.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.241 -0.912 . . . . 0.0 109.526 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.451 HG21 HD13 ' A' ' 153' ' ' LEU . 2.1 mt -123.8 125.65 71.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.257 -0.902 . . . . 0.0 109.412 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -106.74 99.61 26.42 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.192 -0.943 . . . . 0.0 109.674 -179.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.583 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.8 Cg_endo -70.74 170.96 16.49 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.704 2.27 . . . . 0.0 111.677 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.583 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.4 mt-10 81.64 -20.5 0.36 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.362 -0.836 . . . . 0.0 109.868 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.486 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 42.1 mtt180 -128.89 -12.47 4.74 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.997 -1.065 . . . . 0.0 109.694 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.491 ' C ' ' CG2' ' A' ' 170' ' ' VAL . 48.1 mt-30 70.69 48.8 0.42 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.26 -0.9 . . . . 0.0 109.604 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -119.59 142.18 48.62 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.175 -0.953 . . . . 0.0 109.02 179.583 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.533 ' CD2' HG12 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -129.34 112.36 13.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.237 -0.914 . . . . 0.0 110.083 -179.514 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . 0.445 ' HB2' ' HB2' ' A' ' 145' ' ' GLU . 17.6 mttt -79.9 126.41 30.97 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 179.071 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.476 HG22 ' CD1' ' A' ' 168' ' ' LEU . 16.1 m -128.32 152.98 37.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.035 -1.041 . . . . 0.0 110.05 -179.458 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.529 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 86.8 m-20 -98.88 112.9 24.87 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.313 -0.867 . . . . 0.0 109.376 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.527 HG13 ' CG2' ' A' ' 159' ' ' ILE . 38.8 t -99.97 147.69 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.273 -0.892 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 163' ' ' GLU . 29.2 m -94.08 117.76 30.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.415 -0.803 . . . . 0.0 109.802 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.645 ' CD1' ' CZ ' ' A' ' 56' ' ' PHE . 18.8 pt -145.9 138.62 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.348 -0.845 . . . . 0.0 109.387 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.599 ' CZ ' ' CE1' ' A' ' 61' ' ' PHE . 72.2 m-85 62.57 39.36 11.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.909 . . . . 0.0 109.379 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 62.26 16.96 55.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -137.73 142.21 41.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.092 -1.24 . . . . 0.0 109.501 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . 0.53 ' HA ' ' HA ' ' A' ' 158' ' ' THR . 84.8 mt-10 -98.45 110.2 22.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.184 -0.948 . . . . 0.0 109.465 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' THR . . . . . 0.496 HG21 ' N ' ' A' ' 165' ' ' PRO . 16.6 m -112.8 139.9 23.38 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.211 -0.93 . . . . 0.0 109.341 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.496 ' N ' HG21 ' A' ' 164' ' ' THR . 48.7 Cg_endo -69.21 137.3 36.72 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.711 2.274 . . . . 0.0 111.778 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.52 HG23 ' N ' ' A' ' 167' ' ' VAL . 2.1 p -123.41 142.06 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.157 -0.964 . . . . 0.0 109.743 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.52 ' N ' HG23 ' A' ' 166' ' ' VAL . 72.8 t -92.89 119.13 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.383 -0.823 . . . . 0.0 109.552 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.492 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 0.3 OUTLIER -141.27 167.96 20.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.313 -0.867 . . . . 0.0 110.567 -179.719 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.52 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 61.8 m80 -78.59 145.58 34.67 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.491 ' CG2' ' C ' ' A' ' 151' ' ' GLN . 24.0 t -59.67 -35.84 62.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.274 -0.891 . . . . 0.0 108.702 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 87.9 p -75.27 -7.06 52.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.494 -0.754 . . . . 0.0 109.324 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.52 ' CG ' ' HB2' ' A' ' 169' ' ' HIS . 82.5 mt-10 -90.62 4.07 52.37 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.34 -0.85 . . . . 0.0 109.832 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.578 ' CG2' ' N ' ' A' ' 174' ' ' GLU . 1.4 p -141.7 167.74 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.024 -1.048 . . . . 0.0 109.484 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.578 ' N ' ' CG2' ' A' ' 173' ' ' VAL . 52.4 tt0 -142.78 168.77 18.94 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.341 -0.849 . . . . 0.0 108.857 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.576 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 33.1 tttm . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.021 -1.05 . . . . 0.0 109.289 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.4 mttm . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.391 0.615 . . . . 0.0 109.667 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 12.7 mttt -135.49 176.03 9.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 110.009 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.609 ' CD1' ' HG3' ' A' ' 63' ' ' GLU . 60.3 m95 -109.83 125.71 53.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.362 -0.836 . . . . 0.0 109.211 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.583 ' CZ ' ' HG3' ' A' ' 66' ' ' MET . 66.1 m-85 -116.64 171.76 7.66 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.186 -0.946 . . . . 0.0 109.383 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.514 ' CD1' ' CD1' ' A' ' 160' ' ' PHE . 56.2 mt -110.9 109.95 30.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.242 -0.911 . . . . 0.0 109.069 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.558 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 8.9 p -88.6 143.47 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.186 -0.946 . . . . 0.0 109.477 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.584 HD11 ' CE1' ' A' ' 59' ' ' TYR . 4.6 mm? -88.83 141.83 28.17 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.389 -0.819 . . . . 0.0 109.545 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.1 t -154.69 -169.35 3.18 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.281 -0.887 . . . . 0.0 109.393 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.502 ' SD ' ' CE2' ' A' ' 16' ' ' TYR . 36.2 ttm -107.68 119.6 39.88 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.48 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 13' ' ' MET . 54.0 p -42.82 128.19 4.15 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.332 -0.855 . . . . 0.0 109.279 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.65 -19.69 33.13 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.502 ' CE2' ' SD ' ' A' ' 13' ' ' MET . 19.6 m-30 -110.31 -5.84 15.15 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.301 -1.117 . . . . 0.0 109.75 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.473 ' OE1' HG22 ' A' ' 44' ' ' ILE . 87.0 mt-10 -44.58 -65.49 0.51 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.148 -0.97 . . . . 0.0 109.547 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.446 ' O ' ' HG3' ' A' ' 22' ' ' GLU . 95.7 mt-10 -43.2 -33.41 0.92 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.199 -0.938 . . . . 0.0 109.271 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.524 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 46.7 mttm -77.19 -41.12 42.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.3 -0.875 . . . . 0.0 109.324 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.521 ' O ' HG12 ' A' ' 24' ' ' ILE . 18.4 t -59.7 -48.17 88.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.327 -0.858 . . . . 0.0 109.33 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.449 ' HG3' ' CG2' ' A' ' 40' ' ' ILE . 28.1 tttm -60.53 -43.12 97.49 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.897 . . . . 0.0 109.067 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.446 ' HG3' ' O ' ' A' ' 18' ' ' GLU . 93.7 mt-10 -63.87 -42.07 97.61 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.406 -0.809 . . . . 0.0 109.045 179.716 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.629 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 54.9 m-80 -56.91 -52.22 66.01 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.335 -0.853 . . . . 0.0 109.508 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.561 ' CD1' HG23 ' A' ' 77' ' ' VAL . 21.0 mm -50.33 -44.21 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.051 -1.031 . . . . 0.0 109.408 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -54.61 -44.27 72.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.272 -0.893 . . . . 0.0 109.832 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.8 mttp -79.86 -35.09 38.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.09 -1.006 . . . . 0.0 109.905 -179.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.532 ' HD3' ' CG2' ' A' ' 77' ' ' VAL . 12.6 ttpp -56.65 -35.16 68.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.114 -0.991 . . . . 0.0 109.282 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 15.6 t -82.47 -27.05 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.841 . . . . 0.0 109.575 -179.794 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 69.8 mt-10 -66.35 -49.84 65.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.214 -0.929 . . . . 0.0 109.68 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.38 -27.74 69.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.207 -0.933 . . . . 0.0 109.741 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.427 HG21 ' O ' ' A' ' 27' ' ' LYS . 60.9 p -88.83 -12.76 41.01 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.041 -1.037 . . . . 0.0 109.517 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 63.72 15.43 57.67 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.527 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 13.7 mt -94.84 85.6 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.314 -1.11 . . . . 0.0 109.481 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 49.9 mttt -85.59 7.64 22.41 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.149 -0.97 . . . . 0.0 109.074 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -111.77 18.52 18.86 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.339 -0.85 . . . . 0.0 109.433 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.587 ' CD2' ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.6 -52.95 2.75 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.144 -0.972 . . . . 0.0 109.344 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.527 HG21 ' CG2' ' A' ' 24' ' ' ILE . 87.7 t -97.01 137.06 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -107.81 -125.28 5.27 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.426 ' O ' ' CH2' ' A' ' 7' ' ' TRP . 95.2 mtt180 -91.72 138.69 31.35 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -1.112 . . . . 0.0 109.694 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.501 HG22 HD11 ' A' ' 40' ' ' ILE . 46.1 mt -105.78 136.96 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.374 -0.829 . . . . 0.0 109.042 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.587 ' CG2' ' CD1' ' A' ' 107' ' ' LEU . 98.4 t -124.26 150.51 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.499 HG21 ' CD1' ' A' ' 44' ' ' ILE . 5.7 mt -128.38 126.05 23.43 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.341 -0.849 . . . . 0.0 109.413 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.453 ' O ' ' HB2' ' A' ' 55' ' ' LEU . 47.8 Cg_endo -68.5 -2.99 10.18 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.86 2.374 . . . . 0.0 111.814 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.677 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 11.3 pt . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.07 -1.019 . . . . 0.0 109.649 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.677 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 22.6 mttm . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.536 ' CD1' ' N ' ' A' ' 55' ' ' LEU . 6.8 mp -65.91 -25.57 67.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.835 -1.165 . . . . 0.0 109.47 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.491 ' HB3' ' HB2' ' A' ' 59' ' ' TYR . 84.3 m-85 -142.08 98.23 6.22 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.886 . . . . 0.0 108.86 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.406 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 43.2 Cg_endo -66.7 134.39 34.94 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.755 2.303 . . . . 0.0 112.23 -179.082 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.56 -12.87 7.17 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.584 ' CE1' HD11 ' A' ' 11' ' ' LEU . 2.9 m-85 -100.67 131.23 46.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.693 -1.475 . . . . 0.0 110.183 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.558 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 76.8 t -135.32 148.6 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.377 -0.827 . . . . 0.0 108.809 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.634 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 16.8 m-85 -110.7 123.87 50.85 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.874 -1.141 . . . . 0.0 109.926 -179.395 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.42 HG11 ' N ' ' A' ' 63' ' ' GLU . 90.0 t -129.62 142.77 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.405 -0.809 . . . . 0.0 109.793 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.609 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 9.8 tt0 -99.86 125.52 45.83 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.335 -0.853 . . . . 0.0 109.175 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.441 ' HB3' ' HA ' ' A' ' 37' ' ' VAL . 12.5 ptt? -164.96 -175.39 3.71 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.025 -1.047 . . . . 0.0 110.174 -179.665 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.587 ' CD1' ' CD2' ' A' ' 36' ' ' LEU . 38.6 pt -103.35 128.36 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.165 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.583 ' HG3' ' CZ ' ' A' ' 8' ' ' TYR . 33.6 mtm -90.75 101.64 14.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.196 -0.94 . . . . 0.0 109.898 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.543 ' OD1' ' N ' ' A' ' 69' ' ' GLU . 10.3 p30 -137.91 -163.09 1.39 Allowed 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.123 -0.986 . . . . 0.0 109.077 179.591 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -74.98 -50.15 17.56 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.135 -0.978 . . . . 0.0 110.105 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.543 ' N ' ' OD1' ' A' ' 67' ' ' ASN . 98.0 mt-10 -64.85 -54.64 27.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.05 -1.031 . . . . 0.0 109.585 -179.747 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.525 ' O ' ' CG2' ' A' ' 74' ' ' VAL . . . -52.34 -38.75 59.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.265 -0.897 . . . . 0.0 109.727 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.502 ' O ' HG21 ' A' ' 74' ' ' VAL . 72.3 t80 -60.02 -50.51 73.46 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 109.853 -179.818 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -65.59 -28.46 69.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.156 -0.965 . . . . 0.0 110.436 -179.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -82.52 -42.63 18.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.865 -1.147 . . . . 0.0 110.035 -179.443 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.525 ' CG2' ' O ' ' A' ' 70' ' ' ALA . 6.8 m -65.92 -57.37 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.186 -0.947 . . . . 0.0 109.562 -179.78 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.59 ' HG2' ' CE2' ' A' ' 83' ' ' PHE . 12.6 mmt180 -53.87 -40.95 66.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.922 . . . . 0.0 109.751 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 25.7 p -75.42 3.07 9.86 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.204 -0.935 . . . . 0.0 110.149 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.638 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 1.8 p -71.8 130.0 87.52 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 120.875 -1.141 . . . . 0.0 109.136 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.775 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 44.0 Cg_endo -66.14 132.32 29.49 Favored 'Trans proline' 0 C--O 1.212 -0.797 0 C-N-CA 122.83 2.353 . . . . 0.0 112.627 -178.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.775 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 70.8 m-85 95.43 -8.63 0.1 Allowed 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.638 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 16.0 t -99.15 133.72 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.973 -1.079 . . . . 0.0 109.494 179.726 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 64.2 mtt -92.79 -19.23 21.96 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.337 -0.852 . . . . 0.0 109.399 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 150.48 -154.38 25.6 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.59 ' CE2' ' HG2' ' A' ' 75' ' ' ARG . 5.3 m-85 -137.14 149.22 47.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -1.142 . . . . 0.0 109.602 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.465 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 13.8 p -74.86 129.39 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.283 -0.886 . . . . 0.0 109.37 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.543 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 2.2 p -163.06 165.6 24.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.732 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.4 t -92.89 -30.87 15.19 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.396 -0.815 . . . . 0.0 109.24 179.742 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.77 -87.7 0.54 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.527 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -103.19 -135.5 8.7 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.527 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -32.59 153.99 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.568 -0.96 . . . . 0.0 110.259 -179.624 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.543 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 47.8 Cg_endo -67.86 151.2 78.56 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.891 2.394 . . . . 0.0 112.013 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.4 m -84.22 155.07 63.64 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.318 -0.864 . . . . 0.0 109.336 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.81 141.27 44.59 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.676 2.251 . . . . 0.0 111.753 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.435 HG13 ' HG3' ' A' ' 98' ' ' MET . 41.4 t -71.73 141.4 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.209 -0.932 . . . . 0.0 109.367 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 97' ' ' GLU . 93.8 mttt -75.53 130.02 38.17 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.444 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 78.5 m-20 -45.25 -39.4 6.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.883 . . . . 0.0 109.354 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 77.6 mtt180 -60.69 -24.74 65.87 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.483 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.47 ' N ' ' O ' ' A' ' 94' ' ' LYS . 87.6 mt-10 -89.42 -26.06 21.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.556 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.56 ' HE3' ' CD1' ' A' ' 7' ' ' TRP . 89.5 mtp -82.54 -30.93 29.41 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.401 -0.812 . . . . 0.0 109.448 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.606 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 1.2 tpt180 -38.7 -51.95 3.67 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.402 -0.811 . . . . 0.0 109.857 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.606 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.3 Cg_endo -68.78 -28.1 30.69 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.483 2.122 . . . . 0.0 111.801 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.459 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 23.4 mm -81.58 -42.13 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.243 -0.91 . . . . 0.0 109.402 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.577 HD12 ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -67.46 -39.88 85.35 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.207 -0.933 . . . . 0.0 109.051 179.715 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.515 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 26.1 ttm180 -63.62 -49.27 73.96 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.375 -0.828 . . . . 0.0 108.981 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . 0.439 HD23 HD21 ' A' ' 55' ' ' LEU . 0.6 OUTLIER -72.99 -35.24 66.83 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.329 -0.857 . . . . 0.0 109.048 179.532 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -74.38 -2.8 26.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.356 -0.84 . . . . 0.0 109.654 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.42 14.4 82.43 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.587 ' CD1' ' CG2' ' A' ' 41' ' ' VAL . 66.0 mt -81.65 -24.17 36.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.202 -1.176 . . . . 0.0 109.646 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 37.9 tp10 . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.101 -0.999 . . . . 0.0 109.627 -179.871 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.572 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 3.6 m-30 . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.406 ' HB2' ' CG ' ' A' ' 127' ' ' ASP . 74.8 mttt -124.87 154.32 41.25 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.013 -1.054 . . . . 0.0 110.124 -179.462 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.451 ' HA ' HG22 ' A' ' 143' ' ' ILE . 9.8 m -64.66 141.89 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.331 179.738 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 88.22 -31.75 4.65 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.44 ' OD2' ' HE3' ' A' ' 175' ' ' LYS . 28.9 m-20 -49.66 158.74 0.43 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.433 -1.039 . . . . 0.0 109.26 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.4 ttm -98.13 127.86 44.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.205 -0.934 . . . . 0.0 109.052 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.536 HG13 ' CG1' ' A' ' 143' ' ' ILE . 27.4 m -128.11 143.41 40.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.276 -0.89 . . . . 0.0 109.604 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 75.8 tttt -100.31 139.42 36.01 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.575 ' O ' ' CD1' ' A' ' 132' ' ' ILE . 1.2 mp -79.86 152.77 4.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.575 ' CD1' ' O ' ' A' ' 131' ' ' ILE . 1.1 mm -148.79 2.4 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 120.956 -1.09 . . . . 0.0 109.809 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.506 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 41.7 m -147.5 144.66 28.73 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.971 -1.08 . . . . 0.0 110.198 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 103.22 -166.44 16.29 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.515 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 47.5 Cg_endo -68.52 -20.85 40.84 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 123.111 2.541 . . . . 0.0 112.315 -179.663 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.515 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 98.8 m-85 -107.86 19.09 20.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.954 -1.091 . . . . 0.0 109.3 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.562 ' HA ' HG23 ' A' ' 131' ' ' ILE . 4.0 tt0 -43.17 139.9 1.7 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.268 -0.895 . . . . 0.0 109.797 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.549 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 44.3 m-20 72.62 30.74 1.81 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.463 -0.773 . . . . 0.0 110.871 179.191 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.515 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 0.7 OUTLIER -116.66 128.46 55.39 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.76 -1.212 . . . . 0.0 109.573 179.654 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.14 133.49 42.8 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.28 -0.887 . . . . 0.0 109.455 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.05 168.96 26.37 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.432 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.451 HG13 ' N ' ' A' ' 143' ' ' ILE . 53.5 t -118.19 137.47 52.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.578 -0.954 . . . . 0.0 109.311 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.536 ' CG1' HG13 ' A' ' 129' ' ' VAL . 98.7 mt -70.05 115.47 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.177 -0.952 . . . . 0.0 109.42 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -99.03 -33.85 10.65 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.085 -1.009 . . . . 0.0 109.479 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.44 ' HB2' ' HE2' ' A' ' 154' ' ' LYS . 93.7 mt-10 -154.39 149.48 26.88 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.211 -0.931 . . . . 0.0 109.702 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 2.8 mt -125.91 128.46 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.431 -0.793 . . . . 0.0 109.394 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -110.91 102.17 51.79 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.234 -0.916 . . . . 0.0 109.534 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.557 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.0 Cg_endo -70.94 172.54 13.58 Favored 'Trans proline' 0 C--O 1.214 -0.724 0 C-N-CA 122.692 2.261 . . . . 0.0 111.699 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.557 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.6 mt-10 80.37 -20.74 0.36 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.348 -0.845 . . . . 0.0 109.848 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.427 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 74.6 mtt180 -128.53 -14.02 4.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.1 -1.0 . . . . 0.0 109.567 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.427 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 35.9 mt-30 70.51 48.64 0.45 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.216 -0.927 . . . . 0.0 109.851 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . 0.492 ' OE2' ' CG2' ' A' ' 167' ' ' VAL . 84.6 tt0 -117.76 141.83 47.96 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.075 -1.015 . . . . 0.0 109.038 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.482 ' CD2' HG12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -130.77 113.27 13.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.013 -1.054 . . . . 0.0 110.158 -179.512 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . 0.44 ' HE2' ' HB2' ' A' ' 145' ' ' GLU . 2.5 ttpt -78.61 128.58 33.7 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.242 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.442 HG11 ' HA3' ' A' ' 141' ' ' GLY . 47.0 t -124.54 145.82 31.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.168 -0.958 . . . . 0.0 109.985 -179.41 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.502 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 27.0 t-20 -98.32 110.96 23.45 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.377 -0.827 . . . . 0.0 109.37 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.547 HG12 ' CG1' ' A' ' 159' ' ' ILE . 60.4 t -95.22 142.33 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.453 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 41.2 m -100.55 100.03 10.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.255 -0.903 . . . . 0.0 109.728 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.547 ' CG1' HG12 ' A' ' 157' ' ' VAL . 4.1 mt -123.81 146.98 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.178 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.634 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 97.9 m-85 61.84 38.66 14.52 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.238 -0.914 . . . . 0.0 109.205 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 55.24 17.19 10.63 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.464 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 90.7 mtt-85 -125.58 158.71 33.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.094 -1.239 . . . . 0.0 109.563 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.73 128.37 46.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.194 -0.941 . . . . 0.0 109.687 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 48.8 m -139.2 125.78 12.58 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.313 -0.867 . . . . 0.0 109.792 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.502 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.2 Cg_endo -71.51 135.28 26.08 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.7 2.267 . . . . 0.0 111.429 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.434 HG23 ' N ' ' A' ' 167' ' ' VAL . 7.1 p -118.47 163.39 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.167 -0.958 . . . . 0.0 109.966 -179.524 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.492 ' CG2' ' OE2' ' A' ' 152' ' ' GLU . 14.4 p -116.61 117.01 54.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.296 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.536 ' CD1' ' N ' ' A' ' 168' ' ' LEU . 0.0 OUTLIER -143.21 168.85 18.8 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.243 -0.911 . . . . 0.0 110.91 -179.264 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -78.96 144.0 35.21 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 10.8 p -57.78 -36.23 54.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.215 -0.928 . . . . 0.0 108.83 179.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 42.5 p -76.39 -6.64 52.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.45 -0.782 . . . . 0.0 109.401 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.506 ' HA ' ' HB2' ' A' ' 133' ' ' SER . 2.8 mt-10 -89.72 -0.29 57.44 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.239 -0.913 . . . . 0.0 109.394 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.2 m -144.06 174.35 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.253 -0.905 . . . . 0.0 109.21 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.476 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 53.9 tt0 -139.49 168.16 20.46 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.113 -0.992 . . . . 0.0 108.975 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.572 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 73.1 tttt . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.028 -1.045 . . . . 0.0 109.358 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.463 ' HG2' HG22 ' A' ' 65' ' ' ILE . 36.8 mttt . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 121.263 0.554 . . . . 0.0 109.55 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.4 mttt -132.36 176.29 8.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.298 -0.876 . . . . 0.0 109.337 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.586 ' CD1' ' HG3' ' A' ' 63' ' ' GLU . 64.8 m95 -112.67 124.04 51.66 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.924 . . . . 0.0 109.386 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.485 ' OH ' ' HG3' ' A' ' 66' ' ' MET . 78.4 m-85 -113.35 179.79 3.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.18 -0.95 . . . . 0.0 109.266 179.785 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.529 HG12 ' CE1' ' A' ' 61' ' ' PHE . 66.8 mt -119.7 107.38 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.384 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.546 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 13.1 p -86.01 144.6 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.271 -0.893 . . . . 0.0 109.518 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.569 HD13 ' CE1' ' A' ' 59' ' ' TYR . 2.8 mm? -94.8 143.83 26.14 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.336 -0.853 . . . . 0.0 109.601 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.405 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 1.3 p -151.3 -168.59 3.14 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.307 -0.87 . . . . 0.0 109.317 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.414 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 95.4 mtp -106.2 136.15 46.42 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.181 -0.949 . . . . 0.0 109.294 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.8 t -55.8 123.38 14.0 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -0.908 . . . . 0.0 109.424 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.08 -19.67 32.11 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.414 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.8 m-85 -108.15 -11.26 15.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.323 -1.104 . . . . 0.0 109.561 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.473 ' OE2' ' N ' ' A' ' 58' ' ' GLY . 77.5 mt-10 -46.52 -61.5 1.79 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.187 -0.945 . . . . 0.0 109.408 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 67.4 mm-40 -47.98 -36.55 12.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.288 -0.883 . . . . 0.0 109.339 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -71.69 -45.96 60.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.346 -0.847 . . . . 0.0 109.436 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.516 HG22 ' CB ' ' A' ' 79' ' ' TYR . 78.8 t -57.31 -47.14 85.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.186 -0.946 . . . . 0.0 109.444 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.507 ' HD2' ' CD1' ' A' ' 42' ' ' ILE . 21.7 tttt -56.09 -51.54 67.5 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.234 -0.916 . . . . 0.0 109.532 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 61.1 tt0 -63.06 -33.67 75.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.166 -0.959 . . . . 0.0 109.398 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.581 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 23.6 m120 -66.18 -41.26 90.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.318 -0.864 . . . . 0.0 109.501 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.456 HG13 ' O ' ' A' ' 20' ' ' VAL . 92.2 mt -60.52 -44.98 97.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.217 -0.927 . . . . 0.0 109.43 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -55.77 -47.09 77.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.201 -0.937 . . . . 0.0 109.672 -179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 71.5 mttt -70.19 -34.71 73.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.136 -0.977 . . . . 0.0 109.316 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.483 ' HD2' HG23 ' A' ' 77' ' ' VAL . 34.4 tttp -57.14 -35.9 70.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.379 -0.826 . . . . 0.0 109.478 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.511 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 33.8 t -81.32 -25.51 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -71.6 -56.56 5.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.248 -0.908 . . . . 0.0 109.562 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.86 -26.2 45.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.223 -0.923 . . . . 0.0 109.553 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.463 ' OG1' HG12 ' A' ' 33' ' ' ILE . 41.8 p -98.05 -28.66 13.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.192 -0.942 . . . . 0.0 109.57 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 76.88 21.1 75.06 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.511 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 34.1 mm -90.02 94.87 5.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -1.154 . . . . 0.0 109.495 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 16.0 mttp -97.74 5.13 49.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.183 -0.948 . . . . 0.0 109.49 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -110.22 13.45 23.07 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.203 -0.936 . . . . 0.0 109.341 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.534 ' CD2' ' HB3' ' A' ' 70' ' ' ALA . 1.2 tm? -115.73 -54.28 2.52 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.329 -0.857 . . . . 0.0 109.187 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.4 HG12 ' CG2' ' A' ' 24' ' ' ILE . 42.9 t -99.21 130.01 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.443 -0.786 . . . . 0.0 109.219 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -99.82 -124.33 5.22 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 90.7 mtt180 -96.51 141.94 29.19 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.266 -1.138 . . . . 0.0 109.589 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.422 ' CD1' HD11 ' A' ' 24' ' ' ILE . 63.3 mt -101.43 138.1 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.297 -0.877 . . . . 0.0 109.251 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.543 ' CG2' ' CD1' ' A' ' 107' ' ' LEU . 44.4 t -126.42 137.51 57.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.236 -0.915 . . . . 0.0 109.285 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.528 ' CG2' HG12 ' A' ' 44' ' ' ILE . 12.2 mt -128.08 127.84 23.79 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.187 -0.946 . . . . 0.0 109.692 -179.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.513 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -68.05 -3.86 11.45 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.895 2.396 . . . . 0.0 111.461 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.63 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 18.8 pt . . . . . 0 N--CA 1.489 1.505 0 O-C-N 121.307 -0.87 . . . . 0.0 109.561 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.63 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 6.2 mttt . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.513 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 16.7 mt -71.83 -21.47 61.68 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.136 -0.978 . . . . 0.0 109.407 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.553 ' CZ ' HD12 ' A' ' 159' ' ' ILE . 37.2 m-85 -143.95 93.09 6.17 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.285 -0.885 . . . . 0.0 108.826 179.688 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -64.34 135.91 48.61 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.628 2.219 . . . . 0.0 112.267 -179.193 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.473 ' N ' ' OE2' ' A' ' 17' ' ' GLU . . . 78.81 -20.52 4.42 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 179.541 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.569 ' CE1' HD13 ' A' ' 11' ' ' LEU . 3.9 m-30 -96.34 127.81 42.68 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.707 -1.467 . . . . 0.0 110.47 -179.085 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.546 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 94.3 t -135.59 150.41 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.111 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.529 ' CE1' HG12 ' A' ' 9' ' ' ILE . 86.8 m-85 -108.46 122.97 48.14 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.858 -1.151 . . . . 0.0 110.227 -179.248 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 87.9 t -121.98 127.8 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.322 -0.861 . . . . 0.0 109.873 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.586 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 7.6 tt0 -89.68 121.76 32.16 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.282 -0.886 . . . . 0.0 109.278 179.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' MET . . . . . . . . . . . . . 14.8 ptt? -154.04 174.08 15.17 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.03 -1.044 . . . . 0.0 110.538 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.486 HG13 ' O ' ' A' ' 65' ' ' ILE . 39.0 pt -100.35 134.99 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.558 ' O ' ' HB3' ' A' ' 67' ' ' ASN . 84.9 mtp -79.55 142.87 35.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.096 -1.003 . . . . 0.0 110.799 -178.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.558 ' HB3' ' O ' ' A' ' 66' ' ' MET . 16.4 p30 171.67 -174.31 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -76.51 -42.89 41.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.147 -0.971 . . . . 0.0 110.006 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.621 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 85.1 tt0 -66.54 -31.42 72.13 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.216 -0.927 . . . . 0.0 110.383 -179.299 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.536 ' HB3' ' ND2' ' A' ' 67' ' ' ASN . . . -77.11 -40.78 44.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.848 -1.157 . . . . 0.0 109.791 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.496 ' O ' HG11 ' A' ' 74' ' ' VAL . 87.3 t80 -58.79 -51.41 70.1 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.11 -0.994 . . . . 0.0 109.586 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' HB3' ' A' ' 76' ' ' SER . 38.1 t-20 -69.89 -27.27 64.67 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.201 -0.937 . . . . 0.0 110.581 -179.196 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.621 ' CD1' ' O ' ' A' ' 69' ' ' GLU . 5.1 m-85 -78.19 -41.21 35.26 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.693 -1.254 . . . . 0.0 110.073 -179.447 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.609 ' CG2' ' CZ ' ' A' ' 83' ' ' PHE . 7.7 p -66.48 -52.11 50.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.22 -0.925 . . . . 0.0 109.232 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.584 ' HG2' ' CE2' ' A' ' 83' ' ' PHE . 7.5 mmm-85 -67.59 -1.22 4.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.313 -0.867 . . . . 0.0 109.904 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 89.3 p -101.0 -4.94 26.53 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.031 -1.043 . . . . 0.0 110.167 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.616 ' CG1' ' HB ' ' A' ' 80' ' ' VAL . 5.6 p -80.13 137.9 52.95 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 120.994 -1.066 . . . . 0.0 109.377 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.636 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 43.5 Cg_endo -65.77 140.53 61.97 Favored 'Trans proline' 0 C--O 1.213 -0.737 0 C-N-CA 122.763 2.308 . . . . 0.0 112.119 -179.367 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.636 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 42.0 m-85 89.0 -11.89 0.41 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.831 -0.543 . . . . 0.0 109.675 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.616 ' HB ' ' CG1' ' A' ' 77' ' ' VAL . 7.9 p -81.84 119.03 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.957 -1.089 . . . . 0.0 109.299 179.772 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.8 mmm -88.44 -27.16 21.71 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.196 -0.94 . . . . 0.0 109.41 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.588 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.27 -158.03 28.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.609 ' CZ ' ' CG2' ' A' ' 74' ' ' VAL . 7.4 m-85 -139.61 156.95 46.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -1.124 . . . . 0.0 109.573 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' A' ' 84' ' ' VAL . 7.7 p -88.74 118.69 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.232 -0.918 . . . . 0.0 109.339 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.561 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.8 OUTLIER -157.0 166.78 32.38 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -0.915 . . . . 0.0 109.627 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 m -87.06 -29.93 21.54 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.405 -0.809 . . . . 0.0 109.432 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.44 -103.18 1.4 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -99.5 -124.34 5.19 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.559 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -29.24 146.09 0.05 OUTLIER Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.524 -0.986 . . . . 0.0 110.142 -179.751 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.561 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.2 Cg_endo -68.66 153.92 72.41 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.827 2.352 . . . . 0.0 112.001 -179.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.2 m -89.9 149.75 42.43 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.301 -0.874 . . . . 0.0 109.253 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.492 ' HB3' ' HB3' ' A' ' 6' ' ' LYS . 49.5 Cg_endo -69.62 152.37 70.01 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.682 2.255 . . . . 0.0 111.664 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.45 HG21 ' O ' ' A' ' 7' ' ' TRP . 15.5 t -79.93 141.21 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -0.885 . . . . 0.0 109.322 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . 0.512 ' O ' ' N ' ' A' ' 97' ' ' GLU . 69.6 tttt -78.9 130.14 35.3 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.086 -1.009 . . . . 0.0 109.357 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.442 ' C ' ' O ' ' A' ' 94' ' ' LYS . 81.3 m-20 -42.78 -41.96 3.4 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -0.944 . . . . 0.0 109.367 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.468 ' CD ' ' HE2' ' A' ' 94' ' ' LYS . 75.1 mtt180 -56.36 -29.91 62.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.271 -0.893 . . . . 0.0 109.433 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.512 ' N ' ' O ' ' A' ' 94' ' ' LYS . 47.5 mt-10 -88.07 -28.26 21.44 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.221 -0.924 . . . . 0.0 109.589 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.562 ' HE2' ' CG ' ' A' ' 7' ' ' TRP . 94.6 mtp -82.91 -25.51 32.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.148 -0.97 . . . . 0.0 109.431 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.546 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.14 -54.62 1.08 Allowed Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.524 -0.735 . . . . 0.0 109.995 -179.845 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.612 ' CB ' ' CE2' ' A' ' 136' ' ' PHE . 49.4 Cg_endo -70.17 -27.75 24.14 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.591 2.194 . . . . 0.0 112.132 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.525 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 18.9 mm -80.21 -42.74 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.156 -0.965 . . . . 0.0 109.546 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.523 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -67.36 -40.63 85.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.207 -0.933 . . . . 0.0 109.494 -179.884 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.547 ' CG ' ' HB3' ' A' ' 135' ' ' PRO . 22.2 tpt180 -65.13 -49.73 68.78 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.326 -0.859 . . . . 0.0 109.162 179.722 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.4 tt -72.05 -37.86 69.61 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.208 -0.932 . . . . 0.0 109.2 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.52 -1.04 9.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.398 -0.814 . . . . 0.0 109.829 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.75 8.57 86.42 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.543 ' CD1' ' CG2' ' A' ' 41' ' ' VAL . 29.3 mt -78.38 -21.4 49.44 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.19 -1.182 . . . . 0.0 109.613 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 42.6 tp10 . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.15 -0.969 . . . . 0.0 109.365 -179.909 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.533 ' O ' ' CD1' ' A' ' 146' ' ' ILE . 18.0 m-85 . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 80.9 mttt -102.08 148.72 25.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.958 . . . . 0.0 109.915 -179.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.446 HG11 HG13 ' A' ' 146' ' ' ILE . 20.5 m -64.14 144.26 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.433 -0.792 . . . . 0.0 109.375 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 85.72 -29.92 4.38 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.451 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 26.2 m-20 -48.01 165.71 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -1.114 . . . . 0.0 109.127 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 2.9 ttm -103.54 127.8 50.88 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.136 -0.978 . . . . 0.0 109.153 179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.541 HG12 ' CG1' ' A' ' 143' ' ' ILE . 26.8 m -129.06 145.88 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.855 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.421 ' HA ' ' HA ' ' A' ' 140' ' ' ALA . 42.2 tttt -102.81 142.41 33.99 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.493 HG22 ' N ' ' A' ' 132' ' ' ILE . 60.5 mt -83.14 154.34 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.358 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.493 ' N ' HG22 ' A' ' 131' ' ' ILE . 0.2 OUTLIER -152.02 2.78 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 120.948 -1.095 . . . . 0.0 109.65 179.828 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.489 ' HB3' ' HG2' ' A' ' 172' ' ' GLU . 47.3 t -148.03 144.1 27.69 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.07 -1.019 . . . . 0.0 110.252 -179.66 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 99.62 -163.18 19.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.547 ' HB3' ' CG ' ' A' ' 103' ' ' ARG . 46.8 Cg_endo -67.89 -23.46 41.14 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 123.312 2.675 . . . . 0.0 112.541 -179.497 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.612 ' CE2' ' CB ' ' A' ' 100' ' ' PRO . 93.2 m-85 -104.22 17.61 23.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.957 -1.09 . . . . 0.0 109.562 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.545 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 2.9 tt0 -43.83 133.61 4.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.251 -0.906 . . . . 0.0 109.649 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.545 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 16.8 t0 78.92 19.26 0.82 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.262 -0.899 . . . . 0.0 110.36 179.161 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.512 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 0.9 OUTLIER -109.24 130.4 55.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.912 -1.117 . . . . 0.0 109.47 179.825 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.421 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -83.7 136.9 34.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.16 -0.963 . . . . 0.0 109.597 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.498 ' HA3' HG12 ' A' ' 155' ' ' VAL . . . -146.55 175.6 25.89 Favored Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.67 -1.252 . . . . 0.0 110.612 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.573 ' N ' ' CG1' ' A' ' 155' ' ' VAL . 19.4 m -118.42 137.01 53.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.702 -0.881 . . . . 0.0 109.659 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.541 ' CG1' HG12 ' A' ' 129' ' ' VAL . 93.3 mt -67.48 114.6 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.321 -0.862 . . . . 0.0 109.407 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -98.15 -34.51 10.72 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.976 -1.077 . . . . 0.0 109.331 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -150.8 145.58 25.81 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.153 -0.967 . . . . 0.0 109.367 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.533 ' CD1' ' O ' ' A' ' 123' ' ' PHE . 2.2 mt -122.74 126.28 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.678 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -107.41 101.68 40.32 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.314 -0.867 . . . . 0.0 109.447 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.528 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.1 Cg_endo -71.96 170.92 17.73 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.734 2.29 . . . . 0.0 111.899 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.7 tt0 79.85 -20.92 0.36 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.336 -0.852 . . . . 0.0 109.862 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.431 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 66.6 mtp85 -125.35 -13.18 6.7 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.155 -0.965 . . . . 0.0 109.43 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.431 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 36.2 mt-30 68.98 49.08 0.67 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.204 -0.935 . . . . 0.0 109.678 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -121.1 145.25 48.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.111 -0.993 . . . . 0.0 108.896 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.521 HD22 ' CG2' ' A' ' 143' ' ' ILE . 0.0 OUTLIER -135.82 113.13 10.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.035 -1.041 . . . . 0.0 110.262 -179.498 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . 0.409 ' HG2' HG11 ' A' ' 167' ' ' VAL . 10.4 mttt -79.59 133.25 36.43 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.102 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.573 ' CG1' ' N ' ' A' ' 142' ' ' VAL . 21.5 t -126.34 150.49 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.077 -1.014 . . . . 0.0 110.01 -179.27 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.51 ' OD1' ' N ' ' A' ' 164' ' ' THR . 20.9 t-20 -97.26 114.5 26.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.446 -0.784 . . . . 0.0 109.293 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.502 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 50.0 t -95.98 139.77 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.712 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 20.6 m -92.55 95.24 9.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.409 -0.807 . . . . 0.0 109.514 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.553 HD12 ' CZ ' ' A' ' 56' ' ' PHE . 5.5 pt -130.9 150.2 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.269 -0.895 . . . . 0.0 109.488 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.55 ' CE2' HD12 ' A' ' 159' ' ' ILE . 13.7 m-30 62.95 33.13 15.18 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.271 -0.893 . . . . 0.0 109.313 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 60.64 16.35 44.64 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 60.0 mtt-85 -135.63 159.27 42.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.188 -1.183 . . . . 0.0 109.455 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . 0.427 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 95.6 mt-10 -100.46 140.85 34.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.244 -0.91 . . . . 0.0 109.516 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' THR . . . . . 0.51 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 16.4 m -148.0 127.86 6.59 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.325 -0.859 . . . . 0.0 109.46 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.5 Cg_endo -69.86 140.0 41.23 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.751 2.301 . . . . 0.0 111.583 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.506 ' CG2' HD23 ' A' ' 168' ' ' LEU . 35.2 m -121.28 168.19 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.056 -1.028 . . . . 0.0 109.598 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.618 ' O ' ' CD1' ' A' ' 168' ' ' LEU . 8.4 m -118.2 115.66 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.442 -0.786 . . . . 0.0 109.492 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.727 ' N ' ' CD2' ' A' ' 168' ' ' LEU . 0.0 OUTLIER -139.56 166.28 25.0 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-O 121.797 0.808 . . . . 0.0 109.937 179.959 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.45 ' O ' ' HB2' ' A' ' 172' ' ' GLU . 40.5 m80 -79.04 139.72 38.09 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.175 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.491 HG13 ' N ' ' A' ' 171' ' ' SER . 11.4 p -51.43 -37.91 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.067 -1.021 . . . . 0.0 108.521 179.598 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.491 ' N ' HG13 ' A' ' 170' ' ' VAL . 53.3 p -74.86 -4.83 40.16 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.615 -0.678 . . . . 0.0 109.798 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.489 ' HG2' ' HB3' ' A' ' 133' ' ' SER . 23.8 mt-10 -92.7 -6.44 49.19 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.077 -1.014 . . . . 0.0 109.874 -179.712 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.48 ' HA ' HG12 ' A' ' 132' ' ' ILE . 4.1 m -137.29 175.15 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.057 -1.027 . . . . 0.0 109.488 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.528 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 84.4 tt0 -140.02 164.53 29.77 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.132 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.528 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.8 tttt . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.055 -1.028 . . . . 0.0 109.347 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 72.1 mttt . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.318 0.58 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.583 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.0 mtpp -130.56 174.72 9.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.282 -0.886 . . . . 0.0 109.28 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.612 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 61.9 m95 -108.84 124.43 50.61 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.232 -0.917 . . . . 0.0 109.031 179.7 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.482 ' O ' ' HA ' ' A' ' 61' ' ' PHE . 79.5 m-85 -110.92 174.07 6.03 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.163 -0.961 . . . . 0.0 109.569 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.522 HG12 ' CD1' ' A' ' 61' ' ' PHE . 61.7 mt -116.76 109.05 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.316 -0.865 . . . . 0.0 109.141 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.526 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 9.7 p -90.88 142.98 12.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.178 -0.951 . . . . 0.0 109.65 -179.682 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.561 HD12 ' CE1' ' A' ' 59' ' ' TYR . 3.5 mm? -89.5 153.86 20.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.353 -0.842 . . . . 0.0 109.615 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 58' ' ' GLY . 9.2 t -162.84 -172.87 3.24 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.906 . . . . 0.0 109.349 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.531 ' HE3' ' CD2' ' A' ' 16' ' ' TYR . 67.5 mtm -103.54 133.45 48.56 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.227 -0.92 . . . . 0.0 109.658 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.4 m -54.43 127.4 27.36 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.884 . . . . 0.0 109.383 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.23 -20.18 38.43 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.531 ' CD2' ' HE3' ' A' ' 13' ' ' MET . 85.6 m-85 -107.51 -1.56 21.24 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.34 -1.094 . . . . 0.0 109.429 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -55.21 -59.4 4.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.233 -0.917 . . . . 0.0 109.388 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -47.48 -36.38 10.1 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.345 -0.847 . . . . 0.0 109.402 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 12.9 mttp -72.44 -46.46 54.89 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.388 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.409 HG22 ' CB ' ' A' ' 79' ' ' TYR . 73.4 t -55.09 -47.17 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.281 -0.887 . . . . 0.0 109.307 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.521 ' HD2' ' CD1' ' A' ' 42' ' ' ILE . 17.8 tttm -56.23 -50.92 69.92 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.413 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -63.25 -37.39 87.05 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.189 -0.944 . . . . 0.0 109.522 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.583 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 31.5 m120 -61.89 -49.04 77.82 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.203 -0.935 . . . . 0.0 109.565 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 81.2 mt -53.93 -44.22 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.08 -1.013 . . . . 0.0 109.354 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.449 ' O ' HG23 ' A' ' 28' ' ' VAL . 83.1 tt0 -56.56 -47.95 78.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.188 -0.945 . . . . 0.0 110.035 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 40.4 mttp -73.41 -36.95 66.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.145 -0.972 . . . . 0.0 109.939 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.483 ' HD3' HG23 ' A' ' 77' ' ' VAL . 23.7 ttpp -56.31 -34.12 66.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.122 -0.986 . . . . 0.0 109.325 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.536 ' CG1' HG12 ' A' ' 37' ' ' VAL . 12.0 m -87.34 -25.55 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.42 -0.8 . . . . 0.0 109.489 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.427 ' N ' HG22 ' A' ' 28' ' ' VAL . 34.3 tt0 -72.01 -57.75 4.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.303 -0.873 . . . . 0.0 109.298 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.85 -40.79 61.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.397 -0.814 . . . . 0.0 109.243 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 72.7 p -83.07 -26.15 31.38 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.325 -0.859 . . . . 0.0 109.483 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 77.51 25.02 64.02 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.535 HD13 ' CE2' ' A' ' 73' ' ' PHE . 15.9 mt -94.07 92.9 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -1.15 . . . . 0.0 109.359 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.8 mttt -105.71 -12.95 15.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.349 -0.845 . . . . 0.0 109.505 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -86.25 -19.6 29.71 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.182 -0.949 . . . . 0.0 109.428 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.575 ' CD1' ' CB ' ' A' ' 70' ' ' ALA . 15.1 tp -89.36 -51.58 5.49 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.307 -0.87 . . . . 0.0 109.461 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.536 HG12 ' CG1' ' A' ' 28' ' ' VAL . 7.3 p -93.83 136.58 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.52 -0.737 . . . . 0.0 109.018 179.672 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.5 -120.9 4.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.4 mtt85 -104.44 140.04 38.51 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.286 -1.126 . . . . 0.0 109.878 -179.399 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.46 HD11 ' HG3' ' A' ' 21' ' ' LYS . 12.9 pt -112.74 148.26 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.354 -0.841 . . . . 0.0 109.021 179.407 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.554 ' CG2' ' HB2' ' A' ' 61' ' ' PHE . 23.2 m -132.22 161.77 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.076 -1.015 . . . . 0.0 109.91 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.537 ' CG2' HG13 ' A' ' 44' ' ' ILE . 3.8 mt -135.28 130.84 19.36 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.379 -0.826 . . . . 0.0 109.333 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.481 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 43.0 Cg_endo -65.12 -3.59 7.53 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.851 2.368 . . . . 0.0 111.873 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.639 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 15.3 mt . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.146 -0.971 . . . . 0.0 109.446 179.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.639 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 7.2 mttp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.481 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 41.2 mt -68.06 -20.78 65.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.061 -1.025 . . . . 0.0 109.3 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.528 ' HB3' ' HB2' ' A' ' 59' ' ' TYR . 90.0 m-85 -143.66 98.2 5.37 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.304 -0.873 . . . . 0.0 109.044 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.406 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.3 Cg_endo -65.52 132.88 32.5 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.784 2.322 . . . . 0.0 112.216 -179.3 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.485 ' O ' HG23 ' A' ' 12' ' ' THR . . . 77.02 -15.41 6.47 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.561 ' CE1' HD12 ' A' ' 11' ' ' LEU . 2.9 m-85 -97.83 129.59 44.8 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.624 -1.515 . . . . 0.0 110.38 -179.159 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.526 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 79.2 t -137.19 149.19 25.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.41 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.554 ' HB2' ' CG2' ' A' ' 41' ' ' VAL . 63.5 m-85 -109.67 124.39 51.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.025 -1.047 . . . . 0.0 110.23 -179.416 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.497 ' CG2' ' HE2' ' A' ' 64' ' ' MET . 1.3 m -123.44 135.43 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.452 -0.78 . . . . 0.0 109.604 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.612 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 19.5 tt0 -104.87 122.91 46.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.222 -0.923 . . . . 0.0 109.402 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.527 ' HE3' ' CG2' ' A' ' 74' ' ' VAL . 22.3 mtm -157.96 179.47 9.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.085 -1.009 . . . . 0.0 110.344 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.57 ' CG1' HD12 ' A' ' 36' ' ' LEU . 8.4 pt -94.72 129.01 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.463 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 37.0 ttm -77.83 146.22 35.85 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.255 -0.903 . . . . 0.0 110.131 -178.581 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.463 ' HB2' ' O ' ' A' ' 66' ' ' MET . 20.8 t-20 176.58 177.72 0.25 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.596 -0.69 . . . . 0.0 109.258 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -73.38 -42.5 62.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.159 -0.963 . . . . 0.0 109.284 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -76.48 -28.18 56.37 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.23 -0.919 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.575 ' CB ' ' CD1' ' A' ' 36' ' ' LEU . . . -74.55 -48.15 28.53 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.262 -0.899 . . . . 0.0 109.569 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.558 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 84.0 t80 -60.52 -45.66 93.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.227 -0.921 . . . . 0.0 109.57 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -67.4 -27.3 66.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.986 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.535 ' CE2' HD13 ' A' ' 33' ' ' ILE . 10.6 t80 -81.18 -41.59 22.12 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.078 -1.014 . . . . 0.0 109.897 -179.711 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.527 ' CG2' ' HE3' ' A' ' 64' ' ' MET . 14.6 p -69.57 -53.77 22.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.426 -0.796 . . . . 0.0 109.585 -179.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.509 ' N ' ' CG1' ' A' ' 74' ' ' VAL . 14.4 tpt85 -61.15 -11.15 7.89 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.128 -0.983 . . . . 0.0 109.825 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 73' ' ' PHE . 91.4 p -92.77 4.5 53.67 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.169 -0.957 . . . . 0.0 109.963 -179.629 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.575 ' CG1' ' HB ' ' A' ' 80' ' ' VAL . 5.2 p -76.82 135.17 67.92 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.037 -1.039 . . . . 0.0 109.344 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.634 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 42.8 Cg_endo -65.18 140.66 65.92 Favored 'Trans proline' 0 C--O 1.214 -0.72 0 C-N-CA 122.672 2.248 . . . . 0.0 112.109 -179.532 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.634 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 38.5 m-85 89.55 -9.48 0.4 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.918 -0.489 . . . . 0.0 109.744 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.575 ' HB ' ' CG1' ' A' ' 77' ' ' VAL . 7.8 p -88.2 125.01 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.049 -1.032 . . . . 0.0 109.496 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 95.9 mmm -85.09 -26.42 26.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.108 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.531 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.23 -157.52 28.15 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.531 ' CD1' ' O ' ' A' ' 82' ' ' GLY . 14.5 m-85 -132.79 149.28 52.29 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -1.138 . . . . 0.0 109.459 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.474 ' CG1' ' O ' ' A' ' 84' ' ' VAL . 10.9 p -74.33 115.75 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.427 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.51 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.1 p -152.83 166.58 31.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.263 -0.898 . . . . 0.0 109.403 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.2 t -96.01 -29.96 13.84 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.282 -0.886 . . . . 0.0 109.393 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -130.59 -80.24 0.22 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.533 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -110.18 -136.25 7.3 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.558 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -31.81 150.37 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.526 -0.985 . . . . 0.0 110.245 -179.619 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.519 ' HG3' ' HB3' ' A' ' 83' ' ' PHE . 50.5 Cg_endo -69.36 159.05 55.19 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.967 2.445 . . . . 0.0 111.884 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 28.5 m -88.9 151.69 47.61 Favored Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.207 -0.933 . . . . 0.0 109.279 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.531 ' CB ' ' CE ' ' A' ' 6' ' ' LYS . 50.6 Cg_endo -70.45 145.75 54.01 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.686 2.258 . . . . 0.0 111.789 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.449 HG12 ' HG2' ' A' ' 98' ' ' MET . 3.6 t -79.74 129.71 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.182 -0.949 . . . . 0.0 109.169 179.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . 0.504 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.4 mttp -73.92 134.0 43.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.441 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.442 ' C ' ' O ' ' A' ' 94' ' ' LYS . 69.2 m-20 -42.63 -41.65 3.16 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -0.883 . . . . 0.0 109.463 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 56.6 ttt180 -54.6 -28.64 47.87 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.235 -0.915 . . . . 0.0 109.362 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.504 ' N ' ' O ' ' A' ' 94' ' ' LYS . 23.2 mm-40 -89.38 -28.39 19.81 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.558 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.505 ' O ' ' C ' ' A' ' 99' ' ' ARG . 33.6 mmm -84.14 -28.55 27.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.254 -0.904 . . . . 0.0 109.427 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.573 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.88 -53.89 1.42 Allowed Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.465 -0.772 . . . . 0.0 109.903 -179.913 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.573 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -69.65 -28.2 26.05 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.496 2.13 . . . . 0.0 111.707 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.484 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 29.2 mm -80.69 -42.63 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.262 -0.898 . . . . 0.0 109.317 179.667 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.502 ' HA ' ' HB2' ' A' ' 107' ' ' LEU . 0.9 OUTLIER -67.73 -40.13 84.23 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.311 -0.868 . . . . 0.0 109.214 179.76 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -63.77 -50.72 67.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.337 -0.852 . . . . 0.0 109.096 179.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.82 -36.46 70.23 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.387 -0.821 . . . . 0.0 109.366 179.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.484 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.29 -0.41 8.0 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.277 -0.889 . . . . 0.0 109.995 -179.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 77.38 8.75 87.07 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.508 HD11 ' N ' ' A' ' 107' ' ' LEU . 9.9 mp -74.94 -19.17 60.23 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -1.177 . . . . 0.0 109.509 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.937 . . . . 0.0 109.544 -179.934 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.603 ' CE2' ' HB3' ' A' ' 175' ' ' LYS . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.439 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 40.0 mttm -97.22 156.34 16.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.95 -1.094 . . . . 0.0 109.531 -179.652 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 11.0 p -58.39 138.6 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.469 -0.77 . . . . 0.0 109.938 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.99 -31.89 4.84 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.545 ' OD2' ' CD1' ' A' ' 123' ' ' PHE . 45.3 m-20 -48.92 160.33 0.2 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.3 -1.118 . . . . 0.0 109.552 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 2.3 ttp -97.25 127.29 43.08 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.33 -0.857 . . . . 0.0 109.026 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.547 ' CG1' HG12 ' A' ' 143' ' ' ILE . 33.9 m -128.84 146.25 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.115 -0.99 . . . . 0.0 109.834 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 140' ' ' ALA . 28.4 tttt -110.29 140.28 44.62 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.592 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.576 ' O ' ' CD1' ' A' ' 132' ' ' ILE . 74.6 mt -79.61 157.76 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.049 -1.032 . . . . 0.0 108.641 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.576 ' CD1' ' O ' ' A' ' 131' ' ' ILE . 0.6 OUTLIER -149.51 1.96 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.03 -1.043 . . . . 0.0 109.526 179.786 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.458 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 58.5 m -149.65 146.16 27.13 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.011 -1.055 . . . . 0.0 110.232 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.99 -167.05 16.78 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.346 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.08 -21.9 42.11 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 123.135 2.557 . . . . 0.0 112.524 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.542 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 97.2 m-85 -110.29 16.31 21.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.006 -1.059 . . . . 0.0 109.578 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.532 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 2.3 tt0 -43.29 143.94 0.78 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.235 -0.915 . . . . 0.0 109.641 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.532 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 26.9 m-20 72.73 28.12 2.14 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.459 -0.776 . . . . 0.0 110.234 179.406 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.525 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 1.3 t80 -117.82 128.77 55.18 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.115 -0.991 . . . . 0.0 109.444 179.739 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -76.53 131.54 39.03 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.157 -0.965 . . . . 0.0 109.746 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -139.53 165.77 25.72 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.492 ' N ' HG23 ' A' ' 155' ' ' VAL . 37.5 t -113.34 137.53 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -1.088 . . . . 0.0 109.063 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.547 HG12 ' CG1' ' A' ' 129' ' ' VAL . 14.7 mm -68.67 113.86 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.214 -0.929 . . . . 0.0 109.611 -179.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.91 -35.46 8.99 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.056 -1.027 . . . . 0.0 109.421 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -154.17 149.29 26.89 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.967 -1.083 . . . . 0.0 109.924 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.512 HG23 ' HG ' ' A' ' 153' ' ' LEU . 11.3 mt -126.16 128.46 71.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.418 -0.802 . . . . 0.0 109.332 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -110.4 101.73 49.31 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.533 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.586 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.47 172.81 13.5 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.621 2.214 . . . . 0.0 111.801 179.85 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.586 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.6 tt0 82.4 -20.48 0.35 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.405 -0.809 . . . . 0.0 109.795 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.472 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 96.6 mtt180 -129.99 -11.54 4.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.129 -0.982 . . . . 0.0 109.684 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.472 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 19.8 mt-30 70.12 48.53 0.52 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.222 -0.924 . . . . 0.0 109.438 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . 0.493 ' OE2' ' NZ ' ' A' ' 154' ' ' LYS . 53.9 tt0 -121.35 144.24 48.76 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.156 -0.965 . . . . 0.0 109.319 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.545 ' CD2' HG23 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -138.1 112.47 8.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.235 -0.916 . . . . 0.0 109.884 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . 0.493 ' NZ ' ' OE2' ' A' ' 152' ' ' GLU . 10.2 mttm -78.54 131.73 36.9 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.309 -0.869 . . . . 0.0 108.677 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.492 HG23 ' N ' ' A' ' 142' ' ' VAL . 9.2 p -123.2 151.98 27.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.235 -0.915 . . . . 0.0 109.517 -179.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.47 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 17.9 t-20 -98.18 112.3 24.32 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.357 -0.839 . . . . 0.0 109.648 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.525 ' CG2' ' O ' ' A' ' 164' ' ' THR . 3.2 m -93.15 139.88 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.254 -0.904 . . . . 0.0 109.291 179.701 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 53.1 m -98.46 88.65 4.18 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.08 -1.013 . . . . 0.0 109.701 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 2.0 mt -114.24 145.55 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.276 -0.89 . . . . 0.0 109.309 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.43 ' HD2' ' CE1' ' A' ' 56' ' ' PHE . 9.9 m-85 62.23 38.31 13.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.418 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.64 18.06 29.59 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 42.4 mtt-85 -130.1 156.49 44.45 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.171 -1.194 . . . . 0.0 109.553 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -96.68 130.09 43.97 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.364 -0.835 . . . . 0.0 109.55 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' THR . . . . . 0.525 ' O ' ' CG2' ' A' ' 157' ' ' VAL . 97.8 m -137.07 120.1 11.7 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.937 . . . . 0.0 109.76 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.47 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -71.1 137.28 31.26 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.712 2.275 . . . . 0.0 111.549 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.482 ' O ' HD22 ' A' ' 168' ' ' LEU . 2.6 p -128.41 147.24 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.168 -0.958 . . . . 0.0 109.878 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.468 ' N ' HG21 ' A' ' 166' ' ' VAL . 2.4 p -93.12 120.15 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.419 -0.801 . . . . 0.0 109.457 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.571 ' CD1' HG13 ' A' ' 173' ' ' VAL . 0.1 OUTLIER -141.84 167.14 22.86 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.322 -0.861 . . . . 0.0 110.585 -179.25 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.513 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 40.4 m170 -79.82 142.22 35.49 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 p -58.72 -36.82 62.39 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 O-C-N 121.256 -0.902 . . . . 0.0 109.048 179.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 19.8 m -75.34 -7.61 54.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.42 -0.8 . . . . 0.0 109.415 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.513 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 65.5 mt-10 -90.33 5.39 47.52 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.33 -0.856 . . . . 0.0 109.307 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.571 HG13 ' CD1' ' A' ' 168' ' ' LEU . 18.1 m -146.6 173.06 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.344 -0.848 . . . . 0.0 109.582 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.499 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 78.1 tt0 -142.08 168.56 19.45 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.3 -0.875 . . . . 0.0 109.132 179.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.603 ' HB3' ' CE2' ' A' ' 123' ' ' PHE . 42.0 mttt . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.766 -179.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.487 ' HG2' ' CG2' ' A' ' 65' ' ' ILE . 19.4 mttt . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 121.324 0.583 . . . . 0.0 109.491 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.517 ' CE ' ' HB3' ' A' ' 92' ' ' PRO . 28.0 mtpp -128.32 175.19 8.67 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.249 -0.907 . . . . 0.0 109.065 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.615 ' CZ3' ' CG2' ' A' ' 41' ' ' VAL . 63.7 m95 -112.91 124.19 52.05 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.19 -0.943 . . . . 0.0 109.149 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 67.3 m-85 -117.06 168.43 10.27 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.348 -0.845 . . . . 0.0 109.346 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.569 HD11 ' CD1' ' A' ' 160' ' ' PHE . 75.1 mt -110.5 109.72 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.193 -0.942 . . . . 0.0 109.017 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.534 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 12.8 p -86.35 143.96 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.21 -0.931 . . . . 0.0 109.547 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.53 HD12 ' CE1' ' A' ' 59' ' ' TYR . 0.5 OUTLIER -90.28 143.09 27.08 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.441 -0.787 . . . . 0.0 109.395 -179.932 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.454 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 2.4 p -154.19 174.92 14.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.405 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.433 ' O ' ' C ' ' A' ' 14' ' ' SER . 93.4 mtp -91.89 120.32 32.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.23 -0.919 . . . . 0.0 109.329 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 13' ' ' MET . 52.0 p -41.68 126.97 3.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.365 -0.835 . . . . 0.0 109.504 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.63 -19.98 35.22 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.424 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.0 m-85 -107.4 -13.9 14.99 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.266 -1.137 . . . . 0.0 109.632 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.461 ' HG2' ' CG2' ' A' ' 60' ' ' VAL . 95.1 mt-10 -43.08 -60.42 1.65 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.245 -0.909 . . . . 0.0 109.603 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 73.9 mm-40 -48.17 -34.35 9.87 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.13 -0.981 . . . . 0.0 109.523 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.468 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 56.9 mttp -76.32 -46.74 26.27 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.27 -0.894 . . . . 0.0 109.346 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 24.9 t -54.92 -47.58 75.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.308 -0.87 . . . . 0.0 109.472 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 79.0 tttt -59.42 -47.78 84.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.427 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -64.28 -34.89 79.16 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.303 -0.873 . . . . 0.0 109.448 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.581 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 32.6 m120 -66.53 -47.47 72.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.367 -0.833 . . . . 0.0 109.745 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.45 HG12 HG22 ' A' ' 77' ' ' VAL . 76.5 mt -55.71 -43.86 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.187 -0.946 . . . . 0.0 109.745 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -58.15 -44.8 88.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.156 -0.965 . . . . 0.0 109.901 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.3 mttt -74.92 -36.87 62.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.13 -0.981 . . . . 0.0 109.686 -179.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.521 ' HG2' ' CZ ' ' A' ' 73' ' ' PHE . 17.6 tttt -59.28 -30.62 68.44 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -0.929 . . . . 0.0 109.393 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.53 ' O ' ' N ' ' A' ' 32' ' ' GLY . 93.9 t -79.21 -30.15 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.195 -0.941 . . . . 0.0 109.413 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -65.82 -48.16 72.61 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.23 -0.919 . . . . 0.0 109.563 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.97 -34.63 75.07 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 109.859 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.492 HG21 ' CG1' ' A' ' 33' ' ' ILE . 9.6 t -92.56 -21.73 19.92 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 68.27 33.1 77.15 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.527 HD13 HG21 ' A' ' 33' ' ' ILE . 47.9 mm -100.43 91.49 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.245 -1.15 . . . . 0.0 109.598 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -98.54 2.91 47.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.318 -0.864 . . . . 0.0 109.5 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.46 ' O ' HD13 ' A' ' 65' ' ' ILE . 89.8 m-20 -105.39 9.97 33.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.22 -0.925 . . . . 0.0 109.477 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.479 ' HB2' ' CG2' ' A' ' 33' ' ' ILE . 4.1 mm? -114.24 -46.69 2.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.936 . . . . 0.0 109.473 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 58.7 t -105.34 134.24 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.247 -0.908 . . . . 0.0 109.41 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -98.93 -131.27 7.22 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 46.3 mtt85 -91.93 142.02 28.01 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.265 -1.138 . . . . 0.0 109.522 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.441 ' CG2' HG12 ' A' ' 62' ' ' VAL . 53.6 mt -98.66 133.88 39.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.267 -0.896 . . . . 0.0 109.305 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.615 ' CG2' ' CZ3' ' A' ' 7' ' ' TRP . 40.1 t -115.97 155.38 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.253 -0.904 . . . . 0.0 109.495 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.408 ' CG2' HG13 ' A' ' 44' ' ' ILE . 18.2 mt -133.01 126.84 19.85 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.22 -0.925 . . . . 0.0 109.525 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.514 ' O ' ' CD1' ' A' ' 55' ' ' LEU . 46.9 Cg_endo -68.18 -4.75 13.27 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.725 2.284 . . . . 0.0 111.722 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.569 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 20.7 mt . . . . . 0 N--CA 1.489 1.52 0 O-C-N 121.209 -0.932 . . . . 0.0 109.459 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.569 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 37.5 mttp . . . . . 0 N--CA 1.491 1.617 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.514 ' CD1' ' O ' ' A' ' 43' ' ' PRO . 8.6 mt -61.31 -23.37 65.66 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.117 -0.99 . . . . 0.0 109.563 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.49 ' CD1' ' O ' ' A' ' 55' ' ' LEU . 42.6 m-85 -151.06 100.18 3.05 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.167 -0.958 . . . . 0.0 109.069 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -66.17 141.91 65.16 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.672 2.248 . . . . 0.0 111.906 -179.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.402 ' N ' ' OE2' ' A' ' 17' ' ' GLU . . . 75.26 -12.26 7.43 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.53 ' CE1' HD12 ' A' ' 11' ' ' LEU . 3.5 m-30 -103.38 130.9 50.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.789 -1.418 . . . . 0.0 109.942 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.534 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 3.0 t -132.49 146.24 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.694 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 14.9 m-85 -107.04 122.9 47.37 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.892 -1.13 . . . . 0.0 109.952 -179.391 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.441 HG12 ' CG2' ' A' ' 40' ' ' ILE . 30.0 m -129.77 139.94 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.43 -0.794 . . . . 0.0 109.48 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.497 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 48.3 tt0 -88.63 124.47 34.1 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.235 -0.916 . . . . 0.0 108.676 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.493 ' SD ' ' CG2' ' A' ' 74' ' ' VAL . 3.9 mtm -147.0 160.68 42.07 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.013 -1.054 . . . . 0.0 110.784 -178.78 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.487 ' CG2' ' HG2' ' A' ' 5' ' ' LYS . 26.9 pt -104.28 139.67 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' MET . . . . . . . . . . . . . 38.3 mtp -74.33 136.45 42.55 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.971 -1.081 . . . . 0.0 110.16 -178.432 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.437 ' HB3' ' HB3' ' A' ' 70' ' ' ALA . 35.8 t30 -178.47 155.3 0.85 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -61.78 -42.46 99.02 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.183 -0.948 . . . . 0.0 109.807 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 54.6 mt-10 -75.76 -25.23 56.29 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.852 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.437 ' HB3' ' HB3' ' A' ' 67' ' ' ASN . . . -78.05 -47.19 18.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.122 -0.987 . . . . 0.0 109.578 -179.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.575 ' CE1' ' OE1' ' A' ' 89' ' ' GLN . 65.1 t80 -61.93 -45.35 94.09 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.289 -0.882 . . . . 0.0 109.926 -179.674 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 48.2 t-20 -70.25 -29.3 66.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.096 -1.002 . . . . 0.0 110.381 -179.348 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.521 ' CZ ' ' HG2' ' A' ' 27' ' ' LYS . 83.8 t80 -76.84 -39.51 50.96 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.966 -1.084 . . . . 0.0 109.55 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.593 ' CG1' ' N ' ' A' ' 75' ' ' ARG . 2.4 p -75.48 -48.66 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.352 -0.843 . . . . 0.0 109.516 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.593 ' N ' ' CG1' ' A' ' 74' ' ' VAL . 0.0 OUTLIER -58.64 -21.09 52.91 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.212 -0.93 . . . . 0.0 109.86 -179.689 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.6 m -95.9 5.53 51.03 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.116 -0.99 . . . . 0.0 109.837 -179.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.639 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 3.6 p -68.26 132.93 91.48 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.05 -1.031 . . . . 0.0 109.301 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.743 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 44.3 Cg_endo -65.87 136.07 43.75 Favored 'Trans proline' 0 C--O 1.213 -0.763 0 C-N-CA 122.821 2.347 . . . . 0.0 112.369 -179.294 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.743 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 76.3 m-85 91.17 -6.89 0.26 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.95 -0.469 . . . . 0.0 109.844 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.639 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.1 t -98.0 135.93 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.928 -1.107 . . . . 0.0 109.309 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 88.9 mmm -96.6 -24.6 15.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.294 -0.879 . . . . 0.0 109.704 -179.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.55 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 159.89 -159.88 31.05 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.55 ' CD1' ' C ' ' A' ' 82' ' ' GLY . 9.4 m-85 -137.44 148.22 45.95 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.322 -1.105 . . . . 0.0 109.519 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.438 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 9.2 p -72.58 128.12 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.232 -0.918 . . . . 0.0 109.387 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.537 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 5.0 p -160.66 166.09 29.45 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.55 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 m -91.27 -30.27 16.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.296 -0.877 . . . . 0.0 109.164 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -134.17 -83.47 0.2 Allowed Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.531 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -102.88 -137.7 9.65 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.575 ' OE1' ' CE1' ' A' ' 71' ' ' TYR . 0.3 OUTLIER -32.79 154.66 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.566 -0.961 . . . . 0.0 110.15 -179.53 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.537 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 46.6 Cg_endo -67.58 151.05 80.03 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.83 2.353 . . . . 0.0 111.946 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.3 m -83.26 151.68 63.28 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.517 ' HB3' ' CE ' ' A' ' 6' ' ' LYS . 51.2 Cg_endo -70.24 144.5 51.63 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.632 2.221 . . . . 0.0 111.796 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.458 HG13 ' HG3' ' A' ' 98' ' ' MET . 21.4 t -82.0 127.21 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.191 -0.943 . . . . 0.0 109.301 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -67.78 140.37 56.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.242 -0.911 . . . . 0.0 109.417 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -49.76 -40.83 42.39 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.47 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 39.2 ttm180 -57.4 -30.47 64.94 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.309 -0.87 . . . . 0.0 109.569 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 52.7 mt-10 -85.8 -27.79 24.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.156 -0.965 . . . . 0.0 109.493 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.58 ' HE3' ' CD1' ' A' ' 7' ' ' TRP . 93.2 mtp -82.33 -25.82 33.54 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.286 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.593 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 2.4 mtt180 -37.11 -52.65 2.14 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.434 -0.791 . . . . 0.0 109.935 -179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.1 Cg_endo -69.78 -28.79 24.7 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.499 2.133 . . . . 0.0 111.897 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.443 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 38.2 mm -81.47 -43.08 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.206 -0.934 . . . . 0.0 109.56 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.532 HD12 ' CB ' ' A' ' 98' ' ' MET . 0.9 OUTLIER -66.76 -39.91 88.04 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 0.0 109.264 179.819 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 48.2 mtt-85 -64.06 -49.95 70.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.341 -0.849 . . . . 0.0 109.104 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.1 tt -72.09 -35.81 69.31 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.268 -0.895 . . . . 0.0 109.231 179.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.443 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.53 -2.01 12.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.352 -0.842 . . . . 0.0 109.897 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.83 10.43 84.98 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.706 -1.358 . . . . 0.0 109.706 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.588 ' CD1' ' CG2' ' A' ' 41' ' ' VAL . 18.5 mt -78.18 -21.51 50.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.212 -1.17 . . . . 0.0 109.542 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.654 -179.931 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 22.9 mttt -141.5 162.62 35.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.318 -0.864 . . . . 0.0 109.534 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.467 ' HA ' HG22 ' A' ' 143' ' ' ILE . 15.2 m -61.4 141.62 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.747 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 86.85 -33.81 3.68 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.424 ' O ' HG13 ' A' ' 142' ' ' VAL . 27.8 m-20 -47.96 158.74 0.21 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.351 -1.088 . . . . 0.0 109.198 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.3 ttm -100.94 128.5 46.95 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.084 -1.01 . . . . 0.0 108.752 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.54 ' CG1' HG12 ' A' ' 143' ' ' ILE . 16.0 m -129.22 144.8 37.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.337 -0.852 . . . . 0.0 109.878 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.471 ' O ' HG11 ' A' ' 173' ' ' VAL . 10.6 tttp -97.93 140.64 31.98 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.406 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.54 HG23 ' HA ' ' A' ' 137' ' ' GLU . 1.2 mp -80.72 153.55 4.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.353 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.536 ' N ' HG22 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -149.3 2.45 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 120.793 -1.192 . . . . 0.0 109.841 -179.791 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' SER . . . . . 0.534 ' CB ' ' HG3' ' A' ' 172' ' ' GLU . 61.1 m -149.25 145.35 27.05 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.004 -1.06 . . . . 0.0 110.212 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 103.46 -166.74 16.18 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.509 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 48.3 Cg_endo -68.41 -21.12 41.17 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.199 2.599 . . . . 0.0 112.53 -179.614 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.509 ' CD1' ' HG2' ' A' ' 135' ' ' PRO . 92.3 m-85 -108.35 18.72 20.7 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.907 -1.121 . . . . 0.0 109.377 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.54 ' HA ' HG23 ' A' ' 131' ' ' ILE . 3.7 tt0 -42.61 140.61 1.23 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.261 -0.899 . . . . 0.0 109.711 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.532 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 22.4 m-20 72.67 29.79 1.93 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.406 -0.809 . . . . 0.0 110.727 179.147 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.611 ' CE1' HG21 ' A' ' 157' ' ' VAL . 1.2 t80 -117.85 133.27 56.09 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.838 -1.164 . . . . 0.0 109.399 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.92 134.75 36.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.213 -0.93 . . . . 0.0 109.724 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.437 ' HA3' HG21 ' A' ' 155' ' ' VAL . . . -145.47 169.68 26.98 Favored Glycine 0 N--CA 1.491 2.306 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.329 -179.641 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.48 ' N ' ' CG2' ' A' ' 155' ' ' VAL . 43.6 t -119.43 136.4 56.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.567 -0.96 . . . . 0.0 109.281 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.54 HG12 ' CG1' ' A' ' 129' ' ' VAL . 31.7 mm -68.82 119.58 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.63 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . 0.456 ' HD2' ' OD1' ' A' ' 156' ' ' ASN . 63.9 tttt -99.81 -33.26 10.63 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.054 -1.029 . . . . 0.0 109.527 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -154.32 149.48 26.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.123 -0.986 . . . . 0.0 109.656 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.575 ' CG2' ' CD2' ' A' ' 153' ' ' LEU . 3.6 mt -123.9 126.55 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.321 -0.862 . . . . 0.0 109.575 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.22 102.39 46.25 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.239 -0.913 . . . . 0.0 109.589 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.0 Cg_endo -71.99 170.96 17.66 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.749 2.299 . . . . 0.0 111.866 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.3 mt-10 79.44 -21.23 0.34 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.395 -0.815 . . . . 0.0 110.057 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.463 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 75.6 mtt-85 -125.74 -14.99 6.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.063 -1.023 . . . . 0.0 109.478 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.463 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 50.8 mt-30 69.56 48.64 0.6 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.187 -0.946 . . . . 0.0 109.67 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . 0.472 ' O ' HD22 ' A' ' 153' ' ' LEU . 82.5 tt0 -119.07 143.25 47.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.174 -0.954 . . . . 0.0 108.968 179.626 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.575 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 32.3 mt -128.77 127.55 42.22 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.1 -1.0 . . . . 0.0 110.291 -179.469 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -92.03 128.67 37.96 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.077 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.59 ' CG1' ' CG1' ' A' ' 166' ' ' VAL . 12.9 p -131.39 147.93 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.084 -1.01 . . . . 0.0 109.834 -179.496 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.535 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.8 m120 -100.85 125.09 47.35 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.413 -0.804 . . . . 0.0 109.552 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.611 HG21 ' CE1' ' A' ' 139' ' ' PHE . 3.3 p -105.74 144.8 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.921 . . . . 0.0 109.476 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' THR . . . . . 0.402 ' N ' HG22 ' A' ' 157' ' ' VAL . 55.7 m -97.33 92.48 6.0 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.895 . . . . 0.0 109.928 -179.664 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.532 ' CD1' HG11 ' A' ' 157' ' ' VAL . 7.4 mt -116.03 142.96 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.258 -0.901 . . . . 0.0 109.237 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.694 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 91.0 m-85 61.88 37.15 15.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.185 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.6 17.92 35.79 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 26.2 mtp180 -126.88 157.39 39.48 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.067 -1.254 . . . . 0.0 109.555 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -100.91 132.03 46.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.277 -0.889 . . . . 0.0 109.728 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.2 m -142.47 127.06 10.02 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.37 -0.831 . . . . 0.0 109.743 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.1 Cg_endo -70.91 136.67 30.48 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.748 2.299 . . . . 0.0 111.616 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.59 ' CG1' ' CG1' ' A' ' 155' ' ' VAL . 11.7 p -119.64 164.65 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.087 -1.008 . . . . 0.0 109.706 -179.817 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.471 ' O ' HD23 ' A' ' 168' ' ' LEU . 6.7 m -117.53 117.65 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.459 -0.776 . . . . 0.0 109.66 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.479 HD23 HG22 ' A' ' 166' ' ' VAL . 0.2 OUTLIER -142.24 167.33 22.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.241 -0.912 . . . . 0.0 110.207 -179.779 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.483 ' HB2' ' CD ' ' A' ' 172' ' ' GLU . 19.2 m170 -82.7 146.37 29.08 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 171' ' ' SER . 7.1 p -56.32 -32.73 36.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 121.422 -0.798 . . . . 0.0 109.314 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.401 ' N ' HG12 ' A' ' 170' ' ' VAL . 73.5 p -76.86 -7.06 54.79 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.275 -0.891 . . . . 0.0 109.762 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.534 ' HG3' ' CB ' ' A' ' 133' ' ' SER . 0.8 OUTLIER -95.53 2.8 54.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.067 -1.021 . . . . 0.0 109.376 -179.991 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.506 HG12 ' N ' ' A' ' 174' ' ' GLU . 43.5 t -139.78 164.84 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 109.281 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.521 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 54.8 tt0 -141.22 167.16 22.85 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.087 -1.008 . . . . 0.0 108.928 179.73 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.521 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 32.7 tttp . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.058 -1.027 . . . . 0.0 109.476 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.469 ' O ' ' HD3' ' A' ' 6' ' ' LYS . 27.5 mttt . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.331 0.586 . . . . 0.0 109.61 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.567 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 36.0 mmtm -132.07 169.26 16.62 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.355 -0.841 . . . . 0.0 109.339 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.633 ' CD2' ' HB2' ' A' ' 63' ' ' GLU . 68.1 m95 -103.39 129.21 50.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.255 -0.903 . . . . 0.0 109.235 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -118.47 170.33 9.02 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.22 -0.925 . . . . 0.0 109.143 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.457 ' CD1' ' CE1' ' A' ' 160' ' ' PHE . 22.7 mt -103.85 112.78 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.122 -0.986 . . . . 0.0 109.268 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.518 HG12 ' N ' ' A' ' 11' ' ' LEU . 73.5 t -86.18 142.31 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.228 -0.92 . . . . 0.0 109.343 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.518 ' CD2' HG23 ' A' ' 84' ' ' VAL . 0.6 OUTLIER -93.45 142.04 27.78 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.363 -0.836 . . . . 0.0 109.416 179.904 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.0 t -160.44 -173.33 3.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.431 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.426 ' O ' ' C ' ' A' ' 14' ' ' SER . 89.1 mtp -109.18 122.46 47.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.213 -0.93 . . . . 0.0 109.47 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.426 ' C ' ' O ' ' A' ' 13' ' ' MET . 2.2 m -44.3 133.87 5.26 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.259 -0.901 . . . . 0.0 109.443 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.0 -21.37 36.09 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -113.01 -7.99 13.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.25 -1.147 . . . . 0.0 109.355 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.466 ' OE1' HD13 ' A' ' 44' ' ' ILE . 57.3 mt-10 -48.12 -59.96 2.99 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.212 -0.93 . . . . 0.0 109.442 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -45.7 -34.57 3.64 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.187 -0.946 . . . . 0.0 109.37 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.46 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 25.1 mttt -73.68 -43.72 58.58 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.276 -0.89 . . . . 0.0 109.377 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.406 ' O ' HG12 ' A' ' 24' ' ' ILE . 92.4 t -56.76 -50.0 76.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.317 -0.864 . . . . 0.0 109.535 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . 0.404 ' HD2' HD11 ' A' ' 42' ' ' ILE . 24.8 tttt -56.24 -46.95 79.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.911 . . . . 0.0 109.145 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 69.7 tt0 -65.27 -38.81 91.44 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.341 -0.849 . . . . 0.0 109.433 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.529 ' O ' ' CB ' ' A' ' 27' ' ' LYS . 32.6 m120 -62.29 -43.12 99.56 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.241 -0.912 . . . . 0.0 110.045 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.554 ' CD1' ' CG2' ' A' ' 77' ' ' VAL . 49.4 mm -64.69 -44.99 96.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.127 -0.983 . . . . 0.0 109.738 -179.537 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -58.7 -46.91 86.24 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.164 -0.96 . . . . 0.0 109.96 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -82.27 -37.35 26.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.993 -1.067 . . . . 0.0 109.712 -179.724 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.529 ' CB ' ' O ' ' A' ' 23' ' ' ASN . 28.2 tttm -57.22 -30.36 64.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.283 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.579 ' CG2' ' O ' ' A' ' 33' ' ' ILE . 12.3 p -85.43 -26.38 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.296 -0.878 . . . . 0.0 109.555 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.536 ' N ' HG11 ' A' ' 28' ' ' VAL . 44.2 tp10 -67.31 -47.45 70.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.324 -0.86 . . . . 0.0 109.716 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.67 -31.24 66.13 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.176 -0.952 . . . . 0.0 109.548 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 58.8 p -90.06 -21.66 22.21 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.916 . . . . 0.0 109.575 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 78.03 -2.92 63.2 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.579 ' O ' ' CG2' ' A' ' 28' ' ' VAL . 31.2 mm -72.71 71.33 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -1.123 . . . . 0.0 109.268 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 32.5 pttt -85.87 13.79 6.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.279 -0.888 . . . . 0.0 109.453 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.427 ' O ' HD11 ' A' ' 65' ' ' ILE . 29.7 m120 -110.37 -9.57 14.62 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.22 -0.925 . . . . 0.0 109.414 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.563 ' CD1' ' CB ' ' A' ' 70' ' ' ALA . 3.8 mm? -92.1 -51.5 5.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.309 -0.869 . . . . 0.0 109.297 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.7 p -92.03 141.89 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 108.956 179.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.96 -119.01 2.91 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 56.3 mtt180 -97.52 139.54 33.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.33 -1.1 . . . . 0.0 110.142 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.534 ' CG2' HG11 ' A' ' 62' ' ' VAL . 75.4 mt -111.55 134.34 54.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.427 -0.796 . . . . 0.0 109.088 179.522 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.633 ' CG2' ' CZ3' ' A' ' 7' ' ' TRP . 29.8 m -123.8 148.77 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.005 -1.059 . . . . 0.0 109.311 179.803 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.466 HG23 HD13 ' A' ' 44' ' ' ILE . 1.8 mt -129.69 131.77 23.77 Favored Pre-proline 0 C--N 1.302 -1.486 0 O-C-N 121.346 -0.846 . . . . 0.0 109.703 -179.405 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.588 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 42.3 Cg_endo -64.61 -4.5 8.47 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.856 2.371 . . . . 0.0 111.285 179.7 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.672 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 39.5 mt . . . . . 0 N--CA 1.49 1.543 0 O-C-N 121.459 -0.776 . . . . 0.0 109.519 179.589 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.672 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.588 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 14.3 tp -55.4 -47.69 75.5 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.007 -1.058 . . . . 0.0 109.152 179.723 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.583 ' CE2' ' HG ' ' A' ' 55' ' ' LEU . 75.3 m-85 -130.56 106.08 15.76 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.35 -0.844 . . . . 0.0 108.79 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -64.11 144.46 87.22 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.627 2.218 . . . . 0.0 112.022 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.15 -20.21 2.62 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 110.56 -1.016 . . . . 0.0 110.56 179.516 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.5 m-30 -98.05 129.71 44.89 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.569 -1.548 . . . . 0.0 110.626 -178.789 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 59.8 t -131.61 143.34 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.694 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 27.2 m-85 -104.58 129.27 52.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.879 -1.138 . . . . 0.0 110.137 -179.041 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.534 HG11 ' CG2' ' A' ' 40' ' ' ILE . 34.5 m -138.99 149.44 23.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.329 -0.857 . . . . 0.0 109.849 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.633 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 83.9 tt0 -113.79 130.14 56.49 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.319 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' MET . . . . . . . . . . . . . 61.4 mtm -151.32 160.83 43.58 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.858 -1.151 . . . . 0.0 111.184 -178.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.495 ' CD1' HD13 ' A' ' 36' ' ' LEU . 1.4 pt -80.87 125.61 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.44 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.415 ' O ' ' CG ' ' A' ' 67' ' ' ASN . 50.5 ttm -77.24 142.7 39.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.191 -0.943 . . . . 0.0 110.115 -178.533 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.415 ' CG ' ' O ' ' A' ' 66' ' ' MET . 7.6 m-20 176.2 168.47 0.44 Allowed 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -65.85 -40.52 91.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.069 -1.019 . . . . 0.0 109.578 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -75.97 -34.31 59.8 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.93 . . . . 0.0 109.858 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.563 ' CB ' ' CD1' ' A' ' 36' ' ' LEU . . . -71.76 -48.36 47.34 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.209 -0.932 . . . . 0.0 109.733 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.587 ' CG ' ' OE1' ' A' ' 89' ' ' GLN . 83.4 t80 -60.79 -44.44 96.82 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.946 -179.574 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -69.97 -26.14 63.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -0.942 . . . . 0.0 110.037 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -80.11 -36.07 35.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.074 -1.016 . . . . 0.0 109.849 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.524 ' CG2' ' O ' ' A' ' 70' ' ' ALA . 3.3 t -67.58 -56.28 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.224 -0.923 . . . . 0.0 109.976 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -47.46 -37.02 10.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.063 -1.023 . . . . 0.0 110.211 -179.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 m -70.95 2.99 3.67 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.015 -1.053 . . . . 0.0 110.419 -179.37 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.604 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 38.8 t -64.12 134.6 96.0 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 120.941 -1.099 . . . . 0.0 109.237 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.521 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 47.5 Cg_endo -67.85 135.55 35.72 Favored 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 122.715 2.277 . . . . 0.0 111.987 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.521 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 17.3 m-85 78.45 -5.05 2.1 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.432 -0.792 . . . . 0.0 109.712 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.604 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.7 t -85.11 123.96 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.054 -1.029 . . . . 0.0 109.296 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' MET . . . . . 0.457 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 66.0 mtp -82.4 -30.68 30.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.335 -0.853 . . . . 0.0 109.343 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.411 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.11 -157.34 27.97 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.484 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 7.9 m-85 -133.64 137.42 45.39 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.258 -1.143 . . . . 0.0 109.5 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.518 HG23 ' CD2' ' A' ' 11' ' ' LEU . 38.2 t -60.11 131.69 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.894 . . . . 0.0 109.48 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.529 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.7 OUTLIER -168.98 159.81 9.6 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.191 -0.943 . . . . 0.0 109.562 179.995 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.58 -35.46 16.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.307 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.58 -85.16 0.58 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.576 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -108.78 -134.08 7.05 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.303 -1.519 . . . . 0.0 109.303 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.587 ' OE1' ' CG ' ' A' ' 71' ' ' TYR . 0.3 OUTLIER -26.55 145.01 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.593 -0.945 . . . . 0.0 110.551 -179.533 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.529 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.4 Cg_endo -69.31 146.45 63.01 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.896 2.398 . . . . 0.0 111.991 -179.746 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.3 m -80.83 149.2 66.82 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.391 -0.818 . . . . 0.0 109.277 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.71 145.71 58.28 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.666 2.244 . . . . 0.0 111.78 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.469 HG13 ' HG2' ' A' ' 98' ' ' MET . 2.9 t -65.4 144.62 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.196 -0.94 . . . . 0.0 109.382 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.4 mttm -82.29 133.16 35.23 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.177 -0.952 . . . . 0.0 109.411 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.403 ' C ' ' O ' ' A' ' 94' ' ' LYS . 90.8 m-20 -45.99 -44.76 15.29 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.201 -0.937 . . . . 0.0 109.314 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 96' ' ' ARG . 34.4 ttm180 -58.51 -18.24 27.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.574 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.464 ' N ' ' O ' ' A' ' 94' ' ' LYS . 26.5 mt-10 -100.65 -26.45 13.81 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.24 -0.912 . . . . 0.0 109.571 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.524 ' O ' ' C ' ' A' ' 99' ' ' ARG . 50.1 mmm -78.37 -34.61 48.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.939 . . . . 0.0 109.334 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.561 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 2.5 mtt180 -33.45 -54.58 0.71 Allowed Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.588 -0.695 . . . . 0.0 110.228 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.561 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.1 Cg_endo -69.8 -29.46 23.63 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.55 2.167 . . . . 0.0 112.219 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.585 HG23 ' CD2' ' A' ' 61' ' ' PHE . 19.9 mm -78.7 -44.83 25.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.098 -1.001 . . . . 0.0 109.886 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.479 ' HA ' HD11 ' A' ' 107' ' ' LEU . 1.0 OUTLIER -62.83 -43.02 99.9 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.111 -0.993 . . . . 0.0 109.705 -179.877 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.406 ' NH2' ' NH2' ' A' ' 99' ' ' ARG . 46.3 mtt180 -62.3 -52.73 62.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -71.46 -37.59 71.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.393 -0.817 . . . . 0.0 109.279 179.736 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -67.87 -3.97 11.33 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.358 -0.838 . . . . 0.0 109.952 -179.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 78.09 5.24 87.01 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.568 ' CD2' HG13 ' A' ' 41' ' ' VAL . 61.6 mt -71.46 -19.69 62.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -1.148 . . . . 0.0 109.657 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 83.9 mt-10 . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.223 -0.923 . . . . 0.0 109.517 -179.961 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.587 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 22.0 m-30 . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 39.5 mttm -130.16 157.35 42.68 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 0.0 109.688 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.458 ' HA ' HG22 ' A' ' 143' ' ' ILE . 13.6 p -62.13 148.94 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.329 -0.857 . . . . 0.0 109.494 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.48 -30.37 3.1 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.666 -1.373 . . . . 0.0 109.666 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -50.57 164.22 0.14 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.189 -1.183 . . . . 0.0 109.217 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.0 ttm -99.6 129.58 45.76 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.15 -0.969 . . . . 0.0 109.011 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.574 ' CG1' ' CD1' ' A' ' 143' ' ' ILE . 25.1 m -128.67 145.67 35.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.302 -0.874 . . . . 0.0 109.948 -179.836 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . 0.445 ' HG3' ' O ' ' A' ' 139' ' ' PHE . 26.3 tttp -110.47 145.05 38.34 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.588 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.574 HG21 ' N ' ' A' ' 132' ' ' ILE . 64.7 mt -78.75 156.5 4.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.035 -1.041 . . . . 0.0 108.544 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.574 ' N ' HG21 ' A' ' 131' ' ' ILE . 0.7 OUTLIER -148.57 -3.98 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.131 -0.98 . . . . 0.0 108.966 179.54 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.4 m -148.67 146.42 28.15 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.339 -0.851 . . . . 0.0 110.11 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 104.55 -170.58 18.44 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.547 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 49.0 Cg_endo -68.97 -19.66 39.62 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 123.276 2.651 . . . . 0.0 112.508 -179.617 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.547 ' CD1' ' HG2' ' A' ' 135' ' ' PRO . 88.6 m-85 -109.09 9.41 26.25 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.975 -1.078 . . . . 0.0 109.747 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.56 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 0.7 OUTLIER -44.19 145.01 0.84 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 0.0 109.462 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.56 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 14.6 m-20 81.62 20.54 0.35 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.489 -0.757 . . . . 0.0 110.042 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.545 ' CZ ' ' HG3' ' A' ' 100' ' ' PRO . 0.9 OUTLIER -115.42 160.66 19.59 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.11 -0.993 . . . . 0.0 109.315 179.803 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.406 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -114.31 135.83 53.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.145 -0.972 . . . . 0.0 109.383 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.478 ' C ' ' CG2' ' A' ' 155' ' ' VAL . . . -147.98 169.88 28.69 Favored Glycine 0 N--CA 1.49 2.267 0 C-N-CA 119.655 -1.26 . . . . 0.0 110.181 -179.47 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.564 ' N ' ' CG2' ' A' ' 155' ' ' VAL . 94.8 t -109.89 134.46 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.62 -0.93 . . . . 0.0 109.319 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.574 ' CD1' ' CG1' ' A' ' 129' ' ' VAL . 67.8 mt -62.69 117.16 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.134 -0.979 . . . . 0.0 109.353 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . 0.419 ' HG2' ' HG2' ' A' ' 145' ' ' GLU . 16.8 tttp -97.99 -35.86 10.31 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.164 -0.96 . . . . 0.0 109.422 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . 0.419 ' HG2' ' HG2' ' A' ' 144' ' ' LYS . 72.3 mm-40 -151.59 146.63 25.98 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.095 -1.003 . . . . 0.0 109.462 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.527 HG22 ' CD1' ' A' ' 153' ' ' LEU . 1.8 mt -122.44 125.34 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.576 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.68 102.35 44.47 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.203 -0.935 . . . . 0.0 109.603 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.546 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.6 Cg_endo -73.5 171.94 16.72 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.752 2.301 . . . . 0.0 111.846 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.546 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.0 tt0 80.57 -21.45 0.32 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.423 -0.798 . . . . 0.0 110.074 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.435 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 44.0 mtt85 -126.17 -12.48 6.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.053 -1.029 . . . . 0.0 109.323 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.435 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 42.2 mt-30 68.47 49.8 0.75 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.325 -0.86 . . . . 0.0 109.676 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 69.0 tt0 -123.01 146.35 47.71 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.048 -1.032 . . . . 0.0 108.747 179.515 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.527 ' CD1' HG22 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -142.51 113.93 7.83 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.119 -0.988 . . . . 0.0 110.511 -179.276 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 27.1 mtmt -85.08 137.21 33.19 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.564 ' CG2' ' N ' ' A' ' 142' ' ' VAL . 1.8 p -136.72 133.19 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.007 -1.058 . . . . 0.0 110.034 -179.222 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.575 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.2 t-20 -67.02 125.95 27.62 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.396 -0.815 . . . . 0.0 109.689 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.541 ' CG2' HG13 ' A' ' 166' ' ' VAL . 43.7 t -107.59 147.46 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.275 -0.891 . . . . 0.0 109.057 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' THR . . . . . 0.461 ' O ' ' CG2' ' A' ' 158' ' ' THR . 9.4 t -97.4 112.18 24.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.343 -0.848 . . . . 0.0 109.986 -179.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.505 ' CG2' ' CD2' ' A' ' 160' ' ' PHE . 26.6 mt -138.17 137.29 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.357 -0.84 . . . . 0.0 109.183 179.298 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.694 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 99.7 m-85 60.86 42.34 13.29 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 108.963 -179.533 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.37 17.03 17.17 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.472 ' NH1' ' O ' ' A' ' 160' ' ' PHE . 22.5 mtt85 -126.49 147.55 49.81 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -1.184 . . . . 0.0 109.637 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 64.1 mm-40 -97.89 136.64 37.9 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 109.373 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' THR . . . . . 0.503 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 4.3 m -143.68 132.55 11.34 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.673 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.575 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 48.0 Cg_endo -68.88 131.21 21.98 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.792 2.328 . . . . 0.0 111.366 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.541 HG13 ' CG2' ' A' ' 157' ' ' VAL . 24.3 m -115.55 162.89 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.052 -1.03 . . . . 0.0 109.581 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.433 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 41.3 t -117.77 119.14 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.411 -0.806 . . . . 0.0 109.61 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.533 ' CD1' ' N ' ' A' ' 168' ' ' LEU . 0.0 OUTLIER -144.38 168.73 19.4 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.956 0.884 . . . . 0.0 110.503 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -80.65 139.41 36.22 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.434 HG12 ' N ' ' A' ' 171' ' ' SER . 7.9 p -53.7 -34.18 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.156 -0.965 . . . . 0.0 109.008 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.434 ' N ' HG12 ' A' ' 170' ' ' VAL . 54.0 p -75.54 -4.33 39.26 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.394 -0.816 . . . . 0.0 109.539 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -103.97 1.85 31.66 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.072 -1.017 . . . . 0.0 109.644 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 174' ' ' GLU . 49.5 t -131.35 162.99 38.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.146 -0.971 . . . . 0.0 109.626 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . 0.524 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 76.3 tt0 -139.3 159.62 41.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -0.9 . . . . 0.0 109.344 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.587 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 21.7 tttm . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.146 -0.971 . . . . 0.0 109.283 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.5 mttt . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.544 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 21.6 mtpp -130.45 176.18 8.36 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.229 -0.92 . . . . 0.0 109.256 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' TRP . . . . . 0.611 ' CG ' ' CE ' ' A' ' 98' ' ' MET . 39.7 m95 -109.67 124.11 50.63 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.236 -0.915 . . . . 0.0 109.126 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' TYR . . . . . 0.49 ' CE1' ' HE3' ' A' ' 66' ' ' MET . 95.4 m-85 -113.75 170.9 7.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.245 -0.909 . . . . 0.0 109.353 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.473 ' HB ' HG11 ' A' ' 84' ' ' VAL . 25.9 mt -119.2 106.84 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.232 -0.918 . . . . 0.0 109.417 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.555 ' CG2' HG21 ' A' ' 80' ' ' VAL . 0.2 OUTLIER -94.45 148.16 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.183 -0.948 . . . . 0.0 109.292 179.746 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.576 HD11 ' CE1' ' A' ' 59' ' ' TYR . 3.2 mm? -95.37 145.93 24.76 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.382 -0.824 . . . . 0.0 109.817 -179.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.9 p -147.78 -177.96 6.01 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.415 -0.803 . . . . 0.0 109.264 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' MET . . . . . 0.545 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 54.8 mtm -89.9 116.92 28.33 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.157 -0.964 . . . . 0.0 109.489 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 13' ' ' MET . 18.1 t -42.89 125.57 3.51 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.248 -0.908 . . . . 0.0 109.296 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.47 -19.09 40.28 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.129 -1.588 . . . . 0.0 109.129 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' TYR . . . . . 0.545 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.7 m-85 -107.33 -10.14 15.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.446 -1.031 . . . . 0.0 109.465 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . 0.487 ' O ' ' N ' ' A' ' 20' ' ' VAL . 93.9 mt-10 -45.47 -66.66 0.37 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.201 -0.937 . . . . 0.0 109.37 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . 0.409 ' C ' ' O ' ' A' ' 17' ' ' GLU . 94.8 mt-10 -44.05 -35.79 2.26 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 109.302 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.432 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 22.9 mttm -71.58 -31.35 66.86 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.214 -0.929 . . . . 0.0 109.344 179.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.489 ' O ' HG12 ' A' ' 24' ' ' ILE . 98.2 t -72.55 -45.47 58.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.224 -0.923 . . . . 0.0 109.356 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 28.8 tttm -55.82 -50.53 70.28 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.341 -0.849 . . . . 0.0 109.303 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -62.3 -37.33 85.12 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -0.895 . . . . 0.0 109.163 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.578 ' ND2' ' CG ' ' A' ' 78' ' ' PRO . 13.8 t-20 -62.23 -44.58 96.23 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.322 -0.861 . . . . 0.0 109.362 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.542 ' CG2' HG21 ' A' ' 37' ' ' VAL . 29.5 mm -56.11 -45.2 80.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 109.335 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -55.13 -45.46 75.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.229 -0.92 . . . . 0.0 109.657 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 46.7 mttp -76.17 -35.73 59.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.069 -1.02 . . . . 0.0 109.61 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.52 ' HD3' ' CG2' ' A' ' 77' ' ' VAL . 18.1 ttpt -55.07 -33.89 63.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.334 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 89.4 t -82.27 -24.44 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.288 -0.882 . . . . 0.0 109.601 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -67.85 -52.31 38.18 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.654 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.39 -27.12 65.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.249 -0.907 . . . . 0.0 109.933 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 47.4 p -97.58 -32.19 11.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.205 -0.934 . . . . 0.0 109.696 -179.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 79.44 24.01 61.7 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.527 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 62.8 mt -94.65 87.32 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.217 -1.166 . . . . 0.0 109.444 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -87.4 -5.37 58.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.215 -0.928 . . . . 0.0 109.455 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -102.14 16.46 26.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.269 -0.895 . . . . 0.0 109.628 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.545 HD11 ' CB ' ' A' ' 70' ' ' ALA . 7.2 tp -112.17 -58.12 2.18 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.263 -0.898 . . . . 0.0 109.4 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.542 HG21 ' CG2' ' A' ' 24' ' ' ILE . 9.0 p -95.87 134.35 33.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.427 -0.796 . . . . 0.0 109.423 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.21 -123.71 5.32 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 93.4 mtt180 -95.11 143.98 26.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.308 -1.113 . . . . 0.0 109.89 -179.473 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.527 ' CG2' HG23 ' A' ' 62' ' ' VAL . 18.9 mt -107.7 140.39 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.408 -0.807 . . . . 0.0 109.158 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.56 HG22 ' CH2' ' A' ' 7' ' ' TRP . 55.0 t -128.51 156.86 41.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.024 -1.048 . . . . 0.0 109.462 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.478 HG22 ' CG2' ' A' ' 44' ' ' ILE . 6.5 mt -136.72 127.19 16.23 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.367 -0.833 . . . . 0.0 109.469 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.488 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 46.3 Cg_endo -67.4 -4.71 12.37 Favored 'Trans proline' 0 C--O 1.216 -0.583 0 C-N-CA 122.824 2.349 . . . . 0.0 111.547 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.561 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 11.8 pt . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.248 -0.907 . . . . 0.0 109.474 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 24.5 mttt . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.488 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 14.5 tp -64.26 -23.73 67.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.161 -0.962 . . . . 0.0 109.132 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' PHE . . . . . 0.445 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 97.2 m-85 -149.96 99.0 3.31 Favored Pre-proline 0 N--CA 1.49 1.532 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -65.42 139.57 59.89 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.614 2.209 . . . . 0.0 111.979 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.07 -15.84 4.98 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.386 -1.085 . . . . 0.0 110.386 179.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.576 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.2 m-85 -95.73 129.87 42.81 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.759 -1.436 . . . . 0.0 110.205 -179.331 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 41.1 t -133.84 146.02 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.335 -0.853 . . . . 0.0 108.905 179.453 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.404 ' CE2' HG12 ' A' ' 9' ' ' ILE . 24.1 m-85 -110.31 122.47 47.76 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.955 -1.09 . . . . 0.0 109.521 -179.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.527 HG23 ' CG2' ' A' ' 40' ' ' ILE . 96.1 t -128.48 140.97 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.427 -0.795 . . . . 0.0 109.936 -179.632 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.58 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 67.6 tt0 -103.5 123.49 46.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.315 -0.865 . . . . 0.0 108.864 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.549 ' CG ' ' C ' ' A' ' 63' ' ' GLU . 1.1 mtp -162.66 -174.61 4.04 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.102 -0.999 . . . . 0.0 109.778 -179.545 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.504 HG13 ' O ' ' A' ' 65' ' ' ILE . 17.2 pt -97.26 122.95 49.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.236 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' MET . . . . . 0.49 ' HE3' ' CE1' ' A' ' 8' ' ' TYR . 11.1 ttm -88.16 100.31 12.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -0.885 . . . . 0.0 109.736 -179.406 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -137.92 -165.75 1.84 Allowed 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.195 -0.941 . . . . 0.0 108.821 179.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -71.41 -48.72 47.96 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.14 -0.975 . . . . 0.0 109.681 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.403 ' O ' ' C ' ' A' ' 70' ' ' ALA . 73.9 mm-40 -66.64 -58.63 4.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.188 -0.945 . . . . 0.0 109.5 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.545 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -43.85 -41.51 5.14 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.293 -0.879 . . . . 0.0 109.718 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.541 ' CD1' ' CD ' ' A' ' 89' ' ' GLN . 72.2 t80 -61.05 -57.14 13.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.163 -0.961 . . . . 0.0 109.627 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.499 ' O ' ' HB3' ' A' ' 76' ' ' SER . 38.2 t30 -52.87 -31.2 38.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.929 . . . . 0.0 110.0 -179.582 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -82.08 -44.15 16.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.96 -1.088 . . . . 0.0 109.923 -179.626 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.594 ' CG1' ' CZ ' ' A' ' 83' ' ' PHE . 47.6 t -68.49 -56.91 10.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.357 -0.84 . . . . 0.0 109.625 -179.64 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ARG . . . . . 0.449 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 15.6 tpt180 -62.5 -11.92 19.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.165 -0.959 . . . . 0.0 109.966 -179.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.499 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 89.6 p -102.28 3.53 38.23 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.081 -1.012 . . . . 0.0 110.167 -179.645 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.632 HG11 ' HB ' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -69.05 142.27 92.92 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.031 -1.043 . . . . 0.0 109.273 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.621 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 45.2 Cg_endo -67.75 134.51 32.75 Favored 'Trans proline' 0 C--O 1.213 -0.768 0 C-N-CA 122.454 2.103 . . . . 0.0 111.876 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.621 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 13.1 m-85 89.32 -6.55 0.42 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.799 -0.563 . . . . 0.0 110.255 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.632 ' HB ' HG11 ' A' ' 77' ' ' VAL . 12.4 p -88.33 126.98 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.752 -1.218 . . . . 0.0 109.643 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.4 mmm -90.78 -26.36 19.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.32 -0.863 . . . . 0.0 109.335 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . 0.57 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 161.47 -160.34 32.14 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . 0.594 ' CZ ' ' CG1' ' A' ' 74' ' ' VAL . 10.8 m-85 -134.76 156.38 48.94 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.191 -1.182 . . . . 0.0 109.562 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.517 ' N ' HD21 ' A' ' 11' ' ' LEU . 12.5 p -91.71 125.35 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.248 -0.908 . . . . 0.0 109.385 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.535 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.6 OUTLIER -168.87 166.79 11.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.13 -0.981 . . . . 0.0 109.568 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 25.5 t -86.18 -32.97 20.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.238 -0.914 . . . . 0.0 109.427 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -117.42 -106.82 2.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.516 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -96.67 -122.09 4.16 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' GLN . . . . . 0.541 ' CD ' ' CD1' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -34.55 156.11 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.533 -0.981 . . . . 0.0 110.044 -179.659 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.535 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.0 Cg_endo -68.75 149.21 72.91 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.839 2.359 . . . . 0.0 111.994 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.0 m -83.89 154.97 64.74 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 109.436 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.489 ' HB3' ' CE ' ' A' ' 6' ' ' LYS . 49.9 Cg_endo -70.16 142.94 47.46 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.677 2.251 . . . . 0.0 111.673 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 18.6 t -82.3 139.07 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.304 -0.873 . . . . 0.0 109.433 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' LYS . . . . . 0.467 ' O ' ' N ' ' A' ' 97' ' ' GLU . 7.3 tptt -70.74 131.78 44.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.182 -0.949 . . . . 0.0 109.289 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . 0.402 ' C ' ' O ' ' A' ' 94' ' ' LYS . 87.3 m-20 -45.22 -39.52 6.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.178 -0.952 . . . . 0.0 109.436 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.4 mtp180 -61.03 -23.45 65.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.308 -0.87 . . . . 0.0 109.475 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 94' ' ' LYS . 62.9 mt-10 -85.83 -28.38 24.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.913 . . . . 0.0 109.422 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' MET . . . . . 0.611 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 59.0 mtp -84.14 -24.8 30.07 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.365 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.575 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -37.46 -53.53 2.31 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.425 -0.797 . . . . 0.0 109.866 -179.952 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.575 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.4 Cg_endo -69.83 -27.55 25.98 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 122.525 2.15 . . . . 0.0 111.878 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.459 ' O ' ' HB2' ' A' ' 105' ' ' ALA . 37.4 mm -81.19 -42.94 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.178 -0.951 . . . . 0.0 109.304 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' LEU . . . . . 0.575 ' N ' HD11 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -65.8 -38.97 90.41 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.275 -0.891 . . . . 0.0 109.297 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.491 ' HD3' ' HB3' ' A' ' 135' ' ' PRO . 16.1 ttt-85 -65.66 -47.7 74.63 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.334 -0.854 . . . . 0.0 109.279 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 3.0 tt -72.12 -36.31 69.38 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.215 -0.928 . . . . 0.0 109.227 179.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.459 ' HB2' ' O ' ' A' ' 101' ' ' ILE . . . -75.25 -2.22 27.08 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.44 -0.788 . . . . 0.0 109.81 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.9 15.79 81.34 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.532 ' HB2' ' CA ' ' A' ' 102' ' ' LEU . 23.5 mt -81.84 -23.27 36.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.16 -1.2 . . . . 0.0 109.666 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' GLU . . . . . 0.43 ' HG2' ' HB3' ' A' ' 102' ' ' LEU . 68.2 mm-40 . . . . . 0 N--CA 1.491 1.581 0 O-C-N 121.158 -0.964 . . . . 0.0 109.327 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' PHE . . . . . 0.561 ' CD2' ' O ' ' A' ' 123' ' ' PHE . 42.5 p90 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' LYS . . . . . 0.528 ' HA ' ' CD1' ' A' ' 146' ' ' ILE . 14.7 mttp -141.14 175.12 9.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.181 -0.949 . . . . 0.0 109.918 -179.58 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . 0.44 ' HA ' HG21 ' A' ' 143' ' ' ILE . 10.8 p -62.51 139.62 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.529 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 88.13 -34.8 3.68 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . 0.457 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 9.5 m-20 -45.92 158.97 0.08 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.336 -1.096 . . . . 0.0 109.209 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.8 ttm -99.77 127.49 45.92 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.075 -1.016 . . . . 0.0 108.799 179.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.557 ' CG1' HG12 ' A' ' 143' ' ' ILE . 15.4 m -128.51 144.87 36.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.32 -0.862 . . . . 0.0 109.735 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 32.5 ttpt -98.78 141.06 32.05 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.464 ' CD1' ' HB3' ' A' ' 139' ' ' PHE . 78.5 mt -82.84 151.09 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.209 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' ILE . . . . . 0.482 HG12 ' HA ' ' A' ' 173' ' ' VAL . 1.1 pt -149.66 3.64 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 120.923 -1.111 . . . . 0.0 109.957 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 69.9 m -148.26 143.52 27.02 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.846 -1.159 . . . . 0.0 109.983 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.67 -163.9 18.7 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' PRO . . . . . 0.491 ' HB3' ' HD3' ' A' ' 103' ' ' ARG . 46.4 Cg_endo -67.38 -23.18 44.58 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 123.167 2.578 . . . . 0.0 112.952 -179.28 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.528 ' CE1' ' CB ' ' A' ' 100' ' ' PRO . 97.1 m-85 -109.14 19.38 19.55 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.787 -1.196 . . . . 0.0 109.713 -179.765 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' GLU . . . . . 0.526 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 2.3 tt0 -45.51 139.09 3.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.15 -0.969 . . . . 0.0 109.506 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.526 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 17.7 m-20 74.41 28.23 1.34 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.459 -0.776 . . . . 0.0 110.437 179.41 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' PHE . . . . . 0.575 ' CD1' HG11 ' A' ' 157' ' ' VAL . 1.8 t80 -117.08 140.01 50.02 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.96 -1.087 . . . . 0.0 109.45 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.74 132.94 34.04 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.116 -0.99 . . . . 0.0 109.664 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.464 ' HA3' HG22 ' A' ' 155' ' ' VAL . . . -145.57 168.91 27.23 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.775 -1.203 . . . . 0.0 110.304 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.56 ' N ' ' CG2' ' A' ' 155' ' ' VAL . 41.0 t -117.9 137.07 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.634 -0.921 . . . . 0.0 109.348 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' ILE . . . . . 0.557 HG12 ' CG1' ' A' ' 129' ' ' VAL . 25.0 mm -69.85 119.23 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.873 . . . . 0.0 109.532 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -97.76 -31.69 12.12 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.026 -1.046 . . . . 0.0 109.04 179.546 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -151.11 146.17 25.97 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.266 -0.896 . . . . 0.0 109.283 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.599 ' CG2' ' CD2' ' A' ' 153' ' ' LEU . 4.0 mt -121.58 126.21 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.141 -0.974 . . . . 0.0 109.545 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.92 100.08 38.13 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.449 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.4 Cg_endo -71.14 173.28 12.42 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.706 2.271 . . . . 0.0 111.821 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.2 tt0 79.52 -21.58 0.32 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.325 -0.86 . . . . 0.0 110.184 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' ARG . . . . . 0.459 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 83.9 mtt-85 -127.5 -12.77 5.53 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.045 -1.035 . . . . 0.0 109.6 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' GLN . . . . . 0.489 ' O ' ' CG2' ' A' ' 170' ' ' VAL . 49.8 mt-30 69.52 47.04 0.69 Allowed 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.348 -0.845 . . . . 0.0 109.704 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -118.21 143.85 46.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.08 -1.012 . . . . 0.0 108.659 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.599 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 35.3 mt -133.56 122.82 24.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.996 -1.065 . . . . 0.0 110.616 -179.38 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 9.5 mttt -86.55 130.93 34.31 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 178.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.578 HG21 ' N ' ' A' ' 156' ' ' ASN . 7.3 p -133.65 149.77 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.087 -1.008 . . . . 0.0 109.8 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.578 ' N ' HG21 ' A' ' 155' ' ' VAL . 43.3 t-20 -98.75 123.61 43.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.29 -0.881 . . . . 0.0 109.329 179.857 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' VAL . . . . . 0.575 HG11 ' CD1' ' A' ' 139' ' ' PHE . 63.9 t -105.39 146.86 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.198 -0.939 . . . . 0.0 109.663 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' THR . . . . . 0.428 ' N ' HG12 ' A' ' 157' ' ' VAL . 25.9 m -94.9 104.05 15.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.245 -0.91 . . . . 0.0 109.633 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' ILE . . . . . 0.563 HD11 ' CE2' ' A' ' 160' ' ' PHE . 7.0 pt -139.65 149.12 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -0.896 . . . . 0.0 109.38 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' PHE . . . . . 0.563 ' CE2' HD11 ' A' ' 159' ' ' ILE . 11.1 m-30 61.35 36.99 17.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.261 -0.899 . . . . 0.0 109.141 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.52 13.7 17.99 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' ARG . . . . . 0.434 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 3.3 mtp-105 -134.11 159.01 42.14 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.059 -1.259 . . . . 0.0 109.601 -179.844 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' GLU . . . . . 0.454 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 81.7 mt-10 -99.73 140.12 34.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.253 -0.905 . . . . 0.0 109.399 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' THR . . . . . 0.553 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 22.6 m -146.55 129.93 8.23 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.785 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' PRO . . . . . 0.546 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.7 Cg_endo -71.14 139.29 35.22 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.736 2.29 . . . . 0.0 111.437 179.676 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' VAL . . . . . 0.478 HG22 ' HG ' ' A' ' 168' ' ' LEU . 2.9 p -124.93 143.86 36.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.088 -1.007 . . . . 0.0 109.627 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.472 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 14.6 p -96.13 120.75 45.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.408 -0.807 . . . . 0.0 109.533 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' LEU . . . . . 0.499 HD13 ' N ' ' A' ' 168' ' ' LEU . 0.0 OUTLIER -141.4 168.71 19.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.113 -0.992 . . . . 0.0 110.54 -179.52 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' HIS . . . . . 0.465 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 72.1 m80 -83.19 143.26 30.59 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.648 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . 0.571 ' CG2' ' HG ' ' A' ' 153' ' ' LEU . 71.9 t -52.82 -38.39 27.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 84.6 p -75.23 -6.97 52.51 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.492 -0.755 . . . . 0.0 110.06 -179.466 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' GLU . . . . . 0.465 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 80.4 mt-10 -91.12 -5.46 55.06 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.828 -1.17 . . . . 0.0 109.822 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' VAL . . . . . 0.482 ' HA ' HG12 ' A' ' 132' ' ' ILE . 2.8 m -139.48 175.36 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.152 -0.967 . . . . 0.0 109.439 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 57.5 tt0 -138.17 163.03 32.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.196 -0.94 . . . . 0.0 109.045 179.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' LYS . . . . . 0.483 ' CE ' ' CB ' ' A' ' 123' ' ' PHE . 25.2 mmtm . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.088 -1.007 . . . . 0.0 109.246 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -57.23 -40.19 77.05 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.204 -1.174 . . . . 0.0 109.484 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 76.4 mtm -51.37 -44.04 62.02 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.17 -0.956 . . . . 0.0 109.522 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 15.0 mmtt -92.43 144.01 25.8 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.22 -0.925 . . . . 0.0 109.461 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 56.5 mttt -103.43 141.71 35.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.507 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.594 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.2 mttp -125.82 174.51 8.3 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.222 -0.924 . . . . 0.0 109.126 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.628 ' CG ' ' CE ' ' A' ' 98' ' ' MET . 60.0 m95 -109.9 126.66 54.11 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.132 -0.98 . . . . 0.0 109.346 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -118.74 167.39 11.72 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.211 -0.931 . . . . 0.0 109.415 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.51 HD12 ' CE1' ' A' ' 160' ' ' PHE . 95.1 mt -103.25 118.77 50.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.195 -0.94 . . . . 0.0 109.314 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.453 HG23 HG13 ' A' ' 62' ' ' VAL . 85.3 t -90.46 137.32 21.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.466 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.486 ' CD2' ' CG2' ' A' ' 84' ' ' VAL . 0.1 OUTLIER -89.62 141.75 28.31 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.276 -0.89 . . . . 0.0 109.245 179.875 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 58' ' ' GLY . 11.2 t -157.15 -172.48 4.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.23 -0.918 . . . . 0.0 109.358 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.473 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 90.9 mtp -105.56 123.62 48.2 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.2 -0.937 . . . . 0.0 109.516 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.422 ' C ' ' O ' ' A' ' 13' ' ' MET . 9.2 t -43.07 127.07 4.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.299 -0.875 . . . . 0.0 109.397 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.74 -19.85 40.5 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.473 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.2 m-85 -108.47 3.54 23.28 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.239 -1.153 . . . . 0.0 109.64 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.42 ' HG2' HG21 ' A' ' 12' ' ' THR . 98.4 mt-10 -57.92 -59.33 5.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -47.71 -38.11 14.53 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.218 -0.926 . . . . 0.0 109.403 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 24.7 mttt -68.8 -43.66 75.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.282 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.442 ' O ' HG13 ' A' ' 24' ' ' ILE . 89.6 t -58.96 -46.53 91.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 109.566 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.411 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.4 tttm -56.94 -49.8 74.55 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.219 -0.925 . . . . 0.0 109.548 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -64.83 -43.19 93.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.196 -0.94 . . . . 0.0 109.407 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.476 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 89.3 m-20 -54.92 -39.77 69.18 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.222 -0.924 . . . . 0.0 109.391 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.526 ' CG2' HD12 ' A' ' 40' ' ' ILE . 95.1 mt -65.62 -44.04 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.3 -0.875 . . . . 0.0 109.624 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -55.84 -48.22 75.86 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.07 -1.019 . . . . 0.0 109.947 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 42.9 mttm -78.41 -35.34 47.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.093 -1.004 . . . . 0.0 109.612 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.555 ' HG3' ' CE1' ' A' ' 73' ' ' PHE . 10.7 tptt -53.25 -33.0 51.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.247 -0.908 . . . . 0.0 109.13 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.48 HG13 ' O ' ' A' ' 33' ' ' ILE . 22.3 t -89.52 -19.89 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.342 -0.849 . . . . 0.0 109.287 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -72.64 -57.64 3.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.564 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.69 -29.9 66.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.895 . . . . 0.0 109.437 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.408 ' HB ' HG13 ' A' ' 33' ' ' ILE . 80.7 p -96.6 -3.02 43.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.237 -0.915 . . . . 0.0 109.477 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 50.02 30.17 15.82 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.528 ' CG2' HD13 ' A' ' 36' ' ' LEU . 21.6 mt -98.3 72.04 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.248 -1.148 . . . . 0.0 109.519 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.472 ' HA ' HG13 ' A' ' 28' ' ' VAL . 37.9 mttp -90.49 20.36 4.62 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.266 -0.896 . . . . 0.0 109.505 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.486 ' O ' HG23 ' A' ' 65' ' ' ILE . 81.4 m-20 -111.27 -23.04 11.06 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.189 -0.944 . . . . 0.0 109.525 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.535 HD22 ' CA ' ' A' ' 70' ' ' ALA . 18.9 mt -88.36 -31.23 19.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.29 -0.882 . . . . 0.0 109.76 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 93.4 t -108.19 142.87 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.179 -0.951 . . . . 0.0 109.376 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.86 -121.88 3.17 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -92.91 140.92 28.99 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.28 -1.13 . . . . 0.0 109.838 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.526 HD12 ' CG2' ' A' ' 24' ' ' ILE . 85.2 mt -108.91 134.64 50.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.336 -0.853 . . . . 0.0 109.084 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.57 HG21 ' CH2' ' A' ' 7' ' ' TRP . 28.7 t -121.68 159.34 24.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.074 -1.016 . . . . 0.0 109.412 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.491 ' CG2' HG21 ' A' ' 44' ' ' ILE . 2.9 mt -140.44 127.62 12.28 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.292 -0.88 . . . . 0.0 109.479 -179.852 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.599 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 45.2 Cg_endo -66.72 -5.93 14.32 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.799 2.333 . . . . 0.0 111.391 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.568 ' CG1' ' N ' ' A' ' 45' ' ' ARG . 6.1 pt -73.18 -46.01 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.398 -0.814 . . . . 0.0 109.374 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.568 ' N ' ' CG1' ' A' ' 44' ' ' ILE . 93.3 mtt-85 -49.86 134.33 21.1 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.414 -0.804 . . . . 0.0 109.57 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -137.75 -175.39 13.84 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.73 150.08 50.06 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 62.9 tt0 -61.33 -31.89 71.77 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -1.134 . . . . 0.0 109.4 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 42.5 mtp180 -61.47 -38.38 87.03 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.256 -0.903 . . . . 0.0 109.463 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 80.9 mtt85 -147.41 138.37 23.61 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.224 -0.923 . . . . 0.0 109.44 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 19.8 tttp -103.22 124.49 48.72 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.297 -0.877 . . . . 0.0 109.483 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.401 ' O ' ' HB3' ' A' ' 53' ' ' GLU . 91.5 p -62.87 -17.88 62.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.271 -0.893 . . . . 0.0 109.484 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.51 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 80.5 tt0 64.35 52.93 1.78 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.226 -0.921 . . . . 0.0 109.474 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.553 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 5.3 mttp 75.72 88.25 0.08 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.31 -0.869 . . . . 0.0 109.5 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.599 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 0.6 OUTLIER -56.88 -45.82 82.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -0.962 . . . . 0.0 109.235 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.548 ' CD2' HD12 ' A' ' 55' ' ' LEU . 85.2 m-85 -125.25 111.94 26.29 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.937 . . . . 0.0 109.08 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -66.28 133.77 33.92 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.573 2.182 . . . . 0.0 111.985 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.459 ' O ' HG23 ' A' ' 12' ' ' THR . . . 74.46 -11.97 6.31 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.2 m-30 -99.82 131.29 45.89 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.649 -1.501 . . . . 0.0 110.258 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 42.5 t -134.25 148.77 29.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.671 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 17.0 m-85 -108.38 124.44 50.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.887 -1.133 . . . . 0.0 109.733 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.508 ' CG2' HG12 ' A' ' 40' ' ' ILE . 14.3 p -134.13 145.54 32.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.353 -0.842 . . . . 0.0 109.804 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.599 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 18.4 tt0 -108.51 127.3 53.81 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.47 ' SD ' HG13 ' A' ' 74' ' ' VAL . 58.7 mtm -151.93 163.68 38.73 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 118.954 -1.098 . . . . 0.0 111.022 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.525 HG12 ' HA ' ' A' ' 36' ' ' LEU . 3.3 pt -85.87 126.9 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.487 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 47.7 ttm -75.34 141.48 43.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.83 -178.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.487 ' HB2' ' O ' ' A' ' 66' ' ' MET . 47.0 t30 176.4 175.36 0.32 Allowed 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 -179.708 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -72.12 -40.85 67.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.168 -0.957 . . . . 0.0 109.593 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -72.46 -32.06 65.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.234 -0.916 . . . . 0.0 109.75 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.535 ' CA ' HD22 ' A' ' 36' ' ' LEU . . . -71.71 -47.3 54.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.193 -0.942 . . . . 0.0 109.818 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.519 ' O ' HG23 ' A' ' 74' ' ' VAL . 67.9 t80 -60.36 -49.33 78.01 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.154 -0.966 . . . . 0.0 109.682 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -63.14 -28.89 70.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.088 -1.007 . . . . 0.0 110.314 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.555 ' CE1' ' HG3' ' A' ' 27' ' ' LYS . 46.3 t80 -80.72 -41.42 23.62 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.007 -1.058 . . . . 0.0 109.819 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 71' ' ' TYR . 20.1 m -70.68 -53.24 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.242 -0.911 . . . . 0.0 109.405 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 33.0 tpt85 -52.14 -32.46 35.71 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.208 -0.932 . . . . 0.0 109.577 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 51.7 p -79.64 7.05 9.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.366 -0.834 . . . . 0.0 109.917 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.603 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 47.0 t -64.25 133.82 95.76 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.103 -0.998 . . . . 0.0 109.484 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.566 ' HB2' ' CD2' ' A' ' 79' ' ' TYR . 46.9 Cg_endo -68.2 136.9 38.88 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.68 2.253 . . . . 0.0 111.845 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.566 ' CD2' ' HB2' ' A' ' 78' ' ' PRO . 47.2 m-85 76.05 -1.94 2.85 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.418 -0.801 . . . . 0.0 109.623 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.603 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 2.8 t -87.86 127.76 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.129 -0.982 . . . . 0.0 109.273 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.1 mmm -89.02 -5.8 57.66 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.643 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 135.09 -152.8 20.9 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -143.14 141.7 31.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -1.213 . . . . 0.0 109.48 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.486 ' CG2' ' CD2' ' A' ' 11' ' ' LEU . 38.8 t -63.55 128.5 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.504 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 6.9 p -162.84 161.77 26.14 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.257 -0.902 . . . . 0.0 109.507 -179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 m -88.74 -35.61 16.61 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -123.58 -87.71 0.81 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.524 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -105.32 -128.38 6.17 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.524 ' O ' ' O ' ' A' ' 88' ' ' GLY . 6.8 pm0 -34.26 155.98 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.586 -0.949 . . . . 0.0 110.115 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.504 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.4 Cg_endo -69.62 160.12 50.92 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.578 2.185 . . . . 0.0 112.081 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 20.6 m -98.84 154.0 37.59 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.349 -0.844 . . . . 0.0 109.455 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.431 ' CB ' ' HD3' ' A' ' 6' ' ' LYS . 49.6 Cg_endo -70.35 147.64 59.53 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.693 2.262 . . . . 0.0 111.809 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.474 HG23 ' O ' ' A' ' 7' ' ' TRP . 21.3 t -85.4 142.44 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.219 -0.926 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . 0.469 ' O ' ' N ' ' A' ' 97' ' ' GLU . 81.1 tttt -67.66 126.24 28.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -0.9 . . . . 0.0 109.453 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 94' ' ' LYS . 47.3 t0 -43.67 -45.35 6.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.408 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.432 ' HD2' ' NZ ' ' A' ' 94' ' ' LYS . 57.4 mtt180 -55.42 -31.28 61.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.237 -0.914 . . . . 0.0 109.51 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.469 ' N ' ' O ' ' A' ' 94' ' ' LYS . 57.3 mt-10 -79.22 -24.45 43.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.262 -0.899 . . . . 0.0 109.662 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.628 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 75.7 mtp -84.53 -23.71 29.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.157 -0.964 . . . . 0.0 109.352 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.591 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 57.3 mtt180 -37.53 -52.55 2.52 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.351 -0.843 . . . . 0.0 109.919 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -69.39 -28.25 27.27 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.546 2.164 . . . . 0.0 111.989 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.524 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 24.4 mm -81.95 -41.18 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 109.361 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.596 ' N ' HD11 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -68.95 -41.44 78.0 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.198 -0.938 . . . . 0.0 109.136 179.816 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.47 ' HG2' ' HA ' ' A' ' 135' ' ' PRO . 21.4 tpt85 -63.25 -49.49 73.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.861 . . . . 0.0 108.989 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.521 ' CD2' ' O ' ' A' ' 45' ' ' ARG . 0.5 OUTLIER -72.66 -36.29 67.92 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.369 -0.832 . . . . 0.0 109.208 179.703 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.524 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.85 -0.47 9.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.436 -0.79 . . . . 0.0 109.94 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.34 7.79 85.21 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.543 ' CD1' ' CG2' ' A' ' 41' ' ' VAL . 53.5 mt -77.28 -19.97 55.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.28 -1.13 . . . . 0.0 109.446 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 36.1 tp10 -144.23 131.51 20.76 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.217 -0.927 . . . . 0.0 109.557 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -119.55 113.9 21.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.362 -0.836 . . . . 0.0 109.428 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.456 ' CD2' ' HD3' ' A' ' 103' ' ' ARG . 42.0 p90 -125.55 171.13 10.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.223 -0.923 . . . . 0.0 109.545 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 112' ' ' GLU . 94.2 mt-10 -100.33 -92.9 0.28 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.491 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.406 ' C ' ' O ' ' A' ' 111' ' ' GLU . 58.2 tt0 44.45 74.51 0.12 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.191 -0.943 . . . . 0.0 109.512 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 16.2 pttp -163.03 39.04 0.1 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.455 ' O ' ' HG3' ' A' ' 114' ' ' LYS . 7.1 pttp -101.73 33.29 3.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.235 -0.916 . . . . 0.0 109.338 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.87 57.57 30.49 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.2 82.44 0.85 Allowed 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.681 2.254 . . . . 0.0 111.759 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 28.1 t -127.49 128.68 70.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.168 -0.958 . . . . 0.0 109.566 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.561 ' HA ' ' CB ' ' A' ' 171' ' ' SER . 12.3 mttp -85.33 137.09 33.18 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.293 -0.879 . . . . 0.0 109.499 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.423 HG13 ' N ' ' A' ' 120' ' ' GLU . 82.5 t -107.78 139.57 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.444 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.569 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 95.0 mt-10 -150.41 170.47 18.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.301 -0.874 . . . . 0.0 109.465 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.569 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 0.3 OUTLIER 79.92 161.48 0.18 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.391 -0.818 . . . . 0.0 109.613 179.966 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . 42.97 31.06 1.12 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.56 ' HB3' ' CD ' ' A' ' 175' ' ' LYS . 45.6 p90 -110.64 124.01 51.08 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.276 -1.132 . . . . 0.0 109.175 179.617 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.443 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 37.6 mttt -150.64 156.98 42.43 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.072 -1.018 . . . . 0.0 109.972 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.483 ' HA ' HG23 ' A' ' 143' ' ' ILE . 14.1 p -62.93 143.99 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.389 -0.819 . . . . 0.0 109.556 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.49 -32.21 3.41 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.443 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 7.5 m-20 -48.67 163.82 0.07 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.359 -1.083 . . . . 0.0 109.144 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.0 ttm -95.57 126.4 40.83 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.182 -0.949 . . . . 0.0 109.066 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.568 ' CG2' ' O ' ' A' ' 174' ' ' GLU . 5.1 p -124.21 141.93 42.71 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.192 -0.943 . . . . 0.0 109.215 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.408 ' N ' ' O ' ' A' ' 174' ' ' GLU . 12.6 ttpp -107.57 143.34 36.13 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.113 -0.992 . . . . 0.0 109.049 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.537 ' CD1' ' HB3' ' A' ' 139' ' ' PHE . 96.5 mt -83.96 152.46 3.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.127 -0.983 . . . . 0.0 108.798 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.456 ' C ' ' HG2' ' A' ' 137' ' ' GLU . 27.4 pt -150.8 2.26 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.056 -1.028 . . . . 0.0 109.606 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.494 ' HB2' ' CB ' ' A' ' 172' ' ' GLU . 2.5 m -145.42 141.35 28.33 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.146 -0.972 . . . . 0.0 109.665 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.43 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 107.5 -170.75 15.77 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.47 ' HA ' ' HG2' ' A' ' 103' ' ' ARG . 49.7 Cg_endo -69.03 -18.66 40.31 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 123.338 2.692 . . . . 0.0 112.57 -179.606 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.58 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 97.8 m-85 -107.53 15.31 24.93 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.969 -1.082 . . . . 0.0 109.561 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.507 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 35.1 mt-10 -38.45 142.24 0.2 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.417 -0.802 . . . . 0.0 110.148 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 138' ' ' ASP . 0.3 OUTLIER 76.53 20.34 1.47 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.333 -0.854 . . . . 0.0 110.743 178.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.62 ' CE1' ' CG1' ' A' ' 157' ' ' VAL . 1.0 OUTLIER -108.37 131.17 55.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.831 -1.168 . . . . 0.0 109.623 179.901 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -84.97 134.3 34.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.155 -0.966 . . . . 0.0 109.508 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.59 167.89 26.48 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.8 -1.19 . . . . 0.0 110.269 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.438 ' C ' HG13 ' A' ' 155' ' ' VAL . 40.9 t -108.89 136.3 45.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.452 -1.028 . . . . 0.0 109.226 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.534 ' CD1' HG13 ' A' ' 129' ' ' VAL . 18.4 mm -67.38 114.85 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.259 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -97.25 -34.37 11.12 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.088 -1.007 . . . . 0.0 109.482 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -151.75 146.75 25.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.14 -0.975 . . . . 0.0 109.613 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.51 HG22 ' CD2' ' A' ' 153' ' ' LEU . 1.5 mt -120.06 123.7 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.333 -0.854 . . . . 0.0 109.304 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -107.3 98.14 21.78 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.655 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.553 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.8 Cg_endo -71.66 173.86 11.93 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.721 2.281 . . . . 0.0 111.779 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.553 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.0 tt0 80.53 -21.07 0.34 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.345 -0.847 . . . . 0.0 109.879 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.442 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 47.5 mtt85 -128.75 -11.88 4.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.111 -0.993 . . . . 0.0 109.45 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.485 ' C ' ' CG2' ' A' ' 170' ' ' VAL . 31.9 mt-30 69.26 48.25 0.67 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.277 -0.89 . . . . 0.0 109.774 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -122.34 146.08 47.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.132 -0.98 . . . . 0.0 108.87 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.51 ' CD2' HG22 ' A' ' 146' ' ' ILE . 0.4 OUTLIER -135.62 122.47 21.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.101 -1.0 . . . . 0.0 110.565 -179.398 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 5.8 mtmm -81.91 130.97 35.24 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.5 ' CG1' ' CG1' ' A' ' 129' ' ' VAL . 4.2 t -128.46 147.93 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.961 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.522 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 4.4 t30 -97.14 113.02 24.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.392 -0.817 . . . . 0.0 109.26 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.62 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 67.7 t -94.39 141.62 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.241 -0.912 . . . . 0.0 109.642 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.449 ' N ' HG13 ' A' ' 157' ' ' VAL . 60.1 m -94.2 95.71 9.13 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.383 -0.823 . . . . 0.0 109.63 -179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.435 ' O ' ' HB2' ' A' ' 160' ' ' PHE . 5.4 mt -121.72 141.37 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.253 -0.905 . . . . 0.0 109.581 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.671 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 96.6 m-85 61.26 41.26 13.5 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.847 . . . . 0.0 109.523 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.33 16.81 22.31 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 18.5 mtp85 -129.71 151.71 50.0 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.154 -1.203 . . . . 0.0 109.575 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.467 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 73.4 mt-10 -95.97 136.73 36.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.249 -0.907 . . . . 0.0 109.506 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 16.3 m -145.44 128.33 8.22 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.618 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.2 Cg_endo -70.24 136.67 32.28 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.757 2.304 . . . . 0.0 111.618 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.537 HG13 ' CG2' ' A' ' 157' ' ' VAL . 3.7 p -123.23 142.86 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.14 -0.975 . . . . 0.0 109.559 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.45 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 6.3 m -92.83 119.19 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.413 -0.805 . . . . 0.0 109.485 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.482 HD11 ' O ' ' A' ' 166' ' ' VAL . 0.0 OUTLIER -142.12 167.9 21.02 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.238 -0.914 . . . . 0.0 110.384 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.502 ' ND1' ' OE2' ' A' ' 172' ' ' GLU . 47.8 m170 -82.27 141.01 33.3 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.485 ' CG2' ' C ' ' A' ' 151' ' ' GLN . 59.5 t -53.94 -36.78 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.185 -0.947 . . . . 0.0 108.893 179.697 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.561 ' CB ' ' HA ' ' A' ' 118' ' ' LYS . 7.1 p -75.16 -6.77 51.36 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.561 -0.712 . . . . 0.0 109.812 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.502 ' OE2' ' ND1' ' A' ' 169' ' ' HIS . 92.7 mt-10 -96.17 -3.39 44.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.083 -1.011 . . . . 0.0 109.866 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.454 HG22 HG21 ' A' ' 129' ' ' VAL . 3.7 m -133.45 170.68 19.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.106 -0.997 . . . . 0.0 109.993 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.568 ' O ' ' CG2' ' A' ' 129' ' ' VAL . 25.6 tp10 -127.56 144.01 51.11 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.56 ' CD ' ' HB3' ' A' ' 123' ' ' PHE . 9.7 mttp -98.78 30.06 3.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.069 -1.019 . . . . 0.0 109.567 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.444 ' C ' ' O ' ' A' ' 175' ' ' LYS . 27.4 mt 41.85 -95.35 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.328 -0.857 . . . . 0.0 109.636 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.512 ' N ' ' O ' ' A' ' 175' ' ' LYS . 85.4 tt0 . . . . . 0 N--CA 1.488 1.47 0 CA-C-O 117.98 -1.009 . . . . 0.0 109.493 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -61.94 -28.85 69.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -1.156 . . . . 0.0 109.43 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 44.6 ttm -61.55 -23.05 65.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.314 -0.866 . . . . 0.0 109.443 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.1 tttt -95.26 120.22 35.12 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.359 -0.838 . . . . 0.0 109.464 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -133.88 151.96 51.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.261 -0.899 . . . . 0.0 109.506 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.579 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 41.7 mmtt -130.65 171.11 13.43 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.356 -0.84 . . . . 0.0 109.126 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.591 ' CZ3' ' CG2' ' A' ' 41' ' ' VAL . 60.1 m95 -104.55 126.5 51.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.202 -0.936 . . . . 0.0 109.329 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -116.94 168.03 10.6 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.154 -0.966 . . . . 0.0 109.145 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.527 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 65.1 mt -104.37 115.94 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.156 -0.965 . . . . 0.0 109.379 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.527 HG21 ' CE2' ' A' ' 83' ' ' PHE . 65.5 t -92.09 138.21 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.216 -0.927 . . . . 0.0 109.248 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.535 ' CD2' ' N ' ' A' ' 11' ' ' LEU . 3.5 mm? -88.12 141.9 28.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.312 -0.867 . . . . 0.0 109.338 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 1.3 p -153.44 174.85 13.84 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.235 -0.916 . . . . 0.0 109.375 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.436 ' O ' ' C ' ' A' ' 14' ' ' SER . 98.1 mtp -95.63 121.02 36.9 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.165 -0.959 . . . . 0.0 109.439 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 13' ' ' MET . 22.4 t -42.03 126.76 3.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.291 -0.88 . . . . 0.0 109.51 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.23 -19.98 33.69 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.435 ' O ' ' C ' ' A' ' 17' ' ' GLU . 89.0 m-85 -108.77 -18.79 13.62 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.233 -1.157 . . . . 0.0 109.629 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.485 ' OE1' HD11 ' A' ' 44' ' ' ILE . 43.4 mt-10 -41.48 -67.09 0.28 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.311 -0.868 . . . . 0.0 109.596 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -46.76 -38.59 10.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.193 -0.942 . . . . 0.0 109.415 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.444 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 24.0 tttp -69.22 -34.87 75.52 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.242 -0.911 . . . . 0.0 109.179 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.455 ' O ' HG13 ' A' ' 24' ' ' ILE . 43.8 t -68.78 -41.35 82.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.333 -0.854 . . . . 0.0 109.279 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.486 ' HD2' HD11 ' A' ' 42' ' ' ILE . 16.7 tttm -57.06 -50.82 71.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.277 -0.89 . . . . 0.0 109.487 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -62.31 -33.82 75.42 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.177 -0.952 . . . . 0.0 109.151 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.495 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 23.4 m120 -65.62 -33.65 76.4 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.302 -0.874 . . . . 0.0 109.284 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.572 ' CG2' HD11 ' A' ' 40' ' ' ILE . 79.2 mt -67.66 -45.37 84.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.271 -0.893 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -55.6 -46.19 77.35 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.895 . . . . 0.0 109.576 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.9 mttt -75.41 -36.04 60.9 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.605 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.572 ' HE3' ' CE1' ' A' ' 73' ' ' PHE . 28.6 tttp -54.72 -32.42 59.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.21 -0.931 . . . . 0.0 109.27 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.506 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 99.2 t -88.5 -22.89 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.878 . . . . 0.0 109.504 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -72.24 -57.0 4.59 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.237 -0.914 . . . . 0.0 109.609 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.22 -24.17 66.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.536 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 48.1 p -98.43 -17.37 18.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.418 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 62.74 26.14 68.28 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.53 ' CG2' ' CD1' ' A' ' 36' ' ' LEU . 76.7 mt -97.38 77.48 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.176 -1.191 . . . . 0.0 109.438 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.416 ' HG2' ' O ' ' A' ' 34' ' ' LYS . 17.8 tttp -89.72 22.85 2.89 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.29 -0.881 . . . . 0.0 109.129 179.822 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.536 ' O ' ' CD1' ' A' ' 65' ' ' ILE . 92.0 m-20 -118.27 -9.46 10.42 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.37 -0.831 . . . . 0.0 109.572 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.534 ' CD2' HD13 ' A' ' 65' ' ' ILE . 96.9 mt -97.47 -51.74 4.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.905 . . . . 0.0 109.387 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.519 HG11 ' CG2' ' A' ' 24' ' ' ILE . 59.3 t -94.73 136.12 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.258 -0.902 . . . . 0.0 109.245 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.89 -119.99 3.84 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 86.4 mtt180 -91.76 139.97 30.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.295 -1.12 . . . . 0.0 109.825 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.572 HD11 ' CG2' ' A' ' 24' ' ' ILE . 29.4 mt -107.91 133.39 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.397 -0.815 . . . . 0.0 109.115 179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.591 ' CG2' ' CZ3' ' A' ' 7' ' ' TRP . 25.8 t -121.99 132.56 70.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.175 -0.953 . . . . 0.0 109.25 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.486 HD11 ' HD2' ' A' ' 21' ' ' LYS . 4.5 mt -124.67 125.81 25.46 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.267 -0.896 . . . . 0.0 109.577 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.596 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 49.1 Cg_endo -68.4 -2.75 9.66 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.858 2.372 . . . . 0.0 111.422 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.671 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 87.7 mt -67.07 -28.88 44.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.35 -0.843 . . . . 0.0 109.602 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.45 ' C ' ' O ' ' A' ' 44' ' ' ILE . 9.2 tpt85 -42.32 -45.1 4.13 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.305 -0.872 . . . . 0.0 109.543 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 47.4 -111.19 0.72 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 164.97 169.17 28.23 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.434 ' O ' ' C ' ' A' ' 49' ' ' ARG . 71.3 mt-30 -60.64 -19.81 59.13 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -1.141 . . . . 0.0 109.34 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.472 ' HD2' ' HB ' ' A' ' 167' ' ' VAL . 6.5 ttp180 -43.7 -48.68 7.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.271 -0.893 . . . . 0.0 109.435 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.513 ' CZ ' HG22 ' A' ' 167' ' ' VAL . 63.2 mtt-85 -116.19 136.59 52.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.286 -0.884 . . . . 0.0 109.573 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 58.1 mttm -65.23 -40.89 94.68 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.208 -0.933 . . . . 0.0 109.193 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.526 ' O ' ' CG ' ' A' ' 53' ' ' GLU . 60.0 p -60.58 -169.17 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.227 -0.92 . . . . 0.0 109.18 179.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 52' ' ' SER . 89.9 mt-10 -160.33 175.51 12.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.195 -0.941 . . . . 0.0 109.55 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.671 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 1.3 mttp 76.24 83.51 0.09 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.371 -0.831 . . . . 0.0 109.75 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.596 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 35.0 mt -59.7 -41.83 91.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.112 -0.993 . . . . 0.0 108.654 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -129.19 105.1 17.93 Favored Pre-proline 0 N--CA 1.489 1.48 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.7 136.13 48.22 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.484 2.122 . . . . 0.0 112.093 -179.046 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.34 -18.47 4.36 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.482 ' CE1' HD13 ' A' ' 11' ' ' LEU . 3.6 m-30 -95.77 129.24 43.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.666 -1.49 . . . . 0.0 110.51 -178.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 36.1 t -133.23 147.07 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.683 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 9.6 m-85 -108.79 124.67 50.95 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.856 -1.153 . . . . 0.0 109.861 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.502 HG12 ' N ' ' A' ' 63' ' ' GLU . 61.9 t -135.62 146.76 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.904 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.579 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 26.4 tt0 -110.88 127.41 55.43 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.519 ' CE ' HG11 ' A' ' 74' ' ' VAL . 40.4 mtm -152.16 163.65 38.95 Favored 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 118.757 -1.177 . . . . 0.0 111.304 -178.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.536 ' CD1' ' O ' ' A' ' 35' ' ' ASN . 2.3 pt -82.64 124.81 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.472 ' CE ' ' HG2' ' A' ' 89' ' ' GLN . 94.9 mmm -76.23 142.72 41.35 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.146 -0.971 . . . . 0.0 109.885 -178.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 m-20 177.31 170.18 0.58 Allowed 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -68.79 -41.6 78.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.128 -0.982 . . . . 0.0 109.454 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -78.08 -29.61 49.22 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.173 -0.954 . . . . 0.0 109.85 -179.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.48 ' O ' ' CG2' ' A' ' 74' ' ' VAL . . . -72.86 -48.92 33.45 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.12 -0.987 . . . . 0.0 109.479 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.441 ' CE1' ' HG3' ' A' ' 89' ' ' GLN . 75.1 t80 -61.22 -48.1 83.06 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.258 -0.901 . . . . 0.0 109.564 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -61.46 -29.32 69.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.209 -0.932 . . . . 0.0 109.777 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.572 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 48.7 t80 -80.78 -41.74 22.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.121 -0.987 . . . . 0.0 109.472 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.519 HG11 ' CE ' ' A' ' 64' ' ' MET . 4.2 t -68.76 -56.23 12.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.33 -0.856 . . . . 0.0 109.511 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.1 tpt85 -54.59 -17.34 3.18 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.358 -0.838 . . . . 0.0 109.735 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 26.2 p -91.3 6.91 43.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.26 -0.9 . . . . 0.0 109.872 -179.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.598 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 25.1 t -64.43 137.85 97.26 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.052 -1.03 . . . . 0.0 109.542 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.576 ' HB2' ' CE2' ' A' ' 79' ' ' TYR . 47.7 Cg_endo -68.47 137.63 40.01 Favored 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 122.718 2.278 . . . . 0.0 111.778 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.576 ' CE2' ' HB2' ' A' ' 78' ' ' PRO . 17.5 m-85 76.17 -4.64 2.32 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.388 -0.82 . . . . 0.0 109.712 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.598 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 5.4 t -87.02 129.66 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.055 -1.028 . . . . 0.0 109.101 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 98.9 mmm -88.14 -7.17 57.31 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.517 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.07 -145.23 15.84 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.591 ' CB ' ' HG3' ' A' ' 90' ' ' PRO . 1.4 m-85 -140.49 148.6 41.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -1.183 . . . . 0.0 109.708 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.527 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 3.4 p -75.78 134.61 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.246 -0.909 . . . . 0.0 109.344 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 88' ' ' GLY . 4.3 p -162.94 163.74 26.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.204 -0.935 . . . . 0.0 109.664 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.0 m -91.43 -33.34 15.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.37 -0.831 . . . . 0.0 109.421 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -124.98 -84.32 0.58 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.554 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -110.31 -135.24 6.97 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.554 ' C ' ' O ' ' A' ' 88' ' ' GLY . 1.0 OUTLIER -29.49 150.45 0.03 OUTLIER Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.584 -0.951 . . . . 0.0 110.302 -179.484 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.591 ' HG3' ' CB ' ' A' ' 83' ' ' PHE . 50.1 Cg_endo -68.22 142.05 54.14 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.899 2.399 . . . . 0.0 112.153 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . 0.553 ' CG2' ' HD2' ' A' ' 92' ' ' PRO . 3.7 p -75.69 144.67 77.28 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 109.26 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.553 ' HD2' ' CG2' ' A' ' 91' ' ' VAL . 46.0 Cg_endo -68.34 150.28 76.0 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.61 2.207 . . . . 0.0 111.806 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.453 ' HB ' ' SD ' ' A' ' 98' ' ' MET . 2.4 t -76.53 137.95 21.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.291 -0.881 . . . . 0.0 109.533 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.1 tttp -74.19 132.99 42.71 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.313 -0.867 . . . . 0.0 109.415 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.405 ' C ' ' O ' ' A' ' 94' ' ' LYS . 79.3 m-20 -44.11 -41.7 5.79 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.448 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.422 ' HB2' ' HD3' ' A' ' 94' ' ' LYS . 53.1 mtp180 -60.85 -27.03 67.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.278 -0.889 . . . . 0.0 109.497 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.516 ' N ' ' O ' ' A' ' 94' ' ' LYS . 45.1 mt-10 -86.6 -26.06 24.62 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.241 -0.912 . . . . 0.0 109.398 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.536 ' CB ' HD12 ' A' ' 102' ' ' LEU . 27.9 mmm -85.59 -22.97 27.79 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.219 -0.926 . . . . 0.0 109.5 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.591 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.1 OUTLIER -42.61 -49.09 13.23 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.29 -0.881 . . . . 0.0 109.887 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.591 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 51.9 Cg_endo -74.2 -27.32 11.75 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.435 2.09 . . . . 0.0 111.672 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.539 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 33.8 mm -80.87 -38.75 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.333 -0.855 . . . . 0.0 109.344 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.536 HD12 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -69.27 -40.07 78.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.313 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.54 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 19.5 ttm180 -64.36 -50.42 67.78 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.904 . . . . 0.0 109.308 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 6.8 tt -72.29 -36.19 68.88 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.296 -0.877 . . . . 0.0 109.216 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -69.76 -2.93 13.36 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.308 -0.87 . . . . 0.0 109.908 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.86 8.98 86.74 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.417 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 1.0 OUTLIER -72.53 -17.05 61.77 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -1.17 . . . . 0.0 109.416 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -104.33 159.28 15.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.241 -0.912 . . . . 0.0 109.517 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -107.72 101.44 10.75 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.235 -0.916 . . . . 0.0 109.379 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -146.09 158.05 43.86 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.197 -0.939 . . . . 0.0 109.427 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -97.17 -90.77 0.26 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.426 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.483 ' O ' ' C ' ' A' ' 113' ' ' LYS . 82.7 tt0 -146.06 152.72 39.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.199 -0.938 . . . . 0.0 109.458 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.483 ' C ' ' O ' ' A' ' 112' ' ' GLU . 54.3 pttt -38.5 144.82 0.1 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.387 -0.821 . . . . 0.0 109.758 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.18 -58.33 3.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.309 -0.869 . . . . 0.0 109.557 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.435 ' HB2' ' HD2' ' A' ' 116' ' ' PRO . 0.0 OUTLIER -170.3 162.42 6.29 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.233 -0.917 . . . . 0.0 109.476 -179.889 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 115' ' ' LYS . 50.2 Cg_endo -70.2 142.04 44.97 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.763 2.309 . . . . 0.0 111.725 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.454 HG21 HG23 ' A' ' 119' ' ' VAL . 33.9 m -121.64 162.03 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.289 -0.882 . . . . 0.0 109.528 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.49 ' O ' ' CG1' ' A' ' 119' ' ' VAL . 30.9 mtpp -100.31 124.63 46.02 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.271 -0.893 . . . . 0.0 109.419 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.49 ' CG1' ' O ' ' A' ' 118' ' ' LYS . 0.1 OUTLIER -169.3 57.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.282 -0.887 . . . . 0.0 109.425 -179.931 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.534 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 94.6 mt-10 -62.24 -83.68 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.216 -0.928 . . . . 0.0 109.531 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.632 ' O ' ' C ' ' A' ' 122' ' ' GLY . 9.4 mt 77.93 105.93 0.07 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.332 -0.855 . . . . 0.0 109.247 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.632 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -20.24 93.55 0.01 OUTLIER Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.446 -1.061 . . . . 0.0 110.446 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.487 ' N ' ' O ' ' A' ' 121' ' ' LEU . 8.9 p90 -103.03 143.12 32.99 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.29 -1.124 . . . . 0.0 109.281 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.434 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 13.9 mmtt -137.77 165.22 26.97 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -0.925 . . . . 0.0 109.758 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 14.2 p -62.42 143.13 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.316 -0.865 . . . . 0.0 109.536 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 85.68 -33.11 3.54 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.434 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 31.8 m-20 -49.67 159.19 0.39 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.532 -0.981 . . . . 0.0 109.247 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' MET . . . . . 0.478 ' HG2' HD12 ' A' ' 176' ' ' ILE . 2.0 ttp -94.19 127.62 40.14 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.136 -0.978 . . . . 0.0 109.008 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.548 ' CG2' ' CG1' ' A' ' 143' ' ' ILE . 5.9 t -125.99 142.49 42.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.361 -0.837 . . . . 0.0 109.28 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.484 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 22.2 tttp -105.41 142.13 35.7 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.405 -0.809 . . . . 0.0 108.875 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.522 ' CD1' ' HB3' ' A' ' 139' ' ' PHE . 66.9 mt -83.3 155.1 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.186 -0.946 . . . . 0.0 108.618 179.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.522 ' N ' HG21 ' A' ' 131' ' ' ILE . 29.1 pt -150.62 2.8 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.076 -1.015 . . . . 0.0 109.549 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 72.3 m -148.19 144.44 27.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.071 -1.018 . . . . 0.0 109.992 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 104.29 -167.99 16.23 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.54 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 48.3 Cg_endo -68.97 -20.74 38.21 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 123.124 2.549 . . . . 0.0 112.408 -179.544 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.515 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.3 m-85 -110.31 15.95 21.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.829 -1.169 . . . . 0.0 109.435 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.537 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 1.7 tt0 -43.8 143.26 1.09 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.486 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.537 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 16.4 m-20 75.85 27.65 0.94 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.374 -0.829 . . . . 0.0 110.258 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.522 ' HB3' ' CD1' ' A' ' 131' ' ' ILE . 1.3 t80 -117.68 133.58 55.8 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.021 -1.049 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -82.96 133.75 35.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.127 -0.983 . . . . 0.0 109.653 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.449 ' HA3' HG23 ' A' ' 155' ' ' VAL . . . -145.15 167.34 27.36 Favored Glycine 0 N--CA 1.49 2.279 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.098 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.438 ' O ' HG22 ' A' ' 155' ' ' VAL . 58.4 t -110.38 136.92 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.442 -1.034 . . . . 0.0 109.404 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.593 ' CG2' ' CD1' ' A' ' 146' ' ' ILE . 43.2 mm -69.36 118.69 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . 0.518 ' O ' ' CG ' ' A' ' 145' ' ' GLU . 47.3 tttp -98.17 -32.35 11.63 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.041 -1.037 . . . . 0.0 109.557 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 144' ' ' LYS . 85.7 mt-10 -157.68 153.33 26.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.058 -1.026 . . . . 0.0 110.073 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.593 ' CD1' ' CG2' ' A' ' 143' ' ' ILE . 6.1 mm -123.65 126.49 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.406 -0.809 . . . . 0.0 109.591 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -108.85 99.37 34.37 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.349 -0.845 . . . . 0.0 109.476 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.549 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.2 Cg_endo -71.21 173.77 11.74 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.739 2.293 . . . . 0.0 111.764 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.549 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.5 mt-10 79.97 -20.98 0.35 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.358 -0.839 . . . . 0.0 109.865 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.423 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 32.6 mtp180 -128.78 -13.4 4.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.079 -1.013 . . . . 0.0 109.476 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.423 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 37.8 mt-30 69.58 48.22 0.62 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.283 -0.886 . . . . 0.0 109.685 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . 0.522 ' OE2' ' CG1' ' A' ' 167' ' ' VAL . 59.5 tt0 -120.41 144.25 48.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.964 . . . . 0.0 108.936 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.568 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 29.4 mt -130.12 131.01 45.53 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.078 -1.014 . . . . 0.0 110.083 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 13.6 mttt -93.07 130.9 38.53 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.52 HG13 HD11 ' A' ' 168' ' ' LEU . 13.9 p -132.7 147.48 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.096 -1.003 . . . . 0.0 110.057 -179.521 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.542 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.6 m-20 -96.7 117.0 30.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.464 -0.773 . . . . 0.0 109.265 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . . . . . . . . . 44.9 t -96.79 141.38 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 109.501 -179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.402 ' HA ' ' O ' ' A' ' 162' ' ' ARG . 73.5 m -96.07 94.91 7.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.273 -0.892 . . . . 0.0 109.929 -179.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.455 ' O ' ' HB2' ' A' ' 160' ' ' PHE . 6.2 mt -118.22 140.78 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.25 -0.906 . . . . 0.0 109.422 179.483 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.683 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 97.3 m-85 62.25 40.16 11.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.331 -0.855 . . . . 0.0 109.337 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.48 17.9 34.87 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.411 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 36.9 mtt-85 -128.29 156.12 43.52 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.179 -1.189 . . . . 0.0 109.618 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -99.84 134.23 43.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.886 . . . . 0.0 109.558 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 37.3 m -143.11 127.44 9.59 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.303 -0.873 . . . . 0.0 109.554 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.542 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.3 Cg_endo -69.63 135.18 30.09 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.76 2.307 . . . . 0.0 111.544 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.459 ' O ' HD11 ' A' ' 168' ' ' LEU . 34.5 t -123.49 142.59 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.986 . . . . 0.0 109.861 -179.729 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.522 ' CG1' ' OE2' ' A' ' 152' ' ' GLU . 29.4 t -93.78 119.35 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.403 -0.81 . . . . 0.0 109.485 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.52 HD11 HG13 ' A' ' 155' ' ' VAL . 0.0 OUTLIER -141.91 168.65 19.25 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.209 -0.932 . . . . 0.0 110.413 -179.651 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.5 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 42.3 m170 -83.51 140.6 32.2 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.472 ' HB ' ' HG ' ' A' ' 153' ' ' LEU . 7.5 p -54.91 -36.33 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.26 -0.9 . . . . 0.0 109.183 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 84.4 p -75.84 -7.26 54.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -0.868 . . . . 0.0 109.707 -179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.5 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 84.3 mt-10 -87.61 -2.44 58.61 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.069 -1.019 . . . . 0.0 109.647 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.486 ' HA ' HG12 ' A' ' 132' ' ' ILE . 3.7 m -142.05 175.91 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.191 -0.943 . . . . 0.0 109.446 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.532 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 76.2 tt0 -140.57 167.26 22.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.281 -0.887 . . . . 0.0 108.932 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.532 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.1 tttp -86.27 15.12 5.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.03 -1.044 . . . . 0.0 109.6 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.478 HD12 ' HG2' ' A' ' 128' ' ' MET . 10.8 mt 65.74 -70.4 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.306 -0.871 . . . . 0.0 109.477 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.483 ' N ' ' O ' ' A' ' 175' ' ' LYS . 86.3 tt0 . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 117.947 -1.025 . . . . 0.0 109.506 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.449 ' O ' ' HB ' ' A' ' 65' ' ' ILE . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -61.96 -16.14 48.94 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.219 -1.166 . . . . 0.0 109.509 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' MET . . . . . 0.446 ' O ' ' HB2' ' A' ' 4' ' ' LYS . 71.3 mtm -106.6 174.83 5.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.28 -0.887 . . . . 0.0 109.423 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.446 ' HB2' ' O ' ' A' ' 3' ' ' MET . 67.8 mttt 63.23 41.69 7.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.247 -0.908 . . . . 0.0 109.383 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.467 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 74.8 mttt -69.11 148.97 49.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.201 -0.937 . . . . 0.0 109.658 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.552 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 10.9 mttp -129.17 175.63 8.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.291 -0.881 . . . . 0.0 109.259 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.594 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 56.7 m95 -112.38 124.69 53.05 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.262 -0.899 . . . . 0.0 109.233 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.485 ' CD1' ' HA ' ' A' ' 92' ' ' PRO . 62.6 m-85 -117.36 171.81 7.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.189 -0.944 . . . . 0.0 109.335 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.557 HG12 ' CZ ' ' A' ' 61' ' ' PHE . 40.9 mt -112.49 107.83 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.174 -0.954 . . . . 0.0 108.995 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.606 ' CG1' ' CG1' ' A' ' 60' ' ' VAL . 10.8 p -83.5 146.05 7.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.208 -0.932 . . . . 0.0 109.465 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.564 HD22 ' CE1' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -90.77 142.25 27.95 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.525 -0.734 . . . . 0.0 109.67 -179.667 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.477 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.1 t -154.97 -176.07 5.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.299 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.456 ' HE3' ' CE2' ' A' ' 16' ' ' TYR . 58.2 mtm -102.23 125.66 48.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.187 -0.946 . . . . 0.0 109.445 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.4 m -45.59 128.02 8.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -0.936 . . . . 0.0 109.536 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.21 -19.46 37.38 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.456 ' CE2' ' HE3' ' A' ' 13' ' ' MET . 94.1 m-85 -108.19 -7.91 15.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.313 -1.11 . . . . 0.0 109.436 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.505 ' OE1' ' CD1' ' A' ' 44' ' ' ILE . 47.9 mt-10 -47.93 -53.91 14.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.474 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -55.62 -37.05 67.66 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.239 -0.913 . . . . 0.0 109.346 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.516 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 88.5 mttt -73.25 -34.86 66.07 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 109.372 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 13.4 t -66.69 -46.6 85.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.211 -0.931 . . . . 0.0 109.414 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 23.2 tttt -58.92 -48.44 81.48 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.278 -0.889 . . . . 0.0 109.666 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.9 mt-10 -65.71 -40.26 92.06 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.219 -0.926 . . . . 0.0 109.507 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.53 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 92.7 m-20 -60.45 -42.06 95.35 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.218 -0.926 . . . . 0.0 109.379 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.432 HG21 HD11 ' A' ' 40' ' ' ILE . 96.7 mt -64.38 -44.64 97.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.307 -0.871 . . . . 0.0 109.552 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.456 ' O ' ' HG3' ' A' ' 29' ' ' GLU . 87.9 mt-10 -59.23 -47.02 86.91 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.172 -0.955 . . . . 0.0 110.036 -179.613 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.2 ttpt -80.19 -38.39 31.36 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.049 -1.032 . . . . 0.0 109.731 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.584 ' HG2' ' CE1' ' A' ' 73' ' ' PHE . 19.3 tttt -57.16 -25.64 59.26 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.331 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.544 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 89.4 t -88.07 -26.98 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.301 -0.875 . . . . 0.0 109.482 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.456 ' HG3' ' O ' ' A' ' 25' ' ' GLU . 93.1 mt-10 -66.92 -47.65 71.07 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.504 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.12 -28.91 69.96 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -0.888 . . . . 0.0 109.365 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 71.9 p -89.03 -12.02 42.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.286 -0.884 . . . . 0.0 109.322 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 61.07 24.04 62.53 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.544 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 54.7 mt -101.35 74.43 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -1.139 . . . . 0.0 109.552 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.6 mttp -85.26 -3.8 58.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.336 -0.853 . . . . 0.0 109.597 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 90.5 m-20 -93.12 -7.01 46.68 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.209 -0.932 . . . . 0.0 109.4 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.532 ' N ' HD23 ' A' ' 36' ' ' LEU . 4.4 mm? -95.66 -50.83 4.77 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.267 -0.895 . . . . 0.0 109.34 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.462 HG11 HG22 ' A' ' 28' ' ' VAL . 8.7 p -95.35 139.16 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.381 -0.824 . . . . 0.0 109.554 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.1 -122.16 4.07 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 88.6 mtt-85 -95.34 142.7 27.43 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.223 -1.163 . . . . 0.0 109.706 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.49 HG12 HG11 ' A' ' 62' ' ' VAL . 75.4 mt -109.73 137.5 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.196 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.568 ' CG1' ' HB2' ' A' ' 61' ' ' PHE . 7.7 p -127.93 162.08 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.169 -0.957 . . . . 0.0 109.36 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.53 ' CG2' HD11 ' A' ' 44' ' ' ILE . 5.9 mt -144.2 130.13 9.87 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.167 -0.958 . . . . 0.0 109.902 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.49 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.1 Cg_endo -66.36 -3.71 9.33 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.861 2.374 . . . . 0.0 111.478 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.654 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 61.0 mt -72.21 -28.51 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.89 . . . . 0.0 109.508 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.421 ' C ' ' O ' ' A' ' 44' ' ' ILE . 32.4 mmt-85 -43.92 143.42 1.1 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.594 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 152.86 125.47 1.1 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 64.27 -123.72 28.31 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 56.1 tp60 -94.31 133.41 37.89 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.348 -1.09 . . . . 0.0 109.524 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.465 ' O ' ' OG ' ' A' ' 52' ' ' SER . 84.0 mtt-85 -53.53 -44.58 69.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.203 -0.936 . . . . 0.0 109.42 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 46.2 mtm105 -64.84 148.89 50.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.184 -0.948 . . . . 0.0 109.184 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . 0.417 ' O ' ' O ' ' A' ' 52' ' ' SER . 58.4 mttp 46.63 36.32 3.61 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.171 -0.956 . . . . 0.0 109.22 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.515 ' CB ' HG22 ' A' ' 44' ' ' ILE . 29.1 m -50.66 179.68 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.331 -0.855 . . . . 0.0 109.535 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.496 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 92.3 mt-10 -101.22 -36.5 8.9 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.327 -0.858 . . . . 0.0 109.583 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.654 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 3.6 mttp 75.16 89.99 0.08 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -0.945 . . . . 0.0 109.215 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.583 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 16.9 tp -65.25 -22.3 66.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.863 -1.148 . . . . 0.0 109.775 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.583 ' CE2' ' HG ' ' A' ' 55' ' ' LEU . 95.8 m-85 -148.37 98.17 3.73 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.21 -0.931 . . . . 0.0 108.818 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -65.86 140.56 61.53 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.723 2.282 . . . . 0.0 112.205 -179.243 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.4 -10.89 10.21 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.564 ' CE1' HD22 ' A' ' 11' ' ' LEU . 3.0 m-30 -107.25 132.6 52.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.749 -1.442 . . . . 0.0 110.291 -179.244 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.606 ' CG1' ' CG1' ' A' ' 10' ' ' VAL . 0.2 OUTLIER -135.22 151.4 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 179.001 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.568 ' HB2' ' CG1' ' A' ' 41' ' ' VAL . 14.0 m-85 -111.73 126.56 55.18 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.948 -1.095 . . . . 0.0 110.258 -179.14 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.534 HG12 ' CG ' ' A' ' 64' ' ' MET . 67.1 t -130.22 141.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.547 -0.721 . . . . 0.0 109.66 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.594 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 10.8 tt0 -104.16 125.92 50.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 108.766 179.538 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.534 ' CG ' HG12 ' A' ' 62' ' ' VAL . 30.7 mtm -156.18 172.92 17.61 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.019 -1.051 . . . . 0.0 110.783 -179.073 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.494 HD12 HD21 ' A' ' 36' ' ' LEU . 4.8 pt -95.17 130.48 43.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.477 ' SD ' ' NE2' ' A' ' 89' ' ' GLN . 4.1 tpp -76.04 143.34 41.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.3 -0.875 . . . . 0.0 110.037 -178.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.473 ' HB2' ' O ' ' A' ' 66' ' ' MET . 42.6 t30 176.69 175.78 0.33 Allowed 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 69' ' ' GLU . 28.6 p-10 -71.6 -40.45 69.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.145 -0.972 . . . . 0.0 109.406 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.473 ' N ' ' OD1' ' A' ' 68' ' ' ASP . 71.0 mm-40 -73.23 -35.5 66.28 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.362 -0.836 . . . . 0.0 109.716 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.5 ' HB3' ' CD1' ' A' ' 36' ' ' LEU . . . -67.63 -47.87 68.37 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 109.589 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.528 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 84.0 t80 -59.77 -51.57 69.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.676 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -57.48 -29.03 63.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.239 -0.913 . . . . 0.0 109.876 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.584 ' CE1' ' HG2' ' A' ' 27' ' ' LYS . 65.9 t80 -80.4 -40.79 25.78 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.113 -0.992 . . . . 0.0 109.929 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.488 ' CG2' ' O ' ' A' ' 70' ' ' ALA . 2.6 t -64.63 -60.33 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.185 -0.947 . . . . 0.0 109.92 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.474 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 10.8 tpt180 -51.58 -42.92 62.26 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.097 -1.002 . . . . 0.0 109.736 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 22.8 t -67.58 1.24 2.5 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.11 -0.994 . . . . 0.0 110.244 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.616 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 30.7 t -62.29 133.98 94.59 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 120.928 -1.107 . . . . 0.0 109.317 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.584 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 46.0 Cg_endo -68.0 136.08 36.95 Favored 'Trans proline' 0 C--O 1.213 -0.738 0 C-N-CA 122.727 2.285 . . . . 0.0 111.866 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.584 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 54.3 m-85 77.61 -2.26 2.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.528 -0.733 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.616 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.0 t -87.45 126.96 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.102 -0.999 . . . . 0.0 109.162 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 66.1 mtp -90.02 -24.65 21.15 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 109.73 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.486 ' O ' ' N ' ' A' ' 11' ' ' LEU . . . 158.25 -158.04 28.85 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.586 ' CD1' ' HD3' ' A' ' 90' ' ' PRO . 15.3 p90 -140.56 154.13 46.4 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.243 -1.151 . . . . 0.0 109.506 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.493 ' CG2' ' CD2' ' A' ' 11' ' ' LEU . 47.5 t -81.73 113.45 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.137 -0.977 . . . . 0.0 109.466 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.512 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 5.3 p -145.2 164.66 30.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.226 -0.921 . . . . 0.0 109.498 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 23.9 m -86.47 -33.17 20.46 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.287 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -135.58 -76.91 0.09 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.55 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -109.61 -133.56 6.7 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.55 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.4 OUTLIER -29.49 150.31 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.63 -0.924 . . . . 0.0 110.315 -179.636 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.586 ' HD3' ' CD1' ' A' ' 83' ' ' PHE . 44.5 Cg_endo -67.81 147.45 75.1 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.833 2.355 . . . . 0.0 111.973 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . 0.544 ' CG2' ' HD2' ' A' ' 92' ' ' PRO . 3.4 p -80.81 144.69 56.22 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.317 -0.864 . . . . 0.0 109.369 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.544 ' HD2' ' CG2' ' A' ' 91' ' ' VAL . 47.3 Cg_endo -68.6 151.39 75.16 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.66 2.24 . . . . 0.0 111.715 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.463 ' N ' ' O ' ' A' ' 7' ' ' TRP . 11.9 t -83.64 131.76 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.232 -0.918 . . . . 0.0 109.583 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 54.9 mttm -69.87 143.17 52.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.31 -0.868 . . . . 0.0 109.446 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -53.3 -39.97 64.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.25 -0.907 . . . . 0.0 109.596 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -57.98 -34.34 69.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.274 -0.891 . . . . 0.0 109.558 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.7 mt-10 -81.34 -25.41 36.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.266 -0.896 . . . . 0.0 109.525 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.576 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 98.6 mtp -84.1 -26.42 28.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.899 . . . . 0.0 109.58 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.563 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.4 OUTLIER -36.24 -54.24 1.53 Allowed Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.448 -0.783 . . . . 0.0 109.927 -179.838 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.563 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.5 Cg_endo -70.1 -28.2 23.93 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.481 2.121 . . . . 0.0 111.748 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.495 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 33.1 mm -80.57 -41.12 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.567 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.552 ' CB ' ' HB2' ' A' ' 108' ' ' GLU . 1.0 OUTLIER -67.85 -40.65 83.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.226 -0.921 . . . . 0.0 109.505 179.995 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.551 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 1.3 ttt85 -63.91 -49.52 72.33 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 109.212 179.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.21 -36.42 69.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.264 -0.898 . . . . 0.0 108.961 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.518 ' HB3' ' CG2' ' A' ' 41' ' ' VAL . . . -75.62 -4.11 38.23 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.436 -0.79 . . . . 0.0 109.641 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.66 11.47 83.06 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.484 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 7.1 mt -87.3 -28.09 22.48 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.158 -1.201 . . . . 0.0 109.724 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.552 ' HB2' ' CB ' ' A' ' 102' ' ' LEU . 87.9 tt0 -123.71 131.43 53.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.247 -0.908 . . . . 0.0 109.469 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -119.61 110.78 17.26 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.257 -0.902 . . . . 0.0 109.492 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.587 ' CE2' ' O ' ' A' ' 111' ' ' GLU . 47.7 p90 -126.09 -161.52 1.06 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.923 . . . . 0.0 109.308 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.587 ' O ' ' CE2' ' A' ' 110' ' ' TYR . 61.3 mt-10 -81.17 -150.89 0.08 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.264 -0.898 . . . . 0.0 109.663 -179.722 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.478 ' HB2' ' O ' ' A' ' 111' ' ' GLU . 35.4 tt0 175.8 171.21 0.36 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.424 -0.797 . . . . 0.0 109.126 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.405 ' C ' ' O ' ' A' ' 112' ' ' GLU . 3.2 mttp 43.96 62.18 2.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.065 -1.022 . . . . 0.0 109.495 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.483 ' HD2' ' OE2' ' A' ' 137' ' ' GLU . 3.8 mttt -82.09 -30.54 31.21 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.175 -0.953 . . . . 0.0 109.29 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.409 ' HG2' ' CG1' ' A' ' 117' ' ' VAL . 2.5 tptp -103.51 102.8 32.07 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.505 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -73.02 7.95 1.88 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.745 2.296 . . . . 0.0 112.065 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.441 ' O ' ' CG1' ' A' ' 117' ' ' VAL . 8.1 p -82.91 126.26 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.03 -1.044 . . . . 0.0 109.62 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 21.9 tttt -74.13 145.29 44.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.281 -0.887 . . . . 0.0 109.257 179.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.531 ' CG1' ' HA ' ' A' ' 174' ' ' GLU . 77.1 t -117.91 139.49 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.251 -0.906 . . . . 0.0 109.773 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.537 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 80.1 tt0 176.49 168.48 0.48 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.206 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.537 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 0.5 OUTLIER 79.94 163.36 0.18 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.385 -0.822 . . . . 0.0 109.559 179.926 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 45.39 33.52 4.32 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.462 ' HB3' ' HE2' ' A' ' 175' ' ' LYS . 50.7 p90 -109.13 129.17 55.48 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.234 -1.157 . . . . 0.0 109.219 179.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.454 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 20.8 mttm -146.48 155.65 42.69 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.131 -0.98 . . . . 0.0 109.869 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.416 ' HA ' HG22 ' A' ' 143' ' ' ILE . 14.2 p -60.98 143.96 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -0.875 . . . . 0.0 109.584 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.09 -33.45 3.13 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.454 ' OD2' ' HB2' ' A' ' 124' ' ' LYS . 32.7 m-20 -48.78 163.13 0.08 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.38 -1.07 . . . . 0.0 109.207 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.8 ttm -96.3 126.72 41.7 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.051 -1.031 . . . . 0.0 108.807 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.607 ' CG2' ' O ' ' A' ' 174' ' ' GLU . 5.6 p -124.3 141.28 45.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.108 -0.995 . . . . 0.0 109.262 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.522 ' N ' ' O ' ' A' ' 174' ' ' GLU . 35.9 tttp -104.34 144.21 31.94 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.206 -0.934 . . . . 0.0 108.956 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.512 HG22 ' HA ' ' A' ' 137' ' ' GLU . 95.7 mt -85.69 152.01 3.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.116 -0.99 . . . . 0.0 108.623 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.428 HG22 ' O ' ' A' ' 131' ' ' ILE . 42.1 pt -150.32 2.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.162 -0.961 . . . . 0.0 109.434 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.46 ' HB2' ' CB ' ' A' ' 172' ' ' GLU . 75.4 m -148.26 144.48 27.66 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.145 -0.972 . . . . 0.0 109.912 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.75 -165.28 18.89 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.551 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 46.9 Cg_endo -68.03 -21.82 42.51 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 123.202 2.602 . . . . 0.0 112.811 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.522 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.5 m-85 -108.29 15.78 23.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.834 -1.166 . . . . 0.0 109.604 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.536 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 2.4 tt0 -42.96 139.94 1.56 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.176 -0.953 . . . . 0.0 109.384 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.536 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 18.6 m-20 75.21 24.95 1.37 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.368 -0.832 . . . . 0.0 110.335 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.568 ' CE1' HG12 ' A' ' 157' ' ' VAL . 1.5 t80 -115.71 135.8 53.68 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.961 -1.087 . . . . 0.0 109.421 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.34 133.5 34.14 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.177 -0.952 . . . . 0.0 109.692 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.495 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.02 170.89 25.74 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.294 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.457 ' N ' ' CG1' ' A' ' 155' ' ' VAL . 40.8 t -116.12 135.72 55.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.447 -1.031 . . . . 0.0 109.357 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.48 ' CD1' ' HD2' ' A' ' 175' ' ' LYS . 70.8 mt -67.56 115.87 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.257 -0.902 . . . . 0.0 109.192 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . 0.429 ' C ' ' HG2' ' A' ' 145' ' ' GLU . 2.0 tttp -98.08 -33.74 11.04 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.036 -1.04 . . . . 0.0 109.502 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.429 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 75.3 mm-40 -151.01 146.03 25.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.114 -0.991 . . . . 0.0 109.536 179.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.586 ' CG2' ' CD2' ' A' ' 153' ' ' LEU . 23.8 pt -122.25 125.88 73.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.135 -0.978 . . . . 0.0 109.488 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.37 100.6 34.53 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.268 -0.895 . . . . 0.0 109.5 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.56 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.2 Cg_endo -71.18 171.12 16.61 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.704 2.269 . . . . 0.0 111.779 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.56 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.8 mt-10 80.95 -20.48 0.37 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.399 -0.813 . . . . 0.0 109.899 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.429 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 88.6 mtt180 -127.75 -12.01 5.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.086 -1.009 . . . . 0.0 109.526 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.429 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 31.5 mt-30 69.23 48.91 0.64 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.665 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -122.22 145.81 47.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.09 -1.006 . . . . 0.0 109.097 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.586 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 60.6 mt -138.42 115.29 10.78 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.075 -1.016 . . . . 0.0 110.147 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 27.3 mttm -78.85 133.56 37.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.3 -0.875 . . . . 0.0 108.643 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.546 HG12 ' N ' ' A' ' 156' ' ' ASN . 53.9 t -127.44 151.17 33.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.182 -0.949 . . . . 0.0 109.762 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.546 ' N ' HG12 ' A' ' 155' ' ' VAL . 26.2 t-20 -98.0 117.6 32.7 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.237 -0.914 . . . . 0.0 109.352 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.568 HG12 ' CE1' ' A' ' 139' ' ' PHE . 39.7 t -101.03 143.41 14.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.252 -0.905 . . . . 0.0 109.708 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 93.1 m -94.74 91.26 6.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.383 -0.823 . . . . 0.0 109.724 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.492 HG23 ' CE2' ' A' ' 160' ' ' PHE . 8.6 mt -115.78 140.54 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.424 179.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.492 ' CE2' HG23 ' A' ' 159' ' ' ILE . 8.4 m-85 60.54 41.21 15.93 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.376 -0.827 . . . . 0.0 109.334 -179.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.05 16.28 12.9 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 92.4 mtt-85 -126.26 148.3 49.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.201 -1.176 . . . . 0.0 109.39 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.484 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 94.3 mt-10 -94.81 135.77 35.91 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.278 -0.889 . . . . 0.0 109.679 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' THR . . . . . 0.51 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 49.7 m -147.2 128.18 7.1 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.274 -0.891 . . . . 0.0 109.735 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.49 139.69 38.26 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.746 2.297 . . . . 0.0 111.46 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.4 p -126.61 145.79 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.089 -1.007 . . . . 0.0 109.869 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.429 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 5.3 t -92.54 118.86 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.459 -0.775 . . . . 0.0 109.505 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.429 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 19.3 mt -141.52 167.23 22.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.184 -0.947 . . . . 0.0 110.495 -179.302 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -83.97 141.34 31.29 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.71 -0.619 . . . . 0.0 109.5 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 4.1 p -56.42 -36.28 46.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.287 -0.883 . . . . 0.0 109.319 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 53.8 p -75.96 -7.18 54.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -0.883 . . . . 0.0 109.828 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.46 ' CB ' ' HB2' ' A' ' 133' ' ' SER . 64.5 mt-10 -99.75 -2.23 35.73 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.086 -1.009 . . . . 0.0 109.404 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 12.7 m -132.48 170.1 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.23 -0.919 . . . . 0.0 109.627 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.607 ' O ' ' CG2' ' A' ' 129' ' ' VAL . 53.5 tt0 -129.87 145.14 51.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.293 -0.88 . . . . 0.0 109.343 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.522 ' O ' ' N ' ' A' ' 177' ' ' GLU . 34.4 mmtm -87.83 14.82 7.97 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.024 -1.048 . . . . 0.0 109.514 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.481 HG23 ' N ' ' A' ' 177' ' ' GLU . 81.2 mt 43.81 -94.04 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.346 -0.846 . . . . 0.0 109.618 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.522 ' N ' ' O ' ' A' ' 175' ' ' LYS . 96.6 mt-10 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 117.972 -1.013 . . . . 0.0 109.489 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.294 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.61 -11.52 35.85 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.268 -1.136 . . . . 0.0 109.455 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 93.9 mtp -71.42 -8.52 54.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.2 -0.938 . . . . 0.0 109.457 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.422 ' O ' ' HG3' ' A' ' 4' ' ' LYS . 18.8 pttm -160.76 132.83 5.96 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.252 -0.905 . . . . 0.0 109.463 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.459 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 20.0 mttm -114.95 156.82 24.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.177 -0.952 . . . . 0.0 109.625 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 16.8 mmtp -127.47 172.07 11.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.329 -0.857 . . . . 0.0 109.39 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.62 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 46.3 m95 -106.34 128.24 53.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.335 -0.853 . . . . 0.0 109.142 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.541 ' CE1' ' CE ' ' A' ' 66' ' ' MET . 74.8 m-85 -120.35 160.96 22.0 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.214 -0.929 . . . . 0.0 109.359 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.43 ' HA ' ' O ' ' A' ' 60' ' ' VAL . 97.1 mt -102.66 115.35 44.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.233 -0.917 . . . . 0.0 109.252 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 84.2 t -91.35 141.28 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.224 -0.923 . . . . 0.0 109.452 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.452 ' HB3' ' HB2' ' A' ' 81' ' ' MET . 3.2 mm? -84.74 144.23 28.64 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.28 -0.888 . . . . 0.0 109.308 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.498 ' CG2' ' HG2' ' A' ' 17' ' ' GLU . 11.9 t -155.86 -176.56 6.02 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.167 -0.958 . . . . 0.0 109.271 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 56.8 mtm -104.71 123.73 48.13 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.25 -0.906 . . . . 0.0 109.568 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.441 ' OG ' ' HB2' ' A' ' 57' ' ' PRO . 2.6 m -45.32 128.32 7.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.408 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.3 -19.98 33.52 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.501 ' O ' ' N ' ' A' ' 19' ' ' LYS . 77.1 m-85 -111.64 -9.3 14.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.297 -1.119 . . . . 0.0 109.441 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.559 ' HA ' ' CG1' ' A' ' 20' ' ' VAL . 92.6 mt-10 -43.3 -41.54 4.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.23 -0.919 . . . . 0.0 109.543 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -63.57 -31.3 72.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 109.302 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.501 ' N ' ' O ' ' A' ' 16' ' ' TYR . 27.7 mttm -76.94 -56.43 4.6 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.276 -0.89 . . . . 0.0 109.352 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.559 ' CG1' ' HA ' ' A' ' 17' ' ' GLU . 2.0 p -44.72 -49.73 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.415 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.441 ' HD2' HD12 ' A' ' 42' ' ' ILE . 10.5 tttm -61.03 -48.32 82.32 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.207 -0.933 . . . . 0.0 109.874 -179.711 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -62.96 -35.48 80.29 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.07 -1.019 . . . . 0.0 109.504 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.484 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 33.9 m120 -64.92 -37.54 87.99 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.308 -0.87 . . . . 0.0 109.22 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.525 ' CG2' HG11 ' A' ' 37' ' ' VAL . 89.0 mt -63.19 -45.62 98.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.3 -0.875 . . . . 0.0 109.478 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -55.41 -46.77 76.6 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.214 -0.929 . . . . 0.0 109.715 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 27.7 ttmt -76.06 -35.63 59.34 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.261 -0.899 . . . . 0.0 109.456 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.418 ' O ' ' CG2' ' A' ' 31' ' ' THR . 44.2 tptt -54.93 -32.33 61.16 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.918 . . . . 0.0 109.242 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.524 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 77.5 t -87.13 -22.91 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.329 -0.857 . . . . 0.0 109.406 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -71.32 -55.4 8.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.669 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.39 -31.16 71.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.186 -0.946 . . . . 0.0 109.684 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' A' ' 27' ' ' LYS . 29.5 p -87.32 -20.92 26.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.118 -0.989 . . . . 0.0 109.491 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 68.21 22.07 74.26 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.555 ' CG2' ' CB ' ' A' ' 36' ' ' LEU . 63.4 mt -98.89 79.45 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -1.142 . . . . 0.0 109.449 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -85.09 -17.23 38.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.236 -0.915 . . . . 0.0 109.24 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -84.24 5.01 28.25 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.317 -0.865 . . . . 0.0 109.482 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.583 ' CD1' ' CB ' ' A' ' 70' ' ' ALA . 12.5 tp -105.98 -54.26 2.51 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.176 -0.953 . . . . 0.0 109.37 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.525 HG11 ' CG2' ' A' ' 24' ' ' ILE . 86.4 t -96.5 133.32 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.403 -0.81 . . . . 0.0 109.297 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.85 -123.4 5.26 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 89.7 mtt180 -93.52 147.49 22.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -1.125 . . . . 0.0 109.845 -179.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.528 ' CG2' HG21 ' A' ' 62' ' ' VAL . 70.2 mt -110.32 135.55 49.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.291 -0.88 . . . . 0.0 109.344 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.597 ' CG2' ' CZ3' ' A' ' 7' ' ' TRP . 32.8 t -119.72 151.7 22.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.951 . . . . 0.0 109.39 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.464 HG22 HG12 ' A' ' 44' ' ' ILE . 10.5 mt -131.9 127.53 21.23 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.897 . . . . 0.0 109.442 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.509 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 46.2 Cg_endo -66.78 -4.46 11.21 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.862 2.375 . . . . 0.0 111.867 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.586 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 8.4 pt -80.7 133.23 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.12 -0.987 . . . . 0.0 109.387 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.423 ' O ' ' OG ' ' A' ' 52' ' ' SER . 44.6 ttp180 -67.75 150.0 49.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.257 -0.902 . . . . 0.0 109.574 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -96.18 179.64 35.14 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 167.71 -179.33 41.15 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 90.0 mt-30 -62.45 -33.13 74.22 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.27 -1.135 . . . . 0.0 109.384 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 79.0 mtt-85 -80.23 131.29 35.66 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.276 -0.89 . . . . 0.0 109.38 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 74.8 mtp85 -60.19 -35.33 75.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.258 -0.901 . . . . 0.0 109.556 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 53.5 mttm -84.96 138.49 32.45 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.232 -0.917 . . . . 0.0 109.448 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.423 ' OG ' ' O ' ' A' ' 45' ' ' ARG . 34.7 t -128.96 172.14 11.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 109.458 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.525 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 65.7 mm-40 -67.61 -36.71 81.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.586 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 7.6 mttp 75.72 105.47 0.07 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.53 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.509 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 24.7 mt -55.61 -45.43 77.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.105 -0.997 . . . . 0.0 109.269 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.419 ' CE2' ' CE2' ' A' ' 160' ' ' PHE . 89.3 m-85 -131.7 110.34 14.65 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.125 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.441 ' HB2' ' OG ' ' A' ' 14' ' ' SER . 43.1 Cg_endo -66.22 139.35 54.85 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.746 2.297 . . . . 0.0 112.184 -179.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.483 ' O ' HG22 ' A' ' 12' ' ' THR . . . 73.96 -9.83 8.43 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.5 m-30 -94.17 129.07 40.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.669 -1.489 . . . . 0.0 110.395 -179.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.457 ' CG2' HG23 ' A' ' 12' ' ' THR . 44.8 t -130.22 137.75 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.419 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.503 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 8.0 m-85 -110.15 125.95 53.57 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.902 -1.124 . . . . 0.0 110.051 -179.462 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.528 HG21 ' CG2' ' A' ' 40' ' ' ILE . 55.8 t -138.51 149.92 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.418 -0.801 . . . . 0.0 109.805 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.62 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 61.6 tt0 -110.66 129.04 55.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 108.888 179.536 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.556 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 9.2 mtm -161.79 -176.06 5.04 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.137 -0.977 . . . . 0.0 109.804 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.545 ' CD1' HD11 ' A' ' 36' ' ' LEU . 18.9 pt -94.94 119.76 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.541 ' CE ' ' CE1' ' A' ' 8' ' ' TYR . 16.2 ttm -87.36 101.04 13.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.382 -0.824 . . . . 0.0 109.676 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' A' ' 66' ' ' MET . 84.8 m-20 -138.7 -166.54 2.03 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.303 -0.873 . . . . 0.0 108.895 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -71.17 -47.34 58.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.098 -1.001 . . . . 0.0 109.799 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 70' ' ' ALA . 93.7 mt-10 -70.84 -57.14 4.92 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.055 -1.028 . . . . 0.0 109.612 -179.736 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.583 ' CB ' ' CD1' ' A' ' 36' ' ' LEU . . . -44.51 -42.99 7.62 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.551 ' CD1' ' OE1' ' A' ' 89' ' ' GLN . 71.1 t80 -61.39 -54.84 38.4 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.267 -0.896 . . . . 0.0 109.696 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -51.58 -31.0 23.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.18 -0.95 . . . . 0.0 110.049 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -81.01 -41.95 21.9 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.144 -0.972 . . . . 0.0 109.766 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.654 ' CG1' ' CZ ' ' A' ' 83' ' ' PHE . 47.4 t -70.96 -54.58 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.249 -0.907 . . . . 0.0 109.443 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.443 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 25.0 tpt85 -51.45 -18.62 1.11 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.182 -0.949 . . . . 0.0 109.211 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 66.3 p -101.65 5.89 41.73 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.41 -0.806 . . . . 0.0 109.925 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.593 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 17.2 t -60.86 135.57 92.89 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.013 -1.055 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.606 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 48.4 Cg_endo -69.14 129.39 18.16 Favored 'Trans proline' 0 C--O 1.213 -0.74 0 C-N-CA 122.776 2.318 . . . . 0.0 112.002 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.606 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 40.7 m-85 84.45 -10.13 0.88 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.665 -0.647 . . . . 0.0 109.56 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.593 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 4.9 t -84.92 127.3 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.177 -0.952 . . . . 0.0 109.257 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.452 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 78.4 mtp -87.0 -23.99 24.82 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.296 -0.877 . . . . 0.0 109.379 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.544 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 153.07 -155.58 26.21 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.654 ' CZ ' ' CG1' ' A' ' 74' ' ' VAL . 1.6 m-85 -137.42 140.13 41.11 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.322 -1.105 . . . . 0.0 109.402 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.5 p -64.85 125.41 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 109.519 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.529 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.7 p -159.35 161.69 35.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.241 -0.912 . . . . 0.0 109.516 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 85.8 p -92.01 -36.66 13.27 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.249 -0.907 . . . . 0.0 109.391 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -120.47 -88.19 1.04 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.515 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -104.25 -133.93 7.98 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.551 ' OE1' ' CD1' ' A' ' 71' ' ' TYR . 0.9 OUTLIER -34.25 155.06 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.547 -0.972 . . . . 0.0 110.134 -179.599 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.529 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.3 Cg_endo -68.47 163.72 35.55 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.824 2.349 . . . . 0.0 111.855 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.7 m -93.97 154.08 40.78 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.294 -0.879 . . . . 0.0 109.31 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.38 142.45 45.23 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.605 2.203 . . . . 0.0 111.796 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.447 ' CG2' ' O ' ' A' ' 7' ' ' TRP . 2.3 t -73.04 131.49 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -0.899 . . . . 0.0 109.306 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . 0.484 ' O ' ' N ' ' A' ' 97' ' ' GLU . 42.2 mttm -71.6 132.75 45.09 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.193 -0.942 . . . . 0.0 109.264 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 94' ' ' LYS . 82.1 m-20 -44.46 -41.28 6.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.226 -0.921 . . . . 0.0 109.459 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -61.04 -24.91 66.55 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.265 -0.897 . . . . 0.0 109.502 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.484 ' N ' ' O ' ' A' ' 94' ' ' LYS . 54.2 mt-10 -87.14 -27.0 23.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.162 -0.961 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.526 ' CB ' HD11 ' A' ' 102' ' ' LEU . 37.4 mmm -84.63 -26.87 27.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.166 -0.959 . . . . 0.0 109.42 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.557 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 5.1 ttp180 -37.06 -54.98 1.75 Allowed Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.47 -0.769 . . . . 0.0 109.994 -179.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.557 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.1 Cg_endo -69.05 -27.21 30.13 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.535 2.157 . . . . 0.0 111.79 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.546 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 51.1 mm -81.44 -41.94 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.226 -0.921 . . . . 0.0 109.284 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.526 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -68.27 -40.13 81.95 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.219 -0.926 . . . . 0.0 109.231 179.754 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.523 ' HD3' ' CE1' ' A' ' 110' ' ' TYR . 21.2 mtt180 -62.77 -50.57 70.53 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.333 -0.854 . . . . 0.0 108.978 179.587 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -73.35 -35.34 65.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.459 -0.776 . . . . 0.0 109.11 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -71.99 -2.73 19.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.385 -0.822 . . . . 0.0 109.633 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.48 9.68 84.56 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.58 ' CD2' ' CG2' ' A' ' 41' ' ' VAL . 8.0 mp -80.9 -21.95 40.16 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.164 -1.198 . . . . 0.0 109.429 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -120.85 141.26 50.73 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.381 -0.824 . . . . 0.0 109.501 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -114.67 114.28 25.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.354 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.523 ' CE1' ' HD3' ' A' ' 103' ' ' ARG . 37.7 p90 -137.25 163.48 30.82 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.288 -0.882 . . . . 0.0 109.47 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.443 ' O ' ' C ' ' A' ' 112' ' ' GLU . 94.0 mt-10 -100.05 -100.67 0.24 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.274 -0.891 . . . . 0.0 109.507 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.443 ' C ' ' O ' ' A' ' 111' ' ' GLU . 33.2 tt0 42.03 82.26 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.534 ' O ' ' CG ' ' A' ' 114' ' ' LYS . 53.3 pttt -171.53 -158.54 0.14 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.534 ' CG ' ' O ' ' A' ' 113' ' ' LYS . 6.0 pttt 40.12 30.44 0.07 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.263 -0.898 . . . . 0.0 109.594 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.45 ' N ' ' O ' ' A' ' 113' ' ' LYS . 0.0 OUTLIER -128.16 82.15 69.06 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 0.0 109.406 -179.944 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.38 127.68 13.63 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.742 2.294 . . . . 0.0 111.766 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 4.3 p -135.21 129.57 50.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.483 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 23.8 mttt -86.79 145.65 26.54 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.273 -0.892 . . . . 0.0 109.442 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 94.1 t -126.03 155.94 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.149 -0.97 . . . . 0.0 109.448 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.703 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 78.5 tt0 -130.62 153.22 49.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.228 -0.92 . . . . 0.0 109.496 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.716 ' O ' ' N ' ' A' ' 123' ' ' PHE . 13.7 tp 143.71 99.03 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.599 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.76 79.81 0.0 OUTLIER Glycine 0 N--CA 1.496 2.669 0 N-CA-C 111.011 -0.835 . . . . 0.0 111.011 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.716 ' N ' ' O ' ' A' ' 121' ' ' LEU . 31.4 p90 -95.7 130.95 42.44 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.251 -1.147 . . . . 0.0 109.094 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.506 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 14.1 mttt -140.35 -174.52 3.97 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.034 -1.041 . . . . 0.0 110.076 -179.615 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 13.8 p -61.78 141.94 16.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.451 -0.781 . . . . 0.0 109.677 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 86.72 -34.31 3.55 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.506 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 24.0 m-20 -49.29 158.73 0.36 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.316 -1.108 . . . . 0.0 109.633 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' MET . . . . . 0.537 ' HG3' ' CD1' ' A' ' 176' ' ' ILE . 2.7 tpp -95.53 127.91 41.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.336 -0.853 . . . . 0.0 108.871 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.542 ' CG2' ' CG1' ' A' ' 173' ' ' VAL . 2.0 p -127.72 143.83 39.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.264 -0.898 . . . . 0.0 109.816 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.451 ' O ' HG13 ' A' ' 173' ' ' VAL . 21.0 tttt -108.55 142.29 39.21 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.266 -0.896 . . . . 0.0 109.319 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.548 ' O ' ' CD1' ' A' ' 132' ' ' ILE . 96.6 mt -80.14 152.22 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.139 -0.976 . . . . 0.0 108.971 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.548 ' CD1' ' O ' ' A' ' 131' ' ' ILE . 1.1 mm -146.67 2.27 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.088 -1.007 . . . . 0.0 109.391 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.553 ' CA ' ' HG2' ' A' ' 137' ' ' GLU . 50.6 m -148.64 143.12 26.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.259 -0.9 . . . . 0.0 109.758 -179.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.447 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 105.77 -169.23 15.8 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.482 ' HA ' ' OH ' ' A' ' 110' ' ' TYR . 48.5 Cg_endo -68.56 -19.98 41.73 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 123.317 2.678 . . . . 0.0 112.679 -179.414 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.503 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.6 m-85 -106.77 16.71 24.11 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.933 -1.104 . . . . 0.0 109.605 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.568 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 62.9 mt-10 -41.58 139.01 1.22 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.163 -0.961 . . . . 0.0 110.073 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.568 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.8 OUTLIER 80.37 19.41 0.56 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.277 -0.89 . . . . 0.0 110.788 178.775 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.595 ' CD1' HG11 ' A' ' 157' ' ' VAL . 1.0 OUTLIER -108.18 141.67 39.57 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.794 -1.191 . . . . 0.0 109.565 179.798 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -94.53 135.95 35.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.225 -0.922 . . . . 0.0 109.22 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.494 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.83 168.99 27.38 Favored Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.571 -1.299 . . . . 0.0 110.5 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 155' ' ' VAL . 39.5 t -111.14 137.49 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.593 -0.945 . . . . 0.0 109.369 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.43 ' O ' ' N ' ' A' ' 126' ' ' GLY . 69.8 mt -68.71 118.26 12.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 109.303 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . 0.414 ' O ' ' HG2' ' A' ' 145' ' ' GLU . 47.7 tttp -100.39 -33.29 10.43 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.975 -1.078 . . . . 0.0 109.561 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.414 ' HG2' ' O ' ' A' ' 144' ' ' LYS . 64.2 mt-10 -153.85 149.12 27.02 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.132 -0.98 . . . . 0.0 109.812 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.478 HG22 HD22 ' A' ' 153' ' ' LEU . 1.7 mt -124.33 127.59 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.354 -0.841 . . . . 0.0 109.379 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.13 104.1 55.77 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.628 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' HB2' ' A' ' 149' ' ' GLU . 52.4 Cg_endo -72.35 173.21 13.47 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.72 2.28 . . . . 0.0 111.661 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.544 ' HB2' ' O ' ' A' ' 148' ' ' PRO . 39.5 mm-40 78.25 -22.0 0.31 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.397 -0.814 . . . . 0.0 110.062 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.42 ' NH1' ' HG3' ' A' ' 150' ' ' ARG . 0.6 OUTLIER -124.15 -15.5 6.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.1 -1.0 . . . . 0.0 109.119 179.776 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.421 ' HB3' HG13 ' A' ' 170' ' ' VAL . 30.9 mt-30 69.58 47.98 0.63 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.461 -0.774 . . . . 0.0 109.439 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . 0.447 ' O ' HD21 ' A' ' 153' ' ' LEU . 97.8 mt-10 -119.76 143.56 47.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.215 -0.928 . . . . 0.0 109.081 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.478 HD22 HG22 ' A' ' 146' ' ' ILE . 14.4 mt -130.95 122.85 27.64 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.16 -0.963 . . . . 0.0 110.231 -179.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 13.9 mttt -85.57 129.78 34.74 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 142' ' ' VAL . 10.9 p -129.36 146.94 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.222 -0.923 . . . . 0.0 109.951 -179.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.523 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 3.7 m-20 -98.02 108.89 21.71 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.218 -0.926 . . . . 0.0 109.537 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.595 HG11 ' CD1' ' A' ' 139' ' ' PHE . 82.2 t -88.14 140.72 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.18 -0.95 . . . . 0.0 109.376 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.454 ' N ' HG12 ' A' ' 157' ' ' VAL . 47.7 m -96.62 89.23 4.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.332 -0.855 . . . . 0.0 109.617 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.483 ' CG1' HG13 ' A' ' 157' ' ' VAL . 2.6 mt -115.74 144.87 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.192 -0.942 . . . . 0.0 109.395 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.503 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 18.7 m-85 61.93 37.41 15.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.276 -0.89 . . . . 0.0 109.226 -179.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.03 17.95 31.85 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.426 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 89.5 mtt-85 -127.66 157.49 40.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.216 -1.167 . . . . 0.0 109.481 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.44 ' OE2' ' ND2' ' A' ' 156' ' ' ASN . 83.6 tt0 -100.82 133.35 45.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.327 -0.858 . . . . 0.0 109.591 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 79.7 m -144.04 127.3 8.83 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.905 . . . . 0.0 109.684 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.4 Cg_endo -70.98 137.16 31.33 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.723 2.282 . . . . 0.0 111.598 179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 46.1 t -125.66 144.48 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.229 -0.92 . . . . 0.0 109.862 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.406 ' O ' ' HG ' ' A' ' 168' ' ' LEU . 44.4 t -92.68 119.35 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.438 -0.789 . . . . 0.0 109.485 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.406 ' HG ' ' O ' ' A' ' 167' ' ' VAL . 1.4 mt -138.71 164.69 28.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.229 -0.92 . . . . 0.0 110.48 -179.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.504 ' HB2' ' HB2' ' A' ' 172' ' ' GLU . 88.6 m-70 -81.57 145.64 30.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.632 -0.668 . . . . 0.0 109.291 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.421 HG13 ' HB3' ' A' ' 151' ' ' GLN . 6.2 p -62.11 -35.73 70.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.305 -0.872 . . . . 0.0 108.982 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.408 ' N ' HG11 ' A' ' 170' ' ' VAL . 82.9 p -78.59 -9.66 59.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.254 -0.904 . . . . 0.0 109.362 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.504 ' HB2' ' HB2' ' A' ' 169' ' ' HIS . 46.8 mt-10 -97.69 -1.14 44.19 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.405 -0.809 . . . . 0.0 109.022 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.542 ' CG1' ' CG2' ' A' ' 129' ' ' VAL . 97.9 t -126.14 163.25 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.297 -0.877 . . . . 0.0 109.412 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.531 ' N ' HG11 ' A' ' 173' ' ' VAL . 55.8 tt0 -137.26 154.95 50.02 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.314 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.528 ' HE2' ' CG ' ' A' ' 123' ' ' PHE . 19.8 mttt -97.57 37.91 1.33 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.395 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.537 ' CD1' ' HG3' ' A' ' 128' ' ' MET . 7.1 mt 56.72 83.63 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.264 -0.897 . . . . 0.0 109.468 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 72.2 mm-40 . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.557 -179.923 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -98.26 27.52 4.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.235 -1.156 . . . . 0.0 109.518 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 60.4 ttp -62.57 -22.16 66.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.261 -0.9 . . . . 0.0 109.642 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 56.1 mttm -99.62 134.55 42.35 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.901 . . . . 0.0 109.431 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.462 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 21.8 mttm -100.41 148.74 24.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.186 -0.946 . . . . 0.0 109.575 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.59 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.6 mttt -131.53 173.1 11.45 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.16 -0.962 . . . . 0.0 109.407 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.625 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 51.9 m95 -108.82 126.74 53.36 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.415 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.502 ' CZ ' ' SD ' ' A' ' 66' ' ' MET . 91.3 m-85 -116.2 168.55 10.01 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.329 -0.857 . . . . 0.0 109.492 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.502 HG12 ' CE1' ' A' ' 61' ' ' PHE . 36.5 mt -106.49 116.51 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.282 -0.886 . . . . 0.0 109.197 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.508 ' CG1' HG22 ' A' ' 80' ' ' VAL . 72.5 t -91.56 136.52 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.282 -0.886 . . . . 0.0 109.294 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.493 ' CD2' HG21 ' A' ' 84' ' ' VAL . 3.8 mm? -89.18 146.89 24.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.374 -0.829 . . . . 0.0 109.496 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.6 t -161.83 -168.03 1.84 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.302 -0.874 . . . . 0.0 109.362 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 67.3 mtp -107.38 134.5 50.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.242 -0.911 . . . . 0.0 109.492 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 11.0 t -54.74 130.25 39.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.291 -0.881 . . . . 0.0 109.393 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.46 -20.22 37.75 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -109.87 -3.23 16.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.285 -1.127 . . . . 0.0 109.717 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -47.48 -64.56 0.75 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.254 -0.903 . . . . 0.0 109.594 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 75.8 mm-40 -48.73 -38.87 22.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.183 -0.948 . . . . 0.0 109.435 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.466 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 54.1 tttp -66.77 -45.9 77.03 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.304 -0.872 . . . . 0.0 109.278 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.474 HG21 ' HB3' ' A' ' 79' ' ' TYR . 50.7 t -61.65 -44.5 98.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -0.91 . . . . 0.0 109.501 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 48.1 tttt -60.51 -45.62 93.13 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -0.957 . . . . 0.0 109.219 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -65.72 -40.42 92.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.315 -0.866 . . . . 0.0 109.347 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.575 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 31.2 m120 -60.59 -46.15 91.3 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.337 -0.852 . . . . 0.0 109.431 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.405 HG13 ' O ' ' A' ' 20' ' ' VAL . 95.0 mt -56.01 -42.87 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.215 -0.928 . . . . 0.0 109.268 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -56.17 -43.56 78.5 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.193 -0.942 . . . . 0.0 109.594 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.418 ' HB3' ' HE2' ' A' ' 26' ' ' LYS . 47.9 mtpt -80.14 -35.62 36.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.208 -0.933 . . . . 0.0 109.434 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 11.5 tptt -54.69 -31.52 58.05 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.286 -0.883 . . . . 0.0 109.334 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.517 ' CG2' HG21 ' A' ' 37' ' ' VAL . 39.2 t -89.75 -23.3 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.301 -0.874 . . . . 0.0 109.392 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 46.3 tp10 -69.2 -52.63 25.94 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.288 -0.883 . . . . 0.0 109.543 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.37 -32.48 73.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 59.4 p -84.87 -25.29 28.1 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 79.48 -3.42 67.93 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.543 ' CG2' HD22 ' A' ' 36' ' ' LEU . 84.8 mt -76.16 74.38 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.193 -1.18 . . . . 0.0 109.553 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.454 ' HA ' HG11 ' A' ' 28' ' ' VAL . 23.6 mttt -88.49 1.12 55.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.192 -0.942 . . . . 0.0 109.657 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.408 ' O ' HG23 ' A' ' 65' ' ' ILE . 93.2 m-20 -97.06 -13.09 22.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.181 -0.949 . . . . 0.0 109.492 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.579 ' N ' ' CD2' ' A' ' 36' ' ' LEU . 2.5 mm? -88.32 -49.05 7.21 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.291 -0.881 . . . . 0.0 109.467 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.517 HG21 ' CG2' ' A' ' 28' ' ' VAL . 78.5 t -91.12 139.49 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.244 -0.91 . . . . 0.0 109.256 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.467 ' N ' HG11 ' A' ' 37' ' ' VAL . . . -109.04 -127.09 5.44 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 88.2 mtt180 -92.16 146.97 23.3 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.255 -1.144 . . . . 0.0 109.755 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.493 HD13 HG21 ' A' ' 40' ' ' ILE . 67.1 mt -112.55 134.16 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.913 . . . . 0.0 109.336 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.578 HG22 ' CZ3' ' A' ' 7' ' ' TRP . 33.3 m -128.08 155.77 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.235 -0.916 . . . . 0.0 109.45 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.453 HG22 HG12 ' A' ' 44' ' ' ILE . 11.5 mt -133.63 128.63 20.09 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.268 -0.895 . . . . 0.0 109.63 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.498 ' O ' HD13 ' A' ' 55' ' ' LEU . 43.8 Cg_endo -66.45 -3.89 9.77 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.928 2.418 . . . . 0.0 111.744 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.594 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 11.4 pt -80.98 -19.32 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.145 -0.972 . . . . 0.0 109.464 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.402 ' NH2' ' HB3' ' A' ' 105' ' ' ALA . 39.0 mtm180 -58.65 143.69 45.69 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.287 -0.883 . . . . 0.0 109.472 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 85.15 -6.39 79.61 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.477 ' HA3' ' HA ' ' A' ' 53' ' ' GLU . . . -66.75 -37.23 92.22 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -54.4 -36.95 64.5 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -1.157 . . . . 0.0 109.477 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 5.9 mmt85 -60.16 -27.9 67.47 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.294 -0.879 . . . . 0.0 109.525 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 65.8 mtm180 -109.19 167.09 10.36 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.27 -0.894 . . . . 0.0 109.559 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 67.7 mttt -67.72 -17.83 64.7 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.293 -0.879 . . . . 0.0 109.527 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 82.5 p -112.74 145.86 39.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.2 -0.938 . . . . 0.0 109.421 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.497 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 82.5 mt-10 -124.68 155.76 38.69 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -0.885 . . . . 0.0 109.418 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.594 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 4.7 mttp 76.22 87.48 0.08 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 0.0 109.425 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.545 ' CD1' ' N ' ' A' ' 55' ' ' LEU . 5.2 mp -62.29 -24.68 67.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.171 -0.956 . . . . 0.0 109.465 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.648 ' CZ ' ' CD1' ' A' ' 159' ' ' ILE . 97.4 m-85 -148.79 100.59 3.47 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.316 -0.865 . . . . 0.0 109.056 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -66.08 139.75 57.13 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.733 2.288 . . . . 0.0 111.855 -179.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.17 -12.5 6.88 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.44 ' CE1' HD12 ' A' ' 11' ' ' LEU . 2.5 m-30 -100.03 131.3 46.07 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.704 -1.468 . . . . 0.0 110.128 -179.317 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.424 HG11 ' N ' ' A' ' 61' ' ' PHE . 45.6 t -134.62 144.77 33.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.361 -0.837 . . . . 0.0 108.887 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.534 ' HB2' ' CG2' ' A' ' 41' ' ' VAL . 74.2 m-85 -106.55 122.98 47.4 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.978 -1.077 . . . . 0.0 109.779 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 59.7 t -131.37 143.78 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.796 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.625 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 18.0 tt0 -108.2 127.29 53.7 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.328 -0.857 . . . . 0.0 109.166 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.496 ' HE1' ' CG1' ' A' ' 74' ' ' VAL . 32.8 mtm -153.98 170.88 20.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.072 -1.018 . . . . 0.0 110.653 -179.261 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.515 HG12 ' HA ' ' A' ' 36' ' ' LEU . 5.3 pt -95.14 131.34 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.536 ' CE ' ' NE2' ' A' ' 89' ' ' GLN . 59.3 mmm -75.95 143.26 41.7 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.893 . . . . 0.0 109.897 -178.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.438 ' HB2' ' O ' ' A' ' 66' ' ' MET . 37.6 t30 178.23 158.06 0.46 Allowed 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -59.61 -42.06 91.79 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -0.927 . . . . 0.0 109.594 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.573 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 69.3 mm-40 -74.85 -34.1 62.22 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.891 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.518 ' CB ' HD12 ' A' ' 36' ' ' LEU . . . -69.13 -46.36 67.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.149 -0.97 . . . . 0.0 109.756 -179.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.527 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 91.1 t80 -61.06 -47.03 88.25 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.156 -0.965 . . . . 0.0 109.782 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.457 ' O ' ' HB2' ' A' ' 76' ' ' SER . 27.5 m120 -62.07 -28.36 69.55 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 109.861 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.573 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 13.7 m-85 -84.54 -42.55 15.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.15 -0.969 . . . . 0.0 109.756 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.496 ' CG1' ' HE1' ' A' ' 64' ' ' MET . 25.9 t -69.76 -57.58 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.161 -0.962 . . . . 0.0 109.697 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.45 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 0.6 OUTLIER -59.26 -13.89 9.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.189 -0.944 . . . . 0.0 109.311 179.823 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 15.4 m -95.86 5.38 51.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.304 -0.873 . . . . 0.0 109.93 -179.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.604 ' CG1' ' HB ' ' A' ' 80' ' ' VAL . 2.3 p -75.46 134.29 73.31 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 120.965 -1.085 . . . . 0.0 109.457 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.627 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 43.8 Cg_endo -65.17 138.82 57.9 Favored 'Trans proline' 0 C--O 1.214 -0.72 0 C-N-CA 122.88 2.387 . . . . 0.0 112.287 -179.277 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.627 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 24.3 m-85 90.79 -9.32 0.3 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.857 -0.527 . . . . 0.0 109.662 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.604 ' HB ' ' CG1' ' A' ' 77' ' ' VAL . 5.7 p -90.88 127.08 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.979 -1.076 . . . . 0.0 109.332 179.506 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 82.8 mtp -86.24 -29.5 23.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.249 -0.907 . . . . 0.0 109.375 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.524 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 167.4 -164.22 37.74 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.524 ' CD1' ' O ' ' A' ' 82' ' ' GLY . 21.3 m-85 -134.33 141.39 46.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.207 -1.173 . . . . 0.0 109.499 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.493 HG21 ' CD2' ' A' ' 11' ' ' LEU . 19.9 t -64.29 123.82 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.25 -0.906 . . . . 0.0 109.409 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.533 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.6 p -162.76 162.26 26.61 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.28 -0.887 . . . . 0.0 109.522 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.1 t -91.55 -33.33 15.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.276 -0.89 . . . . 0.0 109.343 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -129.66 -82.32 0.29 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.519 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -106.66 -131.57 6.82 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.536 ' NE2' ' CE ' ' A' ' 66' ' ' MET . 1.4 mt-30 -33.31 152.08 0.05 OUTLIER Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.522 -0.987 . . . . 0.0 110.109 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.533 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.7 Cg_endo -69.1 159.25 54.64 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.841 2.361 . . . . 0.0 111.803 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 3.7 m -98.1 154.19 37.81 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.167 -0.958 . . . . 0.0 109.378 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.421 ' CB ' ' HD2' ' A' ' 6' ' ' LYS . 49.0 Cg_endo -70.19 150.99 66.41 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.612 2.208 . . . . 0.0 111.701 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.474 ' HB ' ' SD ' ' A' ' 98' ' ' MET . 31.2 t -85.46 142.38 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.249 -0.907 . . . . 0.0 109.33 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -78.37 139.2 38.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.936 . . . . 0.0 109.446 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.421 ' O ' ' N ' ' A' ' 99' ' ' ARG . 52.9 t0 -50.36 -39.14 45.62 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.497 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.5 mtm180 -52.06 -41.26 62.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.219 -0.926 . . . . 0.0 109.475 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.427 ' C ' ' HD2' ' A' ' 100' ' ' PRO . 63.0 mt-10 -85.38 -23.61 27.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.244 -0.91 . . . . 0.0 109.458 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.567 ' HE3' ' CD1' ' A' ' 7' ' ' TRP . 97.7 mtp -84.24 -23.64 30.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -0.927 . . . . 0.0 109.644 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.623 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 6.0 mmm180 -46.54 -48.04 48.13 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.256 -0.902 . . . . 0.0 109.788 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.623 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 50.6 Cg_endo -72.14 -27.3 17.03 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.394 2.063 . . . . 0.0 111.822 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.537 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 27.3 mm -81.49 -42.27 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.185 -0.947 . . . . 0.0 109.435 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.475 ' HA ' ' HB2' ' A' ' 107' ' ' LEU . 1.2 mt -69.15 -39.9 78.54 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.237 -0.915 . . . . 0.0 109.339 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.557 ' CZ ' ' NH1' ' A' ' 99' ' ' ARG . 23.5 mtt180 -64.27 -51.17 64.86 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.3 -0.875 . . . . 0.0 109.148 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.5 tt -71.44 -36.17 71.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.346 -0.846 . . . . 0.0 109.247 179.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.86 -0.26 8.72 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.328 -0.857 . . . . 0.0 109.989 -179.729 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.19 9.12 84.1 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.51 ' CD2' HG13 ' A' ' 41' ' ' VAL . 10.1 mp -80.72 -22.67 40.1 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.194 -1.18 . . . . 0.0 109.456 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.424 ' HG3' ' CB ' ' A' ' 102' ' ' LEU . 53.7 mt-10 -112.05 144.72 40.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.302 -0.874 . . . . 0.0 109.497 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -98.91 121.99 41.58 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.266 -0.896 . . . . 0.0 109.471 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 24.6 p90 -150.28 154.08 37.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.204 -0.935 . . . . 0.0 109.52 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -91.05 -149.42 0.22 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.235 -0.916 . . . . 0.0 109.415 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.438 ' HG2' ' N ' ' A' ' 113' ' ' LYS . 67.7 tt0 -113.15 154.46 26.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.248 -0.908 . . . . 0.0 109.428 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.505 ' O ' ' CG ' ' A' ' 113' ' ' LYS . 12.1 pttt -44.3 113.8 0.59 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.185 -0.947 . . . . 0.0 109.401 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 6.2 pttt -91.91 3.54 54.96 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.217 -0.927 . . . . 0.0 109.535 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.7 80.96 71.12 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.911 . . . . 0.0 109.462 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -70.85 121.53 7.98 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.694 2.263 . . . . 0.0 111.82 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 5.0 p -125.41 135.03 65.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.235 -0.916 . . . . 0.0 109.311 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 36.3 mtmm -98.49 128.76 44.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.93 . . . . 0.0 109.611 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 22.6 t -96.99 162.75 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.353 -0.842 . . . . 0.0 109.279 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.655 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 88.4 mt-10 -145.16 139.42 27.25 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.143 -0.973 . . . . 0.0 109.658 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.655 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 2.5 mt 146.2 98.29 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.596 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -23.13 94.01 0.01 OUTLIER Glycine 0 N--CA 1.495 2.601 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.58 ' CD1' ' O ' ' A' ' 121' ' ' LEU . 19.1 m-85 -67.41 155.25 39.44 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.131 -1.217 . . . . 0.0 109.096 179.759 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.492 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 77.1 mttt -134.51 151.84 51.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.122 -0.986 . . . . 0.0 109.95 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.456 ' HA ' HG22 ' A' ' 143' ' ' ILE . 22.5 t -65.32 141.58 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.451 -0.781 . . . . 0.0 109.23 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 89.19 -30.63 5.46 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.498 ' OD2' ' HE2' ' A' ' 175' ' ' LYS . 63.4 m-20 -47.8 161.89 0.09 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.309 -1.112 . . . . 0.0 108.989 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 6.1 ttm -102.09 128.23 48.65 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.025 -1.047 . . . . 0.0 109.096 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.559 HG12 ' CD1' ' A' ' 143' ' ' ILE . 11.6 m -128.67 143.88 39.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.387 -0.821 . . . . 0.0 109.715 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.51 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 44.4 tttt -100.84 140.56 34.96 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.539 HG22 ' N ' ' A' ' 132' ' ' ILE . 86.1 mt -79.39 154.62 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.024 -1.048 . . . . 0.0 108.371 179.375 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.594 ' CD1' ' CG ' ' A' ' 174' ' ' GLU . 1.1 pt -149.12 0.46 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.015 -1.053 . . . . 0.0 109.505 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.579 ' CB ' ' HG2' ' A' ' 172' ' ' GLU . 3.1 m -148.68 147.54 29.03 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.058 -1.027 . . . . 0.0 110.372 -179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.77 -170.29 19.92 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.463 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 45.9 Cg_endo -68.24 -21.46 41.76 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.199 2.599 . . . . 0.0 112.487 -179.753 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.469 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 91.5 m-85 -108.81 16.33 22.84 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.002 -1.061 . . . . 0.0 109.284 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.575 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 2.5 tt0 -48.09 142.69 4.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.316 -0.865 . . . . 0.0 109.788 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.575 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 14.5 t0 81.44 23.17 0.29 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.424 -0.797 . . . . 0.0 110.242 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.621 ' CE1' ' CG1' ' A' ' 157' ' ' VAL . 1.0 OUTLIER -116.13 141.75 47.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.984 -1.073 . . . . 0.0 109.463 179.813 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -90.12 136.18 33.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.191 -0.943 . . . . 0.0 109.516 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.491 ' HA3' HG12 ' A' ' 155' ' ' VAL . . . -148.02 171.18 28.56 Favored Glycine 0 N--CA 1.49 2.268 0 C-N-CA 119.636 -1.269 . . . . 0.0 110.538 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.589 ' N ' ' CG1' ' A' ' 155' ' ' VAL . 89.4 t -118.05 136.41 55.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.678 -0.895 . . . . 0.0 109.237 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.559 ' CD1' HG12 ' A' ' 129' ' ' VAL . 79.4 mt -66.78 115.8 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.43 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 33.2 tttt -97.63 -34.56 10.9 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.03 -1.044 . . . . 0.0 109.231 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -149.78 144.62 26.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.201 -0.937 . . . . 0.0 109.329 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.503 ' CG2' ' CD2' ' A' ' 153' ' ' LEU . 31.9 pt -123.98 127.66 73.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.573 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 28.5 t0 -111.81 100.19 47.72 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.484 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.568 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.3 Cg_endo -71.27 176.01 8.5 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.778 2.319 . . . . 0.0 111.71 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.568 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.4 mt-10 81.48 -21.05 0.33 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.434 -0.791 . . . . 0.0 109.84 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.45 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 82.1 mtt180 -131.15 -10.46 3.74 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.15 -0.969 . . . . 0.0 109.495 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.45 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 43.3 mt-30 69.97 48.54 0.54 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.252 -0.905 . . . . 0.0 109.967 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . 0.456 ' O ' HD23 ' A' ' 153' ' ' LEU . 81.3 tt0 -120.44 144.99 47.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.981 -1.075 . . . . 0.0 108.852 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.503 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 70.6 mt -139.91 127.69 21.9 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.102 -0.999 . . . . 0.0 110.441 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -91.74 132.77 36.16 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.589 ' CG1' ' N ' ' A' ' 142' ' ' VAL . 92.9 t -133.99 126.96 51.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.116 -0.99 . . . . 0.0 109.914 -179.358 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.536 ' OD1' ' N ' ' A' ' 164' ' ' THR . 51.9 t-20 -76.1 137.12 39.93 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.341 -0.85 . . . . 0.0 109.862 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.621 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 59.8 t -114.46 147.53 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.329 -0.857 . . . . 0.0 109.069 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 18.2 m -99.41 91.88 5.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.999 -1.063 . . . . 0.0 109.913 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.648 ' CD1' ' CZ ' ' A' ' 56' ' ' PHE . 2.5 pt -124.58 151.53 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.235 -0.916 . . . . 0.0 108.991 179.311 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.576 ' CD2' HD13 ' A' ' 159' ' ' ILE . 16.7 m-30 60.53 35.45 20.16 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -0.926 . . . . 0.0 108.969 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.03 15.37 9.99 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 21.0 mtp180 -128.22 158.22 38.71 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.179 -1.189 . . . . 0.0 109.595 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.434 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 90.7 mt-10 -100.97 132.76 46.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.268 -0.895 . . . . 0.0 109.551 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' THR . . . . . 0.536 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 47.4 m -139.78 127.31 12.85 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.943 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.59 134.1 25.49 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.741 2.294 . . . . 0.0 111.175 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.429 HG12 HD12 ' A' ' 168' ' ' LEU . 2.2 t -120.03 164.09 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 120.962 -1.086 . . . . 0.0 110.153 -179.527 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.626 ' O ' ' CD1' ' A' ' 168' ' ' LEU . 43.0 t -117.03 115.94 50.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 N-CA-C 109.119 -0.696 . . . . 0.0 109.119 179.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.656 ' N ' ' CD2' ' A' ' 168' ' ' LEU . 0.3 OUTLIER -139.49 167.55 21.84 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 121.878 0.847 . . . . 0.0 110.249 -179.52 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.401 ' O ' ' HB2' ' A' ' 172' ' ' GLU . 96.1 m-70 -78.94 141.01 37.92 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.432 ' CG2' HD13 ' A' ' 153' ' ' LEU . 7.2 p -55.01 -36.43 38.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.056 -1.028 . . . . 0.0 108.88 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 33.6 p -75.07 -5.23 43.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.455 -0.778 . . . . 0.0 109.553 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.579 ' HG2' ' CB ' ' A' ' 133' ' ' SER . 2.4 mt-10 -87.17 -1.82 58.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.225 -0.922 . . . . 0.0 109.707 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.51 ' HB ' ' O ' ' A' ' 130' ' ' LYS . 1.3 m -150.91 -178.31 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.138 -0.976 . . . . 0.0 109.465 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.594 ' CG ' ' CD1' ' A' ' 132' ' ' ILE . 3.5 mt-10 -138.01 170.2 16.45 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.082 -1.011 . . . . 0.0 109.1 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.498 ' HE2' ' OD2' ' A' ' 127' ' ' ASP . 52.0 tttm -86.14 5.77 32.34 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.0 -1.062 . . . . 0.0 109.553 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.488 ' CD1' ' HB2' ' A' ' 130' ' ' LYS . 46.4 mt 55.1 -88.88 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.459 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.485 ' N ' ' O ' ' A' ' 175' ' ' LYS . 85.5 tt0 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.016 -0.993 . . . . 0.0 109.483 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.21 -27.77 69.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.218 -1.166 . . . . 0.0 109.412 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 83.4 mtp -52.45 -44.26 65.4 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.462 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 31.4 tttt -70.08 144.52 52.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.29 -0.881 . . . . 0.0 109.573 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.479 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 27.4 mttm -144.43 150.07 37.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.488 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.533 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 1.3 mtpp -125.93 -179.78 4.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.196 -0.94 . . . . 0.0 109.321 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.586 ' CG ' ' CE ' ' A' ' 98' ' ' MET . 69.2 m95 -117.72 122.21 42.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.135 -0.978 . . . . 0.0 109.178 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -115.33 170.94 8.01 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.18 -0.95 . . . . 0.0 109.376 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.43 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 33.0 mt -112.89 110.74 33.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.296 -0.877 . . . . 0.0 109.065 179.681 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.532 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 10.3 p -88.66 142.48 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.215 -0.928 . . . . 0.0 109.512 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.533 HD23 ' CE1' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -89.04 145.68 25.32 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.294 -0.879 . . . . 0.0 109.625 -179.893 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.458 HG23 ' N ' ' A' ' 13' ' ' MET . 96.0 m -156.84 160.78 39.51 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.285 -0.884 . . . . 0.0 109.52 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.568 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 94.9 mmm -76.98 124.19 27.42 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.216 -0.928 . . . . 0.0 109.469 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 13' ' ' MET . 70.2 m -44.59 125.44 4.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.95 . . . . 0.0 109.301 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.0 -19.98 34.26 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.568 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 92.0 m-85 -107.14 -5.64 17.86 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.22 -1.165 . . . . 0.0 109.505 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.45 ' OE1' HD11 ' A' ' 44' ' ' ILE . 68.2 mt-10 -51.52 -54.62 25.37 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 109.486 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -51.48 -34.49 35.95 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.219 -0.926 . . . . 0.0 109.368 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.46 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 64.1 mttm -76.35 -49.54 16.6 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.178 179.783 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.484 HG22 ' CB ' ' A' ' 79' ' ' TYR . 42.0 t -52.22 -49.92 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.337 -0.852 . . . . 0.0 109.365 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.405 ' HG3' ' CG2' ' A' ' 40' ' ' ILE . 29.9 tttt -56.83 -50.33 72.72 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.65 -34.55 77.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.332 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.527 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 32.8 m120 -65.32 -48.14 74.07 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.404 -0.81 . . . . 0.0 109.586 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 77.4 mt -54.02 -44.52 62.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.133 -0.98 . . . . 0.0 109.437 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 75.1 tt0 -56.21 -46.14 79.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.246 -0.909 . . . . 0.0 109.721 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 7.7 mmtp -78.35 -36.13 46.58 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.16 -0.962 . . . . 0.0 109.509 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 8.9 tptt -53.9 -30.72 47.31 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.282 -0.886 . . . . 0.0 109.358 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.435 ' CG1' ' CG1' ' A' ' 37' ' ' VAL . 35.5 m -89.3 -22.04 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.3 -0.875 . . . . 0.0 109.41 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.421 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 44.6 mm-40 -70.71 -54.52 11.49 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.611 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.72 -31.09 71.95 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.185 -0.947 . . . . 0.0 109.451 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 37.8 p -87.54 -8.23 56.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.413 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 60.58 28.54 67.89 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.543 ' CG2' ' CG ' ' A' ' 36' ' ' LEU . 46.7 mt -107.48 73.22 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -1.149 . . . . 0.0 109.515 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.6 mtmt -87.68 -2.36 58.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.225 -0.922 . . . . 0.0 109.573 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -94.08 -12.8 27.73 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -0.929 . . . . 0.0 109.473 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.573 ' N ' ' CD2' ' A' ' 36' ' ' LEU . 1.8 mm? -86.92 -47.82 8.67 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.311 179.835 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.435 ' CG1' ' CG1' ' A' ' 28' ' ' VAL . 11.6 p -94.16 142.65 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.388 -0.82 . . . . 0.0 109.518 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -113.45 -123.97 4.08 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 82.0 mtt180 -94.43 140.07 30.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.253 -1.145 . . . . 0.0 109.619 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.427 HG12 HG11 ' A' ' 62' ' ' VAL . 58.8 mt -106.33 136.06 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 109.361 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.57 HG23 ' CZ3' ' A' ' 7' ' ' TRP . 31.5 m -127.16 161.98 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.223 -0.923 . . . . 0.0 109.06 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.489 HG23 ' CD1' ' A' ' 44' ' ' ILE . 9.7 mt -144.02 126.99 8.72 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.142 -0.974 . . . . 0.0 110.034 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.69 -2.28 9.08 Favored 'Trans proline' 0 C--O 1.217 -0.533 0 C-N-CA 122.917 2.411 . . . . 0.0 111.381 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.816 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 76.8 mt -57.02 -50.31 76.7 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.185 -0.947 . . . . 0.0 109.491 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.472 ' HB3' ' O ' ' A' ' 44' ' ' ILE . 20.6 ttt85 61.37 139.47 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.296 -0.878 . . . . 0.0 109.498 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.59 16.73 38.55 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.91 -25.5 61.78 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -55.13 -31.61 61.42 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.307 -1.113 . . . . 0.0 109.558 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -100.91 145.72 28.26 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.25 -0.906 . . . . 0.0 109.534 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 57.1 ttm-85 -53.27 -41.4 65.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.292 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 3.2 mtpm? -93.91 115.45 27.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.313 -0.867 . . . . 0.0 109.406 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.504 ' HB2' ' CG2' ' A' ' 44' ' ' ILE . 79.1 p -104.89 156.7 17.79 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.185 -0.947 . . . . 0.0 109.421 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.491 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 27.5 mp0 -76.23 -45.16 34.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.256 -0.902 . . . . 0.0 109.433 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.816 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 8.4 mttt 75.13 88.78 0.09 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.179 -0.951 . . . . 0.0 109.238 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.573 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 61.3 tp -67.04 -23.13 65.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.8 -1.188 . . . . 0.0 109.666 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.573 ' CE2' ' HG ' ' A' ' 55' ' ' LEU . 57.1 m-85 -145.46 97.13 4.73 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 108.836 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -66.01 136.48 44.89 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.59 2.193 . . . . 0.0 112.247 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.74 -13.17 8.91 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.533 ' CE1' HD23 ' A' ' 11' ' ' LEU . 2.4 m-30 -100.84 130.47 46.86 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.688 -1.478 . . . . 0.0 110.23 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.532 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 79.2 t -134.38 147.44 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.373 -0.829 . . . . 0.0 108.809 179.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.529 ' HB2' ' CG2' ' A' ' 41' ' ' VAL . 15.7 m-85 -107.58 122.12 46.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.005 -1.06 . . . . 0.0 109.956 -179.532 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.427 HG11 HG12 ' A' ' 40' ' ' ILE . 7.9 m -125.81 136.77 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.405 -0.809 . . . . 0.0 109.642 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.564 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 7.8 tt0 -101.01 123.96 45.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.228 -0.92 . . . . 0.0 108.974 179.553 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.53 ' HB3' ' O ' ' A' ' 36' ' ' LEU . 14.0 mtm -156.06 176.45 12.65 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.999 -1.063 . . . . 0.0 110.36 -179.266 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.543 ' CD1' HD11 ' A' ' 36' ' ' LEU . 7.9 pt -99.38 132.28 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.482 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 47.4 ttm -76.66 144.17 39.63 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.347 -0.846 . . . . 0.0 109.992 -178.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.482 ' HB2' ' O ' ' A' ' 66' ' ' MET . 50.6 t30 176.2 171.53 0.4 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -67.25 -41.64 85.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.1 -1.0 . . . . 0.0 109.446 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.579 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 97.4 mt-10 -71.72 -38.1 70.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.295 -0.878 . . . . 0.0 109.872 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -64.93 -44.9 87.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.19 -0.944 . . . . 0.0 109.466 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.493 ' CD2' ' OE1' ' A' ' 89' ' ' GLN . 27.9 t80 -60.0 -52.02 67.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.284 -0.885 . . . . 0.0 109.641 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.53 ' O ' ' HB3' ' A' ' 76' ' ' SER . 96.1 m-20 -59.34 -28.32 66.72 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.204 -0.935 . . . . 0.0 110.164 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 21.9 m-85 -85.45 -43.53 13.52 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.957 -1.089 . . . . 0.0 109.95 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 71.6 t -70.06 -57.84 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.288 -0.883 . . . . 0.0 110.025 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.521 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 29.3 tpt85 -60.83 -22.58 64.34 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.171 -0.956 . . . . 0.0 109.826 -179.669 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.53 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 35.4 p -93.71 5.89 50.13 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.127 -0.983 . . . . 0.0 109.88 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.642 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 5.1 p -70.15 129.42 90.66 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.125 -0.985 . . . . 0.0 109.331 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.678 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 43.5 Cg_endo -65.48 138.92 56.81 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 122.782 2.322 . . . . 0.0 112.177 -179.382 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.678 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 59.9 m-85 91.54 -11.98 0.23 Allowed 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.642 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 4.7 t -93.96 134.12 32.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.994 -1.066 . . . . 0.0 109.171 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 85.6 mmm -87.95 -27.4 22.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.205 -0.934 . . . . 0.0 109.492 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.457 ' O ' ' N ' ' A' ' 11' ' ' LEU . . . 161.9 -160.24 32.24 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.617 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 1.6 p90 -139.61 153.92 47.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -1.094 . . . . 0.0 109.314 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.488 ' CG1' ' O ' ' A' ' 84' ' ' VAL . 10.6 p -84.71 113.7 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.188 -0.945 . . . . 0.0 109.615 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.526 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.4 p -148.47 163.24 37.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.895 . . . . 0.0 109.438 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 80.6 p -86.5 -34.55 19.98 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.419 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -127.32 -91.11 0.74 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.557 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -102.59 -126.95 5.97 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.557 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -30.27 152.39 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.61 -0.935 . . . . 0.0 110.375 -179.606 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.571 ' HD3' ' CD2' ' A' ' 83' ' ' PHE . 47.1 Cg_endo -68.13 137.69 41.39 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.917 2.411 . . . . 0.0 112.014 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 18.8 m -73.54 144.92 84.25 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.351 -0.843 . . . . 0.0 109.336 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.31 153.81 66.08 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.645 2.23 . . . . 0.0 111.702 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 7' ' ' TRP . 18.6 t -93.9 129.45 44.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.379 -0.826 . . . . 0.0 109.36 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 25.4 mttm -64.29 141.38 58.79 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.227 -0.921 . . . . 0.0 109.512 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -51.37 -38.64 54.36 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.228 -0.92 . . . . 0.0 109.415 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 62.3 mtt85 -58.2 -38.26 76.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.347 -0.846 . . . . 0.0 109.557 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -77.61 -25.93 50.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.196 -0.94 . . . . 0.0 109.454 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.586 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 95.4 mtp -86.03 -22.27 27.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.388 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.586 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 1.1 mtm180 -36.27 -52.8 1.7 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.525 -0.734 . . . . 0.0 109.861 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.586 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 49.7 Cg_endo -70.01 -27.98 24.62 Favored 'Trans proline' 0 C--O 1.214 -0.718 0 C-N-CA 122.469 2.113 . . . . 0.0 111.908 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.526 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 29.8 mm -81.98 -43.41 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.176 -0.952 . . . . 0.0 109.451 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.533 HD13 ' CB ' ' A' ' 98' ' ' MET . 1.2 mt -68.94 -40.0 79.26 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.23 -0.919 . . . . 0.0 109.445 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.547 ' NH2' ' NH1' ' A' ' 99' ' ' ARG . 24.1 mtt180 -64.36 -50.59 67.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.124 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.62 -36.07 70.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.382 -0.824 . . . . 0.0 109.3 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.526 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -71.27 1.47 6.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.323 -0.861 . . . . 0.0 110.035 -179.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.07 8.25 82.88 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.523 ' N ' HD13 ' A' ' 107' ' ' LEU . 9.4 mp -80.91 -22.07 40.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -1.148 . . . . 0.0 109.368 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.469 ' HB3' ' HA ' ' A' ' 103' ' ' ARG . 47.6 tp10 -115.95 142.95 46.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.333 -0.854 . . . . 0.0 109.487 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -115.89 120.74 40.19 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.228 -0.92 . . . . 0.0 109.487 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.473 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 35.8 p90 -138.96 160.12 40.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.243 -0.911 . . . . 0.0 109.414 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.473 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 47.6 mt-10 -77.44 -144.97 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.513 ' O ' ' C ' ' A' ' 113' ' ' LYS . 76.7 tt0 -129.86 155.33 46.19 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.435 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.521 ' NZ ' ' O ' ' A' ' 132' ' ' ILE . 5.6 tttp -34.51 146.0 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.484 -0.76 . . . . 0.0 109.892 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.63 -43.33 85.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 109.55 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.09 158.37 38.84 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.257 -0.902 . . . . 0.0 109.626 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.53 121.9 8.4 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.763 2.309 . . . . 0.0 111.798 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.432 HG12 ' HE2' ' A' ' 113' ' ' LYS . 4.1 p -98.51 147.39 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.197 -0.94 . . . . 0.0 109.518 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 35.9 mttt -86.63 169.97 12.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.238 -0.914 . . . . 0.0 109.446 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.446 HG11 ' O ' ' A' ' 173' ' ' VAL . 32.8 m -113.53 177.28 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.223 -0.923 . . . . 0.0 109.51 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.554 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 6.9 mt-10 -67.99 -24.16 65.11 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.311 -0.868 . . . . 0.0 109.533 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.554 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 3.4 tp 79.67 161.41 0.18 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.358 -0.839 . . . . 0.0 109.625 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 43.19 46.07 6.44 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.494 ' CE1' HG21 ' A' ' 146' ' ' ILE . 0.3 OUTLIER -64.19 178.26 0.71 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.188 -1.184 . . . . 0.0 109.208 179.679 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.439 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 7.1 mttp -141.13 145.42 35.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.076 -1.015 . . . . 0.0 109.868 -179.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 22.4 m -63.98 141.99 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.38 -0.825 . . . . 0.0 109.397 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 87.44 -31.69 4.42 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.017 -1.633 . . . . 0.0 109.017 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.496 ' CG ' ' CE ' ' A' ' 175' ' ' LYS . 13.0 t70 -48.5 164.04 0.06 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.513 -0.992 . . . . 0.0 109.055 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' MET . . . . . 0.466 ' HG2' HD11 ' A' ' 176' ' ' ILE . 4.2 ttm -100.29 127.47 46.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.086 -1.009 . . . . 0.0 109.241 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.562 ' CG1' HG12 ' A' ' 143' ' ' ILE . 35.0 m -125.89 142.35 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.34 -0.85 . . . . 0.0 109.26 179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.488 ' HB2' ' CD1' ' A' ' 176' ' ' ILE . 7.8 tttt -102.79 141.83 34.94 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.357 -0.839 . . . . 0.0 108.858 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.534 HG21 ' N ' ' A' ' 132' ' ' ILE . 89.8 mt -81.73 152.35 4.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.102 -0.999 . . . . 0.0 108.557 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.537 HD12 ' CA ' ' A' ' 173' ' ' VAL . 0.5 OUTLIER -150.45 1.64 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.024 -1.048 . . . . 0.0 109.382 179.647 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.512 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 2.9 m -147.27 143.49 28.15 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.128 -0.982 . . . . 0.0 109.896 -179.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.17 -166.92 17.76 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.6 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 45.7 Cg_endo -68.49 -22.51 38.65 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 123.179 2.586 . . . . 0.0 112.594 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.6 ' CD1' ' HG2' ' A' ' 135' ' ' PRO . 70.7 m-85 -106.46 17.3 23.54 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.786 -1.196 . . . . 0.0 109.533 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.56 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 1.5 tt0 -48.18 137.57 10.56 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.168 -0.957 . . . . 0.0 109.599 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.56 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 10.8 m-20 81.62 22.34 0.3 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.479 -0.763 . . . . 0.0 110.323 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.621 ' CE1' ' CG1' ' A' ' 157' ' ' VAL . 1.5 t80 -115.03 143.04 45.81 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.966 -1.084 . . . . 0.0 109.566 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -92.0 134.7 34.57 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.146 -0.971 . . . . 0.0 109.493 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.41 167.24 27.52 Favored Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.739 -1.22 . . . . 0.0 110.212 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.502 ' N ' HG13 ' A' ' 155' ' ' VAL . 37.6 t -115.07 137.14 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.54 -0.976 . . . . 0.0 109.139 179.651 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.619 ' CG2' ' CD1' ' A' ' 146' ' ' ILE . 28.1 mm -69.13 122.4 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.262 -0.899 . . . . 0.0 109.423 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . 0.468 ' C ' ' HG2' ' A' ' 145' ' ' GLU . 0.2 OUTLIER -106.53 -33.3 7.73 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.04 -1.038 . . . . 0.0 109.627 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.468 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 70.0 mm-40 -151.38 146.58 26.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.014 -1.054 . . . . 0.0 109.874 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.619 ' CD1' ' CG2' ' A' ' 143' ' ' ILE . 6.0 mm -120.86 122.76 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.091 -1.006 . . . . 0.0 109.491 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 14.7 t0 -107.08 99.21 25.38 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.307 -0.87 . . . . 0.0 109.349 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.565 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.6 Cg_endo -71.45 172.26 14.57 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.801 2.334 . . . . 0.0 111.841 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.565 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 4.6 mt-10 80.62 -20.16 0.39 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.377 -0.827 . . . . 0.0 109.786 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 94.8 mtt-85 -128.04 -13.66 5.08 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.142 -0.974 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.432 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 35.9 mt-30 70.33 48.47 0.49 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.245 -0.909 . . . . 0.0 109.38 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -120.01 143.13 48.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.085 -1.01 . . . . 0.0 109.245 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.589 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 98.8 mt -128.64 130.73 47.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.219 -0.926 . . . . 0.0 110.103 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . 0.456 ' HD3' ' HB2' ' A' ' 145' ' ' GLU . 22.7 mtpp -92.93 126.17 37.89 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.502 HG13 ' N ' ' A' ' 142' ' ' VAL . 4.0 t -126.31 145.86 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.252 -0.905 . . . . 0.0 110.086 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.526 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 27.7 t-20 -98.87 114.9 27.7 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.451 -0.781 . . . . 0.0 109.326 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.621 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 41.7 t -97.54 142.59 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.373 -0.829 . . . . 0.0 109.665 -179.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 13.3 m -96.57 95.61 8.1 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.784 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.553 HD13 ' CE2' ' A' ' 160' ' ' PHE . 19.0 pt -125.94 146.72 31.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.319 -0.863 . . . . 0.0 109.301 179.76 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.553 ' CE2' HD13 ' A' ' 159' ' ' ILE . 11.5 m-85 63.24 36.26 12.0 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.219 -0.926 . . . . 0.0 109.321 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.05 16.64 19.53 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.411 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 17.8 mtt-85 -130.15 158.69 38.98 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.291 -1.123 . . . . 0.0 109.548 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -99.42 132.99 44.37 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.202 -0.936 . . . . 0.0 109.375 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' THR . . . . . 0.418 HG22 ' CZ ' ' A' ' 56' ' ' PHE . 27.9 m -144.13 124.84 7.74 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.188 -0.945 . . . . 0.0 109.647 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -70.81 139.47 36.67 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.738 2.292 . . . . 0.0 111.763 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.476 HG12 HG21 ' A' ' 157' ' ' VAL . 5.6 p -124.48 143.58 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.155 -0.965 . . . . 0.0 109.646 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.429 ' O ' ' CG1' ' A' ' 167' ' ' VAL . 10.7 p -92.31 119.36 39.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.414 -0.804 . . . . 0.0 109.33 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.565 ' CD1' ' CG1' ' A' ' 173' ' ' VAL . 0.7 OUTLIER -140.48 165.91 26.14 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.22 -0.925 . . . . 0.0 110.621 -179.054 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.452 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 98.2 m-70 -80.32 145.54 32.05 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.487 HG21 ' CD1' ' A' ' 153' ' ' LEU . 11.0 p -60.14 -34.58 57.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.19 -0.944 . . . . 0.0 108.975 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 54.3 p -76.82 -6.73 53.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.322 -0.861 . . . . 0.0 109.321 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.512 ' HA ' ' HB2' ' A' ' 133' ' ' SER . 74.4 mt-10 -96.33 5.94 49.85 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.299 -0.876 . . . . 0.0 109.25 179.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.565 ' CG1' ' CD1' ' A' ' 168' ' ' LEU . 1.5 p -148.07 169.01 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.279 -0.888 . . . . 0.0 108.723 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.565 ' N ' ' CG2' ' A' ' 173' ' ' VAL . 57.0 mt-10 -138.51 167.79 21.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.011 -1.056 . . . . 0.0 109.202 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.535 ' O ' ' N ' ' A' ' 177' ' ' GLU . 63.0 tttt -92.55 22.57 4.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.077 -1.015 . . . . 0.0 109.485 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.488 ' CD1' ' HB2' ' A' ' 130' ' ' LYS . 84.5 mt 42.01 -94.25 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.869 . . . . 0.0 109.606 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.535 ' N ' ' O ' ' A' ' 175' ' ' LYS . 61.7 tt0 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.531 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.33 -24.15 67.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.293 -1.122 . . . . 0.0 109.451 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 57.4 mtm -63.84 -17.39 63.08 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -0.92 . . . . 0.0 109.497 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 52.0 mttp -110.13 119.0 37.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.23 -0.919 . . . . 0.0 109.452 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.6 mttt -106.83 174.31 5.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.166 -0.959 . . . . 0.0 109.498 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.532 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 24.6 mmtp -128.75 175.5 8.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -0.93 . . . . 0.0 109.307 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.609 ' CD1' ' HG3' ' A' ' 63' ' ' GLU . 64.6 m95 -112.17 124.59 52.77 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.247 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 66' ' ' MET . 81.3 m-85 -117.0 170.98 8.21 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.212 -0.93 . . . . 0.0 109.422 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.601 HG12 ' CE1' ' A' ' 61' ' ' PHE . 42.1 mt -107.45 116.33 50.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.251 -0.905 . . . . 0.0 109.379 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.469 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 50.0 t -93.43 139.14 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.241 -0.912 . . . . 0.0 109.362 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.59 HD12 ' CE1' ' A' ' 59' ' ' TYR . 4.2 mm? -86.78 146.28 26.3 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.316 -0.865 . . . . 0.0 109.33 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.471 HG22 ' HA2' ' A' ' 58' ' ' GLY . 11.2 t -158.24 -176.21 5.78 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.263 -0.898 . . . . 0.0 109.501 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.483 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 64.0 mtm -101.2 120.01 39.6 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.175 -0.953 . . . . 0.0 109.533 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.426 ' OG ' ' HB2' ' A' ' 57' ' ' PRO . 43.0 m -43.39 128.3 4.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 109.385 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.08 -19.88 47.43 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.483 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 87.2 m-85 -109.54 9.59 25.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.346 -1.091 . . . . 0.0 109.511 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -60.03 -45.1 93.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.203 -0.936 . . . . 0.0 109.493 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.467 ' OE2' ' HG2' ' A' ' 49' ' ' ARG . 78.3 mt-10 -58.82 -35.31 72.67 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.183 -0.948 . . . . 0.0 109.329 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -72.73 -34.0 66.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -0.929 . . . . 0.0 109.355 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 87.0 t -72.39 -53.05 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.912 . . . . 0.0 109.461 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 46.2 tttm -57.62 -49.91 74.9 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.301 -0.874 . . . . 0.0 109.372 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -63.4 -35.86 81.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.196 -0.94 . . . . 0.0 109.165 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.471 ' OD1' ' HD2' ' A' ' 78' ' ' PRO . 13.8 t-20 -62.72 -47.59 82.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.345 -0.847 . . . . 0.0 109.48 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.49 ' CG2' HG11 ' A' ' 37' ' ' VAL . 89.7 mt -55.75 -43.58 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.278 -0.889 . . . . 0.0 109.501 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -57.64 -46.87 83.62 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.943 . . . . 0.0 110.11 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 76.4 mttt -75.63 -37.31 59.83 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.984 -1.073 . . . . 0.0 109.824 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.602 ' HE3' ' CE1' ' A' ' 73' ' ' PHE . 42.2 tttp -55.95 -29.68 60.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.133 -0.98 . . . . 0.0 109.204 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.53 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 37.8 t -82.98 -26.42 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.866 . . . . 0.0 109.508 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.41 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 66.8 mm-40 -67.68 -51.65 47.16 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.247 -0.908 . . . . 0.0 109.474 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.07 -43.91 51.54 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.246 -0.909 . . . . 0.0 109.444 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 62.6 p -88.88 -7.95 55.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.187 -0.946 . . . . 0.0 109.624 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 54.95 22.58 28.12 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.561 ' CG2' ' CD1' ' A' ' 36' ' ' LEU . 74.8 mt -84.69 100.91 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.252 -1.146 . . . . 0.0 109.512 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.5 mttt -103.54 35.33 2.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.264 -0.897 . . . . 0.0 109.357 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.451 ' OD1' HG21 ' A' ' 33' ' ' ILE . 18.6 p-10 -136.41 8.45 3.13 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.204 -0.935 . . . . 0.0 109.784 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.592 ' CD2' ' CD1' ' A' ' 65' ' ' ILE . 82.1 mt -113.09 -42.88 3.46 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.22 -0.925 . . . . 0.0 109.34 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.49 HG11 ' CG2' ' A' ' 24' ' ' ILE . 52.5 t -106.93 138.68 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.226 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -109.37 -124.65 4.93 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.409 ' O ' ' CH2' ' A' ' 7' ' ' TRP . 64.8 mtt85 -95.13 140.12 30.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.243 -1.151 . . . . 0.0 109.789 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.402 HD11 HG23 ' A' ' 40' ' ' ILE . 67.9 mt -102.13 135.94 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.307 -0.87 . . . . 0.0 109.032 179.586 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.531 ' CG2' ' CH2' ' A' ' 7' ' ' TRP . 53.5 t -118.51 147.21 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.066 -1.021 . . . . 0.0 109.678 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.526 ' CG2' HG21 ' A' ' 44' ' ' ILE . 2.5 mt -119.74 125.72 27.28 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.254 -0.904 . . . . 0.0 109.411 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.501 ' CB ' ' CD2' ' A' ' 56' ' ' PHE . 49.6 Cg_endo -70.33 -5.33 16.3 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.735 2.29 . . . . 0.0 111.814 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.559 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 14.6 pt -66.09 130.43 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.258 -0.901 . . . . 0.0 109.569 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.439 ' HD2' HD13 ' A' ' 104' ' ' LEU . 34.0 tpt85 -62.61 -48.73 78.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.356 -0.84 . . . . 0.0 109.513 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -77.0 118.97 5.27 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -84.78 11.76 58.74 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -107.02 165.14 11.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.317 -1.107 . . . . 0.0 109.453 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.467 ' HG2' ' OE2' ' A' ' 18' ' ' GLU . 64.2 mtt85 -62.63 -30.58 71.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.277 -0.889 . . . . 0.0 109.463 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 65.8 mtt85 -114.36 174.98 5.68 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.904 . . . . 0.0 109.415 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 69.7 mttt 56.05 28.64 13.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.277 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.38 137.69 32.15 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.326 -0.859 . . . . 0.0 109.462 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.502 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 82.9 tt0 -91.83 -48.99 6.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.269 -0.894 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.559 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 37.8 mttt 75.33 87.54 0.09 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.302 -0.874 . . . . 0.0 109.494 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.618 ' O ' ' CD1' ' A' ' 56' ' ' PHE . 49.4 mt -60.72 -24.77 65.93 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.091 -1.006 . . . . 0.0 109.462 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.618 ' CD1' ' O ' ' A' ' 55' ' ' LEU . 1.0 OUTLIER -151.59 104.58 2.89 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.298 -0.876 . . . . 0.0 108.78 179.655 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.426 ' HB2' ' OG ' ' A' ' 14' ' ' SER . 43.7 Cg_endo -66.93 142.17 61.39 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.541 2.161 . . . . 0.0 111.845 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.471 ' HA2' HG22 ' A' ' 12' ' ' THR . . . 74.48 -9.48 10.31 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.59 ' CE1' HD12 ' A' ' 11' ' ' LEU . 2.9 m-30 -102.52 132.08 48.81 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.8 -1.412 . . . . 0.0 110.046 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.419 HG23 HG23 ' A' ' 12' ' ' THR . 45.8 t -134.74 147.75 29.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.859 . . . . 0.0 108.818 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.601 ' CE1' HG12 ' A' ' 9' ' ' ILE . 93.2 m-85 -110.34 123.19 49.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.937 -1.102 . . . . 0.0 109.902 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.474 HG22 ' O ' ' A' ' 62' ' ' VAL . 4.9 m -130.66 143.34 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.302 -0.874 . . . . 0.0 109.767 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.609 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 8.1 tt0 -101.46 125.35 48.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 109.04 179.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.475 ' CB ' ' O ' ' A' ' 36' ' ' LEU . 14.6 ptt? -163.38 -177.37 5.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.984 -1.072 . . . . 0.0 110.457 -179.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.592 ' CD1' ' CD2' ' A' ' 36' ' ' LEU . 7.5 pt -100.9 125.04 54.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.539 -0.726 . . . . 0.0 109.578 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 8' ' ' TYR . 73.5 mmm -89.56 99.64 12.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 109.398 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.461 ' OD1' HG13 ' A' ' 65' ' ' ILE . 21.3 m120 -139.04 -164.29 1.63 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.062 -1.024 . . . . 0.0 109.174 179.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -73.04 -51.92 16.34 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.249 -0.907 . . . . 0.0 110.005 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -72.82 -58.34 3.41 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.096 -1.003 . . . . 0.0 109.743 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.491 ' O ' ' CG2' ' A' ' 74' ' ' VAL . . . -47.3 -44.19 23.13 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.456 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.577 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 88.0 t80 -61.65 -51.6 67.79 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.164 -0.96 . . . . 0.0 109.586 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.495 ' O ' ' HB3' ' A' ' 76' ' ' SER . 83.6 m-20 -59.16 -29.28 67.32 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.228 -0.92 . . . . 0.0 109.888 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.602 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 15.8 t80 -82.61 -43.21 17.28 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.091 -1.006 . . . . 0.0 109.636 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.491 ' CG2' ' O ' ' A' ' 70' ' ' ALA . 16.4 t -65.22 -58.1 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.41 -0.806 . . . . 0.0 109.505 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.503 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 15.1 tpt180 -58.23 -11.02 2.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.324 -0.86 . . . . 0.0 110.095 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 29.0 p -95.41 5.38 51.79 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.927 -1.108 . . . . 0.0 109.898 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.577 ' CG1' ' HB ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -71.85 128.72 89.11 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.094 -1.004 . . . . 0.0 109.086 179.871 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.644 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 42.0 Cg_endo -64.97 140.45 66.26 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.566 2.177 . . . . 0.0 111.891 -179.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.644 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 8.2 m-85 91.7 -10.02 0.24 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.89 -0.506 . . . . 0.0 109.817 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.577 ' HB ' ' CG1' ' A' ' 77' ' ' VAL . 4.3 p -93.57 134.47 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.879 -1.138 . . . . 0.0 109.85 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 88.6 mtp -86.91 -23.98 24.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.379 -0.825 . . . . 0.0 109.258 179.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.572 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 155.19 -156.38 26.91 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.572 ' CD1' ' O ' ' A' ' 82' ' ' GLY . 15.3 m-85 -135.19 143.22 46.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.266 -1.137 . . . . 0.0 109.474 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 90' ' ' PRO . 9.5 p -69.46 131.81 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.286 -0.884 . . . . 0.0 109.512 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.549 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.3 p -166.92 158.65 12.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.271 -0.893 . . . . 0.0 109.616 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.2 m -86.05 -31.79 21.78 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.282 -0.886 . . . . 0.0 109.269 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -131.03 -85.37 0.34 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.542 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -104.17 -134.24 8.09 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.577 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.6 OUTLIER -30.91 150.79 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.819 0 O-C-N 121.557 -0.967 . . . . 0.0 110.317 -179.622 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.549 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.5 Cg_endo -68.38 141.3 50.92 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.819 2.346 . . . . 0.0 112.087 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . 0.549 ' CG2' ' HD2' ' A' ' 92' ' ' PRO . 4.0 p -77.14 144.35 71.4 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.344 -0.847 . . . . 0.0 109.364 179.801 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.549 ' HD2' ' CG2' ' A' ' 91' ' ' VAL . 47.4 Cg_endo -68.39 153.52 73.92 Favored 'Trans proline' 0 C--O 1.216 -0.575 0 C-N-CA 122.66 2.24 . . . . 0.0 111.743 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.496 ' CG1' ' HB2' ' A' ' 97' ' ' GLU . 86.2 t -89.38 133.66 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.268 -0.895 . . . . 0.0 109.649 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 26.4 mtmt -61.49 138.4 58.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.331 -0.856 . . . . 0.0 109.449 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -49.4 -35.81 20.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.928 . . . . 0.0 109.464 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 76.5 mtt180 -61.57 -28.95 69.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.504 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.496 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . 77.1 mt-10 -82.41 -25.22 33.9 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.92 . . . . 0.0 109.599 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.503 ' O ' ' C ' ' A' ' 99' ' ' ARG . 30.9 mmm -85.37 -28.92 24.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.208 -0.932 . . . . 0.0 109.385 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.577 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -36.33 -54.26 1.56 Allowed Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.413 -0.804 . . . . 0.0 109.844 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.607 ' HB2' ' CE1' ' A' ' 136' ' ' PHE . 48.6 Cg_endo -69.28 -26.91 29.39 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.581 2.188 . . . . 0.0 111.938 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.456 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 22.3 mm -82.67 -39.42 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.255 -0.903 . . . . 0.0 109.352 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.583 ' N ' ' CD1' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -72.05 -40.53 68.27 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.097 179.823 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.486 ' HA ' ' HB2' ' A' ' 108' ' ' GLU . 9.3 ttt180 -64.54 -48.5 74.84 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.869 . . . . 0.0 109.158 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.439 HD13 ' HD2' ' A' ' 45' ' ' ARG . 1.2 tt -71.72 -35.12 70.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.271 -0.893 . . . . 0.0 109.184 179.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -71.83 2.15 5.92 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.335 -0.853 . . . . 0.0 110.178 -179.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.0 9.4 83.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.451 ' HB3' ' HB3' ' A' ' 102' ' ' LEU . 0.4 OUTLIER -76.56 -18.68 58.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.073 -1.251 . . . . 0.0 109.314 179.85 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.486 ' HB2' ' HA ' ' A' ' 103' ' ' ARG . 91.2 mt-10 -109.65 152.87 25.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.278 -0.889 . . . . 0.0 109.555 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -108.27 112.68 25.27 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.27 -0.894 . . . . 0.0 109.468 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.448 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 25.8 p90 -149.53 158.27 44.02 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.327 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.448 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 18.6 mt-10 -89.12 -149.96 0.19 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.23 -0.919 . . . . 0.0 109.5 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.458 ' HG2' ' N ' ' A' ' 113' ' ' LYS . 74.4 tt0 -103.87 153.49 20.7 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.226 -0.921 . . . . 0.0 109.469 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.524 ' CD ' ' OG ' ' A' ' 133' ' ' SER . 15.0 pttm -45.56 -43.71 12.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.204 -0.935 . . . . 0.0 109.524 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.523 ' N ' ' HG3' ' A' ' 113' ' ' LYS . 0.3 OUTLIER 68.63 52.81 0.56 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.365 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -138.64 80.23 26.72 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.31 -0.869 . . . . 0.0 109.362 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -71.13 -6.09 18.44 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.732 2.288 . . . . 0.0 111.933 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 14.4 p -67.47 134.87 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.908 . . . . 0.0 109.51 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -83.92 151.92 24.81 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.296 -0.877 . . . . 0.0 109.38 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.518 ' CG1' ' HA ' ' A' ' 171' ' ' SER . 7.6 p -114.83 144.88 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.249 -0.907 . . . . 0.0 109.523 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.654 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 86.3 mt-10 -126.81 170.85 11.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.438 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.654 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 3.8 mt 146.14 100.91 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.616 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.22 92.05 0.01 OUTLIER Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.508 ' N ' ' O ' ' A' ' 121' ' ' LEU . 45.7 p90 -104.29 141.76 35.73 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.168 -1.195 . . . . 0.0 109.097 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.417 ' HG2' ' C ' ' A' ' 123' ' ' PHE . 12.5 mmtt -138.12 163.75 30.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.094 -1.004 . . . . 0.0 110.063 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 11.0 p -62.9 141.95 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.443 -0.785 . . . . 0.0 109.548 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 86.98 -33.21 3.83 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.467 ' O ' HG23 ' A' ' 142' ' ' VAL . 71.4 m-20 -46.51 161.76 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.378 -1.072 . . . . 0.0 109.102 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 15.4 ttm -99.82 127.88 45.96 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.138 -0.976 . . . . 0.0 108.959 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.536 ' CG1' HG13 ' A' ' 143' ' ' ILE . 33.4 m -127.78 143.21 41.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.193 -0.942 . . . . 0.0 109.612 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.479 ' HG3' ' O ' ' A' ' 139' ' ' PHE . 12.1 ttpt -101.69 143.02 32.16 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.45 -0.781 . . . . 0.0 109.046 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.53 ' C ' HG13 ' A' ' 132' ' ' ILE . 93.1 mt -80.39 147.0 6.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.132 -0.98 . . . . 0.0 108.421 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.53 HG13 ' C ' ' A' ' 131' ' ' ILE . 18.7 mt -145.03 1.22 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.018 -1.051 . . . . 0.0 109.337 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.524 ' OG ' ' CD ' ' A' ' 113' ' ' LYS . 16.7 t -148.48 142.37 25.77 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.188 -0.945 . . . . 0.0 109.689 -179.608 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.436 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 105.38 -166.5 14.44 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.45 ' HA ' ' HD3' ' A' ' 103' ' ' ARG . 47.7 Cg_endo -68.09 -19.88 44.7 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 123.23 2.62 . . . . 0.0 112.714 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.607 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 96.4 m-85 -107.28 19.74 19.92 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.816 -1.177 . . . . 0.0 109.626 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.525 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 36.7 mt-10 -43.85 137.51 3.13 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.206 -0.934 . . . . 0.0 109.991 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.525 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.6 OUTLIER 77.87 26.47 0.62 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.259 -0.901 . . . . 0.0 110.675 178.87 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.635 ' CE1' ' CG1' ' A' ' 157' ' ' VAL . 2.0 t80 -114.62 159.79 20.05 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.774 -1.204 . . . . 0.0 109.556 179.696 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -108.63 135.22 50.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.245 -0.909 . . . . 0.0 109.399 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.475 ' HA3' HG23 ' A' ' 155' ' ' VAL . . . -146.86 170.23 27.84 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.52 -179.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.542 ' N ' ' CG2' ' A' ' 155' ' ' VAL . 8.5 p -119.19 136.94 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.627 -0.926 . . . . 0.0 109.222 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.536 HG13 ' CG1' ' A' ' 129' ' ' VAL . 88.7 mt -67.22 115.14 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.302 -0.874 . . . . 0.0 109.445 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 68.9 tttt -98.33 -34.77 10.55 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.099 -1.001 . . . . 0.0 109.223 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -149.39 144.47 26.41 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.105 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.579 ' CG2' ' CD2' ' A' ' 153' ' ' LEU . 26.7 pt -126.27 129.32 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.101 -0.999 . . . . 0.0 109.695 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.85 103.13 48.5 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.345 -0.847 . . . . 0.0 109.38 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.549 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.3 Cg_endo -71.08 169.37 20.73 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.711 2.274 . . . . 0.0 111.898 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.549 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.2 tt0 80.81 -21.23 0.33 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.433 -0.792 . . . . 0.0 110.044 179.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.461 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 24.0 mtp85 -124.91 -11.73 7.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.063 -1.023 . . . . 0.0 109.515 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.461 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 42.8 mt-30 69.07 48.13 0.7 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.316 -0.865 . . . . 0.0 109.499 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 -121.13 144.93 48.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.104 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.579 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 58.1 mt -139.54 121.89 16.02 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.16 -0.963 . . . . 0.0 110.226 -179.701 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . 0.445 ' HE3' ' CB ' ' A' ' 165' ' ' PRO . 18.5 ttpt -83.18 132.04 35.09 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.242 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.542 ' CG2' ' N ' ' A' ' 142' ' ' VAL . 9.0 p -125.92 149.76 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.781 -179.612 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.518 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 3.5 t30 -99.19 116.21 30.87 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.396 -0.815 . . . . 0.0 109.205 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.635 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 65.7 t -102.59 146.09 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.212 -0.93 . . . . 0.0 109.581 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.505 ' N ' HG13 ' A' ' 157' ' ' VAL . 25.8 m -93.75 113.02 24.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.356 -0.84 . . . . 0.0 109.533 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.584 HD11 ' CE1' ' A' ' 56' ' ' PHE . 15.0 pt -145.35 144.6 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.256 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.56 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 46.5 m-85 60.18 35.78 21.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.133 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.91 15.41 13.09 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 67.7 mtp180 -127.37 154.28 45.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.063 -1.257 . . . . 0.0 109.637 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.436 ' OE1' ' N ' ' A' ' 163' ' ' GLU . 58.0 mp0 -97.73 134.9 40.28 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.151 -0.968 . . . . 0.0 109.427 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 24.5 m -147.9 126.12 5.99 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.257 -0.902 . . . . 0.0 109.764 -179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.518 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.8 Cg_endo -70.83 142.8 44.06 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.702 2.268 . . . . 0.0 111.545 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 41.8 t -125.72 144.08 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.058 -1.026 . . . . 0.0 109.788 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.402 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 55.4 t -91.48 118.4 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.414 -0.804 . . . . 0.0 109.194 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.402 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 27.0 mt -140.71 166.31 25.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.12 -0.987 . . . . 0.0 110.543 -179.014 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.434 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 79.7 m80 -81.54 144.44 31.3 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.503 ' CG2' HD11 ' A' ' 153' ' ' LEU . 11.6 p -59.22 -35.39 57.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.346 -0.846 . . . . 0.0 109.025 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.518 ' HA ' ' CG1' ' A' ' 119' ' ' VAL . 19.4 m -76.96 -8.16 56.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.249 -0.907 . . . . 0.0 109.508 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.483 ' HG2' ' HB3' ' A' ' 133' ' ' SER . 18.6 mt-10 -92.22 2.22 56.74 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.301 -0.874 . . . . 0.0 109.195 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.438 HG13 ' C ' ' A' ' 172' ' ' GLU . 4.1 m -145.06 173.07 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.313 -0.867 . . . . 0.0 109.242 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.518 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 84.2 tt0 -136.94 164.0 29.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.165 -0.959 . . . . 0.0 108.985 179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.528 ' O ' ' N ' ' A' ' 177' ' ' GLU . 36.7 tttm -96.35 33.23 1.81 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.084 -1.01 . . . . 0.0 109.521 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.427 HG22 HD12 ' A' ' 176' ' ' ILE . 75.0 mt 54.41 -86.74 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.914 . . . . 0.0 109.403 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.528 ' N ' ' O ' ' A' ' 175' ' ' LYS . 28.3 tt0 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.397 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.56 -20.15 65.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.238 -1.154 . . . . 0.0 109.486 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 44.0 mtm -76.92 -6.95 54.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.24 -0.913 . . . . 0.0 109.488 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 10.8 tptt -98.14 113.81 25.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.469 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 20.5 mttt -125.92 168.72 13.5 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.179 -0.951 . . . . 0.0 109.536 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.583 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.4 mmtp -129.99 172.11 12.07 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.277 -0.89 . . . . 0.0 109.419 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.606 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 61.3 m95 -107.44 127.17 53.36 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.286 -0.884 . . . . 0.0 109.215 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.423 ' OH ' ' SD ' ' A' ' 66' ' ' MET . 54.0 m-85 -117.86 167.88 11.0 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.179 -0.951 . . . . 0.0 109.288 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.54 HG12 ' CE1' ' A' ' 61' ' ' PHE . 22.7 mt -101.98 118.32 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.903 . . . . 0.0 109.29 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.424 HG22 HG23 ' A' ' 62' ' ' VAL . 84.3 t -93.88 136.79 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.273 -0.892 . . . . 0.0 109.337 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.403 ' HB3' ' HB2' ' A' ' 81' ' ' MET . 0.2 OUTLIER -89.2 141.13 28.78 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.202 -0.936 . . . . 0.0 109.419 -179.901 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 11.3 t -154.48 -170.91 3.68 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.282 -0.886 . . . . 0.0 109.442 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.542 ' HE2' ' CD2' ' A' ' 16' ' ' TYR . 59.2 mtm -105.07 122.93 46.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.203 -0.935 . . . . 0.0 109.496 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 21.0 m -45.75 128.87 8.99 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.223 -0.923 . . . . 0.0 109.278 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.74 -20.18 44.8 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.542 ' CD2' ' HE2' ' A' ' 13' ' ' MET . 98.8 m-85 -111.01 10.23 22.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.278 -1.131 . . . . 0.0 109.57 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -61.8 -46.59 88.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.204 -0.935 . . . . 0.0 109.456 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -56.73 -34.02 67.11 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.19 -0.943 . . . . 0.0 109.524 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -75.31 -44.72 43.95 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.241 -0.912 . . . . 0.0 109.456 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.442 HG23 ' HB2' ' A' ' 79' ' ' TYR . 48.4 t -59.0 -50.98 77.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.318 -0.863 . . . . 0.0 109.385 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 49.5 tttm -59.79 -47.83 84.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.305 -0.872 . . . . 0.0 109.437 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -62.38 -34.81 77.43 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.259 -0.9 . . . . 0.0 109.245 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.459 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 5.7 m120 -64.77 -38.03 89.6 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.251 -0.906 . . . . 0.0 109.517 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.503 ' CD1' HD12 ' A' ' 40' ' ' ILE . 92.6 mt -63.52 -45.26 98.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.226 -0.921 . . . . 0.0 109.755 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -57.32 -46.04 83.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.146 -0.971 . . . . 0.0 109.992 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -81.6 -37.11 28.14 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.03 -1.044 . . . . 0.0 109.825 -179.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.547 ' HG3' ' CZ ' ' A' ' 73' ' ' PHE . 13.3 tptp -55.86 -29.63 60.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.114 -0.991 . . . . 0.0 109.283 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.529 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 70.4 t -87.56 -25.21 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.296 -0.877 . . . . 0.0 109.43 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 48.2 tp10 -66.47 -49.09 67.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.324 -0.86 . . . . 0.0 109.32 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.02 -27.49 65.5 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.379 -0.826 . . . . 0.0 109.313 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 73.0 p -94.25 -25.55 17.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -0.916 . . . . 0.0 109.388 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 73.26 25.49 72.96 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.529 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 76.4 mt -98.09 82.27 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -1.109 . . . . 0.0 109.447 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.431 ' O ' ' HG3' ' A' ' 34' ' ' LYS . 14.8 tptm -89.63 -6.07 56.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.227 -0.921 . . . . 0.0 109.714 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.491 ' O ' HG23 ' A' ' 65' ' ' ILE . 33.1 m120 -94.34 -4.58 48.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.249 -0.907 . . . . 0.0 109.561 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.603 ' CD1' ' CB ' ' A' ' 70' ' ' ALA . 8.3 tp -97.85 -54.39 3.11 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.305 -0.872 . . . . 0.0 109.664 -179.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.508 HG13 ' CG2' ' A' ' 28' ' ' VAL . 3.7 p -92.65 135.2 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.228 -0.92 . . . . 0.0 109.104 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -106.8 -123.14 5.04 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 59.6 mtt85 -94.11 139.7 30.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.34 -1.094 . . . . 0.0 110.006 -179.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.535 ' CG2' HG11 ' A' ' 62' ' ' VAL . 91.8 mt -108.39 136.56 43.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.558 HG23 ' CZ3' ' A' ' 7' ' ' TRP . 33.9 m -130.59 155.09 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.071 -1.018 . . . . 0.0 109.616 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.457 HG21 HG12 ' A' ' 44' ' ' ILE . 11.8 mt -128.48 133.91 25.69 Favored Pre-proline 0 N--CA 1.489 1.482 0 O-C-N 121.371 -0.831 . . . . 0.0 109.353 -179.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.542 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 40.9 Cg_endo -63.33 -6.57 10.32 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.715 2.276 . . . . 0.0 111.502 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.587 ' CB ' ' HA ' ' A' ' 54' ' ' LYS . 3.7 pt -92.43 117.77 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.329 -0.857 . . . . 0.0 109.09 179.324 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.493 ' O ' ' CB ' ' A' ' 52' ' ' SER . 40.9 mtm-85 -45.87 123.79 4.76 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.167 -0.958 . . . . 0.0 109.367 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -131.92 -172.94 13.19 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 70.95 20.63 77.91 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 88.9 mt-30 -122.4 155.67 35.58 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.32 -1.106 . . . . 0.0 109.492 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -61.97 -31.37 71.72 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 109.448 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 53.0 mtp85 -101.78 153.68 19.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 54.4 mttt -72.04 168.08 18.84 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.388 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 45' ' ' ARG . 12.5 t -110.72 167.97 9.83 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.27 -0.894 . . . . 0.0 109.459 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.501 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 97.1 mt-10 -76.85 -19.01 58.0 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.439 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.587 ' HA ' ' CB ' ' A' ' 44' ' ' ILE . 11.3 mttp 75.78 103.85 0.07 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.257 -0.902 . . . . 0.0 109.291 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.542 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 9.9 tp -53.64 -47.93 69.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.1 -1.0 . . . . 0.0 109.423 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.58 ' CZ ' HD13 ' A' ' 159' ' ' ILE . 95.9 m-85 -135.57 111.95 10.7 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.121 -0.987 . . . . 0.0 109.121 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -66.7 142.48 64.05 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.584 2.189 . . . . 0.0 111.879 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.37 -8.18 7.34 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.4 m-30 -100.27 131.94 45.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.793 -1.416 . . . . 0.0 110.122 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.431 HG12 ' N ' ' A' ' 61' ' ' PHE . 46.5 t -134.28 144.69 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.325 -0.859 . . . . 0.0 109.03 179.564 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.54 ' CE1' HG12 ' A' ' 9' ' ' ILE . 59.6 m-85 -107.03 123.38 48.13 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.114 -0.991 . . . . 0.0 109.821 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.535 HG11 ' CG2' ' A' ' 40' ' ' ILE . 29.6 m -132.94 144.46 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.344 -0.848 . . . . 0.0 109.653 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.606 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 37.3 tt0 -110.62 128.95 55.9 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -0.92 . . . . 0.0 109.051 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.529 ' HE2' ' CG1' ' A' ' 74' ' ' VAL . 35.1 mtm -156.01 174.3 15.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.011 -1.056 . . . . 0.0 110.66 -179.35 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.544 ' CG1' HD11 ' A' ' 36' ' ' LEU . 10.2 pt -93.92 128.23 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-O 121.323 0.583 . . . . 0.0 109.577 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.487 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 91.3 mtp -76.82 145.29 38.53 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.372 -0.83 . . . . 0.0 110.046 -178.834 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.487 ' HB2' ' O ' ' A' ' 66' ' ' MET . 45.1 t-20 176.48 173.63 0.38 Allowed 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -70.44 -42.06 72.03 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.056 -1.028 . . . . 0.0 109.292 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -75.92 -30.86 58.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -0.894 . . . . 0.0 109.59 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.603 ' CB ' ' CD1' ' A' ' 36' ' ' LEU . . . -69.58 -48.08 61.39 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.192 -0.942 . . . . 0.0 109.37 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 74.5 t80 -60.21 -48.55 81.24 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.237 -0.914 . . . . 0.0 109.555 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -59.66 -29.4 68.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.193 -0.942 . . . . 0.0 109.987 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.547 ' CZ ' ' HG3' ' A' ' 27' ' ' LYS . 72.4 t80 -82.0 -43.43 18.0 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.112 -0.992 . . . . 0.0 109.578 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.529 ' CG1' ' HE2' ' A' ' 64' ' ' MET . 2.7 t -66.26 -57.01 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.321 -0.862 . . . . 0.0 109.247 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 13.2 tpt180 -50.34 -32.75 18.08 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.427 -0.796 . . . . 0.0 109.612 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 9.4 t -78.33 6.25 8.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.331 -0.856 . . . . 0.0 110.199 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.593 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 54.8 t -63.27 131.48 94.79 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 120.957 -1.09 . . . . 0.0 109.408 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.584 ' HB2' ' CD2' ' A' ' 79' ' ' TYR . 47.2 Cg_endo -67.89 137.73 42.37 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.66 2.24 . . . . 0.0 111.983 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.584 ' CD2' ' HB2' ' A' ' 78' ' ' PRO . 58.9 m-85 76.15 -4.41 2.37 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.503 -0.748 . . . . 0.0 109.797 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.593 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.8 t -87.57 129.94 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.108 -0.995 . . . . 0.0 109.162 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.403 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 95.5 mmm -88.31 -7.2 57.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.153 -0.967 . . . . 0.0 109.49 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 132.44 -150.83 19.75 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.512 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 4.6 m-85 -140.01 145.79 38.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.228 -1.16 . . . . 0.0 109.542 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.505 ' CG1' ' O ' ' A' ' 84' ' ' VAL . 10.0 p -68.06 119.1 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.385 -0.822 . . . . 0.0 109.469 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.528 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 6.1 p -153.81 165.65 35.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.195 -0.941 . . . . 0.0 109.452 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 t -91.11 -30.43 16.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.399 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -134.57 -73.9 0.08 OUTLIER Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -115.4 -133.05 5.3 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.545 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.5 OUTLIER -31.07 146.48 0.06 OUTLIER Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.588 -0.948 . . . . 0.0 110.135 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.528 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.3 Cg_endo -69.12 141.35 47.59 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.957 2.438 . . . . 0.0 112.096 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . 0.539 ' CG1' ' HD2' ' A' ' 92' ' ' PRO . 68.9 t -67.48 143.9 97.45 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.323 -0.861 . . . . 0.0 109.434 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.539 ' HD2' ' CG1' ' A' ' 91' ' ' VAL . 48.0 Cg_endo -69.43 148.14 66.55 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.622 2.215 . . . . 0.0 111.701 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.418 ' CG2' ' O ' ' A' ' 7' ' ' TRP . 3.0 t -81.87 127.49 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.19 -0.944 . . . . 0.0 109.54 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -69.99 139.87 52.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.317 -0.864 . . . . 0.0 109.47 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -48.83 -40.41 29.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.212 -0.93 . . . . 0.0 109.37 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 59.9 mtt180 -59.01 -34.48 71.92 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.235 -0.916 . . . . 0.0 109.418 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -80.2 -25.96 39.42 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.276 -0.89 . . . . 0.0 109.417 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.571 ' HE2' ' CG ' ' A' ' 7' ' ' TRP . 93.2 mtp -84.26 -24.73 29.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.261 -0.9 . . . . 0.0 109.556 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.578 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 3.2 tpt85 -36.43 -53.15 1.74 Allowed Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.39 -0.819 . . . . 0.0 109.829 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.578 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 50.2 Cg_endo -70.49 -28.07 22.23 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.574 2.183 . . . . 0.0 111.724 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.495 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 35.8 mm -80.62 -42.26 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 109.486 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.531 HD12 ' CB ' ' A' ' 98' ' ' MET . 0.7 OUTLIER -67.06 -40.03 87.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.184 -0.948 . . . . 0.0 109.236 179.772 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.626 ' CZ ' ' CE2' ' A' ' 110' ' ' TYR . 39.8 ttt-85 -63.06 -50.57 70.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.155 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.402 ' CD2' ' C ' ' A' ' 104' ' ' LEU . 5.5 tt -72.58 -35.26 67.89 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.267 -0.896 . . . . 0.0 109.078 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.495 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -71.18 -3.12 18.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.425 -0.797 . . . . 0.0 109.778 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.46 11.63 82.5 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.536 ' CD2' HG12 ' A' ' 41' ' ' VAL . 9.9 mp -79.46 -19.38 49.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.308 -1.113 . . . . 0.0 109.698 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.428 ' OE2' HD13 ' A' ' 102' ' ' LEU . 96.5 mt-10 -123.62 159.34 29.48 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.236 -0.915 . . . . 0.0 109.608 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 62.9 mt-10 -109.59 118.81 37.58 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.309 -0.869 . . . . 0.0 109.412 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.626 ' CE2' ' CZ ' ' A' ' 103' ' ' ARG . 42.4 p90 -127.8 -162.93 1.21 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.302 -0.874 . . . . 0.0 109.564 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.574 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 64.3 mm-40 -101.25 -135.81 0.31 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.335 -0.853 . . . . 0.0 109.342 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 68.0 tt0 -113.22 -43.21 3.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.06 -1.025 . . . . 0.0 109.632 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.507 ' NZ ' ' HA ' ' A' ' 116' ' ' PRO . 0.0 OUTLIER -173.05 107.74 0.16 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.186 -0.946 . . . . 0.0 109.647 -179.772 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.519 ' O ' ' HD3' ' A' ' 116' ' ' PRO . 13.1 tptm -45.9 -35.86 4.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.328 -0.857 . . . . 0.0 109.384 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.52 79.08 0.38 Allowed Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.53 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.519 ' HD3' ' O ' ' A' ' 114' ' ' LYS . 51.3 Cg_endo -71.31 3.52 3.49 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.728 2.285 . . . . 0.0 111.837 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.454 ' O ' ' HB2' ' A' ' 171' ' ' SER . 26.9 m -120.21 147.98 23.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.112 -0.993 . . . . 0.0 109.843 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.572 ' HA ' ' CB ' ' A' ' 171' ' ' SER . 24.7 mttt -74.38 154.46 38.81 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.332 -0.855 . . . . 0.0 109.301 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.416 HG11 ' N ' ' A' ' 120' ' ' GLU . 40.7 t -131.01 159.19 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.229 -0.92 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.662 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 58.5 mp0 -115.1 -179.17 3.55 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.249 -0.907 . . . . 0.0 109.373 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.662 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 4.7 mt 145.56 100.77 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.63 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.19 93.54 0.01 OUTLIER Glycine 0 N--CA 1.496 2.69 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.504 ' N ' ' O ' ' A' ' 121' ' ' LEU . 13.3 p90 -107.87 148.42 29.61 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.212 -1.169 . . . . 0.0 109.531 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.405 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 14.7 mttp -150.95 161.43 42.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.238 -0.913 . . . . 0.0 109.397 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.411 ' HA ' HG21 ' A' ' 143' ' ' ILE . 40.2 t -60.15 141.33 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.258 -0.901 . . . . 0.0 109.525 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 86.06 -33.29 3.6 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.405 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 70.3 m-20 -47.74 162.22 0.08 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.374 -1.074 . . . . 0.0 109.132 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 9.4 ttm -96.67 126.66 42.0 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.157 -0.964 . . . . 0.0 109.082 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.525 ' O ' ' O ' ' A' ' 141' ' ' GLY . 2.7 t -125.37 141.27 45.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.23 -0.919 . . . . 0.0 109.214 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.478 ' HB2' HG12 ' A' ' 176' ' ' ILE . 15.8 tttt -102.55 143.02 32.78 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.245 -0.909 . . . . 0.0 108.98 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.511 ' CD1' ' HB3' ' A' ' 139' ' ' PHE . 66.8 mt -83.71 151.78 3.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.448 HD13 HG22 ' A' ' 132' ' ' ILE . 2.2 pt -149.67 2.69 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.038 -1.038 . . . . 0.0 109.382 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.558 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 71.9 m -148.7 143.33 26.38 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.185 -0.947 . . . . 0.0 109.884 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.475 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 101.57 -164.07 17.69 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.577 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 47.4 Cg_endo -68.16 -22.01 41.47 Favored 'Trans proline' 0 C--O 1.216 -0.587 0 C-N-CA 123.215 2.61 . . . . 0.0 112.913 -179.187 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.497 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 94.0 m-85 -106.21 19.59 20.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.743 -1.223 . . . . 0.0 109.418 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.508 ' HG2' ' HA ' ' A' ' 133' ' ' SER . 44.4 mt-10 -40.75 137.04 1.26 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.871 . . . . 0.0 109.988 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.462 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 4.4 m-20 71.08 29.77 2.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.389 -0.82 . . . . 0.0 110.656 179.05 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.579 ' CE1' HG13 ' A' ' 157' ' ' VAL . 1.9 t80 -116.7 128.06 54.98 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.912 -1.117 . . . . 0.0 109.579 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.34 133.3 40.01 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.285 -0.884 . . . . 0.0 109.797 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.525 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -142.66 169.66 25.46 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 41.1 t -115.31 136.61 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.314 -1.109 . . . . 0.0 109.506 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.514 HG22 ' CD2' ' A' ' 153' ' ' LEU . 49.6 mt -67.28 113.82 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.221 -0.924 . . . . 0.0 108.898 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . 0.404 ' HD3' ' ND2' ' A' ' 156' ' ' ASN . 18.1 tptm -98.56 -35.45 10.22 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.926 -1.109 . . . . 0.0 109.768 -179.506 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.441 ' HB2' ' HB2' ' A' ' 154' ' ' LYS . 38.6 mt-10 -153.29 148.31 26.65 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.133 -0.979 . . . . 0.0 109.754 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.439 HG23 HD11 ' A' ' 146' ' ' ILE . 3.4 mt -125.15 127.85 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.277 -0.889 . . . . 0.0 109.434 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -110.61 102.3 51.54 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.192 -0.942 . . . . 0.0 109.525 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.55 ' O ' ' HB2' ' A' ' 149' ' ' GLU . 51.9 Cg_endo -71.54 173.07 13.05 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.607 2.204 . . . . 0.0 111.881 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.55 ' HB2' ' O ' ' A' ' 148' ' ' PRO . 45.2 mm-40 79.86 -21.1 0.35 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.473 -0.767 . . . . 0.0 109.906 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.461 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 46.6 mtt180 -127.63 -13.98 5.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.058 -1.026 . . . . 0.0 109.509 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.461 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 66.9 mm-40 70.82 47.99 0.43 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.32 -0.863 . . . . 0.0 109.802 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -118.43 142.21 47.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.116 -0.99 . . . . 0.0 108.852 179.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.514 ' CD2' HG22 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -129.76 113.06 14.25 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.137 -0.977 . . . . 0.0 110.16 -179.535 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . 0.441 ' HB2' ' HB2' ' A' ' 145' ' ' GLU . 13.7 mttm -78.18 127.66 32.61 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.083 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.455 HG12 ' N ' ' A' ' 156' ' ' ASN . 40.4 t -126.17 147.05 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.088 -1.007 . . . . 0.0 109.908 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.513 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 70.1 m-20 -95.81 113.72 25.38 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.431 -0.793 . . . . 0.0 109.035 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.579 HG13 ' CE1' ' A' ' 139' ' ' PHE . 89.3 t -97.72 142.8 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.205 -0.935 . . . . 0.0 109.613 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 28.2 m -100.32 94.25 6.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.341 -0.85 . . . . 0.0 109.876 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.58 HD13 ' CZ ' ' A' ' 56' ' ' PHE . 2.2 pt -125.85 152.3 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.281 -0.887 . . . . 0.0 109.143 179.586 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.428 ' O ' ' HG3' ' A' ' 162' ' ' ARG . 18.8 m-30 60.47 38.68 19.02 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.143 -0.973 . . . . 0.0 109.111 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 55.05 14.47 5.75 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.428 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 52.3 mtt85 -128.99 156.32 43.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.129 -1.218 . . . . 0.0 109.668 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -99.39 134.52 42.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.32 -0.862 . . . . 0.0 109.255 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 21.7 m -147.51 127.45 6.66 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.271 -0.893 . . . . 0.0 109.674 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.513 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.8 Cg_endo -70.5 139.94 38.8 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.725 2.283 . . . . 0.0 111.701 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.44 ' O ' HD13 ' A' ' 168' ' ' LEU . 5.3 p -125.13 144.35 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.18 -0.95 . . . . 0.0 109.515 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.43 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 14.1 m -93.76 119.23 41.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.386 -0.821 . . . . 0.0 109.534 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.474 ' CD1' ' N ' ' A' ' 168' ' ' LEU . 0.0 OUTLIER -142.07 168.78 18.93 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -0.909 . . . . 0.0 110.576 -179.492 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.429 ' HB2' ' OE1' ' A' ' 172' ' ' GLU . 99.1 m-70 -83.98 142.39 30.53 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.429 HG11 ' C ' ' A' ' 151' ' ' GLN . 3.1 m -53.58 -34.85 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.295 -0.878 . . . . 0.0 109.151 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.572 ' CB ' ' HA ' ' A' ' 118' ' ' LYS . 60.2 p -73.81 -6.05 44.65 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.335 -0.853 . . . . 0.0 109.982 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.558 ' CG ' ' HB2' ' A' ' 133' ' ' SER . 2.4 mt-10 -95.6 3.88 53.63 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.015 -1.053 . . . . 0.0 110.02 -179.54 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.455 HG13 ' O ' ' A' ' 172' ' ' GLU . 11.2 m -144.0 169.36 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.057 -1.027 . . . . 0.0 109.601 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.522 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 80.3 tt0 -140.56 166.15 25.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.223 -0.923 . . . . 0.0 108.893 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.522 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 38.9 tttm -89.38 14.95 10.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.019 -1.05 . . . . 0.0 109.51 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.478 HG12 ' HB2' ' A' ' 130' ' ' LYS . 64.1 mt 63.1 -73.57 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.326 -0.858 . . . . 0.0 109.705 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.516 ' N ' ' O ' ' A' ' 175' ' ' LYS . 95.7 mt-10 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.496 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 N-CA-C 109.489 -1.445 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.8 -13.16 58.94 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.264 -1.139 . . . . 0.0 109.505 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 91.2 mtp -59.12 -24.8 63.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.424 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 11.9 mtpp -126.18 123.91 39.28 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.327 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 55.4 mttt -77.3 164.43 25.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.249 -0.907 . . . . 0.0 109.699 -179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.492 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.9 mmtp -128.0 175.26 8.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.289 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.603 ' CZ3' ' CG2' ' A' ' 41' ' ' VAL . 80.9 m95 -110.33 127.0 54.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.137 -0.977 . . . . 0.0 109.576 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.432 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 60.7 m-85 -121.78 167.07 13.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.229 -0.919 . . . . 0.0 109.488 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.559 ' CD1' ' CD1' ' A' ' 160' ' ' PHE . 76.2 mt -106.61 117.1 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.158 -0.964 . . . . 0.0 109.301 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.434 ' CG1' HG21 ' A' ' 80' ' ' VAL . 85.3 t -88.56 141.98 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.28 -0.888 . . . . 0.0 109.569 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.419 HD11 ' HA ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -93.74 138.84 31.51 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.325 -0.86 . . . . 0.0 109.387 179.905 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 14.9 t -155.58 -169.54 3.15 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.457 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.47 ' CG ' ' HE2' ' A' ' 81' ' ' MET . 90.8 mmm -104.01 119.55 39.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.233 -0.917 . . . . 0.0 109.387 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 13' ' ' MET . 17.8 p -42.46 128.52 3.92 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.232 -0.918 . . . . 0.0 109.475 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.34 -20.31 35.35 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.405 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 90.3 m-85 -110.67 -1.4 16.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -1.133 . . . . 0.0 109.557 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -53.34 -55.24 26.39 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.241 -0.912 . . . . 0.0 109.404 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -49.13 -32.22 9.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.166 -0.958 . . . . 0.0 109.418 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 23' ' ' ASN . 62.3 mttm -76.83 -36.75 56.66 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.286 -0.883 . . . . 0.0 109.311 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 98.4 t -66.73 -52.01 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.33 -0.856 . . . . 0.0 109.523 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -56.89 -50.87 71.19 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.231 -0.918 . . . . 0.0 109.484 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -64.68 -34.82 79.19 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.153 -0.967 . . . . 0.0 109.38 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.452 ' CG ' ' HG2' ' A' ' 78' ' ' PRO . 2.1 t30 -66.0 -44.32 85.14 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.408 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 81.7 mt -57.39 -43.37 82.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.272 -0.892 . . . . 0.0 109.443 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -58.38 -44.44 88.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.205 -0.934 . . . . 0.0 109.789 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 31.9 mtmt -77.88 -37.48 48.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.112 -0.992 . . . . 0.0 109.798 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.585 ' HE3' ' CE1' ' A' ' 73' ' ' PHE . 42.1 tttp -57.04 -28.94 62.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.908 . . . . 0.0 109.313 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.538 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 42.4 t -83.86 -27.43 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.314 -0.866 . . . . 0.0 109.464 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.448 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 54.9 mm-40 -66.8 -49.25 66.45 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.271 -0.893 . . . . 0.0 109.444 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.2 -35.12 66.91 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.241 -0.912 . . . . 0.0 109.482 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.3 p -92.86 -22.71 19.12 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.271 -0.893 . . . . 0.0 109.591 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 74.3 1.59 60.87 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.555 HG22 ' CD1' ' A' ' 36' ' ' LEU . 48.1 mm -69.39 80.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.318 -1.107 . . . . 0.0 109.429 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -90.89 14.54 13.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 109.458 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.476 ' O ' HG22 ' A' ' 65' ' ' ILE . 24.7 m120 -113.39 -3.07 13.81 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.235 -0.916 . . . . 0.0 109.601 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.555 ' CD1' HG22 ' A' ' 33' ' ' ILE . 11.8 mt -98.59 -51.2 4.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.946 . . . . 0.0 109.599 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 99.1 t -95.55 144.58 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.313 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -114.87 -124.75 3.92 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 18.6 mtt85 -91.56 142.18 27.91 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.309 -1.112 . . . . 0.0 109.885 -179.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.483 HG12 ' CG1' ' A' ' 62' ' ' VAL . 65.4 mt -109.94 134.42 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.152 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.603 ' CG2' ' CZ3' ' A' ' 7' ' ' TRP . 30.4 m -127.5 144.54 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.208 -0.932 . . . . 0.0 109.263 179.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.503 HG21 ' CD1' ' A' ' 44' ' ' ILE . 67.6 mt -129.94 129.14 22.98 Favored Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.294 -0.879 . . . . 0.0 109.623 -179.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.541 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.3 Cg_endo -66.71 -2.65 7.93 Favored 'Trans proline' 0 C--O 1.217 -0.544 0 C-N-CA 122.879 2.386 . . . . 0.0 111.348 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.729 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 85.6 mt -66.15 -39.26 83.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.144 -0.972 . . . . 0.0 109.554 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 38.4 ttt85 -45.58 -34.97 3.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.92 . . . . 0.0 109.494 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -72.51 154.55 50.43 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 100.69 15.4 29.32 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 52.6 mt-30 -71.03 -31.38 67.84 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.296 -1.12 . . . . 0.0 109.429 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 20.2 mtp180 -61.31 -32.31 72.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 109.532 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.45 ' HD2' HG11 ' A' ' 167' ' ' VAL . 57.4 mtp85 -112.97 151.0 31.09 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.213 -0.93 . . . . 0.0 109.572 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -53.72 -33.65 56.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.241 -0.912 . . . . 0.0 109.331 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 21.0 t -52.97 136.53 34.68 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.34 -0.85 . . . . 0.0 109.421 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.53 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 84.5 tt0 -125.76 159.39 32.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.253 -0.905 . . . . 0.0 109.462 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.729 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 1.9 mttp 77.21 89.56 0.07 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.245 -0.91 . . . . 0.0 109.629 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.541 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 9.2 tp -59.71 -42.14 92.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.904 -1.123 . . . . 0.0 108.909 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.58 ' CZ ' HD12 ' A' ' 159' ' ' ILE . 19.4 m-85 -126.3 101.15 28.51 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.217 -0.927 . . . . 0.0 108.789 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 41.7 Cg_endo -65.63 137.09 48.75 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.681 2.254 . . . . 0.0 112.26 -179.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.36 -12.61 5.5 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.534 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 1.7 m-30 -100.47 132.15 46.01 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.748 -1.442 . . . . 0.0 110.32 -179.199 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.413 HG11 HG12 ' A' ' 42' ' ' ILE . 40.0 t -132.99 143.07 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.349 -0.844 . . . . 0.0 108.926 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.526 ' CE1' HG12 ' A' ' 9' ' ' ILE . 18.8 m-30 -106.68 123.86 48.75 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.003 -1.061 . . . . 0.0 109.805 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.483 ' CG1' HG12 ' A' ' 40' ' ' ILE . 93.0 t -131.16 142.13 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.339 -0.851 . . . . 0.0 109.653 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.584 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 39.1 tt0 -105.9 128.77 53.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.262 -0.899 . . . . 0.0 108.981 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.494 ' CG ' ' C ' ' A' ' 63' ' ' GLU . 16.5 mtm -155.96 178.65 10.03 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.169 -0.957 . . . . 0.0 110.05 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.537 ' CD1' HD21 ' A' ' 36' ' ' LEU . 6.1 pt -101.01 133.89 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.59 -0.694 . . . . 0.0 109.321 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.478 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 53.9 ttm -77.24 144.33 38.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.224 -0.922 . . . . 0.0 110.1 -178.654 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.478 ' HB2' ' O ' ' A' ' 66' ' ' MET . 29.0 t-20 176.46 175.56 0.32 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -72.6 -43.06 63.83 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.249 -0.907 . . . . 0.0 109.323 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -75.64 -28.01 58.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.686 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.539 ' CB ' HD23 ' A' ' 36' ' ' LEU . . . -70.58 -47.56 59.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.131 -0.981 . . . . 0.0 109.302 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.526 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 89.0 t80 -60.88 -54.94 38.9 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.289 -0.882 . . . . 0.0 109.275 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.447 ' O ' ' OG ' ' A' ' 76' ' ' SER . 42.2 t-20 -52.85 -31.81 41.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.221 -0.924 . . . . 0.0 109.975 -179.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.585 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 81.9 t80 -80.08 -43.27 22.09 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.035 -1.04 . . . . 0.0 109.567 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.522 ' CG2' ' O ' ' A' ' 70' ' ' ALA . 3.2 t -68.26 -55.48 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.295 -0.878 . . . . 0.0 109.414 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.486 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 16.5 tpt180 -61.56 -9.58 6.23 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.338 -0.851 . . . . 0.0 109.837 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 72' ' ' ASN . 42.7 p -101.67 2.09 38.32 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.148 -0.97 . . . . 0.0 109.983 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.625 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -68.75 135.29 90.15 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.057 -1.027 . . . . 0.0 108.954 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.629 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 43.9 Cg_endo -66.21 138.96 53.43 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.394 2.063 . . . . 0.0 111.99 -179.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.629 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 5.5 m-85 89.09 -8.08 0.44 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.801 -0.562 . . . . 0.0 109.829 -179.838 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.625 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 2.4 t -89.34 129.5 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.966 -1.084 . . . . 0.0 109.661 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.47 ' HE2' ' CG ' ' A' ' 13' ' ' MET . 18.7 mtt -93.53 -25.06 17.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.459 -0.776 . . . . 0.0 109.246 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 164.54 -162.61 35.59 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.477 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 48.6 m-85 -136.21 151.74 50.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.187 -1.184 . . . . 0.0 109.559 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.8 t -67.01 101.42 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.282 -0.886 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.543 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.0 OUTLIER -143.98 162.85 35.12 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -0.918 . . . . 0.0 109.505 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.0 m -95.18 -34.52 12.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.349 -0.845 . . . . 0.0 109.278 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -129.39 -72.78 0.14 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.541 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -113.91 -137.89 6.75 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.541 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.3 OUTLIER -31.03 148.45 0.04 OUTLIER Pre-proline 0 N--CA 1.493 1.704 0 O-C-N 121.506 -0.997 . . . . 0.0 110.274 -179.718 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.543 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.3 Cg_endo -69.54 149.61 68.53 Favored 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.82 2.347 . . . . 0.0 111.887 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 36.0 m -80.73 152.31 72.13 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.323 -0.861 . . . . 0.0 109.403 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.07 143.36 49.12 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.693 2.262 . . . . 0.0 111.81 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.437 ' CG1' ' SD ' ' A' ' 98' ' ' MET . 29.3 t -69.48 142.16 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.192 -0.942 . . . . 0.0 109.414 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . 0.429 ' HB2' ' HG3' ' A' ' 97' ' ' GLU . 32.0 mttt -70.67 134.12 47.25 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.537 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -50.27 -41.46 50.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.863 . . . . 0.0 109.419 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -63.14 -24.07 67.72 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.438 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.429 ' HG3' ' HB2' ' A' ' 94' ' ' LYS . 40.9 mt-10 -84.95 -23.66 28.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -0.913 . . . . 0.0 109.456 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.509 ' O ' ' C ' ' A' ' 99' ' ' ARG . 52.5 mmm -85.19 -33.18 22.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.265 -0.897 . . . . 0.0 109.384 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.579 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -36.1 -53.41 1.57 Allowed Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.459 -0.776 . . . . 0.0 109.795 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.584 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 47.4 Cg_endo -69.79 -26.57 27.3 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.494 2.129 . . . . 0.0 111.616 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.531 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 32.3 mm -81.09 -38.51 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.236 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.578 ' N ' HD11 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -71.36 -40.35 70.69 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.328 -0.858 . . . . 0.0 109.16 179.733 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 58.0 mtt-85 -63.15 -50.06 71.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.403 -0.81 . . . . 0.0 109.028 179.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.4 tt -72.35 -35.55 68.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.385 -0.822 . . . . 0.0 109.079 179.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -69.33 -1.62 8.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.393 -0.817 . . . . 0.0 110.023 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.12 8.25 82.97 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.409 ' HB3' ' HB3' ' A' ' 102' ' ' LEU . 0.7 OUTLIER -74.37 -17.55 60.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.16 -1.2 . . . . 0.0 109.431 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.418 ' HG3' ' HB3' ' A' ' 102' ' ' LEU . 88.9 mt-10 -117.12 157.56 25.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.898 . . . . 0.0 109.479 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -106.65 112.64 25.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.273 -0.892 . . . . 0.0 109.513 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.446 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 28.3 p90 -144.63 150.56 37.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.237 -0.914 . . . . 0.0 109.342 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.446 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 37.0 mm-40 -86.47 -147.72 0.13 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.238 -0.914 . . . . 0.0 109.48 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.403 ' O ' ' C ' ' A' ' 113' ' ' LYS . 81.0 tt0 -113.59 163.83 14.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.283 -0.886 . . . . 0.0 109.579 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.403 ' C ' ' O ' ' A' ' 112' ' ' GLU . 3.4 pttm -45.32 126.65 6.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.203 -0.936 . . . . 0.0 109.508 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 6.0 mtpt -105.28 5.22 31.81 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.313 -0.867 . . . . 0.0 109.383 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.42 ' HD2' HG23 ' A' ' 117' ' ' VAL . 4.0 ttmt -109.75 75.28 0.8 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.213 -0.929 . . . . 0.0 109.564 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.25 75.16 1.44 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.702 2.268 . . . . 0.0 111.753 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.42 HG23 ' HD2' ' A' ' 115' ' ' LYS . 32.4 m -126.47 154.61 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.289 -0.882 . . . . 0.0 109.469 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -104.0 151.55 23.08 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.169 -0.957 . . . . 0.0 109.458 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.438 HG12 ' N ' ' A' ' 120' ' ' GLU . 39.7 t -129.77 168.28 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.286 -0.884 . . . . 0.0 109.464 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.527 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 88.8 mt-10 -135.83 -120.07 0.16 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.304 -0.872 . . . . 0.0 109.425 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.595 ' O ' ' C ' ' A' ' 122' ' ' GLY . 6.2 mt 78.53 114.03 0.07 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.196 -0.94 . . . . 0.0 109.368 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.595 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -20.63 90.63 0.01 OUTLIER Glycine 0 N--CA 1.496 2.642 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.603 ' CB ' ' HD3' ' A' ' 175' ' ' LYS . 38.3 p90 -96.81 126.46 41.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.182 -1.187 . . . . 0.0 109.156 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 17.4 mttt -144.27 162.75 35.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.135 -0.978 . . . . 0.0 109.922 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 12.1 t -64.04 141.79 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.472 -0.768 . . . . 0.0 109.297 179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 87.47 -31.23 4.58 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.463 ' O ' HG12 ' A' ' 142' ' ' VAL . 22.6 t70 -49.71 162.92 0.14 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.299 -1.118 . . . . 0.0 109.27 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' MET . . . . . 0.428 ' HE1' ' CD1' ' A' ' 176' ' ' ILE . 3.9 ttp -94.72 125.35 39.31 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.13 -0.982 . . . . 0.0 109.073 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.543 ' CG2' ' O ' ' A' ' 174' ' ' GLU . 2.0 p -124.31 140.77 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.173 -0.954 . . . . 0.0 109.02 179.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 174' ' ' GLU . 59.9 tttt -106.2 142.72 35.41 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.153 -0.967 . . . . 0.0 109.361 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.557 ' O ' ' CD1' ' A' ' 132' ' ' ILE . 88.2 mt -82.75 152.91 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.161 -0.962 . . . . 0.0 108.581 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.557 ' CD1' ' O ' ' A' ' 131' ' ' ILE . 2.6 mm -148.94 1.66 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.103 -0.998 . . . . 0.0 109.463 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.539 ' CB ' ' HG2' ' A' ' 172' ' ' GLU . 28.3 m -150.82 147.64 27.51 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.13 -0.981 . . . . 0.0 110.331 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.84 -164.12 18.56 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 179.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.482 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 46.2 Cg_endo -67.93 -23.52 40.79 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 123.026 2.484 . . . . 0.0 112.535 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.584 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 93.4 m-85 -108.86 18.76 20.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.962 -1.086 . . . . 0.0 109.456 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.532 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 1.8 tt0 -48.35 140.69 7.39 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.289 -0.882 . . . . 0.0 109.687 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.532 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 12.8 m-20 76.93 28.73 0.64 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.468 -0.77 . . . . 0.0 110.243 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.482 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 1.9 t80 -118.42 153.52 33.95 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.08 -1.012 . . . . 0.0 109.485 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -101.2 133.34 45.91 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.246 -0.909 . . . . 0.0 109.197 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.499 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.25 170.38 26.65 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 119.535 -1.317 . . . . 0.0 110.604 -179.413 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.463 HG12 ' O ' ' A' ' 127' ' ' ASP . 44.9 t -115.11 137.71 47.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.602 -0.94 . . . . 0.0 109.348 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.556 ' CG2' HD23 ' A' ' 153' ' ' LEU . 14.9 mm -68.74 115.27 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.226 -0.921 . . . . 0.0 109.502 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . 0.418 ' HG2' ' HG3' ' A' ' 145' ' ' GLU . 21.2 tttp -99.0 -34.46 10.41 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.039 -1.038 . . . . 0.0 109.321 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.418 ' HG3' ' HG2' ' A' ' 144' ' ' LYS . 89.5 mt-10 -152.57 147.6 26.37 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.133 -0.98 . . . . 0.0 109.444 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.42 HG23 ' HG ' ' A' ' 153' ' ' LEU . 6.6 mt -126.56 130.05 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.216 -0.928 . . . . 0.0 109.622 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -110.33 103.39 53.87 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.286 -0.884 . . . . 0.0 109.528 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.557 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.55 171.83 15.52 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.747 2.298 . . . . 0.0 111.631 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.557 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.3 mt-10 80.68 -20.34 0.38 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.319 -0.863 . . . . 0.0 109.876 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.454 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 43.3 mtt85 -128.21 -12.18 5.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.05 -1.031 . . . . 0.0 109.582 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.454 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 37.1 mt-30 69.68 48.97 0.56 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.907 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -120.12 144.54 47.58 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.081 -1.012 . . . . 0.0 109.116 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.556 HD23 ' CG2' ' A' ' 143' ' ' ILE . 0.0 OUTLIER -133.92 115.73 14.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.097 -1.002 . . . . 0.0 110.115 -179.381 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 7.1 mttt -78.04 132.42 37.76 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.328 -0.857 . . . . 0.0 108.786 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.531 HG11 ' CG2' ' A' ' 166' ' ' VAL . 13.2 p -130.21 147.01 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.119 -0.988 . . . . 0.0 110.008 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.488 ' OD1' ' CA ' ' A' ' 165' ' ' PRO . 0.9 OUTLIER -97.53 115.96 28.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.435 -0.791 . . . . 0.0 109.183 179.66 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.479 HG12 HG22 ' A' ' 159' ' ' ILE . 87.1 t -97.64 143.22 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.163 -0.961 . . . . 0.0 109.747 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.3 m -91.88 111.88 23.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.314 -0.867 . . . . 0.0 109.643 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.58 HD12 ' CZ ' ' A' ' 56' ' ' PHE . 13.6 pt -144.56 143.92 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.295 -0.878 . . . . 0.0 109.486 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.559 ' CD1' ' CD1' ' A' ' 9' ' ' ILE . 78.2 m-85 62.1 34.36 16.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.282 -0.886 . . . . 0.0 109.396 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.28 16.47 20.42 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 73.6 mtt-85 -128.91 151.14 49.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -93.7 135.05 35.38 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.233 -0.917 . . . . 0.0 109.392 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 60.8 m -144.64 126.31 7.96 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.242 -0.911 . . . . 0.0 109.67 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.488 ' CA ' ' OD1' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.8 139.58 36.93 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 122.624 2.216 . . . . 0.0 111.39 179.676 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.531 ' CG2' HG11 ' A' ' 155' ' ' VAL . 1.9 m -125.75 144.54 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.059 -1.026 . . . . 0.0 109.988 -179.682 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.526 ' C ' ' CD2' ' A' ' 168' ' ' LEU . 14.7 m -92.05 117.48 35.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.526 ' CD2' ' C ' ' A' ' 167' ' ' VAL . 3.2 mm? -139.78 166.24 25.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.156 -0.965 . . . . 0.0 110.289 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.5 ' HB2' ' HB2' ' A' ' 172' ' ' GLU . 82.2 m-70 -83.95 141.15 31.45 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 9.1 p -56.78 -36.58 49.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.293 -0.879 . . . . 0.0 109.296 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 32.1 p -77.29 -8.47 57.67 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.094 -1.004 . . . . 0.0 109.722 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.539 ' HG2' ' CB ' ' A' ' 133' ' ' SER . 1.3 mt-10 -88.67 -4.79 58.47 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.194 -0.941 . . . . 0.0 109.275 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.9 m -137.22 176.51 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.192 -0.942 . . . . 0.0 109.799 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.543 ' O ' ' CG2' ' A' ' 129' ' ' VAL . 72.9 tt0 -132.15 155.43 48.18 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.603 ' HD3' ' CB ' ' A' ' 123' ' ' PHE . 16.2 mttm -108.42 35.8 3.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.965 -1.084 . . . . 0.0 109.712 -179.462 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.481 ' C ' ' O ' ' A' ' 175' ' ' LYS . 6.6 mt 39.22 -133.84 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.472 -0.767 . . . . 0.0 109.632 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 57.0 tt0 . . . . . 0 N--CA 1.488 1.471 0 CA-C-O 117.961 -1.018 . . . . 0.0 109.526 -179.923 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.24 -27.55 69.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.23 -1.159 . . . . 0.0 109.497 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 91.0 mtp -66.74 -27.32 67.52 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.287 -0.883 . . . . 0.0 109.454 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 34.5 tttt -147.18 131.26 17.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.269 -0.894 . . . . 0.0 109.417 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 33.4 mttm -96.71 146.98 24.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.183 -0.948 . . . . 0.0 109.51 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.58 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 11.6 mttt -130.47 173.76 10.54 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.905 . . . . 0.0 109.192 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.605 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 61.5 m95 -108.59 127.51 54.01 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -0.901 . . . . 0.0 109.3 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.447 ' OH ' ' SD ' ' A' ' 66' ' ' MET . 91.6 m-85 -115.61 169.15 9.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.211 -0.93 . . . . 0.0 109.33 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.569 HG12 ' CE1' ' A' ' 61' ' ' PHE . 27.3 mt -109.89 113.57 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 109.192 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.453 HG23 ' CG2' ' A' ' 62' ' ' VAL . 82.4 t -88.51 140.58 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.221 -0.925 . . . . 0.0 109.369 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.628 ' CD1' ' CE1' ' A' ' 59' ' ' TYR . 2.9 mm? -95.36 146.36 24.45 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.357 -0.839 . . . . 0.0 109.414 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.5 t -161.17 -164.26 1.14 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.265 -0.897 . . . . 0.0 109.114 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.496 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 94.0 mtp -105.32 124.71 50.0 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.186 -0.946 . . . . 0.0 109.516 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.0 t -45.78 131.1 9.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.294 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.94 -19.33 47.08 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.496 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 95.6 m-85 -108.96 6.34 25.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.284 -1.127 . . . . 0.0 109.564 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -62.79 -52.82 61.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.261 -0.899 . . . . 0.0 109.507 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -50.7 -35.78 32.84 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.187 -0.945 . . . . 0.0 109.61 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.48 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 58.4 mttt -73.9 -47.81 35.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.247 -0.908 . . . . 0.0 109.556 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.534 ' CG2' ' HB2' ' A' ' 79' ' ' TYR . 74.8 t -54.32 -48.41 67.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.226 -0.922 . . . . 0.0 109.579 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 40.8 tttm -57.56 -49.66 75.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -0.923 . . . . 0.0 109.615 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -65.42 -39.18 91.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.244 -0.91 . . . . 0.0 109.497 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 19' ' ' LYS . 70.2 m-20 -62.16 -44.62 96.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.869 . . . . 0.0 109.622 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.405 HD13 HG23 ' A' ' 24' ' ' ILE . 96.7 mt -57.76 -43.83 84.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.522 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -56.42 -44.55 80.48 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.206 -0.934 . . . . 0.0 109.823 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -75.55 -35.33 60.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.06 -1.025 . . . . 0.0 109.437 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.468 ' CD ' HG23 ' A' ' 77' ' ' VAL . 10.1 tttm -56.44 -34.16 66.57 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.229 -0.92 . . . . 0.0 109.331 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.529 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 43.4 t -83.99 -25.42 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.334 -0.854 . . . . 0.0 109.593 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 46.7 tp10 -70.32 -53.95 14.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.264 -0.897 . . . . 0.0 109.656 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.92 -33.6 72.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -0.92 . . . . 0.0 109.693 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 50.7 p -83.35 -35.91 24.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.182 -0.949 . . . . 0.0 109.488 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 84.75 17.8 62.91 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.529 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 78.8 mt -95.74 78.31 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.218 -1.166 . . . . 0.0 109.414 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 45.0 mttm -85.68 6.1 29.12 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.486 ' O ' HG22 ' A' ' 65' ' ' ILE . 24.5 m120 -102.3 -6.94 22.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.224 -0.923 . . . . 0.0 109.547 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.575 ' CD1' ' CB ' ' A' ' 70' ' ' ALA . 10.5 tp -97.68 -54.05 3.24 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.302 -0.874 . . . . 0.0 109.681 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.534 HG23 ' CE ' ' A' ' 64' ' ' MET . 87.4 t -90.38 133.66 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.284 -0.885 . . . . 0.0 109.324 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.65 -126.87 5.88 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 44.5 mtt180 -93.58 140.65 29.37 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -1.155 . . . . 0.0 109.887 -179.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . 63.2 mt -103.76 134.0 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.308 -0.87 . . . . 0.0 109.09 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.585 HG21 ' CZ3' ' A' ' 7' ' ' TRP . 34.7 m -124.7 146.7 29.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.132 -0.98 . . . . 0.0 109.692 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.522 ' CG2' HG22 ' A' ' 44' ' ' ILE . 1.2 mt -117.75 128.9 25.7 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.423 -0.798 . . . . 0.0 109.465 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.65 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.6 Cg_endo -66.43 -6.22 14.59 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.903 2.402 . . . . 0.0 111.857 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.551 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 13.1 pt -56.55 137.23 18.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.178 -0.951 . . . . 0.0 109.413 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.479 ' NH1' ' CB ' ' A' ' 49' ' ' ARG . 20.5 ttt-85 -53.1 -47.72 68.36 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.239 -0.913 . . . . 0.0 109.457 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 75.68 156.59 6.12 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.429 ' O ' ' C ' ' A' ' 48' ' ' GLN . . . 91.14 3.93 69.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.429 ' C ' ' O ' ' A' ' 47' ' ' GLY . 16.3 tt0 43.33 27.17 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.317 -1.108 . . . . 0.0 109.549 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.479 ' CB ' ' NH1' ' A' ' 45' ' ' ARG . 4.2 tpt180 -59.49 -38.13 80.08 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.541 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 76.7 mtp85 -134.56 151.43 51.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.266 -0.896 . . . . 0.0 109.472 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 53.4 tttp -51.98 -39.33 59.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 41.3 m -68.86 144.23 54.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.299 -0.876 . . . . 0.0 109.527 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.533 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 88.0 mt-10 -151.38 162.52 40.78 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.199 -0.938 . . . . 0.0 109.415 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.551 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 1.9 mttt 76.96 94.42 0.07 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.267 -0.896 . . . . 0.0 109.348 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.65 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 0.7 OUTLIER -54.16 -45.84 72.15 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.036 -1.04 . . . . 0.0 108.85 179.756 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.491 ' CZ ' ' CD1' ' A' ' 55' ' ' LEU . 16.5 m-85 -123.97 110.32 29.41 Favored Pre-proline 0 N--CA 1.487 1.422 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.368 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -66.92 137.89 46.37 Favored 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.645 2.23 . . . . 0.0 111.942 -179.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.19 -7.71 10.28 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.628 ' CE1' ' CD1' ' A' ' 11' ' ' LEU . 3.7 m-85 -107.54 134.37 50.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.896 -1.355 . . . . 0.0 110.082 -179.351 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 43.3 t -134.52 150.42 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.569 ' CE1' HG12 ' A' ' 9' ' ' ILE . 72.9 m-85 -108.67 123.64 49.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.988 -1.07 . . . . 0.0 109.711 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.453 ' CG2' HG23 ' A' ' 10' ' ' VAL . 19.0 m -131.86 144.24 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.382 -0.824 . . . . 0.0 109.569 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.605 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 22.7 tt0 -105.27 126.7 52.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.364 -0.835 . . . . 0.0 109.038 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.534 ' CE ' HG23 ' A' ' 37' ' ' VAL . 4.9 mtp -156.47 175.0 14.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.107 -0.996 . . . . 0.0 110.293 -179.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.486 HG22 ' O ' ' A' ' 35' ' ' ASN . 10.6 pt -97.39 129.13 47.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.608 -0.683 . . . . 0.0 109.236 179.7 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.486 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 0.0 OUTLIER -76.36 145.87 39.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.919 . . . . 0.0 109.621 -179.026 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.582 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 44.1 t30 175.78 163.61 0.34 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -59.56 -40.47 87.39 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.058 -1.027 . . . . 0.0 109.581 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.544 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 99.1 mt-10 -72.19 -43.74 64.07 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.217 -0.927 . . . . 0.0 109.895 -179.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.575 ' CB ' ' CD1' ' A' ' 36' ' ' LEU . . . -56.4 -44.88 80.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.087 -1.008 . . . . 0.0 109.572 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.582 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 36.2 m-85 -60.32 -62.39 1.9 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.22 -0.925 . . . . 0.0 109.269 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.483 ' O ' ' HB2' ' A' ' 76' ' ' SER . 95.8 m-20 -43.52 -30.86 0.62 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.388 -0.82 . . . . 0.0 109.82 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.544 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 24.4 m-85 -82.94 -42.41 17.69 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.167 -0.958 . . . . 0.0 109.898 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.641 ' CG1' ' CZ ' ' A' ' 83' ' ' PHE . 61.2 t -69.99 -55.33 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.217 -0.927 . . . . 0.0 109.498 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.507 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 6.1 tpt180 -57.77 -14.32 5.65 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.292 -0.88 . . . . 0.0 109.307 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.483 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 3.8 m -105.61 2.5 28.28 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.208 -0.933 . . . . 0.0 109.691 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.608 HG13 ' HB ' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -68.37 150.65 97.63 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.048 -1.033 . . . . 0.0 109.087 179.911 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.672 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 47.7 Cg_endo -68.83 124.75 11.79 Favored 'Trans proline' 0 C--O 1.214 -0.714 0 C-N-CA 122.569 2.179 . . . . 0.0 112.429 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.672 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 53.5 m-85 88.59 0.02 0.38 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.776 -0.577 . . . . 0.0 110.773 179.164 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.608 ' HB ' HG13 ' A' ' 77' ' ' VAL . 7.4 p -84.16 112.9 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.738 -1.226 . . . . 0.0 109.523 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 86.0 mmm -87.43 -30.1 20.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.274 -0.891 . . . . 0.0 109.232 179.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.454 ' O ' ' HB2' ' A' ' 11' ' ' LEU . . . 174.26 -169.03 41.99 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.641 ' CZ ' ' CG1' ' A' ' 74' ' ' VAL . 15.7 m-85 -127.66 147.62 50.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.248 -1.148 . . . . 0.0 109.514 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.481 ' CG2' HD23 ' A' ' 11' ' ' LEU . 59.2 t -67.3 77.1 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.32 -0.862 . . . . 0.0 109.254 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.536 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 3.1 p -127.71 162.78 25.76 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.332 -0.855 . . . . 0.0 109.634 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 87.8 p -95.91 -33.33 12.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.42 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.98 -77.09 0.19 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.508 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -106.58 -145.19 12.41 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.508 ' C ' ' O ' ' A' ' 88' ' ' GLY . 2.5 pm0 -33.31 154.01 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.582 -0.952 . . . . 0.0 110.188 -179.458 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.536 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 51.7 Cg_endo -70.68 168.55 22.42 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.513 2.142 . . . . 0.0 112.032 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . 0.524 ' CG1' ' HD2' ' A' ' 92' ' ' PRO . 0.1 OUTLIER -98.7 148.98 35.29 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.33 -0.856 . . . . 0.0 109.199 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.524 ' HD2' ' CG1' ' A' ' 91' ' ' VAL . 48.7 Cg_endo -69.31 150.8 71.4 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.616 2.21 . . . . 0.0 111.705 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.525 ' CG2' ' O ' ' A' ' 7' ' ' TRP . 2.5 t -80.06 126.65 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.912 . . . . 0.0 109.528 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . 0.487 ' O ' ' N ' ' A' ' 97' ' ' GLU . 51.0 mttt -71.9 136.62 46.96 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.267 -0.895 . . . . 0.0 109.271 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.481 ' O ' ' HG3' ' A' ' 99' ' ' ARG . 82.8 m-20 -43.25 -41.65 3.99 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.918 . . . . 0.0 109.346 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 21.8 mtm180 -56.75 -30.38 63.53 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.336 -0.852 . . . . 0.0 109.692 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.487 ' N ' ' O ' ' A' ' 94' ' ' LYS . 53.6 mt-10 -87.01 -27.75 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.599 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.543 ' CB ' HD13 ' A' ' 102' ' ' LEU . 75.2 mmm -80.08 -24.72 40.43 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.359 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.585 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 25.6 mtp85 -37.37 -53.71 2.2 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.482 -0.761 . . . . 0.0 109.786 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.585 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.9 Cg_endo -69.28 -30.74 24.02 Favored 'Trans proline' 0 C--O 1.216 -0.577 0 C-N-CA 122.587 2.191 . . . . 0.0 111.749 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 16.3 mm -77.52 -43.69 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.139 -0.976 . . . . 0.0 109.238 179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.543 HD13 ' CB ' ' A' ' 98' ' ' MET . 1.1 mt -63.19 -40.77 98.46 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.275 -0.891 . . . . 0.0 109.031 179.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.561 ' HG3' ' CE1' ' A' ' 110' ' ' TYR . 24.7 ttt-85 -60.11 -45.85 91.59 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 108.783 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.512 ' CD2' ' O ' ' A' ' 44' ' ' ILE . 0.6 OUTLIER -68.45 -34.31 75.74 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.391 -0.818 . . . . 0.0 108.912 179.397 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.506 ' O ' ' HG ' ' A' ' 107' ' ' LEU . . . -90.47 17.88 6.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.32 -0.863 . . . . 0.0 109.033 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 43.76 28.89 1.22 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.54 ' CD1' HG13 ' A' ' 41' ' ' VAL . 88.3 mt -90.12 -26.64 20.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -1.158 . . . . 0.0 109.535 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.505 ' HB2' ' CB ' ' A' ' 102' ' ' LEU . 87.2 tt0 -107.78 145.07 34.06 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.238 -0.914 . . . . 0.0 109.63 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -111.11 119.32 38.59 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.305 -0.872 . . . . 0.0 109.354 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.575 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 29.8 p90 -126.22 -167.4 1.7 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.254 -0.904 . . . . 0.0 109.517 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.575 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 50.7 mt-10 -90.82 -145.64 0.19 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.286 -0.884 . . . . 0.0 109.464 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -106.71 -59.56 1.78 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.211 -0.931 . . . . 0.0 109.414 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -158.41 124.84 4.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.356 -0.84 . . . . 0.0 109.519 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.59 -48.48 80.8 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.305 -0.872 . . . . 0.0 109.458 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 1.7 ttpt -147.22 112.68 4.1 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.136 -0.978 . . . . 0.0 109.58 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -73.44 86.55 1.16 Allowed 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.692 2.261 . . . . 0.0 112.128 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.559 ' CG1' ' CD1' ' A' ' 132' ' ' ILE . 8.1 p -99.68 165.02 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.122 -0.986 . . . . 0.0 109.253 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -124.25 134.53 53.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.22 -0.925 . . . . 0.0 109.759 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 11.3 p -49.06 169.71 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.312 -0.867 . . . . 0.0 109.372 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.654 ' O ' ' HB2' ' A' ' 121' ' ' LEU . 14.5 mt-10 -156.68 127.53 6.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.908 . . . . 0.0 109.921 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.654 ' HB2' ' O ' ' A' ' 120' ' ' GLU . 6.0 mp 76.64 94.45 0.07 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.721 -0.612 . . . . 0.0 110.165 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.549 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -29.52 95.48 0.01 OUTLIER Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.625 ' CZ ' ' HB2' ' A' ' 175' ' ' LYS . 0.0 OUTLIER -55.94 178.05 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.929 -1.336 . . . . 0.0 109.188 179.758 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.481 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 12.2 mttt -113.91 157.22 22.67 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.11 -0.994 . . . . 0.0 110.146 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.444 ' HA ' HG23 ' A' ' 143' ' ' ILE . 22.0 t -64.43 144.99 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.512 -0.742 . . . . 0.0 109.469 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.68 -28.23 4.5 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.625 ' HB3' ' CE2' ' A' ' 123' ' ' PHE . 8.3 m-20 -50.48 167.52 0.06 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.466 -1.02 . . . . 0.0 108.898 179.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -99.05 126.36 44.75 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.026 -1.047 . . . . 0.0 109.112 179.838 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.465 HG21 ' O ' ' A' ' 174' ' ' GLU . 2.3 p -124.93 142.8 40.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.373 -0.829 . . . . 0.0 109.08 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 21.1 tttt -104.9 142.91 33.92 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.293 -0.879 . . . . 0.0 109.236 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.458 HD12 ' HB3' ' A' ' 136' ' ' PHE . 74.3 mt -83.01 152.99 3.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.152 -0.967 . . . . 0.0 108.629 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.559 ' CD1' ' CG1' ' A' ' 117' ' ' VAL . 34.2 pt -150.1 2.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.926 -1.109 . . . . 0.0 109.494 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.553 ' CA ' ' HG2' ' A' ' 137' ' ' GLU . 5.9 t -147.11 142.09 26.99 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.048 -1.032 . . . . 0.0 109.634 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.451 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 102.22 -166.0 17.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 179.266 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.542 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 48.4 Cg_endo -68.28 -20.61 42.69 Favored 'Trans proline' 0 C--O 1.214 -0.701 0 C-N-CA 123.382 2.721 . . . . 0.0 113.104 -179.157 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.505 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.1 m-85 -105.77 15.86 26.13 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.836 -1.165 . . . . 0.0 109.54 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.553 ' HG2' ' CA ' ' A' ' 133' ' ' SER . 73.0 mt-10 -41.5 137.35 1.56 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.196 -0.94 . . . . 0.0 109.95 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.491 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.6 OUTLIER 75.48 25.18 1.26 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.303 -0.873 . . . . 0.0 110.656 178.954 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.574 ' CE1' HG22 ' A' ' 157' ' ' VAL . 1.1 t80 -115.96 134.25 55.17 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.876 -1.14 . . . . 0.0 109.579 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -83.79 134.29 34.73 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.196 -0.94 . . . . 0.0 109.551 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.17 169.38 25.78 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.409 HG11 ' N ' ' A' ' 143' ' ' ILE . 71.2 t -115.25 136.3 52.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.404 -1.057 . . . . 0.0 109.42 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.556 HG12 ' CD2' ' A' ' 153' ' ' LEU . 39.4 mt -67.61 117.92 10.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.162 -0.961 . . . . 0.0 109.505 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 24.5 tttm -99.79 -34.5 10.13 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.152 -0.967 . . . . 0.0 109.407 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.462 ' HB3' ' HD2' ' A' ' 154' ' ' LYS . 85.1 tt0 -153.85 148.99 26.89 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.11 -0.994 . . . . 0.0 109.66 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.508 HG22 ' CD1' ' A' ' 153' ' ' LEU . 3.3 mt -124.07 126.79 72.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.287 -0.883 . . . . 0.0 109.425 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.55 101.75 41.14 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.219 -0.925 . . . . 0.0 109.495 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.563 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 49.9 Cg_endo -71.6 170.54 18.34 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.653 2.235 . . . . 0.0 111.665 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.563 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.1 mt-10 80.48 -20.39 0.38 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.441 -0.787 . . . . 0.0 109.952 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.407 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 70.8 mtp180 -127.55 -13.58 5.38 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.12 -0.987 . . . . 0.0 109.67 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.407 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 29.0 mt-30 69.44 48.16 0.64 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.887 . . . . 0.0 109.499 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . 0.415 ' OE2' HG12 ' A' ' 167' ' ' VAL . 82.9 tt0 -118.75 143.05 47.14 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.099 -1.001 . . . . 0.0 108.803 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.556 ' CD2' HG12 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -130.77 117.67 19.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.048 -1.032 . . . . 0.0 110.321 -179.174 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . 0.462 ' HD2' ' HB3' ' A' ' 145' ' ' GLU . 11.2 mttt -79.82 129.65 34.66 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.522 HG21 ' CG2' ' A' ' 166' ' ' VAL . 14.3 m -131.19 148.02 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.157 -0.965 . . . . 0.0 109.724 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.518 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.7 m-20 -100.48 119.04 37.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.37 -0.832 . . . . 0.0 109.437 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.574 HG22 ' CE1' ' A' ' 139' ' ' PHE . 3.4 p -100.35 144.05 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.309 -0.869 . . . . 0.0 109.501 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 28.0 m -96.89 97.05 8.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.391 -0.818 . . . . 0.0 109.984 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.494 HG13 HG23 ' A' ' 157' ' ' VAL . 13.0 mt -118.21 139.27 46.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.914 . . . . 0.0 109.332 179.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.493 ' CE2' HG23 ' A' ' 159' ' ' ILE . 40.0 m-85 59.67 41.74 18.14 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.402 -0.811 . . . . 0.0 109.32 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 54.14 16.61 6.55 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 4.3 mtp-105 -119.21 147.07 44.64 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.089 -1.242 . . . . 0.0 109.628 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -95.66 129.73 42.77 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.28 -0.887 . . . . 0.0 109.573 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.2 m -145.94 128.22 7.87 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.908 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.518 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.5 Cg_endo -70.52 138.72 36.0 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.686 2.257 . . . . 0.0 111.369 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.522 ' CG2' HG21 ' A' ' 155' ' ' VAL . 2.9 m -122.4 168.09 15.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.005 -1.059 . . . . 0.0 110.01 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.415 HG12 ' OE2' ' A' ' 152' ' ' GLU . 42.8 t -116.44 117.95 57.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.541 -0.724 . . . . 0.0 109.309 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.486 ' CD1' ' N ' ' A' ' 168' ' ' LEU . 2.4 mp -141.21 165.75 26.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.258 -0.901 . . . . 0.0 110.519 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -80.2 143.38 33.83 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.431 ' CG1' ' N ' ' A' ' 171' ' ' SER . 4.3 p -57.96 -36.86 57.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.269 -0.895 . . . . 0.0 108.789 179.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.431 ' N ' ' CG1' ' A' ' 170' ' ' VAL . 49.8 m -77.17 -7.47 55.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.482 -0.761 . . . . 0.0 109.417 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.428 ' CG ' ' HB3' ' A' ' 133' ' ' SER . 5.5 mt-10 -95.8 -2.66 47.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.291 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 11.3 m -127.51 164.72 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.225 -0.922 . . . . 0.0 109.392 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.465 ' O ' HG21 ' A' ' 129' ' ' VAL . 58.3 tt0 -134.64 153.81 51.81 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.259 -0.901 . . . . 0.0 109.07 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.625 ' HB2' ' CZ ' ' A' ' 123' ' ' PHE . 33.1 pttt -92.91 20.99 6.03 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.182 -0.949 . . . . 0.0 109.493 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . . . . . . . . . 64.2 mt 61.8 -76.98 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.3 -0.875 . . . . 0.0 109.39 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.522 ' N ' ' O ' ' A' ' 175' ' ' LYS . 95.5 mt-10 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.374 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.5 -30.57 71.37 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.217 -1.166 . . . . 0.0 109.483 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 96.1 mmm -55.22 -41.36 71.95 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.459 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -92.68 143.89 25.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.354 -0.841 . . . . 0.0 109.52 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.462 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 82.9 mttt -95.41 144.48 25.9 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.496 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 18.7 mttp -130.65 176.45 8.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.294 -0.879 . . . . 0.0 109.579 -179.69 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.652 ' CZ3' ' CG2' ' A' ' 41' ' ' VAL . 76.1 m95 -113.16 125.06 53.93 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.279 -0.888 . . . . 0.0 109.179 179.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -115.37 170.4 8.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.164 -0.96 . . . . 0.0 109.139 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.56 HG12 ' CE1' ' A' ' 61' ' ' PHE . 21.5 mt -113.88 97.77 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.101 -1.0 . . . . 0.0 108.818 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.661 ' CG1' ' CG1' ' A' ' 60' ' ' VAL . 3.9 p -81.83 151.09 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.254 -0.903 . . . . 0.0 109.264 -179.771 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.534 ' CD2' ' CE1' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -94.34 142.96 26.82 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.388 -0.82 . . . . 0.0 110.013 -179.312 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.4 p -144.59 -171.59 3.64 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.372 -0.83 . . . . 0.0 109.01 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.504 ' CG ' ' SD ' ' A' ' 81' ' ' MET . 44.4 mtm -102.38 118.98 38.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.165 -0.959 . . . . 0.0 109.596 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 13' ' ' MET . 43.7 m -42.14 121.74 1.94 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.22 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.53 -18.3 32.69 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.069 -1.613 . . . . 0.0 109.069 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.43 ' O ' ' C ' ' A' ' 17' ' ' GLU . 92.9 m-85 -108.91 -13.25 14.78 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.397 -1.061 . . . . 0.0 109.61 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.43 ' C ' ' O ' ' A' ' 16' ' ' TYR . 95.1 mt-10 -42.71 -55.27 3.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.279 -0.888 . . . . 0.0 109.372 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -54.16 -36.46 63.36 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.215 -0.928 . . . . 0.0 109.141 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.421 ' N ' ' O ' ' A' ' 16' ' ' TYR . 28.0 mttp -70.3 -37.41 74.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.275 -0.891 . . . . 0.0 109.131 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 61.2 t -64.07 -47.13 91.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.431 -0.793 . . . . 0.0 109.411 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.6 tttm -55.1 -50.93 67.96 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.224 -0.923 . . . . 0.0 109.331 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -64.55 -41.92 96.01 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.281 -0.887 . . . . 0.0 109.311 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.459 ' ND2' ' HG2' ' A' ' 78' ' ' PRO . 24.1 t-20 -57.62 -39.75 77.62 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.186 -0.946 . . . . 0.0 109.452 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.517 ' CG2' HD12 ' A' ' 40' ' ' ILE . 96.4 mt -62.89 -44.73 99.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -0.927 . . . . 0.0 109.648 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -53.81 -45.29 70.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.15 -0.969 . . . . 0.0 109.64 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.9 mttt -79.99 -32.37 39.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.485 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.413 ' HG2' HG22 ' A' ' 77' ' ' VAL . 48.7 tptt -56.77 -38.3 72.3 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.308 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 40.7 t -83.81 -22.93 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.338 -0.851 . . . . 0.0 109.399 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -69.16 -53.27 20.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.571 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.77 -33.47 64.36 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.619 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 23.1 p -91.42 -19.92 22.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.229 -0.92 . . . . 0.0 109.612 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 68.83 9.97 60.37 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.527 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 54.3 mt -80.16 88.5 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.292 -1.122 . . . . 0.0 109.414 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.3 mttt -91.74 9.18 33.6 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.155 -0.966 . . . . 0.0 109.438 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 38.0 p30 -110.93 9.13 22.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.289 -0.882 . . . . 0.0 109.59 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.541 HD23 ' CG1' ' A' ' 65' ' ' ILE . 0.2 OUTLIER -109.71 -55.22 2.46 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.182 -0.948 . . . . 0.0 109.172 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.455 ' CG2' ' HE3' ' A' ' 64' ' ' MET . 68.9 t -94.15 130.98 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.317 -0.864 . . . . 0.0 109.31 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.75 -122.84 5.16 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -89.74 148.56 23.19 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.275 -1.132 . . . . 0.0 109.822 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.517 HD12 ' CG2' ' A' ' 24' ' ' ILE . 72.2 mt -116.21 132.93 64.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.4 -0.812 . . . . 0.0 108.909 179.641 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.652 ' CG2' ' CZ3' ' A' ' 7' ' ' TRP . 34.3 t -125.87 161.81 30.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 O-C-N 121.049 -1.032 . . . . 0.0 109.346 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.457 HG22 HD12 ' A' ' 44' ' ' ILE . 2.3 mt -140.92 127.61 11.74 Favored Pre-proline 0 N--CA 1.487 1.402 0 O-C-N 121.208 -0.933 . . . . 0.0 109.83 -179.709 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.543 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 45.8 Cg_endo -67.16 -2.64 8.39 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.841 2.36 . . . . 0.0 111.305 179.569 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.706 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 19.0 pt -81.14 -9.59 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.312 -0.868 . . . . 0.0 109.615 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.527 ' HB2' ' CD2' ' A' ' 104' ' ' LEU . 22.5 mtp85 -50.16 -23.64 2.3 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.081 -1.012 . . . . 0.0 109.345 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -101.77 -168.19 27.39 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 60.15 43.41 98.4 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -67.9 -29.32 68.39 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.242 -1.152 . . . . 0.0 109.459 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.414 ' O ' ' O ' ' A' ' 52' ' ' SER . 99.2 mtt180 -53.66 140.49 29.01 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.248 -0.907 . . . . 0.0 109.455 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 58.3 mtt-85 -61.98 -24.88 67.3 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.16 -0.963 . . . . 0.0 109.444 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 28.5 mttm -59.05 -27.74 65.78 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.196 -0.94 . . . . 0.0 109.5 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.414 ' O ' ' O ' ' A' ' 49' ' ' ARG . 48.8 p -146.43 144.84 29.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.934 . . . . 0.0 109.591 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.501 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 75.5 mm-40 -139.77 128.12 22.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 109.479 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.706 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 13.6 mttp 74.83 115.8 0.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.258 -0.901 . . . . 0.0 109.646 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.607 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 18.2 tp -57.48 -45.85 84.38 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.039 -1.038 . . . . 0.0 109.291 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.607 ' CE2' ' HG ' ' A' ' 55' ' ' LEU . 57.9 m-85 -131.44 109.4 14.83 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.141 -0.974 . . . . 0.0 108.864 179.482 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -65.45 138.9 56.89 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.579 2.186 . . . . 0.0 111.974 -179.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.84 -16.7 5.11 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 179.605 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.534 ' CE1' ' CD2' ' A' ' 11' ' ' LEU . 3.3 m-30 -98.63 129.08 45.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.788 -1.419 . . . . 0.0 110.406 -179.207 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.661 ' CG1' ' CG1' ' A' ' 10' ' ' VAL . 7.7 p -136.92 151.58 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.56 ' CE1' HG12 ' A' ' 9' ' ' ILE . 7.7 m-85 -110.0 127.07 54.58 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.914 -1.116 . . . . 0.0 110.756 -178.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.551 HG12 ' CG ' ' A' ' 64' ' ' MET . 90.3 t -129.51 139.82 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.649 -0.657 . . . . 0.0 109.318 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.603 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 9.7 tt0 -101.83 126.94 48.81 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.114 -0.991 . . . . 0.0 109.104 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.551 ' CG ' HG12 ' A' ' 62' ' ' VAL . 1.8 mtp -157.28 178.02 10.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.043 -1.036 . . . . 0.0 110.071 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.541 ' CG1' HD23 ' A' ' 36' ' ' LEU . 12.2 pt -99.95 131.92 46.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.593 -0.692 . . . . 0.0 109.286 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.474 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 42.1 ttm -77.65 145.76 36.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 110.086 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.474 ' HB2' ' O ' ' A' ' 66' ' ' MET . 49.8 t-20 176.74 172.37 0.45 Allowed 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.469 ' N ' ' OD1' ' A' ' 67' ' ' ASN . 90.2 m-20 -69.47 -42.81 74.35 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.163 -0.961 . . . . 0.0 109.275 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.49 ' HG2' ' CD2' ' A' ' 73' ' ' PHE . 69.7 tt0 -73.82 -31.54 63.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.327 -0.858 . . . . 0.0 109.55 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.521 ' HB1' ' CD2' ' A' ' 36' ' ' LEU . . . -70.92 -45.07 64.92 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.146 -0.971 . . . . 0.0 109.356 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.486 ' HA ' ' CG1' ' A' ' 74' ' ' VAL . 71.8 t80 -60.99 -47.0 88.48 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.265 -0.897 . . . . 0.0 109.72 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.492 ' O ' ' HB2' ' A' ' 76' ' ' SER . 96.4 m-20 -64.72 -27.65 69.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.106 -0.996 . . . . 0.0 110.035 -179.518 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.49 ' CD2' ' HG2' ' A' ' 69' ' ' GLU . 3.6 m-85 -84.19 -42.98 15.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.045 -1.034 . . . . 0.0 109.917 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.486 ' CG1' ' HA ' ' A' ' 71' ' ' TYR . 2.9 p -67.12 -57.87 8.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.264 -0.898 . . . . 0.0 109.803 -179.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.463 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 28.5 tpt85 -62.84 -10.27 12.58 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.103 -0.998 . . . . 0.0 109.676 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.492 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 19.4 m -99.25 1.49 44.74 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.147 -0.971 . . . . 0.0 109.953 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.604 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -70.43 140.71 87.57 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.023 -1.048 . . . . 0.0 109.229 -179.976 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.648 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 45.6 Cg_endo -66.73 134.9 36.58 Favored 'Trans proline' 0 C--O 1.213 -0.765 0 C-N-CA 122.706 2.271 . . . . 0.0 111.849 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.648 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 10.0 m-85 92.62 -10.77 0.18 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.816 -0.552 . . . . 0.0 109.52 -179.708 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.604 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 2.3 t -85.7 121.06 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.116 -0.99 . . . . 0.0 109.144 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.504 ' SD ' ' CG ' ' A' ' 13' ' ' MET . 82.8 mtp -88.4 -33.69 17.82 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.241 -0.912 . . . . 0.0 109.565 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' A' ' 11' ' ' LEU . . . 172.01 -168.98 42.12 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.631 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 0.8 OUTLIER -134.21 146.65 50.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.189 -1.183 . . . . 0.0 109.524 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.484 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 14.2 p -81.23 114.38 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.212 -0.93 . . . . 0.0 109.368 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.57 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.9 OUTLIER -154.04 164.88 37.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.256 -0.902 . . . . 0.0 109.639 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 77.0 p -84.5 -30.63 25.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.167 -0.958 . . . . 0.0 109.267 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -130.96 -102.54 0.93 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.548 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -93.16 -129.15 5.08 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.548 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -29.5 150.47 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.675 -0.897 . . . . 0.0 110.315 -179.56 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.57 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 46.2 Cg_endo -67.66 143.03 60.52 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.753 2.302 . . . . 0.0 112.002 -179.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 6.2 m -74.07 147.56 85.96 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.325 -0.86 . . . . 0.0 109.293 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.484 ' CB ' ' HD3' ' A' ' 6' ' ' LYS . 49.2 Cg_endo -69.82 145.39 56.63 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.708 2.272 . . . . 0.0 111.7 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.526 ' CG1' ' HG2' ' A' ' 98' ' ' MET . 9.9 p -70.11 135.16 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.932 . . . . 0.0 109.231 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . 0.468 ' HE2' ' HD2' ' A' ' 96' ' ' ARG . 15.4 tttp -70.95 136.48 48.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.179 -0.95 . . . . 0.0 109.592 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -46.58 -52.05 14.34 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.221 -0.924 . . . . 0.0 109.355 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.468 ' HD2' ' HE2' ' A' ' 94' ' ' LYS . 72.0 mtt85 -60.84 -16.47 41.63 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.292 -0.88 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.504 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 6.7 mt-10 -88.59 -28.5 20.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.274 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.612 ' HE3' ' CD1' ' A' ' 7' ' ' TRP . 31.4 mtp -75.85 -28.69 58.3 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -0.874 . . . . 0.0 109.61 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.576 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.46 -53.37 1.3 Allowed Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.485 -0.76 . . . . 0.0 109.979 -179.609 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.7 Cg_endo -69.01 -34.96 15.85 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.538 2.158 . . . . 0.0 112.111 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.418 HG22 ' CD2' ' A' ' 61' ' ' PHE . 8.7 mm -78.57 -44.51 26.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.118 -0.989 . . . . 0.0 109.444 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.601 ' CD1' ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -62.19 -41.35 98.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.106 -0.996 . . . . 0.0 108.873 179.725 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.465 ' HD2' ' O ' ' A' ' 135' ' ' PRO . 36.3 mtt180 -61.03 -43.21 99.23 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.527 ' CD2' ' HB2' ' A' ' 45' ' ' ARG . 0.7 OUTLIER -70.01 -35.76 74.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 109.134 179.667 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.519 ' HB3' ' CG1' ' A' ' 41' ' ' VAL . . . -88.13 20.96 2.94 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.21 179.681 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 46.92 28.4 3.88 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.538 ' CD1' HD12 ' A' ' 102' ' ' LEU . 35.9 mt -80.04 -22.84 41.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.196 -1.179 . . . . 0.0 109.146 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -112.85 149.51 33.01 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.345 -0.847 . . . . 0.0 109.314 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -93.93 124.09 37.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.235 -0.916 . . . . 0.0 109.585 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.473 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 48.1 p90 -144.27 160.36 41.13 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.27 -0.894 . . . . 0.0 109.477 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.473 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 6.4 mt-10 -68.73 -147.76 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.241 -0.912 . . . . 0.0 109.49 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.47 ' O ' ' HB3' ' A' ' 113' ' ' LYS . 81.8 tt0 -100.61 -48.57 4.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.215 -0.928 . . . . 0.0 109.488 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.47 ' HB3' ' O ' ' A' ' 112' ' ' GLU . 16.6 pttt 173.72 177.83 0.11 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.252 -0.905 . . . . 0.0 109.298 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.504 ' O ' ' CB ' ' A' ' 115' ' ' LYS . 6.6 mttt -70.44 -64.65 0.85 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.176 -0.953 . . . . 0.0 109.238 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.504 ' CB ' ' O ' ' A' ' 114' ' ' LYS . 2.8 mtpt 164.71 148.72 0.05 OUTLIER Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.297 -0.877 . . . . 0.0 109.259 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -68.82 53.83 0.81 Allowed 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.673 2.249 . . . . 0.0 111.7 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.406 ' O ' ' CB ' ' A' ' 118' ' ' LYS . 7.6 p -71.28 -5.3 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.287 -0.883 . . . . 0.0 109.58 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.466 ' HA ' ' HB3' ' A' ' 171' ' ' SER . 26.5 tttt 68.4 125.81 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.282 -0.886 . . . . 0.0 109.464 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.499 ' CG1' ' HA ' ' A' ' 174' ' ' GLU . 74.3 t -128.08 123.83 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.188 -0.945 . . . . 0.0 109.403 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.663 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 89.4 mt-10 -153.81 170.53 20.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.515 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.663 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 4.1 mt 145.33 112.77 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . 42.08 57.67 3.51 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.525 ' CD2' ' O ' ' A' ' 123' ' ' PHE . 51.7 p90 -103.18 121.9 43.62 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.294 -1.121 . . . . 0.0 109.498 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.463 ' N ' ' OD2' ' A' ' 127' ' ' ASP . 27.5 mttp -141.81 164.48 30.07 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.247 -0.908 . . . . 0.0 109.558 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.511 ' HA ' HG23 ' A' ' 143' ' ' ILE . 7.9 p -66.5 126.11 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.318 -0.864 . . . . 0.0 109.659 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 103.68 -33.32 6.67 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.49 ' HB2' HD11 ' A' ' 143' ' ' ILE . 73.2 m-20 -48.15 165.33 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.385 -1.068 . . . . 0.0 108.922 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.4 ttm -97.26 126.91 42.78 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.044 -1.035 . . . . 0.0 108.97 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.585 ' CG2' ' CG1' ' A' ' 143' ' ' ILE . 12.7 t -125.36 141.91 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.248 -0.908 . . . . 0.0 109.535 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.476 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 42.8 tttp -106.61 143.91 34.04 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.357 -0.839 . . . . 0.0 108.946 179.495 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.541 HG22 ' N ' ' A' ' 132' ' ' ILE . 65.8 mt -84.76 155.31 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.129 -0.982 . . . . 0.0 108.817 179.636 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.541 ' N ' HG22 ' A' ' 131' ' ' ILE . 27.2 pt -150.59 2.95 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.126 -0.984 . . . . 0.0 109.488 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 72.7 m -148.66 145.08 27.57 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.151 -0.968 . . . . 0.0 110.107 -179.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.15 -170.55 16.8 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.465 ' O ' ' HD2' ' A' ' 103' ' ' ARG . 48.2 Cg_endo -68.66 -19.8 41.31 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 123.275 2.65 . . . . 0.0 112.467 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.515 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 98.1 m-85 -112.96 13.22 19.48 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.05 -1.031 . . . . 0.0 109.487 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.527 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 1.6 tt0 -42.73 151.74 0.12 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 109.663 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.527 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 25.3 m-20 72.99 28.1 1.98 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.455 -0.778 . . . . 0.0 110.091 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.553 ' CE1' ' CG1' ' A' ' 157' ' ' VAL . 0.9 OUTLIER -120.43 136.99 54.57 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.99 -1.069 . . . . 0.0 109.539 179.877 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.08 133.94 34.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.225 -0.922 . . . . 0.0 109.579 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.92 170.05 25.95 Favored Glycine 0 N--CA 1.492 2.374 0 C-N-CA 119.836 -1.173 . . . . 0.0 110.171 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.537 ' N ' ' CG2' ' A' ' 155' ' ' VAL . 47.9 t -115.76 136.03 53.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.387 -1.066 . . . . 0.0 109.439 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.585 ' CG1' ' CG2' ' A' ' 129' ' ' VAL . 87.7 mt -65.12 115.22 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.89 . . . . 0.0 109.386 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . 0.453 ' C ' ' HG2' ' A' ' 145' ' ' GLU . 36.6 tttp -100.26 -36.38 9.3 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.062 -1.024 . . . . 0.0 109.377 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.453 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 67.2 mm-40 -149.57 144.26 26.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.967 . . . . 0.0 109.351 -179.9 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.545 ' CG2' ' HG ' ' A' ' 153' ' ' LEU . 2.4 mt -123.04 125.85 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.183 -0.948 . . . . 0.0 109.406 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -108.18 101.46 41.9 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.236 -0.915 . . . . 0.0 109.63 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.552 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.7 171.4 16.49 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.72 2.28 . . . . 0.0 111.781 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.552 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 10.8 tt0 80.55 -20.97 0.35 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.3 -0.875 . . . . 0.0 109.791 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.449 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 93.1 mtt-85 -126.59 -12.99 6.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.916 . . . . 0.0 109.437 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.449 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 29.9 mt-30 69.83 48.6 0.56 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.204 -0.935 . . . . 0.0 109.61 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -120.06 143.62 48.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.138 -0.976 . . . . 0.0 109.08 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.545 ' HG ' ' CG2' ' A' ' 146' ' ' ILE . 0.1 OUTLIER -136.99 112.38 9.24 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.15 -0.969 . . . . 0.0 110.12 -179.599 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . 0.419 ' HD2' ' HB2' ' A' ' 145' ' ' GLU . 30.8 mttm -79.85 130.94 35.72 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.06 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.537 ' CG2' ' N ' ' A' ' 142' ' ' VAL . 7.3 p -133.39 127.48 53.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.121 -0.987 . . . . 0.0 109.752 -179.469 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.532 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 50.2 m-20 -73.18 135.4 44.61 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.362 -0.836 . . . . 0.0 109.709 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.553 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 53.9 t -116.8 149.96 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.466 -0.772 . . . . 0.0 109.195 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 57.2 m -96.34 103.01 14.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.107 -0.996 . . . . 0.0 109.711 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.412 ' O ' ' HB2' ' A' ' 160' ' ' PHE . 20.5 mt -129.98 140.77 48.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.285 -0.884 . . . . 0.0 109.311 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.435 ' O ' ' HG3' ' A' ' 162' ' ' ARG . 52.8 m-85 60.3 40.4 17.76 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.186 -0.946 . . . . 0.0 108.97 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.64 16.31 15.88 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.435 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 46.1 mtp180 -128.43 156.13 43.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.111 -1.229 . . . . 0.0 109.57 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -100.24 133.75 44.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.289 -0.882 . . . . 0.0 109.443 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.7 m -141.33 127.77 11.41 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.342 -0.849 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.532 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.9 Cg_endo -70.35 133.68 25.03 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.658 2.238 . . . . 0.0 111.44 179.697 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.463 ' O ' HD11 ' A' ' 168' ' ' LEU . 2.8 p -122.67 141.87 41.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.204 -0.935 . . . . 0.0 109.675 -179.837 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.463 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 18.0 m -93.17 120.11 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.458 -0.776 . . . . 0.0 109.458 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.463 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 0.0 OUTLIER -142.3 167.81 21.22 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.33 -0.857 . . . . 0.0 110.487 -179.471 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.481 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 98.0 m-70 -81.6 142.0 33.19 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.622 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 10.8 p -55.92 -35.98 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.177 -0.952 . . . . 0.0 109.025 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.466 ' HB3' ' HA ' ' A' ' 118' ' ' LYS . 74.6 p -75.71 -6.61 51.39 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.403 -0.811 . . . . 0.0 109.626 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.481 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 41.8 mt-10 -90.99 -0.68 57.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.135 -0.978 . . . . 0.0 109.572 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.476 ' HB ' ' O ' ' A' ' 130' ' ' LYS . 2.8 m -147.13 177.74 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.176 -0.953 . . . . 0.0 109.452 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.525 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 83.5 tt0 -136.55 163.75 29.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.149 -0.969 . . . . 0.0 109.263 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.528 ' O ' ' N ' ' A' ' 177' ' ' GLU . 51.3 mmtt -94.77 18.0 12.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.47 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . . . . . . . . . 63.5 mt 59.8 -79.08 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.29 -0.881 . . . . 0.0 109.684 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.528 ' N ' ' O ' ' A' ' 175' ' ' LYS . 94.1 mt-10 . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 117.905 -1.045 . . . . 0.0 109.515 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.51 -22.92 65.42 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -1.166 . . . . 0.0 109.491 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 91.3 mtp -66.97 -24.76 66.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.288 -0.882 . . . . 0.0 109.479 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 30.1 mttt -112.16 132.51 54.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.283 -0.886 . . . . 0.0 109.476 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -89.12 146.73 24.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.246 -0.909 . . . . 0.0 109.493 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.544 ' HB2' ' CZ ' ' A' ' 8' ' ' TYR . 26.5 mmtp -128.6 175.47 8.54 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.354 -0.841 . . . . 0.0 109.613 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.628 ' CG ' ' CE ' ' A' ' 98' ' ' MET . 47.2 m95 -111.65 124.26 51.94 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.39 -0.819 . . . . 0.0 108.968 179.657 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.544 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 59.3 m-85 -117.94 168.65 10.31 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.141 -0.975 . . . . 0.0 109.478 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.538 HG12 ' CE1' ' A' ' 61' ' ' PHE . 33.9 mt -107.5 114.63 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.208 -0.932 . . . . 0.0 109.367 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.547 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 8.5 p -92.65 141.17 15.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.234 -0.916 . . . . 0.0 109.222 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.561 HD13 ' CE1' ' A' ' 59' ' ' TYR . 3.7 mm? -89.62 143.28 26.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.408 -0.807 . . . . 0.0 109.739 -179.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.437 HG23 ' HA2' ' A' ' 58' ' ' GLY . 9.0 t -152.99 -166.03 2.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.325 -0.859 . . . . 0.0 109.408 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.416 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 46.2 mtt -108.14 130.83 55.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.532 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.0 t -54.26 128.27 30.54 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.196 -0.94 . . . . 0.0 109.391 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.55 -20.31 44.8 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 -179.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.416 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 79.4 m-85 -104.47 5.94 34.48 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.38 -1.071 . . . . 0.0 109.557 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.543 ' OE1' ' CG2' ' A' ' 60' ' ' VAL . 41.1 mm-40 -53.36 -62.32 1.73 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.62 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 17' ' ' GLU . 60.7 mt-10 -42.68 -35.64 1.18 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -0.889 . . . . 0.0 109.583 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.528 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 27.3 mttt -74.18 -44.61 52.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.472 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.411 ' O ' HG13 ' A' ' 24' ' ' ILE . 70.6 t -58.44 -53.11 51.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.48 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.448 ' HD2' HD13 ' A' ' 42' ' ' ILE . 21.5 tttm -58.4 -47.07 85.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.348 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -63.13 -41.17 99.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.329 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.54 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 87.7 m-20 -59.29 -42.78 92.09 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.904 . . . . 0.0 109.503 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.526 ' CD1' HD12 ' A' ' 40' ' ' ILE . 69.7 mt -61.5 -46.46 96.53 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.229 -0.919 . . . . 0.0 109.715 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -54.83 -46.22 74.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.145 -0.972 . . . . 0.0 109.56 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -75.78 -35.57 60.07 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.132 -0.98 . . . . 0.0 109.459 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.428 ' O ' ' CG2' ' A' ' 31' ' ' THR . 7.8 ttpt -56.14 -34.26 65.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.253 -0.905 . . . . 0.0 109.314 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 44.2 t -85.52 -25.15 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -0.873 . . . . 0.0 109.377 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -69.77 -54.17 14.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.186 -0.946 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.22 -24.76 67.79 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.197 -0.94 . . . . 0.0 109.526 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.428 ' CG2' ' O ' ' A' ' 27' ' ' LYS . 40.2 p -94.96 -21.75 18.41 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.165 -0.959 . . . . 0.0 109.531 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 63.68 22.01 65.66 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.592 ' CG2' ' CD1' ' A' ' 36' ' ' LEU . 42.7 mm -95.07 91.79 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.271 -1.134 . . . . 0.0 109.465 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.9 mtpt -98.81 10.03 42.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.27 -0.894 . . . . 0.0 109.52 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -108.24 5.44 25.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.19 -0.944 . . . . 0.0 109.492 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.592 ' CD1' ' CG2' ' A' ' 33' ' ' ILE . 88.3 mt -117.78 -30.94 5.29 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.276 -0.89 . . . . 0.0 109.39 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.496 ' HA ' ' HG2' ' A' ' 64' ' ' MET . 73.0 t -114.68 129.35 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.309 -0.869 . . . . 0.0 109.305 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.73 -129.89 6.84 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 23.4 mtt-85 -90.44 147.89 23.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.274 -1.133 . . . . 0.0 109.777 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.55 HG23 ' CG2' ' A' ' 62' ' ' VAL . 59.9 mt -113.32 136.61 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.337 -0.852 . . . . 0.0 109.383 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.554 ' CG1' ' HB2' ' A' ' 61' ' ' PHE . 9.3 p -130.4 158.29 42.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.199 -0.938 . . . . 0.0 109.54 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.461 ' CG2' HG21 ' A' ' 44' ' ' ILE . 3.3 mt -131.78 129.05 21.86 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.559 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.515 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 46.1 Cg_endo -67.2 -4.73 12.19 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.788 2.325 . . . . 0.0 111.587 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.571 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 12.7 pt -78.08 -17.81 13.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.299 -0.876 . . . . 0.0 109.451 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.447 ' O ' ' CD2' ' A' ' 104' ' ' LEU . 60.0 mtt-85 -54.21 150.16 8.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.485 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 150.94 160.91 9.67 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 53.7 -119.7 11.88 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -103.65 146.66 28.25 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.266 -1.138 . . . . 0.0 109.446 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -57.32 -33.12 67.38 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.217 -0.927 . . . . 0.0 109.544 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -66.81 -33.05 74.75 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.292 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 8.4 mmtp -100.98 148.64 24.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.316 -0.865 . . . . 0.0 109.384 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 6.1 p -146.18 115.83 7.22 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.313 -0.867 . . . . 0.0 109.396 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.505 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 55.4 mm-40 -77.92 -31.3 51.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.305 -0.872 . . . . 0.0 109.545 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.571 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 47.6 mttt 74.86 85.71 0.1 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.42 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.515 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 6.7 mp -61.55 -26.8 68.18 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.097 -1.002 . . . . 0.0 109.527 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.444 ' HB3' ' HB2' ' A' ' 59' ' ' TYR . 97.2 m-85 -145.83 103.8 4.2 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.893 . . . . 0.0 109.31 179.778 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.405 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 43.5 Cg_endo -67.17 137.75 44.96 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.666 2.244 . . . . 0.0 111.865 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.437 ' HA2' HG23 ' A' ' 12' ' ' THR . . . 72.91 -9.28 6.68 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.561 ' CE1' HD13 ' A' ' 11' ' ' LEU . 3.2 m-85 -103.49 132.65 49.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.795 -1.415 . . . . 0.0 109.82 -179.511 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.547 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 4.9 t -135.58 148.65 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.354 -0.841 . . . . 0.0 108.923 179.41 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.554 ' HB2' ' CG1' ' A' ' 41' ' ' VAL . 63.3 m-85 -107.87 121.65 45.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.073 -1.017 . . . . 0.0 109.764 -179.64 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.55 ' CG2' HG23 ' A' ' 40' ' ' ILE . 57.6 t -129.06 141.14 47.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.357 -0.839 . . . . 0.0 109.699 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.602 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 52.4 tt0 -97.03 124.73 41.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.339 -0.851 . . . . 0.0 108.862 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.507 ' CG ' ' O ' ' A' ' 63' ' ' GLU . 37.3 mtm -158.4 -179.82 8.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.147 -0.971 . . . . 0.0 109.777 -179.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.576 ' CD1' ' CD2' ' A' ' 36' ' ' LEU . 8.5 pt -102.64 129.0 54.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.2 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.511 ' O ' ' HG3' ' A' ' 66' ' ' MET . 5.2 ptp -85.58 96.2 9.57 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.129 -0.982 . . . . 0.0 109.668 -179.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.598 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 23.0 t-20 -140.04 170.48 15.78 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -52.81 -47.58 67.53 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.038 -1.039 . . . . 0.0 109.987 -179.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.458 ' O ' ' C ' ' A' ' 70' ' ' ALA . 64.6 mm-40 -64.87 -64.34 0.89 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.095 -1.003 . . . . 0.0 110.132 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.458 ' C ' ' O ' ' A' ' 69' ' ' GLU . . . -39.77 -38.8 0.69 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.263 -0.898 . . . . 0.0 109.926 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.598 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 15.4 m-85 -61.11 -62.16 2.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.226 -0.921 . . . . 0.0 109.362 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -45.76 -34.9 3.93 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.503 -0.748 . . . . 0.0 110.412 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -81.39 -43.85 18.39 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.888 -1.133 . . . . 0.0 110.136 -179.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.642 ' CG1' ' CZ ' ' A' ' 83' ' ' PHE . 45.4 t -64.43 -58.67 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.25 -0.906 . . . . 0.0 109.643 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -35.05 19.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.366 -0.834 . . . . 0.0 110.034 -179.589 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 53.6 p -78.16 4.89 11.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.083 -1.01 . . . . 0.0 110.37 -179.279 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.611 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 41.1 t -64.32 133.62 95.71 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 120.872 -1.143 . . . . 0.0 109.286 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.58 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 46.1 Cg_endo -68.27 134.83 32.43 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.702 2.268 . . . . 0.0 112.02 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.58 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 60.2 m-85 77.61 -1.54 2.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.525 -0.734 . . . . 0.0 109.855 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.611 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.4 t -88.6 127.32 41.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.173 -0.955 . . . . 0.0 109.147 179.609 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 82.5 mmm -90.77 -17.97 25.74 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.21 -0.931 . . . . 0.0 109.645 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.592 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 151.71 -155.61 26.23 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.642 ' CZ ' ' CG1' ' A' ' 74' ' ' VAL . 3.6 m-85 -140.04 152.67 46.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -1.16 . . . . 0.0 109.5 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.465 HG22 ' CD2' ' A' ' 11' ' ' LEU . 4.6 t -77.27 119.58 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.291 -0.881 . . . . 0.0 109.275 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.541 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.9 p -156.49 162.17 39.98 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.227 -0.92 . . . . 0.0 109.596 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.78 -34.8 14.45 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.887 . . . . 0.0 109.393 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -122.09 -86.33 0.83 Allowed Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -107.04 -130.37 6.43 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.545 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.1 OUTLIER -33.82 156.4 0.04 OUTLIER Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.43 -1.041 . . . . 0.0 110.056 -179.693 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.541 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.9 Cg_endo -69.71 157.74 59.44 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 122.492 2.128 . . . . 0.0 112.109 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 10.9 m -90.15 153.64 46.83 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.351 -0.843 . . . . 0.0 109.452 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.442 ' HB3' ' HB3' ' A' ' 6' ' ' LYS . 49.1 Cg_endo -69.81 145.48 56.99 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.658 2.239 . . . . 0.0 111.812 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.464 ' HB ' ' SD ' ' A' ' 98' ' ' MET . 7.6 t -84.22 129.69 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.235 -0.915 . . . . 0.0 109.194 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . 0.414 ' O ' ' C ' ' A' ' 95' ' ' ASP . 23.6 tttt -70.56 132.77 46.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.191 -0.943 . . . . 0.0 109.578 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 94' ' ' LYS . 80.5 m-20 -44.48 -39.86 5.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.205 -0.934 . . . . 0.0 109.356 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.492 ' CZ ' ' HB3' ' A' ' 96' ' ' ARG . 13.4 mtp-105 -53.79 -35.51 61.44 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.272 -0.893 . . . . 0.0 109.374 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.458 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 65.2 mt-10 -84.73 -27.48 26.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.269 -0.894 . . . . 0.0 109.372 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.628 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 94.4 mtp -84.98 -12.31 53.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.295 -0.878 . . . . 0.0 109.505 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.64 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -51.18 -48.42 85.46 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.171 -0.956 . . . . 0.0 109.853 179.864 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.64 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.5 Cg_endo -70.82 -27.6 21.22 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.485 2.123 . . . . 0.0 111.861 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.454 ' O ' ' HB3' ' A' ' 105' ' ' ALA . 35.8 mm -81.52 -44.4 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 109.565 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.551 HD12 ' CB ' ' A' ' 98' ' ' MET . 0.7 OUTLIER -66.46 -38.76 88.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.232 -0.917 . . . . 0.0 109.256 -179.926 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.524 ' CZ ' ' NH1' ' A' ' 99' ' ' ARG . 67.7 mtt180 -65.47 -50.16 66.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.429 -0.794 . . . . 0.0 109.322 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.447 ' CD2' ' O ' ' A' ' 45' ' ' ARG . 0.6 OUTLIER -72.64 -36.24 67.96 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.273 -0.892 . . . . 0.0 109.364 179.762 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.48 ' HB2' ' CG2' ' A' ' 41' ' ' VAL . . . -73.44 -0.99 16.52 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.371 -0.831 . . . . 0.0 109.687 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.03 11.6 81.44 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.512 ' CD1' HG23 ' A' ' 41' ' ' VAL . 61.3 mt -85.51 -24.11 27.45 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.128 -1.219 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.411 ' HB2' ' HB2' ' A' ' 102' ' ' LEU . 73.5 tt0 -116.9 160.92 20.16 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.283 -0.886 . . . . 0.0 109.591 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -100.05 120.32 39.65 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.274 -0.891 . . . . 0.0 109.405 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.582 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 46.9 p90 -133.77 168.07 19.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.236 -0.915 . . . . 0.0 109.505 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.582 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 41.4 mt-10 -79.23 -147.56 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.258 -0.901 . . . . 0.0 109.592 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -111.77 -49.48 2.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.19 -0.944 . . . . 0.0 109.316 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.45 ' HE3' ' HB3' ' A' ' 116' ' ' PRO . 31.0 pttt -151.9 140.94 21.2 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.326 -0.859 . . . . 0.0 109.325 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.49 ' CB ' ' O ' ' A' ' 132' ' ' ILE . 5.3 tttt -74.79 -54.14 7.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.181 -0.949 . . . . 0.0 109.593 -179.787 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.525 ' CG ' HD12 ' A' ' 132' ' ' ILE . 10.5 mttt -103.57 96.96 9.55 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.911 . . . . 0.0 109.545 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' A' ' 114' ' ' LYS . 52.2 Cg_endo -73.49 -4.72 15.9 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.911 2.408 . . . . 0.0 111.651 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.34 142.15 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.225 -0.922 . . . . 0.0 109.366 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.449 ' HG2' ' N ' ' A' ' 119' ' ' VAL . 50.3 tttp -50.51 157.17 0.77 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.118 -0.989 . . . . 0.0 109.487 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.469 HG11 ' N ' ' A' ' 120' ' ' GLU . 60.8 t -121.31 144.4 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.48 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.659 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 83.6 mt-10 -129.81 168.6 16.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.235 -0.916 . . . . 0.0 109.365 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.659 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 2.0 mt 145.82 100.58 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.973 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.617 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.53 93.17 0.01 OUTLIER Glycine 0 N--CA 1.496 2.662 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.496 ' N ' ' O ' ' A' ' 121' ' ' LEU . 3.6 p90 -96.71 149.71 21.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.2 -1.177 . . . . 0.0 109.489 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 22.4 mttt -149.02 157.29 43.3 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.221 -0.925 . . . . 0.0 109.52 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.453 ' HA ' HG21 ' A' ' 143' ' ' ILE . 44.7 t -60.33 140.04 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.488 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 87.85 -34.12 3.81 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.498 ' OD2' ' CE ' ' A' ' 175' ' ' LYS . 43.0 t0 -48.51 157.68 0.34 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.431 -1.041 . . . . 0.0 109.465 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.8 ttm -96.07 127.5 42.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.244 -0.91 . . . . 0.0 108.861 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.563 ' CG2' ' CD1' ' A' ' 143' ' ' ILE . 51.3 t -126.44 142.08 44.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.256 -0.903 . . . . 0.0 109.42 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.541 ' N ' HG11 ' A' ' 129' ' ' VAL . 5.8 ttpp -101.95 142.85 32.6 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.376 -0.828 . . . . 0.0 109.065 179.738 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.458 HG21 ' HA ' ' A' ' 137' ' ' GLU . 70.8 mt -82.9 151.35 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.042 -1.036 . . . . 0.0 108.761 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.546 HD13 ' CG ' ' A' ' 174' ' ' GLU . 33.2 pt -148.99 2.95 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.95 -1.093 . . . . 0.0 109.503 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.533 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 68.8 m -146.35 141.76 27.57 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.11 -0.994 . . . . 0.0 109.712 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.409 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 107.04 -170.85 16.16 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.581 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.52 -18.91 43.23 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 123.213 2.609 . . . . 0.0 112.797 -179.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.509 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.9 m-85 -108.94 19.11 19.97 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.964 -1.085 . . . . 0.0 109.487 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.529 ' HG2' ' CA ' ' A' ' 133' ' ' SER . 43.8 mt-10 -41.31 141.85 0.64 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 110.22 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 138' ' ' ASP . 0.5 OUTLIER 76.03 24.39 1.19 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.299 -0.875 . . . . 0.0 110.757 179.002 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.587 ' CE1' HG12 ' A' ' 157' ' ' VAL . 0.5 OUTLIER -111.73 129.32 56.15 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.828 -1.17 . . . . 0.0 109.729 179.912 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.4 ' N ' ' HD1' ' A' ' 139' ' ' PHE . . . -76.46 134.8 39.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.905 . . . . 0.0 109.392 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.468 ' HA3' HG22 ' A' ' 155' ' ' VAL . . . -143.79 166.62 26.94 Favored Glycine 0 N--CA 1.489 2.221 0 C-N-CA 119.718 -1.23 . . . . 0.0 110.164 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.496 ' N ' ' CG2' ' A' ' 155' ' ' VAL . 47.0 t -116.16 137.34 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.591 -0.946 . . . . 0.0 109.256 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.604 ' CG2' ' CD1' ' A' ' 146' ' ' ILE . 88.6 mt -70.39 120.49 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.305 -0.872 . . . . 0.0 109.268 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . 0.502 ' O ' ' HG2' ' A' ' 145' ' ' GLU . 75.0 tttt -103.65 -33.07 9.1 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.964 -1.085 . . . . 0.0 109.711 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.502 ' HG2' ' O ' ' A' ' 144' ' ' LYS . 15.5 mt-10 -150.5 145.66 26.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.058 -1.027 . . . . 0.0 109.845 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.604 ' CD1' ' CG2' ' A' ' 143' ' ' ILE . 0.9 OUTLIER -115.44 117.91 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.218 -0.926 . . . . 0.0 108.973 179.542 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -106.64 98.13 19.46 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.156 -0.965 . . . . 0.0 109.785 -179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.55 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.5 Cg_endo -72.33 173.65 12.76 Favored 'Trans proline' 0 C--O 1.216 -0.588 0 C-N-CA 122.675 2.25 . . . . 0.0 111.734 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.55 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 4.5 mt-10 78.98 -22.06 0.3 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.26 -0.9 . . . . 0.0 109.876 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.429 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 40.8 mtm180 -126.33 -16.78 5.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.039 -1.038 . . . . 0.0 109.3 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.429 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 6.0 mt-30 71.04 47.54 0.41 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.3 -0.875 . . . . 0.0 109.511 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 64.9 tt0 -116.44 139.83 50.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.124 -0.985 . . . . 0.0 108.885 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.526 HD11 ' CG2' ' A' ' 146' ' ' ILE . 2.7 mm? -124.88 111.79 15.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.153 -0.967 . . . . 0.0 110.108 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . 0.433 ' HD3' ' HB2' ' A' ' 145' ' ' GLU . 17.2 mtpp -78.02 122.68 25.88 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.506 HG13 HG13 ' A' ' 166' ' ' VAL . 10.4 p -126.92 149.27 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.039 -1.038 . . . . 0.0 109.904 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.526 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 1.9 t-20 -97.99 110.54 23.09 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.439 -0.788 . . . . 0.0 109.488 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.587 HG12 ' CE1' ' A' ' 139' ' ' PHE . 87.1 t -96.38 144.64 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.2 -0.938 . . . . 0.0 109.268 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 96.1 m -102.92 111.93 24.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -0.965 . . . . 0.0 109.995 -179.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.494 HG12 ' CZ ' ' A' ' 139' ' ' PHE . 2.9 mt -133.22 143.24 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.276 -0.89 . . . . 0.0 109.036 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.435 ' O ' ' HG3' ' A' ' 162' ' ' ARG . 11.9 m-85 62.18 43.37 8.65 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.152 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 54.35 16.15 6.45 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 179.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.435 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 15.8 mtt-85 -126.59 160.05 31.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.036 -1.273 . . . . 0.0 109.54 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -100.93 127.88 47.22 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.25 -0.907 . . . . 0.0 109.687 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 43.3 m -136.91 121.22 12.39 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 0.0 109.606 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -70.34 136.57 31.75 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.755 2.304 . . . . 0.0 111.541 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.506 HG13 HG13 ' A' ' 155' ' ' VAL . 3.6 p -125.74 144.24 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.035 -1.041 . . . . 0.0 110.165 -179.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.501 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 51.1 t -95.51 120.15 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.554 -0.716 . . . . 0.0 109.465 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.501 HD11 ' CG1' ' A' ' 155' ' ' VAL . 0.1 OUTLIER -141.01 168.38 19.93 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.204 -0.935 . . . . 0.0 110.518 -179.44 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.442 ' CD2' ' OE1' ' A' ' 172' ' ' GLU . 90.7 m-70 -79.45 144.59 33.9 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.486 ' CG2' HD22 ' A' ' 153' ' ' LEU . 9.6 p -58.68 -35.49 55.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.121 -0.987 . . . . 0.0 108.822 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 53.0 p -75.69 -6.67 51.64 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.43 -0.794 . . . . 0.0 109.115 179.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.533 ' CG ' ' HB2' ' A' ' 133' ' ' SER . 1.2 mt-10 -88.65 2.85 52.48 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.289 -0.882 . . . . 0.0 109.44 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.512 HG22 ' CG1' ' A' ' 129' ' ' VAL . 2.9 m -152.03 176.54 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.218 -0.926 . . . . 0.0 109.293 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.546 ' CG ' HD13 ' A' ' 132' ' ' ILE . 5.5 mt-10 -141.54 172.73 12.28 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.141 -0.974 . . . . 0.0 109.01 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.498 ' CE ' ' OD2' ' A' ' 127' ' ' ASP . 24.4 tttt -89.83 3.24 53.52 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.091 -1.006 . . . . 0.0 109.37 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.448 ' HB ' ' O ' ' A' ' 175' ' ' LYS . 22.1 mt 67.92 -65.66 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.291 -0.881 . . . . 0.0 109.387 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 175' ' ' LYS . 96.5 mt-10 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.446 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.248 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.99 -25.16 65.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.233 -1.157 . . . . 0.0 109.455 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 90.7 mmm -62.66 -20.41 64.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.902 . . . . 0.0 109.463 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 73.8 mttt -95.35 124.23 39.28 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.241 -0.912 . . . . 0.0 109.43 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 33.0 mttt -94.31 137.46 33.44 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.228 -0.92 . . . . 0.0 109.546 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.574 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 15.7 mtpp -126.41 175.82 7.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.361 -0.837 . . . . 0.0 109.52 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.605 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 46.6 m95 -110.47 126.72 54.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.278 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -115.53 164.46 14.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.918 . . . . 0.0 109.472 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.538 HG12 ' CE1' ' A' ' 61' ' ' PHE . 62.0 mt -106.03 115.29 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.16 -0.962 . . . . 0.0 109.021 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 92.2 t -92.09 138.25 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.237 -0.914 . . . . 0.0 109.626 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.491 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.0 mm? -92.78 146.5 23.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.321 -0.862 . . . . 0.0 109.209 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.487 HG22 ' HA2' ' A' ' 58' ' ' GLY . 12.6 t -157.22 -177.97 7.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.187 -0.945 . . . . 0.0 109.376 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.568 ' HE1' ' CE2' ' A' ' 16' ' ' TYR . 49.0 mtm -96.72 130.39 43.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.182 -0.949 . . . . 0.0 109.504 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.5 p -50.87 129.37 23.17 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.912 . . . . 0.0 109.544 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.84 -20.27 36.67 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.568 ' CE2' ' HE1' ' A' ' 13' ' ' MET . 80.3 m-85 -108.83 -5.2 16.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.214 -1.168 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.509 ' OE1' ' CD1' ' A' ' 44' ' ' ILE . 88.9 mt-10 -46.72 -52.48 13.82 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.253 -0.904 . . . . 0.0 109.554 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.8 mt-10 -55.11 -36.19 65.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.221 -0.925 . . . . 0.0 109.465 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 60.7 mttp -74.55 -31.37 62.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.256 -0.903 . . . . 0.0 109.291 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.446 ' O ' HG13 ' A' ' 24' ' ' ILE . 51.6 t -67.64 -48.78 75.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.34 -0.85 . . . . 0.0 109.353 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 29.9 tttm -59.05 -44.48 91.82 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.273 -0.892 . . . . 0.0 109.302 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -65.13 -45.08 86.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.906 . . . . 0.0 109.275 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.497 ' ND2' ' O ' ' A' ' 23' ' ' ASN . 1.1 t-20 -51.78 -38.82 57.11 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -0.866 . . . . 0.0 109.402 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.521 ' CG2' HD12 ' A' ' 40' ' ' ILE . 65.9 mt -68.89 -44.29 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.764 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 41.9 tp10 -55.18 -49.13 72.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.047 -1.033 . . . . 0.0 109.858 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 23.6 mttm -75.22 -34.42 61.47 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.105 -0.997 . . . . 0.0 109.456 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.482 ' HD2' HG21 ' A' ' 77' ' ' VAL . 33.1 tttm -55.62 -36.2 66.72 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.325 -0.86 . . . . 0.0 109.205 179.774 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.493 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 84.0 t -83.07 -24.0 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.294 -0.879 . . . . 0.0 109.601 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 -69.9 -55.12 10.53 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.279 -0.888 . . . . 0.0 109.485 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.74 -38.92 50.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.291 -0.881 . . . . 0.0 109.412 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.405 ' CB ' HG13 ' A' ' 33' ' ' ILE . 82.6 p -98.54 0.1 44.34 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.271 -0.893 . . . . 0.0 109.513 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 46.82 34.42 7.13 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.512 HG23 ' CD1' ' A' ' 36' ' ' LEU . 37.4 mt -92.6 75.34 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.331 -1.099 . . . . 0.0 109.498 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -90.19 24.92 2.34 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.211 -0.931 . . . . 0.0 109.049 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.444 ' O ' HG23 ' A' ' 65' ' ' ILE . 85.9 m-20 -117.25 -24.29 7.52 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.346 -0.846 . . . . 0.0 109.456 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.535 HD21 ' CG1' ' A' ' 65' ' ' ILE . 22.9 mt -92.11 -29.29 16.6 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.282 -0.886 . . . . 0.0 109.419 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.43 ' HA ' ' HG2' ' A' ' 64' ' ' MET . 38.9 t -110.43 129.35 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.368 -0.833 . . . . 0.0 109.04 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.51 -124.37 5.42 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 77.5 mtt180 -92.23 146.85 23.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.273 -1.133 . . . . 0.0 109.859 -179.431 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.525 HG12 ' CG2' ' A' ' 62' ' ' VAL . 55.7 mt -113.64 135.27 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.397 -0.815 . . . . 0.0 109.15 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.585 ' CG2' ' CH2' ' A' ' 7' ' ' TRP . 17.3 t -128.76 159.31 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.116 -0.99 . . . . 0.0 109.643 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.459 HG21 HD11 ' A' ' 42' ' ' ILE . 12.3 mt -144.36 128.67 9.13 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.471 -0.768 . . . . 0.0 109.359 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.516 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 44.0 Cg_endo -66.32 -6.19 14.34 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.713 2.275 . . . . 0.0 111.43 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.56 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 14.5 mt -45.58 -47.45 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.406 -0.808 . . . . 0.0 109.397 179.749 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.436 ' C ' ' O ' ' A' ' 44' ' ' ILE . 24.8 mtt-85 -42.6 160.21 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.259 -0.901 . . . . 0.0 109.561 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 113.66 133.36 5.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.92 -150.24 19.4 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -95.68 149.94 20.92 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.174 -1.192 . . . . 0.0 109.505 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 55.3 ttt-85 -62.81 -37.14 85.56 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.471 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 50.7 mtt180 -55.3 -43.0 74.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.909 . . . . 0.0 109.432 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 17.1 tttm -140.01 113.88 8.83 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.327 -0.858 . . . . 0.0 109.441 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 t -85.25 151.68 23.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.31 -0.869 . . . . 0.0 109.476 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.526 ' C ' ' HG3' ' A' ' 54' ' ' LYS . 81.5 mt-10 -100.03 -39.39 8.14 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.198 -0.939 . . . . 0.0 109.471 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.56 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 69.2 mttt 74.06 114.17 0.06 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.18 -0.95 . . . . 0.0 109.388 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.525 ' HB3' ' CE2' ' A' ' 56' ' ' PHE . 6.7 mp -52.7 -47.3 67.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.379 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.525 ' CE2' ' HB3' ' A' ' 55' ' ' LEU . 3.2 m-85 -139.23 113.0 8.08 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.14 -0.975 . . . . 0.0 109.374 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.413 ' C ' ' H ' ' A' ' 59' ' ' TYR . 41.8 Cg_endo -65.67 146.26 83.66 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.546 2.164 . . . . 0.0 111.471 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.487 ' HA2' HG22 ' A' ' 12' ' ' THR . . . 73.04 -13.56 3.26 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.531 ' OH ' ' CZ ' ' A' ' 162' ' ' ARG . 1.9 m-85 -93.69 129.28 40.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.883 -1.363 . . . . 0.0 110.044 -179.422 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 41.9 t -134.69 142.82 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.202 179.703 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.688 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 76.7 m-85 -108.05 124.97 51.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.127 -0.983 . . . . 0.0 109.826 -179.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.525 ' CG2' HG12 ' A' ' 40' ' ' ILE . 3.6 p -130.33 142.2 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.345 -0.847 . . . . 0.0 109.868 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.605 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 37.7 tt0 -103.4 124.62 49.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.215 -0.928 . . . . 0.0 108.844 179.434 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.456 ' HB3' ' O ' ' A' ' 36' ' ' LEU . 41.8 mtm -153.47 169.09 24.03 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.92 -1.113 . . . . 0.0 110.648 -179.259 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.535 ' CG1' HD21 ' A' ' 36' ' ' LEU . 5.4 pt -94.49 130.07 43.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.478 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 36.8 ttm -77.15 144.54 38.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.318 -0.864 . . . . 0.0 109.973 -178.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.478 ' HB2' ' O ' ' A' ' 66' ' ' MET . 35.3 t30 176.81 171.6 0.47 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.677 -0.639 . . . . 0.0 109.289 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -69.27 -42.53 75.41 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.228 -0.92 . . . . 0.0 109.402 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -75.85 -29.17 58.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.309 -0.869 . . . . 0.0 109.71 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -75.27 -47.54 27.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.121 -0.987 . . . . 0.0 109.418 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.412 ' O ' HG12 ' A' ' 74' ' ' VAL . 56.3 t80 -59.97 -46.49 89.26 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.291 -0.88 . . . . 0.0 109.504 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.451 ' O ' ' HB3' ' A' ' 76' ' ' SER . 23.4 m120 -68.18 -26.22 65.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.327 -0.858 . . . . 0.0 109.962 -179.671 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.478 ' CE1' ' NZ ' ' A' ' 27' ' ' LYS . 22.6 t80 -83.42 -42.76 16.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.03 -1.044 . . . . 0.0 109.915 -179.675 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.492 ' CG1' ' H ' ' A' ' 75' ' ' ARG . 7.4 p -67.89 -55.71 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.405 -0.81 . . . . 0.0 109.605 -179.503 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.564 ' HG2' ' CE2' ' A' ' 83' ' ' PHE . 0.2 OUTLIER -57.99 -10.72 1.95 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.145 -0.972 . . . . 0.0 109.747 -179.934 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.451 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 25.6 p -93.24 4.89 53.23 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.073 -1.017 . . . . 0.0 109.98 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.63 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -73.81 126.8 89.25 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.085 -1.009 . . . . 0.0 109.327 -179.978 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.629 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 42.7 Cg_endo -65.1 142.86 76.09 Favored 'Trans proline' 0 C--O 1.213 -0.752 0 C-N-CA 122.65 2.234 . . . . 0.0 111.898 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.629 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 17.9 m-85 89.37 -12.79 0.37 Allowed 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.63 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 1.7 t -89.51 130.12 39.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.077 -1.014 . . . . 0.0 109.361 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 90.9 mmm -84.38 -27.33 27.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.32 -0.862 . . . . 0.0 109.311 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 161.35 -160.58 32.31 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.875 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 82' ' ' GLY . 14.9 m-85 -136.23 140.24 43.35 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.272 -1.134 . . . . 0.0 109.341 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.45 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 7.7 p -66.35 125.09 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.122 -0.986 . . . . 0.0 109.405 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.541 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.6 p -163.72 159.08 21.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.211 -0.931 . . . . 0.0 109.573 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -86.23 -33.85 20.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.272 -0.893 . . . . 0.0 109.314 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.23 -87.59 0.71 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.547 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -108.85 -125.86 5.24 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.547 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.1 OUTLIER -31.17 147.27 0.05 OUTLIER Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 121.614 -0.933 . . . . 0.0 110.015 -179.819 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.541 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.3 Cg_endo -69.2 154.29 70.19 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.8 2.334 . . . . 0.0 112.081 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . 0.573 ' CG1' ' HD2' ' A' ' 92' ' ' PRO . 0.2 OUTLIER -86.97 147.7 43.6 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.308 -0.87 . . . . 0.0 109.25 179.849 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.573 ' HD2' ' CG1' ' A' ' 91' ' ' VAL . 48.7 Cg_endo -69.24 150.6 71.58 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.626 2.217 . . . . 0.0 111.82 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 5.3 t -83.57 135.66 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.911 . . . . 0.0 109.621 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -72.86 136.05 45.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.346 -0.846 . . . . 0.0 109.393 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -47.94 -36.91 13.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.21 -0.931 . . . . 0.0 109.578 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 73.4 mtt85 -56.59 -37.14 70.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.571 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.7 mt-10 -83.36 -24.24 32.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.25 -0.906 . . . . 0.0 109.608 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.54 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 56.5 mtp -84.39 -29.6 26.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.142 -0.974 . . . . 0.0 109.495 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.576 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 31.6 ttt85 -37.01 -53.81 1.9 Allowed Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.344 -0.848 . . . . 0.0 109.931 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -68.82 -27.8 30.82 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.497 2.132 . . . . 0.0 111.777 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.509 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 19.5 mm -80.66 -41.7 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.24 -0.912 . . . . 0.0 109.248 179.71 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.59 ' CD1' ' N ' ' A' ' 102' ' ' LEU . 3.7 mp -68.52 -40.71 80.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.304 -0.872 . . . . 0.0 109.193 179.775 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.592 ' HG3' ' CD1' ' A' ' 110' ' ' TYR . 34.0 ttt180 -64.25 -50.34 68.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.347 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.422 HD22 HD11 ' A' ' 55' ' ' LEU . 0.5 OUTLIER -71.86 -36.88 70.25 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.35 -0.844 . . . . 0.0 109.272 179.736 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.509 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -72.21 0.6 9.39 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.854 -179.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 77.26 8.32 86.98 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.505 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 19.2 mt -79.88 -22.53 42.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.134 -1.215 . . . . 0.0 109.511 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.463 ' HB2' ' HA ' ' A' ' 103' ' ' ARG . 10.3 mt-10 -107.51 143.91 35.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.228 -0.92 . . . . 0.0 109.459 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -96.84 120.1 36.54 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.24 -0.913 . . . . 0.0 109.451 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.592 ' CD1' ' HG3' ' A' ' 103' ' ' ARG . 43.6 p90 -150.21 174.62 12.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.241 -0.912 . . . . 0.0 109.567 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.521 ' O ' ' CB ' ' A' ' 112' ' ' GLU . 92.4 mt-10 -101.55 -91.74 0.32 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.269 -0.894 . . . . 0.0 109.418 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.521 ' CB ' ' O ' ' A' ' 111' ' ' GLU . 30.9 tt0 163.76 161.72 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.291 -0.881 . . . . 0.0 109.245 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.518 ' HB3' ' CB ' ' A' ' 133' ' ' SER . 0.0 OUTLIER -119.81 134.15 55.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.936 . . . . 0.0 109.394 -179.941 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -159.81 103.51 1.52 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.194 -0.941 . . . . 0.0 109.466 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -85.29 143.75 39.73 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.192 -0.943 . . . . 0.0 109.437 179.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.81 -2.18 9.77 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.643 2.228 . . . . 0.0 111.847 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 1.9 t -107.08 124.61 62.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -0.924 . . . . 0.0 109.39 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.431 ' HA ' ' OG ' ' A' ' 171' ' ' SER . 27.3 mttm -68.19 128.82 37.97 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.245 -0.909 . . . . 0.0 109.336 179.777 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.535 ' O ' ' CG ' ' A' ' 120' ' ' GLU . 30.3 t -100.93 128.97 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.581 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.58 ' HA ' ' CE2' ' A' ' 123' ' ' PHE . 82.3 mt-10 -159.44 -167.48 2.05 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.33 -0.857 . . . . 0.0 109.095 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.547 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 0.2 OUTLIER 78.47 162.57 0.21 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.362 -0.837 . . . . 0.0 109.912 179.61 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 44.59 26.46 1.07 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.58 ' CE2' ' HA ' ' A' ' 120' ' ' GLU . 22.8 m-30 -115.17 116.51 28.49 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.083 -1.245 . . . . 0.0 108.879 178.885 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 50.9 mttt -130.89 153.83 48.72 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.155 -0.966 . . . . 0.0 109.863 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.449 HG22 ' O ' ' A' ' 144' ' ' LYS . 7.1 p -61.51 144.43 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.359 -0.838 . . . . 0.0 109.501 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.496 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.32 -33.38 3.19 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 34.3 t0 -50.16 161.27 0.29 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.368 -1.078 . . . . 0.0 109.397 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' MET . . . . . 0.448 ' CG ' HD13 ' A' ' 176' ' ' ILE . 4.6 ttm -95.76 126.88 41.33 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.28 -0.887 . . . . 0.0 108.669 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.571 ' CG2' ' O ' ' A' ' 174' ' ' GLU . 6.7 p -125.64 141.58 45.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.193 -0.942 . . . . 0.0 109.388 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.524 ' N ' ' O ' ' A' ' 174' ' ' GLU . 24.1 tttt -104.41 142.78 33.98 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 108.988 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.51 HG23 ' HA ' ' A' ' 137' ' ' GLU . 81.5 mt -82.3 153.62 4.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.448 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.535 ' CG2' ' HG3' ' A' ' 174' ' ' GLU . 17.9 pt -149.08 1.25 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.967 -1.083 . . . . 0.0 109.499 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.518 ' CB ' ' HB3' ' A' ' 113' ' ' LYS . 31.2 t -145.85 143.23 29.49 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.124 -0.985 . . . . 0.0 110.039 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.03 -168.91 15.3 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.318 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.578 ' HG2' ' CD2' ' A' ' 136' ' ' PHE . 47.5 Cg_endo -68.63 -18.15 42.77 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 123.365 2.71 . . . . 0.0 112.563 -179.565 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.578 ' CD2' ' HG2' ' A' ' 135' ' ' PRO . 73.1 m-85 -111.84 13.92 20.98 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.878 -1.139 . . . . 0.0 109.636 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.51 ' HA ' HG23 ' A' ' 131' ' ' ILE . 1.2 tt0 -41.56 148.09 0.16 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.277 -0.889 . . . . 0.0 109.55 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.5 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 17.0 m-20 72.54 28.14 2.26 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -0.85 . . . . 0.0 110.268 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.534 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 1.1 t80 -117.74 131.51 56.59 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.029 -1.044 . . . . 0.0 109.414 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -82.24 134.15 35.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.123 -0.986 . . . . 0.0 109.6 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.513 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.9 172.93 25.59 Favored Glycine 0 N--CA 1.49 2.269 0 C-N-CA 119.78 -1.2 . . . . 0.0 110.305 -179.567 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.403 ' HA ' ' HA ' ' A' ' 128' ' ' MET . 23.2 t -117.56 136.24 55.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.469 -1.018 . . . . 0.0 109.363 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.516 ' CG2' HD23 ' A' ' 153' ' ' LEU . 67.3 mt -66.33 115.25 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.299 -0.876 . . . . 0.0 109.184 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . 0.449 ' O ' HG22 ' A' ' 125' ' ' VAL . 2.4 tttt -100.02 -35.53 9.67 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.04 -1.037 . . . . 0.0 109.615 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -152.8 147.66 26.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.142 -0.974 . . . . 0.0 109.622 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.501 HG21 ' CD1' ' A' ' 153' ' ' LEU . 3.1 mt -124.96 126.83 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.304 -0.872 . . . . 0.0 109.352 179.792 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.94 99.43 30.53 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.217 -0.927 . . . . 0.0 109.647 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.562 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 50.1 Cg_endo -70.3 171.93 14.12 Favored 'Trans proline' 0 C--O 1.216 -0.59 0 C-N-CA 122.681 2.254 . . . . 0.0 111.747 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.562 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.8 mt-10 81.06 -20.87 0.35 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.35 -0.844 . . . . 0.0 109.887 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.424 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 16.1 mtt-85 -128.83 -12.96 4.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.619 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.541 ' C ' HG23 ' A' ' 170' ' ' VAL . 29.4 mt-30 70.72 48.49 0.42 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.271 -0.893 . . . . 0.0 109.636 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -118.6 141.66 48.38 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.138 -0.976 . . . . 0.0 108.745 179.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.516 HD23 ' CG2' ' A' ' 143' ' ' ILE . 0.1 OUTLIER -133.4 111.82 11.07 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.101 -0.999 . . . . 0.0 109.937 -179.537 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 21.1 mttt -80.61 129.5 34.55 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.532 ' CG1' HG11 ' A' ' 129' ' ' VAL . 35.4 m -123.61 152.54 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.059 -1.026 . . . . 0.0 109.715 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.485 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 47.2 t-20 -96.53 108.56 21.16 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.385 -0.822 . . . . 0.0 109.431 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.547 HG23 ' CG1' ' A' ' 159' ' ' ILE . 2.2 p -92.02 140.19 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.162 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.521 ' N ' HG22 ' A' ' 157' ' ' VAL . 84.9 m -99.79 99.16 9.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.271 -0.893 . . . . 0.0 109.952 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.547 ' CG1' HG23 ' A' ' 157' ' ' VAL . 2.0 mt -122.45 143.66 34.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.296 -0.878 . . . . 0.0 109.092 179.548 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.688 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 85.0 m-85 61.72 39.38 14.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.241 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.77 17.89 29.81 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.531 ' CZ ' ' OH ' ' A' ' 59' ' ' TYR . 25.2 mtt85 -127.26 156.72 41.45 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.106 -1.232 . . . . 0.0 109.568 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.431 ' HB3' ' OD1' ' A' ' 156' ' ' ASN . 91.3 mt-10 -99.92 130.72 46.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.925 . . . . 0.0 109.471 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' THR . . . . . 0.524 ' O ' ' CG1' ' A' ' 157' ' ' VAL . 16.1 m -140.52 121.64 9.21 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.285 -0.884 . . . . 0.0 109.732 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.485 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.8 Cg_endo -70.02 138.21 36.48 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.697 2.264 . . . . 0.0 111.536 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.4 p -126.89 145.65 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.117 -0.989 . . . . 0.0 109.815 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.429 ' O ' ' CG1' ' A' ' 167' ' ' VAL . 11.4 p -91.87 119.73 39.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.416 -0.802 . . . . 0.0 109.326 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.42 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 12.3 mt -140.28 165.29 27.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 110.582 -179.16 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.419 ' O ' HG12 ' A' ' 173' ' ' VAL . 91.6 m-70 -79.07 147.0 32.95 Favored 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 121.345 0.593 . . . . 0.0 109.576 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.541 HG23 ' C ' ' A' ' 151' ' ' GLN . 4.4 t -63.16 -35.17 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.515 ' HA ' ' HB ' ' A' ' 119' ' ' VAL . 37.7 m -77.05 -7.12 55.13 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.467 -0.77 . . . . 0.0 109.295 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.508 ' CB ' ' HB3' ' A' ' 133' ' ' SER . 91.6 mt-10 -103.05 5.41 38.09 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.284 -0.885 . . . . 0.0 109.385 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.419 HG12 ' O ' ' A' ' 169' ' ' HIS . 2.7 m -129.69 160.29 40.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.19 -0.944 . . . . 0.0 109.58 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.571 ' O ' ' CG2' ' A' ' 129' ' ' VAL . 28.8 mt-10 -133.16 150.8 52.0 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.295 -0.878 . . . . 0.0 109.048 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.429 ' O ' ' O ' ' A' ' 176' ' ' ILE . 4.2 pttm -93.13 21.42 5.89 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.094 -1.004 . . . . 0.0 109.514 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.453 HD12 HG22 ' A' ' 176' ' ' ILE . 27.4 mt 54.64 170.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.192 -0.943 . . . . 0.0 109.547 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.462 -179.99 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.235 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 47.32 34.92 3.46 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.287 -1.125 . . . . 0.0 109.466 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 60.4 mtm -73.91 -9.67 58.87 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.458 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 25.7 mttt -107.79 122.26 46.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.275 -0.891 . . . . 0.0 109.465 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.469 ' HG2' HG23 ' A' ' 65' ' ' ILE . 83.5 mttt -100.93 143.42 31.1 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.222 -0.924 . . . . 0.0 109.495 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.562 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 41.2 mmtm -130.24 174.52 9.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.399 -0.813 . . . . 0.0 109.539 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.64 ' CG ' ' CE ' ' A' ' 98' ' ' MET . 40.3 m95 -105.56 125.4 50.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.293 -0.879 . . . . 0.0 109.011 179.664 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -115.48 166.35 11.99 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.11 -0.994 . . . . 0.0 109.343 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.551 HG12 ' CD1' ' A' ' 61' ' ' PHE . 55.8 mt -110.87 112.15 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.194 -0.941 . . . . 0.0 109.087 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.536 ' CG2' ' HB ' ' A' ' 60' ' ' VAL . 20.3 m -90.51 141.1 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.171 -0.956 . . . . 0.0 109.496 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.407 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -85.98 145.07 27.28 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.424 -0.797 . . . . 0.0 109.401 -179.926 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.7 p -149.63 -173.74 4.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.182 -0.949 . . . . 0.0 109.507 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.467 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 70.9 mtp -107.81 128.89 55.0 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.21 -0.931 . . . . 0.0 109.738 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.5 m -47.65 119.82 2.98 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.261 -0.899 . . . . 0.0 109.279 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.59 -20.26 27.63 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.467 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 94.5 m-85 -105.58 -16.36 14.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.198 -1.177 . . . . 0.0 109.496 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 16' ' ' TYR . 49.7 mt-10 -44.0 -62.04 1.26 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.193 -0.942 . . . . 0.0 109.345 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -49.54 -38.83 32.37 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.215 -0.928 . . . . 0.0 109.206 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -66.73 -33.0 74.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.346 -0.846 . . . . 0.0 109.076 179.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 24' ' ' ILE . 91.8 t -72.01 -45.94 61.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.323 -0.861 . . . . 0.0 109.369 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.511 ' HG3' ' CD1' ' A' ' 40' ' ' ILE . 19.0 tttm -51.85 -56.09 16.09 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.23 -0.919 . . . . 0.0 109.246 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -62.04 -34.93 77.16 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.319 -0.863 . . . . 0.0 109.256 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.482 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 23.2 t-20 -65.28 -36.67 84.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.411 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.404 HG13 ' O ' ' A' ' 20' ' ' VAL . 90.4 mt -66.3 -46.47 87.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.145 -0.972 . . . . 0.0 109.782 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.451 ' O ' ' HG2' ' A' ' 29' ' ' GLU . 65.8 mm-40 -56.88 -46.68 81.72 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.099 -1.0 . . . . 0.0 109.874 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 29.0 mttt -77.3 -36.72 53.91 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.104 -0.998 . . . . 0.0 109.576 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.538 ' HG3' ' CZ ' ' A' ' 73' ' ' PHE . 5.3 tptt -56.12 -31.05 62.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 109.095 179.774 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.53 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 11.6 t -84.76 -26.31 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.347 -0.845 . . . . 0.0 109.264 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.451 ' HG2' ' O ' ' A' ' 25' ' ' GLU . 61.7 mm-40 -67.87 -51.48 47.72 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.298 -0.876 . . . . 0.0 109.375 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.42 -32.3 66.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.921 . . . . 0.0 109.386 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 63.1 p -94.71 -11.31 29.36 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.354 -0.842 . . . . 0.0 109.447 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 54.83 24.51 33.84 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.541 ' CG2' HD13 ' A' ' 36' ' ' LEU . 69.8 mt -85.96 116.62 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.198 -1.178 . . . . 0.0 109.352 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.449 ' HG2' ' O ' ' A' ' 34' ' ' LYS . 86.0 tttt -121.98 -10.44 8.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.179 -0.95 . . . . 0.0 109.395 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.554 ' O ' ' CD1' ' A' ' 65' ' ' ILE . 87.5 m-20 -98.67 13.81 30.8 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.207 -0.933 . . . . 0.0 109.426 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.606 ' CD1' ' N ' ' A' ' 36' ' ' LEU . 6.0 mp -120.69 -53.38 2.09 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.336 -0.853 . . . . 0.0 109.111 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 90.3 t -100.66 129.55 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.426 -0.796 . . . . 0.0 109.034 179.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.25 -121.76 4.62 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -98.03 148.4 23.54 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.277 -1.131 . . . . 0.0 109.991 -179.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.511 ' CD1' ' HG3' ' A' ' 21' ' ' LYS . 44.5 pt -119.8 143.21 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.42 -0.8 . . . . 0.0 108.857 179.495 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.565 HG23 ' CH2' ' A' ' 7' ' ' TRP . 25.1 t -129.52 154.6 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.127 -0.983 . . . . 0.0 109.871 -179.527 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.512 ' CG2' HG13 ' A' ' 44' ' ' ILE . 18.4 mt -127.86 128.62 23.83 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.366 -0.834 . . . . 0.0 109.212 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.471 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 45.1 Cg_endo -66.82 -4.27 10.92 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.836 2.357 . . . . 0.0 111.692 -179.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.539 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 54.8 mt -70.66 -49.89 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.336 -0.853 . . . . 0.0 109.551 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.47 ' HB3' ' O ' ' A' ' 44' ' ' ILE . 30.5 ttt85 61.81 144.46 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.225 -0.922 . . . . 0.0 109.502 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.402 ' N ' ' HG2' ' A' ' 45' ' ' ARG . . . -71.28 152.83 50.24 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 178.0 -178.71 48.53 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -80.87 147.83 30.19 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -1.141 . . . . 0.0 109.47 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.487 ' HB3' ' CZ ' ' A' ' 49' ' ' ARG . 12.3 mtp-105 -59.9 -36.12 76.3 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.243 -0.91 . . . . 0.0 109.44 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 19.8 ttp180 -54.01 -37.96 64.61 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.907 . . . . 0.0 109.453 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 30.4 mmtp -80.66 156.89 26.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.235 -0.915 . . . . 0.0 109.456 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 23.6 t -68.53 139.86 55.64 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.381 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.477 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 95.2 mt-10 -124.79 153.62 42.2 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.204 -0.935 . . . . 0.0 109.458 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.539 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 63.6 mttt 74.53 86.85 0.1 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.293 -0.879 . . . . 0.0 109.479 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.5 ' O ' ' CD1' ' A' ' 56' ' ' PHE . 44.2 mt -64.13 -21.54 66.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -1.0 . . . . 0.0 109.181 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.645 ' CZ ' ' CD1' ' A' ' 159' ' ' ILE . 8.8 m-85 -148.97 101.88 3.39 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.323 -0.861 . . . . 0.0 108.986 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -65.47 136.31 46.12 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.7 2.267 . . . . 0.0 112.176 -179.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.44 -15.22 7.55 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -99.31 129.53 45.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.799 -1.412 . . . . 0.0 110.292 -179.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.536 ' HB ' ' CG2' ' A' ' 10' ' ' VAL . 88.2 t -133.23 148.88 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.599 ' CE1' ' CZ ' ' A' ' 160' ' ' PHE . 84.2 m-85 -109.71 124.62 51.55 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.773 -1.205 . . . . 0.0 110.248 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.428 HG11 HG22 ' A' ' 40' ' ' ILE . 91.8 t -133.58 145.16 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.382 -0.824 . . . . 0.0 109.635 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.612 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 28.2 tt0 -112.08 128.01 56.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.24 -0.913 . . . . 0.0 108.976 179.575 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.513 ' CE ' HG21 ' A' ' 74' ' ' VAL . 15.4 mtm -153.9 168.69 25.51 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.867 -1.146 . . . . 0.0 110.805 -179.113 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.554 ' CD1' ' O ' ' A' ' 35' ' ' ASN . 0.5 OUTLIER -89.11 130.39 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.653 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.423 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 56.6 ttm -75.85 141.8 42.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.89 . . . . 0.0 110.191 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.423 ' HB2' ' O ' ' A' ' 66' ' ' MET . 46.0 t30 179.11 166.15 0.96 Allowed 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -66.14 -41.13 90.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.966 . . . . 0.0 109.505 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 64.2 tt0 -76.46 -31.5 57.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.844 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.465 ' O ' ' CG2' ' A' ' 74' ' ' VAL . . . -68.78 -49.36 59.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.972 -1.08 . . . . 0.0 109.621 -179.763 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.568 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 71.8 t80 -60.62 -50.98 71.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.215 -0.928 . . . . 0.0 109.751 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -57.09 -29.69 63.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -0.937 . . . . 0.0 110.059 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.538 ' CZ ' ' HG3' ' A' ' 27' ' ' LYS . 77.4 t80 -80.51 -41.88 23.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.098 -1.001 . . . . 0.0 109.776 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.513 HG21 ' CE ' ' A' ' 64' ' ' MET . 2.8 t -70.08 -55.07 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.466 -0.771 . . . . 0.0 109.602 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.455 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 32.0 tpt85 -61.43 -13.33 19.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.329 -0.857 . . . . 0.0 110.013 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 78.1 p -97.31 4.57 50.79 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.115 -0.99 . . . . 0.0 109.923 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.597 HG11 ' HB ' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -74.85 137.21 73.32 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 120.965 -1.084 . . . . 0.0 109.315 -179.992 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.63 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 44.2 Cg_endo -66.34 137.36 46.95 Favored 'Trans proline' 0 C--O 1.213 -0.75 0 C-N-CA 122.676 2.251 . . . . 0.0 111.893 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.63 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 19.1 m-85 92.45 -13.54 0.18 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.934 -0.479 . . . . 0.0 109.759 -179.773 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.597 ' HB ' HG11 ' A' ' 77' ' ' VAL . 8.6 p -82.43 122.91 37.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.891 -1.131 . . . . 0.0 109.365 179.765 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 95.5 mmm -87.94 -30.71 19.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.294 -0.879 . . . . 0.0 109.362 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.545 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 168.05 -165.85 39.04 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.57 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 4.6 m-85 -137.52 139.61 40.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.332 -1.099 . . . . 0.0 109.46 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.0 t -66.08 125.01 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.258 -0.901 . . . . 0.0 109.331 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.553 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.8 p -160.18 158.97 31.06 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.15 -0.969 . . . . 0.0 109.667 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 59.5 p -82.84 -36.47 25.45 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.329 -0.857 . . . . 0.0 109.234 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.07 -86.56 0.52 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -103.13 -127.87 6.21 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.568 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -33.98 151.93 0.05 OUTLIER Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.512 -0.993 . . . . 0.0 110.046 -179.668 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.553 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.1 Cg_endo -69.38 158.66 56.64 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.807 2.338 . . . . 0.0 112.01 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.8 m -93.38 154.14 41.38 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.423 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -70.06 146.96 59.86 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.654 2.236 . . . . 0.0 111.735 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 45.1 t -83.62 140.18 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.297 -0.877 . . . . 0.0 109.417 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . 0.471 ' HE2' ' NH2' ' A' ' 96' ' ' ARG . 79.8 tttt -73.21 130.69 40.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.491 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -46.53 -39.07 10.26 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.278 -0.889 . . . . 0.0 109.425 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.471 ' NH2' ' HE2' ' A' ' 94' ' ' LYS . 15.5 mtt85 -60.56 -30.77 70.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.344 -0.847 . . . . 0.0 109.417 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.427 ' N ' ' O ' ' A' ' 94' ' ' LYS . 52.7 mt-10 -80.08 -26.8 39.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.892 . . . . 0.0 109.528 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.64 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 55.3 mtp -86.12 -21.77 27.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.226 179.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.557 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.47 -53.23 1.31 Allowed Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.482 -0.761 . . . . 0.0 109.807 179.981 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.591 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 50.4 Cg_endo -71.41 -26.69 20.11 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.463 2.109 . . . . 0.0 111.878 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.479 ' N ' ' O ' ' A' ' 98' ' ' MET . 35.2 mm -82.42 -42.96 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -0.934 . . . . 0.0 109.607 -179.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.59 ' N ' HD11 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -67.83 -40.82 83.74 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.183 -0.948 . . . . 0.0 109.417 179.923 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.47 ' HG2' ' HA ' ' A' ' 135' ' ' PRO . 19.7 tpt180 -65.86 -49.1 69.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.253 -0.904 . . . . 0.0 109.315 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.71 -37.03 70.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.358 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.522 ' CB ' HG13 ' A' ' 41' ' ' VAL . . . -74.35 1.3 11.95 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.315 -0.866 . . . . 0.0 109.773 -179.811 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.47 11.07 85.44 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.528 ' N ' ' O ' ' A' ' 102' ' ' LEU . 3.2 tp -82.05 -24.86 35.07 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.219 -1.166 . . . . 0.0 109.525 179.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -125.19 132.92 52.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.214 -0.929 . . . . 0.0 109.584 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -119.98 123.66 44.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.205 -0.934 . . . . 0.0 109.354 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.572 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 33.0 p90 -140.45 177.5 7.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.229 -0.919 . . . . 0.0 109.615 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.572 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 61.3 mt-10 -67.6 -148.83 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.221 -0.925 . . . . 0.0 109.405 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.468 ' HG2' ' N ' ' A' ' 113' ' ' LYS . 85.2 tt0 -156.29 164.72 37.98 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.307 -0.871 . . . . 0.0 109.341 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.468 ' N ' ' HG2' ' A' ' 112' ' ' GLU . 5.6 pttt -44.16 144.31 0.99 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.423 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 5.0 tttp -105.0 10.19 34.2 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.226 -0.921 . . . . 0.0 109.513 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 8.6 mtmm -129.12 73.4 81.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.203 -0.935 . . . . 0.0 109.459 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -72.51 80.5 1.67 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.689 2.259 . . . . 0.0 111.583 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.444 ' O ' ' HB2' ' A' ' 171' ' ' SER . 12.8 m -133.11 145.8 33.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.35 -0.844 . . . . 0.0 109.546 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.504 ' HA ' ' HB3' ' A' ' 171' ' ' SER . 3.5 ttpm? -62.66 140.22 58.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.323 -0.861 . . . . 0.0 109.37 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.46 ' O ' HG11 ' A' ' 170' ' ' VAL . 53.5 t -128.98 118.45 46.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.213 -0.929 . . . . 0.0 109.638 -179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.657 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 98.3 mt-10 -147.07 147.71 30.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.318 -0.864 . . . . 0.0 109.342 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.657 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 1.4 pp 145.71 145.41 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.425 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . 42.43 33.6 1.46 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.974 -1.251 . . . . 0.0 109.974 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.576 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 14.1 m-85 -107.84 115.53 30.3 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.142 -1.21 . . . . 0.0 109.159 179.554 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.429 ' HD3' ' O ' ' A' ' 123' ' ' PHE . 62.1 mmtt -139.35 156.37 47.05 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.25 -0.906 . . . . 0.0 109.536 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.507 ' HA ' HG22 ' A' ' 143' ' ' ILE . 10.1 t -57.37 137.46 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.258 -0.901 . . . . 0.0 109.606 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.81 -34.55 3.86 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 37.2 m-20 -47.8 160.8 0.12 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.341 -1.094 . . . . 0.0 109.405 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.4 ttm -100.87 127.93 47.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.193 -0.942 . . . . 0.0 109.059 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.552 ' CG1' HG13 ' A' ' 143' ' ' ILE . 25.7 m -128.72 145.31 35.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.358 -0.839 . . . . 0.0 109.667 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.499 ' CB ' HG12 ' A' ' 176' ' ' ILE . 57.7 tttt -103.22 139.39 38.76 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.787 -0.819 . . . . 0.0 108.787 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.513 ' CD1' ' HB3' ' A' ' 139' ' ' PHE . 80.9 mt -78.41 153.71 5.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -149.17 1.26 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.946 -1.096 . . . . 0.0 109.465 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.492 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 70.1 m -148.27 144.3 27.53 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.114 -0.991 . . . . 0.0 110.06 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.59 -164.88 17.73 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.506 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 46.2 Cg_endo -68.35 -21.84 40.53 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 123.071 2.514 . . . . 0.0 112.643 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.591 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 86.9 m-85 -107.67 18.21 21.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.84 -1.163 . . . . 0.0 109.442 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.531 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 3.1 tt0 -45.53 139.05 4.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.255 -0.903 . . . . 0.0 109.617 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.531 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 28.9 m-20 73.74 28.54 1.6 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.385 -0.822 . . . . 0.0 110.423 179.526 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.52 ' CE1' ' CG1' ' A' ' 157' ' ' VAL . 1.7 t80 -117.4 131.87 56.68 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.041 -1.037 . . . . 0.0 109.445 179.668 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.53 132.26 37.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.19 -0.944 . . . . 0.0 109.647 -179.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -142.98 167.46 26.33 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.529 ' CG1' ' HB2' ' A' ' 156' ' ' ASN . 11.1 p -117.42 138.33 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.353 -1.086 . . . . 0.0 109.393 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.552 HG13 ' CG1' ' A' ' 129' ' ' VAL . 60.6 mt -68.81 117.11 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.152 -0.968 . . . . 0.0 109.676 -179.832 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -102.43 -35.52 8.75 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.142 -0.973 . . . . 0.0 109.253 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.445 ' HB2' ' HB2' ' A' ' 154' ' ' LYS . 62.8 mt-10 -152.95 148.19 26.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.241 -0.912 . . . . 0.0 109.526 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.451 HG21 HD13 ' A' ' 153' ' ' LEU . 2.1 mt -123.8 125.65 71.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.257 -0.902 . . . . 0.0 109.412 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -106.74 99.61 26.42 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.192 -0.943 . . . . 0.0 109.674 -179.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.583 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.8 Cg_endo -70.74 170.96 16.49 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.704 2.27 . . . . 0.0 111.677 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.583 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.4 mt-10 81.64 -20.5 0.36 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.362 -0.836 . . . . 0.0 109.868 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.486 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 42.1 mtt180 -128.89 -12.47 4.74 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.997 -1.065 . . . . 0.0 109.694 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.491 ' C ' ' CG2' ' A' ' 170' ' ' VAL . 48.1 mt-30 70.69 48.8 0.42 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.26 -0.9 . . . . 0.0 109.604 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -119.59 142.18 48.62 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.175 -0.953 . . . . 0.0 109.02 179.583 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.533 ' CD2' HG12 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -129.34 112.36 13.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.237 -0.914 . . . . 0.0 110.083 -179.514 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . 0.445 ' HB2' ' HB2' ' A' ' 145' ' ' GLU . 17.6 mttt -79.9 126.41 30.97 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 179.071 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.476 HG22 ' CD1' ' A' ' 168' ' ' LEU . 16.1 m -128.32 152.98 37.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.035 -1.041 . . . . 0.0 110.05 -179.458 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.529 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 86.8 m-20 -98.88 112.9 24.87 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.313 -0.867 . . . . 0.0 109.376 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.527 HG13 ' CG2' ' A' ' 159' ' ' ILE . 38.8 t -99.97 147.69 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.273 -0.892 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 163' ' ' GLU . 29.2 m -94.08 117.76 30.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.415 -0.803 . . . . 0.0 109.802 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.645 ' CD1' ' CZ ' ' A' ' 56' ' ' PHE . 18.8 pt -145.9 138.62 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.348 -0.845 . . . . 0.0 109.387 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.599 ' CZ ' ' CE1' ' A' ' 61' ' ' PHE . 72.2 m-85 62.57 39.36 11.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.909 . . . . 0.0 109.379 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 62.26 16.96 55.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -137.73 142.21 41.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.092 -1.24 . . . . 0.0 109.501 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.53 ' HA ' ' HA ' ' A' ' 158' ' ' THR . 84.8 mt-10 -98.45 110.2 22.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.184 -0.948 . . . . 0.0 109.465 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' THR . . . . . 0.496 HG21 ' N ' ' A' ' 165' ' ' PRO . 16.6 m -112.8 139.9 23.38 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.211 -0.93 . . . . 0.0 109.341 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.496 ' N ' HG21 ' A' ' 164' ' ' THR . 48.7 Cg_endo -69.21 137.3 36.72 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.711 2.274 . . . . 0.0 111.778 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.52 HG23 ' N ' ' A' ' 167' ' ' VAL . 2.1 p -123.41 142.06 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.157 -0.964 . . . . 0.0 109.743 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.52 ' N ' HG23 ' A' ' 166' ' ' VAL . 72.8 t -92.89 119.13 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.383 -0.823 . . . . 0.0 109.552 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.492 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 0.3 OUTLIER -141.27 167.96 20.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.313 -0.867 . . . . 0.0 110.567 -179.719 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.52 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 61.8 m80 -78.59 145.58 34.67 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.491 ' CG2' ' C ' ' A' ' 151' ' ' GLN . 24.0 t -59.67 -35.84 62.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.274 -0.891 . . . . 0.0 108.702 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.504 ' HB3' ' HA ' ' A' ' 118' ' ' LYS . 87.9 p -75.27 -7.06 52.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.494 -0.754 . . . . 0.0 109.324 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.52 ' CG ' ' HB2' ' A' ' 169' ' ' HIS . 82.5 mt-10 -90.62 4.07 52.37 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.34 -0.85 . . . . 0.0 109.832 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.578 ' CG2' ' N ' ' A' ' 174' ' ' GLU . 1.4 p -141.7 167.74 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.024 -1.048 . . . . 0.0 109.484 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.578 ' N ' ' CG2' ' A' ' 173' ' ' VAL . 52.4 tt0 -142.78 168.77 18.94 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.341 -0.849 . . . . 0.0 108.857 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.576 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 33.1 tttm -91.74 33.18 1.04 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.021 -1.05 . . . . 0.0 109.289 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.499 HG12 ' CB ' ' A' ' 130' ' ' LYS . 40.4 mt 43.95 74.47 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.19 -0.944 . . . . 0.0 109.394 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.477 -179.954 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.48 -24.12 66.37 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.299 -1.118 . . . . 0.0 109.475 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 89.6 mtp -64.93 -30.99 72.01 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.231 -0.918 . . . . 0.0 109.519 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 50.5 mttm -118.92 137.08 53.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.422 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.4 mttm -110.08 156.8 20.07 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.177 -0.952 . . . . 0.0 109.667 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 12.7 mttt -135.49 176.03 9.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 110.009 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.609 ' CD1' ' HG3' ' A' ' 63' ' ' GLU . 60.3 m95 -109.83 125.71 53.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.362 -0.836 . . . . 0.0 109.211 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.583 ' CZ ' ' HG3' ' A' ' 66' ' ' MET . 66.1 m-85 -116.64 171.76 7.66 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.186 -0.946 . . . . 0.0 109.383 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.514 ' CD1' ' CD1' ' A' ' 160' ' ' PHE . 56.2 mt -110.9 109.95 30.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.242 -0.911 . . . . 0.0 109.069 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.558 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 8.9 p -88.6 143.47 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.186 -0.946 . . . . 0.0 109.477 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.584 HD11 ' CE1' ' A' ' 59' ' ' TYR . 4.6 mm? -88.83 141.83 28.17 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.389 -0.819 . . . . 0.0 109.545 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 15.1 t -154.69 -169.35 3.18 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.281 -0.887 . . . . 0.0 109.393 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.502 ' SD ' ' CE2' ' A' ' 16' ' ' TYR . 36.2 ttm -107.68 119.6 39.88 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.48 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 13' ' ' MET . 54.0 p -42.82 128.19 4.15 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.332 -0.855 . . . . 0.0 109.279 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.65 -19.69 33.13 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.502 ' CE2' ' SD ' ' A' ' 13' ' ' MET . 19.6 m-30 -110.31 -5.84 15.15 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.301 -1.117 . . . . 0.0 109.75 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.473 ' OE1' HG22 ' A' ' 44' ' ' ILE . 87.0 mt-10 -44.58 -65.49 0.51 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.148 -0.97 . . . . 0.0 109.547 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.446 ' O ' ' HG3' ' A' ' 22' ' ' GLU . 95.7 mt-10 -43.2 -33.41 0.92 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.199 -0.938 . . . . 0.0 109.271 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.524 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 46.7 mttm -77.19 -41.12 42.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.3 -0.875 . . . . 0.0 109.324 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.521 ' O ' HG12 ' A' ' 24' ' ' ILE . 18.4 t -59.7 -48.17 88.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.327 -0.858 . . . . 0.0 109.33 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.449 ' HG3' ' CG2' ' A' ' 40' ' ' ILE . 28.1 tttm -60.53 -43.12 97.49 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.897 . . . . 0.0 109.067 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.446 ' HG3' ' O ' ' A' ' 18' ' ' GLU . 93.7 mt-10 -63.87 -42.07 97.61 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.406 -0.809 . . . . 0.0 109.045 179.716 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.629 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 54.9 m-80 -56.91 -52.22 66.01 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.335 -0.853 . . . . 0.0 109.508 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.561 ' CD1' HG23 ' A' ' 77' ' ' VAL . 21.0 mm -50.33 -44.21 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.051 -1.031 . . . . 0.0 109.408 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -54.61 -44.27 72.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.272 -0.893 . . . . 0.0 109.832 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.8 mttp -79.86 -35.09 38.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.09 -1.006 . . . . 0.0 109.905 -179.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.532 ' HD3' ' CG2' ' A' ' 77' ' ' VAL . 12.6 ttpp -56.65 -35.16 68.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.114 -0.991 . . . . 0.0 109.282 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 15.6 t -82.47 -27.05 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.841 . . . . 0.0 109.575 -179.794 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 69.8 mt-10 -66.35 -49.84 65.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.214 -0.929 . . . . 0.0 109.68 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.38 -27.74 69.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.207 -0.933 . . . . 0.0 109.741 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.427 HG21 ' O ' ' A' ' 27' ' ' LYS . 60.9 p -88.83 -12.76 41.01 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.041 -1.037 . . . . 0.0 109.517 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 63.72 15.43 57.67 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.527 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 13.7 mt -94.84 85.6 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.314 -1.11 . . . . 0.0 109.481 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 49.9 mttt -85.59 7.64 22.41 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.149 -0.97 . . . . 0.0 109.074 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -111.77 18.52 18.86 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.339 -0.85 . . . . 0.0 109.433 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.587 ' CD2' ' CD1' ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.6 -52.95 2.75 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.144 -0.972 . . . . 0.0 109.344 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.527 HG21 ' CG2' ' A' ' 24' ' ' ILE . 87.7 t -97.01 137.06 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -107.81 -125.28 5.27 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.426 ' O ' ' CH2' ' A' ' 7' ' ' TRP . 95.2 mtt180 -91.72 138.69 31.35 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -1.112 . . . . 0.0 109.694 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.501 HG22 HD11 ' A' ' 40' ' ' ILE . 46.1 mt -105.78 136.96 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.374 -0.829 . . . . 0.0 109.042 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.587 ' CG2' ' CD1' ' A' ' 107' ' ' LEU . 98.4 t -124.26 150.51 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.499 HG21 ' CD1' ' A' ' 44' ' ' ILE . 5.7 mt -128.38 126.05 23.43 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.341 -0.849 . . . . 0.0 109.413 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.453 ' O ' ' HB2' ' A' ' 55' ' ' LEU . 47.8 Cg_endo -68.5 -2.99 10.18 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.86 2.374 . . . . 0.0 111.814 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.677 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 11.3 pt -76.44 132.88 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.07 -1.019 . . . . 0.0 109.649 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 43.6 ttp-105 -71.28 -28.49 64.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.389 -0.819 . . . . 0.0 109.466 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 70.1 36.46 72.12 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.27 139.55 9.89 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 83.3 mt-30 -88.63 11.64 16.85 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -1.182 . . . . 0.0 109.453 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 12.1 ttt-85 -54.94 -38.67 67.99 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.445 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 65.8 ttt-85 -104.66 153.28 21.44 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -0.887 . . . . 0.0 109.431 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 16.8 mtmt -62.55 -24.37 67.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.54 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 68.0 p -96.83 157.04 16.09 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.497 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 81.0 tt0 -136.62 145.92 45.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.344 -0.847 . . . . 0.0 109.324 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.677 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 22.6 mttm 74.85 111.27 0.07 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.195 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.536 ' CD1' ' N ' ' A' ' 55' ' ' LEU . 6.8 mp -65.91 -25.57 67.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.835 -1.165 . . . . 0.0 109.47 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.491 ' HB3' ' HB2' ' A' ' 59' ' ' TYR . 84.3 m-85 -142.08 98.23 6.22 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.886 . . . . 0.0 108.86 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.406 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 43.2 Cg_endo -66.7 134.39 34.94 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.755 2.303 . . . . 0.0 112.23 -179.082 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.56 -12.87 7.17 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.584 ' CE1' HD11 ' A' ' 11' ' ' LEU . 2.9 m-85 -100.67 131.23 46.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.693 -1.475 . . . . 0.0 110.183 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.558 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 76.8 t -135.32 148.6 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.377 -0.827 . . . . 0.0 108.809 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.634 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 16.8 m-85 -110.7 123.87 50.85 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.874 -1.141 . . . . 0.0 109.926 -179.395 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.42 HG11 ' N ' ' A' ' 63' ' ' GLU . 90.0 t -129.62 142.77 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.405 -0.809 . . . . 0.0 109.793 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.609 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 9.8 tt0 -99.86 125.52 45.83 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.335 -0.853 . . . . 0.0 109.175 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.441 ' HB3' ' HA ' ' A' ' 37' ' ' VAL . 12.5 ptt? -164.96 -175.39 3.71 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.025 -1.047 . . . . 0.0 110.174 -179.665 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.587 ' CD1' ' CD2' ' A' ' 36' ' ' LEU . 38.6 pt -103.35 128.36 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.165 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.583 ' HG3' ' CZ ' ' A' ' 8' ' ' TYR . 33.6 mtm -90.75 101.64 14.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.196 -0.94 . . . . 0.0 109.898 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.543 ' OD1' ' N ' ' A' ' 69' ' ' GLU . 10.3 p30 -137.91 -163.09 1.39 Allowed 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.123 -0.986 . . . . 0.0 109.077 179.591 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -74.98 -50.15 17.56 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.135 -0.978 . . . . 0.0 110.105 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.543 ' N ' ' OD1' ' A' ' 67' ' ' ASN . 98.0 mt-10 -64.85 -54.64 27.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.05 -1.031 . . . . 0.0 109.585 -179.747 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.525 ' O ' ' CG2' ' A' ' 74' ' ' VAL . . . -52.34 -38.75 59.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.265 -0.897 . . . . 0.0 109.727 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.502 ' O ' HG21 ' A' ' 74' ' ' VAL . 72.3 t80 -60.02 -50.51 73.46 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 109.853 -179.818 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -65.59 -28.46 69.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.156 -0.965 . . . . 0.0 110.436 -179.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -82.52 -42.63 18.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.865 -1.147 . . . . 0.0 110.035 -179.443 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.525 ' CG2' ' O ' ' A' ' 70' ' ' ALA . 6.8 m -65.92 -57.37 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.186 -0.947 . . . . 0.0 109.562 -179.78 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.59 ' HG2' ' CE2' ' A' ' 83' ' ' PHE . 12.6 mmt180 -53.87 -40.95 66.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.922 . . . . 0.0 109.751 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 25.7 p -75.42 3.07 9.86 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.204 -0.935 . . . . 0.0 110.149 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.638 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 1.8 p -71.8 130.0 87.52 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 120.875 -1.141 . . . . 0.0 109.136 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.775 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 44.0 Cg_endo -66.14 132.32 29.49 Favored 'Trans proline' 0 C--O 1.212 -0.797 0 C-N-CA 122.83 2.353 . . . . 0.0 112.627 -178.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.775 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 70.8 m-85 95.43 -8.63 0.1 Allowed 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.638 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 16.0 t -99.15 133.72 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.973 -1.079 . . . . 0.0 109.494 179.726 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 64.2 mtt -92.79 -19.23 21.96 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.337 -0.852 . . . . 0.0 109.399 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 150.48 -154.38 25.6 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.59 ' CE2' ' HG2' ' A' ' 75' ' ' ARG . 5.3 m-85 -137.14 149.22 47.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -1.142 . . . . 0.0 109.602 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.465 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 13.8 p -74.86 129.39 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.283 -0.886 . . . . 0.0 109.37 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.543 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 2.2 p -163.06 165.6 24.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.732 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.4 t -92.89 -30.87 15.19 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.396 -0.815 . . . . 0.0 109.24 179.742 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.77 -87.7 0.54 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.527 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -103.19 -135.5 8.7 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.527 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -32.59 153.99 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.568 -0.96 . . . . 0.0 110.259 -179.624 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.543 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 47.8 Cg_endo -67.86 151.2 78.56 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.891 2.394 . . . . 0.0 112.013 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.4 m -84.22 155.07 63.64 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.318 -0.864 . . . . 0.0 109.336 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -69.81 141.27 44.59 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.676 2.251 . . . . 0.0 111.753 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.435 HG13 ' HG3' ' A' ' 98' ' ' MET . 41.4 t -71.73 141.4 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.209 -0.932 . . . . 0.0 109.367 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 97' ' ' GLU . 93.8 mttt -75.53 130.02 38.17 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.444 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 78.5 m-20 -45.25 -39.4 6.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.883 . . . . 0.0 109.354 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 77.6 mtt180 -60.69 -24.74 65.87 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.483 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.47 ' N ' ' O ' ' A' ' 94' ' ' LYS . 87.6 mt-10 -89.42 -26.06 21.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.556 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.56 ' HE3' ' CD1' ' A' ' 7' ' ' TRP . 89.5 mtp -82.54 -30.93 29.41 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.401 -0.812 . . . . 0.0 109.448 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.606 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 1.2 tpt180 -38.7 -51.95 3.67 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.402 -0.811 . . . . 0.0 109.857 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.606 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.3 Cg_endo -68.78 -28.1 30.69 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.483 2.122 . . . . 0.0 111.801 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.459 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 23.4 mm -81.58 -42.13 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.243 -0.91 . . . . 0.0 109.402 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.577 HD12 ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -67.46 -39.88 85.35 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.207 -0.933 . . . . 0.0 109.051 179.715 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.515 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 26.1 ttm180 -63.62 -49.27 73.96 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.375 -0.828 . . . . 0.0 108.981 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . 0.439 HD23 HD21 ' A' ' 55' ' ' LEU . 0.6 OUTLIER -72.99 -35.24 66.83 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.329 -0.857 . . . . 0.0 109.048 179.532 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -74.38 -2.8 26.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.356 -0.84 . . . . 0.0 109.654 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.42 14.4 82.43 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.587 ' CD1' ' CG2' ' A' ' 41' ' ' VAL . 66.0 mt -81.65 -24.17 36.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.202 -1.176 . . . . 0.0 109.646 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 37.9 tp10 -102.37 138.9 38.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -0.999 . . . . 0.0 109.627 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -93.05 106.96 18.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.875 . . . . 0.0 109.35 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.442 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 22.8 p90 -144.13 153.64 42.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.227 -0.921 . . . . 0.0 109.493 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.442 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 18.4 mt-10 -93.03 -148.91 0.25 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.278 -0.889 . . . . 0.0 109.384 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.488 ' O ' ' C ' ' A' ' 113' ' ' LYS . 30.4 tt0 -98.45 148.18 23.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.172 -0.955 . . . . 0.0 109.482 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.488 ' C ' ' O ' ' A' ' 112' ' ' GLU . 11.3 pttm -36.74 126.55 0.87 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.385 -0.822 . . . . 0.0 109.784 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -79.49 -43.04 23.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.313 -0.867 . . . . 0.0 109.413 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.79 108.12 60.19 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.23 -0.919 . . . . 0.0 109.425 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.08 133.02 24.0 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.645 2.23 . . . . 0.0 111.817 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.8 t -107.03 136.56 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.511 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 48.4 mttt -90.89 138.81 31.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.268 -0.895 . . . . 0.0 109.439 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.532 HG22 ' CG2' ' A' ' 170' ' ' VAL . 13.3 p -47.71 148.18 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.589 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.562 ' O ' ' HB2' ' A' ' 121' ' ' LEU . 2.1 mt-10 -71.25 -13.28 61.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.282 -0.886 . . . . 0.0 109.389 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.562 ' HB2' ' O ' ' A' ' 120' ' ' GLU . 29.5 mt 79.66 163.83 0.19 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.495 -0.753 . . . . 0.0 109.992 179.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 47.77 65.78 2.27 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.572 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 3.6 m-30 -100.75 142.49 32.15 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -1.177 . . . . 0.0 108.61 178.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.406 ' HB2' ' CG ' ' A' ' 127' ' ' ASP . 74.8 mttt -124.87 154.32 41.25 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.013 -1.054 . . . . 0.0 110.124 -179.462 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.451 ' HA ' HG22 ' A' ' 143' ' ' ILE . 9.8 m -64.66 141.89 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.331 179.738 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 88.22 -31.75 4.65 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.44 ' OD2' ' HE3' ' A' ' 175' ' ' LYS . 28.9 m-20 -49.66 158.74 0.43 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.433 -1.039 . . . . 0.0 109.26 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.4 ttm -98.13 127.86 44.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.205 -0.934 . . . . 0.0 109.052 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.536 HG13 ' CG1' ' A' ' 143' ' ' ILE . 27.4 m -128.11 143.41 40.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.276 -0.89 . . . . 0.0 109.604 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.445 ' HB2' ' CD1' ' A' ' 176' ' ' ILE . 75.8 tttt -100.31 139.42 36.01 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 179.485 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.575 ' O ' ' CD1' ' A' ' 132' ' ' ILE . 1.2 mp -79.86 152.77 4.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.575 ' CD1' ' O ' ' A' ' 131' ' ' ILE . 1.1 mm -148.79 2.4 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 120.956 -1.09 . . . . 0.0 109.809 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.506 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 41.7 m -147.5 144.66 28.73 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.971 -1.08 . . . . 0.0 110.198 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 103.22 -166.44 16.29 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.515 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 47.5 Cg_endo -68.52 -20.85 40.84 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 123.111 2.541 . . . . 0.0 112.315 -179.663 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.515 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 98.8 m-85 -107.86 19.09 20.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.954 -1.091 . . . . 0.0 109.3 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.562 ' HA ' HG23 ' A' ' 131' ' ' ILE . 4.0 tt0 -43.17 139.9 1.7 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.268 -0.895 . . . . 0.0 109.797 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.549 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 44.3 m-20 72.62 30.74 1.81 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.463 -0.773 . . . . 0.0 110.871 179.191 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.515 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 0.7 OUTLIER -116.66 128.46 55.39 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.76 -1.212 . . . . 0.0 109.573 179.654 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.14 133.49 42.8 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.28 -0.887 . . . . 0.0 109.455 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.05 168.96 26.37 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.432 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.451 HG13 ' N ' ' A' ' 143' ' ' ILE . 53.5 t -118.19 137.47 52.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.578 -0.954 . . . . 0.0 109.311 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.536 ' CG1' HG13 ' A' ' 129' ' ' VAL . 98.7 mt -70.05 115.47 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.177 -0.952 . . . . 0.0 109.42 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -99.03 -33.85 10.65 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.085 -1.009 . . . . 0.0 109.479 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.44 ' HB2' ' HE2' ' A' ' 154' ' ' LYS . 93.7 mt-10 -154.39 149.48 26.88 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.211 -0.931 . . . . 0.0 109.702 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 2.8 mt -125.91 128.46 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.431 -0.793 . . . . 0.0 109.394 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -110.91 102.17 51.79 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.234 -0.916 . . . . 0.0 109.534 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.557 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.0 Cg_endo -70.94 172.54 13.58 Favored 'Trans proline' 0 C--O 1.214 -0.724 0 C-N-CA 122.692 2.261 . . . . 0.0 111.699 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.557 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.6 mt-10 80.37 -20.74 0.36 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.348 -0.845 . . . . 0.0 109.848 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.427 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 74.6 mtt180 -128.53 -14.02 4.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.1 -1.0 . . . . 0.0 109.567 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.427 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 35.9 mt-30 70.51 48.64 0.45 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.216 -0.927 . . . . 0.0 109.851 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . 0.492 ' OE2' ' CG2' ' A' ' 167' ' ' VAL . 84.6 tt0 -117.76 141.83 47.96 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.075 -1.015 . . . . 0.0 109.038 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.482 ' CD2' HG12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -130.77 113.27 13.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.013 -1.054 . . . . 0.0 110.158 -179.512 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . 0.44 ' HE2' ' HB2' ' A' ' 145' ' ' GLU . 2.5 ttpt -78.61 128.58 33.7 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.242 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.442 HG11 ' HA3' ' A' ' 141' ' ' GLY . 47.0 t -124.54 145.82 31.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.168 -0.958 . . . . 0.0 109.985 -179.41 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.502 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 27.0 t-20 -98.32 110.96 23.45 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.377 -0.827 . . . . 0.0 109.37 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.547 HG12 ' CG1' ' A' ' 159' ' ' ILE . 60.4 t -95.22 142.33 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.453 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 41.2 m -100.55 100.03 10.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.255 -0.903 . . . . 0.0 109.728 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.547 ' CG1' HG12 ' A' ' 157' ' ' VAL . 4.1 mt -123.81 146.98 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.178 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.634 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 97.9 m-85 61.84 38.66 14.52 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.238 -0.914 . . . . 0.0 109.205 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 55.24 17.19 10.63 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.464 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 90.7 mtt-85 -125.58 158.71 33.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.094 -1.239 . . . . 0.0 109.563 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.73 128.37 46.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.194 -0.941 . . . . 0.0 109.687 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 48.8 m -139.2 125.78 12.58 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.313 -0.867 . . . . 0.0 109.792 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.502 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.2 Cg_endo -71.51 135.28 26.08 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.7 2.267 . . . . 0.0 111.429 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.434 HG23 ' N ' ' A' ' 167' ' ' VAL . 7.1 p -118.47 163.39 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.167 -0.958 . . . . 0.0 109.966 -179.524 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.492 ' CG2' ' OE2' ' A' ' 152' ' ' GLU . 14.4 p -116.61 117.01 54.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.296 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.536 ' CD1' ' N ' ' A' ' 168' ' ' LEU . 0.0 OUTLIER -143.21 168.85 18.8 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.243 -0.911 . . . . 0.0 110.91 -179.264 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -78.96 144.0 35.21 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.532 ' CG2' HG22 ' A' ' 119' ' ' VAL . 10.8 p -57.78 -36.23 54.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.215 -0.928 . . . . 0.0 108.83 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 42.5 p -76.39 -6.64 52.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.45 -0.782 . . . . 0.0 109.401 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.506 ' HA ' ' HB2' ' A' ' 133' ' ' SER . 2.8 mt-10 -89.72 -0.29 57.44 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.239 -0.913 . . . . 0.0 109.394 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.2 m -144.06 174.35 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.253 -0.905 . . . . 0.0 109.21 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.476 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 53.9 tt0 -139.49 168.16 20.46 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.113 -0.992 . . . . 0.0 108.975 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.572 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 73.1 tttt -89.31 15.11 9.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.028 -1.045 . . . . 0.0 109.358 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.445 ' CD1' ' HB2' ' A' ' 130' ' ' LYS . 79.8 mt 53.58 -88.42 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.241 -0.912 . . . . 0.0 109.615 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.511 ' N ' ' O ' ' A' ' 175' ' ' LYS . 74.0 mm-40 . . . . . 0 N--CA 1.489 1.49 0 O-C-N 121.114 -0.991 . . . . 0.0 109.459 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.63 -30.06 71.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.146 -1.208 . . . . 0.0 109.449 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 91.0 mtp -64.63 -21.6 66.76 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.205 -0.935 . . . . 0.0 109.469 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 17.1 tttp -106.17 120.08 40.9 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.252 -0.905 . . . . 0.0 109.415 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.463 ' HG2' HG22 ' A' ' 65' ' ' ILE . 36.8 mttt -105.89 159.65 15.86 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.55 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.4 mttt -132.36 176.29 8.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.298 -0.876 . . . . 0.0 109.337 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.586 ' CD1' ' HG3' ' A' ' 63' ' ' GLU . 64.8 m95 -112.67 124.04 51.66 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.924 . . . . 0.0 109.386 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.485 ' OH ' ' HG3' ' A' ' 66' ' ' MET . 78.4 m-85 -113.35 179.79 3.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.18 -0.95 . . . . 0.0 109.266 179.785 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.529 HG12 ' CE1' ' A' ' 61' ' ' PHE . 66.8 mt -119.7 107.38 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.384 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.546 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 13.1 p -86.01 144.6 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.271 -0.893 . . . . 0.0 109.518 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.569 HD13 ' CE1' ' A' ' 59' ' ' TYR . 2.8 mm? -94.8 143.83 26.14 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.336 -0.853 . . . . 0.0 109.601 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.405 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 1.3 p -151.3 -168.59 3.14 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.307 -0.87 . . . . 0.0 109.317 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.414 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 95.4 mtp -106.2 136.15 46.42 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.181 -0.949 . . . . 0.0 109.294 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.8 t -55.8 123.38 14.0 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -0.908 . . . . 0.0 109.424 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.08 -19.67 32.11 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.414 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.8 m-85 -108.15 -11.26 15.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.323 -1.104 . . . . 0.0 109.561 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.473 ' OE2' ' N ' ' A' ' 58' ' ' GLY . 77.5 mt-10 -46.52 -61.5 1.79 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.187 -0.945 . . . . 0.0 109.408 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 67.4 mm-40 -47.98 -36.55 12.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.288 -0.883 . . . . 0.0 109.339 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -71.69 -45.96 60.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.346 -0.847 . . . . 0.0 109.436 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.516 HG22 ' CB ' ' A' ' 79' ' ' TYR . 78.8 t -57.31 -47.14 85.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.186 -0.946 . . . . 0.0 109.444 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.507 ' HD2' ' CD1' ' A' ' 42' ' ' ILE . 21.7 tttt -56.09 -51.54 67.5 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.234 -0.916 . . . . 0.0 109.532 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 61.1 tt0 -63.06 -33.67 75.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.166 -0.959 . . . . 0.0 109.398 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.581 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 23.6 m120 -66.18 -41.26 90.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.318 -0.864 . . . . 0.0 109.501 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.456 HG13 ' O ' ' A' ' 20' ' ' VAL . 92.2 mt -60.52 -44.98 97.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.217 -0.927 . . . . 0.0 109.43 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -55.77 -47.09 77.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.201 -0.937 . . . . 0.0 109.672 -179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 71.5 mttt -70.19 -34.71 73.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.136 -0.977 . . . . 0.0 109.316 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.483 ' HD2' HG23 ' A' ' 77' ' ' VAL . 34.4 tttp -57.14 -35.9 70.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.379 -0.826 . . . . 0.0 109.478 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.511 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 33.8 t -81.32 -25.51 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -71.6 -56.56 5.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.248 -0.908 . . . . 0.0 109.562 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.86 -26.2 45.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.223 -0.923 . . . . 0.0 109.553 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.463 ' OG1' HG12 ' A' ' 33' ' ' ILE . 41.8 p -98.05 -28.66 13.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.192 -0.942 . . . . 0.0 109.57 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 76.88 21.1 75.06 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.511 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 34.1 mm -90.02 94.87 5.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -1.154 . . . . 0.0 109.495 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 16.0 mttp -97.74 5.13 49.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.183 -0.948 . . . . 0.0 109.49 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -110.22 13.45 23.07 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.203 -0.936 . . . . 0.0 109.341 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.534 ' CD2' ' HB3' ' A' ' 70' ' ' ALA . 1.2 tm? -115.73 -54.28 2.52 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.329 -0.857 . . . . 0.0 109.187 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.4 HG12 ' CG2' ' A' ' 24' ' ' ILE . 42.9 t -99.21 130.01 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.443 -0.786 . . . . 0.0 109.219 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -99.82 -124.33 5.22 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 90.7 mtt180 -96.51 141.94 29.19 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.266 -1.138 . . . . 0.0 109.589 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.422 ' CD1' HD11 ' A' ' 24' ' ' ILE . 63.3 mt -101.43 138.1 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.297 -0.877 . . . . 0.0 109.251 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.543 ' CG2' ' CD1' ' A' ' 107' ' ' LEU . 44.4 t -126.42 137.51 57.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.236 -0.915 . . . . 0.0 109.285 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.528 ' CG2' HG12 ' A' ' 44' ' ' ILE . 12.2 mt -128.08 127.84 23.79 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.187 -0.946 . . . . 0.0 109.692 -179.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.513 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -68.05 -3.86 11.45 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.895 2.396 . . . . 0.0 111.461 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.63 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 18.8 pt -76.36 -6.11 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.307 -0.87 . . . . 0.0 109.561 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.439 ' NH1' ' HG3' ' A' ' 45' ' ' ARG . 5.6 ttt85 -44.48 -33.53 1.75 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.212 -0.93 . . . . 0.0 109.428 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.6 -156.62 49.85 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -164.58 -158.01 9.98 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 48.8 tt0 -52.24 -29.53 23.26 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.275 -1.132 . . . . 0.0 109.469 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 66.0 mtm180 -52.04 154.26 2.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 109.346 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.453 ' O ' ' HB2' ' A' ' 51' ' ' LYS . 44.6 mtp180 -127.15 160.67 30.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.928 . . . . 0.0 109.521 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 50' ' ' ARG . 21.8 mttm 62.31 28.72 17.1 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.258 -0.901 . . . . 0.0 109.529 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.412 ' C ' ' HG3' ' A' ' 53' ' ' GLU . 48.2 t -161.81 126.09 3.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.222 -0.923 . . . . 0.0 109.502 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.495 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 82.1 mt-10 -151.67 169.38 22.3 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.578 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.63 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 6.2 mttt 75.1 82.72 0.1 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.642 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.513 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 16.7 mt -71.83 -21.47 61.68 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.136 -0.978 . . . . 0.0 109.407 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.553 ' CZ ' HD12 ' A' ' 159' ' ' ILE . 37.2 m-85 -143.95 93.09 6.17 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.285 -0.885 . . . . 0.0 108.826 179.688 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -64.34 135.91 48.61 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.628 2.219 . . . . 0.0 112.267 -179.193 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.473 ' N ' ' OE2' ' A' ' 17' ' ' GLU . . . 78.81 -20.52 4.42 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 179.541 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.569 ' CE1' HD13 ' A' ' 11' ' ' LEU . 3.9 m-30 -96.34 127.81 42.68 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.707 -1.467 . . . . 0.0 110.47 -179.085 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.546 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 94.3 t -135.59 150.41 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.111 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.529 ' CE1' HG12 ' A' ' 9' ' ' ILE . 86.8 m-85 -108.46 122.97 48.14 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.858 -1.151 . . . . 0.0 110.227 -179.248 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 87.9 t -121.98 127.8 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.322 -0.861 . . . . 0.0 109.873 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.586 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 7.6 tt0 -89.68 121.76 32.16 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.282 -0.886 . . . . 0.0 109.278 179.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' MET . . . . . . . . . . . . . 14.8 ptt? -154.04 174.08 15.17 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.03 -1.044 . . . . 0.0 110.538 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.486 HG13 ' O ' ' A' ' 65' ' ' ILE . 39.0 pt -100.35 134.99 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.558 ' O ' ' HB3' ' A' ' 67' ' ' ASN . 84.9 mtp -79.55 142.87 35.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.096 -1.003 . . . . 0.0 110.799 -178.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.558 ' HB3' ' O ' ' A' ' 66' ' ' MET . 16.4 p30 171.67 -174.31 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -76.51 -42.89 41.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.147 -0.971 . . . . 0.0 110.006 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.621 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 85.1 tt0 -66.54 -31.42 72.13 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.216 -0.927 . . . . 0.0 110.383 -179.299 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.536 ' HB3' ' ND2' ' A' ' 67' ' ' ASN . . . -77.11 -40.78 44.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.848 -1.157 . . . . 0.0 109.791 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.496 ' O ' HG11 ' A' ' 74' ' ' VAL . 87.3 t80 -58.79 -51.41 70.1 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.11 -0.994 . . . . 0.0 109.586 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' HB3' ' A' ' 76' ' ' SER . 38.1 t-20 -69.89 -27.27 64.67 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.201 -0.937 . . . . 0.0 110.581 -179.196 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.621 ' CD1' ' O ' ' A' ' 69' ' ' GLU . 5.1 m-85 -78.19 -41.21 35.26 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.693 -1.254 . . . . 0.0 110.073 -179.447 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.609 ' CG2' ' CZ ' ' A' ' 83' ' ' PHE . 7.7 p -66.48 -52.11 50.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.22 -0.925 . . . . 0.0 109.232 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.584 ' HG2' ' CE2' ' A' ' 83' ' ' PHE . 7.5 mmm-85 -67.59 -1.22 4.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.313 -0.867 . . . . 0.0 109.904 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 89.3 p -101.0 -4.94 26.53 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.031 -1.043 . . . . 0.0 110.167 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.616 ' CG1' ' HB ' ' A' ' 80' ' ' VAL . 5.6 p -80.13 137.9 52.95 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 120.994 -1.066 . . . . 0.0 109.377 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.636 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 43.5 Cg_endo -65.77 140.53 61.97 Favored 'Trans proline' 0 C--O 1.213 -0.737 0 C-N-CA 122.763 2.308 . . . . 0.0 112.119 -179.367 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.636 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 42.0 m-85 89.0 -11.89 0.41 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.831 -0.543 . . . . 0.0 109.675 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.616 ' HB ' ' CG1' ' A' ' 77' ' ' VAL . 7.9 p -81.84 119.03 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.957 -1.089 . . . . 0.0 109.299 179.772 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.8 mmm -88.44 -27.16 21.71 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.196 -0.94 . . . . 0.0 109.41 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.588 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.27 -158.03 28.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.609 ' CZ ' ' CG2' ' A' ' 74' ' ' VAL . 7.4 m-85 -139.61 156.95 46.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -1.124 . . . . 0.0 109.573 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' A' ' 84' ' ' VAL . 7.7 p -88.74 118.69 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.232 -0.918 . . . . 0.0 109.339 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.561 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.8 OUTLIER -157.0 166.78 32.38 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -0.915 . . . . 0.0 109.627 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 m -87.06 -29.93 21.54 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.405 -0.809 . . . . 0.0 109.432 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.44 -103.18 1.4 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -99.5 -124.34 5.19 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.559 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -29.24 146.09 0.05 OUTLIER Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.524 -0.986 . . . . 0.0 110.142 -179.751 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.561 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.2 Cg_endo -68.66 153.92 72.41 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.827 2.352 . . . . 0.0 112.001 -179.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.2 m -89.9 149.75 42.43 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.301 -0.874 . . . . 0.0 109.253 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.492 ' HB3' ' HB3' ' A' ' 6' ' ' LYS . 49.5 Cg_endo -69.62 152.37 70.01 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.682 2.255 . . . . 0.0 111.664 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.45 HG21 ' O ' ' A' ' 7' ' ' TRP . 15.5 t -79.93 141.21 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -0.885 . . . . 0.0 109.322 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . 0.512 ' O ' ' N ' ' A' ' 97' ' ' GLU . 69.6 tttt -78.9 130.14 35.3 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.086 -1.009 . . . . 0.0 109.357 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.442 ' C ' ' O ' ' A' ' 94' ' ' LYS . 81.3 m-20 -42.78 -41.96 3.4 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -0.944 . . . . 0.0 109.367 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.468 ' CD ' ' HE2' ' A' ' 94' ' ' LYS . 75.1 mtt180 -56.36 -29.91 62.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.271 -0.893 . . . . 0.0 109.433 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.512 ' N ' ' O ' ' A' ' 94' ' ' LYS . 47.5 mt-10 -88.07 -28.26 21.44 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.221 -0.924 . . . . 0.0 109.589 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.562 ' HE2' ' CG ' ' A' ' 7' ' ' TRP . 94.6 mtp -82.91 -25.51 32.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.148 -0.97 . . . . 0.0 109.431 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.546 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.14 -54.62 1.08 Allowed Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.524 -0.735 . . . . 0.0 109.995 -179.845 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.612 ' CB ' ' CE2' ' A' ' 136' ' ' PHE . 49.4 Cg_endo -70.17 -27.75 24.14 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.591 2.194 . . . . 0.0 112.132 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.525 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 18.9 mm -80.21 -42.74 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.156 -0.965 . . . . 0.0 109.546 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.523 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -67.36 -40.63 85.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.207 -0.933 . . . . 0.0 109.494 -179.884 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.547 ' CG ' ' HB3' ' A' ' 135' ' ' PRO . 22.2 tpt180 -65.13 -49.73 68.78 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.326 -0.859 . . . . 0.0 109.162 179.722 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.4 tt -72.05 -37.86 69.61 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.208 -0.932 . . . . 0.0 109.2 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.52 -1.04 9.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.398 -0.814 . . . . 0.0 109.829 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.75 8.57 86.42 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.543 ' CD1' ' CG2' ' A' ' 41' ' ' VAL . 29.3 mt -78.38 -21.4 49.44 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.19 -1.182 . . . . 0.0 109.613 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 42.6 tp10 -124.81 134.37 52.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.15 -0.969 . . . . 0.0 109.365 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 64.9 mt-10 -120.4 108.33 14.0 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.918 . . . . 0.0 109.557 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.578 ' CD1' ' O ' ' A' ' 111' ' ' GLU . 35.0 p90 -138.47 164.86 28.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.313 -0.867 . . . . 0.0 109.455 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.578 ' O ' ' CD1' ' A' ' 110' ' ' TYR . 61.9 mm-40 -62.5 -142.05 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.891 . . . . 0.0 109.636 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -161.29 172.21 17.02 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.289 -0.882 . . . . 0.0 109.425 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.621 ' CG ' ' HA ' ' A' ' 133' ' ' SER . 7.3 mmtp -68.3 -56.04 9.97 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.215 -0.928 . . . . 0.0 109.623 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.418 ' HG3' ' C ' ' A' ' 113' ' ' LYS . 8.7 mttt 50.36 23.59 1.28 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.347 -0.846 . . . . 0.0 109.475 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.49 ' HG2' ' HB3' ' A' ' 113' ' ' LYS . 0.4 OUTLIER -101.25 104.66 34.56 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.289 -0.882 . . . . 0.0 109.48 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -70.77 117.98 5.44 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.661 2.24 . . . . 0.0 111.707 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 21.9 t -129.83 129.68 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.18 -0.95 . . . . 0.0 109.44 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 23.4 mttt -65.31 147.63 53.1 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 109.482 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 29.5 m -114.54 167.88 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.308 -0.87 . . . . 0.0 109.405 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.663 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 84.4 mt-10 -60.49 -35.28 75.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.663 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 5.1 mt 145.0 155.16 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.844 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.626 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.95 93.82 0.01 OUTLIER Glycine 0 N--CA 1.494 2.564 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.533 ' O ' ' CD1' ' A' ' 146' ' ' ILE . 18.0 m-85 -47.59 178.56 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.294 -1.121 . . . . 0.0 109.528 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 80.9 mttt -102.08 148.72 25.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.958 . . . . 0.0 109.915 -179.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.446 HG11 HG13 ' A' ' 146' ' ' ILE . 20.5 m -64.14 144.26 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.433 -0.792 . . . . 0.0 109.375 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 85.72 -29.92 4.38 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 -179.751 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.451 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 26.2 m-20 -48.01 165.71 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -1.114 . . . . 0.0 109.127 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 2.9 ttm -103.54 127.8 50.88 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.136 -0.978 . . . . 0.0 109.153 179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.541 HG12 ' CG1' ' A' ' 143' ' ' ILE . 26.8 m -129.06 145.88 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.855 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.421 ' HA ' ' HA ' ' A' ' 140' ' ' ALA . 42.2 tttt -102.81 142.41 33.99 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.493 HG22 ' N ' ' A' ' 132' ' ' ILE . 60.5 mt -83.14 154.34 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.358 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.493 ' N ' HG22 ' A' ' 131' ' ' ILE . 0.2 OUTLIER -152.02 2.78 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 120.948 -1.095 . . . . 0.0 109.65 179.828 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.621 ' HA ' ' CG ' ' A' ' 113' ' ' LYS . 47.3 t -148.03 144.1 27.69 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.07 -1.019 . . . . 0.0 110.252 -179.66 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 99.62 -163.18 19.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.547 ' HB3' ' CG ' ' A' ' 103' ' ' ARG . 46.8 Cg_endo -67.89 -23.46 41.14 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 123.312 2.675 . . . . 0.0 112.541 -179.497 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.612 ' CE2' ' CB ' ' A' ' 100' ' ' PRO . 93.2 m-85 -104.22 17.61 23.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.957 -1.09 . . . . 0.0 109.562 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.545 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 2.9 tt0 -43.83 133.61 4.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.251 -0.906 . . . . 0.0 109.649 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.545 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 16.8 t0 78.92 19.26 0.82 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.262 -0.899 . . . . 0.0 110.36 179.161 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.512 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 0.9 OUTLIER -109.24 130.4 55.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.912 -1.117 . . . . 0.0 109.47 179.825 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.421 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -83.7 136.9 34.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.16 -0.963 . . . . 0.0 109.597 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.498 ' HA3' HG12 ' A' ' 155' ' ' VAL . . . -146.55 175.6 25.89 Favored Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.67 -1.252 . . . . 0.0 110.612 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.573 ' N ' ' CG1' ' A' ' 155' ' ' VAL . 19.4 m -118.42 137.01 53.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.702 -0.881 . . . . 0.0 109.659 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.541 ' CG1' HG12 ' A' ' 129' ' ' VAL . 93.3 mt -67.48 114.6 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.321 -0.862 . . . . 0.0 109.407 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -98.15 -34.51 10.72 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.976 -1.077 . . . . 0.0 109.331 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -150.8 145.58 25.81 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.153 -0.967 . . . . 0.0 109.367 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.533 ' CD1' ' O ' ' A' ' 123' ' ' PHE . 2.2 mt -122.74 126.28 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.678 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -107.41 101.68 40.32 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.314 -0.867 . . . . 0.0 109.447 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.528 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.1 Cg_endo -71.96 170.92 17.73 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.734 2.29 . . . . 0.0 111.899 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.7 tt0 79.85 -20.92 0.36 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.336 -0.852 . . . . 0.0 109.862 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.431 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 66.6 mtp85 -125.35 -13.18 6.7 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.155 -0.965 . . . . 0.0 109.43 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.431 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 36.2 mt-30 68.98 49.08 0.67 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.204 -0.935 . . . . 0.0 109.678 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -121.1 145.25 48.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.111 -0.993 . . . . 0.0 108.896 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.521 HD22 ' CG2' ' A' ' 143' ' ' ILE . 0.0 OUTLIER -135.82 113.13 10.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.035 -1.041 . . . . 0.0 110.262 -179.498 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . 0.409 ' HG2' HG11 ' A' ' 167' ' ' VAL . 10.4 mttt -79.59 133.25 36.43 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.102 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.573 ' CG1' ' N ' ' A' ' 142' ' ' VAL . 21.5 t -126.34 150.49 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.077 -1.014 . . . . 0.0 110.01 -179.27 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.51 ' OD1' ' N ' ' A' ' 164' ' ' THR . 20.9 t-20 -97.26 114.5 26.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.446 -0.784 . . . . 0.0 109.293 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.502 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 50.0 t -95.98 139.77 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.712 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 20.6 m -92.55 95.24 9.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.409 -0.807 . . . . 0.0 109.514 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.553 HD12 ' CZ ' ' A' ' 56' ' ' PHE . 5.5 pt -130.9 150.2 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.269 -0.895 . . . . 0.0 109.488 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.55 ' CE2' HD12 ' A' ' 159' ' ' ILE . 13.7 m-30 62.95 33.13 15.18 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.271 -0.893 . . . . 0.0 109.313 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 60.64 16.35 44.64 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 60.0 mtt-85 -135.63 159.27 42.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.188 -1.183 . . . . 0.0 109.455 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.427 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 95.6 mt-10 -100.46 140.85 34.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.244 -0.91 . . . . 0.0 109.516 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' THR . . . . . 0.51 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 16.4 m -148.0 127.86 6.59 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.325 -0.859 . . . . 0.0 109.46 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.5 Cg_endo -69.86 140.0 41.23 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.751 2.301 . . . . 0.0 111.583 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.506 ' CG2' HD23 ' A' ' 168' ' ' LEU . 35.2 m -121.28 168.19 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.056 -1.028 . . . . 0.0 109.598 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.618 ' O ' ' CD1' ' A' ' 168' ' ' LEU . 8.4 m -118.2 115.66 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.442 -0.786 . . . . 0.0 109.492 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.727 ' N ' ' CD2' ' A' ' 168' ' ' LEU . 0.0 OUTLIER -139.56 166.28 25.0 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-O 121.797 0.808 . . . . 0.0 109.937 179.959 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.45 ' O ' ' HB2' ' A' ' 172' ' ' GLU . 40.5 m80 -79.04 139.72 38.09 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.175 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.491 HG13 ' N ' ' A' ' 171' ' ' SER . 11.4 p -51.43 -37.91 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.067 -1.021 . . . . 0.0 108.521 179.598 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.491 ' N ' HG13 ' A' ' 170' ' ' VAL . 53.3 p -74.86 -4.83 40.16 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.615 -0.678 . . . . 0.0 109.798 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.489 ' HG2' ' HB3' ' A' ' 133' ' ' SER . 23.8 mt-10 -92.7 -6.44 49.19 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.077 -1.014 . . . . 0.0 109.874 -179.712 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.48 ' HA ' HG12 ' A' ' 132' ' ' ILE . 4.1 m -137.29 175.15 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.057 -1.027 . . . . 0.0 109.488 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.528 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 84.4 tt0 -140.02 164.53 29.77 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.132 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.528 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.8 tttt -90.18 19.03 5.32 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.055 -1.028 . . . . 0.0 109.347 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.476 ' O ' ' O ' ' A' ' 175' ' ' LYS . 71.1 mt 54.89 164.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.293 -0.879 . . . . 0.0 109.571 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.417 ' N ' ' CG2' ' A' ' 176' ' ' ILE . 90.5 mt-10 . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.471 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.439 ' HB2' HD11 ' A' ' 65' ' ' ILE . . . -62.05 -25.01 67.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.262 -1.14 . . . . 0.0 109.601 -179.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 90.0 mtp -72.6 -10.92 60.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.221 -0.925 . . . . 0.0 109.535 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 89.2 mttt -112.42 121.08 43.81 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.186 -0.946 . . . . 0.0 109.528 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 72.1 mttt -115.74 143.58 45.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.293 -0.879 . . . . 0.0 109.496 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.583 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.0 mtpp -130.56 174.72 9.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.282 -0.886 . . . . 0.0 109.28 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.612 ' CE2' ' HB2' ' A' ' 63' ' ' GLU . 61.9 m95 -108.84 124.43 50.61 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.232 -0.917 . . . . 0.0 109.031 179.7 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.482 ' O ' ' HA ' ' A' ' 61' ' ' PHE . 79.5 m-85 -110.92 174.07 6.03 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.163 -0.961 . . . . 0.0 109.569 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.522 HG12 ' CD1' ' A' ' 61' ' ' PHE . 61.7 mt -116.76 109.05 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.316 -0.865 . . . . 0.0 109.141 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.526 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 9.7 p -90.88 142.98 12.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.178 -0.951 . . . . 0.0 109.65 -179.682 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.561 HD12 ' CE1' ' A' ' 59' ' ' TYR . 3.5 mm? -89.5 153.86 20.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.353 -0.842 . . . . 0.0 109.615 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 58' ' ' GLY . 9.2 t -162.84 -172.87 3.24 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.906 . . . . 0.0 109.349 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.531 ' HE3' ' CD2' ' A' ' 16' ' ' TYR . 67.5 mtm -103.54 133.45 48.56 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.227 -0.92 . . . . 0.0 109.658 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.4 m -54.43 127.4 27.36 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.884 . . . . 0.0 109.383 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.23 -20.18 38.43 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.531 ' CD2' ' HE3' ' A' ' 13' ' ' MET . 85.6 m-85 -107.51 -1.56 21.24 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.34 -1.094 . . . . 0.0 109.429 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -55.21 -59.4 4.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.233 -0.917 . . . . 0.0 109.388 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -47.48 -36.38 10.1 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.345 -0.847 . . . . 0.0 109.402 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 12.9 mttp -72.44 -46.46 54.89 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.388 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.409 HG22 ' CB ' ' A' ' 79' ' ' TYR . 73.4 t -55.09 -47.17 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.281 -0.887 . . . . 0.0 109.307 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.521 ' HD2' ' CD1' ' A' ' 42' ' ' ILE . 17.8 tttm -56.23 -50.92 69.92 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.413 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -63.25 -37.39 87.05 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.189 -0.944 . . . . 0.0 109.522 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.583 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 31.5 m120 -61.89 -49.04 77.82 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.203 -0.935 . . . . 0.0 109.565 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 81.2 mt -53.93 -44.22 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.08 -1.013 . . . . 0.0 109.354 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.449 ' O ' HG23 ' A' ' 28' ' ' VAL . 83.1 tt0 -56.56 -47.95 78.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.188 -0.945 . . . . 0.0 110.035 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 40.4 mttp -73.41 -36.95 66.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.145 -0.972 . . . . 0.0 109.939 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.483 ' HD3' HG23 ' A' ' 77' ' ' VAL . 23.7 ttpp -56.31 -34.12 66.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.122 -0.986 . . . . 0.0 109.325 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.536 ' CG1' HG12 ' A' ' 37' ' ' VAL . 12.0 m -87.34 -25.55 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.42 -0.8 . . . . 0.0 109.489 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.427 ' N ' HG22 ' A' ' 28' ' ' VAL . 34.3 tt0 -72.01 -57.75 4.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.303 -0.873 . . . . 0.0 109.298 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.85 -40.79 61.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.397 -0.814 . . . . 0.0 109.243 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 72.7 p -83.07 -26.15 31.38 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.325 -0.859 . . . . 0.0 109.483 179.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 77.51 25.02 64.02 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.535 HD13 ' CE2' ' A' ' 73' ' ' PHE . 15.9 mt -94.07 92.9 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -1.15 . . . . 0.0 109.359 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.8 mttt -105.71 -12.95 15.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.349 -0.845 . . . . 0.0 109.505 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -86.25 -19.6 29.71 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.182 -0.949 . . . . 0.0 109.428 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.575 ' CD1' ' CB ' ' A' ' 70' ' ' ALA . 15.1 tp -89.36 -51.58 5.49 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.307 -0.87 . . . . 0.0 109.461 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.536 HG12 ' CG1' ' A' ' 28' ' ' VAL . 7.3 p -93.83 136.58 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.52 -0.737 . . . . 0.0 109.018 179.672 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.5 -120.9 4.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.4 mtt85 -104.44 140.04 38.51 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.286 -1.126 . . . . 0.0 109.878 -179.399 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.46 HD11 ' HG3' ' A' ' 21' ' ' LYS . 12.9 pt -112.74 148.26 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.354 -0.841 . . . . 0.0 109.021 179.407 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.554 ' CG2' ' HB2' ' A' ' 61' ' ' PHE . 23.2 m -132.22 161.77 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.076 -1.015 . . . . 0.0 109.91 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.537 ' CG2' HG13 ' A' ' 44' ' ' ILE . 3.8 mt -135.28 130.84 19.36 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.379 -0.826 . . . . 0.0 109.333 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.481 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 43.0 Cg_endo -65.12 -3.59 7.53 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.851 2.368 . . . . 0.0 111.873 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.639 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 15.3 mt -65.11 -44.09 95.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.146 -0.971 . . . . 0.0 109.446 179.701 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 18.6 ttt180 -47.03 146.16 1.83 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.213 -0.93 . . . . 0.0 109.486 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 113.98 97.22 2.22 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.92 24.7 52.0 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.494 ' O ' ' OE2' ' A' ' 53' ' ' GLU . 50.8 tt0 -51.5 -40.78 60.23 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -1.142 . . . . 0.0 109.486 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 46.1 ttt180 -56.61 -36.61 69.63 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.068 -1.02 . . . . 0.0 109.379 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 39.1 mtp-105 -66.76 154.34 41.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.236 -0.915 . . . . 0.0 109.519 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 24.1 mttm -65.76 -32.8 74.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.247 -0.908 . . . . 0.0 109.538 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.419 ' O ' ' CG ' ' A' ' 53' ' ' GLU . 45.5 p -80.81 138.59 36.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.72 -179.702 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.507 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 69.3 mt-10 -155.55 173.12 17.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.48 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.639 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 7.2 mttp 74.33 87.03 0.1 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.351 -0.843 . . . . 0.0 109.504 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.481 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 41.2 mt -68.06 -20.78 65.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.061 -1.025 . . . . 0.0 109.3 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.528 ' HB3' ' HB2' ' A' ' 59' ' ' TYR . 90.0 m-85 -143.66 98.2 5.37 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.304 -0.873 . . . . 0.0 109.044 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.406 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.3 Cg_endo -65.52 132.88 32.5 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.784 2.322 . . . . 0.0 112.216 -179.3 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.485 ' O ' HG23 ' A' ' 12' ' ' THR . . . 77.02 -15.41 6.47 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.561 ' CE1' HD12 ' A' ' 11' ' ' LEU . 2.9 m-85 -97.83 129.59 44.8 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.624 -1.515 . . . . 0.0 110.38 -179.159 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.526 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 79.2 t -137.19 149.19 25.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.41 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.554 ' HB2' ' CG2' ' A' ' 41' ' ' VAL . 63.5 m-85 -109.67 124.39 51.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.025 -1.047 . . . . 0.0 110.23 -179.416 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.497 ' CG2' ' HE2' ' A' ' 64' ' ' MET . 1.3 m -123.44 135.43 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.452 -0.78 . . . . 0.0 109.604 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.612 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 19.5 tt0 -104.87 122.91 46.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.222 -0.923 . . . . 0.0 109.402 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.527 ' HE3' ' CG2' ' A' ' 74' ' ' VAL . 22.3 mtm -157.96 179.47 9.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.085 -1.009 . . . . 0.0 110.344 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.57 ' CG1' HD12 ' A' ' 36' ' ' LEU . 8.4 pt -94.72 129.01 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.463 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 37.0 ttm -77.83 146.22 35.85 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.255 -0.903 . . . . 0.0 110.131 -178.581 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.463 ' HB2' ' O ' ' A' ' 66' ' ' MET . 20.8 t-20 176.58 177.72 0.25 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.596 -0.69 . . . . 0.0 109.258 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -73.38 -42.5 62.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.159 -0.963 . . . . 0.0 109.284 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -76.48 -28.18 56.37 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.23 -0.919 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.575 ' CB ' ' CD1' ' A' ' 36' ' ' LEU . . . -74.55 -48.15 28.53 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.262 -0.899 . . . . 0.0 109.569 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.558 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 84.0 t80 -60.52 -45.66 93.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.227 -0.921 . . . . 0.0 109.57 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -67.4 -27.3 66.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.986 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.535 ' CE2' HD13 ' A' ' 33' ' ' ILE . 10.6 t80 -81.18 -41.59 22.12 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.078 -1.014 . . . . 0.0 109.897 -179.711 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.527 ' CG2' ' HE3' ' A' ' 64' ' ' MET . 14.6 p -69.57 -53.77 22.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.426 -0.796 . . . . 0.0 109.585 -179.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.509 ' N ' ' CG1' ' A' ' 74' ' ' VAL . 14.4 tpt85 -61.15 -11.15 7.89 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.128 -0.983 . . . . 0.0 109.825 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' A' ' 73' ' ' PHE . 91.4 p -92.77 4.5 53.67 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.169 -0.957 . . . . 0.0 109.963 -179.629 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.575 ' CG1' ' HB ' ' A' ' 80' ' ' VAL . 5.2 p -76.82 135.17 67.92 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.037 -1.039 . . . . 0.0 109.344 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.634 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 42.8 Cg_endo -65.18 140.66 65.92 Favored 'Trans proline' 0 C--O 1.214 -0.72 0 C-N-CA 122.672 2.248 . . . . 0.0 112.109 -179.532 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.634 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 38.5 m-85 89.55 -9.48 0.4 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.918 -0.489 . . . . 0.0 109.744 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.575 ' HB ' ' CG1' ' A' ' 77' ' ' VAL . 7.8 p -88.2 125.01 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.049 -1.032 . . . . 0.0 109.496 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 95.9 mmm -85.09 -26.42 26.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.108 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.531 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.23 -157.52 28.15 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.531 ' CD1' ' O ' ' A' ' 82' ' ' GLY . 14.5 m-85 -132.79 149.28 52.29 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -1.138 . . . . 0.0 109.459 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.474 ' CG1' ' O ' ' A' ' 84' ' ' VAL . 10.9 p -74.33 115.75 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.427 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.51 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.1 p -152.83 166.58 31.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.263 -0.898 . . . . 0.0 109.403 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.2 t -96.01 -29.96 13.84 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.282 -0.886 . . . . 0.0 109.393 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -130.59 -80.24 0.22 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.533 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -110.18 -136.25 7.3 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.558 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -31.81 150.37 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.526 -0.985 . . . . 0.0 110.245 -179.619 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.519 ' HG3' ' HB3' ' A' ' 83' ' ' PHE . 50.5 Cg_endo -69.36 159.05 55.19 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.967 2.445 . . . . 0.0 111.884 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 28.5 m -88.9 151.69 47.61 Favored Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.207 -0.933 . . . . 0.0 109.279 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.531 ' CB ' ' CE ' ' A' ' 6' ' ' LYS . 50.6 Cg_endo -70.45 145.75 54.01 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.686 2.258 . . . . 0.0 111.789 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.449 HG12 ' HG2' ' A' ' 98' ' ' MET . 3.6 t -79.74 129.71 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.182 -0.949 . . . . 0.0 109.169 179.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . 0.504 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.4 mttp -73.92 134.0 43.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.441 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.442 ' C ' ' O ' ' A' ' 94' ' ' LYS . 69.2 m-20 -42.63 -41.65 3.16 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -0.883 . . . . 0.0 109.463 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 56.6 ttt180 -54.6 -28.64 47.87 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.235 -0.915 . . . . 0.0 109.362 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.504 ' N ' ' O ' ' A' ' 94' ' ' LYS . 23.2 mm-40 -89.38 -28.39 19.81 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.558 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.505 ' O ' ' C ' ' A' ' 99' ' ' ARG . 33.6 mmm -84.14 -28.55 27.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.254 -0.904 . . . . 0.0 109.427 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.573 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.88 -53.89 1.42 Allowed Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.465 -0.772 . . . . 0.0 109.903 -179.913 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.573 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -69.65 -28.2 26.05 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.496 2.13 . . . . 0.0 111.707 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.484 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 29.2 mm -80.69 -42.63 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.262 -0.898 . . . . 0.0 109.317 179.667 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.502 ' HA ' ' HB2' ' A' ' 107' ' ' LEU . 0.9 OUTLIER -67.73 -40.13 84.23 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.311 -0.868 . . . . 0.0 109.214 179.76 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -63.77 -50.72 67.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.337 -0.852 . . . . 0.0 109.096 179.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.82 -36.46 70.23 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.387 -0.821 . . . . 0.0 109.366 179.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.484 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.29 -0.41 8.0 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.277 -0.889 . . . . 0.0 109.995 -179.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 77.38 8.75 87.07 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.508 HD11 ' N ' ' A' ' 107' ' ' LEU . 9.9 mp -74.94 -19.17 60.23 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -1.177 . . . . 0.0 109.509 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -130.73 142.53 50.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.937 . . . . 0.0 109.544 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -114.19 122.52 47.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.224 -0.923 . . . . 0.0 109.621 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.462 ' OH ' ' HA ' ' A' ' 135' ' ' PRO . 28.2 p90 -150.78 162.28 41.03 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.344 -0.847 . . . . 0.0 109.441 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 79.8 mt-10 -101.81 -94.35 0.29 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.496 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.412 ' O ' ' CB ' ' A' ' 113' ' ' LYS . 8.3 mt-10 45.57 85.77 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.263 -0.898 . . . . 0.0 109.634 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.412 ' CB ' ' O ' ' A' ' 112' ' ' GLU . 2.9 tttt 170.21 -29.05 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.348 -0.845 . . . . 0.0 109.516 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 8.0 mttm -65.85 -19.47 65.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.205 -0.934 . . . . 0.0 109.377 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.94 112.72 27.1 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.171 -0.956 . . . . 0.0 109.571 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.31 133.8 25.39 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.712 2.275 . . . . 0.0 111.649 179.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 2.5 p -143.38 128.46 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.172 -0.955 . . . . 0.0 109.825 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 41.1 mttm -120.53 131.61 54.78 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.337 -0.852 . . . . 0.0 109.307 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.508 ' O ' ' HG ' ' A' ' 121' ' ' LEU . 6.0 m -138.31 -162.27 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.295 -0.878 . . . . 0.0 109.283 -179.741 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.66 ' O ' ' HB2' ' A' ' 121' ' ' LEU . 16.2 tt0 -44.66 -74.48 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.106 -0.996 . . . . 0.0 108.813 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.66 ' HB2' ' O ' ' A' ' 120' ' ' GLU . 43.6 mt 76.34 168.41 0.26 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.372 -0.83 . . . . 0.0 110.36 179.134 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 50.64 62.38 5.26 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.603 ' CE2' ' HB3' ' A' ' 175' ' ' LYS . 0.2 OUTLIER -77.13 -174.9 3.38 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.318 -1.107 . . . . 0.0 108.431 178.63 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.439 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 40.0 mttm -97.22 156.34 16.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.95 -1.094 . . . . 0.0 109.531 -179.652 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 11.0 p -58.39 138.6 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.469 -0.77 . . . . 0.0 109.938 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.99 -31.89 4.84 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.545 ' OD2' ' CD1' ' A' ' 123' ' ' PHE . 45.3 m-20 -48.92 160.33 0.2 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.3 -1.118 . . . . 0.0 109.552 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 2.3 ttp -97.25 127.29 43.08 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.33 -0.857 . . . . 0.0 109.026 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.547 ' CG1' HG12 ' A' ' 143' ' ' ILE . 33.9 m -128.84 146.25 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.115 -0.99 . . . . 0.0 109.834 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.526 ' CB ' HG12 ' A' ' 176' ' ' ILE . 28.4 tttt -110.29 140.28 44.62 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.592 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.576 ' O ' ' CD1' ' A' ' 132' ' ' ILE . 74.6 mt -79.61 157.76 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.049 -1.032 . . . . 0.0 108.641 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.576 ' CD1' ' O ' ' A' ' 131' ' ' ILE . 0.6 OUTLIER -149.51 1.96 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.03 -1.043 . . . . 0.0 109.526 179.786 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.458 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 58.5 m -149.65 146.16 27.13 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.011 -1.055 . . . . 0.0 110.232 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.433 ' O ' ' OH ' ' A' ' 110' ' ' TYR . . . 102.99 -167.05 16.78 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.346 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.462 ' HA ' ' OH ' ' A' ' 110' ' ' TYR . 46.0 Cg_endo -68.08 -21.9 42.11 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 123.135 2.557 . . . . 0.0 112.524 -179.555 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.542 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 97.2 m-85 -110.29 16.31 21.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.006 -1.059 . . . . 0.0 109.578 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.532 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 2.3 tt0 -43.29 143.94 0.78 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.235 -0.915 . . . . 0.0 109.641 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.532 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 26.9 m-20 72.73 28.12 2.14 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.459 -0.776 . . . . 0.0 110.234 179.406 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.525 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 1.3 t80 -117.82 128.77 55.18 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.115 -0.991 . . . . 0.0 109.444 179.739 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -76.53 131.54 39.03 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.157 -0.965 . . . . 0.0 109.746 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -139.53 165.77 25.72 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.492 ' N ' HG23 ' A' ' 155' ' ' VAL . 37.5 t -113.34 137.53 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -1.088 . . . . 0.0 109.063 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.547 HG12 ' CG1' ' A' ' 129' ' ' VAL . 14.7 mm -68.67 113.86 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.214 -0.929 . . . . 0.0 109.611 -179.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.91 -35.46 8.99 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.056 -1.027 . . . . 0.0 109.421 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -154.17 149.29 26.89 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.967 -1.083 . . . . 0.0 109.924 179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.512 HG23 ' HG ' ' A' ' 153' ' ' LEU . 11.3 mt -126.16 128.46 71.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.418 -0.802 . . . . 0.0 109.332 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -110.4 101.73 49.31 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.533 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.586 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.47 172.81 13.5 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.621 2.214 . . . . 0.0 111.801 179.85 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.586 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.6 tt0 82.4 -20.48 0.35 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.405 -0.809 . . . . 0.0 109.795 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.472 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 96.6 mtt180 -129.99 -11.54 4.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.129 -0.982 . . . . 0.0 109.684 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.472 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 19.8 mt-30 70.12 48.53 0.52 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.222 -0.924 . . . . 0.0 109.438 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . 0.493 ' OE2' ' NZ ' ' A' ' 154' ' ' LYS . 53.9 tt0 -121.35 144.24 48.76 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.156 -0.965 . . . . 0.0 109.319 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.545 ' CD2' HG23 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -138.1 112.47 8.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.235 -0.916 . . . . 0.0 109.884 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . 0.493 ' NZ ' ' OE2' ' A' ' 152' ' ' GLU . 10.2 mttm -78.54 131.73 36.9 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.309 -0.869 . . . . 0.0 108.677 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.492 HG23 ' N ' ' A' ' 142' ' ' VAL . 9.2 p -123.2 151.98 27.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.235 -0.915 . . . . 0.0 109.517 -179.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.47 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 17.9 t-20 -98.18 112.3 24.32 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.357 -0.839 . . . . 0.0 109.648 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.525 ' CG2' ' O ' ' A' ' 164' ' ' THR . 3.2 m -93.15 139.88 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.254 -0.904 . . . . 0.0 109.291 179.701 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 53.1 m -98.46 88.65 4.18 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.08 -1.013 . . . . 0.0 109.701 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . . . . . . . . . 2.0 mt -114.24 145.55 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.276 -0.89 . . . . 0.0 109.309 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.43 ' HD2' ' CE1' ' A' ' 56' ' ' PHE . 9.9 m-85 62.23 38.31 13.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.418 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.64 18.06 29.59 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 42.4 mtt-85 -130.1 156.49 44.45 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.171 -1.194 . . . . 0.0 109.553 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -96.68 130.09 43.97 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.364 -0.835 . . . . 0.0 109.55 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' THR . . . . . 0.525 ' O ' ' CG2' ' A' ' 157' ' ' VAL . 97.8 m -137.07 120.1 11.7 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.937 . . . . 0.0 109.76 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.47 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -71.1 137.28 31.26 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.712 2.275 . . . . 0.0 111.549 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.482 ' O ' HD22 ' A' ' 168' ' ' LEU . 2.6 p -128.41 147.24 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.168 -0.958 . . . . 0.0 109.878 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.468 ' N ' HG21 ' A' ' 166' ' ' VAL . 2.4 p -93.12 120.15 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.419 -0.801 . . . . 0.0 109.457 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.571 ' CD1' HG13 ' A' ' 173' ' ' VAL . 0.1 OUTLIER -141.84 167.14 22.86 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.322 -0.861 . . . . 0.0 110.585 -179.25 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.513 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 40.4 m170 -79.82 142.22 35.49 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.59 HG21 HD22 ' A' ' 121' ' ' LEU . 3.4 p -58.72 -36.82 62.39 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 O-C-N 121.256 -0.902 . . . . 0.0 109.048 179.71 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 19.8 m -75.34 -7.61 54.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.42 -0.8 . . . . 0.0 109.415 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.513 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 65.5 mt-10 -90.33 5.39 47.52 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.33 -0.856 . . . . 0.0 109.307 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.571 HG13 ' CD1' ' A' ' 168' ' ' LEU . 18.1 m -146.6 173.06 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.344 -0.848 . . . . 0.0 109.582 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.499 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 78.1 tt0 -142.08 168.56 19.45 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.3 -0.875 . . . . 0.0 109.132 179.767 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.603 ' HB3' ' CE2' ' A' ' 123' ' ' PHE . 42.0 mttt -87.24 21.16 2.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.766 -179.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.526 HG12 ' CB ' ' A' ' 130' ' ' LYS . 50.2 mt 60.38 146.81 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.164 -0.96 . . . . 0.0 109.565 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.413 ' C ' ' O ' ' A' ' 176' ' ' ILE . 96.2 mt-10 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.997 -1.001 . . . . 0.0 109.556 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -60.37 -29.52 68.98 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.246 -1.149 . . . . 0.0 109.487 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 64.9 mtt -60.48 -29.26 68.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.225 -0.922 . . . . 0.0 109.53 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 83.5 tttt -140.92 120.25 13.05 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.328 -0.857 . . . . 0.0 109.42 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.487 ' HG2' ' CG2' ' A' ' 65' ' ' ILE . 19.4 mttt -87.38 167.06 14.36 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.141 -0.975 . . . . 0.0 109.491 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.517 ' CE ' ' HB3' ' A' ' 92' ' ' PRO . 28.0 mtpp -128.32 175.19 8.67 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.249 -0.907 . . . . 0.0 109.065 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.615 ' CZ3' ' CG2' ' A' ' 41' ' ' VAL . 63.7 m95 -112.91 124.19 52.05 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.19 -0.943 . . . . 0.0 109.149 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 67.3 m-85 -117.06 168.43 10.27 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.348 -0.845 . . . . 0.0 109.346 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.569 HD11 ' CD1' ' A' ' 160' ' ' PHE . 75.1 mt -110.5 109.72 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.193 -0.942 . . . . 0.0 109.017 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.534 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 12.8 p -86.35 143.96 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.21 -0.931 . . . . 0.0 109.547 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.53 HD12 ' CE1' ' A' ' 59' ' ' TYR . 0.5 OUTLIER -90.28 143.09 27.08 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.441 -0.787 . . . . 0.0 109.395 -179.932 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.454 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 2.4 p -154.19 174.92 14.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.405 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.433 ' O ' ' C ' ' A' ' 14' ' ' SER . 93.4 mtp -91.89 120.32 32.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.23 -0.919 . . . . 0.0 109.329 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 13' ' ' MET . 52.0 p -41.68 126.97 3.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.365 -0.835 . . . . 0.0 109.504 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.63 -19.98 35.22 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.424 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.0 m-85 -107.4 -13.9 14.99 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.266 -1.137 . . . . 0.0 109.632 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.461 ' HG2' ' CG2' ' A' ' 60' ' ' VAL . 95.1 mt-10 -43.08 -60.42 1.65 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.245 -0.909 . . . . 0.0 109.603 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 73.9 mm-40 -48.17 -34.35 9.87 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.13 -0.981 . . . . 0.0 109.523 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.468 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 56.9 mttp -76.32 -46.74 26.27 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.27 -0.894 . . . . 0.0 109.346 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 24.9 t -54.92 -47.58 75.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.308 -0.87 . . . . 0.0 109.472 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 79.0 tttt -59.42 -47.78 84.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.427 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -64.28 -34.89 79.16 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.303 -0.873 . . . . 0.0 109.448 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.581 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 32.6 m120 -66.53 -47.47 72.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.367 -0.833 . . . . 0.0 109.745 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.45 HG12 HG22 ' A' ' 77' ' ' VAL . 76.5 mt -55.71 -43.86 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.187 -0.946 . . . . 0.0 109.745 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -58.15 -44.8 88.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.156 -0.965 . . . . 0.0 109.901 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.3 mttt -74.92 -36.87 62.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.13 -0.981 . . . . 0.0 109.686 -179.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.521 ' HG2' ' CZ ' ' A' ' 73' ' ' PHE . 17.6 tttt -59.28 -30.62 68.44 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -0.929 . . . . 0.0 109.393 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.53 ' O ' ' N ' ' A' ' 32' ' ' GLY . 93.9 t -79.21 -30.15 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.195 -0.941 . . . . 0.0 109.413 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -65.82 -48.16 72.61 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.23 -0.919 . . . . 0.0 109.563 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.97 -34.63 75.07 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 109.859 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.492 HG21 ' CG1' ' A' ' 33' ' ' ILE . 9.6 t -92.56 -21.73 19.92 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 68.27 33.1 77.15 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.527 HG21 HD13 ' A' ' 33' ' ' ILE . 47.9 mm -100.43 91.49 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.245 -1.15 . . . . 0.0 109.598 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -98.54 2.91 47.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.318 -0.864 . . . . 0.0 109.5 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.46 ' O ' HD13 ' A' ' 65' ' ' ILE . 89.8 m-20 -105.39 9.97 33.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.22 -0.925 . . . . 0.0 109.477 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.479 ' HB2' ' CG2' ' A' ' 33' ' ' ILE . 4.1 mm? -114.24 -46.69 2.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.936 . . . . 0.0 109.473 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 58.7 t -105.34 134.24 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.247 -0.908 . . . . 0.0 109.41 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -98.93 -131.27 7.22 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 46.3 mtt85 -91.93 142.02 28.01 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.265 -1.138 . . . . 0.0 109.522 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.441 ' CG2' HG12 ' A' ' 62' ' ' VAL . 53.6 mt -98.66 133.88 39.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.267 -0.896 . . . . 0.0 109.305 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.615 ' CG2' ' CZ3' ' A' ' 7' ' ' TRP . 40.1 t -115.97 155.38 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.253 -0.904 . . . . 0.0 109.495 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.408 ' CG2' HG13 ' A' ' 44' ' ' ILE . 18.2 mt -133.01 126.84 19.85 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.22 -0.925 . . . . 0.0 109.525 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.514 ' O ' ' CD1' ' A' ' 55' ' ' LEU . 46.9 Cg_endo -68.18 -4.75 13.27 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.725 2.284 . . . . 0.0 111.722 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.569 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 20.7 mt -79.34 135.22 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.209 -0.932 . . . . 0.0 109.459 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.421 ' NH2' ' OG ' ' A' ' 52' ' ' SER . 14.3 ptt180 -112.56 -2.39 14.62 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.278 -0.889 . . . . 0.0 109.539 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 72.54 33.32 61.08 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -45.1 135.17 7.31 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -61.22 -32.11 71.89 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.208 -1.172 . . . . 0.0 109.467 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 77.5 ttt180 -71.74 118.71 14.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.9 . . . . 0.0 109.513 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 41.0 ttp180 -60.56 -31.49 70.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.274 -0.891 . . . . 0.0 109.441 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 30.9 mttm -68.84 -17.44 64.0 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.191 -0.943 . . . . 0.0 109.475 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.421 ' OG ' ' NH2' ' A' ' 45' ' ' ARG . 14.2 t -123.31 89.18 3.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.233 -0.917 . . . . 0.0 109.582 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.505 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 32.8 tt0 -139.96 128.53 22.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.569 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 37.5 mttp 74.25 106.4 0.07 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.232 -0.917 . . . . 0.0 109.337 -179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.514 ' CD1' ' O ' ' A' ' 43' ' ' PRO . 8.6 mt -61.31 -23.37 65.66 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.117 -0.99 . . . . 0.0 109.563 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.49 ' CD1' ' O ' ' A' ' 55' ' ' LEU . 42.6 m-85 -151.06 100.18 3.05 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.167 -0.958 . . . . 0.0 109.069 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -66.17 141.91 65.16 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.672 2.248 . . . . 0.0 111.906 -179.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.402 ' N ' ' OE2' ' A' ' 17' ' ' GLU . . . 75.26 -12.26 7.43 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.53 ' CE1' HD12 ' A' ' 11' ' ' LEU . 3.5 m-30 -103.38 130.9 50.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.789 -1.418 . . . . 0.0 109.942 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.534 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 3.0 t -132.49 146.24 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.694 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 14.9 m-85 -107.04 122.9 47.37 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.892 -1.13 . . . . 0.0 109.952 -179.391 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.441 HG12 ' CG2' ' A' ' 40' ' ' ILE . 30.0 m -129.77 139.94 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.43 -0.794 . . . . 0.0 109.48 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.497 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 48.3 tt0 -88.63 124.47 34.1 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.235 -0.916 . . . . 0.0 108.676 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.493 ' SD ' ' CG2' ' A' ' 74' ' ' VAL . 3.9 mtm -147.0 160.68 42.07 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.013 -1.054 . . . . 0.0 110.784 -178.78 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.487 ' CG2' ' HG2' ' A' ' 5' ' ' LYS . 26.9 pt -104.28 139.67 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' MET . . . . . . . . . . . . . 38.3 mtp -74.33 136.45 42.55 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.971 -1.081 . . . . 0.0 110.16 -178.432 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.437 ' HB3' ' HB3' ' A' ' 70' ' ' ALA . 35.8 t30 -178.47 155.3 0.85 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -61.78 -42.46 99.02 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.183 -0.948 . . . . 0.0 109.807 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 54.6 mt-10 -75.76 -25.23 56.29 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.852 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.437 ' HB3' ' HB3' ' A' ' 67' ' ' ASN . . . -78.05 -47.19 18.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.122 -0.987 . . . . 0.0 109.578 -179.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.575 ' CE1' ' OE1' ' A' ' 89' ' ' GLN . 65.1 t80 -61.93 -45.35 94.09 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.289 -0.882 . . . . 0.0 109.926 -179.674 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 48.2 t-20 -70.25 -29.3 66.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.096 -1.002 . . . . 0.0 110.381 -179.348 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.521 ' CZ ' ' HG2' ' A' ' 27' ' ' LYS . 83.8 t80 -76.84 -39.51 50.96 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.966 -1.084 . . . . 0.0 109.55 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.593 ' CG1' ' N ' ' A' ' 75' ' ' ARG . 2.4 p -75.48 -48.66 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.352 -0.843 . . . . 0.0 109.516 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.593 ' N ' ' CG1' ' A' ' 74' ' ' VAL . 0.0 OUTLIER -58.64 -21.09 52.91 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.212 -0.93 . . . . 0.0 109.86 -179.689 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.6 m -95.9 5.53 51.03 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.116 -0.99 . . . . 0.0 109.837 -179.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.639 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 3.6 p -68.26 132.93 91.48 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.05 -1.031 . . . . 0.0 109.301 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.743 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 44.3 Cg_endo -65.87 136.07 43.75 Favored 'Trans proline' 0 C--O 1.213 -0.763 0 C-N-CA 122.821 2.347 . . . . 0.0 112.369 -179.294 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.743 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 76.3 m-85 91.17 -6.89 0.26 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.95 -0.469 . . . . 0.0 109.844 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.639 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.1 t -98.0 135.93 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.928 -1.107 . . . . 0.0 109.309 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 88.9 mmm -96.6 -24.6 15.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.294 -0.879 . . . . 0.0 109.704 -179.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.55 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 159.89 -159.88 31.05 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.55 ' CD1' ' C ' ' A' ' 82' ' ' GLY . 9.4 m-85 -137.44 148.22 45.95 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.322 -1.105 . . . . 0.0 109.519 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.438 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 9.2 p -72.58 128.12 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.232 -0.918 . . . . 0.0 109.387 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.537 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 5.0 p -160.66 166.09 29.45 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.55 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 m -91.27 -30.27 16.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.296 -0.877 . . . . 0.0 109.164 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -134.17 -83.47 0.2 Allowed Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.531 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -102.88 -137.7 9.65 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.575 ' OE1' ' CE1' ' A' ' 71' ' ' TYR . 0.3 OUTLIER -32.79 154.66 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.566 -0.961 . . . . 0.0 110.15 -179.53 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.537 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 46.6 Cg_endo -67.58 151.05 80.03 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.83 2.353 . . . . 0.0 111.946 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.3 m -83.26 151.68 63.28 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.517 ' HB3' ' CE ' ' A' ' 6' ' ' LYS . 51.2 Cg_endo -70.24 144.5 51.63 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.632 2.221 . . . . 0.0 111.796 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.458 HG13 ' HG3' ' A' ' 98' ' ' MET . 21.4 t -82.0 127.21 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.191 -0.943 . . . . 0.0 109.301 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -67.78 140.37 56.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.242 -0.911 . . . . 0.0 109.417 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -49.76 -40.83 42.39 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.47 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 39.2 ttm180 -57.4 -30.47 64.94 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.309 -0.87 . . . . 0.0 109.569 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 52.7 mt-10 -85.8 -27.79 24.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.156 -0.965 . . . . 0.0 109.493 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.58 ' HE3' ' CD1' ' A' ' 7' ' ' TRP . 93.2 mtp -82.33 -25.82 33.54 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.286 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.593 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 2.4 mtt180 -37.11 -52.65 2.14 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.434 -0.791 . . . . 0.0 109.935 -179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.1 Cg_endo -69.78 -28.79 24.7 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.499 2.133 . . . . 0.0 111.897 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.443 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 38.2 mm -81.47 -43.08 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.206 -0.934 . . . . 0.0 109.56 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.532 HD12 ' CB ' ' A' ' 98' ' ' MET . 0.9 OUTLIER -66.76 -39.91 88.04 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 0.0 109.264 179.819 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 48.2 mtt-85 -64.06 -49.95 70.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.341 -0.849 . . . . 0.0 109.104 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.1 tt -72.09 -35.81 69.31 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.268 -0.895 . . . . 0.0 109.231 179.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.443 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.53 -2.01 12.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.352 -0.842 . . . . 0.0 109.897 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.83 10.43 84.98 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.706 -1.358 . . . . 0.0 109.706 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.588 ' CD1' ' CG2' ' A' ' 41' ' ' VAL . 18.5 mt -78.18 -21.51 50.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.212 -1.17 . . . . 0.0 109.542 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 84.5 mt-10 -115.53 158.23 22.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.654 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -102.81 120.25 40.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.294 -0.879 . . . . 0.0 109.43 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.43 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 23.5 p90 -148.95 162.81 39.14 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.233 -0.917 . . . . 0.0 109.515 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.43 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 51.0 mm-40 -101.03 -148.01 0.36 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.326 -0.859 . . . . 0.0 109.447 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.619 ' O ' ' C ' ' A' ' 113' ' ' LYS . 62.7 tt0 -125.48 153.52 43.41 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.2 -0.937 . . . . 0.0 109.373 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.619 ' C ' ' O ' ' A' ' 112' ' ' GLU . 0.0 OUTLIER 20.91 93.58 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.669 -0.644 . . . . 0.0 110.522 179.768 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.409 ' O ' ' HD2' ' A' ' 115' ' ' LYS . 0.3 OUTLIER -54.41 -31.77 55.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.227 -0.92 . . . . 0.0 109.211 179.704 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.437 ' HB3' ' HE2' ' A' ' 115' ' ' LYS . 12.1 mmmm -114.68 115.24 44.17 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.401 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.95 -5.2 15.77 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.715 2.277 . . . . 0.0 111.829 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 9.2 t -72.99 133.65 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.875 . . . . 0.0 109.513 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -71.06 160.59 32.62 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.272 -0.892 . . . . 0.0 109.452 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 55.5 t -132.87 150.15 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.127 -0.983 . . . . 0.0 109.556 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.667 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 92.5 mt-10 -142.85 -172.69 3.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.304 -0.872 . . . . 0.0 109.442 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.667 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 2.3 mt 145.82 108.84 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.622 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -20.97 94.61 0.01 OUTLIER Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.481 ' N ' ' O ' ' A' ' 121' ' ' LEU . 0.7 OUTLIER -107.32 145.87 32.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.228 -1.16 . . . . 0.0 109.581 179.995 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 22.9 mttt -141.5 162.62 35.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.318 -0.864 . . . . 0.0 109.534 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.467 ' HA ' HG22 ' A' ' 143' ' ' ILE . 15.2 m -61.4 141.62 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.747 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 86.85 -33.81 3.68 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.424 ' O ' HG13 ' A' ' 142' ' ' VAL . 27.8 m-20 -47.96 158.74 0.21 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.351 -1.088 . . . . 0.0 109.198 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.3 ttm -100.94 128.5 46.95 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.084 -1.01 . . . . 0.0 108.752 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.54 ' CG1' HG12 ' A' ' 143' ' ' ILE . 16.0 m -129.22 144.8 37.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.337 -0.852 . . . . 0.0 109.878 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.532 ' CB ' HG12 ' A' ' 176' ' ' ILE . 10.6 tttp -97.93 140.64 31.98 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.406 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.54 HG23 ' HA ' ' A' ' 137' ' ' GLU . 1.2 mp -80.72 153.55 4.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.353 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.536 ' N ' HG22 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -149.3 2.45 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 120.793 -1.192 . . . . 0.0 109.841 -179.791 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' SER . . . . . 0.534 ' CB ' ' HG3' ' A' ' 172' ' ' GLU . 61.1 m -149.25 145.35 27.05 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.004 -1.06 . . . . 0.0 110.212 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 103.46 -166.74 16.18 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.509 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 48.3 Cg_endo -68.41 -21.12 41.17 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.199 2.599 . . . . 0.0 112.53 -179.614 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.509 ' CD1' ' HG2' ' A' ' 135' ' ' PRO . 92.3 m-85 -108.35 18.72 20.7 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.907 -1.121 . . . . 0.0 109.377 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.54 ' HA ' HG23 ' A' ' 131' ' ' ILE . 3.7 tt0 -42.61 140.61 1.23 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.261 -0.899 . . . . 0.0 109.711 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.532 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 22.4 m-20 72.67 29.79 1.93 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.406 -0.809 . . . . 0.0 110.727 179.147 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.611 ' CE1' HG21 ' A' ' 157' ' ' VAL . 1.2 t80 -117.85 133.27 56.09 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.838 -1.164 . . . . 0.0 109.399 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.92 134.75 36.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.213 -0.93 . . . . 0.0 109.724 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.437 ' HA3' HG21 ' A' ' 155' ' ' VAL . . . -145.47 169.68 26.98 Favored Glycine 0 N--CA 1.491 2.306 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.329 -179.641 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.48 ' N ' ' CG2' ' A' ' 155' ' ' VAL . 43.6 t -119.43 136.4 56.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.567 -0.96 . . . . 0.0 109.281 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.54 HG12 ' CG1' ' A' ' 129' ' ' VAL . 31.7 mm -68.82 119.58 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.63 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . 0.456 ' HD2' ' OD1' ' A' ' 156' ' ' ASN . 63.9 tttt -99.81 -33.26 10.63 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.054 -1.029 . . . . 0.0 109.527 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -154.32 149.48 26.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.123 -0.986 . . . . 0.0 109.656 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.575 ' CG2' ' CD2' ' A' ' 153' ' ' LEU . 3.6 mt -123.9 126.55 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.321 -0.862 . . . . 0.0 109.575 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.22 102.39 46.25 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.239 -0.913 . . . . 0.0 109.589 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.0 Cg_endo -71.99 170.96 17.66 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.749 2.299 . . . . 0.0 111.866 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.3 mt-10 79.44 -21.23 0.34 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.395 -0.815 . . . . 0.0 110.057 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.463 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 75.6 mtt-85 -125.74 -14.99 6.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.063 -1.023 . . . . 0.0 109.478 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.463 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 50.8 mt-30 69.56 48.64 0.6 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.187 -0.946 . . . . 0.0 109.67 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . 0.472 ' O ' HD22 ' A' ' 153' ' ' LEU . 82.5 tt0 -119.07 143.25 47.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.174 -0.954 . . . . 0.0 108.968 179.626 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.575 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 32.3 mt -128.77 127.55 42.22 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.1 -1.0 . . . . 0.0 110.291 -179.469 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -92.03 128.67 37.96 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.077 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.59 ' CG1' ' CG1' ' A' ' 166' ' ' VAL . 12.9 p -131.39 147.93 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.084 -1.01 . . . . 0.0 109.834 -179.496 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.535 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.8 m120 -100.85 125.09 47.35 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.413 -0.804 . . . . 0.0 109.552 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.611 HG21 ' CE1' ' A' ' 139' ' ' PHE . 3.3 p -105.74 144.8 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.921 . . . . 0.0 109.476 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.402 ' N ' HG22 ' A' ' 157' ' ' VAL . 55.7 m -97.33 92.48 6.0 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.895 . . . . 0.0 109.928 -179.664 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.532 ' CD1' HG11 ' A' ' 157' ' ' VAL . 7.4 mt -116.03 142.96 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.258 -0.901 . . . . 0.0 109.237 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.694 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 91.0 m-85 61.88 37.15 15.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.185 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.6 17.92 35.79 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 26.2 mtp180 -126.88 157.39 39.48 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.067 -1.254 . . . . 0.0 109.555 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -100.91 132.03 46.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.277 -0.889 . . . . 0.0 109.728 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.2 m -142.47 127.06 10.02 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.37 -0.831 . . . . 0.0 109.743 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.1 Cg_endo -70.91 136.67 30.48 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.748 2.299 . . . . 0.0 111.616 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.59 ' CG1' ' CG1' ' A' ' 155' ' ' VAL . 11.7 p -119.64 164.65 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.087 -1.008 . . . . 0.0 109.706 -179.817 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.471 ' O ' HD23 ' A' ' 168' ' ' LEU . 6.7 m -117.53 117.65 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.459 -0.776 . . . . 0.0 109.66 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.479 HD23 HG22 ' A' ' 166' ' ' VAL . 0.2 OUTLIER -142.24 167.33 22.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.241 -0.912 . . . . 0.0 110.207 -179.779 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.483 ' HB2' ' CD ' ' A' ' 172' ' ' GLU . 19.2 m170 -82.7 146.37 29.08 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 171' ' ' SER . 7.1 p -56.32 -32.73 36.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 121.422 -0.798 . . . . 0.0 109.314 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.401 ' N ' HG12 ' A' ' 170' ' ' VAL . 73.5 p -76.86 -7.06 54.79 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.275 -0.891 . . . . 0.0 109.762 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.534 ' HG3' ' CB ' ' A' ' 133' ' ' SER . 0.8 OUTLIER -95.53 2.8 54.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.067 -1.021 . . . . 0.0 109.376 -179.991 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.506 HG12 ' N ' ' A' ' 174' ' ' GLU . 43.5 t -139.78 164.84 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 109.281 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.521 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 54.8 tt0 -141.22 167.16 22.85 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.087 -1.008 . . . . 0.0 108.928 179.73 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.521 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 32.7 tttp -93.9 28.83 2.27 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.058 -1.027 . . . . 0.0 109.476 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.532 HG12 ' CB ' ' A' ' 130' ' ' LYS . 53.2 mt 48.27 96.61 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.284 -0.885 . . . . 0.0 109.52 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.476 -179.982 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -58.95 -35.12 72.6 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.252 -1.146 . . . . 0.0 109.413 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 88.8 mtp -59.56 -26.37 65.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.282 -0.886 . . . . 0.0 109.387 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 18.4 mttt -110.72 128.72 55.84 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.282 -0.886 . . . . 0.0 109.292 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.469 ' O ' ' HD3' ' A' ' 6' ' ' LYS . 27.5 mttt -111.61 163.01 14.56 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.192 -0.942 . . . . 0.0 109.61 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.567 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 36.0 mmtm -132.07 169.26 16.62 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.355 -0.841 . . . . 0.0 109.339 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.633 ' CD2' ' HB2' ' A' ' 63' ' ' GLU . 68.1 m95 -103.39 129.21 50.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.255 -0.903 . . . . 0.0 109.235 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -118.47 170.33 9.02 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.22 -0.925 . . . . 0.0 109.143 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.457 ' CD1' ' CE1' ' A' ' 160' ' ' PHE . 22.7 mt -103.85 112.78 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.122 -0.986 . . . . 0.0 109.268 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.518 HG12 ' N ' ' A' ' 11' ' ' LEU . 73.5 t -86.18 142.31 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.228 -0.92 . . . . 0.0 109.343 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.518 ' CD2' HG23 ' A' ' 84' ' ' VAL . 0.6 OUTLIER -93.45 142.04 27.78 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.363 -0.836 . . . . 0.0 109.416 179.904 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.0 t -160.44 -173.33 3.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.431 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.426 ' O ' ' C ' ' A' ' 14' ' ' SER . 89.1 mtp -109.18 122.46 47.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.213 -0.93 . . . . 0.0 109.47 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.426 ' C ' ' O ' ' A' ' 13' ' ' MET . 2.2 m -44.3 133.87 5.26 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.259 -0.901 . . . . 0.0 109.443 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.0 -21.37 36.09 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -113.01 -7.99 13.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.25 -1.147 . . . . 0.0 109.355 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.466 ' OE1' HD13 ' A' ' 44' ' ' ILE . 57.3 mt-10 -48.12 -59.96 2.99 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.212 -0.93 . . . . 0.0 109.442 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -45.7 -34.57 3.64 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.187 -0.946 . . . . 0.0 109.37 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.46 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 25.1 mttt -73.68 -43.72 58.58 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.276 -0.89 . . . . 0.0 109.377 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.406 ' O ' HG12 ' A' ' 24' ' ' ILE . 92.4 t -56.76 -50.0 76.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.317 -0.864 . . . . 0.0 109.535 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . 0.404 ' HD2' HD11 ' A' ' 42' ' ' ILE . 24.8 tttt -56.24 -46.95 79.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.911 . . . . 0.0 109.145 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 69.7 tt0 -65.27 -38.81 91.44 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.341 -0.849 . . . . 0.0 109.433 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.529 ' O ' ' CB ' ' A' ' 27' ' ' LYS . 32.6 m120 -62.29 -43.12 99.56 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.241 -0.912 . . . . 0.0 110.045 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.554 ' CD1' ' CG2' ' A' ' 77' ' ' VAL . 49.4 mm -64.69 -44.99 96.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.127 -0.983 . . . . 0.0 109.738 -179.537 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -58.7 -46.91 86.24 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.164 -0.96 . . . . 0.0 109.96 -179.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -82.27 -37.35 26.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.993 -1.067 . . . . 0.0 109.712 -179.724 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.529 ' CB ' ' O ' ' A' ' 23' ' ' ASN . 28.2 tttm -57.22 -30.36 64.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.283 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.579 ' CG2' ' O ' ' A' ' 33' ' ' ILE . 12.3 p -85.43 -26.38 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.296 -0.878 . . . . 0.0 109.555 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.536 ' N ' HG11 ' A' ' 28' ' ' VAL . 44.2 tp10 -67.31 -47.45 70.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.324 -0.86 . . . . 0.0 109.716 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.67 -31.24 66.13 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.176 -0.952 . . . . 0.0 109.548 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 58.8 p -90.06 -21.66 22.21 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.916 . . . . 0.0 109.575 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 78.03 -2.92 63.2 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.579 ' O ' ' CG2' ' A' ' 28' ' ' VAL . 31.2 mm -72.71 71.33 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -1.123 . . . . 0.0 109.268 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 32.5 pttt -85.87 13.79 6.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.279 -0.888 . . . . 0.0 109.453 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.427 ' O ' HD11 ' A' ' 65' ' ' ILE . 29.7 m120 -110.37 -9.57 14.62 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.22 -0.925 . . . . 0.0 109.414 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.563 ' CD1' ' CB ' ' A' ' 70' ' ' ALA . 3.8 mm? -92.1 -51.5 5.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.309 -0.869 . . . . 0.0 109.297 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 13.7 p -92.03 141.89 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 108.956 179.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.96 -119.01 2.91 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 56.3 mtt180 -97.52 139.54 33.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.33 -1.1 . . . . 0.0 110.142 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.534 ' CG2' HG11 ' A' ' 62' ' ' VAL . 75.4 mt -111.55 134.34 54.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.427 -0.796 . . . . 0.0 109.088 179.522 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.633 ' CG2' ' CZ3' ' A' ' 7' ' ' TRP . 29.8 m -123.8 148.77 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.005 -1.059 . . . . 0.0 109.311 179.803 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.466 HG23 HD13 ' A' ' 44' ' ' ILE . 1.8 mt -129.69 131.77 23.77 Favored Pre-proline 0 C--N 1.302 -1.486 0 O-C-N 121.346 -0.846 . . . . 0.0 109.703 -179.405 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.588 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 42.3 Cg_endo -64.61 -4.5 8.47 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.856 2.371 . . . . 0.0 111.285 179.7 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.672 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 39.5 mt -68.11 -42.04 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.459 -0.776 . . . . 0.0 109.519 179.589 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.433 ' C ' ' O ' ' A' ' 44' ' ' ILE . 84.0 mtt-85 -42.88 149.34 0.2 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.341 -0.849 . . . . 0.0 109.601 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -171.87 -159.48 18.26 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.25 131.05 41.83 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -58.32 -22.2 52.21 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.295 -1.121 . . . . 0.0 109.449 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 18.8 mtp180 -59.83 -24.52 64.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.126 -0.983 . . . . 0.0 109.322 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 66.7 mtm-85 -122.07 136.27 54.9 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.296 -0.877 . . . . 0.0 109.323 179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.2 tttt -59.56 168.89 1.45 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.276 -0.89 . . . . 0.0 109.458 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.523 ' HB3' ' CG2' ' A' ' 44' ' ' ILE . 0.9 OUTLIER -48.64 107.2 0.12 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.193 -0.942 . . . . 0.0 109.428 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.543 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 80.5 tt0 -86.22 -29.21 23.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.364 -0.835 . . . . 0.0 109.619 -179.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.672 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 0.2 OUTLIER 78.41 89.0 0.06 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.875 . . . . 0.0 109.389 -179.95 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.588 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 14.3 tp -55.4 -47.69 75.5 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.007 -1.058 . . . . 0.0 109.152 179.723 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.583 ' CE2' ' HG ' ' A' ' 55' ' ' LEU . 75.3 m-85 -130.56 106.08 15.76 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.35 -0.844 . . . . 0.0 108.79 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -64.11 144.46 87.22 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.627 2.218 . . . . 0.0 112.022 -179.152 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.15 -20.21 2.62 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 110.56 -1.016 . . . . 0.0 110.56 179.516 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.5 m-30 -98.05 129.71 44.89 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.569 -1.548 . . . . 0.0 110.626 -178.789 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 59.8 t -131.61 143.34 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.694 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 27.2 m-85 -104.58 129.27 52.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.879 -1.138 . . . . 0.0 110.137 -179.041 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.534 HG11 ' CG2' ' A' ' 40' ' ' ILE . 34.5 m -138.99 149.44 23.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.329 -0.857 . . . . 0.0 109.849 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.633 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 83.9 tt0 -113.79 130.14 56.49 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.319 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' MET . . . . . . . . . . . . . 61.4 mtm -151.32 160.83 43.58 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.858 -1.151 . . . . 0.0 111.184 -178.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.495 ' CD1' HD13 ' A' ' 36' ' ' LEU . 1.4 pt -80.87 125.61 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.44 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.415 ' O ' ' CG ' ' A' ' 67' ' ' ASN . 50.5 ttm -77.24 142.7 39.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.191 -0.943 . . . . 0.0 110.115 -178.533 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.415 ' CG ' ' O ' ' A' ' 66' ' ' MET . 7.6 m-20 176.2 168.47 0.44 Allowed 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -65.85 -40.52 91.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.069 -1.019 . . . . 0.0 109.578 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -75.97 -34.31 59.8 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.93 . . . . 0.0 109.858 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.563 ' CB ' ' CD1' ' A' ' 36' ' ' LEU . . . -71.76 -48.36 47.34 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.209 -0.932 . . . . 0.0 109.733 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.587 ' CG ' ' OE1' ' A' ' 89' ' ' GLN . 83.4 t80 -60.79 -44.44 96.82 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.946 -179.574 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -69.97 -26.14 63.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -0.942 . . . . 0.0 110.037 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -80.11 -36.07 35.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.074 -1.016 . . . . 0.0 109.849 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.524 ' CG2' ' O ' ' A' ' 70' ' ' ALA . 3.3 t -67.58 -56.28 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.224 -0.923 . . . . 0.0 109.976 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -47.46 -37.02 10.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.063 -1.023 . . . . 0.0 110.211 -179.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 m -70.95 2.99 3.67 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.015 -1.053 . . . . 0.0 110.419 -179.37 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.604 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 38.8 t -64.12 134.6 96.0 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 120.941 -1.099 . . . . 0.0 109.237 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.521 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 47.5 Cg_endo -67.85 135.55 35.72 Favored 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 122.715 2.277 . . . . 0.0 111.987 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.521 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 17.3 m-85 78.45 -5.05 2.1 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.432 -0.792 . . . . 0.0 109.712 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.604 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.7 t -85.11 123.96 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.054 -1.029 . . . . 0.0 109.296 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' MET . . . . . 0.457 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 66.0 mtp -82.4 -30.68 30.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.335 -0.853 . . . . 0.0 109.343 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.411 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.11 -157.34 27.97 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.484 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 7.9 m-85 -133.64 137.42 45.39 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.258 -1.143 . . . . 0.0 109.5 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.518 HG23 ' CD2' ' A' ' 11' ' ' LEU . 38.2 t -60.11 131.69 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.894 . . . . 0.0 109.48 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.529 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.7 OUTLIER -168.98 159.81 9.6 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.191 -0.943 . . . . 0.0 109.562 179.995 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.58 -35.46 16.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.307 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.58 -85.16 0.58 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.576 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -108.78 -134.08 7.05 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.303 -1.519 . . . . 0.0 109.303 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.587 ' OE1' ' CG ' ' A' ' 71' ' ' TYR . 0.3 OUTLIER -26.55 145.01 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.593 -0.945 . . . . 0.0 110.551 -179.533 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.529 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.4 Cg_endo -69.31 146.45 63.01 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.896 2.398 . . . . 0.0 111.991 -179.746 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.3 m -80.83 149.2 66.82 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.391 -0.818 . . . . 0.0 109.277 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.71 145.71 58.28 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.666 2.244 . . . . 0.0 111.78 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.469 HG13 ' HG2' ' A' ' 98' ' ' MET . 2.9 t -65.4 144.62 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.196 -0.94 . . . . 0.0 109.382 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.4 mttm -82.29 133.16 35.23 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.177 -0.952 . . . . 0.0 109.411 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.403 ' C ' ' O ' ' A' ' 94' ' ' LYS . 90.8 m-20 -45.99 -44.76 15.29 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.201 -0.937 . . . . 0.0 109.314 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 96' ' ' ARG . 34.4 ttm180 -58.51 -18.24 27.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.574 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.464 ' N ' ' O ' ' A' ' 94' ' ' LYS . 26.5 mt-10 -100.65 -26.45 13.81 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.24 -0.912 . . . . 0.0 109.571 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.524 ' O ' ' C ' ' A' ' 99' ' ' ARG . 50.1 mmm -78.37 -34.61 48.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.939 . . . . 0.0 109.334 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.561 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 2.5 mtt180 -33.45 -54.58 0.71 Allowed Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.588 -0.695 . . . . 0.0 110.228 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.561 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.1 Cg_endo -69.8 -29.46 23.63 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.55 2.167 . . . . 0.0 112.219 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.585 HG23 ' CD2' ' A' ' 61' ' ' PHE . 19.9 mm -78.7 -44.83 25.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.098 -1.001 . . . . 0.0 109.886 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.479 ' HA ' HD11 ' A' ' 107' ' ' LEU . 1.0 OUTLIER -62.83 -43.02 99.9 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.111 -0.993 . . . . 0.0 109.705 -179.877 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.406 ' NH2' ' NH2' ' A' ' 99' ' ' ARG . 46.3 mtt180 -62.3 -52.73 62.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -71.46 -37.59 71.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.393 -0.817 . . . . 0.0 109.279 179.736 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -67.87 -3.97 11.33 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.358 -0.838 . . . . 0.0 109.952 -179.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 78.09 5.24 87.01 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.568 ' CD2' HG13 ' A' ' 41' ' ' VAL . 61.6 mt -71.46 -19.69 62.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -1.148 . . . . 0.0 109.657 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 83.9 mt-10 -128.63 154.73 45.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.223 -0.923 . . . . 0.0 109.517 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -112.2 115.86 29.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.545 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.492 ' OH ' ' HB3' ' A' ' 135' ' ' PRO . 15.3 p90 -137.12 160.27 39.48 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.261 -0.899 . . . . 0.0 109.372 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.402 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 44.6 mt-10 -99.33 -148.7 0.35 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.129 -0.982 . . . . 0.0 109.354 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 72.6 tt0 -121.6 145.45 47.97 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.142 -0.974 . . . . 0.0 109.478 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . 0.446 ' CD ' ' O ' ' A' ' 132' ' ' ILE . 0.8 OUTLIER -66.49 141.63 57.82 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.476 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.5 mttt -65.97 -35.05 79.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.357 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . 0.411 ' HG2' ' O ' ' A' ' 171' ' ' SER . 7.1 tptt 63.94 69.19 0.78 Allowed Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.288 -0.882 . . . . 0.0 109.457 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -71.16 -5.51 17.17 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.719 2.279 . . . . 0.0 111.79 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 19.2 m -125.27 148.62 29.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.212 -0.93 . . . . 0.0 109.603 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.479 ' O ' ' O ' ' A' ' 119' ' ' VAL . 60.0 mttp -101.81 139.8 36.96 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.296 179.825 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.605 ' HB ' ' CE2' ' A' ' 123' ' ' PHE . 3.1 m -43.65 168.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -0.884 . . . . 0.0 109.677 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.554 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 85.6 mt-10 -158.57 161.45 37.28 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.262 -0.899 . . . . 0.0 109.666 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.572 ' O ' ' C ' ' A' ' 122' ' ' GLY . 0.7 OUTLIER 80.21 95.93 0.05 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.369 -0.832 . . . . 0.0 109.678 179.834 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.572 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -26.42 94.34 0.01 OUTLIER Glycine 0 N--CA 1.494 2.563 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 179.632 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.605 ' CE2' ' HB ' ' A' ' 119' ' ' VAL . 22.0 m-30 -60.74 145.8 48.24 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.022 -1.281 . . . . 0.0 109.151 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 39.5 mttm -130.16 157.35 42.68 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 0.0 109.688 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.458 ' HA ' HG22 ' A' ' 143' ' ' ILE . 13.6 p -62.13 148.94 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.329 -0.857 . . . . 0.0 109.494 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.48 -30.37 3.1 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.666 -1.373 . . . . 0.0 109.666 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 68.6 m-20 -50.57 164.22 0.14 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.189 -1.183 . . . . 0.0 109.217 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.0 ttm -99.6 129.58 45.76 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.15 -0.969 . . . . 0.0 109.011 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.574 ' CG1' ' CD1' ' A' ' 143' ' ' ILE . 25.1 m -128.67 145.67 35.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.302 -0.874 . . . . 0.0 109.948 -179.836 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . 0.527 ' HB2' ' CG1' ' A' ' 176' ' ' ILE . 26.3 tttp -110.47 145.05 38.34 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.588 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.574 HG21 ' N ' ' A' ' 132' ' ' ILE . 64.7 mt -78.75 156.5 4.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.035 -1.041 . . . . 0.0 108.544 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.574 ' N ' HG21 ' A' ' 131' ' ' ILE . 0.7 OUTLIER -148.57 -3.98 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.131 -0.98 . . . . 0.0 108.966 179.54 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.4 m -148.67 146.42 28.15 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.339 -0.851 . . . . 0.0 110.11 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 104.55 -170.58 18.44 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.547 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 49.0 Cg_endo -68.97 -19.66 39.62 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 123.276 2.651 . . . . 0.0 112.508 -179.617 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.547 ' CD1' ' HG2' ' A' ' 135' ' ' PRO . 88.6 m-85 -109.09 9.41 26.25 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.975 -1.078 . . . . 0.0 109.747 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.56 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 0.7 OUTLIER -44.19 145.01 0.84 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 0.0 109.462 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.56 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 14.6 m-20 81.62 20.54 0.35 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.489 -0.757 . . . . 0.0 110.042 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.545 ' CZ ' ' HG3' ' A' ' 100' ' ' PRO . 0.9 OUTLIER -115.42 160.66 19.59 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.11 -0.993 . . . . 0.0 109.315 179.803 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.406 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -114.31 135.83 53.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.145 -0.972 . . . . 0.0 109.383 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.478 ' C ' ' CG2' ' A' ' 155' ' ' VAL . . . -147.98 169.88 28.69 Favored Glycine 0 N--CA 1.49 2.267 0 C-N-CA 119.655 -1.26 . . . . 0.0 110.181 -179.47 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.564 ' N ' ' CG2' ' A' ' 155' ' ' VAL . 94.8 t -109.89 134.46 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.62 -0.93 . . . . 0.0 109.319 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.574 ' CD1' ' CG1' ' A' ' 129' ' ' VAL . 67.8 mt -62.69 117.16 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.134 -0.979 . . . . 0.0 109.353 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . 0.419 ' HG2' ' HG2' ' A' ' 145' ' ' GLU . 16.8 tttp -97.99 -35.86 10.31 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.164 -0.96 . . . . 0.0 109.422 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . 0.419 ' HG2' ' HG2' ' A' ' 144' ' ' LYS . 72.3 mm-40 -151.59 146.63 25.98 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.095 -1.003 . . . . 0.0 109.462 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.527 HG22 ' CD1' ' A' ' 153' ' ' LEU . 1.8 mt -122.44 125.34 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.576 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.68 102.35 44.47 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.203 -0.935 . . . . 0.0 109.603 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.546 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.6 Cg_endo -73.5 171.94 16.72 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.752 2.301 . . . . 0.0 111.846 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.546 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.0 tt0 80.57 -21.45 0.32 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.423 -0.798 . . . . 0.0 110.074 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.435 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 44.0 mtt85 -126.17 -12.48 6.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.053 -1.029 . . . . 0.0 109.323 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.435 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 42.2 mt-30 68.47 49.8 0.75 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.325 -0.86 . . . . 0.0 109.676 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 69.0 tt0 -123.01 146.35 47.71 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.048 -1.032 . . . . 0.0 108.747 179.515 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.527 ' CD1' HG22 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -142.51 113.93 7.83 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.119 -0.988 . . . . 0.0 110.511 -179.276 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 27.1 mtmt -85.08 137.21 33.19 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.564 ' CG2' ' N ' ' A' ' 142' ' ' VAL . 1.8 p -136.72 133.19 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.007 -1.058 . . . . 0.0 110.034 -179.222 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.575 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.2 t-20 -67.02 125.95 27.62 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.396 -0.815 . . . . 0.0 109.689 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.541 ' CG2' HG13 ' A' ' 166' ' ' VAL . 43.7 t -107.59 147.46 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.275 -0.891 . . . . 0.0 109.057 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.461 ' O ' ' CG2' ' A' ' 158' ' ' THR . 9.4 t -97.4 112.18 24.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.343 -0.848 . . . . 0.0 109.986 -179.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.505 ' CG2' ' CD2' ' A' ' 160' ' ' PHE . 26.6 mt -138.17 137.29 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.357 -0.84 . . . . 0.0 109.183 179.298 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.694 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 99.7 m-85 60.86 42.34 13.29 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 108.963 -179.533 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.37 17.03 17.17 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.472 ' NH1' ' O ' ' A' ' 160' ' ' PHE . 22.5 mtt85 -126.49 147.55 49.81 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -1.184 . . . . 0.0 109.637 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 64.1 mm-40 -97.89 136.64 37.9 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 109.373 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' THR . . . . . 0.503 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 4.3 m -143.68 132.55 11.34 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.673 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.575 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 48.0 Cg_endo -68.88 131.21 21.98 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.792 2.328 . . . . 0.0 111.366 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.541 HG13 ' CG2' ' A' ' 157' ' ' VAL . 24.3 m -115.55 162.89 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.052 -1.03 . . . . 0.0 109.581 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.433 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 41.3 t -117.77 119.14 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.411 -0.806 . . . . 0.0 109.61 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.533 ' CD1' ' N ' ' A' ' 168' ' ' LEU . 0.0 OUTLIER -144.38 168.73 19.4 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.956 0.884 . . . . 0.0 110.503 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -80.65 139.41 36.22 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.434 HG12 ' N ' ' A' ' 171' ' ' SER . 7.9 p -53.7 -34.18 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.156 -0.965 . . . . 0.0 109.008 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.434 ' N ' HG12 ' A' ' 170' ' ' VAL . 54.0 p -75.54 -4.33 39.26 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.394 -0.816 . . . . 0.0 109.539 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -103.97 1.85 31.66 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.072 -1.017 . . . . 0.0 109.644 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.492 ' CG1' ' N ' ' A' ' 174' ' ' GLU . 49.5 t -131.35 162.99 38.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.146 -0.971 . . . . 0.0 109.626 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.524 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 76.3 tt0 -139.3 159.62 41.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -0.9 . . . . 0.0 109.344 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.587 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 21.7 tttm -91.82 34.82 0.98 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.146 -0.971 . . . . 0.0 109.283 179.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.527 ' CG1' ' HB2' ' A' ' 130' ' ' LYS . 87.4 mt 43.05 78.05 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.306 -0.871 . . . . 0.0 109.537 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.505 -179.979 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.218 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -61.43 -34.65 75.76 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -1.129 . . . . 0.0 109.475 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 21.9 ttp -53.94 -38.13 64.59 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.514 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -115.31 130.49 56.92 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.252 -0.905 . . . . 0.0 109.549 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.5 mttt -122.24 161.36 23.41 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.544 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 21.6 mtpp -130.45 176.18 8.36 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.229 -0.92 . . . . 0.0 109.256 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.611 ' CG ' ' CE ' ' A' ' 98' ' ' MET . 39.7 m95 -109.67 124.11 50.63 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.236 -0.915 . . . . 0.0 109.126 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' TYR . . . . . 0.49 ' CE1' ' HE3' ' A' ' 66' ' ' MET . 95.4 m-85 -113.75 170.9 7.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.245 -0.909 . . . . 0.0 109.353 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.473 ' HB ' HG11 ' A' ' 84' ' ' VAL . 25.9 mt -119.2 106.84 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.232 -0.918 . . . . 0.0 109.417 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.555 ' CG2' HG21 ' A' ' 80' ' ' VAL . 0.2 OUTLIER -94.45 148.16 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.183 -0.948 . . . . 0.0 109.292 179.746 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.576 HD11 ' CE1' ' A' ' 59' ' ' TYR . 3.2 mm? -95.37 145.93 24.76 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.382 -0.824 . . . . 0.0 109.817 -179.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.9 p -147.78 -177.96 6.01 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.415 -0.803 . . . . 0.0 109.264 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' MET . . . . . 0.545 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 54.8 mtm -89.9 116.92 28.33 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.157 -0.964 . . . . 0.0 109.489 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 13' ' ' MET . 18.1 t -42.89 125.57 3.51 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.248 -0.908 . . . . 0.0 109.296 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.47 -19.09 40.28 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.129 -1.588 . . . . 0.0 109.129 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' TYR . . . . . 0.545 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.7 m-85 -107.33 -10.14 15.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.446 -1.031 . . . . 0.0 109.465 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . 0.487 ' O ' ' N ' ' A' ' 20' ' ' VAL . 93.9 mt-10 -45.47 -66.66 0.37 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.201 -0.937 . . . . 0.0 109.37 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.409 ' C ' ' O ' ' A' ' 17' ' ' GLU . 94.8 mt-10 -44.05 -35.79 2.26 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 109.302 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.432 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 22.9 mttm -71.58 -31.35 66.86 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.214 -0.929 . . . . 0.0 109.344 179.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.489 ' O ' HG12 ' A' ' 24' ' ' ILE . 98.2 t -72.55 -45.47 58.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.224 -0.923 . . . . 0.0 109.356 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 28.8 tttm -55.82 -50.53 70.28 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.341 -0.849 . . . . 0.0 109.303 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -62.3 -37.33 85.12 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -0.895 . . . . 0.0 109.163 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.578 ' ND2' ' CG ' ' A' ' 78' ' ' PRO . 13.8 t-20 -62.23 -44.58 96.23 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.322 -0.861 . . . . 0.0 109.362 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.542 ' CG2' HG21 ' A' ' 37' ' ' VAL . 29.5 mm -56.11 -45.2 80.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 109.335 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -55.13 -45.46 75.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.229 -0.92 . . . . 0.0 109.657 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 46.7 mttp -76.17 -35.73 59.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.069 -1.02 . . . . 0.0 109.61 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.52 ' HD3' ' CG2' ' A' ' 77' ' ' VAL . 18.1 ttpt -55.07 -33.89 63.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.334 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 33' ' ' ILE . 89.4 t -82.27 -24.44 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.288 -0.882 . . . . 0.0 109.601 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -67.85 -52.31 38.18 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.654 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.39 -27.12 65.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.249 -0.907 . . . . 0.0 109.933 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 47.4 p -97.58 -32.19 11.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.205 -0.934 . . . . 0.0 109.696 -179.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 79.44 24.01 61.7 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.527 ' O ' ' CG1' ' A' ' 28' ' ' VAL . 62.8 mt -94.65 87.32 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.217 -1.166 . . . . 0.0 109.444 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -87.4 -5.37 58.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.215 -0.928 . . . . 0.0 109.455 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -102.14 16.46 26.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.269 -0.895 . . . . 0.0 109.628 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.545 HD11 ' CB ' ' A' ' 70' ' ' ALA . 7.2 tp -112.17 -58.12 2.18 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.263 -0.898 . . . . 0.0 109.4 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.542 HG21 ' CG2' ' A' ' 24' ' ' ILE . 9.0 p -95.87 134.35 33.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.427 -0.796 . . . . 0.0 109.423 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.21 -123.71 5.32 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 93.4 mtt180 -95.11 143.98 26.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.308 -1.113 . . . . 0.0 109.89 -179.473 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.527 ' CG2' HG23 ' A' ' 62' ' ' VAL . 18.9 mt -107.7 140.39 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.408 -0.807 . . . . 0.0 109.158 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.56 HG22 ' CH2' ' A' ' 7' ' ' TRP . 55.0 t -128.51 156.86 41.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.024 -1.048 . . . . 0.0 109.462 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.478 HG22 ' CG2' ' A' ' 44' ' ' ILE . 6.5 mt -136.72 127.19 16.23 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.367 -0.833 . . . . 0.0 109.469 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.488 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 46.3 Cg_endo -67.4 -4.71 12.37 Favored 'Trans proline' 0 C--O 1.216 -0.583 0 C-N-CA 122.824 2.349 . . . . 0.0 111.547 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.561 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 11.8 pt -76.76 -22.63 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.248 -0.907 . . . . 0.0 109.474 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 35.2 mtp180 -64.74 163.65 13.64 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.334 -0.854 . . . . 0.0 109.45 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.42 0.97 59.31 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -111.65 60.73 0.32 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 -60.77 -27.41 67.96 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.247 -1.149 . . . . 0.0 109.575 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 20.5 mtm180 -62.86 -26.43 68.76 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.223 -0.923 . . . . 0.0 109.498 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 34.1 mtt-85 -127.83 164.43 22.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.184 -0.948 . . . . 0.0 109.515 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' LYS . . . . . 0.407 ' C ' ' OG ' ' A' ' 52' ' ' SER . 49.2 mttt -59.62 -33.97 72.18 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -0.869 . . . . 0.0 109.54 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' SER . . . . . 0.436 ' O ' ' HG3' ' A' ' 54' ' ' LYS . 0.3 OUTLIER -171.78 98.13 0.18 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.272 -0.892 . . . . 0.0 109.462 -179.895 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.498 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 94.6 mt-10 -64.48 -48.7 74.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.174 -0.954 . . . . 0.0 109.381 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 24.5 mttt 75.44 86.73 0.09 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.238 -0.914 . . . . 0.0 109.577 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.488 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 14.5 tp -64.26 -23.73 67.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.161 -0.962 . . . . 0.0 109.132 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.445 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 97.2 m-85 -149.96 99.0 3.31 Favored Pre-proline 0 N--CA 1.49 1.532 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -65.42 139.57 59.89 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.614 2.209 . . . . 0.0 111.979 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.07 -15.84 4.98 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.386 -1.085 . . . . 0.0 110.386 179.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.576 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.2 m-85 -95.73 129.87 42.81 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.759 -1.436 . . . . 0.0 110.205 -179.331 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 41.1 t -133.84 146.02 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.335 -0.853 . . . . 0.0 108.905 179.453 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.404 ' CE2' HG12 ' A' ' 9' ' ' ILE . 24.1 m-85 -110.31 122.47 47.76 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.955 -1.09 . . . . 0.0 109.521 -179.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.527 HG23 ' CG2' ' A' ' 40' ' ' ILE . 96.1 t -128.48 140.97 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.427 -0.795 . . . . 0.0 109.936 -179.632 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.58 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 67.6 tt0 -103.5 123.49 46.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.315 -0.865 . . . . 0.0 108.864 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.549 ' CG ' ' C ' ' A' ' 63' ' ' GLU . 1.1 mtp -162.66 -174.61 4.04 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.102 -0.999 . . . . 0.0 109.778 -179.545 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.504 HG13 ' O ' ' A' ' 65' ' ' ILE . 17.2 pt -97.26 122.95 49.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.236 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' MET . . . . . 0.49 ' HE3' ' CE1' ' A' ' 8' ' ' TYR . 11.1 ttm -88.16 100.31 12.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -0.885 . . . . 0.0 109.736 -179.406 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -137.92 -165.75 1.84 Allowed 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.195 -0.941 . . . . 0.0 108.821 179.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -71.41 -48.72 47.96 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.14 -0.975 . . . . 0.0 109.681 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.403 ' O ' ' C ' ' A' ' 70' ' ' ALA . 73.9 mm-40 -66.64 -58.63 4.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.188 -0.945 . . . . 0.0 109.5 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.545 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -43.85 -41.51 5.14 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.293 -0.879 . . . . 0.0 109.718 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.541 ' CD1' ' CD ' ' A' ' 89' ' ' GLN . 72.2 t80 -61.05 -57.14 13.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.163 -0.961 . . . . 0.0 109.627 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.499 ' O ' ' HB3' ' A' ' 76' ' ' SER . 38.2 t30 -52.87 -31.2 38.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.929 . . . . 0.0 110.0 -179.582 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -82.08 -44.15 16.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.96 -1.088 . . . . 0.0 109.923 -179.626 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.594 ' CG1' ' CZ ' ' A' ' 83' ' ' PHE . 47.6 t -68.49 -56.91 10.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.357 -0.84 . . . . 0.0 109.625 -179.64 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ARG . . . . . 0.449 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 15.6 tpt180 -62.5 -11.92 19.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.165 -0.959 . . . . 0.0 109.966 -179.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.499 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 89.6 p -102.28 3.53 38.23 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.081 -1.012 . . . . 0.0 110.167 -179.645 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.632 HG11 ' HB ' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -69.05 142.27 92.92 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.031 -1.043 . . . . 0.0 109.273 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.621 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 45.2 Cg_endo -67.75 134.51 32.75 Favored 'Trans proline' 0 C--O 1.213 -0.768 0 C-N-CA 122.454 2.103 . . . . 0.0 111.876 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.621 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 13.1 m-85 89.32 -6.55 0.42 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.799 -0.563 . . . . 0.0 110.255 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.632 ' HB ' HG11 ' A' ' 77' ' ' VAL . 12.4 p -88.33 126.98 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.752 -1.218 . . . . 0.0 109.643 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.4 mmm -90.78 -26.36 19.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.32 -0.863 . . . . 0.0 109.335 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.57 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 161.47 -160.34 32.14 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . 0.594 ' CZ ' ' CG1' ' A' ' 74' ' ' VAL . 10.8 m-85 -134.76 156.38 48.94 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.191 -1.182 . . . . 0.0 109.562 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.517 ' N ' HD21 ' A' ' 11' ' ' LEU . 12.5 p -91.71 125.35 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.248 -0.908 . . . . 0.0 109.385 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.535 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.6 OUTLIER -168.87 166.79 11.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.13 -0.981 . . . . 0.0 109.568 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 25.5 t -86.18 -32.97 20.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.238 -0.914 . . . . 0.0 109.427 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -117.42 -106.82 2.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.516 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -96.67 -122.09 4.16 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.541 ' CD ' ' CD1' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -34.55 156.11 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.533 -0.981 . . . . 0.0 110.044 -179.659 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.535 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.0 Cg_endo -68.75 149.21 72.91 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.839 2.359 . . . . 0.0 111.994 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.0 m -83.89 154.97 64.74 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 109.436 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.489 ' HB3' ' CE ' ' A' ' 6' ' ' LYS . 49.9 Cg_endo -70.16 142.94 47.46 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.677 2.251 . . . . 0.0 111.673 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 18.6 t -82.3 139.07 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.304 -0.873 . . . . 0.0 109.433 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' LYS . . . . . 0.467 ' O ' ' N ' ' A' ' 97' ' ' GLU . 7.3 tptt -70.74 131.78 44.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.182 -0.949 . . . . 0.0 109.289 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . 0.402 ' C ' ' O ' ' A' ' 94' ' ' LYS . 87.3 m-20 -45.22 -39.52 6.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.178 -0.952 . . . . 0.0 109.436 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.4 mtp180 -61.03 -23.45 65.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.308 -0.87 . . . . 0.0 109.475 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 94' ' ' LYS . 62.9 mt-10 -85.83 -28.38 24.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.913 . . . . 0.0 109.422 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' MET . . . . . 0.611 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 59.0 mtp -84.14 -24.8 30.07 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.365 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.575 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -37.46 -53.53 2.31 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.425 -0.797 . . . . 0.0 109.866 -179.952 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.575 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.4 Cg_endo -69.83 -27.55 25.98 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 122.525 2.15 . . . . 0.0 111.878 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.459 ' O ' ' HB2' ' A' ' 105' ' ' ALA . 37.4 mm -81.19 -42.94 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.178 -0.951 . . . . 0.0 109.304 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' LEU . . . . . 0.575 ' N ' HD11 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -65.8 -38.97 90.41 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.275 -0.891 . . . . 0.0 109.297 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.51 ' HG3' ' CE2' ' A' ' 110' ' ' TYR . 16.1 ttt-85 -65.66 -47.7 74.63 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.334 -0.854 . . . . 0.0 109.279 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 3.0 tt -72.12 -36.31 69.38 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.215 -0.928 . . . . 0.0 109.227 179.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.459 ' HB2' ' O ' ' A' ' 101' ' ' ILE . . . -75.25 -2.22 27.08 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.44 -0.788 . . . . 0.0 109.81 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.9 15.79 81.34 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.532 ' HB2' ' CA ' ' A' ' 102' ' ' LEU . 23.5 mt -81.84 -23.27 36.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.16 -1.2 . . . . 0.0 109.666 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' GLU . . . . . 0.43 ' HG2' ' HB3' ' A' ' 102' ' ' LEU . 68.2 mm-40 -133.22 138.59 46.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.158 -0.964 . . . . 0.0 109.327 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 35.4 mp0 -120.7 121.83 39.11 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.281 -0.887 . . . . 0.0 109.72 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.527 ' CD1' ' C ' ' A' ' 110' ' ' TYR . 13.6 p90 -145.16 174.33 11.16 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.253 -0.905 . . . . 0.0 109.219 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 112' ' ' GLU . 90.3 mt-10 -96.18 -102.69 0.17 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.21 -0.931 . . . . 0.0 109.85 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.478 ' HG3' ' OE1' ' A' ' 137' ' ' GLU . 0.2 OUTLIER 44.9 68.12 0.6 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.136 -0.978 . . . . 0.0 109.543 -179.913 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 176.74 -40.99 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.345 -0.847 . . . . 0.0 109.523 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 12.0 pttm -47.49 -23.55 0.65 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.214 -0.929 . . . . 0.0 109.432 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -121.68 83.25 41.97 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.951 . . . . 0.0 109.562 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -71.15 163.1 40.35 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.683 2.255 . . . . 0.0 111.696 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.426 ' C ' ' HB2' ' A' ' 171' ' ' SER . 41.6 t -138.01 120.88 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.185 -0.947 . . . . 0.0 109.622 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.469 ' C ' HG11 ' A' ' 119' ' ' VAL . 53.3 tttt -68.57 156.76 37.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.242 -0.911 . . . . 0.0 109.501 179.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.565 ' CG2' ' O ' ' A' ' 173' ' ' VAL . 27.5 m -150.8 148.38 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.21 -0.931 . . . . 0.0 109.54 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' GLU . . . . . 0.712 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 76.7 mt-10 -158.38 167.0 30.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.205 179.793 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' LEU . . . . . 0.712 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 19.3 tp 144.26 99.37 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.716 -0.615 . . . . 0.0 109.459 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.47 ' O ' ' OD2' ' A' ' 127' ' ' ASP . . . 37.72 36.12 0.27 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' PHE . . . . . 0.561 ' CD2' ' O ' ' A' ' 123' ' ' PHE . 42.5 p90 -76.75 116.65 17.61 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.973 -1.31 . . . . 0.0 109.02 179.607 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' LYS . . . . . 0.528 ' HA ' ' CD1' ' A' ' 146' ' ' ILE . 14.7 mttp -141.14 175.12 9.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.181 -0.949 . . . . 0.0 109.918 -179.58 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . 0.44 ' HA ' HG21 ' A' ' 143' ' ' ILE . 10.8 p -62.51 139.62 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.529 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 88.13 -34.8 3.68 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . 0.47 ' OD2' ' O ' ' A' ' 122' ' ' GLY . 9.5 m-20 -45.92 158.97 0.08 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.336 -1.096 . . . . 0.0 109.209 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' MET . . . . . 0.485 ' HG2' HD13 ' A' ' 176' ' ' ILE . 3.8 ttm -99.77 127.49 45.92 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.075 -1.016 . . . . 0.0 108.799 179.553 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.557 ' CG1' HG12 ' A' ' 143' ' ' ILE . 15.4 m -128.51 144.87 36.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.32 -0.862 . . . . 0.0 109.735 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 32.5 ttpt -98.78 141.06 32.05 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.464 ' CD1' ' HB3' ' A' ' 139' ' ' PHE . 78.5 mt -82.84 151.09 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.209 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' ILE . . . . . 0.482 HG12 ' HA ' ' A' ' 173' ' ' VAL . 1.1 pt -149.66 3.64 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 120.923 -1.111 . . . . 0.0 109.957 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 69.9 m -148.26 143.52 27.02 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.846 -1.159 . . . . 0.0 109.983 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.67 -163.9 18.7 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.491 ' HB3' ' HD3' ' A' ' 103' ' ' ARG . 46.4 Cg_endo -67.38 -23.18 44.58 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 123.167 2.578 . . . . 0.0 112.952 -179.28 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.528 ' CE1' ' CB ' ' A' ' 100' ' ' PRO . 97.1 m-85 -109.14 19.38 19.55 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.787 -1.196 . . . . 0.0 109.713 -179.765 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . 0.526 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 2.3 tt0 -45.51 139.09 3.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.15 -0.969 . . . . 0.0 109.506 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.526 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 17.7 m-20 74.41 28.23 1.34 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.459 -0.776 . . . . 0.0 110.437 179.41 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' PHE . . . . . 0.575 ' CD1' HG11 ' A' ' 157' ' ' VAL . 1.8 t80 -117.08 140.01 50.02 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.96 -1.087 . . . . 0.0 109.45 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.74 132.94 34.04 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.116 -0.99 . . . . 0.0 109.664 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.464 ' HA3' HG22 ' A' ' 155' ' ' VAL . . . -145.57 168.91 27.23 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.775 -1.203 . . . . 0.0 110.304 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.56 ' N ' ' CG2' ' A' ' 155' ' ' VAL . 41.0 t -117.9 137.07 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.634 -0.921 . . . . 0.0 109.348 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' ILE . . . . . 0.557 HG12 ' CG1' ' A' ' 129' ' ' VAL . 25.0 mm -69.85 119.23 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.873 . . . . 0.0 109.532 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -97.76 -31.69 12.12 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.026 -1.046 . . . . 0.0 109.04 179.546 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -151.11 146.17 25.97 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.266 -0.896 . . . . 0.0 109.283 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.599 ' CG2' ' CD2' ' A' ' 153' ' ' LEU . 4.0 mt -121.58 126.21 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.141 -0.974 . . . . 0.0 109.545 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.92 100.08 38.13 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.449 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.4 Cg_endo -71.14 173.28 12.42 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.706 2.271 . . . . 0.0 111.821 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.2 tt0 79.52 -21.58 0.32 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.325 -0.86 . . . . 0.0 110.184 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' ARG . . . . . 0.459 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 83.9 mtt-85 -127.5 -12.77 5.53 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.045 -1.035 . . . . 0.0 109.6 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' GLN . . . . . 0.489 ' O ' ' CG2' ' A' ' 170' ' ' VAL . 49.8 mt-30 69.52 47.04 0.69 Allowed 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.348 -0.845 . . . . 0.0 109.704 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -118.21 143.85 46.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.08 -1.012 . . . . 0.0 108.659 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.599 ' CD2' ' CG2' ' A' ' 146' ' ' ILE . 35.3 mt -133.56 122.82 24.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.996 -1.065 . . . . 0.0 110.616 -179.38 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 9.5 mttt -86.55 130.93 34.31 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 178.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.578 HG21 ' N ' ' A' ' 156' ' ' ASN . 7.3 p -133.65 149.77 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.087 -1.008 . . . . 0.0 109.8 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.578 ' N ' HG21 ' A' ' 155' ' ' VAL . 43.3 t-20 -98.75 123.61 43.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.29 -0.881 . . . . 0.0 109.329 179.857 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' VAL . . . . . 0.575 HG11 ' CD1' ' A' ' 139' ' ' PHE . 63.9 t -105.39 146.86 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.198 -0.939 . . . . 0.0 109.663 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' THR . . . . . 0.428 ' N ' HG12 ' A' ' 157' ' ' VAL . 25.9 m -94.9 104.05 15.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.245 -0.91 . . . . 0.0 109.633 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' ILE . . . . . 0.563 HD11 ' CE2' ' A' ' 160' ' ' PHE . 7.0 pt -139.65 149.12 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -0.896 . . . . 0.0 109.38 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' PHE . . . . . 0.563 ' CE2' HD11 ' A' ' 159' ' ' ILE . 11.1 m-30 61.35 36.99 17.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.261 -0.899 . . . . 0.0 109.141 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.52 13.7 17.99 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' ARG . . . . . 0.434 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 3.3 mtp-105 -134.11 159.01 42.14 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.059 -1.259 . . . . 0.0 109.601 -179.844 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' GLU . . . . . 0.454 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 81.7 mt-10 -99.73 140.12 34.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.253 -0.905 . . . . 0.0 109.399 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' THR . . . . . 0.553 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 22.6 m -146.55 129.93 8.23 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.785 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' PRO . . . . . 0.546 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.7 Cg_endo -71.14 139.29 35.22 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.736 2.29 . . . . 0.0 111.437 179.676 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' VAL . . . . . 0.478 HG22 ' HG ' ' A' ' 168' ' ' LEU . 2.9 p -124.93 143.86 36.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.088 -1.007 . . . . 0.0 109.627 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.472 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 14.6 p -96.13 120.75 45.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.408 -0.807 . . . . 0.0 109.533 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' LEU . . . . . 0.499 HD13 ' N ' ' A' ' 168' ' ' LEU . 0.0 OUTLIER -141.4 168.71 19.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.113 -0.992 . . . . 0.0 110.54 -179.52 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' HIS . . . . . 0.465 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 72.1 m80 -83.19 143.26 30.59 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.648 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . 0.571 ' CG2' ' HG ' ' A' ' 153' ' ' LEU . 71.9 t -52.82 -38.39 27.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.426 ' HB2' ' C ' ' A' ' 117' ' ' VAL . 84.6 p -75.23 -6.97 52.51 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.492 -0.755 . . . . 0.0 110.06 -179.466 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' GLU . . . . . 0.465 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 80.4 mt-10 -91.12 -5.46 55.06 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.828 -1.17 . . . . 0.0 109.822 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' VAL . . . . . 0.565 ' O ' ' CG2' ' A' ' 119' ' ' VAL . 2.8 m -139.48 175.36 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.152 -0.967 . . . . 0.0 109.439 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' GLU . . . . . 0.498 ' HA ' HG21 ' A' ' 119' ' ' VAL . 57.5 tt0 -138.17 163.03 32.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.196 -0.94 . . . . 0.0 109.045 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' LYS . . . . . 0.523 ' O ' ' N ' ' A' ' 177' ' ' GLU . 25.2 mmtm -91.04 12.37 20.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.088 -1.007 . . . . 0.0 109.246 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' ILE . . . . . 0.485 HD13 ' HG2' ' A' ' 128' ' ' MET . 75.8 mt 58.28 -81.06 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.411 -0.806 . . . . 0.0 109.561 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' GLU . . . . . 0.523 ' N ' ' O ' ' A' ' 175' ' ' LYS . 94.6 mt-10 . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 117.954 -1.022 . . . . 0.0 109.431 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.664 ' HG2' HG22 ' A' ' 65' ' ' ILE . 56.5 mttt . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.61 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.2 mttp -125.82 174.51 8.3 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.222 -0.924 . . . . 0.0 109.126 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.683 ' CH2' HG23 ' A' ' 41' ' ' VAL . 60.0 m95 -109.9 126.66 54.11 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.132 -0.98 . . . . 0.0 109.346 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -118.74 167.39 11.72 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.211 -0.931 . . . . 0.0 109.415 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.53 HD11 ' CE1' ' A' ' 160' ' ' PHE . 95.1 mt -103.25 118.77 50.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.195 -0.94 . . . . 0.0 109.314 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.464 HG23 HG12 ' A' ' 62' ' ' VAL . 85.3 t -90.46 137.32 21.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.466 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.486 ' CD2' ' CG2' ' A' ' 84' ' ' VAL . 0.1 OUTLIER -89.62 141.75 28.31 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.276 -0.89 . . . . 0.0 109.245 179.875 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.527 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.2 t -157.15 -172.48 4.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.23 -0.918 . . . . 0.0 109.358 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.496 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 90.9 mtp -105.56 123.62 48.2 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.2 -0.937 . . . . 0.0 109.516 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.422 ' C ' ' O ' ' A' ' 13' ' ' MET . 9.2 t -43.07 127.07 4.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.299 -0.875 . . . . 0.0 109.397 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.74 -19.85 40.5 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.496 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.2 m-85 -108.47 3.54 23.28 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.239 -1.153 . . . . 0.0 109.64 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.527 ' HG2' HG21 ' A' ' 12' ' ' THR . 98.4 mt-10 -57.92 -59.33 5.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -47.71 -38.11 14.53 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.218 -0.926 . . . . 0.0 109.403 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 24.7 mttt -68.8 -43.66 75.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.282 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 16' ' ' TYR . 89.6 t -58.96 -46.53 91.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 109.566 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.819 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.4 tttm -56.94 -49.8 74.55 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.219 -0.925 . . . . 0.0 109.548 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -64.83 -43.19 93.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.196 -0.94 . . . . 0.0 109.407 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.486 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 14.8 m120 -54.92 -39.77 69.18 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.222 -0.924 . . . . 0.0 109.391 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.813 HG21 HD11 ' A' ' 40' ' ' ILE . 95.1 mt -65.62 -44.04 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.3 -0.875 . . . . 0.0 109.624 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -55.84 -48.22 75.86 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.07 -1.019 . . . . 0.0 109.947 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 42.9 mttm -78.41 -35.34 47.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.093 -1.004 . . . . 0.0 109.612 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.579 ' HG3' ' CE1' ' A' ' 73' ' ' PHE . 10.7 tptt -53.25 -33.0 51.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.247 -0.908 . . . . 0.0 109.13 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.756 HG13 ' C ' ' A' ' 33' ' ' ILE . 22.3 t -89.52 -19.89 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.342 -0.849 . . . . 0.0 109.287 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -72.64 -57.64 3.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.564 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.69 -29.9 66.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.895 . . . . 0.0 109.437 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.419 ' HB ' HG13 ' A' ' 33' ' ' ILE . 80.7 p -96.6 -3.02 43.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.237 -0.915 . . . . 0.0 109.477 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 50.02 30.17 15.82 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.045 HG21 HD12 ' A' ' 36' ' ' LEU . 21.6 mt -98.3 72.04 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.248 -1.148 . . . . 0.0 109.519 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 mttp -90.49 20.36 4.62 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.266 -0.896 . . . . 0.0 109.505 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.755 ' O ' HD13 ' A' ' 65' ' ' ILE . 81.4 m-20 -111.27 -23.04 11.06 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.189 -0.944 . . . . 0.0 109.525 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.045 HD12 HG21 ' A' ' 33' ' ' ILE . 18.9 mt -88.36 -31.23 19.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.29 -0.882 . . . . 0.0 109.76 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.414 ' HB ' HG21 ' A' ' 28' ' ' VAL . 93.4 t -108.19 142.87 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.179 -0.951 . . . . 0.0 109.376 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.86 -121.88 3.17 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -92.91 140.92 28.99 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.28 -1.13 . . . . 0.0 109.838 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.881 HG12 HG23 ' A' ' 62' ' ' VAL . 85.2 mt -108.91 134.64 50.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.336 -0.853 . . . . 0.0 109.084 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 1.059 ' CG2' HD11 ' A' ' 107' ' ' LEU . 28.7 t -121.68 159.34 24.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.074 -1.016 . . . . 0.0 109.412 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.953 HG22 HG23 ' A' ' 44' ' ' ILE . 2.9 mt -140.44 127.62 12.28 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.292 -0.88 . . . . 0.0 109.479 -179.852 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.635 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 45.2 Cg_endo -66.72 -5.93 14.32 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.799 2.333 . . . . 0.0 111.391 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.953 HG23 HG22 ' A' ' 42' ' ' ILE . 6.1 pt . . . . . 0 N--CA 1.49 1.557 0 O-C-N 121.398 -0.814 . . . . 0.0 109.374 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.715 ' HA ' HG22 ' A' ' 44' ' ' ILE . 5.3 mttp . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 1.025 HD12 ' CE2' ' A' ' 56' ' ' PHE . 0.6 OUTLIER -56.88 -45.82 82.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -0.962 . . . . 0.0 109.235 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 1.025 ' CE2' HD12 ' A' ' 55' ' ' LEU . 85.2 m-85 -125.25 111.94 26.29 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.937 . . . . 0.0 109.08 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.6 Cg_endo -66.28 133.77 33.92 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.573 2.182 . . . . 0.0 111.985 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.419 ' HA2' HG23 ' A' ' 12' ' ' THR . . . 74.46 -11.97 6.31 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.2 m-30 -99.82 131.29 45.89 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.649 -1.501 . . . . 0.0 110.258 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 42.5 t -134.25 148.77 29.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.671 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 17.0 m-85 -108.38 124.44 50.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.887 -1.133 . . . . 0.0 109.733 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.881 HG23 HG12 ' A' ' 40' ' ' ILE . 14.3 p -134.13 145.54 32.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.353 -0.842 . . . . 0.0 109.804 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.61 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 18.4 tt0 -108.51 127.3 53.81 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.632 ' CE ' HG11 ' A' ' 74' ' ' VAL . 58.7 mtm -151.93 163.68 38.73 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 118.954 -1.098 . . . . 0.0 111.022 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.755 HD13 ' O ' ' A' ' 35' ' ' ASN . 3.3 pt -85.87 126.9 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.485 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 47.7 ttm -75.34 141.48 43.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.83 -178.637 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.485 ' HB2' ' O ' ' A' ' 66' ' ' MET . 47.0 t30 176.4 175.36 0.32 Allowed 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 -179.708 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -72.12 -40.85 67.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.168 -0.957 . . . . 0.0 109.593 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -72.46 -32.06 65.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.234 -0.916 . . . . 0.0 109.75 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.912 ' HB2' HD22 ' A' ' 36' ' ' LEU . . . -71.71 -47.3 54.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.193 -0.942 . . . . 0.0 109.818 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 67.9 t80 -60.36 -49.33 78.01 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.154 -0.966 . . . . 0.0 109.682 -179.739 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -63.14 -28.89 70.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.088 -1.007 . . . . 0.0 110.314 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CE1' ' HG3' ' A' ' 27' ' ' LYS . 46.3 t80 -80.72 -41.42 23.62 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.007 -1.058 . . . . 0.0 109.819 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.716 HG22 ' O ' ' A' ' 70' ' ' ALA . 20.1 m -70.68 -53.24 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.242 -0.911 . . . . 0.0 109.405 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.61 ' N ' HG23 ' A' ' 74' ' ' VAL . 33.0 tpt85 -52.14 -32.46 35.71 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.208 -0.932 . . . . 0.0 109.577 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 51.7 p -79.64 7.05 9.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.366 -0.834 . . . . 0.0 109.917 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.66 HG23 ' O ' ' A' ' 74' ' ' VAL . 47.0 t -64.25 133.82 95.76 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.103 -0.998 . . . . 0.0 109.484 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.556 ' HB2' ' CD2' ' A' ' 79' ' ' TYR . 46.9 Cg_endo -68.2 136.9 38.88 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.68 2.253 . . . . 0.0 111.845 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.556 ' CD2' ' HB2' ' A' ' 78' ' ' PRO . 47.2 m-85 76.05 -1.94 2.85 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.418 -0.801 . . . . 0.0 109.623 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.603 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 2.8 t -87.86 127.76 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.129 -0.982 . . . . 0.0 109.273 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.1 mmm -89.02 -5.8 57.66 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.643 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 135.09 -152.8 20.9 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -143.14 141.7 31.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -1.213 . . . . 0.0 109.48 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.486 ' CG2' ' CD2' ' A' ' 11' ' ' LEU . 38.8 t -63.55 128.5 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.515 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 6.9 p -162.84 161.77 26.14 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.257 -0.902 . . . . 0.0 109.507 -179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 m -88.74 -35.61 16.61 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -123.58 -87.71 0.81 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.524 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -105.32 -128.38 6.17 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.524 ' O ' ' O ' ' A' ' 88' ' ' GLY . 6.8 pm0 -34.26 155.98 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.586 -0.949 . . . . 0.0 110.115 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.515 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.4 Cg_endo -69.62 160.12 50.92 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.578 2.185 . . . . 0.0 112.081 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 20.6 m -98.84 154.0 37.59 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.349 -0.844 . . . . 0.0 109.455 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.457 ' CB ' ' HD3' ' A' ' 6' ' ' LYS . 49.6 Cg_endo -70.35 147.64 59.53 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.693 2.262 . . . . 0.0 111.809 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 7' ' ' TRP . 21.3 t -85.4 142.44 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.219 -0.926 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' LYS . . . . . 0.467 ' HB3' ' HG3' ' A' ' 97' ' ' GLU . 81.1 tttt -67.66 126.24 28.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -0.9 . . . . 0.0 109.453 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 94' ' ' LYS . 47.3 t0 -43.67 -45.35 6.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.408 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.432 ' HD2' ' NZ ' ' A' ' 94' ' ' LYS . 57.4 mtt180 -55.42 -31.28 61.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.237 -0.914 . . . . 0.0 109.51 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.467 ' HG3' ' HB3' ' A' ' 94' ' ' LYS . 57.3 mt-10 -79.22 -24.45 43.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.262 -0.899 . . . . 0.0 109.662 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.628 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 75.7 mtp -84.53 -23.71 29.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.157 -0.964 . . . . 0.0 109.352 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.609 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 57.3 mtt180 -37.53 -52.55 2.52 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.351 -0.843 . . . . 0.0 109.919 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.609 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -69.39 -28.25 27.27 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.546 2.164 . . . . 0.0 111.989 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.54 HG21 ' CD2' ' A' ' 61' ' ' PHE . 24.4 mm -81.95 -41.18 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 109.361 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 1.022 HD12 HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -68.95 -41.44 78.0 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.198 -0.938 . . . . 0.0 109.136 179.816 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.436 ' HG2' ' HA ' ' A' ' 135' ' ' PRO . 21.4 tpt85 -63.25 -49.49 73.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.861 . . . . 0.0 108.989 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -72.66 -36.29 67.92 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.369 -0.832 . . . . 0.0 109.208 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.524 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.85 -0.47 9.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.436 -0.79 . . . . 0.0 109.94 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.34 7.79 85.21 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 1.059 HD11 ' CG2' ' A' ' 41' ' ' VAL . 53.5 mt -77.28 -19.97 55.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.28 -1.13 . . . . 0.0 109.446 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 36.1 tp10 . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.217 -0.927 . . . . 0.0 109.557 -179.94 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.583 ' HB3' ' CD ' ' A' ' 175' ' ' LYS . 45.6 p90 . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.461 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 37.6 mttt -150.64 156.98 42.43 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.072 -1.018 . . . . 0.0 109.972 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.467 HG23 ' O ' ' A' ' 144' ' ' LYS . 14.1 p -62.93 143.99 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.389 -0.819 . . . . 0.0 109.556 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.49 -32.21 3.41 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.437 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 7.5 m-20 -48.67 163.82 0.07 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.359 -1.083 . . . . 0.0 109.144 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.0 ttm -95.57 126.4 40.83 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.182 -0.949 . . . . 0.0 109.066 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.615 HG11 ' CD1' ' A' ' 143' ' ' ILE . 5.1 p -124.21 141.93 42.71 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.192 -0.943 . . . . 0.0 109.215 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.408 ' N ' ' O ' ' A' ' 174' ' ' GLU . 12.6 ttpp -107.57 143.34 36.13 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.113 -0.992 . . . . 0.0 109.049 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 1.002 HD12 ' HB3' ' A' ' 139' ' ' PHE . 96.5 mt -83.96 152.46 3.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.127 -0.983 . . . . 0.0 108.798 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.473 ' C ' ' HG2' ' A' ' 137' ' ' GLU . 27.4 pt -150.8 2.26 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.056 -1.028 . . . . 0.0 109.606 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.515 ' HA ' ' HG2' ' A' ' 137' ' ' GLU . 2.5 m -145.42 141.35 28.33 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.146 -0.972 . . . . 0.0 109.665 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.443 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 107.5 -170.75 15.77 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.436 ' HA ' ' HG2' ' A' ' 103' ' ' ARG . 49.7 Cg_endo -69.03 -18.66 40.31 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 123.338 2.692 . . . . 0.0 112.57 -179.606 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.608 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 97.8 m-85 -107.53 15.31 24.93 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.969 -1.082 . . . . 0.0 109.561 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.515 ' HG2' ' HA ' ' A' ' 133' ' ' SER . 35.1 mt-10 -38.45 142.24 0.2 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.417 -0.802 . . . . 0.0 110.148 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 138' ' ' ASP . 0.3 OUTLIER 76.53 20.34 1.47 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.333 -0.854 . . . . 0.0 110.743 178.991 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 1.002 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.0 OUTLIER -108.37 131.17 55.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.831 -1.168 . . . . 0.0 109.623 179.901 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -84.97 134.3 34.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.155 -0.966 . . . . 0.0 109.508 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.59 167.89 26.48 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.8 -1.19 . . . . 0.0 110.269 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.524 ' C ' HG13 ' A' ' 155' ' ' VAL . 40.9 t -108.89 136.3 45.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.452 -1.028 . . . . 0.0 109.226 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.615 ' CD1' HG11 ' A' ' 129' ' ' VAL . 18.4 mm -67.38 114.85 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.259 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.467 ' O ' HG23 ' A' ' 125' ' ' VAL . 64.4 tttm -97.25 -34.37 11.12 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.088 -1.007 . . . . 0.0 109.482 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -151.75 146.75 25.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.14 -0.975 . . . . 0.0 109.613 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.837 HG23 ' CD2' ' A' ' 153' ' ' LEU . 1.5 mt -120.06 123.7 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.333 -0.854 . . . . 0.0 109.304 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -107.3 98.14 21.78 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.655 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.553 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.8 Cg_endo -71.66 173.86 11.93 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.721 2.281 . . . . 0.0 111.779 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.553 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.0 tt0 80.53 -21.07 0.34 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.345 -0.847 . . . . 0.0 109.879 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.445 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 47.5 mtt85 -128.75 -11.88 4.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.111 -0.993 . . . . 0.0 109.45 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.786 ' O ' HG23 ' A' ' 170' ' ' VAL . 31.9 mt-30 69.26 48.25 0.67 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.277 -0.89 . . . . 0.0 109.774 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -122.34 146.08 47.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.132 -0.98 . . . . 0.0 108.87 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.837 ' CD2' HG23 ' A' ' 146' ' ' ILE . 0.4 OUTLIER -135.62 122.47 21.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.101 -1.0 . . . . 0.0 110.565 -179.398 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 5.8 mtmm -81.91 130.97 35.24 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.605 HG11 ' CG1' ' A' ' 129' ' ' VAL . 4.2 t -128.46 147.93 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.961 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.548 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 4.4 t30 -97.14 113.02 24.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.392 -0.817 . . . . 0.0 109.26 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.757 HG13 ' CE1' ' A' ' 139' ' ' PHE . 67.7 t -94.39 141.62 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.241 -0.912 . . . . 0.0 109.642 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 60.1 m -94.2 95.71 9.13 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.383 -0.823 . . . . 0.0 109.63 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.561 HG22 ' CD2' ' A' ' 160' ' ' PHE . 5.4 mt -121.72 141.37 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.253 -0.905 . . . . 0.0 109.581 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.671 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 96.6 m-85 61.26 41.26 13.5 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.847 . . . . 0.0 109.523 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.33 16.81 22.31 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 18.5 mtp85 -129.71 151.71 50.0 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.154 -1.203 . . . . 0.0 109.575 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' GLU . . . . . 0.486 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 73.4 mt-10 -95.97 136.73 36.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.249 -0.907 . . . . 0.0 109.506 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 16.3 m -145.44 128.33 8.22 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.618 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.548 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.2 Cg_endo -70.24 136.67 32.28 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.757 2.304 . . . . 0.0 111.618 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.713 HG13 HD11 ' A' ' 168' ' ' LEU . 3.7 p -123.23 142.86 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.14 -0.975 . . . . 0.0 109.559 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.457 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 6.3 m -92.83 119.19 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.413 -0.805 . . . . 0.0 109.485 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.713 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -142.12 167.9 21.02 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.238 -0.914 . . . . 0.0 110.384 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.506 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 47.8 m170 -82.27 141.01 33.3 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 151' ' ' GLN . 59.5 t -53.94 -36.78 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.185 -0.947 . . . . 0.0 108.893 179.697 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 7.1 p -75.16 -6.77 51.36 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.561 -0.712 . . . . 0.0 109.812 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.506 ' CG ' ' HB2' ' A' ' 169' ' ' HIS . 92.7 mt-10 -96.17 -3.39 44.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.083 -1.011 . . . . 0.0 109.866 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.7 m -133.45 170.68 19.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.106 -0.997 . . . . 0.0 109.993 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.568 ' O ' ' CG2' ' A' ' 129' ' ' VAL . 25.6 tp10 -127.56 144.01 51.11 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.583 ' CD ' ' HB3' ' A' ' 123' ' ' PHE . 9.7 mttp . . . . . 0 N--CA 1.489 1.51 0 O-C-N 121.069 -1.019 . . . . 0.0 109.567 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.7 mttt . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.592 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 41.7 mmtt -130.65 171.11 13.43 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.356 -0.84 . . . . 0.0 109.126 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.767 ' CH2' HG23 ' A' ' 41' ' ' VAL . 60.1 m95 -104.55 126.5 51.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.202 -0.936 . . . . 0.0 109.329 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -116.94 168.03 10.6 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.154 -0.966 . . . . 0.0 109.145 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.535 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 65.1 mt -104.37 115.94 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.156 -0.965 . . . . 0.0 109.379 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.646 HG22 ' CD2' ' A' ' 83' ' ' PHE . 65.5 t -92.09 138.21 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.216 -0.927 . . . . 0.0 109.248 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.535 ' N ' ' CD2' ' A' ' 11' ' ' LEU . 3.5 mm? -88.12 141.9 28.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.312 -0.867 . . . . 0.0 109.338 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 1.3 p -153.44 174.85 13.84 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.235 -0.916 . . . . 0.0 109.375 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.436 ' O ' ' C ' ' A' ' 14' ' ' SER . 98.1 mtp -95.63 121.02 36.9 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.165 -0.959 . . . . 0.0 109.439 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 13' ' ' MET . 22.4 t -42.03 126.76 3.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.291 -0.88 . . . . 0.0 109.51 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.23 -19.98 33.69 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.527 ' O ' HG23 ' A' ' 20' ' ' VAL . 89.0 m-85 -108.77 -18.79 13.62 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.233 -1.157 . . . . 0.0 109.629 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.736 ' OE1' HD11 ' A' ' 44' ' ' ILE . 43.4 mt-10 -41.48 -67.09 0.28 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.311 -0.868 . . . . 0.0 109.596 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -46.76 -38.59 10.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.193 -0.942 . . . . 0.0 109.415 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.444 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 24.0 tttp -69.22 -34.87 75.52 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.242 -0.911 . . . . 0.0 109.179 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.653 HG22 ' HB2' ' A' ' 79' ' ' TYR . 43.8 t -68.78 -41.35 82.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.333 -0.854 . . . . 0.0 109.279 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.55 ' HB2' HD11 ' A' ' 42' ' ' ILE . 16.7 tttm -57.06 -50.82 71.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.277 -0.89 . . . . 0.0 109.487 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -62.31 -33.82 75.42 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.177 -0.952 . . . . 0.0 109.151 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.506 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 23.4 m120 -65.62 -33.65 76.4 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.302 -0.874 . . . . 0.0 109.284 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.82 HD12 HD13 ' A' ' 40' ' ' ILE . 79.2 mt -67.66 -45.37 84.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.271 -0.893 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -55.6 -46.19 77.35 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.895 . . . . 0.0 109.576 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.9 mttt -75.41 -36.04 60.9 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.605 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.58 ' HE3' ' CE1' ' A' ' 73' ' ' PHE . 28.6 tttp -54.72 -32.42 59.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.21 -0.931 . . . . 0.0 109.27 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 33' ' ' ILE . 99.2 t -88.5 -22.89 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.878 . . . . 0.0 109.504 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -72.24 -57.0 4.59 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.237 -0.914 . . . . 0.0 109.609 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.22 -24.17 66.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.536 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 48.1 p -98.43 -17.37 18.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.418 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 62.74 26.14 68.28 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.037 HG21 HD12 ' A' ' 36' ' ' LEU . 76.7 mt -97.38 77.48 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.176 -1.191 . . . . 0.0 109.438 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.411 ' O ' ' HG2' ' A' ' 34' ' ' LYS . 17.8 tttp -89.72 22.85 2.89 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.29 -0.881 . . . . 0.0 109.129 179.822 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 1.071 ' O ' HD13 ' A' ' 65' ' ' ILE . 92.0 m-20 -118.27 -9.46 10.42 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.37 -0.831 . . . . 0.0 109.572 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.037 HD12 HG21 ' A' ' 33' ' ' ILE . 96.9 mt -97.47 -51.74 4.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.905 . . . . 0.0 109.387 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.569 HG11 ' CG2' ' A' ' 24' ' ' ILE . 59.3 t -94.73 136.12 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.258 -0.902 . . . . 0.0 109.245 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.89 -119.99 3.84 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 86.4 mtt180 -91.76 139.97 30.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.295 -1.12 . . . . 0.0 109.825 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 1.164 HG23 HG22 ' A' ' 62' ' ' VAL . 29.4 mt -107.91 133.39 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.397 -0.815 . . . . 0.0 109.115 179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.767 HG23 ' CH2' ' A' ' 7' ' ' TRP . 25.8 t -121.99 132.56 70.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.175 -0.953 . . . . 0.0 109.25 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.581 HG22 HG13 ' A' ' 44' ' ' ILE . 4.5 mt -124.67 125.81 25.46 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.267 -0.896 . . . . 0.0 109.577 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.614 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 49.1 Cg_endo -68.4 -2.75 9.66 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.858 2.372 . . . . 0.0 111.422 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.878 HG23 ' HG2' ' A' ' 54' ' ' LYS . 87.7 mt . . . . . 0 N--CA 1.49 1.53 0 O-C-N 121.35 -0.843 . . . . 0.0 109.602 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.878 ' HG2' HG23 ' A' ' 44' ' ' ILE . 1.3 mttp . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.614 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 35.0 mt -59.7 -41.83 91.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.112 -0.993 . . . . 0.0 108.654 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.496 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 88.1 m-85 -129.19 105.1 17.93 Favored Pre-proline 0 N--CA 1.489 1.48 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.7 136.13 48.22 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.484 2.122 . . . . 0.0 112.093 -179.046 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.34 -18.47 4.36 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.506 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.6 m-30 -95.77 129.24 43.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.666 -1.49 . . . . 0.0 110.51 -178.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 36.1 t -133.23 147.07 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.683 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 9.6 m-85 -108.79 124.67 50.95 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.856 -1.153 . . . . 0.0 109.861 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 1.164 HG22 HG23 ' A' ' 40' ' ' ILE . 61.9 t -135.62 146.76 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.904 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.592 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 26.4 tt0 -110.88 127.41 55.43 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.4 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.739 ' HE1' HG11 ' A' ' 74' ' ' VAL . 40.4 mtm -152.16 163.65 38.95 Favored 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 118.757 -1.177 . . . . 0.0 111.304 -178.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 1.071 HD13 ' O ' ' A' ' 35' ' ' ASN . 2.3 pt -82.64 124.81 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.488 ' CE ' ' HG2' ' A' ' 89' ' ' GLN . 94.9 mmm -76.23 142.72 41.35 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.146 -0.971 . . . . 0.0 109.885 -178.72 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 m-20 177.31 170.18 0.58 Allowed 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -68.79 -41.6 78.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.128 -0.982 . . . . 0.0 109.454 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -78.08 -29.61 49.22 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.173 -0.954 . . . . 0.0 109.85 -179.703 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.028 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -72.86 -48.92 33.45 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.12 -0.987 . . . . 0.0 109.479 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.469 ' CE1' ' NE2' ' A' ' 89' ' ' GLN . 75.1 t80 -61.22 -48.1 83.06 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.258 -0.901 . . . . 0.0 109.564 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -61.46 -29.32 69.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.209 -0.932 . . . . 0.0 109.777 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.58 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 48.7 t80 -80.78 -41.74 22.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.121 -0.987 . . . . 0.0 109.472 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 1.028 HG23 ' O ' ' A' ' 70' ' ' ALA . 4.2 t -68.76 -56.23 12.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.33 -0.856 . . . . 0.0 109.511 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.1 tpt85 -54.59 -17.34 3.18 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.358 -0.838 . . . . 0.0 109.735 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 26.2 p -91.3 6.91 43.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.26 -0.9 . . . . 0.0 109.872 -179.658 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.598 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 25.1 t -64.43 137.85 97.26 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.052 -1.03 . . . . 0.0 109.542 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.585 ' HB2' ' CE2' ' A' ' 79' ' ' TYR . 47.7 Cg_endo -68.47 137.63 40.01 Favored 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 122.718 2.278 . . . . 0.0 111.778 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.653 ' HB2' HG22 ' A' ' 20' ' ' VAL . 17.5 m-85 76.17 -4.64 2.32 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.388 -0.82 . . . . 0.0 109.712 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.598 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 5.4 t -87.02 129.66 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.055 -1.028 . . . . 0.0 109.101 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 98.9 mmm -88.14 -7.17 57.31 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.517 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.07 -145.23 15.84 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.646 ' CD2' HG22 ' A' ' 10' ' ' VAL . 1.4 m-85 -140.49 148.6 41.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -1.183 . . . . 0.0 109.708 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.535 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 3.4 p -75.78 134.61 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.246 -0.909 . . . . 0.0 109.344 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.465 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.3 p -162.94 163.74 26.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.204 -0.935 . . . . 0.0 109.664 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.0 m -91.43 -33.34 15.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.37 -0.831 . . . . 0.0 109.421 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -124.98 -84.32 0.58 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.554 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -110.31 -135.24 6.97 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.554 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.9 OUTLIER -29.49 150.45 0.03 OUTLIER Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.584 -0.951 . . . . 0.0 110.302 -179.484 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.577 ' HG3' ' CB ' ' A' ' 83' ' ' PHE . 50.1 Cg_endo -68.22 142.05 54.14 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.899 2.399 . . . . 0.0 112.153 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' VAL . . . . . 0.754 HG23 ' HD2' ' A' ' 92' ' ' PRO . 3.7 p -75.69 144.67 77.28 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 109.26 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.754 ' HD2' HG23 ' A' ' 91' ' ' VAL . 46.0 Cg_endo -68.34 150.28 76.0 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.61 2.207 . . . . 0.0 111.806 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.4 t -76.53 137.95 21.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.291 -0.881 . . . . 0.0 109.533 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.1 tttp -74.19 132.99 42.71 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.313 -0.867 . . . . 0.0 109.415 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.405 ' C ' ' O ' ' A' ' 94' ' ' LYS . 79.3 m-20 -44.11 -41.7 5.79 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.448 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.424 ' HB2' ' HD3' ' A' ' 94' ' ' LYS . 53.1 mtp180 -60.85 -27.03 67.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.278 -0.889 . . . . 0.0 109.497 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.516 ' N ' ' O ' ' A' ' 94' ' ' LYS . 45.1 mt-10 -86.6 -26.06 24.62 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.241 -0.912 . . . . 0.0 109.398 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.505 ' O ' HD12 ' A' ' 102' ' ' LEU . 27.9 mmm -85.59 -22.97 27.79 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.219 -0.926 . . . . 0.0 109.5 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.616 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.1 OUTLIER -42.61 -49.09 13.23 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.29 -0.881 . . . . 0.0 109.887 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.616 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 51.9 Cg_endo -74.2 -27.32 11.75 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.435 2.09 . . . . 0.0 111.672 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.578 HG21 ' CD2' ' A' ' 61' ' ' PHE . 33.8 mm -80.87 -38.75 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.333 -0.855 . . . . 0.0 109.344 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -69.27 -40.07 78.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.313 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.582 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 19.5 ttm180 -64.36 -50.42 67.78 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.904 . . . . 0.0 109.308 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.549 HD23 ' C ' ' A' ' 104' ' ' LEU . 6.8 tt -72.29 -36.19 68.88 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.296 -0.877 . . . . 0.0 109.216 179.713 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -69.76 -2.93 13.36 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.308 -0.87 . . . . 0.0 109.908 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.86 8.98 86.74 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.445 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 1.0 OUTLIER -72.53 -17.05 61.77 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -1.17 . . . . 0.0 109.416 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.241 -0.912 . . . . 0.0 109.517 179.897 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.43 ' HE1' HG21 ' A' ' 146' ' ' ILE . 8.9 p90 . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.428 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 13.9 mmtt -137.77 165.22 26.97 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -0.925 . . . . 0.0 109.758 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.614 HG23 ' O ' ' A' ' 144' ' ' LYS . 14.2 p -62.42 143.13 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.316 -0.865 . . . . 0.0 109.536 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.68 -33.11 3.54 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.428 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 31.8 m-20 -49.67 159.19 0.39 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.532 -0.981 . . . . 0.0 109.247 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 2.0 ttp -94.19 127.62 40.14 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.136 -0.978 . . . . 0.0 109.008 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.794 HG21 HD11 ' A' ' 143' ' ' ILE . 5.9 t -125.99 142.49 42.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.361 -0.837 . . . . 0.0 109.28 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.494 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 22.2 tttp -105.41 142.13 35.7 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.405 -0.809 . . . . 0.0 108.875 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 1.029 HD12 ' HB3' ' A' ' 139' ' ' PHE . 66.9 mt -83.3 155.1 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.186 -0.946 . . . . 0.0 108.618 179.62 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.496 HG12 ' HA ' ' A' ' 173' ' ' VAL . 29.1 pt -150.62 2.8 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.076 -1.015 . . . . 0.0 109.549 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 72.3 m -148.19 144.44 27.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.071 -1.018 . . . . 0.0 109.992 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 104.29 -167.99 16.23 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.513 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.582 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 48.3 Cg_endo -68.97 -20.74 38.21 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 123.124 2.549 . . . . 0.0 112.408 -179.544 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.534 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.3 m-85 -110.31 15.95 21.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.829 -1.169 . . . . 0.0 109.435 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.642 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.7 tt0 -43.8 143.26 1.09 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.486 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.521 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 16.4 m-20 75.85 27.65 0.94 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.374 -0.829 . . . . 0.0 110.258 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 1.029 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.3 t80 -117.68 133.58 55.8 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.021 -1.049 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -82.96 133.75 35.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.127 -0.983 . . . . 0.0 109.653 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.412 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.15 167.34 27.36 Favored Glycine 0 N--CA 1.49 2.279 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.098 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.743 ' C ' HG23 ' A' ' 155' ' ' VAL . 58.4 t -110.38 136.92 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.442 -1.034 . . . . 0.0 109.404 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 1.068 HG21 HD11 ' A' ' 146' ' ' ILE . 43.2 mm -69.36 118.69 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.614 ' O ' HG23 ' A' ' 125' ' ' VAL . 47.3 tttp -98.17 -32.35 11.63 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.041 -1.037 . . . . 0.0 109.557 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 144' ' ' LYS . 85.7 mt-10 -157.68 153.33 26.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.058 -1.026 . . . . 0.0 110.073 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 1.082 HG23 HD22 ' A' ' 153' ' ' LEU . 6.1 mm -123.65 126.49 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.406 -0.809 . . . . 0.0 109.591 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -108.85 99.37 34.37 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.349 -0.845 . . . . 0.0 109.476 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.549 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.2 Cg_endo -71.21 173.77 11.74 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.739 2.293 . . . . 0.0 111.764 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.549 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.5 mt-10 79.97 -20.98 0.35 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.358 -0.839 . . . . 0.0 109.865 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.402 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 32.6 mtp180 -128.78 -13.4 4.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.079 -1.013 . . . . 0.0 109.476 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.425 ' O ' HG12 ' A' ' 170' ' ' VAL . 37.8 mt-30 69.58 48.22 0.62 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.283 -0.886 . . . . 0.0 109.685 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.864 ' O ' HD23 ' A' ' 153' ' ' LEU . 59.5 tt0 -120.41 144.25 48.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.964 . . . . 0.0 108.936 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 1.082 HD22 HG23 ' A' ' 146' ' ' ILE . 29.4 mt -130.12 131.01 45.53 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.078 -1.014 . . . . 0.0 110.083 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 13.6 mttt -93.07 130.9 38.53 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.758 HG12 HD11 ' A' ' 168' ' ' LEU . 13.9 p -132.7 147.48 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.096 -1.003 . . . . 0.0 110.057 -179.521 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.562 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.6 m-20 -96.7 117.0 30.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.464 -0.773 . . . . 0.0 109.265 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.415 HG13 ' CE1' ' A' ' 139' ' ' PHE . 44.9 t -96.79 141.38 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 109.501 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.408 ' HA ' ' O ' ' A' ' 162' ' ' ARG . 73.5 m -96.07 94.91 7.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.273 -0.892 . . . . 0.0 109.929 -179.7 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.561 HG22 ' CD2' ' A' ' 160' ' ' PHE . 6.2 mt -118.22 140.78 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.25 -0.906 . . . . 0.0 109.422 179.483 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.683 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 97.3 m-85 62.25 40.16 11.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.331 -0.855 . . . . 0.0 109.337 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.48 17.9 34.87 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.412 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 36.9 mtt-85 -128.29 156.12 43.52 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.179 -1.189 . . . . 0.0 109.618 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -99.84 134.23 43.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.886 . . . . 0.0 109.558 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 37.3 m -143.11 127.44 9.59 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.303 -0.873 . . . . 0.0 109.554 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.562 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.3 Cg_endo -69.63 135.18 30.09 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.76 2.307 . . . . 0.0 111.544 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 34.5 t -123.49 142.59 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.986 . . . . 0.0 109.861 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.737 HG13 ' OE2' ' A' ' 152' ' ' GLU . 29.4 t -93.78 119.35 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.403 -0.81 . . . . 0.0 109.485 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.758 HD11 HG12 ' A' ' 155' ' ' VAL . 0.0 OUTLIER -141.91 168.65 19.25 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.209 -0.932 . . . . 0.0 110.413 -179.651 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.501 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 42.3 m170 -83.51 140.6 32.2 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.932 HG23 HD11 ' A' ' 153' ' ' LEU . 7.5 p -54.91 -36.33 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.26 -0.9 . . . . 0.0 109.183 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.412 ' N ' HG13 ' A' ' 170' ' ' VAL . 84.4 p -75.84 -7.26 54.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -0.868 . . . . 0.0 109.707 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.501 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 84.3 mt-10 -87.61 -2.44 58.61 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.069 -1.019 . . . . 0.0 109.647 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 173' ' ' VAL . . . . . 0.496 ' HA ' HG12 ' A' ' 132' ' ' ILE . 3.7 m -142.05 175.91 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.191 -0.943 . . . . 0.0 109.446 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.546 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 76.2 tt0 -140.57 167.26 22.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.281 -0.887 . . . . 0.0 108.932 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.546 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.1 tttp . . . . . 0 N--CA 1.49 1.557 0 O-C-N 121.03 -1.044 . . . . 0.0 109.6 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.491 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 74.8 mttt . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 121.23 0.538 . . . . 0.0 109.658 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.566 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 10.9 mttp -129.17 175.63 8.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.291 -0.881 . . . . 0.0 109.259 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.876 ' O ' HG23 ' A' ' 93' ' ' VAL . 56.7 m95 -112.38 124.69 53.05 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.262 -0.899 . . . . 0.0 109.233 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.45 ' CD1' ' HA ' ' A' ' 92' ' ' PRO . 62.6 m-85 -117.36 171.81 7.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.189 -0.944 . . . . 0.0 109.335 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.565 HG12 ' CZ ' ' A' ' 61' ' ' PHE . 40.9 mt -112.49 107.83 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.174 -0.954 . . . . 0.0 108.995 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.881 ' CG1' HG13 ' A' ' 60' ' ' VAL . 10.8 p -83.5 146.05 7.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.208 -0.932 . . . . 0.0 109.465 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.526 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.0 OUTLIER -90.77 142.25 27.95 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.525 -0.734 . . . . 0.0 109.67 -179.667 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.764 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.1 t -154.97 -176.07 5.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.299 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.423 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 58.2 mtm -102.23 125.66 48.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.187 -0.946 . . . . 0.0 109.445 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.4 m -45.59 128.02 8.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -0.936 . . . . 0.0 109.536 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.21 -19.46 37.38 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.797 ' O ' HG23 ' A' ' 20' ' ' VAL . 94.1 m-85 -108.19 -7.91 15.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.313 -1.11 . . . . 0.0 109.436 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.832 ' OE1' HD11 ' A' ' 44' ' ' ILE . 47.9 mt-10 -47.93 -53.91 14.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.474 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -55.62 -37.05 67.66 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.239 -0.913 . . . . 0.0 109.346 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.407 ' O ' ' CG ' ' A' ' 23' ' ' ASN . 88.5 mttt -73.25 -34.86 66.07 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 109.372 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.797 HG23 ' O ' ' A' ' 16' ' ' TYR . 13.4 t -66.69 -46.6 85.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.211 -0.931 . . . . 0.0 109.414 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 23.2 tttt -58.92 -48.44 81.48 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.278 -0.889 . . . . 0.0 109.666 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.9 mt-10 -65.71 -40.26 92.06 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.219 -0.926 . . . . 0.0 109.507 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.484 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 14.4 m120 -60.45 -42.06 95.35 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.218 -0.926 . . . . 0.0 109.379 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.62 ' O ' HG23 ' A' ' 28' ' ' VAL . 96.7 mt -64.38 -44.64 97.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.307 -0.871 . . . . 0.0 109.552 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.459 ' O ' ' HG3' ' A' ' 29' ' ' GLU . 87.9 mt-10 -59.23 -47.02 86.91 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.172 -0.955 . . . . 0.0 110.036 -179.613 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.2 ttpt -80.19 -38.39 31.36 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.049 -1.032 . . . . 0.0 109.731 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.585 ' HG2' ' CE1' ' A' ' 73' ' ' PHE . 19.3 tttt -57.16 -25.64 59.26 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.331 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.856 HG21 HG11 ' A' ' 37' ' ' VAL . 89.4 t -88.07 -26.98 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.301 -0.875 . . . . 0.0 109.482 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.459 ' HG3' ' O ' ' A' ' 25' ' ' GLU . 93.1 mt-10 -66.92 -47.65 71.07 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.504 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.12 -28.91 69.96 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -0.888 . . . . 0.0 109.365 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 71.9 p -89.03 -12.02 42.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.286 -0.884 . . . . 0.0 109.322 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 61.07 24.04 62.53 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.844 ' CG2' HD23 ' A' ' 36' ' ' LEU . 54.7 mt -101.35 74.43 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -1.139 . . . . 0.0 109.552 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.6 mttp -85.26 -3.8 58.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.336 -0.853 . . . . 0.0 109.597 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.435 ' O ' HD13 ' A' ' 65' ' ' ILE . 90.5 m-20 -93.12 -7.01 46.68 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.209 -0.932 . . . . 0.0 109.4 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.019 HD12 ' HB2' ' A' ' 70' ' ' ALA . 4.4 mm? -95.66 -50.83 4.77 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.267 -0.895 . . . . 0.0 109.34 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.856 HG11 HG21 ' A' ' 28' ' ' VAL . 8.7 p -95.35 139.16 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.381 -0.824 . . . . 0.0 109.554 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.1 -122.16 4.07 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 88.6 mtt-85 -95.34 142.7 27.43 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.223 -1.163 . . . . 0.0 109.706 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.954 HG23 HG22 ' A' ' 62' ' ' VAL . 75.4 mt -109.73 137.5 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.196 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.632 HG13 ' HB2' ' A' ' 61' ' ' PHE . 7.7 p -127.93 162.08 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.169 -0.957 . . . . 0.0 109.36 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.632 HG21 HD12 ' A' ' 44' ' ' ILE . 5.9 mt -144.2 130.13 9.87 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.167 -0.958 . . . . 0.0 109.902 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.515 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.1 Cg_endo -66.36 -3.71 9.33 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.861 2.374 . . . . 0.0 111.478 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.832 HD11 ' OE1' ' A' ' 17' ' ' GLU . 61.0 mt . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.89 . . . . 0.0 109.508 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.804 ' HG2' HG23 ' A' ' 44' ' ' ILE . 3.6 mttp . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.593 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 16.9 tp -65.25 -22.3 66.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.863 -1.148 . . . . 0.0 109.775 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.593 ' CE2' ' HG ' ' A' ' 55' ' ' LEU . 95.8 m-85 -148.37 98.17 3.73 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.21 -0.931 . . . . 0.0 108.818 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -65.86 140.56 61.53 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.723 2.282 . . . . 0.0 112.205 -179.243 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.4 -10.89 10.21 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -107.25 132.6 52.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.749 -1.442 . . . . 0.0 110.291 -179.244 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.881 HG13 ' CG1' ' A' ' 10' ' ' VAL . 0.2 OUTLIER -135.22 151.4 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 179.001 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.632 ' HB2' HG13 ' A' ' 41' ' ' VAL . 14.0 m-85 -111.73 126.56 55.18 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.948 -1.095 . . . . 0.0 110.258 -179.14 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.954 HG22 HG23 ' A' ' 40' ' ' ILE . 67.1 t -130.22 141.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.547 -0.721 . . . . 0.0 109.66 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.601 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 10.8 tt0 -104.16 125.92 50.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 108.766 179.538 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.495 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 30.7 mtm -156.18 172.92 17.61 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.019 -1.051 . . . . 0.0 110.783 -179.073 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.628 ' CG1' HD13 ' A' ' 36' ' ' LEU . 4.8 pt -95.17 130.48 43.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.468 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 4.1 tpp -76.04 143.34 41.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.3 -0.875 . . . . 0.0 110.037 -178.64 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.468 ' HB2' ' O ' ' A' ' 66' ' ' MET . 42.6 t30 176.69 175.78 0.33 Allowed 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 69' ' ' GLU . 28.6 p-10 -71.6 -40.45 69.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.145 -0.972 . . . . 0.0 109.406 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.473 ' N ' ' OD1' ' A' ' 68' ' ' ASP . 71.0 mm-40 -73.23 -35.5 66.28 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.362 -0.836 . . . . 0.0 109.716 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.019 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -67.63 -47.87 68.37 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 109.589 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.796 ' HB2' HE21 ' A' ' 89' ' ' GLN . 84.0 t80 -59.77 -51.57 69.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.676 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -57.48 -29.03 63.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.239 -0.913 . . . . 0.0 109.876 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.696 ' CE2' HG22 ' A' ' 28' ' ' VAL . 65.9 t80 -80.4 -40.79 25.78 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.113 -0.992 . . . . 0.0 109.929 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 1.008 HG23 ' O ' ' A' ' 70' ' ' ALA . 2.6 t -64.63 -60.33 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.185 -0.947 . . . . 0.0 109.92 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.463 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 10.8 tpt180 -51.58 -42.92 62.26 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.097 -1.002 . . . . 0.0 109.736 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.423 ' HB3' ' HZ1' ' A' ' 27' ' ' LYS . 22.8 t -67.58 1.24 2.5 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.11 -0.994 . . . . 0.0 110.244 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.616 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 30.7 t -62.29 133.98 94.59 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 120.928 -1.107 . . . . 0.0 109.317 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.571 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 46.0 Cg_endo -68.0 136.08 36.95 Favored 'Trans proline' 0 C--O 1.213 -0.738 0 C-N-CA 122.727 2.285 . . . . 0.0 111.866 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.571 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 54.3 m-85 77.61 -2.26 2.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.528 -0.733 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.616 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.0 t -87.45 126.96 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.102 -0.999 . . . . 0.0 109.162 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 66.1 mtp -90.02 -24.65 21.15 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 109.73 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.422 ' O ' ' N ' ' A' ' 11' ' ' LEU . . . 158.25 -158.04 28.85 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.59 ' HB2' ' HB3' ' A' ' 90' ' ' PRO . 15.3 p90 -140.56 154.13 46.4 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.243 -1.151 . . . . 0.0 109.506 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.493 ' CG2' ' CD2' ' A' ' 11' ' ' LEU . 47.5 t -81.73 113.45 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.137 -0.977 . . . . 0.0 109.466 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.533 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 5.3 p -145.2 164.66 30.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.226 -0.921 . . . . 0.0 109.498 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 23.9 m -86.47 -33.17 20.46 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.287 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -135.58 -76.91 0.09 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.55 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -109.61 -133.56 6.7 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.796 HE21 ' HB2' ' A' ' 71' ' ' TYR . 0.7 OUTLIER -29.49 150.31 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.63 -0.924 . . . . 0.0 110.315 -179.636 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.59 ' HB3' ' HB2' ' A' ' 83' ' ' PHE . 44.5 Cg_endo -67.81 147.45 75.1 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.833 2.355 . . . . 0.0 111.973 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' VAL . . . . . 0.766 HG23 ' HD2' ' A' ' 92' ' ' PRO . 3.4 p -80.81 144.69 56.22 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.317 -0.864 . . . . 0.0 109.369 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.766 ' HD2' HG23 ' A' ' 91' ' ' VAL . 47.3 Cg_endo -68.6 151.39 75.16 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.66 2.24 . . . . 0.0 111.715 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.876 HG23 ' O ' ' A' ' 7' ' ' TRP . 11.9 t -83.64 131.76 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.232 -0.918 . . . . 0.0 109.583 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 54.9 mttm -69.87 143.17 52.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.31 -0.868 . . . . 0.0 109.446 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -53.3 -39.97 64.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.25 -0.907 . . . . 0.0 109.596 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -57.98 -34.34 69.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.274 -0.891 . . . . 0.0 109.558 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.7 mt-10 -81.34 -25.41 36.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.266 -0.896 . . . . 0.0 109.525 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.696 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 98.6 mtp -84.1 -26.42 28.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.899 . . . . 0.0 109.58 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.58 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.4 OUTLIER -36.24 -54.24 1.53 Allowed Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.448 -0.783 . . . . 0.0 109.927 -179.838 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.58 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.5 Cg_endo -70.1 -28.2 23.93 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.481 2.121 . . . . 0.0 111.748 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.495 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 33.1 mm -80.57 -41.12 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.567 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.575 ' CB ' ' HB2' ' A' ' 108' ' ' GLU . 1.0 OUTLIER -67.85 -40.65 83.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.226 -0.921 . . . . 0.0 109.505 179.995 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.491 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 1.3 ttt85 -63.91 -49.52 72.33 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 109.212 179.785 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.21 -36.42 69.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.264 -0.898 . . . . 0.0 108.961 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.526 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -75.62 -4.11 38.23 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.436 -0.79 . . . . 0.0 109.641 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.66 11.47 83.06 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.506 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 7.1 mt -87.3 -28.09 22.48 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.158 -1.201 . . . . 0.0 109.724 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' GLU . . . . . 0.575 ' HB2' ' CB ' ' A' ' 102' ' ' LEU . 87.9 tt0 . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.247 -0.908 . . . . 0.0 109.469 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.482 ' HB3' ' HE2' ' A' ' 175' ' ' LYS . 50.7 p90 . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.446 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 20.8 mttm -146.48 155.65 42.69 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.131 -0.98 . . . . 0.0 109.869 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 144' ' ' LYS . 14.2 p -60.98 143.96 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -0.875 . . . . 0.0 109.584 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.09 -33.45 3.13 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.446 ' OD2' ' HB2' ' A' ' 124' ' ' LYS . 32.7 m-20 -48.78 163.13 0.08 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.38 -1.07 . . . . 0.0 109.207 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.8 ttm -96.3 126.72 41.7 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.051 -1.031 . . . . 0.0 108.807 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.907 HG23 ' O ' ' A' ' 174' ' ' GLU . 5.6 p -124.3 141.28 45.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.108 -0.995 . . . . 0.0 109.262 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.522 ' N ' ' O ' ' A' ' 174' ' ' GLU . 35.9 tttp -104.34 144.21 31.94 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.206 -0.934 . . . . 0.0 108.956 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.997 HD12 ' HB3' ' A' ' 139' ' ' PHE . 95.7 mt -85.69 152.01 3.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.116 -0.99 . . . . 0.0 108.623 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' ILE . . . . . . . . . . . . . 42.1 pt -150.32 2.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.162 -0.961 . . . . 0.0 109.434 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.478 ' HB2' ' CB ' ' A' ' 172' ' ' GLU . 75.4 m -148.26 144.48 27.66 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.145 -0.972 . . . . 0.0 109.912 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.75 -165.28 18.89 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.491 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 46.9 Cg_endo -68.03 -21.82 42.51 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 123.202 2.602 . . . . 0.0 112.811 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.555 ' HB2' HD13 ' A' ' 131' ' ' ILE . 97.5 m-85 -108.29 15.78 23.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.834 -1.166 . . . . 0.0 109.604 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.597 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.4 tt0 -42.96 139.94 1.56 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.176 -0.953 . . . . 0.0 109.384 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.522 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 18.6 m-20 75.21 24.95 1.37 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.368 -0.832 . . . . 0.0 110.335 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.997 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.5 t80 -115.71 135.8 53.68 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.961 -1.087 . . . . 0.0 109.421 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.34 133.5 34.14 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.177 -0.952 . . . . 0.0 109.692 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.495 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.02 170.89 25.74 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.294 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.716 ' C ' HG13 ' A' ' 155' ' ' VAL . 40.8 t -116.12 135.72 55.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.447 -1.031 . . . . 0.0 109.357 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.874 HD11 ' HD2' ' A' ' 175' ' ' LYS . 70.8 mt -67.56 115.87 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.257 -0.902 . . . . 0.0 109.192 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.516 ' O ' HG23 ' A' ' 125' ' ' VAL . 2.0 tttp -98.08 -33.74 11.04 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.036 -1.04 . . . . 0.0 109.502 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.412 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 75.3 mm-40 -151.01 146.03 25.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.114 -0.991 . . . . 0.0 109.536 179.872 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 1.044 HG22 HD22 ' A' ' 153' ' ' LEU . 23.8 pt -122.25 125.88 73.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.135 -0.978 . . . . 0.0 109.488 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.37 100.6 34.53 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.268 -0.895 . . . . 0.0 109.5 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.56 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.2 Cg_endo -71.18 171.12 16.61 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.704 2.269 . . . . 0.0 111.779 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.56 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.8 mt-10 80.95 -20.48 0.37 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.399 -0.813 . . . . 0.0 109.899 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.433 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 88.6 mtt180 -127.75 -12.01 5.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.086 -1.009 . . . . 0.0 109.526 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.433 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 31.5 mt-30 69.23 48.91 0.64 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.665 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -122.22 145.81 47.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.09 -1.006 . . . . 0.0 109.097 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 1.044 HD22 HG22 ' A' ' 146' ' ' ILE . 60.6 mt -138.42 115.29 10.78 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.075 -1.016 . . . . 0.0 110.147 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 27.3 mttm -78.85 133.56 37.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.3 -0.875 . . . . 0.0 108.643 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.716 HG13 ' C ' ' A' ' 142' ' ' VAL . 53.9 t -127.44 151.17 33.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.182 -0.949 . . . . 0.0 109.762 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 26.2 t-20 -98.0 117.6 32.7 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.237 -0.914 . . . . 0.0 109.352 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.506 HG13 ' CE1' ' A' ' 139' ' ' PHE . 39.7 t -101.03 143.41 14.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.252 -0.905 . . . . 0.0 109.708 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 93.1 m -94.74 91.26 6.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.383 -0.823 . . . . 0.0 109.724 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.502 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 8.6 mt -115.78 140.54 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.424 179.664 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.411 ' CZ ' ' HZ ' ' A' ' 61' ' ' PHE . 8.4 m-85 60.54 41.21 15.93 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.376 -0.827 . . . . 0.0 109.334 -179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.05 16.28 12.9 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 92.4 mtt-85 -126.26 148.3 49.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.201 -1.176 . . . . 0.0 109.39 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' GLU . . . . . 0.504 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 94.3 mt-10 -94.81 135.77 35.91 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.278 -0.889 . . . . 0.0 109.679 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 164' ' ' THR . . . . . 0.51 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 49.7 m -147.2 128.18 7.1 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.274 -0.891 . . . . 0.0 109.735 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.538 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.49 139.69 38.26 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.746 2.297 . . . . 0.0 111.46 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.4 p -126.61 145.79 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.089 -1.007 . . . . 0.0 109.869 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.434 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 5.3 t -92.54 118.86 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.459 -0.775 . . . . 0.0 109.505 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.434 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 19.3 mt -141.52 167.23 22.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.184 -0.947 . . . . 0.0 110.495 -179.302 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -83.97 141.34 31.29 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.71 -0.619 . . . . 0.0 109.5 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 4.1 p -56.42 -36.28 46.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.287 -0.883 . . . . 0.0 109.319 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 53.8 p -75.96 -7.18 54.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -0.883 . . . . 0.0 109.828 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.478 ' CB ' ' HB2' ' A' ' 133' ' ' SER . 64.5 mt-10 -99.75 -2.23 35.73 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.086 -1.009 . . . . 0.0 109.404 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 12.7 m -132.48 170.1 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.23 -0.919 . . . . 0.0 109.627 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.907 ' O ' HG23 ' A' ' 129' ' ' VAL . 53.5 tt0 -129.87 145.14 51.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.293 -0.88 . . . . 0.0 109.343 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.874 ' HD2' HD11 ' A' ' 143' ' ' ILE . 34.4 mmtm . . . . . 0 N--CA 1.489 1.52 0 O-C-N 121.024 -1.048 . . . . 0.0 109.514 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.476 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 20.0 mttm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.284 0.564 . . . . 0.0 109.625 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 16.8 mmtp -127.47 172.07 11.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.329 -0.857 . . . . 0.0 109.39 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.959 ' O ' HG23 ' A' ' 93' ' ' VAL . 46.3 m95 -106.34 128.24 53.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.335 -0.853 . . . . 0.0 109.142 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.541 ' CE1' ' CE ' ' A' ' 66' ' ' MET . 74.8 m-85 -120.35 160.96 22.0 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.214 -0.929 . . . . 0.0 109.359 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.524 ' HB ' HG12 ' A' ' 84' ' ' VAL . 97.1 mt -102.66 115.35 44.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.233 -0.917 . . . . 0.0 109.252 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.508 HG11 HG22 ' A' ' 80' ' ' VAL . 84.2 t -91.35 141.28 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.224 -0.923 . . . . 0.0 109.452 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.512 HD13 ' HA ' ' A' ' 11' ' ' LEU . 3.2 mm? -84.74 144.23 28.64 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.28 -0.888 . . . . 0.0 109.308 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.693 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.9 t -155.86 -176.56 6.02 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.167 -0.958 . . . . 0.0 109.271 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.417 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 56.8 mtm -104.71 123.73 48.13 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.25 -0.906 . . . . 0.0 109.568 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.455 ' OG ' ' HB2' ' A' ' 57' ' ' PRO . 2.6 m -45.32 128.32 7.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.408 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.3 -19.98 33.52 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.501 ' O ' ' N ' ' A' ' 19' ' ' LYS . 77.1 m-85 -111.64 -9.3 14.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.297 -1.119 . . . . 0.0 109.441 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.693 ' HG2' HG21 ' A' ' 12' ' ' THR . 92.6 mt-10 -43.3 -41.54 4.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.23 -0.919 . . . . 0.0 109.543 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -63.57 -31.3 72.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 109.302 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.501 ' N ' ' O ' ' A' ' 16' ' ' TYR . 27.7 mttm -76.94 -56.43 4.6 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.276 -0.89 . . . . 0.0 109.352 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.565 ' CG1' ' HA ' ' A' ' 17' ' ' GLU . 2.0 p -44.72 -49.73 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.415 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.751 ' HD2' HD11 ' A' ' 42' ' ' ILE . 10.5 tttm -61.03 -48.32 82.32 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.207 -0.933 . . . . 0.0 109.874 -179.711 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -62.96 -35.48 80.29 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.07 -1.019 . . . . 0.0 109.504 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.497 ' HB3' ' HG2' ' A' ' 78' ' ' PRO . 33.9 m120 -64.92 -37.54 87.99 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.308 -0.87 . . . . 0.0 109.22 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.5 HG21 HD11 ' A' ' 40' ' ' ILE . 89.0 mt -63.19 -45.62 98.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.3 -0.875 . . . . 0.0 109.478 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -55.41 -46.77 76.6 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.214 -0.929 . . . . 0.0 109.715 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 27.7 ttmt -76.06 -35.63 59.34 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.261 -0.899 . . . . 0.0 109.456 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.608 ' O ' HG23 ' A' ' 31' ' ' THR . 44.2 tptt -54.93 -32.33 61.16 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.918 . . . . 0.0 109.242 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.851 HG13 ' O ' ' A' ' 33' ' ' ILE . 77.5 t -87.13 -22.91 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.329 -0.857 . . . . 0.0 109.406 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -71.32 -55.4 8.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.669 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.39 -31.16 71.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.186 -0.946 . . . . 0.0 109.684 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.608 HG23 ' O ' ' A' ' 27' ' ' LYS . 29.5 p -87.32 -20.92 26.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.118 -0.989 . . . . 0.0 109.491 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 68.21 22.07 74.26 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.851 ' O ' HG13 ' A' ' 28' ' ' VAL . 63.4 mt -98.89 79.45 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -1.142 . . . . 0.0 109.449 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -85.09 -17.23 38.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.236 -0.915 . . . . 0.0 109.24 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -84.24 5.01 28.25 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.317 -0.865 . . . . 0.0 109.482 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.043 HD12 ' CG1' ' A' ' 65' ' ' ILE . 12.5 tp -105.98 -54.26 2.51 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.176 -0.953 . . . . 0.0 109.37 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.715 ' HB ' HG21 ' A' ' 28' ' ' VAL . 86.4 t -96.5 133.32 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.403 -0.81 . . . . 0.0 109.297 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.85 -123.4 5.26 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 89.7 mtt180 -93.52 147.49 22.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -1.125 . . . . 0.0 109.845 -179.535 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.865 HG23 HG22 ' A' ' 62' ' ' VAL . 70.2 mt -110.32 135.55 49.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.291 -0.88 . . . . 0.0 109.344 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.822 HG23 ' CH2' ' A' ' 7' ' ' TRP . 32.8 t -119.72 151.7 22.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.951 . . . . 0.0 109.39 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.751 HD11 ' HD2' ' A' ' 21' ' ' LYS . 10.5 mt -131.9 127.53 21.23 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.897 . . . . 0.0 109.442 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.527 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 46.2 Cg_endo -66.78 -4.46 11.21 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.862 2.375 . . . . 0.0 111.867 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.728 HG23 HG22 ' A' ' 42' ' ' ILE . 8.4 pt . . . . . 0 N--CA 1.489 1.497 0 O-C-N 121.12 -0.987 . . . . 0.0 109.387 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.604 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 7.6 mttp . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.527 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 24.7 mt -55.61 -45.43 77.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.105 -0.997 . . . . 0.0 109.269 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.455 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 89.3 m-85 -131.7 110.34 14.65 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.125 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.455 ' HB2' ' OG ' ' A' ' 14' ' ' SER . 43.1 Cg_endo -66.22 139.35 54.85 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.746 2.297 . . . . 0.0 112.184 -179.349 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.5 ' O ' HG22 ' A' ' 12' ' ' THR . . . 73.96 -9.83 8.43 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.5 m-30 -94.17 129.07 40.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.669 -1.489 . . . . 0.0 110.395 -179.192 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 44.8 t -130.22 137.75 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.419 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.503 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 8.0 m-85 -110.15 125.95 53.57 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.902 -1.124 . . . . 0.0 110.051 -179.462 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.865 HG22 HG23 ' A' ' 40' ' ' ILE . 55.8 t -138.51 149.92 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.418 -0.801 . . . . 0.0 109.805 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.635 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 61.6 tt0 -110.66 129.04 55.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 108.888 179.536 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.578 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 9.2 mtm -161.79 -176.06 5.04 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.137 -0.977 . . . . 0.0 109.804 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 1.043 ' CG1' HD12 ' A' ' 36' ' ' LEU . 18.9 pt -94.94 119.76 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.367 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.541 ' CE ' ' CE1' ' A' ' 8' ' ' TYR . 16.2 ttm -87.36 101.04 13.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.382 -0.824 . . . . 0.0 109.676 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' A' ' 66' ' ' MET . 84.8 m-20 -138.7 -166.54 2.03 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.303 -0.873 . . . . 0.0 108.895 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -71.17 -47.34 58.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.098 -1.001 . . . . 0.0 109.799 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 70' ' ' ALA . 93.7 mt-10 -70.84 -57.14 4.92 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.055 -1.028 . . . . 0.0 109.612 -179.736 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.007 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -44.51 -42.99 7.62 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.696 ' CD1' ' NE2' ' A' ' 89' ' ' GLN . 71.1 t80 -61.39 -54.84 38.4 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.267 -0.896 . . . . 0.0 109.696 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -51.58 -31.0 23.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.18 -0.95 . . . . 0.0 110.049 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -81.01 -41.95 21.9 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.144 -0.972 . . . . 0.0 109.766 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.976 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 47.4 t -70.96 -54.58 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.249 -0.907 . . . . 0.0 109.443 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.428 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 25.0 tpt85 -51.45 -18.62 1.11 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.182 -0.949 . . . . 0.0 109.211 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 66.3 p -101.65 5.89 41.73 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.41 -0.806 . . . . 0.0 109.925 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.713 HG23 ' HA ' ' A' ' 74' ' ' VAL . 17.2 t -60.86 135.57 92.89 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.013 -1.055 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.592 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 48.4 Cg_endo -69.14 129.39 18.16 Favored 'Trans proline' 0 C--O 1.213 -0.74 0 C-N-CA 122.776 2.318 . . . . 0.0 112.002 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.592 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 40.7 m-85 84.45 -10.13 0.88 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.665 -0.647 . . . . 0.0 109.56 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.593 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 4.9 t -84.92 127.3 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.177 -0.952 . . . . 0.0 109.257 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.484 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 78.4 mtp -87.0 -23.99 24.82 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.296 -0.877 . . . . 0.0 109.379 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.544 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 153.07 -155.58 26.21 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.976 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 1.6 m-85 -137.42 140.13 41.11 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.322 -1.105 . . . . 0.0 109.402 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.543 ' O ' HG13 ' A' ' 84' ' ' VAL . 11.5 p -64.85 125.41 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 109.519 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.545 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.7 p -159.35 161.69 35.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.241 -0.912 . . . . 0.0 109.516 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 85.8 p -92.01 -36.66 13.27 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.249 -0.907 . . . . 0.0 109.391 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -120.47 -88.19 1.04 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.515 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -104.25 -133.93 7.98 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.696 ' NE2' ' CD1' ' A' ' 71' ' ' TYR . 2.9 mp0 -34.25 155.06 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.547 -0.972 . . . . 0.0 110.134 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.545 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.3 Cg_endo -68.47 163.72 35.55 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.824 2.349 . . . . 0.0 111.855 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.7 m -93.97 154.08 40.78 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.294 -0.879 . . . . 0.0 109.31 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.38 142.45 45.23 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.605 2.203 . . . . 0.0 111.796 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.959 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.3 t -73.04 131.49 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -0.899 . . . . 0.0 109.306 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' LYS . . . . . 0.484 ' O ' ' N ' ' A' ' 97' ' ' GLU . 42.2 mttm -71.6 132.75 45.09 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.193 -0.942 . . . . 0.0 109.264 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 94' ' ' LYS . 82.1 m-20 -44.46 -41.28 6.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.226 -0.921 . . . . 0.0 109.459 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -61.04 -24.91 66.55 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.265 -0.897 . . . . 0.0 109.502 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.484 ' N ' ' O ' ' A' ' 94' ' ' LYS . 54.2 mt-10 -87.14 -27.0 23.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.162 -0.961 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.644 ' SD ' HG11 ' A' ' 93' ' ' VAL . 37.4 mmm -84.63 -26.87 27.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.166 -0.959 . . . . 0.0 109.42 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.576 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 5.1 ttp180 -37.06 -54.98 1.75 Allowed Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.47 -0.769 . . . . 0.0 109.994 -179.795 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.1 Cg_endo -69.05 -27.21 30.13 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.535 2.157 . . . . 0.0 111.79 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.59 HG22 HG11 ' A' ' 41' ' ' VAL . 51.1 mm -81.44 -41.94 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.226 -0.921 . . . . 0.0 109.284 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.574 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -68.27 -40.13 81.95 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.219 -0.926 . . . . 0.0 109.231 179.754 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 21.2 mtt180 -62.77 -50.57 70.53 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.333 -0.854 . . . . 0.0 108.978 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -73.35 -35.34 65.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.459 -0.776 . . . . 0.0 109.11 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -71.99 -2.73 19.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.385 -0.822 . . . . 0.0 109.633 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.48 9.68 84.56 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.703 HD22 HG21 ' A' ' 41' ' ' VAL . 8.0 mp -80.9 -21.95 40.16 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.164 -1.198 . . . . 0.0 109.429 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.381 -0.824 . . . . 0.0 109.501 179.914 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.528 ' CG ' ' HE2' ' A' ' 175' ' ' LYS . 31.4 p90 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.642 ' HA ' HD11 ' A' ' 146' ' ' ILE . 14.1 mttt -140.35 -174.52 3.97 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.034 -1.041 . . . . 0.0 110.076 -179.615 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 144' ' ' LYS . 13.8 p -61.78 141.94 16.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.451 -0.781 . . . . 0.0 109.677 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 86.72 -34.31 3.55 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.549 ' HB2' HD12 ' A' ' 143' ' ' ILE . 24.0 m-20 -49.29 158.73 0.36 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.316 -1.108 . . . . 0.0 109.633 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' MET . . . . . 0.454 ' SD ' ' O ' ' A' ' 141' ' ' GLY . 2.7 tpp -95.53 127.91 41.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.336 -0.853 . . . . 0.0 108.871 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.683 HG22 ' CG1' ' A' ' 173' ' ' VAL . 2.0 p -127.72 143.83 39.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.264 -0.898 . . . . 0.0 109.816 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.451 ' O ' HG13 ' A' ' 173' ' ' VAL . 21.0 tttt -108.55 142.29 39.21 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.266 -0.896 . . . . 0.0 109.319 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 1.0 ' O ' HD13 ' A' ' 132' ' ' ILE . 96.6 mt -80.14 152.22 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.139 -0.976 . . . . 0.0 108.971 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 1.0 HD13 ' O ' ' A' ' 131' ' ' ILE . 1.1 mm -146.67 2.27 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.088 -1.007 . . . . 0.0 109.391 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.577 ' CA ' ' HG2' ' A' ' 137' ' ' GLU . 50.6 m -148.64 143.12 26.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.259 -0.9 . . . . 0.0 109.758 -179.575 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.462 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 105.77 -169.23 15.8 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.56 -19.98 41.73 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 123.317 2.678 . . . . 0.0 112.679 -179.414 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.521 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.6 m-85 -106.77 16.71 24.11 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.933 -1.104 . . . . 0.0 109.605 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.577 ' HG2' ' CA ' ' A' ' 133' ' ' SER . 62.9 mt-10 -41.58 139.01 1.22 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.163 -0.961 . . . . 0.0 110.073 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.568 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.8 OUTLIER 80.37 19.41 0.56 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.277 -0.89 . . . . 0.0 110.788 178.775 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.761 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.0 OUTLIER -108.18 141.67 39.57 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.794 -1.191 . . . . 0.0 109.565 179.798 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -94.53 135.95 35.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.225 -0.922 . . . . 0.0 109.22 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.494 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.83 168.99 27.38 Favored Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.571 -1.299 . . . . 0.0 110.5 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.682 ' C ' HG23 ' A' ' 155' ' ' VAL . 39.5 t -111.14 137.49 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.593 -0.945 . . . . 0.0 109.369 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.549 HD12 ' HB2' ' A' ' 127' ' ' ASP . 69.8 mt -68.71 118.26 12.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 109.303 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.661 ' O ' HG23 ' A' ' 125' ' ' VAL . 47.7 tttp -100.39 -33.29 10.43 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.975 -1.078 . . . . 0.0 109.561 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.435 ' HG2' ' O ' ' A' ' 144' ' ' LYS . 64.2 mt-10 -153.85 149.12 27.02 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.132 -0.98 . . . . 0.0 109.812 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 1.065 HG23 HD22 ' A' ' 153' ' ' LEU . 1.7 mt -124.33 127.59 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.354 -0.841 . . . . 0.0 109.379 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.13 104.1 55.77 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.628 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.528 ' O ' ' HB2' ' A' ' 149' ' ' GLU . 52.4 Cg_endo -72.35 173.21 13.47 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.72 2.28 . . . . 0.0 111.661 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.528 ' HB2' ' O ' ' A' ' 148' ' ' PRO . 39.5 mm-40 78.25 -22.0 0.31 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.397 -0.814 . . . . 0.0 110.062 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.437 ' NH1' ' HG3' ' A' ' 150' ' ' ARG . 0.6 OUTLIER -124.15 -15.5 6.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.1 -1.0 . . . . 0.0 109.119 179.776 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.456 ' HB3' HG11 ' A' ' 170' ' ' VAL . 30.9 mt-30 69.58 47.98 0.63 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.461 -0.774 . . . . 0.0 109.439 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.993 ' O ' HD23 ' A' ' 153' ' ' LEU . 97.8 mt-10 -119.76 143.56 47.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.215 -0.928 . . . . 0.0 109.081 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 1.065 HD22 HG23 ' A' ' 146' ' ' ILE . 14.4 mt -130.95 122.85 27.64 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.16 -0.963 . . . . 0.0 110.231 -179.628 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 13.9 mttt -85.57 129.78 34.74 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.403 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.682 HG23 ' C ' ' A' ' 142' ' ' VAL . 10.9 p -129.36 146.94 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.222 -0.923 . . . . 0.0 109.951 -179.608 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.543 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 3.7 m-20 -98.02 108.89 21.71 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.218 -0.926 . . . . 0.0 109.537 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.577 HG13 ' CE1' ' A' ' 139' ' ' PHE . 82.2 t -88.14 140.72 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.18 -0.95 . . . . 0.0 109.376 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 47.7 m -96.62 89.23 4.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.332 -0.855 . . . . 0.0 109.617 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.506 HG13 HG12 ' A' ' 157' ' ' VAL . 2.6 mt -115.74 144.87 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.192 -0.942 . . . . 0.0 109.395 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.503 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 18.7 m-85 61.93 37.41 15.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.276 -0.89 . . . . 0.0 109.226 -179.821 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.03 17.95 31.85 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.426 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 89.5 mtt-85 -127.66 157.49 40.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.216 -1.167 . . . . 0.0 109.481 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 163' ' ' GLU . . . . . 0.44 ' OE2' ' ND2' ' A' ' 156' ' ' ASN . 83.6 tt0 -100.82 133.35 45.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.327 -0.858 . . . . 0.0 109.591 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 79.7 m -144.04 127.3 8.83 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.905 . . . . 0.0 109.684 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.543 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.4 Cg_endo -70.98 137.16 31.33 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.723 2.282 . . . . 0.0 111.598 179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 46.1 t -125.66 144.48 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.229 -0.92 . . . . 0.0 109.862 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.413 ' O ' ' HG ' ' A' ' 168' ' ' LEU . 44.4 t -92.68 119.35 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.438 -0.789 . . . . 0.0 109.485 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.413 ' HG ' ' O ' ' A' ' 167' ' ' VAL . 1.4 mt -138.71 164.69 28.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.229 -0.92 . . . . 0.0 110.48 -179.162 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.495 ' HB2' ' HB2' ' A' ' 172' ' ' GLU . 88.6 m-70 -81.57 145.64 30.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.632 -0.668 . . . . 0.0 109.291 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.702 HG23 HD11 ' A' ' 153' ' ' LEU . 6.2 p -62.11 -35.73 70.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.305 -0.872 . . . . 0.0 108.982 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 82.9 p -78.59 -9.66 59.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.254 -0.904 . . . . 0.0 109.362 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.505 ' CB ' ' HB2' ' A' ' 133' ' ' SER . 46.8 mt-10 -97.69 -1.14 44.19 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.405 -0.809 . . . . 0.0 109.022 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 173' ' ' VAL . . . . . 0.683 ' CG1' HG22 ' A' ' 129' ' ' VAL . 97.9 t -126.14 163.25 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.297 -0.877 . . . . 0.0 109.412 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.548 ' N ' HG12 ' A' ' 173' ' ' VAL . 55.8 tt0 -137.26 154.95 50.02 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.314 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.541 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 19.8 mttt . . . . . 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.395 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.638 ' HG2' HG22 ' A' ' 65' ' ' ILE . 21.8 mttm . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 121.299 0.571 . . . . 0.0 109.575 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.6 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.6 mttt -131.53 173.1 11.45 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.16 -0.962 . . . . 0.0 109.407 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.794 ' HZ3' HG22 ' A' ' 41' ' ' VAL . 51.9 m95 -108.82 126.74 53.36 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.415 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.502 ' CZ ' ' SD ' ' A' ' 66' ' ' MET . 91.3 m-85 -116.2 168.55 10.01 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.329 -0.857 . . . . 0.0 109.492 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.506 HG12 ' CE1' ' A' ' 61' ' ' PHE . 36.5 mt -106.49 116.51 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.282 -0.886 . . . . 0.0 109.197 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.588 ' CG1' HG23 ' A' ' 80' ' ' VAL . 72.5 t -91.56 136.52 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.282 -0.886 . . . . 0.0 109.294 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.829 HD21 HG22 ' A' ' 84' ' ' VAL . 3.8 mm? -89.18 146.89 24.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.374 -0.829 . . . . 0.0 109.496 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.421 ' OG1' HG21 ' A' ' 20' ' ' VAL . 9.6 t -161.83 -168.03 1.84 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.302 -0.874 . . . . 0.0 109.362 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 67.3 mtp -107.38 134.5 50.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.242 -0.911 . . . . 0.0 109.492 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 11.0 t -54.74 130.25 39.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.291 -0.881 . . . . 0.0 109.393 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.46 -20.22 37.75 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -109.87 -3.23 16.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.285 -1.127 . . . . 0.0 109.717 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -47.48 -64.56 0.75 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.254 -0.903 . . . . 0.0 109.594 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.511 ' OE2' HD11 ' A' ' 44' ' ' ILE . 75.8 mm-40 -48.73 -38.87 22.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.183 -0.948 . . . . 0.0 109.435 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.466 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 54.1 tttp -66.77 -45.9 77.03 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.304 -0.872 . . . . 0.0 109.278 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.675 HG22 ' CB ' ' A' ' 79' ' ' TYR . 50.7 t -61.65 -44.5 98.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -0.91 . . . . 0.0 109.501 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.562 ' HG3' HG21 ' A' ' 40' ' ' ILE . 48.1 tttt -60.51 -45.62 93.13 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -0.957 . . . . 0.0 109.219 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -65.72 -40.42 92.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.315 -0.866 . . . . 0.0 109.347 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.575 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 31.2 m120 -60.59 -46.15 91.3 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.337 -0.852 . . . . 0.0 109.431 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.406 HG21 HD11 ' A' ' 40' ' ' ILE . 95.0 mt -56.01 -42.87 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.215 -0.928 . . . . 0.0 109.268 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -56.17 -43.56 78.5 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.193 -0.942 . . . . 0.0 109.594 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.428 ' HB3' ' HE2' ' A' ' 26' ' ' LYS . 47.9 mtpt -80.14 -35.62 36.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.208 -0.933 . . . . 0.0 109.434 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.427 ' HG2' HG23 ' A' ' 77' ' ' VAL . 11.5 tptt -54.69 -31.52 58.05 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.286 -0.883 . . . . 0.0 109.334 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.78 HG13 ' O ' ' A' ' 33' ' ' ILE . 39.2 t -89.75 -23.3 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.301 -0.874 . . . . 0.0 109.392 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 46.3 tp10 -69.2 -52.63 25.94 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.288 -0.883 . . . . 0.0 109.543 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.37 -32.48 73.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 59.4 p -84.87 -25.29 28.1 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 79.48 -3.42 67.93 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.825 HG23 HD23 ' A' ' 36' ' ' LEU . 84.8 mt -76.16 74.38 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.193 -1.18 . . . . 0.0 109.553 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.485 ' HA ' HG11 ' A' ' 28' ' ' VAL . 23.6 mttt -88.49 1.12 55.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.192 -0.942 . . . . 0.0 109.657 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -97.06 -13.09 22.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.181 -0.949 . . . . 0.0 109.492 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.088 HD12 ' HB2' ' A' ' 70' ' ' ALA . 2.5 mm? -88.32 -49.05 7.21 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.291 -0.881 . . . . 0.0 109.467 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.507 ' HB ' HG21 ' A' ' 28' ' ' VAL . 78.5 t -91.12 139.49 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.244 -0.91 . . . . 0.0 109.256 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -127.09 5.44 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 88.2 mtt180 -92.16 146.97 23.3 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.255 -1.144 . . . . 0.0 109.755 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.605 HG12 HG13 ' A' ' 62' ' ' VAL . 67.1 mt -112.55 134.16 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.913 . . . . 0.0 109.336 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.794 HG22 ' HZ3' ' A' ' 7' ' ' TRP . 33.3 m -128.08 155.77 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.235 -0.916 . . . . 0.0 109.45 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.781 HG22 HG23 ' A' ' 44' ' ' ILE . 11.5 mt -133.63 128.63 20.09 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.268 -0.895 . . . . 0.0 109.63 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.508 ' O ' HD13 ' A' ' 55' ' ' LEU . 43.8 Cg_endo -66.45 -3.89 9.77 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.928 2.418 . . . . 0.0 111.744 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.781 HG23 HG22 ' A' ' 42' ' ' ILE . 11.4 pt . . . . . 0 N--CA 1.488 1.469 0 O-C-N 121.145 -0.972 . . . . 0.0 109.464 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.693 ' HA ' HG22 ' A' ' 44' ' ' ILE . 4.7 mttp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.425 -0.584 . . . . 0.0 109.425 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.545 ' CD1' ' N ' ' A' ' 55' ' ' LEU . 5.2 mp -62.29 -24.68 67.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.171 -0.956 . . . . 0.0 109.465 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 1.153 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 97.4 m-85 -148.79 100.59 3.47 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.316 -0.865 . . . . 0.0 109.056 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -66.08 139.75 57.13 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.733 2.288 . . . . 0.0 111.855 -179.336 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.17 -12.5 6.88 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.589 ' CE1' HD11 ' A' ' 11' ' ' LEU . 2.5 m-30 -100.03 131.3 46.07 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.704 -1.468 . . . . 0.0 110.128 -179.317 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 45.6 t -134.62 144.77 33.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.361 -0.837 . . . . 0.0 108.887 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.775 ' HB2' HG23 ' A' ' 41' ' ' VAL . 74.2 m-85 -106.55 122.98 47.4 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.978 -1.077 . . . . 0.0 109.779 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.605 HG13 HG12 ' A' ' 40' ' ' ILE . 59.7 t -131.37 143.78 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.796 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.632 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 18.0 tt0 -108.2 127.29 53.7 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.328 -0.857 . . . . 0.0 109.166 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.462 ' HB3' ' O ' ' A' ' 36' ' ' LEU . 32.8 mtm -153.98 170.88 20.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.072 -1.018 . . . . 0.0 110.653 -179.261 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.813 ' CG1' HD13 ' A' ' 36' ' ' LEU . 5.3 pt -95.14 131.34 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.536 ' CE ' ' NE2' ' A' ' 89' ' ' GLN . 59.3 mmm -75.95 143.26 41.7 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.893 . . . . 0.0 109.897 -178.778 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.434 ' HB2' ' O ' ' A' ' 66' ' ' MET . 37.6 t30 178.23 158.06 0.46 Allowed 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -59.61 -42.06 91.79 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -0.927 . . . . 0.0 109.594 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.573 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 69.3 mm-40 -74.85 -34.1 62.22 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.891 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.088 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -69.13 -46.36 67.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.149 -0.97 . . . . 0.0 109.756 -179.679 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.55 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 91.1 t80 -61.06 -47.03 88.25 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.156 -0.965 . . . . 0.0 109.782 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.444 ' O ' ' HB2' ' A' ' 76' ' ' SER . 27.5 m120 -62.07 -28.36 69.55 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 109.861 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.573 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 13.7 m-85 -84.54 -42.55 15.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.15 -0.969 . . . . 0.0 109.756 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.735 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 25.9 t -69.76 -57.58 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.161 -0.962 . . . . 0.0 109.697 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.453 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 0.6 OUTLIER -59.26 -13.89 9.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.189 -0.944 . . . . 0.0 109.311 179.823 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.444 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 15.4 m -95.86 5.38 51.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.304 -0.873 . . . . 0.0 109.93 -179.72 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.814 ' O ' HG12 ' A' ' 80' ' ' VAL . 2.3 p -75.46 134.29 73.31 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 120.965 -1.085 . . . . 0.0 109.457 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.627 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 43.8 Cg_endo -65.17 138.82 57.9 Favored 'Trans proline' 0 C--O 1.214 -0.72 0 C-N-CA 122.88 2.387 . . . . 0.0 112.287 -179.277 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.675 ' CB ' HG22 ' A' ' 20' ' ' VAL . 24.3 m-85 90.79 -9.32 0.3 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.857 -0.527 . . . . 0.0 109.662 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.814 HG12 ' O ' ' A' ' 77' ' ' VAL . 5.7 p -90.88 127.08 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.979 -1.076 . . . . 0.0 109.332 179.506 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 82.8 mtp -86.24 -29.5 23.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.249 -0.907 . . . . 0.0 109.375 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.524 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 167.4 -164.22 37.74 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.735 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 21.3 m-85 -134.33 141.39 46.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.207 -1.173 . . . . 0.0 109.499 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.829 HG22 HD21 ' A' ' 11' ' ' LEU . 19.9 t -64.29 123.82 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.25 -0.906 . . . . 0.0 109.409 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.551 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.6 p -162.76 162.26 26.61 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.28 -0.887 . . . . 0.0 109.522 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.1 t -91.55 -33.33 15.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.276 -0.89 . . . . 0.0 109.343 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -129.66 -82.32 0.29 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.519 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -106.66 -131.57 6.82 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.55 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 1.4 mt-30 -33.31 152.08 0.05 OUTLIER Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.522 -0.987 . . . . 0.0 110.109 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.551 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.7 Cg_endo -69.1 159.25 54.64 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.841 2.361 . . . . 0.0 111.803 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 3.7 m -98.1 154.19 37.81 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.167 -0.958 . . . . 0.0 109.378 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.443 ' CB ' ' HD2' ' A' ' 6' ' ' LYS . 49.0 Cg_endo -70.19 150.99 66.41 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.612 2.208 . . . . 0.0 111.701 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.633 HG12 ' HG3' ' A' ' 98' ' ' MET . 31.2 t -85.46 142.38 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.249 -0.907 . . . . 0.0 109.33 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -78.37 139.2 38.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.936 . . . . 0.0 109.446 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.421 ' O ' ' N ' ' A' ' 99' ' ' ARG . 52.9 t0 -50.36 -39.14 45.62 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.497 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.5 mtm180 -52.06 -41.26 62.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.219 -0.926 . . . . 0.0 109.475 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.433 ' C ' ' HD2' ' A' ' 100' ' ' PRO . 63.0 mt-10 -85.38 -23.61 27.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.244 -0.91 . . . . 0.0 109.458 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.633 ' HG3' HG12 ' A' ' 93' ' ' VAL . 97.7 mtp -84.24 -23.64 30.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -0.927 . . . . 0.0 109.644 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.646 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 6.0 mmm180 -46.54 -48.04 48.13 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.256 -0.902 . . . . 0.0 109.788 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.646 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 50.6 Cg_endo -72.14 -27.3 17.03 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.394 2.063 . . . . 0.0 111.822 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.537 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 27.3 mm -81.49 -42.27 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.185 -0.947 . . . . 0.0 109.435 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.569 HD11 ' HB3' ' A' ' 98' ' ' MET . 1.2 mt -69.15 -39.9 78.54 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.237 -0.915 . . . . 0.0 109.339 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.557 ' CZ ' ' NH1' ' A' ' 99' ' ' ARG . 23.5 mtt180 -64.27 -51.17 64.86 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.3 -0.875 . . . . 0.0 109.148 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.5 tt -71.44 -36.17 71.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.346 -0.846 . . . . 0.0 109.247 179.557 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.56 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -70.86 -0.26 8.72 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.328 -0.857 . . . . 0.0 109.989 -179.729 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.19 9.12 84.1 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.719 HD21 HG11 ' A' ' 41' ' ' VAL . 10.1 mp -80.72 -22.67 40.1 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.194 -1.18 . . . . 0.0 109.456 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' GLU . . . . . 0.42 ' HG3' ' CB ' ' A' ' 102' ' ' LEU . 53.7 mt-10 . . . . . 0 N--CA 1.491 1.581 0 O-C-N 121.302 -0.874 . . . . 0.0 109.497 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.484 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 77.1 mttt -134.51 151.84 51.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.122 -0.986 . . . . 0.0 109.95 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 22.5 t -65.32 141.58 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.451 -0.781 . . . . 0.0 109.23 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.518 ' O ' HG13 ' A' ' 142' ' ' VAL . . . 89.19 -30.63 5.46 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.553 ' HB2' HD12 ' A' ' 143' ' ' ILE . 63.4 m-20 -47.8 161.89 0.09 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.309 -1.112 . . . . 0.0 108.989 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 6.1 ttm -102.09 128.23 48.65 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.025 -1.047 . . . . 0.0 109.096 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.735 HG11 HD11 ' A' ' 143' ' ' ILE . 11.6 m -128.67 143.88 39.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.387 -0.821 . . . . 0.0 109.715 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.52 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 44.4 tttt -100.84 140.56 34.96 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.913 HD12 ' HB3' ' A' ' 139' ' ' PHE . 86.1 mt -79.39 154.62 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.024 -1.048 . . . . 0.0 108.371 179.375 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.857 HD13 ' HG3' ' A' ' 174' ' ' GLU . 1.1 pt -149.12 0.46 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.015 -1.053 . . . . 0.0 109.505 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.601 ' CB ' ' HG2' ' A' ' 172' ' ' GLU . 3.1 m -148.68 147.54 29.03 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.058 -1.027 . . . . 0.0 110.372 -179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.77 -170.29 19.92 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.465 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 45.9 Cg_endo -68.24 -21.46 41.76 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.199 2.599 . . . . 0.0 112.487 -179.753 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.496 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 91.5 m-85 -108.81 16.33 22.84 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.002 -1.061 . . . . 0.0 109.284 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.718 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.5 tt0 -48.09 142.69 4.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.316 -0.865 . . . . 0.0 109.788 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.575 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 14.5 t0 81.44 23.17 0.29 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.424 -0.797 . . . . 0.0 110.242 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.913 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.0 OUTLIER -116.13 141.75 47.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.984 -1.073 . . . . 0.0 109.463 179.813 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -90.12 136.18 33.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.191 -0.943 . . . . 0.0 109.516 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.404 ' C ' ' CG1' ' A' ' 155' ' ' VAL . . . -148.02 171.18 28.56 Favored Glycine 0 N--CA 1.49 2.268 0 C-N-CA 119.636 -1.269 . . . . 0.0 110.538 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.908 ' C ' HG13 ' A' ' 155' ' ' VAL . 89.4 t -118.05 136.41 55.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.678 -0.895 . . . . 0.0 109.237 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.735 HD11 HG11 ' A' ' 129' ' ' VAL . 79.4 mt -66.78 115.8 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.43 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 33.2 tttt -97.63 -34.56 10.9 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.03 -1.044 . . . . 0.0 109.231 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -149.78 144.62 26.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.201 -0.937 . . . . 0.0 109.329 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 1.01 HG22 HD22 ' A' ' 153' ' ' LEU . 31.9 pt -123.98 127.66 73.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.573 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 28.5 t0 -111.81 100.19 47.72 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.484 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.568 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.3 Cg_endo -71.27 176.01 8.5 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.778 2.319 . . . . 0.0 111.71 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.568 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.4 mt-10 81.48 -21.05 0.33 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.434 -0.791 . . . . 0.0 109.84 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.431 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 82.1 mtt180 -131.15 -10.46 3.74 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.15 -0.969 . . . . 0.0 109.495 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.431 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 43.3 mt-30 69.97 48.54 0.54 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.252 -0.905 . . . . 0.0 109.967 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.541 ' OE2' HG13 ' A' ' 167' ' ' VAL . 81.3 tt0 -120.44 144.99 47.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.981 -1.075 . . . . 0.0 108.852 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 1.01 HD22 HG22 ' A' ' 146' ' ' ILE . 70.6 mt -139.91 127.69 21.9 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.102 -0.999 . . . . 0.0 110.441 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -91.74 132.77 36.16 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.908 HG13 ' C ' ' A' ' 142' ' ' VAL . 92.9 t -133.99 126.96 51.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.116 -0.99 . . . . 0.0 109.914 -179.358 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.577 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 51.9 t-20 -76.1 137.12 39.93 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.341 -0.85 . . . . 0.0 109.862 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.621 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 59.8 t -114.46 147.53 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.329 -0.857 . . . . 0.0 109.069 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 18.2 m -99.41 91.88 5.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.999 -1.063 . . . . 0.0 109.913 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 1.153 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 2.5 pt -124.58 151.53 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.235 -0.916 . . . . 0.0 108.991 179.311 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.724 ' CE2' HD12 ' A' ' 159' ' ' ILE . 16.7 m-30 60.53 35.45 20.16 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -0.926 . . . . 0.0 108.969 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.03 15.37 9.99 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 21.0 mtp180 -128.22 158.22 38.71 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.179 -1.189 . . . . 0.0 109.595 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' GLU . . . . . 0.452 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 90.7 mt-10 -100.97 132.76 46.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.268 -0.895 . . . . 0.0 109.551 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 164' ' ' THR . . . . . 0.536 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 47.4 m -139.78 127.31 12.85 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.943 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.577 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.59 134.1 25.49 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.741 2.294 . . . . 0.0 111.175 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.684 ' HB ' HD21 ' A' ' 168' ' ' LEU . 2.2 t -120.03 164.09 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 120.962 -1.086 . . . . 0.0 110.153 -179.527 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 1.143 ' O ' HD13 ' A' ' 168' ' ' LEU . 43.0 t -117.03 115.94 50.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 N-CA-C 109.119 -0.696 . . . . 0.0 109.119 179.481 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 1.143 HD13 ' O ' ' A' ' 167' ' ' VAL . 0.3 OUTLIER -139.49 167.55 21.84 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 121.878 0.847 . . . . 0.0 110.249 -179.52 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.415 ' O ' ' HB2' ' A' ' 172' ' ' GLU . 96.1 m-70 -78.94 141.01 37.92 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.584 HG23 HD12 ' A' ' 153' ' ' LEU . 7.2 p -55.01 -36.43 38.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.056 -1.028 . . . . 0.0 108.88 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.406 ' N ' HG13 ' A' ' 170' ' ' VAL . 33.6 p -75.07 -5.23 43.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.455 -0.778 . . . . 0.0 109.553 179.746 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.601 ' HG2' ' CB ' ' A' ' 133' ' ' SER . 2.4 mt-10 -87.17 -1.82 58.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.225 -0.922 . . . . 0.0 109.707 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 173' ' ' VAL . . . . . 0.52 ' HB ' ' O ' ' A' ' 130' ' ' LYS . 1.3 m -150.91 -178.31 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.138 -0.976 . . . . 0.0 109.465 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.857 ' HG3' HD13 ' A' ' 132' ' ' ILE . 3.5 mt-10 -138.01 170.2 16.45 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.082 -1.011 . . . . 0.0 109.1 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.519 ' HE2' ' OD2' ' A' ' 127' ' ' ASP . 52.0 tttm . . . . . 0 N--CA 1.489 1.513 0 O-C-N 121.0 -1.062 . . . . 0.0 109.553 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.505 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 27.4 mttm . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 1.3 mtpp -125.93 -179.78 4.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.196 -0.94 . . . . 0.0 109.321 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.787 ' CZ3' HG22 ' A' ' 41' ' ' VAL . 69.2 m95 -117.72 122.21 42.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.135 -0.978 . . . . 0.0 109.178 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -115.33 170.94 8.01 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.18 -0.95 . . . . 0.0 109.376 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.439 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 33.0 mt -112.89 110.74 33.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.296 -0.877 . . . . 0.0 109.065 179.681 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.541 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 10.3 p -88.66 142.48 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.215 -0.928 . . . . 0.0 109.512 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.548 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.2 OUTLIER -89.04 145.68 25.32 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.294 -0.879 . . . . 0.0 109.625 -179.893 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.704 ' CG2' HG21 ' A' ' 20' ' ' VAL . 96.0 m -156.84 160.78 39.51 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.285 -0.884 . . . . 0.0 109.52 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.591 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 94.9 mmm -76.98 124.19 27.42 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.216 -0.928 . . . . 0.0 109.469 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 13' ' ' MET . 70.2 m -44.59 125.44 4.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.95 . . . . 0.0 109.301 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.0 -19.98 34.26 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.591 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 92.0 m-85 -107.14 -5.64 17.86 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.22 -1.165 . . . . 0.0 109.505 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.684 ' OE1' HD11 ' A' ' 44' ' ' ILE . 68.2 mt-10 -51.52 -54.62 25.37 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 109.486 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -51.48 -34.49 35.95 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.219 -0.926 . . . . 0.0 109.368 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.46 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 64.1 mttm -76.35 -49.54 16.6 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.178 179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.704 HG21 ' CG2' ' A' ' 12' ' ' THR . 42.0 t -52.22 -49.92 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.337 -0.852 . . . . 0.0 109.365 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.681 ' HG3' HG21 ' A' ' 40' ' ' ILE . 29.9 tttt -56.83 -50.33 72.72 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.65 -34.55 77.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.332 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.527 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 32.8 m120 -65.32 -48.14 74.07 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.404 -0.81 . . . . 0.0 109.586 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 77.4 mt -54.02 -44.52 62.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.133 -0.98 . . . . 0.0 109.437 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.535 ' O ' HG22 ' A' ' 28' ' ' VAL . 75.1 tt0 -56.21 -46.14 79.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.246 -0.909 . . . . 0.0 109.721 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 7.7 mmtp -78.35 -36.13 46.58 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.16 -0.962 . . . . 0.0 109.509 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.465 ' O ' HG23 ' A' ' 31' ' ' THR . 8.9 tptt -53.9 -30.72 47.31 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.282 -0.886 . . . . 0.0 109.358 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.957 HG11 ' CG1' ' A' ' 37' ' ' VAL . 35.5 m -89.3 -22.04 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.3 -0.875 . . . . 0.0 109.41 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.422 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 44.6 mm-40 -70.71 -54.52 11.49 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.611 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.72 -31.09 71.95 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.185 -0.947 . . . . 0.0 109.451 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.465 HG23 ' O ' ' A' ' 27' ' ' LYS . 37.8 p -87.54 -8.23 56.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.413 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 60.58 28.54 67.89 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.719 HG23 HD23 ' A' ' 36' ' ' LEU . 46.7 mt -107.48 73.22 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -1.149 . . . . 0.0 109.515 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.6 mtmt -87.68 -2.36 58.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.225 -0.922 . . . . 0.0 109.573 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -94.08 -12.8 27.73 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -0.929 . . . . 0.0 109.473 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.769 HD12 ' HB2' ' A' ' 70' ' ' ALA . 1.8 mm? -86.92 -47.82 8.67 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.311 179.835 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.957 ' CG1' HG11 ' A' ' 28' ' ' VAL . 11.6 p -94.16 142.65 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.388 -0.82 . . . . 0.0 109.518 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -113.45 -123.97 4.08 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 82.0 mtt180 -94.43 140.07 30.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.253 -1.145 . . . . 0.0 109.619 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.681 HG21 ' HG3' ' A' ' 21' ' ' LYS . 58.8 mt -106.33 136.06 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 109.361 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.93 HG23 ' HB2' ' A' ' 61' ' ' PHE . 31.5 m -127.16 161.98 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.223 -0.923 . . . . 0.0 109.06 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.65 HD11 ' HD2' ' A' ' 21' ' ' LYS . 9.7 mt -144.02 126.99 8.72 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.142 -0.974 . . . . 0.0 110.034 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.69 -2.28 9.08 Favored 'Trans proline' 0 C--O 1.217 -0.533 0 C-N-CA 122.917 2.411 . . . . 0.0 111.381 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.833 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 76.8 mt . . . . . 0 C--N 1.303 -1.429 0 O-C-N 121.185 -0.947 . . . . 0.0 109.491 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.833 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 8.4 mttt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.581 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 61.3 tp -67.04 -23.13 65.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.8 -1.188 . . . . 0.0 109.666 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.741 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 57.1 m-85 -145.46 97.13 4.73 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 108.836 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -66.01 136.48 44.89 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.59 2.193 . . . . 0.0 112.247 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 12' ' ' THR . . . 76.74 -13.17 8.91 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.544 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 2.4 m-30 -100.84 130.47 46.86 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.688 -1.478 . . . . 0.0 110.23 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.541 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 79.2 t -134.38 147.44 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.373 -0.829 . . . . 0.0 108.809 179.457 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.93 ' HB2' HG23 ' A' ' 41' ' ' VAL . 15.7 m-85 -107.58 122.12 46.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.005 -1.06 . . . . 0.0 109.956 -179.532 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.441 HG12 HG23 ' A' ' 40' ' ' ILE . 7.9 m -125.81 136.77 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.405 -0.809 . . . . 0.0 109.642 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.572 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 7.8 tt0 -101.01 123.96 45.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.228 -0.92 . . . . 0.0 108.974 179.553 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.529 ' HB3' ' O ' ' A' ' 36' ' ' LEU . 14.0 mtm -156.06 176.45 12.65 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.999 -1.063 . . . . 0.0 110.36 -179.266 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.621 ' CG1' HD13 ' A' ' 36' ' ' LEU . 7.9 pt -99.38 132.28 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.479 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 47.4 ttm -76.66 144.17 39.63 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.347 -0.846 . . . . 0.0 109.992 -178.805 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.479 ' HB2' ' O ' ' A' ' 66' ' ' MET . 50.6 t30 176.2 171.53 0.4 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -67.25 -41.64 85.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.1 -1.0 . . . . 0.0 109.446 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.579 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 97.4 mt-10 -71.72 -38.1 70.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.295 -0.878 . . . . 0.0 109.872 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.769 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -64.93 -44.9 87.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.19 -0.944 . . . . 0.0 109.466 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.493 ' CD2' ' OE1' ' A' ' 89' ' ' GLN . 27.9 t80 -60.0 -52.02 67.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.284 -0.885 . . . . 0.0 109.641 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.523 ' O ' ' HB3' ' A' ' 76' ' ' SER . 96.1 m-20 -59.34 -28.32 66.72 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.204 -0.935 . . . . 0.0 110.164 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 21.9 m-85 -85.45 -43.53 13.52 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.957 -1.089 . . . . 0.0 109.95 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.407 ' O ' HG12 ' A' ' 77' ' ' VAL . 71.6 t -70.06 -57.84 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.288 -0.883 . . . . 0.0 110.025 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.513 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 29.3 tpt85 -60.83 -22.58 64.34 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.171 -0.956 . . . . 0.0 109.826 -179.669 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.523 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 35.4 p -93.71 5.89 50.13 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.127 -0.983 . . . . 0.0 109.88 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.718 HG11 HG21 ' A' ' 80' ' ' VAL . 5.1 p -70.15 129.42 90.66 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.125 -0.985 . . . . 0.0 109.331 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.671 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 43.5 Cg_endo -65.48 138.92 56.81 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 122.782 2.322 . . . . 0.0 112.177 -179.382 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.671 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 59.9 m-85 91.54 -11.98 0.23 Allowed 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.718 HG21 HG11 ' A' ' 77' ' ' VAL . 4.7 t -93.96 134.12 32.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.994 -1.066 . . . . 0.0 109.171 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 85.6 mmm -87.95 -27.4 22.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.205 -0.934 . . . . 0.0 109.492 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.9 -160.24 32.24 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.617 ' CD1' ' N ' ' A' ' 83' ' ' PHE . 1.6 p90 -139.61 153.92 47.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -1.094 . . . . 0.0 109.314 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.669 ' O ' HG13 ' A' ' 84' ' ' VAL . 10.6 p -84.71 113.7 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.188 -0.945 . . . . 0.0 109.615 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.557 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.4 p -148.47 163.24 37.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.895 . . . . 0.0 109.438 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 80.6 p -86.5 -34.55 19.98 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.419 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -127.32 -91.11 0.74 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.557 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -102.59 -126.95 5.97 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.557 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -30.27 152.39 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.61 -0.935 . . . . 0.0 110.375 -179.606 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.565 ' HD3' ' CD2' ' A' ' 83' ' ' PHE . 47.1 Cg_endo -68.13 137.69 41.39 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.917 2.411 . . . . 0.0 112.014 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 18.8 m -73.54 144.92 84.25 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.351 -0.843 . . . . 0.0 109.336 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.31 153.81 66.08 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.645 2.23 . . . . 0.0 111.702 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 7' ' ' TRP . 18.6 t -93.9 129.45 44.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.379 -0.826 . . . . 0.0 109.36 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 25.4 mttm -64.29 141.38 58.79 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.227 -0.921 . . . . 0.0 109.512 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -51.37 -38.64 54.36 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.228 -0.92 . . . . 0.0 109.415 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 62.3 mtt85 -58.2 -38.26 76.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.347 -0.846 . . . . 0.0 109.557 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -77.61 -25.93 50.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.196 -0.94 . . . . 0.0 109.454 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.608 ' CB ' HD11 ' A' ' 102' ' ' LEU . 95.4 mtp -86.03 -22.27 27.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.388 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.609 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 1.1 mtm180 -36.27 -52.8 1.7 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.525 -0.734 . . . . 0.0 109.861 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.612 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 49.7 Cg_endo -70.01 -27.98 24.62 Favored 'Trans proline' 0 C--O 1.214 -0.718 0 C-N-CA 122.469 2.113 . . . . 0.0 111.908 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.526 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 29.8 mm -81.98 -43.41 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.176 -0.952 . . . . 0.0 109.451 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.608 HD11 ' CB ' ' A' ' 98' ' ' MET . 1.2 mt -68.94 -40.0 79.26 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.23 -0.919 . . . . 0.0 109.445 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.547 ' NH2' ' NH1' ' A' ' 99' ' ' ARG . 24.1 mtt180 -64.36 -50.59 67.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.124 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.62 -36.07 70.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.382 -0.824 . . . . 0.0 109.3 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.618 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -71.27 1.47 6.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.323 -0.861 . . . . 0.0 110.035 -179.776 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.07 8.25 82.88 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.633 HD21 HG11 ' A' ' 41' ' ' VAL . 9.4 mp -80.91 -22.07 40.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -1.148 . . . . 0.0 109.368 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' GLU . . . . . 0.491 ' HB3' ' HA ' ' A' ' 103' ' ' ARG . 47.6 tp10 . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.333 -0.854 . . . . 0.0 109.487 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.746 ' CE1' HG21 ' A' ' 146' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.452 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 7.1 mttp -141.13 145.42 35.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.076 -1.015 . . . . 0.0 109.868 -179.734 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.52 HG12 HG12 ' A' ' 146' ' ' ILE . 22.4 m -63.98 141.99 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.38 -0.825 . . . . 0.0 109.397 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 87.44 -31.69 4.42 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.017 -1.633 . . . . 0.0 109.017 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.496 ' CG ' ' CE ' ' A' ' 175' ' ' LYS . 13.0 t70 -48.5 164.04 0.06 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.513 -0.992 . . . . 0.0 109.055 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.2 ttm -100.29 127.47 46.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.086 -1.009 . . . . 0.0 109.241 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.585 ' CG1' HG12 ' A' ' 143' ' ' ILE . 35.0 m -125.89 142.35 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.34 -0.85 . . . . 0.0 109.26 179.795 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.451 ' O ' HG23 ' A' ' 173' ' ' VAL . 7.8 tttt -102.79 141.83 34.94 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.357 -0.839 . . . . 0.0 108.858 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 1.041 HD12 ' HB3' ' A' ' 139' ' ' PHE . 89.8 mt -81.73 152.35 4.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.102 -0.999 . . . . 0.0 108.557 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.586 HD11 ' CA ' ' A' ' 173' ' ' VAL . 0.5 OUTLIER -150.45 1.64 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.024 -1.048 . . . . 0.0 109.382 179.647 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.521 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 2.9 m -147.27 143.49 28.15 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.128 -0.982 . . . . 0.0 109.896 -179.726 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.17 -166.92 17.76 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.603 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 45.7 Cg_endo -68.49 -22.51 38.65 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 123.179 2.586 . . . . 0.0 112.594 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.612 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 70.7 m-85 -106.46 17.3 23.54 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.786 -1.196 . . . . 0.0 109.533 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.689 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.5 tt0 -48.18 137.57 10.56 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.168 -0.957 . . . . 0.0 109.599 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.555 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 10.8 m-20 81.62 22.34 0.3 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.479 -0.763 . . . . 0.0 110.323 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 1.041 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.5 t80 -115.03 143.04 45.81 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.966 -1.084 . . . . 0.0 109.566 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -92.0 134.7 34.57 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.146 -0.971 . . . . 0.0 109.493 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.41 167.24 27.52 Favored Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.739 -1.22 . . . . 0.0 110.212 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.662 ' C ' HG13 ' A' ' 155' ' ' VAL . 37.6 t -115.07 137.14 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.54 -0.976 . . . . 0.0 109.139 179.651 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 1.067 ' CG2' HD11 ' A' ' 146' ' ' ILE . 28.1 mm -69.13 122.4 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.262 -0.899 . . . . 0.0 109.423 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.456 ' C ' ' HG2' ' A' ' 145' ' ' GLU . 0.2 OUTLIER -106.53 -33.3 7.73 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.04 -1.038 . . . . 0.0 109.627 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.761 ' O ' HD13 ' A' ' 146' ' ' ILE . 70.0 mm-40 -151.38 146.58 26.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.014 -1.054 . . . . 0.0 109.874 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 1.149 HG23 ' CD2' ' A' ' 153' ' ' LEU . 6.0 mm -120.86 122.76 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.091 -1.006 . . . . 0.0 109.491 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 14.7 t0 -107.08 99.21 25.38 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.307 -0.87 . . . . 0.0 109.349 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.565 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.6 Cg_endo -71.45 172.26 14.57 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.801 2.334 . . . . 0.0 111.841 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.565 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 4.6 mt-10 80.62 -20.16 0.39 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.377 -0.827 . . . . 0.0 109.786 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 94.8 mtt-85 -128.04 -13.66 5.08 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.142 -0.974 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.432 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 35.9 mt-30 70.33 48.47 0.49 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.245 -0.909 . . . . 0.0 109.38 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -120.01 143.13 48.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.085 -1.01 . . . . 0.0 109.245 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 1.149 ' CD2' HG23 ' A' ' 146' ' ' ILE . 98.8 mt -128.64 130.73 47.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.219 -0.926 . . . . 0.0 110.103 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.469 ' HD3' ' HB2' ' A' ' 145' ' ' GLU . 22.7 mtpp -92.93 126.17 37.89 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.892 HG22 HD13 ' A' ' 143' ' ' ILE . 4.0 t -126.31 145.86 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.252 -0.905 . . . . 0.0 110.086 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 27.7 t-20 -98.87 114.9 27.7 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.451 -0.781 . . . . 0.0 109.326 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.621 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 41.7 t -97.54 142.59 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.373 -0.829 . . . . 0.0 109.665 -179.793 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 13.3 m -96.57 95.61 8.1 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.784 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.753 HD12 ' CE2' ' A' ' 160' ' ' PHE . 19.0 pt -125.94 146.72 31.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.319 -0.863 . . . . 0.0 109.301 179.76 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.753 ' CE2' HD12 ' A' ' 159' ' ' ILE . 11.5 m-85 63.24 36.26 12.0 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.219 -0.926 . . . . 0.0 109.321 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.05 16.64 19.53 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.41 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 17.8 mtt-85 -130.15 158.69 38.98 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.291 -1.123 . . . . 0.0 109.548 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 163' ' ' GLU . . . . . 0.405 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 94.7 mt-10 -99.42 132.99 44.37 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.202 -0.936 . . . . 0.0 109.375 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 164' ' ' THR . . . . . 0.433 HG21 ' CZ ' ' A' ' 56' ' ' PHE . 27.9 m -144.13 124.84 7.74 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.188 -0.945 . . . . 0.0 109.647 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.538 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -70.81 139.47 36.67 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.738 2.292 . . . . 0.0 111.763 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.653 HG13 HD23 ' A' ' 168' ' ' LEU . 5.6 p -124.48 143.58 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.155 -0.965 . . . . 0.0 109.646 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.59 HG13 ' O ' ' A' ' 167' ' ' VAL . 10.7 p -92.31 119.36 39.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.414 -0.804 . . . . 0.0 109.33 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.653 HD23 HG13 ' A' ' 166' ' ' VAL . 0.7 OUTLIER -140.48 165.91 26.14 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.22 -0.925 . . . . 0.0 110.621 -179.054 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.451 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 53.2 m80 -80.32 145.54 32.05 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.726 HG23 HD11 ' A' ' 153' ' ' LEU . 11.0 p -60.14 -34.58 57.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.19 -0.944 . . . . 0.0 108.975 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 54.3 p -76.82 -6.73 53.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.322 -0.861 . . . . 0.0 109.321 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.521 ' HA ' ' HB2' ' A' ' 133' ' ' SER . 74.4 mt-10 -96.33 5.94 49.85 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.299 -0.876 . . . . 0.0 109.25 179.755 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 173' ' ' VAL . . . . . 0.607 HG11 HD11 ' A' ' 168' ' ' LEU . 1.5 p -148.07 169.01 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.279 -0.888 . . . . 0.0 108.723 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.603 ' N ' HG22 ' A' ' 173' ' ' VAL . 57.0 mt-10 -138.51 167.79 21.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.011 -1.056 . . . . 0.0 109.202 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.519 ' HA ' HG12 ' A' ' 129' ' ' VAL . 63.0 tttt . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.077 -1.015 . . . . 0.0 109.485 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.6 mttt . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 121.296 0.57 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 24.6 mmtp -128.75 175.5 8.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -0.93 . . . . 0.0 109.307 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.908 ' CH2' HG23 ' A' ' 41' ' ' VAL . 64.6 m95 -112.17 124.59 52.77 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.247 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.612 ' CZ ' ' HG3' ' A' ' 66' ' ' MET . 81.3 m-85 -117.0 170.98 8.21 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.212 -0.93 . . . . 0.0 109.422 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.612 HG12 ' CE1' ' A' ' 61' ' ' PHE . 42.1 mt -107.45 116.33 50.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.251 -0.905 . . . . 0.0 109.379 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.621 ' CG1' HG23 ' A' ' 80' ' ' VAL . 50.0 t -93.43 139.14 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.241 -0.912 . . . . 0.0 109.362 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.567 HD11 ' HE1' ' A' ' 59' ' ' TYR . 4.2 mm? -86.78 146.28 26.3 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.316 -0.865 . . . . 0.0 109.33 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.561 ' OG1' HG21 ' A' ' 20' ' ' VAL . 11.2 t -158.24 -176.21 5.78 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.263 -0.898 . . . . 0.0 109.501 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.507 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 64.0 mtm -101.2 120.01 39.6 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.175 -0.953 . . . . 0.0 109.533 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.435 ' OG ' ' HB2' ' A' ' 57' ' ' PRO . 43.0 m -43.39 128.3 4.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 109.385 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.08 -19.88 47.43 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.507 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 87.2 m-85 -109.54 9.59 25.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.346 -1.091 . . . . 0.0 109.511 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.531 ' HG2' HG21 ' A' ' 12' ' ' THR . 95.6 mt-10 -60.03 -45.1 93.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.203 -0.936 . . . . 0.0 109.493 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -58.82 -35.31 72.67 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.183 -0.948 . . . . 0.0 109.329 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.401 ' O ' ' HB2' ' A' ' 23' ' ' ASN . 83.7 mttt -72.73 -34.0 66.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -0.929 . . . . 0.0 109.355 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.561 HG21 ' OG1' ' A' ' 12' ' ' THR . 87.0 t -72.39 -53.05 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.912 . . . . 0.0 109.461 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.507 ' HG3' HG21 ' A' ' 40' ' ' ILE . 46.2 tttm -57.62 -49.91 74.9 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.301 -0.874 . . . . 0.0 109.372 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -63.4 -35.86 81.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.196 -0.94 . . . . 0.0 109.165 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.744 ' OD1' HG22 ' A' ' 77' ' ' VAL . 13.8 t-20 -62.72 -47.59 82.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.345 -0.847 . . . . 0.0 109.48 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.415 ' CG2' HG11 ' A' ' 37' ' ' VAL . 89.7 mt -55.75 -43.58 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.278 -0.889 . . . . 0.0 109.501 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -57.64 -46.87 83.62 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.943 . . . . 0.0 110.11 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 76.4 mttt -75.63 -37.31 59.83 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.984 -1.073 . . . . 0.0 109.824 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.93 ' CD ' HG23 ' A' ' 77' ' ' VAL . 42.2 tttp -55.95 -29.68 60.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.133 -0.98 . . . . 0.0 109.204 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.818 HG13 ' O ' ' A' ' 33' ' ' ILE . 37.8 t -82.98 -26.42 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.866 . . . . 0.0 109.508 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.416 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 66.8 mm-40 -67.68 -51.65 47.16 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.247 -0.908 . . . . 0.0 109.474 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.07 -43.91 51.54 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.246 -0.909 . . . . 0.0 109.444 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.401 HG21 ' CZ ' ' A' ' 73' ' ' PHE . 62.6 p -88.88 -7.95 55.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.187 -0.946 . . . . 0.0 109.624 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 54.95 22.58 28.12 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.073 HG21 ' CD1' ' A' ' 36' ' ' LEU . 74.8 mt -84.69 100.91 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.252 -1.146 . . . . 0.0 109.512 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.5 mttt -103.54 35.33 2.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.264 -0.897 . . . . 0.0 109.357 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.566 ' OD1' HG23 ' A' ' 33' ' ' ILE . 18.6 p-10 -136.41 8.45 3.13 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.204 -0.935 . . . . 0.0 109.784 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.073 ' CD1' HG21 ' A' ' 33' ' ' ILE . 82.1 mt -113.09 -42.88 3.46 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.22 -0.925 . . . . 0.0 109.34 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.48 ' HA ' ' HB3' ' A' ' 64' ' ' MET . 52.5 t -106.93 138.68 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.226 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -109.37 -124.65 4.93 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.409 ' O ' ' CH2' ' A' ' 7' ' ' TRP . 64.8 mtt85 -95.13 140.12 30.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.243 -1.151 . . . . 0.0 109.789 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.548 HG23 HG12 ' A' ' 62' ' ' VAL . 67.9 mt -102.13 135.94 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.307 -0.87 . . . . 0.0 109.032 179.586 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.908 HG23 ' CH2' ' A' ' 7' ' ' TRP . 53.5 t -118.51 147.21 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.066 -1.021 . . . . 0.0 109.678 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.9 HG22 HG23 ' A' ' 44' ' ' ILE . 2.5 mt -119.74 125.72 27.28 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.254 -0.904 . . . . 0.0 109.411 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.501 ' CB ' ' CD2' ' A' ' 56' ' ' PHE . 49.6 Cg_endo -70.33 -5.33 16.3 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.735 2.29 . . . . 0.0 111.814 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.9 HG23 HG22 ' A' ' 42' ' ' ILE . 14.6 pt . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.258 -0.901 . . . . 0.0 109.569 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.571 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 37.8 mttt . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.618 ' O ' ' CD1' ' A' ' 56' ' ' PHE . 49.4 mt -60.72 -24.77 65.93 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.091 -1.006 . . . . 0.0 109.462 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 1.058 ' CE1' HD11 ' A' ' 159' ' ' ILE . 1.0 OUTLIER -151.59 104.58 2.89 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.298 -0.876 . . . . 0.0 108.78 179.655 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.435 ' HB2' ' OG ' ' A' ' 14' ' ' SER . 43.7 Cg_endo -66.93 142.17 61.39 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.541 2.161 . . . . 0.0 111.845 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.48 -9.48 10.31 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.567 ' HE1' HD11 ' A' ' 11' ' ' LEU . 2.9 m-30 -102.52 132.08 48.81 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.8 -1.412 . . . . 0.0 110.046 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 45.8 t -134.74 147.75 29.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.859 . . . . 0.0 108.818 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.612 ' CE1' HG12 ' A' ' 9' ' ' ILE . 93.2 m-85 -110.34 123.19 49.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.937 -1.102 . . . . 0.0 109.902 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.548 HG12 HG23 ' A' ' 40' ' ' ILE . 4.9 m -130.66 143.34 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.302 -0.874 . . . . 0.0 109.767 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.608 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 8.1 tt0 -101.46 125.35 48.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 109.04 179.662 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.523 ' CE ' HG11 ' A' ' 74' ' ' VAL . 14.6 ptt? -163.38 -177.37 5.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.984 -1.072 . . . . 0.0 110.457 -179.532 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.843 HD11 ' CD2' ' A' ' 36' ' ' LEU . 7.5 pt -100.9 125.04 54.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.539 -0.726 . . . . 0.0 109.578 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.612 ' HG3' ' CZ ' ' A' ' 8' ' ' TYR . 73.5 mmm -89.56 99.64 12.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 109.398 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.446 ' OD1' HG13 ' A' ' 65' ' ' ILE . 21.3 m120 -139.04 -164.29 1.63 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.062 -1.024 . . . . 0.0 109.174 179.843 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -73.04 -51.92 16.34 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.249 -0.907 . . . . 0.0 110.005 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -72.82 -58.34 3.41 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.096 -1.003 . . . . 0.0 109.743 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.007 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -47.3 -44.19 23.13 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.456 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.663 ' CD1' ' NE2' ' A' ' 89' ' ' GLN . 88.0 t80 -61.65 -51.6 67.79 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.164 -0.96 . . . . 0.0 109.586 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.492 ' O ' ' HB3' ' A' ' 76' ' ' SER . 83.6 m-20 -59.16 -29.28 67.32 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.228 -0.92 . . . . 0.0 109.888 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.604 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 15.8 t80 -82.61 -43.21 17.28 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.091 -1.006 . . . . 0.0 109.636 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 1.007 HG23 ' O ' ' A' ' 70' ' ' ALA . 16.4 t -65.22 -58.1 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.41 -0.806 . . . . 0.0 109.505 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.511 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 15.1 tpt180 -58.23 -11.02 2.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.324 -0.86 . . . . 0.0 110.095 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.492 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 29.0 p -95.41 5.38 51.79 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.927 -1.108 . . . . 0.0 109.898 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.93 HG23 ' CD ' ' A' ' 27' ' ' LYS . 0.3 OUTLIER -71.85 128.72 89.11 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.094 -1.004 . . . . 0.0 109.086 179.871 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.644 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 42.0 Cg_endo -64.97 140.45 66.26 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.566 2.177 . . . . 0.0 111.891 -179.546 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.644 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 8.2 m-85 91.7 -10.02 0.24 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.89 -0.506 . . . . 0.0 109.817 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.72 HG12 ' O ' ' A' ' 77' ' ' VAL . 4.3 p -93.57 134.47 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.879 -1.138 . . . . 0.0 109.85 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 88.6 mtp -86.91 -23.98 24.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.379 -0.825 . . . . 0.0 109.258 179.644 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.572 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 155.19 -156.38 26.91 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.572 ' CD1' ' O ' ' A' ' 82' ' ' GLY . 15.3 m-85 -135.19 143.22 46.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.266 -1.137 . . . . 0.0 109.474 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.461 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 9.5 p -69.46 131.81 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.286 -0.884 . . . . 0.0 109.512 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.56 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.3 p -166.92 158.65 12.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.271 -0.893 . . . . 0.0 109.616 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.2 m -86.05 -31.79 21.78 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.282 -0.886 . . . . 0.0 109.269 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -131.03 -85.37 0.34 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.542 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -104.17 -134.24 8.09 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.663 ' NE2' ' CD1' ' A' ' 71' ' ' TYR . 2.6 mp0 -30.91 150.79 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.819 0 O-C-N 121.557 -0.967 . . . . 0.0 110.317 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.56 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.5 Cg_endo -68.38 141.3 50.92 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.819 2.346 . . . . 0.0 112.087 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' VAL . . . . . 0.758 HG23 ' HD2' ' A' ' 92' ' ' PRO . 4.0 p -77.14 144.35 71.4 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.344 -0.847 . . . . 0.0 109.364 179.801 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.758 ' HD2' HG23 ' A' ' 91' ' ' VAL . 47.4 Cg_endo -68.39 153.52 73.92 Favored 'Trans proline' 0 C--O 1.216 -0.575 0 C-N-CA 122.66 2.24 . . . . 0.0 111.743 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.52 ' CG1' ' HB2' ' A' ' 97' ' ' GLU . 86.2 t -89.38 133.66 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.268 -0.895 . . . . 0.0 109.649 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 26.4 mtmt -61.49 138.4 58.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.331 -0.856 . . . . 0.0 109.449 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -49.4 -35.81 20.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.928 . . . . 0.0 109.464 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 76.5 mtt180 -61.57 -28.95 69.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.504 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.52 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . 77.1 mt-10 -82.41 -25.22 33.9 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.92 . . . . 0.0 109.599 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.509 ' HE3' HD11 ' A' ' 102' ' ' LEU . 30.9 mmm -85.37 -28.92 24.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.208 -0.932 . . . . 0.0 109.385 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.597 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -36.33 -54.26 1.56 Allowed Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.413 -0.804 . . . . 0.0 109.844 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.639 ' HB2' ' CE1' ' A' ' 136' ' ' PHE . 48.6 Cg_endo -69.28 -26.91 29.39 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.581 2.188 . . . . 0.0 111.938 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.456 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 22.3 mm -82.67 -39.42 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.255 -0.903 . . . . 0.0 109.352 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.688 HD13 ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -72.05 -40.53 68.27 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.097 179.823 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.496 ' HA ' ' HB2' ' A' ' 108' ' ' GLU . 9.3 ttt180 -64.54 -48.5 74.84 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.869 . . . . 0.0 109.158 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.2 tt -71.72 -35.12 70.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.271 -0.893 . . . . 0.0 109.184 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.46 ' CB ' HG13 ' A' ' 41' ' ' VAL . . . -71.83 2.15 5.92 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.335 -0.853 . . . . 0.0 110.178 -179.68 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.0 9.4 83.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.455 ' HB3' ' HB3' ' A' ' 102' ' ' LEU . 0.4 OUTLIER -76.56 -18.68 58.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.073 -1.251 . . . . 0.0 109.314 179.85 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 108' ' ' GLU . . . . . 0.496 ' HB2' ' HA ' ' A' ' 103' ' ' ARG . 91.2 mt-10 . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.278 -0.889 . . . . 0.0 109.555 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.449 ' HA ' ' HD2' ' A' ' 175' ' ' LYS . 45.7 p90 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.405 ' HG2' ' C ' ' A' ' 123' ' ' PHE . 12.5 mmtt -138.12 163.75 30.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.094 -1.004 . . . . 0.0 110.063 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 11.0 p -62.9 141.95 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.443 -0.785 . . . . 0.0 109.548 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.461 ' O ' HG23 ' A' ' 142' ' ' VAL . . . 86.98 -33.21 3.83 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.531 ' HB2' HD12 ' A' ' 143' ' ' ILE . 71.4 m-20 -46.51 161.76 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.378 -1.072 . . . . 0.0 109.102 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 15.4 ttm -99.82 127.88 45.96 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.138 -0.976 . . . . 0.0 108.959 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.679 HG11 HD11 ' A' ' 143' ' ' ILE . 33.4 m -127.78 143.21 41.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.193 -0.942 . . . . 0.0 109.612 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.5 ' HG3' ' O ' ' A' ' 139' ' ' PHE . 12.1 ttpt -101.69 143.02 32.16 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.45 -0.781 . . . . 0.0 109.046 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.776 HD12 ' HB3' ' A' ' 139' ' ' PHE . 93.1 mt -80.39 147.0 6.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.132 -0.98 . . . . 0.0 108.421 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.547 HG13 ' C ' ' A' ' 131' ' ' ILE . 18.7 mt -145.03 1.22 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.018 -1.051 . . . . 0.0 109.337 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.517 ' HA ' ' HG2' ' A' ' 137' ' ' GLU . 16.7 t -148.48 142.37 25.77 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.188 -0.945 . . . . 0.0 109.689 -179.608 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.449 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 105.38 -166.5 14.44 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.472 ' HA ' ' HD3' ' A' ' 103' ' ' ARG . 47.7 Cg_endo -68.09 -19.88 44.7 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 123.23 2.62 . . . . 0.0 112.714 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.655 ' HB2' HD13 ' A' ' 131' ' ' ILE . 96.4 m-85 -107.28 19.74 19.92 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.816 -1.177 . . . . 0.0 109.626 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.525 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 36.7 mt-10 -43.85 137.51 3.13 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.206 -0.934 . . . . 0.0 109.991 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.525 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.6 OUTLIER 77.87 26.47 0.62 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.259 -0.901 . . . . 0.0 110.675 178.87 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.805 ' CE1' HG13 ' A' ' 157' ' ' VAL . 2.0 t80 -114.62 159.79 20.05 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.774 -1.204 . . . . 0.0 109.556 179.696 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -108.63 135.22 50.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.245 -0.909 . . . . 0.0 109.399 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -146.86 170.23 27.84 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.52 -179.458 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.733 ' C ' HG23 ' A' ' 155' ' ' VAL . 8.5 p -119.19 136.94 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.627 -0.926 . . . . 0.0 109.222 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.679 HD11 HG11 ' A' ' 129' ' ' VAL . 88.7 mt -67.22 115.14 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.302 -0.874 . . . . 0.0 109.445 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 68.9 tttt -98.33 -34.77 10.55 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.099 -1.001 . . . . 0.0 109.223 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -149.39 144.47 26.41 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.105 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 1.001 HG22 HD22 ' A' ' 153' ' ' LEU . 26.7 pt -126.27 129.32 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.101 -0.999 . . . . 0.0 109.695 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.85 103.13 48.5 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.345 -0.847 . . . . 0.0 109.38 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.549 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.3 Cg_endo -71.08 169.37 20.73 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.711 2.274 . . . . 0.0 111.898 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.549 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.2 tt0 80.81 -21.23 0.33 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.433 -0.792 . . . . 0.0 110.044 179.683 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.443 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 24.0 mtp85 -124.91 -11.73 7.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.063 -1.023 . . . . 0.0 109.515 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.443 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 42.8 mt-30 69.07 48.13 0.7 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.316 -0.865 . . . . 0.0 109.499 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.72 ' OE2' HG13 ' A' ' 167' ' ' VAL . 56.3 tt0 -121.13 144.93 48.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.104 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 1.001 HD22 HG22 ' A' ' 146' ' ' ILE . 58.1 mt -139.54 121.89 16.02 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.16 -0.963 . . . . 0.0 110.226 -179.701 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.448 ' HE3' ' CB ' ' A' ' 165' ' ' PRO . 18.5 ttpt -83.18 132.04 35.09 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.242 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.733 HG23 ' C ' ' A' ' 142' ' ' VAL . 9.0 p -125.92 149.76 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.781 -179.612 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.531 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 3.5 t30 -99.19 116.21 30.87 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.396 -0.815 . . . . 0.0 109.205 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.805 HG13 ' CE1' ' A' ' 139' ' ' PHE . 65.7 t -102.59 146.09 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.212 -0.93 . . . . 0.0 109.581 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 25.8 m -93.75 113.02 24.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.356 -0.84 . . . . 0.0 109.533 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 1.058 HD11 ' CE1' ' A' ' 56' ' ' PHE . 15.0 pt -145.35 144.6 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.256 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.567 ' CE2' HD12 ' A' ' 159' ' ' ILE . 46.5 m-85 60.18 35.78 21.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.133 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.91 15.41 13.09 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 67.7 mtp180 -127.37 154.28 45.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.063 -1.257 . . . . 0.0 109.637 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' GLU . . . . . 0.436 ' N ' ' OE1' ' A' ' 163' ' ' GLU . 58.0 mp0 -97.73 134.9 40.28 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.151 -0.968 . . . . 0.0 109.427 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 24.5 m -147.9 126.12 5.99 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.257 -0.902 . . . . 0.0 109.764 -179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.531 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.8 Cg_endo -70.83 142.8 44.06 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.702 2.268 . . . . 0.0 111.545 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 41.8 t -125.72 144.08 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.058 -1.026 . . . . 0.0 109.788 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.72 HG13 ' OE2' ' A' ' 152' ' ' GLU . 55.4 t -91.48 118.4 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.414 -0.804 . . . . 0.0 109.194 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.407 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 27.0 mt -140.71 166.31 25.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.12 -0.987 . . . . 0.0 110.543 -179.014 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.438 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 79.7 m80 -81.54 144.44 31.3 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.6 HG23 ' CD1' ' A' ' 153' ' ' LEU . 11.6 p -59.22 -35.39 57.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.346 -0.846 . . . . 0.0 109.025 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.421 ' N ' HG13 ' A' ' 170' ' ' VAL . 19.4 m -76.96 -8.16 56.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.249 -0.907 . . . . 0.0 109.508 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.467 ' HG2' ' HB3' ' A' ' 133' ' ' SER . 18.6 mt-10 -92.22 2.22 56.74 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.301 -0.874 . . . . 0.0 109.195 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 4.1 m -145.06 173.07 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.313 -0.867 . . . . 0.0 109.242 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.533 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 84.2 tt0 -136.94 164.0 29.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.165 -0.959 . . . . 0.0 108.985 179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.533 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 36.7 tttm . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.084 -1.01 . . . . 0.0 109.521 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.709 ' HG2' HG22 ' A' ' 65' ' ' ILE . 20.5 mttt . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.595 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.4 mmtp -129.99 172.11 12.07 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.277 -0.89 . . . . 0.0 109.419 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.938 ' O ' HG23 ' A' ' 93' ' ' VAL . 61.3 m95 -107.44 127.17 53.36 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.286 -0.884 . . . . 0.0 109.215 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.428 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 54.0 m-85 -117.86 167.88 11.0 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.179 -0.951 . . . . 0.0 109.288 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.555 ' HB ' HG12 ' A' ' 84' ' ' VAL . 22.7 mt -101.98 118.32 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.903 . . . . 0.0 109.29 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.539 HG23 HG22 ' A' ' 62' ' ' VAL . 84.3 t -93.88 136.79 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.273 -0.892 . . . . 0.0 109.337 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.489 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.2 OUTLIER -89.2 141.13 28.78 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.202 -0.936 . . . . 0.0 109.419 -179.901 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.533 ' OG1' HG21 ' A' ' 20' ' ' VAL . 11.3 t -154.48 -170.91 3.68 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.282 -0.886 . . . . 0.0 109.442 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 59.2 mtm -105.07 122.93 46.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.203 -0.935 . . . . 0.0 109.496 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 21.0 m -45.75 128.87 8.99 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.223 -0.923 . . . . 0.0 109.278 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.74 -20.18 44.8 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -111.01 10.23 22.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.278 -1.131 . . . . 0.0 109.57 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.594 ' OE1' HD13 ' A' ' 44' ' ' ILE . 94.8 mt-10 -61.8 -46.59 88.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.204 -0.935 . . . . 0.0 109.456 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -56.73 -34.02 67.11 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.19 -0.943 . . . . 0.0 109.524 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -75.31 -44.72 43.95 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.241 -0.912 . . . . 0.0 109.456 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.533 HG21 ' OG1' ' A' ' 12' ' ' THR . 48.4 t -59.0 -50.98 77.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.318 -0.863 . . . . 0.0 109.385 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 49.5 tttm -59.79 -47.83 84.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.305 -0.872 . . . . 0.0 109.437 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -62.38 -34.81 77.43 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.259 -0.9 . . . . 0.0 109.245 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.478 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 5.7 m120 -64.77 -38.03 89.6 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.251 -0.906 . . . . 0.0 109.517 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.886 HG21 HD11 ' A' ' 40' ' ' ILE . 92.6 mt -63.52 -45.26 98.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.226 -0.921 . . . . 0.0 109.755 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -57.32 -46.04 83.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.146 -0.971 . . . . 0.0 109.992 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -81.6 -37.11 28.14 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.03 -1.044 . . . . 0.0 109.825 -179.634 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.566 ' HG3' ' CZ ' ' A' ' 73' ' ' PHE . 13.3 tptp -55.86 -29.63 60.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.114 -0.991 . . . . 0.0 109.283 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.051 HG21 HG11 ' A' ' 37' ' ' VAL . 70.4 t -87.56 -25.21 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.296 -0.877 . . . . 0.0 109.43 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 48.2 tp10 -66.47 -49.09 67.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.324 -0.86 . . . . 0.0 109.32 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.02 -27.49 65.5 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.379 -0.826 . . . . 0.0 109.313 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 73.0 p -94.25 -25.55 17.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -0.916 . . . . 0.0 109.388 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 73.26 25.49 72.96 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.535 ' CG2' ' HB2' ' A' ' 36' ' ' LEU . 76.4 mt -98.09 82.27 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -1.109 . . . . 0.0 109.447 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.424 ' O ' ' HG3' ' A' ' 34' ' ' LYS . 14.8 tptm -89.63 -6.07 56.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.227 -0.921 . . . . 0.0 109.714 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.508 ' O ' HD13 ' A' ' 65' ' ' ILE . 33.1 m120 -94.34 -4.58 48.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.249 -0.907 . . . . 0.0 109.561 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.136 HD11 ' CB ' ' A' ' 70' ' ' ALA . 8.3 tp -97.85 -54.39 3.11 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.305 -0.872 . . . . 0.0 109.664 -179.677 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 1.051 HG11 HG21 ' A' ' 28' ' ' VAL . 3.7 p -92.65 135.2 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.228 -0.92 . . . . 0.0 109.104 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -106.8 -123.14 5.04 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 59.6 mtt85 -94.11 139.7 30.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.34 -1.094 . . . . 0.0 110.006 -179.374 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 1.081 HG23 HG12 ' A' ' 62' ' ' VAL . 91.8 mt -108.39 136.56 43.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.931 HG23 ' HB2' ' A' ' 61' ' ' PHE . 33.9 m -130.59 155.09 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.071 -1.018 . . . . 0.0 109.616 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.54 HG22 HG23 ' A' ' 44' ' ' ILE . 11.8 mt -128.48 133.91 25.69 Favored Pre-proline 0 N--CA 1.489 1.482 0 O-C-N 121.371 -0.831 . . . . 0.0 109.353 -179.763 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.58 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 40.9 Cg_endo -63.33 -6.57 10.32 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.715 2.276 . . . . 0.0 111.502 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.598 ' CB ' ' HA ' ' A' ' 54' ' ' LYS . 3.7 pt . . . . . 0 N--CA 1.489 1.482 0 O-C-N 121.329 -0.857 . . . . 0.0 109.09 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.598 ' HA ' ' CB ' ' A' ' 44' ' ' ILE . 11.3 mttp . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.58 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 9.9 tp -53.64 -47.93 69.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.1 -1.0 . . . . 0.0 109.423 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 1.029 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 95.9 m-85 -135.57 111.95 10.7 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.121 -0.987 . . . . 0.0 109.121 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -66.7 142.48 64.05 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.584 2.189 . . . . 0.0 111.879 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.37 -8.18 7.34 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.4 m-30 -100.27 131.94 45.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.793 -1.416 . . . . 0.0 110.122 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.457 HG13 HG12 ' A' ' 42' ' ' ILE . 46.5 t -134.28 144.69 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.325 -0.859 . . . . 0.0 109.03 179.564 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.931 ' HB2' HG23 ' A' ' 41' ' ' VAL . 59.6 m-85 -107.03 123.38 48.13 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.114 -0.991 . . . . 0.0 109.821 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 1.081 HG12 HG23 ' A' ' 40' ' ' ILE . 29.6 m -132.94 144.46 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.344 -0.848 . . . . 0.0 109.653 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.622 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 37.3 tt0 -110.62 128.95 55.9 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -0.92 . . . . 0.0 109.051 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.493 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 35.1 mtm -156.01 174.3 15.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.011 -1.056 . . . . 0.0 110.66 -179.35 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 1.02 ' CG1' HD12 ' A' ' 36' ' ' LEU . 10.2 pt -93.92 128.23 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-O 121.323 0.583 . . . . 0.0 109.577 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.569 ' HE3' ' HG2' ' A' ' 89' ' ' GLN . 91.3 mtp -76.82 145.29 38.53 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.372 -0.83 . . . . 0.0 110.046 -178.834 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.482 ' HB2' ' O ' ' A' ' 66' ' ' MET . 45.1 t-20 176.48 173.63 0.38 Allowed 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -70.44 -42.06 72.03 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.056 -1.028 . . . . 0.0 109.292 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -75.92 -30.86 58.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -0.894 . . . . 0.0 109.59 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.136 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -69.58 -48.08 61.39 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.192 -0.942 . . . . 0.0 109.37 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.4 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 74.5 t80 -60.21 -48.55 81.24 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.237 -0.914 . . . . 0.0 109.555 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -59.66 -29.4 68.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.193 -0.942 . . . . 0.0 109.987 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.566 ' CZ ' ' HG3' ' A' ' 27' ' ' LYS . 72.4 t80 -82.0 -43.43 18.0 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.112 -0.992 . . . . 0.0 109.578 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 1.028 HG23 ' O ' ' A' ' 70' ' ' ALA . 2.7 t -66.26 -57.01 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.321 -0.862 . . . . 0.0 109.247 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 13.2 tpt180 -50.34 -32.75 18.08 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.427 -0.796 . . . . 0.0 109.612 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 9.4 t -78.33 6.25 8.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.331 -0.856 . . . . 0.0 110.199 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 74' ' ' VAL . 54.8 t -63.27 131.48 94.79 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 120.957 -1.09 . . . . 0.0 109.408 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.578 ' HB2' ' CD2' ' A' ' 79' ' ' TYR . 47.2 Cg_endo -67.89 137.73 42.37 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.66 2.24 . . . . 0.0 111.983 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.578 ' CD2' ' HB2' ' A' ' 78' ' ' PRO . 58.9 m-85 76.15 -4.41 2.37 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.503 -0.748 . . . . 0.0 109.797 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.593 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.8 t -87.57 129.94 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.108 -0.995 . . . . 0.0 109.162 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.431 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 95.5 mmm -88.31 -7.2 57.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.153 -0.967 . . . . 0.0 109.49 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.403 ' H ' ' CG1' ' A' ' 80' ' ' VAL . . . 132.44 -150.83 19.75 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.65 ' CE2' HG12 ' A' ' 74' ' ' VAL . 4.6 m-85 -140.01 145.79 38.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.228 -1.16 . . . . 0.0 109.542 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.657 ' O ' HG13 ' A' ' 84' ' ' VAL . 10.0 p -68.06 119.1 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.385 -0.822 . . . . 0.0 109.469 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.541 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 6.1 p -153.81 165.65 35.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.195 -0.941 . . . . 0.0 109.452 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 t -91.11 -30.43 16.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.399 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -134.57 -73.9 0.08 OUTLIER Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -115.4 -133.05 5.3 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.569 ' HG2' ' HE3' ' A' ' 66' ' ' MET . 0.5 OUTLIER -31.07 146.48 0.06 OUTLIER Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.588 -0.948 . . . . 0.0 110.135 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.541 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.3 Cg_endo -69.12 141.35 47.59 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.957 2.438 . . . . 0.0 112.096 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' VAL . . . . . 0.743 HG13 ' HD2' ' A' ' 92' ' ' PRO . 68.9 t -67.48 143.9 97.45 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.323 -0.861 . . . . 0.0 109.434 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.743 ' HD2' HG13 ' A' ' 91' ' ' VAL . 48.0 Cg_endo -69.43 148.14 66.55 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.622 2.215 . . . . 0.0 111.701 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.938 HG23 ' O ' ' A' ' 7' ' ' TRP . 3.0 t -81.87 127.49 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.19 -0.944 . . . . 0.0 109.54 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -69.99 139.87 52.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.317 -0.864 . . . . 0.0 109.47 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -48.83 -40.41 29.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.212 -0.93 . . . . 0.0 109.37 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 59.9 mtt180 -59.01 -34.48 71.92 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.235 -0.916 . . . . 0.0 109.418 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -80.2 -25.96 39.42 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.276 -0.89 . . . . 0.0 109.417 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.542 ' CB ' HD11 ' A' ' 102' ' ' LEU . 93.2 mtp -84.26 -24.73 29.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.261 -0.9 . . . . 0.0 109.556 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.599 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 3.2 tpt85 -36.43 -53.15 1.74 Allowed Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.39 -0.819 . . . . 0.0 109.829 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.599 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 50.2 Cg_endo -70.49 -28.07 22.23 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.574 2.183 . . . . 0.0 111.724 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.495 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 35.8 mm -80.62 -42.26 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 109.486 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.542 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.7 OUTLIER -67.06 -40.03 87.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.184 -0.948 . . . . 0.0 109.236 179.772 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.531 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 39.8 ttt-85 -63.06 -50.57 70.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.155 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.628 HD23 ' C ' ' A' ' 104' ' ' LEU . 5.5 tt -72.58 -35.26 67.89 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.267 -0.896 . . . . 0.0 109.078 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.564 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -71.18 -3.12 18.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.425 -0.797 . . . . 0.0 109.778 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.46 11.63 82.5 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.898 HD21 HG11 ' A' ' 41' ' ' VAL . 9.9 mp -79.46 -19.38 49.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.308 -1.113 . . . . 0.0 109.698 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' GLU . . . . . 0.431 ' OE2' HD13 ' A' ' 102' ' ' LEU . 96.5 mt-10 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.236 -0.915 . . . . 0.0 109.608 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.412 ' O ' ' HG2' ' A' ' 124' ' ' LYS . 13.3 p90 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.337 0.589 . . . . 0.0 109.531 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.412 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 14.7 mttp -150.95 161.43 42.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.238 -0.913 . . . . 0.0 109.397 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 144' ' ' LYS . 40.2 t -60.15 141.33 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.258 -0.901 . . . . 0.0 109.525 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 86.06 -33.29 3.6 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 70.3 m-20 -47.74 162.22 0.08 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.374 -1.074 . . . . 0.0 109.132 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 9.4 ttm -96.67 126.66 42.0 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.157 -0.964 . . . . 0.0 109.082 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.552 ' CG2' HD11 ' A' ' 143' ' ' ILE . 2.7 t -125.37 141.27 45.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.23 -0.919 . . . . 0.0 109.214 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 15.8 tttt -102.55 143.02 32.78 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.245 -0.909 . . . . 0.0 108.98 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.956 HD12 ' HB3' ' A' ' 139' ' ' PHE . 66.8 mt -83.71 151.78 3.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.434 ' C ' ' HG2' ' A' ' 137' ' ' GLU . 2.2 pt -149.67 2.69 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.038 -1.038 . . . . 0.0 109.382 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.587 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 71.9 m -148.7 143.33 26.38 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.185 -0.947 . . . . 0.0 109.884 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.488 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 101.57 -164.07 17.69 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.531 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 47.4 Cg_endo -68.16 -22.01 41.47 Favored 'Trans proline' 0 C--O 1.216 -0.587 0 C-N-CA 123.215 2.61 . . . . 0.0 112.913 -179.187 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.556 ' HB2' HD13 ' A' ' 131' ' ' ILE . 94.0 m-85 -106.21 19.59 20.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.743 -1.223 . . . . 0.0 109.418 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.543 ' HG2' ' HA ' ' A' ' 133' ' ' SER . 44.4 mt-10 -40.75 137.04 1.26 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.871 . . . . 0.0 109.988 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.445 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 4.4 m-20 71.08 29.77 2.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.389 -0.82 . . . . 0.0 110.656 179.05 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.956 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.9 t80 -116.7 128.06 54.98 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.912 -1.117 . . . . 0.0 109.579 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.34 133.3 40.01 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.285 -0.884 . . . . 0.0 109.797 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.525 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -142.66 169.66 25.46 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.801 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 155' ' ' VAL . 41.1 t -115.31 136.61 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.314 -1.109 . . . . 0.0 109.506 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.606 HG23 HD23 ' A' ' 153' ' ' LEU . 49.6 mt -67.28 113.82 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.221 -0.924 . . . . 0.0 108.898 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.484 ' O ' HG13 ' A' ' 125' ' ' VAL . 18.1 tptm -98.56 -35.45 10.22 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.926 -1.109 . . . . 0.0 109.768 -179.506 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.46 ' HB2' ' HB2' ' A' ' 154' ' ' LYS . 38.6 mt-10 -153.29 148.31 26.65 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.133 -0.979 . . . . 0.0 109.754 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.719 HG23 ' HG ' ' A' ' 153' ' ' LEU . 3.4 mt -125.15 127.85 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.277 -0.889 . . . . 0.0 109.434 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -110.61 102.3 51.54 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.192 -0.942 . . . . 0.0 109.525 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.538 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.9 Cg_endo -71.54 173.07 13.05 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.607 2.204 . . . . 0.0 111.881 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.538 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 45.2 mm-40 79.86 -21.1 0.35 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.473 -0.767 . . . . 0.0 109.906 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.443 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 46.6 mtt180 -127.63 -13.98 5.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.058 -1.026 . . . . 0.0 109.509 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.825 ' O ' HG13 ' A' ' 170' ' ' VAL . 66.9 mm-40 70.82 47.99 0.43 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.32 -0.863 . . . . 0.0 109.802 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -118.43 142.21 47.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.116 -0.99 . . . . 0.0 108.852 179.526 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.719 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -129.76 113.06 14.25 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.137 -0.977 . . . . 0.0 110.16 -179.535 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.46 ' HB2' ' HB2' ' A' ' 145' ' ' GLU . 13.7 mttm -78.18 127.66 32.61 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.083 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.679 HG13 ' O ' ' A' ' 142' ' ' VAL . 40.4 t -126.17 147.05 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.088 -1.007 . . . . 0.0 109.908 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.54 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 70.1 m-20 -95.81 113.72 25.38 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.431 -0.793 . . . . 0.0 109.035 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.722 HG12 HG23 ' A' ' 159' ' ' ILE . 89.3 t -97.72 142.8 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.205 -0.935 . . . . 0.0 109.613 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 28.2 m -100.32 94.25 6.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.341 -0.85 . . . . 0.0 109.876 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 1.029 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 2.2 pt -125.85 152.3 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.281 -0.887 . . . . 0.0 109.143 179.586 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.572 ' CD2' HD12 ' A' ' 159' ' ' ILE . 18.8 m-30 60.47 38.68 19.02 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.143 -0.973 . . . . 0.0 109.111 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 55.05 14.47 5.75 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.419 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 52.3 mtt85 -128.99 156.32 43.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.129 -1.218 . . . . 0.0 109.668 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -99.39 134.52 42.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.32 -0.862 . . . . 0.0 109.255 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 21.7 m -147.51 127.45 6.66 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.271 -0.893 . . . . 0.0 109.674 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.54 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.8 Cg_endo -70.5 139.94 38.8 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.725 2.283 . . . . 0.0 111.701 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.762 HG13 HD11 ' A' ' 168' ' ' LEU . 5.3 p -125.13 144.35 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.18 -0.95 . . . . 0.0 109.515 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.435 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 14.1 m -93.76 119.23 41.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.386 -0.821 . . . . 0.0 109.534 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.762 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -142.07 168.78 18.93 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -0.909 . . . . 0.0 110.576 -179.492 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.417 ' HB2' ' OE1' ' A' ' 172' ' ' GLU . 47.0 m80 -83.98 142.39 30.53 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.682 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.825 HG13 ' O ' ' A' ' 151' ' ' GLN . 3.1 m -53.58 -34.85 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.295 -0.878 . . . . 0.0 109.151 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 60.2 p -73.81 -6.05 44.65 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.335 -0.853 . . . . 0.0 109.982 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.587 ' CG ' ' HB2' ' A' ' 133' ' ' SER . 2.4 mt-10 -95.6 3.88 53.63 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.015 -1.053 . . . . 0.0 110.02 -179.54 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 11.2 m -144.0 169.36 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.057 -1.027 . . . . 0.0 109.601 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.537 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 80.3 tt0 -140.56 166.15 25.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.223 -0.923 . . . . 0.0 108.893 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.537 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 38.9 tttm . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.019 -1.05 . . . . 0.0 109.51 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.79 ' HG2' HG22 ' A' ' 65' ' ' ILE . 55.4 mttt . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 121.263 0.554 . . . . 0.0 109.699 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.9 mmtp -128.0 175.26 8.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.289 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.949 ' CZ3' HG22 ' A' ' 41' ' ' VAL . 80.9 m95 -110.33 127.0 54.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.137 -0.977 . . . . 0.0 109.576 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.453 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 60.7 m-85 -121.78 167.07 13.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.229 -0.919 . . . . 0.0 109.488 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.964 HD11 ' CE1' ' A' ' 160' ' ' PHE . 76.2 mt -106.61 117.1 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.158 -0.964 . . . . 0.0 109.301 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.417 ' CG1' HG22 ' A' ' 80' ' ' VAL . 85.3 t -88.56 141.98 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.28 -0.888 . . . . 0.0 109.569 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.49 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -93.74 138.84 31.51 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.325 -0.86 . . . . 0.0 109.387 179.905 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.589 HG21 ' HG2' ' A' ' 17' ' ' GLU . 14.9 t -155.58 -169.54 3.15 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.457 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.44 ' O ' ' C ' ' A' ' 14' ' ' SER . 90.8 mmm -104.01 119.55 39.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.233 -0.917 . . . . 0.0 109.387 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 13' ' ' MET . 17.8 p -42.46 128.52 3.92 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.232 -0.918 . . . . 0.0 109.475 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.34 -20.31 35.35 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.429 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 90.3 m-85 -110.67 -1.4 16.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -1.133 . . . . 0.0 109.557 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.646 ' OE1' HD11 ' A' ' 44' ' ' ILE . 49.4 mt-10 -53.34 -55.24 26.39 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.241 -0.912 . . . . 0.0 109.404 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -49.13 -32.22 9.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.166 -0.958 . . . . 0.0 109.418 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.47 ' O ' ' HB2' ' A' ' 23' ' ' ASN . 62.3 mttm -76.83 -36.75 56.66 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.286 -0.883 . . . . 0.0 109.311 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.666 HG22 ' HB2' ' A' ' 79' ' ' TYR . 98.4 t -66.73 -52.01 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.33 -0.856 . . . . 0.0 109.523 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.44 ' HB2' HD11 ' A' ' 42' ' ' ILE . 63.1 tttm -56.89 -50.87 71.19 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.231 -0.918 . . . . 0.0 109.484 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -64.68 -34.82 79.19 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.153 -0.967 . . . . 0.0 109.38 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.518 ' ND2' ' HG2' ' A' ' 78' ' ' PRO . 20.1 t-20 -66.0 -44.32 85.14 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.408 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.659 ' O ' HG23 ' A' ' 28' ' ' VAL . 81.7 mt -57.39 -43.37 82.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.272 -0.892 . . . . 0.0 109.443 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -58.38 -44.44 88.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.205 -0.934 . . . . 0.0 109.789 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 31.9 mtmt -77.88 -37.48 48.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.112 -0.992 . . . . 0.0 109.798 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.759 ' CD ' HG23 ' A' ' 77' ' ' VAL . 42.1 tttp -57.04 -28.94 62.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.908 . . . . 0.0 109.313 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 24' ' ' ILE . 42.4 t -83.86 -27.43 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.314 -0.866 . . . . 0.0 109.464 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.454 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 54.9 mm-40 -66.8 -49.25 66.45 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.271 -0.893 . . . . 0.0 109.444 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.2 -35.12 66.91 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.241 -0.912 . . . . 0.0 109.482 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.3 p -92.86 -22.71 19.12 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.271 -0.893 . . . . 0.0 109.591 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 74.3 1.59 60.87 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.038 HG21 HD12 ' A' ' 36' ' ' LEU . 48.1 mm -69.39 80.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.318 -1.107 . . . . 0.0 109.429 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -90.89 14.54 13.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 109.458 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.877 ' O ' HD13 ' A' ' 65' ' ' ILE . 86.2 m-20 -113.39 -3.07 13.81 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.235 -0.916 . . . . 0.0 109.601 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.038 HD12 HG21 ' A' ' 33' ' ' ILE . 11.8 mt -98.59 -51.2 4.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.946 . . . . 0.0 109.599 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 99.1 t -95.55 144.58 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.313 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.87 -124.75 3.92 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 18.6 mtt85 -91.56 142.18 27.91 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.309 -1.112 . . . . 0.0 109.885 -179.497 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 1.016 HG23 HG22 ' A' ' 62' ' ' VAL . 65.4 mt -109.94 134.42 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.152 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.963 HG23 ' HB2' ' A' ' 61' ' ' PHE . 30.4 m -127.5 144.54 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.208 -0.932 . . . . 0.0 109.263 179.831 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.92 HG21 HD12 ' A' ' 44' ' ' ILE . 67.6 mt -129.94 129.14 22.98 Favored Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.294 -0.879 . . . . 0.0 109.623 -179.754 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.565 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.3 Cg_endo -66.71 -2.65 7.93 Favored 'Trans proline' 0 C--O 1.217 -0.544 0 C-N-CA 122.879 2.386 . . . . 0.0 111.348 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.92 HD12 HG21 ' A' ' 42' ' ' ILE . 85.6 mt . . . . . 0 N--CA 1.488 1.462 0 O-C-N 121.144 -0.972 . . . . 0.0 109.554 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.751 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 1.9 mttp . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.565 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 9.2 tp -59.71 -42.14 92.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.904 -1.123 . . . . 0.0 108.909 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.922 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 19.4 m-85 -126.3 101.15 28.51 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.217 -0.927 . . . . 0.0 108.789 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.431 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 41.7 Cg_endo -65.63 137.09 48.75 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.681 2.254 . . . . 0.0 112.26 -179.087 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.36 -12.61 5.5 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.417 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.574 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 1.7 m-30 -100.47 132.15 46.01 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.748 -1.442 . . . . 0.0 110.32 -179.199 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.847 HG13 HG12 ' A' ' 42' ' ' ILE . 40.0 t -132.99 143.07 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.349 -0.844 . . . . 0.0 108.926 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.963 ' HB2' HG23 ' A' ' 41' ' ' VAL . 18.8 m-30 -106.68 123.86 48.75 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.003 -1.061 . . . . 0.0 109.805 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 1.016 HG22 HG23 ' A' ' 40' ' ' ILE . 93.0 t -131.16 142.13 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.339 -0.851 . . . . 0.0 109.653 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.591 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 39.1 tt0 -105.9 128.77 53.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.262 -0.899 . . . . 0.0 108.981 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.494 ' CG ' ' C ' ' A' ' 63' ' ' GLU . 16.5 mtm -155.96 178.65 10.03 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.169 -0.957 . . . . 0.0 110.05 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.879 ' CG1' HD23 ' A' ' 36' ' ' LEU . 6.1 pt -101.01 133.89 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.59 -0.694 . . . . 0.0 109.321 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.473 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 53.9 ttm -77.24 144.33 38.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.224 -0.922 . . . . 0.0 110.1 -178.654 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.473 ' HB2' ' O ' ' A' ' 66' ' ' MET . 29.0 t-20 176.46 175.56 0.32 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -72.6 -43.06 63.83 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.249 -0.907 . . . . 0.0 109.323 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -75.64 -28.01 58.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.686 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.058 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -70.58 -47.56 59.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.131 -0.981 . . . . 0.0 109.302 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.617 ' HB2' ' NE2' ' A' ' 89' ' ' GLN . 89.0 t80 -60.88 -54.94 38.9 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.289 -0.882 . . . . 0.0 109.275 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.447 ' O ' ' OG ' ' A' ' 76' ' ' SER . 42.2 t-20 -52.85 -31.81 41.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.221 -0.924 . . . . 0.0 109.975 -179.788 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 81.9 t80 -80.08 -43.27 22.09 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.035 -1.04 . . . . 0.0 109.567 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 1.058 HG23 ' O ' ' A' ' 70' ' ' ALA . 3.2 t -68.26 -55.48 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.295 -0.878 . . . . 0.0 109.414 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.473 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 16.5 tpt180 -61.56 -9.58 6.23 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.338 -0.851 . . . . 0.0 109.837 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 72' ' ' ASN . 42.7 p -101.67 2.09 38.32 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.148 -0.97 . . . . 0.0 109.983 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.759 HG23 ' CD ' ' A' ' 27' ' ' LYS . 0.5 OUTLIER -68.75 135.29 90.15 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.057 -1.027 . . . . 0.0 108.954 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.629 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 43.9 Cg_endo -66.21 138.96 53.43 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.394 2.063 . . . . 0.0 111.99 -179.422 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.666 ' HB2' HG22 ' A' ' 20' ' ' VAL . 5.5 m-85 89.09 -8.08 0.44 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.801 -0.562 . . . . 0.0 109.829 -179.838 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.713 ' CG2' HG12 ' A' ' 77' ' ' VAL . 2.4 t -89.34 129.5 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.966 -1.084 . . . . 0.0 109.661 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.428 ' HE1' ' SD ' ' A' ' 13' ' ' MET . 18.7 mtt -93.53 -25.06 17.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.459 -0.776 . . . . 0.0 109.246 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 164.54 -162.61 35.59 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.479 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 48.6 m-85 -136.21 151.74 50.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.187 -1.184 . . . . 0.0 109.559 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.8 t -67.01 101.42 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.282 -0.886 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.538 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.0 OUTLIER -143.98 162.85 35.12 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -0.918 . . . . 0.0 109.505 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.0 m -95.18 -34.52 12.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.349 -0.845 . . . . 0.0 109.278 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -129.39 -72.78 0.14 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.541 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -113.91 -137.89 6.75 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.617 ' NE2' ' HB2' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -31.03 148.45 0.04 OUTLIER Pre-proline 0 N--CA 1.493 1.704 0 O-C-N 121.506 -0.997 . . . . 0.0 110.274 -179.718 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.538 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.3 Cg_endo -69.54 149.61 68.53 Favored 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.82 2.347 . . . . 0.0 111.887 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 36.0 m -80.73 152.31 72.13 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.323 -0.861 . . . . 0.0 109.403 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.07 143.36 49.12 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.693 2.262 . . . . 0.0 111.81 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.659 HG11 ' SD ' ' A' ' 98' ' ' MET . 29.3 t -69.48 142.16 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.192 -0.942 . . . . 0.0 109.414 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' LYS . . . . . 0.434 ' HB2' ' HG3' ' A' ' 97' ' ' GLU . 32.0 mttt -70.67 134.12 47.25 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.537 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -50.27 -41.46 50.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.863 . . . . 0.0 109.419 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -63.14 -24.07 67.72 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.438 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.434 ' HG3' ' HB2' ' A' ' 94' ' ' LYS . 40.9 mt-10 -84.95 -23.66 28.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -0.913 . . . . 0.0 109.456 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.659 ' SD ' HG11 ' A' ' 93' ' ' VAL . 52.5 mmm -85.19 -33.18 22.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.265 -0.897 . . . . 0.0 109.384 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.6 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -36.1 -53.41 1.57 Allowed Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.459 -0.776 . . . . 0.0 109.795 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.615 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 47.4 Cg_endo -69.79 -26.57 27.3 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.494 2.129 . . . . 0.0 111.616 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.531 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 32.3 mm -81.09 -38.51 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.236 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.715 HD13 ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -71.36 -40.35 70.69 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.328 -0.858 . . . . 0.0 109.16 179.733 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 58.0 mtt-85 -63.15 -50.06 71.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.403 -0.81 . . . . 0.0 109.028 179.78 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.4 tt -72.35 -35.55 68.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.385 -0.822 . . . . 0.0 109.079 179.553 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -69.33 -1.62 8.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.393 -0.817 . . . . 0.0 110.023 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.12 8.25 82.97 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.406 ' HB3' ' HB3' ' A' ' 102' ' ' LEU . 0.7 OUTLIER -74.37 -17.55 60.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.16 -1.2 . . . . 0.0 109.431 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 108' ' ' GLU . . . . . 0.447 ' HG3' ' HB3' ' A' ' 102' ' ' LEU . 88.9 mt-10 . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.898 . . . . 0.0 109.479 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.615 ' CB ' ' HD3' ' A' ' 175' ' ' LYS . 38.3 p90 . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 17.4 mttt -144.27 162.75 35.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.135 -0.978 . . . . 0.0 109.922 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 144' ' ' LYS . 12.1 t -64.04 141.79 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.472 -0.768 . . . . 0.0 109.297 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 87.47 -31.23 4.58 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -49.71 162.92 0.14 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.299 -1.118 . . . . 0.0 109.27 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.9 ttp -94.72 125.35 39.31 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.13 -0.982 . . . . 0.0 109.073 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.544 HG11 ' CD1' ' A' ' 143' ' ' ILE . 2.0 p -124.31 140.77 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.173 -0.954 . . . . 0.0 109.02 179.756 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 174' ' ' GLU . 59.9 tttt -106.2 142.72 35.41 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.153 -0.967 . . . . 0.0 109.361 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.927 ' O ' HD13 ' A' ' 132' ' ' ILE . 88.2 mt -82.75 152.91 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.161 -0.962 . . . . 0.0 108.581 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.927 HD13 ' O ' ' A' ' 131' ' ' ILE . 2.6 mm -148.94 1.66 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.103 -0.998 . . . . 0.0 109.463 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.566 ' CB ' ' HG2' ' A' ' 172' ' ' GLU . 28.3 m -150.82 147.64 27.51 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.13 -0.981 . . . . 0.0 110.331 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.84 -164.12 18.56 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 179.435 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.483 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 46.2 Cg_endo -67.93 -23.52 40.79 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 123.026 2.484 . . . . 0.0 112.535 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.615 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 93.4 m-85 -108.86 18.76 20.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.962 -1.086 . . . . 0.0 109.456 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.629 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.8 tt0 -48.35 140.69 7.39 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.289 -0.882 . . . . 0.0 109.687 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 12.8 m-20 76.93 28.73 0.64 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.468 -0.77 . . . . 0.0 110.243 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.91 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.9 t80 -118.42 153.52 33.95 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.08 -1.012 . . . . 0.0 109.485 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -101.2 133.34 45.91 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.246 -0.909 . . . . 0.0 109.197 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.499 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.25 170.38 26.65 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 119.535 -1.317 . . . . 0.0 110.604 -179.413 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.646 ' C ' HG23 ' A' ' 155' ' ' VAL . 44.9 t -115.11 137.71 47.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.602 -0.94 . . . . 0.0 109.348 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.94 HD12 HD23 ' A' ' 153' ' ' LEU . 14.9 mm -68.74 115.27 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.226 -0.921 . . . . 0.0 109.502 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.457 ' O ' HG13 ' A' ' 125' ' ' VAL . 21.2 tttp -99.0 -34.46 10.41 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.039 -1.038 . . . . 0.0 109.321 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.43 ' HG3' ' HG2' ' A' ' 144' ' ' LYS . 89.5 mt-10 -152.57 147.6 26.37 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.133 -0.98 . . . . 0.0 109.444 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.838 HG23 ' HG ' ' A' ' 153' ' ' LEU . 6.6 mt -126.56 130.05 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.216 -0.928 . . . . 0.0 109.622 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -110.33 103.39 53.87 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.286 -0.884 . . . . 0.0 109.528 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.557 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.55 171.83 15.52 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.747 2.298 . . . . 0.0 111.631 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.557 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.3 mt-10 80.68 -20.34 0.38 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.319 -0.863 . . . . 0.0 109.876 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.434 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 43.3 mtt85 -128.21 -12.18 5.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.05 -1.031 . . . . 0.0 109.582 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.539 ' O ' HG12 ' A' ' 170' ' ' VAL . 37.1 mt-30 69.68 48.97 0.56 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.907 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -120.12 144.54 47.58 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.081 -1.012 . . . . 0.0 109.116 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.94 HD23 HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -133.92 115.73 14.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.097 -1.002 . . . . 0.0 110.115 -179.381 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 7.1 mttt -78.04 132.42 37.76 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.328 -0.857 . . . . 0.0 108.786 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.646 HG23 ' C ' ' A' ' 142' ' ' VAL . 13.2 p -130.21 147.01 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.119 -0.988 . . . . 0.0 110.008 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.488 ' OD1' ' CA ' ' A' ' 165' ' ' PRO . 0.9 OUTLIER -97.53 115.96 28.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.435 -0.791 . . . . 0.0 109.183 179.66 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.579 HG13 ' CE1' ' A' ' 139' ' ' PHE . 87.1 t -97.64 143.22 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.163 -0.961 . . . . 0.0 109.747 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.3 m -91.88 111.88 23.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.314 -0.867 . . . . 0.0 109.643 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.922 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 13.6 pt -144.56 143.92 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.295 -0.878 . . . . 0.0 109.486 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.964 ' CE1' HD11 ' A' ' 9' ' ' ILE . 78.2 m-85 62.1 34.36 16.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.282 -0.886 . . . . 0.0 109.396 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.28 16.47 20.42 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 73.6 mtt-85 -128.91 151.14 49.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -93.7 135.05 35.38 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.233 -0.917 . . . . 0.0 109.392 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 60.8 m -144.64 126.31 7.96 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.242 -0.911 . . . . 0.0 109.67 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.488 ' CA ' ' OD1' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.8 139.58 36.93 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 122.624 2.216 . . . . 0.0 111.39 179.676 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.563 ' HB ' HD21 ' A' ' 168' ' ' LEU . 1.9 m -125.75 144.54 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.059 -1.026 . . . . 0.0 109.988 -179.682 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 1.018 ' C ' HD22 ' A' ' 168' ' ' LEU . 14.7 m -92.05 117.48 35.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 1.018 HD22 ' C ' ' A' ' 167' ' ' VAL . 3.2 mm? -139.78 166.24 25.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.156 -0.965 . . . . 0.0 110.289 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.493 ' HB2' ' HB2' ' A' ' 172' ' ' GLU . 82.2 m-70 -83.95 141.15 31.45 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.634 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 151' ' ' GLN . 9.1 p -56.78 -36.58 49.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.293 -0.879 . . . . 0.0 109.296 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.424 ' N ' HG13 ' A' ' 170' ' ' VAL . 32.1 p -77.29 -8.47 57.67 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.094 -1.004 . . . . 0.0 109.722 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.566 ' HG2' ' CB ' ' A' ' 133' ' ' SER . 1.3 mt-10 -88.67 -4.79 58.47 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.194 -0.941 . . . . 0.0 109.275 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.9 m -137.22 176.51 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.192 -0.942 . . . . 0.0 109.799 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.544 ' O ' HG22 ' A' ' 129' ' ' VAL . 72.9 tt0 -132.15 155.43 48.18 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.615 ' HD3' ' CB ' ' A' ' 123' ' ' PHE . 16.2 mttm . . . . . 0 N--CA 1.489 1.523 0 O-C-N 120.965 -1.084 . . . . 0.0 109.712 -179.462 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 33.4 mttm . . . . . 0 N--CA 1.488 1.464 0 CA-C-O 121.342 0.591 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.593 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 11.6 mttt -130.47 173.76 10.54 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.905 . . . . 0.0 109.192 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 1.063 ' O ' HG23 ' A' ' 93' ' ' VAL . 61.5 m95 -108.59 127.51 54.01 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -0.901 . . . . 0.0 109.3 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.447 ' OH ' ' SD ' ' A' ' 66' ' ' MET . 91.6 m-85 -115.61 169.15 9.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.211 -0.93 . . . . 0.0 109.33 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.597 HD11 ' CE1' ' A' ' 160' ' ' PHE . 27.3 mt -109.89 113.57 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 109.192 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 82.4 t -88.51 140.58 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.221 -0.925 . . . . 0.0 109.369 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 59' ' ' TYR . 2.9 mm? -95.36 146.36 24.45 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.357 -0.839 . . . . 0.0 109.414 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.5 t -161.17 -164.26 1.14 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.265 -0.897 . . . . 0.0 109.114 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.518 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 94.0 mtp -105.32 124.71 50.0 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.186 -0.946 . . . . 0.0 109.516 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.0 t -45.78 131.1 9.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.294 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.94 -19.33 47.08 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.518 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 95.6 m-85 -108.96 6.34 25.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.284 -1.127 . . . . 0.0 109.564 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -62.79 -52.82 61.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.261 -0.899 . . . . 0.0 109.507 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -50.7 -35.78 32.84 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.187 -0.945 . . . . 0.0 109.61 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -73.9 -47.81 35.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.247 -0.908 . . . . 0.0 109.556 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.963 HG22 ' HB2' ' A' ' 79' ' ' TYR . 74.8 t -54.32 -48.41 67.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.226 -0.922 . . . . 0.0 109.579 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.604 ' HD2' HD11 ' A' ' 42' ' ' ILE . 40.8 tttm -57.56 -49.66 75.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -0.923 . . . . 0.0 109.615 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -65.42 -39.18 91.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.244 -0.91 . . . . 0.0 109.497 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.0 m120 -62.16 -44.62 96.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.869 . . . . 0.0 109.622 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.404 HG21 HD11 ' A' ' 40' ' ' ILE . 96.7 mt -57.76 -43.83 84.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.522 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -56.42 -44.55 80.48 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.206 -0.934 . . . . 0.0 109.823 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -75.55 -35.33 60.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.06 -1.025 . . . . 0.0 109.437 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.88 ' HD3' HG23 ' A' ' 77' ' ' VAL . 10.1 tttm -56.44 -34.16 66.57 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.229 -0.92 . . . . 0.0 109.331 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.691 HG13 ' O ' ' A' ' 33' ' ' ILE . 43.4 t -83.99 -25.42 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.334 -0.854 . . . . 0.0 109.593 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 46.7 tp10 -70.32 -53.95 14.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.264 -0.897 . . . . 0.0 109.656 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.92 -33.6 72.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -0.92 . . . . 0.0 109.693 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.5 HG23 ' O ' ' A' ' 27' ' ' LYS . 50.7 p -83.35 -35.91 24.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.182 -0.949 . . . . 0.0 109.488 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 84.75 17.8 62.91 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.691 ' O ' HG13 ' A' ' 28' ' ' VAL . 78.8 mt -95.74 78.31 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.218 -1.166 . . . . 0.0 109.414 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 45.0 mttm -85.68 6.1 29.12 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 24.5 m120 -102.3 -6.94 22.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.224 -0.923 . . . . 0.0 109.547 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.101 HD11 ' HB2' ' A' ' 70' ' ' ALA . 10.5 tp -97.68 -54.05 3.24 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.302 -0.874 . . . . 0.0 109.681 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.878 HG22 ' CE ' ' A' ' 64' ' ' MET . 87.4 t -90.38 133.66 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.284 -0.885 . . . . 0.0 109.324 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.65 -126.87 5.88 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 44.5 mtt180 -93.58 140.65 29.37 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -1.155 . . . . 0.0 109.887 -179.664 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.682 HG23 HG12 ' A' ' 62' ' ' VAL . 63.2 mt -103.76 134.0 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.308 -0.87 . . . . 0.0 109.09 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.863 HG23 ' HB2' ' A' ' 61' ' ' PHE . 34.7 m -124.7 146.7 29.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.132 -0.98 . . . . 0.0 109.692 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.811 HG22 HG23 ' A' ' 44' ' ' ILE . 1.2 mt -117.75 128.9 25.7 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.423 -0.798 . . . . 0.0 109.465 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.696 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.6 Cg_endo -66.43 -6.22 14.59 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.903 2.402 . . . . 0.0 111.857 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.994 ' O ' HD21 ' A' ' 104' ' ' LEU . 13.1 pt . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.178 -0.951 . . . . 0.0 109.413 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.776 ' HA ' HG22 ' A' ' 44' ' ' ILE . 1.9 mttt . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.889 HD12 ' CZ ' ' A' ' 56' ' ' PHE . 0.7 OUTLIER -54.16 -45.84 72.15 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.036 -1.04 . . . . 0.0 108.85 179.756 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.889 ' CZ ' HD12 ' A' ' 55' ' ' LEU . 16.5 m-85 -123.97 110.32 29.41 Favored Pre-proline 0 N--CA 1.487 1.422 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.368 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 44.2 Cg_endo -66.92 137.89 46.37 Favored 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.645 2.23 . . . . 0.0 111.942 -179.481 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.19 -7.71 10.28 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.972 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.7 m-85 -107.54 134.37 50.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.896 -1.355 . . . . 0.0 110.082 -179.351 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 43.3 t -134.52 150.42 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.328 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.863 ' HB2' HG23 ' A' ' 41' ' ' VAL . 72.9 m-85 -108.67 123.64 49.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.988 -1.07 . . . . 0.0 109.711 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.682 HG12 HG23 ' A' ' 40' ' ' ILE . 19.0 m -131.86 144.24 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.382 -0.824 . . . . 0.0 109.569 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.62 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 22.7 tt0 -105.27 126.7 52.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.364 -0.835 . . . . 0.0 109.038 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.878 ' CE ' HG22 ' A' ' 37' ' ' VAL . 4.9 mtp -156.47 175.0 14.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.107 -0.996 . . . . 0.0 110.293 -179.442 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.96 HG12 HD12 ' A' ' 36' ' ' LEU . 10.6 pt -97.39 129.13 47.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.608 -0.683 . . . . 0.0 109.236 179.7 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.479 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 0.0 OUTLIER -76.36 145.87 39.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.919 . . . . 0.0 109.621 -179.026 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.582 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 44.1 t30 175.78 163.61 0.34 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -59.56 -40.47 87.39 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.058 -1.027 . . . . 0.0 109.581 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.544 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 99.1 mt-10 -72.19 -43.74 64.07 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.217 -0.927 . . . . 0.0 109.895 -179.706 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.101 ' HB2' HD11 ' A' ' 36' ' ' LEU . . . -56.4 -44.88 80.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.087 -1.008 . . . . 0.0 109.572 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.582 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 36.2 m-85 -60.32 -62.39 1.9 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.22 -0.925 . . . . 0.0 109.269 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.479 ' O ' ' HB2' ' A' ' 76' ' ' SER . 95.8 m-20 -43.52 -30.86 0.62 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.388 -0.82 . . . . 0.0 109.82 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.544 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 24.4 m-85 -82.94 -42.41 17.69 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.167 -0.958 . . . . 0.0 109.898 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.955 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 61.2 t -69.99 -55.33 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.217 -0.927 . . . . 0.0 109.498 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.493 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 6.1 tpt180 -57.77 -14.32 5.65 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.292 -0.88 . . . . 0.0 109.307 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.479 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 3.8 m -105.61 2.5 28.28 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.208 -0.933 . . . . 0.0 109.691 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 1.015 ' O ' HG12 ' A' ' 80' ' ' VAL . 0.4 OUTLIER -68.37 150.65 97.63 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.048 -1.033 . . . . 0.0 109.087 179.911 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.904 ' HD2' HG22 ' A' ' 77' ' ' VAL . 47.7 Cg_endo -68.83 124.75 11.79 Favored 'Trans proline' 0 C--O 1.214 -0.714 0 C-N-CA 122.569 2.179 . . . . 0.0 112.429 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.963 ' HB2' HG22 ' A' ' 20' ' ' VAL . 53.5 m-85 88.59 0.02 0.38 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.776 -0.577 . . . . 0.0 110.773 179.164 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 1.015 HG12 ' O ' ' A' ' 77' ' ' VAL . 7.4 p -84.16 112.9 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.738 -1.226 . . . . 0.0 109.523 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 86.0 mmm -87.43 -30.1 20.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.274 -0.891 . . . . 0.0 109.232 179.659 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 11' ' ' LEU . . . 174.26 -169.03 41.99 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.955 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 15.7 m-85 -127.66 147.62 50.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.248 -1.148 . . . . 0.0 109.514 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.719 ' CG2' HD21 ' A' ' 11' ' ' LEU . 59.2 t -67.3 77.1 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.32 -0.862 . . . . 0.0 109.254 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.529 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 3.1 p -127.71 162.78 25.76 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.332 -0.855 . . . . 0.0 109.634 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 87.8 p -95.91 -33.33 12.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.42 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.98 -77.09 0.19 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.508 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -106.58 -145.19 12.41 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.508 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.1 OUTLIER -33.31 154.01 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.582 -0.952 . . . . 0.0 110.188 -179.458 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.529 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 51.7 Cg_endo -70.68 168.55 22.42 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.513 2.142 . . . . 0.0 112.032 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' VAL . . . . . 0.914 HG12 ' HD2' ' A' ' 92' ' ' PRO . 0.1 OUTLIER -98.7 148.98 35.29 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.33 -0.856 . . . . 0.0 109.199 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.914 ' HD2' HG12 ' A' ' 91' ' ' VAL . 48.7 Cg_endo -69.31 150.8 71.4 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.616 2.21 . . . . 0.0 111.705 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 1.063 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.5 t -80.06 126.65 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.912 . . . . 0.0 109.528 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' LYS . . . . . 0.487 ' O ' ' N ' ' A' ' 97' ' ' GLU . 51.0 mttt -71.9 136.62 46.96 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.267 -0.895 . . . . 0.0 109.271 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.485 ' O ' ' HG3' ' A' ' 99' ' ' ARG . 82.8 m-20 -43.25 -41.65 3.99 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.918 . . . . 0.0 109.346 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 21.8 mtm180 -56.75 -30.38 63.53 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.336 -0.852 . . . . 0.0 109.692 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.487 ' N ' ' O ' ' A' ' 94' ' ' LYS . 53.6 mt-10 -87.01 -27.75 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.599 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.593 ' SD ' HG11 ' A' ' 93' ' ' VAL . 75.2 mmm -80.08 -24.72 40.43 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.359 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.603 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 25.6 mtp85 -37.37 -53.71 2.2 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.482 -0.761 . . . . 0.0 109.786 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.603 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.9 Cg_endo -69.28 -30.74 24.02 Favored 'Trans proline' 0 C--O 1.216 -0.577 0 C-N-CA 122.587 2.191 . . . . 0.0 111.749 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.42 ' HA ' HD13 ' A' ' 101' ' ' ILE . 16.3 mm -77.52 -43.69 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.139 -0.976 . . . . 0.0 109.238 179.804 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.529 ' CB ' ' HB2' ' A' ' 108' ' ' GLU . 1.1 mt -63.19 -40.77 98.46 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.275 -0.891 . . . . 0.0 109.031 179.795 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.527 ' HD3' ' CA ' ' A' ' 135' ' ' PRO . 24.7 ttt-85 -60.11 -45.85 91.59 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 108.783 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.994 HD21 ' O ' ' A' ' 44' ' ' ILE . 0.6 OUTLIER -68.45 -34.31 75.74 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.391 -0.818 . . . . 0.0 108.912 179.397 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.514 ' O ' ' HG ' ' A' ' 107' ' ' LEU . . . -90.47 17.88 6.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.32 -0.863 . . . . 0.0 109.033 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 43.76 28.89 1.22 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.723 HD11 ' CG1' ' A' ' 41' ' ' VAL . 88.3 mt -90.12 -26.64 20.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -1.158 . . . . 0.0 109.535 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' GLU . . . . . 0.529 ' HB2' ' CB ' ' A' ' 102' ' ' LEU . 87.2 tt0 . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.238 -0.914 . . . . 0.0 109.63 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.652 ' CE2' ' HB3' ' A' ' 127' ' ' ASP . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.475 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 12.2 mttt -113.91 157.22 22.67 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.11 -0.994 . . . . 0.0 110.146 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 22.0 t -64.43 144.99 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.512 -0.742 . . . . 0.0 109.469 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.423 ' O ' HG13 ' A' ' 142' ' ' VAL . . . 84.68 -28.23 4.5 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.652 ' HB3' ' CE2' ' A' ' 123' ' ' PHE . 8.3 m-20 -50.48 167.52 0.06 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.466 -1.02 . . . . 0.0 108.898 179.841 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -99.05 126.36 44.75 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.026 -1.047 . . . . 0.0 109.112 179.838 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.547 HG22 ' O ' ' A' ' 174' ' ' GLU . 2.3 p -124.93 142.8 40.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.373 -0.829 . . . . 0.0 109.08 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.466 ' N ' ' O ' ' A' ' 174' ' ' GLU . 21.1 tttt -104.9 142.91 33.92 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.293 -0.879 . . . . 0.0 109.236 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.932 HD12 ' HB3' ' A' ' 139' ' ' PHE . 74.3 mt -83.01 152.99 3.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.152 -0.967 . . . . 0.0 108.629 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.509 HD13 ' HB2' ' A' ' 174' ' ' GLU . 34.2 pt -150.1 2.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.926 -1.109 . . . . 0.0 109.494 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.578 ' CA ' ' HG2' ' A' ' 137' ' ' GLU . 5.9 t -147.11 142.09 26.99 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.048 -1.032 . . . . 0.0 109.634 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.464 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 102.22 -166.0 17.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 179.266 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.527 ' CA ' ' HD3' ' A' ' 103' ' ' ARG . 48.4 Cg_endo -68.28 -20.61 42.69 Favored 'Trans proline' 0 C--O 1.214 -0.701 0 C-N-CA 123.382 2.721 . . . . 0.0 113.104 -179.157 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.525 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.1 m-85 -105.77 15.86 26.13 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.836 -1.165 . . . . 0.0 109.54 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.578 ' HG2' ' CA ' ' A' ' 133' ' ' SER . 73.0 mt-10 -41.5 137.35 1.56 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.196 -0.94 . . . . 0.0 109.95 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.491 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.6 OUTLIER 75.48 25.18 1.26 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.303 -0.873 . . . . 0.0 110.656 178.954 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.932 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.1 t80 -115.96 134.25 55.17 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.876 -1.14 . . . . 0.0 109.579 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -83.79 134.29 34.73 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.196 -0.94 . . . . 0.0 109.551 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.17 169.38 25.78 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 126' ' ' GLY . 71.2 t -115.25 136.3 52.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.404 -1.057 . . . . 0.0 109.42 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.945 HD13 HD21 ' A' ' 153' ' ' LEU . 39.4 mt -67.61 117.92 10.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.162 -0.961 . . . . 0.0 109.505 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 24.5 tttm -99.79 -34.5 10.13 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.152 -0.967 . . . . 0.0 109.407 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.478 ' HB3' ' HD2' ' A' ' 154' ' ' LYS . 85.1 tt0 -153.85 148.99 26.89 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.11 -0.994 . . . . 0.0 109.66 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.703 HG23 ' CD1' ' A' ' 153' ' ' LEU . 3.3 mt -124.07 126.79 72.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.287 -0.883 . . . . 0.0 109.425 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.55 101.75 41.14 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.219 -0.925 . . . . 0.0 109.495 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.563 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 49.9 Cg_endo -71.6 170.54 18.34 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.653 2.235 . . . . 0.0 111.665 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.563 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.1 mt-10 80.48 -20.39 0.38 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.441 -0.787 . . . . 0.0 109.952 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.405 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 70.8 mtp180 -127.55 -13.58 5.38 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.12 -0.987 . . . . 0.0 109.67 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.405 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 29.0 mt-30 69.44 48.16 0.64 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.887 . . . . 0.0 109.499 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.765 ' OE2' HG13 ' A' ' 167' ' ' VAL . 82.9 tt0 -118.75 143.05 47.14 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.099 -1.001 . . . . 0.0 108.803 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.945 HD21 HD13 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -130.77 117.67 19.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.048 -1.032 . . . . 0.0 110.321 -179.174 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.478 ' HD2' ' HB3' ' A' ' 145' ' ' GLU . 11.2 mttt -79.82 129.65 34.66 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.677 ' O ' HG22 ' A' ' 166' ' ' VAL . 14.3 m -131.19 148.02 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.157 -0.965 . . . . 0.0 109.724 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.564 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.7 m-20 -100.48 119.04 37.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.37 -0.832 . . . . 0.0 109.437 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.581 HG23 ' CE1' ' A' ' 139' ' ' PHE . 3.4 p -100.35 144.05 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.309 -0.869 . . . . 0.0 109.501 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 28.0 m -96.89 97.05 8.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.391 -0.818 . . . . 0.0 109.984 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.644 HG22 ' CD2' ' A' ' 160' ' ' PHE . 13.0 mt -118.21 139.27 46.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.914 . . . . 0.0 109.332 179.608 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.644 ' CD2' HG22 ' A' ' 159' ' ' ILE . 40.0 m-85 59.67 41.74 18.14 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.402 -0.811 . . . . 0.0 109.32 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 54.14 16.61 6.55 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.731 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 4.3 mtp-105 -119.21 147.07 44.64 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.089 -1.242 . . . . 0.0 109.628 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -95.66 129.73 42.77 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.28 -0.887 . . . . 0.0 109.573 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.2 m -145.94 128.22 7.87 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.908 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.564 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.5 Cg_endo -70.52 138.72 36.0 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.686 2.257 . . . . 0.0 111.369 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.677 HG22 ' O ' ' A' ' 155' ' ' VAL . 2.9 m -122.4 168.09 15.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.005 -1.059 . . . . 0.0 110.01 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.765 HG13 ' OE2' ' A' ' 152' ' ' GLU . 42.8 t -116.44 117.95 57.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.541 -0.724 . . . . 0.0 109.309 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.749 HD12 ' N ' ' A' ' 168' ' ' LEU . 2.4 mp -141.21 165.75 26.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.258 -0.901 . . . . 0.0 110.519 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -80.2 143.38 33.83 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.526 HG23 HD13 ' A' ' 153' ' ' LEU . 4.3 p -57.96 -36.86 57.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.269 -0.895 . . . . 0.0 108.789 179.639 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.431 ' N ' ' CG1' ' A' ' 170' ' ' VAL . 49.8 m -77.17 -7.47 55.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.482 -0.761 . . . . 0.0 109.417 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.434 ' CG ' ' HB3' ' A' ' 133' ' ' SER . 5.5 mt-10 -95.8 -2.66 47.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.291 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 11.3 m -127.51 164.72 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.225 -0.922 . . . . 0.0 109.392 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.547 ' O ' HG22 ' A' ' 129' ' ' VAL . 58.3 tt0 -134.64 153.81 51.81 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.259 -0.901 . . . . 0.0 109.07 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.643 ' HB2' ' CZ ' ' A' ' 123' ' ' PHE . 33.1 pttt . . . . . 0 N--CA 1.489 1.478 0 O-C-N 121.182 -0.949 . . . . 0.0 109.493 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.487 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 82.9 mttt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.304 0.573 . . . . 0.0 109.496 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.521 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 18.7 mttp -130.65 176.45 8.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.294 -0.879 . . . . 0.0 109.579 -179.69 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 1.055 ' CZ3' HG23 ' A' ' 41' ' ' VAL . 76.1 m95 -113.16 125.06 53.93 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.279 -0.888 . . . . 0.0 109.179 179.742 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -115.37 170.4 8.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.164 -0.96 . . . . 0.0 109.139 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.562 HG12 ' CE1' ' A' ' 61' ' ' PHE . 21.5 mt -113.88 97.77 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.101 -1.0 . . . . 0.0 108.818 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.802 HG13 ' CG1' ' A' ' 60' ' ' VAL . 3.9 p -81.83 151.09 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.254 -0.903 . . . . 0.0 109.264 -179.771 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.874 HD21 ' CE1' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -94.34 142.96 26.82 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.388 -0.82 . . . . 0.0 110.013 -179.312 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.4 p -144.59 -171.59 3.64 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.372 -0.83 . . . . 0.0 109.01 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.504 ' CG ' ' SD ' ' A' ' 81' ' ' MET . 44.4 mtm -102.38 118.98 38.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.165 -0.959 . . . . 0.0 109.596 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 13' ' ' MET . 43.7 m -42.14 121.74 1.94 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.22 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.53 -18.3 32.69 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.069 -1.613 . . . . 0.0 109.069 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.43 ' O ' ' C ' ' A' ' 17' ' ' GLU . 92.9 m-85 -108.91 -13.25 14.78 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.397 -1.061 . . . . 0.0 109.61 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.43 ' C ' ' O ' ' A' ' 16' ' ' TYR . 95.1 mt-10 -42.71 -55.27 3.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.279 -0.888 . . . . 0.0 109.372 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -54.16 -36.46 63.36 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.215 -0.928 . . . . 0.0 109.141 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.421 ' N ' ' O ' ' A' ' 16' ' ' TYR . 28.0 mttp -70.3 -37.41 74.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.275 -0.891 . . . . 0.0 109.131 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 61.2 t -64.07 -47.13 91.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.431 -0.793 . . . . 0.0 109.411 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.6 tttm -55.1 -50.93 67.96 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.224 -0.923 . . . . 0.0 109.331 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -64.55 -41.92 96.01 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.281 -0.887 . . . . 0.0 109.311 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.489 ' ND2' ' HG2' ' A' ' 78' ' ' PRO . 24.1 t-20 -57.62 -39.75 77.62 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.186 -0.946 . . . . 0.0 109.452 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.798 HG21 HD11 ' A' ' 40' ' ' ILE . 96.4 mt -62.89 -44.73 99.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -0.927 . . . . 0.0 109.648 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -53.81 -45.29 70.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.15 -0.969 . . . . 0.0 109.64 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.9 mttt -79.99 -32.37 39.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.485 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.748 ' HG2' HG23 ' A' ' 77' ' ' VAL . 48.7 tptt -56.77 -38.3 72.3 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.308 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.788 HG13 ' O ' ' A' ' 33' ' ' ILE . 40.7 t -83.81 -22.93 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.338 -0.851 . . . . 0.0 109.399 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -69.16 -53.27 20.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.571 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.77 -33.47 64.36 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.619 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 23.1 p -91.42 -19.92 22.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.229 -0.92 . . . . 0.0 109.612 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 68.83 9.97 60.37 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.788 ' O ' HG13 ' A' ' 28' ' ' VAL . 54.3 mt -80.16 88.5 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.292 -1.122 . . . . 0.0 109.414 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.3 mttt -91.74 9.18 33.6 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.155 -0.966 . . . . 0.0 109.438 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.47 ' O ' HD13 ' A' ' 65' ' ' ILE . 38.0 p30 -110.93 9.13 22.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.289 -0.882 . . . . 0.0 109.59 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.988 HD21 ' HB2' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -109.71 -55.22 2.46 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.182 -0.948 . . . . 0.0 109.172 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.805 HG22 ' HE3' ' A' ' 64' ' ' MET . 68.9 t -94.15 130.98 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.317 -0.864 . . . . 0.0 109.31 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.75 -122.84 5.16 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -89.74 148.56 23.19 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.275 -1.132 . . . . 0.0 109.822 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.798 HD11 HG21 ' A' ' 24' ' ' ILE . 72.2 mt -116.21 132.93 64.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.4 -0.812 . . . . 0.0 108.909 179.641 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 1.055 HG23 ' CZ3' ' A' ' 7' ' ' TRP . 34.3 t -125.87 161.81 30.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 O-C-N 121.049 -1.032 . . . . 0.0 109.346 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.659 HG22 HG23 ' A' ' 44' ' ' ILE . 2.3 mt -140.92 127.61 11.74 Favored Pre-proline 0 N--CA 1.487 1.402 0 O-C-N 121.208 -0.933 . . . . 0.0 109.83 -179.709 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.562 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 45.8 Cg_endo -67.16 -2.64 8.39 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.841 2.36 . . . . 0.0 111.305 179.569 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.769 HG22 ' HB3' ' A' ' 54' ' ' LYS . 19.0 pt . . . . . 0 N--CA 1.489 1.48 0 O-C-N 121.312 -0.868 . . . . 0.0 109.615 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.769 ' HB3' HG22 ' A' ' 44' ' ' ILE . 13.6 mttp . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.656 HD23 ' HE2' ' A' ' 56' ' ' PHE . 18.2 tp -57.48 -45.85 84.38 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.039 -1.038 . . . . 0.0 109.291 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.656 ' HE2' HD23 ' A' ' 55' ' ' LEU . 57.9 m-85 -131.44 109.4 14.83 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.141 -0.974 . . . . 0.0 108.864 179.482 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -65.45 138.9 56.89 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.579 2.186 . . . . 0.0 111.974 -179.53 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.59 ' O ' HD13 ' A' ' 11' ' ' LEU . . . 76.84 -16.7 5.11 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 179.605 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.874 ' CE1' HD21 ' A' ' 11' ' ' LEU . 3.3 m-30 -98.63 129.08 45.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.788 -1.419 . . . . 0.0 110.406 -179.207 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.802 ' CG1' HG13 ' A' ' 10' ' ' VAL . 7.7 p -136.92 151.58 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.562 ' CE1' HG12 ' A' ' 9' ' ' ILE . 7.7 m-85 -110.0 127.07 54.58 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.914 -1.116 . . . . 0.0 110.756 -178.71 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.783 HG13 HG12 ' A' ' 40' ' ' ILE . 90.3 t -129.51 139.82 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.649 -0.657 . . . . 0.0 109.318 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.604 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 9.7 tt0 -101.83 126.94 48.81 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.114 -0.991 . . . . 0.0 109.104 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.805 ' HE3' HG22 ' A' ' 37' ' ' VAL . 1.8 mtp -157.28 178.02 10.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.043 -1.036 . . . . 0.0 110.071 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.616 ' CG1' HD22 ' A' ' 36' ' ' LEU . 12.2 pt -99.95 131.92 46.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.593 -0.692 . . . . 0.0 109.286 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.47 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 42.1 ttm -77.65 145.76 36.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 110.086 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.508 ' OD1' ' N ' ' A' ' 68' ' ' ASP . 49.8 t-20 176.74 172.37 0.45 Allowed 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.508 ' N ' ' OD1' ' A' ' 67' ' ' ASN . 90.2 m-20 -69.47 -42.81 74.35 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.163 -0.961 . . . . 0.0 109.275 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.504 ' HG2' ' CD2' ' A' ' 73' ' ' PHE . 69.7 tt0 -73.82 -31.54 63.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.327 -0.858 . . . . 0.0 109.55 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.988 ' HB2' HD21 ' A' ' 36' ' ' LEU . . . -70.92 -45.07 64.92 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.146 -0.971 . . . . 0.0 109.356 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.495 ' HA ' ' CG1' ' A' ' 74' ' ' VAL . 71.8 t80 -60.99 -47.0 88.48 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.265 -0.897 . . . . 0.0 109.72 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' HB2' ' A' ' 76' ' ' SER . 96.4 m-20 -64.72 -27.65 69.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.106 -0.996 . . . . 0.0 110.035 -179.518 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.504 ' CD2' ' HG2' ' A' ' 69' ' ' GLU . 3.6 m-85 -84.19 -42.98 15.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.045 -1.034 . . . . 0.0 109.917 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.848 HG12 ' O ' ' A' ' 70' ' ' ALA . 2.9 p -67.12 -57.87 8.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.264 -0.898 . . . . 0.0 109.803 -179.426 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.696 ' H ' HG13 ' A' ' 74' ' ' VAL . 28.5 tpt85 -62.84 -10.27 12.58 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.103 -0.998 . . . . 0.0 109.676 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.481 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 19.4 m -99.25 1.49 44.74 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.147 -0.971 . . . . 0.0 109.953 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.787 HG12 ' CG2' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -70.43 140.71 87.57 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.023 -1.048 . . . . 0.0 109.229 -179.976 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.648 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 45.6 Cg_endo -66.73 134.9 36.58 Favored 'Trans proline' 0 C--O 1.213 -0.765 0 C-N-CA 122.706 2.271 . . . . 0.0 111.849 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.648 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 10.0 m-85 92.62 -10.77 0.18 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.816 -0.552 . . . . 0.0 109.52 -179.708 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.787 ' CG2' HG12 ' A' ' 77' ' ' VAL . 2.3 t -85.7 121.06 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.116 -0.99 . . . . 0.0 109.144 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.504 ' SD ' ' CG ' ' A' ' 13' ' ' MET . 82.8 mtp -88.4 -33.69 17.82 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.241 -0.912 . . . . 0.0 109.565 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 11' ' ' LEU . . . 172.01 -168.98 42.12 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.631 ' CD1' ' N ' ' A' ' 83' ' ' PHE . 0.8 OUTLIER -134.21 146.65 50.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.189 -1.183 . . . . 0.0 109.524 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.675 ' O ' HG13 ' A' ' 84' ' ' VAL . 14.2 p -81.23 114.38 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.212 -0.93 . . . . 0.0 109.368 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.598 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.9 OUTLIER -154.04 164.88 37.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.256 -0.902 . . . . 0.0 109.639 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 77.0 p -84.5 -30.63 25.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.167 -0.958 . . . . 0.0 109.267 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -130.96 -102.54 0.93 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.548 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -93.16 -129.15 5.08 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.548 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -29.5 150.47 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.675 -0.897 . . . . 0.0 110.315 -179.56 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.598 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 46.2 Cg_endo -67.66 143.03 60.52 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.753 2.302 . . . . 0.0 112.002 -179.84 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 6.2 m -74.07 147.56 85.96 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.325 -0.86 . . . . 0.0 109.293 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.506 ' CB ' ' HD3' ' A' ' 6' ' ' LYS . 49.2 Cg_endo -69.82 145.39 56.63 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.708 2.272 . . . . 0.0 111.7 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.529 ' CG1' ' HG2' ' A' ' 98' ' ' MET . 9.9 p -70.11 135.16 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.932 . . . . 0.0 109.231 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' LYS . . . . . 0.487 ' HE2' ' HD2' ' A' ' 96' ' ' ARG . 15.4 tttp -70.95 136.48 48.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.179 -0.95 . . . . 0.0 109.592 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -46.58 -52.05 14.34 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.221 -0.924 . . . . 0.0 109.355 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.487 ' HD2' ' HE2' ' A' ' 94' ' ' LYS . 72.0 mtt85 -60.84 -16.47 41.63 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.292 -0.88 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.489 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 6.7 mt-10 -88.59 -28.5 20.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.274 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.651 ' HE3' ' CD1' ' A' ' 7' ' ' TRP . 31.4 mtp -75.85 -28.69 58.3 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -0.874 . . . . 0.0 109.61 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.59 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.46 -53.37 1.3 Allowed Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.485 -0.76 . . . . 0.0 109.979 -179.609 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.59 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.7 Cg_endo -69.01 -34.96 15.85 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.538 2.158 . . . . 0.0 112.111 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.489 ' HA ' HD13 ' A' ' 101' ' ' ILE . 8.7 mm -78.57 -44.51 26.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.118 -0.989 . . . . 0.0 109.444 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.908 ' HA ' HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -62.19 -41.35 98.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.106 -0.996 . . . . 0.0 108.873 179.725 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.478 ' HD2' ' O ' ' A' ' 135' ' ' PRO . 36.3 mtt180 -61.03 -43.21 99.23 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -70.01 -35.76 74.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 109.134 179.667 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.451 ' HB3' ' CD1' ' A' ' 107' ' ' LEU . . . -88.13 20.96 2.94 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.21 179.681 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 46.92 28.4 3.88 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.908 HD12 ' HA ' ' A' ' 102' ' ' LEU . 35.9 mt -80.04 -22.84 41.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.196 -1.179 . . . . 0.0 109.146 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.345 -0.847 . . . . 0.0 109.314 179.959 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.525 ' CD2' ' O ' ' A' ' 123' ' ' PHE . 51.7 p90 . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.463 ' N ' ' OD2' ' A' ' 127' ' ' ASP . 27.5 mttp -141.81 164.48 30.07 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.247 -0.908 . . . . 0.0 109.558 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.55 HG23 ' O ' ' A' ' 144' ' ' LYS . 7.9 p -66.5 126.11 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.318 -0.864 . . . . 0.0 109.659 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 103.68 -33.32 6.67 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.751 ' HB2' HD12 ' A' ' 143' ' ' ILE . 73.2 m-20 -48.15 165.33 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.385 -1.068 . . . . 0.0 108.922 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.4 ttm -97.26 126.91 42.78 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.044 -1.035 . . . . 0.0 108.97 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.707 ' CG2' HD11 ' A' ' 143' ' ' ILE . 12.7 t -125.36 141.91 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.248 -0.908 . . . . 0.0 109.535 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.484 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 42.8 tttp -106.61 143.91 34.04 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.357 -0.839 . . . . 0.0 108.946 179.495 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 1.009 HD12 ' HB3' ' A' ' 139' ' ' PHE . 65.8 mt -84.76 155.31 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.129 -0.982 . . . . 0.0 108.817 179.636 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.437 HG12 ' HA ' ' A' ' 173' ' ' VAL . 27.2 pt -150.59 2.95 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.126 -0.984 . . . . 0.0 109.488 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 72.7 m -148.66 145.08 27.57 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.151 -0.968 . . . . 0.0 110.107 -179.672 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.15 -170.55 16.8 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.478 ' O ' ' HD2' ' A' ' 103' ' ' ARG . 48.2 Cg_endo -68.66 -19.8 41.31 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 123.275 2.65 . . . . 0.0 112.467 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.534 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 98.1 m-85 -112.96 13.22 19.48 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.05 -1.031 . . . . 0.0 109.487 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.727 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.6 tt0 -42.73 151.74 0.12 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 109.663 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.515 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 25.3 m-20 72.99 28.1 1.98 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.455 -0.778 . . . . 0.0 110.091 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 1.009 ' HB3' HD12 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -120.43 136.99 54.57 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.99 -1.069 . . . . 0.0 109.539 179.877 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.08 133.94 34.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.225 -0.922 . . . . 0.0 109.579 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.92 170.05 25.95 Favored Glycine 0 N--CA 1.492 2.374 0 C-N-CA 119.836 -1.173 . . . . 0.0 110.171 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.887 ' C ' HG23 ' A' ' 155' ' ' VAL . 47.9 t -115.76 136.03 53.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.387 -1.066 . . . . 0.0 109.439 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.815 HG23 HD23 ' A' ' 153' ' ' LEU . 87.7 mt -65.12 115.22 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.89 . . . . 0.0 109.386 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.55 ' O ' HG23 ' A' ' 125' ' ' VAL . 36.6 tttp -100.26 -36.38 9.3 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.062 -1.024 . . . . 0.0 109.377 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.441 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 67.2 mm-40 -149.57 144.26 26.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.967 . . . . 0.0 109.351 -179.9 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 1.084 HG23 ' HG ' ' A' ' 153' ' ' LEU . 2.4 mt -123.04 125.85 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.183 -0.948 . . . . 0.0 109.406 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -108.18 101.46 41.9 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.236 -0.915 . . . . 0.0 109.63 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.552 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.7 171.4 16.49 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.72 2.28 . . . . 0.0 111.781 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.552 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 10.8 tt0 80.55 -20.97 0.35 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.3 -0.875 . . . . 0.0 109.791 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.452 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 93.1 mtt-85 -126.59 -12.99 6.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.916 . . . . 0.0 109.437 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.452 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 29.9 mt-30 69.83 48.6 0.56 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.204 -0.935 . . . . 0.0 109.61 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -120.06 143.62 48.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.138 -0.976 . . . . 0.0 109.08 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 1.084 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -136.99 112.38 9.24 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.15 -0.969 . . . . 0.0 110.12 -179.599 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.429 ' HD2' ' HB2' ' A' ' 145' ' ' GLU . 30.8 mttm -79.85 130.94 35.72 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.06 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.887 HG23 ' C ' ' A' ' 142' ' ' VAL . 7.3 p -133.39 127.48 53.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.121 -0.987 . . . . 0.0 109.752 -179.469 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.56 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 50.2 m-20 -73.18 135.4 44.61 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.362 -0.836 . . . . 0.0 109.709 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.553 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 53.9 t -116.8 149.96 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.466 -0.772 . . . . 0.0 109.195 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 57.2 m -96.34 103.01 14.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.107 -0.996 . . . . 0.0 109.711 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.509 HG22 ' CD2' ' A' ' 160' ' ' PHE . 20.5 mt -129.98 140.77 48.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.285 -0.884 . . . . 0.0 109.311 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.509 ' CD2' HG22 ' A' ' 159' ' ' ILE . 52.8 m-85 60.3 40.4 17.76 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.186 -0.946 . . . . 0.0 108.97 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.64 16.31 15.88 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 46.1 mtp180 -128.43 156.13 43.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.111 -1.229 . . . . 0.0 109.57 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -100.24 133.75 44.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.289 -0.882 . . . . 0.0 109.443 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.7 m -141.33 127.77 11.41 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.342 -0.849 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.56 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.9 Cg_endo -70.35 133.68 25.03 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.658 2.238 . . . . 0.0 111.44 179.697 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.635 HG12 ' O ' ' A' ' 155' ' ' VAL . 2.8 p -122.67 141.87 41.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.204 -0.935 . . . . 0.0 109.675 -179.837 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.588 ' O ' HG23 ' A' ' 167' ' ' VAL . 18.0 m -93.17 120.11 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.458 -0.776 . . . . 0.0 109.458 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.867 HD11 HG12 ' A' ' 155' ' ' VAL . 0.0 OUTLIER -142.3 167.81 21.22 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.33 -0.857 . . . . 0.0 110.487 -179.471 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.482 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 48.1 m80 -81.6 142.0 33.19 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.622 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.425 HG13 ' N ' ' A' ' 171' ' ' SER . 10.8 p -55.92 -35.98 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.177 -0.952 . . . . 0.0 109.025 179.782 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.425 ' N ' HG13 ' A' ' 170' ' ' VAL . 74.6 p -75.71 -6.61 51.39 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.403 -0.811 . . . . 0.0 109.626 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.482 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 41.8 mt-10 -90.99 -0.68 57.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.135 -0.978 . . . . 0.0 109.572 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 173' ' ' VAL . . . . . 0.484 ' HB ' ' O ' ' A' ' 130' ' ' LYS . 2.8 m -147.13 177.74 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.176 -0.953 . . . . 0.0 109.452 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.63 ' O ' HG13 ' A' ' 129' ' ' VAL . 83.5 tt0 -136.55 163.75 29.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.149 -0.969 . . . . 0.0 109.263 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.538 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.3 mmtt . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.47 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 47.0 mttt . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.561 ' HB2' ' CZ ' ' A' ' 8' ' ' TYR . 26.5 mmtp -128.6 175.47 8.54 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.354 -0.841 . . . . 0.0 109.613 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.932 ' O ' HG23 ' A' ' 93' ' ' VAL . 47.2 m95 -111.65 124.26 51.94 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.39 -0.819 . . . . 0.0 108.968 179.657 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.561 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 59.3 m-85 -117.94 168.65 10.31 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.141 -0.975 . . . . 0.0 109.478 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.537 HG12 ' CE1' ' A' ' 61' ' ' PHE . 33.9 mt -107.5 114.63 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.208 -0.932 . . . . 0.0 109.367 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.604 HG12 ' HB ' ' A' ' 60' ' ' VAL . 8.5 p -92.65 141.17 15.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.234 -0.916 . . . . 0.0 109.222 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.674 HD11 ' CE1' ' A' ' 59' ' ' TYR . 3.7 mm? -89.62 143.28 26.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.408 -0.807 . . . . 0.0 109.739 -179.572 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.731 HG21 ' OE1' ' A' ' 17' ' ' GLU . 9.0 t -152.99 -166.03 2.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.325 -0.859 . . . . 0.0 109.408 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.441 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 46.2 mtt -108.14 130.83 55.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.532 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.0 t -54.26 128.27 30.54 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.196 -0.94 . . . . 0.0 109.391 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.55 -20.31 44.8 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 -179.79 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.441 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 79.4 m-85 -104.47 5.94 34.48 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.38 -1.071 . . . . 0.0 109.557 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.731 ' OE1' HG21 ' A' ' 12' ' ' THR . 41.1 mm-40 -53.36 -62.32 1.73 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.62 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 17' ' ' GLU . 60.7 mt-10 -42.68 -35.64 1.18 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -0.889 . . . . 0.0 109.583 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 27.3 mttt -74.18 -44.61 52.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.472 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.688 HG21 ' OG1' ' A' ' 12' ' ' THR . 70.6 t -58.44 -53.11 51.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.48 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.417 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.5 tttm -58.4 -47.07 85.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.348 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -63.13 -41.17 99.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.329 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.473 ' HB3' ' HG2' ' A' ' 78' ' ' PRO . 22.1 m120 -59.29 -42.78 92.09 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.904 . . . . 0.0 109.503 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.911 HG21 HD11 ' A' ' 40' ' ' ILE . 69.7 mt -61.5 -46.46 96.53 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.229 -0.919 . . . . 0.0 109.715 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -54.83 -46.22 74.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.145 -0.972 . . . . 0.0 109.56 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -75.78 -35.57 60.07 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.132 -0.98 . . . . 0.0 109.459 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.604 ' O ' HG23 ' A' ' 31' ' ' THR . 7.8 ttpt -56.14 -34.26 65.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.253 -0.905 . . . . 0.0 109.314 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.793 HG13 ' O ' ' A' ' 33' ' ' ILE . 44.2 t -85.52 -25.15 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -0.873 . . . . 0.0 109.377 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -69.77 -54.17 14.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.186 -0.946 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.22 -24.76 67.79 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.197 -0.94 . . . . 0.0 109.526 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.604 HG23 ' O ' ' A' ' 27' ' ' LYS . 40.2 p -94.96 -21.75 18.41 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.165 -0.959 . . . . 0.0 109.531 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 63.68 22.01 65.66 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.014 HG21 HD12 ' A' ' 36' ' ' LEU . 42.7 mm -95.07 91.79 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.271 -1.134 . . . . 0.0 109.465 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.9 mtpt -98.81 10.03 42.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.27 -0.894 . . . . 0.0 109.52 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -108.24 5.44 25.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.19 -0.944 . . . . 0.0 109.492 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.014 HD12 HG21 ' A' ' 33' ' ' ILE . 88.3 mt -117.78 -30.94 5.29 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.276 -0.89 . . . . 0.0 109.39 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.499 ' HA ' ' HG2' ' A' ' 64' ' ' MET . 73.0 t -114.68 129.35 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.309 -0.869 . . . . 0.0 109.305 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.73 -129.89 6.84 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 23.4 mtt-85 -90.44 147.89 23.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.274 -1.133 . . . . 0.0 109.777 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 1.061 HG23 HG22 ' A' ' 62' ' ' VAL . 59.9 mt -113.32 136.61 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.337 -0.852 . . . . 0.0 109.383 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.575 ' CG1' ' HB2' ' A' ' 61' ' ' PHE . 9.3 p -130.4 158.29 42.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.199 -0.938 . . . . 0.0 109.54 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.773 HG22 HG23 ' A' ' 44' ' ' ILE . 3.3 mt -131.78 129.05 21.86 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.559 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.533 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 46.1 Cg_endo -67.2 -4.73 12.19 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.788 2.325 . . . . 0.0 111.587 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.773 HG23 HG22 ' A' ' 42' ' ' ILE . 12.7 pt . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.299 -0.876 . . . . 0.0 109.451 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.703 ' HA ' HG22 ' A' ' 44' ' ' ILE . 47.6 mttt . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.533 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 6.7 mp -61.55 -26.8 68.18 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.097 -1.002 . . . . 0.0 109.527 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.616 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 97.2 m-85 -145.83 103.8 4.2 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.893 . . . . 0.0 109.31 179.778 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 43.5 Cg_endo -67.17 137.75 44.96 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.666 2.244 . . . . 0.0 111.865 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.91 -9.28 6.68 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.674 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.2 m-85 -103.49 132.65 49.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.795 -1.415 . . . . 0.0 109.82 -179.511 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.604 ' HB ' HG12 ' A' ' 10' ' ' VAL . 4.9 t -135.58 148.65 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.354 -0.841 . . . . 0.0 108.923 179.41 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.575 ' HB2' ' CG1' ' A' ' 41' ' ' VAL . 63.3 m-85 -107.87 121.65 45.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.073 -1.017 . . . . 0.0 109.764 -179.64 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 1.061 HG22 HG23 ' A' ' 40' ' ' ILE . 57.6 t -129.06 141.14 47.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.357 -0.839 . . . . 0.0 109.699 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.618 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 52.4 tt0 -97.03 124.73 41.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.339 -0.851 . . . . 0.0 108.862 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.512 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 37.3 mtm -158.4 -179.82 8.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.147 -0.971 . . . . 0.0 109.777 -179.582 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.851 HD11 ' CD2' ' A' ' 36' ' ' LEU . 8.5 pt -102.64 129.0 54.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.2 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.501 ' O ' ' HG3' ' A' ' 66' ' ' MET . 5.2 ptp -85.58 96.2 9.57 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.129 -0.982 . . . . 0.0 109.668 -179.364 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.598 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 23.0 t-20 -140.04 170.48 15.78 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -52.81 -47.58 67.53 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.038 -1.039 . . . . 0.0 109.987 -179.507 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.458 ' O ' ' C ' ' A' ' 70' ' ' ALA . 64.6 mm-40 -64.87 -64.34 0.89 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.095 -1.003 . . . . 0.0 110.132 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.854 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -39.77 -38.8 0.69 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.263 -0.898 . . . . 0.0 109.926 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.598 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 15.4 m-85 -61.11 -62.16 2.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.226 -0.921 . . . . 0.0 109.362 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -45.76 -34.9 3.93 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.503 -0.748 . . . . 0.0 110.412 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -81.39 -43.85 18.39 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.888 -1.133 . . . . 0.0 110.136 -179.381 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.995 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 45.4 t -64.43 -58.67 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.25 -0.906 . . . . 0.0 109.643 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -35.05 19.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.366 -0.834 . . . . 0.0 110.034 -179.589 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 53.6 p -78.16 4.89 11.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.083 -1.01 . . . . 0.0 110.37 -179.279 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.611 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 41.1 t -64.32 133.62 95.71 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 120.872 -1.143 . . . . 0.0 109.286 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.569 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 46.1 Cg_endo -68.27 134.83 32.43 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.702 2.268 . . . . 0.0 112.02 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.569 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 60.2 m-85 77.61 -1.54 2.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.525 -0.734 . . . . 0.0 109.855 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.611 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.4 t -88.6 127.32 41.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.173 -0.955 . . . . 0.0 109.147 179.609 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 82.5 mmm -90.77 -17.97 25.74 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.21 -0.931 . . . . 0.0 109.645 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.592 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 151.71 -155.61 26.23 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.995 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 3.6 m-85 -140.04 152.67 46.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -1.16 . . . . 0.0 109.5 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.571 HG22 HD21 ' A' ' 11' ' ' LEU . 4.6 t -77.27 119.58 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.291 -0.881 . . . . 0.0 109.275 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.556 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.9 p -156.49 162.17 39.98 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.227 -0.92 . . . . 0.0 109.596 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.78 -34.8 14.45 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.887 . . . . 0.0 109.393 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -122.09 -86.33 0.83 Allowed Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -107.04 -130.37 6.43 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.545 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.1 OUTLIER -33.82 156.4 0.04 OUTLIER Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.43 -1.041 . . . . 0.0 110.056 -179.693 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.556 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.9 Cg_endo -69.71 157.74 59.44 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 122.492 2.128 . . . . 0.0 112.109 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' VAL . . . . . 0.402 ' H ' HG22 ' A' ' 91' ' ' VAL . 10.9 m -90.15 153.64 46.83 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.351 -0.843 . . . . 0.0 109.452 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.453 ' HB3' ' HB3' ' A' ' 6' ' ' LYS . 49.1 Cg_endo -69.81 145.48 56.99 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.658 2.239 . . . . 0.0 111.812 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.932 HG23 ' O ' ' A' ' 7' ' ' TRP . 7.6 t -84.22 129.69 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.235 -0.915 . . . . 0.0 109.194 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' LYS . . . . . 0.414 ' O ' ' C ' ' A' ' 95' ' ' ASP . 23.6 tttt -70.56 132.77 46.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.191 -0.943 . . . . 0.0 109.578 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 94' ' ' LYS . 80.5 m-20 -44.48 -39.86 5.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.205 -0.934 . . . . 0.0 109.356 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.5 ' CZ ' ' HB3' ' A' ' 96' ' ' ARG . 13.4 mtp-105 -53.79 -35.51 61.44 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.272 -0.893 . . . . 0.0 109.374 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.446 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 65.2 mt-10 -84.73 -27.48 26.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.269 -0.894 . . . . 0.0 109.372 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.628 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 94.4 mtp -84.98 -12.31 53.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.295 -0.878 . . . . 0.0 109.505 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.667 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -51.18 -48.42 85.46 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.171 -0.956 . . . . 0.0 109.853 179.864 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.667 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.5 Cg_endo -70.82 -27.6 21.22 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.485 2.123 . . . . 0.0 111.861 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.439 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 35.8 mm -81.52 -44.4 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 109.565 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.601 HD12 ' O ' ' A' ' 98' ' ' MET . 0.7 OUTLIER -66.46 -38.76 88.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.232 -0.917 . . . . 0.0 109.256 -179.926 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.524 ' CZ ' ' NH1' ' A' ' 99' ' ' ARG . 67.7 mtt180 -65.47 -50.16 66.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.429 -0.794 . . . . 0.0 109.322 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -72.64 -36.24 67.96 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.273 -0.892 . . . . 0.0 109.364 179.762 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.535 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -73.44 -0.99 16.52 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.371 -0.831 . . . . 0.0 109.687 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.03 11.6 81.44 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.452 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 61.3 mt -85.51 -24.11 27.45 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.128 -1.219 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' GLU . . . . . 0.46 ' HB2' ' HB2' ' A' ' 102' ' ' LEU . 73.5 tt0 . . . . . 0 N--CA 1.49 1.553 0 O-C-N 121.283 -0.886 . . . . 0.0 109.591 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 3.6 p90 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 22.4 mttt -149.02 157.29 43.3 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.221 -0.925 . . . . 0.0 109.52 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.613 HG13 ' O ' ' A' ' 144' ' ' LYS . 44.7 t -60.33 140.04 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 87.85 -34.12 3.81 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.768 ' HB3' HD12 ' A' ' 143' ' ' ILE . 43.0 t0 -48.51 157.68 0.34 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.431 -1.041 . . . . 0.0 109.465 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.8 ttm -96.07 127.5 42.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.244 -0.91 . . . . 0.0 108.861 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 1.021 HG13 ' O ' ' A' ' 174' ' ' GLU . 51.3 t -126.44 142.08 44.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.256 -0.903 . . . . 0.0 109.42 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 5.8 ttpp -101.95 142.85 32.6 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.376 -0.828 . . . . 0.0 109.065 179.738 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.86 HD12 ' HB3' ' A' ' 139' ' ' PHE . 70.8 mt -82.9 151.35 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.042 -1.036 . . . . 0.0 108.761 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.669 HD13 ' CD ' ' A' ' 174' ' ' GLU . 33.2 pt -148.99 2.95 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.95 -1.093 . . . . 0.0 109.503 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.559 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 68.8 m -146.35 141.76 27.57 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.11 -0.994 . . . . 0.0 109.712 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.423 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 107.04 -170.85 16.16 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.581 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.52 -18.91 43.23 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 123.213 2.609 . . . . 0.0 112.797 -179.445 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.529 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.9 m-85 -108.94 19.11 19.97 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.964 -1.085 . . . . 0.0 109.487 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.559 ' HA ' HG22 ' A' ' 131' ' ' ILE . 43.8 mt-10 -41.31 141.85 0.64 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 110.22 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 138' ' ' ASP . 0.5 OUTLIER 76.03 24.39 1.19 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.299 -0.875 . . . . 0.0 110.757 179.002 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.86 ' HB3' HD12 ' A' ' 131' ' ' ILE . 0.5 OUTLIER -111.73 129.32 56.15 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.828 -1.17 . . . . 0.0 109.729 179.912 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.401 ' N ' ' HD1' ' A' ' 139' ' ' PHE . . . -76.46 134.8 39.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.905 . . . . 0.0 109.392 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.79 166.62 26.94 Favored Glycine 0 N--CA 1.489 2.221 0 C-N-CA 119.718 -1.23 . . . . 0.0 110.164 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.814 ' C ' HG23 ' A' ' 155' ' ' VAL . 47.0 t -116.16 137.34 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.591 -0.946 . . . . 0.0 109.256 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.768 HD12 ' HB3' ' A' ' 127' ' ' ASP . 88.6 mt -70.39 120.49 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.305 -0.872 . . . . 0.0 109.268 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.613 ' O ' HG13 ' A' ' 125' ' ' VAL . 75.0 tttt -103.65 -33.07 9.1 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.964 -1.085 . . . . 0.0 109.711 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.519 ' HG2' ' O ' ' A' ' 144' ' ' LYS . 15.5 mt-10 -150.5 145.66 26.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.058 -1.027 . . . . 0.0 109.845 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 1.032 HG23 HD11 ' A' ' 153' ' ' LEU . 0.9 OUTLIER -115.44 117.91 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.218 -0.926 . . . . 0.0 108.973 179.542 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -106.64 98.13 19.46 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.156 -0.965 . . . . 0.0 109.785 -179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.55 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.5 Cg_endo -72.33 173.65 12.76 Favored 'Trans proline' 0 C--O 1.216 -0.588 0 C-N-CA 122.675 2.25 . . . . 0.0 111.734 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.55 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 4.5 mt-10 78.98 -22.06 0.3 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.26 -0.9 . . . . 0.0 109.876 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.441 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 40.8 mtm180 -126.33 -16.78 5.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.039 -1.038 . . . . 0.0 109.3 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.441 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 6.0 mt-30 71.04 47.54 0.41 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.3 -0.875 . . . . 0.0 109.511 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.704 ' OE2' HG13 ' A' ' 167' ' ' VAL . 64.9 tt0 -116.44 139.83 50.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.124 -0.985 . . . . 0.0 108.885 179.651 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 1.032 HD11 HG23 ' A' ' 146' ' ' ILE . 2.7 mm? -124.88 111.79 15.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.153 -0.967 . . . . 0.0 110.108 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.441 ' HD3' ' HB2' ' A' ' 145' ' ' GLU . 17.2 mtpp -78.02 122.68 25.88 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.814 HG23 ' C ' ' A' ' 142' ' ' VAL . 10.4 p -126.92 149.27 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.039 -1.038 . . . . 0.0 109.904 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 1.9 t-20 -97.99 110.54 23.09 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.439 -0.788 . . . . 0.0 109.488 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.577 HG13 ' CD1' ' A' ' 139' ' ' PHE . 87.1 t -96.38 144.64 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.2 -0.938 . . . . 0.0 109.268 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 96.1 m -102.92 111.93 24.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -0.965 . . . . 0.0 109.995 -179.548 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.616 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 2.9 mt -133.22 143.24 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.276 -0.89 . . . . 0.0 109.036 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.431 ' O ' ' HG3' ' A' ' 162' ' ' ARG . 11.9 m-85 62.18 43.37 8.65 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.152 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 54.35 16.15 6.45 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 179.774 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 15.8 mtt-85 -126.59 160.05 31.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.036 -1.273 . . . . 0.0 109.54 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -100.93 127.88 47.22 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.25 -0.907 . . . . 0.0 109.687 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 43.3 m -136.91 121.22 12.39 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 0.0 109.606 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.538 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -70.34 136.57 31.75 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.755 2.304 . . . . 0.0 111.541 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.982 HG13 HD11 ' A' ' 168' ' ' LEU . 3.6 p -125.74 144.24 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.035 -1.041 . . . . 0.0 110.165 -179.616 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.704 HG13 ' OE2' ' A' ' 152' ' ' GLU . 51.1 t -95.51 120.15 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.554 -0.716 . . . . 0.0 109.465 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.982 HD11 HG13 ' A' ' 166' ' ' VAL . 0.1 OUTLIER -141.01 168.38 19.93 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.204 -0.935 . . . . 0.0 110.518 -179.44 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.4 ' HB2' ' OE1' ' A' ' 172' ' ' GLU . 40.2 m80 -79.45 144.59 33.9 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.829 ' HB ' HD23 ' A' ' 153' ' ' LEU . 9.6 p -58.68 -35.49 55.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.121 -0.987 . . . . 0.0 108.822 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.411 ' N ' HG13 ' A' ' 170' ' ' VAL . 53.0 p -75.69 -6.67 51.64 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.43 -0.794 . . . . 0.0 109.115 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.559 ' CG ' ' HB2' ' A' ' 133' ' ' SER . 1.2 mt-10 -88.65 2.85 52.48 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.289 -0.882 . . . . 0.0 109.44 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 173' ' ' VAL . . . . . 0.453 ' CG2' HG11 ' A' ' 129' ' ' VAL . 2.9 m -152.03 176.54 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.218 -0.926 . . . . 0.0 109.293 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 1.021 ' O ' HG13 ' A' ' 129' ' ' VAL . 5.5 mt-10 -141.54 172.73 12.28 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.141 -0.974 . . . . 0.0 109.01 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.498 ' CE ' ' OD2' ' A' ' 127' ' ' ASP . 24.4 tttt . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.091 -1.006 . . . . 0.0 109.37 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.627 ' HG2' HG22 ' A' ' 65' ' ' ILE . 33.0 mttt . . . . . 0 N--CA 1.489 1.477 0 CA-C-O 121.261 0.553 . . . . 0.0 109.546 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.585 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 15.7 mtpp -126.41 175.82 7.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.361 -0.837 . . . . 0.0 109.52 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.792 ' CZ3' HG23 ' A' ' 41' ' ' VAL . 46.6 m95 -110.47 126.72 54.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.278 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -115.53 164.46 14.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.918 . . . . 0.0 109.472 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.542 HG12 ' CE1' ' A' ' 61' ' ' PHE . 62.0 mt -106.03 115.29 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.16 -0.962 . . . . 0.0 109.021 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.493 HG13 ' CE1' ' A' ' 83' ' ' PHE . 92.2 t -92.09 138.25 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.237 -0.914 . . . . 0.0 109.626 -179.719 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.518 ' N ' HD22 ' A' ' 11' ' ' LEU . 4.0 mm? -92.78 146.5 23.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.321 -0.862 . . . . 0.0 109.209 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.574 ' OG1' HG21 ' A' ' 20' ' ' VAL . 12.6 t -157.22 -177.97 7.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.187 -0.945 . . . . 0.0 109.376 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.515 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 49.0 mtm -96.72 130.39 43.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.182 -0.949 . . . . 0.0 109.504 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.5 p -50.87 129.37 23.17 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.912 . . . . 0.0 109.544 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.84 -20.27 36.67 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.515 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 80.3 m-85 -108.83 -5.2 16.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.214 -1.168 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.733 ' OE1' HD11 ' A' ' 44' ' ' ILE . 88.9 mt-10 -46.72 -52.48 13.82 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.253 -0.904 . . . . 0.0 109.554 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.8 mt-10 -55.11 -36.19 65.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.221 -0.925 . . . . 0.0 109.465 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 60.7 mttp -74.55 -31.37 62.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.256 -0.903 . . . . 0.0 109.291 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.574 HG21 ' OG1' ' A' ' 12' ' ' THR . 51.6 t -67.64 -48.78 75.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.34 -0.85 . . . . 0.0 109.353 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.582 ' HB2' HD11 ' A' ' 42' ' ' ILE . 29.9 tttm -59.05 -44.48 91.82 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.273 -0.892 . . . . 0.0 109.302 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -65.13 -45.08 86.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.906 . . . . 0.0 109.275 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.954 ' OD1' HG22 ' A' ' 77' ' ' VAL . 1.1 t-20 -51.78 -38.82 57.11 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -0.866 . . . . 0.0 109.402 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.586 HG21 HD11 ' A' ' 40' ' ' ILE . 65.9 mt -68.89 -44.29 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.764 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 41.9 tp10 -55.18 -49.13 72.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.047 -1.033 . . . . 0.0 109.858 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 23.6 mttm -75.22 -34.42 61.47 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.105 -0.997 . . . . 0.0 109.456 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.926 ' CD ' HG23 ' A' ' 77' ' ' VAL . 33.1 tttm -55.62 -36.2 66.72 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.325 -0.86 . . . . 0.0 109.205 179.774 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.739 HG13 ' O ' ' A' ' 33' ' ' ILE . 84.0 t -83.07 -24.0 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.294 -0.879 . . . . 0.0 109.601 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 -69.9 -55.12 10.53 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.279 -0.888 . . . . 0.0 109.485 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.74 -38.92 50.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.291 -0.881 . . . . 0.0 109.412 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.403 ' CB ' HG13 ' A' ' 33' ' ' ILE . 82.6 p -98.54 0.1 44.34 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.271 -0.893 . . . . 0.0 109.513 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 46.82 34.42 7.13 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.069 HG21 HD12 ' A' ' 36' ' ' LEU . 37.4 mt -92.6 75.34 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.331 -1.099 . . . . 0.0 109.498 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -90.19 24.92 2.34 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.211 -0.931 . . . . 0.0 109.049 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -117.25 -24.29 7.52 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.346 -0.846 . . . . 0.0 109.456 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.091 HD23 HD11 ' A' ' 65' ' ' ILE . 22.9 mt -92.11 -29.29 16.6 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.282 -0.886 . . . . 0.0 109.419 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.433 ' HA ' ' HG2' ' A' ' 64' ' ' MET . 38.9 t -110.43 129.35 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.368 -0.833 . . . . 0.0 109.04 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.51 -124.37 5.42 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 77.5 mtt180 -92.23 146.85 23.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.273 -1.133 . . . . 0.0 109.859 -179.431 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.901 HG12 HG23 ' A' ' 62' ' ' VAL . 55.7 mt -113.64 135.27 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.397 -0.815 . . . . 0.0 109.15 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.884 HG21 HD11 ' A' ' 107' ' ' LEU . 17.3 t -128.76 159.31 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.116 -0.99 . . . . 0.0 109.643 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.582 HD11 ' HB2' ' A' ' 21' ' ' LYS . 12.3 mt -144.36 128.67 9.13 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.471 -0.768 . . . . 0.0 109.359 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.544 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 44.0 Cg_endo -66.32 -6.19 14.34 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.713 2.275 . . . . 0.0 111.43 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.733 HD11 ' OE1' ' A' ' 17' ' ' GLU . 14.5 mt . . . . . 0 N--CA 1.489 1.477 0 O-C-N 121.406 -0.808 . . . . 0.0 109.397 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.58 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 69.2 mttt . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.548 ' HB3' ' CE2' ' A' ' 56' ' ' PHE . 6.7 mp -52.7 -47.3 67.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.379 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.632 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 3.2 m-85 -139.23 113.0 8.08 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.14 -0.975 . . . . 0.0 109.374 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -65.67 146.26 83.66 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.546 2.164 . . . . 0.0 111.471 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.04 -13.56 3.26 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.533 ' HB2' ' HB2' ' A' ' 56' ' ' PHE . 1.9 m-85 -93.69 129.28 40.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.883 -1.363 . . . . 0.0 110.044 -179.422 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.502 HG13 HG12 ' A' ' 42' ' ' ILE . 41.9 t -134.69 142.82 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.202 179.703 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.688 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 76.7 m-85 -108.05 124.97 51.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.127 -0.983 . . . . 0.0 109.826 -179.594 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.901 HG23 HG12 ' A' ' 40' ' ' ILE . 3.6 p -130.33 142.2 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.345 -0.847 . . . . 0.0 109.868 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.613 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 37.7 tt0 -103.4 124.62 49.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.215 -0.928 . . . . 0.0 108.844 179.434 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.505 ' HE1' HG21 ' A' ' 74' ' ' VAL . 41.8 mtm -153.47 169.09 24.03 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.92 -1.113 . . . . 0.0 110.648 -179.259 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 1.091 HD11 HD23 ' A' ' 36' ' ' LEU . 5.4 pt -94.49 130.07 43.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.47 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 36.8 ttm -77.15 144.54 38.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.318 -0.864 . . . . 0.0 109.973 -178.781 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.47 ' HB2' ' O ' ' A' ' 66' ' ' MET . 35.3 t30 176.81 171.6 0.47 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.677 -0.639 . . . . 0.0 109.289 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -69.27 -42.53 75.41 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.228 -0.92 . . . . 0.0 109.402 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -75.85 -29.17 58.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.309 -0.869 . . . . 0.0 109.71 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.733 ' HB2' HD22 ' A' ' 36' ' ' LEU . . . -75.27 -47.54 27.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.121 -0.987 . . . . 0.0 109.418 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 56.3 t80 -59.97 -46.49 89.26 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.291 -0.88 . . . . 0.0 109.504 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.451 ' O ' ' HB3' ' A' ' 76' ' ' SER . 23.4 m120 -68.18 -26.22 65.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.327 -0.858 . . . . 0.0 109.962 -179.671 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.476 ' CE1' ' NZ ' ' A' ' 27' ' ' LYS . 22.6 t80 -83.42 -42.76 16.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.03 -1.044 . . . . 0.0 109.915 -179.675 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.76 HG22 ' CZ ' ' A' ' 83' ' ' PHE . 7.4 p -67.89 -55.71 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.405 -0.81 . . . . 0.0 109.605 -179.503 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.674 ' N ' HG13 ' A' ' 74' ' ' VAL . 0.2 OUTLIER -57.99 -10.72 1.95 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.145 -0.972 . . . . 0.0 109.747 -179.934 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.451 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 25.6 p -93.24 4.89 53.23 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.073 -1.017 . . . . 0.0 109.98 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.954 HG22 ' OD1' ' A' ' 23' ' ' ASN . 0.4 OUTLIER -73.81 126.8 89.25 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.085 -1.009 . . . . 0.0 109.327 -179.978 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.629 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 42.7 Cg_endo -65.1 142.86 76.09 Favored 'Trans proline' 0 C--O 1.213 -0.752 0 C-N-CA 122.65 2.234 . . . . 0.0 111.898 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.629 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 17.9 m-85 89.37 -12.79 0.37 Allowed 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.63 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 1.7 t -89.51 130.12 39.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.077 -1.014 . . . . 0.0 109.361 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 90.9 mmm -84.38 -27.33 27.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.32 -0.862 . . . . 0.0 109.311 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 161.35 -160.58 32.31 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.76 ' CZ ' HG22 ' A' ' 74' ' ' VAL . 14.9 m-85 -136.23 140.24 43.35 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.272 -1.134 . . . . 0.0 109.341 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.536 ' O ' HG13 ' A' ' 84' ' ' VAL . 7.7 p -66.35 125.09 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.122 -0.986 . . . . 0.0 109.405 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.547 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.6 p -163.72 159.08 21.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.211 -0.931 . . . . 0.0 109.573 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -86.23 -33.85 20.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.272 -0.893 . . . . 0.0 109.314 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.23 -87.59 0.71 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.547 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -108.85 -125.86 5.24 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.547 ' C ' ' O ' ' A' ' 88' ' ' GLY . 4.1 pm0 -31.17 147.27 0.05 OUTLIER Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 121.614 -0.933 . . . . 0.0 110.015 -179.819 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.547 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.3 Cg_endo -69.2 154.29 70.19 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.8 2.334 . . . . 0.0 112.081 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' VAL . . . . . 0.905 HG12 ' HD2' ' A' ' 92' ' ' PRO . 0.2 OUTLIER -86.97 147.7 43.6 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.308 -0.87 . . . . 0.0 109.25 179.849 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.905 ' HD2' HG12 ' A' ' 91' ' ' VAL . 48.7 Cg_endo -69.24 150.6 71.58 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.626 2.217 . . . . 0.0 111.82 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 7' ' ' TRP . 5.3 t -83.57 135.66 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.911 . . . . 0.0 109.621 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -72.86 136.05 45.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.346 -0.846 . . . . 0.0 109.393 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -47.94 -36.91 13.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.21 -0.931 . . . . 0.0 109.578 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 73.4 mtt85 -56.59 -37.14 70.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.571 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.7 mt-10 -83.36 -24.24 32.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.25 -0.906 . . . . 0.0 109.608 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.49 ' O ' ' C ' ' A' ' 99' ' ' ARG . 56.5 mtp -84.39 -29.6 26.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.142 -0.974 . . . . 0.0 109.495 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.597 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 31.6 ttt85 -37.01 -53.81 1.9 Allowed Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.344 -0.848 . . . . 0.0 109.931 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.597 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -68.82 -27.8 30.82 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.497 2.132 . . . . 0.0 111.777 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.509 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 19.5 mm -80.66 -41.7 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.24 -0.912 . . . . 0.0 109.248 179.71 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.59 ' CD1' ' N ' ' A' ' 102' ' ' LEU . 3.7 mp -68.52 -40.71 80.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.304 -0.872 . . . . 0.0 109.193 179.775 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.576 ' NE ' ' HA ' ' A' ' 135' ' ' PRO . 34.0 ttt180 -64.25 -50.34 68.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.347 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.86 -36.88 70.25 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.35 -0.844 . . . . 0.0 109.272 179.736 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.509 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -72.21 0.6 9.39 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.854 -179.707 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 77.26 8.32 86.98 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.884 HD11 HG21 ' A' ' 41' ' ' VAL . 19.2 mt -79.88 -22.53 42.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.134 -1.215 . . . . 0.0 109.511 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' GLU . . . . . 0.485 ' HB2' ' HA ' ' A' ' 103' ' ' ARG . 10.3 mt-10 . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.228 -0.92 . . . . 0.0 109.459 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 22.8 m-30 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 50.9 mttt -130.89 153.83 48.72 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.155 -0.966 . . . . 0.0 109.863 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.512 HG23 ' O ' ' A' ' 144' ' ' LYS . 7.1 p -61.51 144.43 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.359 -0.838 . . . . 0.0 109.501 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.32 -33.38 3.19 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.587 ' HB3' HD12 ' A' ' 143' ' ' ILE . 34.3 t0 -50.16 161.27 0.29 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.368 -1.078 . . . . 0.0 109.397 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' MET . . . . . 0.42 ' HA ' ' HA ' ' A' ' 142' ' ' VAL . 4.6 ttm -95.76 126.88 41.33 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.28 -0.887 . . . . 0.0 108.669 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.761 HG11 HG11 ' A' ' 155' ' ' VAL . 6.7 p -125.64 141.58 45.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.193 -0.942 . . . . 0.0 109.388 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.524 ' N ' ' O ' ' A' ' 174' ' ' GLU . 24.1 tttt -104.41 142.78 33.98 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 108.988 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.952 HD12 ' HB3' ' A' ' 139' ' ' PHE . 81.5 mt -82.3 153.62 4.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.448 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.848 HD13 ' CD ' ' A' ' 174' ' ' GLU . 17.9 pt -149.08 1.25 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.967 -1.083 . . . . 0.0 109.499 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.517 ' HB3' ' CB ' ' A' ' 172' ' ' GLU . 31.2 t -145.85 143.23 29.49 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.124 -0.985 . . . . 0.0 110.039 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.03 -168.91 15.3 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.318 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.58 ' HG2' ' CD2' ' A' ' 136' ' ' PHE . 47.5 Cg_endo -68.63 -18.15 42.77 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 123.365 2.71 . . . . 0.0 112.563 -179.565 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.58 ' CD2' ' HG2' ' A' ' 135' ' ' PRO . 73.1 m-85 -111.84 13.92 20.98 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.878 -1.139 . . . . 0.0 109.636 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.519 ' HG2' ' OD2' ' A' ' 138' ' ' ASP . 1.2 tt0 -41.56 148.09 0.16 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.277 -0.889 . . . . 0.0 109.55 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.519 ' OD2' ' HG2' ' A' ' 137' ' ' GLU . 17.0 m-20 72.54 28.14 2.26 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -0.85 . . . . 0.0 110.268 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.952 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.1 t80 -117.74 131.51 56.59 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.029 -1.044 . . . . 0.0 109.414 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -82.24 134.15 35.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.123 -0.986 . . . . 0.0 109.6 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.513 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.9 172.93 25.59 Favored Glycine 0 N--CA 1.49 2.269 0 C-N-CA 119.78 -1.2 . . . . 0.0 110.305 -179.567 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 128' ' ' MET . 23.2 t -117.56 136.24 55.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.469 -1.018 . . . . 0.0 109.363 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.587 HD12 ' HB3' ' A' ' 127' ' ' ASP . 67.3 mt -66.33 115.25 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.299 -0.876 . . . . 0.0 109.184 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.512 ' O ' HG23 ' A' ' 125' ' ' VAL . 2.4 tttt -100.02 -35.53 9.67 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.04 -1.037 . . . . 0.0 109.615 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -152.8 147.66 26.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.142 -0.974 . . . . 0.0 109.622 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.816 HG23 ' CD1' ' A' ' 153' ' ' LEU . 3.1 mt -124.96 126.83 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.304 -0.872 . . . . 0.0 109.352 179.792 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.94 99.43 30.53 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.217 -0.927 . . . . 0.0 109.647 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.562 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 50.1 Cg_endo -70.3 171.93 14.12 Favored 'Trans proline' 0 C--O 1.216 -0.59 0 C-N-CA 122.681 2.254 . . . . 0.0 111.747 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.562 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.8 mt-10 81.06 -20.87 0.35 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.35 -0.844 . . . . 0.0 109.887 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.43 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 16.1 mtt-85 -128.83 -12.96 4.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.619 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.995 ' O ' HG23 ' A' ' 170' ' ' VAL . 29.4 mt-30 70.72 48.49 0.42 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.271 -0.893 . . . . 0.0 109.636 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -118.6 141.66 48.38 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.138 -0.976 . . . . 0.0 108.745 179.297 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.816 ' CD1' HG23 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -133.4 111.82 11.07 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.101 -0.999 . . . . 0.0 109.937 -179.537 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 21.1 mttt -80.61 129.5 34.55 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.761 HG11 HG11 ' A' ' 129' ' ' VAL . 35.4 m -123.61 152.54 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.059 -1.026 . . . . 0.0 109.715 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.507 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 47.2 t-20 -96.53 108.56 21.16 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.385 -0.822 . . . . 0.0 109.431 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.73 HG12 ' O ' ' A' ' 164' ' ' THR . 2.2 p -92.02 140.19 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.162 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 84.9 m -99.79 99.16 9.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.271 -0.893 . . . . 0.0 109.952 -179.612 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.692 HG13 HG22 ' A' ' 157' ' ' VAL . 2.0 mt -122.45 143.66 34.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.296 -0.878 . . . . 0.0 109.092 179.548 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.688 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 85.0 m-85 61.72 39.38 14.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.241 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.77 17.89 29.81 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.531 ' CZ ' ' OH ' ' A' ' 59' ' ' TYR . 25.2 mtt85 -127.26 156.72 41.45 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.106 -1.232 . . . . 0.0 109.568 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 163' ' ' GLU . . . . . 0.431 ' HB3' ' OD1' ' A' ' 156' ' ' ASN . 91.3 mt-10 -99.92 130.72 46.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.925 . . . . 0.0 109.471 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 164' ' ' THR . . . . . 0.73 ' O ' HG12 ' A' ' 157' ' ' VAL . 16.1 m -140.52 121.64 9.21 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.285 -0.884 . . . . 0.0 109.732 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.523 ' HA ' ' O ' ' A' ' 155' ' ' VAL . 49.8 Cg_endo -70.02 138.21 36.48 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.697 2.264 . . . . 0.0 111.536 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.4 p -126.89 145.65 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.117 -0.989 . . . . 0.0 109.815 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.591 HG13 ' O ' ' A' ' 167' ' ' VAL . 11.4 p -91.87 119.73 39.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.416 -0.802 . . . . 0.0 109.326 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.427 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 12.3 mt -140.28 165.29 27.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 110.582 -179.16 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.628 ' O ' HG13 ' A' ' 173' ' ' VAL . 91.6 m-70 -79.07 147.0 32.95 Favored 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 121.345 0.593 . . . . 0.0 109.576 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.995 HG23 ' O ' ' A' ' 151' ' ' GLN . 4.4 t -63.16 -35.17 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.557 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 37.7 m -77.05 -7.12 55.13 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.467 -0.77 . . . . 0.0 109.295 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.517 ' CB ' ' HB3' ' A' ' 133' ' ' SER . 91.6 mt-10 -103.05 5.41 38.09 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.284 -0.885 . . . . 0.0 109.385 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 173' ' ' VAL . . . . . 0.628 HG13 ' O ' ' A' ' 169' ' ' HIS . 2.7 m -129.69 160.29 40.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.19 -0.944 . . . . 0.0 109.58 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.848 ' CD ' HD13 ' A' ' 132' ' ' ILE . 28.8 mt-10 -133.16 150.8 52.0 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.295 -0.878 . . . . 0.0 109.048 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 129' ' ' VAL . 4.2 pttm . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.094 -1.004 . . . . 0.0 109.514 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.808 ' HG2' HG22 ' A' ' 65' ' ' ILE . 83.5 mttt . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 121.343 0.592 . . . . 0.0 109.495 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.574 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 41.2 mmtm -130.24 174.52 9.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.399 -0.813 . . . . 0.0 109.539 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.782 ' CH2' HG23 ' A' ' 41' ' ' VAL . 40.3 m95 -105.56 125.4 50.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.293 -0.879 . . . . 0.0 109.011 179.664 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -115.48 166.35 11.99 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.11 -0.994 . . . . 0.0 109.343 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.568 HG12 ' CD1' ' A' ' 61' ' ' PHE . 55.8 mt -110.87 112.15 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.194 -0.941 . . . . 0.0 109.087 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.632 HG12 ' CD2' ' A' ' 83' ' ' PHE . 20.3 m -90.51 141.1 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.171 -0.956 . . . . 0.0 109.496 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.534 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -85.98 145.07 27.28 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.424 -0.797 . . . . 0.0 109.401 -179.926 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.7 p -149.63 -173.74 4.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.182 -0.949 . . . . 0.0 109.507 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.49 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 70.9 mtp -107.81 128.89 55.0 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.21 -0.931 . . . . 0.0 109.738 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.5 m -47.65 119.82 2.98 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.261 -0.899 . . . . 0.0 109.279 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.59 -20.26 27.63 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.49 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 94.5 m-85 -105.58 -16.36 14.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.198 -1.177 . . . . 0.0 109.496 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 16' ' ' TYR . 49.7 mt-10 -44.0 -62.04 1.26 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.193 -0.942 . . . . 0.0 109.345 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -49.54 -38.83 32.37 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.215 -0.928 . . . . 0.0 109.206 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -66.73 -33.0 74.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.346 -0.846 . . . . 0.0 109.076 179.651 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.672 HG22 ' HB2' ' A' ' 79' ' ' TYR . 91.8 t -72.01 -45.94 61.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.323 -0.861 . . . . 0.0 109.369 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.624 ' HB2' HD11 ' A' ' 42' ' ' ILE . 19.0 tttm -51.85 -56.09 16.09 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.23 -0.919 . . . . 0.0 109.246 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -62.04 -34.93 77.16 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.319 -0.863 . . . . 0.0 109.256 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.503 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 23.2 t-20 -65.28 -36.67 84.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.411 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.401 HG13 ' O ' ' A' ' 20' ' ' VAL . 90.4 mt -66.3 -46.47 87.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.145 -0.972 . . . . 0.0 109.782 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.461 ' O ' ' HG2' ' A' ' 29' ' ' GLU . 65.8 mm-40 -56.88 -46.68 81.72 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.099 -1.0 . . . . 0.0 109.874 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 29.0 mttt -77.3 -36.72 53.91 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.104 -0.998 . . . . 0.0 109.576 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.89 ' HG2' HG23 ' A' ' 77' ' ' VAL . 5.3 tptt -56.12 -31.05 62.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 109.095 179.774 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.806 HG13 ' O ' ' A' ' 33' ' ' ILE . 11.6 t -84.76 -26.31 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.347 -0.845 . . . . 0.0 109.264 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.461 ' HG2' ' O ' ' A' ' 25' ' ' GLU . 61.7 mm-40 -67.87 -51.48 47.72 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.298 -0.876 . . . . 0.0 109.375 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.42 -32.3 66.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.921 . . . . 0.0 109.386 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.701 HG21 ' CE1' ' A' ' 73' ' ' PHE . 63.1 p -94.71 -11.31 29.36 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.354 -0.842 . . . . 0.0 109.447 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 54.83 24.51 33.84 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.991 HG21 HD22 ' A' ' 36' ' ' LEU . 69.8 mt -85.96 116.62 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.198 -1.178 . . . . 0.0 109.352 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.459 ' O ' ' HG2' ' A' ' 34' ' ' LYS . 86.0 tttt -121.98 -10.44 8.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.179 -0.95 . . . . 0.0 109.395 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 1.057 ' O ' HD13 ' A' ' 65' ' ' ILE . 87.5 m-20 -98.67 13.81 30.8 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.207 -0.933 . . . . 0.0 109.426 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.991 HD22 HG21 ' A' ' 33' ' ' ILE . 6.0 mp -120.69 -53.38 2.09 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.336 -0.853 . . . . 0.0 109.111 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.544 HG22 ' SD ' ' A' ' 64' ' ' MET . 90.3 t -100.66 129.55 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.426 -0.796 . . . . 0.0 109.034 179.53 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.25 -121.76 4.62 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -98.03 148.4 23.54 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.277 -1.131 . . . . 0.0 109.991 -179.334 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 1.058 HG22 HG13 ' A' ' 62' ' ' VAL . 44.5 pt -119.8 143.21 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.42 -0.8 . . . . 0.0 108.857 179.495 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.82 HG21 HD22 ' A' ' 107' ' ' LEU . 25.1 t -129.52 154.6 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.127 -0.983 . . . . 0.0 109.871 -179.527 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.913 HG22 ' H ' ' A' ' 44' ' ' ILE . 18.4 mt -127.86 128.62 23.83 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.366 -0.834 . . . . 0.0 109.212 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.489 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 45.1 Cg_endo -66.82 -4.27 10.92 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.836 2.357 . . . . 0.0 111.692 -179.809 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.913 ' H ' HG22 ' A' ' 42' ' ' ILE . 54.8 mt . . . . . 0 N--CA 1.491 1.584 0 O-C-N 121.336 -0.853 . . . . 0.0 109.551 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.693 ' HG2' HG23 ' A' ' 44' ' ' ILE . 63.6 mttt . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.5 ' O ' ' CD1' ' A' ' 56' ' ' PHE . 44.2 mt -64.13 -21.54 66.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -1.0 . . . . 0.0 109.181 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 1.054 ' CE1' HD11 ' A' ' 159' ' ' ILE . 8.8 m-85 -148.97 101.88 3.39 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.323 -0.861 . . . . 0.0 108.986 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -65.47 136.31 46.12 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.7 2.267 . . . . 0.0 112.176 -179.446 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.472 ' O ' HD13 ' A' ' 11' ' ' LEU . . . 77.44 -15.22 7.55 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 179.576 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -99.31 129.53 45.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.799 -1.412 . . . . 0.0 110.292 -179.177 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.546 ' HB ' ' CG2' ' A' ' 10' ' ' VAL . 88.2 t -133.23 148.88 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.599 ' CE1' ' CZ ' ' A' ' 160' ' ' PHE . 84.2 m-85 -109.71 124.62 51.55 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.773 -1.205 . . . . 0.0 110.248 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 1.058 HG13 HG22 ' A' ' 40' ' ' ILE . 91.8 t -133.58 145.16 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.382 -0.824 . . . . 0.0 109.635 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.626 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 28.2 tt0 -112.08 128.01 56.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.24 -0.913 . . . . 0.0 108.976 179.575 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.832 ' HE1' HG11 ' A' ' 74' ' ' VAL . 15.4 mtm -153.9 168.69 25.51 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.867 -1.146 . . . . 0.0 110.805 -179.113 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 1.057 HD13 ' O ' ' A' ' 35' ' ' ASN . 0.5 OUTLIER -89.11 130.39 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.653 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.417 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 56.6 ttm -75.85 141.8 42.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.89 . . . . 0.0 110.191 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.417 ' HB2' ' O ' ' A' ' 66' ' ' MET . 46.0 t30 179.11 166.15 0.96 Allowed 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -66.14 -41.13 90.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.966 . . . . 0.0 109.505 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 64.2 tt0 -76.46 -31.5 57.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.844 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.023 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -68.78 -49.36 59.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.972 -1.08 . . . . 0.0 109.621 -179.763 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.579 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 71.8 t80 -60.62 -50.98 71.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.215 -0.928 . . . . 0.0 109.751 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -57.09 -29.69 63.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -0.937 . . . . 0.0 110.059 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.701 ' CE1' HG21 ' A' ' 31' ' ' THR . 77.4 t80 -80.51 -41.88 23.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.098 -1.001 . . . . 0.0 109.776 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 1.023 HG23 ' O ' ' A' ' 70' ' ' ALA . 2.8 t -70.08 -55.07 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.466 -0.771 . . . . 0.0 109.602 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.437 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 32.0 tpt85 -61.43 -13.33 19.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.329 -0.857 . . . . 0.0 110.013 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 78.1 p -97.31 4.57 50.79 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.115 -0.99 . . . . 0.0 109.923 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.912 ' O ' HG12 ' A' ' 80' ' ' VAL . 0.4 OUTLIER -74.85 137.21 73.32 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 120.965 -1.084 . . . . 0.0 109.315 -179.992 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.63 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 44.2 Cg_endo -66.34 137.36 46.95 Favored 'Trans proline' 0 C--O 1.213 -0.75 0 C-N-CA 122.676 2.251 . . . . 0.0 111.893 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.672 ' HB2' HG22 ' A' ' 20' ' ' VAL . 19.1 m-85 92.45 -13.54 0.18 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.934 -0.479 . . . . 0.0 109.759 -179.773 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.912 HG12 ' O ' ' A' ' 77' ' ' VAL . 8.6 p -82.43 122.91 37.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.891 -1.131 . . . . 0.0 109.365 179.765 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 95.5 mmm -87.94 -30.71 19.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.294 -0.879 . . . . 0.0 109.362 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.545 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 168.05 -165.85 39.04 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.632 ' CD2' HG12 ' A' ' 10' ' ' VAL . 4.6 m-85 -137.52 139.61 40.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.332 -1.099 . . . . 0.0 109.46 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.412 HG22 ' CD2' ' A' ' 11' ' ' LEU . 21.0 t -66.08 125.01 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.258 -0.901 . . . . 0.0 109.331 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.568 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.8 p -160.18 158.97 31.06 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.15 -0.969 . . . . 0.0 109.667 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 59.5 p -82.84 -36.47 25.45 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.329 -0.857 . . . . 0.0 109.234 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.07 -86.56 0.52 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -103.13 -127.87 6.21 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.579 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -33.98 151.93 0.05 OUTLIER Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.512 -0.993 . . . . 0.0 110.046 -179.668 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.568 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.1 Cg_endo -69.38 158.66 56.64 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.807 2.338 . . . . 0.0 112.01 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.8 m -93.38 154.14 41.38 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.423 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -70.06 146.96 59.86 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.654 2.236 . . . . 0.0 111.735 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 7' ' ' TRP . 45.1 t -83.62 140.18 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.297 -0.877 . . . . 0.0 109.417 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' LYS . . . . . 0.492 ' HE2' ' NH2' ' A' ' 96' ' ' ARG . 79.8 tttt -73.21 130.69 40.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.491 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -46.53 -39.07 10.26 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.278 -0.889 . . . . 0.0 109.425 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.492 ' NH2' ' HE2' ' A' ' 94' ' ' LYS . 15.5 mtt85 -60.56 -30.77 70.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.344 -0.847 . . . . 0.0 109.417 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.427 ' N ' ' O ' ' A' ' 94' ' ' LYS . 52.7 mt-10 -80.08 -26.8 39.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.892 . . . . 0.0 109.528 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.686 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 55.3 mtp -86.12 -21.77 27.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.226 179.79 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.581 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.47 -53.23 1.31 Allowed Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.482 -0.761 . . . . 0.0 109.807 179.981 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.624 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 50.4 Cg_endo -71.41 -26.69 20.11 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.463 2.109 . . . . 0.0 111.878 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.479 ' N ' ' O ' ' A' ' 98' ' ' MET . 35.2 mm -82.42 -42.96 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -0.934 . . . . 0.0 109.607 -179.877 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.654 HD13 ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -67.83 -40.82 83.74 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.183 -0.948 . . . . 0.0 109.417 179.923 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.42 ' HG2' ' HA ' ' A' ' 135' ' ' PRO . 19.7 tpt180 -65.86 -49.1 69.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.253 -0.904 . . . . 0.0 109.315 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.71 -37.03 70.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.358 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.557 ' CB ' HG11 ' A' ' 41' ' ' VAL . . . -74.35 1.3 11.95 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.315 -0.866 . . . . 0.0 109.773 -179.811 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.47 11.07 85.44 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.762 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.82 HD22 HG21 ' A' ' 41' ' ' VAL . 3.2 tp -82.05 -24.86 35.07 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.219 -1.166 . . . . 0.0 109.525 179.81 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 . . . . . 0 N--CA 1.49 1.559 0 O-C-N 121.214 -0.929 . . . . 0.0 109.584 -179.871 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.573 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 14.1 m-85 . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.419 ' HD3' ' O ' ' A' ' 123' ' ' PHE . 62.1 mmtt -139.35 156.37 47.05 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.25 -0.906 . . . . 0.0 109.536 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 144' ' ' LYS . 10.1 t -57.37 137.46 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.258 -0.901 . . . . 0.0 109.606 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.81 -34.55 3.86 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.432 ' O ' HG23 ' A' ' 142' ' ' VAL . 37.2 m-20 -47.8 160.8 0.12 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.341 -1.094 . . . . 0.0 109.405 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.4 ttm -100.87 127.93 47.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.193 -0.942 . . . . 0.0 109.059 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.616 HG13 HG13 ' A' ' 143' ' ' ILE . 25.7 m -128.72 145.31 35.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.358 -0.839 . . . . 0.0 109.667 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.469 ' O ' HG23 ' A' ' 173' ' ' VAL . 57.7 tttt -103.22 139.39 38.76 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.787 -0.819 . . . . 0.0 108.787 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 1.031 HD12 ' HB3' ' A' ' 139' ' ' PHE . 80.9 mt -78.41 153.71 5.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -149.17 1.26 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.946 -1.096 . . . . 0.0 109.465 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.51 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 70.1 m -148.27 144.3 27.53 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.114 -0.991 . . . . 0.0 110.06 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.59 -164.88 17.73 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.506 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 46.2 Cg_endo -68.35 -21.84 40.53 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 123.071 2.514 . . . . 0.0 112.643 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.624 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 86.9 m-85 -107.67 18.21 21.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.84 -1.163 . . . . 0.0 109.442 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.518 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 3.1 tt0 -45.53 139.05 4.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.255 -0.903 . . . . 0.0 109.617 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 28.9 m-20 73.74 28.54 1.6 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.385 -0.822 . . . . 0.0 110.423 179.526 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 1.031 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.7 t80 -117.4 131.87 56.68 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.041 -1.037 . . . . 0.0 109.445 179.668 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.409 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -78.53 132.26 37.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.19 -0.944 . . . . 0.0 109.647 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -142.98 167.46 26.33 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.537 ' CG1' ' HB2' ' A' ' 156' ' ' ASN . 11.1 p -117.42 138.33 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.353 -1.086 . . . . 0.0 109.393 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.735 ' HA ' HG12 ' A' ' 155' ' ' VAL . 60.6 mt -68.81 117.11 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.152 -0.968 . . . . 0.0 109.676 -179.832 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.439 ' O ' HG13 ' A' ' 125' ' ' VAL . 15.6 tttt -102.43 -35.52 8.75 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.142 -0.973 . . . . 0.0 109.253 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.464 ' HB2' ' HB2' ' A' ' 154' ' ' LYS . 62.8 mt-10 -152.95 148.19 26.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.241 -0.912 . . . . 0.0 109.526 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.653 HG23 ' HG ' ' A' ' 153' ' ' LEU . 2.1 mt -123.8 125.65 71.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.257 -0.902 . . . . 0.0 109.412 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -106.74 99.61 26.42 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.192 -0.943 . . . . 0.0 109.674 -179.806 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.583 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.8 Cg_endo -70.74 170.96 16.49 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.704 2.27 . . . . 0.0 111.677 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.583 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.4 mt-10 81.64 -20.5 0.36 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.362 -0.836 . . . . 0.0 109.868 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.47 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 42.1 mtt180 -128.89 -12.47 4.74 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.997 -1.065 . . . . 0.0 109.694 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.876 ' O ' HG23 ' A' ' 170' ' ' VAL . 48.1 mt-30 70.69 48.8 0.42 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.26 -0.9 . . . . 0.0 109.604 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -119.59 142.18 48.62 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.175 -0.953 . . . . 0.0 109.02 179.583 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.653 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -129.34 112.36 13.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.237 -0.914 . . . . 0.0 110.083 -179.514 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.464 ' HB2' ' HB2' ' A' ' 145' ' ' GLU . 17.6 mttt -79.9 126.41 30.97 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 179.071 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.735 HG12 ' HA ' ' A' ' 143' ' ' ILE . 16.1 m -128.32 152.98 37.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.035 -1.041 . . . . 0.0 110.05 -179.458 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.537 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 86.8 m-20 -98.88 112.9 24.87 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.313 -0.867 . . . . 0.0 109.376 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.792 HG13 ' CE1' ' A' ' 139' ' ' PHE . 38.8 t -99.97 147.69 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.273 -0.892 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 163' ' ' GLU . 29.2 m -94.08 117.76 30.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.415 -0.803 . . . . 0.0 109.802 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 1.054 HD11 ' CE1' ' A' ' 56' ' ' PHE . 18.8 pt -145.9 138.62 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.348 -0.845 . . . . 0.0 109.387 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.599 ' CZ ' ' CE1' ' A' ' 61' ' ' PHE . 72.2 m-85 62.57 39.36 11.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.909 . . . . 0.0 109.379 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 62.26 16.96 55.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -137.73 142.21 41.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.092 -1.24 . . . . 0.0 109.501 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' GLU . . . . . 0.553 ' HA ' ' HA ' ' A' ' 158' ' ' THR . 84.8 mt-10 -98.45 110.2 22.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.184 -0.948 . . . . 0.0 109.465 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 164' ' ' THR . . . . . 0.579 HG23 ' HD2' ' A' ' 165' ' ' PRO . 16.6 m -112.8 139.9 23.38 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.211 -0.93 . . . . 0.0 109.341 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.579 ' HD2' HG23 ' A' ' 164' ' ' THR . 48.7 Cg_endo -69.21 137.3 36.72 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.711 2.274 . . . . 0.0 111.778 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 1.02 HG13 HD11 ' A' ' 168' ' ' LEU . 2.1 p -123.41 142.06 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.157 -0.964 . . . . 0.0 109.743 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.501 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 72.8 t -92.89 119.13 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.383 -0.823 . . . . 0.0 109.552 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 1.02 HD11 HG13 ' A' ' 166' ' ' VAL . 0.3 OUTLIER -141.27 167.96 20.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.313 -0.867 . . . . 0.0 110.567 -179.719 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.531 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 61.8 m80 -78.59 145.58 34.67 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.876 HG23 ' O ' ' A' ' 151' ' ' GLN . 24.0 t -59.67 -35.84 62.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.274 -0.891 . . . . 0.0 108.702 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 87.9 p -75.27 -7.06 52.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.494 -0.754 . . . . 0.0 109.324 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.531 ' CG ' ' HB2' ' A' ' 169' ' ' HIS . 82.5 mt-10 -90.62 4.07 52.37 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.34 -0.85 . . . . 0.0 109.832 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 173' ' ' VAL . . . . . 0.578 ' CG2' ' N ' ' A' ' 174' ' ' GLU . 1.4 p -141.7 167.74 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.024 -1.048 . . . . 0.0 109.484 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.578 ' N ' ' CG2' ' A' ' 173' ' ' VAL . 52.4 tt0 -142.78 168.77 18.94 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.341 -0.849 . . . . 0.0 108.857 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.573 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 33.1 tttm . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.021 -1.05 . . . . 0.0 109.289 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.4 mttm . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.391 0.615 . . . . 0.0 109.667 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 12.7 mttt -135.49 176.03 9.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 110.009 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.837 ' CH2' HG23 ' A' ' 41' ' ' VAL . 60.3 m95 -109.83 125.71 53.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.362 -0.836 . . . . 0.0 109.211 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.58 ' CE2' ' HG3' ' A' ' 66' ' ' MET . 66.1 m-85 -116.64 171.76 7.66 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.186 -0.946 . . . . 0.0 109.383 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.657 HD11 ' CE1' ' A' ' 160' ' ' PHE . 56.2 mt -110.9 109.95 30.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.242 -0.911 . . . . 0.0 109.069 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.608 HG23 ' CE1' ' A' ' 83' ' ' PHE . 8.9 p -88.6 143.47 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.186 -0.946 . . . . 0.0 109.477 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.51 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.6 mm? -88.83 141.83 28.17 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.389 -0.819 . . . . 0.0 109.545 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.69 ' OG1' HG21 ' A' ' 20' ' ' VAL . 15.1 t -154.69 -169.35 3.18 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.281 -0.887 . . . . 0.0 109.393 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.502 ' SD ' ' CE2' ' A' ' 16' ' ' TYR . 36.2 ttm -107.68 119.6 39.88 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.48 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 13' ' ' MET . 54.0 p -42.82 128.19 4.15 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.332 -0.855 . . . . 0.0 109.279 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.65 -19.69 33.13 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.523 ' O ' HG23 ' A' ' 20' ' ' VAL . 19.6 m-30 -110.31 -5.84 15.15 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.301 -1.117 . . . . 0.0 109.75 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.486 ' HG2' HG21 ' A' ' 12' ' ' THR . 87.0 mt-10 -44.58 -65.49 0.51 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.148 -0.97 . . . . 0.0 109.547 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.44 ' O ' ' HG3' ' A' ' 22' ' ' GLU . 95.7 mt-10 -43.2 -33.41 0.92 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.199 -0.938 . . . . 0.0 109.271 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 46.7 mttm -77.19 -41.12 42.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.3 -0.875 . . . . 0.0 109.324 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.69 HG21 ' OG1' ' A' ' 12' ' ' THR . 18.4 t -59.7 -48.17 88.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.327 -0.858 . . . . 0.0 109.33 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.58 ' HG3' HG21 ' A' ' 40' ' ' ILE . 28.1 tttm -60.53 -43.12 97.49 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.897 . . . . 0.0 109.067 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.44 ' HG3' ' O ' ' A' ' 18' ' ' GLU . 93.7 mt-10 -63.87 -42.07 97.61 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.406 -0.809 . . . . 0.0 109.045 179.716 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.479 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 17.1 m120 -56.91 -52.22 66.01 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.335 -0.853 . . . . 0.0 109.508 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.925 ' CD1' HG21 ' A' ' 77' ' ' VAL . 21.0 mm -50.33 -44.21 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.051 -1.031 . . . . 0.0 109.408 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -54.61 -44.27 72.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.272 -0.893 . . . . 0.0 109.832 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.8 mttp -79.86 -35.09 38.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.09 -1.006 . . . . 0.0 109.905 -179.639 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.91 ' HD3' HG23 ' A' ' 77' ' ' VAL . 12.6 ttpp -56.65 -35.16 68.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.114 -0.991 . . . . 0.0 109.282 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.828 HG13 ' O ' ' A' ' 33' ' ' ILE . 15.6 t -82.47 -27.05 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.841 . . . . 0.0 109.575 -179.794 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 69.8 mt-10 -66.35 -49.84 65.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.214 -0.929 . . . . 0.0 109.68 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.38 -27.74 69.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.207 -0.933 . . . . 0.0 109.741 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.454 HG23 ' O ' ' A' ' 27' ' ' LYS . 60.9 p -88.83 -12.76 41.01 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.041 -1.037 . . . . 0.0 109.517 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 63.72 15.43 57.67 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.828 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.7 mt -94.84 85.6 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.314 -1.11 . . . . 0.0 109.481 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 49.9 mttt -85.59 7.64 22.41 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.149 -0.97 . . . . 0.0 109.074 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -111.77 18.52 18.86 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.339 -0.85 . . . . 0.0 109.433 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.845 ' CD2' HD11 ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.6 -52.95 2.75 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.144 -0.972 . . . . 0.0 109.344 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.464 ' HA ' ' HB3' ' A' ' 64' ' ' MET . 87.7 t -97.01 137.06 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -107.81 -125.28 5.27 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.426 ' O ' ' CH2' ' A' ' 7' ' ' TRP . 95.2 mtt180 -91.72 138.69 31.35 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -1.112 . . . . 0.0 109.694 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.876 HG12 HG13 ' A' ' 62' ' ' VAL . 46.1 mt -105.78 136.96 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.374 -0.829 . . . . 0.0 109.042 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 1.113 ' CG2' HD11 ' A' ' 107' ' ' LEU . 98.4 t -124.26 150.51 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.747 HG22 HG23 ' A' ' 44' ' ' ILE . 5.7 mt -128.38 126.05 23.43 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.341 -0.849 . . . . 0.0 109.413 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.462 ' O ' HD13 ' A' ' 55' ' ' LEU . 47.8 Cg_endo -68.5 -2.99 10.18 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.86 2.374 . . . . 0.0 111.814 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.747 HG23 HG22 ' A' ' 42' ' ' ILE . 11.3 pt . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.07 -1.019 . . . . 0.0 109.649 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.692 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 22.6 mttm . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.54 HD12 ' N ' ' A' ' 55' ' ' LEU . 6.8 mp -65.91 -25.57 67.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.835 -1.165 . . . . 0.0 109.47 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.533 ' HB3' ' HB2' ' A' ' 59' ' ' TYR . 84.3 m-85 -142.08 98.23 6.22 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.886 . . . . 0.0 108.86 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 43.2 Cg_endo -66.7 134.39 34.94 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.755 2.303 . . . . 0.0 112.23 -179.082 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.56 -12.87 7.17 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.533 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 2.9 m-85 -100.67 131.23 46.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.693 -1.475 . . . . 0.0 110.183 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.569 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 76.8 t -135.32 148.6 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.377 -0.827 . . . . 0.0 108.809 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.634 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 16.8 m-85 -110.7 123.87 50.85 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.874 -1.141 . . . . 0.0 109.926 -179.395 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.876 HG13 HG12 ' A' ' 40' ' ' ILE . 90.0 t -129.62 142.77 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.405 -0.809 . . . . 0.0 109.793 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.612 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 9.8 tt0 -99.86 125.52 45.83 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.335 -0.853 . . . . 0.0 109.175 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.464 ' HB3' ' HA ' ' A' ' 37' ' ' VAL . 12.5 ptt? -164.96 -175.39 3.71 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.025 -1.047 . . . . 0.0 110.174 -179.665 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.845 HD11 ' CD2' ' A' ' 36' ' ' LEU . 38.6 pt -103.35 128.36 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.165 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.58 ' HG3' ' CE2' ' A' ' 8' ' ' TYR . 33.6 mtm -90.75 101.64 14.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.196 -0.94 . . . . 0.0 109.898 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.543 ' OD1' ' N ' ' A' ' 69' ' ' GLU . 10.3 p30 -137.91 -163.09 1.39 Allowed 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.123 -0.986 . . . . 0.0 109.077 179.591 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -74.98 -50.15 17.56 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.135 -0.978 . . . . 0.0 110.105 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.543 ' N ' ' OD1' ' A' ' 67' ' ' ASN . 98.0 mt-10 -64.85 -54.64 27.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.05 -1.031 . . . . 0.0 109.585 -179.747 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.011 ' O ' HG22 ' A' ' 74' ' ' VAL . . . -52.34 -38.75 59.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.265 -0.897 . . . . 0.0 109.727 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.433 ' CD1' ' CD ' ' A' ' 89' ' ' GLN . 72.3 t80 -60.02 -50.51 73.46 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 109.853 -179.818 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -65.59 -28.46 69.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.156 -0.965 . . . . 0.0 110.436 -179.355 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -82.52 -42.63 18.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.865 -1.147 . . . . 0.0 110.035 -179.443 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 1.011 HG22 ' O ' ' A' ' 70' ' ' ALA . 6.8 m -65.92 -57.37 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.186 -0.947 . . . . 0.0 109.562 -179.78 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.681 ' H ' HG23 ' A' ' 74' ' ' VAL . 12.6 mmt180 -53.87 -40.95 66.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.922 . . . . 0.0 109.751 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 25.7 p -75.42 3.07 9.86 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.204 -0.935 . . . . 0.0 110.149 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.925 HG21 ' CD1' ' A' ' 24' ' ' ILE . 1.8 p -71.8 130.0 87.52 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 120.875 -1.141 . . . . 0.0 109.136 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.765 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 44.0 Cg_endo -66.14 132.32 29.49 Favored 'Trans proline' 0 C--O 1.212 -0.797 0 C-N-CA 122.83 2.353 . . . . 0.0 112.627 -178.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.765 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 70.8 m-85 95.43 -8.63 0.1 Allowed 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.683 HG21 HG11 ' A' ' 77' ' ' VAL . 16.0 t -99.15 133.72 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.973 -1.079 . . . . 0.0 109.494 179.726 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 64.2 mtt -92.79 -19.23 21.96 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.337 -0.852 . . . . 0.0 109.399 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 150.48 -154.38 25.6 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.608 ' CE1' HG23 ' A' ' 10' ' ' VAL . 5.3 m-85 -137.14 149.22 47.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -1.142 . . . . 0.0 109.602 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.524 HG12 ' HB ' ' A' ' 9' ' ' ILE . 13.8 p -74.86 129.39 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.283 -0.886 . . . . 0.0 109.37 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.553 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 2.2 p -163.06 165.6 24.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.732 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.4 t -92.89 -30.87 15.19 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.396 -0.815 . . . . 0.0 109.24 179.742 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.77 -87.7 0.54 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.527 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -103.19 -135.5 8.7 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.527 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -32.59 153.99 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.568 -0.96 . . . . 0.0 110.259 -179.624 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.553 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 47.8 Cg_endo -67.86 151.2 78.56 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.891 2.394 . . . . 0.0 112.013 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.4 m -84.22 155.07 63.64 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.318 -0.864 . . . . 0.0 109.336 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.41 ' HB3' ' HD3' ' A' ' 6' ' ' LYS . 49.0 Cg_endo -69.81 141.27 44.59 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.676 2.251 . . . . 0.0 111.753 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 7' ' ' TRP . 41.4 t -71.73 141.4 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.209 -0.932 . . . . 0.0 109.367 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 97' ' ' GLU . 93.8 mttt -75.53 130.02 38.17 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.444 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 78.5 m-20 -45.25 -39.4 6.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.883 . . . . 0.0 109.354 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 77.6 mtt180 -60.69 -24.74 65.87 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.483 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.464 ' N ' ' O ' ' A' ' 94' ' ' LYS . 87.6 mt-10 -89.42 -26.06 21.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.556 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.594 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 89.5 mtp -82.54 -30.93 29.41 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.401 -0.812 . . . . 0.0 109.448 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.623 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 1.2 tpt180 -38.7 -51.95 3.67 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.402 -0.811 . . . . 0.0 109.857 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.623 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.3 Cg_endo -68.78 -28.1 30.69 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.483 2.122 . . . . 0.0 111.801 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.459 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 23.4 mm -81.58 -42.13 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.243 -0.91 . . . . 0.0 109.402 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 1.021 HD12 HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -67.46 -39.88 85.35 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.207 -0.933 . . . . 0.0 109.051 179.715 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.568 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 26.1 ttm180 -63.62 -49.27 73.96 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.375 -0.828 . . . . 0.0 108.981 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -72.99 -35.24 66.83 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.329 -0.857 . . . . 0.0 109.048 179.532 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.517 ' HB1' HG13 ' A' ' 41' ' ' VAL . . . -74.38 -2.8 26.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.356 -0.84 . . . . 0.0 109.654 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.42 14.4 82.43 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 1.113 HD11 ' CG2' ' A' ' 41' ' ' VAL . 66.0 mt -81.65 -24.17 36.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.202 -1.176 . . . . 0.0 109.646 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 37.9 tp10 . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.101 -0.999 . . . . 0.0 109.627 -179.871 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.588 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 3.6 m-30 . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.409 ' HB2' ' CG ' ' A' ' 127' ' ' ASP . 74.8 mttt -124.87 154.32 41.25 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.013 -1.054 . . . . 0.0 110.124 -179.462 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 9.8 m -64.66 141.89 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.331 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 88.22 -31.75 4.65 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.506 ' HB2' HD12 ' A' ' 143' ' ' ILE . 28.9 m-20 -49.66 158.74 0.43 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.433 -1.039 . . . . 0.0 109.26 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.4 ttm -98.13 127.86 44.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.205 -0.934 . . . . 0.0 109.052 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.672 HG11 HD11 ' A' ' 143' ' ' ILE . 27.4 m -128.11 143.41 40.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.276 -0.89 . . . . 0.0 109.604 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 75.8 tttt -100.31 139.42 36.01 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.989 ' O ' HD13 ' A' ' 132' ' ' ILE . 1.2 mp -79.86 152.77 4.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.989 HD13 ' O ' ' A' ' 131' ' ' ILE . 1.1 mm -148.79 2.4 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 120.956 -1.09 . . . . 0.0 109.809 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.526 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 41.7 m -147.5 144.66 28.73 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.971 -1.08 . . . . 0.0 110.198 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 103.22 -166.44 16.29 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.568 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 47.5 Cg_endo -68.52 -20.85 40.84 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 123.111 2.541 . . . . 0.0 112.315 -179.663 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.535 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 98.8 m-85 -107.86 19.09 20.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.954 -1.091 . . . . 0.0 109.3 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.614 ' HA ' HG22 ' A' ' 131' ' ' ILE . 4.0 tt0 -43.17 139.9 1.7 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.268 -0.895 . . . . 0.0 109.797 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.537 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 44.3 m-20 72.62 30.74 1.81 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.463 -0.773 . . . . 0.0 110.871 179.191 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.535 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 0.7 OUTLIER -116.66 128.46 55.39 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.76 -1.212 . . . . 0.0 109.573 179.654 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.14 133.49 42.8 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.28 -0.887 . . . . 0.0 109.455 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.05 168.96 26.37 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.432 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.616 ' C ' HG13 ' A' ' 155' ' ' VAL . 53.5 t -118.19 137.47 52.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.578 -0.954 . . . . 0.0 109.311 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.672 HD11 HG11 ' A' ' 129' ' ' VAL . 98.7 mt -70.05 115.47 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.177 -0.952 . . . . 0.0 109.42 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -99.03 -33.85 10.65 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.085 -1.009 . . . . 0.0 109.479 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.454 ' HB2' ' HE2' ' A' ' 154' ' ' LYS . 93.7 mt-10 -154.39 149.48 26.88 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.211 -0.931 . . . . 0.0 109.702 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.642 HG23 ' HG ' ' A' ' 153' ' ' LEU . 2.8 mt -125.91 128.46 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.431 -0.793 . . . . 0.0 109.394 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -110.91 102.17 51.79 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.234 -0.916 . . . . 0.0 109.534 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.557 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.0 Cg_endo -70.94 172.54 13.58 Favored 'Trans proline' 0 C--O 1.214 -0.724 0 C-N-CA 122.692 2.261 . . . . 0.0 111.699 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.557 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.6 mt-10 80.37 -20.74 0.36 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.348 -0.845 . . . . 0.0 109.848 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.427 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 74.6 mtt180 -128.53 -14.02 4.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.1 -1.0 . . . . 0.0 109.567 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.427 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 35.9 mt-30 70.51 48.64 0.45 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.216 -0.927 . . . . 0.0 109.851 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.576 ' OE2' HG23 ' A' ' 167' ' ' VAL . 84.6 tt0 -117.76 141.83 47.96 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.075 -1.015 . . . . 0.0 109.038 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.642 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -130.77 113.27 13.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.013 -1.054 . . . . 0.0 110.158 -179.512 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.454 ' HE2' ' HB2' ' A' ' 145' ' ' GLU . 2.5 ttpt -78.61 128.58 33.7 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.242 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.72 ' O ' HG12 ' A' ' 166' ' ' VAL . 47.0 t -124.54 145.82 31.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.168 -0.958 . . . . 0.0 109.985 -179.41 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.534 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 27.0 t-20 -98.32 110.96 23.45 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.377 -0.827 . . . . 0.0 109.37 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.492 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 60.4 t -95.22 142.33 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.453 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 41.2 m -100.55 100.03 10.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.255 -0.903 . . . . 0.0 109.728 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.497 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 4.1 mt -123.81 146.98 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.178 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.657 ' CE1' HD11 ' A' ' 9' ' ' ILE . 97.9 m-85 61.84 38.66 14.52 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.238 -0.914 . . . . 0.0 109.205 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 55.24 17.19 10.63 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.463 ' CZ ' ' OH ' ' A' ' 59' ' ' TYR . 90.7 mtt-85 -125.58 158.71 33.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.094 -1.239 . . . . 0.0 109.563 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.73 128.37 46.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.194 -0.941 . . . . 0.0 109.687 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 48.8 m -139.2 125.78 12.58 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.313 -0.867 . . . . 0.0 109.792 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.2 Cg_endo -71.51 135.28 26.08 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.7 2.267 . . . . 0.0 111.429 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 1.008 HG13 HD11 ' A' ' 168' ' ' LEU . 7.1 p -118.47 163.39 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.167 -0.958 . . . . 0.0 109.966 -179.524 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 167' ' ' VAL . 14.4 p -116.61 117.01 54.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.296 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 1.008 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -143.21 168.85 18.8 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.243 -0.911 . . . . 0.0 110.91 -179.264 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 40.4 m80 -78.96 144.0 35.21 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.572 HG23 HD13 ' A' ' 153' ' ' LEU . 10.8 p -57.78 -36.23 54.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.215 -0.928 . . . . 0.0 108.83 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.432 ' N ' HG13 ' A' ' 170' ' ' VAL . 42.5 p -76.39 -6.64 52.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.45 -0.782 . . . . 0.0 109.401 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.526 ' HA ' ' HB2' ' A' ' 133' ' ' SER . 2.8 mt-10 -89.72 -0.29 57.44 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.239 -0.913 . . . . 0.0 109.394 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.2 m -144.06 174.35 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.253 -0.905 . . . . 0.0 109.21 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.491 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 53.9 tt0 -139.49 168.16 20.46 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.113 -0.992 . . . . 0.0 108.975 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.588 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 73.1 tttt . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.028 -1.045 . . . . 0.0 109.358 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.557 ' HG2' HG22 ' A' ' 65' ' ' ILE . 36.8 mttt . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 121.263 0.554 . . . . 0.0 109.55 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.533 ' HB3' ' HB3' ' A' ' 92' ' ' PRO . 9.4 mttt -132.36 176.29 8.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.298 -0.876 . . . . 0.0 109.337 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.864 ' O ' HG23 ' A' ' 93' ' ' VAL . 64.8 m95 -112.67 124.04 51.66 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.924 . . . . 0.0 109.386 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.494 ' OH ' ' HG3' ' A' ' 66' ' ' MET . 78.4 m-85 -113.35 179.79 3.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.18 -0.95 . . . . 0.0 109.266 179.785 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.542 HG12 ' CE1' ' A' ' 61' ' ' PHE . 66.8 mt -119.7 107.38 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.384 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.555 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 13.1 p -86.01 144.6 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.271 -0.893 . . . . 0.0 109.518 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.797 HD11 ' HE1' ' A' ' 59' ' ' TYR . 2.8 mm? -94.8 143.83 26.14 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.336 -0.853 . . . . 0.0 109.601 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.405 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 1.3 p -151.3 -168.59 3.14 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.307 -0.87 . . . . 0.0 109.317 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.437 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 95.4 mtp -106.2 136.15 46.42 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.181 -0.949 . . . . 0.0 109.294 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.8 t -55.8 123.38 14.0 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -0.908 . . . . 0.0 109.424 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.08 -19.67 32.11 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.437 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.8 m-85 -108.15 -11.26 15.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.323 -1.104 . . . . 0.0 109.561 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.473 ' OE2' ' N ' ' A' ' 58' ' ' GLY . 77.5 mt-10 -46.52 -61.5 1.79 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.187 -0.945 . . . . 0.0 109.408 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.891 ' OE2' HD11 ' A' ' 44' ' ' ILE . 67.4 mm-40 -47.98 -36.55 12.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.288 -0.883 . . . . 0.0 109.339 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -71.69 -45.96 60.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.346 -0.847 . . . . 0.0 109.436 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.852 HG22 ' CB ' ' A' ' 79' ' ' TYR . 78.8 t -57.31 -47.14 85.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.186 -0.946 . . . . 0.0 109.444 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.738 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.7 tttt -56.09 -51.54 67.5 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.234 -0.916 . . . . 0.0 109.532 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 61.1 tt0 -63.06 -33.67 75.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.166 -0.959 . . . . 0.0 109.398 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.581 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 23.6 m120 -66.18 -41.26 90.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.318 -0.864 . . . . 0.0 109.501 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.453 HG13 ' O ' ' A' ' 20' ' ' VAL . 92.2 mt -60.52 -44.98 97.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.217 -0.927 . . . . 0.0 109.43 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -55.77 -47.09 77.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.201 -0.937 . . . . 0.0 109.672 -179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 71.5 mttt -70.19 -34.71 73.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.136 -0.977 . . . . 0.0 109.316 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.562 ' HD2' HG23 ' A' ' 77' ' ' VAL . 34.4 tttp -57.14 -35.9 70.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.379 -0.826 . . . . 0.0 109.478 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.816 HG13 ' O ' ' A' ' 33' ' ' ILE . 33.8 t -81.32 -25.51 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -71.6 -56.56 5.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.248 -0.908 . . . . 0.0 109.562 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.86 -26.2 45.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.223 -0.923 . . . . 0.0 109.553 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.476 ' OG1' HG12 ' A' ' 33' ' ' ILE . 41.8 p -98.05 -28.66 13.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.192 -0.942 . . . . 0.0 109.57 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 76.88 21.1 75.06 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.816 ' O ' HG13 ' A' ' 28' ' ' VAL . 34.1 mm -90.02 94.87 5.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -1.154 . . . . 0.0 109.495 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 16.0 mttp -97.74 5.13 49.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.183 -0.948 . . . . 0.0 109.49 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -110.22 13.45 23.07 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.203 -0.936 . . . . 0.0 109.341 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.052 HD21 ' HB2' ' A' ' 70' ' ' ALA . 1.2 tm? -115.73 -54.28 2.52 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.329 -0.857 . . . . 0.0 109.187 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.572 ' HB ' HG21 ' A' ' 28' ' ' VAL . 42.9 t -99.21 130.01 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.443 -0.786 . . . . 0.0 109.219 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.82 -124.33 5.22 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 90.7 mtt180 -96.51 141.94 29.19 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.266 -1.138 . . . . 0.0 109.589 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.409 HD13 HD12 ' A' ' 24' ' ' ILE . 63.3 mt -101.43 138.1 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.297 -0.877 . . . . 0.0 109.251 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 1.13 HG21 HD11 ' A' ' 107' ' ' LEU . 44.4 t -126.42 137.51 57.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.236 -0.915 . . . . 0.0 109.285 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.807 HG22 HG23 ' A' ' 44' ' ' ILE . 12.2 mt -128.08 127.84 23.79 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.187 -0.946 . . . . 0.0 109.692 -179.686 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.53 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -68.05 -3.86 11.45 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.895 2.396 . . . . 0.0 111.461 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.891 HD11 ' OE2' ' A' ' 18' ' ' GLU . 18.8 pt . . . . . 0 N--CA 1.489 1.505 0 O-C-N 121.307 -0.87 . . . . 0.0 109.561 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.727 ' HA ' HG22 ' A' ' 44' ' ' ILE . 6.2 mttt . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.53 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 16.7 mt -71.83 -21.47 61.68 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.136 -0.978 . . . . 0.0 109.407 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.968 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 37.2 m-85 -143.95 93.09 6.17 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.285 -0.885 . . . . 0.0 108.826 179.688 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -64.34 135.91 48.61 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.628 2.219 . . . . 0.0 112.267 -179.193 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.473 ' N ' ' OE2' ' A' ' 17' ' ' GLU . . . 78.81 -20.52 4.42 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 179.541 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.797 ' HE1' HD11 ' A' ' 11' ' ' LEU . 3.9 m-30 -96.34 127.81 42.68 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.707 -1.467 . . . . 0.0 110.47 -179.085 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.555 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 94.3 t -135.59 150.41 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.111 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.542 ' CE1' HG12 ' A' ' 9' ' ' ILE . 86.8 m-85 -108.46 122.97 48.14 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.858 -1.151 . . . . 0.0 110.227 -179.248 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 87.9 t -121.98 127.8 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.322 -0.861 . . . . 0.0 109.873 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.587 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 7.6 tt0 -89.68 121.76 32.16 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.282 -0.886 . . . . 0.0 109.278 179.769 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' MET . . . . . . . . . . . . . 14.8 ptt? -154.04 174.08 15.17 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.03 -1.044 . . . . 0.0 110.538 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.662 HG12 HD22 ' A' ' 36' ' ' LEU . 39.0 pt -100.35 134.99 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.755 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.551 ' O ' ' HB3' ' A' ' 67' ' ' ASN . 84.9 mtp -79.55 142.87 35.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.096 -1.003 . . . . 0.0 110.799 -178.355 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.551 ' HB3' ' O ' ' A' ' 66' ' ' MET . 16.4 p30 171.67 -174.31 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -76.51 -42.89 41.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.147 -0.971 . . . . 0.0 110.006 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.621 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 85.1 tt0 -66.54 -31.42 72.13 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.216 -0.927 . . . . 0.0 110.383 -179.299 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.052 ' HB2' HD21 ' A' ' 36' ' ' LEU . . . -77.11 -40.78 44.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.848 -1.157 . . . . 0.0 109.791 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.468 ' CD1' ' OE1' ' A' ' 89' ' ' GLN . 87.3 t80 -58.79 -51.41 70.1 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.11 -0.994 . . . . 0.0 109.586 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.471 ' O ' ' HB3' ' A' ' 76' ' ' SER . 38.1 t-20 -69.89 -27.27 64.67 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.201 -0.937 . . . . 0.0 110.581 -179.196 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.621 ' CD1' ' O ' ' A' ' 69' ' ' GLU . 5.1 m-85 -78.19 -41.21 35.26 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.693 -1.254 . . . . 0.0 110.073 -179.447 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.848 HG22 ' CZ ' ' A' ' 83' ' ' PHE . 7.7 p -66.48 -52.11 50.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.22 -0.925 . . . . 0.0 109.232 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.662 ' N ' HG13 ' A' ' 74' ' ' VAL . 7.5 mmm-85 -67.59 -1.22 4.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.313 -0.867 . . . . 0.0 109.904 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 89.3 p -101.0 -4.94 26.53 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.031 -1.043 . . . . 0.0 110.167 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.873 ' O ' HG12 ' A' ' 80' ' ' VAL . 5.6 p -80.13 137.9 52.95 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 120.994 -1.066 . . . . 0.0 109.377 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.624 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 43.5 Cg_endo -65.77 140.53 61.97 Favored 'Trans proline' 0 C--O 1.213 -0.737 0 C-N-CA 122.763 2.308 . . . . 0.0 112.119 -179.367 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.852 ' CB ' HG22 ' A' ' 20' ' ' VAL . 42.0 m-85 89.0 -11.89 0.41 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.831 -0.543 . . . . 0.0 109.675 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.873 HG12 ' O ' ' A' ' 77' ' ' VAL . 7.9 p -81.84 119.03 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.957 -1.089 . . . . 0.0 109.299 179.772 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.8 mmm -88.44 -27.16 21.71 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.196 -0.94 . . . . 0.0 109.41 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.588 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.27 -158.03 28.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.848 ' CZ ' HG22 ' A' ' 74' ' ' VAL . 7.4 m-85 -139.61 156.95 46.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -1.124 . . . . 0.0 109.573 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.649 ' O ' HG13 ' A' ' 84' ' ' VAL . 7.7 p -88.74 118.69 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.232 -0.918 . . . . 0.0 109.339 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.596 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.8 OUTLIER -157.0 166.78 32.38 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -0.915 . . . . 0.0 109.627 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 m -87.06 -29.93 21.54 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.405 -0.809 . . . . 0.0 109.432 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.44 -103.18 1.4 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -99.5 -124.34 5.19 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.559 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -29.24 146.09 0.05 OUTLIER Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.524 -0.986 . . . . 0.0 110.142 -179.751 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.596 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.2 Cg_endo -68.66 153.92 72.41 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.827 2.352 . . . . 0.0 112.001 -179.73 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.2 m -89.9 149.75 42.43 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.301 -0.874 . . . . 0.0 109.253 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.533 ' HB3' ' HB3' ' A' ' 6' ' ' LYS . 49.5 Cg_endo -69.62 152.37 70.01 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.682 2.255 . . . . 0.0 111.664 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.864 HG23 ' O ' ' A' ' 7' ' ' TRP . 15.5 t -79.93 141.21 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -0.885 . . . . 0.0 109.322 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' LYS . . . . . 0.5 ' O ' ' N ' ' A' ' 97' ' ' GLU . 69.6 tttt -78.9 130.14 35.3 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.086 -1.009 . . . . 0.0 109.357 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.442 ' C ' ' O ' ' A' ' 94' ' ' LYS . 81.3 m-20 -42.78 -41.96 3.4 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -0.944 . . . . 0.0 109.367 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.462 ' CD ' ' HE2' ' A' ' 94' ' ' LYS . 75.1 mtt180 -56.36 -29.91 62.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.271 -0.893 . . . . 0.0 109.433 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.5 ' N ' ' O ' ' A' ' 94' ' ' LYS . 47.5 mt-10 -88.07 -28.26 21.44 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.221 -0.924 . . . . 0.0 109.589 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.599 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 94.6 mtp -82.91 -25.51 32.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.148 -0.97 . . . . 0.0 109.431 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.567 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.14 -54.62 1.08 Allowed Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.524 -0.735 . . . . 0.0 109.995 -179.845 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.614 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 49.4 Cg_endo -70.17 -27.75 24.14 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.591 2.194 . . . . 0.0 112.132 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.525 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 18.9 mm -80.21 -42.74 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.156 -0.965 . . . . 0.0 109.546 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.557 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -67.36 -40.63 85.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.207 -0.933 . . . . 0.0 109.494 -179.884 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.54 ' CG ' ' HB3' ' A' ' 135' ' ' PRO . 22.2 tpt180 -65.13 -49.73 68.78 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.326 -0.859 . . . . 0.0 109.162 179.722 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.4 tt -72.05 -37.86 69.61 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.208 -0.932 . . . . 0.0 109.2 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.52 -1.04 9.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.398 -0.814 . . . . 0.0 109.829 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.75 8.57 86.42 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 1.13 HD11 HG21 ' A' ' 41' ' ' VAL . 29.3 mt -78.38 -21.4 49.44 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.19 -1.182 . . . . 0.0 109.613 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 42.6 tp10 . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.15 -0.969 . . . . 0.0 109.365 -179.909 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.533 ' O ' ' CD1' ' A' ' 146' ' ' ILE . 18.0 m-85 . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.443 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 80.9 mttt -102.08 148.72 25.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.958 . . . . 0.0 109.915 -179.758 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 20.5 m -64.14 144.26 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.433 -0.792 . . . . 0.0 109.375 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.72 -29.92 4.38 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 -179.751 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.553 ' HB2' HD12 ' A' ' 143' ' ' ILE . 26.2 m-20 -48.01 165.71 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -1.114 . . . . 0.0 109.127 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' MET . . . . . 0.481 ' HG3' HG12 ' A' ' 142' ' ' VAL . 2.9 ttm -103.54 127.8 50.88 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.136 -0.978 . . . . 0.0 109.153 179.775 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.674 HG11 HD11 ' A' ' 143' ' ' ILE . 26.8 m -129.06 145.88 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.855 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 140' ' ' ALA . 42.2 tttt -102.81 142.41 33.99 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.87 HD12 ' HB3' ' A' ' 139' ' ' PHE . 60.5 mt -83.14 154.34 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.358 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.488 HG12 ' HA ' ' A' ' 173' ' ' VAL . 0.2 OUTLIER -152.02 2.78 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 120.948 -1.095 . . . . 0.0 109.65 179.828 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.479 ' HB3' ' HG2' ' A' ' 172' ' ' GLU . 47.3 t -148.03 144.1 27.69 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.07 -1.019 . . . . 0.0 110.252 -179.66 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 99.62 -163.18 19.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.54 ' HB3' ' CG ' ' A' ' 103' ' ' ARG . 46.8 Cg_endo -67.89 -23.46 41.14 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 123.312 2.675 . . . . 0.0 112.541 -179.497 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.649 ' HB2' HD13 ' A' ' 131' ' ' ILE . 93.2 m-85 -104.22 17.61 23.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.957 -1.09 . . . . 0.0 109.562 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.553 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.9 tt0 -43.83 133.61 4.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.251 -0.906 . . . . 0.0 109.649 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.545 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 16.8 t0 78.92 19.26 0.82 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.262 -0.899 . . . . 0.0 110.36 179.161 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.87 ' HB3' HD12 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -109.24 130.4 55.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.912 -1.117 . . . . 0.0 109.47 179.825 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -83.7 136.9 34.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.16 -0.963 . . . . 0.0 109.597 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -146.55 175.6 25.89 Favored Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.67 -1.252 . . . . 0.0 110.612 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.828 ' C ' HG13 ' A' ' 155' ' ' VAL . 19.4 m -118.42 137.01 53.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.702 -0.881 . . . . 0.0 109.659 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.674 HD11 HG11 ' A' ' 129' ' ' VAL . 93.3 mt -67.48 114.6 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.321 -0.862 . . . . 0.0 109.407 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -98.15 -34.51 10.72 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.976 -1.077 . . . . 0.0 109.331 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -150.8 145.58 25.81 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.153 -0.967 . . . . 0.0 109.367 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.686 HG23 ' CD1' ' A' ' 153' ' ' LEU . 2.2 mt -122.74 126.28 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.678 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -107.41 101.68 40.32 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.314 -0.867 . . . . 0.0 109.447 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.528 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.1 Cg_endo -71.96 170.92 17.73 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.734 2.29 . . . . 0.0 111.899 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.7 tt0 79.85 -20.92 0.36 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.336 -0.852 . . . . 0.0 109.862 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.412 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 66.6 mtp85 -125.35 -13.18 6.7 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.155 -0.965 . . . . 0.0 109.43 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.412 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 36.2 mt-30 68.98 49.08 0.67 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.204 -0.935 . . . . 0.0 109.678 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -121.1 145.25 48.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.111 -0.993 . . . . 0.0 108.896 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.686 ' CD1' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -135.82 113.13 10.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.035 -1.041 . . . . 0.0 110.262 -179.498 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 10.4 mttt -79.59 133.25 36.43 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.102 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.828 HG13 ' C ' ' A' ' 142' ' ' VAL . 21.5 t -126.34 150.49 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.077 -1.014 . . . . 0.0 110.01 -179.27 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.51 ' OD1' ' N ' ' A' ' 164' ' ' THR . 20.9 t-20 -97.26 114.5 26.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.446 -0.784 . . . . 0.0 109.293 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.709 HG12 HG23 ' A' ' 159' ' ' ILE . 50.0 t -95.98 139.77 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.712 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 20.6 m -92.55 95.24 9.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.409 -0.807 . . . . 0.0 109.514 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.968 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 5.5 pt -130.9 150.2 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.269 -0.895 . . . . 0.0 109.488 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.601 ' CE2' HD12 ' A' ' 159' ' ' ILE . 13.7 m-30 62.95 33.13 15.18 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.271 -0.893 . . . . 0.0 109.313 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 60.64 16.35 44.64 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 60.0 mtt-85 -135.63 159.27 42.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.188 -1.183 . . . . 0.0 109.455 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 163' ' ' GLU . . . . . 0.449 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 95.6 mt-10 -100.46 140.85 34.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.244 -0.91 . . . . 0.0 109.516 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 164' ' ' THR . . . . . 0.51 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 16.4 m -148.0 127.86 6.59 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.325 -0.859 . . . . 0.0 109.46 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.5 Cg_endo -69.86 140.0 41.23 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.751 2.301 . . . . 0.0 111.583 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 1.024 HG23 HD21 ' A' ' 168' ' ' LEU . 35.2 m -121.28 168.19 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.056 -1.028 . . . . 0.0 109.598 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 1.136 ' O ' HD13 ' A' ' 168' ' ' LEU . 8.4 m -118.2 115.66 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.442 -0.786 . . . . 0.0 109.492 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 1.136 HD13 ' O ' ' A' ' 167' ' ' VAL . 0.0 OUTLIER -139.56 166.28 25.0 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-O 121.797 0.808 . . . . 0.0 109.937 179.959 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.452 ' O ' ' HB2' ' A' ' 172' ' ' GLU . 40.5 m80 -79.04 139.72 38.09 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.175 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 171' ' ' SER . 11.4 p -51.43 -37.91 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.067 -1.021 . . . . 0.0 108.521 179.598 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.484 ' N ' HG13 ' A' ' 170' ' ' VAL . 53.3 p -74.86 -4.83 40.16 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.615 -0.678 . . . . 0.0 109.798 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.479 ' HG2' ' HB3' ' A' ' 133' ' ' SER . 23.8 mt-10 -92.7 -6.44 49.19 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.077 -1.014 . . . . 0.0 109.874 -179.712 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 173' ' ' VAL . . . . . 0.488 ' HA ' HG12 ' A' ' 132' ' ' ILE . 4.1 m -137.29 175.15 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.057 -1.027 . . . . 0.0 109.488 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.543 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 84.4 tt0 -140.02 164.53 29.77 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.132 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.543 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.8 tttt . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.055 -1.028 . . . . 0.0 109.347 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.514 ' HG2' HG22 ' A' ' 65' ' ' ILE . 72.1 mttt . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.318 0.58 . . . . 0.0 109.496 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.591 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.0 mtpp -130.56 174.72 9.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.282 -0.886 . . . . 0.0 109.28 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.903 ' O ' HG23 ' A' ' 93' ' ' VAL . 61.9 m95 -108.84 124.43 50.61 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.232 -0.917 . . . . 0.0 109.031 179.7 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.487 ' O ' ' HA ' ' A' ' 61' ' ' PHE . 79.5 m-85 -110.92 174.07 6.03 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.163 -0.961 . . . . 0.0 109.569 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.535 HG12 ' CD1' ' A' ' 61' ' ' PHE . 61.7 mt -116.76 109.05 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.316 -0.865 . . . . 0.0 109.141 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.716 ' CG2' HG23 ' A' ' 80' ' ' VAL . 9.7 p -90.88 142.98 12.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.178 -0.951 . . . . 0.0 109.65 -179.682 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.55 ' N ' HD22 ' A' ' 11' ' ' LEU . 3.5 mm? -89.5 153.86 20.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.353 -0.842 . . . . 0.0 109.615 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.499 HG21 ' HG2' ' A' ' 17' ' ' GLU . 9.2 t -162.84 -172.87 3.24 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.906 . . . . 0.0 109.349 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.519 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 67.5 mtm -103.54 133.45 48.56 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.227 -0.92 . . . . 0.0 109.658 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.4 m -54.43 127.4 27.36 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.884 . . . . 0.0 109.383 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.23 -20.18 38.43 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.519 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 85.6 m-85 -107.51 -1.56 21.24 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.34 -1.094 . . . . 0.0 109.429 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.499 ' HG2' HG21 ' A' ' 12' ' ' THR . 46.3 mt-10 -55.21 -59.4 4.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.233 -0.917 . . . . 0.0 109.388 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -47.48 -36.38 10.1 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.345 -0.847 . . . . 0.0 109.402 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 12.9 mttp -72.44 -46.46 54.89 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.388 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.527 HG22 ' HB2' ' A' ' 79' ' ' TYR . 73.4 t -55.09 -47.17 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.281 -0.887 . . . . 0.0 109.307 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.871 ' HD2' HD11 ' A' ' 42' ' ' ILE . 17.8 tttm -56.23 -50.92 69.92 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.413 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -63.25 -37.39 87.05 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.189 -0.944 . . . . 0.0 109.522 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.583 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 31.5 m120 -61.89 -49.04 77.82 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.203 -0.935 . . . . 0.0 109.565 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.465 ' O ' HG13 ' A' ' 28' ' ' VAL . 81.2 mt -53.93 -44.22 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.08 -1.013 . . . . 0.0 109.354 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.636 ' O ' HG22 ' A' ' 28' ' ' VAL . 83.1 tt0 -56.56 -47.95 78.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.188 -0.945 . . . . 0.0 110.035 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 40.4 mttp -73.41 -36.95 66.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.145 -0.972 . . . . 0.0 109.939 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.482 ' HD3' HG23 ' A' ' 77' ' ' VAL . 23.7 ttpp -56.31 -34.12 66.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.122 -0.986 . . . . 0.0 109.325 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 1.079 HG11 HG11 ' A' ' 37' ' ' VAL . 12.0 m -87.34 -25.55 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.42 -0.8 . . . . 0.0 109.489 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -72.01 -57.75 4.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.303 -0.873 . . . . 0.0 109.298 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.85 -40.79 61.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.397 -0.814 . . . . 0.0 109.243 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.698 HG21 ' CZ ' ' A' ' 73' ' ' PHE . 72.7 p -83.07 -26.15 31.38 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.325 -0.859 . . . . 0.0 109.483 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 77.51 25.02 64.02 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.628 HD12 ' CE2' ' A' ' 73' ' ' PHE . 15.9 mt -94.07 92.9 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -1.15 . . . . 0.0 109.359 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.8 mttt -105.71 -12.95 15.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.349 -0.845 . . . . 0.0 109.505 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -86.25 -19.6 29.71 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.182 -0.949 . . . . 0.0 109.428 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.1 HD11 ' CB ' ' A' ' 70' ' ' ALA . 15.1 tp -89.36 -51.58 5.49 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.307 -0.87 . . . . 0.0 109.461 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 1.079 HG11 HG11 ' A' ' 28' ' ' VAL . 7.3 p -93.83 136.58 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.52 -0.737 . . . . 0.0 109.018 179.672 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.5 -120.9 4.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.4 mtt85 -104.44 140.04 38.51 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.286 -1.126 . . . . 0.0 109.878 -179.399 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.547 HG22 ' HB ' ' A' ' 62' ' ' VAL . 12.9 pt -112.74 148.26 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.354 -0.841 . . . . 0.0 109.021 179.407 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.829 HG13 ' CH2' ' A' ' 7' ' ' TRP . 23.2 m -132.22 161.77 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.076 -1.015 . . . . 0.0 109.91 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.871 HD11 ' HD2' ' A' ' 21' ' ' LYS . 3.8 mt -135.28 130.84 19.36 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.379 -0.826 . . . . 0.0 109.333 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.492 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 43.0 Cg_endo -65.12 -3.59 7.53 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.851 2.368 . . . . 0.0 111.873 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.819 HG13 HG22 ' A' ' 42' ' ' ILE . 15.3 mt . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.146 -0.971 . . . . 0.0 109.446 179.701 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.656 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 7.2 mttp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.492 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 41.2 mt -68.06 -20.78 65.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.061 -1.025 . . . . 0.0 109.3 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.762 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 90.0 m-85 -143.66 98.2 5.37 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.304 -0.873 . . . . 0.0 109.044 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.3 Cg_endo -65.52 132.88 32.5 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.784 2.322 . . . . 0.0 112.216 -179.3 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.496 ' HA2' HG23 ' A' ' 12' ' ' THR . . . 77.02 -15.41 6.47 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.571 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 2.9 m-85 -97.83 129.59 44.8 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.624 -1.515 . . . . 0.0 110.38 -179.159 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.533 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 79.2 t -137.19 149.19 25.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.41 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.57 ' HB2' ' CG2' ' A' ' 41' ' ' VAL . 63.5 m-85 -109.67 124.39 51.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.025 -1.047 . . . . 0.0 110.23 -179.416 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.547 ' HB ' HG22 ' A' ' 40' ' ' ILE . 1.3 m -123.44 135.43 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.452 -0.78 . . . . 0.0 109.604 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.619 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 19.5 tt0 -104.87 122.91 46.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.222 -0.923 . . . . 0.0 109.402 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.544 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 22.3 mtm -157.96 179.47 9.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.085 -1.009 . . . . 0.0 110.344 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 1.046 ' CG1' HD12 ' A' ' 36' ' ' LEU . 8.4 pt -94.72 129.01 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.454 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 37.0 ttm -77.83 146.22 35.85 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.255 -0.903 . . . . 0.0 110.131 -178.581 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.454 ' HB2' ' O ' ' A' ' 66' ' ' MET . 20.8 t-20 176.58 177.72 0.25 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.596 -0.69 . . . . 0.0 109.258 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -73.38 -42.5 62.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.159 -0.963 . . . . 0.0 109.284 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -76.48 -28.18 56.37 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.23 -0.919 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.1 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -74.55 -48.15 28.53 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.262 -0.899 . . . . 0.0 109.569 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.568 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 84.0 t80 -60.52 -45.66 93.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.227 -0.921 . . . . 0.0 109.57 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -67.4 -27.3 66.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.986 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.698 ' CZ ' HG21 ' A' ' 31' ' ' THR . 10.6 t80 -81.18 -41.59 22.12 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.078 -1.014 . . . . 0.0 109.897 -179.711 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.683 HG13 ' N ' ' A' ' 75' ' ' ARG . 14.6 p -69.57 -53.77 22.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.426 -0.796 . . . . 0.0 109.585 -179.627 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.683 ' N ' HG13 ' A' ' 74' ' ' VAL . 14.4 tpt85 -61.15 -11.15 7.89 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.128 -0.983 . . . . 0.0 109.825 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 91.4 p -92.77 4.5 53.67 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.169 -0.957 . . . . 0.0 109.963 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.917 ' O ' HG12 ' A' ' 80' ' ' VAL . 5.2 p -76.82 135.17 67.92 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.037 -1.039 . . . . 0.0 109.344 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.622 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 42.8 Cg_endo -65.18 140.66 65.92 Favored 'Trans proline' 0 C--O 1.214 -0.72 0 C-N-CA 122.672 2.248 . . . . 0.0 112.109 -179.532 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.622 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 38.5 m-85 89.55 -9.48 0.4 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.918 -0.489 . . . . 0.0 109.744 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.917 HG12 ' O ' ' A' ' 77' ' ' VAL . 7.8 p -88.2 125.01 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.049 -1.032 . . . . 0.0 109.496 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 95.9 mmm -85.09 -26.42 26.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.108 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.531 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.23 -157.52 28.15 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.634 ' CE1' HG23 ' A' ' 10' ' ' VAL . 14.5 m-85 -132.79 149.28 52.29 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -1.138 . . . . 0.0 109.459 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.675 ' O ' HG13 ' A' ' 84' ' ' VAL . 10.9 p -74.33 115.75 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.427 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.528 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.1 p -152.83 166.58 31.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.263 -0.898 . . . . 0.0 109.403 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.2 t -96.01 -29.96 13.84 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.282 -0.886 . . . . 0.0 109.393 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -130.59 -80.24 0.22 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.533 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -110.18 -136.25 7.3 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.568 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -31.81 150.37 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.526 -0.985 . . . . 0.0 110.245 -179.619 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.528 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.5 Cg_endo -69.36 159.05 55.19 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.967 2.445 . . . . 0.0 111.884 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 28.5 m -88.9 151.69 47.61 Favored Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.207 -0.933 . . . . 0.0 109.279 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.541 ' CB ' ' HE2' ' A' ' 6' ' ' LYS . 50.6 Cg_endo -70.45 145.75 54.01 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.686 2.258 . . . . 0.0 111.789 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.903 HG23 ' O ' ' A' ' 7' ' ' TRP . 3.6 t -79.74 129.71 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.182 -0.949 . . . . 0.0 109.169 179.841 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' LYS . . . . . 0.442 ' O ' ' C ' ' A' ' 95' ' ' ASP . 32.4 mttp -73.92 134.0 43.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.441 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.442 ' C ' ' O ' ' A' ' 94' ' ' LYS . 69.2 m-20 -42.63 -41.65 3.16 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -0.883 . . . . 0.0 109.463 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 56.6 ttt180 -54.6 -28.64 47.87 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.235 -0.915 . . . . 0.0 109.362 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.44 ' N ' ' O ' ' A' ' 94' ' ' LYS . 23.2 mm-40 -89.38 -28.39 19.81 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.558 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.558 ' CB ' HD11 ' A' ' 102' ' ' LEU . 33.6 mmm -84.14 -28.55 27.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.254 -0.904 . . . . 0.0 109.427 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.593 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.88 -53.89 1.42 Allowed Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.465 -0.772 . . . . 0.0 109.903 -179.913 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -69.65 -28.2 26.05 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.496 2.13 . . . . 0.0 111.707 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.484 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 29.2 mm -80.69 -42.63 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.262 -0.898 . . . . 0.0 109.317 179.667 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.696 HD23 ' CD2' ' A' ' 107' ' ' LEU . 0.9 OUTLIER -67.73 -40.13 84.23 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.311 -0.868 . . . . 0.0 109.214 179.76 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -63.77 -50.72 67.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.337 -0.852 . . . . 0.0 109.096 179.709 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.82 -36.46 70.23 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.387 -0.821 . . . . 0.0 109.366 179.598 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.56 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -70.29 -0.41 8.0 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.277 -0.889 . . . . 0.0 109.995 -179.838 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 77.38 8.75 87.07 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.696 ' CD2' HD23 ' A' ' 102' ' ' LEU . 9.9 mp -74.94 -19.17 60.23 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -1.177 . . . . 0.0 109.509 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.937 . . . . 0.0 109.544 -179.934 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.614 ' CE2' ' HB3' ' A' ' 175' ' ' LYS . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.435 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 40.0 mttm -97.22 156.34 16.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.95 -1.094 . . . . 0.0 109.531 -179.652 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 11.0 p -58.39 138.6 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.469 -0.77 . . . . 0.0 109.938 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.99 -31.89 4.84 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.561 ' HB3' ' CD2' ' A' ' 123' ' ' PHE . 45.3 m-20 -48.92 160.33 0.2 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.3 -1.118 . . . . 0.0 109.552 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 2.3 ttp -97.25 127.29 43.08 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.33 -0.857 . . . . 0.0 109.026 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.587 HG13 HG12 ' A' ' 143' ' ' ILE . 33.9 m -128.84 146.25 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.115 -0.99 . . . . 0.0 109.834 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 140' ' ' ALA . 28.4 tttt -110.29 140.28 44.62 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.592 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 1.007 ' O ' HD13 ' A' ' 132' ' ' ILE . 74.6 mt -79.61 157.76 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.049 -1.032 . . . . 0.0 108.641 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 1.007 HD13 ' O ' ' A' ' 131' ' ' ILE . 0.6 OUTLIER -149.51 1.96 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.03 -1.043 . . . . 0.0 109.526 179.786 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.479 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 58.5 m -149.65 146.16 27.13 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.011 -1.055 . . . . 0.0 110.232 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.99 -167.05 16.78 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.346 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.08 -21.9 42.11 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 123.135 2.557 . . . . 0.0 112.524 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.561 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 97.2 m-85 -110.29 16.31 21.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.006 -1.059 . . . . 0.0 109.578 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.581 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.3 tt0 -43.29 143.94 0.78 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.235 -0.915 . . . . 0.0 109.641 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 26.9 m-20 72.73 28.12 2.14 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.459 -0.776 . . . . 0.0 110.234 179.406 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.994 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.3 t80 -117.82 128.77 55.18 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.115 -0.991 . . . . 0.0 109.444 179.739 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.489 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -76.53 131.54 39.03 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.157 -0.965 . . . . 0.0 109.746 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -139.53 165.77 25.72 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.786 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.649 ' C ' HG23 ' A' ' 155' ' ' VAL . 37.5 t -113.34 137.53 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -1.088 . . . . 0.0 109.063 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.869 HD12 ' CD2' ' A' ' 153' ' ' LEU . 14.7 mm -68.67 113.86 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.214 -0.929 . . . . 0.0 109.611 -179.822 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.91 -35.46 8.99 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.056 -1.027 . . . . 0.0 109.421 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.401 ' HG2' ' N ' ' A' ' 146' ' ' ILE . 81.9 tt0 -154.17 149.29 26.89 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.967 -1.083 . . . . 0.0 109.924 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.82 HG23 ' CD1' ' A' ' 153' ' ' LEU . 11.3 mt -126.16 128.46 71.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.418 -0.802 . . . . 0.0 109.332 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -110.4 101.73 49.31 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.533 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.586 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.47 172.81 13.5 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.621 2.214 . . . . 0.0 111.801 179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.586 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.6 tt0 82.4 -20.48 0.35 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.405 -0.809 . . . . 0.0 109.795 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.481 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 96.6 mtt180 -129.99 -11.54 4.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.129 -0.982 . . . . 0.0 109.684 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.481 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 19.8 mt-30 70.12 48.53 0.52 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.222 -0.924 . . . . 0.0 109.438 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.706 ' OE2' HG23 ' A' ' 167' ' ' VAL . 53.9 tt0 -121.35 144.24 48.76 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.156 -0.965 . . . . 0.0 109.319 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.869 ' CD2' HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -138.1 112.47 8.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.235 -0.916 . . . . 0.0 109.884 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.493 ' NZ ' ' OE2' ' A' ' 152' ' ' GLU . 10.2 mttm -78.54 131.73 36.9 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.309 -0.869 . . . . 0.0 108.677 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.839 HG12 HD21 ' A' ' 168' ' ' LEU . 9.2 p -123.2 151.98 27.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.235 -0.915 . . . . 0.0 109.517 -179.594 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.476 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 17.9 t-20 -98.18 112.3 24.32 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.357 -0.839 . . . . 0.0 109.648 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.668 HG22 ' O ' ' A' ' 164' ' ' THR . 3.2 m -93.15 139.88 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.254 -0.904 . . . . 0.0 109.291 179.701 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 53.1 m -98.46 88.65 4.18 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.08 -1.013 . . . . 0.0 109.701 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.762 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 2.0 mt -114.24 145.55 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.276 -0.89 . . . . 0.0 109.309 179.78 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.431 ' HD2' ' CE1' ' A' ' 56' ' ' PHE . 9.9 m-85 62.23 38.31 13.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.418 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.64 18.06 29.59 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 42.4 mtt-85 -130.1 156.49 44.45 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.171 -1.194 . . . . 0.0 109.553 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -96.68 130.09 43.97 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.364 -0.835 . . . . 0.0 109.55 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 164' ' ' THR . . . . . 0.668 ' O ' HG22 ' A' ' 157' ' ' VAL . 97.8 m -137.07 120.1 11.7 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.937 . . . . 0.0 109.76 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -71.1 137.28 31.26 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.712 2.275 . . . . 0.0 111.549 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.822 HG13 ' CD2' ' A' ' 168' ' ' LEU . 2.6 p -128.41 147.24 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.168 -0.958 . . . . 0.0 109.878 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.706 HG23 ' OE2' ' A' ' 152' ' ' GLU . 2.4 p -93.12 120.15 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.419 -0.801 . . . . 0.0 109.457 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.898 ' CD1' HG11 ' A' ' 173' ' ' VAL . 0.1 OUTLIER -141.84 167.14 22.86 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.322 -0.861 . . . . 0.0 110.585 -179.25 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.511 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 40.4 m170 -79.82 142.22 35.49 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.407 HG12 ' O ' ' A' ' 151' ' ' GLN . 3.4 p -58.72 -36.82 62.39 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 O-C-N 121.256 -0.902 . . . . 0.0 109.048 179.71 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 19.8 m -75.34 -7.61 54.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.42 -0.8 . . . . 0.0 109.415 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.511 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 65.5 mt-10 -90.33 5.39 47.52 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.33 -0.856 . . . . 0.0 109.307 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 173' ' ' VAL . . . . . 0.898 HG11 ' CD1' ' A' ' 168' ' ' LEU . 18.1 m -146.6 173.06 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.344 -0.848 . . . . 0.0 109.582 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.514 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 78.1 tt0 -142.08 168.56 19.45 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.3 -0.875 . . . . 0.0 109.132 179.767 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.614 ' HB3' ' CE2' ' A' ' 123' ' ' PHE . 42.0 mttt . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.766 -179.689 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.49 ' HG2' ' CG2' ' A' ' 65' ' ' ILE . 19.4 mttt . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 121.324 0.583 . . . . 0.0 109.491 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.552 ' CE ' ' HB3' ' A' ' 92' ' ' PRO . 28.0 mtpp -128.32 175.19 8.67 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.249 -0.907 . . . . 0.0 109.065 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.958 ' CH2' HG23 ' A' ' 41' ' ' VAL . 63.7 m95 -112.91 124.19 52.05 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.19 -0.943 . . . . 0.0 109.149 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 67.3 m-85 -117.06 168.43 10.27 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.348 -0.845 . . . . 0.0 109.346 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.735 HD11 ' CE1' ' A' ' 160' ' ' PHE . 75.1 mt -110.5 109.72 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.193 -0.942 . . . . 0.0 109.017 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.544 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 12.8 p -86.35 143.96 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.21 -0.931 . . . . 0.0 109.547 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.538 HD11 ' HE1' ' A' ' 59' ' ' TYR . 0.5 OUTLIER -90.28 143.09 27.08 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.441 -0.787 . . . . 0.0 109.395 -179.932 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.454 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 2.4 p -154.19 174.92 14.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.405 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.447 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 93.4 mtp -91.89 120.32 32.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.23 -0.919 . . . . 0.0 109.329 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 13' ' ' MET . 52.0 p -41.68 126.97 3.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.365 -0.835 . . . . 0.0 109.504 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.63 -19.98 35.22 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.447 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.0 m-85 -107.4 -13.9 14.99 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.266 -1.137 . . . . 0.0 109.632 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.453 ' HG2' ' CG2' ' A' ' 60' ' ' VAL . 95.1 mt-10 -43.08 -60.42 1.65 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.245 -0.909 . . . . 0.0 109.603 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 73.9 mm-40 -48.17 -34.35 9.87 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.13 -0.981 . . . . 0.0 109.523 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.468 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 56.9 mttp -76.32 -46.74 26.27 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.27 -0.894 . . . . 0.0 109.346 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.583 HG13 HG23 ' A' ' 80' ' ' VAL . 24.9 t -54.92 -47.58 75.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.308 -0.87 . . . . 0.0 109.472 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.539 ' HG3' HG21 ' A' ' 40' ' ' ILE . 79.0 tttt -59.42 -47.78 84.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.427 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -64.28 -34.89 79.16 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.303 -0.873 . . . . 0.0 109.448 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.581 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 32.6 m120 -66.53 -47.47 72.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.367 -0.833 . . . . 0.0 109.745 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.556 HG12 HG21 ' A' ' 77' ' ' VAL . 76.5 mt -55.71 -43.86 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.187 -0.946 . . . . 0.0 109.745 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -58.15 -44.8 88.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.156 -0.965 . . . . 0.0 109.901 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.3 mttt -74.92 -36.87 62.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.13 -0.981 . . . . 0.0 109.686 -179.788 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.707 ' HD2' HG23 ' A' ' 77' ' ' VAL . 17.6 tttt -59.28 -30.62 68.44 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -0.929 . . . . 0.0 109.393 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.674 HG13 ' O ' ' A' ' 33' ' ' ILE . 93.9 t -79.21 -30.15 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.195 -0.941 . . . . 0.0 109.413 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -65.82 -48.16 72.61 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.23 -0.919 . . . . 0.0 109.563 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.97 -34.63 75.07 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 109.859 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.636 HG23 ' H ' ' A' ' 33' ' ' ILE . 9.6 t -92.56 -21.73 19.92 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 68.27 33.1 77.15 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.686 ' CG2' HD23 ' A' ' 36' ' ' LEU . 47.9 mm -100.43 91.49 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.245 -1.15 . . . . 0.0 109.598 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -98.54 2.91 47.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.318 -0.864 . . . . 0.0 109.5 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.693 ' C ' HD22 ' A' ' 36' ' ' LEU . 89.8 m-20 -105.39 9.97 33.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.22 -0.925 . . . . 0.0 109.477 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.986 HD12 ' HB2' ' A' ' 70' ' ' ALA . 4.1 mm? -114.24 -46.69 2.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.936 . . . . 0.0 109.473 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 58.7 t -105.34 134.24 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.247 -0.908 . . . . 0.0 109.41 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -98.93 -131.27 7.22 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 46.3 mtt85 -91.93 142.02 28.01 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.265 -1.138 . . . . 0.0 109.522 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.91 HG23 HG12 ' A' ' 62' ' ' VAL . 53.6 mt -98.66 133.88 39.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.267 -0.896 . . . . 0.0 109.305 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 1.05 ' CG2' HD11 ' A' ' 107' ' ' LEU . 40.1 t -115.97 155.38 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.253 -0.904 . . . . 0.0 109.495 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.809 HG22 ' H ' ' A' ' 44' ' ' ILE . 18.2 mt -133.01 126.84 19.85 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.22 -0.925 . . . . 0.0 109.525 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.884 ' O ' HD12 ' A' ' 55' ' ' LEU . 46.9 Cg_endo -68.18 -4.75 13.27 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.725 2.284 . . . . 0.0 111.722 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.809 ' H ' HG22 ' A' ' 42' ' ' ILE . 20.7 mt . . . . . 0 N--CA 1.489 1.52 0 O-C-N 121.209 -0.932 . . . . 0.0 109.459 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.654 ' HG2' HD13 ' A' ' 44' ' ' ILE . 37.5 mttp . . . . . 0 N--CA 1.491 1.617 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.884 HD12 ' O ' ' A' ' 43' ' ' PRO . 8.6 mt -61.31 -23.37 65.66 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.117 -0.99 . . . . 0.0 109.563 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.553 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 42.6 m-85 -151.06 100.18 3.05 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.167 -0.958 . . . . 0.0 109.069 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.7 Cg_endo -66.17 141.91 65.16 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.672 2.248 . . . . 0.0 111.906 -179.639 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.402 ' N ' ' OE2' ' A' ' 17' ' ' GLU . . . 75.26 -12.26 7.43 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.538 ' HE1' HD11 ' A' ' 11' ' ' LEU . 3.5 m-30 -103.38 130.9 50.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.789 -1.418 . . . . 0.0 109.942 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.544 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 3.0 t -132.49 146.24 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.215 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.694 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 14.9 m-85 -107.04 122.9 47.37 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.892 -1.13 . . . . 0.0 109.952 -179.391 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.91 HG12 HG23 ' A' ' 40' ' ' ILE . 30.0 m -129.77 139.94 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.43 -0.794 . . . . 0.0 109.48 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.505 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 48.3 tt0 -88.63 124.47 34.1 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.235 -0.916 . . . . 0.0 108.676 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.669 ' SD ' HG21 ' A' ' 74' ' ' VAL . 3.9 mtm -147.0 160.68 42.07 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.013 -1.054 . . . . 0.0 110.784 -178.78 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.525 HD11 HD13 ' A' ' 36' ' ' LEU . 26.9 pt -104.28 139.67 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.904 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' MET . . . . . . . . . . . . . 38.3 mtp -74.33 136.45 42.55 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.971 -1.081 . . . . 0.0 110.16 -178.432 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -178.47 155.3 0.85 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -61.78 -42.46 99.02 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.183 -0.948 . . . . 0.0 109.807 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 54.6 mt-10 -75.76 -25.23 56.29 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.852 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.986 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -78.05 -47.19 18.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.122 -0.987 . . . . 0.0 109.578 -179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.575 ' CE1' ' OE1' ' A' ' 89' ' ' GLN . 65.1 t80 -61.93 -45.35 94.09 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.289 -0.882 . . . . 0.0 109.926 -179.674 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 48.2 t-20 -70.25 -29.3 66.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.096 -1.002 . . . . 0.0 110.381 -179.348 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.52 ' O ' ' NZ ' ' A' ' 27' ' ' LYS . 83.8 t80 -76.84 -39.51 50.96 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.966 -1.084 . . . . 0.0 109.55 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.669 HG21 ' SD ' ' A' ' 64' ' ' MET . 2.4 p -75.48 -48.66 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.352 -0.843 . . . . 0.0 109.516 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.593 ' N ' ' CG1' ' A' ' 74' ' ' VAL . 0.0 OUTLIER -58.64 -21.09 52.91 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.212 -0.93 . . . . 0.0 109.86 -179.689 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.6 m -95.9 5.53 51.03 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.116 -0.99 . . . . 0.0 109.837 -179.631 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.707 HG23 ' HD2' ' A' ' 27' ' ' LYS . 3.6 p -68.26 132.93 91.48 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.05 -1.031 . . . . 0.0 109.301 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.734 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 44.3 Cg_endo -65.87 136.07 43.75 Favored 'Trans proline' 0 C--O 1.213 -0.763 0 C-N-CA 122.821 2.347 . . . . 0.0 112.369 -179.294 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.734 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 76.3 m-85 91.17 -6.89 0.26 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.95 -0.469 . . . . 0.0 109.844 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.687 HG21 HG11 ' A' ' 77' ' ' VAL . 3.1 t -98.0 135.93 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.928 -1.107 . . . . 0.0 109.309 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 88.9 mmm -96.6 -24.6 15.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.294 -0.879 . . . . 0.0 109.704 -179.772 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.55 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 159.89 -159.88 31.05 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.573 ' HZ ' HG22 ' A' ' 74' ' ' VAL . 9.4 m-85 -137.44 148.22 45.95 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.322 -1.105 . . . . 0.0 109.519 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.52 ' O ' HG13 ' A' ' 84' ' ' VAL . 9.2 p -72.58 128.12 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.232 -0.918 . . . . 0.0 109.387 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.545 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 5.0 p -160.66 166.09 29.45 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.55 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 m -91.27 -30.27 16.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.296 -0.877 . . . . 0.0 109.164 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -134.17 -83.47 0.2 Allowed Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.531 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -102.88 -137.7 9.65 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.575 ' OE1' ' CE1' ' A' ' 71' ' ' TYR . 0.3 OUTLIER -32.79 154.66 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.566 -0.961 . . . . 0.0 110.15 -179.53 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.545 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 46.6 Cg_endo -67.58 151.05 80.03 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.83 2.353 . . . . 0.0 111.946 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.3 m -83.26 151.68 63.28 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.552 ' HB3' ' CE ' ' A' ' 6' ' ' LYS . 51.2 Cg_endo -70.24 144.5 51.63 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.632 2.221 . . . . 0.0 111.796 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.565 HG12 ' HG3' ' A' ' 98' ' ' MET . 21.4 t -82.0 127.21 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.191 -0.943 . . . . 0.0 109.301 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -67.78 140.37 56.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.242 -0.911 . . . . 0.0 109.417 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -49.76 -40.83 42.39 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.47 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 39.2 ttm180 -57.4 -30.47 64.94 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.309 -0.87 . . . . 0.0 109.569 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 52.7 mt-10 -85.8 -27.79 24.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.156 -0.965 . . . . 0.0 109.493 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.591 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 93.2 mtp -82.33 -25.82 33.54 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.286 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.612 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 2.4 mtt180 -37.11 -52.65 2.14 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.434 -0.791 . . . . 0.0 109.935 -179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.612 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.1 Cg_endo -69.78 -28.79 24.7 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.499 2.133 . . . . 0.0 111.897 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.558 HG21 ' CD2' ' A' ' 61' ' ' PHE . 38.2 mm -81.47 -43.08 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.206 -0.934 . . . . 0.0 109.56 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.627 HD23 HD12 ' A' ' 107' ' ' LEU . 0.9 OUTLIER -66.76 -39.91 88.04 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 0.0 109.264 179.819 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 48.2 mtt-85 -64.06 -49.95 70.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.341 -0.849 . . . . 0.0 109.104 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.465 HD22 ' CD1' ' A' ' 55' ' ' LEU . 1.1 tt -72.09 -35.81 69.31 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.268 -0.895 . . . . 0.0 109.231 179.529 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.443 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.53 -2.01 12.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.352 -0.842 . . . . 0.0 109.897 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.83 10.43 84.98 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.706 -1.358 . . . . 0.0 109.706 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 1.05 HD11 ' CG2' ' A' ' 41' ' ' VAL . 18.5 mt -78.18 -21.51 50.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.212 -1.17 . . . . 0.0 109.542 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' GLU . . . . . 0.401 ' HG3' ' CB ' ' A' ' 102' ' ' LEU . 84.5 mt-10 . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.654 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 22.9 mttt -141.5 162.62 35.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.318 -0.864 . . . . 0.0 109.534 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 15.2 m -61.4 141.62 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.747 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 86.85 -33.81 3.68 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -47.96 158.74 0.21 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.351 -1.088 . . . . 0.0 109.198 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.3 ttm -100.94 128.5 46.95 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.084 -1.01 . . . . 0.0 108.752 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.652 HG13 HG12 ' A' ' 143' ' ' ILE . 16.0 m -129.22 144.8 37.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.337 -0.852 . . . . 0.0 109.878 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.471 ' O ' HG13 ' A' ' 173' ' ' VAL . 10.6 tttp -97.93 140.64 31.98 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.406 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.65 HG22 ' HA ' ' A' ' 137' ' ' GLU . 1.2 mp -80.72 153.55 4.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.353 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.532 ' CD1' ' HB2' ' A' ' 174' ' ' GLU . 0.9 OUTLIER -149.3 2.45 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 120.793 -1.192 . . . . 0.0 109.841 -179.791 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.547 ' CB ' ' HG3' ' A' ' 172' ' ' GLU . 61.1 m -149.25 145.35 27.05 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.004 -1.06 . . . . 0.0 110.212 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 103.46 -166.74 16.18 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.511 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 48.3 Cg_endo -68.41 -21.12 41.17 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.199 2.599 . . . . 0.0 112.53 -179.614 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.521 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 92.3 m-85 -108.35 18.72 20.7 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.907 -1.121 . . . . 0.0 109.377 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.65 ' HA ' HG22 ' A' ' 131' ' ' ILE . 3.7 tt0 -42.61 140.61 1.23 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.261 -0.899 . . . . 0.0 109.711 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 22.4 m-20 72.67 29.79 1.93 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.406 -0.809 . . . . 0.0 110.727 179.147 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.612 ' CE1' HG23 ' A' ' 157' ' ' VAL . 1.2 t80 -117.85 133.27 56.09 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.838 -1.164 . . . . 0.0 109.399 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.92 134.75 36.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.213 -0.93 . . . . 0.0 109.724 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.47 169.68 26.98 Favored Glycine 0 N--CA 1.491 2.306 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.329 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.796 ' C ' HG23 ' A' ' 155' ' ' VAL . 43.6 t -119.43 136.4 56.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.567 -0.96 . . . . 0.0 109.281 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.652 HG12 HG13 ' A' ' 129' ' ' VAL . 31.7 mm -68.82 119.58 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.63 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.479 ' HD2' ' OD1' ' A' ' 156' ' ' ASN . 63.9 tttt -99.81 -33.26 10.63 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.054 -1.029 . . . . 0.0 109.527 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -154.32 149.48 26.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.123 -0.986 . . . . 0.0 109.656 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 1.029 HG23 HD22 ' A' ' 153' ' ' LEU . 3.6 mt -123.9 126.55 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.321 -0.862 . . . . 0.0 109.575 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.22 102.39 46.25 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.239 -0.913 . . . . 0.0 109.589 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.0 Cg_endo -71.99 170.96 17.66 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.749 2.299 . . . . 0.0 111.866 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.3 mt-10 79.44 -21.23 0.34 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.395 -0.815 . . . . 0.0 110.057 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.446 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 75.6 mtt-85 -125.74 -14.99 6.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.063 -1.023 . . . . 0.0 109.478 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.446 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 50.8 mt-30 69.56 48.64 0.6 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.187 -0.946 . . . . 0.0 109.67 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.816 ' O ' HD23 ' A' ' 153' ' ' LEU . 82.5 tt0 -119.07 143.25 47.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.174 -0.954 . . . . 0.0 108.968 179.626 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 1.029 HD22 HG23 ' A' ' 146' ' ' ILE . 32.3 mt -128.77 127.55 42.22 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.1 -1.0 . . . . 0.0 110.291 -179.469 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -92.03 128.67 37.96 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.077 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.796 HG23 ' C ' ' A' ' 142' ' ' VAL . 12.9 p -131.39 147.93 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.084 -1.01 . . . . 0.0 109.834 -179.496 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.588 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.8 m120 -100.85 125.09 47.35 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.413 -0.804 . . . . 0.0 109.552 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.653 HG22 HG13 ' A' ' 159' ' ' ILE . 3.3 p -105.74 144.8 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.921 . . . . 0.0 109.476 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 55.7 m -97.33 92.48 6.0 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.895 . . . . 0.0 109.928 -179.664 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.653 HG13 HG22 ' A' ' 157' ' ' VAL . 7.4 mt -116.03 142.96 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.258 -0.901 . . . . 0.0 109.237 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.735 ' CE1' HD11 ' A' ' 9' ' ' ILE . 91.0 m-85 61.88 37.15 15.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.185 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.6 17.92 35.79 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 26.2 mtp180 -126.88 157.39 39.48 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.067 -1.254 . . . . 0.0 109.555 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -100.91 132.03 46.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.277 -0.889 . . . . 0.0 109.728 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.2 m -142.47 127.06 10.02 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.37 -0.831 . . . . 0.0 109.743 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.588 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.1 Cg_endo -70.91 136.67 30.48 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.748 2.299 . . . . 0.0 111.616 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.743 HG12 HG13 ' A' ' 155' ' ' VAL . 11.7 p -119.64 164.65 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.087 -1.008 . . . . 0.0 109.706 -179.817 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.533 ' O ' HD23 ' A' ' 168' ' ' LEU . 6.7 m -117.53 117.65 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.459 -0.776 . . . . 0.0 109.66 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.641 HD21 ' CG2' ' A' ' 166' ' ' VAL . 0.2 OUTLIER -142.24 167.33 22.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.241 -0.912 . . . . 0.0 110.207 -179.779 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.504 ' HB2' ' CD ' ' A' ' 172' ' ' GLU . 19.2 m170 -82.7 146.37 29.08 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.576 HG23 HD11 ' A' ' 153' ' ' LEU . 7.1 p -56.32 -32.73 36.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 121.422 -0.798 . . . . 0.0 109.314 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 73.5 p -76.86 -7.06 54.79 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.275 -0.891 . . . . 0.0 109.762 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.547 ' HG3' ' CB ' ' A' ' 133' ' ' SER . 0.8 OUTLIER -95.53 2.8 54.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.067 -1.021 . . . . 0.0 109.376 -179.991 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 173' ' ' VAL . . . . . 0.516 HG12 ' N ' ' A' ' 174' ' ' GLU . 43.5 t -139.78 164.84 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 109.281 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.539 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 54.8 tt0 -141.22 167.16 22.85 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.087 -1.008 . . . . 0.0 108.928 179.73 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.539 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 32.7 tttp . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.058 -1.027 . . . . 0.0 109.476 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.467 ' O ' ' HD3' ' A' ' 6' ' ' LYS . 27.5 mttt . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.331 0.586 . . . . 0.0 109.61 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 36.0 mmtm -132.07 169.26 16.62 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.355 -0.841 . . . . 0.0 109.339 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.954 ' CZ3' HG22 ' A' ' 41' ' ' VAL . 68.1 m95 -103.39 129.21 50.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.255 -0.903 . . . . 0.0 109.235 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -118.47 170.33 9.02 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.22 -0.925 . . . . 0.0 109.143 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.756 HD11 ' CE1' ' A' ' 160' ' ' PHE . 22.7 mt -103.85 112.78 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.122 -0.986 . . . . 0.0 109.268 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.489 HG23 HG22 ' A' ' 62' ' ' VAL . 73.5 t -86.18 142.31 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.228 -0.92 . . . . 0.0 109.343 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.532 HD21 HG22 ' A' ' 84' ' ' VAL . 0.6 OUTLIER -93.45 142.04 27.78 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.363 -0.836 . . . . 0.0 109.416 179.904 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.726 HG21 ' HG2' ' A' ' 17' ' ' GLU . 7.0 t -160.44 -173.33 3.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.431 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.426 ' O ' ' C ' ' A' ' 14' ' ' SER . 89.1 mtp -109.18 122.46 47.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.213 -0.93 . . . . 0.0 109.47 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.426 ' C ' ' O ' ' A' ' 13' ' ' MET . 2.2 m -44.3 133.87 5.26 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.259 -0.901 . . . . 0.0 109.443 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.0 -21.37 36.09 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -113.01 -7.99 13.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.25 -1.147 . . . . 0.0 109.355 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.862 ' OE1' HD11 ' A' ' 44' ' ' ILE . 57.3 mt-10 -48.12 -59.96 2.99 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.212 -0.93 . . . . 0.0 109.442 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -45.7 -34.57 3.64 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.187 -0.946 . . . . 0.0 109.37 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.46 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 25.1 mttt -73.68 -43.72 58.58 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.276 -0.89 . . . . 0.0 109.377 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.425 HG22 ' HB2' ' A' ' 79' ' ' TYR . 92.4 t -56.76 -50.0 76.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.317 -0.864 . . . . 0.0 109.535 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' LYS . . . . . 0.666 ' HD2' HD11 ' A' ' 42' ' ' ILE . 24.8 tttt -56.24 -46.95 79.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.911 . . . . 0.0 109.145 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 69.7 tt0 -65.27 -38.81 91.44 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.341 -0.849 . . . . 0.0 109.433 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.529 ' O ' ' CB ' ' A' ' 27' ' ' LYS . 32.6 m120 -62.29 -43.12 99.56 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.241 -0.912 . . . . 0.0 110.045 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.793 HD11 HG11 ' A' ' 77' ' ' VAL . 49.4 mm -64.69 -44.99 96.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.127 -0.983 . . . . 0.0 109.738 -179.537 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.566 ' O ' HG12 ' A' ' 28' ' ' VAL . 77.8 tt0 -58.7 -46.91 86.24 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.164 -0.96 . . . . 0.0 109.96 -179.63 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -82.27 -37.35 26.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.993 -1.067 . . . . 0.0 109.712 -179.724 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.529 ' CB ' ' O ' ' A' ' 23' ' ' ASN . 28.2 tttm -57.22 -30.36 64.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.283 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.697 HG21 HG12 ' A' ' 37' ' ' VAL . 12.3 p -85.43 -26.38 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.296 -0.878 . . . . 0.0 109.555 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 -67.31 -47.45 70.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.324 -0.86 . . . . 0.0 109.716 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.67 -31.24 66.13 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.176 -0.952 . . . . 0.0 109.548 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 58.8 p -90.06 -21.66 22.21 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.916 . . . . 0.0 109.575 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 78.03 -2.92 63.2 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.871 HG23 HD23 ' A' ' 36' ' ' LEU . 31.2 mm -72.71 71.33 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -1.123 . . . . 0.0 109.268 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 32.5 pttt -85.87 13.79 6.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.279 -0.888 . . . . 0.0 109.453 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.633 ' O ' HD13 ' A' ' 65' ' ' ILE . 29.7 m120 -110.37 -9.57 14.62 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.22 -0.925 . . . . 0.0 109.414 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 1.098 HD12 ' HB2' ' A' ' 70' ' ' ALA . 3.8 mm? -92.1 -51.5 5.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.309 -0.869 . . . . 0.0 109.297 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.697 HG12 HG21 ' A' ' 28' ' ' VAL . 13.7 p -92.03 141.89 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 108.956 179.672 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.96 -119.01 2.91 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 56.3 mtt180 -97.52 139.54 33.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.33 -1.1 . . . . 0.0 110.142 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 1.026 HG23 HG12 ' A' ' 62' ' ' VAL . 75.4 mt -111.55 134.34 54.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.427 -0.796 . . . . 0.0 109.088 179.522 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 1.03 HG23 ' HB2' ' A' ' 61' ' ' PHE . 29.8 m -123.8 148.77 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.005 -1.059 . . . . 0.0 109.311 179.803 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.666 HD11 ' HD2' ' A' ' 21' ' ' LYS . 1.8 mt -129.69 131.77 23.77 Favored Pre-proline 0 C--N 1.302 -1.486 0 O-C-N 121.346 -0.846 . . . . 0.0 109.703 -179.405 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.626 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 42.3 Cg_endo -64.61 -4.5 8.47 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.856 2.371 . . . . 0.0 111.285 179.7 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.868 HG23 ' HG2' ' A' ' 54' ' ' LYS . 39.5 mt . . . . . 0 N--CA 1.49 1.543 0 O-C-N 121.459 -0.776 . . . . 0.0 109.519 179.589 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.868 ' HG2' HG23 ' A' ' 44' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.626 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 14.3 tp -55.4 -47.69 75.5 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.007 -1.058 . . . . 0.0 109.152 179.723 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.747 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 75.3 m-85 -130.56 106.08 15.76 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.35 -0.844 . . . . 0.0 108.79 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 40.6 Cg_endo -64.11 144.46 87.22 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.627 2.218 . . . . 0.0 112.022 -179.152 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.15 -20.21 2.62 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 110.56 -1.016 . . . . 0.0 110.56 179.516 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.5 m-30 -98.05 129.71 44.89 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.569 -1.548 . . . . 0.0 110.626 -178.789 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 59.8 t -131.61 143.34 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 1.03 ' HB2' HG23 ' A' ' 41' ' ' VAL . 27.2 m-85 -104.58 129.27 52.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.879 -1.138 . . . . 0.0 110.137 -179.041 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 1.026 HG12 HG23 ' A' ' 40' ' ' ILE . 34.5 m -138.99 149.44 23.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.329 -0.857 . . . . 0.0 109.849 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.644 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 83.9 tt0 -113.79 130.14 56.49 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.319 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.508 ' HE1' HG11 ' A' ' 74' ' ' VAL . 61.4 mtm -151.32 160.83 43.58 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.858 -1.151 . . . . 0.0 111.184 -178.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.753 ' CG1' HD13 ' A' ' 36' ' ' LEU . 1.4 pt -80.87 125.61 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.44 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.415 ' O ' ' CG ' ' A' ' 67' ' ' ASN . 50.5 ttm -77.24 142.7 39.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.191 -0.943 . . . . 0.0 110.115 -178.533 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.415 ' CG ' ' O ' ' A' ' 66' ' ' MET . 7.6 m-20 176.2 168.47 0.44 Allowed 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -65.85 -40.52 91.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.069 -1.019 . . . . 0.0 109.578 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -75.97 -34.31 59.8 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.93 . . . . 0.0 109.858 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 1.098 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -71.76 -48.36 47.34 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.209 -0.932 . . . . 0.0 109.733 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.743 ' CG ' ' NE2' ' A' ' 89' ' ' GLN . 83.4 t80 -60.79 -44.44 96.82 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.946 -179.574 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -69.97 -26.14 63.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -0.942 . . . . 0.0 110.037 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -80.11 -36.07 35.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.074 -1.016 . . . . 0.0 109.849 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 1.046 HG23 ' O ' ' A' ' 70' ' ' ALA . 3.3 t -67.58 -56.28 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.224 -0.923 . . . . 0.0 109.976 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -47.46 -37.02 10.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.063 -1.023 . . . . 0.0 110.211 -179.528 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 m -70.95 2.99 3.67 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.015 -1.053 . . . . 0.0 110.419 -179.37 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.793 HG11 HD11 ' A' ' 24' ' ' ILE . 38.8 t -64.12 134.6 96.0 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 120.941 -1.099 . . . . 0.0 109.237 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.521 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 47.5 Cg_endo -67.85 135.55 35.72 Favored 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 122.715 2.277 . . . . 0.0 111.987 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.521 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 17.3 m-85 78.45 -5.05 2.1 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.432 -0.792 . . . . 0.0 109.712 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.604 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.7 t -85.11 123.96 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.054 -1.029 . . . . 0.0 109.296 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' MET . . . . . 0.494 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 66.0 mtp -82.4 -30.68 30.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.335 -0.853 . . . . 0.0 109.343 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.411 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.11 -157.34 27.97 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 0.487 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 7.9 m-85 -133.64 137.42 45.39 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.258 -1.143 . . . . 0.0 109.5 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.532 HG22 HD21 ' A' ' 11' ' ' LEU . 38.2 t -60.11 131.69 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.894 . . . . 0.0 109.48 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.542 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.7 OUTLIER -168.98 159.81 9.6 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.191 -0.943 . . . . 0.0 109.562 179.995 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.58 -35.46 16.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.307 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.58 -85.16 0.58 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.576 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -108.78 -134.08 7.05 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.303 -1.519 . . . . 0.0 109.303 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.743 ' NE2' ' CG ' ' A' ' 71' ' ' TYR . 2.1 mp0 -26.55 145.01 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.593 -0.945 . . . . 0.0 110.551 -179.533 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.542 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.4 Cg_endo -69.31 146.45 63.01 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.896 2.398 . . . . 0.0 111.991 -179.746 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.3 m -80.83 149.2 66.82 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.391 -0.818 . . . . 0.0 109.277 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.71 145.71 58.28 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.666 2.244 . . . . 0.0 111.78 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.921 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.9 t -65.4 144.62 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.196 -0.94 . . . . 0.0 109.382 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' LYS . . . . . 0.419 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.4 mttm -82.29 133.16 35.23 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.177 -0.952 . . . . 0.0 109.411 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.403 ' C ' ' O ' ' A' ' 94' ' ' LYS . 90.8 m-20 -45.99 -44.76 15.29 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.201 -0.937 . . . . 0.0 109.314 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.494 ' HG2' ' O ' ' A' ' 96' ' ' ARG . 34.4 ttm180 -58.51 -18.24 27.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.574 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.419 ' N ' ' O ' ' A' ' 94' ' ' LYS . 26.5 mt-10 -100.65 -26.45 13.81 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.24 -0.912 . . . . 0.0 109.571 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.527 ' SD ' HG11 ' A' ' 93' ' ' VAL . 50.1 mmm -78.37 -34.61 48.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.939 . . . . 0.0 109.334 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.581 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 2.5 mtt180 -33.45 -54.58 0.71 Allowed Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.588 -0.695 . . . . 0.0 110.228 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.581 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.1 Cg_endo -69.8 -29.46 23.63 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.55 2.167 . . . . 0.0 112.219 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.537 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 19.9 mm -78.7 -44.83 25.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.098 -1.001 . . . . 0.0 109.886 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.61 ' HA ' HD12 ' A' ' 107' ' ' LEU . 1.0 OUTLIER -62.83 -43.02 99.9 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.111 -0.993 . . . . 0.0 109.705 -179.877 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.406 ' NH2' ' NH2' ' A' ' 99' ' ' ARG . 46.3 mtt180 -62.3 -52.73 62.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -71.46 -37.59 71.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.393 -0.817 . . . . 0.0 109.279 179.736 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -67.87 -3.97 11.33 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.358 -0.838 . . . . 0.0 109.952 -179.755 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 78.09 5.24 87.01 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.957 HD11 HG11 ' A' ' 41' ' ' VAL . 61.6 mt -71.46 -19.69 62.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -1.148 . . . . 0.0 109.657 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' GLU . . . . . 0.422 ' HG3' ' HB3' ' A' ' 102' ' ' LEU . 83.9 mt-10 . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.223 -0.923 . . . . 0.0 109.517 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.607 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 22.0 m-30 . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 39.5 mttm -130.16 157.35 42.68 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 0.0 109.688 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 13.6 p -62.13 148.94 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.329 -0.857 . . . . 0.0 109.494 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.48 -30.37 3.1 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.666 -1.373 . . . . 0.0 109.666 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.589 ' HB2' HD12 ' A' ' 143' ' ' ILE . 68.6 m-20 -50.57 164.22 0.14 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.189 -1.183 . . . . 0.0 109.217 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.0 ttm -99.6 129.58 45.76 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.15 -0.969 . . . . 0.0 109.011 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.696 ' CG1' HD11 ' A' ' 143' ' ' ILE . 25.1 m -128.67 145.67 35.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.302 -0.874 . . . . 0.0 109.948 -179.836 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.465 ' HG3' ' O ' ' A' ' 139' ' ' PHE . 26.3 tttp -110.47 145.05 38.34 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.588 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.999 ' O ' HD13 ' A' ' 132' ' ' ILE . 64.7 mt -78.75 156.5 4.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.035 -1.041 . . . . 0.0 108.544 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.999 HD13 ' O ' ' A' ' 131' ' ' ILE . 0.7 OUTLIER -148.57 -3.98 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.131 -0.98 . . . . 0.0 108.966 179.54 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.4 m -148.67 146.42 28.15 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.339 -0.851 . . . . 0.0 110.11 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 104.55 -170.58 18.44 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.55 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 49.0 Cg_endo -68.97 -19.66 39.62 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 123.276 2.651 . . . . 0.0 112.508 -179.617 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.55 ' CD1' ' HG2' ' A' ' 135' ' ' PRO . 88.6 m-85 -109.09 9.41 26.25 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.975 -1.078 . . . . 0.0 109.747 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.843 ' HA ' HG22 ' A' ' 131' ' ' ILE . 0.7 OUTLIER -44.19 145.01 0.84 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 0.0 109.462 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.545 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 14.6 m-20 81.62 20.54 0.35 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.489 -0.757 . . . . 0.0 110.042 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.784 ' CB ' HD12 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -115.42 160.66 19.59 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.11 -0.993 . . . . 0.0 109.315 179.803 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.427 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -114.31 135.83 53.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.145 -0.972 . . . . 0.0 109.383 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.478 ' C ' ' CG2' ' A' ' 155' ' ' VAL . . . -147.98 169.88 28.69 Favored Glycine 0 N--CA 1.49 2.267 0 C-N-CA 119.655 -1.26 . . . . 0.0 110.181 -179.47 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.983 ' C ' HG23 ' A' ' 155' ' ' VAL . 94.8 t -109.89 134.46 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.62 -0.93 . . . . 0.0 109.319 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.696 HD11 ' CG1' ' A' ' 129' ' ' VAL . 67.8 mt -62.69 117.16 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.134 -0.979 . . . . 0.0 109.353 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.424 ' HG2' ' HG2' ' A' ' 145' ' ' GLU . 16.8 tttp -97.99 -35.86 10.31 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.164 -0.96 . . . . 0.0 109.422 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' GLU . . . . . 0.424 ' HG2' ' HG2' ' A' ' 144' ' ' LYS . 72.3 mm-40 -151.59 146.63 25.98 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.095 -1.003 . . . . 0.0 109.462 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.903 HG23 ' CG ' ' A' ' 153' ' ' LEU . 1.8 mt -122.44 125.34 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.576 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.68 102.35 44.47 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.203 -0.935 . . . . 0.0 109.603 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.546 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.6 Cg_endo -73.5 171.94 16.72 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.752 2.301 . . . . 0.0 111.846 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.546 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.0 tt0 80.57 -21.45 0.32 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.423 -0.798 . . . . 0.0 110.074 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.417 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 44.0 mtt85 -126.17 -12.48 6.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.053 -1.029 . . . . 0.0 109.323 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.417 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 42.2 mt-30 68.47 49.8 0.75 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.325 -0.86 . . . . 0.0 109.676 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.682 ' OE2' HG13 ' A' ' 167' ' ' VAL . 69.0 tt0 -123.01 146.35 47.71 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.048 -1.032 . . . . 0.0 108.747 179.515 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.903 ' CG ' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -142.51 113.93 7.83 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.119 -0.988 . . . . 0.0 110.511 -179.276 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 154' ' ' LYS . . . . . 0.691 ' HG2' HG22 ' A' ' 167' ' ' VAL . 27.1 mtmt -85.08 137.21 33.19 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.765 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.983 HG23 ' C ' ' A' ' 142' ' ' VAL . 1.8 p -136.72 133.19 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.007 -1.058 . . . . 0.0 110.034 -179.222 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.598 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.2 t-20 -67.02 125.95 27.62 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.396 -0.815 . . . . 0.0 109.689 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.564 HG12 HG13 ' A' ' 159' ' ' ILE . 43.7 t -107.59 147.46 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.275 -0.891 . . . . 0.0 109.057 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.683 ' O ' HG23 ' A' ' 158' ' ' THR . 9.4 t -97.4 112.18 24.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.343 -0.848 . . . . 0.0 109.986 -179.379 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.965 HG22 ' CD2' ' A' ' 160' ' ' PHE . 26.6 mt -138.17 137.29 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.357 -0.84 . . . . 0.0 109.183 179.298 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.965 ' CD2' HG22 ' A' ' 159' ' ' ILE . 99.7 m-85 60.86 42.34 13.29 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 108.963 -179.533 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.37 17.03 17.17 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.472 ' NH1' ' O ' ' A' ' 160' ' ' PHE . 22.5 mtt85 -126.49 147.55 49.81 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -1.184 . . . . 0.0 109.637 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 64.1 mm-40 -97.89 136.64 37.9 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 109.373 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 164' ' ' THR . . . . . 0.503 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 4.3 m -143.68 132.55 11.34 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.673 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.598 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 48.0 Cg_endo -68.88 131.21 21.98 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.792 2.328 . . . . 0.0 111.366 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.915 HG23 HD11 ' A' ' 168' ' ' LEU . 24.3 m -115.55 162.89 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.052 -1.03 . . . . 0.0 109.581 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.691 HG22 ' HG2' ' A' ' 154' ' ' LYS . 41.3 t -117.77 119.14 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.411 -0.806 . . . . 0.0 109.61 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.915 HD11 HG23 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -144.38 168.73 19.4 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.956 0.884 . . . . 0.0 110.503 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -80.65 139.41 36.22 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 7.9 p -53.7 -34.18 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.156 -0.965 . . . . 0.0 109.008 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 54.0 p -75.54 -4.33 39.26 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.394 -0.816 . . . . 0.0 109.539 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -103.97 1.85 31.66 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.072 -1.017 . . . . 0.0 109.644 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 173' ' ' VAL . . . . . 0.538 HG12 ' N ' ' A' ' 174' ' ' GLU . 49.5 t -131.35 162.99 38.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.146 -0.971 . . . . 0.0 109.626 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 174' ' ' GLU . . . . . 0.538 ' N ' HG12 ' A' ' 173' ' ' VAL . 76.3 tt0 -139.3 159.62 41.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -0.9 . . . . 0.0 109.344 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.607 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 21.7 tttm . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.146 -0.971 . . . . 0.0 109.283 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.5 mttt . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 21.6 mtpp -130.45 176.18 8.36 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.229 -0.92 . . . . 0.0 109.256 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' TRP . . . . . 0.702 ' CH2' HG23 ' A' ' 41' ' ' VAL . 39.7 m95 -109.67 124.11 50.63 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.236 -0.915 . . . . 0.0 109.126 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' TYR . . . . . 0.462 ' CE1' ' CE ' ' A' ' 66' ' ' MET . 95.4 m-85 -113.75 170.9 7.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.245 -0.909 . . . . 0.0 109.353 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.459 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 25.9 mt -119.2 106.84 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.232 -0.918 . . . . 0.0 109.417 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.487 ' CG2' HG23 ' A' ' 80' ' ' VAL . 0.2 OUTLIER -94.45 148.16 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.183 -0.948 . . . . 0.0 109.292 179.746 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.758 ' N ' HD22 ' A' ' 11' ' ' LEU . 3.2 mm? -95.37 145.93 24.76 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.382 -0.824 . . . . 0.0 109.817 -179.598 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.9 p -147.78 -177.96 6.01 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.415 -0.803 . . . . 0.0 109.264 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' MET . . . . . 0.569 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 54.8 mtm -89.9 116.92 28.33 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.157 -0.964 . . . . 0.0 109.489 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 13' ' ' MET . 18.1 t -42.89 125.57 3.51 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.248 -0.908 . . . . 0.0 109.296 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.47 -19.09 40.28 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.129 -1.588 . . . . 0.0 109.129 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' TYR . . . . . 0.569 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.7 m-85 -107.33 -10.14 15.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.446 -1.031 . . . . 0.0 109.465 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLU . . . . . 0.487 ' O ' ' N ' ' A' ' 20' ' ' VAL . 93.9 mt-10 -45.47 -66.66 0.37 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.201 -0.937 . . . . 0.0 109.37 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLU . . . . . 0.409 ' C ' ' O ' ' A' ' 17' ' ' GLU . 94.8 mt-10 -44.05 -35.79 2.26 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 109.302 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.43 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 22.9 mttm -71.58 -31.35 66.86 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.214 -0.929 . . . . 0.0 109.344 179.854 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.73 HG22 ' HB2' ' A' ' 79' ' ' TYR . 98.2 t -72.55 -45.47 58.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.224 -0.923 . . . . 0.0 109.356 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 28.8 tttm -55.82 -50.53 70.28 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.341 -0.849 . . . . 0.0 109.303 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -62.3 -37.33 85.12 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -0.895 . . . . 0.0 109.163 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.832 ' OD1' HG22 ' A' ' 77' ' ' VAL . 13.8 t-20 -62.23 -44.58 96.23 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.322 -0.861 . . . . 0.0 109.362 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.949 ' CD1' HG21 ' A' ' 77' ' ' VAL . 29.5 mm -56.11 -45.2 80.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 109.335 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -55.13 -45.46 75.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.229 -0.92 . . . . 0.0 109.657 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 46.7 mttp -76.17 -35.73 59.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.069 -1.02 . . . . 0.0 109.61 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 1.029 ' HD3' HG23 ' A' ' 77' ' ' VAL . 18.1 ttpt -55.07 -33.89 63.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.334 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.865 HG21 HG11 ' A' ' 37' ' ' VAL . 89.4 t -82.27 -24.44 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.288 -0.882 . . . . 0.0 109.601 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -67.85 -52.31 38.18 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.654 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.39 -27.12 65.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.249 -0.907 . . . . 0.0 109.933 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 47.4 p -97.58 -32.19 11.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.205 -0.934 . . . . 0.0 109.696 -179.653 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 79.44 24.01 61.7 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.643 ' O ' HG13 ' A' ' 28' ' ' VAL . 62.8 mt -94.65 87.32 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.217 -1.166 . . . . 0.0 109.444 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -87.4 -5.37 58.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.215 -0.928 . . . . 0.0 109.455 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 -102.14 16.46 26.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.269 -0.895 . . . . 0.0 109.628 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.929 HD11 ' CB ' ' A' ' 70' ' ' ALA . 7.2 tp -112.17 -58.12 2.18 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.263 -0.898 . . . . 0.0 109.4 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.865 HG11 HG21 ' A' ' 28' ' ' VAL . 9.0 p -95.87 134.35 33.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.427 -0.796 . . . . 0.0 109.423 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.21 -123.71 5.32 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 93.4 mtt180 -95.11 143.98 26.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.308 -1.113 . . . . 0.0 109.89 -179.473 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 1.01 HG23 HG22 ' A' ' 62' ' ' VAL . 18.9 mt -107.7 140.39 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.408 -0.807 . . . . 0.0 109.158 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 1.038 HG21 HD11 ' A' ' 107' ' ' LEU . 55.0 t -128.51 156.86 41.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.024 -1.048 . . . . 0.0 109.462 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.791 HG22 HG23 ' A' ' 44' ' ' ILE . 6.5 mt -136.72 127.19 16.23 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.367 -0.833 . . . . 0.0 109.469 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.517 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 46.3 Cg_endo -67.4 -4.71 12.37 Favored 'Trans proline' 0 C--O 1.216 -0.583 0 C-N-CA 122.824 2.349 . . . . 0.0 111.547 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.791 HG23 HG22 ' A' ' 42' ' ' ILE . 11.8 pt . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.248 -0.907 . . . . 0.0 109.474 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.71 ' HA ' HG22 ' A' ' 44' ' ' ILE . 24.5 mttt . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.635 HD23 ' HE2' ' A' ' 56' ' ' PHE . 14.5 tp -64.26 -23.73 67.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.161 -0.962 . . . . 0.0 109.132 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' PHE . . . . . 0.89 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 97.2 m-85 -149.96 99.0 3.31 Favored Pre-proline 0 N--CA 1.49 1.532 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -65.42 139.57 59.89 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.614 2.209 . . . . 0.0 111.979 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.07 -15.84 4.98 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.386 -1.085 . . . . 0.0 110.386 179.629 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.444 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.2 m-85 -95.73 129.87 42.81 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.759 -1.436 . . . . 0.0 110.205 -179.331 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 41.1 t -133.84 146.02 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.335 -0.853 . . . . 0.0 108.905 179.453 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.418 ' CE2' HG12 ' A' ' 9' ' ' ILE . 24.1 m-85 -110.31 122.47 47.76 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.955 -1.09 . . . . 0.0 109.521 -179.848 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 1.01 HG22 HG23 ' A' ' 40' ' ' ILE . 96.1 t -128.48 140.97 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.427 -0.795 . . . . 0.0 109.936 -179.632 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.596 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 67.6 tt0 -103.5 123.49 46.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.315 -0.865 . . . . 0.0 108.864 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.576 ' CG ' HG12 ' A' ' 62' ' ' VAL . 1.1 mtp -162.66 -174.61 4.04 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.102 -0.999 . . . . 0.0 109.778 -179.545 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.902 HG12 HD12 ' A' ' 36' ' ' LEU . 17.2 pt -97.26 122.95 49.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.236 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' MET . . . . . 0.462 ' CE ' ' CE1' ' A' ' 8' ' ' TYR . 11.1 ttm -88.16 100.31 12.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -0.885 . . . . 0.0 109.736 -179.406 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.438 ' H ' ' HB3' ' A' ' 70' ' ' ALA . 9.6 t30 -137.92 -165.75 1.84 Allowed 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.195 -0.941 . . . . 0.0 108.821 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -71.41 -48.72 47.96 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.14 -0.975 . . . . 0.0 109.681 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.403 ' O ' ' C ' ' A' ' 70' ' ' ALA . 73.9 mm-40 -66.64 -58.63 4.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.188 -0.945 . . . . 0.0 109.5 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.929 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -43.85 -41.51 5.14 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.293 -0.879 . . . . 0.0 109.718 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.541 ' CD1' ' CD ' ' A' ' 89' ' ' GLN . 72.2 t80 -61.05 -57.14 13.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.163 -0.961 . . . . 0.0 109.627 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' HB3' ' A' ' 76' ' ' SER . 38.2 t30 -52.87 -31.2 38.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.929 . . . . 0.0 110.0 -179.582 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -82.08 -44.15 16.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.96 -1.088 . . . . 0.0 109.923 -179.626 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 1.081 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 47.6 t -68.49 -56.91 10.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.357 -0.84 . . . . 0.0 109.625 -179.64 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ARG . . . . . 0.457 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 15.6 tpt180 -62.5 -11.92 19.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.165 -0.959 . . . . 0.0 109.966 -179.718 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.485 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 89.6 p -102.28 3.53 38.23 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.081 -1.012 . . . . 0.0 110.167 -179.645 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 1.033 ' O ' HG12 ' A' ' 80' ' ' VAL . 0.4 OUTLIER -69.05 142.27 92.92 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.031 -1.043 . . . . 0.0 109.273 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.664 ' HD2' HG22 ' A' ' 77' ' ' VAL . 45.2 Cg_endo -67.75 134.51 32.75 Favored 'Trans proline' 0 C--O 1.213 -0.768 0 C-N-CA 122.454 2.103 . . . . 0.0 111.876 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.73 ' HB2' HG22 ' A' ' 20' ' ' VAL . 13.1 m-85 89.32 -6.55 0.42 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.799 -0.563 . . . . 0.0 110.255 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 1.033 HG12 ' O ' ' A' ' 77' ' ' VAL . 12.4 p -88.33 126.98 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.752 -1.218 . . . . 0.0 109.643 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.4 mmm -90.78 -26.36 19.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.32 -0.863 . . . . 0.0 109.335 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLY . . . . . 0.57 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 161.47 -160.34 32.14 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' PHE . . . . . 1.081 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 10.8 m-85 -134.76 156.38 48.94 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.191 -1.182 . . . . 0.0 109.562 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 84' ' ' VAL . 12.5 p -91.71 125.35 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.248 -0.908 . . . . 0.0 109.385 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.574 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.6 OUTLIER -168.87 166.79 11.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.13 -0.981 . . . . 0.0 109.568 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 25.5 t -86.18 -32.97 20.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.238 -0.914 . . . . 0.0 109.427 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -117.42 -106.82 2.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.516 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -96.67 -122.09 4.16 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' GLN . . . . . 0.541 ' CD ' ' CD1' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -34.55 156.11 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.533 -0.981 . . . . 0.0 110.044 -179.659 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.574 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.0 Cg_endo -68.75 149.21 72.91 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.839 2.359 . . . . 0.0 111.994 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.0 m -83.89 154.97 64.74 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 109.436 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.525 ' HB3' ' CE ' ' A' ' 6' ' ' LYS . 49.9 Cg_endo -70.16 142.94 47.46 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.677 2.251 . . . . 0.0 111.673 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.512 HG12 ' HB2' ' A' ' 97' ' ' GLU . 18.6 t -82.3 139.07 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.304 -0.873 . . . . 0.0 109.433 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' LYS . . . . . 0.467 ' O ' ' N ' ' A' ' 97' ' ' GLU . 7.3 tptt -70.74 131.78 44.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.182 -0.949 . . . . 0.0 109.289 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ASP . . . . . 0.402 ' C ' ' O ' ' A' ' 94' ' ' LYS . 87.3 m-20 -45.22 -39.52 6.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.178 -0.952 . . . . 0.0 109.436 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.4 mtp180 -61.03 -23.45 65.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.308 -0.87 . . . . 0.0 109.475 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.512 ' HB2' HG12 ' A' ' 93' ' ' VAL . 62.9 mt-10 -85.83 -28.38 24.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.913 . . . . 0.0 109.422 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' MET . . . . . 0.612 ' HE3' ' CB ' ' A' ' 7' ' ' TRP . 59.0 mtp -84.14 -24.8 30.07 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.365 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.593 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -37.46 -53.53 2.31 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.425 -0.797 . . . . 0.0 109.866 -179.952 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.4 Cg_endo -69.83 -27.55 25.98 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 122.525 2.15 . . . . 0.0 111.878 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.418 ' N ' ' O ' ' A' ' 98' ' ' MET . 37.4 mm -81.19 -42.94 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.178 -0.951 . . . . 0.0 109.304 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' LEU . . . . . 0.868 HD12 HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -65.8 -38.97 90.41 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.275 -0.891 . . . . 0.0 109.297 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.482 ' HD3' ' HB3' ' A' ' 135' ' ' PRO . 16.1 ttt-85 -65.66 -47.7 74.63 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.334 -0.854 . . . . 0.0 109.279 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.429 HD23 ' C ' ' A' ' 104' ' ' LEU . 3.0 tt -72.12 -36.31 69.38 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.215 -0.928 . . . . 0.0 109.227 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -75.25 -2.22 27.08 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.44 -0.788 . . . . 0.0 109.81 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.9 15.79 81.34 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 1.038 HD11 HG21 ' A' ' 41' ' ' VAL . 23.5 mt -81.84 -23.27 36.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.16 -1.2 . . . . 0.0 109.666 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' GLU . . . . . 0.466 ' HG2' ' HB3' ' A' ' 102' ' ' LEU . 68.2 mm-40 . . . . . 0 N--CA 1.491 1.581 0 O-C-N 121.158 -0.964 . . . . 0.0 109.327 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' PHE . . . . . 0.561 ' CD2' ' O ' ' A' ' 123' ' ' PHE . 42.5 p90 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' LYS . . . . . 0.686 ' C ' HD11 ' A' ' 146' ' ' ILE . 14.7 mttp -141.14 175.12 9.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.181 -0.949 . . . . 0.0 109.918 -179.58 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' VAL . . . . . 0.584 HG23 ' O ' ' A' ' 144' ' ' LYS . 10.8 p -62.51 139.62 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.529 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.13 -34.8 3.68 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' ASP . . . . . 0.452 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 9.5 m-20 -45.92 158.97 0.08 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.336 -1.096 . . . . 0.0 109.209 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.8 ttm -99.77 127.49 45.92 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.075 -1.016 . . . . 0.0 108.799 179.553 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.609 HG13 HG12 ' A' ' 143' ' ' ILE . 15.4 m -128.51 144.87 36.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.32 -0.862 . . . . 0.0 109.735 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' LYS . . . . . 0.412 ' HE3' ' CG2' ' A' ' 132' ' ' ILE . 32.5 ttpt -98.78 141.06 32.05 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.618 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.931 HD12 ' HB3' ' A' ' 139' ' ' PHE . 78.5 mt -82.84 151.09 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.209 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' ILE . . . . . 0.498 HG12 ' HA ' ' A' ' 173' ' ' VAL . 1.1 pt -149.66 3.64 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 120.923 -1.111 . . . . 0.0 109.957 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 69.9 m -148.26 143.52 27.02 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.846 -1.159 . . . . 0.0 109.983 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.67 -163.9 18.7 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' PRO . . . . . 0.482 ' HB3' ' HD3' ' A' ' 103' ' ' ARG . 46.4 Cg_endo -67.38 -23.18 44.58 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 123.167 2.578 . . . . 0.0 112.952 -179.28 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.528 ' CE1' ' CB ' ' A' ' 100' ' ' PRO . 97.1 m-85 -109.14 19.38 19.55 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.787 -1.196 . . . . 0.0 109.713 -179.765 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' GLU . . . . . 0.621 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.3 tt0 -45.51 139.09 3.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.15 -0.969 . . . . 0.0 109.506 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.511 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 17.7 m-20 74.41 28.23 1.34 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.459 -0.776 . . . . 0.0 110.437 179.41 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' PHE . . . . . 0.931 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.8 t80 -117.08 140.01 50.02 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.96 -1.087 . . . . 0.0 109.45 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.74 132.94 34.04 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.116 -0.99 . . . . 0.0 109.664 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.57 168.91 27.23 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.775 -1.203 . . . . 0.0 110.304 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.916 ' C ' HG23 ' A' ' 155' ' ' VAL . 41.0 t -117.9 137.07 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.634 -0.921 . . . . 0.0 109.348 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' ILE . . . . . 0.609 HG12 HG13 ' A' ' 129' ' ' VAL . 25.0 mm -69.85 119.23 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.873 . . . . 0.0 109.532 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' LYS . . . . . 0.584 ' O ' HG23 ' A' ' 125' ' ' VAL . 0.2 OUTLIER -97.76 -31.69 12.12 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.026 -1.046 . . . . 0.0 109.04 179.546 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -151.11 146.17 25.97 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.266 -0.896 . . . . 0.0 109.283 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 1.051 HG23 HD22 ' A' ' 153' ' ' LEU . 4.0 mt -121.58 126.21 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.141 -0.974 . . . . 0.0 109.545 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.92 100.08 38.13 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.449 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.4 Cg_endo -71.14 173.28 12.42 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.706 2.271 . . . . 0.0 111.821 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.2 tt0 79.52 -21.58 0.32 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.325 -0.86 . . . . 0.0 110.184 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 150' ' ' ARG . . . . . 0.44 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 83.9 mtt-85 -127.5 -12.77 5.53 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.045 -1.035 . . . . 0.0 109.6 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 151' ' ' GLN . . . . . 0.882 ' O ' HG23 ' A' ' 170' ' ' VAL . 49.8 mt-30 69.52 47.04 0.69 Allowed 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.348 -0.845 . . . . 0.0 109.704 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 152' ' ' GLU . . . . . 0.742 ' O ' HD23 ' A' ' 153' ' ' LEU . 40.8 tt0 -118.21 143.85 46.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.08 -1.012 . . . . 0.0 108.659 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 1.051 HD22 HG23 ' A' ' 146' ' ' ILE . 35.3 mt -133.56 122.82 24.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.996 -1.065 . . . . 0.0 110.616 -179.38 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 9.5 mttt -86.55 130.93 34.31 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 178.573 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.916 HG23 ' C ' ' A' ' 142' ' ' VAL . 7.3 p -133.65 149.77 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.087 -1.008 . . . . 0.0 109.8 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.565 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 43.3 t-20 -98.75 123.61 43.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.29 -0.881 . . . . 0.0 109.329 179.857 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 157' ' ' VAL . . . . . 0.557 HG13 ' CE1' ' A' ' 139' ' ' PHE . 63.9 t -105.39 146.86 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.198 -0.939 . . . . 0.0 109.663 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 25.9 m -94.9 104.05 15.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.245 -0.91 . . . . 0.0 109.633 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 159' ' ' ILE . . . . . 0.89 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 7.0 pt -139.65 149.12 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -0.896 . . . . 0.0 109.38 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 160' ' ' PHE . . . . . 0.658 ' CE2' HD12 ' A' ' 159' ' ' ILE . 11.1 m-30 61.35 36.99 17.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.261 -0.899 . . . . 0.0 109.141 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.52 13.7 17.99 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 162' ' ' ARG . . . . . 0.424 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 3.3 mtp-105 -134.11 159.01 42.14 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.059 -1.259 . . . . 0.0 109.601 -179.844 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 163' ' ' GLU . . . . . 0.478 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 81.7 mt-10 -99.73 140.12 34.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.253 -0.905 . . . . 0.0 109.399 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 164' ' ' THR . . . . . 0.553 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 22.6 m -146.55 129.93 8.23 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.785 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 165' ' ' PRO . . . . . 0.565 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.7 Cg_endo -71.14 139.29 35.22 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.736 2.29 . . . . 0.0 111.437 179.676 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 166' ' ' VAL . . . . . 0.966 HG13 HD11 ' A' ' 168' ' ' LEU . 2.9 p -124.93 143.86 36.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.088 -1.007 . . . . 0.0 109.627 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.576 HG13 ' O ' ' A' ' 167' ' ' VAL . 14.6 p -96.13 120.75 45.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.408 -0.807 . . . . 0.0 109.533 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 168' ' ' LEU . . . . . 0.966 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -141.4 168.71 19.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.113 -0.992 . . . . 0.0 110.54 -179.52 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 169' ' ' HIS . . . . . 0.468 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 72.1 m80 -83.19 143.26 30.59 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.648 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.891 HG22 ' HG ' ' A' ' 153' ' ' LEU . 71.9 t -52.82 -38.39 27.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 84.6 p -75.23 -6.97 52.51 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.492 -0.755 . . . . 0.0 110.06 -179.466 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 172' ' ' GLU . . . . . 0.468 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 80.4 mt-10 -91.12 -5.46 55.06 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.828 -1.17 . . . . 0.0 109.822 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 173' ' ' VAL . . . . . 0.498 ' HA ' HG12 ' A' ' 132' ' ' ILE . 2.8 m -139.48 175.36 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.152 -0.967 . . . . 0.0 109.439 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 57.5 tt0 -138.17 163.03 32.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.196 -0.94 . . . . 0.0 109.045 179.834 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 175' ' ' LYS . . . . . 0.483 ' CE ' ' CB ' ' A' ' 123' ' ' PHE . 25.2 mmtm . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.088 -1.007 . . . . 0.0 109.246 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -57.23 -40.19 77.05 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.204 -1.174 . . . . 0.0 109.484 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 76.4 mtm -51.37 -44.04 62.02 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.17 -0.956 . . . . 0.0 109.522 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 15.0 mmtt -92.43 144.01 25.8 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.22 -0.925 . . . . 0.0 109.461 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.664 ' HG2' HG22 ' A' ' 65' ' ' ILE . 56.5 mttt -103.43 141.71 35.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.507 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.61 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.2 mttp -125.82 174.51 8.3 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.222 -0.924 . . . . 0.0 109.126 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.683 ' CH2' HG23 ' A' ' 41' ' ' VAL . 60.0 m95 -109.9 126.66 54.11 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.132 -0.98 . . . . 0.0 109.346 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -118.74 167.39 11.72 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.211 -0.931 . . . . 0.0 109.415 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.53 HD11 ' CE1' ' A' ' 160' ' ' PHE . 95.1 mt -103.25 118.77 50.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.195 -0.94 . . . . 0.0 109.314 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.464 HG23 HG12 ' A' ' 62' ' ' VAL . 85.3 t -90.46 137.32 21.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.466 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.486 ' CD2' ' CG2' ' A' ' 84' ' ' VAL . 0.1 OUTLIER -89.62 141.75 28.31 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.276 -0.89 . . . . 0.0 109.245 179.875 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.527 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.2 t -157.15 -172.48 4.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.23 -0.918 . . . . 0.0 109.358 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.496 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 90.9 mtp -105.56 123.62 48.2 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.2 -0.937 . . . . 0.0 109.516 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.422 ' C ' ' O ' ' A' ' 13' ' ' MET . 9.2 t -43.07 127.07 4.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.299 -0.875 . . . . 0.0 109.397 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.74 -19.85 40.5 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.496 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.2 m-85 -108.47 3.54 23.28 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.239 -1.153 . . . . 0.0 109.64 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.527 ' HG2' HG21 ' A' ' 12' ' ' THR . 98.4 mt-10 -57.92 -59.33 5.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -47.71 -38.11 14.53 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.218 -0.926 . . . . 0.0 109.403 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 24.7 mttt -68.8 -43.66 75.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.282 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 16' ' ' TYR . 89.6 t -58.96 -46.53 91.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 109.566 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.819 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.4 tttm -56.94 -49.8 74.55 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.219 -0.925 . . . . 0.0 109.548 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -64.83 -43.19 93.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.196 -0.94 . . . . 0.0 109.407 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.486 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 14.8 m120 -54.92 -39.77 69.18 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.222 -0.924 . . . . 0.0 109.391 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.813 HG21 HD11 ' A' ' 40' ' ' ILE . 95.1 mt -65.62 -44.04 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.3 -0.875 . . . . 0.0 109.624 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -55.84 -48.22 75.86 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.07 -1.019 . . . . 0.0 109.947 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 42.9 mttm -78.41 -35.34 47.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.093 -1.004 . . . . 0.0 109.612 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.579 ' HG3' ' CE1' ' A' ' 73' ' ' PHE . 10.7 tptt -53.25 -33.0 51.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.247 -0.908 . . . . 0.0 109.13 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.756 HG13 ' C ' ' A' ' 33' ' ' ILE . 22.3 t -89.52 -19.89 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.342 -0.849 . . . . 0.0 109.287 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -72.64 -57.64 3.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.564 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.69 -29.9 66.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.895 . . . . 0.0 109.437 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.419 ' HB ' HG13 ' A' ' 33' ' ' ILE . 80.7 p -96.6 -3.02 43.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.237 -0.915 . . . . 0.0 109.477 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 50.02 30.17 15.82 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.045 HG21 HD12 ' A' ' 36' ' ' LEU . 21.6 mt -98.3 72.04 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.248 -1.148 . . . . 0.0 109.519 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 mttp -90.49 20.36 4.62 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.266 -0.896 . . . . 0.0 109.505 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.755 ' O ' HD13 ' A' ' 65' ' ' ILE . 81.4 m-20 -111.27 -23.04 11.06 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.189 -0.944 . . . . 0.0 109.525 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.045 HD12 HG21 ' A' ' 33' ' ' ILE . 18.9 mt -88.36 -31.23 19.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.29 -0.882 . . . . 0.0 109.76 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.414 ' HB ' HG21 ' A' ' 28' ' ' VAL . 93.4 t -108.19 142.87 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.179 -0.951 . . . . 0.0 109.376 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.86 -121.88 3.17 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -92.91 140.92 28.99 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.28 -1.13 . . . . 0.0 109.838 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.881 HG12 HG23 ' A' ' 62' ' ' VAL . 85.2 mt -108.91 134.64 50.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.336 -0.853 . . . . 0.0 109.084 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 1.059 ' CG2' HD11 ' A' ' 107' ' ' LEU . 28.7 t -121.68 159.34 24.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.074 -1.016 . . . . 0.0 109.412 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.953 HG22 HG23 ' A' ' 44' ' ' ILE . 2.9 mt -140.44 127.62 12.28 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.292 -0.88 . . . . 0.0 109.479 -179.852 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.635 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 45.2 Cg_endo -66.72 -5.93 14.32 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.799 2.333 . . . . 0.0 111.391 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.953 HG23 HG22 ' A' ' 42' ' ' ILE . 6.1 pt -73.18 -46.01 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.398 -0.814 . . . . 0.0 109.374 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.849 ' O ' HD21 ' A' ' 104' ' ' LEU . 93.3 mtt-85 -49.86 134.33 21.1 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.414 -0.804 . . . . 0.0 109.57 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -137.75 -175.39 13.84 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.73 150.08 50.06 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 62.9 tt0 -61.33 -31.89 71.77 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -1.134 . . . . 0.0 109.4 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 42.5 mtp180 -61.47 -38.38 87.03 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.256 -0.903 . . . . 0.0 109.463 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 80.9 mtt85 -147.41 138.37 23.61 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.224 -0.923 . . . . 0.0 109.44 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 19.8 tttp -103.22 124.49 48.72 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.297 -0.877 . . . . 0.0 109.483 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.409 ' O ' ' HB3' ' A' ' 53' ' ' GLU . 91.5 p -62.87 -17.88 62.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.271 -0.893 . . . . 0.0 109.484 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.51 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 80.5 tt0 64.35 52.93 1.78 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.226 -0.921 . . . . 0.0 109.474 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.715 ' HA ' HG22 ' A' ' 44' ' ' ILE . 5.3 mttp 75.72 88.25 0.08 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.31 -0.869 . . . . 0.0 109.5 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 1.025 HD12 ' CE2' ' A' ' 56' ' ' PHE . 0.6 OUTLIER -56.88 -45.82 82.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -0.962 . . . . 0.0 109.235 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 1.025 ' CE2' HD12 ' A' ' 55' ' ' LEU . 85.2 m-85 -125.25 111.94 26.29 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.937 . . . . 0.0 109.08 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.6 Cg_endo -66.28 133.77 33.92 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.573 2.182 . . . . 0.0 111.985 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.419 ' HA2' HG23 ' A' ' 12' ' ' THR . . . 74.46 -11.97 6.31 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.2 m-30 -99.82 131.29 45.89 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.649 -1.501 . . . . 0.0 110.258 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 42.5 t -134.25 148.77 29.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.671 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 17.0 m-85 -108.38 124.44 50.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.887 -1.133 . . . . 0.0 109.733 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.881 HG23 HG12 ' A' ' 40' ' ' ILE . 14.3 p -134.13 145.54 32.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.353 -0.842 . . . . 0.0 109.804 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.61 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 18.4 tt0 -108.51 127.3 53.81 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.632 ' CE ' HG11 ' A' ' 74' ' ' VAL . 58.7 mtm -151.93 163.68 38.73 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 118.954 -1.098 . . . . 0.0 111.022 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.755 HD13 ' O ' ' A' ' 35' ' ' ASN . 3.3 pt -85.87 126.9 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.485 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 47.7 ttm -75.34 141.48 43.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.83 -178.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.485 ' HB2' ' O ' ' A' ' 66' ' ' MET . 47.0 t30 176.4 175.36 0.32 Allowed 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 -179.708 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -72.12 -40.85 67.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.168 -0.957 . . . . 0.0 109.593 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -72.46 -32.06 65.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.234 -0.916 . . . . 0.0 109.75 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.912 ' HB2' HD22 ' A' ' 36' ' ' LEU . . . -71.71 -47.3 54.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.193 -0.942 . . . . 0.0 109.818 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 67.9 t80 -60.36 -49.33 78.01 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.154 -0.966 . . . . 0.0 109.682 -179.739 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -63.14 -28.89 70.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.088 -1.007 . . . . 0.0 110.314 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CE1' ' HG3' ' A' ' 27' ' ' LYS . 46.3 t80 -80.72 -41.42 23.62 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.007 -1.058 . . . . 0.0 109.819 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.716 HG22 ' O ' ' A' ' 70' ' ' ALA . 20.1 m -70.68 -53.24 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.242 -0.911 . . . . 0.0 109.405 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.61 ' N ' HG23 ' A' ' 74' ' ' VAL . 33.0 tpt85 -52.14 -32.46 35.71 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.208 -0.932 . . . . 0.0 109.577 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 51.7 p -79.64 7.05 9.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.366 -0.834 . . . . 0.0 109.917 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.66 HG23 ' O ' ' A' ' 74' ' ' VAL . 47.0 t -64.25 133.82 95.76 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.103 -0.998 . . . . 0.0 109.484 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.556 ' HB2' ' CD2' ' A' ' 79' ' ' TYR . 46.9 Cg_endo -68.2 136.9 38.88 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.68 2.253 . . . . 0.0 111.845 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.556 ' CD2' ' HB2' ' A' ' 78' ' ' PRO . 47.2 m-85 76.05 -1.94 2.85 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.418 -0.801 . . . . 0.0 109.623 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.603 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 2.8 t -87.86 127.76 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.129 -0.982 . . . . 0.0 109.273 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.1 mmm -89.02 -5.8 57.66 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.643 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 135.09 -152.8 20.9 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -143.14 141.7 31.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -1.213 . . . . 0.0 109.48 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.486 ' CG2' ' CD2' ' A' ' 11' ' ' LEU . 38.8 t -63.55 128.5 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.515 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 6.9 p -162.84 161.77 26.14 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.257 -0.902 . . . . 0.0 109.507 -179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 m -88.74 -35.61 16.61 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -123.58 -87.71 0.81 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.524 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -105.32 -128.38 6.17 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.524 ' O ' ' O ' ' A' ' 88' ' ' GLY . 6.8 pm0 -34.26 155.98 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.586 -0.949 . . . . 0.0 110.115 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.515 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.4 Cg_endo -69.62 160.12 50.92 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.578 2.185 . . . . 0.0 112.081 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 20.6 m -98.84 154.0 37.59 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.349 -0.844 . . . . 0.0 109.455 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.457 ' CB ' ' HD3' ' A' ' 6' ' ' LYS . 49.6 Cg_endo -70.35 147.64 59.53 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.693 2.262 . . . . 0.0 111.809 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 7' ' ' TRP . 21.3 t -85.4 142.44 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.219 -0.926 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' LYS . . . . . 0.467 ' HB3' ' HG3' ' A' ' 97' ' ' GLU . 81.1 tttt -67.66 126.24 28.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -0.9 . . . . 0.0 109.453 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 94' ' ' LYS . 47.3 t0 -43.67 -45.35 6.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.408 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.432 ' HD2' ' NZ ' ' A' ' 94' ' ' LYS . 57.4 mtt180 -55.42 -31.28 61.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.237 -0.914 . . . . 0.0 109.51 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.467 ' HG3' ' HB3' ' A' ' 94' ' ' LYS . 57.3 mt-10 -79.22 -24.45 43.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.262 -0.899 . . . . 0.0 109.662 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.628 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 75.7 mtp -84.53 -23.71 29.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.157 -0.964 . . . . 0.0 109.352 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.609 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 57.3 mtt180 -37.53 -52.55 2.52 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.351 -0.843 . . . . 0.0 109.919 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.609 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -69.39 -28.25 27.27 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.546 2.164 . . . . 0.0 111.989 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.54 HG21 ' CD2' ' A' ' 61' ' ' PHE . 24.4 mm -81.95 -41.18 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 109.361 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 1.022 HD12 HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -68.95 -41.44 78.0 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.198 -0.938 . . . . 0.0 109.136 179.816 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.449 ' HD3' ' CD2' ' A' ' 110' ' ' TYR . 21.4 tpt85 -63.25 -49.49 73.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.861 . . . . 0.0 108.989 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.849 HD21 ' O ' ' A' ' 45' ' ' ARG . 0.5 OUTLIER -72.66 -36.29 67.92 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.369 -0.832 . . . . 0.0 109.208 179.703 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.524 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.85 -0.47 9.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.436 -0.79 . . . . 0.0 109.94 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.34 7.79 85.21 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 1.059 HD11 ' CG2' ' A' ' 41' ' ' VAL . 53.5 mt -77.28 -19.97 55.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.28 -1.13 . . . . 0.0 109.446 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 36.1 tp10 -144.23 131.51 20.76 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.217 -0.927 . . . . 0.0 109.557 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -119.55 113.9 21.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.362 -0.836 . . . . 0.0 109.428 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.449 ' CD2' ' HD3' ' A' ' 103' ' ' ARG . 42.0 p90 -125.55 171.13 10.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.223 -0.923 . . . . 0.0 109.545 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 112' ' ' GLU . 94.2 mt-10 -100.33 -92.9 0.28 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.491 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.406 ' C ' ' O ' ' A' ' 111' ' ' GLU . 58.2 tt0 44.45 74.51 0.12 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.191 -0.943 . . . . 0.0 109.512 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 16.2 pttp -163.03 39.04 0.1 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.458 ' O ' ' HG3' ' A' ' 114' ' ' LYS . 7.1 pttp -101.73 33.29 3.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.235 -0.916 . . . . 0.0 109.338 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.87 57.57 30.49 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.2 82.44 0.85 Allowed 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.681 2.254 . . . . 0.0 111.759 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 28.1 t -127.49 128.68 70.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.168 -0.958 . . . . 0.0 109.566 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.571 ' HA ' ' CB ' ' A' ' 171' ' ' SER . 12.3 mttp -85.33 137.09 33.18 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.293 -0.879 . . . . 0.0 109.499 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 82.5 t -107.78 139.57 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.444 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.569 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 95.0 mt-10 -150.41 170.47 18.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.301 -0.874 . . . . 0.0 109.465 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.569 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 0.3 OUTLIER 79.92 161.48 0.18 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.391 -0.818 . . . . 0.0 109.613 179.966 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . 42.97 31.06 1.12 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.583 ' HB3' ' CD ' ' A' ' 175' ' ' LYS . 45.6 p90 -110.64 124.01 51.08 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.276 -1.132 . . . . 0.0 109.175 179.617 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.461 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 37.6 mttt -150.64 156.98 42.43 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.072 -1.018 . . . . 0.0 109.972 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.467 HG23 ' O ' ' A' ' 144' ' ' LYS . 14.1 p -62.93 143.99 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.389 -0.819 . . . . 0.0 109.556 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.49 -32.21 3.41 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.437 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 7.5 m-20 -48.67 163.82 0.07 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.359 -1.083 . . . . 0.0 109.144 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.0 ttm -95.57 126.4 40.83 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.182 -0.949 . . . . 0.0 109.066 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.615 HG11 ' CD1' ' A' ' 143' ' ' ILE . 5.1 p -124.21 141.93 42.71 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.192 -0.943 . . . . 0.0 109.215 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.408 ' N ' ' O ' ' A' ' 174' ' ' GLU . 12.6 ttpp -107.57 143.34 36.13 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.113 -0.992 . . . . 0.0 109.049 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 1.002 HD12 ' HB3' ' A' ' 139' ' ' PHE . 96.5 mt -83.96 152.46 3.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.127 -0.983 . . . . 0.0 108.798 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.473 ' C ' ' HG2' ' A' ' 137' ' ' GLU . 27.4 pt -150.8 2.26 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.056 -1.028 . . . . 0.0 109.606 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.515 ' HA ' ' HG2' ' A' ' 137' ' ' GLU . 2.5 m -145.42 141.35 28.33 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.146 -0.972 . . . . 0.0 109.665 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.443 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 107.5 -170.75 15.77 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.436 ' HA ' ' HG2' ' A' ' 103' ' ' ARG . 49.7 Cg_endo -69.03 -18.66 40.31 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 123.338 2.692 . . . . 0.0 112.57 -179.606 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.608 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 97.8 m-85 -107.53 15.31 24.93 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.969 -1.082 . . . . 0.0 109.561 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.515 ' HG2' ' HA ' ' A' ' 133' ' ' SER . 35.1 mt-10 -38.45 142.24 0.2 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.417 -0.802 . . . . 0.0 110.148 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 138' ' ' ASP . 0.3 OUTLIER 76.53 20.34 1.47 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.333 -0.854 . . . . 0.0 110.743 178.991 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 1.002 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.0 OUTLIER -108.37 131.17 55.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.831 -1.168 . . . . 0.0 109.623 179.901 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -84.97 134.3 34.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.155 -0.966 . . . . 0.0 109.508 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.59 167.89 26.48 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.8 -1.19 . . . . 0.0 110.269 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.524 ' C ' HG13 ' A' ' 155' ' ' VAL . 40.9 t -108.89 136.3 45.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.452 -1.028 . . . . 0.0 109.226 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.615 ' CD1' HG11 ' A' ' 129' ' ' VAL . 18.4 mm -67.38 114.85 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.259 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.467 ' O ' HG23 ' A' ' 125' ' ' VAL . 64.4 tttm -97.25 -34.37 11.12 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.088 -1.007 . . . . 0.0 109.482 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -151.75 146.75 25.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.14 -0.975 . . . . 0.0 109.613 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.837 HG23 ' CD2' ' A' ' 153' ' ' LEU . 1.5 mt -120.06 123.7 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.333 -0.854 . . . . 0.0 109.304 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -107.3 98.14 21.78 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.655 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.553 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.8 Cg_endo -71.66 173.86 11.93 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.721 2.281 . . . . 0.0 111.779 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.553 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.0 tt0 80.53 -21.07 0.34 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.345 -0.847 . . . . 0.0 109.879 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.445 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 47.5 mtt85 -128.75 -11.88 4.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.111 -0.993 . . . . 0.0 109.45 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.786 ' O ' HG23 ' A' ' 170' ' ' VAL . 31.9 mt-30 69.26 48.25 0.67 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.277 -0.89 . . . . 0.0 109.774 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -122.34 146.08 47.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.132 -0.98 . . . . 0.0 108.87 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.837 ' CD2' HG23 ' A' ' 146' ' ' ILE . 0.4 OUTLIER -135.62 122.47 21.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.101 -1.0 . . . . 0.0 110.565 -179.398 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 5.8 mtmm -81.91 130.97 35.24 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.605 HG11 ' CG1' ' A' ' 129' ' ' VAL . 4.2 t -128.46 147.93 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.961 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.548 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 4.4 t30 -97.14 113.02 24.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.392 -0.817 . . . . 0.0 109.26 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.757 HG13 ' CE1' ' A' ' 139' ' ' PHE . 67.7 t -94.39 141.62 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.241 -0.912 . . . . 0.0 109.642 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 60.1 m -94.2 95.71 9.13 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.383 -0.823 . . . . 0.0 109.63 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.561 HG22 ' CD2' ' A' ' 160' ' ' PHE . 5.4 mt -121.72 141.37 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.253 -0.905 . . . . 0.0 109.581 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.671 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 96.6 m-85 61.26 41.26 13.5 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.847 . . . . 0.0 109.523 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.33 16.81 22.31 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 18.5 mtp85 -129.71 151.71 50.0 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.154 -1.203 . . . . 0.0 109.575 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.486 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 73.4 mt-10 -95.97 136.73 36.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.249 -0.907 . . . . 0.0 109.506 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 16.3 m -145.44 128.33 8.22 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.618 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.548 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.2 Cg_endo -70.24 136.67 32.28 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.757 2.304 . . . . 0.0 111.618 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.713 HG13 HD11 ' A' ' 168' ' ' LEU . 3.7 p -123.23 142.86 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.14 -0.975 . . . . 0.0 109.559 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.457 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 6.3 m -92.83 119.19 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.413 -0.805 . . . . 0.0 109.485 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.713 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -142.12 167.9 21.02 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.238 -0.914 . . . . 0.0 110.384 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.506 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 47.8 m170 -82.27 141.01 33.3 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 151' ' ' GLN . 59.5 t -53.94 -36.78 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.185 -0.947 . . . . 0.0 108.893 179.697 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.571 ' CB ' ' HA ' ' A' ' 118' ' ' LYS . 7.1 p -75.16 -6.77 51.36 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.561 -0.712 . . . . 0.0 109.812 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.506 ' CG ' ' HB2' ' A' ' 169' ' ' HIS . 92.7 mt-10 -96.17 -3.39 44.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.083 -1.011 . . . . 0.0 109.866 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.7 m -133.45 170.68 19.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.106 -0.997 . . . . 0.0 109.993 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.568 ' O ' ' CG2' ' A' ' 129' ' ' VAL . 25.6 tp10 -127.56 144.01 51.11 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.583 ' CD ' ' HB3' ' A' ' 123' ' ' PHE . 9.7 mttp -98.78 30.06 3.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.069 -1.019 . . . . 0.0 109.567 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.444 ' C ' ' O ' ' A' ' 175' ' ' LYS . 27.4 mt 41.85 -95.35 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.328 -0.857 . . . . 0.0 109.636 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.512 ' N ' ' O ' ' A' ' 175' ' ' LYS . 85.4 tt0 . . . . . 0 N--CA 1.488 1.47 0 CA-C-O 117.98 -1.009 . . . . 0.0 109.493 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -61.94 -28.85 69.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -1.156 . . . . 0.0 109.43 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 44.6 ttm -61.55 -23.05 65.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.314 -0.866 . . . . 0.0 109.443 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.1 tttt -95.26 120.22 35.12 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.359 -0.838 . . . . 0.0 109.464 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -133.88 151.96 51.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.261 -0.899 . . . . 0.0 109.506 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.592 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 41.7 mmtt -130.65 171.11 13.43 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.356 -0.84 . . . . 0.0 109.126 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.767 ' CH2' HG23 ' A' ' 41' ' ' VAL . 60.1 m95 -104.55 126.5 51.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.202 -0.936 . . . . 0.0 109.329 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -116.94 168.03 10.6 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.154 -0.966 . . . . 0.0 109.145 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.535 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 65.1 mt -104.37 115.94 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.156 -0.965 . . . . 0.0 109.379 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.646 HG22 ' CD2' ' A' ' 83' ' ' PHE . 65.5 t -92.09 138.21 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.216 -0.927 . . . . 0.0 109.248 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.535 ' N ' ' CD2' ' A' ' 11' ' ' LEU . 3.5 mm? -88.12 141.9 28.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.312 -0.867 . . . . 0.0 109.338 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 1.3 p -153.44 174.85 13.84 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.235 -0.916 . . . . 0.0 109.375 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.436 ' O ' ' C ' ' A' ' 14' ' ' SER . 98.1 mtp -95.63 121.02 36.9 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.165 -0.959 . . . . 0.0 109.439 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 13' ' ' MET . 22.4 t -42.03 126.76 3.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.291 -0.88 . . . . 0.0 109.51 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.23 -19.98 33.69 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.527 ' O ' HG23 ' A' ' 20' ' ' VAL . 89.0 m-85 -108.77 -18.79 13.62 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.233 -1.157 . . . . 0.0 109.629 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.736 ' OE1' HD11 ' A' ' 44' ' ' ILE . 43.4 mt-10 -41.48 -67.09 0.28 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.311 -0.868 . . . . 0.0 109.596 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -46.76 -38.59 10.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.193 -0.942 . . . . 0.0 109.415 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.444 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 24.0 tttp -69.22 -34.87 75.52 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.242 -0.911 . . . . 0.0 109.179 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.653 HG22 ' HB2' ' A' ' 79' ' ' TYR . 43.8 t -68.78 -41.35 82.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.333 -0.854 . . . . 0.0 109.279 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.55 ' HB2' HD11 ' A' ' 42' ' ' ILE . 16.7 tttm -57.06 -50.82 71.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.277 -0.89 . . . . 0.0 109.487 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -62.31 -33.82 75.42 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.177 -0.952 . . . . 0.0 109.151 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.506 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 23.4 m120 -65.62 -33.65 76.4 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.302 -0.874 . . . . 0.0 109.284 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.82 HD12 HD13 ' A' ' 40' ' ' ILE . 79.2 mt -67.66 -45.37 84.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.271 -0.893 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -55.6 -46.19 77.35 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.895 . . . . 0.0 109.576 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.9 mttt -75.41 -36.04 60.9 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.605 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.58 ' HE3' ' CE1' ' A' ' 73' ' ' PHE . 28.6 tttp -54.72 -32.42 59.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.21 -0.931 . . . . 0.0 109.27 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 33' ' ' ILE . 99.2 t -88.5 -22.89 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.878 . . . . 0.0 109.504 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -72.24 -57.0 4.59 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.237 -0.914 . . . . 0.0 109.609 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.22 -24.17 66.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.536 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 48.1 p -98.43 -17.37 18.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.418 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 62.74 26.14 68.28 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.037 HG21 HD12 ' A' ' 36' ' ' LEU . 76.7 mt -97.38 77.48 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.176 -1.191 . . . . 0.0 109.438 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.411 ' O ' ' HG2' ' A' ' 34' ' ' LYS . 17.8 tttp -89.72 22.85 2.89 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.29 -0.881 . . . . 0.0 109.129 179.822 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 1.071 ' O ' HD13 ' A' ' 65' ' ' ILE . 92.0 m-20 -118.27 -9.46 10.42 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.37 -0.831 . . . . 0.0 109.572 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.037 HD12 HG21 ' A' ' 33' ' ' ILE . 96.9 mt -97.47 -51.74 4.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.905 . . . . 0.0 109.387 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.569 HG11 ' CG2' ' A' ' 24' ' ' ILE . 59.3 t -94.73 136.12 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.258 -0.902 . . . . 0.0 109.245 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.89 -119.99 3.84 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 86.4 mtt180 -91.76 139.97 30.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.295 -1.12 . . . . 0.0 109.825 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 1.164 HG23 HG22 ' A' ' 62' ' ' VAL . 29.4 mt -107.91 133.39 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.397 -0.815 . . . . 0.0 109.115 179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.767 HG23 ' CH2' ' A' ' 7' ' ' TRP . 25.8 t -121.99 132.56 70.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.175 -0.953 . . . . 0.0 109.25 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.581 HG22 HG13 ' A' ' 44' ' ' ILE . 4.5 mt -124.67 125.81 25.46 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.267 -0.896 . . . . 0.0 109.577 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.614 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 49.1 Cg_endo -68.4 -2.75 9.66 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.858 2.372 . . . . 0.0 111.422 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.878 HG23 ' HG2' ' A' ' 54' ' ' LYS . 87.7 mt -67.07 -28.88 44.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.35 -0.843 . . . . 0.0 109.602 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.45 ' C ' ' O ' ' A' ' 44' ' ' ILE . 9.2 tpt85 -42.32 -45.1 4.13 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.305 -0.872 . . . . 0.0 109.543 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 47.4 -111.19 0.72 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 164.97 169.17 28.23 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.434 ' O ' ' C ' ' A' ' 49' ' ' ARG . 71.3 mt-30 -60.64 -19.81 59.13 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -1.141 . . . . 0.0 109.34 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.47 ' HD2' ' HB ' ' A' ' 167' ' ' VAL . 6.5 ttp180 -43.7 -48.68 7.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.271 -0.893 . . . . 0.0 109.435 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.881 ' CZ ' HG23 ' A' ' 167' ' ' VAL . 63.2 mtt-85 -116.19 136.59 52.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.286 -0.884 . . . . 0.0 109.573 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 58.1 mttm -65.23 -40.89 94.68 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.208 -0.933 . . . . 0.0 109.193 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.526 ' O ' ' CG ' ' A' ' 53' ' ' GLU . 60.0 p -60.58 -169.17 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.227 -0.92 . . . . 0.0 109.18 179.731 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 52' ' ' SER . 89.9 mt-10 -160.33 175.51 12.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.195 -0.941 . . . . 0.0 109.55 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.878 ' HG2' HG23 ' A' ' 44' ' ' ILE . 1.3 mttp 76.24 83.51 0.09 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.371 -0.831 . . . . 0.0 109.75 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.614 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 35.0 mt -59.7 -41.83 91.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.112 -0.993 . . . . 0.0 108.654 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.496 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 88.1 m-85 -129.19 105.1 17.93 Favored Pre-proline 0 N--CA 1.489 1.48 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.7 136.13 48.22 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.484 2.122 . . . . 0.0 112.093 -179.046 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.34 -18.47 4.36 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.506 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.6 m-30 -95.77 129.24 43.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.666 -1.49 . . . . 0.0 110.51 -178.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 36.1 t -133.23 147.07 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.683 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 9.6 m-85 -108.79 124.67 50.95 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.856 -1.153 . . . . 0.0 109.861 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 1.164 HG22 HG23 ' A' ' 40' ' ' ILE . 61.9 t -135.62 146.76 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.904 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.592 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 26.4 tt0 -110.88 127.41 55.43 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.4 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.739 ' HE1' HG11 ' A' ' 74' ' ' VAL . 40.4 mtm -152.16 163.65 38.95 Favored 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 118.757 -1.177 . . . . 0.0 111.304 -178.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 1.071 HD13 ' O ' ' A' ' 35' ' ' ASN . 2.3 pt -82.64 124.81 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.488 ' CE ' ' HG2' ' A' ' 89' ' ' GLN . 94.9 mmm -76.23 142.72 41.35 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.146 -0.971 . . . . 0.0 109.885 -178.72 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 m-20 177.31 170.18 0.58 Allowed 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -68.79 -41.6 78.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.128 -0.982 . . . . 0.0 109.454 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -78.08 -29.61 49.22 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.173 -0.954 . . . . 0.0 109.85 -179.703 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.028 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -72.86 -48.92 33.45 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.12 -0.987 . . . . 0.0 109.479 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.469 ' CE1' ' NE2' ' A' ' 89' ' ' GLN . 75.1 t80 -61.22 -48.1 83.06 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.258 -0.901 . . . . 0.0 109.564 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -61.46 -29.32 69.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.209 -0.932 . . . . 0.0 109.777 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.58 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 48.7 t80 -80.78 -41.74 22.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.121 -0.987 . . . . 0.0 109.472 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 1.028 HG23 ' O ' ' A' ' 70' ' ' ALA . 4.2 t -68.76 -56.23 12.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.33 -0.856 . . . . 0.0 109.511 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.1 tpt85 -54.59 -17.34 3.18 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.358 -0.838 . . . . 0.0 109.735 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 26.2 p -91.3 6.91 43.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.26 -0.9 . . . . 0.0 109.872 -179.658 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.598 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 25.1 t -64.43 137.85 97.26 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.052 -1.03 . . . . 0.0 109.542 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.585 ' HB2' ' CE2' ' A' ' 79' ' ' TYR . 47.7 Cg_endo -68.47 137.63 40.01 Favored 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 122.718 2.278 . . . . 0.0 111.778 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.653 ' HB2' HG22 ' A' ' 20' ' ' VAL . 17.5 m-85 76.17 -4.64 2.32 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.388 -0.82 . . . . 0.0 109.712 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.598 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 5.4 t -87.02 129.66 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.055 -1.028 . . . . 0.0 109.101 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 98.9 mmm -88.14 -7.17 57.31 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.517 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.07 -145.23 15.84 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.646 ' CD2' HG22 ' A' ' 10' ' ' VAL . 1.4 m-85 -140.49 148.6 41.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -1.183 . . . . 0.0 109.708 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.535 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 3.4 p -75.78 134.61 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.246 -0.909 . . . . 0.0 109.344 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.465 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.3 p -162.94 163.74 26.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.204 -0.935 . . . . 0.0 109.664 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.0 m -91.43 -33.34 15.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.37 -0.831 . . . . 0.0 109.421 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -124.98 -84.32 0.58 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.554 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -110.31 -135.24 6.97 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.554 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.9 OUTLIER -29.49 150.45 0.03 OUTLIER Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.584 -0.951 . . . . 0.0 110.302 -179.484 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.577 ' HG3' ' CB ' ' A' ' 83' ' ' PHE . 50.1 Cg_endo -68.22 142.05 54.14 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.899 2.399 . . . . 0.0 112.153 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.754 HG23 ' HD2' ' A' ' 92' ' ' PRO . 3.7 p -75.69 144.67 77.28 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 109.26 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.754 ' HD2' HG23 ' A' ' 91' ' ' VAL . 46.0 Cg_endo -68.34 150.28 76.0 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.61 2.207 . . . . 0.0 111.806 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.4 t -76.53 137.95 21.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.291 -0.881 . . . . 0.0 109.533 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.1 tttp -74.19 132.99 42.71 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.313 -0.867 . . . . 0.0 109.415 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.405 ' C ' ' O ' ' A' ' 94' ' ' LYS . 79.3 m-20 -44.11 -41.7 5.79 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.448 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.424 ' HB2' ' HD3' ' A' ' 94' ' ' LYS . 53.1 mtp180 -60.85 -27.03 67.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.278 -0.889 . . . . 0.0 109.497 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.516 ' N ' ' O ' ' A' ' 94' ' ' LYS . 45.1 mt-10 -86.6 -26.06 24.62 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.241 -0.912 . . . . 0.0 109.398 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.505 ' O ' HD12 ' A' ' 102' ' ' LEU . 27.9 mmm -85.59 -22.97 27.79 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.219 -0.926 . . . . 0.0 109.5 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.616 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.1 OUTLIER -42.61 -49.09 13.23 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.29 -0.881 . . . . 0.0 109.887 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.616 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 51.9 Cg_endo -74.2 -27.32 11.75 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.435 2.09 . . . . 0.0 111.672 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.578 HG21 ' CD2' ' A' ' 61' ' ' PHE . 33.8 mm -80.87 -38.75 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.333 -0.855 . . . . 0.0 109.344 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -69.27 -40.07 78.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.313 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.582 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 19.5 ttm180 -64.36 -50.42 67.78 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.904 . . . . 0.0 109.308 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.549 HD23 ' C ' ' A' ' 104' ' ' LEU . 6.8 tt -72.29 -36.19 68.88 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.296 -0.877 . . . . 0.0 109.216 179.713 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -69.76 -2.93 13.36 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.308 -0.87 . . . . 0.0 109.908 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.86 8.98 86.74 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.445 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 1.0 OUTLIER -72.53 -17.05 61.77 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -1.17 . . . . 0.0 109.416 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -104.33 159.28 15.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.241 -0.912 . . . . 0.0 109.517 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -107.72 101.44 10.75 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.235 -0.916 . . . . 0.0 109.379 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -146.09 158.05 43.86 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.197 -0.939 . . . . 0.0 109.427 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -97.17 -90.77 0.26 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.426 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.483 ' O ' ' C ' ' A' ' 113' ' ' LYS . 82.7 tt0 -146.06 152.72 39.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.199 -0.938 . . . . 0.0 109.458 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.483 ' C ' ' O ' ' A' ' 112' ' ' GLU . 54.3 pttt -38.5 144.82 0.1 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.387 -0.821 . . . . 0.0 109.758 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.18 -58.33 3.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.309 -0.869 . . . . 0.0 109.557 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.45 ' HB2' ' HD2' ' A' ' 116' ' ' PRO . 0.0 OUTLIER -170.3 162.42 6.29 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.233 -0.917 . . . . 0.0 109.476 -179.889 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.45 ' HD2' ' HB2' ' A' ' 115' ' ' LYS . 50.2 Cg_endo -70.2 142.04 44.97 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.763 2.309 . . . . 0.0 111.725 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 33.9 m -121.64 162.03 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.289 -0.882 . . . . 0.0 109.528 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.846 ' O ' HG13 ' A' ' 119' ' ' VAL . 30.9 mtpp -100.31 124.63 46.02 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.271 -0.893 . . . . 0.0 109.419 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.846 HG13 ' O ' ' A' ' 118' ' ' LYS . 0.1 OUTLIER -169.3 57.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.282 -0.887 . . . . 0.0 109.425 -179.931 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.534 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 94.6 mt-10 -62.24 -83.68 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.216 -0.928 . . . . 0.0 109.531 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.632 ' O ' ' C ' ' A' ' 122' ' ' GLY . 9.4 mt 77.93 105.93 0.07 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.332 -0.855 . . . . 0.0 109.247 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.632 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -20.24 93.55 0.01 OUTLIER Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.446 -1.061 . . . . 0.0 110.446 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.487 ' N ' ' O ' ' A' ' 121' ' ' LEU . 8.9 p90 -103.03 143.12 32.99 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.29 -1.124 . . . . 0.0 109.281 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.428 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 13.9 mmtt -137.77 165.22 26.97 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -0.925 . . . . 0.0 109.758 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.614 HG23 ' O ' ' A' ' 144' ' ' LYS . 14.2 p -62.42 143.13 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.316 -0.865 . . . . 0.0 109.536 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.68 -33.11 3.54 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.428 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 31.8 m-20 -49.67 159.19 0.39 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.532 -0.981 . . . . 0.0 109.247 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' MET . . . . . 0.661 ' CE ' HD12 ' A' ' 176' ' ' ILE . 2.0 ttp -94.19 127.62 40.14 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.136 -0.978 . . . . 0.0 109.008 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.794 HG21 HD11 ' A' ' 143' ' ' ILE . 5.9 t -125.99 142.49 42.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.361 -0.837 . . . . 0.0 109.28 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.494 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 22.2 tttp -105.41 142.13 35.7 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.405 -0.809 . . . . 0.0 108.875 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 1.029 HD12 ' HB3' ' A' ' 139' ' ' PHE . 66.9 mt -83.3 155.1 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.186 -0.946 . . . . 0.0 108.618 179.62 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.496 HG12 ' HA ' ' A' ' 173' ' ' VAL . 29.1 pt -150.62 2.8 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.076 -1.015 . . . . 0.0 109.549 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 72.3 m -148.19 144.44 27.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.071 -1.018 . . . . 0.0 109.992 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 104.29 -167.99 16.23 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.513 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.582 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 48.3 Cg_endo -68.97 -20.74 38.21 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 123.124 2.549 . . . . 0.0 112.408 -179.544 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.534 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.3 m-85 -110.31 15.95 21.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.829 -1.169 . . . . 0.0 109.435 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.642 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.7 tt0 -43.8 143.26 1.09 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.486 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.521 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 16.4 m-20 75.85 27.65 0.94 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.374 -0.829 . . . . 0.0 110.258 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 1.029 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.3 t80 -117.68 133.58 55.8 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.021 -1.049 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -82.96 133.75 35.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.127 -0.983 . . . . 0.0 109.653 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.412 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.15 167.34 27.36 Favored Glycine 0 N--CA 1.49 2.279 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.098 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.743 ' C ' HG23 ' A' ' 155' ' ' VAL . 58.4 t -110.38 136.92 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.442 -1.034 . . . . 0.0 109.404 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 1.068 HG21 HD11 ' A' ' 146' ' ' ILE . 43.2 mm -69.36 118.69 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.614 ' O ' HG23 ' A' ' 125' ' ' VAL . 47.3 tttp -98.17 -32.35 11.63 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.041 -1.037 . . . . 0.0 109.557 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 144' ' ' LYS . 85.7 mt-10 -157.68 153.33 26.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.058 -1.026 . . . . 0.0 110.073 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 1.082 HG23 HD22 ' A' ' 153' ' ' LEU . 6.1 mm -123.65 126.49 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.406 -0.809 . . . . 0.0 109.591 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -108.85 99.37 34.37 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.349 -0.845 . . . . 0.0 109.476 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.549 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.2 Cg_endo -71.21 173.77 11.74 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.739 2.293 . . . . 0.0 111.764 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.549 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.5 mt-10 79.97 -20.98 0.35 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.358 -0.839 . . . . 0.0 109.865 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.402 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 32.6 mtp180 -128.78 -13.4 4.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.079 -1.013 . . . . 0.0 109.476 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.425 ' O ' HG12 ' A' ' 170' ' ' VAL . 37.8 mt-30 69.58 48.22 0.62 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.283 -0.886 . . . . 0.0 109.685 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.864 ' O ' HD23 ' A' ' 153' ' ' LEU . 59.5 tt0 -120.41 144.25 48.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.964 . . . . 0.0 108.936 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 1.082 HD22 HG23 ' A' ' 146' ' ' ILE . 29.4 mt -130.12 131.01 45.53 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.078 -1.014 . . . . 0.0 110.083 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 13.6 mttt -93.07 130.9 38.53 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.758 HG12 HD11 ' A' ' 168' ' ' LEU . 13.9 p -132.7 147.48 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.096 -1.003 . . . . 0.0 110.057 -179.521 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.562 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.6 m-20 -96.7 117.0 30.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.464 -0.773 . . . . 0.0 109.265 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.415 HG13 ' CE1' ' A' ' 139' ' ' PHE . 44.9 t -96.79 141.38 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 109.501 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.408 ' HA ' ' O ' ' A' ' 162' ' ' ARG . 73.5 m -96.07 94.91 7.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.273 -0.892 . . . . 0.0 109.929 -179.7 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.561 HG22 ' CD2' ' A' ' 160' ' ' PHE . 6.2 mt -118.22 140.78 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.25 -0.906 . . . . 0.0 109.422 179.483 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.683 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 97.3 m-85 62.25 40.16 11.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.331 -0.855 . . . . 0.0 109.337 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.48 17.9 34.87 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.412 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 36.9 mtt-85 -128.29 156.12 43.52 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.179 -1.189 . . . . 0.0 109.618 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -99.84 134.23 43.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.886 . . . . 0.0 109.558 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 37.3 m -143.11 127.44 9.59 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.303 -0.873 . . . . 0.0 109.554 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.562 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.3 Cg_endo -69.63 135.18 30.09 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.76 2.307 . . . . 0.0 111.544 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 34.5 t -123.49 142.59 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.986 . . . . 0.0 109.861 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.881 HG23 ' CZ ' ' A' ' 50' ' ' ARG . 29.4 t -93.78 119.35 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.403 -0.81 . . . . 0.0 109.485 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.758 HD11 HG12 ' A' ' 155' ' ' VAL . 0.0 OUTLIER -141.91 168.65 19.25 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.209 -0.932 . . . . 0.0 110.413 -179.651 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.501 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 42.3 m170 -83.51 140.6 32.2 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.932 HG23 HD11 ' A' ' 153' ' ' LEU . 7.5 p -54.91 -36.33 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.26 -0.9 . . . . 0.0 109.183 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.412 ' N ' HG13 ' A' ' 170' ' ' VAL . 84.4 p -75.84 -7.26 54.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -0.868 . . . . 0.0 109.707 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.501 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 84.3 mt-10 -87.61 -2.44 58.61 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.069 -1.019 . . . . 0.0 109.647 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.496 ' HA ' HG12 ' A' ' 132' ' ' ILE . 3.7 m -142.05 175.91 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.191 -0.943 . . . . 0.0 109.446 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.546 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 76.2 tt0 -140.57 167.26 22.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.281 -0.887 . . . . 0.0 108.932 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.546 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.1 tttp -86.27 15.12 5.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.03 -1.044 . . . . 0.0 109.6 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.661 HD12 ' CE ' ' A' ' 128' ' ' MET . 10.8 mt 65.74 -70.4 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.306 -0.871 . . . . 0.0 109.477 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.483 ' N ' ' O ' ' A' ' 175' ' ' LYS . 86.3 tt0 . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 117.947 -1.025 . . . . 0.0 109.506 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.452 ' O ' ' HB ' ' A' ' 65' ' ' ILE . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.452 ' HA ' HG21 ' A' ' 65' ' ' ILE . . . -61.96 -16.14 48.94 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.219 -1.166 . . . . 0.0 109.509 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' MET . . . . . 0.438 ' O ' ' HB2' ' A' ' 4' ' ' LYS . 71.3 mtm -106.6 174.83 5.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.28 -0.887 . . . . 0.0 109.423 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.438 ' HB2' ' O ' ' A' ' 3' ' ' MET . 67.8 mttt 63.23 41.69 7.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.247 -0.908 . . . . 0.0 109.383 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.491 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 74.8 mttt -69.11 148.97 49.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.201 -0.937 . . . . 0.0 109.658 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.566 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 10.9 mttp -129.17 175.63 8.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.291 -0.881 . . . . 0.0 109.259 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.876 ' O ' HG23 ' A' ' 93' ' ' VAL . 56.7 m95 -112.38 124.69 53.05 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.262 -0.899 . . . . 0.0 109.233 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.45 ' CD1' ' HA ' ' A' ' 92' ' ' PRO . 62.6 m-85 -117.36 171.81 7.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.189 -0.944 . . . . 0.0 109.335 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.565 HG12 ' CZ ' ' A' ' 61' ' ' PHE . 40.9 mt -112.49 107.83 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.174 -0.954 . . . . 0.0 108.995 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.881 ' CG1' HG13 ' A' ' 60' ' ' VAL . 10.8 p -83.5 146.05 7.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.208 -0.932 . . . . 0.0 109.465 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.526 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.0 OUTLIER -90.77 142.25 27.95 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.525 -0.734 . . . . 0.0 109.67 -179.667 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.764 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.1 t -154.97 -176.07 5.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.299 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.423 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 58.2 mtm -102.23 125.66 48.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.187 -0.946 . . . . 0.0 109.445 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.4 m -45.59 128.02 8.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -0.936 . . . . 0.0 109.536 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.21 -19.46 37.38 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.797 ' O ' HG23 ' A' ' 20' ' ' VAL . 94.1 m-85 -108.19 -7.91 15.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.313 -1.11 . . . . 0.0 109.436 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.832 ' OE1' HD11 ' A' ' 44' ' ' ILE . 47.9 mt-10 -47.93 -53.91 14.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.474 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -55.62 -37.05 67.66 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.239 -0.913 . . . . 0.0 109.346 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.407 ' O ' ' CG ' ' A' ' 23' ' ' ASN . 88.5 mttt -73.25 -34.86 66.07 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 109.372 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.797 HG23 ' O ' ' A' ' 16' ' ' TYR . 13.4 t -66.69 -46.6 85.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.211 -0.931 . . . . 0.0 109.414 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 23.2 tttt -58.92 -48.44 81.48 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.278 -0.889 . . . . 0.0 109.666 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.9 mt-10 -65.71 -40.26 92.06 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.219 -0.926 . . . . 0.0 109.507 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.484 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 14.4 m120 -60.45 -42.06 95.35 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.218 -0.926 . . . . 0.0 109.379 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.62 ' O ' HG23 ' A' ' 28' ' ' VAL . 96.7 mt -64.38 -44.64 97.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.307 -0.871 . . . . 0.0 109.552 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.459 ' O ' ' HG3' ' A' ' 29' ' ' GLU . 87.9 mt-10 -59.23 -47.02 86.91 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.172 -0.955 . . . . 0.0 110.036 -179.613 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.2 ttpt -80.19 -38.39 31.36 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.049 -1.032 . . . . 0.0 109.731 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.585 ' HG2' ' CE1' ' A' ' 73' ' ' PHE . 19.3 tttt -57.16 -25.64 59.26 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.331 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.856 HG21 HG11 ' A' ' 37' ' ' VAL . 89.4 t -88.07 -26.98 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.301 -0.875 . . . . 0.0 109.482 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.459 ' HG3' ' O ' ' A' ' 25' ' ' GLU . 93.1 mt-10 -66.92 -47.65 71.07 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.504 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.12 -28.91 69.96 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -0.888 . . . . 0.0 109.365 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 71.9 p -89.03 -12.02 42.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.286 -0.884 . . . . 0.0 109.322 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 61.07 24.04 62.53 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.844 ' CG2' HD23 ' A' ' 36' ' ' LEU . 54.7 mt -101.35 74.43 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -1.139 . . . . 0.0 109.552 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.6 mttp -85.26 -3.8 58.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.336 -0.853 . . . . 0.0 109.597 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.435 ' O ' HD13 ' A' ' 65' ' ' ILE . 90.5 m-20 -93.12 -7.01 46.68 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.209 -0.932 . . . . 0.0 109.4 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.019 HD12 ' HB2' ' A' ' 70' ' ' ALA . 4.4 mm? -95.66 -50.83 4.77 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.267 -0.895 . . . . 0.0 109.34 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.856 HG11 HG21 ' A' ' 28' ' ' VAL . 8.7 p -95.35 139.16 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.381 -0.824 . . . . 0.0 109.554 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.1 -122.16 4.07 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 88.6 mtt-85 -95.34 142.7 27.43 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.223 -1.163 . . . . 0.0 109.706 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.954 HG23 HG22 ' A' ' 62' ' ' VAL . 75.4 mt -109.73 137.5 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.196 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.632 HG13 ' HB2' ' A' ' 61' ' ' PHE . 7.7 p -127.93 162.08 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.169 -0.957 . . . . 0.0 109.36 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.632 HG21 HD12 ' A' ' 44' ' ' ILE . 5.9 mt -144.2 130.13 9.87 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.167 -0.958 . . . . 0.0 109.902 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.515 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.1 Cg_endo -66.36 -3.71 9.33 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.861 2.374 . . . . 0.0 111.478 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.832 HD11 ' OE1' ' A' ' 17' ' ' GLU . 61.0 mt -72.21 -28.51 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.89 . . . . 0.0 109.508 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.421 ' C ' ' O ' ' A' ' 44' ' ' ILE . 32.4 mmt-85 -43.92 143.42 1.1 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.594 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 152.86 125.47 1.1 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 64.27 -123.72 28.31 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 56.1 tp60 -94.31 133.41 37.89 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.348 -1.09 . . . . 0.0 109.524 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 84.0 mtt-85 -53.53 -44.58 69.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.203 -0.936 . . . . 0.0 109.42 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 46.2 mtm105 -64.84 148.89 50.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.184 -0.948 . . . . 0.0 109.184 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LYS . . . . . 0.417 ' O ' ' O ' ' A' ' 52' ' ' SER . 58.4 mttp 46.63 36.32 3.61 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.171 -0.956 . . . . 0.0 109.22 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.695 ' HB3' HG22 ' A' ' 44' ' ' ILE . 29.1 m -50.66 179.68 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.331 -0.855 . . . . 0.0 109.535 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.496 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 92.3 mt-10 -101.22 -36.5 8.9 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.327 -0.858 . . . . 0.0 109.583 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.804 ' HG2' HG23 ' A' ' 44' ' ' ILE . 3.6 mttp 75.16 89.99 0.08 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -0.945 . . . . 0.0 109.215 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.593 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 16.9 tp -65.25 -22.3 66.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.863 -1.148 . . . . 0.0 109.775 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.593 ' CE2' ' HG ' ' A' ' 55' ' ' LEU . 95.8 m-85 -148.37 98.17 3.73 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.21 -0.931 . . . . 0.0 108.818 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -65.86 140.56 61.53 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.723 2.282 . . . . 0.0 112.205 -179.243 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.4 -10.89 10.21 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -107.25 132.6 52.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.749 -1.442 . . . . 0.0 110.291 -179.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.881 HG13 ' CG1' ' A' ' 10' ' ' VAL . 0.2 OUTLIER -135.22 151.4 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 179.001 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.632 ' HB2' HG13 ' A' ' 41' ' ' VAL . 14.0 m-85 -111.73 126.56 55.18 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.948 -1.095 . . . . 0.0 110.258 -179.14 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.954 HG22 HG23 ' A' ' 40' ' ' ILE . 67.1 t -130.22 141.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.547 -0.721 . . . . 0.0 109.66 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.601 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 10.8 tt0 -104.16 125.92 50.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 108.766 179.538 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.495 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 30.7 mtm -156.18 172.92 17.61 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.019 -1.051 . . . . 0.0 110.783 -179.073 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.628 ' CG1' HD13 ' A' ' 36' ' ' LEU . 4.8 pt -95.17 130.48 43.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.468 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 4.1 tpp -76.04 143.34 41.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.3 -0.875 . . . . 0.0 110.037 -178.64 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.468 ' HB2' ' O ' ' A' ' 66' ' ' MET . 42.6 t30 176.69 175.78 0.33 Allowed 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 69' ' ' GLU . 28.6 p-10 -71.6 -40.45 69.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.145 -0.972 . . . . 0.0 109.406 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.473 ' N ' ' OD1' ' A' ' 68' ' ' ASP . 71.0 mm-40 -73.23 -35.5 66.28 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.362 -0.836 . . . . 0.0 109.716 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.019 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -67.63 -47.87 68.37 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 109.589 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.796 ' HB2' HE21 ' A' ' 89' ' ' GLN . 84.0 t80 -59.77 -51.57 69.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.676 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -57.48 -29.03 63.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.239 -0.913 . . . . 0.0 109.876 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.696 ' CE2' HG22 ' A' ' 28' ' ' VAL . 65.9 t80 -80.4 -40.79 25.78 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.113 -0.992 . . . . 0.0 109.929 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 1.008 HG23 ' O ' ' A' ' 70' ' ' ALA . 2.6 t -64.63 -60.33 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.185 -0.947 . . . . 0.0 109.92 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.463 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 10.8 tpt180 -51.58 -42.92 62.26 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.097 -1.002 . . . . 0.0 109.736 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.423 ' HB3' ' HZ1' ' A' ' 27' ' ' LYS . 22.8 t -67.58 1.24 2.5 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.11 -0.994 . . . . 0.0 110.244 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.616 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 30.7 t -62.29 133.98 94.59 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 120.928 -1.107 . . . . 0.0 109.317 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.571 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 46.0 Cg_endo -68.0 136.08 36.95 Favored 'Trans proline' 0 C--O 1.213 -0.738 0 C-N-CA 122.727 2.285 . . . . 0.0 111.866 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.571 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 54.3 m-85 77.61 -2.26 2.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.528 -0.733 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.616 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.0 t -87.45 126.96 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.102 -0.999 . . . . 0.0 109.162 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 66.1 mtp -90.02 -24.65 21.15 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 109.73 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.422 ' O ' ' N ' ' A' ' 11' ' ' LEU . . . 158.25 -158.04 28.85 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.59 ' HB2' ' HB3' ' A' ' 90' ' ' PRO . 15.3 p90 -140.56 154.13 46.4 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.243 -1.151 . . . . 0.0 109.506 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.493 ' CG2' ' CD2' ' A' ' 11' ' ' LEU . 47.5 t -81.73 113.45 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.137 -0.977 . . . . 0.0 109.466 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.533 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 5.3 p -145.2 164.66 30.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.226 -0.921 . . . . 0.0 109.498 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 23.9 m -86.47 -33.17 20.46 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.287 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -135.58 -76.91 0.09 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.55 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -109.61 -133.56 6.7 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.796 HE21 ' HB2' ' A' ' 71' ' ' TYR . 0.7 OUTLIER -29.49 150.31 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.63 -0.924 . . . . 0.0 110.315 -179.636 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.59 ' HB3' ' HB2' ' A' ' 83' ' ' PHE . 44.5 Cg_endo -67.81 147.45 75.1 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.833 2.355 . . . . 0.0 111.973 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.766 HG23 ' HD2' ' A' ' 92' ' ' PRO . 3.4 p -80.81 144.69 56.22 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.317 -0.864 . . . . 0.0 109.369 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.766 ' HD2' HG23 ' A' ' 91' ' ' VAL . 47.3 Cg_endo -68.6 151.39 75.16 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.66 2.24 . . . . 0.0 111.715 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.876 HG23 ' O ' ' A' ' 7' ' ' TRP . 11.9 t -83.64 131.76 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.232 -0.918 . . . . 0.0 109.583 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 54.9 mttm -69.87 143.17 52.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.31 -0.868 . . . . 0.0 109.446 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -53.3 -39.97 64.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.25 -0.907 . . . . 0.0 109.596 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -57.98 -34.34 69.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.274 -0.891 . . . . 0.0 109.558 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.7 mt-10 -81.34 -25.41 36.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.266 -0.896 . . . . 0.0 109.525 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.696 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 98.6 mtp -84.1 -26.42 28.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.899 . . . . 0.0 109.58 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.58 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.4 OUTLIER -36.24 -54.24 1.53 Allowed Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.448 -0.783 . . . . 0.0 109.927 -179.838 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.58 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.5 Cg_endo -70.1 -28.2 23.93 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.481 2.121 . . . . 0.0 111.748 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.495 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 33.1 mm -80.57 -41.12 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.567 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.575 ' CB ' ' HB2' ' A' ' 108' ' ' GLU . 1.0 OUTLIER -67.85 -40.65 83.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.226 -0.921 . . . . 0.0 109.505 179.995 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.491 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 1.3 ttt85 -63.91 -49.52 72.33 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 109.212 179.785 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.407 HD21 ' O ' ' A' ' 45' ' ' ARG . 0.4 OUTLIER -72.21 -36.42 69.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.264 -0.898 . . . . 0.0 108.961 179.467 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.526 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -75.62 -4.11 38.23 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.436 -0.79 . . . . 0.0 109.641 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.66 11.47 83.06 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.506 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 7.1 mt -87.3 -28.09 22.48 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.158 -1.201 . . . . 0.0 109.724 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.575 ' HB2' ' CB ' ' A' ' 102' ' ' LEU . 87.9 tt0 -123.71 131.43 53.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.247 -0.908 . . . . 0.0 109.469 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -119.61 110.78 17.26 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.257 -0.902 . . . . 0.0 109.492 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.587 ' CE2' ' O ' ' A' ' 111' ' ' GLU . 47.7 p90 -126.09 -161.52 1.06 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.923 . . . . 0.0 109.308 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.587 ' O ' ' CE2' ' A' ' 110' ' ' TYR . 61.3 mt-10 -81.17 -150.89 0.08 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.264 -0.898 . . . . 0.0 109.663 -179.722 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.484 ' HB2' ' O ' ' A' ' 111' ' ' GLU . 35.4 tt0 175.8 171.21 0.36 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.424 -0.797 . . . . 0.0 109.126 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.405 ' C ' ' O ' ' A' ' 112' ' ' GLU . 3.2 mttp 43.96 62.18 2.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.065 -1.022 . . . . 0.0 109.495 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.466 ' HD2' ' OE2' ' A' ' 137' ' ' GLU . 3.8 mttt -82.09 -30.54 31.21 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.175 -0.953 . . . . 0.0 109.29 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.658 ' HG2' HG12 ' A' ' 117' ' ' VAL . 2.5 tptp -103.51 102.8 32.07 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.505 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -73.02 7.95 1.88 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.745 2.296 . . . . 0.0 112.065 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.658 HG12 ' HG2' ' A' ' 115' ' ' LYS . 8.1 p -82.91 126.26 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.03 -1.044 . . . . 0.0 109.62 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 21.9 tttt -74.13 145.29 44.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.281 -0.887 . . . . 0.0 109.257 179.717 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 1.025 HG11 ' HA ' ' A' ' 174' ' ' GLU . 77.1 t -117.91 139.49 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.251 -0.906 . . . . 0.0 109.773 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.537 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 80.1 tt0 176.49 168.48 0.48 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.206 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.537 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 0.5 OUTLIER 79.94 163.36 0.18 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.385 -0.822 . . . . 0.0 109.559 179.926 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 45.39 33.52 4.32 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.482 ' HB3' ' HE2' ' A' ' 175' ' ' LYS . 50.7 p90 -109.13 129.17 55.48 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.234 -1.157 . . . . 0.0 109.219 179.532 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.446 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 20.8 mttm -146.48 155.65 42.69 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.131 -0.98 . . . . 0.0 109.869 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 144' ' ' LYS . 14.2 p -60.98 143.96 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -0.875 . . . . 0.0 109.584 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.09 -33.45 3.13 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.446 ' OD2' ' HB2' ' A' ' 124' ' ' LYS . 32.7 m-20 -48.78 163.13 0.08 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.38 -1.07 . . . . 0.0 109.207 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.8 ttm -96.3 126.72 41.7 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.051 -1.031 . . . . 0.0 108.807 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.907 HG23 ' O ' ' A' ' 174' ' ' GLU . 5.6 p -124.3 141.28 45.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.108 -0.995 . . . . 0.0 109.262 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.608 ' HB2' HD11 ' A' ' 176' ' ' ILE . 35.9 tttp -104.34 144.21 31.94 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.206 -0.934 . . . . 0.0 108.956 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.997 HD12 ' HB3' ' A' ' 139' ' ' PHE . 95.7 mt -85.69 152.01 3.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.116 -0.99 . . . . 0.0 108.623 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' ILE . . . . . . . . . . . . . 42.1 pt -150.32 2.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.162 -0.961 . . . . 0.0 109.434 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.478 ' HB2' ' CB ' ' A' ' 172' ' ' GLU . 75.4 m -148.26 144.48 27.66 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.145 -0.972 . . . . 0.0 109.912 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.75 -165.28 18.89 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.491 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 46.9 Cg_endo -68.03 -21.82 42.51 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 123.202 2.602 . . . . 0.0 112.811 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.555 ' HB2' HD13 ' A' ' 131' ' ' ILE . 97.5 m-85 -108.29 15.78 23.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.834 -1.166 . . . . 0.0 109.604 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.597 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.4 tt0 -42.96 139.94 1.56 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.176 -0.953 . . . . 0.0 109.384 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.522 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 18.6 m-20 75.21 24.95 1.37 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.368 -0.832 . . . . 0.0 110.335 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.997 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.5 t80 -115.71 135.8 53.68 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.961 -1.087 . . . . 0.0 109.421 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.34 133.5 34.14 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.177 -0.952 . . . . 0.0 109.692 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.495 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.02 170.89 25.74 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.294 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.716 ' C ' HG13 ' A' ' 155' ' ' VAL . 40.8 t -116.12 135.72 55.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.447 -1.031 . . . . 0.0 109.357 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.874 HD11 ' HD2' ' A' ' 175' ' ' LYS . 70.8 mt -67.56 115.87 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.257 -0.902 . . . . 0.0 109.192 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.516 ' O ' HG23 ' A' ' 125' ' ' VAL . 2.0 tttp -98.08 -33.74 11.04 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.036 -1.04 . . . . 0.0 109.502 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.412 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 75.3 mm-40 -151.01 146.03 25.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.114 -0.991 . . . . 0.0 109.536 179.872 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 1.044 HG22 HD22 ' A' ' 153' ' ' LEU . 23.8 pt -122.25 125.88 73.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.135 -0.978 . . . . 0.0 109.488 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.37 100.6 34.53 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.268 -0.895 . . . . 0.0 109.5 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.56 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.2 Cg_endo -71.18 171.12 16.61 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.704 2.269 . . . . 0.0 111.779 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.56 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.8 mt-10 80.95 -20.48 0.37 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.399 -0.813 . . . . 0.0 109.899 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.433 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 88.6 mtt180 -127.75 -12.01 5.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.086 -1.009 . . . . 0.0 109.526 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.433 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 31.5 mt-30 69.23 48.91 0.64 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.665 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -122.22 145.81 47.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.09 -1.006 . . . . 0.0 109.097 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 1.044 HD22 HG22 ' A' ' 146' ' ' ILE . 60.6 mt -138.42 115.29 10.78 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.075 -1.016 . . . . 0.0 110.147 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 27.3 mttm -78.85 133.56 37.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.3 -0.875 . . . . 0.0 108.643 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.716 HG13 ' C ' ' A' ' 142' ' ' VAL . 53.9 t -127.44 151.17 33.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.182 -0.949 . . . . 0.0 109.762 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 26.2 t-20 -98.0 117.6 32.7 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.237 -0.914 . . . . 0.0 109.352 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.506 HG13 ' CE1' ' A' ' 139' ' ' PHE . 39.7 t -101.03 143.41 14.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.252 -0.905 . . . . 0.0 109.708 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 93.1 m -94.74 91.26 6.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.383 -0.823 . . . . 0.0 109.724 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.502 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 8.6 mt -115.78 140.54 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.424 179.664 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.411 ' CZ ' ' HZ ' ' A' ' 61' ' ' PHE . 8.4 m-85 60.54 41.21 15.93 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.376 -0.827 . . . . 0.0 109.334 -179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.05 16.28 12.9 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 92.4 mtt-85 -126.26 148.3 49.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.201 -1.176 . . . . 0.0 109.39 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.504 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 94.3 mt-10 -94.81 135.77 35.91 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.278 -0.889 . . . . 0.0 109.679 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' THR . . . . . 0.51 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 49.7 m -147.2 128.18 7.1 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.274 -0.891 . . . . 0.0 109.735 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.538 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.49 139.69 38.26 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.746 2.297 . . . . 0.0 111.46 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.4 p -126.61 145.79 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.089 -1.007 . . . . 0.0 109.869 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.434 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 5.3 t -92.54 118.86 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.459 -0.775 . . . . 0.0 109.505 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.434 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 19.3 mt -141.52 167.23 22.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.184 -0.947 . . . . 0.0 110.495 -179.302 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -83.97 141.34 31.29 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.71 -0.619 . . . . 0.0 109.5 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 4.1 p -56.42 -36.28 46.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.287 -0.883 . . . . 0.0 109.319 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 53.8 p -75.96 -7.18 54.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -0.883 . . . . 0.0 109.828 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.478 ' CB ' ' HB2' ' A' ' 133' ' ' SER . 64.5 mt-10 -99.75 -2.23 35.73 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.086 -1.009 . . . . 0.0 109.404 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.403 ' O ' HG11 ' A' ' 119' ' ' VAL . 12.7 m -132.48 170.1 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.23 -0.919 . . . . 0.0 109.627 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 1.025 ' HA ' HG11 ' A' ' 119' ' ' VAL . 53.5 tt0 -129.87 145.14 51.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.293 -0.88 . . . . 0.0 109.343 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.874 ' HD2' HD11 ' A' ' 143' ' ' ILE . 34.4 mmtm -87.83 14.82 7.97 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.024 -1.048 . . . . 0.0 109.514 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.608 HD11 ' HB2' ' A' ' 130' ' ' LYS . 81.2 mt 43.81 -94.04 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.346 -0.846 . . . . 0.0 109.618 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.524 ' N ' HG22 ' A' ' 176' ' ' ILE . 96.6 mt-10 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 117.972 -1.013 . . . . 0.0 109.489 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.294 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.61 -11.52 35.85 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.268 -1.136 . . . . 0.0 109.455 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 93.9 mtp -71.42 -8.52 54.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.2 -0.938 . . . . 0.0 109.457 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.438 ' O ' ' HG3' ' A' ' 4' ' ' LYS . 18.8 pttm -160.76 132.83 5.96 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.252 -0.905 . . . . 0.0 109.463 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.476 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 20.0 mttm -114.95 156.82 24.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.177 -0.952 . . . . 0.0 109.625 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 16.8 mmtp -127.47 172.07 11.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.329 -0.857 . . . . 0.0 109.39 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.959 ' O ' HG23 ' A' ' 93' ' ' VAL . 46.3 m95 -106.34 128.24 53.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.335 -0.853 . . . . 0.0 109.142 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.541 ' CE1' ' CE ' ' A' ' 66' ' ' MET . 74.8 m-85 -120.35 160.96 22.0 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.214 -0.929 . . . . 0.0 109.359 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.524 ' HB ' HG12 ' A' ' 84' ' ' VAL . 97.1 mt -102.66 115.35 44.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.233 -0.917 . . . . 0.0 109.252 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.508 HG11 HG22 ' A' ' 80' ' ' VAL . 84.2 t -91.35 141.28 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.224 -0.923 . . . . 0.0 109.452 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.512 HD13 ' HA ' ' A' ' 11' ' ' LEU . 3.2 mm? -84.74 144.23 28.64 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.28 -0.888 . . . . 0.0 109.308 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.693 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.9 t -155.86 -176.56 6.02 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.167 -0.958 . . . . 0.0 109.271 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.417 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 56.8 mtm -104.71 123.73 48.13 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.25 -0.906 . . . . 0.0 109.568 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.455 ' OG ' ' HB2' ' A' ' 57' ' ' PRO . 2.6 m -45.32 128.32 7.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.408 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.3 -19.98 33.52 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.501 ' O ' ' N ' ' A' ' 19' ' ' LYS . 77.1 m-85 -111.64 -9.3 14.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.297 -1.119 . . . . 0.0 109.441 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.693 ' HG2' HG21 ' A' ' 12' ' ' THR . 92.6 mt-10 -43.3 -41.54 4.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.23 -0.919 . . . . 0.0 109.543 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -63.57 -31.3 72.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 109.302 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.501 ' N ' ' O ' ' A' ' 16' ' ' TYR . 27.7 mttm -76.94 -56.43 4.6 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.276 -0.89 . . . . 0.0 109.352 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.565 ' CG1' ' HA ' ' A' ' 17' ' ' GLU . 2.0 p -44.72 -49.73 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.415 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.751 ' HD2' HD11 ' A' ' 42' ' ' ILE . 10.5 tttm -61.03 -48.32 82.32 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.207 -0.933 . . . . 0.0 109.874 -179.711 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -62.96 -35.48 80.29 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.07 -1.019 . . . . 0.0 109.504 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.497 ' HB3' ' HG2' ' A' ' 78' ' ' PRO . 33.9 m120 -64.92 -37.54 87.99 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.308 -0.87 . . . . 0.0 109.22 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.5 HG21 HD11 ' A' ' 40' ' ' ILE . 89.0 mt -63.19 -45.62 98.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.3 -0.875 . . . . 0.0 109.478 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -55.41 -46.77 76.6 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.214 -0.929 . . . . 0.0 109.715 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 27.7 ttmt -76.06 -35.63 59.34 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.261 -0.899 . . . . 0.0 109.456 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.608 ' O ' HG23 ' A' ' 31' ' ' THR . 44.2 tptt -54.93 -32.33 61.16 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.918 . . . . 0.0 109.242 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.851 HG13 ' O ' ' A' ' 33' ' ' ILE . 77.5 t -87.13 -22.91 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.329 -0.857 . . . . 0.0 109.406 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -71.32 -55.4 8.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.669 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.39 -31.16 71.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.186 -0.946 . . . . 0.0 109.684 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.608 HG23 ' O ' ' A' ' 27' ' ' LYS . 29.5 p -87.32 -20.92 26.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.118 -0.989 . . . . 0.0 109.491 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 68.21 22.07 74.26 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.851 ' O ' HG13 ' A' ' 28' ' ' VAL . 63.4 mt -98.89 79.45 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -1.142 . . . . 0.0 109.449 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -85.09 -17.23 38.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.236 -0.915 . . . . 0.0 109.24 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -84.24 5.01 28.25 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.317 -0.865 . . . . 0.0 109.482 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.043 HD12 ' CG1' ' A' ' 65' ' ' ILE . 12.5 tp -105.98 -54.26 2.51 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.176 -0.953 . . . . 0.0 109.37 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.715 ' HB ' HG21 ' A' ' 28' ' ' VAL . 86.4 t -96.5 133.32 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.403 -0.81 . . . . 0.0 109.297 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.85 -123.4 5.26 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 89.7 mtt180 -93.52 147.49 22.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -1.125 . . . . 0.0 109.845 -179.535 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.865 HG23 HG22 ' A' ' 62' ' ' VAL . 70.2 mt -110.32 135.55 49.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.291 -0.88 . . . . 0.0 109.344 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.822 HG23 ' CH2' ' A' ' 7' ' ' TRP . 32.8 t -119.72 151.7 22.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.951 . . . . 0.0 109.39 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.751 HD11 ' HD2' ' A' ' 21' ' ' LYS . 10.5 mt -131.9 127.53 21.23 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.897 . . . . 0.0 109.442 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.527 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 46.2 Cg_endo -66.78 -4.46 11.21 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.862 2.375 . . . . 0.0 111.867 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.728 HG23 HG22 ' A' ' 42' ' ' ILE . 8.4 pt -80.7 133.23 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.12 -0.987 . . . . 0.0 109.387 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.423 ' O ' ' OG ' ' A' ' 52' ' ' SER . 44.6 ttp180 -67.75 150.0 49.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.257 -0.902 . . . . 0.0 109.574 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -96.18 179.64 35.14 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 167.71 -179.33 41.15 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 90.0 mt-30 -62.45 -33.13 74.22 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.27 -1.135 . . . . 0.0 109.384 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 79.0 mtt-85 -80.23 131.29 35.66 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.276 -0.89 . . . . 0.0 109.38 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 74.8 mtp85 -60.19 -35.33 75.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.258 -0.901 . . . . 0.0 109.556 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 53.5 mttm -84.96 138.49 32.45 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.232 -0.917 . . . . 0.0 109.448 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.423 ' OG ' ' O ' ' A' ' 45' ' ' ARG . 34.7 t -128.96 172.14 11.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 109.458 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.525 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 65.7 mm-40 -67.61 -36.71 81.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.604 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 7.6 mttp 75.72 105.47 0.07 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.53 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.527 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 24.7 mt -55.61 -45.43 77.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.105 -0.997 . . . . 0.0 109.269 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.455 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 89.3 m-85 -131.7 110.34 14.65 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.125 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.455 ' HB2' ' OG ' ' A' ' 14' ' ' SER . 43.1 Cg_endo -66.22 139.35 54.85 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.746 2.297 . . . . 0.0 112.184 -179.349 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.5 ' O ' HG22 ' A' ' 12' ' ' THR . . . 73.96 -9.83 8.43 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.5 m-30 -94.17 129.07 40.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.669 -1.489 . . . . 0.0 110.395 -179.192 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 44.8 t -130.22 137.75 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.419 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.503 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 8.0 m-85 -110.15 125.95 53.57 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.902 -1.124 . . . . 0.0 110.051 -179.462 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.865 HG22 HG23 ' A' ' 40' ' ' ILE . 55.8 t -138.51 149.92 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.418 -0.801 . . . . 0.0 109.805 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.635 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 61.6 tt0 -110.66 129.04 55.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 108.888 179.536 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.578 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 9.2 mtm -161.79 -176.06 5.04 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.137 -0.977 . . . . 0.0 109.804 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 1.043 ' CG1' HD12 ' A' ' 36' ' ' LEU . 18.9 pt -94.94 119.76 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.367 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.541 ' CE ' ' CE1' ' A' ' 8' ' ' TYR . 16.2 ttm -87.36 101.04 13.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.382 -0.824 . . . . 0.0 109.676 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' A' ' 66' ' ' MET . 84.8 m-20 -138.7 -166.54 2.03 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.303 -0.873 . . . . 0.0 108.895 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -71.17 -47.34 58.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.098 -1.001 . . . . 0.0 109.799 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 70' ' ' ALA . 93.7 mt-10 -70.84 -57.14 4.92 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.055 -1.028 . . . . 0.0 109.612 -179.736 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.007 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -44.51 -42.99 7.62 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.696 ' CD1' ' NE2' ' A' ' 89' ' ' GLN . 71.1 t80 -61.39 -54.84 38.4 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.267 -0.896 . . . . 0.0 109.696 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -51.58 -31.0 23.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.18 -0.95 . . . . 0.0 110.049 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -81.01 -41.95 21.9 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.144 -0.972 . . . . 0.0 109.766 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.976 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 47.4 t -70.96 -54.58 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.249 -0.907 . . . . 0.0 109.443 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.428 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 25.0 tpt85 -51.45 -18.62 1.11 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.182 -0.949 . . . . 0.0 109.211 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 66.3 p -101.65 5.89 41.73 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.41 -0.806 . . . . 0.0 109.925 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.713 HG23 ' HA ' ' A' ' 74' ' ' VAL . 17.2 t -60.86 135.57 92.89 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.013 -1.055 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.592 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 48.4 Cg_endo -69.14 129.39 18.16 Favored 'Trans proline' 0 C--O 1.213 -0.74 0 C-N-CA 122.776 2.318 . . . . 0.0 112.002 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.592 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 40.7 m-85 84.45 -10.13 0.88 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.665 -0.647 . . . . 0.0 109.56 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.593 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 4.9 t -84.92 127.3 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.177 -0.952 . . . . 0.0 109.257 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.484 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 78.4 mtp -87.0 -23.99 24.82 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.296 -0.877 . . . . 0.0 109.379 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.544 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 153.07 -155.58 26.21 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.976 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 1.6 m-85 -137.42 140.13 41.11 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.322 -1.105 . . . . 0.0 109.402 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.543 ' O ' HG13 ' A' ' 84' ' ' VAL . 11.5 p -64.85 125.41 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 109.519 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.545 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.7 p -159.35 161.69 35.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.241 -0.912 . . . . 0.0 109.516 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 85.8 p -92.01 -36.66 13.27 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.249 -0.907 . . . . 0.0 109.391 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -120.47 -88.19 1.04 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.515 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -104.25 -133.93 7.98 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.696 ' NE2' ' CD1' ' A' ' 71' ' ' TYR . 2.9 mp0 -34.25 155.06 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.547 -0.972 . . . . 0.0 110.134 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.545 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.3 Cg_endo -68.47 163.72 35.55 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.824 2.349 . . . . 0.0 111.855 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.7 m -93.97 154.08 40.78 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.294 -0.879 . . . . 0.0 109.31 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.38 142.45 45.23 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.605 2.203 . . . . 0.0 111.796 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.959 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.3 t -73.04 131.49 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -0.899 . . . . 0.0 109.306 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' LYS . . . . . 0.484 ' O ' ' N ' ' A' ' 97' ' ' GLU . 42.2 mttm -71.6 132.75 45.09 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.193 -0.942 . . . . 0.0 109.264 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 94' ' ' LYS . 82.1 m-20 -44.46 -41.28 6.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.226 -0.921 . . . . 0.0 109.459 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -61.04 -24.91 66.55 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.265 -0.897 . . . . 0.0 109.502 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.484 ' N ' ' O ' ' A' ' 94' ' ' LYS . 54.2 mt-10 -87.14 -27.0 23.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.162 -0.961 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.644 ' SD ' HG11 ' A' ' 93' ' ' VAL . 37.4 mmm -84.63 -26.87 27.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.166 -0.959 . . . . 0.0 109.42 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.576 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 5.1 ttp180 -37.06 -54.98 1.75 Allowed Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.47 -0.769 . . . . 0.0 109.994 -179.795 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.1 Cg_endo -69.05 -27.21 30.13 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.535 2.157 . . . . 0.0 111.79 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.59 HG22 HG11 ' A' ' 41' ' ' VAL . 51.1 mm -81.44 -41.94 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.226 -0.921 . . . . 0.0 109.284 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.574 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -68.27 -40.13 81.95 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.219 -0.926 . . . . 0.0 109.231 179.754 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.52 ' HD3' ' CE1' ' A' ' 110' ' ' TYR . 21.2 mtt180 -62.77 -50.57 70.53 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.333 -0.854 . . . . 0.0 108.978 179.587 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -73.35 -35.34 65.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.459 -0.776 . . . . 0.0 109.11 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -71.99 -2.73 19.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.385 -0.822 . . . . 0.0 109.633 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.48 9.68 84.56 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.703 HD22 HG21 ' A' ' 41' ' ' VAL . 8.0 mp -80.9 -21.95 40.16 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.164 -1.198 . . . . 0.0 109.429 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -120.85 141.26 50.73 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.381 -0.824 . . . . 0.0 109.501 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -114.67 114.28 25.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.354 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.52 ' CE1' ' HD3' ' A' ' 103' ' ' ARG . 37.7 p90 -137.25 163.48 30.82 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.288 -0.882 . . . . 0.0 109.47 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.443 ' O ' ' C ' ' A' ' 112' ' ' GLU . 94.0 mt-10 -100.05 -100.67 0.24 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.274 -0.891 . . . . 0.0 109.507 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.443 ' C ' ' O ' ' A' ' 111' ' ' GLU . 33.2 tt0 42.03 82.26 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.534 ' O ' ' CG ' ' A' ' 114' ' ' LYS . 53.3 pttt -171.53 -158.54 0.14 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.534 ' CG ' ' O ' ' A' ' 113' ' ' LYS . 6.0 pttt 40.12 30.44 0.07 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.263 -0.898 . . . . 0.0 109.594 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.45 ' N ' ' O ' ' A' ' 113' ' ' LYS . 0.0 OUTLIER -128.16 82.15 69.06 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 0.0 109.406 -179.944 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.38 127.68 13.63 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.742 2.294 . . . . 0.0 111.766 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 4.3 p -135.21 129.57 50.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.483 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 23.8 mttt -86.79 145.65 26.54 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.273 -0.892 . . . . 0.0 109.442 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.423 HG12 ' N ' ' A' ' 120' ' ' GLU . 94.1 t -126.03 155.94 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.149 -0.97 . . . . 0.0 109.448 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.703 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 78.5 tt0 -130.62 153.22 49.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.228 -0.92 . . . . 0.0 109.496 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.732 HD23 ' HB2' ' A' ' 175' ' ' LYS . 13.7 tp 143.71 99.03 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.599 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.76 79.81 0.0 OUTLIER Glycine 0 N--CA 1.496 2.669 0 N-CA-C 111.011 -0.835 . . . . 0.0 111.011 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.716 ' N ' ' O ' ' A' ' 121' ' ' LEU . 31.4 p90 -95.7 130.95 42.44 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.251 -1.147 . . . . 0.0 109.094 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.642 ' HA ' HD11 ' A' ' 146' ' ' ILE . 14.1 mttt -140.35 -174.52 3.97 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.034 -1.041 . . . . 0.0 110.076 -179.615 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 144' ' ' LYS . 13.8 p -61.78 141.94 16.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.451 -0.781 . . . . 0.0 109.677 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 86.72 -34.31 3.55 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.549 ' HB2' HD12 ' A' ' 143' ' ' ILE . 24.0 m-20 -49.29 158.73 0.36 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.316 -1.108 . . . . 0.0 109.633 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' MET . . . . . 0.71 ' HG3' HD11 ' A' ' 176' ' ' ILE . 2.7 tpp -95.53 127.91 41.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.336 -0.853 . . . . 0.0 108.871 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.683 HG22 ' CG1' ' A' ' 173' ' ' VAL . 2.0 p -127.72 143.83 39.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.264 -0.898 . . . . 0.0 109.816 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.451 ' O ' HG13 ' A' ' 173' ' ' VAL . 21.0 tttt -108.55 142.29 39.21 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.266 -0.896 . . . . 0.0 109.319 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 1.0 ' O ' HD13 ' A' ' 132' ' ' ILE . 96.6 mt -80.14 152.22 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.139 -0.976 . . . . 0.0 108.971 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 1.0 HD13 ' O ' ' A' ' 131' ' ' ILE . 1.1 mm -146.67 2.27 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.088 -1.007 . . . . 0.0 109.391 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.577 ' CA ' ' HG2' ' A' ' 137' ' ' GLU . 50.6 m -148.64 143.12 26.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.259 -0.9 . . . . 0.0 109.758 -179.575 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.462 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 105.77 -169.23 15.8 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.479 ' HA ' ' OH ' ' A' ' 110' ' ' TYR . 48.5 Cg_endo -68.56 -19.98 41.73 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 123.317 2.678 . . . . 0.0 112.679 -179.414 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.521 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.6 m-85 -106.77 16.71 24.11 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.933 -1.104 . . . . 0.0 109.605 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.577 ' HG2' ' CA ' ' A' ' 133' ' ' SER . 62.9 mt-10 -41.58 139.01 1.22 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.163 -0.961 . . . . 0.0 110.073 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.568 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.8 OUTLIER 80.37 19.41 0.56 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.277 -0.89 . . . . 0.0 110.788 178.775 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.761 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.0 OUTLIER -108.18 141.67 39.57 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.794 -1.191 . . . . 0.0 109.565 179.798 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -94.53 135.95 35.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.225 -0.922 . . . . 0.0 109.22 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.494 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.83 168.99 27.38 Favored Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.571 -1.299 . . . . 0.0 110.5 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.682 ' C ' HG23 ' A' ' 155' ' ' VAL . 39.5 t -111.14 137.49 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.593 -0.945 . . . . 0.0 109.369 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.549 HD12 ' HB2' ' A' ' 127' ' ' ASP . 69.8 mt -68.71 118.26 12.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 109.303 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.661 ' O ' HG23 ' A' ' 125' ' ' VAL . 47.7 tttp -100.39 -33.29 10.43 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.975 -1.078 . . . . 0.0 109.561 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.435 ' HG2' ' O ' ' A' ' 144' ' ' LYS . 64.2 mt-10 -153.85 149.12 27.02 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.132 -0.98 . . . . 0.0 109.812 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 1.065 HG23 HD22 ' A' ' 153' ' ' LEU . 1.7 mt -124.33 127.59 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.354 -0.841 . . . . 0.0 109.379 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.13 104.1 55.77 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.628 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.528 ' O ' ' HB2' ' A' ' 149' ' ' GLU . 52.4 Cg_endo -72.35 173.21 13.47 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.72 2.28 . . . . 0.0 111.661 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.528 ' HB2' ' O ' ' A' ' 148' ' ' PRO . 39.5 mm-40 78.25 -22.0 0.31 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.397 -0.814 . . . . 0.0 110.062 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.437 ' NH1' ' HG3' ' A' ' 150' ' ' ARG . 0.6 OUTLIER -124.15 -15.5 6.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.1 -1.0 . . . . 0.0 109.119 179.776 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.456 ' HB3' HG11 ' A' ' 170' ' ' VAL . 30.9 mt-30 69.58 47.98 0.63 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.461 -0.774 . . . . 0.0 109.439 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.993 ' O ' HD23 ' A' ' 153' ' ' LEU . 97.8 mt-10 -119.76 143.56 47.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.215 -0.928 . . . . 0.0 109.081 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 1.065 HD22 HG23 ' A' ' 146' ' ' ILE . 14.4 mt -130.95 122.85 27.64 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.16 -0.963 . . . . 0.0 110.231 -179.628 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 13.9 mttt -85.57 129.78 34.74 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.403 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.682 HG23 ' C ' ' A' ' 142' ' ' VAL . 10.9 p -129.36 146.94 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.222 -0.923 . . . . 0.0 109.951 -179.608 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.543 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 3.7 m-20 -98.02 108.89 21.71 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.218 -0.926 . . . . 0.0 109.537 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.577 HG13 ' CE1' ' A' ' 139' ' ' PHE . 82.2 t -88.14 140.72 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.18 -0.95 . . . . 0.0 109.376 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 47.7 m -96.62 89.23 4.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.332 -0.855 . . . . 0.0 109.617 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.506 HG13 HG12 ' A' ' 157' ' ' VAL . 2.6 mt -115.74 144.87 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.192 -0.942 . . . . 0.0 109.395 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.503 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 18.7 m-85 61.93 37.41 15.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.276 -0.89 . . . . 0.0 109.226 -179.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.03 17.95 31.85 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.426 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 89.5 mtt-85 -127.66 157.49 40.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.216 -1.167 . . . . 0.0 109.481 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.44 ' OE2' ' ND2' ' A' ' 156' ' ' ASN . 83.6 tt0 -100.82 133.35 45.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.327 -0.858 . . . . 0.0 109.591 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 79.7 m -144.04 127.3 8.83 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.905 . . . . 0.0 109.684 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.543 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.4 Cg_endo -70.98 137.16 31.33 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.723 2.282 . . . . 0.0 111.598 179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 46.1 t -125.66 144.48 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.229 -0.92 . . . . 0.0 109.862 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.413 ' O ' ' HG ' ' A' ' 168' ' ' LEU . 44.4 t -92.68 119.35 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.438 -0.789 . . . . 0.0 109.485 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.413 ' HG ' ' O ' ' A' ' 167' ' ' VAL . 1.4 mt -138.71 164.69 28.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.229 -0.92 . . . . 0.0 110.48 -179.162 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.495 ' HB2' ' HB2' ' A' ' 172' ' ' GLU . 88.6 m-70 -81.57 145.64 30.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.632 -0.668 . . . . 0.0 109.291 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.702 HG23 HD11 ' A' ' 153' ' ' LEU . 6.2 p -62.11 -35.73 70.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.305 -0.872 . . . . 0.0 108.982 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 82.9 p -78.59 -9.66 59.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.254 -0.904 . . . . 0.0 109.362 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.505 ' CB ' ' HB2' ' A' ' 133' ' ' SER . 46.8 mt-10 -97.69 -1.14 44.19 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.405 -0.809 . . . . 0.0 109.022 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.683 ' CG1' HG22 ' A' ' 129' ' ' VAL . 97.9 t -126.14 163.25 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.297 -0.877 . . . . 0.0 109.412 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.548 ' N ' HG12 ' A' ' 173' ' ' VAL . 55.8 tt0 -137.26 154.95 50.02 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.314 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.732 ' HB2' HD23 ' A' ' 121' ' ' LEU . 19.8 mttt -97.57 37.91 1.33 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.395 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.71 HD11 ' HG3' ' A' ' 128' ' ' MET . 7.1 mt 56.72 83.63 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.264 -0.897 . . . . 0.0 109.468 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 72.2 mm-40 . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.557 -179.923 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.468 ' HB1' ' HB ' ' A' ' 65' ' ' ILE . . . -98.26 27.52 4.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.235 -1.156 . . . . 0.0 109.518 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 60.4 ttp -62.57 -22.16 66.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.261 -0.9 . . . . 0.0 109.642 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 56.1 mttm -99.62 134.55 42.35 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.901 . . . . 0.0 109.431 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.638 ' HG2' HG22 ' A' ' 65' ' ' ILE . 21.8 mttm -100.41 148.74 24.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.186 -0.946 . . . . 0.0 109.575 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.6 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.6 mttt -131.53 173.1 11.45 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.16 -0.962 . . . . 0.0 109.407 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.794 ' HZ3' HG22 ' A' ' 41' ' ' VAL . 51.9 m95 -108.82 126.74 53.36 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.415 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.502 ' CZ ' ' SD ' ' A' ' 66' ' ' MET . 91.3 m-85 -116.2 168.55 10.01 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.329 -0.857 . . . . 0.0 109.492 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.506 HG12 ' CE1' ' A' ' 61' ' ' PHE . 36.5 mt -106.49 116.51 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.282 -0.886 . . . . 0.0 109.197 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.588 ' CG1' HG23 ' A' ' 80' ' ' VAL . 72.5 t -91.56 136.52 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.282 -0.886 . . . . 0.0 109.294 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.829 HD21 HG22 ' A' ' 84' ' ' VAL . 3.8 mm? -89.18 146.89 24.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.374 -0.829 . . . . 0.0 109.496 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.421 ' OG1' HG21 ' A' ' 20' ' ' VAL . 9.6 t -161.83 -168.03 1.84 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.302 -0.874 . . . . 0.0 109.362 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 67.3 mtp -107.38 134.5 50.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.242 -0.911 . . . . 0.0 109.492 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 11.0 t -54.74 130.25 39.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.291 -0.881 . . . . 0.0 109.393 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.46 -20.22 37.75 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -109.87 -3.23 16.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.285 -1.127 . . . . 0.0 109.717 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -47.48 -64.56 0.75 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.254 -0.903 . . . . 0.0 109.594 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.511 ' OE2' HD11 ' A' ' 44' ' ' ILE . 75.8 mm-40 -48.73 -38.87 22.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.183 -0.948 . . . . 0.0 109.435 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.466 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 54.1 tttp -66.77 -45.9 77.03 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.304 -0.872 . . . . 0.0 109.278 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.675 HG22 ' CB ' ' A' ' 79' ' ' TYR . 50.7 t -61.65 -44.5 98.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -0.91 . . . . 0.0 109.501 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.562 ' HG3' HG21 ' A' ' 40' ' ' ILE . 48.1 tttt -60.51 -45.62 93.13 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -0.957 . . . . 0.0 109.219 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -65.72 -40.42 92.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.315 -0.866 . . . . 0.0 109.347 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.575 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 31.2 m120 -60.59 -46.15 91.3 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.337 -0.852 . . . . 0.0 109.431 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.406 HG21 HD11 ' A' ' 40' ' ' ILE . 95.0 mt -56.01 -42.87 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.215 -0.928 . . . . 0.0 109.268 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -56.17 -43.56 78.5 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.193 -0.942 . . . . 0.0 109.594 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.428 ' HB3' ' HE2' ' A' ' 26' ' ' LYS . 47.9 mtpt -80.14 -35.62 36.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.208 -0.933 . . . . 0.0 109.434 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.427 ' HG2' HG23 ' A' ' 77' ' ' VAL . 11.5 tptt -54.69 -31.52 58.05 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.286 -0.883 . . . . 0.0 109.334 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.78 HG13 ' O ' ' A' ' 33' ' ' ILE . 39.2 t -89.75 -23.3 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.301 -0.874 . . . . 0.0 109.392 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 46.3 tp10 -69.2 -52.63 25.94 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.288 -0.883 . . . . 0.0 109.543 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.37 -32.48 73.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 59.4 p -84.87 -25.29 28.1 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 79.48 -3.42 67.93 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.825 HG23 HD23 ' A' ' 36' ' ' LEU . 84.8 mt -76.16 74.38 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.193 -1.18 . . . . 0.0 109.553 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.485 ' HA ' HG11 ' A' ' 28' ' ' VAL . 23.6 mttt -88.49 1.12 55.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.192 -0.942 . . . . 0.0 109.657 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -97.06 -13.09 22.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.181 -0.949 . . . . 0.0 109.492 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.088 HD12 ' HB2' ' A' ' 70' ' ' ALA . 2.5 mm? -88.32 -49.05 7.21 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.291 -0.881 . . . . 0.0 109.467 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.507 ' HB ' HG21 ' A' ' 28' ' ' VAL . 78.5 t -91.12 139.49 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.244 -0.91 . . . . 0.0 109.256 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -127.09 5.44 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 88.2 mtt180 -92.16 146.97 23.3 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.255 -1.144 . . . . 0.0 109.755 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.605 HG12 HG13 ' A' ' 62' ' ' VAL . 67.1 mt -112.55 134.16 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.913 . . . . 0.0 109.336 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.794 HG22 ' HZ3' ' A' ' 7' ' ' TRP . 33.3 m -128.08 155.77 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.235 -0.916 . . . . 0.0 109.45 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.781 HG22 HG23 ' A' ' 44' ' ' ILE . 11.5 mt -133.63 128.63 20.09 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.268 -0.895 . . . . 0.0 109.63 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.508 ' O ' HD13 ' A' ' 55' ' ' LEU . 43.8 Cg_endo -66.45 -3.89 9.77 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.928 2.418 . . . . 0.0 111.744 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.781 HG23 HG22 ' A' ' 42' ' ' ILE . 11.4 pt -80.98 -19.32 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.145 -0.972 . . . . 0.0 109.464 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 39.0 mtm180 -58.65 143.69 45.69 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.287 -0.883 . . . . 0.0 109.472 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 85.15 -6.39 79.61 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.507 ' HA3' ' HA ' ' A' ' 53' ' ' GLU . . . -66.75 -37.23 92.22 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -54.4 -36.95 64.5 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -1.157 . . . . 0.0 109.477 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 5.9 mmt85 -60.16 -27.9 67.47 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.294 -0.879 . . . . 0.0 109.525 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 65.8 mtm180 -109.19 167.09 10.36 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.27 -0.894 . . . . 0.0 109.559 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 67.7 mttt -67.72 -17.83 64.7 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.293 -0.879 . . . . 0.0 109.527 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 82.5 p -112.74 145.86 39.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.2 -0.938 . . . . 0.0 109.421 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.507 ' HA ' ' HA3' ' A' ' 47' ' ' GLY . 82.5 mt-10 -124.68 155.76 38.69 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -0.885 . . . . 0.0 109.418 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.693 ' HA ' HG22 ' A' ' 44' ' ' ILE . 4.7 mttp 76.22 87.48 0.08 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 0.0 109.425 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.545 ' CD1' ' N ' ' A' ' 55' ' ' LEU . 5.2 mp -62.29 -24.68 67.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.171 -0.956 . . . . 0.0 109.465 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 1.153 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 97.4 m-85 -148.79 100.59 3.47 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.316 -0.865 . . . . 0.0 109.056 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -66.08 139.75 57.13 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.733 2.288 . . . . 0.0 111.855 -179.336 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.17 -12.5 6.88 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.589 ' CE1' HD11 ' A' ' 11' ' ' LEU . 2.5 m-30 -100.03 131.3 46.07 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.704 -1.468 . . . . 0.0 110.128 -179.317 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 45.6 t -134.62 144.77 33.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.361 -0.837 . . . . 0.0 108.887 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.775 ' HB2' HG23 ' A' ' 41' ' ' VAL . 74.2 m-85 -106.55 122.98 47.4 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.978 -1.077 . . . . 0.0 109.779 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.605 HG13 HG12 ' A' ' 40' ' ' ILE . 59.7 t -131.37 143.78 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.796 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.632 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 18.0 tt0 -108.2 127.29 53.7 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.328 -0.857 . . . . 0.0 109.166 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.462 ' HB3' ' O ' ' A' ' 36' ' ' LEU . 32.8 mtm -153.98 170.88 20.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.072 -1.018 . . . . 0.0 110.653 -179.261 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.813 ' CG1' HD13 ' A' ' 36' ' ' LEU . 5.3 pt -95.14 131.34 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.536 ' CE ' ' NE2' ' A' ' 89' ' ' GLN . 59.3 mmm -75.95 143.26 41.7 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.893 . . . . 0.0 109.897 -178.778 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.434 ' HB2' ' O ' ' A' ' 66' ' ' MET . 37.6 t30 178.23 158.06 0.46 Allowed 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -59.61 -42.06 91.79 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -0.927 . . . . 0.0 109.594 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.573 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 69.3 mm-40 -74.85 -34.1 62.22 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.891 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.088 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -69.13 -46.36 67.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.149 -0.97 . . . . 0.0 109.756 -179.679 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.55 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 91.1 t80 -61.06 -47.03 88.25 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.156 -0.965 . . . . 0.0 109.782 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.444 ' O ' ' HB2' ' A' ' 76' ' ' SER . 27.5 m120 -62.07 -28.36 69.55 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 109.861 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.573 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 13.7 m-85 -84.54 -42.55 15.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.15 -0.969 . . . . 0.0 109.756 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.735 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 25.9 t -69.76 -57.58 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.161 -0.962 . . . . 0.0 109.697 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.453 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 0.6 OUTLIER -59.26 -13.89 9.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.189 -0.944 . . . . 0.0 109.311 179.823 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.444 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 15.4 m -95.86 5.38 51.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.304 -0.873 . . . . 0.0 109.93 -179.72 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.814 ' O ' HG12 ' A' ' 80' ' ' VAL . 2.3 p -75.46 134.29 73.31 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 120.965 -1.085 . . . . 0.0 109.457 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.627 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 43.8 Cg_endo -65.17 138.82 57.9 Favored 'Trans proline' 0 C--O 1.214 -0.72 0 C-N-CA 122.88 2.387 . . . . 0.0 112.287 -179.277 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.675 ' CB ' HG22 ' A' ' 20' ' ' VAL . 24.3 m-85 90.79 -9.32 0.3 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.857 -0.527 . . . . 0.0 109.662 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.814 HG12 ' O ' ' A' ' 77' ' ' VAL . 5.7 p -90.88 127.08 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.979 -1.076 . . . . 0.0 109.332 179.506 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 82.8 mtp -86.24 -29.5 23.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.249 -0.907 . . . . 0.0 109.375 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.524 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 167.4 -164.22 37.74 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.735 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 21.3 m-85 -134.33 141.39 46.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.207 -1.173 . . . . 0.0 109.499 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.829 HG22 HD21 ' A' ' 11' ' ' LEU . 19.9 t -64.29 123.82 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.25 -0.906 . . . . 0.0 109.409 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.551 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.6 p -162.76 162.26 26.61 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.28 -0.887 . . . . 0.0 109.522 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.1 t -91.55 -33.33 15.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.276 -0.89 . . . . 0.0 109.343 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -129.66 -82.32 0.29 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.519 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -106.66 -131.57 6.82 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.55 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 1.4 mt-30 -33.31 152.08 0.05 OUTLIER Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.522 -0.987 . . . . 0.0 110.109 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.551 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.7 Cg_endo -69.1 159.25 54.64 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.841 2.361 . . . . 0.0 111.803 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 3.7 m -98.1 154.19 37.81 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.167 -0.958 . . . . 0.0 109.378 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.443 ' CB ' ' HD2' ' A' ' 6' ' ' LYS . 49.0 Cg_endo -70.19 150.99 66.41 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.612 2.208 . . . . 0.0 111.701 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.633 HG12 ' HG3' ' A' ' 98' ' ' MET . 31.2 t -85.46 142.38 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.249 -0.907 . . . . 0.0 109.33 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -78.37 139.2 38.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.936 . . . . 0.0 109.446 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.421 ' O ' ' N ' ' A' ' 99' ' ' ARG . 52.9 t0 -50.36 -39.14 45.62 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.497 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.5 mtm180 -52.06 -41.26 62.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.219 -0.926 . . . . 0.0 109.475 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.433 ' C ' ' HD2' ' A' ' 100' ' ' PRO . 63.0 mt-10 -85.38 -23.61 27.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.244 -0.91 . . . . 0.0 109.458 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.633 ' HG3' HG12 ' A' ' 93' ' ' VAL . 97.7 mtp -84.24 -23.64 30.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -0.927 . . . . 0.0 109.644 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.646 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 6.0 mmm180 -46.54 -48.04 48.13 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.256 -0.902 . . . . 0.0 109.788 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.646 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 50.6 Cg_endo -72.14 -27.3 17.03 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.394 2.063 . . . . 0.0 111.822 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.537 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 27.3 mm -81.49 -42.27 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.185 -0.947 . . . . 0.0 109.435 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.569 HD11 ' HB3' ' A' ' 98' ' ' MET . 1.2 mt -69.15 -39.9 78.54 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.237 -0.915 . . . . 0.0 109.339 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.557 ' CZ ' ' NH1' ' A' ' 99' ' ' ARG . 23.5 mtt180 -64.27 -51.17 64.86 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.3 -0.875 . . . . 0.0 109.148 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.5 tt -71.44 -36.17 71.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.346 -0.846 . . . . 0.0 109.247 179.557 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.56 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -70.86 -0.26 8.72 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.328 -0.857 . . . . 0.0 109.989 -179.729 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.19 9.12 84.1 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.719 HD21 HG11 ' A' ' 41' ' ' VAL . 10.1 mp -80.72 -22.67 40.1 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.194 -1.18 . . . . 0.0 109.456 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.42 ' HG3' ' CB ' ' A' ' 102' ' ' LEU . 53.7 mt-10 -112.05 144.72 40.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.302 -0.874 . . . . 0.0 109.497 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -98.91 121.99 41.58 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.266 -0.896 . . . . 0.0 109.471 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 24.6 p90 -150.28 154.08 37.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.204 -0.935 . . . . 0.0 109.52 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -91.05 -149.42 0.22 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.235 -0.916 . . . . 0.0 109.415 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.444 ' HG2' ' N ' ' A' ' 113' ' ' LYS . 67.7 tt0 -113.15 154.46 26.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.248 -0.908 . . . . 0.0 109.428 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.505 ' O ' ' CG ' ' A' ' 113' ' ' LYS . 12.1 pttt -44.3 113.8 0.59 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.185 -0.947 . . . . 0.0 109.401 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 6.2 pttt -91.91 3.54 54.96 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.217 -0.927 . . . . 0.0 109.535 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.7 80.96 71.12 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.911 . . . . 0.0 109.462 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -70.85 121.53 7.98 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.694 2.263 . . . . 0.0 111.82 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 5.0 p -125.41 135.03 65.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.235 -0.916 . . . . 0.0 109.311 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 36.3 mtmm -98.49 128.76 44.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.93 . . . . 0.0 109.611 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.477 HG12 ' N ' ' A' ' 120' ' ' GLU . 22.6 t -96.99 162.75 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.353 -0.842 . . . . 0.0 109.279 179.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.655 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 88.4 mt-10 -145.16 139.42 27.25 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.143 -0.973 . . . . 0.0 109.658 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.655 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 2.5 mt 146.2 98.29 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.596 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -23.13 94.01 0.01 OUTLIER Glycine 0 N--CA 1.495 2.601 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.58 ' CD1' ' O ' ' A' ' 121' ' ' LEU . 19.1 m-85 -67.41 155.25 39.44 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.131 -1.217 . . . . 0.0 109.096 179.759 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.484 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 77.1 mttt -134.51 151.84 51.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.122 -0.986 . . . . 0.0 109.95 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 22.5 t -65.32 141.58 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.451 -0.781 . . . . 0.0 109.23 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.518 ' O ' HG13 ' A' ' 142' ' ' VAL . . . 89.19 -30.63 5.46 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.553 ' HB2' HD12 ' A' ' 143' ' ' ILE . 63.4 m-20 -47.8 161.89 0.09 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.309 -1.112 . . . . 0.0 108.989 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' MET . . . . . 0.565 ' HG2' HD12 ' A' ' 176' ' ' ILE . 6.1 ttm -102.09 128.23 48.65 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.025 -1.047 . . . . 0.0 109.096 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.735 HG11 HD11 ' A' ' 143' ' ' ILE . 11.6 m -128.67 143.88 39.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.387 -0.821 . . . . 0.0 109.715 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.75 ' HB2' HD11 ' A' ' 176' ' ' ILE . 44.4 tttt -100.84 140.56 34.96 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.913 HD12 ' HB3' ' A' ' 139' ' ' PHE . 86.1 mt -79.39 154.62 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.024 -1.048 . . . . 0.0 108.371 179.375 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.857 HD13 ' HG3' ' A' ' 174' ' ' GLU . 1.1 pt -149.12 0.46 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.015 -1.053 . . . . 0.0 109.505 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.601 ' CB ' ' HG2' ' A' ' 172' ' ' GLU . 3.1 m -148.68 147.54 29.03 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.058 -1.027 . . . . 0.0 110.372 -179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.77 -170.29 19.92 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.465 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 45.9 Cg_endo -68.24 -21.46 41.76 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.199 2.599 . . . . 0.0 112.487 -179.753 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.496 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 91.5 m-85 -108.81 16.33 22.84 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.002 -1.061 . . . . 0.0 109.284 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.718 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.5 tt0 -48.09 142.69 4.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.316 -0.865 . . . . 0.0 109.788 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.575 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 14.5 t0 81.44 23.17 0.29 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.424 -0.797 . . . . 0.0 110.242 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.913 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.0 OUTLIER -116.13 141.75 47.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.984 -1.073 . . . . 0.0 109.463 179.813 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -90.12 136.18 33.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.191 -0.943 . . . . 0.0 109.516 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.404 ' C ' ' CG1' ' A' ' 155' ' ' VAL . . . -148.02 171.18 28.56 Favored Glycine 0 N--CA 1.49 2.268 0 C-N-CA 119.636 -1.269 . . . . 0.0 110.538 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.908 ' C ' HG13 ' A' ' 155' ' ' VAL . 89.4 t -118.05 136.41 55.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.678 -0.895 . . . . 0.0 109.237 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.735 HD11 HG11 ' A' ' 129' ' ' VAL . 79.4 mt -66.78 115.8 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.43 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 33.2 tttt -97.63 -34.56 10.9 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.03 -1.044 . . . . 0.0 109.231 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -149.78 144.62 26.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.201 -0.937 . . . . 0.0 109.329 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 1.01 HG22 HD22 ' A' ' 153' ' ' LEU . 31.9 pt -123.98 127.66 73.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.573 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 28.5 t0 -111.81 100.19 47.72 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.484 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.568 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.3 Cg_endo -71.27 176.01 8.5 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.778 2.319 . . . . 0.0 111.71 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.568 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.4 mt-10 81.48 -21.05 0.33 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.434 -0.791 . . . . 0.0 109.84 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.431 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 82.1 mtt180 -131.15 -10.46 3.74 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.15 -0.969 . . . . 0.0 109.495 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.431 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 43.3 mt-30 69.97 48.54 0.54 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.252 -0.905 . . . . 0.0 109.967 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.541 ' OE2' HG13 ' A' ' 167' ' ' VAL . 81.3 tt0 -120.44 144.99 47.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.981 -1.075 . . . . 0.0 108.852 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 1.01 HD22 HG22 ' A' ' 146' ' ' ILE . 70.6 mt -139.91 127.69 21.9 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.102 -0.999 . . . . 0.0 110.441 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -91.74 132.77 36.16 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.908 HG13 ' C ' ' A' ' 142' ' ' VAL . 92.9 t -133.99 126.96 51.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.116 -0.99 . . . . 0.0 109.914 -179.358 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.577 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 51.9 t-20 -76.1 137.12 39.93 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.341 -0.85 . . . . 0.0 109.862 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.621 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 59.8 t -114.46 147.53 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.329 -0.857 . . . . 0.0 109.069 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 18.2 m -99.41 91.88 5.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.999 -1.063 . . . . 0.0 109.913 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 1.153 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 2.5 pt -124.58 151.53 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.235 -0.916 . . . . 0.0 108.991 179.311 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.724 ' CE2' HD12 ' A' ' 159' ' ' ILE . 16.7 m-30 60.53 35.45 20.16 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -0.926 . . . . 0.0 108.969 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.03 15.37 9.99 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 21.0 mtp180 -128.22 158.22 38.71 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.179 -1.189 . . . . 0.0 109.595 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.452 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 90.7 mt-10 -100.97 132.76 46.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.268 -0.895 . . . . 0.0 109.551 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 164' ' ' THR . . . . . 0.536 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 47.4 m -139.78 127.31 12.85 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.943 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.577 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.59 134.1 25.49 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.741 2.294 . . . . 0.0 111.175 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.684 ' HB ' HD21 ' A' ' 168' ' ' LEU . 2.2 t -120.03 164.09 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 120.962 -1.086 . . . . 0.0 110.153 -179.527 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 1.143 ' O ' HD13 ' A' ' 168' ' ' LEU . 43.0 t -117.03 115.94 50.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 N-CA-C 109.119 -0.696 . . . . 0.0 109.119 179.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 1.143 HD13 ' O ' ' A' ' 167' ' ' VAL . 0.3 OUTLIER -139.49 167.55 21.84 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 121.878 0.847 . . . . 0.0 110.249 -179.52 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.415 ' O ' ' HB2' ' A' ' 172' ' ' GLU . 96.1 m-70 -78.94 141.01 37.92 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.584 HG23 HD12 ' A' ' 153' ' ' LEU . 7.2 p -55.01 -36.43 38.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.056 -1.028 . . . . 0.0 108.88 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.406 ' N ' HG13 ' A' ' 170' ' ' VAL . 33.6 p -75.07 -5.23 43.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.455 -0.778 . . . . 0.0 109.553 179.746 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.601 ' HG2' ' CB ' ' A' ' 133' ' ' SER . 2.4 mt-10 -87.17 -1.82 58.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.225 -0.922 . . . . 0.0 109.707 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.52 ' HB ' ' O ' ' A' ' 130' ' ' LYS . 1.3 m -150.91 -178.31 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.138 -0.976 . . . . 0.0 109.465 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.857 ' HG3' HD13 ' A' ' 132' ' ' ILE . 3.5 mt-10 -138.01 170.2 16.45 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.082 -1.011 . . . . 0.0 109.1 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.519 ' HE2' ' OD2' ' A' ' 127' ' ' ASP . 52.0 tttm -86.14 5.77 32.34 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.0 -1.062 . . . . 0.0 109.553 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.75 HD11 ' HB2' ' A' ' 130' ' ' LYS . 46.4 mt 55.1 -88.88 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.459 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.485 ' N ' ' O ' ' A' ' 175' ' ' LYS . 85.5 tt0 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.016 -0.993 . . . . 0.0 109.483 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.21 -27.77 69.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.218 -1.166 . . . . 0.0 109.412 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 83.4 mtp -52.45 -44.26 65.4 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.462 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 31.4 tttt -70.08 144.52 52.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.29 -0.881 . . . . 0.0 109.573 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.505 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 27.4 mttm -144.43 150.07 37.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.488 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 1.3 mtpp -125.93 -179.78 4.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.196 -0.94 . . . . 0.0 109.321 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.787 ' CZ3' HG22 ' A' ' 41' ' ' VAL . 69.2 m95 -117.72 122.21 42.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.135 -0.978 . . . . 0.0 109.178 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -115.33 170.94 8.01 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.18 -0.95 . . . . 0.0 109.376 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.439 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 33.0 mt -112.89 110.74 33.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.296 -0.877 . . . . 0.0 109.065 179.681 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.541 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 10.3 p -88.66 142.48 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.215 -0.928 . . . . 0.0 109.512 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.548 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.2 OUTLIER -89.04 145.68 25.32 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.294 -0.879 . . . . 0.0 109.625 -179.893 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.704 ' CG2' HG21 ' A' ' 20' ' ' VAL . 96.0 m -156.84 160.78 39.51 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.285 -0.884 . . . . 0.0 109.52 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.591 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 94.9 mmm -76.98 124.19 27.42 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.216 -0.928 . . . . 0.0 109.469 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 13' ' ' MET . 70.2 m -44.59 125.44 4.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.95 . . . . 0.0 109.301 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.0 -19.98 34.26 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.591 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 92.0 m-85 -107.14 -5.64 17.86 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.22 -1.165 . . . . 0.0 109.505 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.684 ' OE1' HD11 ' A' ' 44' ' ' ILE . 68.2 mt-10 -51.52 -54.62 25.37 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 109.486 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -51.48 -34.49 35.95 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.219 -0.926 . . . . 0.0 109.368 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.46 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 64.1 mttm -76.35 -49.54 16.6 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.178 179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.704 HG21 ' CG2' ' A' ' 12' ' ' THR . 42.0 t -52.22 -49.92 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.337 -0.852 . . . . 0.0 109.365 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.681 ' HG3' HG21 ' A' ' 40' ' ' ILE . 29.9 tttt -56.83 -50.33 72.72 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.65 -34.55 77.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.332 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.527 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 32.8 m120 -65.32 -48.14 74.07 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.404 -0.81 . . . . 0.0 109.586 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 77.4 mt -54.02 -44.52 62.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.133 -0.98 . . . . 0.0 109.437 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.535 ' O ' HG22 ' A' ' 28' ' ' VAL . 75.1 tt0 -56.21 -46.14 79.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.246 -0.909 . . . . 0.0 109.721 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 7.7 mmtp -78.35 -36.13 46.58 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.16 -0.962 . . . . 0.0 109.509 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.465 ' O ' HG23 ' A' ' 31' ' ' THR . 8.9 tptt -53.9 -30.72 47.31 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.282 -0.886 . . . . 0.0 109.358 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.957 HG11 ' CG1' ' A' ' 37' ' ' VAL . 35.5 m -89.3 -22.04 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.3 -0.875 . . . . 0.0 109.41 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.422 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 44.6 mm-40 -70.71 -54.52 11.49 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.611 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.72 -31.09 71.95 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.185 -0.947 . . . . 0.0 109.451 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.465 HG23 ' O ' ' A' ' 27' ' ' LYS . 37.8 p -87.54 -8.23 56.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.413 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 60.58 28.54 67.89 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.719 HG23 HD23 ' A' ' 36' ' ' LEU . 46.7 mt -107.48 73.22 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -1.149 . . . . 0.0 109.515 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.6 mtmt -87.68 -2.36 58.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.225 -0.922 . . . . 0.0 109.573 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -94.08 -12.8 27.73 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -0.929 . . . . 0.0 109.473 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.769 HD12 ' HB2' ' A' ' 70' ' ' ALA . 1.8 mm? -86.92 -47.82 8.67 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.311 179.835 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.957 ' CG1' HG11 ' A' ' 28' ' ' VAL . 11.6 p -94.16 142.65 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.388 -0.82 . . . . 0.0 109.518 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -113.45 -123.97 4.08 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 82.0 mtt180 -94.43 140.07 30.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.253 -1.145 . . . . 0.0 109.619 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.681 HG21 ' HG3' ' A' ' 21' ' ' LYS . 58.8 mt -106.33 136.06 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 109.361 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.93 HG23 ' HB2' ' A' ' 61' ' ' PHE . 31.5 m -127.16 161.98 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.223 -0.923 . . . . 0.0 109.06 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.65 HD11 ' HD2' ' A' ' 21' ' ' LYS . 9.7 mt -144.02 126.99 8.72 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.142 -0.974 . . . . 0.0 110.034 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.69 -2.28 9.08 Favored 'Trans proline' 0 C--O 1.217 -0.533 0 C-N-CA 122.917 2.411 . . . . 0.0 111.381 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.833 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 76.8 mt -57.02 -50.31 76.7 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.185 -0.947 . . . . 0.0 109.491 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.468 ' HB3' ' O ' ' A' ' 44' ' ' ILE . 20.6 ttt85 61.37 139.47 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.296 -0.878 . . . . 0.0 109.498 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.59 16.73 38.55 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.91 -25.5 61.78 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -55.13 -31.61 61.42 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.307 -1.113 . . . . 0.0 109.558 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -100.91 145.72 28.26 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.25 -0.906 . . . . 0.0 109.534 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 57.1 ttm-85 -53.27 -41.4 65.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.292 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 3.2 mtpm? -93.91 115.45 27.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.313 -0.867 . . . . 0.0 109.406 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.507 ' HB2' ' CG2' ' A' ' 44' ' ' ILE . 79.1 p -104.89 156.7 17.79 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.185 -0.947 . . . . 0.0 109.421 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.491 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 27.5 mp0 -76.23 -45.16 34.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.256 -0.902 . . . . 0.0 109.433 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.833 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 8.4 mttt 75.13 88.78 0.09 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.179 -0.951 . . . . 0.0 109.238 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.581 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 61.3 tp -67.04 -23.13 65.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.8 -1.188 . . . . 0.0 109.666 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.741 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 57.1 m-85 -145.46 97.13 4.73 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 108.836 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -66.01 136.48 44.89 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.59 2.193 . . . . 0.0 112.247 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 12' ' ' THR . . . 76.74 -13.17 8.91 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.544 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 2.4 m-30 -100.84 130.47 46.86 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.688 -1.478 . . . . 0.0 110.23 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.541 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 79.2 t -134.38 147.44 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.373 -0.829 . . . . 0.0 108.809 179.457 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.93 ' HB2' HG23 ' A' ' 41' ' ' VAL . 15.7 m-85 -107.58 122.12 46.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.005 -1.06 . . . . 0.0 109.956 -179.532 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.441 HG12 HG23 ' A' ' 40' ' ' ILE . 7.9 m -125.81 136.77 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.405 -0.809 . . . . 0.0 109.642 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.572 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 7.8 tt0 -101.01 123.96 45.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.228 -0.92 . . . . 0.0 108.974 179.553 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.529 ' HB3' ' O ' ' A' ' 36' ' ' LEU . 14.0 mtm -156.06 176.45 12.65 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.999 -1.063 . . . . 0.0 110.36 -179.266 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.621 ' CG1' HD13 ' A' ' 36' ' ' LEU . 7.9 pt -99.38 132.28 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.479 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 47.4 ttm -76.66 144.17 39.63 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.347 -0.846 . . . . 0.0 109.992 -178.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.479 ' HB2' ' O ' ' A' ' 66' ' ' MET . 50.6 t30 176.2 171.53 0.4 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -67.25 -41.64 85.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.1 -1.0 . . . . 0.0 109.446 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.579 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 97.4 mt-10 -71.72 -38.1 70.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.295 -0.878 . . . . 0.0 109.872 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.769 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -64.93 -44.9 87.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.19 -0.944 . . . . 0.0 109.466 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.493 ' CD2' ' OE1' ' A' ' 89' ' ' GLN . 27.9 t80 -60.0 -52.02 67.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.284 -0.885 . . . . 0.0 109.641 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.523 ' O ' ' HB3' ' A' ' 76' ' ' SER . 96.1 m-20 -59.34 -28.32 66.72 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.204 -0.935 . . . . 0.0 110.164 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 21.9 m-85 -85.45 -43.53 13.52 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.957 -1.089 . . . . 0.0 109.95 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.407 ' O ' HG12 ' A' ' 77' ' ' VAL . 71.6 t -70.06 -57.84 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.288 -0.883 . . . . 0.0 110.025 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.513 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 29.3 tpt85 -60.83 -22.58 64.34 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.171 -0.956 . . . . 0.0 109.826 -179.669 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.523 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 35.4 p -93.71 5.89 50.13 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.127 -0.983 . . . . 0.0 109.88 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.718 HG11 HG21 ' A' ' 80' ' ' VAL . 5.1 p -70.15 129.42 90.66 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.125 -0.985 . . . . 0.0 109.331 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.671 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 43.5 Cg_endo -65.48 138.92 56.81 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 122.782 2.322 . . . . 0.0 112.177 -179.382 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.671 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 59.9 m-85 91.54 -11.98 0.23 Allowed 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.718 HG21 HG11 ' A' ' 77' ' ' VAL . 4.7 t -93.96 134.12 32.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.994 -1.066 . . . . 0.0 109.171 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 85.6 mmm -87.95 -27.4 22.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.205 -0.934 . . . . 0.0 109.492 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.9 -160.24 32.24 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.617 ' CD1' ' N ' ' A' ' 83' ' ' PHE . 1.6 p90 -139.61 153.92 47.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -1.094 . . . . 0.0 109.314 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.669 ' O ' HG13 ' A' ' 84' ' ' VAL . 10.6 p -84.71 113.7 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.188 -0.945 . . . . 0.0 109.615 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.557 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.4 p -148.47 163.24 37.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.895 . . . . 0.0 109.438 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 80.6 p -86.5 -34.55 19.98 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.419 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -127.32 -91.11 0.74 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.557 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -102.59 -126.95 5.97 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.557 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -30.27 152.39 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.61 -0.935 . . . . 0.0 110.375 -179.606 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.565 ' HD3' ' CD2' ' A' ' 83' ' ' PHE . 47.1 Cg_endo -68.13 137.69 41.39 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.917 2.411 . . . . 0.0 112.014 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 18.8 m -73.54 144.92 84.25 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.351 -0.843 . . . . 0.0 109.336 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.31 153.81 66.08 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.645 2.23 . . . . 0.0 111.702 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 7' ' ' TRP . 18.6 t -93.9 129.45 44.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.379 -0.826 . . . . 0.0 109.36 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 25.4 mttm -64.29 141.38 58.79 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.227 -0.921 . . . . 0.0 109.512 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -51.37 -38.64 54.36 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.228 -0.92 . . . . 0.0 109.415 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 62.3 mtt85 -58.2 -38.26 76.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.347 -0.846 . . . . 0.0 109.557 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -77.61 -25.93 50.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.196 -0.94 . . . . 0.0 109.454 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.608 ' CB ' HD11 ' A' ' 102' ' ' LEU . 95.4 mtp -86.03 -22.27 27.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.388 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.609 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 1.1 mtm180 -36.27 -52.8 1.7 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.525 -0.734 . . . . 0.0 109.861 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.612 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 49.7 Cg_endo -70.01 -27.98 24.62 Favored 'Trans proline' 0 C--O 1.214 -0.718 0 C-N-CA 122.469 2.113 . . . . 0.0 111.908 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.526 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 29.8 mm -81.98 -43.41 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.176 -0.952 . . . . 0.0 109.451 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.608 HD11 ' CB ' ' A' ' 98' ' ' MET . 1.2 mt -68.94 -40.0 79.26 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.23 -0.919 . . . . 0.0 109.445 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.547 ' NH2' ' NH1' ' A' ' 99' ' ' ARG . 24.1 mtt180 -64.36 -50.59 67.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.124 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.62 -36.07 70.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.382 -0.824 . . . . 0.0 109.3 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.618 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -71.27 1.47 6.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.323 -0.861 . . . . 0.0 110.035 -179.776 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.07 8.25 82.88 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.633 HD21 HG11 ' A' ' 41' ' ' VAL . 9.4 mp -80.91 -22.07 40.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -1.148 . . . . 0.0 109.368 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.491 ' HB3' ' HA ' ' A' ' 103' ' ' ARG . 47.6 tp10 -115.95 142.95 46.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.333 -0.854 . . . . 0.0 109.487 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -115.89 120.74 40.19 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.228 -0.92 . . . . 0.0 109.487 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.473 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 35.8 p90 -138.96 160.12 40.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.243 -0.911 . . . . 0.0 109.414 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.473 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 47.6 mt-10 -77.44 -144.97 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.522 ' HG2' ' N ' ' A' ' 113' ' ' LYS . 76.7 tt0 -129.86 155.33 46.19 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.435 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.522 ' N ' ' HG2' ' A' ' 112' ' ' GLU . 5.6 tttp -34.51 146.0 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.484 -0.76 . . . . 0.0 109.892 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.63 -43.33 85.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 109.55 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.09 158.37 38.84 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.257 -0.902 . . . . 0.0 109.626 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.53 121.9 8.4 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.763 2.309 . . . . 0.0 111.798 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.452 HG21 ' OE2' ' A' ' 174' ' ' GLU . 4.1 p -98.51 147.39 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.197 -0.94 . . . . 0.0 109.518 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 35.9 mttt -86.63 169.97 12.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.238 -0.914 . . . . 0.0 109.446 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.471 HG11 HG22 ' A' ' 170' ' ' VAL . 32.8 m -113.53 177.28 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.223 -0.923 . . . . 0.0 109.51 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.554 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 6.9 mt-10 -67.99 -24.16 65.11 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.311 -0.868 . . . . 0.0 109.533 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.554 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 3.4 tp 79.67 161.41 0.18 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.358 -0.839 . . . . 0.0 109.625 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 43.19 46.07 6.44 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.746 ' CE1' HG21 ' A' ' 146' ' ' ILE . 0.3 OUTLIER -64.19 178.26 0.71 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.188 -1.184 . . . . 0.0 109.208 179.679 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.452 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 7.1 mttp -141.13 145.42 35.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.076 -1.015 . . . . 0.0 109.868 -179.734 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.52 HG12 HG12 ' A' ' 146' ' ' ILE . 22.4 m -63.98 141.99 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.38 -0.825 . . . . 0.0 109.397 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 87.44 -31.69 4.42 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.017 -1.633 . . . . 0.0 109.017 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.496 ' CG ' ' CE ' ' A' ' 175' ' ' LYS . 13.0 t70 -48.5 164.04 0.06 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.513 -0.992 . . . . 0.0 109.055 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' MET . . . . . 0.588 ' HG2' HD12 ' A' ' 176' ' ' ILE . 4.2 ttm -100.29 127.47 46.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.086 -1.009 . . . . 0.0 109.241 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.585 ' CG1' HG12 ' A' ' 143' ' ' ILE . 35.0 m -125.89 142.35 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.34 -0.85 . . . . 0.0 109.26 179.795 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.768 ' HB2' HD11 ' A' ' 176' ' ' ILE . 7.8 tttt -102.79 141.83 34.94 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.357 -0.839 . . . . 0.0 108.858 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 1.041 HD12 ' HB3' ' A' ' 139' ' ' PHE . 89.8 mt -81.73 152.35 4.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.102 -0.999 . . . . 0.0 108.557 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.586 HD11 ' CA ' ' A' ' 173' ' ' VAL . 0.5 OUTLIER -150.45 1.64 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.024 -1.048 . . . . 0.0 109.382 179.647 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.521 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 2.9 m -147.27 143.49 28.15 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.128 -0.982 . . . . 0.0 109.896 -179.726 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.17 -166.92 17.76 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.603 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 45.7 Cg_endo -68.49 -22.51 38.65 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 123.179 2.586 . . . . 0.0 112.594 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.612 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 70.7 m-85 -106.46 17.3 23.54 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.786 -1.196 . . . . 0.0 109.533 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.689 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.5 tt0 -48.18 137.57 10.56 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.168 -0.957 . . . . 0.0 109.599 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.555 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 10.8 m-20 81.62 22.34 0.3 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.479 -0.763 . . . . 0.0 110.323 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 1.041 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.5 t80 -115.03 143.04 45.81 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.966 -1.084 . . . . 0.0 109.566 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -92.0 134.7 34.57 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.146 -0.971 . . . . 0.0 109.493 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.41 167.24 27.52 Favored Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.739 -1.22 . . . . 0.0 110.212 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.662 ' C ' HG13 ' A' ' 155' ' ' VAL . 37.6 t -115.07 137.14 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.54 -0.976 . . . . 0.0 109.139 179.651 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 1.067 ' CG2' HD11 ' A' ' 146' ' ' ILE . 28.1 mm -69.13 122.4 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.262 -0.899 . . . . 0.0 109.423 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.456 ' C ' ' HG2' ' A' ' 145' ' ' GLU . 0.2 OUTLIER -106.53 -33.3 7.73 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.04 -1.038 . . . . 0.0 109.627 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.761 ' O ' HD13 ' A' ' 146' ' ' ILE . 70.0 mm-40 -151.38 146.58 26.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.014 -1.054 . . . . 0.0 109.874 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 1.149 HG23 ' CD2' ' A' ' 153' ' ' LEU . 6.0 mm -120.86 122.76 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.091 -1.006 . . . . 0.0 109.491 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 14.7 t0 -107.08 99.21 25.38 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.307 -0.87 . . . . 0.0 109.349 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.565 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.6 Cg_endo -71.45 172.26 14.57 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.801 2.334 . . . . 0.0 111.841 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.565 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 4.6 mt-10 80.62 -20.16 0.39 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.377 -0.827 . . . . 0.0 109.786 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 94.8 mtt-85 -128.04 -13.66 5.08 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.142 -0.974 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.432 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 35.9 mt-30 70.33 48.47 0.49 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.245 -0.909 . . . . 0.0 109.38 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -120.01 143.13 48.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.085 -1.01 . . . . 0.0 109.245 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 1.149 ' CD2' HG23 ' A' ' 146' ' ' ILE . 98.8 mt -128.64 130.73 47.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.219 -0.926 . . . . 0.0 110.103 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.469 ' HD3' ' HB2' ' A' ' 145' ' ' GLU . 22.7 mtpp -92.93 126.17 37.89 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.892 HG22 HD13 ' A' ' 143' ' ' ILE . 4.0 t -126.31 145.86 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.252 -0.905 . . . . 0.0 110.086 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 27.7 t-20 -98.87 114.9 27.7 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.451 -0.781 . . . . 0.0 109.326 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.621 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 41.7 t -97.54 142.59 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.373 -0.829 . . . . 0.0 109.665 -179.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 13.3 m -96.57 95.61 8.1 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.784 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.753 HD12 ' CE2' ' A' ' 160' ' ' PHE . 19.0 pt -125.94 146.72 31.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.319 -0.863 . . . . 0.0 109.301 179.76 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.753 ' CE2' HD12 ' A' ' 159' ' ' ILE . 11.5 m-85 63.24 36.26 12.0 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.219 -0.926 . . . . 0.0 109.321 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.05 16.64 19.53 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.41 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 17.8 mtt-85 -130.15 158.69 38.98 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.291 -1.123 . . . . 0.0 109.548 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.405 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 94.7 mt-10 -99.42 132.99 44.37 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.202 -0.936 . . . . 0.0 109.375 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 164' ' ' THR . . . . . 0.433 HG21 ' CZ ' ' A' ' 56' ' ' PHE . 27.9 m -144.13 124.84 7.74 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.188 -0.945 . . . . 0.0 109.647 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.538 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -70.81 139.47 36.67 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.738 2.292 . . . . 0.0 111.763 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.653 HG13 HD23 ' A' ' 168' ' ' LEU . 5.6 p -124.48 143.58 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.155 -0.965 . . . . 0.0 109.646 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.59 HG13 ' O ' ' A' ' 167' ' ' VAL . 10.7 p -92.31 119.36 39.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.414 -0.804 . . . . 0.0 109.33 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.653 HD23 HG13 ' A' ' 166' ' ' VAL . 0.7 OUTLIER -140.48 165.91 26.14 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.22 -0.925 . . . . 0.0 110.621 -179.054 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.451 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 53.2 m80 -80.32 145.54 32.05 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.726 HG23 HD11 ' A' ' 153' ' ' LEU . 11.0 p -60.14 -34.58 57.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.19 -0.944 . . . . 0.0 108.975 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 54.3 p -76.82 -6.73 53.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.322 -0.861 . . . . 0.0 109.321 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.521 ' HA ' ' HB2' ' A' ' 133' ' ' SER . 74.4 mt-10 -96.33 5.94 49.85 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.299 -0.876 . . . . 0.0 109.25 179.755 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.607 HG11 HD11 ' A' ' 168' ' ' LEU . 1.5 p -148.07 169.01 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.279 -0.888 . . . . 0.0 108.723 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.603 ' N ' HG22 ' A' ' 173' ' ' VAL . 57.0 mt-10 -138.51 167.79 21.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.011 -1.056 . . . . 0.0 109.202 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.535 ' O ' ' N ' ' A' ' 177' ' ' GLU . 63.0 tttt -92.55 22.57 4.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.077 -1.015 . . . . 0.0 109.485 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.768 HD11 ' HB2' ' A' ' 130' ' ' LYS . 84.5 mt 42.01 -94.25 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.869 . . . . 0.0 109.606 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.535 ' N ' ' O ' ' A' ' 175' ' ' LYS . 61.7 tt0 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.531 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.33 -24.15 67.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.293 -1.122 . . . . 0.0 109.451 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 57.4 mtm -63.84 -17.39 63.08 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -0.92 . . . . 0.0 109.497 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 52.0 mttp -110.13 119.0 37.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.23 -0.919 . . . . 0.0 109.452 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.6 mttt -106.83 174.31 5.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.166 -0.959 . . . . 0.0 109.498 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 24.6 mmtp -128.75 175.5 8.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -0.93 . . . . 0.0 109.307 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.908 ' CH2' HG23 ' A' ' 41' ' ' VAL . 64.6 m95 -112.17 124.59 52.77 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.247 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.612 ' CZ ' ' HG3' ' A' ' 66' ' ' MET . 81.3 m-85 -117.0 170.98 8.21 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.212 -0.93 . . . . 0.0 109.422 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.612 HG12 ' CE1' ' A' ' 61' ' ' PHE . 42.1 mt -107.45 116.33 50.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.251 -0.905 . . . . 0.0 109.379 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.621 ' CG1' HG23 ' A' ' 80' ' ' VAL . 50.0 t -93.43 139.14 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.241 -0.912 . . . . 0.0 109.362 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.567 HD11 ' HE1' ' A' ' 59' ' ' TYR . 4.2 mm? -86.78 146.28 26.3 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.316 -0.865 . . . . 0.0 109.33 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.561 ' OG1' HG21 ' A' ' 20' ' ' VAL . 11.2 t -158.24 -176.21 5.78 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.263 -0.898 . . . . 0.0 109.501 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.507 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 64.0 mtm -101.2 120.01 39.6 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.175 -0.953 . . . . 0.0 109.533 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.435 ' OG ' ' HB2' ' A' ' 57' ' ' PRO . 43.0 m -43.39 128.3 4.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 109.385 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.08 -19.88 47.43 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.507 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 87.2 m-85 -109.54 9.59 25.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.346 -1.091 . . . . 0.0 109.511 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.531 ' HG2' HG21 ' A' ' 12' ' ' THR . 95.6 mt-10 -60.03 -45.1 93.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.203 -0.936 . . . . 0.0 109.493 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.475 ' OE2' ' HG2' ' A' ' 49' ' ' ARG . 78.3 mt-10 -58.82 -35.31 72.67 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.183 -0.948 . . . . 0.0 109.329 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.401 ' O ' ' HB2' ' A' ' 23' ' ' ASN . 83.7 mttt -72.73 -34.0 66.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -0.929 . . . . 0.0 109.355 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.561 HG21 ' OG1' ' A' ' 12' ' ' THR . 87.0 t -72.39 -53.05 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.912 . . . . 0.0 109.461 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.507 ' HG3' HG21 ' A' ' 40' ' ' ILE . 46.2 tttm -57.62 -49.91 74.9 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.301 -0.874 . . . . 0.0 109.372 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -63.4 -35.86 81.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.196 -0.94 . . . . 0.0 109.165 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.744 ' OD1' HG22 ' A' ' 77' ' ' VAL . 13.8 t-20 -62.72 -47.59 82.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.345 -0.847 . . . . 0.0 109.48 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.415 ' CG2' HG11 ' A' ' 37' ' ' VAL . 89.7 mt -55.75 -43.58 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.278 -0.889 . . . . 0.0 109.501 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -57.64 -46.87 83.62 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.943 . . . . 0.0 110.11 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 76.4 mttt -75.63 -37.31 59.83 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.984 -1.073 . . . . 0.0 109.824 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.93 ' CD ' HG23 ' A' ' 77' ' ' VAL . 42.2 tttp -55.95 -29.68 60.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.133 -0.98 . . . . 0.0 109.204 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.818 HG13 ' O ' ' A' ' 33' ' ' ILE . 37.8 t -82.98 -26.42 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.866 . . . . 0.0 109.508 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.416 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 66.8 mm-40 -67.68 -51.65 47.16 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.247 -0.908 . . . . 0.0 109.474 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.07 -43.91 51.54 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.246 -0.909 . . . . 0.0 109.444 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.401 HG21 ' CZ ' ' A' ' 73' ' ' PHE . 62.6 p -88.88 -7.95 55.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.187 -0.946 . . . . 0.0 109.624 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 54.95 22.58 28.12 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.073 HG21 ' CD1' ' A' ' 36' ' ' LEU . 74.8 mt -84.69 100.91 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.252 -1.146 . . . . 0.0 109.512 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.5 mttt -103.54 35.33 2.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.264 -0.897 . . . . 0.0 109.357 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.566 ' OD1' HG23 ' A' ' 33' ' ' ILE . 18.6 p-10 -136.41 8.45 3.13 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.204 -0.935 . . . . 0.0 109.784 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.073 ' CD1' HG21 ' A' ' 33' ' ' ILE . 82.1 mt -113.09 -42.88 3.46 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.22 -0.925 . . . . 0.0 109.34 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.48 ' HA ' ' HB3' ' A' ' 64' ' ' MET . 52.5 t -106.93 138.68 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.226 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -109.37 -124.65 4.93 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.409 ' O ' ' CH2' ' A' ' 7' ' ' TRP . 64.8 mtt85 -95.13 140.12 30.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.243 -1.151 . . . . 0.0 109.789 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.548 HG23 HG12 ' A' ' 62' ' ' VAL . 67.9 mt -102.13 135.94 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.307 -0.87 . . . . 0.0 109.032 179.586 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.908 HG23 ' CH2' ' A' ' 7' ' ' TRP . 53.5 t -118.51 147.21 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.066 -1.021 . . . . 0.0 109.678 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.9 HG22 HG23 ' A' ' 44' ' ' ILE . 2.5 mt -119.74 125.72 27.28 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.254 -0.904 . . . . 0.0 109.411 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.501 ' CB ' ' CD2' ' A' ' 56' ' ' PHE . 49.6 Cg_endo -70.33 -5.33 16.3 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.735 2.29 . . . . 0.0 111.814 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.9 HG23 HG22 ' A' ' 42' ' ' ILE . 14.6 pt -66.09 130.43 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.258 -0.901 . . . . 0.0 109.569 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.617 ' HD2' HD11 ' A' ' 104' ' ' LEU . 34.0 tpt85 -62.61 -48.73 78.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.356 -0.84 . . . . 0.0 109.513 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -77.0 118.97 5.27 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -84.78 11.76 58.74 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -107.02 165.14 11.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.317 -1.107 . . . . 0.0 109.453 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.475 ' HG2' ' OE2' ' A' ' 18' ' ' GLU . 64.2 mtt85 -62.63 -30.58 71.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.277 -0.889 . . . . 0.0 109.463 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 65.8 mtt85 -114.36 174.98 5.68 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.904 . . . . 0.0 109.415 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 69.7 mttt 56.05 28.64 13.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.277 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.38 137.69 32.15 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.326 -0.859 . . . . 0.0 109.462 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.502 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 82.9 tt0 -91.83 -48.99 6.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.269 -0.894 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.571 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 37.8 mttt 75.33 87.54 0.09 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.302 -0.874 . . . . 0.0 109.494 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.618 ' O ' ' CD1' ' A' ' 56' ' ' PHE . 49.4 mt -60.72 -24.77 65.93 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.091 -1.006 . . . . 0.0 109.462 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 1.058 ' CE1' HD11 ' A' ' 159' ' ' ILE . 1.0 OUTLIER -151.59 104.58 2.89 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.298 -0.876 . . . . 0.0 108.78 179.655 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.435 ' HB2' ' OG ' ' A' ' 14' ' ' SER . 43.7 Cg_endo -66.93 142.17 61.39 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.541 2.161 . . . . 0.0 111.845 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.48 -9.48 10.31 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.567 ' HE1' HD11 ' A' ' 11' ' ' LEU . 2.9 m-30 -102.52 132.08 48.81 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.8 -1.412 . . . . 0.0 110.046 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 45.8 t -134.74 147.75 29.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.859 . . . . 0.0 108.818 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.612 ' CE1' HG12 ' A' ' 9' ' ' ILE . 93.2 m-85 -110.34 123.19 49.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.937 -1.102 . . . . 0.0 109.902 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.548 HG12 HG23 ' A' ' 40' ' ' ILE . 4.9 m -130.66 143.34 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.302 -0.874 . . . . 0.0 109.767 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.608 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 8.1 tt0 -101.46 125.35 48.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 109.04 179.662 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.523 ' CE ' HG11 ' A' ' 74' ' ' VAL . 14.6 ptt? -163.38 -177.37 5.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.984 -1.072 . . . . 0.0 110.457 -179.532 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.843 HD11 ' CD2' ' A' ' 36' ' ' LEU . 7.5 pt -100.9 125.04 54.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.539 -0.726 . . . . 0.0 109.578 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.612 ' HG3' ' CZ ' ' A' ' 8' ' ' TYR . 73.5 mmm -89.56 99.64 12.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 109.398 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.446 ' OD1' HG13 ' A' ' 65' ' ' ILE . 21.3 m120 -139.04 -164.29 1.63 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.062 -1.024 . . . . 0.0 109.174 179.843 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -73.04 -51.92 16.34 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.249 -0.907 . . . . 0.0 110.005 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -72.82 -58.34 3.41 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.096 -1.003 . . . . 0.0 109.743 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.007 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -47.3 -44.19 23.13 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.456 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.663 ' CD1' ' NE2' ' A' ' 89' ' ' GLN . 88.0 t80 -61.65 -51.6 67.79 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.164 -0.96 . . . . 0.0 109.586 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.492 ' O ' ' HB3' ' A' ' 76' ' ' SER . 83.6 m-20 -59.16 -29.28 67.32 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.228 -0.92 . . . . 0.0 109.888 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.604 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 15.8 t80 -82.61 -43.21 17.28 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.091 -1.006 . . . . 0.0 109.636 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 1.007 HG23 ' O ' ' A' ' 70' ' ' ALA . 16.4 t -65.22 -58.1 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.41 -0.806 . . . . 0.0 109.505 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.511 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 15.1 tpt180 -58.23 -11.02 2.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.324 -0.86 . . . . 0.0 110.095 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.492 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 29.0 p -95.41 5.38 51.79 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.927 -1.108 . . . . 0.0 109.898 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.93 HG23 ' CD ' ' A' ' 27' ' ' LYS . 0.3 OUTLIER -71.85 128.72 89.11 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.094 -1.004 . . . . 0.0 109.086 179.871 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.644 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 42.0 Cg_endo -64.97 140.45 66.26 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.566 2.177 . . . . 0.0 111.891 -179.546 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.644 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 8.2 m-85 91.7 -10.02 0.24 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.89 -0.506 . . . . 0.0 109.817 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.72 HG12 ' O ' ' A' ' 77' ' ' VAL . 4.3 p -93.57 134.47 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.879 -1.138 . . . . 0.0 109.85 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 88.6 mtp -86.91 -23.98 24.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.379 -0.825 . . . . 0.0 109.258 179.644 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.572 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 155.19 -156.38 26.91 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.572 ' CD1' ' O ' ' A' ' 82' ' ' GLY . 15.3 m-85 -135.19 143.22 46.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.266 -1.137 . . . . 0.0 109.474 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.461 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 9.5 p -69.46 131.81 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.286 -0.884 . . . . 0.0 109.512 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.56 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.3 p -166.92 158.65 12.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.271 -0.893 . . . . 0.0 109.616 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.2 m -86.05 -31.79 21.78 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.282 -0.886 . . . . 0.0 109.269 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -131.03 -85.37 0.34 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.542 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -104.17 -134.24 8.09 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.663 ' NE2' ' CD1' ' A' ' 71' ' ' TYR . 2.6 mp0 -30.91 150.79 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.819 0 O-C-N 121.557 -0.967 . . . . 0.0 110.317 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.56 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.5 Cg_endo -68.38 141.3 50.92 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.819 2.346 . . . . 0.0 112.087 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.758 HG23 ' HD2' ' A' ' 92' ' ' PRO . 4.0 p -77.14 144.35 71.4 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.344 -0.847 . . . . 0.0 109.364 179.801 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.758 ' HD2' HG23 ' A' ' 91' ' ' VAL . 47.4 Cg_endo -68.39 153.52 73.92 Favored 'Trans proline' 0 C--O 1.216 -0.575 0 C-N-CA 122.66 2.24 . . . . 0.0 111.743 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.52 ' CG1' ' HB2' ' A' ' 97' ' ' GLU . 86.2 t -89.38 133.66 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.268 -0.895 . . . . 0.0 109.649 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 26.4 mtmt -61.49 138.4 58.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.331 -0.856 . . . . 0.0 109.449 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -49.4 -35.81 20.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.928 . . . . 0.0 109.464 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 76.5 mtt180 -61.57 -28.95 69.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.504 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.52 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . 77.1 mt-10 -82.41 -25.22 33.9 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.92 . . . . 0.0 109.599 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.509 ' HE3' HD11 ' A' ' 102' ' ' LEU . 30.9 mmm -85.37 -28.92 24.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.208 -0.932 . . . . 0.0 109.385 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.597 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -36.33 -54.26 1.56 Allowed Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.413 -0.804 . . . . 0.0 109.844 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.639 ' HB2' ' CE1' ' A' ' 136' ' ' PHE . 48.6 Cg_endo -69.28 -26.91 29.39 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.581 2.188 . . . . 0.0 111.938 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.456 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 22.3 mm -82.67 -39.42 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.255 -0.903 . . . . 0.0 109.352 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.688 HD13 ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -72.05 -40.53 68.27 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.097 179.823 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.496 ' HA ' ' HB2' ' A' ' 108' ' ' GLU . 9.3 ttt180 -64.54 -48.5 74.84 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.869 . . . . 0.0 109.158 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.617 HD11 ' HD2' ' A' ' 45' ' ' ARG . 1.2 tt -71.72 -35.12 70.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.271 -0.893 . . . . 0.0 109.184 179.756 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.46 ' CB ' HG13 ' A' ' 41' ' ' VAL . . . -71.83 2.15 5.92 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.335 -0.853 . . . . 0.0 110.178 -179.68 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.0 9.4 83.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.455 ' HB3' ' HB3' ' A' ' 102' ' ' LEU . 0.4 OUTLIER -76.56 -18.68 58.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.073 -1.251 . . . . 0.0 109.314 179.85 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.496 ' HB2' ' HA ' ' A' ' 103' ' ' ARG . 91.2 mt-10 -109.65 152.87 25.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.278 -0.889 . . . . 0.0 109.555 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -108.27 112.68 25.27 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.27 -0.894 . . . . 0.0 109.468 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.448 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 25.8 p90 -149.53 158.27 44.02 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.327 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.448 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 18.6 mt-10 -89.12 -149.96 0.19 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.23 -0.919 . . . . 0.0 109.5 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.471 ' HG2' ' N ' ' A' ' 113' ' ' LYS . 74.4 tt0 -103.87 153.49 20.7 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.226 -0.921 . . . . 0.0 109.469 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.539 ' HG3' ' N ' ' A' ' 114' ' ' LYS . 15.0 pttm -45.56 -43.71 12.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.204 -0.935 . . . . 0.0 109.524 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.539 ' N ' ' HG3' ' A' ' 113' ' ' LYS . 0.3 OUTLIER 68.63 52.81 0.56 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.365 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.57 ' HG3' HG12 ' A' ' 117' ' ' VAL . 0.1 OUTLIER -138.64 80.23 26.72 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.31 -0.869 . . . . 0.0 109.362 -179.973 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -71.13 -6.09 18.44 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.732 2.288 . . . . 0.0 111.933 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.57 HG12 ' HG3' ' A' ' 115' ' ' LYS . 14.4 p -67.47 134.87 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.908 . . . . 0.0 109.51 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -83.92 151.92 24.81 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.296 -0.877 . . . . 0.0 109.38 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.56 HG12 ' HA ' ' A' ' 171' ' ' SER . 7.6 p -114.83 144.88 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.249 -0.907 . . . . 0.0 109.523 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.654 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 86.3 mt-10 -126.81 170.85 11.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.438 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.654 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 3.8 mt 146.14 100.91 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.616 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.22 92.05 0.01 OUTLIER Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.508 ' N ' ' O ' ' A' ' 121' ' ' LEU . 45.7 p90 -104.29 141.76 35.73 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.168 -1.195 . . . . 0.0 109.097 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.405 ' HG2' ' C ' ' A' ' 123' ' ' PHE . 12.5 mmtt -138.12 163.75 30.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.094 -1.004 . . . . 0.0 110.063 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 11.0 p -62.9 141.95 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.443 -0.785 . . . . 0.0 109.548 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.461 ' O ' HG23 ' A' ' 142' ' ' VAL . . . 86.98 -33.21 3.83 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.531 ' HB2' HD12 ' A' ' 143' ' ' ILE . 71.4 m-20 -46.51 161.76 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.378 -1.072 . . . . 0.0 109.102 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 15.4 ttm -99.82 127.88 45.96 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.138 -0.976 . . . . 0.0 108.959 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.679 HG11 HD11 ' A' ' 143' ' ' ILE . 33.4 m -127.78 143.21 41.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.193 -0.942 . . . . 0.0 109.612 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.5 ' HG3' ' O ' ' A' ' 139' ' ' PHE . 12.1 ttpt -101.69 143.02 32.16 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.45 -0.781 . . . . 0.0 109.046 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.776 HD12 ' HB3' ' A' ' 139' ' ' PHE . 93.1 mt -80.39 147.0 6.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.132 -0.98 . . . . 0.0 108.421 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.547 HG13 ' C ' ' A' ' 131' ' ' ILE . 18.7 mt -145.03 1.22 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.018 -1.051 . . . . 0.0 109.337 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.524 ' OG ' ' CD ' ' A' ' 113' ' ' LYS . 16.7 t -148.48 142.37 25.77 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.188 -0.945 . . . . 0.0 109.689 -179.608 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.449 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 105.38 -166.5 14.44 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.472 ' HA ' ' HD3' ' A' ' 103' ' ' ARG . 47.7 Cg_endo -68.09 -19.88 44.7 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 123.23 2.62 . . . . 0.0 112.714 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.655 ' HB2' HD13 ' A' ' 131' ' ' ILE . 96.4 m-85 -107.28 19.74 19.92 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.816 -1.177 . . . . 0.0 109.626 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.525 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 36.7 mt-10 -43.85 137.51 3.13 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.206 -0.934 . . . . 0.0 109.991 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.525 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.6 OUTLIER 77.87 26.47 0.62 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.259 -0.901 . . . . 0.0 110.675 178.87 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.805 ' CE1' HG13 ' A' ' 157' ' ' VAL . 2.0 t80 -114.62 159.79 20.05 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.774 -1.204 . . . . 0.0 109.556 179.696 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -108.63 135.22 50.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.245 -0.909 . . . . 0.0 109.399 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -146.86 170.23 27.84 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.52 -179.458 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.733 ' C ' HG23 ' A' ' 155' ' ' VAL . 8.5 p -119.19 136.94 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.627 -0.926 . . . . 0.0 109.222 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.679 HD11 HG11 ' A' ' 129' ' ' VAL . 88.7 mt -67.22 115.14 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.302 -0.874 . . . . 0.0 109.445 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 68.9 tttt -98.33 -34.77 10.55 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.099 -1.001 . . . . 0.0 109.223 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -149.39 144.47 26.41 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.105 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 1.001 HG22 HD22 ' A' ' 153' ' ' LEU . 26.7 pt -126.27 129.32 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.101 -0.999 . . . . 0.0 109.695 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.85 103.13 48.5 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.345 -0.847 . . . . 0.0 109.38 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.549 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.3 Cg_endo -71.08 169.37 20.73 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.711 2.274 . . . . 0.0 111.898 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.549 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.2 tt0 80.81 -21.23 0.33 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.433 -0.792 . . . . 0.0 110.044 179.683 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.443 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 24.0 mtp85 -124.91 -11.73 7.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.063 -1.023 . . . . 0.0 109.515 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.443 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 42.8 mt-30 69.07 48.13 0.7 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.316 -0.865 . . . . 0.0 109.499 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.72 ' OE2' HG13 ' A' ' 167' ' ' VAL . 56.3 tt0 -121.13 144.93 48.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.104 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 1.001 HD22 HG22 ' A' ' 146' ' ' ILE . 58.1 mt -139.54 121.89 16.02 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.16 -0.963 . . . . 0.0 110.226 -179.701 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.448 ' HE3' ' CB ' ' A' ' 165' ' ' PRO . 18.5 ttpt -83.18 132.04 35.09 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.242 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.733 HG23 ' C ' ' A' ' 142' ' ' VAL . 9.0 p -125.92 149.76 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.781 -179.612 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.531 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 3.5 t30 -99.19 116.21 30.87 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.396 -0.815 . . . . 0.0 109.205 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.805 HG13 ' CE1' ' A' ' 139' ' ' PHE . 65.7 t -102.59 146.09 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.212 -0.93 . . . . 0.0 109.581 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 25.8 m -93.75 113.02 24.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.356 -0.84 . . . . 0.0 109.533 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 1.058 HD11 ' CE1' ' A' ' 56' ' ' PHE . 15.0 pt -145.35 144.6 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.256 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.567 ' CE2' HD12 ' A' ' 159' ' ' ILE . 46.5 m-85 60.18 35.78 21.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.133 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.91 15.41 13.09 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 67.7 mtp180 -127.37 154.28 45.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.063 -1.257 . . . . 0.0 109.637 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.436 ' N ' ' OE1' ' A' ' 163' ' ' GLU . 58.0 mp0 -97.73 134.9 40.28 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.151 -0.968 . . . . 0.0 109.427 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 24.5 m -147.9 126.12 5.99 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.257 -0.902 . . . . 0.0 109.764 -179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.531 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.8 Cg_endo -70.83 142.8 44.06 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.702 2.268 . . . . 0.0 111.545 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 41.8 t -125.72 144.08 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.058 -1.026 . . . . 0.0 109.788 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.72 HG13 ' OE2' ' A' ' 152' ' ' GLU . 55.4 t -91.48 118.4 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.414 -0.804 . . . . 0.0 109.194 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.407 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 27.0 mt -140.71 166.31 25.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.12 -0.987 . . . . 0.0 110.543 -179.014 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.438 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 79.7 m80 -81.54 144.44 31.3 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.6 HG23 ' CD1' ' A' ' 153' ' ' LEU . 11.6 p -59.22 -35.39 57.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.346 -0.846 . . . . 0.0 109.025 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.56 ' HA ' HG12 ' A' ' 119' ' ' VAL . 19.4 m -76.96 -8.16 56.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.249 -0.907 . . . . 0.0 109.508 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.467 ' HG2' ' HB3' ' A' ' 133' ' ' SER . 18.6 mt-10 -92.22 2.22 56.74 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.301 -0.874 . . . . 0.0 109.195 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 4.1 m -145.06 173.07 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.313 -0.867 . . . . 0.0 109.242 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.533 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 84.2 tt0 -136.94 164.0 29.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.165 -0.959 . . . . 0.0 108.985 179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.533 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 36.7 tttm -96.35 33.23 1.81 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.084 -1.01 . . . . 0.0 109.521 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 176' ' ' ILE . . . . . . . . . . . . . 75.0 mt 54.41 -86.74 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.914 . . . . 0.0 109.403 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.528 ' N ' ' O ' ' A' ' 175' ' ' LYS . 28.3 tt0 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.397 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.56 -20.15 65.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.238 -1.154 . . . . 0.0 109.486 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 44.0 mtm -76.92 -6.95 54.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.24 -0.913 . . . . 0.0 109.488 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 10.8 tptt -98.14 113.81 25.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.709 ' HG2' HG22 ' A' ' 65' ' ' ILE . 20.5 mttt -125.92 168.72 13.5 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.179 -0.951 . . . . 0.0 109.536 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.595 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.4 mmtp -129.99 172.11 12.07 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.277 -0.89 . . . . 0.0 109.419 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.938 ' O ' HG23 ' A' ' 93' ' ' VAL . 61.3 m95 -107.44 127.17 53.36 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.286 -0.884 . . . . 0.0 109.215 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.428 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 54.0 m-85 -117.86 167.88 11.0 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.179 -0.951 . . . . 0.0 109.288 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.555 ' HB ' HG12 ' A' ' 84' ' ' VAL . 22.7 mt -101.98 118.32 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.903 . . . . 0.0 109.29 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.539 HG23 HG22 ' A' ' 62' ' ' VAL . 84.3 t -93.88 136.79 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.273 -0.892 . . . . 0.0 109.337 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.489 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.2 OUTLIER -89.2 141.13 28.78 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.202 -0.936 . . . . 0.0 109.419 -179.901 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.533 ' OG1' HG21 ' A' ' 20' ' ' VAL . 11.3 t -154.48 -170.91 3.68 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.282 -0.886 . . . . 0.0 109.442 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 59.2 mtm -105.07 122.93 46.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.203 -0.935 . . . . 0.0 109.496 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 21.0 m -45.75 128.87 8.99 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.223 -0.923 . . . . 0.0 109.278 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.74 -20.18 44.8 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -111.01 10.23 22.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.278 -1.131 . . . . 0.0 109.57 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.594 ' OE1' HD13 ' A' ' 44' ' ' ILE . 94.8 mt-10 -61.8 -46.59 88.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.204 -0.935 . . . . 0.0 109.456 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -56.73 -34.02 67.11 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.19 -0.943 . . . . 0.0 109.524 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -75.31 -44.72 43.95 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.241 -0.912 . . . . 0.0 109.456 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.533 HG21 ' OG1' ' A' ' 12' ' ' THR . 48.4 t -59.0 -50.98 77.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.318 -0.863 . . . . 0.0 109.385 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 49.5 tttm -59.79 -47.83 84.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.305 -0.872 . . . . 0.0 109.437 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -62.38 -34.81 77.43 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.259 -0.9 . . . . 0.0 109.245 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.478 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 5.7 m120 -64.77 -38.03 89.6 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.251 -0.906 . . . . 0.0 109.517 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.886 HG21 HD11 ' A' ' 40' ' ' ILE . 92.6 mt -63.52 -45.26 98.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.226 -0.921 . . . . 0.0 109.755 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -57.32 -46.04 83.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.146 -0.971 . . . . 0.0 109.992 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -81.6 -37.11 28.14 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.03 -1.044 . . . . 0.0 109.825 -179.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.566 ' HG3' ' CZ ' ' A' ' 73' ' ' PHE . 13.3 tptp -55.86 -29.63 60.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.114 -0.991 . . . . 0.0 109.283 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.051 HG21 HG11 ' A' ' 37' ' ' VAL . 70.4 t -87.56 -25.21 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.296 -0.877 . . . . 0.0 109.43 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 48.2 tp10 -66.47 -49.09 67.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.324 -0.86 . . . . 0.0 109.32 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.02 -27.49 65.5 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.379 -0.826 . . . . 0.0 109.313 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 73.0 p -94.25 -25.55 17.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -0.916 . . . . 0.0 109.388 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 73.26 25.49 72.96 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.535 ' CG2' ' HB2' ' A' ' 36' ' ' LEU . 76.4 mt -98.09 82.27 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -1.109 . . . . 0.0 109.447 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.424 ' O ' ' HG3' ' A' ' 34' ' ' LYS . 14.8 tptm -89.63 -6.07 56.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.227 -0.921 . . . . 0.0 109.714 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.508 ' O ' HD13 ' A' ' 65' ' ' ILE . 33.1 m120 -94.34 -4.58 48.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.249 -0.907 . . . . 0.0 109.561 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.136 HD11 ' CB ' ' A' ' 70' ' ' ALA . 8.3 tp -97.85 -54.39 3.11 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.305 -0.872 . . . . 0.0 109.664 -179.677 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 1.051 HG11 HG21 ' A' ' 28' ' ' VAL . 3.7 p -92.65 135.2 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.228 -0.92 . . . . 0.0 109.104 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -106.8 -123.14 5.04 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 59.6 mtt85 -94.11 139.7 30.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.34 -1.094 . . . . 0.0 110.006 -179.374 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 1.081 HG23 HG12 ' A' ' 62' ' ' VAL . 91.8 mt -108.39 136.56 43.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.931 HG23 ' HB2' ' A' ' 61' ' ' PHE . 33.9 m -130.59 155.09 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.071 -1.018 . . . . 0.0 109.616 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.54 HG22 HG23 ' A' ' 44' ' ' ILE . 11.8 mt -128.48 133.91 25.69 Favored Pre-proline 0 N--CA 1.489 1.482 0 O-C-N 121.371 -0.831 . . . . 0.0 109.353 -179.763 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.58 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 40.9 Cg_endo -63.33 -6.57 10.32 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.715 2.276 . . . . 0.0 111.502 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.598 ' CB ' ' HA ' ' A' ' 54' ' ' LYS . 3.7 pt -92.43 117.77 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.329 -0.857 . . . . 0.0 109.09 179.324 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.493 ' O ' ' HB2' ' A' ' 52' ' ' SER . 40.9 mtm-85 -45.87 123.79 4.76 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.167 -0.958 . . . . 0.0 109.367 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -131.92 -172.94 13.19 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 70.95 20.63 77.91 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 88.9 mt-30 -122.4 155.67 35.58 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.32 -1.106 . . . . 0.0 109.492 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -61.97 -31.37 71.72 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 109.448 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 53.0 mtp85 -101.78 153.68 19.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 54.4 mttt -72.04 168.08 18.84 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.388 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.493 ' HB2' ' O ' ' A' ' 45' ' ' ARG . 12.5 t -110.72 167.97 9.83 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.27 -0.894 . . . . 0.0 109.459 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.501 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 97.1 mt-10 -76.85 -19.01 58.0 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.439 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.598 ' HA ' ' CB ' ' A' ' 44' ' ' ILE . 11.3 mttp 75.78 103.85 0.07 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.257 -0.902 . . . . 0.0 109.291 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.58 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 9.9 tp -53.64 -47.93 69.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.1 -1.0 . . . . 0.0 109.423 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 1.029 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 95.9 m-85 -135.57 111.95 10.7 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.121 -0.987 . . . . 0.0 109.121 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -66.7 142.48 64.05 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.584 2.189 . . . . 0.0 111.879 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.37 -8.18 7.34 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.4 m-30 -100.27 131.94 45.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.793 -1.416 . . . . 0.0 110.122 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.457 HG13 HG12 ' A' ' 42' ' ' ILE . 46.5 t -134.28 144.69 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.325 -0.859 . . . . 0.0 109.03 179.564 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.931 ' HB2' HG23 ' A' ' 41' ' ' VAL . 59.6 m-85 -107.03 123.38 48.13 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.114 -0.991 . . . . 0.0 109.821 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 1.081 HG12 HG23 ' A' ' 40' ' ' ILE . 29.6 m -132.94 144.46 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.344 -0.848 . . . . 0.0 109.653 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.622 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 37.3 tt0 -110.62 128.95 55.9 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -0.92 . . . . 0.0 109.051 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.493 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 35.1 mtm -156.01 174.3 15.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.011 -1.056 . . . . 0.0 110.66 -179.35 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 1.02 ' CG1' HD12 ' A' ' 36' ' ' LEU . 10.2 pt -93.92 128.23 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-O 121.323 0.583 . . . . 0.0 109.577 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.569 ' HE3' ' HG2' ' A' ' 89' ' ' GLN . 91.3 mtp -76.82 145.29 38.53 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.372 -0.83 . . . . 0.0 110.046 -178.834 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.482 ' HB2' ' O ' ' A' ' 66' ' ' MET . 45.1 t-20 176.48 173.63 0.38 Allowed 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -70.44 -42.06 72.03 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.056 -1.028 . . . . 0.0 109.292 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -75.92 -30.86 58.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -0.894 . . . . 0.0 109.59 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.136 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -69.58 -48.08 61.39 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.192 -0.942 . . . . 0.0 109.37 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.4 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 74.5 t80 -60.21 -48.55 81.24 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.237 -0.914 . . . . 0.0 109.555 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -59.66 -29.4 68.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.193 -0.942 . . . . 0.0 109.987 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.566 ' CZ ' ' HG3' ' A' ' 27' ' ' LYS . 72.4 t80 -82.0 -43.43 18.0 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.112 -0.992 . . . . 0.0 109.578 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 1.028 HG23 ' O ' ' A' ' 70' ' ' ALA . 2.7 t -66.26 -57.01 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.321 -0.862 . . . . 0.0 109.247 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 13.2 tpt180 -50.34 -32.75 18.08 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.427 -0.796 . . . . 0.0 109.612 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 9.4 t -78.33 6.25 8.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.331 -0.856 . . . . 0.0 110.199 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 74' ' ' VAL . 54.8 t -63.27 131.48 94.79 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 120.957 -1.09 . . . . 0.0 109.408 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.578 ' HB2' ' CD2' ' A' ' 79' ' ' TYR . 47.2 Cg_endo -67.89 137.73 42.37 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.66 2.24 . . . . 0.0 111.983 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.578 ' CD2' ' HB2' ' A' ' 78' ' ' PRO . 58.9 m-85 76.15 -4.41 2.37 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.503 -0.748 . . . . 0.0 109.797 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.593 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.8 t -87.57 129.94 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.108 -0.995 . . . . 0.0 109.162 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.431 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 95.5 mmm -88.31 -7.2 57.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.153 -0.967 . . . . 0.0 109.49 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.403 ' H ' ' CG1' ' A' ' 80' ' ' VAL . . . 132.44 -150.83 19.75 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.65 ' CE2' HG12 ' A' ' 74' ' ' VAL . 4.6 m-85 -140.01 145.79 38.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.228 -1.16 . . . . 0.0 109.542 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.657 ' O ' HG13 ' A' ' 84' ' ' VAL . 10.0 p -68.06 119.1 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.385 -0.822 . . . . 0.0 109.469 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.541 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 6.1 p -153.81 165.65 35.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.195 -0.941 . . . . 0.0 109.452 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 t -91.11 -30.43 16.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.399 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -134.57 -73.9 0.08 OUTLIER Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -115.4 -133.05 5.3 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.569 ' HG2' ' HE3' ' A' ' 66' ' ' MET . 0.5 OUTLIER -31.07 146.48 0.06 OUTLIER Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.588 -0.948 . . . . 0.0 110.135 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.541 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.3 Cg_endo -69.12 141.35 47.59 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.957 2.438 . . . . 0.0 112.096 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.743 HG13 ' HD2' ' A' ' 92' ' ' PRO . 68.9 t -67.48 143.9 97.45 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.323 -0.861 . . . . 0.0 109.434 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.743 ' HD2' HG13 ' A' ' 91' ' ' VAL . 48.0 Cg_endo -69.43 148.14 66.55 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.622 2.215 . . . . 0.0 111.701 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.938 HG23 ' O ' ' A' ' 7' ' ' TRP . 3.0 t -81.87 127.49 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.19 -0.944 . . . . 0.0 109.54 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -69.99 139.87 52.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.317 -0.864 . . . . 0.0 109.47 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -48.83 -40.41 29.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.212 -0.93 . . . . 0.0 109.37 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 59.9 mtt180 -59.01 -34.48 71.92 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.235 -0.916 . . . . 0.0 109.418 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -80.2 -25.96 39.42 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.276 -0.89 . . . . 0.0 109.417 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.542 ' CB ' HD11 ' A' ' 102' ' ' LEU . 93.2 mtp -84.26 -24.73 29.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.261 -0.9 . . . . 0.0 109.556 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.599 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 3.2 tpt85 -36.43 -53.15 1.74 Allowed Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.39 -0.819 . . . . 0.0 109.829 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.599 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 50.2 Cg_endo -70.49 -28.07 22.23 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.574 2.183 . . . . 0.0 111.724 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.495 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 35.8 mm -80.62 -42.26 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 109.486 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.542 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.7 OUTLIER -67.06 -40.03 87.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.184 -0.948 . . . . 0.0 109.236 179.772 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.626 ' CZ ' ' CE2' ' A' ' 110' ' ' TYR . 39.8 ttt-85 -63.06 -50.57 70.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.155 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.628 HD23 ' C ' ' A' ' 104' ' ' LEU . 5.5 tt -72.58 -35.26 67.89 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.267 -0.896 . . . . 0.0 109.078 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.564 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -71.18 -3.12 18.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.425 -0.797 . . . . 0.0 109.778 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.46 11.63 82.5 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.898 HD21 HG11 ' A' ' 41' ' ' VAL . 9.9 mp -79.46 -19.38 49.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.308 -1.113 . . . . 0.0 109.698 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.431 ' OE2' HD13 ' A' ' 102' ' ' LEU . 96.5 mt-10 -123.62 159.34 29.48 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.236 -0.915 . . . . 0.0 109.608 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 62.9 mt-10 -109.59 118.81 37.58 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.309 -0.869 . . . . 0.0 109.412 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.626 ' CE2' ' CZ ' ' A' ' 103' ' ' ARG . 42.4 p90 -127.8 -162.93 1.21 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.302 -0.874 . . . . 0.0 109.564 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.574 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 64.3 mm-40 -101.25 -135.81 0.31 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.335 -0.853 . . . . 0.0 109.342 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 68.0 tt0 -113.22 -43.21 3.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.06 -1.025 . . . . 0.0 109.632 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.564 ' NZ ' ' HA ' ' A' ' 116' ' ' PRO . 0.0 OUTLIER -173.05 107.74 0.16 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.186 -0.946 . . . . 0.0 109.647 -179.772 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.549 ' O ' ' HD3' ' A' ' 116' ' ' PRO . 13.1 tptm -45.9 -35.86 4.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.328 -0.857 . . . . 0.0 109.384 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.52 79.08 0.38 Allowed Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.53 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.564 ' HA ' ' NZ ' ' A' ' 113' ' ' LYS . 51.3 Cg_endo -71.31 3.52 3.49 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.728 2.285 . . . . 0.0 111.837 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.469 ' O ' ' HB2' ' A' ' 171' ' ' SER . 26.9 m -120.21 147.98 23.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.112 -0.993 . . . . 0.0 109.843 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.583 ' HA ' ' CB ' ' A' ' 171' ' ' SER . 24.7 mttt -74.38 154.46 38.81 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.332 -0.855 . . . . 0.0 109.301 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.451 HG12 ' N ' ' A' ' 120' ' ' GLU . 40.7 t -131.01 159.19 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.229 -0.92 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.662 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 58.5 mp0 -115.1 -179.17 3.55 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.249 -0.907 . . . . 0.0 109.373 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.662 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 4.7 mt 145.56 100.77 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.63 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.19 93.54 0.01 OUTLIER Glycine 0 N--CA 1.496 2.69 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.504 ' N ' ' O ' ' A' ' 121' ' ' LEU . 13.3 p90 -107.87 148.42 29.61 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.212 -1.169 . . . . 0.0 109.531 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.412 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 14.7 mttp -150.95 161.43 42.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.238 -0.913 . . . . 0.0 109.397 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 144' ' ' LYS . 40.2 t -60.15 141.33 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.258 -0.901 . . . . 0.0 109.525 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 86.06 -33.29 3.6 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 70.3 m-20 -47.74 162.22 0.08 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.374 -1.074 . . . . 0.0 109.132 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 9.4 ttm -96.67 126.66 42.0 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.157 -0.964 . . . . 0.0 109.082 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.552 ' CG2' HD11 ' A' ' 143' ' ' ILE . 2.7 t -125.37 141.27 45.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.23 -0.919 . . . . 0.0 109.214 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.514 ' HB2' HG12 ' A' ' 176' ' ' ILE . 15.8 tttt -102.55 143.02 32.78 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.245 -0.909 . . . . 0.0 108.98 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.956 HD12 ' HB3' ' A' ' 139' ' ' PHE . 66.8 mt -83.71 151.78 3.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.434 ' C ' ' HG2' ' A' ' 137' ' ' GLU . 2.2 pt -149.67 2.69 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.038 -1.038 . . . . 0.0 109.382 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.587 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 71.9 m -148.7 143.33 26.38 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.185 -0.947 . . . . 0.0 109.884 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.488 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 101.57 -164.07 17.69 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.531 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 47.4 Cg_endo -68.16 -22.01 41.47 Favored 'Trans proline' 0 C--O 1.216 -0.587 0 C-N-CA 123.215 2.61 . . . . 0.0 112.913 -179.187 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.556 ' HB2' HD13 ' A' ' 131' ' ' ILE . 94.0 m-85 -106.21 19.59 20.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.743 -1.223 . . . . 0.0 109.418 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.543 ' HG2' ' HA ' ' A' ' 133' ' ' SER . 44.4 mt-10 -40.75 137.04 1.26 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.871 . . . . 0.0 109.988 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.445 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 4.4 m-20 71.08 29.77 2.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.389 -0.82 . . . . 0.0 110.656 179.05 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.956 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.9 t80 -116.7 128.06 54.98 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.912 -1.117 . . . . 0.0 109.579 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.34 133.3 40.01 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.285 -0.884 . . . . 0.0 109.797 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.525 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -142.66 169.66 25.46 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 155' ' ' VAL . 41.1 t -115.31 136.61 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.314 -1.109 . . . . 0.0 109.506 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.606 HG23 HD23 ' A' ' 153' ' ' LEU . 49.6 mt -67.28 113.82 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.221 -0.924 . . . . 0.0 108.898 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.484 ' O ' HG13 ' A' ' 125' ' ' VAL . 18.1 tptm -98.56 -35.45 10.22 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.926 -1.109 . . . . 0.0 109.768 -179.506 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.46 ' HB2' ' HB2' ' A' ' 154' ' ' LYS . 38.6 mt-10 -153.29 148.31 26.65 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.133 -0.979 . . . . 0.0 109.754 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.719 HG23 ' HG ' ' A' ' 153' ' ' LEU . 3.4 mt -125.15 127.85 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.277 -0.889 . . . . 0.0 109.434 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -110.61 102.3 51.54 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.192 -0.942 . . . . 0.0 109.525 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.538 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.9 Cg_endo -71.54 173.07 13.05 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.607 2.204 . . . . 0.0 111.881 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.538 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 45.2 mm-40 79.86 -21.1 0.35 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.473 -0.767 . . . . 0.0 109.906 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.443 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 46.6 mtt180 -127.63 -13.98 5.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.058 -1.026 . . . . 0.0 109.509 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.825 ' O ' HG13 ' A' ' 170' ' ' VAL . 66.9 mm-40 70.82 47.99 0.43 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.32 -0.863 . . . . 0.0 109.802 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -118.43 142.21 47.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.116 -0.99 . . . . 0.0 108.852 179.526 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.719 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -129.76 113.06 14.25 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.137 -0.977 . . . . 0.0 110.16 -179.535 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.46 ' HB2' ' HB2' ' A' ' 145' ' ' GLU . 13.7 mttm -78.18 127.66 32.61 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.083 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.679 HG13 ' O ' ' A' ' 142' ' ' VAL . 40.4 t -126.17 147.05 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.088 -1.007 . . . . 0.0 109.908 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.54 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 70.1 m-20 -95.81 113.72 25.38 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.431 -0.793 . . . . 0.0 109.035 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.722 HG12 HG23 ' A' ' 159' ' ' ILE . 89.3 t -97.72 142.8 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.205 -0.935 . . . . 0.0 109.613 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 28.2 m -100.32 94.25 6.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.341 -0.85 . . . . 0.0 109.876 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 1.029 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 2.2 pt -125.85 152.3 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.281 -0.887 . . . . 0.0 109.143 179.586 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.572 ' CD2' HD12 ' A' ' 159' ' ' ILE . 18.8 m-30 60.47 38.68 19.02 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.143 -0.973 . . . . 0.0 109.111 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 55.05 14.47 5.75 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.419 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 52.3 mtt85 -128.99 156.32 43.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.129 -1.218 . . . . 0.0 109.668 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -99.39 134.52 42.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.32 -0.862 . . . . 0.0 109.255 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 21.7 m -147.51 127.45 6.66 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.271 -0.893 . . . . 0.0 109.674 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.54 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.8 Cg_endo -70.5 139.94 38.8 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.725 2.283 . . . . 0.0 111.701 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.762 HG13 HD11 ' A' ' 168' ' ' LEU . 5.3 p -125.13 144.35 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.18 -0.95 . . . . 0.0 109.515 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.435 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 14.1 m -93.76 119.23 41.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.386 -0.821 . . . . 0.0 109.534 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.762 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -142.07 168.78 18.93 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -0.909 . . . . 0.0 110.576 -179.492 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.417 ' HB2' ' OE1' ' A' ' 172' ' ' GLU . 47.0 m80 -83.98 142.39 30.53 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.682 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.825 HG13 ' O ' ' A' ' 151' ' ' GLN . 3.1 m -53.58 -34.85 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.295 -0.878 . . . . 0.0 109.151 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.583 ' CB ' ' HA ' ' A' ' 118' ' ' LYS . 60.2 p -73.81 -6.05 44.65 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.335 -0.853 . . . . 0.0 109.982 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.587 ' CG ' ' HB2' ' A' ' 133' ' ' SER . 2.4 mt-10 -95.6 3.88 53.63 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.015 -1.053 . . . . 0.0 110.02 -179.54 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 11.2 m -144.0 169.36 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.057 -1.027 . . . . 0.0 109.601 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.537 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 80.3 tt0 -140.56 166.15 25.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.223 -0.923 . . . . 0.0 108.893 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.537 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 38.9 tttm -89.38 14.95 10.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.019 -1.05 . . . . 0.0 109.51 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.542 HG22 ' HG3' ' A' ' 177' ' ' GLU . 64.1 mt 63.1 -73.57 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.326 -0.858 . . . . 0.0 109.705 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.542 ' HG3' HG22 ' A' ' 176' ' ' ILE . 95.7 mt-10 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.496 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 N-CA-C 109.489 -1.445 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.8 -13.16 58.94 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.264 -1.139 . . . . 0.0 109.505 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 91.2 mtp -59.12 -24.8 63.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.424 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 11.9 mtpp -126.18 123.91 39.28 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.327 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.79 ' HG2' HG22 ' A' ' 65' ' ' ILE . 55.4 mttt -77.3 164.43 25.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.249 -0.907 . . . . 0.0 109.699 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.9 mmtp -128.0 175.26 8.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.289 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.949 ' CZ3' HG22 ' A' ' 41' ' ' VAL . 80.9 m95 -110.33 127.0 54.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.137 -0.977 . . . . 0.0 109.576 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.453 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 60.7 m-85 -121.78 167.07 13.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.229 -0.919 . . . . 0.0 109.488 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.964 HD11 ' CE1' ' A' ' 160' ' ' PHE . 76.2 mt -106.61 117.1 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.158 -0.964 . . . . 0.0 109.301 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.417 ' CG1' HG22 ' A' ' 80' ' ' VAL . 85.3 t -88.56 141.98 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.28 -0.888 . . . . 0.0 109.569 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.49 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -93.74 138.84 31.51 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.325 -0.86 . . . . 0.0 109.387 179.905 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.589 HG21 ' HG2' ' A' ' 17' ' ' GLU . 14.9 t -155.58 -169.54 3.15 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.457 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.44 ' O ' ' C ' ' A' ' 14' ' ' SER . 90.8 mmm -104.01 119.55 39.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.233 -0.917 . . . . 0.0 109.387 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 13' ' ' MET . 17.8 p -42.46 128.52 3.92 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.232 -0.918 . . . . 0.0 109.475 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.34 -20.31 35.35 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.429 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 90.3 m-85 -110.67 -1.4 16.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -1.133 . . . . 0.0 109.557 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.646 ' OE1' HD11 ' A' ' 44' ' ' ILE . 49.4 mt-10 -53.34 -55.24 26.39 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.241 -0.912 . . . . 0.0 109.404 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -49.13 -32.22 9.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.166 -0.958 . . . . 0.0 109.418 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.47 ' O ' ' HB2' ' A' ' 23' ' ' ASN . 62.3 mttm -76.83 -36.75 56.66 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.286 -0.883 . . . . 0.0 109.311 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.666 HG22 ' HB2' ' A' ' 79' ' ' TYR . 98.4 t -66.73 -52.01 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.33 -0.856 . . . . 0.0 109.523 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.44 ' HB2' HD11 ' A' ' 42' ' ' ILE . 63.1 tttm -56.89 -50.87 71.19 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.231 -0.918 . . . . 0.0 109.484 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -64.68 -34.82 79.19 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.153 -0.967 . . . . 0.0 109.38 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.518 ' ND2' ' HG2' ' A' ' 78' ' ' PRO . 20.1 t-20 -66.0 -44.32 85.14 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.408 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.659 ' O ' HG23 ' A' ' 28' ' ' VAL . 81.7 mt -57.39 -43.37 82.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.272 -0.892 . . . . 0.0 109.443 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -58.38 -44.44 88.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.205 -0.934 . . . . 0.0 109.789 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 31.9 mtmt -77.88 -37.48 48.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.112 -0.992 . . . . 0.0 109.798 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.759 ' CD ' HG23 ' A' ' 77' ' ' VAL . 42.1 tttp -57.04 -28.94 62.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.908 . . . . 0.0 109.313 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 24' ' ' ILE . 42.4 t -83.86 -27.43 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.314 -0.866 . . . . 0.0 109.464 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.454 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 54.9 mm-40 -66.8 -49.25 66.45 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.271 -0.893 . . . . 0.0 109.444 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.2 -35.12 66.91 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.241 -0.912 . . . . 0.0 109.482 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.3 p -92.86 -22.71 19.12 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.271 -0.893 . . . . 0.0 109.591 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 74.3 1.59 60.87 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.038 HG21 HD12 ' A' ' 36' ' ' LEU . 48.1 mm -69.39 80.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.318 -1.107 . . . . 0.0 109.429 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -90.89 14.54 13.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 109.458 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.877 ' O ' HD13 ' A' ' 65' ' ' ILE . 86.2 m-20 -113.39 -3.07 13.81 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.235 -0.916 . . . . 0.0 109.601 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.038 HD12 HG21 ' A' ' 33' ' ' ILE . 11.8 mt -98.59 -51.2 4.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.946 . . . . 0.0 109.599 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 99.1 t -95.55 144.58 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.313 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.87 -124.75 3.92 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 18.6 mtt85 -91.56 142.18 27.91 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.309 -1.112 . . . . 0.0 109.885 -179.497 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 1.016 HG23 HG22 ' A' ' 62' ' ' VAL . 65.4 mt -109.94 134.42 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.152 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.963 HG23 ' HB2' ' A' ' 61' ' ' PHE . 30.4 m -127.5 144.54 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.208 -0.932 . . . . 0.0 109.263 179.831 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.92 HG21 HD12 ' A' ' 44' ' ' ILE . 67.6 mt -129.94 129.14 22.98 Favored Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.294 -0.879 . . . . 0.0 109.623 -179.754 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.565 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.3 Cg_endo -66.71 -2.65 7.93 Favored 'Trans proline' 0 C--O 1.217 -0.544 0 C-N-CA 122.879 2.386 . . . . 0.0 111.348 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.92 HD12 HG21 ' A' ' 42' ' ' ILE . 85.6 mt -66.15 -39.26 83.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.144 -0.972 . . . . 0.0 109.554 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 38.4 ttt85 -45.58 -34.97 3.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.92 . . . . 0.0 109.494 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.639 ' HA3' HD11 ' A' ' 104' ' ' LEU . . . -72.51 154.55 50.43 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 100.69 15.4 29.32 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 52.6 mt-30 -71.03 -31.38 67.84 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.296 -1.12 . . . . 0.0 109.429 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 20.2 mtp180 -61.31 -32.31 72.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 109.532 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.735 ' HD2' HG11 ' A' ' 167' ' ' VAL . 57.4 mtp85 -112.97 151.0 31.09 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.213 -0.93 . . . . 0.0 109.572 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -53.72 -33.65 56.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.241 -0.912 . . . . 0.0 109.331 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 21.0 t -52.97 136.53 34.68 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.34 -0.85 . . . . 0.0 109.421 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.53 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 84.5 tt0 -125.76 159.39 32.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.253 -0.905 . . . . 0.0 109.462 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.751 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 1.9 mttp 77.21 89.56 0.07 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.245 -0.91 . . . . 0.0 109.629 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.565 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 9.2 tp -59.71 -42.14 92.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.904 -1.123 . . . . 0.0 108.909 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.922 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 19.4 m-85 -126.3 101.15 28.51 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.217 -0.927 . . . . 0.0 108.789 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.431 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 41.7 Cg_endo -65.63 137.09 48.75 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.681 2.254 . . . . 0.0 112.26 -179.087 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.36 -12.61 5.5 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.417 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.574 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 1.7 m-30 -100.47 132.15 46.01 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.748 -1.442 . . . . 0.0 110.32 -179.199 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.847 HG13 HG12 ' A' ' 42' ' ' ILE . 40.0 t -132.99 143.07 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.349 -0.844 . . . . 0.0 108.926 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.963 ' HB2' HG23 ' A' ' 41' ' ' VAL . 18.8 m-30 -106.68 123.86 48.75 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.003 -1.061 . . . . 0.0 109.805 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 1.016 HG22 HG23 ' A' ' 40' ' ' ILE . 93.0 t -131.16 142.13 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.339 -0.851 . . . . 0.0 109.653 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.591 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 39.1 tt0 -105.9 128.77 53.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.262 -0.899 . . . . 0.0 108.981 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.494 ' CG ' ' C ' ' A' ' 63' ' ' GLU . 16.5 mtm -155.96 178.65 10.03 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.169 -0.957 . . . . 0.0 110.05 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.879 ' CG1' HD23 ' A' ' 36' ' ' LEU . 6.1 pt -101.01 133.89 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.59 -0.694 . . . . 0.0 109.321 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.473 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 53.9 ttm -77.24 144.33 38.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.224 -0.922 . . . . 0.0 110.1 -178.654 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.473 ' HB2' ' O ' ' A' ' 66' ' ' MET . 29.0 t-20 176.46 175.56 0.32 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -72.6 -43.06 63.83 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.249 -0.907 . . . . 0.0 109.323 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -75.64 -28.01 58.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.686 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.058 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -70.58 -47.56 59.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.131 -0.981 . . . . 0.0 109.302 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.617 ' HB2' ' NE2' ' A' ' 89' ' ' GLN . 89.0 t80 -60.88 -54.94 38.9 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.289 -0.882 . . . . 0.0 109.275 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.447 ' O ' ' OG ' ' A' ' 76' ' ' SER . 42.2 t-20 -52.85 -31.81 41.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.221 -0.924 . . . . 0.0 109.975 -179.788 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 81.9 t80 -80.08 -43.27 22.09 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.035 -1.04 . . . . 0.0 109.567 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 1.058 HG23 ' O ' ' A' ' 70' ' ' ALA . 3.2 t -68.26 -55.48 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.295 -0.878 . . . . 0.0 109.414 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.473 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 16.5 tpt180 -61.56 -9.58 6.23 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.338 -0.851 . . . . 0.0 109.837 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 72' ' ' ASN . 42.7 p -101.67 2.09 38.32 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.148 -0.97 . . . . 0.0 109.983 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.759 HG23 ' CD ' ' A' ' 27' ' ' LYS . 0.5 OUTLIER -68.75 135.29 90.15 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.057 -1.027 . . . . 0.0 108.954 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.629 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 43.9 Cg_endo -66.21 138.96 53.43 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.394 2.063 . . . . 0.0 111.99 -179.422 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.666 ' HB2' HG22 ' A' ' 20' ' ' VAL . 5.5 m-85 89.09 -8.08 0.44 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.801 -0.562 . . . . 0.0 109.829 -179.838 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.713 ' CG2' HG12 ' A' ' 77' ' ' VAL . 2.4 t -89.34 129.5 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.966 -1.084 . . . . 0.0 109.661 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.428 ' HE1' ' SD ' ' A' ' 13' ' ' MET . 18.7 mtt -93.53 -25.06 17.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.459 -0.776 . . . . 0.0 109.246 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 164.54 -162.61 35.59 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.479 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 48.6 m-85 -136.21 151.74 50.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.187 -1.184 . . . . 0.0 109.559 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.8 t -67.01 101.42 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.282 -0.886 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.538 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.0 OUTLIER -143.98 162.85 35.12 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -0.918 . . . . 0.0 109.505 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.0 m -95.18 -34.52 12.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.349 -0.845 . . . . 0.0 109.278 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -129.39 -72.78 0.14 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.541 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -113.91 -137.89 6.75 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.617 ' NE2' ' HB2' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -31.03 148.45 0.04 OUTLIER Pre-proline 0 N--CA 1.493 1.704 0 O-C-N 121.506 -0.997 . . . . 0.0 110.274 -179.718 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.538 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.3 Cg_endo -69.54 149.61 68.53 Favored 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.82 2.347 . . . . 0.0 111.887 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 36.0 m -80.73 152.31 72.13 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.323 -0.861 . . . . 0.0 109.403 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.07 143.36 49.12 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.693 2.262 . . . . 0.0 111.81 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.659 HG11 ' SD ' ' A' ' 98' ' ' MET . 29.3 t -69.48 142.16 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.192 -0.942 . . . . 0.0 109.414 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' LYS . . . . . 0.434 ' HB2' ' HG3' ' A' ' 97' ' ' GLU . 32.0 mttt -70.67 134.12 47.25 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.537 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -50.27 -41.46 50.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.863 . . . . 0.0 109.419 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -63.14 -24.07 67.72 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.438 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.434 ' HG3' ' HB2' ' A' ' 94' ' ' LYS . 40.9 mt-10 -84.95 -23.66 28.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -0.913 . . . . 0.0 109.456 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.659 ' SD ' HG11 ' A' ' 93' ' ' VAL . 52.5 mmm -85.19 -33.18 22.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.265 -0.897 . . . . 0.0 109.384 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.6 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -36.1 -53.41 1.57 Allowed Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.459 -0.776 . . . . 0.0 109.795 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.615 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 47.4 Cg_endo -69.79 -26.57 27.3 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.494 2.129 . . . . 0.0 111.616 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.531 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 32.3 mm -81.09 -38.51 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.236 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.715 HD13 ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -71.36 -40.35 70.69 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.328 -0.858 . . . . 0.0 109.16 179.733 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 58.0 mtt-85 -63.15 -50.06 71.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.403 -0.81 . . . . 0.0 109.028 179.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.639 HD11 ' HA3' ' A' ' 46' ' ' GLY . 1.4 tt -72.35 -35.55 68.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.385 -0.822 . . . . 0.0 109.079 179.553 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -69.33 -1.62 8.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.393 -0.817 . . . . 0.0 110.023 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.12 8.25 82.97 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.406 ' HB3' ' HB3' ' A' ' 102' ' ' LEU . 0.7 OUTLIER -74.37 -17.55 60.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.16 -1.2 . . . . 0.0 109.431 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.447 ' HG3' ' HB3' ' A' ' 102' ' ' LEU . 88.9 mt-10 -117.12 157.56 25.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.898 . . . . 0.0 109.479 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -106.65 112.64 25.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.273 -0.892 . . . . 0.0 109.513 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.446 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 28.3 p90 -144.63 150.56 37.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.237 -0.914 . . . . 0.0 109.342 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.446 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 37.0 mm-40 -86.47 -147.72 0.13 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.238 -0.914 . . . . 0.0 109.48 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.408 ' HG2' ' N ' ' A' ' 113' ' ' LYS . 81.0 tt0 -113.59 163.83 14.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.283 -0.886 . . . . 0.0 109.579 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.408 ' N ' ' HG2' ' A' ' 112' ' ' GLU . 3.4 pttm -45.32 126.65 6.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.203 -0.936 . . . . 0.0 109.508 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 6.0 mtpt -105.28 5.22 31.81 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.313 -0.867 . . . . 0.0 109.383 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.424 ' HD2' HG22 ' A' ' 117' ' ' VAL . 4.0 ttmt -109.75 75.28 0.8 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.213 -0.929 . . . . 0.0 109.564 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.25 75.16 1.44 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.702 2.268 . . . . 0.0 111.753 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.424 HG22 ' HD2' ' A' ' 115' ' ' LYS . 32.4 m -126.47 154.61 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.289 -0.882 . . . . 0.0 109.469 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -104.0 151.55 23.08 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.169 -0.957 . . . . 0.0 109.458 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.598 HG12 ' N ' ' A' ' 120' ' ' GLU . 39.7 t -129.77 168.28 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.286 -0.884 . . . . 0.0 109.464 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.598 ' N ' HG12 ' A' ' 119' ' ' VAL . 88.8 mt-10 -135.83 -120.07 0.16 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.304 -0.872 . . . . 0.0 109.425 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.595 ' O ' ' C ' ' A' ' 122' ' ' GLY . 6.2 mt 78.53 114.03 0.07 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.196 -0.94 . . . . 0.0 109.368 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.595 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -20.63 90.63 0.01 OUTLIER Glycine 0 N--CA 1.496 2.642 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.615 ' CB ' ' HD3' ' A' ' 175' ' ' LYS . 38.3 p90 -96.81 126.46 41.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.182 -1.187 . . . . 0.0 109.156 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 17.4 mttt -144.27 162.75 35.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.135 -0.978 . . . . 0.0 109.922 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 144' ' ' LYS . 12.1 t -64.04 141.79 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.472 -0.768 . . . . 0.0 109.297 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 87.47 -31.23 4.58 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -49.71 162.92 0.14 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.299 -1.118 . . . . 0.0 109.27 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.9 ttp -94.72 125.35 39.31 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.13 -0.982 . . . . 0.0 109.073 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.544 HG11 ' CD1' ' A' ' 143' ' ' ILE . 2.0 p -124.31 140.77 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.173 -0.954 . . . . 0.0 109.02 179.756 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 174' ' ' GLU . 59.9 tttt -106.2 142.72 35.41 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.153 -0.967 . . . . 0.0 109.361 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.927 ' O ' HD13 ' A' ' 132' ' ' ILE . 88.2 mt -82.75 152.91 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.161 -0.962 . . . . 0.0 108.581 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.927 HD13 ' O ' ' A' ' 131' ' ' ILE . 2.6 mm -148.94 1.66 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.103 -0.998 . . . . 0.0 109.463 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.566 ' CB ' ' HG2' ' A' ' 172' ' ' GLU . 28.3 m -150.82 147.64 27.51 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.13 -0.981 . . . . 0.0 110.331 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.84 -164.12 18.56 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 179.435 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.483 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 46.2 Cg_endo -67.93 -23.52 40.79 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 123.026 2.484 . . . . 0.0 112.535 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.615 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 93.4 m-85 -108.86 18.76 20.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.962 -1.086 . . . . 0.0 109.456 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.629 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.8 tt0 -48.35 140.69 7.39 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.289 -0.882 . . . . 0.0 109.687 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 12.8 m-20 76.93 28.73 0.64 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.468 -0.77 . . . . 0.0 110.243 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.91 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.9 t80 -118.42 153.52 33.95 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.08 -1.012 . . . . 0.0 109.485 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -101.2 133.34 45.91 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.246 -0.909 . . . . 0.0 109.197 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.499 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.25 170.38 26.65 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 119.535 -1.317 . . . . 0.0 110.604 -179.413 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.646 ' C ' HG23 ' A' ' 155' ' ' VAL . 44.9 t -115.11 137.71 47.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.602 -0.94 . . . . 0.0 109.348 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.94 HD12 HD23 ' A' ' 153' ' ' LEU . 14.9 mm -68.74 115.27 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.226 -0.921 . . . . 0.0 109.502 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.457 ' O ' HG13 ' A' ' 125' ' ' VAL . 21.2 tttp -99.0 -34.46 10.41 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.039 -1.038 . . . . 0.0 109.321 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.43 ' HG3' ' HG2' ' A' ' 144' ' ' LYS . 89.5 mt-10 -152.57 147.6 26.37 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.133 -0.98 . . . . 0.0 109.444 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.838 HG23 ' HG ' ' A' ' 153' ' ' LEU . 6.6 mt -126.56 130.05 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.216 -0.928 . . . . 0.0 109.622 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -110.33 103.39 53.87 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.286 -0.884 . . . . 0.0 109.528 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.557 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.55 171.83 15.52 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.747 2.298 . . . . 0.0 111.631 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.557 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.3 mt-10 80.68 -20.34 0.38 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.319 -0.863 . . . . 0.0 109.876 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.434 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 43.3 mtt85 -128.21 -12.18 5.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.05 -1.031 . . . . 0.0 109.582 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.539 ' O ' HG12 ' A' ' 170' ' ' VAL . 37.1 mt-30 69.68 48.97 0.56 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.907 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -120.12 144.54 47.58 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.081 -1.012 . . . . 0.0 109.116 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.94 HD23 HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -133.92 115.73 14.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.097 -1.002 . . . . 0.0 110.115 -179.381 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 7.1 mttt -78.04 132.42 37.76 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.328 -0.857 . . . . 0.0 108.786 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.646 HG23 ' C ' ' A' ' 142' ' ' VAL . 13.2 p -130.21 147.01 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.119 -0.988 . . . . 0.0 110.008 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.488 ' OD1' ' CA ' ' A' ' 165' ' ' PRO . 0.9 OUTLIER -97.53 115.96 28.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.435 -0.791 . . . . 0.0 109.183 179.66 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.579 HG13 ' CE1' ' A' ' 139' ' ' PHE . 87.1 t -97.64 143.22 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.163 -0.961 . . . . 0.0 109.747 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.3 m -91.88 111.88 23.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.314 -0.867 . . . . 0.0 109.643 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.922 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 13.6 pt -144.56 143.92 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.295 -0.878 . . . . 0.0 109.486 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.964 ' CE1' HD11 ' A' ' 9' ' ' ILE . 78.2 m-85 62.1 34.36 16.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.282 -0.886 . . . . 0.0 109.396 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.28 16.47 20.42 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 73.6 mtt-85 -128.91 151.14 49.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -93.7 135.05 35.38 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.233 -0.917 . . . . 0.0 109.392 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 60.8 m -144.64 126.31 7.96 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.242 -0.911 . . . . 0.0 109.67 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.488 ' CA ' ' OD1' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.8 139.58 36.93 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 122.624 2.216 . . . . 0.0 111.39 179.676 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.563 ' HB ' HD21 ' A' ' 168' ' ' LEU . 1.9 m -125.75 144.54 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.059 -1.026 . . . . 0.0 109.988 -179.682 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 1.018 ' C ' HD22 ' A' ' 168' ' ' LEU . 14.7 m -92.05 117.48 35.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 1.018 HD22 ' C ' ' A' ' 167' ' ' VAL . 3.2 mm? -139.78 166.24 25.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.156 -0.965 . . . . 0.0 110.289 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.493 ' HB2' ' HB2' ' A' ' 172' ' ' GLU . 82.2 m-70 -83.95 141.15 31.45 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.634 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 151' ' ' GLN . 9.1 p -56.78 -36.58 49.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.293 -0.879 . . . . 0.0 109.296 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.424 ' N ' HG13 ' A' ' 170' ' ' VAL . 32.1 p -77.29 -8.47 57.67 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.094 -1.004 . . . . 0.0 109.722 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.566 ' HG2' ' CB ' ' A' ' 133' ' ' SER . 1.3 mt-10 -88.67 -4.79 58.47 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.194 -0.941 . . . . 0.0 109.275 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.9 m -137.22 176.51 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.192 -0.942 . . . . 0.0 109.799 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.544 ' O ' HG22 ' A' ' 129' ' ' VAL . 72.9 tt0 -132.15 155.43 48.18 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.615 ' HD3' ' CB ' ' A' ' 123' ' ' PHE . 16.2 mttm -108.42 35.8 3.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.965 -1.084 . . . . 0.0 109.712 -179.462 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.481 ' C ' ' O ' ' A' ' 175' ' ' LYS . 6.6 mt 39.22 -133.84 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.472 -0.767 . . . . 0.0 109.632 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.442 ' H ' HG22 ' A' ' 176' ' ' ILE . 57.0 tt0 . . . . . 0 N--CA 1.488 1.471 0 CA-C-O 117.961 -1.018 . . . . 0.0 109.526 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.24 -27.55 69.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.23 -1.159 . . . . 0.0 109.497 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 91.0 mtp -66.74 -27.32 67.52 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.287 -0.883 . . . . 0.0 109.454 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 34.5 tttt -147.18 131.26 17.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.269 -0.894 . . . . 0.0 109.417 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 33.4 mttm -96.71 146.98 24.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.183 -0.948 . . . . 0.0 109.51 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.593 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 11.6 mttt -130.47 173.76 10.54 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.905 . . . . 0.0 109.192 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 1.063 ' O ' HG23 ' A' ' 93' ' ' VAL . 61.5 m95 -108.59 127.51 54.01 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -0.901 . . . . 0.0 109.3 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.447 ' OH ' ' SD ' ' A' ' 66' ' ' MET . 91.6 m-85 -115.61 169.15 9.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.211 -0.93 . . . . 0.0 109.33 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.597 HD11 ' CE1' ' A' ' 160' ' ' PHE . 27.3 mt -109.89 113.57 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 109.192 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 82.4 t -88.51 140.58 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.221 -0.925 . . . . 0.0 109.369 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 59' ' ' TYR . 2.9 mm? -95.36 146.36 24.45 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.357 -0.839 . . . . 0.0 109.414 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.5 t -161.17 -164.26 1.14 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.265 -0.897 . . . . 0.0 109.114 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.518 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 94.0 mtp -105.32 124.71 50.0 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.186 -0.946 . . . . 0.0 109.516 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.0 t -45.78 131.1 9.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.294 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.94 -19.33 47.08 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.518 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 95.6 m-85 -108.96 6.34 25.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.284 -1.127 . . . . 0.0 109.564 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -62.79 -52.82 61.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.261 -0.899 . . . . 0.0 109.507 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -50.7 -35.78 32.84 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.187 -0.945 . . . . 0.0 109.61 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 58.4 mttt -73.9 -47.81 35.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.247 -0.908 . . . . 0.0 109.556 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.963 HG22 ' HB2' ' A' ' 79' ' ' TYR . 74.8 t -54.32 -48.41 67.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.226 -0.922 . . . . 0.0 109.579 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.604 ' HD2' HD11 ' A' ' 42' ' ' ILE . 40.8 tttm -57.56 -49.66 75.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -0.923 . . . . 0.0 109.615 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -65.42 -39.18 91.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.244 -0.91 . . . . 0.0 109.497 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 25.0 m120 -62.16 -44.62 96.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.869 . . . . 0.0 109.622 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.404 HG21 HD11 ' A' ' 40' ' ' ILE . 96.7 mt -57.76 -43.83 84.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.522 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -56.42 -44.55 80.48 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.206 -0.934 . . . . 0.0 109.823 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -75.55 -35.33 60.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.06 -1.025 . . . . 0.0 109.437 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.88 ' HD3' HG23 ' A' ' 77' ' ' VAL . 10.1 tttm -56.44 -34.16 66.57 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.229 -0.92 . . . . 0.0 109.331 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.691 HG13 ' O ' ' A' ' 33' ' ' ILE . 43.4 t -83.99 -25.42 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.334 -0.854 . . . . 0.0 109.593 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 46.7 tp10 -70.32 -53.95 14.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.264 -0.897 . . . . 0.0 109.656 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.92 -33.6 72.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -0.92 . . . . 0.0 109.693 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.5 HG23 ' O ' ' A' ' 27' ' ' LYS . 50.7 p -83.35 -35.91 24.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.182 -0.949 . . . . 0.0 109.488 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 84.75 17.8 62.91 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.691 ' O ' HG13 ' A' ' 28' ' ' VAL . 78.8 mt -95.74 78.31 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.218 -1.166 . . . . 0.0 109.414 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 45.0 mttm -85.68 6.1 29.12 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 24.5 m120 -102.3 -6.94 22.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.224 -0.923 . . . . 0.0 109.547 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.101 HD11 ' HB2' ' A' ' 70' ' ' ALA . 10.5 tp -97.68 -54.05 3.24 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.302 -0.874 . . . . 0.0 109.681 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.878 HG22 ' CE ' ' A' ' 64' ' ' MET . 87.4 t -90.38 133.66 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.284 -0.885 . . . . 0.0 109.324 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.65 -126.87 5.88 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 44.5 mtt180 -93.58 140.65 29.37 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -1.155 . . . . 0.0 109.887 -179.664 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.682 HG23 HG12 ' A' ' 62' ' ' VAL . 63.2 mt -103.76 134.0 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.308 -0.87 . . . . 0.0 109.09 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.863 HG23 ' HB2' ' A' ' 61' ' ' PHE . 34.7 m -124.7 146.7 29.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.132 -0.98 . . . . 0.0 109.692 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.811 HG22 HG23 ' A' ' 44' ' ' ILE . 1.2 mt -117.75 128.9 25.7 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.423 -0.798 . . . . 0.0 109.465 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.696 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.6 Cg_endo -66.43 -6.22 14.59 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.903 2.402 . . . . 0.0 111.857 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.994 ' O ' HD21 ' A' ' 104' ' ' LEU . 13.1 pt -56.55 137.23 18.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.178 -0.951 . . . . 0.0 109.413 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.977 ' HA ' HD11 ' A' ' 104' ' ' LEU . 20.5 ttt-85 -53.1 -47.72 68.36 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.239 -0.913 . . . . 0.0 109.457 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 75.68 156.59 6.12 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.429 ' O ' ' C ' ' A' ' 48' ' ' GLN . . . 91.14 3.93 69.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.429 ' C ' ' O ' ' A' ' 47' ' ' GLY . 16.3 tt0 43.33 27.17 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.317 -1.108 . . . . 0.0 109.549 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.483 ' HB2' ' NH1' ' A' ' 45' ' ' ARG . 4.2 tpt180 -59.49 -38.13 80.08 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.541 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 76.7 mtp85 -134.56 151.43 51.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.266 -0.896 . . . . 0.0 109.472 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 53.4 tttp -51.98 -39.33 59.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 41.3 m -68.86 144.23 54.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.299 -0.876 . . . . 0.0 109.527 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.533 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 88.0 mt-10 -151.38 162.52 40.78 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.199 -0.938 . . . . 0.0 109.415 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.776 ' HA ' HG22 ' A' ' 44' ' ' ILE . 1.9 mttt 76.96 94.42 0.07 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.267 -0.896 . . . . 0.0 109.348 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.889 HD12 ' CZ ' ' A' ' 56' ' ' PHE . 0.7 OUTLIER -54.16 -45.84 72.15 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.036 -1.04 . . . . 0.0 108.85 179.756 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.889 ' CZ ' HD12 ' A' ' 55' ' ' LEU . 16.5 m-85 -123.97 110.32 29.41 Favored Pre-proline 0 N--CA 1.487 1.422 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.368 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 44.2 Cg_endo -66.92 137.89 46.37 Favored 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.645 2.23 . . . . 0.0 111.942 -179.481 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.19 -7.71 10.28 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.972 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.7 m-85 -107.54 134.37 50.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.896 -1.355 . . . . 0.0 110.082 -179.351 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 43.3 t -134.52 150.42 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.328 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.863 ' HB2' HG23 ' A' ' 41' ' ' VAL . 72.9 m-85 -108.67 123.64 49.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.988 -1.07 . . . . 0.0 109.711 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.682 HG12 HG23 ' A' ' 40' ' ' ILE . 19.0 m -131.86 144.24 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.382 -0.824 . . . . 0.0 109.569 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.62 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 22.7 tt0 -105.27 126.7 52.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.364 -0.835 . . . . 0.0 109.038 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.878 ' CE ' HG22 ' A' ' 37' ' ' VAL . 4.9 mtp -156.47 175.0 14.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.107 -0.996 . . . . 0.0 110.293 -179.442 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.96 HG12 HD12 ' A' ' 36' ' ' LEU . 10.6 pt -97.39 129.13 47.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.608 -0.683 . . . . 0.0 109.236 179.7 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.479 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 0.0 OUTLIER -76.36 145.87 39.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.919 . . . . 0.0 109.621 -179.026 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.582 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 44.1 t30 175.78 163.61 0.34 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -59.56 -40.47 87.39 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.058 -1.027 . . . . 0.0 109.581 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.544 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 99.1 mt-10 -72.19 -43.74 64.07 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.217 -0.927 . . . . 0.0 109.895 -179.706 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.101 ' HB2' HD11 ' A' ' 36' ' ' LEU . . . -56.4 -44.88 80.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.087 -1.008 . . . . 0.0 109.572 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.582 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 36.2 m-85 -60.32 -62.39 1.9 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.22 -0.925 . . . . 0.0 109.269 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.479 ' O ' ' HB2' ' A' ' 76' ' ' SER . 95.8 m-20 -43.52 -30.86 0.62 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.388 -0.82 . . . . 0.0 109.82 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.544 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 24.4 m-85 -82.94 -42.41 17.69 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.167 -0.958 . . . . 0.0 109.898 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.955 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 61.2 t -69.99 -55.33 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.217 -0.927 . . . . 0.0 109.498 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.493 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 6.1 tpt180 -57.77 -14.32 5.65 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.292 -0.88 . . . . 0.0 109.307 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.479 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 3.8 m -105.61 2.5 28.28 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.208 -0.933 . . . . 0.0 109.691 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 1.015 ' O ' HG12 ' A' ' 80' ' ' VAL . 0.4 OUTLIER -68.37 150.65 97.63 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.048 -1.033 . . . . 0.0 109.087 179.911 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.904 ' HD2' HG22 ' A' ' 77' ' ' VAL . 47.7 Cg_endo -68.83 124.75 11.79 Favored 'Trans proline' 0 C--O 1.214 -0.714 0 C-N-CA 122.569 2.179 . . . . 0.0 112.429 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.963 ' HB2' HG22 ' A' ' 20' ' ' VAL . 53.5 m-85 88.59 0.02 0.38 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.776 -0.577 . . . . 0.0 110.773 179.164 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 1.015 HG12 ' O ' ' A' ' 77' ' ' VAL . 7.4 p -84.16 112.9 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.738 -1.226 . . . . 0.0 109.523 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 86.0 mmm -87.43 -30.1 20.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.274 -0.891 . . . . 0.0 109.232 179.659 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 11' ' ' LEU . . . 174.26 -169.03 41.99 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.955 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 15.7 m-85 -127.66 147.62 50.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.248 -1.148 . . . . 0.0 109.514 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.719 ' CG2' HD21 ' A' ' 11' ' ' LEU . 59.2 t -67.3 77.1 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.32 -0.862 . . . . 0.0 109.254 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.529 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 3.1 p -127.71 162.78 25.76 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.332 -0.855 . . . . 0.0 109.634 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 87.8 p -95.91 -33.33 12.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.42 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.98 -77.09 0.19 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.508 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -106.58 -145.19 12.41 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.508 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.1 OUTLIER -33.31 154.01 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.582 -0.952 . . . . 0.0 110.188 -179.458 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.529 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 51.7 Cg_endo -70.68 168.55 22.42 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.513 2.142 . . . . 0.0 112.032 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.914 HG12 ' HD2' ' A' ' 92' ' ' PRO . 0.1 OUTLIER -98.7 148.98 35.29 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.33 -0.856 . . . . 0.0 109.199 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.914 ' HD2' HG12 ' A' ' 91' ' ' VAL . 48.7 Cg_endo -69.31 150.8 71.4 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.616 2.21 . . . . 0.0 111.705 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 1.063 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.5 t -80.06 126.65 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.912 . . . . 0.0 109.528 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' LYS . . . . . 0.487 ' O ' ' N ' ' A' ' 97' ' ' GLU . 51.0 mttt -71.9 136.62 46.96 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.267 -0.895 . . . . 0.0 109.271 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.485 ' O ' ' HG3' ' A' ' 99' ' ' ARG . 82.8 m-20 -43.25 -41.65 3.99 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.918 . . . . 0.0 109.346 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 21.8 mtm180 -56.75 -30.38 63.53 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.336 -0.852 . . . . 0.0 109.692 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.487 ' N ' ' O ' ' A' ' 94' ' ' LYS . 53.6 mt-10 -87.01 -27.75 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.599 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.593 ' SD ' HG11 ' A' ' 93' ' ' VAL . 75.2 mmm -80.08 -24.72 40.43 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.359 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.603 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 25.6 mtp85 -37.37 -53.71 2.2 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.482 -0.761 . . . . 0.0 109.786 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.603 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.9 Cg_endo -69.28 -30.74 24.02 Favored 'Trans proline' 0 C--O 1.216 -0.577 0 C-N-CA 122.587 2.191 . . . . 0.0 111.749 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.42 ' HA ' HD13 ' A' ' 101' ' ' ILE . 16.3 mm -77.52 -43.69 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.139 -0.976 . . . . 0.0 109.238 179.804 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.529 ' CB ' ' HB2' ' A' ' 108' ' ' GLU . 1.1 mt -63.19 -40.77 98.46 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.275 -0.891 . . . . 0.0 109.031 179.795 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.577 ' HG3' ' CE1' ' A' ' 110' ' ' TYR . 24.7 ttt-85 -60.11 -45.85 91.59 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 108.783 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.994 HD21 ' O ' ' A' ' 44' ' ' ILE . 0.6 OUTLIER -68.45 -34.31 75.74 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.391 -0.818 . . . . 0.0 108.912 179.397 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.514 ' O ' ' HG ' ' A' ' 107' ' ' LEU . . . -90.47 17.88 6.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.32 -0.863 . . . . 0.0 109.033 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 43.76 28.89 1.22 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.723 HD11 ' CG1' ' A' ' 41' ' ' VAL . 88.3 mt -90.12 -26.64 20.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -1.158 . . . . 0.0 109.535 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.529 ' HB2' ' CB ' ' A' ' 102' ' ' LEU . 87.2 tt0 -107.78 145.07 34.06 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.238 -0.914 . . . . 0.0 109.63 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -111.11 119.32 38.59 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.305 -0.872 . . . . 0.0 109.354 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.577 ' CE1' ' HG3' ' A' ' 103' ' ' ARG . 29.8 p90 -126.22 -167.4 1.7 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.254 -0.904 . . . . 0.0 109.517 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.575 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 50.7 mt-10 -90.82 -145.64 0.19 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.286 -0.884 . . . . 0.0 109.464 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -106.71 -59.56 1.78 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.211 -0.931 . . . . 0.0 109.414 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -158.41 124.84 4.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.356 -0.84 . . . . 0.0 109.519 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.42 ' HG2' ' HB2' ' A' ' 115' ' ' LYS . 0.0 OUTLIER -58.59 -48.48 80.8 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.305 -0.872 . . . . 0.0 109.458 -179.952 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.42 ' HB2' ' HG2' ' A' ' 114' ' ' LYS . 1.7 ttpt -147.22 112.68 4.1 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.136 -0.978 . . . . 0.0 109.58 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -73.44 86.55 1.16 Allowed 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.692 2.261 . . . . 0.0 112.128 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.59 HG12 ' CD1' ' A' ' 132' ' ' ILE . 8.1 p -99.68 165.02 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.122 -0.986 . . . . 0.0 109.253 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.482 ' N ' HG22 ' A' ' 117' ' ' VAL . 33.3 mttm -124.25 134.53 53.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.22 -0.925 . . . . 0.0 109.759 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.578 HG22 ' N ' ' A' ' 120' ' ' GLU . 11.3 p -49.06 169.71 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.312 -0.867 . . . . 0.0 109.372 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.649 ' C ' HD12 ' A' ' 121' ' ' LEU . 14.5 mt-10 -156.68 127.53 6.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.908 . . . . 0.0 109.921 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.7 HD12 ' N ' ' A' ' 121' ' ' LEU . 6.0 mp 76.64 94.45 0.07 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.721 -0.612 . . . . 0.0 110.165 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.549 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -29.52 95.48 0.01 OUTLIER Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.652 ' CE2' ' HB3' ' A' ' 127' ' ' ASP . 0.0 OUTLIER -55.94 178.05 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.929 -1.336 . . . . 0.0 109.188 179.758 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.475 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 12.2 mttt -113.91 157.22 22.67 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.11 -0.994 . . . . 0.0 110.146 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 22.0 t -64.43 144.99 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.512 -0.742 . . . . 0.0 109.469 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.423 ' O ' HG13 ' A' ' 142' ' ' VAL . . . 84.68 -28.23 4.5 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.652 ' HB3' ' CE2' ' A' ' 123' ' ' PHE . 8.3 m-20 -50.48 167.52 0.06 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.466 -1.02 . . . . 0.0 108.898 179.841 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' MET . . . . . 0.485 ' HG2' HD12 ' A' ' 176' ' ' ILE . 0.1 OUTLIER -99.05 126.36 44.75 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.026 -1.047 . . . . 0.0 109.112 179.838 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.547 HG22 ' O ' ' A' ' 174' ' ' GLU . 2.3 p -124.93 142.8 40.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.373 -0.829 . . . . 0.0 109.08 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.466 ' N ' ' O ' ' A' ' 174' ' ' GLU . 21.1 tttt -104.9 142.91 33.92 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.293 -0.879 . . . . 0.0 109.236 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.932 HD12 ' HB3' ' A' ' 139' ' ' PHE . 74.3 mt -83.01 152.99 3.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.152 -0.967 . . . . 0.0 108.629 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.59 ' CD1' HG12 ' A' ' 117' ' ' VAL . 34.2 pt -150.1 2.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.926 -1.109 . . . . 0.0 109.494 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.578 ' CA ' ' HG2' ' A' ' 137' ' ' GLU . 5.9 t -147.11 142.09 26.99 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.048 -1.032 . . . . 0.0 109.634 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.464 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 102.22 -166.0 17.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 179.266 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.527 ' CA ' ' HD3' ' A' ' 103' ' ' ARG . 48.4 Cg_endo -68.28 -20.61 42.69 Favored 'Trans proline' 0 C--O 1.214 -0.701 0 C-N-CA 123.382 2.721 . . . . 0.0 113.104 -179.157 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.525 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.1 m-85 -105.77 15.86 26.13 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.836 -1.165 . . . . 0.0 109.54 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.578 ' HG2' ' CA ' ' A' ' 133' ' ' SER . 73.0 mt-10 -41.5 137.35 1.56 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.196 -0.94 . . . . 0.0 109.95 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.491 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.6 OUTLIER 75.48 25.18 1.26 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.303 -0.873 . . . . 0.0 110.656 178.954 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.932 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.1 t80 -115.96 134.25 55.17 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.876 -1.14 . . . . 0.0 109.579 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -83.79 134.29 34.73 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.196 -0.94 . . . . 0.0 109.551 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.17 169.38 25.78 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 126' ' ' GLY . 71.2 t -115.25 136.3 52.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.404 -1.057 . . . . 0.0 109.42 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.945 HD13 HD21 ' A' ' 153' ' ' LEU . 39.4 mt -67.61 117.92 10.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.162 -0.961 . . . . 0.0 109.505 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 24.5 tttm -99.79 -34.5 10.13 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.152 -0.967 . . . . 0.0 109.407 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.478 ' HB3' ' HD2' ' A' ' 154' ' ' LYS . 85.1 tt0 -153.85 148.99 26.89 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.11 -0.994 . . . . 0.0 109.66 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.703 HG23 ' CD1' ' A' ' 153' ' ' LEU . 3.3 mt -124.07 126.79 72.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.287 -0.883 . . . . 0.0 109.425 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.55 101.75 41.14 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.219 -0.925 . . . . 0.0 109.495 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.563 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 49.9 Cg_endo -71.6 170.54 18.34 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.653 2.235 . . . . 0.0 111.665 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.563 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.1 mt-10 80.48 -20.39 0.38 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.441 -0.787 . . . . 0.0 109.952 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.405 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 70.8 mtp180 -127.55 -13.58 5.38 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.12 -0.987 . . . . 0.0 109.67 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.405 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 29.0 mt-30 69.44 48.16 0.64 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.887 . . . . 0.0 109.499 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.765 ' OE2' HG13 ' A' ' 167' ' ' VAL . 82.9 tt0 -118.75 143.05 47.14 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.099 -1.001 . . . . 0.0 108.803 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.945 HD21 HD13 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -130.77 117.67 19.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.048 -1.032 . . . . 0.0 110.321 -179.174 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.478 ' HD2' ' HB3' ' A' ' 145' ' ' GLU . 11.2 mttt -79.82 129.65 34.66 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.677 ' O ' HG22 ' A' ' 166' ' ' VAL . 14.3 m -131.19 148.02 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.157 -0.965 . . . . 0.0 109.724 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.564 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.7 m-20 -100.48 119.04 37.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.37 -0.832 . . . . 0.0 109.437 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.581 HG23 ' CE1' ' A' ' 139' ' ' PHE . 3.4 p -100.35 144.05 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.309 -0.869 . . . . 0.0 109.501 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 28.0 m -96.89 97.05 8.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.391 -0.818 . . . . 0.0 109.984 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.644 HG22 ' CD2' ' A' ' 160' ' ' PHE . 13.0 mt -118.21 139.27 46.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.914 . . . . 0.0 109.332 179.608 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.644 ' CD2' HG22 ' A' ' 159' ' ' ILE . 40.0 m-85 59.67 41.74 18.14 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.402 -0.811 . . . . 0.0 109.32 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 54.14 16.61 6.55 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.731 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 4.3 mtp-105 -119.21 147.07 44.64 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.089 -1.242 . . . . 0.0 109.628 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -95.66 129.73 42.77 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.28 -0.887 . . . . 0.0 109.573 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.2 m -145.94 128.22 7.87 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.908 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.564 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.5 Cg_endo -70.52 138.72 36.0 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.686 2.257 . . . . 0.0 111.369 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.677 HG22 ' O ' ' A' ' 155' ' ' VAL . 2.9 m -122.4 168.09 15.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.005 -1.059 . . . . 0.0 110.01 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.765 HG13 ' OE2' ' A' ' 152' ' ' GLU . 42.8 t -116.44 117.95 57.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.541 -0.724 . . . . 0.0 109.309 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.749 HD12 ' N ' ' A' ' 168' ' ' LEU . 2.4 mp -141.21 165.75 26.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.258 -0.901 . . . . 0.0 110.519 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -80.2 143.38 33.83 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.526 HG23 HD13 ' A' ' 153' ' ' LEU . 4.3 p -57.96 -36.86 57.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.269 -0.895 . . . . 0.0 108.789 179.639 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.431 ' N ' ' CG1' ' A' ' 170' ' ' VAL . 49.8 m -77.17 -7.47 55.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.482 -0.761 . . . . 0.0 109.417 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.434 ' CG ' ' HB3' ' A' ' 133' ' ' SER . 5.5 mt-10 -95.8 -2.66 47.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.291 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 11.3 m -127.51 164.72 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.225 -0.922 . . . . 0.0 109.392 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.547 ' O ' HG22 ' A' ' 129' ' ' VAL . 58.3 tt0 -134.64 153.81 51.81 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.259 -0.901 . . . . 0.0 109.07 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.643 ' HB2' ' CZ ' ' A' ' 123' ' ' PHE . 33.1 pttt -92.91 20.99 6.03 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.182 -0.949 . . . . 0.0 109.493 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.485 HD12 ' HG2' ' A' ' 128' ' ' MET . 64.2 mt 61.8 -76.98 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.3 -0.875 . . . . 0.0 109.39 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.522 ' N ' ' O ' ' A' ' 175' ' ' LYS . 95.5 mt-10 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.374 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.5 -30.57 71.37 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.217 -1.166 . . . . 0.0 109.483 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 96.1 mmm -55.22 -41.36 71.95 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.459 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -92.68 143.89 25.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.354 -0.841 . . . . 0.0 109.52 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.487 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 82.9 mttt -95.41 144.48 25.9 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.496 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.521 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 18.7 mttp -130.65 176.45 8.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.294 -0.879 . . . . 0.0 109.579 -179.69 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 1.055 ' CZ3' HG23 ' A' ' 41' ' ' VAL . 76.1 m95 -113.16 125.06 53.93 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.279 -0.888 . . . . 0.0 109.179 179.742 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -115.37 170.4 8.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.164 -0.96 . . . . 0.0 109.139 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.562 HG12 ' CE1' ' A' ' 61' ' ' PHE . 21.5 mt -113.88 97.77 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.101 -1.0 . . . . 0.0 108.818 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.802 HG13 ' CG1' ' A' ' 60' ' ' VAL . 3.9 p -81.83 151.09 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.254 -0.903 . . . . 0.0 109.264 -179.771 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.874 HD21 ' CE1' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -94.34 142.96 26.82 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.388 -0.82 . . . . 0.0 110.013 -179.312 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.4 p -144.59 -171.59 3.64 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.372 -0.83 . . . . 0.0 109.01 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.504 ' CG ' ' SD ' ' A' ' 81' ' ' MET . 44.4 mtm -102.38 118.98 38.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.165 -0.959 . . . . 0.0 109.596 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 13' ' ' MET . 43.7 m -42.14 121.74 1.94 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.22 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.53 -18.3 32.69 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.069 -1.613 . . . . 0.0 109.069 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.43 ' O ' ' C ' ' A' ' 17' ' ' GLU . 92.9 m-85 -108.91 -13.25 14.78 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.397 -1.061 . . . . 0.0 109.61 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.43 ' C ' ' O ' ' A' ' 16' ' ' TYR . 95.1 mt-10 -42.71 -55.27 3.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.279 -0.888 . . . . 0.0 109.372 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -54.16 -36.46 63.36 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.215 -0.928 . . . . 0.0 109.141 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.421 ' N ' ' O ' ' A' ' 16' ' ' TYR . 28.0 mttp -70.3 -37.41 74.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.275 -0.891 . . . . 0.0 109.131 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 61.2 t -64.07 -47.13 91.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.431 -0.793 . . . . 0.0 109.411 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.6 tttm -55.1 -50.93 67.96 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.224 -0.923 . . . . 0.0 109.331 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -64.55 -41.92 96.01 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.281 -0.887 . . . . 0.0 109.311 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.489 ' ND2' ' HG2' ' A' ' 78' ' ' PRO . 24.1 t-20 -57.62 -39.75 77.62 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.186 -0.946 . . . . 0.0 109.452 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.798 HG21 HD11 ' A' ' 40' ' ' ILE . 96.4 mt -62.89 -44.73 99.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -0.927 . . . . 0.0 109.648 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -53.81 -45.29 70.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.15 -0.969 . . . . 0.0 109.64 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.9 mttt -79.99 -32.37 39.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.485 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.748 ' HG2' HG23 ' A' ' 77' ' ' VAL . 48.7 tptt -56.77 -38.3 72.3 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.308 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.788 HG13 ' O ' ' A' ' 33' ' ' ILE . 40.7 t -83.81 -22.93 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.338 -0.851 . . . . 0.0 109.399 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -69.16 -53.27 20.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.571 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.77 -33.47 64.36 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.619 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 23.1 p -91.42 -19.92 22.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.229 -0.92 . . . . 0.0 109.612 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 68.83 9.97 60.37 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.788 ' O ' HG13 ' A' ' 28' ' ' VAL . 54.3 mt -80.16 88.5 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.292 -1.122 . . . . 0.0 109.414 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.3 mttt -91.74 9.18 33.6 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.155 -0.966 . . . . 0.0 109.438 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.47 ' O ' HD13 ' A' ' 65' ' ' ILE . 38.0 p30 -110.93 9.13 22.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.289 -0.882 . . . . 0.0 109.59 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.988 HD21 ' HB2' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -109.71 -55.22 2.46 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.182 -0.948 . . . . 0.0 109.172 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.805 HG22 ' HE3' ' A' ' 64' ' ' MET . 68.9 t -94.15 130.98 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.317 -0.864 . . . . 0.0 109.31 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.75 -122.84 5.16 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -89.74 148.56 23.19 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.275 -1.132 . . . . 0.0 109.822 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.798 HD11 HG21 ' A' ' 24' ' ' ILE . 72.2 mt -116.21 132.93 64.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.4 -0.812 . . . . 0.0 108.909 179.641 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 1.055 HG23 ' CZ3' ' A' ' 7' ' ' TRP . 34.3 t -125.87 161.81 30.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 O-C-N 121.049 -1.032 . . . . 0.0 109.346 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.659 HG22 HG23 ' A' ' 44' ' ' ILE . 2.3 mt -140.92 127.61 11.74 Favored Pre-proline 0 N--CA 1.487 1.402 0 O-C-N 121.208 -0.933 . . . . 0.0 109.83 -179.709 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.562 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 45.8 Cg_endo -67.16 -2.64 8.39 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.841 2.36 . . . . 0.0 111.305 179.569 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.769 HG22 ' HB3' ' A' ' 54' ' ' LYS . 19.0 pt -81.14 -9.59 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.312 -0.868 . . . . 0.0 109.615 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.568 ' HB2' HD21 ' A' ' 104' ' ' LEU . 22.5 mtp85 -50.16 -23.64 2.3 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.081 -1.012 . . . . 0.0 109.345 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.472 ' HA3' HD11 ' A' ' 104' ' ' LEU . . . -101.77 -168.19 27.39 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 60.15 43.41 98.4 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -67.9 -29.32 68.39 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.242 -1.152 . . . . 0.0 109.459 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.414 ' O ' ' O ' ' A' ' 52' ' ' SER . 99.2 mtt180 -53.66 140.49 29.01 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.248 -0.907 . . . . 0.0 109.455 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 58.3 mtt-85 -61.98 -24.88 67.3 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.16 -0.963 . . . . 0.0 109.444 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 28.5 mttm -59.05 -27.74 65.78 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.196 -0.94 . . . . 0.0 109.5 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.414 ' O ' ' O ' ' A' ' 49' ' ' ARG . 48.8 p -146.43 144.84 29.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.934 . . . . 0.0 109.591 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.489 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 75.5 mm-40 -139.77 128.12 22.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 109.479 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.769 ' HB3' HG22 ' A' ' 44' ' ' ILE . 13.6 mttp 74.83 115.8 0.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.258 -0.901 . . . . 0.0 109.646 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.656 HD23 ' HE2' ' A' ' 56' ' ' PHE . 18.2 tp -57.48 -45.85 84.38 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.039 -1.038 . . . . 0.0 109.291 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.656 ' HE2' HD23 ' A' ' 55' ' ' LEU . 57.9 m-85 -131.44 109.4 14.83 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.141 -0.974 . . . . 0.0 108.864 179.482 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -65.45 138.9 56.89 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.579 2.186 . . . . 0.0 111.974 -179.53 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.59 ' O ' HD13 ' A' ' 11' ' ' LEU . . . 76.84 -16.7 5.11 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 179.605 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.874 ' CE1' HD21 ' A' ' 11' ' ' LEU . 3.3 m-30 -98.63 129.08 45.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.788 -1.419 . . . . 0.0 110.406 -179.207 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.802 ' CG1' HG13 ' A' ' 10' ' ' VAL . 7.7 p -136.92 151.58 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.562 ' CE1' HG12 ' A' ' 9' ' ' ILE . 7.7 m-85 -110.0 127.07 54.58 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.914 -1.116 . . . . 0.0 110.756 -178.71 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.783 HG13 HG12 ' A' ' 40' ' ' ILE . 90.3 t -129.51 139.82 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.649 -0.657 . . . . 0.0 109.318 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.604 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 9.7 tt0 -101.83 126.94 48.81 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.114 -0.991 . . . . 0.0 109.104 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.805 ' HE3' HG22 ' A' ' 37' ' ' VAL . 1.8 mtp -157.28 178.02 10.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.043 -1.036 . . . . 0.0 110.071 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.616 ' CG1' HD22 ' A' ' 36' ' ' LEU . 12.2 pt -99.95 131.92 46.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.593 -0.692 . . . . 0.0 109.286 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.47 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 42.1 ttm -77.65 145.76 36.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 110.086 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.508 ' OD1' ' N ' ' A' ' 68' ' ' ASP . 49.8 t-20 176.74 172.37 0.45 Allowed 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.508 ' N ' ' OD1' ' A' ' 67' ' ' ASN . 90.2 m-20 -69.47 -42.81 74.35 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.163 -0.961 . . . . 0.0 109.275 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.504 ' HG2' ' CD2' ' A' ' 73' ' ' PHE . 69.7 tt0 -73.82 -31.54 63.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.327 -0.858 . . . . 0.0 109.55 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.988 ' HB2' HD21 ' A' ' 36' ' ' LEU . . . -70.92 -45.07 64.92 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.146 -0.971 . . . . 0.0 109.356 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.495 ' HA ' ' CG1' ' A' ' 74' ' ' VAL . 71.8 t80 -60.99 -47.0 88.48 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.265 -0.897 . . . . 0.0 109.72 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' HB2' ' A' ' 76' ' ' SER . 96.4 m-20 -64.72 -27.65 69.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.106 -0.996 . . . . 0.0 110.035 -179.518 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.504 ' CD2' ' HG2' ' A' ' 69' ' ' GLU . 3.6 m-85 -84.19 -42.98 15.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.045 -1.034 . . . . 0.0 109.917 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.848 HG12 ' O ' ' A' ' 70' ' ' ALA . 2.9 p -67.12 -57.87 8.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.264 -0.898 . . . . 0.0 109.803 -179.426 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.696 ' H ' HG13 ' A' ' 74' ' ' VAL . 28.5 tpt85 -62.84 -10.27 12.58 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.103 -0.998 . . . . 0.0 109.676 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.481 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 19.4 m -99.25 1.49 44.74 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.147 -0.971 . . . . 0.0 109.953 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.787 HG12 ' CG2' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -70.43 140.71 87.57 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.023 -1.048 . . . . 0.0 109.229 -179.976 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.648 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 45.6 Cg_endo -66.73 134.9 36.58 Favored 'Trans proline' 0 C--O 1.213 -0.765 0 C-N-CA 122.706 2.271 . . . . 0.0 111.849 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.648 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 10.0 m-85 92.62 -10.77 0.18 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.816 -0.552 . . . . 0.0 109.52 -179.708 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.787 ' CG2' HG12 ' A' ' 77' ' ' VAL . 2.3 t -85.7 121.06 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.116 -0.99 . . . . 0.0 109.144 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.504 ' SD ' ' CG ' ' A' ' 13' ' ' MET . 82.8 mtp -88.4 -33.69 17.82 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.241 -0.912 . . . . 0.0 109.565 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 11' ' ' LEU . . . 172.01 -168.98 42.12 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.631 ' CD1' ' N ' ' A' ' 83' ' ' PHE . 0.8 OUTLIER -134.21 146.65 50.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.189 -1.183 . . . . 0.0 109.524 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.675 ' O ' HG13 ' A' ' 84' ' ' VAL . 14.2 p -81.23 114.38 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.212 -0.93 . . . . 0.0 109.368 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.598 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.9 OUTLIER -154.04 164.88 37.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.256 -0.902 . . . . 0.0 109.639 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 77.0 p -84.5 -30.63 25.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.167 -0.958 . . . . 0.0 109.267 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -130.96 -102.54 0.93 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.548 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -93.16 -129.15 5.08 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.548 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -29.5 150.47 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.675 -0.897 . . . . 0.0 110.315 -179.56 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.598 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 46.2 Cg_endo -67.66 143.03 60.52 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.753 2.302 . . . . 0.0 112.002 -179.84 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 6.2 m -74.07 147.56 85.96 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.325 -0.86 . . . . 0.0 109.293 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.506 ' CB ' ' HD3' ' A' ' 6' ' ' LYS . 49.2 Cg_endo -69.82 145.39 56.63 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.708 2.272 . . . . 0.0 111.7 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.529 ' CG1' ' HG2' ' A' ' 98' ' ' MET . 9.9 p -70.11 135.16 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.932 . . . . 0.0 109.231 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' LYS . . . . . 0.487 ' HE2' ' HD2' ' A' ' 96' ' ' ARG . 15.4 tttp -70.95 136.48 48.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.179 -0.95 . . . . 0.0 109.592 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -46.58 -52.05 14.34 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.221 -0.924 . . . . 0.0 109.355 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.487 ' HD2' ' HE2' ' A' ' 94' ' ' LYS . 72.0 mtt85 -60.84 -16.47 41.63 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.292 -0.88 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.489 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 6.7 mt-10 -88.59 -28.5 20.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.274 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.651 ' HE3' ' CD1' ' A' ' 7' ' ' TRP . 31.4 mtp -75.85 -28.69 58.3 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -0.874 . . . . 0.0 109.61 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.59 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.46 -53.37 1.3 Allowed Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.485 -0.76 . . . . 0.0 109.979 -179.609 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.59 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.7 Cg_endo -69.01 -34.96 15.85 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.538 2.158 . . . . 0.0 112.111 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.489 ' HA ' HD13 ' A' ' 101' ' ' ILE . 8.7 mm -78.57 -44.51 26.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.118 -0.989 . . . . 0.0 109.444 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.908 ' HA ' HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -62.19 -41.35 98.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.106 -0.996 . . . . 0.0 108.873 179.725 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.478 ' HD2' ' O ' ' A' ' 135' ' ' PRO . 36.3 mtt180 -61.03 -43.21 99.23 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.568 HD21 ' HB2' ' A' ' 45' ' ' ARG . 0.7 OUTLIER -70.01 -35.76 74.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 109.134 179.667 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.508 ' HA ' ' HD3' ' A' ' 45' ' ' ARG . . . -88.13 20.96 2.94 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.21 179.681 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 46.92 28.4 3.88 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.908 HD12 ' HA ' ' A' ' 102' ' ' LEU . 35.9 mt -80.04 -22.84 41.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.196 -1.179 . . . . 0.0 109.146 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -112.85 149.51 33.01 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.345 -0.847 . . . . 0.0 109.314 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -93.93 124.09 37.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.235 -0.916 . . . . 0.0 109.585 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.473 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 48.1 p90 -144.27 160.36 41.13 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.27 -0.894 . . . . 0.0 109.477 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.473 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 6.4 mt-10 -68.73 -147.76 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.241 -0.912 . . . . 0.0 109.49 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.458 ' O ' ' HB3' ' A' ' 113' ' ' LYS . 81.8 tt0 -100.61 -48.57 4.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.215 -0.928 . . . . 0.0 109.488 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.458 ' HB3' ' O ' ' A' ' 112' ' ' GLU . 16.6 pttt 173.72 177.83 0.11 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.252 -0.905 . . . . 0.0 109.298 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.504 ' O ' ' CB ' ' A' ' 115' ' ' LYS . 6.6 mttt -70.44 -64.65 0.85 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.176 -0.953 . . . . 0.0 109.238 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.504 ' CB ' ' O ' ' A' ' 114' ' ' LYS . 2.8 mtpt 164.71 148.72 0.05 OUTLIER Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.297 -0.877 . . . . 0.0 109.259 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -68.82 53.83 0.81 Allowed 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.673 2.249 . . . . 0.0 111.7 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.516 HG22 ' O ' ' A' ' 117' ' ' VAL . 7.6 p -71.28 -5.3 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.287 -0.883 . . . . 0.0 109.58 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.493 ' HA ' ' HB3' ' A' ' 171' ' ' SER . 26.5 tttt 68.4 125.81 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.282 -0.886 . . . . 0.0 109.464 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.65 HG11 ' HA ' ' A' ' 174' ' ' GLU . 74.3 t -128.08 123.83 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.188 -0.945 . . . . 0.0 109.403 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.663 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 89.4 mt-10 -153.81 170.53 20.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.515 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.663 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 4.1 mt 145.33 112.77 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . 42.08 57.67 3.51 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.525 ' CD2' ' O ' ' A' ' 123' ' ' PHE . 51.7 p90 -103.18 121.9 43.62 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.294 -1.121 . . . . 0.0 109.498 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.463 ' N ' ' OD2' ' A' ' 127' ' ' ASP . 27.5 mttp -141.81 164.48 30.07 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.247 -0.908 . . . . 0.0 109.558 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.55 HG23 ' O ' ' A' ' 144' ' ' LYS . 7.9 p -66.5 126.11 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.318 -0.864 . . . . 0.0 109.659 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 103.68 -33.32 6.67 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.751 ' HB2' HD12 ' A' ' 143' ' ' ILE . 73.2 m-20 -48.15 165.33 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.385 -1.068 . . . . 0.0 108.922 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.4 ttm -97.26 126.91 42.78 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.044 -1.035 . . . . 0.0 108.97 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.707 ' CG2' HD11 ' A' ' 143' ' ' ILE . 12.7 t -125.36 141.91 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.248 -0.908 . . . . 0.0 109.535 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.484 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 42.8 tttp -106.61 143.91 34.04 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.357 -0.839 . . . . 0.0 108.946 179.495 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 1.009 HD12 ' HB3' ' A' ' 139' ' ' PHE . 65.8 mt -84.76 155.31 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.129 -0.982 . . . . 0.0 108.817 179.636 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.459 ' O ' ' HE3' ' A' ' 114' ' ' LYS . 27.2 pt -150.59 2.95 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.126 -0.984 . . . . 0.0 109.488 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 72.7 m -148.66 145.08 27.57 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.151 -0.968 . . . . 0.0 110.107 -179.672 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.15 -170.55 16.8 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.478 ' O ' ' HD2' ' A' ' 103' ' ' ARG . 48.2 Cg_endo -68.66 -19.8 41.31 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 123.275 2.65 . . . . 0.0 112.467 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.534 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 98.1 m-85 -112.96 13.22 19.48 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.05 -1.031 . . . . 0.0 109.487 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.727 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.6 tt0 -42.73 151.74 0.12 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 109.663 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.515 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 25.3 m-20 72.99 28.1 1.98 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.455 -0.778 . . . . 0.0 110.091 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 1.009 ' HB3' HD12 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -120.43 136.99 54.57 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.99 -1.069 . . . . 0.0 109.539 179.877 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.08 133.94 34.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.225 -0.922 . . . . 0.0 109.579 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.92 170.05 25.95 Favored Glycine 0 N--CA 1.492 2.374 0 C-N-CA 119.836 -1.173 . . . . 0.0 110.171 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.887 ' C ' HG23 ' A' ' 155' ' ' VAL . 47.9 t -115.76 136.03 53.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.387 -1.066 . . . . 0.0 109.439 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.815 HG23 HD23 ' A' ' 153' ' ' LEU . 87.7 mt -65.12 115.22 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.89 . . . . 0.0 109.386 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.55 ' O ' HG23 ' A' ' 125' ' ' VAL . 36.6 tttp -100.26 -36.38 9.3 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.062 -1.024 . . . . 0.0 109.377 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.441 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 67.2 mm-40 -149.57 144.26 26.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.967 . . . . 0.0 109.351 -179.9 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 1.084 HG23 ' HG ' ' A' ' 153' ' ' LEU . 2.4 mt -123.04 125.85 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.183 -0.948 . . . . 0.0 109.406 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -108.18 101.46 41.9 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.236 -0.915 . . . . 0.0 109.63 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.552 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.7 171.4 16.49 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.72 2.28 . . . . 0.0 111.781 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.552 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 10.8 tt0 80.55 -20.97 0.35 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.3 -0.875 . . . . 0.0 109.791 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.452 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 93.1 mtt-85 -126.59 -12.99 6.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.916 . . . . 0.0 109.437 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.452 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 29.9 mt-30 69.83 48.6 0.56 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.204 -0.935 . . . . 0.0 109.61 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -120.06 143.62 48.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.138 -0.976 . . . . 0.0 109.08 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 1.084 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -136.99 112.38 9.24 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.15 -0.969 . . . . 0.0 110.12 -179.599 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.429 ' HD2' ' HB2' ' A' ' 145' ' ' GLU . 30.8 mttm -79.85 130.94 35.72 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.06 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.887 HG23 ' C ' ' A' ' 142' ' ' VAL . 7.3 p -133.39 127.48 53.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.121 -0.987 . . . . 0.0 109.752 -179.469 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.56 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 50.2 m-20 -73.18 135.4 44.61 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.362 -0.836 . . . . 0.0 109.709 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.553 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 53.9 t -116.8 149.96 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.466 -0.772 . . . . 0.0 109.195 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 57.2 m -96.34 103.01 14.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.107 -0.996 . . . . 0.0 109.711 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.509 HG22 ' CD2' ' A' ' 160' ' ' PHE . 20.5 mt -129.98 140.77 48.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.285 -0.884 . . . . 0.0 109.311 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.509 ' CD2' HG22 ' A' ' 159' ' ' ILE . 52.8 m-85 60.3 40.4 17.76 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.186 -0.946 . . . . 0.0 108.97 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.64 16.31 15.88 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 46.1 mtp180 -128.43 156.13 43.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.111 -1.229 . . . . 0.0 109.57 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -100.24 133.75 44.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.289 -0.882 . . . . 0.0 109.443 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.7 m -141.33 127.77 11.41 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.342 -0.849 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.56 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.9 Cg_endo -70.35 133.68 25.03 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.658 2.238 . . . . 0.0 111.44 179.697 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.635 HG12 ' O ' ' A' ' 155' ' ' VAL . 2.8 p -122.67 141.87 41.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.204 -0.935 . . . . 0.0 109.675 -179.837 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.588 ' O ' HG23 ' A' ' 167' ' ' VAL . 18.0 m -93.17 120.11 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.458 -0.776 . . . . 0.0 109.458 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.867 HD11 HG12 ' A' ' 155' ' ' VAL . 0.0 OUTLIER -142.3 167.81 21.22 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.33 -0.857 . . . . 0.0 110.487 -179.471 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.482 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 48.1 m80 -81.6 142.0 33.19 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.622 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.533 HG22 ' O ' ' A' ' 119' ' ' VAL . 10.8 p -55.92 -35.98 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.177 -0.952 . . . . 0.0 109.025 179.782 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.493 ' HB3' ' HA ' ' A' ' 118' ' ' LYS . 74.6 p -75.71 -6.61 51.39 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.403 -0.811 . . . . 0.0 109.626 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.482 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 41.8 mt-10 -90.99 -0.68 57.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.135 -0.978 . . . . 0.0 109.572 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.484 ' HB ' ' O ' ' A' ' 130' ' ' LYS . 2.8 m -147.13 177.74 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.176 -0.953 . . . . 0.0 109.452 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.65 ' HA ' HG11 ' A' ' 119' ' ' VAL . 83.5 tt0 -136.55 163.75 29.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.149 -0.969 . . . . 0.0 109.263 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.538 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.3 mmtt -94.77 18.0 12.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.47 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.452 HG22 ' HG3' ' A' ' 177' ' ' GLU . 63.5 mt 59.8 -79.08 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.29 -0.881 . . . . 0.0 109.684 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.528 ' N ' ' O ' ' A' ' 175' ' ' LYS . 94.1 mt-10 . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 117.905 -1.045 . . . . 0.0 109.515 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.51 -22.92 65.42 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -1.166 . . . . 0.0 109.491 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 91.3 mtp -66.97 -24.76 66.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.288 -0.882 . . . . 0.0 109.479 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 30.1 mttt -112.16 132.51 54.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.283 -0.886 . . . . 0.0 109.476 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -89.12 146.73 24.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.246 -0.909 . . . . 0.0 109.493 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.561 ' HB2' ' CZ ' ' A' ' 8' ' ' TYR . 26.5 mmtp -128.6 175.47 8.54 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.354 -0.841 . . . . 0.0 109.613 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.932 ' O ' HG23 ' A' ' 93' ' ' VAL . 47.2 m95 -111.65 124.26 51.94 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.39 -0.819 . . . . 0.0 108.968 179.657 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.561 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 59.3 m-85 -117.94 168.65 10.31 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.141 -0.975 . . . . 0.0 109.478 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.537 HG12 ' CE1' ' A' ' 61' ' ' PHE . 33.9 mt -107.5 114.63 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.208 -0.932 . . . . 0.0 109.367 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.604 HG12 ' HB ' ' A' ' 60' ' ' VAL . 8.5 p -92.65 141.17 15.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.234 -0.916 . . . . 0.0 109.222 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.674 HD11 ' CE1' ' A' ' 59' ' ' TYR . 3.7 mm? -89.62 143.28 26.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.408 -0.807 . . . . 0.0 109.739 -179.572 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.731 HG21 ' OE1' ' A' ' 17' ' ' GLU . 9.0 t -152.99 -166.03 2.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.325 -0.859 . . . . 0.0 109.408 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.441 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 46.2 mtt -108.14 130.83 55.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.532 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.0 t -54.26 128.27 30.54 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.196 -0.94 . . . . 0.0 109.391 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.55 -20.31 44.8 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 -179.79 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.441 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 79.4 m-85 -104.47 5.94 34.48 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.38 -1.071 . . . . 0.0 109.557 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.731 ' OE1' HG21 ' A' ' 12' ' ' THR . 41.1 mm-40 -53.36 -62.32 1.73 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.62 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 17' ' ' GLU . 60.7 mt-10 -42.68 -35.64 1.18 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -0.889 . . . . 0.0 109.583 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 27.3 mttt -74.18 -44.61 52.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.472 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.688 HG21 ' OG1' ' A' ' 12' ' ' THR . 70.6 t -58.44 -53.11 51.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.48 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.417 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.5 tttm -58.4 -47.07 85.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.348 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -63.13 -41.17 99.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.329 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.473 ' HB3' ' HG2' ' A' ' 78' ' ' PRO . 22.1 m120 -59.29 -42.78 92.09 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.904 . . . . 0.0 109.503 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.911 HG21 HD11 ' A' ' 40' ' ' ILE . 69.7 mt -61.5 -46.46 96.53 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.229 -0.919 . . . . 0.0 109.715 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -54.83 -46.22 74.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.145 -0.972 . . . . 0.0 109.56 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -75.78 -35.57 60.07 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.132 -0.98 . . . . 0.0 109.459 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.604 ' O ' HG23 ' A' ' 31' ' ' THR . 7.8 ttpt -56.14 -34.26 65.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.253 -0.905 . . . . 0.0 109.314 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.793 HG13 ' O ' ' A' ' 33' ' ' ILE . 44.2 t -85.52 -25.15 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -0.873 . . . . 0.0 109.377 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -69.77 -54.17 14.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.186 -0.946 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.22 -24.76 67.79 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.197 -0.94 . . . . 0.0 109.526 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.604 HG23 ' O ' ' A' ' 27' ' ' LYS . 40.2 p -94.96 -21.75 18.41 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.165 -0.959 . . . . 0.0 109.531 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 63.68 22.01 65.66 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.014 HG21 HD12 ' A' ' 36' ' ' LEU . 42.7 mm -95.07 91.79 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.271 -1.134 . . . . 0.0 109.465 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.9 mtpt -98.81 10.03 42.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.27 -0.894 . . . . 0.0 109.52 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -108.24 5.44 25.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.19 -0.944 . . . . 0.0 109.492 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.014 HD12 HG21 ' A' ' 33' ' ' ILE . 88.3 mt -117.78 -30.94 5.29 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.276 -0.89 . . . . 0.0 109.39 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.499 ' HA ' ' HG2' ' A' ' 64' ' ' MET . 73.0 t -114.68 129.35 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.309 -0.869 . . . . 0.0 109.305 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.73 -129.89 6.84 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 23.4 mtt-85 -90.44 147.89 23.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.274 -1.133 . . . . 0.0 109.777 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 1.061 HG23 HG22 ' A' ' 62' ' ' VAL . 59.9 mt -113.32 136.61 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.337 -0.852 . . . . 0.0 109.383 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.575 ' CG1' ' HB2' ' A' ' 61' ' ' PHE . 9.3 p -130.4 158.29 42.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.199 -0.938 . . . . 0.0 109.54 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.773 HG22 HG23 ' A' ' 44' ' ' ILE . 3.3 mt -131.78 129.05 21.86 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.559 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.533 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 46.1 Cg_endo -67.2 -4.73 12.19 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.788 2.325 . . . . 0.0 111.587 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.773 HG23 HG22 ' A' ' 42' ' ' ILE . 12.7 pt -78.08 -17.81 13.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.299 -0.876 . . . . 0.0 109.451 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.98 ' O ' HD21 ' A' ' 104' ' ' LEU . 60.0 mtt-85 -54.21 150.16 8.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.485 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 150.94 160.91 9.67 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 53.7 -119.7 11.88 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -103.65 146.66 28.25 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.266 -1.138 . . . . 0.0 109.446 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -57.32 -33.12 67.38 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.217 -0.927 . . . . 0.0 109.544 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -66.81 -33.05 74.75 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.292 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 8.4 mmtp -100.98 148.64 24.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.316 -0.865 . . . . 0.0 109.384 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 6.1 p -146.18 115.83 7.22 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.313 -0.867 . . . . 0.0 109.396 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.505 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 55.4 mm-40 -77.92 -31.3 51.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.305 -0.872 . . . . 0.0 109.545 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.703 ' HA ' HG22 ' A' ' 44' ' ' ILE . 47.6 mttt 74.86 85.71 0.1 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.42 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.533 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 6.7 mp -61.55 -26.8 68.18 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.097 -1.002 . . . . 0.0 109.527 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.616 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 97.2 m-85 -145.83 103.8 4.2 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.893 . . . . 0.0 109.31 179.778 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 43.5 Cg_endo -67.17 137.75 44.96 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.666 2.244 . . . . 0.0 111.865 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.91 -9.28 6.68 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.674 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.2 m-85 -103.49 132.65 49.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.795 -1.415 . . . . 0.0 109.82 -179.511 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.604 ' HB ' HG12 ' A' ' 10' ' ' VAL . 4.9 t -135.58 148.65 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.354 -0.841 . . . . 0.0 108.923 179.41 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.575 ' HB2' ' CG1' ' A' ' 41' ' ' VAL . 63.3 m-85 -107.87 121.65 45.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.073 -1.017 . . . . 0.0 109.764 -179.64 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 1.061 HG22 HG23 ' A' ' 40' ' ' ILE . 57.6 t -129.06 141.14 47.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.357 -0.839 . . . . 0.0 109.699 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.618 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 52.4 tt0 -97.03 124.73 41.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.339 -0.851 . . . . 0.0 108.862 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.512 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 37.3 mtm -158.4 -179.82 8.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.147 -0.971 . . . . 0.0 109.777 -179.582 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.851 HD11 ' CD2' ' A' ' 36' ' ' LEU . 8.5 pt -102.64 129.0 54.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.2 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.501 ' O ' ' HG3' ' A' ' 66' ' ' MET . 5.2 ptp -85.58 96.2 9.57 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.129 -0.982 . . . . 0.0 109.668 -179.364 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.598 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 23.0 t-20 -140.04 170.48 15.78 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -52.81 -47.58 67.53 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.038 -1.039 . . . . 0.0 109.987 -179.507 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.458 ' O ' ' C ' ' A' ' 70' ' ' ALA . 64.6 mm-40 -64.87 -64.34 0.89 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.095 -1.003 . . . . 0.0 110.132 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.854 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -39.77 -38.8 0.69 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.263 -0.898 . . . . 0.0 109.926 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.598 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 15.4 m-85 -61.11 -62.16 2.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.226 -0.921 . . . . 0.0 109.362 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -45.76 -34.9 3.93 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.503 -0.748 . . . . 0.0 110.412 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -81.39 -43.85 18.39 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.888 -1.133 . . . . 0.0 110.136 -179.381 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.995 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 45.4 t -64.43 -58.67 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.25 -0.906 . . . . 0.0 109.643 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -35.05 19.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.366 -0.834 . . . . 0.0 110.034 -179.589 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 53.6 p -78.16 4.89 11.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.083 -1.01 . . . . 0.0 110.37 -179.279 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.611 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 41.1 t -64.32 133.62 95.71 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 120.872 -1.143 . . . . 0.0 109.286 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.569 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 46.1 Cg_endo -68.27 134.83 32.43 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.702 2.268 . . . . 0.0 112.02 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.569 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 60.2 m-85 77.61 -1.54 2.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.525 -0.734 . . . . 0.0 109.855 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.611 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.4 t -88.6 127.32 41.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.173 -0.955 . . . . 0.0 109.147 179.609 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 82.5 mmm -90.77 -17.97 25.74 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.21 -0.931 . . . . 0.0 109.645 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.592 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 151.71 -155.61 26.23 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.995 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 3.6 m-85 -140.04 152.67 46.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -1.16 . . . . 0.0 109.5 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.571 HG22 HD21 ' A' ' 11' ' ' LEU . 4.6 t -77.27 119.58 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.291 -0.881 . . . . 0.0 109.275 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.556 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.9 p -156.49 162.17 39.98 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.227 -0.92 . . . . 0.0 109.596 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.78 -34.8 14.45 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.887 . . . . 0.0 109.393 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -122.09 -86.33 0.83 Allowed Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -107.04 -130.37 6.43 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.545 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.1 OUTLIER -33.82 156.4 0.04 OUTLIER Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.43 -1.041 . . . . 0.0 110.056 -179.693 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.556 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.9 Cg_endo -69.71 157.74 59.44 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 122.492 2.128 . . . . 0.0 112.109 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.402 ' H ' HG22 ' A' ' 91' ' ' VAL . 10.9 m -90.15 153.64 46.83 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.351 -0.843 . . . . 0.0 109.452 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.453 ' HB3' ' HB3' ' A' ' 6' ' ' LYS . 49.1 Cg_endo -69.81 145.48 56.99 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.658 2.239 . . . . 0.0 111.812 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.932 HG23 ' O ' ' A' ' 7' ' ' TRP . 7.6 t -84.22 129.69 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.235 -0.915 . . . . 0.0 109.194 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' LYS . . . . . 0.414 ' O ' ' C ' ' A' ' 95' ' ' ASP . 23.6 tttt -70.56 132.77 46.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.191 -0.943 . . . . 0.0 109.578 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 94' ' ' LYS . 80.5 m-20 -44.48 -39.86 5.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.205 -0.934 . . . . 0.0 109.356 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.5 ' CZ ' ' HB3' ' A' ' 96' ' ' ARG . 13.4 mtp-105 -53.79 -35.51 61.44 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.272 -0.893 . . . . 0.0 109.374 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.446 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 65.2 mt-10 -84.73 -27.48 26.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.269 -0.894 . . . . 0.0 109.372 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.628 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 94.4 mtp -84.98 -12.31 53.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.295 -0.878 . . . . 0.0 109.505 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.667 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -51.18 -48.42 85.46 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.171 -0.956 . . . . 0.0 109.853 179.864 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.667 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.5 Cg_endo -70.82 -27.6 21.22 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.485 2.123 . . . . 0.0 111.861 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.439 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 35.8 mm -81.52 -44.4 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 109.565 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.601 HD12 ' O ' ' A' ' 98' ' ' MET . 0.7 OUTLIER -66.46 -38.76 88.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.232 -0.917 . . . . 0.0 109.256 -179.926 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.524 ' CZ ' ' NH1' ' A' ' 99' ' ' ARG . 67.7 mtt180 -65.47 -50.16 66.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.429 -0.794 . . . . 0.0 109.322 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.98 HD21 ' O ' ' A' ' 45' ' ' ARG . 0.6 OUTLIER -72.64 -36.24 67.96 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.273 -0.892 . . . . 0.0 109.364 179.762 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.535 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -73.44 -0.99 16.52 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.371 -0.831 . . . . 0.0 109.687 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.03 11.6 81.44 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.452 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 61.3 mt -85.51 -24.11 27.45 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.128 -1.219 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.46 ' HB2' ' HB2' ' A' ' 102' ' ' LEU . 73.5 tt0 -116.9 160.92 20.16 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.283 -0.886 . . . . 0.0 109.591 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -100.05 120.32 39.65 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.274 -0.891 . . . . 0.0 109.405 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.582 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 46.9 p90 -133.77 168.07 19.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.236 -0.915 . . . . 0.0 109.505 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.582 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 41.4 mt-10 -79.23 -147.56 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.258 -0.901 . . . . 0.0 109.592 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -111.77 -49.48 2.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.19 -0.944 . . . . 0.0 109.316 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.457 ' HE3' ' HB3' ' A' ' 116' ' ' PRO . 31.0 pttt -151.9 140.94 21.2 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.326 -0.859 . . . . 0.0 109.325 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.49 ' CB ' ' O ' ' A' ' 132' ' ' ILE . 5.3 tttt -74.79 -54.14 7.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.181 -0.949 . . . . 0.0 109.593 -179.787 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.626 ' HG3' HD12 ' A' ' 132' ' ' ILE . 10.5 mttt -103.57 96.96 9.55 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.911 . . . . 0.0 109.545 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' PRO . . . . . 0.482 ' HD3' ' O ' ' A' ' 114' ' ' LYS . 52.2 Cg_endo -73.49 -4.72 15.9 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.911 2.408 . . . . 0.0 111.651 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.34 142.15 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.225 -0.922 . . . . 0.0 109.366 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.461 ' HG2' ' N ' ' A' ' 119' ' ' VAL . 50.3 tttp -50.51 157.17 0.77 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.118 -0.989 . . . . 0.0 109.487 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.461 ' N ' ' HG2' ' A' ' 118' ' ' LYS . 60.8 t -121.31 144.4 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.48 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.659 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 83.6 mt-10 -129.81 168.6 16.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.235 -0.916 . . . . 0.0 109.365 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.659 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 2.0 mt 145.82 100.58 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.973 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.617 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.53 93.17 0.01 OUTLIER Glycine 0 N--CA 1.496 2.662 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.496 ' N ' ' O ' ' A' ' 121' ' ' LEU . 3.6 p90 -96.71 149.71 21.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.2 -1.177 . . . . 0.0 109.489 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 22.4 mttt -149.02 157.29 43.3 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.221 -0.925 . . . . 0.0 109.52 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.613 HG13 ' O ' ' A' ' 144' ' ' LYS . 44.7 t -60.33 140.04 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 87.85 -34.12 3.81 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.768 ' HB3' HD12 ' A' ' 143' ' ' ILE . 43.0 t0 -48.51 157.68 0.34 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.431 -1.041 . . . . 0.0 109.465 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' MET . . . . . 0.442 ' HG2' HD12 ' A' ' 176' ' ' ILE . 4.8 ttm -96.07 127.5 42.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.244 -0.91 . . . . 0.0 108.861 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 1.021 HG13 ' O ' ' A' ' 174' ' ' GLU . 51.3 t -126.44 142.08 44.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.256 -0.903 . . . . 0.0 109.42 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 5.8 ttpp -101.95 142.85 32.6 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.376 -0.828 . . . . 0.0 109.065 179.738 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.86 HD12 ' HB3' ' A' ' 139' ' ' PHE . 70.8 mt -82.9 151.35 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.042 -1.036 . . . . 0.0 108.761 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.669 HD13 ' CD ' ' A' ' 174' ' ' GLU . 33.2 pt -148.99 2.95 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.95 -1.093 . . . . 0.0 109.503 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.559 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 68.8 m -146.35 141.76 27.57 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.11 -0.994 . . . . 0.0 109.712 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.423 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 107.04 -170.85 16.16 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.581 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.52 -18.91 43.23 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 123.213 2.609 . . . . 0.0 112.797 -179.445 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.529 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.9 m-85 -108.94 19.11 19.97 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.964 -1.085 . . . . 0.0 109.487 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.559 ' HA ' HG22 ' A' ' 131' ' ' ILE . 43.8 mt-10 -41.31 141.85 0.64 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 110.22 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 138' ' ' ASP . 0.5 OUTLIER 76.03 24.39 1.19 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.299 -0.875 . . . . 0.0 110.757 179.002 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.86 ' HB3' HD12 ' A' ' 131' ' ' ILE . 0.5 OUTLIER -111.73 129.32 56.15 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.828 -1.17 . . . . 0.0 109.729 179.912 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.401 ' N ' ' HD1' ' A' ' 139' ' ' PHE . . . -76.46 134.8 39.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.905 . . . . 0.0 109.392 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.79 166.62 26.94 Favored Glycine 0 N--CA 1.489 2.221 0 C-N-CA 119.718 -1.23 . . . . 0.0 110.164 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.814 ' C ' HG23 ' A' ' 155' ' ' VAL . 47.0 t -116.16 137.34 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.591 -0.946 . . . . 0.0 109.256 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.768 HD12 ' HB3' ' A' ' 127' ' ' ASP . 88.6 mt -70.39 120.49 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.305 -0.872 . . . . 0.0 109.268 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.613 ' O ' HG13 ' A' ' 125' ' ' VAL . 75.0 tttt -103.65 -33.07 9.1 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.964 -1.085 . . . . 0.0 109.711 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.519 ' HG2' ' O ' ' A' ' 144' ' ' LYS . 15.5 mt-10 -150.5 145.66 26.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.058 -1.027 . . . . 0.0 109.845 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 1.032 HG23 HD11 ' A' ' 153' ' ' LEU . 0.9 OUTLIER -115.44 117.91 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.218 -0.926 . . . . 0.0 108.973 179.542 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -106.64 98.13 19.46 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.156 -0.965 . . . . 0.0 109.785 -179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.55 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.5 Cg_endo -72.33 173.65 12.76 Favored 'Trans proline' 0 C--O 1.216 -0.588 0 C-N-CA 122.675 2.25 . . . . 0.0 111.734 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.55 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 4.5 mt-10 78.98 -22.06 0.3 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.26 -0.9 . . . . 0.0 109.876 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.441 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 40.8 mtm180 -126.33 -16.78 5.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.039 -1.038 . . . . 0.0 109.3 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.441 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 6.0 mt-30 71.04 47.54 0.41 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.3 -0.875 . . . . 0.0 109.511 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.704 ' OE2' HG13 ' A' ' 167' ' ' VAL . 64.9 tt0 -116.44 139.83 50.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.124 -0.985 . . . . 0.0 108.885 179.651 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 1.032 HD11 HG23 ' A' ' 146' ' ' ILE . 2.7 mm? -124.88 111.79 15.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.153 -0.967 . . . . 0.0 110.108 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.441 ' HD3' ' HB2' ' A' ' 145' ' ' GLU . 17.2 mtpp -78.02 122.68 25.88 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.814 HG23 ' C ' ' A' ' 142' ' ' VAL . 10.4 p -126.92 149.27 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.039 -1.038 . . . . 0.0 109.904 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 1.9 t-20 -97.99 110.54 23.09 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.439 -0.788 . . . . 0.0 109.488 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.577 HG13 ' CD1' ' A' ' 139' ' ' PHE . 87.1 t -96.38 144.64 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.2 -0.938 . . . . 0.0 109.268 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 96.1 m -102.92 111.93 24.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -0.965 . . . . 0.0 109.995 -179.548 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.616 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 2.9 mt -133.22 143.24 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.276 -0.89 . . . . 0.0 109.036 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.431 ' O ' ' HG3' ' A' ' 162' ' ' ARG . 11.9 m-85 62.18 43.37 8.65 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.152 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 54.35 16.15 6.45 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 179.774 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 15.8 mtt-85 -126.59 160.05 31.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.036 -1.273 . . . . 0.0 109.54 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -100.93 127.88 47.22 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.25 -0.907 . . . . 0.0 109.687 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 43.3 m -136.91 121.22 12.39 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 0.0 109.606 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.538 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -70.34 136.57 31.75 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.755 2.304 . . . . 0.0 111.541 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.982 HG13 HD11 ' A' ' 168' ' ' LEU . 3.6 p -125.74 144.24 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.035 -1.041 . . . . 0.0 110.165 -179.616 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.704 HG13 ' OE2' ' A' ' 152' ' ' GLU . 51.1 t -95.51 120.15 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.554 -0.716 . . . . 0.0 109.465 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.982 HD11 HG13 ' A' ' 166' ' ' VAL . 0.1 OUTLIER -141.01 168.38 19.93 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.204 -0.935 . . . . 0.0 110.518 -179.44 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.4 ' HB2' ' OE1' ' A' ' 172' ' ' GLU . 40.2 m80 -79.45 144.59 33.9 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.829 ' HB ' HD23 ' A' ' 153' ' ' LEU . 9.6 p -58.68 -35.49 55.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.121 -0.987 . . . . 0.0 108.822 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.411 ' N ' HG13 ' A' ' 170' ' ' VAL . 53.0 p -75.69 -6.67 51.64 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.43 -0.794 . . . . 0.0 109.115 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.559 ' CG ' ' HB2' ' A' ' 133' ' ' SER . 1.2 mt-10 -88.65 2.85 52.48 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.289 -0.882 . . . . 0.0 109.44 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.453 ' CG2' HG11 ' A' ' 129' ' ' VAL . 2.9 m -152.03 176.54 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.218 -0.926 . . . . 0.0 109.293 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 1.021 ' O ' HG13 ' A' ' 129' ' ' VAL . 5.5 mt-10 -141.54 172.73 12.28 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.141 -0.974 . . . . 0.0 109.01 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.498 ' CE ' ' OD2' ' A' ' 127' ' ' ASP . 24.4 tttt -89.83 3.24 53.52 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.091 -1.006 . . . . 0.0 109.37 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.452 ' HB ' ' O ' ' A' ' 175' ' ' LYS . 22.1 mt 67.92 -65.66 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.291 -0.881 . . . . 0.0 109.387 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 175' ' ' LYS . 96.5 mt-10 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.446 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.248 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.99 -25.16 65.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.233 -1.157 . . . . 0.0 109.455 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 90.7 mmm -62.66 -20.41 64.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.902 . . . . 0.0 109.463 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 73.8 mttt -95.35 124.23 39.28 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.241 -0.912 . . . . 0.0 109.43 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.627 ' HG2' HG22 ' A' ' 65' ' ' ILE . 33.0 mttt -94.31 137.46 33.44 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.228 -0.92 . . . . 0.0 109.546 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.585 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 15.7 mtpp -126.41 175.82 7.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.361 -0.837 . . . . 0.0 109.52 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.792 ' CZ3' HG23 ' A' ' 41' ' ' VAL . 46.6 m95 -110.47 126.72 54.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.278 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -115.53 164.46 14.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.918 . . . . 0.0 109.472 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.542 HG12 ' CE1' ' A' ' 61' ' ' PHE . 62.0 mt -106.03 115.29 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.16 -0.962 . . . . 0.0 109.021 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.493 HG13 ' CE1' ' A' ' 83' ' ' PHE . 92.2 t -92.09 138.25 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.237 -0.914 . . . . 0.0 109.626 -179.719 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.518 ' N ' HD22 ' A' ' 11' ' ' LEU . 4.0 mm? -92.78 146.5 23.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.321 -0.862 . . . . 0.0 109.209 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.574 ' OG1' HG21 ' A' ' 20' ' ' VAL . 12.6 t -157.22 -177.97 7.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.187 -0.945 . . . . 0.0 109.376 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.515 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 49.0 mtm -96.72 130.39 43.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.182 -0.949 . . . . 0.0 109.504 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.5 p -50.87 129.37 23.17 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.912 . . . . 0.0 109.544 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.84 -20.27 36.67 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.515 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 80.3 m-85 -108.83 -5.2 16.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.214 -1.168 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.733 ' OE1' HD11 ' A' ' 44' ' ' ILE . 88.9 mt-10 -46.72 -52.48 13.82 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.253 -0.904 . . . . 0.0 109.554 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.8 mt-10 -55.11 -36.19 65.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.221 -0.925 . . . . 0.0 109.465 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 60.7 mttp -74.55 -31.37 62.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.256 -0.903 . . . . 0.0 109.291 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.574 HG21 ' OG1' ' A' ' 12' ' ' THR . 51.6 t -67.64 -48.78 75.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.34 -0.85 . . . . 0.0 109.353 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.582 ' HB2' HD11 ' A' ' 42' ' ' ILE . 29.9 tttm -59.05 -44.48 91.82 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.273 -0.892 . . . . 0.0 109.302 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -65.13 -45.08 86.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.906 . . . . 0.0 109.275 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.954 ' OD1' HG22 ' A' ' 77' ' ' VAL . 1.1 t-20 -51.78 -38.82 57.11 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -0.866 . . . . 0.0 109.402 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.586 HG21 HD11 ' A' ' 40' ' ' ILE . 65.9 mt -68.89 -44.29 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.764 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 41.9 tp10 -55.18 -49.13 72.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.047 -1.033 . . . . 0.0 109.858 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 23.6 mttm -75.22 -34.42 61.47 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.105 -0.997 . . . . 0.0 109.456 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.926 ' CD ' HG23 ' A' ' 77' ' ' VAL . 33.1 tttm -55.62 -36.2 66.72 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.325 -0.86 . . . . 0.0 109.205 179.774 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.739 HG13 ' O ' ' A' ' 33' ' ' ILE . 84.0 t -83.07 -24.0 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.294 -0.879 . . . . 0.0 109.601 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 -69.9 -55.12 10.53 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.279 -0.888 . . . . 0.0 109.485 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.74 -38.92 50.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.291 -0.881 . . . . 0.0 109.412 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.403 ' CB ' HG13 ' A' ' 33' ' ' ILE . 82.6 p -98.54 0.1 44.34 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.271 -0.893 . . . . 0.0 109.513 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 46.82 34.42 7.13 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.069 HG21 HD12 ' A' ' 36' ' ' LEU . 37.4 mt -92.6 75.34 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.331 -1.099 . . . . 0.0 109.498 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -90.19 24.92 2.34 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.211 -0.931 . . . . 0.0 109.049 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -117.25 -24.29 7.52 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.346 -0.846 . . . . 0.0 109.456 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.091 HD23 HD11 ' A' ' 65' ' ' ILE . 22.9 mt -92.11 -29.29 16.6 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.282 -0.886 . . . . 0.0 109.419 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.433 ' HA ' ' HG2' ' A' ' 64' ' ' MET . 38.9 t -110.43 129.35 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.368 -0.833 . . . . 0.0 109.04 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.51 -124.37 5.42 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 77.5 mtt180 -92.23 146.85 23.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.273 -1.133 . . . . 0.0 109.859 -179.431 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.901 HG12 HG23 ' A' ' 62' ' ' VAL . 55.7 mt -113.64 135.27 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.397 -0.815 . . . . 0.0 109.15 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.884 HG21 HD11 ' A' ' 107' ' ' LEU . 17.3 t -128.76 159.31 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.116 -0.99 . . . . 0.0 109.643 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.582 HD11 ' HB2' ' A' ' 21' ' ' LYS . 12.3 mt -144.36 128.67 9.13 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.471 -0.768 . . . . 0.0 109.359 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.544 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 44.0 Cg_endo -66.32 -6.19 14.34 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.713 2.275 . . . . 0.0 111.43 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.733 HD11 ' OE1' ' A' ' 17' ' ' GLU . 14.5 mt -45.58 -47.45 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.406 -0.808 . . . . 0.0 109.397 179.749 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.436 ' C ' ' O ' ' A' ' 44' ' ' ILE . 24.8 mtt-85 -42.6 160.21 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.259 -0.901 . . . . 0.0 109.561 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 113.66 133.36 5.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.92 -150.24 19.4 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -95.68 149.94 20.92 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.174 -1.192 . . . . 0.0 109.505 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 55.3 ttt-85 -62.81 -37.14 85.56 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.471 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 50.7 mtt180 -55.3 -43.0 74.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.909 . . . . 0.0 109.432 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 17.1 tttm -140.01 113.88 8.83 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.327 -0.858 . . . . 0.0 109.441 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 t -85.25 151.68 23.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.31 -0.869 . . . . 0.0 109.476 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.531 ' C ' ' HG3' ' A' ' 54' ' ' LYS . 81.5 mt-10 -100.03 -39.39 8.14 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.198 -0.939 . . . . 0.0 109.471 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.58 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 69.2 mttt 74.06 114.17 0.06 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.18 -0.95 . . . . 0.0 109.388 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.548 ' HB3' ' CE2' ' A' ' 56' ' ' PHE . 6.7 mp -52.7 -47.3 67.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.379 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.632 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 3.2 m-85 -139.23 113.0 8.08 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.14 -0.975 . . . . 0.0 109.374 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -65.67 146.26 83.66 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.546 2.164 . . . . 0.0 111.471 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.04 -13.56 3.26 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.533 ' HB2' ' HB2' ' A' ' 56' ' ' PHE . 1.9 m-85 -93.69 129.28 40.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.883 -1.363 . . . . 0.0 110.044 -179.422 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.502 HG13 HG12 ' A' ' 42' ' ' ILE . 41.9 t -134.69 142.82 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.202 179.703 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.688 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 76.7 m-85 -108.05 124.97 51.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.127 -0.983 . . . . 0.0 109.826 -179.594 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.901 HG23 HG12 ' A' ' 40' ' ' ILE . 3.6 p -130.33 142.2 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.345 -0.847 . . . . 0.0 109.868 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.613 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 37.7 tt0 -103.4 124.62 49.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.215 -0.928 . . . . 0.0 108.844 179.434 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.505 ' HE1' HG21 ' A' ' 74' ' ' VAL . 41.8 mtm -153.47 169.09 24.03 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.92 -1.113 . . . . 0.0 110.648 -179.259 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 1.091 HD11 HD23 ' A' ' 36' ' ' LEU . 5.4 pt -94.49 130.07 43.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.47 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 36.8 ttm -77.15 144.54 38.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.318 -0.864 . . . . 0.0 109.973 -178.781 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.47 ' HB2' ' O ' ' A' ' 66' ' ' MET . 35.3 t30 176.81 171.6 0.47 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.677 -0.639 . . . . 0.0 109.289 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -69.27 -42.53 75.41 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.228 -0.92 . . . . 0.0 109.402 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -75.85 -29.17 58.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.309 -0.869 . . . . 0.0 109.71 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.733 ' HB2' HD22 ' A' ' 36' ' ' LEU . . . -75.27 -47.54 27.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.121 -0.987 . . . . 0.0 109.418 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 56.3 t80 -59.97 -46.49 89.26 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.291 -0.88 . . . . 0.0 109.504 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.451 ' O ' ' HB3' ' A' ' 76' ' ' SER . 23.4 m120 -68.18 -26.22 65.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.327 -0.858 . . . . 0.0 109.962 -179.671 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.476 ' CE1' ' NZ ' ' A' ' 27' ' ' LYS . 22.6 t80 -83.42 -42.76 16.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.03 -1.044 . . . . 0.0 109.915 -179.675 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.76 HG22 ' CZ ' ' A' ' 83' ' ' PHE . 7.4 p -67.89 -55.71 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.405 -0.81 . . . . 0.0 109.605 -179.503 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.674 ' N ' HG13 ' A' ' 74' ' ' VAL . 0.2 OUTLIER -57.99 -10.72 1.95 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.145 -0.972 . . . . 0.0 109.747 -179.934 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.451 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 25.6 p -93.24 4.89 53.23 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.073 -1.017 . . . . 0.0 109.98 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.954 HG22 ' OD1' ' A' ' 23' ' ' ASN . 0.4 OUTLIER -73.81 126.8 89.25 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.085 -1.009 . . . . 0.0 109.327 -179.978 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.629 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 42.7 Cg_endo -65.1 142.86 76.09 Favored 'Trans proline' 0 C--O 1.213 -0.752 0 C-N-CA 122.65 2.234 . . . . 0.0 111.898 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.629 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 17.9 m-85 89.37 -12.79 0.37 Allowed 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.63 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 1.7 t -89.51 130.12 39.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.077 -1.014 . . . . 0.0 109.361 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 90.9 mmm -84.38 -27.33 27.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.32 -0.862 . . . . 0.0 109.311 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 161.35 -160.58 32.31 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.875 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.76 ' CZ ' HG22 ' A' ' 74' ' ' VAL . 14.9 m-85 -136.23 140.24 43.35 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.272 -1.134 . . . . 0.0 109.341 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.536 ' O ' HG13 ' A' ' 84' ' ' VAL . 7.7 p -66.35 125.09 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.122 -0.986 . . . . 0.0 109.405 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.547 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.6 p -163.72 159.08 21.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.211 -0.931 . . . . 0.0 109.573 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -86.23 -33.85 20.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.272 -0.893 . . . . 0.0 109.314 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.23 -87.59 0.71 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.547 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -108.85 -125.86 5.24 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.547 ' C ' ' O ' ' A' ' 88' ' ' GLY . 4.1 pm0 -31.17 147.27 0.05 OUTLIER Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 121.614 -0.933 . . . . 0.0 110.015 -179.819 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.547 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.3 Cg_endo -69.2 154.29 70.19 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.8 2.334 . . . . 0.0 112.081 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' VAL . . . . . 0.905 HG12 ' HD2' ' A' ' 92' ' ' PRO . 0.2 OUTLIER -86.97 147.7 43.6 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.308 -0.87 . . . . 0.0 109.25 179.849 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.905 ' HD2' HG12 ' A' ' 91' ' ' VAL . 48.7 Cg_endo -69.24 150.6 71.58 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.626 2.217 . . . . 0.0 111.82 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 7' ' ' TRP . 5.3 t -83.57 135.66 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.911 . . . . 0.0 109.621 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -72.86 136.05 45.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.346 -0.846 . . . . 0.0 109.393 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -47.94 -36.91 13.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.21 -0.931 . . . . 0.0 109.578 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 73.4 mtt85 -56.59 -37.14 70.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.571 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.7 mt-10 -83.36 -24.24 32.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.25 -0.906 . . . . 0.0 109.608 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.49 ' O ' ' C ' ' A' ' 99' ' ' ARG . 56.5 mtp -84.39 -29.6 26.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.142 -0.974 . . . . 0.0 109.495 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.597 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 31.6 ttt85 -37.01 -53.81 1.9 Allowed Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.344 -0.848 . . . . 0.0 109.931 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.597 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -68.82 -27.8 30.82 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.497 2.132 . . . . 0.0 111.777 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.509 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 19.5 mm -80.66 -41.7 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.24 -0.912 . . . . 0.0 109.248 179.71 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.59 ' CD1' ' N ' ' A' ' 102' ' ' LEU . 3.7 mp -68.52 -40.71 80.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.304 -0.872 . . . . 0.0 109.193 179.775 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.614 ' HG3' ' CD1' ' A' ' 110' ' ' TYR . 34.0 ttt180 -64.25 -50.34 68.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.347 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.86 -36.88 70.25 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.35 -0.844 . . . . 0.0 109.272 179.736 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.509 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -72.21 0.6 9.39 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.854 -179.707 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 77.26 8.32 86.98 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.884 HD11 HG21 ' A' ' 41' ' ' VAL . 19.2 mt -79.88 -22.53 42.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.134 -1.215 . . . . 0.0 109.511 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.485 ' HB2' ' HA ' ' A' ' 103' ' ' ARG . 10.3 mt-10 -107.51 143.91 35.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.228 -0.92 . . . . 0.0 109.459 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -96.84 120.1 36.54 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.24 -0.913 . . . . 0.0 109.451 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.614 ' CD1' ' HG3' ' A' ' 103' ' ' ARG . 43.6 p90 -150.21 174.62 12.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.241 -0.912 . . . . 0.0 109.567 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.521 ' O ' ' CB ' ' A' ' 112' ' ' GLU . 92.4 mt-10 -101.55 -91.74 0.32 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.269 -0.894 . . . . 0.0 109.418 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.521 ' CB ' ' O ' ' A' ' 111' ' ' GLU . 30.9 tt0 163.76 161.72 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.291 -0.881 . . . . 0.0 109.245 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.542 ' HB3' ' CB ' ' A' ' 133' ' ' SER . 0.0 OUTLIER -119.81 134.15 55.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.936 . . . . 0.0 109.394 -179.941 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -159.81 103.51 1.52 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.194 -0.941 . . . . 0.0 109.466 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -85.29 143.75 39.73 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.192 -0.943 . . . . 0.0 109.437 179.881 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.81 -2.18 9.77 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.643 2.228 . . . . 0.0 111.847 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 1.9 t -107.08 124.61 62.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -0.924 . . . . 0.0 109.39 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.435 ' HA ' ' OG ' ' A' ' 171' ' ' SER . 27.3 mttm -68.19 128.82 37.97 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.245 -0.909 . . . . 0.0 109.336 179.777 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.56 ' O ' HG12 ' A' ' 170' ' ' VAL . 30.3 t -100.93 128.97 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.581 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.582 ' HA ' ' CE2' ' A' ' 123' ' ' PHE . 82.3 mt-10 -159.44 -167.48 2.05 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.33 -0.857 . . . . 0.0 109.095 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.547 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 0.2 OUTLIER 78.47 162.57 0.21 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.362 -0.837 . . . . 0.0 109.912 179.61 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.406 ' H ' HD13 ' A' ' 121' ' ' LEU . . . 44.59 26.46 1.07 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.582 ' CE2' ' HA ' ' A' ' 120' ' ' GLU . 22.8 m-30 -115.17 116.51 28.49 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.083 -1.245 . . . . 0.0 108.879 178.885 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 50.9 mttt -130.89 153.83 48.72 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.155 -0.966 . . . . 0.0 109.863 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.512 HG23 ' O ' ' A' ' 144' ' ' LYS . 7.1 p -61.51 144.43 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.359 -0.838 . . . . 0.0 109.501 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.32 -33.38 3.19 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.587 ' HB3' HD12 ' A' ' 143' ' ' ILE . 34.3 t0 -50.16 161.27 0.29 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.368 -1.078 . . . . 0.0 109.397 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' MET . . . . . 0.481 ' SD ' HD12 ' A' ' 176' ' ' ILE . 4.6 ttm -95.76 126.88 41.33 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.28 -0.887 . . . . 0.0 108.669 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.761 HG11 HG11 ' A' ' 155' ' ' VAL . 6.7 p -125.64 141.58 45.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.193 -0.942 . . . . 0.0 109.388 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.524 ' N ' ' O ' ' A' ' 174' ' ' GLU . 24.1 tttt -104.41 142.78 33.98 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 108.988 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.952 HD12 ' HB3' ' A' ' 139' ' ' PHE . 81.5 mt -82.3 153.62 4.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.448 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.848 HD13 ' CD ' ' A' ' 174' ' ' GLU . 17.9 pt -149.08 1.25 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.967 -1.083 . . . . 0.0 109.499 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.542 ' CB ' ' HB3' ' A' ' 113' ' ' LYS . 31.2 t -145.85 143.23 29.49 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.124 -0.985 . . . . 0.0 110.039 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.03 -168.91 15.3 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.318 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.58 ' HG2' ' CD2' ' A' ' 136' ' ' PHE . 47.5 Cg_endo -68.63 -18.15 42.77 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 123.365 2.71 . . . . 0.0 112.563 -179.565 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.58 ' CD2' ' HG2' ' A' ' 135' ' ' PRO . 73.1 m-85 -111.84 13.92 20.98 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.878 -1.139 . . . . 0.0 109.636 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.519 ' HG2' ' OD2' ' A' ' 138' ' ' ASP . 1.2 tt0 -41.56 148.09 0.16 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.277 -0.889 . . . . 0.0 109.55 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.519 ' OD2' ' HG2' ' A' ' 137' ' ' GLU . 17.0 m-20 72.54 28.14 2.26 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -0.85 . . . . 0.0 110.268 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.952 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.1 t80 -117.74 131.51 56.59 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.029 -1.044 . . . . 0.0 109.414 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -82.24 134.15 35.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.123 -0.986 . . . . 0.0 109.6 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.513 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.9 172.93 25.59 Favored Glycine 0 N--CA 1.49 2.269 0 C-N-CA 119.78 -1.2 . . . . 0.0 110.305 -179.567 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 128' ' ' MET . 23.2 t -117.56 136.24 55.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.469 -1.018 . . . . 0.0 109.363 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.587 HD12 ' HB3' ' A' ' 127' ' ' ASP . 67.3 mt -66.33 115.25 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.299 -0.876 . . . . 0.0 109.184 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.512 ' O ' HG23 ' A' ' 125' ' ' VAL . 2.4 tttt -100.02 -35.53 9.67 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.04 -1.037 . . . . 0.0 109.615 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -152.8 147.66 26.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.142 -0.974 . . . . 0.0 109.622 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.816 HG23 ' CD1' ' A' ' 153' ' ' LEU . 3.1 mt -124.96 126.83 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.304 -0.872 . . . . 0.0 109.352 179.792 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.94 99.43 30.53 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.217 -0.927 . . . . 0.0 109.647 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.562 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 50.1 Cg_endo -70.3 171.93 14.12 Favored 'Trans proline' 0 C--O 1.216 -0.59 0 C-N-CA 122.681 2.254 . . . . 0.0 111.747 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.562 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.8 mt-10 81.06 -20.87 0.35 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.35 -0.844 . . . . 0.0 109.887 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.43 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 16.1 mtt-85 -128.83 -12.96 4.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.619 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.995 ' O ' HG23 ' A' ' 170' ' ' VAL . 29.4 mt-30 70.72 48.49 0.42 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.271 -0.893 . . . . 0.0 109.636 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -118.6 141.66 48.38 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.138 -0.976 . . . . 0.0 108.745 179.297 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.816 ' CD1' HG23 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -133.4 111.82 11.07 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.101 -0.999 . . . . 0.0 109.937 -179.537 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 21.1 mttt -80.61 129.5 34.55 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.761 HG11 HG11 ' A' ' 129' ' ' VAL . 35.4 m -123.61 152.54 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.059 -1.026 . . . . 0.0 109.715 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.507 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 47.2 t-20 -96.53 108.56 21.16 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.385 -0.822 . . . . 0.0 109.431 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.73 HG12 ' O ' ' A' ' 164' ' ' THR . 2.2 p -92.02 140.19 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.162 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 84.9 m -99.79 99.16 9.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.271 -0.893 . . . . 0.0 109.952 -179.612 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.692 HG13 HG22 ' A' ' 157' ' ' VAL . 2.0 mt -122.45 143.66 34.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.296 -0.878 . . . . 0.0 109.092 179.548 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.688 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 85.0 m-85 61.72 39.38 14.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.241 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.77 17.89 29.81 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.531 ' CZ ' ' OH ' ' A' ' 59' ' ' TYR . 25.2 mtt85 -127.26 156.72 41.45 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.106 -1.232 . . . . 0.0 109.568 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.431 ' HB3' ' OD1' ' A' ' 156' ' ' ASN . 91.3 mt-10 -99.92 130.72 46.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.925 . . . . 0.0 109.471 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 164' ' ' THR . . . . . 0.73 ' O ' HG12 ' A' ' 157' ' ' VAL . 16.1 m -140.52 121.64 9.21 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.285 -0.884 . . . . 0.0 109.732 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.523 ' HA ' ' O ' ' A' ' 155' ' ' VAL . 49.8 Cg_endo -70.02 138.21 36.48 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.697 2.264 . . . . 0.0 111.536 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.4 p -126.89 145.65 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.117 -0.989 . . . . 0.0 109.815 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.591 HG13 ' O ' ' A' ' 167' ' ' VAL . 11.4 p -91.87 119.73 39.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.416 -0.802 . . . . 0.0 109.326 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.427 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 12.3 mt -140.28 165.29 27.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 110.582 -179.16 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.628 ' O ' HG13 ' A' ' 173' ' ' VAL . 91.6 m-70 -79.07 147.0 32.95 Favored 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 121.345 0.593 . . . . 0.0 109.576 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.995 HG23 ' O ' ' A' ' 151' ' ' GLN . 4.4 t -63.16 -35.17 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.557 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.533 ' HA ' ' HB ' ' A' ' 119' ' ' VAL . 37.7 m -77.05 -7.12 55.13 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.467 -0.77 . . . . 0.0 109.295 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.517 ' CB ' ' HB3' ' A' ' 133' ' ' SER . 91.6 mt-10 -103.05 5.41 38.09 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.284 -0.885 . . . . 0.0 109.385 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.628 HG13 ' O ' ' A' ' 169' ' ' HIS . 2.7 m -129.69 160.29 40.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.19 -0.944 . . . . 0.0 109.58 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.848 ' CD ' HD13 ' A' ' 132' ' ' ILE . 28.8 mt-10 -133.16 150.8 52.0 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.295 -0.878 . . . . 0.0 109.048 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 129' ' ' VAL . 4.2 pttm -93.13 21.42 5.89 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.094 -1.004 . . . . 0.0 109.514 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.591 HG22 ' N ' ' A' ' 177' ' ' GLU . 27.4 mt 54.64 170.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.192 -0.943 . . . . 0.0 109.547 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.591 ' N ' HG22 ' A' ' 176' ' ' ILE . 85.8 tt0 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.462 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.235 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 47.32 34.92 3.46 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.287 -1.125 . . . . 0.0 109.466 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 60.4 mtm -73.91 -9.67 58.87 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.458 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 25.7 mttt -107.79 122.26 46.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.275 -0.891 . . . . 0.0 109.465 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.808 ' HG2' HG22 ' A' ' 65' ' ' ILE . 83.5 mttt -100.93 143.42 31.1 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.222 -0.924 . . . . 0.0 109.495 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.574 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 41.2 mmtm -130.24 174.52 9.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.399 -0.813 . . . . 0.0 109.539 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.782 ' CH2' HG23 ' A' ' 41' ' ' VAL . 40.3 m95 -105.56 125.4 50.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.293 -0.879 . . . . 0.0 109.011 179.664 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -115.48 166.35 11.99 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.11 -0.994 . . . . 0.0 109.343 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.568 HG12 ' CD1' ' A' ' 61' ' ' PHE . 55.8 mt -110.87 112.15 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.194 -0.941 . . . . 0.0 109.087 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.632 HG12 ' CD2' ' A' ' 83' ' ' PHE . 20.3 m -90.51 141.1 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.171 -0.956 . . . . 0.0 109.496 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.534 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -85.98 145.07 27.28 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.424 -0.797 . . . . 0.0 109.401 -179.926 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.7 p -149.63 -173.74 4.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.182 -0.949 . . . . 0.0 109.507 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.49 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 70.9 mtp -107.81 128.89 55.0 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.21 -0.931 . . . . 0.0 109.738 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.5 m -47.65 119.82 2.98 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.261 -0.899 . . . . 0.0 109.279 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.59 -20.26 27.63 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.49 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 94.5 m-85 -105.58 -16.36 14.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.198 -1.177 . . . . 0.0 109.496 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 16' ' ' TYR . 49.7 mt-10 -44.0 -62.04 1.26 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.193 -0.942 . . . . 0.0 109.345 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -49.54 -38.83 32.37 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.215 -0.928 . . . . 0.0 109.206 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -66.73 -33.0 74.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.346 -0.846 . . . . 0.0 109.076 179.651 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.672 HG22 ' HB2' ' A' ' 79' ' ' TYR . 91.8 t -72.01 -45.94 61.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.323 -0.861 . . . . 0.0 109.369 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.624 ' HB2' HD11 ' A' ' 42' ' ' ILE . 19.0 tttm -51.85 -56.09 16.09 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.23 -0.919 . . . . 0.0 109.246 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -62.04 -34.93 77.16 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.319 -0.863 . . . . 0.0 109.256 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.503 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 23.2 t-20 -65.28 -36.67 84.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.411 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.401 HG13 ' O ' ' A' ' 20' ' ' VAL . 90.4 mt -66.3 -46.47 87.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.145 -0.972 . . . . 0.0 109.782 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.461 ' O ' ' HG2' ' A' ' 29' ' ' GLU . 65.8 mm-40 -56.88 -46.68 81.72 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.099 -1.0 . . . . 0.0 109.874 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 29.0 mttt -77.3 -36.72 53.91 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.104 -0.998 . . . . 0.0 109.576 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.89 ' HG2' HG23 ' A' ' 77' ' ' VAL . 5.3 tptt -56.12 -31.05 62.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 109.095 179.774 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.806 HG13 ' O ' ' A' ' 33' ' ' ILE . 11.6 t -84.76 -26.31 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.347 -0.845 . . . . 0.0 109.264 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.461 ' HG2' ' O ' ' A' ' 25' ' ' GLU . 61.7 mm-40 -67.87 -51.48 47.72 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.298 -0.876 . . . . 0.0 109.375 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.42 -32.3 66.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.921 . . . . 0.0 109.386 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.701 HG21 ' CE1' ' A' ' 73' ' ' PHE . 63.1 p -94.71 -11.31 29.36 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.354 -0.842 . . . . 0.0 109.447 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 54.83 24.51 33.84 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.991 HG21 HD22 ' A' ' 36' ' ' LEU . 69.8 mt -85.96 116.62 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.198 -1.178 . . . . 0.0 109.352 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.459 ' O ' ' HG2' ' A' ' 34' ' ' LYS . 86.0 tttt -121.98 -10.44 8.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.179 -0.95 . . . . 0.0 109.395 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 1.057 ' O ' HD13 ' A' ' 65' ' ' ILE . 87.5 m-20 -98.67 13.81 30.8 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.207 -0.933 . . . . 0.0 109.426 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.991 HD22 HG21 ' A' ' 33' ' ' ILE . 6.0 mp -120.69 -53.38 2.09 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.336 -0.853 . . . . 0.0 109.111 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.544 HG22 ' SD ' ' A' ' 64' ' ' MET . 90.3 t -100.66 129.55 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.426 -0.796 . . . . 0.0 109.034 179.53 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.25 -121.76 4.62 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -98.03 148.4 23.54 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.277 -1.131 . . . . 0.0 109.991 -179.334 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 1.058 HG22 HG13 ' A' ' 62' ' ' VAL . 44.5 pt -119.8 143.21 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.42 -0.8 . . . . 0.0 108.857 179.495 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.82 HG21 HD22 ' A' ' 107' ' ' LEU . 25.1 t -129.52 154.6 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.127 -0.983 . . . . 0.0 109.871 -179.527 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.913 HG22 ' H ' ' A' ' 44' ' ' ILE . 18.4 mt -127.86 128.62 23.83 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.366 -0.834 . . . . 0.0 109.212 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.489 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 45.1 Cg_endo -66.82 -4.27 10.92 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.836 2.357 . . . . 0.0 111.692 -179.809 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.913 ' H ' HG22 ' A' ' 42' ' ' ILE . 54.8 mt -70.66 -49.89 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.336 -0.853 . . . . 0.0 109.551 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.47 ' HB3' ' O ' ' A' ' 44' ' ' ILE . 30.5 ttt85 61.81 144.46 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.225 -0.922 . . . . 0.0 109.502 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.418 ' N ' ' HG2' ' A' ' 45' ' ' ARG . . . -71.28 152.83 50.24 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 178.0 -178.71 48.53 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -80.87 147.83 30.19 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -1.141 . . . . 0.0 109.47 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.497 ' CZ ' ' HB3' ' A' ' 49' ' ' ARG . 12.3 mtp-105 -59.9 -36.12 76.3 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.243 -0.91 . . . . 0.0 109.44 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 19.8 ttp180 -54.01 -37.96 64.61 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.907 . . . . 0.0 109.453 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 30.4 mmtp -80.66 156.89 26.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.235 -0.915 . . . . 0.0 109.456 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 23.6 t -68.53 139.86 55.64 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.381 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.469 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 95.2 mt-10 -124.79 153.62 42.2 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.204 -0.935 . . . . 0.0 109.458 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.693 ' HG2' HG23 ' A' ' 44' ' ' ILE . 63.6 mttt 74.53 86.85 0.1 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.293 -0.879 . . . . 0.0 109.479 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.5 ' O ' ' CD1' ' A' ' 56' ' ' PHE . 44.2 mt -64.13 -21.54 66.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -1.0 . . . . 0.0 109.181 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 1.054 ' CE1' HD11 ' A' ' 159' ' ' ILE . 8.8 m-85 -148.97 101.88 3.39 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.323 -0.861 . . . . 0.0 108.986 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -65.47 136.31 46.12 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.7 2.267 . . . . 0.0 112.176 -179.446 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.472 ' O ' HD13 ' A' ' 11' ' ' LEU . . . 77.44 -15.22 7.55 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 179.576 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -99.31 129.53 45.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.799 -1.412 . . . . 0.0 110.292 -179.177 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.546 ' HB ' ' CG2' ' A' ' 10' ' ' VAL . 88.2 t -133.23 148.88 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.599 ' CE1' ' CZ ' ' A' ' 160' ' ' PHE . 84.2 m-85 -109.71 124.62 51.55 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.773 -1.205 . . . . 0.0 110.248 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 1.058 HG13 HG22 ' A' ' 40' ' ' ILE . 91.8 t -133.58 145.16 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.382 -0.824 . . . . 0.0 109.635 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.626 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 28.2 tt0 -112.08 128.01 56.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.24 -0.913 . . . . 0.0 108.976 179.575 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.832 ' HE1' HG11 ' A' ' 74' ' ' VAL . 15.4 mtm -153.9 168.69 25.51 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.867 -1.146 . . . . 0.0 110.805 -179.113 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 1.057 HD13 ' O ' ' A' ' 35' ' ' ASN . 0.5 OUTLIER -89.11 130.39 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.653 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.417 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 56.6 ttm -75.85 141.8 42.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.89 . . . . 0.0 110.191 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.417 ' HB2' ' O ' ' A' ' 66' ' ' MET . 46.0 t30 179.11 166.15 0.96 Allowed 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -66.14 -41.13 90.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.966 . . . . 0.0 109.505 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 64.2 tt0 -76.46 -31.5 57.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.844 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.023 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -68.78 -49.36 59.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.972 -1.08 . . . . 0.0 109.621 -179.763 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.579 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 71.8 t80 -60.62 -50.98 71.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.215 -0.928 . . . . 0.0 109.751 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -57.09 -29.69 63.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -0.937 . . . . 0.0 110.059 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.701 ' CE1' HG21 ' A' ' 31' ' ' THR . 77.4 t80 -80.51 -41.88 23.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.098 -1.001 . . . . 0.0 109.776 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 1.023 HG23 ' O ' ' A' ' 70' ' ' ALA . 2.8 t -70.08 -55.07 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.466 -0.771 . . . . 0.0 109.602 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.437 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 32.0 tpt85 -61.43 -13.33 19.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.329 -0.857 . . . . 0.0 110.013 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 78.1 p -97.31 4.57 50.79 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.115 -0.99 . . . . 0.0 109.923 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.912 ' O ' HG12 ' A' ' 80' ' ' VAL . 0.4 OUTLIER -74.85 137.21 73.32 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 120.965 -1.084 . . . . 0.0 109.315 -179.992 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.63 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 44.2 Cg_endo -66.34 137.36 46.95 Favored 'Trans proline' 0 C--O 1.213 -0.75 0 C-N-CA 122.676 2.251 . . . . 0.0 111.893 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.672 ' HB2' HG22 ' A' ' 20' ' ' VAL . 19.1 m-85 92.45 -13.54 0.18 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.934 -0.479 . . . . 0.0 109.759 -179.773 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.912 HG12 ' O ' ' A' ' 77' ' ' VAL . 8.6 p -82.43 122.91 37.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.891 -1.131 . . . . 0.0 109.365 179.765 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 95.5 mmm -87.94 -30.71 19.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.294 -0.879 . . . . 0.0 109.362 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.545 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 168.05 -165.85 39.04 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.632 ' CD2' HG12 ' A' ' 10' ' ' VAL . 4.6 m-85 -137.52 139.61 40.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.332 -1.099 . . . . 0.0 109.46 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.412 HG22 ' CD2' ' A' ' 11' ' ' LEU . 21.0 t -66.08 125.01 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.258 -0.901 . . . . 0.0 109.331 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.568 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.8 p -160.18 158.97 31.06 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.15 -0.969 . . . . 0.0 109.667 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 59.5 p -82.84 -36.47 25.45 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.329 -0.857 . . . . 0.0 109.234 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.07 -86.56 0.52 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -103.13 -127.87 6.21 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.579 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -33.98 151.93 0.05 OUTLIER Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.512 -0.993 . . . . 0.0 110.046 -179.668 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.568 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.1 Cg_endo -69.38 158.66 56.64 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.807 2.338 . . . . 0.0 112.01 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.8 m -93.38 154.14 41.38 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.423 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -70.06 146.96 59.86 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.654 2.236 . . . . 0.0 111.735 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 7' ' ' TRP . 45.1 t -83.62 140.18 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.297 -0.877 . . . . 0.0 109.417 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' LYS . . . . . 0.492 ' HE2' ' NH2' ' A' ' 96' ' ' ARG . 79.8 tttt -73.21 130.69 40.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.491 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -46.53 -39.07 10.26 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.278 -0.889 . . . . 0.0 109.425 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.492 ' NH2' ' HE2' ' A' ' 94' ' ' LYS . 15.5 mtt85 -60.56 -30.77 70.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.344 -0.847 . . . . 0.0 109.417 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.427 ' N ' ' O ' ' A' ' 94' ' ' LYS . 52.7 mt-10 -80.08 -26.8 39.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.892 . . . . 0.0 109.528 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.686 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 55.3 mtp -86.12 -21.77 27.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.226 179.79 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.581 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.47 -53.23 1.31 Allowed Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.482 -0.761 . . . . 0.0 109.807 179.981 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.624 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 50.4 Cg_endo -71.41 -26.69 20.11 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.463 2.109 . . . . 0.0 111.878 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.479 ' N ' ' O ' ' A' ' 98' ' ' MET . 35.2 mm -82.42 -42.96 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -0.934 . . . . 0.0 109.607 -179.877 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.654 HD13 ' N ' ' A' ' 102' ' ' LEU . 0.0 OUTLIER -67.83 -40.82 83.74 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.183 -0.948 . . . . 0.0 109.417 179.923 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.42 ' HG2' ' HA ' ' A' ' 135' ' ' PRO . 19.7 tpt180 -65.86 -49.1 69.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.253 -0.904 . . . . 0.0 109.315 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.71 -37.03 70.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.358 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.557 ' CB ' HG11 ' A' ' 41' ' ' VAL . . . -74.35 1.3 11.95 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.315 -0.866 . . . . 0.0 109.773 -179.811 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.47 11.07 85.44 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.762 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.82 HD22 HG21 ' A' ' 41' ' ' VAL . 3.2 tp -82.05 -24.86 35.07 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.219 -1.166 . . . . 0.0 109.525 179.81 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -125.19 132.92 52.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.214 -0.929 . . . . 0.0 109.584 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -119.98 123.66 44.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.205 -0.934 . . . . 0.0 109.354 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.572 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 33.0 p90 -140.45 177.5 7.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.229 -0.919 . . . . 0.0 109.615 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.572 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 61.3 mt-10 -67.6 -148.83 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.221 -0.925 . . . . 0.0 109.405 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.481 ' HG2' ' N ' ' A' ' 113' ' ' LYS . 85.2 tt0 -156.29 164.72 37.98 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.307 -0.871 . . . . 0.0 109.341 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.481 ' N ' ' HG2' ' A' ' 112' ' ' GLU . 5.6 pttt -44.16 144.31 0.99 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.423 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 5.0 tttp -105.0 10.19 34.2 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.226 -0.921 . . . . 0.0 109.513 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 8.6 mtmm -129.12 73.4 81.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.203 -0.935 . . . . 0.0 109.459 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -72.51 80.5 1.67 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.689 2.259 . . . . 0.0 111.583 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.467 ' O ' ' HB2' ' A' ' 171' ' ' SER . 12.8 m -133.11 145.8 33.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.35 -0.844 . . . . 0.0 109.546 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.536 ' HA ' ' HB3' ' A' ' 171' ' ' SER . 3.5 ttpm? -62.66 140.22 58.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.323 -0.861 . . . . 0.0 109.37 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.609 ' O ' HG12 ' A' ' 170' ' ' VAL . 53.5 t -128.98 118.45 46.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.213 -0.929 . . . . 0.0 109.638 -179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.758 ' O ' HD23 ' A' ' 121' ' ' LEU . 98.3 mt-10 -147.07 147.71 30.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.318 -0.864 . . . . 0.0 109.342 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.758 HD23 ' O ' ' A' ' 120' ' ' GLU . 1.4 pp 145.71 145.41 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.425 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . 42.43 33.6 1.46 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.974 -1.251 . . . . 0.0 109.974 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.573 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 14.1 m-85 -107.84 115.53 30.3 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.142 -1.21 . . . . 0.0 109.159 179.554 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.419 ' HD3' ' O ' ' A' ' 123' ' ' PHE . 62.1 mmtt -139.35 156.37 47.05 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.25 -0.906 . . . . 0.0 109.536 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 144' ' ' LYS . 10.1 t -57.37 137.46 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.258 -0.901 . . . . 0.0 109.606 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.81 -34.55 3.86 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.432 ' O ' HG23 ' A' ' 142' ' ' VAL . 37.2 m-20 -47.8 160.8 0.12 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.341 -1.094 . . . . 0.0 109.405 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.4 ttm -100.87 127.93 47.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.193 -0.942 . . . . 0.0 109.059 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.616 HG13 HG13 ' A' ' 143' ' ' ILE . 25.7 m -128.72 145.31 35.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.358 -0.839 . . . . 0.0 109.667 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.521 ' CB ' HG12 ' A' ' 176' ' ' ILE . 57.7 tttt -103.22 139.39 38.76 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.787 -0.819 . . . . 0.0 108.787 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 1.031 HD12 ' HB3' ' A' ' 139' ' ' PHE . 80.9 mt -78.41 153.71 5.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -149.17 1.26 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.946 -1.096 . . . . 0.0 109.465 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.51 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 70.1 m -148.27 144.3 27.53 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.114 -0.991 . . . . 0.0 110.06 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.59 -164.88 17.73 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.506 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 46.2 Cg_endo -68.35 -21.84 40.53 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 123.071 2.514 . . . . 0.0 112.643 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.624 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 86.9 m-85 -107.67 18.21 21.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.84 -1.163 . . . . 0.0 109.442 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.518 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 3.1 tt0 -45.53 139.05 4.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.255 -0.903 . . . . 0.0 109.617 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 28.9 m-20 73.74 28.54 1.6 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.385 -0.822 . . . . 0.0 110.423 179.526 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 1.031 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.7 t80 -117.4 131.87 56.68 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.041 -1.037 . . . . 0.0 109.445 179.668 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.409 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -78.53 132.26 37.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.19 -0.944 . . . . 0.0 109.647 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -142.98 167.46 26.33 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.537 ' CG1' ' HB2' ' A' ' 156' ' ' ASN . 11.1 p -117.42 138.33 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.353 -1.086 . . . . 0.0 109.393 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.735 ' HA ' HG12 ' A' ' 155' ' ' VAL . 60.6 mt -68.81 117.11 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.152 -0.968 . . . . 0.0 109.676 -179.832 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.439 ' O ' HG13 ' A' ' 125' ' ' VAL . 15.6 tttt -102.43 -35.52 8.75 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.142 -0.973 . . . . 0.0 109.253 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.464 ' HB2' ' HB2' ' A' ' 154' ' ' LYS . 62.8 mt-10 -152.95 148.19 26.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.241 -0.912 . . . . 0.0 109.526 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.653 HG23 ' HG ' ' A' ' 153' ' ' LEU . 2.1 mt -123.8 125.65 71.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.257 -0.902 . . . . 0.0 109.412 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -106.74 99.61 26.42 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.192 -0.943 . . . . 0.0 109.674 -179.806 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.583 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.8 Cg_endo -70.74 170.96 16.49 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.704 2.27 . . . . 0.0 111.677 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.583 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.4 mt-10 81.64 -20.5 0.36 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.362 -0.836 . . . . 0.0 109.868 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.47 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 42.1 mtt180 -128.89 -12.47 4.74 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.997 -1.065 . . . . 0.0 109.694 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.876 ' O ' HG23 ' A' ' 170' ' ' VAL . 48.1 mt-30 70.69 48.8 0.42 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.26 -0.9 . . . . 0.0 109.604 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -119.59 142.18 48.62 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.175 -0.953 . . . . 0.0 109.02 179.583 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.653 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -129.34 112.36 13.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.237 -0.914 . . . . 0.0 110.083 -179.514 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.464 ' HB2' ' HB2' ' A' ' 145' ' ' GLU . 17.6 mttt -79.9 126.41 30.97 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 179.071 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.735 HG12 ' HA ' ' A' ' 143' ' ' ILE . 16.1 m -128.32 152.98 37.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.035 -1.041 . . . . 0.0 110.05 -179.458 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.537 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 86.8 m-20 -98.88 112.9 24.87 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.313 -0.867 . . . . 0.0 109.376 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.792 HG13 ' CE1' ' A' ' 139' ' ' PHE . 38.8 t -99.97 147.69 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.273 -0.892 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 163' ' ' GLU . 29.2 m -94.08 117.76 30.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.415 -0.803 . . . . 0.0 109.802 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 1.054 HD11 ' CE1' ' A' ' 56' ' ' PHE . 18.8 pt -145.9 138.62 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.348 -0.845 . . . . 0.0 109.387 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.599 ' CZ ' ' CE1' ' A' ' 61' ' ' PHE . 72.2 m-85 62.57 39.36 11.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.909 . . . . 0.0 109.379 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 62.26 16.96 55.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -137.73 142.21 41.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.092 -1.24 . . . . 0.0 109.501 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.553 ' HA ' ' HA ' ' A' ' 158' ' ' THR . 84.8 mt-10 -98.45 110.2 22.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.184 -0.948 . . . . 0.0 109.465 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 164' ' ' THR . . . . . 0.579 HG23 ' HD2' ' A' ' 165' ' ' PRO . 16.6 m -112.8 139.9 23.38 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.211 -0.93 . . . . 0.0 109.341 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.579 ' HD2' HG23 ' A' ' 164' ' ' THR . 48.7 Cg_endo -69.21 137.3 36.72 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.711 2.274 . . . . 0.0 111.778 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 1.02 HG13 HD11 ' A' ' 168' ' ' LEU . 2.1 p -123.41 142.06 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.157 -0.964 . . . . 0.0 109.743 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.501 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 72.8 t -92.89 119.13 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.383 -0.823 . . . . 0.0 109.552 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 1.02 HD11 HG13 ' A' ' 166' ' ' VAL . 0.3 OUTLIER -141.27 167.96 20.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.313 -0.867 . . . . 0.0 110.567 -179.719 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.531 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 61.8 m80 -78.59 145.58 34.67 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.876 HG23 ' O ' ' A' ' 151' ' ' GLN . 24.0 t -59.67 -35.84 62.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.274 -0.891 . . . . 0.0 108.702 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.536 ' HB3' ' HA ' ' A' ' 118' ' ' LYS . 87.9 p -75.27 -7.06 52.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.494 -0.754 . . . . 0.0 109.324 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.531 ' CG ' ' HB2' ' A' ' 169' ' ' HIS . 82.5 mt-10 -90.62 4.07 52.37 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.34 -0.85 . . . . 0.0 109.832 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.578 ' CG2' ' N ' ' A' ' 174' ' ' GLU . 1.4 p -141.7 167.74 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.024 -1.048 . . . . 0.0 109.484 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.578 ' N ' ' CG2' ' A' ' 173' ' ' VAL . 52.4 tt0 -142.78 168.77 18.94 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.341 -0.849 . . . . 0.0 108.857 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.573 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 33.1 tttm -91.74 33.18 1.04 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.021 -1.05 . . . . 0.0 109.289 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.521 HG12 ' CB ' ' A' ' 130' ' ' LYS . 40.4 mt 43.95 74.47 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.19 -0.944 . . . . 0.0 109.394 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.477 -179.954 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.48 -24.12 66.37 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.299 -1.118 . . . . 0.0 109.475 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 89.6 mtp -64.93 -30.99 72.01 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.231 -0.918 . . . . 0.0 109.519 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 50.5 mttm -118.92 137.08 53.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.422 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.4 mttm -110.08 156.8 20.07 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.177 -0.952 . . . . 0.0 109.667 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 12.7 mttt -135.49 176.03 9.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 110.009 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.837 ' CH2' HG23 ' A' ' 41' ' ' VAL . 60.3 m95 -109.83 125.71 53.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.362 -0.836 . . . . 0.0 109.211 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.58 ' CE2' ' HG3' ' A' ' 66' ' ' MET . 66.1 m-85 -116.64 171.76 7.66 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.186 -0.946 . . . . 0.0 109.383 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.657 HD11 ' CE1' ' A' ' 160' ' ' PHE . 56.2 mt -110.9 109.95 30.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.242 -0.911 . . . . 0.0 109.069 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.608 HG23 ' CE1' ' A' ' 83' ' ' PHE . 8.9 p -88.6 143.47 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.186 -0.946 . . . . 0.0 109.477 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.51 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.6 mm? -88.83 141.83 28.17 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.389 -0.819 . . . . 0.0 109.545 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.69 ' OG1' HG21 ' A' ' 20' ' ' VAL . 15.1 t -154.69 -169.35 3.18 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.281 -0.887 . . . . 0.0 109.393 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.502 ' SD ' ' CE2' ' A' ' 16' ' ' TYR . 36.2 ttm -107.68 119.6 39.88 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.48 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 13' ' ' MET . 54.0 p -42.82 128.19 4.15 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.332 -0.855 . . . . 0.0 109.279 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.65 -19.69 33.13 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.523 ' O ' HG23 ' A' ' 20' ' ' VAL . 19.6 m-30 -110.31 -5.84 15.15 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.301 -1.117 . . . . 0.0 109.75 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.486 ' HG2' HG21 ' A' ' 12' ' ' THR . 87.0 mt-10 -44.58 -65.49 0.51 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.148 -0.97 . . . . 0.0 109.547 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.44 ' O ' ' HG3' ' A' ' 22' ' ' GLU . 95.7 mt-10 -43.2 -33.41 0.92 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.199 -0.938 . . . . 0.0 109.271 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.407 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 46.7 mttm -77.19 -41.12 42.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.3 -0.875 . . . . 0.0 109.324 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.69 HG21 ' OG1' ' A' ' 12' ' ' THR . 18.4 t -59.7 -48.17 88.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.327 -0.858 . . . . 0.0 109.33 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.58 ' HG3' HG21 ' A' ' 40' ' ' ILE . 28.1 tttm -60.53 -43.12 97.49 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.897 . . . . 0.0 109.067 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.44 ' HG3' ' O ' ' A' ' 18' ' ' GLU . 93.7 mt-10 -63.87 -42.07 97.61 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.406 -0.809 . . . . 0.0 109.045 179.716 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.479 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 17.1 m120 -56.91 -52.22 66.01 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.335 -0.853 . . . . 0.0 109.508 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.925 ' CD1' HG21 ' A' ' 77' ' ' VAL . 21.0 mm -50.33 -44.21 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.051 -1.031 . . . . 0.0 109.408 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -54.61 -44.27 72.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.272 -0.893 . . . . 0.0 109.832 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.8 mttp -79.86 -35.09 38.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.09 -1.006 . . . . 0.0 109.905 -179.639 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.91 ' HD3' HG23 ' A' ' 77' ' ' VAL . 12.6 ttpp -56.65 -35.16 68.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.114 -0.991 . . . . 0.0 109.282 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.828 HG13 ' O ' ' A' ' 33' ' ' ILE . 15.6 t -82.47 -27.05 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.841 . . . . 0.0 109.575 -179.794 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 69.8 mt-10 -66.35 -49.84 65.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.214 -0.929 . . . . 0.0 109.68 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.38 -27.74 69.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.207 -0.933 . . . . 0.0 109.741 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.454 HG23 ' O ' ' A' ' 27' ' ' LYS . 60.9 p -88.83 -12.76 41.01 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.041 -1.037 . . . . 0.0 109.517 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 63.72 15.43 57.67 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.828 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.7 mt -94.84 85.6 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.314 -1.11 . . . . 0.0 109.481 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 49.9 mttt -85.59 7.64 22.41 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.149 -0.97 . . . . 0.0 109.074 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -111.77 18.52 18.86 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.339 -0.85 . . . . 0.0 109.433 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.845 ' CD2' HD11 ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.6 -52.95 2.75 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.144 -0.972 . . . . 0.0 109.344 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.464 ' HA ' ' HB3' ' A' ' 64' ' ' MET . 87.7 t -97.01 137.06 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -107.81 -125.28 5.27 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.426 ' O ' ' CH2' ' A' ' 7' ' ' TRP . 95.2 mtt180 -91.72 138.69 31.35 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -1.112 . . . . 0.0 109.694 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.876 HG12 HG13 ' A' ' 62' ' ' VAL . 46.1 mt -105.78 136.96 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.374 -0.829 . . . . 0.0 109.042 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 1.113 ' CG2' HD11 ' A' ' 107' ' ' LEU . 98.4 t -124.26 150.51 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.747 HG22 HG23 ' A' ' 44' ' ' ILE . 5.7 mt -128.38 126.05 23.43 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.341 -0.849 . . . . 0.0 109.413 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.462 ' O ' HD13 ' A' ' 55' ' ' LEU . 47.8 Cg_endo -68.5 -2.99 10.18 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.86 2.374 . . . . 0.0 111.814 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.747 HG23 HG22 ' A' ' 42' ' ' ILE . 11.3 pt -76.44 132.88 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.07 -1.019 . . . . 0.0 109.649 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 43.6 ttp-105 -71.28 -28.49 64.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.389 -0.819 . . . . 0.0 109.466 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 70.1 36.46 72.12 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.27 139.55 9.89 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 83.3 mt-30 -88.63 11.64 16.85 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -1.182 . . . . 0.0 109.453 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 12.1 ttt-85 -54.94 -38.67 67.99 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.445 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 65.8 ttt-85 -104.66 153.28 21.44 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -0.887 . . . . 0.0 109.431 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 16.8 mtmt -62.55 -24.37 67.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.54 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 68.0 p -96.83 157.04 16.09 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.497 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 81.0 tt0 -136.62 145.92 45.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.344 -0.847 . . . . 0.0 109.324 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.692 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 22.6 mttm 74.85 111.27 0.07 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.195 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.54 HD12 ' N ' ' A' ' 55' ' ' LEU . 6.8 mp -65.91 -25.57 67.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.835 -1.165 . . . . 0.0 109.47 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.533 ' HB3' ' HB2' ' A' ' 59' ' ' TYR . 84.3 m-85 -142.08 98.23 6.22 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.886 . . . . 0.0 108.86 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 43.2 Cg_endo -66.7 134.39 34.94 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.755 2.303 . . . . 0.0 112.23 -179.082 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.56 -12.87 7.17 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.533 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 2.9 m-85 -100.67 131.23 46.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.693 -1.475 . . . . 0.0 110.183 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.569 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 76.8 t -135.32 148.6 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.377 -0.827 . . . . 0.0 108.809 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.634 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 16.8 m-85 -110.7 123.87 50.85 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.874 -1.141 . . . . 0.0 109.926 -179.395 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.876 HG13 HG12 ' A' ' 40' ' ' ILE . 90.0 t -129.62 142.77 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.405 -0.809 . . . . 0.0 109.793 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.612 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 9.8 tt0 -99.86 125.52 45.83 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.335 -0.853 . . . . 0.0 109.175 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.464 ' HB3' ' HA ' ' A' ' 37' ' ' VAL . 12.5 ptt? -164.96 -175.39 3.71 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.025 -1.047 . . . . 0.0 110.174 -179.665 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.845 HD11 ' CD2' ' A' ' 36' ' ' LEU . 38.6 pt -103.35 128.36 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.165 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.58 ' HG3' ' CE2' ' A' ' 8' ' ' TYR . 33.6 mtm -90.75 101.64 14.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.196 -0.94 . . . . 0.0 109.898 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.543 ' OD1' ' N ' ' A' ' 69' ' ' GLU . 10.3 p30 -137.91 -163.09 1.39 Allowed 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.123 -0.986 . . . . 0.0 109.077 179.591 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -74.98 -50.15 17.56 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.135 -0.978 . . . . 0.0 110.105 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.543 ' N ' ' OD1' ' A' ' 67' ' ' ASN . 98.0 mt-10 -64.85 -54.64 27.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.05 -1.031 . . . . 0.0 109.585 -179.747 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.011 ' O ' HG22 ' A' ' 74' ' ' VAL . . . -52.34 -38.75 59.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.265 -0.897 . . . . 0.0 109.727 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.433 ' CD1' ' CD ' ' A' ' 89' ' ' GLN . 72.3 t80 -60.02 -50.51 73.46 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 109.853 -179.818 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -65.59 -28.46 69.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.156 -0.965 . . . . 0.0 110.436 -179.355 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -82.52 -42.63 18.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.865 -1.147 . . . . 0.0 110.035 -179.443 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 1.011 HG22 ' O ' ' A' ' 70' ' ' ALA . 6.8 m -65.92 -57.37 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.186 -0.947 . . . . 0.0 109.562 -179.78 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.681 ' H ' HG23 ' A' ' 74' ' ' VAL . 12.6 mmt180 -53.87 -40.95 66.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.922 . . . . 0.0 109.751 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 25.7 p -75.42 3.07 9.86 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.204 -0.935 . . . . 0.0 110.149 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.925 HG21 ' CD1' ' A' ' 24' ' ' ILE . 1.8 p -71.8 130.0 87.52 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 120.875 -1.141 . . . . 0.0 109.136 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.765 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 44.0 Cg_endo -66.14 132.32 29.49 Favored 'Trans proline' 0 C--O 1.212 -0.797 0 C-N-CA 122.83 2.353 . . . . 0.0 112.627 -178.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.765 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 70.8 m-85 95.43 -8.63 0.1 Allowed 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.683 HG21 HG11 ' A' ' 77' ' ' VAL . 16.0 t -99.15 133.72 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.973 -1.079 . . . . 0.0 109.494 179.726 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 64.2 mtt -92.79 -19.23 21.96 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.337 -0.852 . . . . 0.0 109.399 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 150.48 -154.38 25.6 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.608 ' CE1' HG23 ' A' ' 10' ' ' VAL . 5.3 m-85 -137.14 149.22 47.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -1.142 . . . . 0.0 109.602 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.524 HG12 ' HB ' ' A' ' 9' ' ' ILE . 13.8 p -74.86 129.39 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.283 -0.886 . . . . 0.0 109.37 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.553 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 2.2 p -163.06 165.6 24.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.732 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.4 t -92.89 -30.87 15.19 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.396 -0.815 . . . . 0.0 109.24 179.742 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.77 -87.7 0.54 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.527 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -103.19 -135.5 8.7 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.527 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -32.59 153.99 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.568 -0.96 . . . . 0.0 110.259 -179.624 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.553 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 47.8 Cg_endo -67.86 151.2 78.56 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.891 2.394 . . . . 0.0 112.013 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.4 m -84.22 155.07 63.64 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.318 -0.864 . . . . 0.0 109.336 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.41 ' HB3' ' HD3' ' A' ' 6' ' ' LYS . 49.0 Cg_endo -69.81 141.27 44.59 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.676 2.251 . . . . 0.0 111.753 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 7' ' ' TRP . 41.4 t -71.73 141.4 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.209 -0.932 . . . . 0.0 109.367 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 97' ' ' GLU . 93.8 mttt -75.53 130.02 38.17 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.444 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 78.5 m-20 -45.25 -39.4 6.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.883 . . . . 0.0 109.354 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 77.6 mtt180 -60.69 -24.74 65.87 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.483 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.464 ' N ' ' O ' ' A' ' 94' ' ' LYS . 87.6 mt-10 -89.42 -26.06 21.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.556 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.594 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 89.5 mtp -82.54 -30.93 29.41 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.401 -0.812 . . . . 0.0 109.448 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.623 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 1.2 tpt180 -38.7 -51.95 3.67 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.402 -0.811 . . . . 0.0 109.857 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.623 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.3 Cg_endo -68.78 -28.1 30.69 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.483 2.122 . . . . 0.0 111.801 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.459 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 23.4 mm -81.58 -42.13 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.243 -0.91 . . . . 0.0 109.402 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 1.021 HD12 HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -67.46 -39.88 85.35 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.207 -0.933 . . . . 0.0 109.051 179.715 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.568 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 26.1 ttm180 -63.62 -49.27 73.96 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.375 -0.828 . . . . 0.0 108.981 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -72.99 -35.24 66.83 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.329 -0.857 . . . . 0.0 109.048 179.532 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.517 ' HB1' HG13 ' A' ' 41' ' ' VAL . . . -74.38 -2.8 26.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.356 -0.84 . . . . 0.0 109.654 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.42 14.4 82.43 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 1.113 HD11 ' CG2' ' A' ' 41' ' ' VAL . 66.0 mt -81.65 -24.17 36.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.202 -1.176 . . . . 0.0 109.646 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 37.9 tp10 -102.37 138.9 38.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -0.999 . . . . 0.0 109.627 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -93.05 106.96 18.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.875 . . . . 0.0 109.35 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.459 ' CE1' ' HG2' ' A' ' 103' ' ' ARG . 22.8 p90 -144.13 153.64 42.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.227 -0.921 . . . . 0.0 109.493 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.442 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 18.4 mt-10 -93.03 -148.91 0.25 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.278 -0.889 . . . . 0.0 109.384 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.488 ' O ' ' C ' ' A' ' 113' ' ' LYS . 30.4 tt0 -98.45 148.18 23.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.172 -0.955 . . . . 0.0 109.482 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.488 ' C ' ' O ' ' A' ' 112' ' ' GLU . 11.3 pttm -36.74 126.55 0.87 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.385 -0.822 . . . . 0.0 109.784 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -79.49 -43.04 23.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.313 -0.867 . . . . 0.0 109.413 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.79 108.12 60.19 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.23 -0.919 . . . . 0.0 109.425 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.08 133.02 24.0 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.645 2.23 . . . . 0.0 111.817 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.8 t -107.03 136.56 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.511 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 48.4 mttt -90.89 138.81 31.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.268 -0.895 . . . . 0.0 109.439 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.842 HG22 ' H ' ' A' ' 121' ' ' LEU . 13.3 p -47.71 148.18 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.589 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.549 ' O ' ' HB2' ' A' ' 121' ' ' LEU . 2.1 mt-10 -71.25 -13.28 61.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.282 -0.886 . . . . 0.0 109.389 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.842 ' H ' HG22 ' A' ' 119' ' ' VAL . 29.5 mt 79.66 163.83 0.19 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.495 -0.753 . . . . 0.0 109.992 179.786 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 47.77 65.78 2.27 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 179.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.588 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 3.6 m-30 -100.75 142.49 32.15 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -1.177 . . . . 0.0 108.61 178.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.409 ' HB2' ' CG ' ' A' ' 127' ' ' ASP . 74.8 mttt -124.87 154.32 41.25 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.013 -1.054 . . . . 0.0 110.124 -179.462 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 9.8 m -64.66 141.89 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.331 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 88.22 -31.75 4.65 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.506 ' HB2' HD12 ' A' ' 143' ' ' ILE . 28.9 m-20 -49.66 158.74 0.43 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.433 -1.039 . . . . 0.0 109.26 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' MET . . . . . 0.592 ' HG2' HD12 ' A' ' 176' ' ' ILE . 4.4 ttm -98.13 127.86 44.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.205 -0.934 . . . . 0.0 109.052 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.672 HG11 HD11 ' A' ' 143' ' ' ILE . 27.4 m -128.11 143.41 40.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.276 -0.89 . . . . 0.0 109.604 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.571 ' HB2' HD11 ' A' ' 176' ' ' ILE . 75.8 tttt -100.31 139.42 36.01 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 179.485 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.989 ' O ' HD13 ' A' ' 132' ' ' ILE . 1.2 mp -79.86 152.77 4.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.989 HD13 ' O ' ' A' ' 131' ' ' ILE . 1.1 mm -148.79 2.4 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 120.956 -1.09 . . . . 0.0 109.809 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.526 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 41.7 m -147.5 144.66 28.73 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.971 -1.08 . . . . 0.0 110.198 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 103.22 -166.44 16.29 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.568 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 47.5 Cg_endo -68.52 -20.85 40.84 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 123.111 2.541 . . . . 0.0 112.315 -179.663 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.535 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 98.8 m-85 -107.86 19.09 20.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.954 -1.091 . . . . 0.0 109.3 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.614 ' HA ' HG22 ' A' ' 131' ' ' ILE . 4.0 tt0 -43.17 139.9 1.7 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.268 -0.895 . . . . 0.0 109.797 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.537 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 44.3 m-20 72.62 30.74 1.81 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.463 -0.773 . . . . 0.0 110.871 179.191 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.535 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 0.7 OUTLIER -116.66 128.46 55.39 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.76 -1.212 . . . . 0.0 109.573 179.654 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.14 133.49 42.8 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.28 -0.887 . . . . 0.0 109.455 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.05 168.96 26.37 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.432 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.616 ' C ' HG13 ' A' ' 155' ' ' VAL . 53.5 t -118.19 137.47 52.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.578 -0.954 . . . . 0.0 109.311 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.672 HD11 HG11 ' A' ' 129' ' ' VAL . 98.7 mt -70.05 115.47 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.177 -0.952 . . . . 0.0 109.42 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -99.03 -33.85 10.65 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.085 -1.009 . . . . 0.0 109.479 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.454 ' HB2' ' HE2' ' A' ' 154' ' ' LYS . 93.7 mt-10 -154.39 149.48 26.88 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.211 -0.931 . . . . 0.0 109.702 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.642 HG23 ' HG ' ' A' ' 153' ' ' LEU . 2.8 mt -125.91 128.46 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.431 -0.793 . . . . 0.0 109.394 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -110.91 102.17 51.79 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.234 -0.916 . . . . 0.0 109.534 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.557 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.0 Cg_endo -70.94 172.54 13.58 Favored 'Trans proline' 0 C--O 1.214 -0.724 0 C-N-CA 122.692 2.261 . . . . 0.0 111.699 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.557 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.6 mt-10 80.37 -20.74 0.36 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.348 -0.845 . . . . 0.0 109.848 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.427 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 74.6 mtt180 -128.53 -14.02 4.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.1 -1.0 . . . . 0.0 109.567 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.427 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 35.9 mt-30 70.51 48.64 0.45 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.216 -0.927 . . . . 0.0 109.851 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.576 ' OE2' HG23 ' A' ' 167' ' ' VAL . 84.6 tt0 -117.76 141.83 47.96 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.075 -1.015 . . . . 0.0 109.038 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.642 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -130.77 113.27 13.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.013 -1.054 . . . . 0.0 110.158 -179.512 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.454 ' HE2' ' HB2' ' A' ' 145' ' ' GLU . 2.5 ttpt -78.61 128.58 33.7 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.242 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.72 ' O ' HG12 ' A' ' 166' ' ' VAL . 47.0 t -124.54 145.82 31.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.168 -0.958 . . . . 0.0 109.985 -179.41 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.534 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 27.0 t-20 -98.32 110.96 23.45 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.377 -0.827 . . . . 0.0 109.37 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.492 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 60.4 t -95.22 142.33 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.453 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 41.2 m -100.55 100.03 10.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.255 -0.903 . . . . 0.0 109.728 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.497 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 4.1 mt -123.81 146.98 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.178 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.657 ' CE1' HD11 ' A' ' 9' ' ' ILE . 97.9 m-85 61.84 38.66 14.52 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.238 -0.914 . . . . 0.0 109.205 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 55.24 17.19 10.63 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.463 ' CZ ' ' OH ' ' A' ' 59' ' ' TYR . 90.7 mtt-85 -125.58 158.71 33.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.094 -1.239 . . . . 0.0 109.563 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.73 128.37 46.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.194 -0.941 . . . . 0.0 109.687 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 48.8 m -139.2 125.78 12.58 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.313 -0.867 . . . . 0.0 109.792 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.2 Cg_endo -71.51 135.28 26.08 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.7 2.267 . . . . 0.0 111.429 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 1.008 HG13 HD11 ' A' ' 168' ' ' LEU . 7.1 p -118.47 163.39 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.167 -0.958 . . . . 0.0 109.966 -179.524 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 167' ' ' VAL . 14.4 p -116.61 117.01 54.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.296 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 1.008 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -143.21 168.85 18.8 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.243 -0.911 . . . . 0.0 110.91 -179.264 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 40.4 m80 -78.96 144.0 35.21 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.572 HG23 HD13 ' A' ' 153' ' ' LEU . 10.8 p -57.78 -36.23 54.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.215 -0.928 . . . . 0.0 108.83 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.432 ' N ' HG13 ' A' ' 170' ' ' VAL . 42.5 p -76.39 -6.64 52.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.45 -0.782 . . . . 0.0 109.401 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.526 ' HA ' ' HB2' ' A' ' 133' ' ' SER . 2.8 mt-10 -89.72 -0.29 57.44 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.239 -0.913 . . . . 0.0 109.394 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.2 m -144.06 174.35 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.253 -0.905 . . . . 0.0 109.21 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.491 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 53.9 tt0 -139.49 168.16 20.46 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.113 -0.992 . . . . 0.0 108.975 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.588 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 73.1 tttt -89.31 15.11 9.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.028 -1.045 . . . . 0.0 109.358 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.592 HD12 ' HG2' ' A' ' 128' ' ' MET . 79.8 mt 53.58 -88.42 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.241 -0.912 . . . . 0.0 109.615 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.511 ' N ' ' O ' ' A' ' 175' ' ' LYS . 74.0 mm-40 . . . . . 0 N--CA 1.489 1.49 0 O-C-N 121.114 -0.991 . . . . 0.0 109.459 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.63 -30.06 71.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.146 -1.208 . . . . 0.0 109.449 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 91.0 mtp -64.63 -21.6 66.76 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.205 -0.935 . . . . 0.0 109.469 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 17.1 tttp -106.17 120.08 40.9 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.252 -0.905 . . . . 0.0 109.415 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.557 ' HG2' HG22 ' A' ' 65' ' ' ILE . 36.8 mttt -105.89 159.65 15.86 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.55 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.533 ' HB3' ' HB3' ' A' ' 92' ' ' PRO . 9.4 mttt -132.36 176.29 8.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.298 -0.876 . . . . 0.0 109.337 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.864 ' O ' HG23 ' A' ' 93' ' ' VAL . 64.8 m95 -112.67 124.04 51.66 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.924 . . . . 0.0 109.386 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.494 ' OH ' ' HG3' ' A' ' 66' ' ' MET . 78.4 m-85 -113.35 179.79 3.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.18 -0.95 . . . . 0.0 109.266 179.785 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.542 HG12 ' CE1' ' A' ' 61' ' ' PHE . 66.8 mt -119.7 107.38 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.384 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.555 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 13.1 p -86.01 144.6 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.271 -0.893 . . . . 0.0 109.518 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.797 HD11 ' HE1' ' A' ' 59' ' ' TYR . 2.8 mm? -94.8 143.83 26.14 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.336 -0.853 . . . . 0.0 109.601 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.405 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 1.3 p -151.3 -168.59 3.14 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.307 -0.87 . . . . 0.0 109.317 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.437 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 95.4 mtp -106.2 136.15 46.42 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.181 -0.949 . . . . 0.0 109.294 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.8 t -55.8 123.38 14.0 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -0.908 . . . . 0.0 109.424 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.08 -19.67 32.11 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.437 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.8 m-85 -108.15 -11.26 15.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.323 -1.104 . . . . 0.0 109.561 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.473 ' OE2' ' N ' ' A' ' 58' ' ' GLY . 77.5 mt-10 -46.52 -61.5 1.79 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.187 -0.945 . . . . 0.0 109.408 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.891 ' OE2' HD11 ' A' ' 44' ' ' ILE . 67.4 mm-40 -47.98 -36.55 12.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.288 -0.883 . . . . 0.0 109.339 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -71.69 -45.96 60.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.346 -0.847 . . . . 0.0 109.436 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.852 HG22 ' CB ' ' A' ' 79' ' ' TYR . 78.8 t -57.31 -47.14 85.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.186 -0.946 . . . . 0.0 109.444 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.738 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.7 tttt -56.09 -51.54 67.5 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.234 -0.916 . . . . 0.0 109.532 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 61.1 tt0 -63.06 -33.67 75.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.166 -0.959 . . . . 0.0 109.398 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.581 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 23.6 m120 -66.18 -41.26 90.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.318 -0.864 . . . . 0.0 109.501 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.453 HG13 ' O ' ' A' ' 20' ' ' VAL . 92.2 mt -60.52 -44.98 97.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.217 -0.927 . . . . 0.0 109.43 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -55.77 -47.09 77.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.201 -0.937 . . . . 0.0 109.672 -179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 71.5 mttt -70.19 -34.71 73.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.136 -0.977 . . . . 0.0 109.316 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.562 ' HD2' HG23 ' A' ' 77' ' ' VAL . 34.4 tttp -57.14 -35.9 70.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.379 -0.826 . . . . 0.0 109.478 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.816 HG13 ' O ' ' A' ' 33' ' ' ILE . 33.8 t -81.32 -25.51 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -71.6 -56.56 5.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.248 -0.908 . . . . 0.0 109.562 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.86 -26.2 45.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.223 -0.923 . . . . 0.0 109.553 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.476 ' OG1' HG12 ' A' ' 33' ' ' ILE . 41.8 p -98.05 -28.66 13.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.192 -0.942 . . . . 0.0 109.57 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 76.88 21.1 75.06 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.816 ' O ' HG13 ' A' ' 28' ' ' VAL . 34.1 mm -90.02 94.87 5.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -1.154 . . . . 0.0 109.495 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 16.0 mttp -97.74 5.13 49.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.183 -0.948 . . . . 0.0 109.49 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -110.22 13.45 23.07 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.203 -0.936 . . . . 0.0 109.341 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.052 HD21 ' HB2' ' A' ' 70' ' ' ALA . 1.2 tm? -115.73 -54.28 2.52 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.329 -0.857 . . . . 0.0 109.187 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.572 ' HB ' HG21 ' A' ' 28' ' ' VAL . 42.9 t -99.21 130.01 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.443 -0.786 . . . . 0.0 109.219 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.82 -124.33 5.22 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 90.7 mtt180 -96.51 141.94 29.19 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.266 -1.138 . . . . 0.0 109.589 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.409 HD13 HD12 ' A' ' 24' ' ' ILE . 63.3 mt -101.43 138.1 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.297 -0.877 . . . . 0.0 109.251 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 1.13 HG21 HD11 ' A' ' 107' ' ' LEU . 44.4 t -126.42 137.51 57.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.236 -0.915 . . . . 0.0 109.285 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.807 HG22 HG23 ' A' ' 44' ' ' ILE . 12.2 mt -128.08 127.84 23.79 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.187 -0.946 . . . . 0.0 109.692 -179.686 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.53 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -68.05 -3.86 11.45 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.895 2.396 . . . . 0.0 111.461 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.891 HD11 ' OE2' ' A' ' 18' ' ' GLU . 18.8 pt -76.36 -6.11 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.307 -0.87 . . . . 0.0 109.561 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.439 ' NH1' ' HG3' ' A' ' 45' ' ' ARG . 5.6 ttt85 -44.48 -33.53 1.75 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.212 -0.93 . . . . 0.0 109.428 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.6 -156.62 49.85 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -164.58 -158.01 9.98 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 48.8 tt0 -52.24 -29.53 23.26 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.275 -1.132 . . . . 0.0 109.469 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.792 ' HD3' HG21 ' A' ' 167' ' ' VAL . 66.0 mtm180 -52.04 154.26 2.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 109.346 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.442 ' O ' ' HB2' ' A' ' 51' ' ' LYS . 44.6 mtp180 -127.15 160.67 30.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.928 . . . . 0.0 109.521 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' LYS . . . . . 0.442 ' HB2' ' O ' ' A' ' 50' ' ' ARG . 21.8 mttm 62.31 28.72 17.1 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.258 -0.901 . . . . 0.0 109.529 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.425 ' C ' ' HG3' ' A' ' 53' ' ' GLU . 48.2 t -161.81 126.09 3.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.222 -0.923 . . . . 0.0 109.502 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.495 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 82.1 mt-10 -151.67 169.38 22.3 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.578 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.727 ' HA ' HG22 ' A' ' 44' ' ' ILE . 6.2 mttt 75.1 82.72 0.1 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.642 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.53 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 16.7 mt -71.83 -21.47 61.68 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.136 -0.978 . . . . 0.0 109.407 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.968 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 37.2 m-85 -143.95 93.09 6.17 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.285 -0.885 . . . . 0.0 108.826 179.688 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -64.34 135.91 48.61 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.628 2.219 . . . . 0.0 112.267 -179.193 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.473 ' N ' ' OE2' ' A' ' 17' ' ' GLU . . . 78.81 -20.52 4.42 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 179.541 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.797 ' HE1' HD11 ' A' ' 11' ' ' LEU . 3.9 m-30 -96.34 127.81 42.68 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.707 -1.467 . . . . 0.0 110.47 -179.085 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.555 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 94.3 t -135.59 150.41 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.111 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.542 ' CE1' HG12 ' A' ' 9' ' ' ILE . 86.8 m-85 -108.46 122.97 48.14 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.858 -1.151 . . . . 0.0 110.227 -179.248 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 87.9 t -121.98 127.8 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.322 -0.861 . . . . 0.0 109.873 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.587 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 7.6 tt0 -89.68 121.76 32.16 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.282 -0.886 . . . . 0.0 109.278 179.769 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' MET . . . . . . . . . . . . . 14.8 ptt? -154.04 174.08 15.17 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.03 -1.044 . . . . 0.0 110.538 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.662 HG12 HD22 ' A' ' 36' ' ' LEU . 39.0 pt -100.35 134.99 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.755 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.551 ' O ' ' HB3' ' A' ' 67' ' ' ASN . 84.9 mtp -79.55 142.87 35.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.096 -1.003 . . . . 0.0 110.799 -178.355 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.551 ' HB3' ' O ' ' A' ' 66' ' ' MET . 16.4 p30 171.67 -174.31 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -76.51 -42.89 41.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.147 -0.971 . . . . 0.0 110.006 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.621 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 85.1 tt0 -66.54 -31.42 72.13 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.216 -0.927 . . . . 0.0 110.383 -179.299 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.052 ' HB2' HD21 ' A' ' 36' ' ' LEU . . . -77.11 -40.78 44.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.848 -1.157 . . . . 0.0 109.791 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.468 ' CD1' ' OE1' ' A' ' 89' ' ' GLN . 87.3 t80 -58.79 -51.41 70.1 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.11 -0.994 . . . . 0.0 109.586 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.471 ' O ' ' HB3' ' A' ' 76' ' ' SER . 38.1 t-20 -69.89 -27.27 64.67 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.201 -0.937 . . . . 0.0 110.581 -179.196 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.621 ' CD1' ' O ' ' A' ' 69' ' ' GLU . 5.1 m-85 -78.19 -41.21 35.26 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.693 -1.254 . . . . 0.0 110.073 -179.447 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.848 HG22 ' CZ ' ' A' ' 83' ' ' PHE . 7.7 p -66.48 -52.11 50.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.22 -0.925 . . . . 0.0 109.232 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.662 ' N ' HG13 ' A' ' 74' ' ' VAL . 7.5 mmm-85 -67.59 -1.22 4.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.313 -0.867 . . . . 0.0 109.904 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 89.3 p -101.0 -4.94 26.53 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.031 -1.043 . . . . 0.0 110.167 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.873 ' O ' HG12 ' A' ' 80' ' ' VAL . 5.6 p -80.13 137.9 52.95 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 120.994 -1.066 . . . . 0.0 109.377 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.624 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 43.5 Cg_endo -65.77 140.53 61.97 Favored 'Trans proline' 0 C--O 1.213 -0.737 0 C-N-CA 122.763 2.308 . . . . 0.0 112.119 -179.367 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.852 ' CB ' HG22 ' A' ' 20' ' ' VAL . 42.0 m-85 89.0 -11.89 0.41 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.831 -0.543 . . . . 0.0 109.675 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.873 HG12 ' O ' ' A' ' 77' ' ' VAL . 7.9 p -81.84 119.03 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.957 -1.089 . . . . 0.0 109.299 179.772 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.8 mmm -88.44 -27.16 21.71 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.196 -0.94 . . . . 0.0 109.41 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.588 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.27 -158.03 28.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.848 ' CZ ' HG22 ' A' ' 74' ' ' VAL . 7.4 m-85 -139.61 156.95 46.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -1.124 . . . . 0.0 109.573 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.649 ' O ' HG13 ' A' ' 84' ' ' VAL . 7.7 p -88.74 118.69 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.232 -0.918 . . . . 0.0 109.339 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.596 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.8 OUTLIER -157.0 166.78 32.38 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -0.915 . . . . 0.0 109.627 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 m -87.06 -29.93 21.54 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.405 -0.809 . . . . 0.0 109.432 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.44 -103.18 1.4 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -99.5 -124.34 5.19 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.559 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -29.24 146.09 0.05 OUTLIER Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.524 -0.986 . . . . 0.0 110.142 -179.751 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.596 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.2 Cg_endo -68.66 153.92 72.41 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.827 2.352 . . . . 0.0 112.001 -179.73 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.2 m -89.9 149.75 42.43 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.301 -0.874 . . . . 0.0 109.253 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.533 ' HB3' ' HB3' ' A' ' 6' ' ' LYS . 49.5 Cg_endo -69.62 152.37 70.01 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.682 2.255 . . . . 0.0 111.664 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.864 HG23 ' O ' ' A' ' 7' ' ' TRP . 15.5 t -79.93 141.21 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -0.885 . . . . 0.0 109.322 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' LYS . . . . . 0.5 ' O ' ' N ' ' A' ' 97' ' ' GLU . 69.6 tttt -78.9 130.14 35.3 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.086 -1.009 . . . . 0.0 109.357 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.442 ' C ' ' O ' ' A' ' 94' ' ' LYS . 81.3 m-20 -42.78 -41.96 3.4 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -0.944 . . . . 0.0 109.367 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.462 ' CD ' ' HE2' ' A' ' 94' ' ' LYS . 75.1 mtt180 -56.36 -29.91 62.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.271 -0.893 . . . . 0.0 109.433 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.5 ' N ' ' O ' ' A' ' 94' ' ' LYS . 47.5 mt-10 -88.07 -28.26 21.44 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.221 -0.924 . . . . 0.0 109.589 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.599 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 94.6 mtp -82.91 -25.51 32.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.148 -0.97 . . . . 0.0 109.431 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.567 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.14 -54.62 1.08 Allowed Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.524 -0.735 . . . . 0.0 109.995 -179.845 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.614 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 49.4 Cg_endo -70.17 -27.75 24.14 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.591 2.194 . . . . 0.0 112.132 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.525 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 18.9 mm -80.21 -42.74 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.156 -0.965 . . . . 0.0 109.546 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.557 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -67.36 -40.63 85.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.207 -0.933 . . . . 0.0 109.494 -179.884 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.54 ' CG ' ' HB3' ' A' ' 135' ' ' PRO . 22.2 tpt180 -65.13 -49.73 68.78 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.326 -0.859 . . . . 0.0 109.162 179.722 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.4 tt -72.05 -37.86 69.61 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.208 -0.932 . . . . 0.0 109.2 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.52 -1.04 9.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.398 -0.814 . . . . 0.0 109.829 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.75 8.57 86.42 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 1.13 HD11 HG21 ' A' ' 41' ' ' VAL . 29.3 mt -78.38 -21.4 49.44 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.19 -1.182 . . . . 0.0 109.613 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 42.6 tp10 -124.81 134.37 52.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.15 -0.969 . . . . 0.0 109.365 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 64.9 mt-10 -120.4 108.33 14.0 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.918 . . . . 0.0 109.557 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.578 ' CD1' ' O ' ' A' ' 111' ' ' GLU . 35.0 p90 -138.47 164.86 28.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.313 -0.867 . . . . 0.0 109.455 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.578 ' O ' ' CD1' ' A' ' 110' ' ' TYR . 61.9 mm-40 -62.5 -142.05 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.891 . . . . 0.0 109.636 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -161.29 172.21 17.02 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.289 -0.882 . . . . 0.0 109.425 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.615 ' CG ' ' HA ' ' A' ' 133' ' ' SER . 7.3 mmtp -68.3 -56.04 9.97 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.215 -0.928 . . . . 0.0 109.623 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.424 ' HG3' ' C ' ' A' ' 113' ' ' LYS . 8.7 mttt 50.36 23.59 1.28 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.347 -0.846 . . . . 0.0 109.475 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.52 ' HG2' ' HB3' ' A' ' 113' ' ' LYS . 0.4 OUTLIER -101.25 104.66 34.56 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.289 -0.882 . . . . 0.0 109.48 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -70.77 117.98 5.44 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.661 2.24 . . . . 0.0 111.707 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 21.9 t -129.83 129.68 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.18 -0.95 . . . . 0.0 109.44 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 23.4 mttt -65.31 147.63 53.1 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 109.482 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 29.5 m -114.54 167.88 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.308 -0.87 . . . . 0.0 109.405 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.663 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 84.4 mt-10 -60.49 -35.28 75.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.663 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 5.1 mt 145.0 155.16 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.844 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.626 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.95 93.82 0.01 OUTLIER Glycine 0 N--CA 1.494 2.564 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.533 ' O ' ' CD1' ' A' ' 146' ' ' ILE . 18.0 m-85 -47.59 178.56 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.294 -1.121 . . . . 0.0 109.528 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.443 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 80.9 mttt -102.08 148.72 25.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.958 . . . . 0.0 109.915 -179.758 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 20.5 m -64.14 144.26 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.433 -0.792 . . . . 0.0 109.375 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.72 -29.92 4.38 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 -179.751 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.553 ' HB2' HD12 ' A' ' 143' ' ' ILE . 26.2 m-20 -48.01 165.71 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -1.114 . . . . 0.0 109.127 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' MET . . . . . 0.481 ' HG3' HG12 ' A' ' 142' ' ' VAL . 2.9 ttm -103.54 127.8 50.88 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.136 -0.978 . . . . 0.0 109.153 179.775 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.674 HG11 HD11 ' A' ' 143' ' ' ILE . 26.8 m -129.06 145.88 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.855 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 140' ' ' ALA . 42.2 tttt -102.81 142.41 33.99 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.87 HD12 ' HB3' ' A' ' 139' ' ' PHE . 60.5 mt -83.14 154.34 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.358 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.488 HG12 ' HA ' ' A' ' 173' ' ' VAL . 0.2 OUTLIER -152.02 2.78 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 120.948 -1.095 . . . . 0.0 109.65 179.828 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.615 ' HA ' ' CG ' ' A' ' 113' ' ' LYS . 47.3 t -148.03 144.1 27.69 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.07 -1.019 . . . . 0.0 110.252 -179.66 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 99.62 -163.18 19.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.54 ' HB3' ' CG ' ' A' ' 103' ' ' ARG . 46.8 Cg_endo -67.89 -23.46 41.14 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 123.312 2.675 . . . . 0.0 112.541 -179.497 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.649 ' HB2' HD13 ' A' ' 131' ' ' ILE . 93.2 m-85 -104.22 17.61 23.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.957 -1.09 . . . . 0.0 109.562 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.553 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.9 tt0 -43.83 133.61 4.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.251 -0.906 . . . . 0.0 109.649 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.545 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 16.8 t0 78.92 19.26 0.82 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.262 -0.899 . . . . 0.0 110.36 179.161 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.87 ' HB3' HD12 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -109.24 130.4 55.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.912 -1.117 . . . . 0.0 109.47 179.825 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -83.7 136.9 34.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.16 -0.963 . . . . 0.0 109.597 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -146.55 175.6 25.89 Favored Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.67 -1.252 . . . . 0.0 110.612 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.828 ' C ' HG13 ' A' ' 155' ' ' VAL . 19.4 m -118.42 137.01 53.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.702 -0.881 . . . . 0.0 109.659 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.674 HD11 HG11 ' A' ' 129' ' ' VAL . 93.3 mt -67.48 114.6 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.321 -0.862 . . . . 0.0 109.407 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -98.15 -34.51 10.72 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.976 -1.077 . . . . 0.0 109.331 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -150.8 145.58 25.81 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.153 -0.967 . . . . 0.0 109.367 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.686 HG23 ' CD1' ' A' ' 153' ' ' LEU . 2.2 mt -122.74 126.28 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.678 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -107.41 101.68 40.32 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.314 -0.867 . . . . 0.0 109.447 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.528 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.1 Cg_endo -71.96 170.92 17.73 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.734 2.29 . . . . 0.0 111.899 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.7 tt0 79.85 -20.92 0.36 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.336 -0.852 . . . . 0.0 109.862 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.412 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 66.6 mtp85 -125.35 -13.18 6.7 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.155 -0.965 . . . . 0.0 109.43 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.412 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 36.2 mt-30 68.98 49.08 0.67 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.204 -0.935 . . . . 0.0 109.678 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -121.1 145.25 48.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.111 -0.993 . . . . 0.0 108.896 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.686 ' CD1' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -135.82 113.13 10.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.035 -1.041 . . . . 0.0 110.262 -179.498 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 10.4 mttt -79.59 133.25 36.43 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.102 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.828 HG13 ' C ' ' A' ' 142' ' ' VAL . 21.5 t -126.34 150.49 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.077 -1.014 . . . . 0.0 110.01 -179.27 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.51 ' OD1' ' N ' ' A' ' 164' ' ' THR . 20.9 t-20 -97.26 114.5 26.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.446 -0.784 . . . . 0.0 109.293 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.709 HG12 HG23 ' A' ' 159' ' ' ILE . 50.0 t -95.98 139.77 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.712 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 20.6 m -92.55 95.24 9.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.409 -0.807 . . . . 0.0 109.514 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.968 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 5.5 pt -130.9 150.2 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.269 -0.895 . . . . 0.0 109.488 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.601 ' CE2' HD12 ' A' ' 159' ' ' ILE . 13.7 m-30 62.95 33.13 15.18 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.271 -0.893 . . . . 0.0 109.313 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 60.64 16.35 44.64 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 60.0 mtt-85 -135.63 159.27 42.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.188 -1.183 . . . . 0.0 109.455 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.449 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 95.6 mt-10 -100.46 140.85 34.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.244 -0.91 . . . . 0.0 109.516 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 164' ' ' THR . . . . . 0.51 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 16.4 m -148.0 127.86 6.59 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.325 -0.859 . . . . 0.0 109.46 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.5 Cg_endo -69.86 140.0 41.23 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.751 2.301 . . . . 0.0 111.583 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 1.024 HG23 HD21 ' A' ' 168' ' ' LEU . 35.2 m -121.28 168.19 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.056 -1.028 . . . . 0.0 109.598 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 1.136 ' O ' HD13 ' A' ' 168' ' ' LEU . 8.4 m -118.2 115.66 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.442 -0.786 . . . . 0.0 109.492 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 1.136 HD13 ' O ' ' A' ' 167' ' ' VAL . 0.0 OUTLIER -139.56 166.28 25.0 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-O 121.797 0.808 . . . . 0.0 109.937 179.959 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.452 ' O ' ' HB2' ' A' ' 172' ' ' GLU . 40.5 m80 -79.04 139.72 38.09 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.175 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 171' ' ' SER . 11.4 p -51.43 -37.91 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.067 -1.021 . . . . 0.0 108.521 179.598 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.484 ' N ' HG13 ' A' ' 170' ' ' VAL . 53.3 p -74.86 -4.83 40.16 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.615 -0.678 . . . . 0.0 109.798 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.479 ' HG2' ' HB3' ' A' ' 133' ' ' SER . 23.8 mt-10 -92.7 -6.44 49.19 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.077 -1.014 . . . . 0.0 109.874 -179.712 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.488 ' HA ' HG12 ' A' ' 132' ' ' ILE . 4.1 m -137.29 175.15 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.057 -1.027 . . . . 0.0 109.488 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.543 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 84.4 tt0 -140.02 164.53 29.77 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.132 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.543 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.8 tttt -90.18 19.03 5.32 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.055 -1.028 . . . . 0.0 109.347 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.563 HG22 ' N ' ' A' ' 177' ' ' GLU . 71.1 mt 54.89 164.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.293 -0.879 . . . . 0.0 109.571 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.563 ' N ' HG22 ' A' ' 176' ' ' ILE . 90.5 mt-10 . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.471 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.05 -25.01 67.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.262 -1.14 . . . . 0.0 109.601 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 90.0 mtp -72.6 -10.92 60.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.221 -0.925 . . . . 0.0 109.535 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 89.2 mttt -112.42 121.08 43.81 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.186 -0.946 . . . . 0.0 109.528 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.514 ' HG2' HG22 ' A' ' 65' ' ' ILE . 72.1 mttt -115.74 143.58 45.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.293 -0.879 . . . . 0.0 109.496 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.591 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.0 mtpp -130.56 174.72 9.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.282 -0.886 . . . . 0.0 109.28 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.903 ' O ' HG23 ' A' ' 93' ' ' VAL . 61.9 m95 -108.84 124.43 50.61 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.232 -0.917 . . . . 0.0 109.031 179.7 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.487 ' O ' ' HA ' ' A' ' 61' ' ' PHE . 79.5 m-85 -110.92 174.07 6.03 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.163 -0.961 . . . . 0.0 109.569 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.535 HG12 ' CD1' ' A' ' 61' ' ' PHE . 61.7 mt -116.76 109.05 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.316 -0.865 . . . . 0.0 109.141 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.716 ' CG2' HG23 ' A' ' 80' ' ' VAL . 9.7 p -90.88 142.98 12.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.178 -0.951 . . . . 0.0 109.65 -179.682 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.55 ' N ' HD22 ' A' ' 11' ' ' LEU . 3.5 mm? -89.5 153.86 20.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.353 -0.842 . . . . 0.0 109.615 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.499 HG21 ' HG2' ' A' ' 17' ' ' GLU . 9.2 t -162.84 -172.87 3.24 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.906 . . . . 0.0 109.349 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.519 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 67.5 mtm -103.54 133.45 48.56 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.227 -0.92 . . . . 0.0 109.658 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.4 m -54.43 127.4 27.36 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.884 . . . . 0.0 109.383 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.23 -20.18 38.43 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.519 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 85.6 m-85 -107.51 -1.56 21.24 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.34 -1.094 . . . . 0.0 109.429 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.499 ' HG2' HG21 ' A' ' 12' ' ' THR . 46.3 mt-10 -55.21 -59.4 4.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.233 -0.917 . . . . 0.0 109.388 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -47.48 -36.38 10.1 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.345 -0.847 . . . . 0.0 109.402 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 12.9 mttp -72.44 -46.46 54.89 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.388 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.527 HG22 ' HB2' ' A' ' 79' ' ' TYR . 73.4 t -55.09 -47.17 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.281 -0.887 . . . . 0.0 109.307 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.871 ' HD2' HD11 ' A' ' 42' ' ' ILE . 17.8 tttm -56.23 -50.92 69.92 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.413 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -63.25 -37.39 87.05 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.189 -0.944 . . . . 0.0 109.522 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.583 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 31.5 m120 -61.89 -49.04 77.82 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.203 -0.935 . . . . 0.0 109.565 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.465 ' O ' HG13 ' A' ' 28' ' ' VAL . 81.2 mt -53.93 -44.22 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.08 -1.013 . . . . 0.0 109.354 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.636 ' O ' HG22 ' A' ' 28' ' ' VAL . 83.1 tt0 -56.56 -47.95 78.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.188 -0.945 . . . . 0.0 110.035 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 40.4 mttp -73.41 -36.95 66.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.145 -0.972 . . . . 0.0 109.939 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.482 ' HD3' HG23 ' A' ' 77' ' ' VAL . 23.7 ttpp -56.31 -34.12 66.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.122 -0.986 . . . . 0.0 109.325 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 1.079 HG11 HG11 ' A' ' 37' ' ' VAL . 12.0 m -87.34 -25.55 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.42 -0.8 . . . . 0.0 109.489 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -72.01 -57.75 4.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.303 -0.873 . . . . 0.0 109.298 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.85 -40.79 61.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.397 -0.814 . . . . 0.0 109.243 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.698 HG21 ' CZ ' ' A' ' 73' ' ' PHE . 72.7 p -83.07 -26.15 31.38 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.325 -0.859 . . . . 0.0 109.483 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 77.51 25.02 64.02 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.628 HD12 ' CE2' ' A' ' 73' ' ' PHE . 15.9 mt -94.07 92.9 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -1.15 . . . . 0.0 109.359 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.8 mttt -105.71 -12.95 15.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.349 -0.845 . . . . 0.0 109.505 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -86.25 -19.6 29.71 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.182 -0.949 . . . . 0.0 109.428 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.1 HD11 ' CB ' ' A' ' 70' ' ' ALA . 15.1 tp -89.36 -51.58 5.49 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.307 -0.87 . . . . 0.0 109.461 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 1.079 HG11 HG11 ' A' ' 28' ' ' VAL . 7.3 p -93.83 136.58 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.52 -0.737 . . . . 0.0 109.018 179.672 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.5 -120.9 4.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.4 mtt85 -104.44 140.04 38.51 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.286 -1.126 . . . . 0.0 109.878 -179.399 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.547 HG22 ' HB ' ' A' ' 62' ' ' VAL . 12.9 pt -112.74 148.26 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.354 -0.841 . . . . 0.0 109.021 179.407 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.829 HG13 ' CH2' ' A' ' 7' ' ' TRP . 23.2 m -132.22 161.77 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.076 -1.015 . . . . 0.0 109.91 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.871 HD11 ' HD2' ' A' ' 21' ' ' LYS . 3.8 mt -135.28 130.84 19.36 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.379 -0.826 . . . . 0.0 109.333 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.492 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 43.0 Cg_endo -65.12 -3.59 7.53 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.851 2.368 . . . . 0.0 111.873 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.819 HG13 HG22 ' A' ' 42' ' ' ILE . 15.3 mt -65.11 -44.09 95.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.146 -0.971 . . . . 0.0 109.446 179.701 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.935 ' O ' HD21 ' A' ' 104' ' ' LEU . 18.6 ttt180 -47.03 146.16 1.83 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.213 -0.93 . . . . 0.0 109.486 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.666 ' HA3' HD11 ' A' ' 104' ' ' LEU . . . 113.98 97.22 2.22 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.92 24.7 52.0 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.494 ' O ' ' OE2' ' A' ' 53' ' ' GLU . 50.8 tt0 -51.5 -40.78 60.23 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -1.142 . . . . 0.0 109.486 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 46.1 ttt180 -56.61 -36.61 69.63 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.068 -1.02 . . . . 0.0 109.379 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.72 HH11 HG11 ' A' ' 167' ' ' VAL . 39.1 mtp-105 -66.76 154.34 41.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.236 -0.915 . . . . 0.0 109.519 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 24.1 mttm -65.76 -32.8 74.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.247 -0.908 . . . . 0.0 109.538 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.42 ' C ' ' HG3' ' A' ' 53' ' ' GLU . 45.5 p -80.81 138.59 36.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.72 -179.702 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.494 ' OE2' ' O ' ' A' ' 48' ' ' GLN . 69.3 mt-10 -155.55 173.12 17.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.48 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.656 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 7.2 mttp 74.33 87.03 0.1 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.351 -0.843 . . . . 0.0 109.504 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.492 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 41.2 mt -68.06 -20.78 65.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.061 -1.025 . . . . 0.0 109.3 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.762 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 90.0 m-85 -143.66 98.2 5.37 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.304 -0.873 . . . . 0.0 109.044 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.3 Cg_endo -65.52 132.88 32.5 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.784 2.322 . . . . 0.0 112.216 -179.3 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.496 ' HA2' HG23 ' A' ' 12' ' ' THR . . . 77.02 -15.41 6.47 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.571 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 2.9 m-85 -97.83 129.59 44.8 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.624 -1.515 . . . . 0.0 110.38 -179.159 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.533 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 79.2 t -137.19 149.19 25.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.41 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.57 ' HB2' ' CG2' ' A' ' 41' ' ' VAL . 63.5 m-85 -109.67 124.39 51.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.025 -1.047 . . . . 0.0 110.23 -179.416 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.547 ' HB ' HG22 ' A' ' 40' ' ' ILE . 1.3 m -123.44 135.43 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.452 -0.78 . . . . 0.0 109.604 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.619 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 19.5 tt0 -104.87 122.91 46.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.222 -0.923 . . . . 0.0 109.402 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.544 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 22.3 mtm -157.96 179.47 9.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.085 -1.009 . . . . 0.0 110.344 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 1.046 ' CG1' HD12 ' A' ' 36' ' ' LEU . 8.4 pt -94.72 129.01 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.454 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 37.0 ttm -77.83 146.22 35.85 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.255 -0.903 . . . . 0.0 110.131 -178.581 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.454 ' HB2' ' O ' ' A' ' 66' ' ' MET . 20.8 t-20 176.58 177.72 0.25 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.596 -0.69 . . . . 0.0 109.258 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -73.38 -42.5 62.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.159 -0.963 . . . . 0.0 109.284 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -76.48 -28.18 56.37 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.23 -0.919 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.1 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -74.55 -48.15 28.53 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.262 -0.899 . . . . 0.0 109.569 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.568 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 84.0 t80 -60.52 -45.66 93.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.227 -0.921 . . . . 0.0 109.57 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -67.4 -27.3 66.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.986 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.698 ' CZ ' HG21 ' A' ' 31' ' ' THR . 10.6 t80 -81.18 -41.59 22.12 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.078 -1.014 . . . . 0.0 109.897 -179.711 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.683 HG13 ' N ' ' A' ' 75' ' ' ARG . 14.6 p -69.57 -53.77 22.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.426 -0.796 . . . . 0.0 109.585 -179.627 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.683 ' N ' HG13 ' A' ' 74' ' ' VAL . 14.4 tpt85 -61.15 -11.15 7.89 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.128 -0.983 . . . . 0.0 109.825 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 91.4 p -92.77 4.5 53.67 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.169 -0.957 . . . . 0.0 109.963 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.917 ' O ' HG12 ' A' ' 80' ' ' VAL . 5.2 p -76.82 135.17 67.92 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.037 -1.039 . . . . 0.0 109.344 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.622 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 42.8 Cg_endo -65.18 140.66 65.92 Favored 'Trans proline' 0 C--O 1.214 -0.72 0 C-N-CA 122.672 2.248 . . . . 0.0 112.109 -179.532 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.622 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 38.5 m-85 89.55 -9.48 0.4 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.918 -0.489 . . . . 0.0 109.744 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.917 HG12 ' O ' ' A' ' 77' ' ' VAL . 7.8 p -88.2 125.01 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.049 -1.032 . . . . 0.0 109.496 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 95.9 mmm -85.09 -26.42 26.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.108 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.531 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.23 -157.52 28.15 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.634 ' CE1' HG23 ' A' ' 10' ' ' VAL . 14.5 m-85 -132.79 149.28 52.29 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -1.138 . . . . 0.0 109.459 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.675 ' O ' HG13 ' A' ' 84' ' ' VAL . 10.9 p -74.33 115.75 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.427 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.528 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.1 p -152.83 166.58 31.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.263 -0.898 . . . . 0.0 109.403 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.2 t -96.01 -29.96 13.84 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.282 -0.886 . . . . 0.0 109.393 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -130.59 -80.24 0.22 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.533 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -110.18 -136.25 7.3 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.568 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -31.81 150.37 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.526 -0.985 . . . . 0.0 110.245 -179.619 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.528 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.5 Cg_endo -69.36 159.05 55.19 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.967 2.445 . . . . 0.0 111.884 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 28.5 m -88.9 151.69 47.61 Favored Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.207 -0.933 . . . . 0.0 109.279 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.541 ' CB ' ' HE2' ' A' ' 6' ' ' LYS . 50.6 Cg_endo -70.45 145.75 54.01 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.686 2.258 . . . . 0.0 111.789 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.903 HG23 ' O ' ' A' ' 7' ' ' TRP . 3.6 t -79.74 129.71 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.182 -0.949 . . . . 0.0 109.169 179.841 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' LYS . . . . . 0.442 ' O ' ' C ' ' A' ' 95' ' ' ASP . 32.4 mttp -73.92 134.0 43.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.441 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.442 ' C ' ' O ' ' A' ' 94' ' ' LYS . 69.2 m-20 -42.63 -41.65 3.16 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -0.883 . . . . 0.0 109.463 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 56.6 ttt180 -54.6 -28.64 47.87 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.235 -0.915 . . . . 0.0 109.362 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.44 ' N ' ' O ' ' A' ' 94' ' ' LYS . 23.2 mm-40 -89.38 -28.39 19.81 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.558 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.558 ' CB ' HD11 ' A' ' 102' ' ' LEU . 33.6 mmm -84.14 -28.55 27.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.254 -0.904 . . . . 0.0 109.427 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.593 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.88 -53.89 1.42 Allowed Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.465 -0.772 . . . . 0.0 109.903 -179.913 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -69.65 -28.2 26.05 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.496 2.13 . . . . 0.0 111.707 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.484 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 29.2 mm -80.69 -42.63 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.262 -0.898 . . . . 0.0 109.317 179.667 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.696 HD23 ' CD2' ' A' ' 107' ' ' LEU . 0.9 OUTLIER -67.73 -40.13 84.23 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.311 -0.868 . . . . 0.0 109.214 179.76 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -63.77 -50.72 67.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.337 -0.852 . . . . 0.0 109.096 179.709 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.935 HD21 ' O ' ' A' ' 45' ' ' ARG . 0.4 OUTLIER -71.82 -36.46 70.23 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.387 -0.821 . . . . 0.0 109.366 179.598 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.56 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -70.29 -0.41 8.0 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.277 -0.889 . . . . 0.0 109.995 -179.838 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 77.38 8.75 87.07 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.696 ' CD2' HD23 ' A' ' 102' ' ' LEU . 9.9 mp -74.94 -19.17 60.23 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -1.177 . . . . 0.0 109.509 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -130.73 142.53 50.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.937 . . . . 0.0 109.544 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -114.19 122.52 47.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.224 -0.923 . . . . 0.0 109.621 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.483 ' OH ' ' HA ' ' A' ' 135' ' ' PRO . 28.2 p90 -150.78 162.28 41.03 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.344 -0.847 . . . . 0.0 109.441 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 79.8 mt-10 -101.81 -94.35 0.29 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.496 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.412 ' O ' ' CB ' ' A' ' 113' ' ' LYS . 8.3 mt-10 45.57 85.77 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.263 -0.898 . . . . 0.0 109.634 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.412 ' CB ' ' O ' ' A' ' 112' ' ' GLU . 2.9 tttt 170.21 -29.05 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.348 -0.845 . . . . 0.0 109.516 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 8.0 mttm -65.85 -19.47 65.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.205 -0.934 . . . . 0.0 109.377 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.94 112.72 27.1 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.171 -0.956 . . . . 0.0 109.571 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.31 133.8 25.39 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.712 2.275 . . . . 0.0 111.649 179.731 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 2.5 p -143.38 128.46 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.172 -0.955 . . . . 0.0 109.825 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 41.1 mttm -120.53 131.61 54.78 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.337 -0.852 . . . . 0.0 109.307 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.515 ' O ' ' HG ' ' A' ' 121' ' ' LEU . 6.0 m -138.31 -162.27 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.295 -0.878 . . . . 0.0 109.283 -179.741 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.649 ' O ' ' HB2' ' A' ' 121' ' ' LEU . 16.2 tt0 -44.66 -74.48 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.106 -0.996 . . . . 0.0 108.813 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.774 HD22 HG22 ' A' ' 170' ' ' VAL . 43.6 mt 76.34 168.41 0.26 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.372 -0.83 . . . . 0.0 110.36 179.134 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 50.64 62.38 5.26 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.614 ' CE2' ' HB3' ' A' ' 175' ' ' LYS . 0.2 OUTLIER -77.13 -174.9 3.38 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.318 -1.107 . . . . 0.0 108.431 178.63 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.435 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 40.0 mttm -97.22 156.34 16.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.95 -1.094 . . . . 0.0 109.531 -179.652 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 11.0 p -58.39 138.6 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.469 -0.77 . . . . 0.0 109.938 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.99 -31.89 4.84 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.561 ' HB3' ' CD2' ' A' ' 123' ' ' PHE . 45.3 m-20 -48.92 160.33 0.2 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.3 -1.118 . . . . 0.0 109.552 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 2.3 ttp -97.25 127.29 43.08 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.33 -0.857 . . . . 0.0 109.026 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.587 HG13 HG12 ' A' ' 143' ' ' ILE . 33.9 m -128.84 146.25 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.115 -0.99 . . . . 0.0 109.834 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.545 ' CB ' HG12 ' A' ' 176' ' ' ILE . 28.4 tttt -110.29 140.28 44.62 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.592 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 1.007 ' O ' HD13 ' A' ' 132' ' ' ILE . 74.6 mt -79.61 157.76 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.049 -1.032 . . . . 0.0 108.641 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 1.007 HD13 ' O ' ' A' ' 131' ' ' ILE . 0.6 OUTLIER -149.51 1.96 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.03 -1.043 . . . . 0.0 109.526 179.786 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.479 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 58.5 m -149.65 146.16 27.13 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.011 -1.055 . . . . 0.0 110.232 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.447 ' C ' ' HH ' ' A' ' 110' ' ' TYR . . . 102.99 -167.05 16.78 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.346 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.483 ' HA ' ' OH ' ' A' ' 110' ' ' TYR . 46.0 Cg_endo -68.08 -21.9 42.11 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 123.135 2.557 . . . . 0.0 112.524 -179.555 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.561 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 97.2 m-85 -110.29 16.31 21.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.006 -1.059 . . . . 0.0 109.578 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.581 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.3 tt0 -43.29 143.94 0.78 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.235 -0.915 . . . . 0.0 109.641 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 26.9 m-20 72.73 28.12 2.14 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.459 -0.776 . . . . 0.0 110.234 179.406 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.994 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.3 t80 -117.82 128.77 55.18 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.115 -0.991 . . . . 0.0 109.444 179.739 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.489 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -76.53 131.54 39.03 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.157 -0.965 . . . . 0.0 109.746 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -139.53 165.77 25.72 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.786 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.649 ' C ' HG23 ' A' ' 155' ' ' VAL . 37.5 t -113.34 137.53 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -1.088 . . . . 0.0 109.063 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.869 HD12 ' CD2' ' A' ' 153' ' ' LEU . 14.7 mm -68.67 113.86 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.214 -0.929 . . . . 0.0 109.611 -179.822 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.91 -35.46 8.99 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.056 -1.027 . . . . 0.0 109.421 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.401 ' HG2' ' N ' ' A' ' 146' ' ' ILE . 81.9 tt0 -154.17 149.29 26.89 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.967 -1.083 . . . . 0.0 109.924 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.82 HG23 ' CD1' ' A' ' 153' ' ' LEU . 11.3 mt -126.16 128.46 71.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.418 -0.802 . . . . 0.0 109.332 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -110.4 101.73 49.31 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.533 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.586 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.47 172.81 13.5 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.621 2.214 . . . . 0.0 111.801 179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.586 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.6 tt0 82.4 -20.48 0.35 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.405 -0.809 . . . . 0.0 109.795 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.481 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 96.6 mtt180 -129.99 -11.54 4.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.129 -0.982 . . . . 0.0 109.684 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.481 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 19.8 mt-30 70.12 48.53 0.52 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.222 -0.924 . . . . 0.0 109.438 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.706 ' OE2' HG23 ' A' ' 167' ' ' VAL . 53.9 tt0 -121.35 144.24 48.76 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.156 -0.965 . . . . 0.0 109.319 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.869 ' CD2' HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -138.1 112.47 8.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.235 -0.916 . . . . 0.0 109.884 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.493 ' NZ ' ' OE2' ' A' ' 152' ' ' GLU . 10.2 mttm -78.54 131.73 36.9 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.309 -0.869 . . . . 0.0 108.677 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.839 HG12 HD21 ' A' ' 168' ' ' LEU . 9.2 p -123.2 151.98 27.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.235 -0.915 . . . . 0.0 109.517 -179.594 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.476 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 17.9 t-20 -98.18 112.3 24.32 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.357 -0.839 . . . . 0.0 109.648 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.668 HG22 ' O ' ' A' ' 164' ' ' THR . 3.2 m -93.15 139.88 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.254 -0.904 . . . . 0.0 109.291 179.701 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 53.1 m -98.46 88.65 4.18 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.08 -1.013 . . . . 0.0 109.701 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.762 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 2.0 mt -114.24 145.55 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.276 -0.89 . . . . 0.0 109.309 179.78 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.431 ' HD2' ' CE1' ' A' ' 56' ' ' PHE . 9.9 m-85 62.23 38.31 13.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.418 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.64 18.06 29.59 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 42.4 mtt-85 -130.1 156.49 44.45 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.171 -1.194 . . . . 0.0 109.553 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -96.68 130.09 43.97 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.364 -0.835 . . . . 0.0 109.55 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 164' ' ' THR . . . . . 0.668 ' O ' HG22 ' A' ' 157' ' ' VAL . 97.8 m -137.07 120.1 11.7 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.937 . . . . 0.0 109.76 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -71.1 137.28 31.26 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.712 2.275 . . . . 0.0 111.549 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.822 HG13 ' CD2' ' A' ' 168' ' ' LEU . 2.6 p -128.41 147.24 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.168 -0.958 . . . . 0.0 109.878 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.72 HG11 HH11 ' A' ' 50' ' ' ARG . 2.4 p -93.12 120.15 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.419 -0.801 . . . . 0.0 109.457 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.898 ' CD1' HG11 ' A' ' 173' ' ' VAL . 0.1 OUTLIER -141.84 167.14 22.86 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.322 -0.861 . . . . 0.0 110.585 -179.25 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.511 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 40.4 m170 -79.82 142.22 35.49 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.774 HG22 HD22 ' A' ' 121' ' ' LEU . 3.4 p -58.72 -36.82 62.39 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 O-C-N 121.256 -0.902 . . . . 0.0 109.048 179.71 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 19.8 m -75.34 -7.61 54.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.42 -0.8 . . . . 0.0 109.415 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.511 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 65.5 mt-10 -90.33 5.39 47.52 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.33 -0.856 . . . . 0.0 109.307 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.898 HG11 ' CD1' ' A' ' 168' ' ' LEU . 18.1 m -146.6 173.06 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.344 -0.848 . . . . 0.0 109.582 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.514 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 78.1 tt0 -142.08 168.56 19.45 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.3 -0.875 . . . . 0.0 109.132 179.767 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.614 ' HB3' ' CE2' ' A' ' 123' ' ' PHE . 42.0 mttt -87.24 21.16 2.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.766 -179.689 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.558 HG22 ' HG3' ' A' ' 177' ' ' GLU . 50.2 mt 60.38 146.81 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.164 -0.96 . . . . 0.0 109.565 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.558 ' HG3' HG22 ' A' ' 176' ' ' ILE . 96.2 mt-10 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.997 -1.001 . . . . 0.0 109.556 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -60.37 -29.52 68.98 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.246 -1.149 . . . . 0.0 109.487 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 64.9 mtt -60.48 -29.26 68.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.225 -0.922 . . . . 0.0 109.53 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 83.5 tttt -140.92 120.25 13.05 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.328 -0.857 . . . . 0.0 109.42 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.49 ' HG2' ' CG2' ' A' ' 65' ' ' ILE . 19.4 mttt -87.38 167.06 14.36 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.141 -0.975 . . . . 0.0 109.491 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.552 ' CE ' ' HB3' ' A' ' 92' ' ' PRO . 28.0 mtpp -128.32 175.19 8.67 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.249 -0.907 . . . . 0.0 109.065 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.958 ' CH2' HG23 ' A' ' 41' ' ' VAL . 63.7 m95 -112.91 124.19 52.05 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.19 -0.943 . . . . 0.0 109.149 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 67.3 m-85 -117.06 168.43 10.27 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.348 -0.845 . . . . 0.0 109.346 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.735 HD11 ' CE1' ' A' ' 160' ' ' PHE . 75.1 mt -110.5 109.72 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.193 -0.942 . . . . 0.0 109.017 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.544 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 12.8 p -86.35 143.96 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.21 -0.931 . . . . 0.0 109.547 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.538 HD11 ' HE1' ' A' ' 59' ' ' TYR . 0.5 OUTLIER -90.28 143.09 27.08 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.441 -0.787 . . . . 0.0 109.395 -179.932 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.454 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 2.4 p -154.19 174.92 14.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.405 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.447 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 93.4 mtp -91.89 120.32 32.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.23 -0.919 . . . . 0.0 109.329 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 13' ' ' MET . 52.0 p -41.68 126.97 3.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.365 -0.835 . . . . 0.0 109.504 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.63 -19.98 35.22 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.447 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.0 m-85 -107.4 -13.9 14.99 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.266 -1.137 . . . . 0.0 109.632 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.453 ' HG2' ' CG2' ' A' ' 60' ' ' VAL . 95.1 mt-10 -43.08 -60.42 1.65 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.245 -0.909 . . . . 0.0 109.603 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 73.9 mm-40 -48.17 -34.35 9.87 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.13 -0.981 . . . . 0.0 109.523 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.468 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 56.9 mttp -76.32 -46.74 26.27 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.27 -0.894 . . . . 0.0 109.346 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.583 HG13 HG23 ' A' ' 80' ' ' VAL . 24.9 t -54.92 -47.58 75.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.308 -0.87 . . . . 0.0 109.472 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.539 ' HG3' HG21 ' A' ' 40' ' ' ILE . 79.0 tttt -59.42 -47.78 84.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.427 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -64.28 -34.89 79.16 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.303 -0.873 . . . . 0.0 109.448 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.581 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 32.6 m120 -66.53 -47.47 72.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.367 -0.833 . . . . 0.0 109.745 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.556 HG12 HG21 ' A' ' 77' ' ' VAL . 76.5 mt -55.71 -43.86 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.187 -0.946 . . . . 0.0 109.745 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -58.15 -44.8 88.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.156 -0.965 . . . . 0.0 109.901 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.3 mttt -74.92 -36.87 62.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.13 -0.981 . . . . 0.0 109.686 -179.788 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.707 ' HD2' HG23 ' A' ' 77' ' ' VAL . 17.6 tttt -59.28 -30.62 68.44 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -0.929 . . . . 0.0 109.393 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.674 HG13 ' O ' ' A' ' 33' ' ' ILE . 93.9 t -79.21 -30.15 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.195 -0.941 . . . . 0.0 109.413 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -65.82 -48.16 72.61 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.23 -0.919 . . . . 0.0 109.563 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.97 -34.63 75.07 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 109.859 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.636 HG23 ' H ' ' A' ' 33' ' ' ILE . 9.6 t -92.56 -21.73 19.92 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 68.27 33.1 77.15 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.686 ' CG2' HD23 ' A' ' 36' ' ' LEU . 47.9 mm -100.43 91.49 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.245 -1.15 . . . . 0.0 109.598 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -98.54 2.91 47.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.318 -0.864 . . . . 0.0 109.5 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.693 ' C ' HD22 ' A' ' 36' ' ' LEU . 89.8 m-20 -105.39 9.97 33.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.22 -0.925 . . . . 0.0 109.477 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.986 HD12 ' HB2' ' A' ' 70' ' ' ALA . 4.1 mm? -114.24 -46.69 2.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.936 . . . . 0.0 109.473 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 58.7 t -105.34 134.24 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.247 -0.908 . . . . 0.0 109.41 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -98.93 -131.27 7.22 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 46.3 mtt85 -91.93 142.02 28.01 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.265 -1.138 . . . . 0.0 109.522 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.91 HG23 HG12 ' A' ' 62' ' ' VAL . 53.6 mt -98.66 133.88 39.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.267 -0.896 . . . . 0.0 109.305 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 1.05 ' CG2' HD11 ' A' ' 107' ' ' LEU . 40.1 t -115.97 155.38 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.253 -0.904 . . . . 0.0 109.495 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.809 HG22 ' H ' ' A' ' 44' ' ' ILE . 18.2 mt -133.01 126.84 19.85 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.22 -0.925 . . . . 0.0 109.525 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.884 ' O ' HD12 ' A' ' 55' ' ' LEU . 46.9 Cg_endo -68.18 -4.75 13.27 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.725 2.284 . . . . 0.0 111.722 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.809 ' H ' HG22 ' A' ' 42' ' ' ILE . 20.7 mt -79.34 135.22 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.209 -0.932 . . . . 0.0 109.459 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.421 ' NH2' ' OG ' ' A' ' 52' ' ' SER . 14.3 ptt180 -112.56 -2.39 14.62 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.278 -0.889 . . . . 0.0 109.539 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 72.54 33.32 61.08 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -45.1 135.17 7.31 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -61.22 -32.11 71.89 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.208 -1.172 . . . . 0.0 109.467 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.405 ' NE ' ' HB2' ' A' ' 51' ' ' LYS . 77.5 ttt180 -71.74 118.71 14.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.9 . . . . 0.0 109.513 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 41.0 ttp180 -60.56 -31.49 70.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.274 -0.891 . . . . 0.0 109.441 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' LYS . . . . . 0.405 ' HB2' ' NE ' ' A' ' 49' ' ' ARG . 30.9 mttm -68.84 -17.44 64.0 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.191 -0.943 . . . . 0.0 109.475 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.421 ' OG ' ' NH2' ' A' ' 45' ' ' ARG . 14.2 t -123.31 89.18 3.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.233 -0.917 . . . . 0.0 109.582 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.489 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 32.8 tt0 -139.96 128.53 22.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.654 ' HG2' HD13 ' A' ' 44' ' ' ILE . 37.5 mttp 74.25 106.4 0.07 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.232 -0.917 . . . . 0.0 109.337 -179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.884 HD12 ' O ' ' A' ' 43' ' ' PRO . 8.6 mt -61.31 -23.37 65.66 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.117 -0.99 . . . . 0.0 109.563 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.553 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 42.6 m-85 -151.06 100.18 3.05 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.167 -0.958 . . . . 0.0 109.069 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.7 Cg_endo -66.17 141.91 65.16 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.672 2.248 . . . . 0.0 111.906 -179.639 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.402 ' N ' ' OE2' ' A' ' 17' ' ' GLU . . . 75.26 -12.26 7.43 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.538 ' HE1' HD11 ' A' ' 11' ' ' LEU . 3.5 m-30 -103.38 130.9 50.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.789 -1.418 . . . . 0.0 109.942 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.544 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 3.0 t -132.49 146.24 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.215 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.694 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 14.9 m-85 -107.04 122.9 47.37 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.892 -1.13 . . . . 0.0 109.952 -179.391 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.91 HG12 HG23 ' A' ' 40' ' ' ILE . 30.0 m -129.77 139.94 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.43 -0.794 . . . . 0.0 109.48 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.505 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 48.3 tt0 -88.63 124.47 34.1 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.235 -0.916 . . . . 0.0 108.676 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.669 ' SD ' HG21 ' A' ' 74' ' ' VAL . 3.9 mtm -147.0 160.68 42.07 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.013 -1.054 . . . . 0.0 110.784 -178.78 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.525 HD11 HD13 ' A' ' 36' ' ' LEU . 26.9 pt -104.28 139.67 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.904 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' MET . . . . . . . . . . . . . 38.3 mtp -74.33 136.45 42.55 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.971 -1.081 . . . . 0.0 110.16 -178.432 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -178.47 155.3 0.85 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -61.78 -42.46 99.02 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.183 -0.948 . . . . 0.0 109.807 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 54.6 mt-10 -75.76 -25.23 56.29 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.852 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.986 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -78.05 -47.19 18.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.122 -0.987 . . . . 0.0 109.578 -179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.575 ' CE1' ' OE1' ' A' ' 89' ' ' GLN . 65.1 t80 -61.93 -45.35 94.09 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.289 -0.882 . . . . 0.0 109.926 -179.674 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 48.2 t-20 -70.25 -29.3 66.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.096 -1.002 . . . . 0.0 110.381 -179.348 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.52 ' O ' ' NZ ' ' A' ' 27' ' ' LYS . 83.8 t80 -76.84 -39.51 50.96 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.966 -1.084 . . . . 0.0 109.55 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.669 HG21 ' SD ' ' A' ' 64' ' ' MET . 2.4 p -75.48 -48.66 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.352 -0.843 . . . . 0.0 109.516 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.593 ' N ' ' CG1' ' A' ' 74' ' ' VAL . 0.0 OUTLIER -58.64 -21.09 52.91 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.212 -0.93 . . . . 0.0 109.86 -179.689 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.6 m -95.9 5.53 51.03 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.116 -0.99 . . . . 0.0 109.837 -179.631 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.707 HG23 ' HD2' ' A' ' 27' ' ' LYS . 3.6 p -68.26 132.93 91.48 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.05 -1.031 . . . . 0.0 109.301 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.734 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 44.3 Cg_endo -65.87 136.07 43.75 Favored 'Trans proline' 0 C--O 1.213 -0.763 0 C-N-CA 122.821 2.347 . . . . 0.0 112.369 -179.294 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.734 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 76.3 m-85 91.17 -6.89 0.26 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.95 -0.469 . . . . 0.0 109.844 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.687 HG21 HG11 ' A' ' 77' ' ' VAL . 3.1 t -98.0 135.93 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.928 -1.107 . . . . 0.0 109.309 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 88.9 mmm -96.6 -24.6 15.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.294 -0.879 . . . . 0.0 109.704 -179.772 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.55 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 159.89 -159.88 31.05 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.573 ' HZ ' HG22 ' A' ' 74' ' ' VAL . 9.4 m-85 -137.44 148.22 45.95 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.322 -1.105 . . . . 0.0 109.519 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.52 ' O ' HG13 ' A' ' 84' ' ' VAL . 9.2 p -72.58 128.12 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.232 -0.918 . . . . 0.0 109.387 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.545 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 5.0 p -160.66 166.09 29.45 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.55 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 m -91.27 -30.27 16.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.296 -0.877 . . . . 0.0 109.164 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -134.17 -83.47 0.2 Allowed Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.531 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -102.88 -137.7 9.65 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.575 ' OE1' ' CE1' ' A' ' 71' ' ' TYR . 0.3 OUTLIER -32.79 154.66 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.566 -0.961 . . . . 0.0 110.15 -179.53 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.545 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 46.6 Cg_endo -67.58 151.05 80.03 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.83 2.353 . . . . 0.0 111.946 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.3 m -83.26 151.68 63.28 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.552 ' HB3' ' CE ' ' A' ' 6' ' ' LYS . 51.2 Cg_endo -70.24 144.5 51.63 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.632 2.221 . . . . 0.0 111.796 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.565 HG12 ' HG3' ' A' ' 98' ' ' MET . 21.4 t -82.0 127.21 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.191 -0.943 . . . . 0.0 109.301 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -67.78 140.37 56.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.242 -0.911 . . . . 0.0 109.417 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -49.76 -40.83 42.39 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.47 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 39.2 ttm180 -57.4 -30.47 64.94 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.309 -0.87 . . . . 0.0 109.569 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 52.7 mt-10 -85.8 -27.79 24.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.156 -0.965 . . . . 0.0 109.493 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.591 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 93.2 mtp -82.33 -25.82 33.54 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.286 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.612 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 2.4 mtt180 -37.11 -52.65 2.14 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.434 -0.791 . . . . 0.0 109.935 -179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.612 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.1 Cg_endo -69.78 -28.79 24.7 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.499 2.133 . . . . 0.0 111.897 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.558 HG21 ' CD2' ' A' ' 61' ' ' PHE . 38.2 mm -81.47 -43.08 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.206 -0.934 . . . . 0.0 109.56 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.627 HD23 HD12 ' A' ' 107' ' ' LEU . 0.9 OUTLIER -66.76 -39.91 88.04 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 0.0 109.264 179.819 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 48.2 mtt-85 -64.06 -49.95 70.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.341 -0.849 . . . . 0.0 109.104 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.465 HD22 ' CD1' ' A' ' 55' ' ' LEU . 1.1 tt -72.09 -35.81 69.31 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.268 -0.895 . . . . 0.0 109.231 179.529 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.443 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.53 -2.01 12.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.352 -0.842 . . . . 0.0 109.897 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.83 10.43 84.98 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.706 -1.358 . . . . 0.0 109.706 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 1.05 HD11 ' CG2' ' A' ' 41' ' ' VAL . 18.5 mt -78.18 -21.51 50.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.212 -1.17 . . . . 0.0 109.542 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.401 ' HG3' ' CB ' ' A' ' 102' ' ' LEU . 84.5 mt-10 -115.53 158.23 22.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.654 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -102.81 120.25 40.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.294 -0.879 . . . . 0.0 109.43 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.43 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 23.5 p90 -148.95 162.81 39.14 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.233 -0.917 . . . . 0.0 109.515 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.43 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 51.0 mm-40 -101.03 -148.01 0.36 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.326 -0.859 . . . . 0.0 109.447 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.619 ' O ' ' C ' ' A' ' 113' ' ' LYS . 62.7 tt0 -125.48 153.52 43.41 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.2 -0.937 . . . . 0.0 109.373 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.619 ' C ' ' O ' ' A' ' 112' ' ' GLU . 0.0 OUTLIER 20.91 93.58 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.669 -0.644 . . . . 0.0 110.522 179.768 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.418 ' O ' ' HD2' ' A' ' 115' ' ' LYS . 0.3 OUTLIER -54.41 -31.77 55.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.227 -0.92 . . . . 0.0 109.211 179.704 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.419 ' HB3' ' HE2' ' A' ' 115' ' ' LYS . 12.1 mmmm -114.68 115.24 44.17 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.401 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.95 -5.2 15.77 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.715 2.277 . . . . 0.0 111.829 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 9.2 t -72.99 133.65 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.875 . . . . 0.0 109.513 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -71.06 160.59 32.62 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.272 -0.892 . . . . 0.0 109.452 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 55.5 t -132.87 150.15 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.127 -0.983 . . . . 0.0 109.556 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.667 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 92.5 mt-10 -142.85 -172.69 3.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.304 -0.872 . . . . 0.0 109.442 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.667 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 2.3 mt 145.82 108.84 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.622 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -20.97 94.61 0.01 OUTLIER Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.481 ' N ' ' O ' ' A' ' 121' ' ' LEU . 0.7 OUTLIER -107.32 145.87 32.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.228 -1.16 . . . . 0.0 109.581 179.995 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 22.9 mttt -141.5 162.62 35.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.318 -0.864 . . . . 0.0 109.534 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 15.2 m -61.4 141.62 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.747 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 86.85 -33.81 3.68 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -47.96 158.74 0.21 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.351 -1.088 . . . . 0.0 109.198 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.3 ttm -100.94 128.5 46.95 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.084 -1.01 . . . . 0.0 108.752 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.652 HG13 HG12 ' A' ' 143' ' ' ILE . 16.0 m -129.22 144.8 37.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.337 -0.852 . . . . 0.0 109.878 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.55 ' CB ' HG12 ' A' ' 176' ' ' ILE . 10.6 tttp -97.93 140.64 31.98 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.406 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.65 HG22 ' HA ' ' A' ' 137' ' ' GLU . 1.2 mp -80.72 153.55 4.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.353 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.532 ' CD1' ' HB2' ' A' ' 174' ' ' GLU . 0.9 OUTLIER -149.3 2.45 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 120.793 -1.192 . . . . 0.0 109.841 -179.791 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.547 ' CB ' ' HG3' ' A' ' 172' ' ' GLU . 61.1 m -149.25 145.35 27.05 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.004 -1.06 . . . . 0.0 110.212 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 103.46 -166.74 16.18 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.511 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 48.3 Cg_endo -68.41 -21.12 41.17 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.199 2.599 . . . . 0.0 112.53 -179.614 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.521 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 92.3 m-85 -108.35 18.72 20.7 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.907 -1.121 . . . . 0.0 109.377 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.65 ' HA ' HG22 ' A' ' 131' ' ' ILE . 3.7 tt0 -42.61 140.61 1.23 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.261 -0.899 . . . . 0.0 109.711 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 22.4 m-20 72.67 29.79 1.93 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.406 -0.809 . . . . 0.0 110.727 179.147 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.612 ' CE1' HG23 ' A' ' 157' ' ' VAL . 1.2 t80 -117.85 133.27 56.09 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.838 -1.164 . . . . 0.0 109.399 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.92 134.75 36.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.213 -0.93 . . . . 0.0 109.724 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.47 169.68 26.98 Favored Glycine 0 N--CA 1.491 2.306 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.329 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.796 ' C ' HG23 ' A' ' 155' ' ' VAL . 43.6 t -119.43 136.4 56.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.567 -0.96 . . . . 0.0 109.281 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.652 HG12 HG13 ' A' ' 129' ' ' VAL . 31.7 mm -68.82 119.58 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.63 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.479 ' HD2' ' OD1' ' A' ' 156' ' ' ASN . 63.9 tttt -99.81 -33.26 10.63 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.054 -1.029 . . . . 0.0 109.527 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -154.32 149.48 26.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.123 -0.986 . . . . 0.0 109.656 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 1.029 HG23 HD22 ' A' ' 153' ' ' LEU . 3.6 mt -123.9 126.55 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.321 -0.862 . . . . 0.0 109.575 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.22 102.39 46.25 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.239 -0.913 . . . . 0.0 109.589 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.0 Cg_endo -71.99 170.96 17.66 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.749 2.299 . . . . 0.0 111.866 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.3 mt-10 79.44 -21.23 0.34 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.395 -0.815 . . . . 0.0 110.057 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.446 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 75.6 mtt-85 -125.74 -14.99 6.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.063 -1.023 . . . . 0.0 109.478 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.446 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 50.8 mt-30 69.56 48.64 0.6 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.187 -0.946 . . . . 0.0 109.67 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.816 ' O ' HD23 ' A' ' 153' ' ' LEU . 82.5 tt0 -119.07 143.25 47.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.174 -0.954 . . . . 0.0 108.968 179.626 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 1.029 HD22 HG23 ' A' ' 146' ' ' ILE . 32.3 mt -128.77 127.55 42.22 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.1 -1.0 . . . . 0.0 110.291 -179.469 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -92.03 128.67 37.96 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.077 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.796 HG23 ' C ' ' A' ' 142' ' ' VAL . 12.9 p -131.39 147.93 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.084 -1.01 . . . . 0.0 109.834 -179.496 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.588 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.8 m120 -100.85 125.09 47.35 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.413 -0.804 . . . . 0.0 109.552 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.653 HG22 HG13 ' A' ' 159' ' ' ILE . 3.3 p -105.74 144.8 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.921 . . . . 0.0 109.476 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 55.7 m -97.33 92.48 6.0 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.895 . . . . 0.0 109.928 -179.664 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.653 HG13 HG22 ' A' ' 157' ' ' VAL . 7.4 mt -116.03 142.96 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.258 -0.901 . . . . 0.0 109.237 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.735 ' CE1' HD11 ' A' ' 9' ' ' ILE . 91.0 m-85 61.88 37.15 15.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.185 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.6 17.92 35.79 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 26.2 mtp180 -126.88 157.39 39.48 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.067 -1.254 . . . . 0.0 109.555 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -100.91 132.03 46.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.277 -0.889 . . . . 0.0 109.728 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.2 m -142.47 127.06 10.02 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.37 -0.831 . . . . 0.0 109.743 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.588 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.1 Cg_endo -70.91 136.67 30.48 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.748 2.299 . . . . 0.0 111.616 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.743 HG12 HG13 ' A' ' 155' ' ' VAL . 11.7 p -119.64 164.65 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.087 -1.008 . . . . 0.0 109.706 -179.817 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.533 ' O ' HD23 ' A' ' 168' ' ' LEU . 6.7 m -117.53 117.65 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.459 -0.776 . . . . 0.0 109.66 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.641 HD21 ' CG2' ' A' ' 166' ' ' VAL . 0.2 OUTLIER -142.24 167.33 22.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.241 -0.912 . . . . 0.0 110.207 -179.779 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.504 ' HB2' ' CD ' ' A' ' 172' ' ' GLU . 19.2 m170 -82.7 146.37 29.08 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.576 HG23 HD11 ' A' ' 153' ' ' LEU . 7.1 p -56.32 -32.73 36.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 121.422 -0.798 . . . . 0.0 109.314 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 73.5 p -76.86 -7.06 54.79 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.275 -0.891 . . . . 0.0 109.762 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.547 ' HG3' ' CB ' ' A' ' 133' ' ' SER . 0.8 OUTLIER -95.53 2.8 54.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.067 -1.021 . . . . 0.0 109.376 -179.991 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.516 HG12 ' N ' ' A' ' 174' ' ' GLU . 43.5 t -139.78 164.84 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 109.281 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.539 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 54.8 tt0 -141.22 167.16 22.85 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.087 -1.008 . . . . 0.0 108.928 179.73 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.539 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 32.7 tttp -93.9 28.83 2.27 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.058 -1.027 . . . . 0.0 109.476 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.55 HG12 ' CB ' ' A' ' 130' ' ' LYS . 53.2 mt 48.27 96.61 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.284 -0.885 . . . . 0.0 109.52 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.476 -179.982 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -58.95 -35.12 72.6 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.252 -1.146 . . . . 0.0 109.413 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 88.8 mtp -59.56 -26.37 65.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.282 -0.886 . . . . 0.0 109.387 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 18.4 mttt -110.72 128.72 55.84 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.282 -0.886 . . . . 0.0 109.292 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.467 ' O ' ' HD3' ' A' ' 6' ' ' LYS . 27.5 mttt -111.61 163.01 14.56 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.192 -0.942 . . . . 0.0 109.61 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 36.0 mmtm -132.07 169.26 16.62 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.355 -0.841 . . . . 0.0 109.339 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.954 ' CZ3' HG22 ' A' ' 41' ' ' VAL . 68.1 m95 -103.39 129.21 50.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.255 -0.903 . . . . 0.0 109.235 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -118.47 170.33 9.02 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.22 -0.925 . . . . 0.0 109.143 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.756 HD11 ' CE1' ' A' ' 160' ' ' PHE . 22.7 mt -103.85 112.78 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.122 -0.986 . . . . 0.0 109.268 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.489 HG23 HG22 ' A' ' 62' ' ' VAL . 73.5 t -86.18 142.31 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.228 -0.92 . . . . 0.0 109.343 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.532 HD21 HG22 ' A' ' 84' ' ' VAL . 0.6 OUTLIER -93.45 142.04 27.78 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.363 -0.836 . . . . 0.0 109.416 179.904 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.726 HG21 ' HG2' ' A' ' 17' ' ' GLU . 7.0 t -160.44 -173.33 3.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.431 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.426 ' O ' ' C ' ' A' ' 14' ' ' SER . 89.1 mtp -109.18 122.46 47.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.213 -0.93 . . . . 0.0 109.47 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.426 ' C ' ' O ' ' A' ' 13' ' ' MET . 2.2 m -44.3 133.87 5.26 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.259 -0.901 . . . . 0.0 109.443 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.0 -21.37 36.09 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -113.01 -7.99 13.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.25 -1.147 . . . . 0.0 109.355 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.862 ' OE1' HD11 ' A' ' 44' ' ' ILE . 57.3 mt-10 -48.12 -59.96 2.99 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.212 -0.93 . . . . 0.0 109.442 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -45.7 -34.57 3.64 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.187 -0.946 . . . . 0.0 109.37 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.46 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 25.1 mttt -73.68 -43.72 58.58 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.276 -0.89 . . . . 0.0 109.377 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.425 HG22 ' HB2' ' A' ' 79' ' ' TYR . 92.4 t -56.76 -50.0 76.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.317 -0.864 . . . . 0.0 109.535 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' LYS . . . . . 0.666 ' HD2' HD11 ' A' ' 42' ' ' ILE . 24.8 tttt -56.24 -46.95 79.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.911 . . . . 0.0 109.145 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 69.7 tt0 -65.27 -38.81 91.44 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.341 -0.849 . . . . 0.0 109.433 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.529 ' O ' ' CB ' ' A' ' 27' ' ' LYS . 32.6 m120 -62.29 -43.12 99.56 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.241 -0.912 . . . . 0.0 110.045 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.793 HD11 HG11 ' A' ' 77' ' ' VAL . 49.4 mm -64.69 -44.99 96.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.127 -0.983 . . . . 0.0 109.738 -179.537 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.566 ' O ' HG12 ' A' ' 28' ' ' VAL . 77.8 tt0 -58.7 -46.91 86.24 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.164 -0.96 . . . . 0.0 109.96 -179.63 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -82.27 -37.35 26.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.993 -1.067 . . . . 0.0 109.712 -179.724 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.529 ' CB ' ' O ' ' A' ' 23' ' ' ASN . 28.2 tttm -57.22 -30.36 64.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.283 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.697 HG21 HG12 ' A' ' 37' ' ' VAL . 12.3 p -85.43 -26.38 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.296 -0.878 . . . . 0.0 109.555 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 -67.31 -47.45 70.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.324 -0.86 . . . . 0.0 109.716 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.67 -31.24 66.13 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.176 -0.952 . . . . 0.0 109.548 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 58.8 p -90.06 -21.66 22.21 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.916 . . . . 0.0 109.575 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 78.03 -2.92 63.2 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.871 HG23 HD23 ' A' ' 36' ' ' LEU . 31.2 mm -72.71 71.33 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -1.123 . . . . 0.0 109.268 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 32.5 pttt -85.87 13.79 6.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.279 -0.888 . . . . 0.0 109.453 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.633 ' O ' HD13 ' A' ' 65' ' ' ILE . 29.7 m120 -110.37 -9.57 14.62 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.22 -0.925 . . . . 0.0 109.414 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 1.098 HD12 ' HB2' ' A' ' 70' ' ' ALA . 3.8 mm? -92.1 -51.5 5.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.309 -0.869 . . . . 0.0 109.297 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.697 HG12 HG21 ' A' ' 28' ' ' VAL . 13.7 p -92.03 141.89 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 108.956 179.672 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.96 -119.01 2.91 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 56.3 mtt180 -97.52 139.54 33.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.33 -1.1 . . . . 0.0 110.142 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 1.026 HG23 HG12 ' A' ' 62' ' ' VAL . 75.4 mt -111.55 134.34 54.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.427 -0.796 . . . . 0.0 109.088 179.522 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 1.03 HG23 ' HB2' ' A' ' 61' ' ' PHE . 29.8 m -123.8 148.77 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.005 -1.059 . . . . 0.0 109.311 179.803 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.666 HD11 ' HD2' ' A' ' 21' ' ' LYS . 1.8 mt -129.69 131.77 23.77 Favored Pre-proline 0 C--N 1.302 -1.486 0 O-C-N 121.346 -0.846 . . . . 0.0 109.703 -179.405 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.626 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 42.3 Cg_endo -64.61 -4.5 8.47 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.856 2.371 . . . . 0.0 111.285 179.7 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.868 HG23 ' HG2' ' A' ' 54' ' ' LYS . 39.5 mt -68.11 -42.04 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.459 -0.776 . . . . 0.0 109.519 179.589 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.433 ' C ' ' O ' ' A' ' 44' ' ' ILE . 84.0 mtt-85 -42.88 149.34 0.2 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.341 -0.849 . . . . 0.0 109.601 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -171.87 -159.48 18.26 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.25 131.05 41.83 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -58.32 -22.2 52.21 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.295 -1.121 . . . . 0.0 109.449 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 18.8 mtp180 -59.83 -24.52 64.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.126 -0.983 . . . . 0.0 109.322 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 66.7 mtm-85 -122.07 136.27 54.9 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.296 -0.877 . . . . 0.0 109.323 179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.2 tttt -59.56 168.89 1.45 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.276 -0.89 . . . . 0.0 109.458 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.51 ' HB3' ' CG2' ' A' ' 44' ' ' ILE . 0.9 OUTLIER -48.64 107.2 0.12 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.193 -0.942 . . . . 0.0 109.428 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.543 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 80.5 tt0 -86.22 -29.21 23.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.364 -0.835 . . . . 0.0 109.619 -179.889 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.868 ' HG2' HG23 ' A' ' 44' ' ' ILE . 0.2 OUTLIER 78.41 89.0 0.06 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.875 . . . . 0.0 109.389 -179.95 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.626 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 14.3 tp -55.4 -47.69 75.5 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.007 -1.058 . . . . 0.0 109.152 179.723 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.747 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 75.3 m-85 -130.56 106.08 15.76 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.35 -0.844 . . . . 0.0 108.79 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 40.6 Cg_endo -64.11 144.46 87.22 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.627 2.218 . . . . 0.0 112.022 -179.152 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.15 -20.21 2.62 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 110.56 -1.016 . . . . 0.0 110.56 179.516 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.5 m-30 -98.05 129.71 44.89 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.569 -1.548 . . . . 0.0 110.626 -178.789 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 59.8 t -131.61 143.34 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 1.03 ' HB2' HG23 ' A' ' 41' ' ' VAL . 27.2 m-85 -104.58 129.27 52.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.879 -1.138 . . . . 0.0 110.137 -179.041 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 1.026 HG12 HG23 ' A' ' 40' ' ' ILE . 34.5 m -138.99 149.44 23.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.329 -0.857 . . . . 0.0 109.849 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.644 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 83.9 tt0 -113.79 130.14 56.49 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.319 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.508 ' HE1' HG11 ' A' ' 74' ' ' VAL . 61.4 mtm -151.32 160.83 43.58 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.858 -1.151 . . . . 0.0 111.184 -178.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.753 ' CG1' HD13 ' A' ' 36' ' ' LEU . 1.4 pt -80.87 125.61 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.44 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.415 ' O ' ' CG ' ' A' ' 67' ' ' ASN . 50.5 ttm -77.24 142.7 39.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.191 -0.943 . . . . 0.0 110.115 -178.533 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.415 ' CG ' ' O ' ' A' ' 66' ' ' MET . 7.6 m-20 176.2 168.47 0.44 Allowed 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -65.85 -40.52 91.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.069 -1.019 . . . . 0.0 109.578 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -75.97 -34.31 59.8 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.93 . . . . 0.0 109.858 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 1.098 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -71.76 -48.36 47.34 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.209 -0.932 . . . . 0.0 109.733 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.743 ' CG ' ' NE2' ' A' ' 89' ' ' GLN . 83.4 t80 -60.79 -44.44 96.82 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.946 -179.574 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -69.97 -26.14 63.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -0.942 . . . . 0.0 110.037 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -80.11 -36.07 35.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.074 -1.016 . . . . 0.0 109.849 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 1.046 HG23 ' O ' ' A' ' 70' ' ' ALA . 3.3 t -67.58 -56.28 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.224 -0.923 . . . . 0.0 109.976 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -47.46 -37.02 10.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.063 -1.023 . . . . 0.0 110.211 -179.528 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 m -70.95 2.99 3.67 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.015 -1.053 . . . . 0.0 110.419 -179.37 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.793 HG11 HD11 ' A' ' 24' ' ' ILE . 38.8 t -64.12 134.6 96.0 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 120.941 -1.099 . . . . 0.0 109.237 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.521 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 47.5 Cg_endo -67.85 135.55 35.72 Favored 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 122.715 2.277 . . . . 0.0 111.987 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.521 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 17.3 m-85 78.45 -5.05 2.1 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.432 -0.792 . . . . 0.0 109.712 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.604 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.7 t -85.11 123.96 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.054 -1.029 . . . . 0.0 109.296 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' MET . . . . . 0.494 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 66.0 mtp -82.4 -30.68 30.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.335 -0.853 . . . . 0.0 109.343 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.411 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.11 -157.34 27.97 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 0.487 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 7.9 m-85 -133.64 137.42 45.39 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.258 -1.143 . . . . 0.0 109.5 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.532 HG22 HD21 ' A' ' 11' ' ' LEU . 38.2 t -60.11 131.69 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.894 . . . . 0.0 109.48 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.542 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.7 OUTLIER -168.98 159.81 9.6 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.191 -0.943 . . . . 0.0 109.562 179.995 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.58 -35.46 16.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.307 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.58 -85.16 0.58 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.576 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -108.78 -134.08 7.05 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.303 -1.519 . . . . 0.0 109.303 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.743 ' NE2' ' CG ' ' A' ' 71' ' ' TYR . 2.1 mp0 -26.55 145.01 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.593 -0.945 . . . . 0.0 110.551 -179.533 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.542 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.4 Cg_endo -69.31 146.45 63.01 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.896 2.398 . . . . 0.0 111.991 -179.746 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.3 m -80.83 149.2 66.82 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.391 -0.818 . . . . 0.0 109.277 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.71 145.71 58.28 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.666 2.244 . . . . 0.0 111.78 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.921 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.9 t -65.4 144.62 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.196 -0.94 . . . . 0.0 109.382 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' LYS . . . . . 0.419 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.4 mttm -82.29 133.16 35.23 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.177 -0.952 . . . . 0.0 109.411 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.403 ' C ' ' O ' ' A' ' 94' ' ' LYS . 90.8 m-20 -45.99 -44.76 15.29 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.201 -0.937 . . . . 0.0 109.314 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.494 ' HG2' ' O ' ' A' ' 96' ' ' ARG . 34.4 ttm180 -58.51 -18.24 27.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.574 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.419 ' N ' ' O ' ' A' ' 94' ' ' LYS . 26.5 mt-10 -100.65 -26.45 13.81 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.24 -0.912 . . . . 0.0 109.571 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.527 ' SD ' HG11 ' A' ' 93' ' ' VAL . 50.1 mmm -78.37 -34.61 48.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.939 . . . . 0.0 109.334 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.581 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 2.5 mtt180 -33.45 -54.58 0.71 Allowed Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.588 -0.695 . . . . 0.0 110.228 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.581 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.1 Cg_endo -69.8 -29.46 23.63 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.55 2.167 . . . . 0.0 112.219 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.537 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 19.9 mm -78.7 -44.83 25.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.098 -1.001 . . . . 0.0 109.886 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.61 ' HA ' HD12 ' A' ' 107' ' ' LEU . 1.0 OUTLIER -62.83 -43.02 99.9 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.111 -0.993 . . . . 0.0 109.705 -179.877 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.406 ' NH2' ' NH2' ' A' ' 99' ' ' ARG . 46.3 mtt180 -62.3 -52.73 62.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -71.46 -37.59 71.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.393 -0.817 . . . . 0.0 109.279 179.736 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -67.87 -3.97 11.33 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.358 -0.838 . . . . 0.0 109.952 -179.755 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 78.09 5.24 87.01 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.957 HD11 HG11 ' A' ' 41' ' ' VAL . 61.6 mt -71.46 -19.69 62.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -1.148 . . . . 0.0 109.657 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.422 ' HG3' ' HB3' ' A' ' 102' ' ' LEU . 83.9 mt-10 -128.63 154.73 45.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.223 -0.923 . . . . 0.0 109.517 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -112.2 115.86 29.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.545 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.474 ' OH ' ' HB3' ' A' ' 135' ' ' PRO . 15.3 p90 -137.12 160.27 39.48 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.261 -0.899 . . . . 0.0 109.372 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.402 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 44.6 mt-10 -99.33 -148.7 0.35 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.129 -0.982 . . . . 0.0 109.354 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 72.6 tt0 -121.6 145.45 47.97 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.142 -0.974 . . . . 0.0 109.478 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' LYS . . . . . 0.446 ' CD ' ' O ' ' A' ' 132' ' ' ILE . 0.8 OUTLIER -66.49 141.63 57.82 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.476 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.5 mttt -65.97 -35.05 79.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.357 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' LYS . . . . . 0.416 ' HD2' ' HA ' ' A' ' 115' ' ' LYS . 7.1 tptt 63.94 69.19 0.78 Allowed Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.288 -0.882 . . . . 0.0 109.457 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -71.16 -5.51 17.17 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.719 2.279 . . . . 0.0 111.79 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 19.2 m -125.27 148.62 29.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.212 -0.93 . . . . 0.0 109.603 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.479 ' O ' ' O ' ' A' ' 119' ' ' VAL . 60.0 mttp -101.81 139.8 36.96 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.296 179.825 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.61 ' HB ' ' CE2' ' A' ' 123' ' ' PHE . 3.1 m -43.65 168.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -0.884 . . . . 0.0 109.677 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.554 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 85.6 mt-10 -158.57 161.45 37.28 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.262 -0.899 . . . . 0.0 109.666 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.572 ' O ' ' C ' ' A' ' 122' ' ' GLY . 0.7 OUTLIER 80.21 95.93 0.05 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.369 -0.832 . . . . 0.0 109.678 179.834 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.572 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -26.42 94.34 0.01 OUTLIER Glycine 0 N--CA 1.494 2.563 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 179.632 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.61 ' CE2' ' HB ' ' A' ' 119' ' ' VAL . 22.0 m-30 -60.74 145.8 48.24 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.022 -1.281 . . . . 0.0 109.151 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 39.5 mttm -130.16 157.35 42.68 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 0.0 109.688 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 13.6 p -62.13 148.94 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.329 -0.857 . . . . 0.0 109.494 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.48 -30.37 3.1 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.666 -1.373 . . . . 0.0 109.666 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.589 ' HB2' HD12 ' A' ' 143' ' ' ILE . 68.6 m-20 -50.57 164.22 0.14 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.189 -1.183 . . . . 0.0 109.217 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.0 ttm -99.6 129.58 45.76 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.15 -0.969 . . . . 0.0 109.011 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.696 ' CG1' HD11 ' A' ' 143' ' ' ILE . 25.1 m -128.67 145.67 35.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.302 -0.874 . . . . 0.0 109.948 -179.836 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.551 ' HB2' ' CG1' ' A' ' 176' ' ' ILE . 26.3 tttp -110.47 145.05 38.34 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.588 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.999 ' O ' HD13 ' A' ' 132' ' ' ILE . 64.7 mt -78.75 156.5 4.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.035 -1.041 . . . . 0.0 108.544 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.999 HD13 ' O ' ' A' ' 131' ' ' ILE . 0.7 OUTLIER -148.57 -3.98 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.131 -0.98 . . . . 0.0 108.966 179.54 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.4 m -148.67 146.42 28.15 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.339 -0.851 . . . . 0.0 110.11 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 104.55 -170.58 18.44 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.55 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 49.0 Cg_endo -68.97 -19.66 39.62 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 123.276 2.651 . . . . 0.0 112.508 -179.617 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.55 ' CD1' ' HG2' ' A' ' 135' ' ' PRO . 88.6 m-85 -109.09 9.41 26.25 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.975 -1.078 . . . . 0.0 109.747 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.843 ' HA ' HG22 ' A' ' 131' ' ' ILE . 0.7 OUTLIER -44.19 145.01 0.84 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 0.0 109.462 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.545 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 14.6 m-20 81.62 20.54 0.35 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.489 -0.757 . . . . 0.0 110.042 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.784 ' CB ' HD12 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -115.42 160.66 19.59 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.11 -0.993 . . . . 0.0 109.315 179.803 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.427 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -114.31 135.83 53.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.145 -0.972 . . . . 0.0 109.383 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.478 ' C ' ' CG2' ' A' ' 155' ' ' VAL . . . -147.98 169.88 28.69 Favored Glycine 0 N--CA 1.49 2.267 0 C-N-CA 119.655 -1.26 . . . . 0.0 110.181 -179.47 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.983 ' C ' HG23 ' A' ' 155' ' ' VAL . 94.8 t -109.89 134.46 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.62 -0.93 . . . . 0.0 109.319 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.696 HD11 ' CG1' ' A' ' 129' ' ' VAL . 67.8 mt -62.69 117.16 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.134 -0.979 . . . . 0.0 109.353 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.424 ' HG2' ' HG2' ' A' ' 145' ' ' GLU . 16.8 tttp -97.99 -35.86 10.31 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.164 -0.96 . . . . 0.0 109.422 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' GLU . . . . . 0.424 ' HG2' ' HG2' ' A' ' 144' ' ' LYS . 72.3 mm-40 -151.59 146.63 25.98 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.095 -1.003 . . . . 0.0 109.462 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.903 HG23 ' CG ' ' A' ' 153' ' ' LEU . 1.8 mt -122.44 125.34 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.576 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.68 102.35 44.47 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.203 -0.935 . . . . 0.0 109.603 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.546 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.6 Cg_endo -73.5 171.94 16.72 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.752 2.301 . . . . 0.0 111.846 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.546 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.0 tt0 80.57 -21.45 0.32 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.423 -0.798 . . . . 0.0 110.074 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.417 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 44.0 mtt85 -126.17 -12.48 6.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.053 -1.029 . . . . 0.0 109.323 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.417 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 42.2 mt-30 68.47 49.8 0.75 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.325 -0.86 . . . . 0.0 109.676 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.682 ' OE2' HG13 ' A' ' 167' ' ' VAL . 69.0 tt0 -123.01 146.35 47.71 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.048 -1.032 . . . . 0.0 108.747 179.515 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.903 ' CG ' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -142.51 113.93 7.83 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.119 -0.988 . . . . 0.0 110.511 -179.276 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 154' ' ' LYS . . . . . 0.691 ' HG2' HG22 ' A' ' 167' ' ' VAL . 27.1 mtmt -85.08 137.21 33.19 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.765 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.983 HG23 ' C ' ' A' ' 142' ' ' VAL . 1.8 p -136.72 133.19 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.007 -1.058 . . . . 0.0 110.034 -179.222 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.598 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.2 t-20 -67.02 125.95 27.62 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.396 -0.815 . . . . 0.0 109.689 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.564 HG12 HG13 ' A' ' 159' ' ' ILE . 43.7 t -107.59 147.46 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.275 -0.891 . . . . 0.0 109.057 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.683 ' O ' HG23 ' A' ' 158' ' ' THR . 9.4 t -97.4 112.18 24.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.343 -0.848 . . . . 0.0 109.986 -179.379 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.965 HG22 ' CD2' ' A' ' 160' ' ' PHE . 26.6 mt -138.17 137.29 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.357 -0.84 . . . . 0.0 109.183 179.298 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.965 ' CD2' HG22 ' A' ' 159' ' ' ILE . 99.7 m-85 60.86 42.34 13.29 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 108.963 -179.533 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.37 17.03 17.17 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.472 ' NH1' ' O ' ' A' ' 160' ' ' PHE . 22.5 mtt85 -126.49 147.55 49.81 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -1.184 . . . . 0.0 109.637 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 64.1 mm-40 -97.89 136.64 37.9 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 109.373 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' THR . . . . . 0.503 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 4.3 m -143.68 132.55 11.34 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.673 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.598 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 48.0 Cg_endo -68.88 131.21 21.98 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.792 2.328 . . . . 0.0 111.366 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.915 HG23 HD11 ' A' ' 168' ' ' LEU . 24.3 m -115.55 162.89 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.052 -1.03 . . . . 0.0 109.581 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.691 HG22 ' HG2' ' A' ' 154' ' ' LYS . 41.3 t -117.77 119.14 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.411 -0.806 . . . . 0.0 109.61 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.915 HD11 HG23 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -144.38 168.73 19.4 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.956 0.884 . . . . 0.0 110.503 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -80.65 139.41 36.22 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.416 HG22 HG21 ' A' ' 119' ' ' VAL . 7.9 p -53.7 -34.18 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.156 -0.965 . . . . 0.0 109.008 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.4 ' O ' ' HG2' ' A' ' 115' ' ' LYS . 54.0 p -75.54 -4.33 39.26 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.394 -0.816 . . . . 0.0 109.539 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -103.97 1.85 31.66 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.072 -1.017 . . . . 0.0 109.644 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.538 HG12 ' N ' ' A' ' 174' ' ' GLU . 49.5 t -131.35 162.99 38.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.146 -0.971 . . . . 0.0 109.626 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.538 ' N ' HG12 ' A' ' 173' ' ' VAL . 76.3 tt0 -139.3 159.62 41.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -0.9 . . . . 0.0 109.344 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.607 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 21.7 tttm -91.82 34.82 0.98 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.146 -0.971 . . . . 0.0 109.283 179.818 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.551 ' CG1' ' HB2' ' A' ' 130' ' ' LYS . 87.4 mt 43.05 78.05 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.306 -0.871 . . . . 0.0 109.537 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.505 -179.979 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.218 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.496 ' HA ' HG21 ' A' ' 65' ' ' ILE . . . -61.43 -34.65 75.76 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -1.129 . . . . 0.0 109.475 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 21.9 ttp -53.94 -38.13 64.59 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.514 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -115.31 130.49 56.92 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.252 -0.905 . . . . 0.0 109.549 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.5 mttt -122.24 161.36 23.41 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 21.6 mtpp -130.45 176.18 8.36 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.229 -0.92 . . . . 0.0 109.256 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.702 ' CH2' HG23 ' A' ' 41' ' ' VAL . 39.7 m95 -109.67 124.11 50.63 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.236 -0.915 . . . . 0.0 109.126 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' TYR . . . . . 0.462 ' CE1' ' CE ' ' A' ' 66' ' ' MET . 95.4 m-85 -113.75 170.9 7.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.245 -0.909 . . . . 0.0 109.353 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.459 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 25.9 mt -119.2 106.84 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.232 -0.918 . . . . 0.0 109.417 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.487 ' CG2' HG23 ' A' ' 80' ' ' VAL . 0.2 OUTLIER -94.45 148.16 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.183 -0.948 . . . . 0.0 109.292 179.746 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.758 ' N ' HD22 ' A' ' 11' ' ' LEU . 3.2 mm? -95.37 145.93 24.76 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.382 -0.824 . . . . 0.0 109.817 -179.598 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.9 p -147.78 -177.96 6.01 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.415 -0.803 . . . . 0.0 109.264 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' MET . . . . . 0.569 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 54.8 mtm -89.9 116.92 28.33 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.157 -0.964 . . . . 0.0 109.489 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 13' ' ' MET . 18.1 t -42.89 125.57 3.51 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.248 -0.908 . . . . 0.0 109.296 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.47 -19.09 40.28 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.129 -1.588 . . . . 0.0 109.129 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' TYR . . . . . 0.569 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.7 m-85 -107.33 -10.14 15.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.446 -1.031 . . . . 0.0 109.465 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.487 ' O ' ' N ' ' A' ' 20' ' ' VAL . 93.9 mt-10 -45.47 -66.66 0.37 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.201 -0.937 . . . . 0.0 109.37 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.409 ' C ' ' O ' ' A' ' 17' ' ' GLU . 94.8 mt-10 -44.05 -35.79 2.26 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 109.302 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.43 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 22.9 mttm -71.58 -31.35 66.86 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.214 -0.929 . . . . 0.0 109.344 179.854 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.73 HG22 ' HB2' ' A' ' 79' ' ' TYR . 98.2 t -72.55 -45.47 58.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.224 -0.923 . . . . 0.0 109.356 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 28.8 tttm -55.82 -50.53 70.28 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.341 -0.849 . . . . 0.0 109.303 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -62.3 -37.33 85.12 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -0.895 . . . . 0.0 109.163 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.832 ' OD1' HG22 ' A' ' 77' ' ' VAL . 13.8 t-20 -62.23 -44.58 96.23 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.322 -0.861 . . . . 0.0 109.362 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.949 ' CD1' HG21 ' A' ' 77' ' ' VAL . 29.5 mm -56.11 -45.2 80.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 109.335 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -55.13 -45.46 75.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.229 -0.92 . . . . 0.0 109.657 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 46.7 mttp -76.17 -35.73 59.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.069 -1.02 . . . . 0.0 109.61 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 1.029 ' HD3' HG23 ' A' ' 77' ' ' VAL . 18.1 ttpt -55.07 -33.89 63.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.334 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.865 HG21 HG11 ' A' ' 37' ' ' VAL . 89.4 t -82.27 -24.44 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.288 -0.882 . . . . 0.0 109.601 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -67.85 -52.31 38.18 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.654 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.39 -27.12 65.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.249 -0.907 . . . . 0.0 109.933 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 47.4 p -97.58 -32.19 11.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.205 -0.934 . . . . 0.0 109.696 -179.653 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 79.44 24.01 61.7 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.643 ' O ' HG13 ' A' ' 28' ' ' VAL . 62.8 mt -94.65 87.32 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.217 -1.166 . . . . 0.0 109.444 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -87.4 -5.37 58.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.215 -0.928 . . . . 0.0 109.455 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 -102.14 16.46 26.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.269 -0.895 . . . . 0.0 109.628 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.929 HD11 ' CB ' ' A' ' 70' ' ' ALA . 7.2 tp -112.17 -58.12 2.18 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.263 -0.898 . . . . 0.0 109.4 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.865 HG11 HG21 ' A' ' 28' ' ' VAL . 9.0 p -95.87 134.35 33.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.427 -0.796 . . . . 0.0 109.423 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.21 -123.71 5.32 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 93.4 mtt180 -95.11 143.98 26.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.308 -1.113 . . . . 0.0 109.89 -179.473 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 1.01 HG23 HG22 ' A' ' 62' ' ' VAL . 18.9 mt -107.7 140.39 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.408 -0.807 . . . . 0.0 109.158 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 1.038 HG21 HD11 ' A' ' 107' ' ' LEU . 55.0 t -128.51 156.86 41.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.024 -1.048 . . . . 0.0 109.462 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.791 HG22 HG23 ' A' ' 44' ' ' ILE . 6.5 mt -136.72 127.19 16.23 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.367 -0.833 . . . . 0.0 109.469 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.517 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 46.3 Cg_endo -67.4 -4.71 12.37 Favored 'Trans proline' 0 C--O 1.216 -0.583 0 C-N-CA 122.824 2.349 . . . . 0.0 111.547 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.791 HG23 HG22 ' A' ' 42' ' ' ILE . 11.8 pt -76.76 -22.63 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.248 -0.907 . . . . 0.0 109.474 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.444 ' O ' HD21 ' A' ' 104' ' ' LEU . 35.2 mtp180 -64.74 163.65 13.64 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.334 -0.854 . . . . 0.0 109.45 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.42 0.97 59.31 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -111.65 60.73 0.32 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 -60.77 -27.41 67.96 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.247 -1.149 . . . . 0.0 109.575 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 20.5 mtm180 -62.86 -26.43 68.76 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.223 -0.923 . . . . 0.0 109.498 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 34.1 mtt-85 -127.83 164.43 22.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.184 -0.948 . . . . 0.0 109.515 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' LYS . . . . . 0.407 ' C ' ' OG ' ' A' ' 52' ' ' SER . 49.2 mttt -59.62 -33.97 72.18 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -0.869 . . . . 0.0 109.54 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' SER . . . . . 0.455 ' O ' ' HG3' ' A' ' 54' ' ' LYS . 0.3 OUTLIER -171.78 98.13 0.18 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.272 -0.892 . . . . 0.0 109.462 -179.895 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.498 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 94.6 mt-10 -64.48 -48.7 74.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.174 -0.954 . . . . 0.0 109.381 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.71 ' HA ' HG22 ' A' ' 44' ' ' ILE . 24.5 mttt 75.44 86.73 0.09 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.238 -0.914 . . . . 0.0 109.577 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.635 HD23 ' HE2' ' A' ' 56' ' ' PHE . 14.5 tp -64.26 -23.73 67.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.161 -0.962 . . . . 0.0 109.132 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.89 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 97.2 m-85 -149.96 99.0 3.31 Favored Pre-proline 0 N--CA 1.49 1.532 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -65.42 139.57 59.89 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.614 2.209 . . . . 0.0 111.979 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.07 -15.84 4.98 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.386 -1.085 . . . . 0.0 110.386 179.629 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.444 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.2 m-85 -95.73 129.87 42.81 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.759 -1.436 . . . . 0.0 110.205 -179.331 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 41.1 t -133.84 146.02 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.335 -0.853 . . . . 0.0 108.905 179.453 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.418 ' CE2' HG12 ' A' ' 9' ' ' ILE . 24.1 m-85 -110.31 122.47 47.76 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.955 -1.09 . . . . 0.0 109.521 -179.848 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 1.01 HG22 HG23 ' A' ' 40' ' ' ILE . 96.1 t -128.48 140.97 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.427 -0.795 . . . . 0.0 109.936 -179.632 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.596 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 67.6 tt0 -103.5 123.49 46.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.315 -0.865 . . . . 0.0 108.864 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.576 ' CG ' HG12 ' A' ' 62' ' ' VAL . 1.1 mtp -162.66 -174.61 4.04 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.102 -0.999 . . . . 0.0 109.778 -179.545 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.902 HG12 HD12 ' A' ' 36' ' ' LEU . 17.2 pt -97.26 122.95 49.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.236 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' MET . . . . . 0.462 ' CE ' ' CE1' ' A' ' 8' ' ' TYR . 11.1 ttm -88.16 100.31 12.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -0.885 . . . . 0.0 109.736 -179.406 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.438 ' H ' ' HB3' ' A' ' 70' ' ' ALA . 9.6 t30 -137.92 -165.75 1.84 Allowed 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.195 -0.941 . . . . 0.0 108.821 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -71.41 -48.72 47.96 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.14 -0.975 . . . . 0.0 109.681 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.403 ' O ' ' C ' ' A' ' 70' ' ' ALA . 73.9 mm-40 -66.64 -58.63 4.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.188 -0.945 . . . . 0.0 109.5 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.929 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -43.85 -41.51 5.14 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.293 -0.879 . . . . 0.0 109.718 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.541 ' CD1' ' CD ' ' A' ' 89' ' ' GLN . 72.2 t80 -61.05 -57.14 13.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.163 -0.961 . . . . 0.0 109.627 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' HB3' ' A' ' 76' ' ' SER . 38.2 t30 -52.87 -31.2 38.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.929 . . . . 0.0 110.0 -179.582 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -82.08 -44.15 16.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.96 -1.088 . . . . 0.0 109.923 -179.626 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 1.081 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 47.6 t -68.49 -56.91 10.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.357 -0.84 . . . . 0.0 109.625 -179.64 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ARG . . . . . 0.457 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 15.6 tpt180 -62.5 -11.92 19.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.165 -0.959 . . . . 0.0 109.966 -179.718 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.485 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 89.6 p -102.28 3.53 38.23 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.081 -1.012 . . . . 0.0 110.167 -179.645 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 1.033 ' O ' HG12 ' A' ' 80' ' ' VAL . 0.4 OUTLIER -69.05 142.27 92.92 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.031 -1.043 . . . . 0.0 109.273 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.664 ' HD2' HG22 ' A' ' 77' ' ' VAL . 45.2 Cg_endo -67.75 134.51 32.75 Favored 'Trans proline' 0 C--O 1.213 -0.768 0 C-N-CA 122.454 2.103 . . . . 0.0 111.876 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.73 ' HB2' HG22 ' A' ' 20' ' ' VAL . 13.1 m-85 89.32 -6.55 0.42 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.799 -0.563 . . . . 0.0 110.255 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 1.033 HG12 ' O ' ' A' ' 77' ' ' VAL . 12.4 p -88.33 126.98 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.752 -1.218 . . . . 0.0 109.643 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.4 mmm -90.78 -26.36 19.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.32 -0.863 . . . . 0.0 109.335 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.57 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 161.47 -160.34 32.14 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' PHE . . . . . 1.081 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 10.8 m-85 -134.76 156.38 48.94 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.191 -1.182 . . . . 0.0 109.562 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.547 ' O ' HG13 ' A' ' 84' ' ' VAL . 12.5 p -91.71 125.35 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.248 -0.908 . . . . 0.0 109.385 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.574 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.6 OUTLIER -168.87 166.79 11.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.13 -0.981 . . . . 0.0 109.568 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 25.5 t -86.18 -32.97 20.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.238 -0.914 . . . . 0.0 109.427 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -117.42 -106.82 2.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.516 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -96.67 -122.09 4.16 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.541 ' CD ' ' CD1' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -34.55 156.11 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.533 -0.981 . . . . 0.0 110.044 -179.659 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.574 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.0 Cg_endo -68.75 149.21 72.91 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.839 2.359 . . . . 0.0 111.994 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.0 m -83.89 154.97 64.74 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 109.436 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.525 ' HB3' ' CE ' ' A' ' 6' ' ' LYS . 49.9 Cg_endo -70.16 142.94 47.46 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.677 2.251 . . . . 0.0 111.673 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.512 HG12 ' HB2' ' A' ' 97' ' ' GLU . 18.6 t -82.3 139.07 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.304 -0.873 . . . . 0.0 109.433 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' LYS . . . . . 0.467 ' O ' ' N ' ' A' ' 97' ' ' GLU . 7.3 tptt -70.74 131.78 44.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.182 -0.949 . . . . 0.0 109.289 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ASP . . . . . 0.402 ' C ' ' O ' ' A' ' 94' ' ' LYS . 87.3 m-20 -45.22 -39.52 6.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.178 -0.952 . . . . 0.0 109.436 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.4 mtp180 -61.03 -23.45 65.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.308 -0.87 . . . . 0.0 109.475 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.512 ' HB2' HG12 ' A' ' 93' ' ' VAL . 62.9 mt-10 -85.83 -28.38 24.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.913 . . . . 0.0 109.422 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' MET . . . . . 0.612 ' HE3' ' CB ' ' A' ' 7' ' ' TRP . 59.0 mtp -84.14 -24.8 30.07 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.365 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.593 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -37.46 -53.53 2.31 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.425 -0.797 . . . . 0.0 109.866 -179.952 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.4 Cg_endo -69.83 -27.55 25.98 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 122.525 2.15 . . . . 0.0 111.878 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.418 ' N ' ' O ' ' A' ' 98' ' ' MET . 37.4 mm -81.19 -42.94 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.178 -0.951 . . . . 0.0 109.304 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' LEU . . . . . 0.868 HD12 HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -65.8 -38.97 90.41 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.275 -0.891 . . . . 0.0 109.297 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.5 ' HG3' ' CE2' ' A' ' 110' ' ' TYR . 16.1 ttt-85 -65.66 -47.7 74.63 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.334 -0.854 . . . . 0.0 109.279 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.444 HD21 ' O ' ' A' ' 45' ' ' ARG . 3.0 tt -72.12 -36.31 69.38 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.215 -0.928 . . . . 0.0 109.227 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -75.25 -2.22 27.08 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.44 -0.788 . . . . 0.0 109.81 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.9 15.79 81.34 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 1.038 HD11 HG21 ' A' ' 41' ' ' VAL . 23.5 mt -81.84 -23.27 36.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.16 -1.2 . . . . 0.0 109.666 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' GLU . . . . . 0.466 ' HG2' ' HB3' ' A' ' 102' ' ' LEU . 68.2 mm-40 -133.22 138.59 46.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.158 -0.964 . . . . 0.0 109.327 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 35.4 mp0 -120.7 121.83 39.11 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.281 -0.887 . . . . 0.0 109.72 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.527 ' C ' ' CD1' ' A' ' 110' ' ' TYR . 13.6 p90 -145.16 174.33 11.16 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.253 -0.905 . . . . 0.0 109.219 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 112' ' ' GLU . 90.3 mt-10 -96.18 -102.69 0.17 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.21 -0.931 . . . . 0.0 109.85 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.479 ' HG3' ' OE1' ' A' ' 137' ' ' GLU . 0.2 OUTLIER 44.9 68.12 0.6 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.136 -0.978 . . . . 0.0 109.543 -179.913 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 176.74 -40.99 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.345 -0.847 . . . . 0.0 109.523 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 12.0 pttm -47.49 -23.55 0.65 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.214 -0.929 . . . . 0.0 109.432 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -121.68 83.25 41.97 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.951 . . . . 0.0 109.562 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -71.15 163.1 40.35 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.683 2.255 . . . . 0.0 111.696 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.436 ' C ' ' HB2' ' A' ' 171' ' ' SER . 41.6 t -138.01 120.88 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.185 -0.947 . . . . 0.0 109.622 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 53.3 tttt -68.57 156.76 37.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.242 -0.911 . . . . 0.0 109.501 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.995 HG21 ' O ' ' A' ' 173' ' ' VAL . 27.5 m -150.8 148.38 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.21 -0.931 . . . . 0.0 109.54 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' GLU . . . . . 0.712 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 76.7 mt-10 -158.38 167.0 30.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.205 179.793 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' LEU . . . . . 0.712 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 19.3 tp 144.26 99.37 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.716 -0.615 . . . . 0.0 109.459 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' GLY . . . . . 0.47 ' O ' ' OD2' ' A' ' 127' ' ' ASP . . . 37.72 36.12 0.27 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' PHE . . . . . 0.561 ' CD2' ' O ' ' A' ' 123' ' ' PHE . 42.5 p90 -76.75 116.65 17.61 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.973 -1.31 . . . . 0.0 109.02 179.607 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' LYS . . . . . 0.686 ' C ' HD11 ' A' ' 146' ' ' ILE . 14.7 mttp -141.14 175.12 9.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.181 -0.949 . . . . 0.0 109.918 -179.58 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' VAL . . . . . 0.584 HG23 ' O ' ' A' ' 144' ' ' LYS . 10.8 p -62.51 139.62 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.529 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.13 -34.8 3.68 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ASP . . . . . 0.47 ' OD2' ' O ' ' A' ' 122' ' ' GLY . 9.5 m-20 -45.92 158.97 0.08 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.336 -1.096 . . . . 0.0 109.209 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' MET . . . . . 0.576 ' HG2' HD12 ' A' ' 176' ' ' ILE . 3.8 ttm -99.77 127.49 45.92 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.075 -1.016 . . . . 0.0 108.799 179.553 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.609 HG13 HG12 ' A' ' 143' ' ' ILE . 15.4 m -128.51 144.87 36.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.32 -0.862 . . . . 0.0 109.735 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' LYS . . . . . 0.412 ' HE3' ' CG2' ' A' ' 132' ' ' ILE . 32.5 ttpt -98.78 141.06 32.05 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.618 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.931 HD12 ' HB3' ' A' ' 139' ' ' PHE . 78.5 mt -82.84 151.09 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.209 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' ILE . . . . . 0.498 HG12 ' HA ' ' A' ' 173' ' ' VAL . 1.1 pt -149.66 3.64 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 120.923 -1.111 . . . . 0.0 109.957 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 69.9 m -148.26 143.52 27.02 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.846 -1.159 . . . . 0.0 109.983 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.67 -163.9 18.7 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.482 ' HB3' ' HD3' ' A' ' 103' ' ' ARG . 46.4 Cg_endo -67.38 -23.18 44.58 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 123.167 2.578 . . . . 0.0 112.952 -179.28 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.528 ' CE1' ' CB ' ' A' ' 100' ' ' PRO . 97.1 m-85 -109.14 19.38 19.55 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.787 -1.196 . . . . 0.0 109.713 -179.765 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' GLU . . . . . 0.621 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.3 tt0 -45.51 139.09 3.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.15 -0.969 . . . . 0.0 109.506 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.511 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 17.7 m-20 74.41 28.23 1.34 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.459 -0.776 . . . . 0.0 110.437 179.41 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' PHE . . . . . 0.931 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.8 t80 -117.08 140.01 50.02 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.96 -1.087 . . . . 0.0 109.45 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.74 132.94 34.04 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.116 -0.99 . . . . 0.0 109.664 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.57 168.91 27.23 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.775 -1.203 . . . . 0.0 110.304 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.916 ' C ' HG23 ' A' ' 155' ' ' VAL . 41.0 t -117.9 137.07 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.634 -0.921 . . . . 0.0 109.348 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' ILE . . . . . 0.609 HG12 HG13 ' A' ' 129' ' ' VAL . 25.0 mm -69.85 119.23 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.873 . . . . 0.0 109.532 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' LYS . . . . . 0.584 ' O ' HG23 ' A' ' 125' ' ' VAL . 0.2 OUTLIER -97.76 -31.69 12.12 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.026 -1.046 . . . . 0.0 109.04 179.546 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -151.11 146.17 25.97 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.266 -0.896 . . . . 0.0 109.283 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 1.051 HG23 HD22 ' A' ' 153' ' ' LEU . 4.0 mt -121.58 126.21 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.141 -0.974 . . . . 0.0 109.545 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.92 100.08 38.13 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.449 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.4 Cg_endo -71.14 173.28 12.42 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.706 2.271 . . . . 0.0 111.821 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.2 tt0 79.52 -21.58 0.32 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.325 -0.86 . . . . 0.0 110.184 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 150' ' ' ARG . . . . . 0.44 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 83.9 mtt-85 -127.5 -12.77 5.53 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.045 -1.035 . . . . 0.0 109.6 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 151' ' ' GLN . . . . . 0.882 ' O ' HG23 ' A' ' 170' ' ' VAL . 49.8 mt-30 69.52 47.04 0.69 Allowed 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.348 -0.845 . . . . 0.0 109.704 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 152' ' ' GLU . . . . . 0.742 ' O ' HD23 ' A' ' 153' ' ' LEU . 40.8 tt0 -118.21 143.85 46.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.08 -1.012 . . . . 0.0 108.659 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 1.051 HD22 HG23 ' A' ' 146' ' ' ILE . 35.3 mt -133.56 122.82 24.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.996 -1.065 . . . . 0.0 110.616 -179.38 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 9.5 mttt -86.55 130.93 34.31 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 178.573 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.916 HG23 ' C ' ' A' ' 142' ' ' VAL . 7.3 p -133.65 149.77 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.087 -1.008 . . . . 0.0 109.8 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.565 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 43.3 t-20 -98.75 123.61 43.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.29 -0.881 . . . . 0.0 109.329 179.857 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 157' ' ' VAL . . . . . 0.557 HG13 ' CE1' ' A' ' 139' ' ' PHE . 63.9 t -105.39 146.86 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.198 -0.939 . . . . 0.0 109.663 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 25.9 m -94.9 104.05 15.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.245 -0.91 . . . . 0.0 109.633 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' ILE . . . . . 0.89 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 7.0 pt -139.65 149.12 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -0.896 . . . . 0.0 109.38 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 160' ' ' PHE . . . . . 0.658 ' CE2' HD12 ' A' ' 159' ' ' ILE . 11.1 m-30 61.35 36.99 17.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.261 -0.899 . . . . 0.0 109.141 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.52 13.7 17.99 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' ARG . . . . . 0.424 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 3.3 mtp-105 -134.11 159.01 42.14 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.059 -1.259 . . . . 0.0 109.601 -179.844 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 163' ' ' GLU . . . . . 0.478 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 81.7 mt-10 -99.73 140.12 34.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.253 -0.905 . . . . 0.0 109.399 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 164' ' ' THR . . . . . 0.553 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 22.6 m -146.55 129.93 8.23 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.785 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 165' ' ' PRO . . . . . 0.565 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.7 Cg_endo -71.14 139.29 35.22 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.736 2.29 . . . . 0.0 111.437 179.676 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 166' ' ' VAL . . . . . 0.966 HG13 HD11 ' A' ' 168' ' ' LEU . 2.9 p -124.93 143.86 36.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.088 -1.007 . . . . 0.0 109.627 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.576 HG13 ' O ' ' A' ' 167' ' ' VAL . 14.6 p -96.13 120.75 45.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.408 -0.807 . . . . 0.0 109.533 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 168' ' ' LEU . . . . . 0.966 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -141.4 168.71 19.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.113 -0.992 . . . . 0.0 110.54 -179.52 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 169' ' ' HIS . . . . . 0.468 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 72.1 m80 -83.19 143.26 30.59 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.648 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.891 HG22 ' HG ' ' A' ' 153' ' ' LEU . 71.9 t -52.82 -38.39 27.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.436 ' HB2' ' C ' ' A' ' 117' ' ' VAL . 84.6 p -75.23 -6.97 52.51 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.492 -0.755 . . . . 0.0 110.06 -179.466 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 172' ' ' GLU . . . . . 0.468 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 80.4 mt-10 -91.12 -5.46 55.06 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.828 -1.17 . . . . 0.0 109.822 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 173' ' ' VAL . . . . . 0.995 ' O ' HG21 ' A' ' 119' ' ' VAL . 2.8 m -139.48 175.36 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.152 -0.967 . . . . 0.0 109.439 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 174' ' ' GLU . . . . . 0.407 ' HA ' HG21 ' A' ' 119' ' ' VAL . 57.5 tt0 -138.17 163.03 32.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.196 -0.94 . . . . 0.0 109.045 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 175' ' ' LYS . . . . . 0.523 ' O ' ' N ' ' A' ' 177' ' ' GLU . 25.2 mmtm -91.04 12.37 20.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.088 -1.007 . . . . 0.0 109.246 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 176' ' ' ILE . . . . . 0.576 HD12 ' HG2' ' A' ' 128' ' ' MET . 75.8 mt 58.28 -81.06 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.411 -0.806 . . . . 0.0 109.561 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 177' ' ' GLU . . . . . 0.578 ' O ' HD23 ' A' ' 121' ' ' LEU . 94.6 mt-10 . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 117.954 -1.022 . . . . 0.0 109.431 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.664 ' HG2' HG22 ' A' ' 65' ' ' ILE . 56.5 mttt . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.61 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.2 mttp -125.82 174.51 8.3 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.222 -0.924 . . . . 0.0 109.126 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.683 ' CH2' HG23 ' A' ' 41' ' ' VAL . 60.0 m95 -109.9 126.66 54.11 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.132 -0.98 . . . . 0.0 109.346 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -118.74 167.39 11.72 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.211 -0.931 . . . . 0.0 109.415 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.53 HD11 ' CE1' ' A' ' 160' ' ' PHE . 95.1 mt -103.25 118.77 50.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.195 -0.94 . . . . 0.0 109.314 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.464 HG23 HG12 ' A' ' 62' ' ' VAL . 85.3 t -90.46 137.32 21.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.466 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.486 ' CD2' ' CG2' ' A' ' 84' ' ' VAL . 0.1 OUTLIER -89.62 141.75 28.31 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.276 -0.89 . . . . 0.0 109.245 179.875 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.527 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.2 t -157.15 -172.48 4.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.23 -0.918 . . . . 0.0 109.358 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.496 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 90.9 mtp -105.56 123.62 48.2 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.2 -0.937 . . . . 0.0 109.516 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.422 ' C ' ' O ' ' A' ' 13' ' ' MET . 9.2 t -43.07 127.07 4.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.299 -0.875 . . . . 0.0 109.397 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.74 -19.85 40.5 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.496 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.2 m-85 -108.47 3.54 23.28 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.239 -1.153 . . . . 0.0 109.64 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.527 ' HG2' HG21 ' A' ' 12' ' ' THR . 98.4 mt-10 -57.92 -59.33 5.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -47.71 -38.11 14.53 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.218 -0.926 . . . . 0.0 109.403 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 24.7 mttt -68.8 -43.66 75.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.282 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 16' ' ' TYR . 89.6 t -58.96 -46.53 91.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 109.566 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.819 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.4 tttm -56.94 -49.8 74.55 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.219 -0.925 . . . . 0.0 109.548 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -64.83 -43.19 93.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.196 -0.94 . . . . 0.0 109.407 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.486 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 89.3 m-20 -54.92 -39.77 69.18 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.222 -0.924 . . . . 0.0 109.391 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.813 HG21 HD11 ' A' ' 40' ' ' ILE . 95.1 mt -65.62 -44.04 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.3 -0.875 . . . . 0.0 109.624 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -55.84 -48.22 75.86 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.07 -1.019 . . . . 0.0 109.947 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 42.9 mttm -78.41 -35.34 47.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.093 -1.004 . . . . 0.0 109.612 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.579 ' HG3' ' CE1' ' A' ' 73' ' ' PHE . 10.7 tptt -53.25 -33.0 51.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.247 -0.908 . . . . 0.0 109.13 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.756 HG13 ' C ' ' A' ' 33' ' ' ILE . 22.3 t -89.52 -19.89 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.342 -0.849 . . . . 0.0 109.287 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -72.64 -57.64 3.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.564 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.69 -29.9 66.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.895 . . . . 0.0 109.437 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.419 ' HB ' HG13 ' A' ' 33' ' ' ILE . 80.7 p -96.6 -3.02 43.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.237 -0.915 . . . . 0.0 109.477 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 50.02 30.17 15.82 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.045 HG21 HD12 ' A' ' 36' ' ' LEU . 21.6 mt -98.3 72.04 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.248 -1.148 . . . . 0.0 109.519 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 mttp -90.49 20.36 4.62 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.266 -0.896 . . . . 0.0 109.505 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.755 ' O ' HD13 ' A' ' 65' ' ' ILE . 81.4 m-20 -111.27 -23.04 11.06 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.189 -0.944 . . . . 0.0 109.525 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.045 HD12 HG21 ' A' ' 33' ' ' ILE . 18.9 mt -88.36 -31.23 19.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.29 -0.882 . . . . 0.0 109.76 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.414 ' HB ' HG21 ' A' ' 28' ' ' VAL . 93.4 t -108.19 142.87 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.179 -0.951 . . . . 0.0 109.376 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.86 -121.88 3.17 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -92.91 140.92 28.99 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.28 -1.13 . . . . 0.0 109.838 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.881 HG12 HG23 ' A' ' 62' ' ' VAL . 85.2 mt -108.91 134.64 50.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.336 -0.853 . . . . 0.0 109.084 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 1.059 ' CG2' HD11 ' A' ' 107' ' ' LEU . 28.7 t -121.68 159.34 24.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.074 -1.016 . . . . 0.0 109.412 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.953 HG22 HG23 ' A' ' 44' ' ' ILE . 2.9 mt -140.44 127.62 12.28 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.292 -0.88 . . . . 0.0 109.479 -179.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.635 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 45.2 Cg_endo -66.72 -5.93 14.32 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.799 2.333 . . . . 0.0 111.391 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.953 HG23 HG22 ' A' ' 42' ' ' ILE . 6.1 pt . . . . . 0 N--CA 1.49 1.557 0 O-C-N 121.398 -0.814 . . . . 0.0 109.374 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.715 ' HA ' HG22 ' A' ' 44' ' ' ILE . 5.3 mttp . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 1.025 HD12 ' CE2' ' A' ' 56' ' ' PHE . 0.6 OUTLIER -56.88 -45.82 82.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -0.962 . . . . 0.0 109.235 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 1.025 ' CE2' HD12 ' A' ' 55' ' ' LEU . 85.2 m-85 -125.25 111.94 26.29 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.937 . . . . 0.0 109.08 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.6 Cg_endo -66.28 133.77 33.92 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.573 2.182 . . . . 0.0 111.985 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.419 ' HA2' HG23 ' A' ' 12' ' ' THR . . . 74.46 -11.97 6.31 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.2 m-30 -99.82 131.29 45.89 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.649 -1.501 . . . . 0.0 110.258 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 42.5 t -134.25 148.77 29.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.671 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 17.0 m-85 -108.38 124.44 50.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.887 -1.133 . . . . 0.0 109.733 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.881 HG23 HG12 ' A' ' 40' ' ' ILE . 14.3 p -134.13 145.54 32.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.353 -0.842 . . . . 0.0 109.804 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.61 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 18.4 tt0 -108.51 127.3 53.81 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.632 ' CE ' HG11 ' A' ' 74' ' ' VAL . 58.7 mtm -151.93 163.68 38.73 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 118.954 -1.098 . . . . 0.0 111.022 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.755 HD13 ' O ' ' A' ' 35' ' ' ASN . 3.3 pt -85.87 126.9 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.485 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 47.7 ttm -75.34 141.48 43.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.83 -178.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.485 ' HB2' ' O ' ' A' ' 66' ' ' MET . 47.0 t30 176.4 175.36 0.32 Allowed 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 -179.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -72.12 -40.85 67.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.168 -0.957 . . . . 0.0 109.593 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -72.46 -32.06 65.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.234 -0.916 . . . . 0.0 109.75 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.912 ' HB2' HD22 ' A' ' 36' ' ' LEU . . . -71.71 -47.3 54.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.193 -0.942 . . . . 0.0 109.818 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 67.9 t80 -60.36 -49.33 78.01 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.154 -0.966 . . . . 0.0 109.682 -179.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -63.14 -28.89 70.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.088 -1.007 . . . . 0.0 110.314 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CE1' ' HG3' ' A' ' 27' ' ' LYS . 46.3 t80 -80.72 -41.42 23.62 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.007 -1.058 . . . . 0.0 109.819 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.716 HG22 ' O ' ' A' ' 70' ' ' ALA . 20.1 m -70.68 -53.24 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.242 -0.911 . . . . 0.0 109.405 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.61 ' N ' HG23 ' A' ' 74' ' ' VAL . 33.0 tpt85 -52.14 -32.46 35.71 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.208 -0.932 . . . . 0.0 109.577 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 51.7 p -79.64 7.05 9.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.366 -0.834 . . . . 0.0 109.917 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.66 HG23 ' O ' ' A' ' 74' ' ' VAL . 47.0 t -64.25 133.82 95.76 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.103 -0.998 . . . . 0.0 109.484 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.556 ' HB2' ' CD2' ' A' ' 79' ' ' TYR . 46.9 Cg_endo -68.2 136.9 38.88 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.68 2.253 . . . . 0.0 111.845 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.556 ' CD2' ' HB2' ' A' ' 78' ' ' PRO . 47.2 m-85 76.05 -1.94 2.85 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.418 -0.801 . . . . 0.0 109.623 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.603 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 2.8 t -87.86 127.76 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.129 -0.982 . . . . 0.0 109.273 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.1 mmm -89.02 -5.8 57.66 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.643 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 135.09 -152.8 20.9 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -143.14 141.7 31.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -1.213 . . . . 0.0 109.48 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.486 ' CG2' ' CD2' ' A' ' 11' ' ' LEU . 38.8 t -63.55 128.5 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.515 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 6.9 p -162.84 161.77 26.14 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.257 -0.902 . . . . 0.0 109.507 -179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 m -88.74 -35.61 16.61 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -123.58 -87.71 0.81 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.524 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -105.32 -128.38 6.17 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.524 ' O ' ' O ' ' A' ' 88' ' ' GLY . 6.8 pm0 -34.26 155.98 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.586 -0.949 . . . . 0.0 110.115 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.515 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.4 Cg_endo -69.62 160.12 50.92 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.578 2.185 . . . . 0.0 112.081 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 20.6 m -98.84 154.0 37.59 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.349 -0.844 . . . . 0.0 109.455 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.457 ' CB ' ' HD3' ' A' ' 6' ' ' LYS . 49.6 Cg_endo -70.35 147.64 59.53 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.693 2.262 . . . . 0.0 111.809 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 7' ' ' TRP . 21.3 t -85.4 142.44 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.219 -0.926 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . 0.467 ' HB3' ' HG3' ' A' ' 97' ' ' GLU . 81.1 tttt -67.66 126.24 28.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -0.9 . . . . 0.0 109.453 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 94' ' ' LYS . 47.3 t0 -43.67 -45.35 6.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.408 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.432 ' HD2' ' NZ ' ' A' ' 94' ' ' LYS . 57.4 mtt180 -55.42 -31.28 61.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.237 -0.914 . . . . 0.0 109.51 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.467 ' HG3' ' HB3' ' A' ' 94' ' ' LYS . 57.3 mt-10 -79.22 -24.45 43.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.262 -0.899 . . . . 0.0 109.662 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.628 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 75.7 mtp -84.53 -23.71 29.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.157 -0.964 . . . . 0.0 109.352 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.609 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 57.3 mtt180 -37.53 -52.55 2.52 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.351 -0.843 . . . . 0.0 109.919 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.609 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -69.39 -28.25 27.27 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.546 2.164 . . . . 0.0 111.989 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.54 HG21 ' CD2' ' A' ' 61' ' ' PHE . 24.4 mm -81.95 -41.18 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 109.361 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 1.022 HD12 HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -68.95 -41.44 78.0 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.198 -0.938 . . . . 0.0 109.136 179.816 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.436 ' HG2' ' HA ' ' A' ' 135' ' ' PRO . 21.4 tpt85 -63.25 -49.49 73.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.861 . . . . 0.0 108.989 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -72.66 -36.29 67.92 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.369 -0.832 . . . . 0.0 109.208 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.524 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.85 -0.47 9.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.436 -0.79 . . . . 0.0 109.94 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.34 7.79 85.21 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 1.059 HD11 ' CG2' ' A' ' 41' ' ' VAL . 53.5 mt -77.28 -19.97 55.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.28 -1.13 . . . . 0.0 109.446 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 36.1 tp10 . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.217 -0.927 . . . . 0.0 109.557 -179.94 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.583 ' HB3' ' CD ' ' A' ' 175' ' ' LYS . 45.6 p90 . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.461 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 37.6 mttt -150.64 156.98 42.43 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.072 -1.018 . . . . 0.0 109.972 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.467 HG23 ' O ' ' A' ' 144' ' ' LYS . 14.1 p -62.93 143.99 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.389 -0.819 . . . . 0.0 109.556 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.49 -32.21 3.41 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.437 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 7.5 m-20 -48.67 163.82 0.07 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.359 -1.083 . . . . 0.0 109.144 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.0 ttm -95.57 126.4 40.83 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.182 -0.949 . . . . 0.0 109.066 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.615 HG11 ' CD1' ' A' ' 143' ' ' ILE . 5.1 p -124.21 141.93 42.71 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.192 -0.943 . . . . 0.0 109.215 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.408 ' N ' ' O ' ' A' ' 174' ' ' GLU . 12.6 ttpp -107.57 143.34 36.13 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.113 -0.992 . . . . 0.0 109.049 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 1.002 HD12 ' HB3' ' A' ' 139' ' ' PHE . 96.5 mt -83.96 152.46 3.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.127 -0.983 . . . . 0.0 108.798 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.473 ' C ' ' HG2' ' A' ' 137' ' ' GLU . 27.4 pt -150.8 2.26 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.056 -1.028 . . . . 0.0 109.606 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.515 ' HA ' ' HG2' ' A' ' 137' ' ' GLU . 2.5 m -145.42 141.35 28.33 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.146 -0.972 . . . . 0.0 109.665 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.443 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 107.5 -170.75 15.77 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.436 ' HA ' ' HG2' ' A' ' 103' ' ' ARG . 49.7 Cg_endo -69.03 -18.66 40.31 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 123.338 2.692 . . . . 0.0 112.57 -179.606 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.608 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 97.8 m-85 -107.53 15.31 24.93 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.969 -1.082 . . . . 0.0 109.561 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.515 ' HG2' ' HA ' ' A' ' 133' ' ' SER . 35.1 mt-10 -38.45 142.24 0.2 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.417 -0.802 . . . . 0.0 110.148 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 138' ' ' ASP . 0.3 OUTLIER 76.53 20.34 1.47 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.333 -0.854 . . . . 0.0 110.743 178.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 1.002 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.0 OUTLIER -108.37 131.17 55.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.831 -1.168 . . . . 0.0 109.623 179.901 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -84.97 134.3 34.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.155 -0.966 . . . . 0.0 109.508 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.59 167.89 26.48 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.8 -1.19 . . . . 0.0 110.269 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.524 ' C ' HG13 ' A' ' 155' ' ' VAL . 40.9 t -108.89 136.3 45.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.452 -1.028 . . . . 0.0 109.226 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.615 ' CD1' HG11 ' A' ' 129' ' ' VAL . 18.4 mm -67.38 114.85 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.259 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.467 ' O ' HG23 ' A' ' 125' ' ' VAL . 64.4 tttm -97.25 -34.37 11.12 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.088 -1.007 . . . . 0.0 109.482 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -151.75 146.75 25.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.14 -0.975 . . . . 0.0 109.613 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.837 HG23 ' CD2' ' A' ' 153' ' ' LEU . 1.5 mt -120.06 123.7 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.333 -0.854 . . . . 0.0 109.304 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -107.3 98.14 21.78 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.655 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.553 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.8 Cg_endo -71.66 173.86 11.93 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.721 2.281 . . . . 0.0 111.779 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.553 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.0 tt0 80.53 -21.07 0.34 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.345 -0.847 . . . . 0.0 109.879 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.445 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 47.5 mtt85 -128.75 -11.88 4.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.111 -0.993 . . . . 0.0 109.45 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.786 ' O ' HG23 ' A' ' 170' ' ' VAL . 31.9 mt-30 69.26 48.25 0.67 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.277 -0.89 . . . . 0.0 109.774 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -122.34 146.08 47.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.132 -0.98 . . . . 0.0 108.87 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.837 ' CD2' HG23 ' A' ' 146' ' ' ILE . 0.4 OUTLIER -135.62 122.47 21.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.101 -1.0 . . . . 0.0 110.565 -179.398 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 5.8 mtmm -81.91 130.97 35.24 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.605 HG11 ' CG1' ' A' ' 129' ' ' VAL . 4.2 t -128.46 147.93 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.961 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.548 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 4.4 t30 -97.14 113.02 24.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.392 -0.817 . . . . 0.0 109.26 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.757 HG13 ' CE1' ' A' ' 139' ' ' PHE . 67.7 t -94.39 141.62 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.241 -0.912 . . . . 0.0 109.642 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 60.1 m -94.2 95.71 9.13 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.383 -0.823 . . . . 0.0 109.63 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.561 HG22 ' CD2' ' A' ' 160' ' ' PHE . 5.4 mt -121.72 141.37 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.253 -0.905 . . . . 0.0 109.581 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.671 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 96.6 m-85 61.26 41.26 13.5 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.847 . . . . 0.0 109.523 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.33 16.81 22.31 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 18.5 mtp85 -129.71 151.71 50.0 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.154 -1.203 . . . . 0.0 109.575 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . 0.486 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 73.4 mt-10 -95.97 136.73 36.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.249 -0.907 . . . . 0.0 109.506 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 16.3 m -145.44 128.33 8.22 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.618 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.548 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.2 Cg_endo -70.24 136.67 32.28 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.757 2.304 . . . . 0.0 111.618 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.713 HG13 HD11 ' A' ' 168' ' ' LEU . 3.7 p -123.23 142.86 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.14 -0.975 . . . . 0.0 109.559 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.457 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 6.3 m -92.83 119.19 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.413 -0.805 . . . . 0.0 109.485 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.713 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -142.12 167.9 21.02 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.238 -0.914 . . . . 0.0 110.384 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.506 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 47.8 m170 -82.27 141.01 33.3 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 151' ' ' GLN . 59.5 t -53.94 -36.78 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.185 -0.947 . . . . 0.0 108.893 179.697 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 7.1 p -75.16 -6.77 51.36 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.561 -0.712 . . . . 0.0 109.812 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.506 ' CG ' ' HB2' ' A' ' 169' ' ' HIS . 92.7 mt-10 -96.17 -3.39 44.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.083 -1.011 . . . . 0.0 109.866 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.7 m -133.45 170.68 19.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.106 -0.997 . . . . 0.0 109.993 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.568 ' O ' ' CG2' ' A' ' 129' ' ' VAL . 25.6 tp10 -127.56 144.01 51.11 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.583 ' CD ' ' HB3' ' A' ' 123' ' ' PHE . 9.7 mttp . . . . . 0 N--CA 1.489 1.51 0 O-C-N 121.069 -1.019 . . . . 0.0 109.567 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.7 mttt . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.592 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 41.7 mmtt -130.65 171.11 13.43 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.356 -0.84 . . . . 0.0 109.126 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.767 ' CH2' HG23 ' A' ' 41' ' ' VAL . 60.1 m95 -104.55 126.5 51.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.202 -0.936 . . . . 0.0 109.329 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -116.94 168.03 10.6 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.154 -0.966 . . . . 0.0 109.145 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.535 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 65.1 mt -104.37 115.94 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.156 -0.965 . . . . 0.0 109.379 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.646 HG22 ' CD2' ' A' ' 83' ' ' PHE . 65.5 t -92.09 138.21 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.216 -0.927 . . . . 0.0 109.248 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.535 ' CD2' ' N ' ' A' ' 11' ' ' LEU . 3.5 mm? -88.12 141.9 28.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.312 -0.867 . . . . 0.0 109.338 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 1.3 p -153.44 174.85 13.84 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.235 -0.916 . . . . 0.0 109.375 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.436 ' O ' ' C ' ' A' ' 14' ' ' SER . 98.1 mtp -95.63 121.02 36.9 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.165 -0.959 . . . . 0.0 109.439 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 13' ' ' MET . 22.4 t -42.03 126.76 3.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.291 -0.88 . . . . 0.0 109.51 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.23 -19.98 33.69 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.527 ' O ' HG23 ' A' ' 20' ' ' VAL . 89.0 m-85 -108.77 -18.79 13.62 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.233 -1.157 . . . . 0.0 109.629 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.736 ' OE1' HD11 ' A' ' 44' ' ' ILE . 43.4 mt-10 -41.48 -67.09 0.28 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.311 -0.868 . . . . 0.0 109.596 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -46.76 -38.59 10.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.193 -0.942 . . . . 0.0 109.415 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.444 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 24.0 tttp -69.22 -34.87 75.52 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.242 -0.911 . . . . 0.0 109.179 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.653 HG22 ' HB2' ' A' ' 79' ' ' TYR . 43.8 t -68.78 -41.35 82.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.333 -0.854 . . . . 0.0 109.279 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.55 ' HB2' HD11 ' A' ' 42' ' ' ILE . 16.7 tttm -57.06 -50.82 71.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.277 -0.89 . . . . 0.0 109.487 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -62.31 -33.82 75.42 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.177 -0.952 . . . . 0.0 109.151 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.506 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 23.4 m120 -65.62 -33.65 76.4 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.302 -0.874 . . . . 0.0 109.284 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.82 HD12 HD13 ' A' ' 40' ' ' ILE . 79.2 mt -67.66 -45.37 84.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.271 -0.893 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -55.6 -46.19 77.35 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.895 . . . . 0.0 109.576 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.9 mttt -75.41 -36.04 60.9 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.605 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.58 ' HE3' ' CE1' ' A' ' 73' ' ' PHE . 28.6 tttp -54.72 -32.42 59.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.21 -0.931 . . . . 0.0 109.27 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 33' ' ' ILE . 99.2 t -88.5 -22.89 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.878 . . . . 0.0 109.504 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -72.24 -57.0 4.59 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.237 -0.914 . . . . 0.0 109.609 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.22 -24.17 66.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.536 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 48.1 p -98.43 -17.37 18.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.418 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 62.74 26.14 68.28 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.037 HG21 HD12 ' A' ' 36' ' ' LEU . 76.7 mt -97.38 77.48 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.176 -1.191 . . . . 0.0 109.438 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.411 ' O ' ' HG2' ' A' ' 34' ' ' LYS . 17.8 tttp -89.72 22.85 2.89 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.29 -0.881 . . . . 0.0 109.129 179.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 1.071 ' O ' HD13 ' A' ' 65' ' ' ILE . 92.0 m-20 -118.27 -9.46 10.42 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.37 -0.831 . . . . 0.0 109.572 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.037 HD12 HG21 ' A' ' 33' ' ' ILE . 96.9 mt -97.47 -51.74 4.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.905 . . . . 0.0 109.387 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.569 HG11 ' CG2' ' A' ' 24' ' ' ILE . 59.3 t -94.73 136.12 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.258 -0.902 . . . . 0.0 109.245 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.89 -119.99 3.84 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 86.4 mtt180 -91.76 139.97 30.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.295 -1.12 . . . . 0.0 109.825 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 1.164 HG23 HG22 ' A' ' 62' ' ' VAL . 29.4 mt -107.91 133.39 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.397 -0.815 . . . . 0.0 109.115 179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.767 HG23 ' CH2' ' A' ' 7' ' ' TRP . 25.8 t -121.99 132.56 70.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.175 -0.953 . . . . 0.0 109.25 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.581 HG22 HG13 ' A' ' 44' ' ' ILE . 4.5 mt -124.67 125.81 25.46 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.267 -0.896 . . . . 0.0 109.577 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.614 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 49.1 Cg_endo -68.4 -2.75 9.66 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.858 2.372 . . . . 0.0 111.422 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.878 HG23 ' HG2' ' A' ' 54' ' ' LYS . 87.7 mt . . . . . 0 N--CA 1.49 1.53 0 O-C-N 121.35 -0.843 . . . . 0.0 109.602 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.878 ' HG2' HG23 ' A' ' 44' ' ' ILE . 1.3 mttp . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.614 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 35.0 mt -59.7 -41.83 91.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.112 -0.993 . . . . 0.0 108.654 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.496 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 88.1 m-85 -129.19 105.1 17.93 Favored Pre-proline 0 N--CA 1.489 1.48 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.7 136.13 48.22 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.484 2.122 . . . . 0.0 112.093 -179.046 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.34 -18.47 4.36 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.6 m-30 -95.77 129.24 43.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.666 -1.49 . . . . 0.0 110.51 -178.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 36.1 t -133.23 147.07 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.683 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 9.6 m-85 -108.79 124.67 50.95 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.856 -1.153 . . . . 0.0 109.861 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 1.164 HG22 HG23 ' A' ' 40' ' ' ILE . 61.9 t -135.62 146.76 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.904 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.592 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 26.4 tt0 -110.88 127.41 55.43 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.739 ' HE1' HG11 ' A' ' 74' ' ' VAL . 40.4 mtm -152.16 163.65 38.95 Favored 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 118.757 -1.177 . . . . 0.0 111.304 -178.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 1.071 HD13 ' O ' ' A' ' 35' ' ' ASN . 2.3 pt -82.64 124.81 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.488 ' CE ' ' HG2' ' A' ' 89' ' ' GLN . 94.9 mmm -76.23 142.72 41.35 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.146 -0.971 . . . . 0.0 109.885 -178.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 m-20 177.31 170.18 0.58 Allowed 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -68.79 -41.6 78.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.128 -0.982 . . . . 0.0 109.454 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -78.08 -29.61 49.22 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.173 -0.954 . . . . 0.0 109.85 -179.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.028 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -72.86 -48.92 33.45 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.12 -0.987 . . . . 0.0 109.479 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.442 ' CE1' ' HG3' ' A' ' 89' ' ' GLN . 75.1 t80 -61.22 -48.1 83.06 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.258 -0.901 . . . . 0.0 109.564 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -61.46 -29.32 69.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.209 -0.932 . . . . 0.0 109.777 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.58 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 48.7 t80 -80.78 -41.74 22.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.121 -0.987 . . . . 0.0 109.472 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 1.028 HG23 ' O ' ' A' ' 70' ' ' ALA . 4.2 t -68.76 -56.23 12.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.33 -0.856 . . . . 0.0 109.511 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.1 tpt85 -54.59 -17.34 3.18 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.358 -0.838 . . . . 0.0 109.735 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 26.2 p -91.3 6.91 43.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.26 -0.9 . . . . 0.0 109.872 -179.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.598 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 25.1 t -64.43 137.85 97.26 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.052 -1.03 . . . . 0.0 109.542 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.585 ' HB2' ' CE2' ' A' ' 79' ' ' TYR . 47.7 Cg_endo -68.47 137.63 40.01 Favored 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 122.718 2.278 . . . . 0.0 111.778 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.653 ' HB2' HG22 ' A' ' 20' ' ' VAL . 17.5 m-85 76.17 -4.64 2.32 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.388 -0.82 . . . . 0.0 109.712 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.598 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 5.4 t -87.02 129.66 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.055 -1.028 . . . . 0.0 109.101 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 98.9 mmm -88.14 -7.17 57.31 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.517 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.07 -145.23 15.84 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.646 ' CD2' HG22 ' A' ' 10' ' ' VAL . 1.4 m-85 -140.49 148.6 41.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -1.183 . . . . 0.0 109.708 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.535 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 3.4 p -75.78 134.61 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.246 -0.909 . . . . 0.0 109.344 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.465 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.3 p -162.94 163.74 26.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.204 -0.935 . . . . 0.0 109.664 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.0 m -91.43 -33.34 15.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.37 -0.831 . . . . 0.0 109.421 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -124.98 -84.32 0.58 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.554 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -110.31 -135.24 6.97 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.554 ' C ' ' O ' ' A' ' 88' ' ' GLY . 1.0 OUTLIER -29.49 150.45 0.03 OUTLIER Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.584 -0.951 . . . . 0.0 110.302 -179.484 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.577 ' HG3' ' CB ' ' A' ' 83' ' ' PHE . 50.1 Cg_endo -68.22 142.05 54.14 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.899 2.399 . . . . 0.0 112.153 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . 0.754 HG23 ' HD2' ' A' ' 92' ' ' PRO . 3.7 p -75.69 144.67 77.28 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 109.26 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.754 ' HD2' HG23 ' A' ' 91' ' ' VAL . 46.0 Cg_endo -68.34 150.28 76.0 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.61 2.207 . . . . 0.0 111.806 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.4 t -76.53 137.95 21.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.291 -0.881 . . . . 0.0 109.533 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.1 tttp -74.19 132.99 42.71 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.313 -0.867 . . . . 0.0 109.415 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.405 ' C ' ' O ' ' A' ' 94' ' ' LYS . 79.3 m-20 -44.11 -41.7 5.79 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.448 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.424 ' HB2' ' HD3' ' A' ' 94' ' ' LYS . 53.1 mtp180 -60.85 -27.03 67.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.278 -0.889 . . . . 0.0 109.497 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.516 ' N ' ' O ' ' A' ' 94' ' ' LYS . 45.1 mt-10 -86.6 -26.06 24.62 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.241 -0.912 . . . . 0.0 109.398 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.505 ' O ' HD12 ' A' ' 102' ' ' LEU . 27.9 mmm -85.59 -22.97 27.79 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.219 -0.926 . . . . 0.0 109.5 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.616 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.1 OUTLIER -42.61 -49.09 13.23 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.29 -0.881 . . . . 0.0 109.887 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.616 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 51.9 Cg_endo -74.2 -27.32 11.75 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.435 2.09 . . . . 0.0 111.672 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.578 HG21 ' CD2' ' A' ' 61' ' ' PHE . 33.8 mm -80.87 -38.75 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.333 -0.855 . . . . 0.0 109.344 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -69.27 -40.07 78.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.313 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.582 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 19.5 ttm180 -64.36 -50.42 67.78 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.904 . . . . 0.0 109.308 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.549 HD23 ' C ' ' A' ' 104' ' ' LEU . 6.8 tt -72.29 -36.19 68.88 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.296 -0.877 . . . . 0.0 109.216 179.713 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -69.76 -2.93 13.36 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.308 -0.87 . . . . 0.0 109.908 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.86 8.98 86.74 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.445 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 1.0 OUTLIER -72.53 -17.05 61.77 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -1.17 . . . . 0.0 109.416 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.241 -0.912 . . . . 0.0 109.517 179.897 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.43 ' HE1' HG21 ' A' ' 146' ' ' ILE . 8.9 p90 . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.428 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 13.9 mmtt -137.77 165.22 26.97 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -0.925 . . . . 0.0 109.758 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.614 HG23 ' O ' ' A' ' 144' ' ' LYS . 14.2 p -62.42 143.13 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.316 -0.865 . . . . 0.0 109.536 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.68 -33.11 3.54 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.428 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 31.8 m-20 -49.67 159.19 0.39 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.532 -0.981 . . . . 0.0 109.247 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 2.0 ttp -94.19 127.62 40.14 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.136 -0.978 . . . . 0.0 109.008 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.794 HG21 HD11 ' A' ' 143' ' ' ILE . 5.9 t -125.99 142.49 42.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.361 -0.837 . . . . 0.0 109.28 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.494 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 22.2 tttp -105.41 142.13 35.7 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.405 -0.809 . . . . 0.0 108.875 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 1.029 HD12 ' HB3' ' A' ' 139' ' ' PHE . 66.9 mt -83.3 155.1 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.186 -0.946 . . . . 0.0 108.618 179.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.496 HG12 ' HA ' ' A' ' 173' ' ' VAL . 29.1 pt -150.62 2.8 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.076 -1.015 . . . . 0.0 109.549 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 72.3 m -148.19 144.44 27.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.071 -1.018 . . . . 0.0 109.992 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 104.29 -167.99 16.23 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.582 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 48.3 Cg_endo -68.97 -20.74 38.21 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 123.124 2.549 . . . . 0.0 112.408 -179.544 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.534 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.3 m-85 -110.31 15.95 21.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.829 -1.169 . . . . 0.0 109.435 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.642 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.7 tt0 -43.8 143.26 1.09 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.486 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.521 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 16.4 m-20 75.85 27.65 0.94 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.374 -0.829 . . . . 0.0 110.258 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 1.029 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.3 t80 -117.68 133.58 55.8 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.021 -1.049 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -82.96 133.75 35.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.127 -0.983 . . . . 0.0 109.653 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.412 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.15 167.34 27.36 Favored Glycine 0 N--CA 1.49 2.279 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.098 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.743 ' C ' HG23 ' A' ' 155' ' ' VAL . 58.4 t -110.38 136.92 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.442 -1.034 . . . . 0.0 109.404 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 1.068 HG21 HD11 ' A' ' 146' ' ' ILE . 43.2 mm -69.36 118.69 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.614 ' O ' HG23 ' A' ' 125' ' ' VAL . 47.3 tttp -98.17 -32.35 11.63 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.041 -1.037 . . . . 0.0 109.557 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 144' ' ' LYS . 85.7 mt-10 -157.68 153.33 26.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.058 -1.026 . . . . 0.0 110.073 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 1.082 HG23 HD22 ' A' ' 153' ' ' LEU . 6.1 mm -123.65 126.49 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.406 -0.809 . . . . 0.0 109.591 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -108.85 99.37 34.37 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.349 -0.845 . . . . 0.0 109.476 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.549 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.2 Cg_endo -71.21 173.77 11.74 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.739 2.293 . . . . 0.0 111.764 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.549 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.5 mt-10 79.97 -20.98 0.35 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.358 -0.839 . . . . 0.0 109.865 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.402 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 32.6 mtp180 -128.78 -13.4 4.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.079 -1.013 . . . . 0.0 109.476 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.425 ' O ' HG12 ' A' ' 170' ' ' VAL . 37.8 mt-30 69.58 48.22 0.62 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.283 -0.886 . . . . 0.0 109.685 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.864 ' O ' HD23 ' A' ' 153' ' ' LEU . 59.5 tt0 -120.41 144.25 48.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.964 . . . . 0.0 108.936 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 1.082 HD22 HG23 ' A' ' 146' ' ' ILE . 29.4 mt -130.12 131.01 45.53 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.078 -1.014 . . . . 0.0 110.083 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 13.6 mttt -93.07 130.9 38.53 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.758 HG12 HD11 ' A' ' 168' ' ' LEU . 13.9 p -132.7 147.48 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.096 -1.003 . . . . 0.0 110.057 -179.521 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.562 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.6 m-20 -96.7 117.0 30.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.464 -0.773 . . . . 0.0 109.265 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.415 HG13 ' CE1' ' A' ' 139' ' ' PHE . 44.9 t -96.79 141.38 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 109.501 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.408 ' HA ' ' O ' ' A' ' 162' ' ' ARG . 73.5 m -96.07 94.91 7.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.273 -0.892 . . . . 0.0 109.929 -179.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.561 HG22 ' CD2' ' A' ' 160' ' ' PHE . 6.2 mt -118.22 140.78 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.25 -0.906 . . . . 0.0 109.422 179.483 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.683 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 97.3 m-85 62.25 40.16 11.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.331 -0.855 . . . . 0.0 109.337 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.48 17.9 34.87 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.412 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 36.9 mtt-85 -128.29 156.12 43.52 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.179 -1.189 . . . . 0.0 109.618 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -99.84 134.23 43.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.886 . . . . 0.0 109.558 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 37.3 m -143.11 127.44 9.59 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.303 -0.873 . . . . 0.0 109.554 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.562 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.3 Cg_endo -69.63 135.18 30.09 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.76 2.307 . . . . 0.0 111.544 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 34.5 t -123.49 142.59 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.986 . . . . 0.0 109.861 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.737 HG13 ' OE2' ' A' ' 152' ' ' GLU . 29.4 t -93.78 119.35 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.403 -0.81 . . . . 0.0 109.485 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.758 HD11 HG12 ' A' ' 155' ' ' VAL . 0.0 OUTLIER -141.91 168.65 19.25 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.209 -0.932 . . . . 0.0 110.413 -179.651 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.501 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 42.3 m170 -83.51 140.6 32.2 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.932 HG23 HD11 ' A' ' 153' ' ' LEU . 7.5 p -54.91 -36.33 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.26 -0.9 . . . . 0.0 109.183 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.412 ' N ' HG13 ' A' ' 170' ' ' VAL . 84.4 p -75.84 -7.26 54.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -0.868 . . . . 0.0 109.707 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.501 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 84.3 mt-10 -87.61 -2.44 58.61 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.069 -1.019 . . . . 0.0 109.647 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . 0.496 ' HA ' HG12 ' A' ' 132' ' ' ILE . 3.7 m -142.05 175.91 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.191 -0.943 . . . . 0.0 109.446 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.546 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 76.2 tt0 -140.57 167.26 22.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.281 -0.887 . . . . 0.0 108.932 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.546 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.1 tttp . . . . . 0 N--CA 1.49 1.557 0 O-C-N 121.03 -1.044 . . . . 0.0 109.6 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.491 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 74.8 mttt . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 121.23 0.538 . . . . 0.0 109.658 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.566 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 10.9 mttp -129.17 175.63 8.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.291 -0.881 . . . . 0.0 109.259 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.876 ' O ' HG23 ' A' ' 93' ' ' VAL . 56.7 m95 -112.38 124.69 53.05 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.262 -0.899 . . . . 0.0 109.233 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.45 ' CD1' ' HA ' ' A' ' 92' ' ' PRO . 62.6 m-85 -117.36 171.81 7.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.189 -0.944 . . . . 0.0 109.335 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.565 HG12 ' CZ ' ' A' ' 61' ' ' PHE . 40.9 mt -112.49 107.83 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.174 -0.954 . . . . 0.0 108.995 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.881 ' CG1' HG13 ' A' ' 60' ' ' VAL . 10.8 p -83.5 146.05 7.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.208 -0.932 . . . . 0.0 109.465 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.526 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.0 OUTLIER -90.77 142.25 27.95 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.525 -0.734 . . . . 0.0 109.67 -179.667 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.764 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.1 t -154.97 -176.07 5.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.299 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.423 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 58.2 mtm -102.23 125.66 48.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.187 -0.946 . . . . 0.0 109.445 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.4 m -45.59 128.02 8.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -0.936 . . . . 0.0 109.536 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.21 -19.46 37.38 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.797 ' O ' HG23 ' A' ' 20' ' ' VAL . 94.1 m-85 -108.19 -7.91 15.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.313 -1.11 . . . . 0.0 109.436 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.832 ' OE1' HD11 ' A' ' 44' ' ' ILE . 47.9 mt-10 -47.93 -53.91 14.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.474 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -55.62 -37.05 67.66 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.239 -0.913 . . . . 0.0 109.346 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.516 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 88.5 mttt -73.25 -34.86 66.07 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 109.372 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.797 HG23 ' O ' ' A' ' 16' ' ' TYR . 13.4 t -66.69 -46.6 85.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.211 -0.931 . . . . 0.0 109.414 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 23.2 tttt -58.92 -48.44 81.48 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.278 -0.889 . . . . 0.0 109.666 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.9 mt-10 -65.71 -40.26 92.06 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.219 -0.926 . . . . 0.0 109.507 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.53 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 92.7 m-20 -60.45 -42.06 95.35 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.218 -0.926 . . . . 0.0 109.379 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.62 ' O ' HG23 ' A' ' 28' ' ' VAL . 96.7 mt -64.38 -44.64 97.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.307 -0.871 . . . . 0.0 109.552 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.459 ' O ' ' HG3' ' A' ' 29' ' ' GLU . 87.9 mt-10 -59.23 -47.02 86.91 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.172 -0.955 . . . . 0.0 110.036 -179.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.2 ttpt -80.19 -38.39 31.36 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.049 -1.032 . . . . 0.0 109.731 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.585 ' HG2' ' CE1' ' A' ' 73' ' ' PHE . 19.3 tttt -57.16 -25.64 59.26 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.331 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.856 HG21 HG11 ' A' ' 37' ' ' VAL . 89.4 t -88.07 -26.98 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.301 -0.875 . . . . 0.0 109.482 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.459 ' HG3' ' O ' ' A' ' 25' ' ' GLU . 93.1 mt-10 -66.92 -47.65 71.07 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.504 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.12 -28.91 69.96 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -0.888 . . . . 0.0 109.365 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 71.9 p -89.03 -12.02 42.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.286 -0.884 . . . . 0.0 109.322 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 61.07 24.04 62.53 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.844 ' CG2' HD23 ' A' ' 36' ' ' LEU . 54.7 mt -101.35 74.43 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -1.139 . . . . 0.0 109.552 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.6 mttp -85.26 -3.8 58.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.336 -0.853 . . . . 0.0 109.597 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.435 ' O ' HD13 ' A' ' 65' ' ' ILE . 90.5 m-20 -93.12 -7.01 46.68 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.209 -0.932 . . . . 0.0 109.4 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.019 HD12 ' HB2' ' A' ' 70' ' ' ALA . 4.4 mm? -95.66 -50.83 4.77 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.267 -0.895 . . . . 0.0 109.34 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.856 HG11 HG21 ' A' ' 28' ' ' VAL . 8.7 p -95.35 139.16 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.381 -0.824 . . . . 0.0 109.554 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.1 -122.16 4.07 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 88.6 mtt-85 -95.34 142.7 27.43 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.223 -1.163 . . . . 0.0 109.706 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.954 HG23 HG22 ' A' ' 62' ' ' VAL . 75.4 mt -109.73 137.5 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.196 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.632 HG13 ' HB2' ' A' ' 61' ' ' PHE . 7.7 p -127.93 162.08 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.169 -0.957 . . . . 0.0 109.36 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.632 HG21 HD12 ' A' ' 44' ' ' ILE . 5.9 mt -144.2 130.13 9.87 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.167 -0.958 . . . . 0.0 109.902 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.515 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.1 Cg_endo -66.36 -3.71 9.33 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.861 2.374 . . . . 0.0 111.478 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.832 HD11 ' OE1' ' A' ' 17' ' ' GLU . 61.0 mt . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.89 . . . . 0.0 109.508 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.804 ' HG2' HG23 ' A' ' 44' ' ' ILE . 3.6 mttp . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.593 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 16.9 tp -65.25 -22.3 66.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.863 -1.148 . . . . 0.0 109.775 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.593 ' CE2' ' HG ' ' A' ' 55' ' ' LEU . 95.8 m-85 -148.37 98.17 3.73 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.21 -0.931 . . . . 0.0 108.818 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -65.86 140.56 61.53 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.723 2.282 . . . . 0.0 112.205 -179.243 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.4 -10.89 10.21 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -107.25 132.6 52.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.749 -1.442 . . . . 0.0 110.291 -179.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.881 HG13 ' CG1' ' A' ' 10' ' ' VAL . 0.2 OUTLIER -135.22 151.4 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 179.001 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.632 ' HB2' HG13 ' A' ' 41' ' ' VAL . 14.0 m-85 -111.73 126.56 55.18 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.948 -1.095 . . . . 0.0 110.258 -179.14 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.954 HG22 HG23 ' A' ' 40' ' ' ILE . 67.1 t -130.22 141.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.547 -0.721 . . . . 0.0 109.66 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.601 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 10.8 tt0 -104.16 125.92 50.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 108.766 179.538 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.495 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 30.7 mtm -156.18 172.92 17.61 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.019 -1.051 . . . . 0.0 110.783 -179.073 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.628 ' CG1' HD13 ' A' ' 36' ' ' LEU . 4.8 pt -95.17 130.48 43.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.477 ' SD ' ' NE2' ' A' ' 89' ' ' GLN . 4.1 tpp -76.04 143.34 41.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.3 -0.875 . . . . 0.0 110.037 -178.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.468 ' HB2' ' O ' ' A' ' 66' ' ' MET . 42.6 t30 176.69 175.78 0.33 Allowed 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 69' ' ' GLU . 28.6 p-10 -71.6 -40.45 69.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.145 -0.972 . . . . 0.0 109.406 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.473 ' N ' ' OD1' ' A' ' 68' ' ' ASP . 71.0 mm-40 -73.23 -35.5 66.28 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.362 -0.836 . . . . 0.0 109.716 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.019 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -67.63 -47.87 68.37 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 109.589 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.546 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 84.0 t80 -59.77 -51.57 69.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.676 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -57.48 -29.03 63.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.239 -0.913 . . . . 0.0 109.876 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.696 ' CE2' HG22 ' A' ' 28' ' ' VAL . 65.9 t80 -80.4 -40.79 25.78 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.113 -0.992 . . . . 0.0 109.929 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 1.008 HG23 ' O ' ' A' ' 70' ' ' ALA . 2.6 t -64.63 -60.33 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.185 -0.947 . . . . 0.0 109.92 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.463 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 10.8 tpt180 -51.58 -42.92 62.26 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.097 -1.002 . . . . 0.0 109.736 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.423 ' HB3' ' HZ1' ' A' ' 27' ' ' LYS . 22.8 t -67.58 1.24 2.5 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.11 -0.994 . . . . 0.0 110.244 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.616 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 30.7 t -62.29 133.98 94.59 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 120.928 -1.107 . . . . 0.0 109.317 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.571 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 46.0 Cg_endo -68.0 136.08 36.95 Favored 'Trans proline' 0 C--O 1.213 -0.738 0 C-N-CA 122.727 2.285 . . . . 0.0 111.866 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.571 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 54.3 m-85 77.61 -2.26 2.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.528 -0.733 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.616 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.0 t -87.45 126.96 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.102 -0.999 . . . . 0.0 109.162 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 66.1 mtp -90.02 -24.65 21.15 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 109.73 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.422 ' O ' ' N ' ' A' ' 11' ' ' LEU . . . 158.25 -158.04 28.85 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.59 ' HB2' ' HB3' ' A' ' 90' ' ' PRO . 15.3 p90 -140.56 154.13 46.4 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.243 -1.151 . . . . 0.0 109.506 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.493 ' CG2' ' CD2' ' A' ' 11' ' ' LEU . 47.5 t -81.73 113.45 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.137 -0.977 . . . . 0.0 109.466 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.533 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 5.3 p -145.2 164.66 30.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.226 -0.921 . . . . 0.0 109.498 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 23.9 m -86.47 -33.17 20.46 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.287 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -135.58 -76.91 0.09 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.55 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -109.61 -133.56 6.7 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.55 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.4 OUTLIER -29.49 150.31 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.63 -0.924 . . . . 0.0 110.315 -179.636 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.59 ' HB3' ' HB2' ' A' ' 83' ' ' PHE . 44.5 Cg_endo -67.81 147.45 75.1 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.833 2.355 . . . . 0.0 111.973 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . 0.766 HG23 ' HD2' ' A' ' 92' ' ' PRO . 3.4 p -80.81 144.69 56.22 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.317 -0.864 . . . . 0.0 109.369 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.766 ' HD2' HG23 ' A' ' 91' ' ' VAL . 47.3 Cg_endo -68.6 151.39 75.16 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.66 2.24 . . . . 0.0 111.715 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.876 HG23 ' O ' ' A' ' 7' ' ' TRP . 11.9 t -83.64 131.76 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.232 -0.918 . . . . 0.0 109.583 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 54.9 mttm -69.87 143.17 52.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.31 -0.868 . . . . 0.0 109.446 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -53.3 -39.97 64.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.25 -0.907 . . . . 0.0 109.596 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -57.98 -34.34 69.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.274 -0.891 . . . . 0.0 109.558 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.7 mt-10 -81.34 -25.41 36.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.266 -0.896 . . . . 0.0 109.525 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.696 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 98.6 mtp -84.1 -26.42 28.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.899 . . . . 0.0 109.58 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.58 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.4 OUTLIER -36.24 -54.24 1.53 Allowed Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.448 -0.783 . . . . 0.0 109.927 -179.838 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.58 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.5 Cg_endo -70.1 -28.2 23.93 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.481 2.121 . . . . 0.0 111.748 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.495 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 33.1 mm -80.57 -41.12 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.567 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.575 ' CB ' ' HB2' ' A' ' 108' ' ' GLU . 1.0 OUTLIER -67.85 -40.65 83.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.226 -0.921 . . . . 0.0 109.505 179.995 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.491 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 1.3 ttt85 -63.91 -49.52 72.33 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 109.212 179.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.21 -36.42 69.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.264 -0.898 . . . . 0.0 108.961 179.467 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.526 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -75.62 -4.11 38.23 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.436 -0.79 . . . . 0.0 109.641 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.66 11.47 83.06 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.506 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 7.1 mt -87.3 -28.09 22.48 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.158 -1.201 . . . . 0.0 109.724 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . 0.575 ' HB2' ' CB ' ' A' ' 102' ' ' LEU . 87.9 tt0 . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.247 -0.908 . . . . 0.0 109.469 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.482 ' HB3' ' HE2' ' A' ' 175' ' ' LYS . 50.7 p90 . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.446 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 20.8 mttm -146.48 155.65 42.69 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.131 -0.98 . . . . 0.0 109.869 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 144' ' ' LYS . 14.2 p -60.98 143.96 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -0.875 . . . . 0.0 109.584 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.09 -33.45 3.13 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.446 ' OD2' ' HB2' ' A' ' 124' ' ' LYS . 32.7 m-20 -48.78 163.13 0.08 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.38 -1.07 . . . . 0.0 109.207 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.8 ttm -96.3 126.72 41.7 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.051 -1.031 . . . . 0.0 108.807 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.907 HG23 ' O ' ' A' ' 174' ' ' GLU . 5.6 p -124.3 141.28 45.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.108 -0.995 . . . . 0.0 109.262 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.522 ' N ' ' O ' ' A' ' 174' ' ' GLU . 35.9 tttp -104.34 144.21 31.94 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.206 -0.934 . . . . 0.0 108.956 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.997 HD12 ' HB3' ' A' ' 139' ' ' PHE . 95.7 mt -85.69 152.01 3.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.116 -0.99 . . . . 0.0 108.623 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . . . . . . . . . 42.1 pt -150.32 2.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.162 -0.961 . . . . 0.0 109.434 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.478 ' HB2' ' CB ' ' A' ' 172' ' ' GLU . 75.4 m -148.26 144.48 27.66 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.145 -0.972 . . . . 0.0 109.912 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.75 -165.28 18.89 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.491 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 46.9 Cg_endo -68.03 -21.82 42.51 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 123.202 2.602 . . . . 0.0 112.811 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.555 ' HB2' HD13 ' A' ' 131' ' ' ILE . 97.5 m-85 -108.29 15.78 23.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.834 -1.166 . . . . 0.0 109.604 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.597 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.4 tt0 -42.96 139.94 1.56 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.176 -0.953 . . . . 0.0 109.384 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.522 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 18.6 m-20 75.21 24.95 1.37 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.368 -0.832 . . . . 0.0 110.335 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.997 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.5 t80 -115.71 135.8 53.68 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.961 -1.087 . . . . 0.0 109.421 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.34 133.5 34.14 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.177 -0.952 . . . . 0.0 109.692 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.495 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.02 170.89 25.74 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.294 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.716 ' C ' HG13 ' A' ' 155' ' ' VAL . 40.8 t -116.12 135.72 55.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.447 -1.031 . . . . 0.0 109.357 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.874 HD11 ' HD2' ' A' ' 175' ' ' LYS . 70.8 mt -67.56 115.87 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.257 -0.902 . . . . 0.0 109.192 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.516 ' O ' HG23 ' A' ' 125' ' ' VAL . 2.0 tttp -98.08 -33.74 11.04 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.036 -1.04 . . . . 0.0 109.502 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.412 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 75.3 mm-40 -151.01 146.03 25.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.114 -0.991 . . . . 0.0 109.536 179.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 1.044 HG22 HD22 ' A' ' 153' ' ' LEU . 23.8 pt -122.25 125.88 73.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.135 -0.978 . . . . 0.0 109.488 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.37 100.6 34.53 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.268 -0.895 . . . . 0.0 109.5 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.56 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.2 Cg_endo -71.18 171.12 16.61 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.704 2.269 . . . . 0.0 111.779 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.56 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.8 mt-10 80.95 -20.48 0.37 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.399 -0.813 . . . . 0.0 109.899 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.433 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 88.6 mtt180 -127.75 -12.01 5.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.086 -1.009 . . . . 0.0 109.526 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.433 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 31.5 mt-30 69.23 48.91 0.64 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.665 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -122.22 145.81 47.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.09 -1.006 . . . . 0.0 109.097 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 1.044 HD22 HG22 ' A' ' 146' ' ' ILE . 60.6 mt -138.42 115.29 10.78 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.075 -1.016 . . . . 0.0 110.147 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 27.3 mttm -78.85 133.56 37.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.3 -0.875 . . . . 0.0 108.643 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.716 HG13 ' C ' ' A' ' 142' ' ' VAL . 53.9 t -127.44 151.17 33.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.182 -0.949 . . . . 0.0 109.762 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 26.2 t-20 -98.0 117.6 32.7 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.237 -0.914 . . . . 0.0 109.352 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.506 HG13 ' CE1' ' A' ' 139' ' ' PHE . 39.7 t -101.03 143.41 14.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.252 -0.905 . . . . 0.0 109.708 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 93.1 m -94.74 91.26 6.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.383 -0.823 . . . . 0.0 109.724 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.502 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 8.6 mt -115.78 140.54 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.424 179.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.411 ' CZ ' ' HZ ' ' A' ' 61' ' ' PHE . 8.4 m-85 60.54 41.21 15.93 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.376 -0.827 . . . . 0.0 109.334 -179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.05 16.28 12.9 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 92.4 mtt-85 -126.26 148.3 49.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.201 -1.176 . . . . 0.0 109.39 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . 0.504 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 94.3 mt-10 -94.81 135.77 35.91 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.278 -0.889 . . . . 0.0 109.679 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . 0.51 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 49.7 m -147.2 128.18 7.1 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.274 -0.891 . . . . 0.0 109.735 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.538 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.49 139.69 38.26 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.746 2.297 . . . . 0.0 111.46 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.4 p -126.61 145.79 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.089 -1.007 . . . . 0.0 109.869 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.434 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 5.3 t -92.54 118.86 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.459 -0.775 . . . . 0.0 109.505 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.434 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 19.3 mt -141.52 167.23 22.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.184 -0.947 . . . . 0.0 110.495 -179.302 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -83.97 141.34 31.29 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.71 -0.619 . . . . 0.0 109.5 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 4.1 p -56.42 -36.28 46.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.287 -0.883 . . . . 0.0 109.319 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 53.8 p -75.96 -7.18 54.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -0.883 . . . . 0.0 109.828 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.478 ' CB ' ' HB2' ' A' ' 133' ' ' SER . 64.5 mt-10 -99.75 -2.23 35.73 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.086 -1.009 . . . . 0.0 109.404 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 12.7 m -132.48 170.1 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.23 -0.919 . . . . 0.0 109.627 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.907 ' O ' HG23 ' A' ' 129' ' ' VAL . 53.5 tt0 -129.87 145.14 51.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.293 -0.88 . . . . 0.0 109.343 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.874 ' HD2' HD11 ' A' ' 143' ' ' ILE . 34.4 mmtm . . . . . 0 N--CA 1.489 1.52 0 O-C-N 121.024 -1.048 . . . . 0.0 109.514 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.476 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 20.0 mttm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.284 0.564 . . . . 0.0 109.625 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 16.8 mmtp -127.47 172.07 11.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.329 -0.857 . . . . 0.0 109.39 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.959 ' O ' HG23 ' A' ' 93' ' ' VAL . 46.3 m95 -106.34 128.24 53.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.335 -0.853 . . . . 0.0 109.142 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.541 ' CE1' ' CE ' ' A' ' 66' ' ' MET . 74.8 m-85 -120.35 160.96 22.0 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.214 -0.929 . . . . 0.0 109.359 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.524 ' HB ' HG12 ' A' ' 84' ' ' VAL . 97.1 mt -102.66 115.35 44.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.233 -0.917 . . . . 0.0 109.252 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.508 HG11 HG22 ' A' ' 80' ' ' VAL . 84.2 t -91.35 141.28 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.224 -0.923 . . . . 0.0 109.452 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.512 HD13 ' HA ' ' A' ' 11' ' ' LEU . 3.2 mm? -84.74 144.23 28.64 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.28 -0.888 . . . . 0.0 109.308 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.693 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.9 t -155.86 -176.56 6.02 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.167 -0.958 . . . . 0.0 109.271 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.417 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 56.8 mtm -104.71 123.73 48.13 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.25 -0.906 . . . . 0.0 109.568 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.455 ' OG ' ' HB2' ' A' ' 57' ' ' PRO . 2.6 m -45.32 128.32 7.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.408 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.3 -19.98 33.52 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.501 ' O ' ' N ' ' A' ' 19' ' ' LYS . 77.1 m-85 -111.64 -9.3 14.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.297 -1.119 . . . . 0.0 109.441 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.693 ' HG2' HG21 ' A' ' 12' ' ' THR . 92.6 mt-10 -43.3 -41.54 4.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.23 -0.919 . . . . 0.0 109.543 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -63.57 -31.3 72.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 109.302 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.501 ' N ' ' O ' ' A' ' 16' ' ' TYR . 27.7 mttm -76.94 -56.43 4.6 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.276 -0.89 . . . . 0.0 109.352 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.565 ' CG1' ' HA ' ' A' ' 17' ' ' GLU . 2.0 p -44.72 -49.73 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.415 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.751 ' HD2' HD11 ' A' ' 42' ' ' ILE . 10.5 tttm -61.03 -48.32 82.32 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.207 -0.933 . . . . 0.0 109.874 -179.711 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -62.96 -35.48 80.29 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.07 -1.019 . . . . 0.0 109.504 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.497 ' HB3' ' HG2' ' A' ' 78' ' ' PRO . 33.9 m120 -64.92 -37.54 87.99 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.308 -0.87 . . . . 0.0 109.22 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.5 HG21 HD11 ' A' ' 40' ' ' ILE . 89.0 mt -63.19 -45.62 98.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.3 -0.875 . . . . 0.0 109.478 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -55.41 -46.77 76.6 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.214 -0.929 . . . . 0.0 109.715 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 27.7 ttmt -76.06 -35.63 59.34 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.261 -0.899 . . . . 0.0 109.456 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.608 ' O ' HG23 ' A' ' 31' ' ' THR . 44.2 tptt -54.93 -32.33 61.16 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.918 . . . . 0.0 109.242 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.851 HG13 ' O ' ' A' ' 33' ' ' ILE . 77.5 t -87.13 -22.91 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.329 -0.857 . . . . 0.0 109.406 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -71.32 -55.4 8.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.669 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.39 -31.16 71.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.186 -0.946 . . . . 0.0 109.684 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.608 HG23 ' O ' ' A' ' 27' ' ' LYS . 29.5 p -87.32 -20.92 26.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.118 -0.989 . . . . 0.0 109.491 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 68.21 22.07 74.26 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.851 ' O ' HG13 ' A' ' 28' ' ' VAL . 63.4 mt -98.89 79.45 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -1.142 . . . . 0.0 109.449 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -85.09 -17.23 38.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.236 -0.915 . . . . 0.0 109.24 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -84.24 5.01 28.25 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.317 -0.865 . . . . 0.0 109.482 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.043 HD12 ' CG1' ' A' ' 65' ' ' ILE . 12.5 tp -105.98 -54.26 2.51 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.176 -0.953 . . . . 0.0 109.37 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.715 ' HB ' HG21 ' A' ' 28' ' ' VAL . 86.4 t -96.5 133.32 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.403 -0.81 . . . . 0.0 109.297 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.85 -123.4 5.26 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 89.7 mtt180 -93.52 147.49 22.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -1.125 . . . . 0.0 109.845 -179.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.865 HG23 HG22 ' A' ' 62' ' ' VAL . 70.2 mt -110.32 135.55 49.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.291 -0.88 . . . . 0.0 109.344 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.822 HG23 ' CH2' ' A' ' 7' ' ' TRP . 32.8 t -119.72 151.7 22.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.951 . . . . 0.0 109.39 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.751 HD11 ' HD2' ' A' ' 21' ' ' LYS . 10.5 mt -131.9 127.53 21.23 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.897 . . . . 0.0 109.442 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.527 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 46.2 Cg_endo -66.78 -4.46 11.21 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.862 2.375 . . . . 0.0 111.867 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.728 HG23 HG22 ' A' ' 42' ' ' ILE . 8.4 pt . . . . . 0 N--CA 1.489 1.497 0 O-C-N 121.12 -0.987 . . . . 0.0 109.387 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.604 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 7.6 mttp . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.527 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 24.7 mt -55.61 -45.43 77.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.105 -0.997 . . . . 0.0 109.269 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.455 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 89.3 m-85 -131.7 110.34 14.65 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.125 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.455 ' HB2' ' OG ' ' A' ' 14' ' ' SER . 43.1 Cg_endo -66.22 139.35 54.85 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.746 2.297 . . . . 0.0 112.184 -179.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.5 ' O ' HG22 ' A' ' 12' ' ' THR . . . 73.96 -9.83 8.43 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.5 m-30 -94.17 129.07 40.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.669 -1.489 . . . . 0.0 110.395 -179.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 44.8 t -130.22 137.75 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.419 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.503 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 8.0 m-85 -110.15 125.95 53.57 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.902 -1.124 . . . . 0.0 110.051 -179.462 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.865 HG22 HG23 ' A' ' 40' ' ' ILE . 55.8 t -138.51 149.92 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.418 -0.801 . . . . 0.0 109.805 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.635 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 61.6 tt0 -110.66 129.04 55.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 108.888 179.536 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.578 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 9.2 mtm -161.79 -176.06 5.04 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.137 -0.977 . . . . 0.0 109.804 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 1.043 ' CG1' HD12 ' A' ' 36' ' ' LEU . 18.9 pt -94.94 119.76 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.541 ' CE ' ' CE1' ' A' ' 8' ' ' TYR . 16.2 ttm -87.36 101.04 13.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.382 -0.824 . . . . 0.0 109.676 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' A' ' 66' ' ' MET . 84.8 m-20 -138.7 -166.54 2.03 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.303 -0.873 . . . . 0.0 108.895 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -71.17 -47.34 58.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.098 -1.001 . . . . 0.0 109.799 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 70' ' ' ALA . 93.7 mt-10 -70.84 -57.14 4.92 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.055 -1.028 . . . . 0.0 109.612 -179.736 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.007 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -44.51 -42.99 7.62 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.551 ' CD1' ' OE1' ' A' ' 89' ' ' GLN . 71.1 t80 -61.39 -54.84 38.4 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.267 -0.896 . . . . 0.0 109.696 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -51.58 -31.0 23.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.18 -0.95 . . . . 0.0 110.049 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -81.01 -41.95 21.9 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.144 -0.972 . . . . 0.0 109.766 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.976 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 47.4 t -70.96 -54.58 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.249 -0.907 . . . . 0.0 109.443 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.428 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 25.0 tpt85 -51.45 -18.62 1.11 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.182 -0.949 . . . . 0.0 109.211 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 66.3 p -101.65 5.89 41.73 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.41 -0.806 . . . . 0.0 109.925 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.713 HG23 ' HA ' ' A' ' 74' ' ' VAL . 17.2 t -60.86 135.57 92.89 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.013 -1.055 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.592 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 48.4 Cg_endo -69.14 129.39 18.16 Favored 'Trans proline' 0 C--O 1.213 -0.74 0 C-N-CA 122.776 2.318 . . . . 0.0 112.002 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.592 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 40.7 m-85 84.45 -10.13 0.88 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.665 -0.647 . . . . 0.0 109.56 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.593 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 4.9 t -84.92 127.3 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.177 -0.952 . . . . 0.0 109.257 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.484 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 78.4 mtp -87.0 -23.99 24.82 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.296 -0.877 . . . . 0.0 109.379 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.544 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 153.07 -155.58 26.21 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.976 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 1.6 m-85 -137.42 140.13 41.11 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.322 -1.105 . . . . 0.0 109.402 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.543 HG13 ' O ' ' A' ' 84' ' ' VAL . 11.5 p -64.85 125.41 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 109.519 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.545 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.7 p -159.35 161.69 35.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.241 -0.912 . . . . 0.0 109.516 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 85.8 p -92.01 -36.66 13.27 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.249 -0.907 . . . . 0.0 109.391 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -120.47 -88.19 1.04 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.515 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -104.25 -133.93 7.98 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.551 ' OE1' ' CD1' ' A' ' 71' ' ' TYR . 0.9 OUTLIER -34.25 155.06 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.547 -0.972 . . . . 0.0 110.134 -179.599 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.545 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.3 Cg_endo -68.47 163.72 35.55 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.824 2.349 . . . . 0.0 111.855 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.7 m -93.97 154.08 40.78 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.294 -0.879 . . . . 0.0 109.31 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.38 142.45 45.23 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.605 2.203 . . . . 0.0 111.796 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.959 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.3 t -73.04 131.49 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -0.899 . . . . 0.0 109.306 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . 0.484 ' O ' ' N ' ' A' ' 97' ' ' GLU . 42.2 mttm -71.6 132.75 45.09 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.193 -0.942 . . . . 0.0 109.264 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 94' ' ' LYS . 82.1 m-20 -44.46 -41.28 6.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.226 -0.921 . . . . 0.0 109.459 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -61.04 -24.91 66.55 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.265 -0.897 . . . . 0.0 109.502 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.484 ' N ' ' O ' ' A' ' 94' ' ' LYS . 54.2 mt-10 -87.14 -27.0 23.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.162 -0.961 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.644 ' SD ' HG11 ' A' ' 93' ' ' VAL . 37.4 mmm -84.63 -26.87 27.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.166 -0.959 . . . . 0.0 109.42 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.576 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 5.1 ttp180 -37.06 -54.98 1.75 Allowed Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.47 -0.769 . . . . 0.0 109.994 -179.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.1 Cg_endo -69.05 -27.21 30.13 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.535 2.157 . . . . 0.0 111.79 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.59 HG22 HG11 ' A' ' 41' ' ' VAL . 51.1 mm -81.44 -41.94 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.226 -0.921 . . . . 0.0 109.284 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.574 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -68.27 -40.13 81.95 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.219 -0.926 . . . . 0.0 109.231 179.754 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 21.2 mtt180 -62.77 -50.57 70.53 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.333 -0.854 . . . . 0.0 108.978 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -73.35 -35.34 65.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.459 -0.776 . . . . 0.0 109.11 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -71.99 -2.73 19.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.385 -0.822 . . . . 0.0 109.633 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.48 9.68 84.56 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.703 HD22 HG21 ' A' ' 41' ' ' VAL . 8.0 mp -80.9 -21.95 40.16 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.164 -1.198 . . . . 0.0 109.429 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 . . . . . 0 N--CA 1.49 1.536 0 O-C-N 121.381 -0.824 . . . . 0.0 109.501 179.914 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.528 ' CG ' ' HE2' ' A' ' 175' ' ' LYS . 31.4 p90 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.642 ' HA ' HD11 ' A' ' 146' ' ' ILE . 14.1 mttt -140.35 -174.52 3.97 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.034 -1.041 . . . . 0.0 110.076 -179.615 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 144' ' ' LYS . 13.8 p -61.78 141.94 16.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.451 -0.781 . . . . 0.0 109.677 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 86.72 -34.31 3.55 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.549 ' HB2' HD12 ' A' ' 143' ' ' ILE . 24.0 m-20 -49.29 158.73 0.36 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.316 -1.108 . . . . 0.0 109.633 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . 0.454 ' SD ' ' O ' ' A' ' 141' ' ' GLY . 2.7 tpp -95.53 127.91 41.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.336 -0.853 . . . . 0.0 108.871 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.683 HG22 ' CG1' ' A' ' 173' ' ' VAL . 2.0 p -127.72 143.83 39.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.264 -0.898 . . . . 0.0 109.816 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.451 ' O ' HG13 ' A' ' 173' ' ' VAL . 21.0 tttt -108.55 142.29 39.21 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.266 -0.896 . . . . 0.0 109.319 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 1.0 ' O ' HD13 ' A' ' 132' ' ' ILE . 96.6 mt -80.14 152.22 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.139 -0.976 . . . . 0.0 108.971 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 1.0 HD13 ' O ' ' A' ' 131' ' ' ILE . 1.1 mm -146.67 2.27 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.088 -1.007 . . . . 0.0 109.391 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.577 ' CA ' ' HG2' ' A' ' 137' ' ' GLU . 50.6 m -148.64 143.12 26.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.259 -0.9 . . . . 0.0 109.758 -179.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.462 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 105.77 -169.23 15.8 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -68.56 -19.98 41.73 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 123.317 2.678 . . . . 0.0 112.679 -179.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.521 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.6 m-85 -106.77 16.71 24.11 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.933 -1.104 . . . . 0.0 109.605 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.577 ' HG2' ' CA ' ' A' ' 133' ' ' SER . 62.9 mt-10 -41.58 139.01 1.22 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.163 -0.961 . . . . 0.0 110.073 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.568 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.8 OUTLIER 80.37 19.41 0.56 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.277 -0.89 . . . . 0.0 110.788 178.775 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.761 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.0 OUTLIER -108.18 141.67 39.57 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.794 -1.191 . . . . 0.0 109.565 179.798 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -94.53 135.95 35.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.225 -0.922 . . . . 0.0 109.22 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.494 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.83 168.99 27.38 Favored Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.571 -1.299 . . . . 0.0 110.5 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.682 ' C ' HG23 ' A' ' 155' ' ' VAL . 39.5 t -111.14 137.49 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.593 -0.945 . . . . 0.0 109.369 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.549 HD12 ' HB2' ' A' ' 127' ' ' ASP . 69.8 mt -68.71 118.26 12.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 109.303 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.661 ' O ' HG23 ' A' ' 125' ' ' VAL . 47.7 tttp -100.39 -33.29 10.43 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.975 -1.078 . . . . 0.0 109.561 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.435 ' HG2' ' O ' ' A' ' 144' ' ' LYS . 64.2 mt-10 -153.85 149.12 27.02 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.132 -0.98 . . . . 0.0 109.812 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 1.065 HG23 HD22 ' A' ' 153' ' ' LEU . 1.7 mt -124.33 127.59 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.354 -0.841 . . . . 0.0 109.379 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.13 104.1 55.77 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.628 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.528 ' O ' ' HB2' ' A' ' 149' ' ' GLU . 52.4 Cg_endo -72.35 173.21 13.47 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.72 2.28 . . . . 0.0 111.661 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.528 ' HB2' ' O ' ' A' ' 148' ' ' PRO . 39.5 mm-40 78.25 -22.0 0.31 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.397 -0.814 . . . . 0.0 110.062 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.437 ' NH1' ' HG3' ' A' ' 150' ' ' ARG . 0.6 OUTLIER -124.15 -15.5 6.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.1 -1.0 . . . . 0.0 109.119 179.776 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.456 ' HB3' HG11 ' A' ' 170' ' ' VAL . 30.9 mt-30 69.58 47.98 0.63 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.461 -0.774 . . . . 0.0 109.439 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.993 ' O ' HD23 ' A' ' 153' ' ' LEU . 97.8 mt-10 -119.76 143.56 47.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.215 -0.928 . . . . 0.0 109.081 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 1.065 HD22 HG23 ' A' ' 146' ' ' ILE . 14.4 mt -130.95 122.85 27.64 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.16 -0.963 . . . . 0.0 110.231 -179.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 13.9 mttt -85.57 129.78 34.74 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.682 HG23 ' C ' ' A' ' 142' ' ' VAL . 10.9 p -129.36 146.94 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.222 -0.923 . . . . 0.0 109.951 -179.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.543 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 3.7 m-20 -98.02 108.89 21.71 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.218 -0.926 . . . . 0.0 109.537 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.577 HG13 ' CE1' ' A' ' 139' ' ' PHE . 82.2 t -88.14 140.72 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.18 -0.95 . . . . 0.0 109.376 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 47.7 m -96.62 89.23 4.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.332 -0.855 . . . . 0.0 109.617 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.506 HG13 HG12 ' A' ' 157' ' ' VAL . 2.6 mt -115.74 144.87 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.192 -0.942 . . . . 0.0 109.395 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.503 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 18.7 m-85 61.93 37.41 15.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.276 -0.89 . . . . 0.0 109.226 -179.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.03 17.95 31.85 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.426 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 89.5 mtt-85 -127.66 157.49 40.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.216 -1.167 . . . . 0.0 109.481 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . 0.44 ' OE2' ' ND2' ' A' ' 156' ' ' ASN . 83.6 tt0 -100.82 133.35 45.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.327 -0.858 . . . . 0.0 109.591 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 79.7 m -144.04 127.3 8.83 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.905 . . . . 0.0 109.684 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.543 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.4 Cg_endo -70.98 137.16 31.33 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.723 2.282 . . . . 0.0 111.598 179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 46.1 t -125.66 144.48 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.229 -0.92 . . . . 0.0 109.862 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.413 ' O ' ' HG ' ' A' ' 168' ' ' LEU . 44.4 t -92.68 119.35 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.438 -0.789 . . . . 0.0 109.485 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.413 ' HG ' ' O ' ' A' ' 167' ' ' VAL . 1.4 mt -138.71 164.69 28.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.229 -0.92 . . . . 0.0 110.48 -179.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.495 ' HB2' ' HB2' ' A' ' 172' ' ' GLU . 88.6 m-70 -81.57 145.64 30.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.632 -0.668 . . . . 0.0 109.291 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.702 HG23 HD11 ' A' ' 153' ' ' LEU . 6.2 p -62.11 -35.73 70.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.305 -0.872 . . . . 0.0 108.982 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 82.9 p -78.59 -9.66 59.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.254 -0.904 . . . . 0.0 109.362 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.505 ' CB ' ' HB2' ' A' ' 133' ' ' SER . 46.8 mt-10 -97.69 -1.14 44.19 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.405 -0.809 . . . . 0.0 109.022 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . 0.683 ' CG1' HG22 ' A' ' 129' ' ' VAL . 97.9 t -126.14 163.25 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.297 -0.877 . . . . 0.0 109.412 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.548 ' N ' HG12 ' A' ' 173' ' ' VAL . 55.8 tt0 -137.26 154.95 50.02 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.314 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.541 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 19.8 mttt . . . . . 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.395 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.638 ' HG2' HG22 ' A' ' 65' ' ' ILE . 21.8 mttm . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 121.299 0.571 . . . . 0.0 109.575 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.6 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.6 mttt -131.53 173.1 11.45 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.16 -0.962 . . . . 0.0 109.407 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.794 ' HZ3' HG22 ' A' ' 41' ' ' VAL . 51.9 m95 -108.82 126.74 53.36 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.415 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.502 ' CZ ' ' SD ' ' A' ' 66' ' ' MET . 91.3 m-85 -116.2 168.55 10.01 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.329 -0.857 . . . . 0.0 109.492 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.506 HG12 ' CE1' ' A' ' 61' ' ' PHE . 36.5 mt -106.49 116.51 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.282 -0.886 . . . . 0.0 109.197 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.588 ' CG1' HG23 ' A' ' 80' ' ' VAL . 72.5 t -91.56 136.52 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.282 -0.886 . . . . 0.0 109.294 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.829 HD21 HG22 ' A' ' 84' ' ' VAL . 3.8 mm? -89.18 146.89 24.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.374 -0.829 . . . . 0.0 109.496 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.421 ' OG1' HG21 ' A' ' 20' ' ' VAL . 9.6 t -161.83 -168.03 1.84 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.302 -0.874 . . . . 0.0 109.362 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 67.3 mtp -107.38 134.5 50.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.242 -0.911 . . . . 0.0 109.492 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 11.0 t -54.74 130.25 39.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.291 -0.881 . . . . 0.0 109.393 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.46 -20.22 37.75 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -109.87 -3.23 16.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.285 -1.127 . . . . 0.0 109.717 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -47.48 -64.56 0.75 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.254 -0.903 . . . . 0.0 109.594 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.511 ' OE2' HD11 ' A' ' 44' ' ' ILE . 75.8 mm-40 -48.73 -38.87 22.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.183 -0.948 . . . . 0.0 109.435 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.466 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 54.1 tttp -66.77 -45.9 77.03 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.304 -0.872 . . . . 0.0 109.278 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.675 HG22 ' CB ' ' A' ' 79' ' ' TYR . 50.7 t -61.65 -44.5 98.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -0.91 . . . . 0.0 109.501 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.562 ' HG3' HG21 ' A' ' 40' ' ' ILE . 48.1 tttt -60.51 -45.62 93.13 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -0.957 . . . . 0.0 109.219 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -65.72 -40.42 92.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.315 -0.866 . . . . 0.0 109.347 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.575 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 31.2 m120 -60.59 -46.15 91.3 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.337 -0.852 . . . . 0.0 109.431 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.406 HG21 HD11 ' A' ' 40' ' ' ILE . 95.0 mt -56.01 -42.87 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.215 -0.928 . . . . 0.0 109.268 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -56.17 -43.56 78.5 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.193 -0.942 . . . . 0.0 109.594 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.428 ' HB3' ' HE2' ' A' ' 26' ' ' LYS . 47.9 mtpt -80.14 -35.62 36.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.208 -0.933 . . . . 0.0 109.434 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.427 ' HG2' HG23 ' A' ' 77' ' ' VAL . 11.5 tptt -54.69 -31.52 58.05 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.286 -0.883 . . . . 0.0 109.334 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.78 HG13 ' O ' ' A' ' 33' ' ' ILE . 39.2 t -89.75 -23.3 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.301 -0.874 . . . . 0.0 109.392 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 46.3 tp10 -69.2 -52.63 25.94 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.288 -0.883 . . . . 0.0 109.543 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.37 -32.48 73.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 59.4 p -84.87 -25.29 28.1 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 79.48 -3.42 67.93 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.825 HG23 HD23 ' A' ' 36' ' ' LEU . 84.8 mt -76.16 74.38 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.193 -1.18 . . . . 0.0 109.553 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.485 ' HA ' HG11 ' A' ' 28' ' ' VAL . 23.6 mttt -88.49 1.12 55.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.192 -0.942 . . . . 0.0 109.657 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -97.06 -13.09 22.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.181 -0.949 . . . . 0.0 109.492 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.088 HD12 ' HB2' ' A' ' 70' ' ' ALA . 2.5 mm? -88.32 -49.05 7.21 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.291 -0.881 . . . . 0.0 109.467 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.507 ' HB ' HG21 ' A' ' 28' ' ' VAL . 78.5 t -91.12 139.49 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.244 -0.91 . . . . 0.0 109.256 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -127.09 5.44 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 88.2 mtt180 -92.16 146.97 23.3 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.255 -1.144 . . . . 0.0 109.755 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.605 HG12 HG13 ' A' ' 62' ' ' VAL . 67.1 mt -112.55 134.16 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.913 . . . . 0.0 109.336 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.794 HG22 ' HZ3' ' A' ' 7' ' ' TRP . 33.3 m -128.08 155.77 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.235 -0.916 . . . . 0.0 109.45 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.781 HG22 HG23 ' A' ' 44' ' ' ILE . 11.5 mt -133.63 128.63 20.09 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.268 -0.895 . . . . 0.0 109.63 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.508 ' O ' HD13 ' A' ' 55' ' ' LEU . 43.8 Cg_endo -66.45 -3.89 9.77 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.928 2.418 . . . . 0.0 111.744 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.781 HG23 HG22 ' A' ' 42' ' ' ILE . 11.4 pt . . . . . 0 N--CA 1.488 1.469 0 O-C-N 121.145 -0.972 . . . . 0.0 109.464 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.693 ' HA ' HG22 ' A' ' 44' ' ' ILE . 4.7 mttp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.425 -0.584 . . . . 0.0 109.425 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.545 ' CD1' ' N ' ' A' ' 55' ' ' LEU . 5.2 mp -62.29 -24.68 67.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.171 -0.956 . . . . 0.0 109.465 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 1.153 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 97.4 m-85 -148.79 100.59 3.47 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.316 -0.865 . . . . 0.0 109.056 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -66.08 139.75 57.13 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.733 2.288 . . . . 0.0 111.855 -179.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.17 -12.5 6.88 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.589 ' CE1' HD11 ' A' ' 11' ' ' LEU . 2.5 m-30 -100.03 131.3 46.07 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.704 -1.468 . . . . 0.0 110.128 -179.317 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 45.6 t -134.62 144.77 33.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.361 -0.837 . . . . 0.0 108.887 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.775 ' HB2' HG23 ' A' ' 41' ' ' VAL . 74.2 m-85 -106.55 122.98 47.4 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.978 -1.077 . . . . 0.0 109.779 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.605 HG13 HG12 ' A' ' 40' ' ' ILE . 59.7 t -131.37 143.78 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.796 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.632 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 18.0 tt0 -108.2 127.29 53.7 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.328 -0.857 . . . . 0.0 109.166 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.462 ' HB3' ' O ' ' A' ' 36' ' ' LEU . 32.8 mtm -153.98 170.88 20.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.072 -1.018 . . . . 0.0 110.653 -179.261 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.813 ' CG1' HD13 ' A' ' 36' ' ' LEU . 5.3 pt -95.14 131.34 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.536 ' CE ' ' NE2' ' A' ' 89' ' ' GLN . 59.3 mmm -75.95 143.26 41.7 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.893 . . . . 0.0 109.897 -178.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.434 ' HB2' ' O ' ' A' ' 66' ' ' MET . 37.6 t30 178.23 158.06 0.46 Allowed 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -59.61 -42.06 91.79 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -0.927 . . . . 0.0 109.594 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.573 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 69.3 mm-40 -74.85 -34.1 62.22 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.891 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.088 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -69.13 -46.36 67.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.149 -0.97 . . . . 0.0 109.756 -179.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.55 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 91.1 t80 -61.06 -47.03 88.25 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.156 -0.965 . . . . 0.0 109.782 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.444 ' O ' ' HB2' ' A' ' 76' ' ' SER . 27.5 m120 -62.07 -28.36 69.55 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 109.861 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.573 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 13.7 m-85 -84.54 -42.55 15.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.15 -0.969 . . . . 0.0 109.756 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.735 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 25.9 t -69.76 -57.58 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.161 -0.962 . . . . 0.0 109.697 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.453 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 0.6 OUTLIER -59.26 -13.89 9.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.189 -0.944 . . . . 0.0 109.311 179.823 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.444 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 15.4 m -95.86 5.38 51.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.304 -0.873 . . . . 0.0 109.93 -179.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.814 ' O ' HG12 ' A' ' 80' ' ' VAL . 2.3 p -75.46 134.29 73.31 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 120.965 -1.085 . . . . 0.0 109.457 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.627 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 43.8 Cg_endo -65.17 138.82 57.9 Favored 'Trans proline' 0 C--O 1.214 -0.72 0 C-N-CA 122.88 2.387 . . . . 0.0 112.287 -179.277 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.675 ' CB ' HG22 ' A' ' 20' ' ' VAL . 24.3 m-85 90.79 -9.32 0.3 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.857 -0.527 . . . . 0.0 109.662 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.814 HG12 ' O ' ' A' ' 77' ' ' VAL . 5.7 p -90.88 127.08 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.979 -1.076 . . . . 0.0 109.332 179.506 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 82.8 mtp -86.24 -29.5 23.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.249 -0.907 . . . . 0.0 109.375 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.524 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 167.4 -164.22 37.74 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.735 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 21.3 m-85 -134.33 141.39 46.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.207 -1.173 . . . . 0.0 109.499 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.829 HG22 HD21 ' A' ' 11' ' ' LEU . 19.9 t -64.29 123.82 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.25 -0.906 . . . . 0.0 109.409 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.551 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.6 p -162.76 162.26 26.61 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.28 -0.887 . . . . 0.0 109.522 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.1 t -91.55 -33.33 15.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.276 -0.89 . . . . 0.0 109.343 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -129.66 -82.32 0.29 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.519 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -106.66 -131.57 6.82 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.55 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 1.4 mt-30 -33.31 152.08 0.05 OUTLIER Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.522 -0.987 . . . . 0.0 110.109 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.551 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.7 Cg_endo -69.1 159.25 54.64 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.841 2.361 . . . . 0.0 111.803 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 3.7 m -98.1 154.19 37.81 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.167 -0.958 . . . . 0.0 109.378 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.443 ' CB ' ' HD2' ' A' ' 6' ' ' LYS . 49.0 Cg_endo -70.19 150.99 66.41 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.612 2.208 . . . . 0.0 111.701 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.633 HG12 ' HG3' ' A' ' 98' ' ' MET . 31.2 t -85.46 142.38 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.249 -0.907 . . . . 0.0 109.33 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -78.37 139.2 38.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.936 . . . . 0.0 109.446 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.421 ' O ' ' N ' ' A' ' 99' ' ' ARG . 52.9 t0 -50.36 -39.14 45.62 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.497 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.5 mtm180 -52.06 -41.26 62.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.219 -0.926 . . . . 0.0 109.475 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.433 ' C ' ' HD2' ' A' ' 100' ' ' PRO . 63.0 mt-10 -85.38 -23.61 27.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.244 -0.91 . . . . 0.0 109.458 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.633 ' HG3' HG12 ' A' ' 93' ' ' VAL . 97.7 mtp -84.24 -23.64 30.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -0.927 . . . . 0.0 109.644 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.646 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 6.0 mmm180 -46.54 -48.04 48.13 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.256 -0.902 . . . . 0.0 109.788 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.646 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 50.6 Cg_endo -72.14 -27.3 17.03 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.394 2.063 . . . . 0.0 111.822 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.537 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 27.3 mm -81.49 -42.27 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.185 -0.947 . . . . 0.0 109.435 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.569 HD11 ' HB3' ' A' ' 98' ' ' MET . 1.2 mt -69.15 -39.9 78.54 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.237 -0.915 . . . . 0.0 109.339 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.557 ' CZ ' ' NH1' ' A' ' 99' ' ' ARG . 23.5 mtt180 -64.27 -51.17 64.86 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.3 -0.875 . . . . 0.0 109.148 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.5 tt -71.44 -36.17 71.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.346 -0.846 . . . . 0.0 109.247 179.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.56 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -70.86 -0.26 8.72 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.328 -0.857 . . . . 0.0 109.989 -179.729 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.19 9.12 84.1 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.719 HD21 HG11 ' A' ' 41' ' ' VAL . 10.1 mp -80.72 -22.67 40.1 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.194 -1.18 . . . . 0.0 109.456 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . 0.42 ' HG3' ' CB ' ' A' ' 102' ' ' LEU . 53.7 mt-10 . . . . . 0 N--CA 1.491 1.581 0 O-C-N 121.302 -0.874 . . . . 0.0 109.497 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.484 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 77.1 mttt -134.51 151.84 51.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.122 -0.986 . . . . 0.0 109.95 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 22.5 t -65.32 141.58 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.451 -0.781 . . . . 0.0 109.23 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.518 ' O ' HG13 ' A' ' 142' ' ' VAL . . . 89.19 -30.63 5.46 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.553 ' HB2' HD12 ' A' ' 143' ' ' ILE . 63.4 m-20 -47.8 161.89 0.09 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.309 -1.112 . . . . 0.0 108.989 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 6.1 ttm -102.09 128.23 48.65 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.025 -1.047 . . . . 0.0 109.096 179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.735 HG11 HD11 ' A' ' 143' ' ' ILE . 11.6 m -128.67 143.88 39.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.387 -0.821 . . . . 0.0 109.715 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.52 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 44.4 tttt -100.84 140.56 34.96 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.913 HD12 ' HB3' ' A' ' 139' ' ' PHE . 86.1 mt -79.39 154.62 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.024 -1.048 . . . . 0.0 108.371 179.375 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.857 HD13 ' HG3' ' A' ' 174' ' ' GLU . 1.1 pt -149.12 0.46 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.015 -1.053 . . . . 0.0 109.505 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.601 ' CB ' ' HG2' ' A' ' 172' ' ' GLU . 3.1 m -148.68 147.54 29.03 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.058 -1.027 . . . . 0.0 110.372 -179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.77 -170.29 19.92 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.465 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 45.9 Cg_endo -68.24 -21.46 41.76 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.199 2.599 . . . . 0.0 112.487 -179.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.496 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 91.5 m-85 -108.81 16.33 22.84 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.002 -1.061 . . . . 0.0 109.284 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.718 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.5 tt0 -48.09 142.69 4.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.316 -0.865 . . . . 0.0 109.788 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.575 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 14.5 t0 81.44 23.17 0.29 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.424 -0.797 . . . . 0.0 110.242 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.913 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.0 OUTLIER -116.13 141.75 47.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.984 -1.073 . . . . 0.0 109.463 179.813 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -90.12 136.18 33.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.191 -0.943 . . . . 0.0 109.516 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.404 ' C ' ' CG1' ' A' ' 155' ' ' VAL . . . -148.02 171.18 28.56 Favored Glycine 0 N--CA 1.49 2.268 0 C-N-CA 119.636 -1.269 . . . . 0.0 110.538 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.908 ' C ' HG13 ' A' ' 155' ' ' VAL . 89.4 t -118.05 136.41 55.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.678 -0.895 . . . . 0.0 109.237 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.735 HD11 HG11 ' A' ' 129' ' ' VAL . 79.4 mt -66.78 115.8 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.43 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 33.2 tttt -97.63 -34.56 10.9 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.03 -1.044 . . . . 0.0 109.231 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -149.78 144.62 26.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.201 -0.937 . . . . 0.0 109.329 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 1.01 HG22 HD22 ' A' ' 153' ' ' LEU . 31.9 pt -123.98 127.66 73.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.573 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 28.5 t0 -111.81 100.19 47.72 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.484 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.568 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.3 Cg_endo -71.27 176.01 8.5 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.778 2.319 . . . . 0.0 111.71 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.568 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.4 mt-10 81.48 -21.05 0.33 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.434 -0.791 . . . . 0.0 109.84 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.431 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 82.1 mtt180 -131.15 -10.46 3.74 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.15 -0.969 . . . . 0.0 109.495 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.431 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 43.3 mt-30 69.97 48.54 0.54 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.252 -0.905 . . . . 0.0 109.967 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.541 ' OE2' HG13 ' A' ' 167' ' ' VAL . 81.3 tt0 -120.44 144.99 47.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.981 -1.075 . . . . 0.0 108.852 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 1.01 HD22 HG22 ' A' ' 146' ' ' ILE . 70.6 mt -139.91 127.69 21.9 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.102 -0.999 . . . . 0.0 110.441 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -91.74 132.77 36.16 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.908 HG13 ' C ' ' A' ' 142' ' ' VAL . 92.9 t -133.99 126.96 51.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.116 -0.99 . . . . 0.0 109.914 -179.358 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.577 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 51.9 t-20 -76.1 137.12 39.93 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.341 -0.85 . . . . 0.0 109.862 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.621 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 59.8 t -114.46 147.53 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.329 -0.857 . . . . 0.0 109.069 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 18.2 m -99.41 91.88 5.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.999 -1.063 . . . . 0.0 109.913 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 1.153 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 2.5 pt -124.58 151.53 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.235 -0.916 . . . . 0.0 108.991 179.311 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.724 ' CE2' HD12 ' A' ' 159' ' ' ILE . 16.7 m-30 60.53 35.45 20.16 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -0.926 . . . . 0.0 108.969 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.03 15.37 9.99 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 21.0 mtp180 -128.22 158.22 38.71 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.179 -1.189 . . . . 0.0 109.595 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . 0.452 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 90.7 mt-10 -100.97 132.76 46.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.268 -0.895 . . . . 0.0 109.551 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . 0.536 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 47.4 m -139.78 127.31 12.85 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.943 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.577 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.59 134.1 25.49 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.741 2.294 . . . . 0.0 111.175 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.684 ' HB ' HD21 ' A' ' 168' ' ' LEU . 2.2 t -120.03 164.09 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 120.962 -1.086 . . . . 0.0 110.153 -179.527 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 1.143 ' O ' HD13 ' A' ' 168' ' ' LEU . 43.0 t -117.03 115.94 50.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 N-CA-C 109.119 -0.696 . . . . 0.0 109.119 179.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 1.143 HD13 ' O ' ' A' ' 167' ' ' VAL . 0.3 OUTLIER -139.49 167.55 21.84 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 121.878 0.847 . . . . 0.0 110.249 -179.52 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.415 ' O ' ' HB2' ' A' ' 172' ' ' GLU . 96.1 m-70 -78.94 141.01 37.92 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.584 HG23 HD12 ' A' ' 153' ' ' LEU . 7.2 p -55.01 -36.43 38.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.056 -1.028 . . . . 0.0 108.88 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.406 ' N ' HG13 ' A' ' 170' ' ' VAL . 33.6 p -75.07 -5.23 43.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.455 -0.778 . . . . 0.0 109.553 179.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.601 ' HG2' ' CB ' ' A' ' 133' ' ' SER . 2.4 mt-10 -87.17 -1.82 58.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.225 -0.922 . . . . 0.0 109.707 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . 0.52 ' HB ' ' O ' ' A' ' 130' ' ' LYS . 1.3 m -150.91 -178.31 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.138 -0.976 . . . . 0.0 109.465 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.857 ' HG3' HD13 ' A' ' 132' ' ' ILE . 3.5 mt-10 -138.01 170.2 16.45 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.082 -1.011 . . . . 0.0 109.1 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.519 ' HE2' ' OD2' ' A' ' 127' ' ' ASP . 52.0 tttm . . . . . 0 N--CA 1.489 1.513 0 O-C-N 121.0 -1.062 . . . . 0.0 109.553 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.505 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 27.4 mttm . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 1.3 mtpp -125.93 -179.78 4.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.196 -0.94 . . . . 0.0 109.321 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.787 ' CZ3' HG22 ' A' ' 41' ' ' VAL . 69.2 m95 -117.72 122.21 42.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.135 -0.978 . . . . 0.0 109.178 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -115.33 170.94 8.01 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.18 -0.95 . . . . 0.0 109.376 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.439 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 33.0 mt -112.89 110.74 33.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.296 -0.877 . . . . 0.0 109.065 179.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.541 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 10.3 p -88.66 142.48 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.215 -0.928 . . . . 0.0 109.512 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.548 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.2 OUTLIER -89.04 145.68 25.32 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.294 -0.879 . . . . 0.0 109.625 -179.893 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.704 ' CG2' HG21 ' A' ' 20' ' ' VAL . 96.0 m -156.84 160.78 39.51 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.285 -0.884 . . . . 0.0 109.52 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.591 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 94.9 mmm -76.98 124.19 27.42 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.216 -0.928 . . . . 0.0 109.469 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 13' ' ' MET . 70.2 m -44.59 125.44 4.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.95 . . . . 0.0 109.301 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.0 -19.98 34.26 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.591 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 92.0 m-85 -107.14 -5.64 17.86 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.22 -1.165 . . . . 0.0 109.505 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.684 ' OE1' HD11 ' A' ' 44' ' ' ILE . 68.2 mt-10 -51.52 -54.62 25.37 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 109.486 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -51.48 -34.49 35.95 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.219 -0.926 . . . . 0.0 109.368 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.46 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 64.1 mttm -76.35 -49.54 16.6 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.178 179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.704 HG21 ' CG2' ' A' ' 12' ' ' THR . 42.0 t -52.22 -49.92 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.337 -0.852 . . . . 0.0 109.365 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.681 ' HG3' HG21 ' A' ' 40' ' ' ILE . 29.9 tttt -56.83 -50.33 72.72 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.65 -34.55 77.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.332 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.527 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 32.8 m120 -65.32 -48.14 74.07 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.404 -0.81 . . . . 0.0 109.586 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 77.4 mt -54.02 -44.52 62.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.133 -0.98 . . . . 0.0 109.437 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.535 ' O ' HG22 ' A' ' 28' ' ' VAL . 75.1 tt0 -56.21 -46.14 79.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.246 -0.909 . . . . 0.0 109.721 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 7.7 mmtp -78.35 -36.13 46.58 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.16 -0.962 . . . . 0.0 109.509 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.465 ' O ' HG23 ' A' ' 31' ' ' THR . 8.9 tptt -53.9 -30.72 47.31 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.282 -0.886 . . . . 0.0 109.358 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.957 HG11 ' CG1' ' A' ' 37' ' ' VAL . 35.5 m -89.3 -22.04 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.3 -0.875 . . . . 0.0 109.41 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.422 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 44.6 mm-40 -70.71 -54.52 11.49 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.611 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.72 -31.09 71.95 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.185 -0.947 . . . . 0.0 109.451 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.465 HG23 ' O ' ' A' ' 27' ' ' LYS . 37.8 p -87.54 -8.23 56.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.413 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 60.58 28.54 67.89 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.719 HG23 HD23 ' A' ' 36' ' ' LEU . 46.7 mt -107.48 73.22 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -1.149 . . . . 0.0 109.515 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.6 mtmt -87.68 -2.36 58.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.225 -0.922 . . . . 0.0 109.573 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -94.08 -12.8 27.73 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -0.929 . . . . 0.0 109.473 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.769 HD12 ' HB2' ' A' ' 70' ' ' ALA . 1.8 mm? -86.92 -47.82 8.67 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.311 179.835 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.957 ' CG1' HG11 ' A' ' 28' ' ' VAL . 11.6 p -94.16 142.65 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.388 -0.82 . . . . 0.0 109.518 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -113.45 -123.97 4.08 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 82.0 mtt180 -94.43 140.07 30.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.253 -1.145 . . . . 0.0 109.619 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.681 HG21 ' HG3' ' A' ' 21' ' ' LYS . 58.8 mt -106.33 136.06 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 109.361 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.93 HG23 ' HB2' ' A' ' 61' ' ' PHE . 31.5 m -127.16 161.98 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.223 -0.923 . . . . 0.0 109.06 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.65 HD11 ' HD2' ' A' ' 21' ' ' LYS . 9.7 mt -144.02 126.99 8.72 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.142 -0.974 . . . . 0.0 110.034 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.69 -2.28 9.08 Favored 'Trans proline' 0 C--O 1.217 -0.533 0 C-N-CA 122.917 2.411 . . . . 0.0 111.381 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.833 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 76.8 mt . . . . . 0 C--N 1.303 -1.429 0 O-C-N 121.185 -0.947 . . . . 0.0 109.491 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.833 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 8.4 mttt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.581 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 61.3 tp -67.04 -23.13 65.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.8 -1.188 . . . . 0.0 109.666 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.741 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 57.1 m-85 -145.46 97.13 4.73 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 108.836 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -66.01 136.48 44.89 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.59 2.193 . . . . 0.0 112.247 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 12' ' ' THR . . . 76.74 -13.17 8.91 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.544 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 2.4 m-30 -100.84 130.47 46.86 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.688 -1.478 . . . . 0.0 110.23 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.541 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 79.2 t -134.38 147.44 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.373 -0.829 . . . . 0.0 108.809 179.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.93 ' HB2' HG23 ' A' ' 41' ' ' VAL . 15.7 m-85 -107.58 122.12 46.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.005 -1.06 . . . . 0.0 109.956 -179.532 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.441 HG12 HG23 ' A' ' 40' ' ' ILE . 7.9 m -125.81 136.77 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.405 -0.809 . . . . 0.0 109.642 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.572 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 7.8 tt0 -101.01 123.96 45.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.228 -0.92 . . . . 0.0 108.974 179.553 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.529 ' HB3' ' O ' ' A' ' 36' ' ' LEU . 14.0 mtm -156.06 176.45 12.65 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.999 -1.063 . . . . 0.0 110.36 -179.266 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.621 ' CG1' HD13 ' A' ' 36' ' ' LEU . 7.9 pt -99.38 132.28 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.479 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 47.4 ttm -76.66 144.17 39.63 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.347 -0.846 . . . . 0.0 109.992 -178.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.479 ' HB2' ' O ' ' A' ' 66' ' ' MET . 50.6 t30 176.2 171.53 0.4 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -67.25 -41.64 85.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.1 -1.0 . . . . 0.0 109.446 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.579 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 97.4 mt-10 -71.72 -38.1 70.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.295 -0.878 . . . . 0.0 109.872 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.769 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -64.93 -44.9 87.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.19 -0.944 . . . . 0.0 109.466 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.493 ' CD2' ' OE1' ' A' ' 89' ' ' GLN . 27.9 t80 -60.0 -52.02 67.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.284 -0.885 . . . . 0.0 109.641 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.523 ' O ' ' HB3' ' A' ' 76' ' ' SER . 96.1 m-20 -59.34 -28.32 66.72 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.204 -0.935 . . . . 0.0 110.164 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 21.9 m-85 -85.45 -43.53 13.52 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.957 -1.089 . . . . 0.0 109.95 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.407 ' O ' HG12 ' A' ' 77' ' ' VAL . 71.6 t -70.06 -57.84 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.288 -0.883 . . . . 0.0 110.025 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.513 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 29.3 tpt85 -60.83 -22.58 64.34 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.171 -0.956 . . . . 0.0 109.826 -179.669 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.523 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 35.4 p -93.71 5.89 50.13 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.127 -0.983 . . . . 0.0 109.88 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.718 HG11 HG21 ' A' ' 80' ' ' VAL . 5.1 p -70.15 129.42 90.66 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.125 -0.985 . . . . 0.0 109.331 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.671 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 43.5 Cg_endo -65.48 138.92 56.81 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 122.782 2.322 . . . . 0.0 112.177 -179.382 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.671 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 59.9 m-85 91.54 -11.98 0.23 Allowed 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.718 HG21 HG11 ' A' ' 77' ' ' VAL . 4.7 t -93.96 134.12 32.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.994 -1.066 . . . . 0.0 109.171 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 85.6 mmm -87.95 -27.4 22.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.205 -0.934 . . . . 0.0 109.492 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.9 -160.24 32.24 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.617 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 1.6 p90 -139.61 153.92 47.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -1.094 . . . . 0.0 109.314 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.669 HG13 ' O ' ' A' ' 84' ' ' VAL . 10.6 p -84.71 113.7 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.188 -0.945 . . . . 0.0 109.615 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.557 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.4 p -148.47 163.24 37.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.895 . . . . 0.0 109.438 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 80.6 p -86.5 -34.55 19.98 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.419 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -127.32 -91.11 0.74 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.557 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -102.59 -126.95 5.97 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.557 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -30.27 152.39 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.61 -0.935 . . . . 0.0 110.375 -179.606 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.565 ' HD3' ' CD2' ' A' ' 83' ' ' PHE . 47.1 Cg_endo -68.13 137.69 41.39 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.917 2.411 . . . . 0.0 112.014 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 18.8 m -73.54 144.92 84.25 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.351 -0.843 . . . . 0.0 109.336 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.31 153.81 66.08 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.645 2.23 . . . . 0.0 111.702 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 7' ' ' TRP . 18.6 t -93.9 129.45 44.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.379 -0.826 . . . . 0.0 109.36 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 25.4 mttm -64.29 141.38 58.79 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.227 -0.921 . . . . 0.0 109.512 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -51.37 -38.64 54.36 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.228 -0.92 . . . . 0.0 109.415 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 62.3 mtt85 -58.2 -38.26 76.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.347 -0.846 . . . . 0.0 109.557 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -77.61 -25.93 50.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.196 -0.94 . . . . 0.0 109.454 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.608 ' CB ' HD11 ' A' ' 102' ' ' LEU . 95.4 mtp -86.03 -22.27 27.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.388 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.609 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 1.1 mtm180 -36.27 -52.8 1.7 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.525 -0.734 . . . . 0.0 109.861 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.612 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 49.7 Cg_endo -70.01 -27.98 24.62 Favored 'Trans proline' 0 C--O 1.214 -0.718 0 C-N-CA 122.469 2.113 . . . . 0.0 111.908 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.526 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 29.8 mm -81.98 -43.41 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.176 -0.952 . . . . 0.0 109.451 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.608 HD11 ' CB ' ' A' ' 98' ' ' MET . 1.2 mt -68.94 -40.0 79.26 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.23 -0.919 . . . . 0.0 109.445 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.547 ' NH2' ' NH1' ' A' ' 99' ' ' ARG . 24.1 mtt180 -64.36 -50.59 67.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.124 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.62 -36.07 70.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.382 -0.824 . . . . 0.0 109.3 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.618 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -71.27 1.47 6.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.323 -0.861 . . . . 0.0 110.035 -179.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.07 8.25 82.88 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.633 HD21 HG11 ' A' ' 41' ' ' VAL . 9.4 mp -80.91 -22.07 40.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -1.148 . . . . 0.0 109.368 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . 0.491 ' HB3' ' HA ' ' A' ' 103' ' ' ARG . 47.6 tp10 . . . . . 0 N--CA 1.491 1.598 0 O-C-N 121.333 -0.854 . . . . 0.0 109.487 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.746 ' CE1' HG21 ' A' ' 146' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.626 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.452 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 7.1 mttp -141.13 145.42 35.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.076 -1.015 . . . . 0.0 109.868 -179.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.52 HG12 HG12 ' A' ' 146' ' ' ILE . 22.4 m -63.98 141.99 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.38 -0.825 . . . . 0.0 109.397 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 87.44 -31.69 4.42 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.017 -1.633 . . . . 0.0 109.017 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.496 ' CG ' ' CE ' ' A' ' 175' ' ' LYS . 13.0 t70 -48.5 164.04 0.06 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.513 -0.992 . . . . 0.0 109.055 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.2 ttm -100.29 127.47 46.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.086 -1.009 . . . . 0.0 109.241 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.585 ' CG1' HG12 ' A' ' 143' ' ' ILE . 35.0 m -125.89 142.35 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.34 -0.85 . . . . 0.0 109.26 179.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.451 ' O ' HG23 ' A' ' 173' ' ' VAL . 7.8 tttt -102.79 141.83 34.94 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.357 -0.839 . . . . 0.0 108.858 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 1.041 HD12 ' HB3' ' A' ' 139' ' ' PHE . 89.8 mt -81.73 152.35 4.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.102 -0.999 . . . . 0.0 108.557 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.586 HD11 ' CA ' ' A' ' 173' ' ' VAL . 0.5 OUTLIER -150.45 1.64 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.024 -1.048 . . . . 0.0 109.382 179.647 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.521 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 2.9 m -147.27 143.49 28.15 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.128 -0.982 . . . . 0.0 109.896 -179.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.17 -166.92 17.76 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.603 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 45.7 Cg_endo -68.49 -22.51 38.65 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 123.179 2.586 . . . . 0.0 112.594 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.612 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 70.7 m-85 -106.46 17.3 23.54 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.786 -1.196 . . . . 0.0 109.533 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.689 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.5 tt0 -48.18 137.57 10.56 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.168 -0.957 . . . . 0.0 109.599 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.555 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 10.8 m-20 81.62 22.34 0.3 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.479 -0.763 . . . . 0.0 110.323 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 1.041 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.5 t80 -115.03 143.04 45.81 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.966 -1.084 . . . . 0.0 109.566 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -92.0 134.7 34.57 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.146 -0.971 . . . . 0.0 109.493 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.41 167.24 27.52 Favored Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.739 -1.22 . . . . 0.0 110.212 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.662 ' C ' HG13 ' A' ' 155' ' ' VAL . 37.6 t -115.07 137.14 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.54 -0.976 . . . . 0.0 109.139 179.651 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 1.067 ' CG2' HD11 ' A' ' 146' ' ' ILE . 28.1 mm -69.13 122.4 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.262 -0.899 . . . . 0.0 109.423 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.456 ' C ' ' HG2' ' A' ' 145' ' ' GLU . 0.2 OUTLIER -106.53 -33.3 7.73 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.04 -1.038 . . . . 0.0 109.627 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.761 ' O ' HD13 ' A' ' 146' ' ' ILE . 70.0 mm-40 -151.38 146.58 26.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.014 -1.054 . . . . 0.0 109.874 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 1.149 HG23 ' CD2' ' A' ' 153' ' ' LEU . 6.0 mm -120.86 122.76 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.091 -1.006 . . . . 0.0 109.491 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 14.7 t0 -107.08 99.21 25.38 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.307 -0.87 . . . . 0.0 109.349 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.565 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.6 Cg_endo -71.45 172.26 14.57 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.801 2.334 . . . . 0.0 111.841 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.565 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 4.6 mt-10 80.62 -20.16 0.39 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.377 -0.827 . . . . 0.0 109.786 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 94.8 mtt-85 -128.04 -13.66 5.08 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.142 -0.974 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.432 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 35.9 mt-30 70.33 48.47 0.49 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.245 -0.909 . . . . 0.0 109.38 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -120.01 143.13 48.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.085 -1.01 . . . . 0.0 109.245 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 1.149 ' CD2' HG23 ' A' ' 146' ' ' ILE . 98.8 mt -128.64 130.73 47.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.219 -0.926 . . . . 0.0 110.103 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.469 ' HD3' ' HB2' ' A' ' 145' ' ' GLU . 22.7 mtpp -92.93 126.17 37.89 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.892 HG22 HD13 ' A' ' 143' ' ' ILE . 4.0 t -126.31 145.86 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.252 -0.905 . . . . 0.0 110.086 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 27.7 t-20 -98.87 114.9 27.7 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.451 -0.781 . . . . 0.0 109.326 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.621 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 41.7 t -97.54 142.59 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.373 -0.829 . . . . 0.0 109.665 -179.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 13.3 m -96.57 95.61 8.1 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.784 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.753 HD12 ' CE2' ' A' ' 160' ' ' PHE . 19.0 pt -125.94 146.72 31.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.319 -0.863 . . . . 0.0 109.301 179.76 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.753 ' CE2' HD12 ' A' ' 159' ' ' ILE . 11.5 m-85 63.24 36.26 12.0 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.219 -0.926 . . . . 0.0 109.321 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.05 16.64 19.53 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.41 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 17.8 mtt-85 -130.15 158.69 38.98 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.291 -1.123 . . . . 0.0 109.548 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . 0.405 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 94.7 mt-10 -99.42 132.99 44.37 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.202 -0.936 . . . . 0.0 109.375 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . 0.433 HG21 ' CZ ' ' A' ' 56' ' ' PHE . 27.9 m -144.13 124.84 7.74 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.188 -0.945 . . . . 0.0 109.647 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.538 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -70.81 139.47 36.67 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.738 2.292 . . . . 0.0 111.763 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.653 HG13 HD23 ' A' ' 168' ' ' LEU . 5.6 p -124.48 143.58 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.155 -0.965 . . . . 0.0 109.646 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.59 HG13 ' O ' ' A' ' 167' ' ' VAL . 10.7 p -92.31 119.36 39.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.414 -0.804 . . . . 0.0 109.33 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.653 HD23 HG13 ' A' ' 166' ' ' VAL . 0.7 OUTLIER -140.48 165.91 26.14 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.22 -0.925 . . . . 0.0 110.621 -179.054 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.451 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 98.2 m-70 -80.32 145.54 32.05 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.726 HG23 HD11 ' A' ' 153' ' ' LEU . 11.0 p -60.14 -34.58 57.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.19 -0.944 . . . . 0.0 108.975 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 54.3 p -76.82 -6.73 53.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.322 -0.861 . . . . 0.0 109.321 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.521 ' HA ' ' HB2' ' A' ' 133' ' ' SER . 74.4 mt-10 -96.33 5.94 49.85 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.299 -0.876 . . . . 0.0 109.25 179.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . 0.607 HG11 HD11 ' A' ' 168' ' ' LEU . 1.5 p -148.07 169.01 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.279 -0.888 . . . . 0.0 108.723 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.603 ' N ' HG22 ' A' ' 173' ' ' VAL . 57.0 mt-10 -138.51 167.79 21.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.011 -1.056 . . . . 0.0 109.202 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.519 ' HA ' HG12 ' A' ' 129' ' ' VAL . 63.0 tttt . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.077 -1.015 . . . . 0.0 109.485 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.6 mttt . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 121.296 0.57 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 24.6 mmtp -128.75 175.5 8.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -0.93 . . . . 0.0 109.307 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.908 ' CH2' HG23 ' A' ' 41' ' ' VAL . 64.6 m95 -112.17 124.59 52.77 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.247 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.612 ' CZ ' ' HG3' ' A' ' 66' ' ' MET . 81.3 m-85 -117.0 170.98 8.21 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.212 -0.93 . . . . 0.0 109.422 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.612 HG12 ' CE1' ' A' ' 61' ' ' PHE . 42.1 mt -107.45 116.33 50.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.251 -0.905 . . . . 0.0 109.379 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.621 ' CG1' HG23 ' A' ' 80' ' ' VAL . 50.0 t -93.43 139.14 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.241 -0.912 . . . . 0.0 109.362 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.567 HD11 ' HE1' ' A' ' 59' ' ' TYR . 4.2 mm? -86.78 146.28 26.3 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.316 -0.865 . . . . 0.0 109.33 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.561 ' OG1' HG21 ' A' ' 20' ' ' VAL . 11.2 t -158.24 -176.21 5.78 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.263 -0.898 . . . . 0.0 109.501 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.507 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 64.0 mtm -101.2 120.01 39.6 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.175 -0.953 . . . . 0.0 109.533 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.435 ' OG ' ' HB2' ' A' ' 57' ' ' PRO . 43.0 m -43.39 128.3 4.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 109.385 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.08 -19.88 47.43 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.507 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 87.2 m-85 -109.54 9.59 25.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.346 -1.091 . . . . 0.0 109.511 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.531 ' HG2' HG21 ' A' ' 12' ' ' THR . 95.6 mt-10 -60.03 -45.1 93.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.203 -0.936 . . . . 0.0 109.493 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -58.82 -35.31 72.67 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.183 -0.948 . . . . 0.0 109.329 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.401 ' O ' ' HB2' ' A' ' 23' ' ' ASN . 83.7 mttt -72.73 -34.0 66.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -0.929 . . . . 0.0 109.355 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.561 HG21 ' OG1' ' A' ' 12' ' ' THR . 87.0 t -72.39 -53.05 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.912 . . . . 0.0 109.461 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.507 ' HG3' HG21 ' A' ' 40' ' ' ILE . 46.2 tttm -57.62 -49.91 74.9 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.301 -0.874 . . . . 0.0 109.372 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -63.4 -35.86 81.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.196 -0.94 . . . . 0.0 109.165 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.744 ' OD1' HG22 ' A' ' 77' ' ' VAL . 13.8 t-20 -62.72 -47.59 82.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.345 -0.847 . . . . 0.0 109.48 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.415 ' CG2' HG11 ' A' ' 37' ' ' VAL . 89.7 mt -55.75 -43.58 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.278 -0.889 . . . . 0.0 109.501 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -57.64 -46.87 83.62 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.943 . . . . 0.0 110.11 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 76.4 mttt -75.63 -37.31 59.83 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.984 -1.073 . . . . 0.0 109.824 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.93 ' CD ' HG23 ' A' ' 77' ' ' VAL . 42.2 tttp -55.95 -29.68 60.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.133 -0.98 . . . . 0.0 109.204 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.818 HG13 ' O ' ' A' ' 33' ' ' ILE . 37.8 t -82.98 -26.42 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.866 . . . . 0.0 109.508 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.416 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 66.8 mm-40 -67.68 -51.65 47.16 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.247 -0.908 . . . . 0.0 109.474 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.07 -43.91 51.54 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.246 -0.909 . . . . 0.0 109.444 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.401 HG21 ' CZ ' ' A' ' 73' ' ' PHE . 62.6 p -88.88 -7.95 55.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.187 -0.946 . . . . 0.0 109.624 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 54.95 22.58 28.12 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.073 HG21 ' CD1' ' A' ' 36' ' ' LEU . 74.8 mt -84.69 100.91 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.252 -1.146 . . . . 0.0 109.512 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.5 mttt -103.54 35.33 2.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.264 -0.897 . . . . 0.0 109.357 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.566 ' OD1' HG23 ' A' ' 33' ' ' ILE . 18.6 p-10 -136.41 8.45 3.13 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.204 -0.935 . . . . 0.0 109.784 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.073 ' CD1' HG21 ' A' ' 33' ' ' ILE . 82.1 mt -113.09 -42.88 3.46 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.22 -0.925 . . . . 0.0 109.34 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.48 ' HA ' ' HB3' ' A' ' 64' ' ' MET . 52.5 t -106.93 138.68 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.226 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -109.37 -124.65 4.93 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.409 ' O ' ' CH2' ' A' ' 7' ' ' TRP . 64.8 mtt85 -95.13 140.12 30.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.243 -1.151 . . . . 0.0 109.789 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.548 HG23 HG12 ' A' ' 62' ' ' VAL . 67.9 mt -102.13 135.94 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.307 -0.87 . . . . 0.0 109.032 179.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.908 HG23 ' CH2' ' A' ' 7' ' ' TRP . 53.5 t -118.51 147.21 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.066 -1.021 . . . . 0.0 109.678 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.9 HG22 HG23 ' A' ' 44' ' ' ILE . 2.5 mt -119.74 125.72 27.28 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.254 -0.904 . . . . 0.0 109.411 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.501 ' CB ' ' CD2' ' A' ' 56' ' ' PHE . 49.6 Cg_endo -70.33 -5.33 16.3 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.735 2.29 . . . . 0.0 111.814 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.9 HG23 HG22 ' A' ' 42' ' ' ILE . 14.6 pt . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.258 -0.901 . . . . 0.0 109.569 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.571 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 37.8 mttt . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.618 ' O ' ' CD1' ' A' ' 56' ' ' PHE . 49.4 mt -60.72 -24.77 65.93 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.091 -1.006 . . . . 0.0 109.462 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 1.058 ' CE1' HD11 ' A' ' 159' ' ' ILE . 1.0 OUTLIER -151.59 104.58 2.89 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.298 -0.876 . . . . 0.0 108.78 179.655 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.435 ' HB2' ' OG ' ' A' ' 14' ' ' SER . 43.7 Cg_endo -66.93 142.17 61.39 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.541 2.161 . . . . 0.0 111.845 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.48 -9.48 10.31 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.567 ' HE1' HD11 ' A' ' 11' ' ' LEU . 2.9 m-30 -102.52 132.08 48.81 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.8 -1.412 . . . . 0.0 110.046 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 45.8 t -134.74 147.75 29.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.859 . . . . 0.0 108.818 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.612 ' CE1' HG12 ' A' ' 9' ' ' ILE . 93.2 m-85 -110.34 123.19 49.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.937 -1.102 . . . . 0.0 109.902 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.548 HG12 HG23 ' A' ' 40' ' ' ILE . 4.9 m -130.66 143.34 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.302 -0.874 . . . . 0.0 109.767 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.608 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 8.1 tt0 -101.46 125.35 48.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 109.04 179.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.523 ' CE ' HG11 ' A' ' 74' ' ' VAL . 14.6 ptt? -163.38 -177.37 5.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.984 -1.072 . . . . 0.0 110.457 -179.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.843 HD11 ' CD2' ' A' ' 36' ' ' LEU . 7.5 pt -100.9 125.04 54.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.539 -0.726 . . . . 0.0 109.578 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.612 ' HG3' ' CZ ' ' A' ' 8' ' ' TYR . 73.5 mmm -89.56 99.64 12.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 109.398 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.446 ' OD1' HG13 ' A' ' 65' ' ' ILE . 21.3 m120 -139.04 -164.29 1.63 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.062 -1.024 . . . . 0.0 109.174 179.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -73.04 -51.92 16.34 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.249 -0.907 . . . . 0.0 110.005 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -72.82 -58.34 3.41 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.096 -1.003 . . . . 0.0 109.743 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.007 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -47.3 -44.19 23.13 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.456 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.587 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 88.0 t80 -61.65 -51.6 67.79 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.164 -0.96 . . . . 0.0 109.586 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.492 ' O ' ' HB3' ' A' ' 76' ' ' SER . 83.6 m-20 -59.16 -29.28 67.32 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.228 -0.92 . . . . 0.0 109.888 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.604 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 15.8 t80 -82.61 -43.21 17.28 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.091 -1.006 . . . . 0.0 109.636 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 1.007 HG23 ' O ' ' A' ' 70' ' ' ALA . 16.4 t -65.22 -58.1 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.41 -0.806 . . . . 0.0 109.505 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.511 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 15.1 tpt180 -58.23 -11.02 2.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.324 -0.86 . . . . 0.0 110.095 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.492 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 29.0 p -95.41 5.38 51.79 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.927 -1.108 . . . . 0.0 109.898 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.93 HG23 ' CD ' ' A' ' 27' ' ' LYS . 0.3 OUTLIER -71.85 128.72 89.11 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.094 -1.004 . . . . 0.0 109.086 179.871 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.644 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 42.0 Cg_endo -64.97 140.45 66.26 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.566 2.177 . . . . 0.0 111.891 -179.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.644 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 8.2 m-85 91.7 -10.02 0.24 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.89 -0.506 . . . . 0.0 109.817 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.72 HG12 ' O ' ' A' ' 77' ' ' VAL . 4.3 p -93.57 134.47 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.879 -1.138 . . . . 0.0 109.85 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 88.6 mtp -86.91 -23.98 24.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.379 -0.825 . . . . 0.0 109.258 179.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.572 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 155.19 -156.38 26.91 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.572 ' CD1' ' O ' ' A' ' 82' ' ' GLY . 15.3 m-85 -135.19 143.22 46.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.266 -1.137 . . . . 0.0 109.474 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.461 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 9.5 p -69.46 131.81 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.286 -0.884 . . . . 0.0 109.512 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.56 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.3 p -166.92 158.65 12.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.271 -0.893 . . . . 0.0 109.616 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.2 m -86.05 -31.79 21.78 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.282 -0.886 . . . . 0.0 109.269 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -131.03 -85.37 0.34 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.542 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -104.17 -134.24 8.09 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.587 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.6 OUTLIER -30.91 150.79 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.819 0 O-C-N 121.557 -0.967 . . . . 0.0 110.317 -179.622 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.56 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.5 Cg_endo -68.38 141.3 50.92 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.819 2.346 . . . . 0.0 112.087 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . 0.758 HG23 ' HD2' ' A' ' 92' ' ' PRO . 4.0 p -77.14 144.35 71.4 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.344 -0.847 . . . . 0.0 109.364 179.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.758 ' HD2' HG23 ' A' ' 91' ' ' VAL . 47.4 Cg_endo -68.39 153.52 73.92 Favored 'Trans proline' 0 C--O 1.216 -0.575 0 C-N-CA 122.66 2.24 . . . . 0.0 111.743 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.52 ' CG1' ' HB2' ' A' ' 97' ' ' GLU . 86.2 t -89.38 133.66 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.268 -0.895 . . . . 0.0 109.649 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 26.4 mtmt -61.49 138.4 58.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.331 -0.856 . . . . 0.0 109.449 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -49.4 -35.81 20.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.928 . . . . 0.0 109.464 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 76.5 mtt180 -61.57 -28.95 69.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.504 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.52 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . 77.1 mt-10 -82.41 -25.22 33.9 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.92 . . . . 0.0 109.599 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.509 ' HE3' HD11 ' A' ' 102' ' ' LEU . 30.9 mmm -85.37 -28.92 24.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.208 -0.932 . . . . 0.0 109.385 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.597 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -36.33 -54.26 1.56 Allowed Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.413 -0.804 . . . . 0.0 109.844 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.639 ' HB2' ' CE1' ' A' ' 136' ' ' PHE . 48.6 Cg_endo -69.28 -26.91 29.39 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.581 2.188 . . . . 0.0 111.938 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.456 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 22.3 mm -82.67 -39.42 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.255 -0.903 . . . . 0.0 109.352 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.688 ' N ' HD13 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -72.05 -40.53 68.27 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.097 179.823 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.496 ' HA ' ' HB2' ' A' ' 108' ' ' GLU . 9.3 ttt180 -64.54 -48.5 74.84 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.869 . . . . 0.0 109.158 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.2 tt -71.72 -35.12 70.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.271 -0.893 . . . . 0.0 109.184 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.46 ' CB ' HG13 ' A' ' 41' ' ' VAL . . . -71.83 2.15 5.92 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.335 -0.853 . . . . 0.0 110.178 -179.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.0 9.4 83.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.455 ' HB3' ' HB3' ' A' ' 102' ' ' LEU . 0.4 OUTLIER -76.56 -18.68 58.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.073 -1.251 . . . . 0.0 109.314 179.85 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . 0.496 ' HB2' ' HA ' ' A' ' 103' ' ' ARG . 91.2 mt-10 . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.278 -0.889 . . . . 0.0 109.555 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.449 ' HA ' ' HD2' ' A' ' 175' ' ' LYS . 45.7 p90 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.405 ' HG2' ' C ' ' A' ' 123' ' ' PHE . 12.5 mmtt -138.12 163.75 30.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.094 -1.004 . . . . 0.0 110.063 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 11.0 p -62.9 141.95 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.443 -0.785 . . . . 0.0 109.548 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.461 ' O ' HG23 ' A' ' 142' ' ' VAL . . . 86.98 -33.21 3.83 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.531 ' HB2' HD12 ' A' ' 143' ' ' ILE . 71.4 m-20 -46.51 161.76 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.378 -1.072 . . . . 0.0 109.102 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 15.4 ttm -99.82 127.88 45.96 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.138 -0.976 . . . . 0.0 108.959 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.679 HG11 HD11 ' A' ' 143' ' ' ILE . 33.4 m -127.78 143.21 41.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.193 -0.942 . . . . 0.0 109.612 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.5 ' HG3' ' O ' ' A' ' 139' ' ' PHE . 12.1 ttpt -101.69 143.02 32.16 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.45 -0.781 . . . . 0.0 109.046 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.776 HD12 ' HB3' ' A' ' 139' ' ' PHE . 93.1 mt -80.39 147.0 6.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.132 -0.98 . . . . 0.0 108.421 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.547 HG13 ' C ' ' A' ' 131' ' ' ILE . 18.7 mt -145.03 1.22 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.018 -1.051 . . . . 0.0 109.337 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.517 ' HA ' ' HG2' ' A' ' 137' ' ' GLU . 16.7 t -148.48 142.37 25.77 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.188 -0.945 . . . . 0.0 109.689 -179.608 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.449 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 105.38 -166.5 14.44 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.472 ' HA ' ' HD3' ' A' ' 103' ' ' ARG . 47.7 Cg_endo -68.09 -19.88 44.7 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 123.23 2.62 . . . . 0.0 112.714 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.655 ' HB2' HD13 ' A' ' 131' ' ' ILE . 96.4 m-85 -107.28 19.74 19.92 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.816 -1.177 . . . . 0.0 109.626 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.525 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 36.7 mt-10 -43.85 137.51 3.13 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.206 -0.934 . . . . 0.0 109.991 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.525 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.6 OUTLIER 77.87 26.47 0.62 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.259 -0.901 . . . . 0.0 110.675 178.87 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.805 ' CE1' HG13 ' A' ' 157' ' ' VAL . 2.0 t80 -114.62 159.79 20.05 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.774 -1.204 . . . . 0.0 109.556 179.696 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -108.63 135.22 50.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.245 -0.909 . . . . 0.0 109.399 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -146.86 170.23 27.84 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.52 -179.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.733 ' C ' HG23 ' A' ' 155' ' ' VAL . 8.5 p -119.19 136.94 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.627 -0.926 . . . . 0.0 109.222 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.679 HD11 HG11 ' A' ' 129' ' ' VAL . 88.7 mt -67.22 115.14 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.302 -0.874 . . . . 0.0 109.445 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 68.9 tttt -98.33 -34.77 10.55 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.099 -1.001 . . . . 0.0 109.223 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -149.39 144.47 26.41 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.105 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 1.001 HG22 HD22 ' A' ' 153' ' ' LEU . 26.7 pt -126.27 129.32 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.101 -0.999 . . . . 0.0 109.695 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.85 103.13 48.5 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.345 -0.847 . . . . 0.0 109.38 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.549 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.3 Cg_endo -71.08 169.37 20.73 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.711 2.274 . . . . 0.0 111.898 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.549 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.2 tt0 80.81 -21.23 0.33 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.433 -0.792 . . . . 0.0 110.044 179.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.443 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 24.0 mtp85 -124.91 -11.73 7.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.063 -1.023 . . . . 0.0 109.515 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.443 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 42.8 mt-30 69.07 48.13 0.7 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.316 -0.865 . . . . 0.0 109.499 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.72 ' OE2' HG13 ' A' ' 167' ' ' VAL . 56.3 tt0 -121.13 144.93 48.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.104 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 1.001 HD22 HG22 ' A' ' 146' ' ' ILE . 58.1 mt -139.54 121.89 16.02 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.16 -0.963 . . . . 0.0 110.226 -179.701 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.448 ' HE3' ' CB ' ' A' ' 165' ' ' PRO . 18.5 ttpt -83.18 132.04 35.09 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.242 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.733 HG23 ' C ' ' A' ' 142' ' ' VAL . 9.0 p -125.92 149.76 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.781 -179.612 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.531 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 3.5 t30 -99.19 116.21 30.87 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.396 -0.815 . . . . 0.0 109.205 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.805 HG13 ' CE1' ' A' ' 139' ' ' PHE . 65.7 t -102.59 146.09 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.212 -0.93 . . . . 0.0 109.581 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 25.8 m -93.75 113.02 24.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.356 -0.84 . . . . 0.0 109.533 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 1.058 HD11 ' CE1' ' A' ' 56' ' ' PHE . 15.0 pt -145.35 144.6 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.256 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.567 ' CE2' HD12 ' A' ' 159' ' ' ILE . 46.5 m-85 60.18 35.78 21.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.133 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.91 15.41 13.09 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 67.7 mtp180 -127.37 154.28 45.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.063 -1.257 . . . . 0.0 109.637 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . 0.436 ' OE1' ' N ' ' A' ' 163' ' ' GLU . 58.0 mp0 -97.73 134.9 40.28 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.151 -0.968 . . . . 0.0 109.427 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 24.5 m -147.9 126.12 5.99 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.257 -0.902 . . . . 0.0 109.764 -179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.531 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.8 Cg_endo -70.83 142.8 44.06 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.702 2.268 . . . . 0.0 111.545 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 41.8 t -125.72 144.08 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.058 -1.026 . . . . 0.0 109.788 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.72 HG13 ' OE2' ' A' ' 152' ' ' GLU . 55.4 t -91.48 118.4 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.414 -0.804 . . . . 0.0 109.194 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.407 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 27.0 mt -140.71 166.31 25.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.12 -0.987 . . . . 0.0 110.543 -179.014 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.438 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 79.7 m80 -81.54 144.44 31.3 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.6 HG23 ' CD1' ' A' ' 153' ' ' LEU . 11.6 p -59.22 -35.39 57.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.346 -0.846 . . . . 0.0 109.025 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.421 ' N ' HG13 ' A' ' 170' ' ' VAL . 19.4 m -76.96 -8.16 56.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.249 -0.907 . . . . 0.0 109.508 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.467 ' HG2' ' HB3' ' A' ' 133' ' ' SER . 18.6 mt-10 -92.22 2.22 56.74 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.301 -0.874 . . . . 0.0 109.195 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 4.1 m -145.06 173.07 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.313 -0.867 . . . . 0.0 109.242 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.533 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 84.2 tt0 -136.94 164.0 29.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.165 -0.959 . . . . 0.0 108.985 179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.533 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 36.7 tttm . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.084 -1.01 . . . . 0.0 109.521 -179.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.709 ' HG2' HG22 ' A' ' 65' ' ' ILE . 20.5 mttt . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.595 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.4 mmtp -129.99 172.11 12.07 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.277 -0.89 . . . . 0.0 109.419 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.938 ' O ' HG23 ' A' ' 93' ' ' VAL . 61.3 m95 -107.44 127.17 53.36 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.286 -0.884 . . . . 0.0 109.215 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.428 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 54.0 m-85 -117.86 167.88 11.0 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.179 -0.951 . . . . 0.0 109.288 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.555 ' HB ' HG12 ' A' ' 84' ' ' VAL . 22.7 mt -101.98 118.32 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.903 . . . . 0.0 109.29 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.539 HG23 HG22 ' A' ' 62' ' ' VAL . 84.3 t -93.88 136.79 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.273 -0.892 . . . . 0.0 109.337 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.489 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.2 OUTLIER -89.2 141.13 28.78 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.202 -0.936 . . . . 0.0 109.419 -179.901 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.533 ' OG1' HG21 ' A' ' 20' ' ' VAL . 11.3 t -154.48 -170.91 3.68 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.282 -0.886 . . . . 0.0 109.442 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 59.2 mtm -105.07 122.93 46.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.203 -0.935 . . . . 0.0 109.496 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 21.0 m -45.75 128.87 8.99 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.223 -0.923 . . . . 0.0 109.278 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.74 -20.18 44.8 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -111.01 10.23 22.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.278 -1.131 . . . . 0.0 109.57 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.594 ' OE1' HD13 ' A' ' 44' ' ' ILE . 94.8 mt-10 -61.8 -46.59 88.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.204 -0.935 . . . . 0.0 109.456 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -56.73 -34.02 67.11 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.19 -0.943 . . . . 0.0 109.524 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -75.31 -44.72 43.95 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.241 -0.912 . . . . 0.0 109.456 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.533 HG21 ' OG1' ' A' ' 12' ' ' THR . 48.4 t -59.0 -50.98 77.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.318 -0.863 . . . . 0.0 109.385 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 49.5 tttm -59.79 -47.83 84.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.305 -0.872 . . . . 0.0 109.437 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -62.38 -34.81 77.43 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.259 -0.9 . . . . 0.0 109.245 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.478 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 5.7 m120 -64.77 -38.03 89.6 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.251 -0.906 . . . . 0.0 109.517 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.886 HG21 HD11 ' A' ' 40' ' ' ILE . 92.6 mt -63.52 -45.26 98.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.226 -0.921 . . . . 0.0 109.755 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -57.32 -46.04 83.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.146 -0.971 . . . . 0.0 109.992 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -81.6 -37.11 28.14 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.03 -1.044 . . . . 0.0 109.825 -179.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.566 ' HG3' ' CZ ' ' A' ' 73' ' ' PHE . 13.3 tptp -55.86 -29.63 60.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.114 -0.991 . . . . 0.0 109.283 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.051 HG21 HG11 ' A' ' 37' ' ' VAL . 70.4 t -87.56 -25.21 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.296 -0.877 . . . . 0.0 109.43 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 48.2 tp10 -66.47 -49.09 67.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.324 -0.86 . . . . 0.0 109.32 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.02 -27.49 65.5 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.379 -0.826 . . . . 0.0 109.313 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 73.0 p -94.25 -25.55 17.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -0.916 . . . . 0.0 109.388 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 73.26 25.49 72.96 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.535 ' CG2' ' HB2' ' A' ' 36' ' ' LEU . 76.4 mt -98.09 82.27 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -1.109 . . . . 0.0 109.447 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.424 ' O ' ' HG3' ' A' ' 34' ' ' LYS . 14.8 tptm -89.63 -6.07 56.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.227 -0.921 . . . . 0.0 109.714 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.508 ' O ' HD13 ' A' ' 65' ' ' ILE . 33.1 m120 -94.34 -4.58 48.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.249 -0.907 . . . . 0.0 109.561 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.136 HD11 ' CB ' ' A' ' 70' ' ' ALA . 8.3 tp -97.85 -54.39 3.11 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.305 -0.872 . . . . 0.0 109.664 -179.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 1.051 HG11 HG21 ' A' ' 28' ' ' VAL . 3.7 p -92.65 135.2 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.228 -0.92 . . . . 0.0 109.104 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -106.8 -123.14 5.04 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 59.6 mtt85 -94.11 139.7 30.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.34 -1.094 . . . . 0.0 110.006 -179.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 1.081 HG23 HG12 ' A' ' 62' ' ' VAL . 91.8 mt -108.39 136.56 43.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.931 HG23 ' HB2' ' A' ' 61' ' ' PHE . 33.9 m -130.59 155.09 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.071 -1.018 . . . . 0.0 109.616 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.54 HG22 HG23 ' A' ' 44' ' ' ILE . 11.8 mt -128.48 133.91 25.69 Favored Pre-proline 0 N--CA 1.489 1.482 0 O-C-N 121.371 -0.831 . . . . 0.0 109.353 -179.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.58 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 40.9 Cg_endo -63.33 -6.57 10.32 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.715 2.276 . . . . 0.0 111.502 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.598 ' CB ' ' HA ' ' A' ' 54' ' ' LYS . 3.7 pt . . . . . 0 N--CA 1.489 1.482 0 O-C-N 121.329 -0.857 . . . . 0.0 109.09 179.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.598 ' HA ' ' CB ' ' A' ' 44' ' ' ILE . 11.3 mttp . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.58 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 9.9 tp -53.64 -47.93 69.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.1 -1.0 . . . . 0.0 109.423 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 1.029 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 95.9 m-85 -135.57 111.95 10.7 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.121 -0.987 . . . . 0.0 109.121 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -66.7 142.48 64.05 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.584 2.189 . . . . 0.0 111.879 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.37 -8.18 7.34 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.4 m-30 -100.27 131.94 45.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.793 -1.416 . . . . 0.0 110.122 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.457 HG13 HG12 ' A' ' 42' ' ' ILE . 46.5 t -134.28 144.69 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.325 -0.859 . . . . 0.0 109.03 179.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.931 ' HB2' HG23 ' A' ' 41' ' ' VAL . 59.6 m-85 -107.03 123.38 48.13 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.114 -0.991 . . . . 0.0 109.821 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 1.081 HG12 HG23 ' A' ' 40' ' ' ILE . 29.6 m -132.94 144.46 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.344 -0.848 . . . . 0.0 109.653 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.622 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 37.3 tt0 -110.62 128.95 55.9 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -0.92 . . . . 0.0 109.051 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.493 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 35.1 mtm -156.01 174.3 15.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.011 -1.056 . . . . 0.0 110.66 -179.35 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 1.02 ' CG1' HD12 ' A' ' 36' ' ' LEU . 10.2 pt -93.92 128.23 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-O 121.323 0.583 . . . . 0.0 109.577 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.569 ' HE3' ' HG2' ' A' ' 89' ' ' GLN . 91.3 mtp -76.82 145.29 38.53 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.372 -0.83 . . . . 0.0 110.046 -178.834 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.482 ' HB2' ' O ' ' A' ' 66' ' ' MET . 45.1 t-20 176.48 173.63 0.38 Allowed 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -70.44 -42.06 72.03 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.056 -1.028 . . . . 0.0 109.292 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -75.92 -30.86 58.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -0.894 . . . . 0.0 109.59 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.136 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -69.58 -48.08 61.39 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.192 -0.942 . . . . 0.0 109.37 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.4 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 74.5 t80 -60.21 -48.55 81.24 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.237 -0.914 . . . . 0.0 109.555 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -59.66 -29.4 68.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.193 -0.942 . . . . 0.0 109.987 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.566 ' CZ ' ' HG3' ' A' ' 27' ' ' LYS . 72.4 t80 -82.0 -43.43 18.0 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.112 -0.992 . . . . 0.0 109.578 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 1.028 HG23 ' O ' ' A' ' 70' ' ' ALA . 2.7 t -66.26 -57.01 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.321 -0.862 . . . . 0.0 109.247 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 13.2 tpt180 -50.34 -32.75 18.08 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.427 -0.796 . . . . 0.0 109.612 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 9.4 t -78.33 6.25 8.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.331 -0.856 . . . . 0.0 110.199 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 74' ' ' VAL . 54.8 t -63.27 131.48 94.79 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 120.957 -1.09 . . . . 0.0 109.408 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.578 ' HB2' ' CD2' ' A' ' 79' ' ' TYR . 47.2 Cg_endo -67.89 137.73 42.37 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.66 2.24 . . . . 0.0 111.983 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.578 ' CD2' ' HB2' ' A' ' 78' ' ' PRO . 58.9 m-85 76.15 -4.41 2.37 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.503 -0.748 . . . . 0.0 109.797 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.593 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.8 t -87.57 129.94 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.108 -0.995 . . . . 0.0 109.162 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.431 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 95.5 mmm -88.31 -7.2 57.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.153 -0.967 . . . . 0.0 109.49 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.403 ' H ' ' CG1' ' A' ' 80' ' ' VAL . . . 132.44 -150.83 19.75 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.65 ' CE2' HG12 ' A' ' 74' ' ' VAL . 4.6 m-85 -140.01 145.79 38.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.228 -1.16 . . . . 0.0 109.542 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.657 HG13 ' O ' ' A' ' 84' ' ' VAL . 10.0 p -68.06 119.1 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.385 -0.822 . . . . 0.0 109.469 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.541 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 6.1 p -153.81 165.65 35.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.195 -0.941 . . . . 0.0 109.452 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 t -91.11 -30.43 16.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.399 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -134.57 -73.9 0.08 OUTLIER Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -115.4 -133.05 5.3 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.569 ' HG2' ' HE3' ' A' ' 66' ' ' MET . 0.5 OUTLIER -31.07 146.48 0.06 OUTLIER Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.588 -0.948 . . . . 0.0 110.135 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.541 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.3 Cg_endo -69.12 141.35 47.59 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.957 2.438 . . . . 0.0 112.096 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . 0.743 HG13 ' HD2' ' A' ' 92' ' ' PRO . 68.9 t -67.48 143.9 97.45 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.323 -0.861 . . . . 0.0 109.434 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.743 ' HD2' HG13 ' A' ' 91' ' ' VAL . 48.0 Cg_endo -69.43 148.14 66.55 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.622 2.215 . . . . 0.0 111.701 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.938 HG23 ' O ' ' A' ' 7' ' ' TRP . 3.0 t -81.87 127.49 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.19 -0.944 . . . . 0.0 109.54 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -69.99 139.87 52.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.317 -0.864 . . . . 0.0 109.47 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -48.83 -40.41 29.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.212 -0.93 . . . . 0.0 109.37 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 59.9 mtt180 -59.01 -34.48 71.92 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.235 -0.916 . . . . 0.0 109.418 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -80.2 -25.96 39.42 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.276 -0.89 . . . . 0.0 109.417 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.542 ' CB ' HD11 ' A' ' 102' ' ' LEU . 93.2 mtp -84.26 -24.73 29.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.261 -0.9 . . . . 0.0 109.556 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.599 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 3.2 tpt85 -36.43 -53.15 1.74 Allowed Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.39 -0.819 . . . . 0.0 109.829 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.599 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 50.2 Cg_endo -70.49 -28.07 22.23 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.574 2.183 . . . . 0.0 111.724 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.495 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 35.8 mm -80.62 -42.26 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 109.486 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.542 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.7 OUTLIER -67.06 -40.03 87.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.184 -0.948 . . . . 0.0 109.236 179.772 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.531 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 39.8 ttt-85 -63.06 -50.57 70.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.155 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.628 HD23 ' C ' ' A' ' 104' ' ' LEU . 5.5 tt -72.58 -35.26 67.89 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.267 -0.896 . . . . 0.0 109.078 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.564 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -71.18 -3.12 18.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.425 -0.797 . . . . 0.0 109.778 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.46 11.63 82.5 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.898 HD21 HG11 ' A' ' 41' ' ' VAL . 9.9 mp -79.46 -19.38 49.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.308 -1.113 . . . . 0.0 109.698 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . 0.431 ' OE2' HD13 ' A' ' 102' ' ' LEU . 96.5 mt-10 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.236 -0.915 . . . . 0.0 109.608 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.412 ' O ' ' HG2' ' A' ' 124' ' ' LYS . 13.3 p90 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.337 0.589 . . . . 0.0 109.531 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.412 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 14.7 mttp -150.95 161.43 42.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.238 -0.913 . . . . 0.0 109.397 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 144' ' ' LYS . 40.2 t -60.15 141.33 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.258 -0.901 . . . . 0.0 109.525 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 86.06 -33.29 3.6 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 70.3 m-20 -47.74 162.22 0.08 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.374 -1.074 . . . . 0.0 109.132 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 9.4 ttm -96.67 126.66 42.0 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.157 -0.964 . . . . 0.0 109.082 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.552 ' CG2' HD11 ' A' ' 143' ' ' ILE . 2.7 t -125.37 141.27 45.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.23 -0.919 . . . . 0.0 109.214 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 15.8 tttt -102.55 143.02 32.78 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.245 -0.909 . . . . 0.0 108.98 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.956 HD12 ' HB3' ' A' ' 139' ' ' PHE . 66.8 mt -83.71 151.78 3.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.434 ' C ' ' HG2' ' A' ' 137' ' ' GLU . 2.2 pt -149.67 2.69 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.038 -1.038 . . . . 0.0 109.382 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.587 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 71.9 m -148.7 143.33 26.38 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.185 -0.947 . . . . 0.0 109.884 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.488 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 101.57 -164.07 17.69 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.531 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 47.4 Cg_endo -68.16 -22.01 41.47 Favored 'Trans proline' 0 C--O 1.216 -0.587 0 C-N-CA 123.215 2.61 . . . . 0.0 112.913 -179.187 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.556 ' HB2' HD13 ' A' ' 131' ' ' ILE . 94.0 m-85 -106.21 19.59 20.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.743 -1.223 . . . . 0.0 109.418 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.543 ' HG2' ' HA ' ' A' ' 133' ' ' SER . 44.4 mt-10 -40.75 137.04 1.26 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.871 . . . . 0.0 109.988 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.445 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 4.4 m-20 71.08 29.77 2.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.389 -0.82 . . . . 0.0 110.656 179.05 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.956 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.9 t80 -116.7 128.06 54.98 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.912 -1.117 . . . . 0.0 109.579 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.34 133.3 40.01 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.285 -0.884 . . . . 0.0 109.797 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.525 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -142.66 169.66 25.46 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 155' ' ' VAL . 41.1 t -115.31 136.61 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.314 -1.109 . . . . 0.0 109.506 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.606 HG23 HD23 ' A' ' 153' ' ' LEU . 49.6 mt -67.28 113.82 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.221 -0.924 . . . . 0.0 108.898 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.484 ' O ' HG13 ' A' ' 125' ' ' VAL . 18.1 tptm -98.56 -35.45 10.22 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.926 -1.109 . . . . 0.0 109.768 -179.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.46 ' HB2' ' HB2' ' A' ' 154' ' ' LYS . 38.6 mt-10 -153.29 148.31 26.65 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.133 -0.979 . . . . 0.0 109.754 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.719 HG23 ' HG ' ' A' ' 153' ' ' LEU . 3.4 mt -125.15 127.85 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.277 -0.889 . . . . 0.0 109.434 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -110.61 102.3 51.54 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.192 -0.942 . . . . 0.0 109.525 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.538 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.9 Cg_endo -71.54 173.07 13.05 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.607 2.204 . . . . 0.0 111.881 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.538 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 45.2 mm-40 79.86 -21.1 0.35 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.473 -0.767 . . . . 0.0 109.906 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.443 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 46.6 mtt180 -127.63 -13.98 5.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.058 -1.026 . . . . 0.0 109.509 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.825 ' O ' HG13 ' A' ' 170' ' ' VAL . 66.9 mm-40 70.82 47.99 0.43 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.32 -0.863 . . . . 0.0 109.802 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -118.43 142.21 47.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.116 -0.99 . . . . 0.0 108.852 179.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.719 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -129.76 113.06 14.25 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.137 -0.977 . . . . 0.0 110.16 -179.535 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.46 ' HB2' ' HB2' ' A' ' 145' ' ' GLU . 13.7 mttm -78.18 127.66 32.61 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.083 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.679 HG13 ' O ' ' A' ' 142' ' ' VAL . 40.4 t -126.17 147.05 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.088 -1.007 . . . . 0.0 109.908 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.54 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 70.1 m-20 -95.81 113.72 25.38 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.431 -0.793 . . . . 0.0 109.035 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.722 HG12 HG23 ' A' ' 159' ' ' ILE . 89.3 t -97.72 142.8 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.205 -0.935 . . . . 0.0 109.613 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 28.2 m -100.32 94.25 6.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.341 -0.85 . . . . 0.0 109.876 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 1.029 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 2.2 pt -125.85 152.3 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.281 -0.887 . . . . 0.0 109.143 179.586 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.572 ' CD2' HD12 ' A' ' 159' ' ' ILE . 18.8 m-30 60.47 38.68 19.02 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.143 -0.973 . . . . 0.0 109.111 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 55.05 14.47 5.75 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.419 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 52.3 mtt85 -128.99 156.32 43.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.129 -1.218 . . . . 0.0 109.668 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -99.39 134.52 42.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.32 -0.862 . . . . 0.0 109.255 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 21.7 m -147.51 127.45 6.66 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.271 -0.893 . . . . 0.0 109.674 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.54 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.8 Cg_endo -70.5 139.94 38.8 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.725 2.283 . . . . 0.0 111.701 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.762 HG13 HD11 ' A' ' 168' ' ' LEU . 5.3 p -125.13 144.35 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.18 -0.95 . . . . 0.0 109.515 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.435 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 14.1 m -93.76 119.23 41.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.386 -0.821 . . . . 0.0 109.534 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.762 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -142.07 168.78 18.93 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -0.909 . . . . 0.0 110.576 -179.492 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.417 ' HB2' ' OE1' ' A' ' 172' ' ' GLU . 99.1 m-70 -83.98 142.39 30.53 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.825 HG13 ' O ' ' A' ' 151' ' ' GLN . 3.1 m -53.58 -34.85 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.295 -0.878 . . . . 0.0 109.151 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 60.2 p -73.81 -6.05 44.65 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.335 -0.853 . . . . 0.0 109.982 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.587 ' CG ' ' HB2' ' A' ' 133' ' ' SER . 2.4 mt-10 -95.6 3.88 53.63 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.015 -1.053 . . . . 0.0 110.02 -179.54 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 11.2 m -144.0 169.36 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.057 -1.027 . . . . 0.0 109.601 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.537 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 80.3 tt0 -140.56 166.15 25.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.223 -0.923 . . . . 0.0 108.893 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.537 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 38.9 tttm . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.019 -1.05 . . . . 0.0 109.51 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.79 ' HG2' HG22 ' A' ' 65' ' ' ILE . 55.4 mttt . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 121.263 0.554 . . . . 0.0 109.699 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.9 mmtp -128.0 175.26 8.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.289 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.949 ' CZ3' HG22 ' A' ' 41' ' ' VAL . 80.9 m95 -110.33 127.0 54.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.137 -0.977 . . . . 0.0 109.576 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.453 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 60.7 m-85 -121.78 167.07 13.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.229 -0.919 . . . . 0.0 109.488 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.964 HD11 ' CE1' ' A' ' 160' ' ' PHE . 76.2 mt -106.61 117.1 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.158 -0.964 . . . . 0.0 109.301 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.417 ' CG1' HG22 ' A' ' 80' ' ' VAL . 85.3 t -88.56 141.98 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.28 -0.888 . . . . 0.0 109.569 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.49 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -93.74 138.84 31.51 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.325 -0.86 . . . . 0.0 109.387 179.905 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.589 HG21 ' HG2' ' A' ' 17' ' ' GLU . 14.9 t -155.58 -169.54 3.15 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.457 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.44 ' O ' ' C ' ' A' ' 14' ' ' SER . 90.8 mmm -104.01 119.55 39.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.233 -0.917 . . . . 0.0 109.387 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 13' ' ' MET . 17.8 p -42.46 128.52 3.92 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.232 -0.918 . . . . 0.0 109.475 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.34 -20.31 35.35 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.429 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 90.3 m-85 -110.67 -1.4 16.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -1.133 . . . . 0.0 109.557 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.646 ' OE1' HD11 ' A' ' 44' ' ' ILE . 49.4 mt-10 -53.34 -55.24 26.39 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.241 -0.912 . . . . 0.0 109.404 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -49.13 -32.22 9.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.166 -0.958 . . . . 0.0 109.418 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.47 ' O ' ' HB2' ' A' ' 23' ' ' ASN . 62.3 mttm -76.83 -36.75 56.66 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.286 -0.883 . . . . 0.0 109.311 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.666 HG22 ' HB2' ' A' ' 79' ' ' TYR . 98.4 t -66.73 -52.01 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.33 -0.856 . . . . 0.0 109.523 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.44 ' HB2' HD11 ' A' ' 42' ' ' ILE . 63.1 tttm -56.89 -50.87 71.19 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.231 -0.918 . . . . 0.0 109.484 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -64.68 -34.82 79.19 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.153 -0.967 . . . . 0.0 109.38 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.479 ' CG ' ' HG2' ' A' ' 78' ' ' PRO . 2.1 t30 -66.0 -44.32 85.14 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.408 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.659 ' O ' HG23 ' A' ' 28' ' ' VAL . 81.7 mt -57.39 -43.37 82.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.272 -0.892 . . . . 0.0 109.443 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -58.38 -44.44 88.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.205 -0.934 . . . . 0.0 109.789 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 31.9 mtmt -77.88 -37.48 48.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.112 -0.992 . . . . 0.0 109.798 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.759 ' CD ' HG23 ' A' ' 77' ' ' VAL . 42.1 tttp -57.04 -28.94 62.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.908 . . . . 0.0 109.313 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 24' ' ' ILE . 42.4 t -83.86 -27.43 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.314 -0.866 . . . . 0.0 109.464 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.454 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 54.9 mm-40 -66.8 -49.25 66.45 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.271 -0.893 . . . . 0.0 109.444 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.2 -35.12 66.91 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.241 -0.912 . . . . 0.0 109.482 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.3 p -92.86 -22.71 19.12 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.271 -0.893 . . . . 0.0 109.591 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 74.3 1.59 60.87 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.038 HG21 HD12 ' A' ' 36' ' ' LEU . 48.1 mm -69.39 80.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.318 -1.107 . . . . 0.0 109.429 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -90.89 14.54 13.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 109.458 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.877 ' O ' HD13 ' A' ' 65' ' ' ILE . 24.7 m120 -113.39 -3.07 13.81 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.235 -0.916 . . . . 0.0 109.601 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.038 HD12 HG21 ' A' ' 33' ' ' ILE . 11.8 mt -98.59 -51.2 4.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.946 . . . . 0.0 109.599 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 99.1 t -95.55 144.58 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.313 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.87 -124.75 3.92 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 18.6 mtt85 -91.56 142.18 27.91 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.309 -1.112 . . . . 0.0 109.885 -179.497 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 1.016 HG23 HG22 ' A' ' 62' ' ' VAL . 65.4 mt -109.94 134.42 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.152 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.963 HG23 ' HB2' ' A' ' 61' ' ' PHE . 30.4 m -127.5 144.54 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.208 -0.932 . . . . 0.0 109.263 179.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.92 HG21 HD12 ' A' ' 44' ' ' ILE . 67.6 mt -129.94 129.14 22.98 Favored Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.294 -0.879 . . . . 0.0 109.623 -179.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.565 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.3 Cg_endo -66.71 -2.65 7.93 Favored 'Trans proline' 0 C--O 1.217 -0.544 0 C-N-CA 122.879 2.386 . . . . 0.0 111.348 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.92 HD12 HG21 ' A' ' 42' ' ' ILE . 85.6 mt . . . . . 0 N--CA 1.488 1.462 0 O-C-N 121.144 -0.972 . . . . 0.0 109.554 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.751 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 1.9 mttp . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.565 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 9.2 tp -59.71 -42.14 92.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.904 -1.123 . . . . 0.0 108.909 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.922 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 19.4 m-85 -126.3 101.15 28.51 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.217 -0.927 . . . . 0.0 108.789 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.431 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 41.7 Cg_endo -65.63 137.09 48.75 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.681 2.254 . . . . 0.0 112.26 -179.087 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.36 -12.61 5.5 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.574 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 1.7 m-30 -100.47 132.15 46.01 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.748 -1.442 . . . . 0.0 110.32 -179.199 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.847 HG13 HG12 ' A' ' 42' ' ' ILE . 40.0 t -132.99 143.07 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.349 -0.844 . . . . 0.0 108.926 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.963 ' HB2' HG23 ' A' ' 41' ' ' VAL . 18.8 m-30 -106.68 123.86 48.75 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.003 -1.061 . . . . 0.0 109.805 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 1.016 HG22 HG23 ' A' ' 40' ' ' ILE . 93.0 t -131.16 142.13 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.339 -0.851 . . . . 0.0 109.653 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.591 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 39.1 tt0 -105.9 128.77 53.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.262 -0.899 . . . . 0.0 108.981 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.494 ' CG ' ' C ' ' A' ' 63' ' ' GLU . 16.5 mtm -155.96 178.65 10.03 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.169 -0.957 . . . . 0.0 110.05 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.879 ' CG1' HD23 ' A' ' 36' ' ' LEU . 6.1 pt -101.01 133.89 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.59 -0.694 . . . . 0.0 109.321 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.473 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 53.9 ttm -77.24 144.33 38.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.224 -0.922 . . . . 0.0 110.1 -178.654 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.473 ' HB2' ' O ' ' A' ' 66' ' ' MET . 29.0 t-20 176.46 175.56 0.32 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -72.6 -43.06 63.83 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.249 -0.907 . . . . 0.0 109.323 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -75.64 -28.01 58.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.686 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.058 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -70.58 -47.56 59.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.131 -0.981 . . . . 0.0 109.302 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.536 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 89.0 t80 -60.88 -54.94 38.9 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.289 -0.882 . . . . 0.0 109.275 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.447 ' O ' ' OG ' ' A' ' 76' ' ' SER . 42.2 t-20 -52.85 -31.81 41.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.221 -0.924 . . . . 0.0 109.975 -179.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 81.9 t80 -80.08 -43.27 22.09 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.035 -1.04 . . . . 0.0 109.567 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 1.058 HG23 ' O ' ' A' ' 70' ' ' ALA . 3.2 t -68.26 -55.48 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.295 -0.878 . . . . 0.0 109.414 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.473 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 16.5 tpt180 -61.56 -9.58 6.23 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.338 -0.851 . . . . 0.0 109.837 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 72' ' ' ASN . 42.7 p -101.67 2.09 38.32 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.148 -0.97 . . . . 0.0 109.983 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.759 HG23 ' CD ' ' A' ' 27' ' ' LYS . 0.5 OUTLIER -68.75 135.29 90.15 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.057 -1.027 . . . . 0.0 108.954 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.629 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 43.9 Cg_endo -66.21 138.96 53.43 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.394 2.063 . . . . 0.0 111.99 -179.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.666 ' HB2' HG22 ' A' ' 20' ' ' VAL . 5.5 m-85 89.09 -8.08 0.44 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.801 -0.562 . . . . 0.0 109.829 -179.838 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.713 ' CG2' HG12 ' A' ' 77' ' ' VAL . 2.4 t -89.34 129.5 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.966 -1.084 . . . . 0.0 109.661 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.428 ' HE1' ' SD ' ' A' ' 13' ' ' MET . 18.7 mtt -93.53 -25.06 17.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.459 -0.776 . . . . 0.0 109.246 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 164.54 -162.61 35.59 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.479 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 48.6 m-85 -136.21 151.74 50.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.187 -1.184 . . . . 0.0 109.559 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.8 t -67.01 101.42 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.282 -0.886 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.538 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.0 OUTLIER -143.98 162.85 35.12 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -0.918 . . . . 0.0 109.505 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.0 m -95.18 -34.52 12.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.349 -0.845 . . . . 0.0 109.278 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -129.39 -72.78 0.14 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.541 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -113.91 -137.89 6.75 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.541 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.3 OUTLIER -31.03 148.45 0.04 OUTLIER Pre-proline 0 N--CA 1.493 1.704 0 O-C-N 121.506 -0.997 . . . . 0.0 110.274 -179.718 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.538 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.3 Cg_endo -69.54 149.61 68.53 Favored 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.82 2.347 . . . . 0.0 111.887 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 36.0 m -80.73 152.31 72.13 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.323 -0.861 . . . . 0.0 109.403 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.07 143.36 49.12 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.693 2.262 . . . . 0.0 111.81 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.659 HG11 ' SD ' ' A' ' 98' ' ' MET . 29.3 t -69.48 142.16 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.192 -0.942 . . . . 0.0 109.414 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . 0.434 ' HB2' ' HG3' ' A' ' 97' ' ' GLU . 32.0 mttt -70.67 134.12 47.25 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.537 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -50.27 -41.46 50.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.863 . . . . 0.0 109.419 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -63.14 -24.07 67.72 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.438 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.434 ' HG3' ' HB2' ' A' ' 94' ' ' LYS . 40.9 mt-10 -84.95 -23.66 28.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -0.913 . . . . 0.0 109.456 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.659 ' SD ' HG11 ' A' ' 93' ' ' VAL . 52.5 mmm -85.19 -33.18 22.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.265 -0.897 . . . . 0.0 109.384 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.6 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -36.1 -53.41 1.57 Allowed Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.459 -0.776 . . . . 0.0 109.795 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.615 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 47.4 Cg_endo -69.79 -26.57 27.3 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.494 2.129 . . . . 0.0 111.616 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.531 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 32.3 mm -81.09 -38.51 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.236 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.715 ' N ' HD13 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -71.36 -40.35 70.69 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.328 -0.858 . . . . 0.0 109.16 179.733 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 58.0 mtt-85 -63.15 -50.06 71.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.403 -0.81 . . . . 0.0 109.028 179.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.4 tt -72.35 -35.55 68.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.385 -0.822 . . . . 0.0 109.079 179.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -69.33 -1.62 8.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.393 -0.817 . . . . 0.0 110.023 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.12 8.25 82.97 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.406 ' HB3' ' HB3' ' A' ' 102' ' ' LEU . 0.7 OUTLIER -74.37 -17.55 60.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.16 -1.2 . . . . 0.0 109.431 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . 0.447 ' HG3' ' HB3' ' A' ' 102' ' ' LEU . 88.9 mt-10 . . . . . 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.898 . . . . 0.0 109.479 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.615 ' CB ' ' HD3' ' A' ' 175' ' ' LYS . 38.3 p90 . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 17.4 mttt -144.27 162.75 35.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.135 -0.978 . . . . 0.0 109.922 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 144' ' ' LYS . 12.1 t -64.04 141.79 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.472 -0.768 . . . . 0.0 109.297 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 87.47 -31.23 4.58 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -49.71 162.92 0.14 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.299 -1.118 . . . . 0.0 109.27 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.9 ttp -94.72 125.35 39.31 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.13 -0.982 . . . . 0.0 109.073 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.544 HG11 ' CD1' ' A' ' 143' ' ' ILE . 2.0 p -124.31 140.77 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.173 -0.954 . . . . 0.0 109.02 179.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 174' ' ' GLU . 59.9 tttt -106.2 142.72 35.41 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.153 -0.967 . . . . 0.0 109.361 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.927 ' O ' HD13 ' A' ' 132' ' ' ILE . 88.2 mt -82.75 152.91 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.161 -0.962 . . . . 0.0 108.581 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.927 HD13 ' O ' ' A' ' 131' ' ' ILE . 2.6 mm -148.94 1.66 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.103 -0.998 . . . . 0.0 109.463 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.566 ' CB ' ' HG2' ' A' ' 172' ' ' GLU . 28.3 m -150.82 147.64 27.51 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.13 -0.981 . . . . 0.0 110.331 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.84 -164.12 18.56 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 179.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.483 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 46.2 Cg_endo -67.93 -23.52 40.79 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 123.026 2.484 . . . . 0.0 112.535 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.615 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 93.4 m-85 -108.86 18.76 20.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.962 -1.086 . . . . 0.0 109.456 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.629 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.8 tt0 -48.35 140.69 7.39 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.289 -0.882 . . . . 0.0 109.687 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 12.8 m-20 76.93 28.73 0.64 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.468 -0.77 . . . . 0.0 110.243 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.91 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.9 t80 -118.42 153.52 33.95 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.08 -1.012 . . . . 0.0 109.485 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -101.2 133.34 45.91 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.246 -0.909 . . . . 0.0 109.197 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.499 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.25 170.38 26.65 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 119.535 -1.317 . . . . 0.0 110.604 -179.413 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.646 ' C ' HG23 ' A' ' 155' ' ' VAL . 44.9 t -115.11 137.71 47.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.602 -0.94 . . . . 0.0 109.348 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.94 HD12 HD23 ' A' ' 153' ' ' LEU . 14.9 mm -68.74 115.27 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.226 -0.921 . . . . 0.0 109.502 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.457 ' O ' HG13 ' A' ' 125' ' ' VAL . 21.2 tttp -99.0 -34.46 10.41 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.039 -1.038 . . . . 0.0 109.321 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.43 ' HG3' ' HG2' ' A' ' 144' ' ' LYS . 89.5 mt-10 -152.57 147.6 26.37 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.133 -0.98 . . . . 0.0 109.444 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.838 HG23 ' HG ' ' A' ' 153' ' ' LEU . 6.6 mt -126.56 130.05 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.216 -0.928 . . . . 0.0 109.622 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -110.33 103.39 53.87 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.286 -0.884 . . . . 0.0 109.528 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.557 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.55 171.83 15.52 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.747 2.298 . . . . 0.0 111.631 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.557 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.3 mt-10 80.68 -20.34 0.38 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.319 -0.863 . . . . 0.0 109.876 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.434 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 43.3 mtt85 -128.21 -12.18 5.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.05 -1.031 . . . . 0.0 109.582 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.539 ' O ' HG12 ' A' ' 170' ' ' VAL . 37.1 mt-30 69.68 48.97 0.56 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.907 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -120.12 144.54 47.58 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.081 -1.012 . . . . 0.0 109.116 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.94 HD23 HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -133.92 115.73 14.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.097 -1.002 . . . . 0.0 110.115 -179.381 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 7.1 mttt -78.04 132.42 37.76 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.328 -0.857 . . . . 0.0 108.786 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.646 HG23 ' C ' ' A' ' 142' ' ' VAL . 13.2 p -130.21 147.01 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.119 -0.988 . . . . 0.0 110.008 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.488 ' OD1' ' CA ' ' A' ' 165' ' ' PRO . 0.9 OUTLIER -97.53 115.96 28.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.435 -0.791 . . . . 0.0 109.183 179.66 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.579 HG13 ' CE1' ' A' ' 139' ' ' PHE . 87.1 t -97.64 143.22 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.163 -0.961 . . . . 0.0 109.747 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.3 m -91.88 111.88 23.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.314 -0.867 . . . . 0.0 109.643 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.922 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 13.6 pt -144.56 143.92 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.295 -0.878 . . . . 0.0 109.486 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.964 ' CE1' HD11 ' A' ' 9' ' ' ILE . 78.2 m-85 62.1 34.36 16.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.282 -0.886 . . . . 0.0 109.396 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.28 16.47 20.42 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 73.6 mtt-85 -128.91 151.14 49.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -93.7 135.05 35.38 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.233 -0.917 . . . . 0.0 109.392 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 60.8 m -144.64 126.31 7.96 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.242 -0.911 . . . . 0.0 109.67 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.488 ' CA ' ' OD1' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.8 139.58 36.93 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 122.624 2.216 . . . . 0.0 111.39 179.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.563 ' HB ' HD21 ' A' ' 168' ' ' LEU . 1.9 m -125.75 144.54 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.059 -1.026 . . . . 0.0 109.988 -179.682 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 1.018 ' C ' HD22 ' A' ' 168' ' ' LEU . 14.7 m -92.05 117.48 35.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 1.018 HD22 ' C ' ' A' ' 167' ' ' VAL . 3.2 mm? -139.78 166.24 25.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.156 -0.965 . . . . 0.0 110.289 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.493 ' HB2' ' HB2' ' A' ' 172' ' ' GLU . 82.2 m-70 -83.95 141.15 31.45 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 151' ' ' GLN . 9.1 p -56.78 -36.58 49.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.293 -0.879 . . . . 0.0 109.296 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.424 ' N ' HG13 ' A' ' 170' ' ' VAL . 32.1 p -77.29 -8.47 57.67 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.094 -1.004 . . . . 0.0 109.722 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.566 ' HG2' ' CB ' ' A' ' 133' ' ' SER . 1.3 mt-10 -88.67 -4.79 58.47 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.194 -0.941 . . . . 0.0 109.275 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.9 m -137.22 176.51 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.192 -0.942 . . . . 0.0 109.799 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.544 ' O ' HG22 ' A' ' 129' ' ' VAL . 72.9 tt0 -132.15 155.43 48.18 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.615 ' HD3' ' CB ' ' A' ' 123' ' ' PHE . 16.2 mttm . . . . . 0 N--CA 1.489 1.523 0 O-C-N 120.965 -1.084 . . . . 0.0 109.712 -179.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 33.4 mttm . . . . . 0 N--CA 1.488 1.464 0 CA-C-O 121.342 0.591 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.593 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 11.6 mttt -130.47 173.76 10.54 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.905 . . . . 0.0 109.192 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 1.063 ' O ' HG23 ' A' ' 93' ' ' VAL . 61.5 m95 -108.59 127.51 54.01 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -0.901 . . . . 0.0 109.3 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.447 ' OH ' ' SD ' ' A' ' 66' ' ' MET . 91.6 m-85 -115.61 169.15 9.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.211 -0.93 . . . . 0.0 109.33 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.597 HD11 ' CE1' ' A' ' 160' ' ' PHE . 27.3 mt -109.89 113.57 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 109.192 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 82.4 t -88.51 140.58 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.221 -0.925 . . . . 0.0 109.369 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 59' ' ' TYR . 2.9 mm? -95.36 146.36 24.45 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.357 -0.839 . . . . 0.0 109.414 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.5 t -161.17 -164.26 1.14 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.265 -0.897 . . . . 0.0 109.114 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.518 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 94.0 mtp -105.32 124.71 50.0 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.186 -0.946 . . . . 0.0 109.516 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.0 t -45.78 131.1 9.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.294 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.94 -19.33 47.08 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.518 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 95.6 m-85 -108.96 6.34 25.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.284 -1.127 . . . . 0.0 109.564 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -62.79 -52.82 61.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.261 -0.899 . . . . 0.0 109.507 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -50.7 -35.78 32.84 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.187 -0.945 . . . . 0.0 109.61 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.48 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 58.4 mttt -73.9 -47.81 35.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.247 -0.908 . . . . 0.0 109.556 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.963 HG22 ' HB2' ' A' ' 79' ' ' TYR . 74.8 t -54.32 -48.41 67.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.226 -0.922 . . . . 0.0 109.579 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.604 ' HD2' HD11 ' A' ' 42' ' ' ILE . 40.8 tttm -57.56 -49.66 75.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -0.923 . . . . 0.0 109.615 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -65.42 -39.18 91.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.244 -0.91 . . . . 0.0 109.497 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 19' ' ' LYS . 70.2 m-20 -62.16 -44.62 96.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.869 . . . . 0.0 109.622 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.404 HG21 HD11 ' A' ' 40' ' ' ILE . 96.7 mt -57.76 -43.83 84.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.522 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -56.42 -44.55 80.48 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.206 -0.934 . . . . 0.0 109.823 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -75.55 -35.33 60.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.06 -1.025 . . . . 0.0 109.437 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.88 ' HD3' HG23 ' A' ' 77' ' ' VAL . 10.1 tttm -56.44 -34.16 66.57 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.229 -0.92 . . . . 0.0 109.331 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.691 HG13 ' O ' ' A' ' 33' ' ' ILE . 43.4 t -83.99 -25.42 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.334 -0.854 . . . . 0.0 109.593 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 46.7 tp10 -70.32 -53.95 14.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.264 -0.897 . . . . 0.0 109.656 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.92 -33.6 72.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -0.92 . . . . 0.0 109.693 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.5 HG23 ' O ' ' A' ' 27' ' ' LYS . 50.7 p -83.35 -35.91 24.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.182 -0.949 . . . . 0.0 109.488 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 84.75 17.8 62.91 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.691 ' O ' HG13 ' A' ' 28' ' ' VAL . 78.8 mt -95.74 78.31 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.218 -1.166 . . . . 0.0 109.414 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 45.0 mttm -85.68 6.1 29.12 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 24.5 m120 -102.3 -6.94 22.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.224 -0.923 . . . . 0.0 109.547 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.101 HD11 ' HB2' ' A' ' 70' ' ' ALA . 10.5 tp -97.68 -54.05 3.24 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.302 -0.874 . . . . 0.0 109.681 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.878 HG22 ' CE ' ' A' ' 64' ' ' MET . 87.4 t -90.38 133.66 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.284 -0.885 . . . . 0.0 109.324 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.65 -126.87 5.88 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 44.5 mtt180 -93.58 140.65 29.37 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -1.155 . . . . 0.0 109.887 -179.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.682 HG23 HG12 ' A' ' 62' ' ' VAL . 63.2 mt -103.76 134.0 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.308 -0.87 . . . . 0.0 109.09 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.863 HG23 ' HB2' ' A' ' 61' ' ' PHE . 34.7 m -124.7 146.7 29.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.132 -0.98 . . . . 0.0 109.692 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.811 HG22 HG23 ' A' ' 44' ' ' ILE . 1.2 mt -117.75 128.9 25.7 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.423 -0.798 . . . . 0.0 109.465 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.696 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.6 Cg_endo -66.43 -6.22 14.59 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.903 2.402 . . . . 0.0 111.857 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.994 ' O ' HD21 ' A' ' 104' ' ' LEU . 13.1 pt . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.178 -0.951 . . . . 0.0 109.413 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.776 ' HA ' HG22 ' A' ' 44' ' ' ILE . 1.9 mttt . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.889 HD12 ' CZ ' ' A' ' 56' ' ' PHE . 0.7 OUTLIER -54.16 -45.84 72.15 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.036 -1.04 . . . . 0.0 108.85 179.756 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.889 ' CZ ' HD12 ' A' ' 55' ' ' LEU . 16.5 m-85 -123.97 110.32 29.41 Favored Pre-proline 0 N--CA 1.487 1.422 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.368 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 44.2 Cg_endo -66.92 137.89 46.37 Favored 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.645 2.23 . . . . 0.0 111.942 -179.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.19 -7.71 10.28 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.972 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.7 m-85 -107.54 134.37 50.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.896 -1.355 . . . . 0.0 110.082 -179.351 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 43.3 t -134.52 150.42 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.863 ' HB2' HG23 ' A' ' 41' ' ' VAL . 72.9 m-85 -108.67 123.64 49.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.988 -1.07 . . . . 0.0 109.711 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.682 HG12 HG23 ' A' ' 40' ' ' ILE . 19.0 m -131.86 144.24 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.382 -0.824 . . . . 0.0 109.569 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.62 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 22.7 tt0 -105.27 126.7 52.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.364 -0.835 . . . . 0.0 109.038 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.878 ' CE ' HG22 ' A' ' 37' ' ' VAL . 4.9 mtp -156.47 175.0 14.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.107 -0.996 . . . . 0.0 110.293 -179.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.96 HG12 HD12 ' A' ' 36' ' ' LEU . 10.6 pt -97.39 129.13 47.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.608 -0.683 . . . . 0.0 109.236 179.7 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.479 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 0.0 OUTLIER -76.36 145.87 39.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.919 . . . . 0.0 109.621 -179.026 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.582 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 44.1 t30 175.78 163.61 0.34 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -59.56 -40.47 87.39 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.058 -1.027 . . . . 0.0 109.581 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.544 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 99.1 mt-10 -72.19 -43.74 64.07 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.217 -0.927 . . . . 0.0 109.895 -179.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.101 ' HB2' HD11 ' A' ' 36' ' ' LEU . . . -56.4 -44.88 80.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.087 -1.008 . . . . 0.0 109.572 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.582 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 36.2 m-85 -60.32 -62.39 1.9 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.22 -0.925 . . . . 0.0 109.269 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.479 ' O ' ' HB2' ' A' ' 76' ' ' SER . 95.8 m-20 -43.52 -30.86 0.62 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.388 -0.82 . . . . 0.0 109.82 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.544 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 24.4 m-85 -82.94 -42.41 17.69 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.167 -0.958 . . . . 0.0 109.898 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.955 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 61.2 t -69.99 -55.33 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.217 -0.927 . . . . 0.0 109.498 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.493 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 6.1 tpt180 -57.77 -14.32 5.65 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.292 -0.88 . . . . 0.0 109.307 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.479 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 3.8 m -105.61 2.5 28.28 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.208 -0.933 . . . . 0.0 109.691 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 1.015 ' O ' HG12 ' A' ' 80' ' ' VAL . 0.4 OUTLIER -68.37 150.65 97.63 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.048 -1.033 . . . . 0.0 109.087 179.911 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.904 ' HD2' HG22 ' A' ' 77' ' ' VAL . 47.7 Cg_endo -68.83 124.75 11.79 Favored 'Trans proline' 0 C--O 1.214 -0.714 0 C-N-CA 122.569 2.179 . . . . 0.0 112.429 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.963 ' HB2' HG22 ' A' ' 20' ' ' VAL . 53.5 m-85 88.59 0.02 0.38 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.776 -0.577 . . . . 0.0 110.773 179.164 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 1.015 HG12 ' O ' ' A' ' 77' ' ' VAL . 7.4 p -84.16 112.9 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.738 -1.226 . . . . 0.0 109.523 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 86.0 mmm -87.43 -30.1 20.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.274 -0.891 . . . . 0.0 109.232 179.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 11' ' ' LEU . . . 174.26 -169.03 41.99 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.955 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 15.7 m-85 -127.66 147.62 50.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.248 -1.148 . . . . 0.0 109.514 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.719 ' CG2' HD21 ' A' ' 11' ' ' LEU . 59.2 t -67.3 77.1 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.32 -0.862 . . . . 0.0 109.254 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.529 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 3.1 p -127.71 162.78 25.76 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.332 -0.855 . . . . 0.0 109.634 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 87.8 p -95.91 -33.33 12.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.42 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.98 -77.09 0.19 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.508 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -106.58 -145.19 12.41 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.508 ' C ' ' O ' ' A' ' 88' ' ' GLY . 2.5 pm0 -33.31 154.01 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.582 -0.952 . . . . 0.0 110.188 -179.458 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.529 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 51.7 Cg_endo -70.68 168.55 22.42 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.513 2.142 . . . . 0.0 112.032 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . 0.914 HG12 ' HD2' ' A' ' 92' ' ' PRO . 0.1 OUTLIER -98.7 148.98 35.29 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.33 -0.856 . . . . 0.0 109.199 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.914 ' HD2' HG12 ' A' ' 91' ' ' VAL . 48.7 Cg_endo -69.31 150.8 71.4 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.616 2.21 . . . . 0.0 111.705 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 1.063 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.5 t -80.06 126.65 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.912 . . . . 0.0 109.528 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . 0.487 ' O ' ' N ' ' A' ' 97' ' ' GLU . 51.0 mttt -71.9 136.62 46.96 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.267 -0.895 . . . . 0.0 109.271 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.485 ' O ' ' HG3' ' A' ' 99' ' ' ARG . 82.8 m-20 -43.25 -41.65 3.99 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.918 . . . . 0.0 109.346 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 21.8 mtm180 -56.75 -30.38 63.53 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.336 -0.852 . . . . 0.0 109.692 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.487 ' N ' ' O ' ' A' ' 94' ' ' LYS . 53.6 mt-10 -87.01 -27.75 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.599 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.593 ' SD ' HG11 ' A' ' 93' ' ' VAL . 75.2 mmm -80.08 -24.72 40.43 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.359 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.603 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 25.6 mtp85 -37.37 -53.71 2.2 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.482 -0.761 . . . . 0.0 109.786 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.603 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.9 Cg_endo -69.28 -30.74 24.02 Favored 'Trans proline' 0 C--O 1.216 -0.577 0 C-N-CA 122.587 2.191 . . . . 0.0 111.749 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.42 HD13 ' HA ' ' A' ' 101' ' ' ILE . 16.3 mm -77.52 -43.69 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.139 -0.976 . . . . 0.0 109.238 179.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.529 ' CB ' ' HB2' ' A' ' 108' ' ' GLU . 1.1 mt -63.19 -40.77 98.46 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.275 -0.891 . . . . 0.0 109.031 179.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.527 ' HD3' ' CA ' ' A' ' 135' ' ' PRO . 24.7 ttt-85 -60.11 -45.85 91.59 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 108.783 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.994 HD21 ' O ' ' A' ' 44' ' ' ILE . 0.6 OUTLIER -68.45 -34.31 75.74 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.391 -0.818 . . . . 0.0 108.912 179.397 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.514 ' O ' ' HG ' ' A' ' 107' ' ' LEU . . . -90.47 17.88 6.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.32 -0.863 . . . . 0.0 109.033 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 43.76 28.89 1.22 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.723 HD11 ' CG1' ' A' ' 41' ' ' VAL . 88.3 mt -90.12 -26.64 20.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -1.158 . . . . 0.0 109.535 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . 0.529 ' HB2' ' CB ' ' A' ' 102' ' ' LEU . 87.2 tt0 . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.238 -0.914 . . . . 0.0 109.63 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.652 ' CE2' ' HB3' ' A' ' 127' ' ' ASP . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.475 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 12.2 mttt -113.91 157.22 22.67 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.11 -0.994 . . . . 0.0 110.146 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 22.0 t -64.43 144.99 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.512 -0.742 . . . . 0.0 109.469 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.423 ' O ' HG13 ' A' ' 142' ' ' VAL . . . 84.68 -28.23 4.5 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.652 ' HB3' ' CE2' ' A' ' 123' ' ' PHE . 8.3 m-20 -50.48 167.52 0.06 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.466 -1.02 . . . . 0.0 108.898 179.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -99.05 126.36 44.75 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.026 -1.047 . . . . 0.0 109.112 179.838 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.547 HG22 ' O ' ' A' ' 174' ' ' GLU . 2.3 p -124.93 142.8 40.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.373 -0.829 . . . . 0.0 109.08 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.466 ' N ' ' O ' ' A' ' 174' ' ' GLU . 21.1 tttt -104.9 142.91 33.92 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.293 -0.879 . . . . 0.0 109.236 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.932 HD12 ' HB3' ' A' ' 139' ' ' PHE . 74.3 mt -83.01 152.99 3.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.152 -0.967 . . . . 0.0 108.629 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.509 HD13 ' HB2' ' A' ' 174' ' ' GLU . 34.2 pt -150.1 2.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.926 -1.109 . . . . 0.0 109.494 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.578 ' CA ' ' HG2' ' A' ' 137' ' ' GLU . 5.9 t -147.11 142.09 26.99 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.048 -1.032 . . . . 0.0 109.634 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.464 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 102.22 -166.0 17.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 179.266 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.527 ' CA ' ' HD3' ' A' ' 103' ' ' ARG . 48.4 Cg_endo -68.28 -20.61 42.69 Favored 'Trans proline' 0 C--O 1.214 -0.701 0 C-N-CA 123.382 2.721 . . . . 0.0 113.104 -179.157 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.525 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.1 m-85 -105.77 15.86 26.13 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.836 -1.165 . . . . 0.0 109.54 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.578 ' HG2' ' CA ' ' A' ' 133' ' ' SER . 73.0 mt-10 -41.5 137.35 1.56 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.196 -0.94 . . . . 0.0 109.95 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.491 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.6 OUTLIER 75.48 25.18 1.26 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.303 -0.873 . . . . 0.0 110.656 178.954 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.932 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.1 t80 -115.96 134.25 55.17 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.876 -1.14 . . . . 0.0 109.579 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -83.79 134.29 34.73 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.196 -0.94 . . . . 0.0 109.551 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.17 169.38 25.78 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 126' ' ' GLY . 71.2 t -115.25 136.3 52.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.404 -1.057 . . . . 0.0 109.42 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.945 HD13 HD21 ' A' ' 153' ' ' LEU . 39.4 mt -67.61 117.92 10.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.162 -0.961 . . . . 0.0 109.505 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 24.5 tttm -99.79 -34.5 10.13 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.152 -0.967 . . . . 0.0 109.407 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.478 ' HB3' ' HD2' ' A' ' 154' ' ' LYS . 85.1 tt0 -153.85 148.99 26.89 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.11 -0.994 . . . . 0.0 109.66 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.703 HG23 ' CD1' ' A' ' 153' ' ' LEU . 3.3 mt -124.07 126.79 72.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.287 -0.883 . . . . 0.0 109.425 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.55 101.75 41.14 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.219 -0.925 . . . . 0.0 109.495 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.563 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 49.9 Cg_endo -71.6 170.54 18.34 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.653 2.235 . . . . 0.0 111.665 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.563 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.1 mt-10 80.48 -20.39 0.38 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.441 -0.787 . . . . 0.0 109.952 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.405 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 70.8 mtp180 -127.55 -13.58 5.38 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.12 -0.987 . . . . 0.0 109.67 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.405 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 29.0 mt-30 69.44 48.16 0.64 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.887 . . . . 0.0 109.499 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.765 ' OE2' HG13 ' A' ' 167' ' ' VAL . 82.9 tt0 -118.75 143.05 47.14 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.099 -1.001 . . . . 0.0 108.803 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.945 HD21 HD13 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -130.77 117.67 19.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.048 -1.032 . . . . 0.0 110.321 -179.174 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.478 ' HD2' ' HB3' ' A' ' 145' ' ' GLU . 11.2 mttt -79.82 129.65 34.66 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.677 ' O ' HG22 ' A' ' 166' ' ' VAL . 14.3 m -131.19 148.02 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.157 -0.965 . . . . 0.0 109.724 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.564 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.7 m-20 -100.48 119.04 37.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.37 -0.832 . . . . 0.0 109.437 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.581 HG23 ' CE1' ' A' ' 139' ' ' PHE . 3.4 p -100.35 144.05 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.309 -0.869 . . . . 0.0 109.501 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 28.0 m -96.89 97.05 8.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.391 -0.818 . . . . 0.0 109.984 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.644 HG22 ' CD2' ' A' ' 160' ' ' PHE . 13.0 mt -118.21 139.27 46.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.914 . . . . 0.0 109.332 179.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.644 ' CD2' HG22 ' A' ' 159' ' ' ILE . 40.0 m-85 59.67 41.74 18.14 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.402 -0.811 . . . . 0.0 109.32 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 54.14 16.61 6.55 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 4.3 mtp-105 -119.21 147.07 44.64 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.089 -1.242 . . . . 0.0 109.628 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -95.66 129.73 42.77 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.28 -0.887 . . . . 0.0 109.573 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.2 m -145.94 128.22 7.87 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.908 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.564 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.5 Cg_endo -70.52 138.72 36.0 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.686 2.257 . . . . 0.0 111.369 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.677 HG22 ' O ' ' A' ' 155' ' ' VAL . 2.9 m -122.4 168.09 15.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.005 -1.059 . . . . 0.0 110.01 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.765 HG13 ' OE2' ' A' ' 152' ' ' GLU . 42.8 t -116.44 117.95 57.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.541 -0.724 . . . . 0.0 109.309 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.749 HD12 ' N ' ' A' ' 168' ' ' LEU . 2.4 mp -141.21 165.75 26.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.258 -0.901 . . . . 0.0 110.519 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -80.2 143.38 33.83 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.526 HG23 HD13 ' A' ' 153' ' ' LEU . 4.3 p -57.96 -36.86 57.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.269 -0.895 . . . . 0.0 108.789 179.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.431 ' N ' ' CG1' ' A' ' 170' ' ' VAL . 49.8 m -77.17 -7.47 55.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.482 -0.761 . . . . 0.0 109.417 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.434 ' CG ' ' HB3' ' A' ' 133' ' ' SER . 5.5 mt-10 -95.8 -2.66 47.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.291 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 11.3 m -127.51 164.72 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.225 -0.922 . . . . 0.0 109.392 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.547 ' O ' HG22 ' A' ' 129' ' ' VAL . 58.3 tt0 -134.64 153.81 51.81 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.259 -0.901 . . . . 0.0 109.07 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.643 ' HB2' ' CZ ' ' A' ' 123' ' ' PHE . 33.1 pttt . . . . . 0 N--CA 1.489 1.478 0 O-C-N 121.182 -0.949 . . . . 0.0 109.493 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.487 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 82.9 mttt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.304 0.573 . . . . 0.0 109.496 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.521 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 18.7 mttp -130.65 176.45 8.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.294 -0.879 . . . . 0.0 109.579 -179.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 1.055 ' CZ3' HG23 ' A' ' 41' ' ' VAL . 76.1 m95 -113.16 125.06 53.93 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.279 -0.888 . . . . 0.0 109.179 179.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -115.37 170.4 8.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.164 -0.96 . . . . 0.0 109.139 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.562 HG12 ' CE1' ' A' ' 61' ' ' PHE . 21.5 mt -113.88 97.77 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.101 -1.0 . . . . 0.0 108.818 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.802 HG13 ' CG1' ' A' ' 60' ' ' VAL . 3.9 p -81.83 151.09 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.254 -0.903 . . . . 0.0 109.264 -179.771 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.874 HD21 ' CE1' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -94.34 142.96 26.82 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.388 -0.82 . . . . 0.0 110.013 -179.312 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.4 p -144.59 -171.59 3.64 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.372 -0.83 . . . . 0.0 109.01 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.504 ' CG ' ' SD ' ' A' ' 81' ' ' MET . 44.4 mtm -102.38 118.98 38.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.165 -0.959 . . . . 0.0 109.596 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 13' ' ' MET . 43.7 m -42.14 121.74 1.94 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.22 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.53 -18.3 32.69 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.069 -1.613 . . . . 0.0 109.069 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.43 ' O ' ' C ' ' A' ' 17' ' ' GLU . 92.9 m-85 -108.91 -13.25 14.78 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.397 -1.061 . . . . 0.0 109.61 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.43 ' C ' ' O ' ' A' ' 16' ' ' TYR . 95.1 mt-10 -42.71 -55.27 3.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.279 -0.888 . . . . 0.0 109.372 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -54.16 -36.46 63.36 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.215 -0.928 . . . . 0.0 109.141 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.421 ' N ' ' O ' ' A' ' 16' ' ' TYR . 28.0 mttp -70.3 -37.41 74.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.275 -0.891 . . . . 0.0 109.131 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 61.2 t -64.07 -47.13 91.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.431 -0.793 . . . . 0.0 109.411 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.6 tttm -55.1 -50.93 67.96 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.224 -0.923 . . . . 0.0 109.331 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -64.55 -41.92 96.01 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.281 -0.887 . . . . 0.0 109.311 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.489 ' ND2' ' HG2' ' A' ' 78' ' ' PRO . 24.1 t-20 -57.62 -39.75 77.62 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.186 -0.946 . . . . 0.0 109.452 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.798 HG21 HD11 ' A' ' 40' ' ' ILE . 96.4 mt -62.89 -44.73 99.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -0.927 . . . . 0.0 109.648 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -53.81 -45.29 70.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.15 -0.969 . . . . 0.0 109.64 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.9 mttt -79.99 -32.37 39.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.485 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.748 ' HG2' HG23 ' A' ' 77' ' ' VAL . 48.7 tptt -56.77 -38.3 72.3 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.308 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.788 HG13 ' O ' ' A' ' 33' ' ' ILE . 40.7 t -83.81 -22.93 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.338 -0.851 . . . . 0.0 109.399 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -69.16 -53.27 20.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.571 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.77 -33.47 64.36 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.619 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 23.1 p -91.42 -19.92 22.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.229 -0.92 . . . . 0.0 109.612 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 68.83 9.97 60.37 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.788 ' O ' HG13 ' A' ' 28' ' ' VAL . 54.3 mt -80.16 88.5 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.292 -1.122 . . . . 0.0 109.414 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.3 mttt -91.74 9.18 33.6 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.155 -0.966 . . . . 0.0 109.438 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.47 ' O ' HD13 ' A' ' 65' ' ' ILE . 38.0 p30 -110.93 9.13 22.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.289 -0.882 . . . . 0.0 109.59 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.988 HD21 ' HB2' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -109.71 -55.22 2.46 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.182 -0.948 . . . . 0.0 109.172 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.805 HG22 ' HE3' ' A' ' 64' ' ' MET . 68.9 t -94.15 130.98 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.317 -0.864 . . . . 0.0 109.31 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.75 -122.84 5.16 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -89.74 148.56 23.19 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.275 -1.132 . . . . 0.0 109.822 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.798 HD11 HG21 ' A' ' 24' ' ' ILE . 72.2 mt -116.21 132.93 64.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.4 -0.812 . . . . 0.0 108.909 179.641 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 1.055 HG23 ' CZ3' ' A' ' 7' ' ' TRP . 34.3 t -125.87 161.81 30.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 O-C-N 121.049 -1.032 . . . . 0.0 109.346 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.659 HG22 HG23 ' A' ' 44' ' ' ILE . 2.3 mt -140.92 127.61 11.74 Favored Pre-proline 0 N--CA 1.487 1.402 0 O-C-N 121.208 -0.933 . . . . 0.0 109.83 -179.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.562 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 45.8 Cg_endo -67.16 -2.64 8.39 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.841 2.36 . . . . 0.0 111.305 179.569 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.769 HG22 ' HB3' ' A' ' 54' ' ' LYS . 19.0 pt . . . . . 0 N--CA 1.489 1.48 0 O-C-N 121.312 -0.868 . . . . 0.0 109.615 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.769 ' HB3' HG22 ' A' ' 44' ' ' ILE . 13.6 mttp . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.656 HD23 ' HE2' ' A' ' 56' ' ' PHE . 18.2 tp -57.48 -45.85 84.38 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.039 -1.038 . . . . 0.0 109.291 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.656 ' HE2' HD23 ' A' ' 55' ' ' LEU . 57.9 m-85 -131.44 109.4 14.83 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.141 -0.974 . . . . 0.0 108.864 179.482 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -65.45 138.9 56.89 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.579 2.186 . . . . 0.0 111.974 -179.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.59 ' O ' HD13 ' A' ' 11' ' ' LEU . . . 76.84 -16.7 5.11 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 179.605 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.874 ' CE1' HD21 ' A' ' 11' ' ' LEU . 3.3 m-30 -98.63 129.08 45.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.788 -1.419 . . . . 0.0 110.406 -179.207 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.802 ' CG1' HG13 ' A' ' 10' ' ' VAL . 7.7 p -136.92 151.58 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.562 ' CE1' HG12 ' A' ' 9' ' ' ILE . 7.7 m-85 -110.0 127.07 54.58 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.914 -1.116 . . . . 0.0 110.756 -178.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.783 HG13 HG12 ' A' ' 40' ' ' ILE . 90.3 t -129.51 139.82 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.649 -0.657 . . . . 0.0 109.318 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.604 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 9.7 tt0 -101.83 126.94 48.81 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.114 -0.991 . . . . 0.0 109.104 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.805 ' HE3' HG22 ' A' ' 37' ' ' VAL . 1.8 mtp -157.28 178.02 10.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.043 -1.036 . . . . 0.0 110.071 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.616 ' CG1' HD22 ' A' ' 36' ' ' LEU . 12.2 pt -99.95 131.92 46.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.593 -0.692 . . . . 0.0 109.286 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.47 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 42.1 ttm -77.65 145.76 36.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 110.086 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.508 ' OD1' ' N ' ' A' ' 68' ' ' ASP . 49.8 t-20 176.74 172.37 0.45 Allowed 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.508 ' N ' ' OD1' ' A' ' 67' ' ' ASN . 90.2 m-20 -69.47 -42.81 74.35 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.163 -0.961 . . . . 0.0 109.275 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.504 ' HG2' ' CD2' ' A' ' 73' ' ' PHE . 69.7 tt0 -73.82 -31.54 63.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.327 -0.858 . . . . 0.0 109.55 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.988 ' HB2' HD21 ' A' ' 36' ' ' LEU . . . -70.92 -45.07 64.92 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.146 -0.971 . . . . 0.0 109.356 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.495 ' HA ' ' CG1' ' A' ' 74' ' ' VAL . 71.8 t80 -60.99 -47.0 88.48 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.265 -0.897 . . . . 0.0 109.72 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' HB2' ' A' ' 76' ' ' SER . 96.4 m-20 -64.72 -27.65 69.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.106 -0.996 . . . . 0.0 110.035 -179.518 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.504 ' CD2' ' HG2' ' A' ' 69' ' ' GLU . 3.6 m-85 -84.19 -42.98 15.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.045 -1.034 . . . . 0.0 109.917 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.848 HG12 ' O ' ' A' ' 70' ' ' ALA . 2.9 p -67.12 -57.87 8.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.264 -0.898 . . . . 0.0 109.803 -179.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.696 ' H ' HG13 ' A' ' 74' ' ' VAL . 28.5 tpt85 -62.84 -10.27 12.58 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.103 -0.998 . . . . 0.0 109.676 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.481 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 19.4 m -99.25 1.49 44.74 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.147 -0.971 . . . . 0.0 109.953 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.787 HG12 ' CG2' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -70.43 140.71 87.57 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.023 -1.048 . . . . 0.0 109.229 -179.976 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.648 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 45.6 Cg_endo -66.73 134.9 36.58 Favored 'Trans proline' 0 C--O 1.213 -0.765 0 C-N-CA 122.706 2.271 . . . . 0.0 111.849 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.648 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 10.0 m-85 92.62 -10.77 0.18 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.816 -0.552 . . . . 0.0 109.52 -179.708 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.787 ' CG2' HG12 ' A' ' 77' ' ' VAL . 2.3 t -85.7 121.06 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.116 -0.99 . . . . 0.0 109.144 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.504 ' SD ' ' CG ' ' A' ' 13' ' ' MET . 82.8 mtp -88.4 -33.69 17.82 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.241 -0.912 . . . . 0.0 109.565 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 11' ' ' LEU . . . 172.01 -168.98 42.12 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.631 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 0.8 OUTLIER -134.21 146.65 50.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.189 -1.183 . . . . 0.0 109.524 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.675 HG13 ' O ' ' A' ' 84' ' ' VAL . 14.2 p -81.23 114.38 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.212 -0.93 . . . . 0.0 109.368 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.598 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.9 OUTLIER -154.04 164.88 37.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.256 -0.902 . . . . 0.0 109.639 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 77.0 p -84.5 -30.63 25.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.167 -0.958 . . . . 0.0 109.267 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -130.96 -102.54 0.93 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.548 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -93.16 -129.15 5.08 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.548 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -29.5 150.47 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.675 -0.897 . . . . 0.0 110.315 -179.56 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.598 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 46.2 Cg_endo -67.66 143.03 60.52 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.753 2.302 . . . . 0.0 112.002 -179.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 6.2 m -74.07 147.56 85.96 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.325 -0.86 . . . . 0.0 109.293 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.506 ' CB ' ' HD3' ' A' ' 6' ' ' LYS . 49.2 Cg_endo -69.82 145.39 56.63 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.708 2.272 . . . . 0.0 111.7 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.529 ' CG1' ' HG2' ' A' ' 98' ' ' MET . 9.9 p -70.11 135.16 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.932 . . . . 0.0 109.231 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . 0.487 ' HE2' ' HD2' ' A' ' 96' ' ' ARG . 15.4 tttp -70.95 136.48 48.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.179 -0.95 . . . . 0.0 109.592 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -46.58 -52.05 14.34 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.221 -0.924 . . . . 0.0 109.355 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.487 ' HD2' ' HE2' ' A' ' 94' ' ' LYS . 72.0 mtt85 -60.84 -16.47 41.63 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.292 -0.88 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.489 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 6.7 mt-10 -88.59 -28.5 20.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.274 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.651 ' HE3' ' CD1' ' A' ' 7' ' ' TRP . 31.4 mtp -75.85 -28.69 58.3 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -0.874 . . . . 0.0 109.61 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.59 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.46 -53.37 1.3 Allowed Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.485 -0.76 . . . . 0.0 109.979 -179.609 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.59 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.7 Cg_endo -69.01 -34.96 15.85 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.538 2.158 . . . . 0.0 112.111 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.489 HD13 ' HA ' ' A' ' 101' ' ' ILE . 8.7 mm -78.57 -44.51 26.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.118 -0.989 . . . . 0.0 109.444 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.908 ' HA ' HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -62.19 -41.35 98.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.106 -0.996 . . . . 0.0 108.873 179.725 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.478 ' HD2' ' O ' ' A' ' 135' ' ' PRO . 36.3 mtt180 -61.03 -43.21 99.23 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -70.01 -35.76 74.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 109.134 179.667 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.451 ' HB3' ' CD1' ' A' ' 107' ' ' LEU . . . -88.13 20.96 2.94 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.21 179.681 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 46.92 28.4 3.88 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.908 HD12 ' HA ' ' A' ' 102' ' ' LEU . 35.9 mt -80.04 -22.84 41.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.196 -1.179 . . . . 0.0 109.146 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.345 -0.847 . . . . 0.0 109.314 179.959 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.525 ' CD2' ' O ' ' A' ' 123' ' ' PHE . 51.7 p90 . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.463 ' N ' ' OD2' ' A' ' 127' ' ' ASP . 27.5 mttp -141.81 164.48 30.07 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.247 -0.908 . . . . 0.0 109.558 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.55 HG23 ' O ' ' A' ' 144' ' ' LYS . 7.9 p -66.5 126.11 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.318 -0.864 . . . . 0.0 109.659 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 103.68 -33.32 6.67 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.751 ' HB2' HD12 ' A' ' 143' ' ' ILE . 73.2 m-20 -48.15 165.33 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.385 -1.068 . . . . 0.0 108.922 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.4 ttm -97.26 126.91 42.78 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.044 -1.035 . . . . 0.0 108.97 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.707 ' CG2' HD11 ' A' ' 143' ' ' ILE . 12.7 t -125.36 141.91 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.248 -0.908 . . . . 0.0 109.535 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.484 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 42.8 tttp -106.61 143.91 34.04 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.357 -0.839 . . . . 0.0 108.946 179.495 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 1.009 HD12 ' HB3' ' A' ' 139' ' ' PHE . 65.8 mt -84.76 155.31 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.129 -0.982 . . . . 0.0 108.817 179.636 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.437 HG12 ' HA ' ' A' ' 173' ' ' VAL . 27.2 pt -150.59 2.95 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.126 -0.984 . . . . 0.0 109.488 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 72.7 m -148.66 145.08 27.57 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.151 -0.968 . . . . 0.0 110.107 -179.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.15 -170.55 16.8 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.478 ' O ' ' HD2' ' A' ' 103' ' ' ARG . 48.2 Cg_endo -68.66 -19.8 41.31 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 123.275 2.65 . . . . 0.0 112.467 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.534 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 98.1 m-85 -112.96 13.22 19.48 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.05 -1.031 . . . . 0.0 109.487 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.727 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.6 tt0 -42.73 151.74 0.12 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 109.663 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.515 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 25.3 m-20 72.99 28.1 1.98 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.455 -0.778 . . . . 0.0 110.091 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 1.009 ' HB3' HD12 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -120.43 136.99 54.57 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.99 -1.069 . . . . 0.0 109.539 179.877 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.08 133.94 34.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.225 -0.922 . . . . 0.0 109.579 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.92 170.05 25.95 Favored Glycine 0 N--CA 1.492 2.374 0 C-N-CA 119.836 -1.173 . . . . 0.0 110.171 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.887 ' C ' HG23 ' A' ' 155' ' ' VAL . 47.9 t -115.76 136.03 53.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.387 -1.066 . . . . 0.0 109.439 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.815 HG23 HD23 ' A' ' 153' ' ' LEU . 87.7 mt -65.12 115.22 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.89 . . . . 0.0 109.386 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.55 ' O ' HG23 ' A' ' 125' ' ' VAL . 36.6 tttp -100.26 -36.38 9.3 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.062 -1.024 . . . . 0.0 109.377 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.441 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 67.2 mm-40 -149.57 144.26 26.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.967 . . . . 0.0 109.351 -179.9 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 1.084 HG23 ' HG ' ' A' ' 153' ' ' LEU . 2.4 mt -123.04 125.85 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.183 -0.948 . . . . 0.0 109.406 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -108.18 101.46 41.9 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.236 -0.915 . . . . 0.0 109.63 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.552 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.7 171.4 16.49 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.72 2.28 . . . . 0.0 111.781 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.552 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 10.8 tt0 80.55 -20.97 0.35 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.3 -0.875 . . . . 0.0 109.791 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.452 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 93.1 mtt-85 -126.59 -12.99 6.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.916 . . . . 0.0 109.437 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.452 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 29.9 mt-30 69.83 48.6 0.56 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.204 -0.935 . . . . 0.0 109.61 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -120.06 143.62 48.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.138 -0.976 . . . . 0.0 109.08 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 1.084 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -136.99 112.38 9.24 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.15 -0.969 . . . . 0.0 110.12 -179.599 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.429 ' HD2' ' HB2' ' A' ' 145' ' ' GLU . 30.8 mttm -79.85 130.94 35.72 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.06 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.887 HG23 ' C ' ' A' ' 142' ' ' VAL . 7.3 p -133.39 127.48 53.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.121 -0.987 . . . . 0.0 109.752 -179.469 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.56 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 50.2 m-20 -73.18 135.4 44.61 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.362 -0.836 . . . . 0.0 109.709 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.553 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 53.9 t -116.8 149.96 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.466 -0.772 . . . . 0.0 109.195 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 57.2 m -96.34 103.01 14.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.107 -0.996 . . . . 0.0 109.711 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.509 HG22 ' CD2' ' A' ' 160' ' ' PHE . 20.5 mt -129.98 140.77 48.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.285 -0.884 . . . . 0.0 109.311 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.509 ' CD2' HG22 ' A' ' 159' ' ' ILE . 52.8 m-85 60.3 40.4 17.76 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.186 -0.946 . . . . 0.0 108.97 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.64 16.31 15.88 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 46.1 mtp180 -128.43 156.13 43.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.111 -1.229 . . . . 0.0 109.57 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -100.24 133.75 44.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.289 -0.882 . . . . 0.0 109.443 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.7 m -141.33 127.77 11.41 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.342 -0.849 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.56 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.9 Cg_endo -70.35 133.68 25.03 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.658 2.238 . . . . 0.0 111.44 179.697 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.635 HG12 ' O ' ' A' ' 155' ' ' VAL . 2.8 p -122.67 141.87 41.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.204 -0.935 . . . . 0.0 109.675 -179.837 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.588 ' O ' HG23 ' A' ' 167' ' ' VAL . 18.0 m -93.17 120.11 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.458 -0.776 . . . . 0.0 109.458 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.867 HD11 HG12 ' A' ' 155' ' ' VAL . 0.0 OUTLIER -142.3 167.81 21.22 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.33 -0.857 . . . . 0.0 110.487 -179.471 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.482 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 98.0 m-70 -81.6 142.0 33.19 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.622 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.425 HG13 ' N ' ' A' ' 171' ' ' SER . 10.8 p -55.92 -35.98 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.177 -0.952 . . . . 0.0 109.025 179.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.425 ' N ' HG13 ' A' ' 170' ' ' VAL . 74.6 p -75.71 -6.61 51.39 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.403 -0.811 . . . . 0.0 109.626 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.482 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 41.8 mt-10 -90.99 -0.68 57.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.135 -0.978 . . . . 0.0 109.572 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . 0.484 ' HB ' ' O ' ' A' ' 130' ' ' LYS . 2.8 m -147.13 177.74 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.176 -0.953 . . . . 0.0 109.452 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.63 ' O ' HG13 ' A' ' 129' ' ' VAL . 83.5 tt0 -136.55 163.75 29.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.149 -0.969 . . . . 0.0 109.263 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.538 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.3 mmtt . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.47 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 47.0 mttt . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.561 ' HB2' ' CZ ' ' A' ' 8' ' ' TYR . 26.5 mmtp -128.6 175.47 8.54 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.354 -0.841 . . . . 0.0 109.613 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.932 ' O ' HG23 ' A' ' 93' ' ' VAL . 47.2 m95 -111.65 124.26 51.94 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.39 -0.819 . . . . 0.0 108.968 179.657 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.561 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 59.3 m-85 -117.94 168.65 10.31 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.141 -0.975 . . . . 0.0 109.478 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.537 HG12 ' CE1' ' A' ' 61' ' ' PHE . 33.9 mt -107.5 114.63 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.208 -0.932 . . . . 0.0 109.367 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.604 HG12 ' HB ' ' A' ' 60' ' ' VAL . 8.5 p -92.65 141.17 15.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.234 -0.916 . . . . 0.0 109.222 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.674 HD11 ' CE1' ' A' ' 59' ' ' TYR . 3.7 mm? -89.62 143.28 26.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.408 -0.807 . . . . 0.0 109.739 -179.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.731 HG21 ' OE1' ' A' ' 17' ' ' GLU . 9.0 t -152.99 -166.03 2.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.325 -0.859 . . . . 0.0 109.408 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.441 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 46.2 mtt -108.14 130.83 55.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.532 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.0 t -54.26 128.27 30.54 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.196 -0.94 . . . . 0.0 109.391 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.55 -20.31 44.8 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 -179.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.441 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 79.4 m-85 -104.47 5.94 34.48 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.38 -1.071 . . . . 0.0 109.557 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.731 ' OE1' HG21 ' A' ' 12' ' ' THR . 41.1 mm-40 -53.36 -62.32 1.73 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.62 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 17' ' ' GLU . 60.7 mt-10 -42.68 -35.64 1.18 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -0.889 . . . . 0.0 109.583 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.528 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 27.3 mttt -74.18 -44.61 52.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.472 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.688 HG21 ' OG1' ' A' ' 12' ' ' THR . 70.6 t -58.44 -53.11 51.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.48 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.417 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.5 tttm -58.4 -47.07 85.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.348 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -63.13 -41.17 99.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.329 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.54 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 87.7 m-20 -59.29 -42.78 92.09 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.904 . . . . 0.0 109.503 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.911 HG21 HD11 ' A' ' 40' ' ' ILE . 69.7 mt -61.5 -46.46 96.53 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.229 -0.919 . . . . 0.0 109.715 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -54.83 -46.22 74.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.145 -0.972 . . . . 0.0 109.56 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -75.78 -35.57 60.07 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.132 -0.98 . . . . 0.0 109.459 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.604 ' O ' HG23 ' A' ' 31' ' ' THR . 7.8 ttpt -56.14 -34.26 65.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.253 -0.905 . . . . 0.0 109.314 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.793 HG13 ' O ' ' A' ' 33' ' ' ILE . 44.2 t -85.52 -25.15 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -0.873 . . . . 0.0 109.377 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -69.77 -54.17 14.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.186 -0.946 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.22 -24.76 67.79 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.197 -0.94 . . . . 0.0 109.526 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.604 HG23 ' O ' ' A' ' 27' ' ' LYS . 40.2 p -94.96 -21.75 18.41 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.165 -0.959 . . . . 0.0 109.531 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 63.68 22.01 65.66 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.014 HG21 HD12 ' A' ' 36' ' ' LEU . 42.7 mm -95.07 91.79 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.271 -1.134 . . . . 0.0 109.465 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.9 mtpt -98.81 10.03 42.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.27 -0.894 . . . . 0.0 109.52 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -108.24 5.44 25.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.19 -0.944 . . . . 0.0 109.492 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.014 HD12 HG21 ' A' ' 33' ' ' ILE . 88.3 mt -117.78 -30.94 5.29 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.276 -0.89 . . . . 0.0 109.39 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.499 ' HA ' ' HG2' ' A' ' 64' ' ' MET . 73.0 t -114.68 129.35 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.309 -0.869 . . . . 0.0 109.305 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.73 -129.89 6.84 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 23.4 mtt-85 -90.44 147.89 23.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.274 -1.133 . . . . 0.0 109.777 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 1.061 HG23 HG22 ' A' ' 62' ' ' VAL . 59.9 mt -113.32 136.61 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.337 -0.852 . . . . 0.0 109.383 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.575 ' CG1' ' HB2' ' A' ' 61' ' ' PHE . 9.3 p -130.4 158.29 42.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.199 -0.938 . . . . 0.0 109.54 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.773 HG22 HG23 ' A' ' 44' ' ' ILE . 3.3 mt -131.78 129.05 21.86 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.559 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.533 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 46.1 Cg_endo -67.2 -4.73 12.19 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.788 2.325 . . . . 0.0 111.587 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.773 HG23 HG22 ' A' ' 42' ' ' ILE . 12.7 pt . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.299 -0.876 . . . . 0.0 109.451 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.703 ' HA ' HG22 ' A' ' 44' ' ' ILE . 47.6 mttt . . . . . 0 N--CA 1.491 1.604 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.533 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 6.7 mp -61.55 -26.8 68.18 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.097 -1.002 . . . . 0.0 109.527 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.616 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 97.2 m-85 -145.83 103.8 4.2 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.893 . . . . 0.0 109.31 179.778 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 43.5 Cg_endo -67.17 137.75 44.96 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.666 2.244 . . . . 0.0 111.865 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.91 -9.28 6.68 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.674 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.2 m-85 -103.49 132.65 49.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.795 -1.415 . . . . 0.0 109.82 -179.511 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.604 ' HB ' HG12 ' A' ' 10' ' ' VAL . 4.9 t -135.58 148.65 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.354 -0.841 . . . . 0.0 108.923 179.41 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.575 ' HB2' ' CG1' ' A' ' 41' ' ' VAL . 63.3 m-85 -107.87 121.65 45.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.073 -1.017 . . . . 0.0 109.764 -179.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 1.061 HG22 HG23 ' A' ' 40' ' ' ILE . 57.6 t -129.06 141.14 47.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.357 -0.839 . . . . 0.0 109.699 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.618 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 52.4 tt0 -97.03 124.73 41.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.339 -0.851 . . . . 0.0 108.862 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.512 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 37.3 mtm -158.4 -179.82 8.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.147 -0.971 . . . . 0.0 109.777 -179.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.851 HD11 ' CD2' ' A' ' 36' ' ' LEU . 8.5 pt -102.64 129.0 54.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.2 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.501 ' O ' ' HG3' ' A' ' 66' ' ' MET . 5.2 ptp -85.58 96.2 9.57 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.129 -0.982 . . . . 0.0 109.668 -179.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.598 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 23.0 t-20 -140.04 170.48 15.78 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -52.81 -47.58 67.53 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.038 -1.039 . . . . 0.0 109.987 -179.507 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.458 ' O ' ' C ' ' A' ' 70' ' ' ALA . 64.6 mm-40 -64.87 -64.34 0.89 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.095 -1.003 . . . . 0.0 110.132 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.854 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -39.77 -38.8 0.69 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.263 -0.898 . . . . 0.0 109.926 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.598 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 15.4 m-85 -61.11 -62.16 2.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.226 -0.921 . . . . 0.0 109.362 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -45.76 -34.9 3.93 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.503 -0.748 . . . . 0.0 110.412 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -81.39 -43.85 18.39 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.888 -1.133 . . . . 0.0 110.136 -179.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.995 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 45.4 t -64.43 -58.67 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.25 -0.906 . . . . 0.0 109.643 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -35.05 19.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.366 -0.834 . . . . 0.0 110.034 -179.589 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 53.6 p -78.16 4.89 11.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.083 -1.01 . . . . 0.0 110.37 -179.279 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.611 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 41.1 t -64.32 133.62 95.71 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 120.872 -1.143 . . . . 0.0 109.286 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.569 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 46.1 Cg_endo -68.27 134.83 32.43 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.702 2.268 . . . . 0.0 112.02 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.569 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 60.2 m-85 77.61 -1.54 2.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.525 -0.734 . . . . 0.0 109.855 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.611 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.4 t -88.6 127.32 41.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.173 -0.955 . . . . 0.0 109.147 179.609 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 82.5 mmm -90.77 -17.97 25.74 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.21 -0.931 . . . . 0.0 109.645 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.592 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 151.71 -155.61 26.23 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.995 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 3.6 m-85 -140.04 152.67 46.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -1.16 . . . . 0.0 109.5 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.571 HG22 HD21 ' A' ' 11' ' ' LEU . 4.6 t -77.27 119.58 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.291 -0.881 . . . . 0.0 109.275 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.556 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.9 p -156.49 162.17 39.98 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.227 -0.92 . . . . 0.0 109.596 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.78 -34.8 14.45 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.887 . . . . 0.0 109.393 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -122.09 -86.33 0.83 Allowed Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -107.04 -130.37 6.43 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.545 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.1 OUTLIER -33.82 156.4 0.04 OUTLIER Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.43 -1.041 . . . . 0.0 110.056 -179.693 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.556 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.9 Cg_endo -69.71 157.74 59.44 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 122.492 2.128 . . . . 0.0 112.109 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . 0.402 ' H ' HG22 ' A' ' 91' ' ' VAL . 10.9 m -90.15 153.64 46.83 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.351 -0.843 . . . . 0.0 109.452 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.453 ' HB3' ' HB3' ' A' ' 6' ' ' LYS . 49.1 Cg_endo -69.81 145.48 56.99 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.658 2.239 . . . . 0.0 111.812 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.932 HG23 ' O ' ' A' ' 7' ' ' TRP . 7.6 t -84.22 129.69 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.235 -0.915 . . . . 0.0 109.194 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . 0.414 ' O ' ' C ' ' A' ' 95' ' ' ASP . 23.6 tttt -70.56 132.77 46.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.191 -0.943 . . . . 0.0 109.578 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 94' ' ' LYS . 80.5 m-20 -44.48 -39.86 5.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.205 -0.934 . . . . 0.0 109.356 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.5 ' CZ ' ' HB3' ' A' ' 96' ' ' ARG . 13.4 mtp-105 -53.79 -35.51 61.44 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.272 -0.893 . . . . 0.0 109.374 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.446 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 65.2 mt-10 -84.73 -27.48 26.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.269 -0.894 . . . . 0.0 109.372 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.628 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 94.4 mtp -84.98 -12.31 53.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.295 -0.878 . . . . 0.0 109.505 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.667 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -51.18 -48.42 85.46 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.171 -0.956 . . . . 0.0 109.853 179.864 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.667 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.5 Cg_endo -70.82 -27.6 21.22 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.485 2.123 . . . . 0.0 111.861 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.439 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 35.8 mm -81.52 -44.4 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 109.565 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.601 HD12 ' O ' ' A' ' 98' ' ' MET . 0.7 OUTLIER -66.46 -38.76 88.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.232 -0.917 . . . . 0.0 109.256 -179.926 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.524 ' CZ ' ' NH1' ' A' ' 99' ' ' ARG . 67.7 mtt180 -65.47 -50.16 66.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.429 -0.794 . . . . 0.0 109.322 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -72.64 -36.24 67.96 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.273 -0.892 . . . . 0.0 109.364 179.762 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.535 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -73.44 -0.99 16.52 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.371 -0.831 . . . . 0.0 109.687 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.03 11.6 81.44 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.452 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 61.3 mt -85.51 -24.11 27.45 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.128 -1.219 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . 0.46 ' HB2' ' HB2' ' A' ' 102' ' ' LEU . 73.5 tt0 . . . . . 0 N--CA 1.49 1.553 0 O-C-N 121.283 -0.886 . . . . 0.0 109.591 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 3.6 p90 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 22.4 mttt -149.02 157.29 43.3 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.221 -0.925 . . . . 0.0 109.52 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.613 HG13 ' O ' ' A' ' 144' ' ' LYS . 44.7 t -60.33 140.04 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 87.85 -34.12 3.81 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.768 ' HB3' HD12 ' A' ' 143' ' ' ILE . 43.0 t0 -48.51 157.68 0.34 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.431 -1.041 . . . . 0.0 109.465 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.8 ttm -96.07 127.5 42.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.244 -0.91 . . . . 0.0 108.861 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 1.021 HG13 ' O ' ' A' ' 174' ' ' GLU . 51.3 t -126.44 142.08 44.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.256 -0.903 . . . . 0.0 109.42 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 5.8 ttpp -101.95 142.85 32.6 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.376 -0.828 . . . . 0.0 109.065 179.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.86 HD12 ' HB3' ' A' ' 139' ' ' PHE . 70.8 mt -82.9 151.35 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.042 -1.036 . . . . 0.0 108.761 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.669 HD13 ' CD ' ' A' ' 174' ' ' GLU . 33.2 pt -148.99 2.95 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.95 -1.093 . . . . 0.0 109.503 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.559 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 68.8 m -146.35 141.76 27.57 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.11 -0.994 . . . . 0.0 109.712 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.423 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 107.04 -170.85 16.16 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.581 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.52 -18.91 43.23 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 123.213 2.609 . . . . 0.0 112.797 -179.445 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.529 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.9 m-85 -108.94 19.11 19.97 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.964 -1.085 . . . . 0.0 109.487 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.559 ' HA ' HG22 ' A' ' 131' ' ' ILE . 43.8 mt-10 -41.31 141.85 0.64 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 110.22 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 138' ' ' ASP . 0.5 OUTLIER 76.03 24.39 1.19 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.299 -0.875 . . . . 0.0 110.757 179.002 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.86 ' HB3' HD12 ' A' ' 131' ' ' ILE . 0.5 OUTLIER -111.73 129.32 56.15 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.828 -1.17 . . . . 0.0 109.729 179.912 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.401 ' N ' ' HD1' ' A' ' 139' ' ' PHE . . . -76.46 134.8 39.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.905 . . . . 0.0 109.392 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.79 166.62 26.94 Favored Glycine 0 N--CA 1.489 2.221 0 C-N-CA 119.718 -1.23 . . . . 0.0 110.164 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.814 ' C ' HG23 ' A' ' 155' ' ' VAL . 47.0 t -116.16 137.34 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.591 -0.946 . . . . 0.0 109.256 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.768 HD12 ' HB3' ' A' ' 127' ' ' ASP . 88.6 mt -70.39 120.49 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.305 -0.872 . . . . 0.0 109.268 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.613 ' O ' HG13 ' A' ' 125' ' ' VAL . 75.0 tttt -103.65 -33.07 9.1 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.964 -1.085 . . . . 0.0 109.711 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.519 ' HG2' ' O ' ' A' ' 144' ' ' LYS . 15.5 mt-10 -150.5 145.66 26.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.058 -1.027 . . . . 0.0 109.845 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 1.032 HG23 HD11 ' A' ' 153' ' ' LEU . 0.9 OUTLIER -115.44 117.91 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.218 -0.926 . . . . 0.0 108.973 179.542 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -106.64 98.13 19.46 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.156 -0.965 . . . . 0.0 109.785 -179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.55 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.5 Cg_endo -72.33 173.65 12.76 Favored 'Trans proline' 0 C--O 1.216 -0.588 0 C-N-CA 122.675 2.25 . . . . 0.0 111.734 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.55 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 4.5 mt-10 78.98 -22.06 0.3 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.26 -0.9 . . . . 0.0 109.876 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.441 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 40.8 mtm180 -126.33 -16.78 5.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.039 -1.038 . . . . 0.0 109.3 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.441 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 6.0 mt-30 71.04 47.54 0.41 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.3 -0.875 . . . . 0.0 109.511 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.704 ' OE2' HG13 ' A' ' 167' ' ' VAL . 64.9 tt0 -116.44 139.83 50.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.124 -0.985 . . . . 0.0 108.885 179.651 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 1.032 HD11 HG23 ' A' ' 146' ' ' ILE . 2.7 mm? -124.88 111.79 15.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.153 -0.967 . . . . 0.0 110.108 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.441 ' HD3' ' HB2' ' A' ' 145' ' ' GLU . 17.2 mtpp -78.02 122.68 25.88 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.814 HG23 ' C ' ' A' ' 142' ' ' VAL . 10.4 p -126.92 149.27 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.039 -1.038 . . . . 0.0 109.904 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 1.9 t-20 -97.99 110.54 23.09 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.439 -0.788 . . . . 0.0 109.488 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.577 HG13 ' CD1' ' A' ' 139' ' ' PHE . 87.1 t -96.38 144.64 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.2 -0.938 . . . . 0.0 109.268 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 96.1 m -102.92 111.93 24.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -0.965 . . . . 0.0 109.995 -179.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.616 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 2.9 mt -133.22 143.24 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.276 -0.89 . . . . 0.0 109.036 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.431 ' O ' ' HG3' ' A' ' 162' ' ' ARG . 11.9 m-85 62.18 43.37 8.65 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.152 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 54.35 16.15 6.45 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 179.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 15.8 mtt-85 -126.59 160.05 31.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.036 -1.273 . . . . 0.0 109.54 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -100.93 127.88 47.22 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.25 -0.907 . . . . 0.0 109.687 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 43.3 m -136.91 121.22 12.39 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 0.0 109.606 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.538 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -70.34 136.57 31.75 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.755 2.304 . . . . 0.0 111.541 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.982 HG13 HD11 ' A' ' 168' ' ' LEU . 3.6 p -125.74 144.24 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.035 -1.041 . . . . 0.0 110.165 -179.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.704 HG13 ' OE2' ' A' ' 152' ' ' GLU . 51.1 t -95.51 120.15 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.554 -0.716 . . . . 0.0 109.465 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.982 HD11 HG13 ' A' ' 166' ' ' VAL . 0.1 OUTLIER -141.01 168.38 19.93 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.204 -0.935 . . . . 0.0 110.518 -179.44 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.442 ' CD2' ' OE1' ' A' ' 172' ' ' GLU . 90.7 m-70 -79.45 144.59 33.9 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.829 ' HB ' HD23 ' A' ' 153' ' ' LEU . 9.6 p -58.68 -35.49 55.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.121 -0.987 . . . . 0.0 108.822 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.411 ' N ' HG13 ' A' ' 170' ' ' VAL . 53.0 p -75.69 -6.67 51.64 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.43 -0.794 . . . . 0.0 109.115 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.559 ' CG ' ' HB2' ' A' ' 133' ' ' SER . 1.2 mt-10 -88.65 2.85 52.48 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.289 -0.882 . . . . 0.0 109.44 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . 0.453 ' CG2' HG11 ' A' ' 129' ' ' VAL . 2.9 m -152.03 176.54 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.218 -0.926 . . . . 0.0 109.293 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 1.021 ' O ' HG13 ' A' ' 129' ' ' VAL . 5.5 mt-10 -141.54 172.73 12.28 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.141 -0.974 . . . . 0.0 109.01 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.498 ' CE ' ' OD2' ' A' ' 127' ' ' ASP . 24.4 tttt . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.091 -1.006 . . . . 0.0 109.37 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.627 ' HG2' HG22 ' A' ' 65' ' ' ILE . 33.0 mttt . . . . . 0 N--CA 1.489 1.477 0 CA-C-O 121.261 0.553 . . . . 0.0 109.546 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.585 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 15.7 mtpp -126.41 175.82 7.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.361 -0.837 . . . . 0.0 109.52 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.792 ' CZ3' HG23 ' A' ' 41' ' ' VAL . 46.6 m95 -110.47 126.72 54.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.278 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -115.53 164.46 14.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.918 . . . . 0.0 109.472 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.542 HG12 ' CE1' ' A' ' 61' ' ' PHE . 62.0 mt -106.03 115.29 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.16 -0.962 . . . . 0.0 109.021 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.493 HG13 ' CE1' ' A' ' 83' ' ' PHE . 92.2 t -92.09 138.25 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.237 -0.914 . . . . 0.0 109.626 -179.719 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.518 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.0 mm? -92.78 146.5 23.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.321 -0.862 . . . . 0.0 109.209 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.574 ' OG1' HG21 ' A' ' 20' ' ' VAL . 12.6 t -157.22 -177.97 7.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.187 -0.945 . . . . 0.0 109.376 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.515 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 49.0 mtm -96.72 130.39 43.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.182 -0.949 . . . . 0.0 109.504 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.5 p -50.87 129.37 23.17 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.912 . . . . 0.0 109.544 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.84 -20.27 36.67 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.515 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 80.3 m-85 -108.83 -5.2 16.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.214 -1.168 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.733 ' OE1' HD11 ' A' ' 44' ' ' ILE . 88.9 mt-10 -46.72 -52.48 13.82 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.253 -0.904 . . . . 0.0 109.554 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.8 mt-10 -55.11 -36.19 65.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.221 -0.925 . . . . 0.0 109.465 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 60.7 mttp -74.55 -31.37 62.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.256 -0.903 . . . . 0.0 109.291 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.574 HG21 ' OG1' ' A' ' 12' ' ' THR . 51.6 t -67.64 -48.78 75.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.34 -0.85 . . . . 0.0 109.353 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.582 ' HB2' HD11 ' A' ' 42' ' ' ILE . 29.9 tttm -59.05 -44.48 91.82 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.273 -0.892 . . . . 0.0 109.302 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -65.13 -45.08 86.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.906 . . . . 0.0 109.275 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.954 ' OD1' HG22 ' A' ' 77' ' ' VAL . 1.1 t-20 -51.78 -38.82 57.11 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -0.866 . . . . 0.0 109.402 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.586 HG21 HD11 ' A' ' 40' ' ' ILE . 65.9 mt -68.89 -44.29 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.764 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 41.9 tp10 -55.18 -49.13 72.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.047 -1.033 . . . . 0.0 109.858 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 23.6 mttm -75.22 -34.42 61.47 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.105 -0.997 . . . . 0.0 109.456 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.926 ' CD ' HG23 ' A' ' 77' ' ' VAL . 33.1 tttm -55.62 -36.2 66.72 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.325 -0.86 . . . . 0.0 109.205 179.774 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.739 HG13 ' O ' ' A' ' 33' ' ' ILE . 84.0 t -83.07 -24.0 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.294 -0.879 . . . . 0.0 109.601 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 -69.9 -55.12 10.53 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.279 -0.888 . . . . 0.0 109.485 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.74 -38.92 50.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.291 -0.881 . . . . 0.0 109.412 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.403 ' CB ' HG13 ' A' ' 33' ' ' ILE . 82.6 p -98.54 0.1 44.34 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.271 -0.893 . . . . 0.0 109.513 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 46.82 34.42 7.13 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.069 HG21 HD12 ' A' ' 36' ' ' LEU . 37.4 mt -92.6 75.34 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.331 -1.099 . . . . 0.0 109.498 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -90.19 24.92 2.34 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.211 -0.931 . . . . 0.0 109.049 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -117.25 -24.29 7.52 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.346 -0.846 . . . . 0.0 109.456 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.091 HD23 HD11 ' A' ' 65' ' ' ILE . 22.9 mt -92.11 -29.29 16.6 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.282 -0.886 . . . . 0.0 109.419 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.433 ' HA ' ' HG2' ' A' ' 64' ' ' MET . 38.9 t -110.43 129.35 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.368 -0.833 . . . . 0.0 109.04 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.51 -124.37 5.42 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 77.5 mtt180 -92.23 146.85 23.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.273 -1.133 . . . . 0.0 109.859 -179.431 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.901 HG12 HG23 ' A' ' 62' ' ' VAL . 55.7 mt -113.64 135.27 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.397 -0.815 . . . . 0.0 109.15 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.884 HG21 HD11 ' A' ' 107' ' ' LEU . 17.3 t -128.76 159.31 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.116 -0.99 . . . . 0.0 109.643 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.582 HD11 ' HB2' ' A' ' 21' ' ' LYS . 12.3 mt -144.36 128.67 9.13 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.471 -0.768 . . . . 0.0 109.359 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.544 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 44.0 Cg_endo -66.32 -6.19 14.34 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.713 2.275 . . . . 0.0 111.43 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.733 HD11 ' OE1' ' A' ' 17' ' ' GLU . 14.5 mt . . . . . 0 N--CA 1.489 1.477 0 O-C-N 121.406 -0.808 . . . . 0.0 109.397 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.58 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 69.2 mttt . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.548 ' HB3' ' CE2' ' A' ' 56' ' ' PHE . 6.7 mp -52.7 -47.3 67.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.379 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.632 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 3.2 m-85 -139.23 113.0 8.08 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.14 -0.975 . . . . 0.0 109.374 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -65.67 146.26 83.66 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.546 2.164 . . . . 0.0 111.471 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.04 -13.56 3.26 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.533 ' HB2' ' HB2' ' A' ' 56' ' ' PHE . 1.9 m-85 -93.69 129.28 40.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.883 -1.363 . . . . 0.0 110.044 -179.422 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.502 HG13 HG12 ' A' ' 42' ' ' ILE . 41.9 t -134.69 142.82 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.202 179.703 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.688 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 76.7 m-85 -108.05 124.97 51.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.127 -0.983 . . . . 0.0 109.826 -179.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.901 HG23 HG12 ' A' ' 40' ' ' ILE . 3.6 p -130.33 142.2 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.345 -0.847 . . . . 0.0 109.868 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.613 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 37.7 tt0 -103.4 124.62 49.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.215 -0.928 . . . . 0.0 108.844 179.434 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.505 ' HE1' HG21 ' A' ' 74' ' ' VAL . 41.8 mtm -153.47 169.09 24.03 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.92 -1.113 . . . . 0.0 110.648 -179.259 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 1.091 HD11 HD23 ' A' ' 36' ' ' LEU . 5.4 pt -94.49 130.07 43.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.47 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 36.8 ttm -77.15 144.54 38.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.318 -0.864 . . . . 0.0 109.973 -178.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.47 ' HB2' ' O ' ' A' ' 66' ' ' MET . 35.3 t30 176.81 171.6 0.47 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.677 -0.639 . . . . 0.0 109.289 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -69.27 -42.53 75.41 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.228 -0.92 . . . . 0.0 109.402 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -75.85 -29.17 58.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.309 -0.869 . . . . 0.0 109.71 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.733 ' HB2' HD22 ' A' ' 36' ' ' LEU . . . -75.27 -47.54 27.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.121 -0.987 . . . . 0.0 109.418 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 56.3 t80 -59.97 -46.49 89.26 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.291 -0.88 . . . . 0.0 109.504 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.451 ' O ' ' HB3' ' A' ' 76' ' ' SER . 23.4 m120 -68.18 -26.22 65.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.327 -0.858 . . . . 0.0 109.962 -179.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.476 ' CE1' ' NZ ' ' A' ' 27' ' ' LYS . 22.6 t80 -83.42 -42.76 16.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.03 -1.044 . . . . 0.0 109.915 -179.675 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.76 HG22 ' CZ ' ' A' ' 83' ' ' PHE . 7.4 p -67.89 -55.71 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.405 -0.81 . . . . 0.0 109.605 -179.503 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.674 ' N ' HG13 ' A' ' 74' ' ' VAL . 0.2 OUTLIER -57.99 -10.72 1.95 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.145 -0.972 . . . . 0.0 109.747 -179.934 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.451 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 25.6 p -93.24 4.89 53.23 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.073 -1.017 . . . . 0.0 109.98 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.954 HG22 ' OD1' ' A' ' 23' ' ' ASN . 0.4 OUTLIER -73.81 126.8 89.25 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.085 -1.009 . . . . 0.0 109.327 -179.978 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.629 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 42.7 Cg_endo -65.1 142.86 76.09 Favored 'Trans proline' 0 C--O 1.213 -0.752 0 C-N-CA 122.65 2.234 . . . . 0.0 111.898 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.629 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 17.9 m-85 89.37 -12.79 0.37 Allowed 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.63 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 1.7 t -89.51 130.12 39.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.077 -1.014 . . . . 0.0 109.361 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 90.9 mmm -84.38 -27.33 27.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.32 -0.862 . . . . 0.0 109.311 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 161.35 -160.58 32.31 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.76 ' CZ ' HG22 ' A' ' 74' ' ' VAL . 14.9 m-85 -136.23 140.24 43.35 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.272 -1.134 . . . . 0.0 109.341 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.536 HG13 ' O ' ' A' ' 84' ' ' VAL . 7.7 p -66.35 125.09 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.122 -0.986 . . . . 0.0 109.405 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.547 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.6 p -163.72 159.08 21.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.211 -0.931 . . . . 0.0 109.573 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -86.23 -33.85 20.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.272 -0.893 . . . . 0.0 109.314 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.23 -87.59 0.71 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.547 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -108.85 -125.86 5.24 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.547 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.1 OUTLIER -31.17 147.27 0.05 OUTLIER Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 121.614 -0.933 . . . . 0.0 110.015 -179.819 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.547 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.3 Cg_endo -69.2 154.29 70.19 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.8 2.334 . . . . 0.0 112.081 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . 0.905 HG12 ' HD2' ' A' ' 92' ' ' PRO . 0.2 OUTLIER -86.97 147.7 43.6 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.308 -0.87 . . . . 0.0 109.25 179.849 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.905 ' HD2' HG12 ' A' ' 91' ' ' VAL . 48.7 Cg_endo -69.24 150.6 71.58 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.626 2.217 . . . . 0.0 111.82 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 7' ' ' TRP . 5.3 t -83.57 135.66 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.911 . . . . 0.0 109.621 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -72.86 136.05 45.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.346 -0.846 . . . . 0.0 109.393 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -47.94 -36.91 13.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.21 -0.931 . . . . 0.0 109.578 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 73.4 mtt85 -56.59 -37.14 70.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.571 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.7 mt-10 -83.36 -24.24 32.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.25 -0.906 . . . . 0.0 109.608 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.49 ' O ' ' C ' ' A' ' 99' ' ' ARG . 56.5 mtp -84.39 -29.6 26.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.142 -0.974 . . . . 0.0 109.495 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.597 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 31.6 ttt85 -37.01 -53.81 1.9 Allowed Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.344 -0.848 . . . . 0.0 109.931 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.597 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -68.82 -27.8 30.82 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.497 2.132 . . . . 0.0 111.777 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.509 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 19.5 mm -80.66 -41.7 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.24 -0.912 . . . . 0.0 109.248 179.71 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.59 ' CD1' ' N ' ' A' ' 102' ' ' LEU . 3.7 mp -68.52 -40.71 80.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.304 -0.872 . . . . 0.0 109.193 179.775 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.576 ' NE ' ' HA ' ' A' ' 135' ' ' PRO . 34.0 ttt180 -64.25 -50.34 68.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.347 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.86 -36.88 70.25 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.35 -0.844 . . . . 0.0 109.272 179.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.509 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -72.21 0.6 9.39 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.854 -179.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 77.26 8.32 86.98 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.884 HD11 HG21 ' A' ' 41' ' ' VAL . 19.2 mt -79.88 -22.53 42.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.134 -1.215 . . . . 0.0 109.511 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . 0.485 ' HB2' ' HA ' ' A' ' 103' ' ' ARG . 10.3 mt-10 . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.228 -0.92 . . . . 0.0 109.459 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 22.8 m-30 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 50.9 mttt -130.89 153.83 48.72 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.155 -0.966 . . . . 0.0 109.863 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.512 HG23 ' O ' ' A' ' 144' ' ' LYS . 7.1 p -61.51 144.43 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.359 -0.838 . . . . 0.0 109.501 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.32 -33.38 3.19 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.587 ' HB3' HD12 ' A' ' 143' ' ' ILE . 34.3 t0 -50.16 161.27 0.29 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.368 -1.078 . . . . 0.0 109.397 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . 0.42 ' HA ' ' HA ' ' A' ' 142' ' ' VAL . 4.6 ttm -95.76 126.88 41.33 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.28 -0.887 . . . . 0.0 108.669 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.761 HG11 HG11 ' A' ' 155' ' ' VAL . 6.7 p -125.64 141.58 45.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.193 -0.942 . . . . 0.0 109.388 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.524 ' N ' ' O ' ' A' ' 174' ' ' GLU . 24.1 tttt -104.41 142.78 33.98 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 108.988 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.952 HD12 ' HB3' ' A' ' 139' ' ' PHE . 81.5 mt -82.3 153.62 4.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.448 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.848 HD13 ' CD ' ' A' ' 174' ' ' GLU . 17.9 pt -149.08 1.25 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.967 -1.083 . . . . 0.0 109.499 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.517 ' HB3' ' CB ' ' A' ' 172' ' ' GLU . 31.2 t -145.85 143.23 29.49 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.124 -0.985 . . . . 0.0 110.039 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.03 -168.91 15.3 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.318 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.58 ' HG2' ' CD2' ' A' ' 136' ' ' PHE . 47.5 Cg_endo -68.63 -18.15 42.77 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 123.365 2.71 . . . . 0.0 112.563 -179.565 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.58 ' CD2' ' HG2' ' A' ' 135' ' ' PRO . 73.1 m-85 -111.84 13.92 20.98 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.878 -1.139 . . . . 0.0 109.636 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.519 ' HG2' ' OD2' ' A' ' 138' ' ' ASP . 1.2 tt0 -41.56 148.09 0.16 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.277 -0.889 . . . . 0.0 109.55 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.519 ' OD2' ' HG2' ' A' ' 137' ' ' GLU . 17.0 m-20 72.54 28.14 2.26 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -0.85 . . . . 0.0 110.268 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.952 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.1 t80 -117.74 131.51 56.59 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.029 -1.044 . . . . 0.0 109.414 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -82.24 134.15 35.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.123 -0.986 . . . . 0.0 109.6 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.513 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.9 172.93 25.59 Favored Glycine 0 N--CA 1.49 2.269 0 C-N-CA 119.78 -1.2 . . . . 0.0 110.305 -179.567 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 128' ' ' MET . 23.2 t -117.56 136.24 55.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.469 -1.018 . . . . 0.0 109.363 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.587 HD12 ' HB3' ' A' ' 127' ' ' ASP . 67.3 mt -66.33 115.25 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.299 -0.876 . . . . 0.0 109.184 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.512 ' O ' HG23 ' A' ' 125' ' ' VAL . 2.4 tttt -100.02 -35.53 9.67 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.04 -1.037 . . . . 0.0 109.615 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -152.8 147.66 26.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.142 -0.974 . . . . 0.0 109.622 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.816 HG23 ' CD1' ' A' ' 153' ' ' LEU . 3.1 mt -124.96 126.83 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.304 -0.872 . . . . 0.0 109.352 179.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.94 99.43 30.53 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.217 -0.927 . . . . 0.0 109.647 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.562 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 50.1 Cg_endo -70.3 171.93 14.12 Favored 'Trans proline' 0 C--O 1.216 -0.59 0 C-N-CA 122.681 2.254 . . . . 0.0 111.747 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.562 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.8 mt-10 81.06 -20.87 0.35 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.35 -0.844 . . . . 0.0 109.887 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.43 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 16.1 mtt-85 -128.83 -12.96 4.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.619 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.995 ' O ' HG23 ' A' ' 170' ' ' VAL . 29.4 mt-30 70.72 48.49 0.42 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.271 -0.893 . . . . 0.0 109.636 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -118.6 141.66 48.38 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.138 -0.976 . . . . 0.0 108.745 179.297 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.816 ' CD1' HG23 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -133.4 111.82 11.07 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.101 -0.999 . . . . 0.0 109.937 -179.537 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 21.1 mttt -80.61 129.5 34.55 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.761 HG11 HG11 ' A' ' 129' ' ' VAL . 35.4 m -123.61 152.54 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.059 -1.026 . . . . 0.0 109.715 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.507 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 47.2 t-20 -96.53 108.56 21.16 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.385 -0.822 . . . . 0.0 109.431 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.73 HG12 ' O ' ' A' ' 164' ' ' THR . 2.2 p -92.02 140.19 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.162 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 84.9 m -99.79 99.16 9.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.271 -0.893 . . . . 0.0 109.952 -179.612 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.692 HG13 HG22 ' A' ' 157' ' ' VAL . 2.0 mt -122.45 143.66 34.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.296 -0.878 . . . . 0.0 109.092 179.548 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.688 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 85.0 m-85 61.72 39.38 14.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.241 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.77 17.89 29.81 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.531 ' CZ ' ' OH ' ' A' ' 59' ' ' TYR . 25.2 mtt85 -127.26 156.72 41.45 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.106 -1.232 . . . . 0.0 109.568 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . 0.431 ' HB3' ' OD1' ' A' ' 156' ' ' ASN . 91.3 mt-10 -99.92 130.72 46.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.925 . . . . 0.0 109.471 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . 0.73 ' O ' HG12 ' A' ' 157' ' ' VAL . 16.1 m -140.52 121.64 9.21 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.285 -0.884 . . . . 0.0 109.732 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.523 ' HA ' ' O ' ' A' ' 155' ' ' VAL . 49.8 Cg_endo -70.02 138.21 36.48 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.697 2.264 . . . . 0.0 111.536 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.4 p -126.89 145.65 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.117 -0.989 . . . . 0.0 109.815 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.591 HG13 ' O ' ' A' ' 167' ' ' VAL . 11.4 p -91.87 119.73 39.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.416 -0.802 . . . . 0.0 109.326 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.427 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 12.3 mt -140.28 165.29 27.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 110.582 -179.16 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.628 ' O ' HG13 ' A' ' 173' ' ' VAL . 91.6 m-70 -79.07 147.0 32.95 Favored 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 121.345 0.593 . . . . 0.0 109.576 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.995 HG23 ' O ' ' A' ' 151' ' ' GLN . 4.4 t -63.16 -35.17 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 37.7 m -77.05 -7.12 55.13 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.467 -0.77 . . . . 0.0 109.295 179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.517 ' CB ' ' HB3' ' A' ' 133' ' ' SER . 91.6 mt-10 -103.05 5.41 38.09 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.284 -0.885 . . . . 0.0 109.385 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . 0.628 HG13 ' O ' ' A' ' 169' ' ' HIS . 2.7 m -129.69 160.29 40.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.19 -0.944 . . . . 0.0 109.58 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.848 ' CD ' HD13 ' A' ' 132' ' ' ILE . 28.8 mt-10 -133.16 150.8 52.0 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.295 -0.878 . . . . 0.0 109.048 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 129' ' ' VAL . 4.2 pttm . . . . . 0 N--CA 1.489 1.507 0 O-C-N 121.094 -1.004 . . . . 0.0 109.514 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.808 ' HG2' HG22 ' A' ' 65' ' ' ILE . 83.5 mttt . . . . . 0 N--CA 1.489 1.495 0 CA-C-O 121.343 0.592 . . . . 0.0 109.495 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.574 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 41.2 mmtm -130.24 174.52 9.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.399 -0.813 . . . . 0.0 109.539 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.782 ' CH2' HG23 ' A' ' 41' ' ' VAL . 40.3 m95 -105.56 125.4 50.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.293 -0.879 . . . . 0.0 109.011 179.664 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -115.48 166.35 11.99 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.11 -0.994 . . . . 0.0 109.343 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.568 HG12 ' CD1' ' A' ' 61' ' ' PHE . 55.8 mt -110.87 112.15 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.194 -0.941 . . . . 0.0 109.087 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.632 HG12 ' CD2' ' A' ' 83' ' ' PHE . 20.3 m -90.51 141.1 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.171 -0.956 . . . . 0.0 109.496 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.534 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -85.98 145.07 27.28 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.424 -0.797 . . . . 0.0 109.401 -179.926 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.7 p -149.63 -173.74 4.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.182 -0.949 . . . . 0.0 109.507 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.49 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 70.9 mtp -107.81 128.89 55.0 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.21 -0.931 . . . . 0.0 109.738 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.5 m -47.65 119.82 2.98 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.261 -0.899 . . . . 0.0 109.279 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.59 -20.26 27.63 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.49 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 94.5 m-85 -105.58 -16.36 14.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.198 -1.177 . . . . 0.0 109.496 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 16' ' ' TYR . 49.7 mt-10 -44.0 -62.04 1.26 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.193 -0.942 . . . . 0.0 109.345 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -49.54 -38.83 32.37 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.215 -0.928 . . . . 0.0 109.206 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -66.73 -33.0 74.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.346 -0.846 . . . . 0.0 109.076 179.651 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.672 HG22 ' HB2' ' A' ' 79' ' ' TYR . 91.8 t -72.01 -45.94 61.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.323 -0.861 . . . . 0.0 109.369 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.624 ' HB2' HD11 ' A' ' 42' ' ' ILE . 19.0 tttm -51.85 -56.09 16.09 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.23 -0.919 . . . . 0.0 109.246 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -62.04 -34.93 77.16 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.319 -0.863 . . . . 0.0 109.256 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.503 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 23.2 t-20 -65.28 -36.67 84.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.411 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.401 HG13 ' O ' ' A' ' 20' ' ' VAL . 90.4 mt -66.3 -46.47 87.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.145 -0.972 . . . . 0.0 109.782 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.461 ' O ' ' HG2' ' A' ' 29' ' ' GLU . 65.8 mm-40 -56.88 -46.68 81.72 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.099 -1.0 . . . . 0.0 109.874 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 29.0 mttt -77.3 -36.72 53.91 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.104 -0.998 . . . . 0.0 109.576 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.89 ' HG2' HG23 ' A' ' 77' ' ' VAL . 5.3 tptt -56.12 -31.05 62.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 109.095 179.774 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.806 HG13 ' O ' ' A' ' 33' ' ' ILE . 11.6 t -84.76 -26.31 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.347 -0.845 . . . . 0.0 109.264 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.461 ' HG2' ' O ' ' A' ' 25' ' ' GLU . 61.7 mm-40 -67.87 -51.48 47.72 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.298 -0.876 . . . . 0.0 109.375 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.42 -32.3 66.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.921 . . . . 0.0 109.386 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.701 HG21 ' CE1' ' A' ' 73' ' ' PHE . 63.1 p -94.71 -11.31 29.36 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.354 -0.842 . . . . 0.0 109.447 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 54.83 24.51 33.84 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.991 HG21 HD22 ' A' ' 36' ' ' LEU . 69.8 mt -85.96 116.62 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.198 -1.178 . . . . 0.0 109.352 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.459 ' HG2' ' O ' ' A' ' 34' ' ' LYS . 86.0 tttt -121.98 -10.44 8.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.179 -0.95 . . . . 0.0 109.395 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 1.057 ' O ' HD13 ' A' ' 65' ' ' ILE . 87.5 m-20 -98.67 13.81 30.8 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.207 -0.933 . . . . 0.0 109.426 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.991 HD22 HG21 ' A' ' 33' ' ' ILE . 6.0 mp -120.69 -53.38 2.09 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.336 -0.853 . . . . 0.0 109.111 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.544 HG22 ' SD ' ' A' ' 64' ' ' MET . 90.3 t -100.66 129.55 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.426 -0.796 . . . . 0.0 109.034 179.53 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.25 -121.76 4.62 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -98.03 148.4 23.54 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.277 -1.131 . . . . 0.0 109.991 -179.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 1.058 HG22 HG13 ' A' ' 62' ' ' VAL . 44.5 pt -119.8 143.21 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.42 -0.8 . . . . 0.0 108.857 179.495 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.82 HG21 HD22 ' A' ' 107' ' ' LEU . 25.1 t -129.52 154.6 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.127 -0.983 . . . . 0.0 109.871 -179.527 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.913 HG22 ' H ' ' A' ' 44' ' ' ILE . 18.4 mt -127.86 128.62 23.83 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.366 -0.834 . . . . 0.0 109.212 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.489 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 45.1 Cg_endo -66.82 -4.27 10.92 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.836 2.357 . . . . 0.0 111.692 -179.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.913 ' H ' HG22 ' A' ' 42' ' ' ILE . 54.8 mt . . . . . 0 N--CA 1.491 1.584 0 O-C-N 121.336 -0.853 . . . . 0.0 109.551 179.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.693 ' HG2' HG23 ' A' ' 44' ' ' ILE . 63.6 mttt . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.5 ' O ' ' CD1' ' A' ' 56' ' ' PHE . 44.2 mt -64.13 -21.54 66.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -1.0 . . . . 0.0 109.181 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 1.054 ' CE1' HD11 ' A' ' 159' ' ' ILE . 8.8 m-85 -148.97 101.88 3.39 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.323 -0.861 . . . . 0.0 108.986 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -65.47 136.31 46.12 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.7 2.267 . . . . 0.0 112.176 -179.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.472 ' O ' HD13 ' A' ' 11' ' ' LEU . . . 77.44 -15.22 7.55 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 179.576 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -99.31 129.53 45.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.799 -1.412 . . . . 0.0 110.292 -179.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.546 ' HB ' ' CG2' ' A' ' 10' ' ' VAL . 88.2 t -133.23 148.88 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.599 ' CE1' ' CZ ' ' A' ' 160' ' ' PHE . 84.2 m-85 -109.71 124.62 51.55 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.773 -1.205 . . . . 0.0 110.248 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 1.058 HG13 HG22 ' A' ' 40' ' ' ILE . 91.8 t -133.58 145.16 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.382 -0.824 . . . . 0.0 109.635 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.626 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 28.2 tt0 -112.08 128.01 56.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.24 -0.913 . . . . 0.0 108.976 179.575 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.832 ' HE1' HG11 ' A' ' 74' ' ' VAL . 15.4 mtm -153.9 168.69 25.51 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.867 -1.146 . . . . 0.0 110.805 -179.113 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 1.057 HD13 ' O ' ' A' ' 35' ' ' ASN . 0.5 OUTLIER -89.11 130.39 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.653 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.417 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 56.6 ttm -75.85 141.8 42.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.89 . . . . 0.0 110.191 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.417 ' HB2' ' O ' ' A' ' 66' ' ' MET . 46.0 t30 179.11 166.15 0.96 Allowed 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -66.14 -41.13 90.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.966 . . . . 0.0 109.505 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 64.2 tt0 -76.46 -31.5 57.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.844 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.023 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -68.78 -49.36 59.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.972 -1.08 . . . . 0.0 109.621 -179.763 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.579 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 71.8 t80 -60.62 -50.98 71.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.215 -0.928 . . . . 0.0 109.751 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -57.09 -29.69 63.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -0.937 . . . . 0.0 110.059 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.701 ' CE1' HG21 ' A' ' 31' ' ' THR . 77.4 t80 -80.51 -41.88 23.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.098 -1.001 . . . . 0.0 109.776 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 1.023 HG23 ' O ' ' A' ' 70' ' ' ALA . 2.8 t -70.08 -55.07 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.466 -0.771 . . . . 0.0 109.602 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.437 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 32.0 tpt85 -61.43 -13.33 19.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.329 -0.857 . . . . 0.0 110.013 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 78.1 p -97.31 4.57 50.79 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.115 -0.99 . . . . 0.0 109.923 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.912 ' O ' HG12 ' A' ' 80' ' ' VAL . 0.4 OUTLIER -74.85 137.21 73.32 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 120.965 -1.084 . . . . 0.0 109.315 -179.992 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.63 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 44.2 Cg_endo -66.34 137.36 46.95 Favored 'Trans proline' 0 C--O 1.213 -0.75 0 C-N-CA 122.676 2.251 . . . . 0.0 111.893 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.672 ' HB2' HG22 ' A' ' 20' ' ' VAL . 19.1 m-85 92.45 -13.54 0.18 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.934 -0.479 . . . . 0.0 109.759 -179.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.912 HG12 ' O ' ' A' ' 77' ' ' VAL . 8.6 p -82.43 122.91 37.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.891 -1.131 . . . . 0.0 109.365 179.765 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 95.5 mmm -87.94 -30.71 19.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.294 -0.879 . . . . 0.0 109.362 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.545 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 168.05 -165.85 39.04 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.632 ' CD2' HG12 ' A' ' 10' ' ' VAL . 4.6 m-85 -137.52 139.61 40.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.332 -1.099 . . . . 0.0 109.46 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.412 HG22 ' CD2' ' A' ' 11' ' ' LEU . 21.0 t -66.08 125.01 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.258 -0.901 . . . . 0.0 109.331 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.568 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.8 p -160.18 158.97 31.06 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.15 -0.969 . . . . 0.0 109.667 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 59.5 p -82.84 -36.47 25.45 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.329 -0.857 . . . . 0.0 109.234 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.07 -86.56 0.52 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -103.13 -127.87 6.21 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.579 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -33.98 151.93 0.05 OUTLIER Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.512 -0.993 . . . . 0.0 110.046 -179.668 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.568 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.1 Cg_endo -69.38 158.66 56.64 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.807 2.338 . . . . 0.0 112.01 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.8 m -93.38 154.14 41.38 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.423 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -70.06 146.96 59.86 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.654 2.236 . . . . 0.0 111.735 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 7' ' ' TRP . 45.1 t -83.62 140.18 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.297 -0.877 . . . . 0.0 109.417 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . 0.492 ' HE2' ' NH2' ' A' ' 96' ' ' ARG . 79.8 tttt -73.21 130.69 40.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.491 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -46.53 -39.07 10.26 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.278 -0.889 . . . . 0.0 109.425 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.492 ' NH2' ' HE2' ' A' ' 94' ' ' LYS . 15.5 mtt85 -60.56 -30.77 70.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.344 -0.847 . . . . 0.0 109.417 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.427 ' N ' ' O ' ' A' ' 94' ' ' LYS . 52.7 mt-10 -80.08 -26.8 39.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.892 . . . . 0.0 109.528 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.686 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 55.3 mtp -86.12 -21.77 27.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.226 179.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.581 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.47 -53.23 1.31 Allowed Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.482 -0.761 . . . . 0.0 109.807 179.981 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.624 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 50.4 Cg_endo -71.41 -26.69 20.11 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.463 2.109 . . . . 0.0 111.878 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.479 ' N ' ' O ' ' A' ' 98' ' ' MET . 35.2 mm -82.42 -42.96 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -0.934 . . . . 0.0 109.607 -179.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.654 ' N ' HD13 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -67.83 -40.82 83.74 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.183 -0.948 . . . . 0.0 109.417 179.923 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.42 ' HG2' ' HA ' ' A' ' 135' ' ' PRO . 19.7 tpt180 -65.86 -49.1 69.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.253 -0.904 . . . . 0.0 109.315 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.71 -37.03 70.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.358 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.557 ' CB ' HG11 ' A' ' 41' ' ' VAL . . . -74.35 1.3 11.95 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.315 -0.866 . . . . 0.0 109.773 -179.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.47 11.07 85.44 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.82 HD22 HG21 ' A' ' 41' ' ' VAL . 3.2 tp -82.05 -24.86 35.07 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.219 -1.166 . . . . 0.0 109.525 179.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 . . . . . 0 N--CA 1.49 1.559 0 O-C-N 121.214 -0.929 . . . . 0.0 109.584 -179.871 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.573 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 14.1 m-85 . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.419 ' HD3' ' O ' ' A' ' 123' ' ' PHE . 62.1 mmtt -139.35 156.37 47.05 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.25 -0.906 . . . . 0.0 109.536 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 144' ' ' LYS . 10.1 t -57.37 137.46 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.258 -0.901 . . . . 0.0 109.606 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.81 -34.55 3.86 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.432 ' O ' HG23 ' A' ' 142' ' ' VAL . 37.2 m-20 -47.8 160.8 0.12 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.341 -1.094 . . . . 0.0 109.405 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.4 ttm -100.87 127.93 47.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.193 -0.942 . . . . 0.0 109.059 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.616 HG13 HG13 ' A' ' 143' ' ' ILE . 25.7 m -128.72 145.31 35.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.358 -0.839 . . . . 0.0 109.667 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.469 ' O ' HG23 ' A' ' 173' ' ' VAL . 57.7 tttt -103.22 139.39 38.76 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.787 -0.819 . . . . 0.0 108.787 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 1.031 HD12 ' HB3' ' A' ' 139' ' ' PHE . 80.9 mt -78.41 153.71 5.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -149.17 1.26 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.946 -1.096 . . . . 0.0 109.465 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.51 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 70.1 m -148.27 144.3 27.53 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.114 -0.991 . . . . 0.0 110.06 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.59 -164.88 17.73 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.506 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 46.2 Cg_endo -68.35 -21.84 40.53 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 123.071 2.514 . . . . 0.0 112.643 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.624 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 86.9 m-85 -107.67 18.21 21.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.84 -1.163 . . . . 0.0 109.442 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.518 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 3.1 tt0 -45.53 139.05 4.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.255 -0.903 . . . . 0.0 109.617 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 28.9 m-20 73.74 28.54 1.6 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.385 -0.822 . . . . 0.0 110.423 179.526 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 1.031 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.7 t80 -117.4 131.87 56.68 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.041 -1.037 . . . . 0.0 109.445 179.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.409 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -78.53 132.26 37.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.19 -0.944 . . . . 0.0 109.647 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -142.98 167.46 26.33 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.537 ' CG1' ' HB2' ' A' ' 156' ' ' ASN . 11.1 p -117.42 138.33 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.353 -1.086 . . . . 0.0 109.393 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.735 ' HA ' HG12 ' A' ' 155' ' ' VAL . 60.6 mt -68.81 117.11 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.152 -0.968 . . . . 0.0 109.676 -179.832 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.439 ' O ' HG13 ' A' ' 125' ' ' VAL . 15.6 tttt -102.43 -35.52 8.75 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.142 -0.973 . . . . 0.0 109.253 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.464 ' HB2' ' HB2' ' A' ' 154' ' ' LYS . 62.8 mt-10 -152.95 148.19 26.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.241 -0.912 . . . . 0.0 109.526 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.653 HG23 ' HG ' ' A' ' 153' ' ' LEU . 2.1 mt -123.8 125.65 71.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.257 -0.902 . . . . 0.0 109.412 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -106.74 99.61 26.42 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.192 -0.943 . . . . 0.0 109.674 -179.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.583 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.8 Cg_endo -70.74 170.96 16.49 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.704 2.27 . . . . 0.0 111.677 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.583 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.4 mt-10 81.64 -20.5 0.36 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.362 -0.836 . . . . 0.0 109.868 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.47 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 42.1 mtt180 -128.89 -12.47 4.74 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.997 -1.065 . . . . 0.0 109.694 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.876 ' O ' HG23 ' A' ' 170' ' ' VAL . 48.1 mt-30 70.69 48.8 0.42 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.26 -0.9 . . . . 0.0 109.604 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -119.59 142.18 48.62 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.175 -0.953 . . . . 0.0 109.02 179.583 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.653 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -129.34 112.36 13.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.237 -0.914 . . . . 0.0 110.083 -179.514 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.464 ' HB2' ' HB2' ' A' ' 145' ' ' GLU . 17.6 mttt -79.9 126.41 30.97 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 179.071 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.735 HG12 ' HA ' ' A' ' 143' ' ' ILE . 16.1 m -128.32 152.98 37.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.035 -1.041 . . . . 0.0 110.05 -179.458 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.537 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 86.8 m-20 -98.88 112.9 24.87 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.313 -0.867 . . . . 0.0 109.376 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.792 HG13 ' CE1' ' A' ' 139' ' ' PHE . 38.8 t -99.97 147.69 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.273 -0.892 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 163' ' ' GLU . 29.2 m -94.08 117.76 30.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.415 -0.803 . . . . 0.0 109.802 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 1.054 HD11 ' CE1' ' A' ' 56' ' ' PHE . 18.8 pt -145.9 138.62 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.348 -0.845 . . . . 0.0 109.387 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.599 ' CZ ' ' CE1' ' A' ' 61' ' ' PHE . 72.2 m-85 62.57 39.36 11.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.909 . . . . 0.0 109.379 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 62.26 16.96 55.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -137.73 142.21 41.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.092 -1.24 . . . . 0.0 109.501 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . 0.553 ' HA ' ' HA ' ' A' ' 158' ' ' THR . 84.8 mt-10 -98.45 110.2 22.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.184 -0.948 . . . . 0.0 109.465 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . 0.579 HG23 ' HD2' ' A' ' 165' ' ' PRO . 16.6 m -112.8 139.9 23.38 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.211 -0.93 . . . . 0.0 109.341 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.579 ' HD2' HG23 ' A' ' 164' ' ' THR . 48.7 Cg_endo -69.21 137.3 36.72 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.711 2.274 . . . . 0.0 111.778 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 1.02 HG13 HD11 ' A' ' 168' ' ' LEU . 2.1 p -123.41 142.06 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.157 -0.964 . . . . 0.0 109.743 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.501 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 72.8 t -92.89 119.13 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.383 -0.823 . . . . 0.0 109.552 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 1.02 HD11 HG13 ' A' ' 166' ' ' VAL . 0.3 OUTLIER -141.27 167.96 20.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.313 -0.867 . . . . 0.0 110.567 -179.719 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.531 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 61.8 m80 -78.59 145.58 34.67 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.876 HG23 ' O ' ' A' ' 151' ' ' GLN . 24.0 t -59.67 -35.84 62.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.274 -0.891 . . . . 0.0 108.702 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 87.9 p -75.27 -7.06 52.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.494 -0.754 . . . . 0.0 109.324 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.531 ' CG ' ' HB2' ' A' ' 169' ' ' HIS . 82.5 mt-10 -90.62 4.07 52.37 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.34 -0.85 . . . . 0.0 109.832 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . 0.578 ' CG2' ' N ' ' A' ' 174' ' ' GLU . 1.4 p -141.7 167.74 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.024 -1.048 . . . . 0.0 109.484 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.578 ' N ' ' CG2' ' A' ' 173' ' ' VAL . 52.4 tt0 -142.78 168.77 18.94 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.341 -0.849 . . . . 0.0 108.857 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.573 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 33.1 tttm . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.021 -1.05 . . . . 0.0 109.289 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.4 mttm . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.391 0.615 . . . . 0.0 109.667 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 12.7 mttt -135.49 176.03 9.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 110.009 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.837 ' CH2' HG23 ' A' ' 41' ' ' VAL . 60.3 m95 -109.83 125.71 53.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.362 -0.836 . . . . 0.0 109.211 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.58 ' CE2' ' HG3' ' A' ' 66' ' ' MET . 66.1 m-85 -116.64 171.76 7.66 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.186 -0.946 . . . . 0.0 109.383 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.657 HD11 ' CE1' ' A' ' 160' ' ' PHE . 56.2 mt -110.9 109.95 30.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.242 -0.911 . . . . 0.0 109.069 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.608 HG23 ' CE1' ' A' ' 83' ' ' PHE . 8.9 p -88.6 143.47 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.186 -0.946 . . . . 0.0 109.477 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.51 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.6 mm? -88.83 141.83 28.17 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.389 -0.819 . . . . 0.0 109.545 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.69 ' OG1' HG21 ' A' ' 20' ' ' VAL . 15.1 t -154.69 -169.35 3.18 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.281 -0.887 . . . . 0.0 109.393 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.502 ' SD ' ' CE2' ' A' ' 16' ' ' TYR . 36.2 ttm -107.68 119.6 39.88 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.48 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 13' ' ' MET . 54.0 p -42.82 128.19 4.15 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.332 -0.855 . . . . 0.0 109.279 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.65 -19.69 33.13 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.523 ' O ' HG23 ' A' ' 20' ' ' VAL . 19.6 m-30 -110.31 -5.84 15.15 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.301 -1.117 . . . . 0.0 109.75 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.486 ' HG2' HG21 ' A' ' 12' ' ' THR . 87.0 mt-10 -44.58 -65.49 0.51 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.148 -0.97 . . . . 0.0 109.547 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.44 ' O ' ' HG3' ' A' ' 22' ' ' GLU . 95.7 mt-10 -43.2 -33.41 0.92 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.199 -0.938 . . . . 0.0 109.271 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.524 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 46.7 mttm -77.19 -41.12 42.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.3 -0.875 . . . . 0.0 109.324 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.69 HG21 ' OG1' ' A' ' 12' ' ' THR . 18.4 t -59.7 -48.17 88.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.327 -0.858 . . . . 0.0 109.33 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.58 ' HG3' HG21 ' A' ' 40' ' ' ILE . 28.1 tttm -60.53 -43.12 97.49 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.897 . . . . 0.0 109.067 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.44 ' HG3' ' O ' ' A' ' 18' ' ' GLU . 93.7 mt-10 -63.87 -42.07 97.61 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.406 -0.809 . . . . 0.0 109.045 179.716 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.629 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 54.9 m-80 -56.91 -52.22 66.01 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.335 -0.853 . . . . 0.0 109.508 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.925 ' CD1' HG21 ' A' ' 77' ' ' VAL . 21.0 mm -50.33 -44.21 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.051 -1.031 . . . . 0.0 109.408 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -54.61 -44.27 72.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.272 -0.893 . . . . 0.0 109.832 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.8 mttp -79.86 -35.09 38.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.09 -1.006 . . . . 0.0 109.905 -179.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.91 ' HD3' HG23 ' A' ' 77' ' ' VAL . 12.6 ttpp -56.65 -35.16 68.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.114 -0.991 . . . . 0.0 109.282 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.828 HG13 ' O ' ' A' ' 33' ' ' ILE . 15.6 t -82.47 -27.05 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.841 . . . . 0.0 109.575 -179.794 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 69.8 mt-10 -66.35 -49.84 65.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.214 -0.929 . . . . 0.0 109.68 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.38 -27.74 69.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.207 -0.933 . . . . 0.0 109.741 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.454 HG23 ' O ' ' A' ' 27' ' ' LYS . 60.9 p -88.83 -12.76 41.01 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.041 -1.037 . . . . 0.0 109.517 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 63.72 15.43 57.67 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.828 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.7 mt -94.84 85.6 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.314 -1.11 . . . . 0.0 109.481 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 49.9 mttt -85.59 7.64 22.41 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.149 -0.97 . . . . 0.0 109.074 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -111.77 18.52 18.86 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.339 -0.85 . . . . 0.0 109.433 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.845 ' CD2' HD11 ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.6 -52.95 2.75 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.144 -0.972 . . . . 0.0 109.344 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.464 ' HA ' ' HB3' ' A' ' 64' ' ' MET . 87.7 t -97.01 137.06 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -107.81 -125.28 5.27 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.426 ' O ' ' CH2' ' A' ' 7' ' ' TRP . 95.2 mtt180 -91.72 138.69 31.35 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -1.112 . . . . 0.0 109.694 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.876 HG12 HG13 ' A' ' 62' ' ' VAL . 46.1 mt -105.78 136.96 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.374 -0.829 . . . . 0.0 109.042 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 1.113 ' CG2' HD11 ' A' ' 107' ' ' LEU . 98.4 t -124.26 150.51 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.747 HG22 HG23 ' A' ' 44' ' ' ILE . 5.7 mt -128.38 126.05 23.43 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.341 -0.849 . . . . 0.0 109.413 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.462 ' O ' HD13 ' A' ' 55' ' ' LEU . 47.8 Cg_endo -68.5 -2.99 10.18 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.86 2.374 . . . . 0.0 111.814 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.747 HG23 HG22 ' A' ' 42' ' ' ILE . 11.3 pt . . . . . 0 N--CA 1.489 1.499 0 O-C-N 121.07 -1.019 . . . . 0.0 109.649 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.692 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 22.6 mttm . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.54 ' N ' HD12 ' A' ' 55' ' ' LEU . 6.8 mp -65.91 -25.57 67.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.835 -1.165 . . . . 0.0 109.47 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.533 ' HB3' ' HB2' ' A' ' 59' ' ' TYR . 84.3 m-85 -142.08 98.23 6.22 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.886 . . . . 0.0 108.86 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 43.2 Cg_endo -66.7 134.39 34.94 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.755 2.303 . . . . 0.0 112.23 -179.082 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.56 -12.87 7.17 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.533 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 2.9 m-85 -100.67 131.23 46.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.693 -1.475 . . . . 0.0 110.183 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.569 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 76.8 t -135.32 148.6 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.377 -0.827 . . . . 0.0 108.809 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.634 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 16.8 m-85 -110.7 123.87 50.85 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.874 -1.141 . . . . 0.0 109.926 -179.395 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.876 HG13 HG12 ' A' ' 40' ' ' ILE . 90.0 t -129.62 142.77 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.405 -0.809 . . . . 0.0 109.793 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.612 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 9.8 tt0 -99.86 125.52 45.83 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.335 -0.853 . . . . 0.0 109.175 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.464 ' HB3' ' HA ' ' A' ' 37' ' ' VAL . 12.5 ptt? -164.96 -175.39 3.71 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.025 -1.047 . . . . 0.0 110.174 -179.665 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.845 HD11 ' CD2' ' A' ' 36' ' ' LEU . 38.6 pt -103.35 128.36 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.165 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.58 ' HG3' ' CE2' ' A' ' 8' ' ' TYR . 33.6 mtm -90.75 101.64 14.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.196 -0.94 . . . . 0.0 109.898 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.543 ' OD1' ' N ' ' A' ' 69' ' ' GLU . 10.3 p30 -137.91 -163.09 1.39 Allowed 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.123 -0.986 . . . . 0.0 109.077 179.591 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -74.98 -50.15 17.56 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.135 -0.978 . . . . 0.0 110.105 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.543 ' N ' ' OD1' ' A' ' 67' ' ' ASN . 98.0 mt-10 -64.85 -54.64 27.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.05 -1.031 . . . . 0.0 109.585 -179.747 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.011 ' O ' HG22 ' A' ' 74' ' ' VAL . . . -52.34 -38.75 59.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.265 -0.897 . . . . 0.0 109.727 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.433 ' CD1' ' CD ' ' A' ' 89' ' ' GLN . 72.3 t80 -60.02 -50.51 73.46 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 109.853 -179.818 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -65.59 -28.46 69.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.156 -0.965 . . . . 0.0 110.436 -179.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -82.52 -42.63 18.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.865 -1.147 . . . . 0.0 110.035 -179.443 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 1.011 HG22 ' O ' ' A' ' 70' ' ' ALA . 6.8 m -65.92 -57.37 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.186 -0.947 . . . . 0.0 109.562 -179.78 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.681 ' H ' HG23 ' A' ' 74' ' ' VAL . 12.6 mmt180 -53.87 -40.95 66.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.922 . . . . 0.0 109.751 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 25.7 p -75.42 3.07 9.86 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.204 -0.935 . . . . 0.0 110.149 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.925 HG21 ' CD1' ' A' ' 24' ' ' ILE . 1.8 p -71.8 130.0 87.52 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 120.875 -1.141 . . . . 0.0 109.136 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.765 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 44.0 Cg_endo -66.14 132.32 29.49 Favored 'Trans proline' 0 C--O 1.212 -0.797 0 C-N-CA 122.83 2.353 . . . . 0.0 112.627 -178.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.765 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 70.8 m-85 95.43 -8.63 0.1 Allowed 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.683 HG21 HG11 ' A' ' 77' ' ' VAL . 16.0 t -99.15 133.72 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.973 -1.079 . . . . 0.0 109.494 179.726 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 64.2 mtt -92.79 -19.23 21.96 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.337 -0.852 . . . . 0.0 109.399 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 150.48 -154.38 25.6 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.608 ' CE1' HG23 ' A' ' 10' ' ' VAL . 5.3 m-85 -137.14 149.22 47.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -1.142 . . . . 0.0 109.602 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.524 HG12 ' HB ' ' A' ' 9' ' ' ILE . 13.8 p -74.86 129.39 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.283 -0.886 . . . . 0.0 109.37 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.553 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 2.2 p -163.06 165.6 24.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.732 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.4 t -92.89 -30.87 15.19 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.396 -0.815 . . . . 0.0 109.24 179.742 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.77 -87.7 0.54 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.527 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -103.19 -135.5 8.7 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.527 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -32.59 153.99 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.568 -0.96 . . . . 0.0 110.259 -179.624 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.553 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 47.8 Cg_endo -67.86 151.2 78.56 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.891 2.394 . . . . 0.0 112.013 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.4 m -84.22 155.07 63.64 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.318 -0.864 . . . . 0.0 109.336 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.41 ' HB3' ' HD3' ' A' ' 6' ' ' LYS . 49.0 Cg_endo -69.81 141.27 44.59 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.676 2.251 . . . . 0.0 111.753 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 7' ' ' TRP . 41.4 t -71.73 141.4 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.209 -0.932 . . . . 0.0 109.367 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 97' ' ' GLU . 93.8 mttt -75.53 130.02 38.17 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.444 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 78.5 m-20 -45.25 -39.4 6.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.883 . . . . 0.0 109.354 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 77.6 mtt180 -60.69 -24.74 65.87 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.483 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.464 ' N ' ' O ' ' A' ' 94' ' ' LYS . 87.6 mt-10 -89.42 -26.06 21.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.556 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.594 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 89.5 mtp -82.54 -30.93 29.41 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.401 -0.812 . . . . 0.0 109.448 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.623 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 1.2 tpt180 -38.7 -51.95 3.67 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.402 -0.811 . . . . 0.0 109.857 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.623 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.3 Cg_endo -68.78 -28.1 30.69 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.483 2.122 . . . . 0.0 111.801 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.459 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 23.4 mm -81.58 -42.13 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.243 -0.91 . . . . 0.0 109.402 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 1.021 HD12 HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -67.46 -39.88 85.35 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.207 -0.933 . . . . 0.0 109.051 179.715 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.568 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 26.1 ttm180 -63.62 -49.27 73.96 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.375 -0.828 . . . . 0.0 108.981 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -72.99 -35.24 66.83 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.329 -0.857 . . . . 0.0 109.048 179.532 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.517 ' HB1' HG13 ' A' ' 41' ' ' VAL . . . -74.38 -2.8 26.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.356 -0.84 . . . . 0.0 109.654 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.42 14.4 82.43 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 1.113 HD11 ' CG2' ' A' ' 41' ' ' VAL . 66.0 mt -81.65 -24.17 36.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.202 -1.176 . . . . 0.0 109.646 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 37.9 tp10 . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.101 -0.999 . . . . 0.0 109.627 -179.871 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.588 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 3.6 m-30 . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.409 ' HB2' ' CG ' ' A' ' 127' ' ' ASP . 74.8 mttt -124.87 154.32 41.25 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.013 -1.054 . . . . 0.0 110.124 -179.462 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 9.8 m -64.66 141.89 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.331 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 88.22 -31.75 4.65 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.506 ' HB2' HD12 ' A' ' 143' ' ' ILE . 28.9 m-20 -49.66 158.74 0.43 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.433 -1.039 . . . . 0.0 109.26 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.4 ttm -98.13 127.86 44.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.205 -0.934 . . . . 0.0 109.052 179.659 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.672 HG11 HD11 ' A' ' 143' ' ' ILE . 27.4 m -128.11 143.41 40.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.276 -0.89 . . . . 0.0 109.604 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 75.8 tttt -100.31 139.42 36.01 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.989 ' O ' HD13 ' A' ' 132' ' ' ILE . 1.2 mp -79.86 152.77 4.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.989 HD13 ' O ' ' A' ' 131' ' ' ILE . 1.1 mm -148.79 2.4 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 120.956 -1.09 . . . . 0.0 109.809 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.526 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 41.7 m -147.5 144.66 28.73 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.971 -1.08 . . . . 0.0 110.198 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 103.22 -166.44 16.29 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.568 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 47.5 Cg_endo -68.52 -20.85 40.84 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 123.111 2.541 . . . . 0.0 112.315 -179.663 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.535 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 98.8 m-85 -107.86 19.09 20.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.954 -1.091 . . . . 0.0 109.3 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.614 ' HA ' HG22 ' A' ' 131' ' ' ILE . 4.0 tt0 -43.17 139.9 1.7 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.268 -0.895 . . . . 0.0 109.797 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.537 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 44.3 m-20 72.62 30.74 1.81 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.463 -0.773 . . . . 0.0 110.871 179.191 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.535 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 0.7 OUTLIER -116.66 128.46 55.39 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.76 -1.212 . . . . 0.0 109.573 179.654 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.14 133.49 42.8 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.28 -0.887 . . . . 0.0 109.455 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.05 168.96 26.37 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.432 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.616 ' C ' HG13 ' A' ' 155' ' ' VAL . 53.5 t -118.19 137.47 52.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.578 -0.954 . . . . 0.0 109.311 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.672 HD11 HG11 ' A' ' 129' ' ' VAL . 98.7 mt -70.05 115.47 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.177 -0.952 . . . . 0.0 109.42 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -99.03 -33.85 10.65 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.085 -1.009 . . . . 0.0 109.479 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.454 ' HB2' ' HE2' ' A' ' 154' ' ' LYS . 93.7 mt-10 -154.39 149.48 26.88 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.211 -0.931 . . . . 0.0 109.702 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.642 HG23 ' HG ' ' A' ' 153' ' ' LEU . 2.8 mt -125.91 128.46 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.431 -0.793 . . . . 0.0 109.394 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -110.91 102.17 51.79 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.234 -0.916 . . . . 0.0 109.534 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.557 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.0 Cg_endo -70.94 172.54 13.58 Favored 'Trans proline' 0 C--O 1.214 -0.724 0 C-N-CA 122.692 2.261 . . . . 0.0 111.699 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.557 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.6 mt-10 80.37 -20.74 0.36 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.348 -0.845 . . . . 0.0 109.848 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.427 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 74.6 mtt180 -128.53 -14.02 4.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.1 -1.0 . . . . 0.0 109.567 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.427 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 35.9 mt-30 70.51 48.64 0.45 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.216 -0.927 . . . . 0.0 109.851 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.576 ' OE2' HG23 ' A' ' 167' ' ' VAL . 84.6 tt0 -117.76 141.83 47.96 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.075 -1.015 . . . . 0.0 109.038 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.642 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -130.77 113.27 13.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.013 -1.054 . . . . 0.0 110.158 -179.512 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.454 ' HE2' ' HB2' ' A' ' 145' ' ' GLU . 2.5 ttpt -78.61 128.58 33.7 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.242 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.72 ' O ' HG12 ' A' ' 166' ' ' VAL . 47.0 t -124.54 145.82 31.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.168 -0.958 . . . . 0.0 109.985 -179.41 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.534 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 27.0 t-20 -98.32 110.96 23.45 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.377 -0.827 . . . . 0.0 109.37 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.492 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 60.4 t -95.22 142.33 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.453 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 41.2 m -100.55 100.03 10.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.255 -0.903 . . . . 0.0 109.728 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.497 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 4.1 mt -123.81 146.98 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.178 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.657 ' CE1' HD11 ' A' ' 9' ' ' ILE . 97.9 m-85 61.84 38.66 14.52 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.238 -0.914 . . . . 0.0 109.205 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 55.24 17.19 10.63 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.463 ' CZ ' ' OH ' ' A' ' 59' ' ' TYR . 90.7 mtt-85 -125.58 158.71 33.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.094 -1.239 . . . . 0.0 109.563 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.73 128.37 46.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.194 -0.941 . . . . 0.0 109.687 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 48.8 m -139.2 125.78 12.58 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.313 -0.867 . . . . 0.0 109.792 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.2 Cg_endo -71.51 135.28 26.08 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.7 2.267 . . . . 0.0 111.429 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 1.008 HG13 HD11 ' A' ' 168' ' ' LEU . 7.1 p -118.47 163.39 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.167 -0.958 . . . . 0.0 109.966 -179.524 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 167' ' ' VAL . 14.4 p -116.61 117.01 54.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.296 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 1.008 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -143.21 168.85 18.8 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.243 -0.911 . . . . 0.0 110.91 -179.264 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -78.96 144.0 35.21 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.572 HG23 HD13 ' A' ' 153' ' ' LEU . 10.8 p -57.78 -36.23 54.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.215 -0.928 . . . . 0.0 108.83 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.432 ' N ' HG13 ' A' ' 170' ' ' VAL . 42.5 p -76.39 -6.64 52.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.45 -0.782 . . . . 0.0 109.401 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.526 ' HA ' ' HB2' ' A' ' 133' ' ' SER . 2.8 mt-10 -89.72 -0.29 57.44 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.239 -0.913 . . . . 0.0 109.394 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.2 m -144.06 174.35 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.253 -0.905 . . . . 0.0 109.21 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.491 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 53.9 tt0 -139.49 168.16 20.46 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.113 -0.992 . . . . 0.0 108.975 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.588 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 73.1 tttt . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.028 -1.045 . . . . 0.0 109.358 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.557 ' HG2' HG22 ' A' ' 65' ' ' ILE . 36.8 mttt . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 121.263 0.554 . . . . 0.0 109.55 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.533 ' HB3' ' HB3' ' A' ' 92' ' ' PRO . 9.4 mttt -132.36 176.29 8.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.298 -0.876 . . . . 0.0 109.337 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.864 ' O ' HG23 ' A' ' 93' ' ' VAL . 64.8 m95 -112.67 124.04 51.66 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.924 . . . . 0.0 109.386 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.494 ' OH ' ' HG3' ' A' ' 66' ' ' MET . 78.4 m-85 -113.35 179.79 3.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.18 -0.95 . . . . 0.0 109.266 179.785 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.542 HG12 ' CE1' ' A' ' 61' ' ' PHE . 66.8 mt -119.7 107.38 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.384 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.555 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 13.1 p -86.01 144.6 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.271 -0.893 . . . . 0.0 109.518 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.797 HD11 ' HE1' ' A' ' 59' ' ' TYR . 2.8 mm? -94.8 143.83 26.14 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.336 -0.853 . . . . 0.0 109.601 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.405 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 1.3 p -151.3 -168.59 3.14 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.307 -0.87 . . . . 0.0 109.317 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.437 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 95.4 mtp -106.2 136.15 46.42 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.181 -0.949 . . . . 0.0 109.294 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.8 t -55.8 123.38 14.0 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -0.908 . . . . 0.0 109.424 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.08 -19.67 32.11 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.437 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.8 m-85 -108.15 -11.26 15.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.323 -1.104 . . . . 0.0 109.561 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.473 ' OE2' ' N ' ' A' ' 58' ' ' GLY . 77.5 mt-10 -46.52 -61.5 1.79 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.187 -0.945 . . . . 0.0 109.408 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.891 ' OE2' HD11 ' A' ' 44' ' ' ILE . 67.4 mm-40 -47.98 -36.55 12.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.288 -0.883 . . . . 0.0 109.339 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -71.69 -45.96 60.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.346 -0.847 . . . . 0.0 109.436 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.852 HG22 ' CB ' ' A' ' 79' ' ' TYR . 78.8 t -57.31 -47.14 85.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.186 -0.946 . . . . 0.0 109.444 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.738 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.7 tttt -56.09 -51.54 67.5 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.234 -0.916 . . . . 0.0 109.532 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 61.1 tt0 -63.06 -33.67 75.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.166 -0.959 . . . . 0.0 109.398 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.581 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 23.6 m120 -66.18 -41.26 90.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.318 -0.864 . . . . 0.0 109.501 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.453 HG13 ' O ' ' A' ' 20' ' ' VAL . 92.2 mt -60.52 -44.98 97.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.217 -0.927 . . . . 0.0 109.43 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -55.77 -47.09 77.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.201 -0.937 . . . . 0.0 109.672 -179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 71.5 mttt -70.19 -34.71 73.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.136 -0.977 . . . . 0.0 109.316 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.562 ' HD2' HG23 ' A' ' 77' ' ' VAL . 34.4 tttp -57.14 -35.9 70.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.379 -0.826 . . . . 0.0 109.478 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.816 HG13 ' O ' ' A' ' 33' ' ' ILE . 33.8 t -81.32 -25.51 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -71.6 -56.56 5.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.248 -0.908 . . . . 0.0 109.562 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.86 -26.2 45.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.223 -0.923 . . . . 0.0 109.553 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.476 ' OG1' HG12 ' A' ' 33' ' ' ILE . 41.8 p -98.05 -28.66 13.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.192 -0.942 . . . . 0.0 109.57 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 76.88 21.1 75.06 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.816 ' O ' HG13 ' A' ' 28' ' ' VAL . 34.1 mm -90.02 94.87 5.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -1.154 . . . . 0.0 109.495 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 16.0 mttp -97.74 5.13 49.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.183 -0.948 . . . . 0.0 109.49 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -110.22 13.45 23.07 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.203 -0.936 . . . . 0.0 109.341 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.052 HD21 ' HB2' ' A' ' 70' ' ' ALA . 1.2 tm? -115.73 -54.28 2.52 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.329 -0.857 . . . . 0.0 109.187 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.572 ' HB ' HG21 ' A' ' 28' ' ' VAL . 42.9 t -99.21 130.01 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.443 -0.786 . . . . 0.0 109.219 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.82 -124.33 5.22 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 90.7 mtt180 -96.51 141.94 29.19 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.266 -1.138 . . . . 0.0 109.589 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.409 HD13 HD12 ' A' ' 24' ' ' ILE . 63.3 mt -101.43 138.1 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.297 -0.877 . . . . 0.0 109.251 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 1.13 HG21 HD11 ' A' ' 107' ' ' LEU . 44.4 t -126.42 137.51 57.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.236 -0.915 . . . . 0.0 109.285 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.807 HG22 HG23 ' A' ' 44' ' ' ILE . 12.2 mt -128.08 127.84 23.79 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.187 -0.946 . . . . 0.0 109.692 -179.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.53 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -68.05 -3.86 11.45 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.895 2.396 . . . . 0.0 111.461 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.891 HD11 ' OE2' ' A' ' 18' ' ' GLU . 18.8 pt . . . . . 0 N--CA 1.489 1.505 0 O-C-N 121.307 -0.87 . . . . 0.0 109.561 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.727 ' HA ' HG22 ' A' ' 44' ' ' ILE . 6.2 mttt . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.53 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 16.7 mt -71.83 -21.47 61.68 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.136 -0.978 . . . . 0.0 109.407 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.968 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 37.2 m-85 -143.95 93.09 6.17 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.285 -0.885 . . . . 0.0 108.826 179.688 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -64.34 135.91 48.61 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.628 2.219 . . . . 0.0 112.267 -179.193 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.473 ' N ' ' OE2' ' A' ' 17' ' ' GLU . . . 78.81 -20.52 4.42 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 179.541 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.797 ' HE1' HD11 ' A' ' 11' ' ' LEU . 3.9 m-30 -96.34 127.81 42.68 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.707 -1.467 . . . . 0.0 110.47 -179.085 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.555 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 94.3 t -135.59 150.41 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.111 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.542 ' CE1' HG12 ' A' ' 9' ' ' ILE . 86.8 m-85 -108.46 122.97 48.14 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.858 -1.151 . . . . 0.0 110.227 -179.248 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 87.9 t -121.98 127.8 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.322 -0.861 . . . . 0.0 109.873 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.587 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 7.6 tt0 -89.68 121.76 32.16 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.282 -0.886 . . . . 0.0 109.278 179.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . . . . . . . . . 14.8 ptt? -154.04 174.08 15.17 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.03 -1.044 . . . . 0.0 110.538 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.662 HG12 HD22 ' A' ' 36' ' ' LEU . 39.0 pt -100.35 134.99 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.755 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.551 ' O ' ' HB3' ' A' ' 67' ' ' ASN . 84.9 mtp -79.55 142.87 35.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.096 -1.003 . . . . 0.0 110.799 -178.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.551 ' HB3' ' O ' ' A' ' 66' ' ' MET . 16.4 p30 171.67 -174.31 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -76.51 -42.89 41.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.147 -0.971 . . . . 0.0 110.006 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.621 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 85.1 tt0 -66.54 -31.42 72.13 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.216 -0.927 . . . . 0.0 110.383 -179.299 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.052 ' HB2' HD21 ' A' ' 36' ' ' LEU . . . -77.11 -40.78 44.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.848 -1.157 . . . . 0.0 109.791 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.468 ' CD1' ' OE1' ' A' ' 89' ' ' GLN . 87.3 t80 -58.79 -51.41 70.1 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.11 -0.994 . . . . 0.0 109.586 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.471 ' O ' ' HB3' ' A' ' 76' ' ' SER . 38.1 t-20 -69.89 -27.27 64.67 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.201 -0.937 . . . . 0.0 110.581 -179.196 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.621 ' CD1' ' O ' ' A' ' 69' ' ' GLU . 5.1 m-85 -78.19 -41.21 35.26 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.693 -1.254 . . . . 0.0 110.073 -179.447 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.848 HG22 ' CZ ' ' A' ' 83' ' ' PHE . 7.7 p -66.48 -52.11 50.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.22 -0.925 . . . . 0.0 109.232 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.662 ' N ' HG13 ' A' ' 74' ' ' VAL . 7.5 mmm-85 -67.59 -1.22 4.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.313 -0.867 . . . . 0.0 109.904 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 89.3 p -101.0 -4.94 26.53 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.031 -1.043 . . . . 0.0 110.167 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.873 ' O ' HG12 ' A' ' 80' ' ' VAL . 5.6 p -80.13 137.9 52.95 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 120.994 -1.066 . . . . 0.0 109.377 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.624 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 43.5 Cg_endo -65.77 140.53 61.97 Favored 'Trans proline' 0 C--O 1.213 -0.737 0 C-N-CA 122.763 2.308 . . . . 0.0 112.119 -179.367 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.852 ' CB ' HG22 ' A' ' 20' ' ' VAL . 42.0 m-85 89.0 -11.89 0.41 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.831 -0.543 . . . . 0.0 109.675 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.873 HG12 ' O ' ' A' ' 77' ' ' VAL . 7.9 p -81.84 119.03 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.957 -1.089 . . . . 0.0 109.299 179.772 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.8 mmm -88.44 -27.16 21.71 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.196 -0.94 . . . . 0.0 109.41 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.588 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.27 -158.03 28.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.848 ' CZ ' HG22 ' A' ' 74' ' ' VAL . 7.4 m-85 -139.61 156.95 46.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -1.124 . . . . 0.0 109.573 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 84' ' ' VAL . 7.7 p -88.74 118.69 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.232 -0.918 . . . . 0.0 109.339 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.596 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.8 OUTLIER -157.0 166.78 32.38 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -0.915 . . . . 0.0 109.627 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 m -87.06 -29.93 21.54 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.405 -0.809 . . . . 0.0 109.432 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.44 -103.18 1.4 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -99.5 -124.34 5.19 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.559 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -29.24 146.09 0.05 OUTLIER Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.524 -0.986 . . . . 0.0 110.142 -179.751 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.596 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.2 Cg_endo -68.66 153.92 72.41 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.827 2.352 . . . . 0.0 112.001 -179.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.2 m -89.9 149.75 42.43 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.301 -0.874 . . . . 0.0 109.253 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.533 ' HB3' ' HB3' ' A' ' 6' ' ' LYS . 49.5 Cg_endo -69.62 152.37 70.01 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.682 2.255 . . . . 0.0 111.664 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.864 HG23 ' O ' ' A' ' 7' ' ' TRP . 15.5 t -79.93 141.21 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -0.885 . . . . 0.0 109.322 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . 0.5 ' O ' ' N ' ' A' ' 97' ' ' GLU . 69.6 tttt -78.9 130.14 35.3 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.086 -1.009 . . . . 0.0 109.357 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.442 ' C ' ' O ' ' A' ' 94' ' ' LYS . 81.3 m-20 -42.78 -41.96 3.4 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -0.944 . . . . 0.0 109.367 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.462 ' CD ' ' HE2' ' A' ' 94' ' ' LYS . 75.1 mtt180 -56.36 -29.91 62.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.271 -0.893 . . . . 0.0 109.433 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.5 ' N ' ' O ' ' A' ' 94' ' ' LYS . 47.5 mt-10 -88.07 -28.26 21.44 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.221 -0.924 . . . . 0.0 109.589 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.599 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 94.6 mtp -82.91 -25.51 32.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.148 -0.97 . . . . 0.0 109.431 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.567 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.14 -54.62 1.08 Allowed Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.524 -0.735 . . . . 0.0 109.995 -179.845 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.614 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 49.4 Cg_endo -70.17 -27.75 24.14 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.591 2.194 . . . . 0.0 112.132 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.525 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 18.9 mm -80.21 -42.74 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.156 -0.965 . . . . 0.0 109.546 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.557 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -67.36 -40.63 85.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.207 -0.933 . . . . 0.0 109.494 -179.884 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.54 ' CG ' ' HB3' ' A' ' 135' ' ' PRO . 22.2 tpt180 -65.13 -49.73 68.78 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.326 -0.859 . . . . 0.0 109.162 179.722 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.4 tt -72.05 -37.86 69.61 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.208 -0.932 . . . . 0.0 109.2 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.52 -1.04 9.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.398 -0.814 . . . . 0.0 109.829 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.75 8.57 86.42 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 1.13 HD11 HG21 ' A' ' 41' ' ' VAL . 29.3 mt -78.38 -21.4 49.44 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.19 -1.182 . . . . 0.0 109.613 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 42.6 tp10 . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.15 -0.969 . . . . 0.0 109.365 -179.909 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.533 ' O ' ' CD1' ' A' ' 146' ' ' ILE . 18.0 m-85 . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.443 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 80.9 mttt -102.08 148.72 25.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.958 . . . . 0.0 109.915 -179.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 20.5 m -64.14 144.26 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.433 -0.792 . . . . 0.0 109.375 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.72 -29.92 4.38 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 -179.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.553 ' HB2' HD12 ' A' ' 143' ' ' ILE . 26.2 m-20 -48.01 165.71 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -1.114 . . . . 0.0 109.127 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . 0.481 ' HG3' HG12 ' A' ' 142' ' ' VAL . 2.9 ttm -103.54 127.8 50.88 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.136 -0.978 . . . . 0.0 109.153 179.775 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.674 HG11 HD11 ' A' ' 143' ' ' ILE . 26.8 m -129.06 145.88 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.855 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 140' ' ' ALA . 42.2 tttt -102.81 142.41 33.99 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.87 HD12 ' HB3' ' A' ' 139' ' ' PHE . 60.5 mt -83.14 154.34 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.488 HG12 ' HA ' ' A' ' 173' ' ' VAL . 0.2 OUTLIER -152.02 2.78 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 120.948 -1.095 . . . . 0.0 109.65 179.828 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.479 ' HB3' ' HG2' ' A' ' 172' ' ' GLU . 47.3 t -148.03 144.1 27.69 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.07 -1.019 . . . . 0.0 110.252 -179.66 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 99.62 -163.18 19.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.54 ' HB3' ' CG ' ' A' ' 103' ' ' ARG . 46.8 Cg_endo -67.89 -23.46 41.14 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 123.312 2.675 . . . . 0.0 112.541 -179.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.649 ' HB2' HD13 ' A' ' 131' ' ' ILE . 93.2 m-85 -104.22 17.61 23.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.957 -1.09 . . . . 0.0 109.562 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.553 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.9 tt0 -43.83 133.61 4.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.251 -0.906 . . . . 0.0 109.649 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.545 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 16.8 t0 78.92 19.26 0.82 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.262 -0.899 . . . . 0.0 110.36 179.161 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.87 ' HB3' HD12 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -109.24 130.4 55.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.912 -1.117 . . . . 0.0 109.47 179.825 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -83.7 136.9 34.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.16 -0.963 . . . . 0.0 109.597 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -146.55 175.6 25.89 Favored Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.67 -1.252 . . . . 0.0 110.612 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.828 ' C ' HG13 ' A' ' 155' ' ' VAL . 19.4 m -118.42 137.01 53.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.702 -0.881 . . . . 0.0 109.659 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.674 HD11 HG11 ' A' ' 129' ' ' VAL . 93.3 mt -67.48 114.6 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.321 -0.862 . . . . 0.0 109.407 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -98.15 -34.51 10.72 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.976 -1.077 . . . . 0.0 109.331 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -150.8 145.58 25.81 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.153 -0.967 . . . . 0.0 109.367 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.686 HG23 ' CD1' ' A' ' 153' ' ' LEU . 2.2 mt -122.74 126.28 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.678 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -107.41 101.68 40.32 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.314 -0.867 . . . . 0.0 109.447 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.528 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.1 Cg_endo -71.96 170.92 17.73 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.734 2.29 . . . . 0.0 111.899 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.7 tt0 79.85 -20.92 0.36 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.336 -0.852 . . . . 0.0 109.862 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.412 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 66.6 mtp85 -125.35 -13.18 6.7 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.155 -0.965 . . . . 0.0 109.43 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.412 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 36.2 mt-30 68.98 49.08 0.67 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.204 -0.935 . . . . 0.0 109.678 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -121.1 145.25 48.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.111 -0.993 . . . . 0.0 108.896 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.686 ' CD1' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -135.82 113.13 10.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.035 -1.041 . . . . 0.0 110.262 -179.498 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 10.4 mttt -79.59 133.25 36.43 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.102 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.828 HG13 ' C ' ' A' ' 142' ' ' VAL . 21.5 t -126.34 150.49 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.077 -1.014 . . . . 0.0 110.01 -179.27 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.51 ' OD1' ' N ' ' A' ' 164' ' ' THR . 20.9 t-20 -97.26 114.5 26.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.446 -0.784 . . . . 0.0 109.293 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.709 HG12 HG23 ' A' ' 159' ' ' ILE . 50.0 t -95.98 139.77 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.712 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 20.6 m -92.55 95.24 9.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.409 -0.807 . . . . 0.0 109.514 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.968 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 5.5 pt -130.9 150.2 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.269 -0.895 . . . . 0.0 109.488 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.601 ' CE2' HD12 ' A' ' 159' ' ' ILE . 13.7 m-30 62.95 33.13 15.18 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.271 -0.893 . . . . 0.0 109.313 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 60.64 16.35 44.64 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 60.0 mtt-85 -135.63 159.27 42.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.188 -1.183 . . . . 0.0 109.455 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . 0.449 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 95.6 mt-10 -100.46 140.85 34.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.244 -0.91 . . . . 0.0 109.516 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . 0.51 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 16.4 m -148.0 127.86 6.59 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.325 -0.859 . . . . 0.0 109.46 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.5 Cg_endo -69.86 140.0 41.23 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.751 2.301 . . . . 0.0 111.583 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 1.024 HG23 HD21 ' A' ' 168' ' ' LEU . 35.2 m -121.28 168.19 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.056 -1.028 . . . . 0.0 109.598 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 1.136 ' O ' HD13 ' A' ' 168' ' ' LEU . 8.4 m -118.2 115.66 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.442 -0.786 . . . . 0.0 109.492 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 1.136 HD13 ' O ' ' A' ' 167' ' ' VAL . 0.0 OUTLIER -139.56 166.28 25.0 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-O 121.797 0.808 . . . . 0.0 109.937 179.959 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.452 ' O ' ' HB2' ' A' ' 172' ' ' GLU . 40.5 m80 -79.04 139.72 38.09 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.175 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 171' ' ' SER . 11.4 p -51.43 -37.91 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.067 -1.021 . . . . 0.0 108.521 179.598 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.484 ' N ' HG13 ' A' ' 170' ' ' VAL . 53.3 p -74.86 -4.83 40.16 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.615 -0.678 . . . . 0.0 109.798 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.479 ' HG2' ' HB3' ' A' ' 133' ' ' SER . 23.8 mt-10 -92.7 -6.44 49.19 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.077 -1.014 . . . . 0.0 109.874 -179.712 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . 0.488 ' HA ' HG12 ' A' ' 132' ' ' ILE . 4.1 m -137.29 175.15 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.057 -1.027 . . . . 0.0 109.488 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.543 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 84.4 tt0 -140.02 164.53 29.77 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.132 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.543 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.8 tttt . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.055 -1.028 . . . . 0.0 109.347 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.514 ' HG2' HG22 ' A' ' 65' ' ' ILE . 72.1 mttt . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.318 0.58 . . . . 0.0 109.496 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.591 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.0 mtpp -130.56 174.72 9.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.282 -0.886 . . . . 0.0 109.28 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.903 ' O ' HG23 ' A' ' 93' ' ' VAL . 61.9 m95 -108.84 124.43 50.61 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.232 -0.917 . . . . 0.0 109.031 179.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.487 ' O ' ' HA ' ' A' ' 61' ' ' PHE . 79.5 m-85 -110.92 174.07 6.03 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.163 -0.961 . . . . 0.0 109.569 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.535 HG12 ' CD1' ' A' ' 61' ' ' PHE . 61.7 mt -116.76 109.05 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.316 -0.865 . . . . 0.0 109.141 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.716 ' CG2' HG23 ' A' ' 80' ' ' VAL . 9.7 p -90.88 142.98 12.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.178 -0.951 . . . . 0.0 109.65 -179.682 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.55 HD22 ' N ' ' A' ' 11' ' ' LEU . 3.5 mm? -89.5 153.86 20.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.353 -0.842 . . . . 0.0 109.615 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.499 HG21 ' HG2' ' A' ' 17' ' ' GLU . 9.2 t -162.84 -172.87 3.24 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.906 . . . . 0.0 109.349 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.519 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 67.5 mtm -103.54 133.45 48.56 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.227 -0.92 . . . . 0.0 109.658 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.4 m -54.43 127.4 27.36 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.884 . . . . 0.0 109.383 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.23 -20.18 38.43 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.519 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 85.6 m-85 -107.51 -1.56 21.24 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.34 -1.094 . . . . 0.0 109.429 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.499 ' HG2' HG21 ' A' ' 12' ' ' THR . 46.3 mt-10 -55.21 -59.4 4.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.233 -0.917 . . . . 0.0 109.388 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -47.48 -36.38 10.1 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.345 -0.847 . . . . 0.0 109.402 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 12.9 mttp -72.44 -46.46 54.89 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.388 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.527 HG22 ' HB2' ' A' ' 79' ' ' TYR . 73.4 t -55.09 -47.17 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.281 -0.887 . . . . 0.0 109.307 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.871 ' HD2' HD11 ' A' ' 42' ' ' ILE . 17.8 tttm -56.23 -50.92 69.92 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.413 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -63.25 -37.39 87.05 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.189 -0.944 . . . . 0.0 109.522 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.583 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 31.5 m120 -61.89 -49.04 77.82 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.203 -0.935 . . . . 0.0 109.565 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.465 ' O ' HG13 ' A' ' 28' ' ' VAL . 81.2 mt -53.93 -44.22 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.08 -1.013 . . . . 0.0 109.354 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.636 ' O ' HG22 ' A' ' 28' ' ' VAL . 83.1 tt0 -56.56 -47.95 78.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.188 -0.945 . . . . 0.0 110.035 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 40.4 mttp -73.41 -36.95 66.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.145 -0.972 . . . . 0.0 109.939 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.482 ' HD3' HG23 ' A' ' 77' ' ' VAL . 23.7 ttpp -56.31 -34.12 66.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.122 -0.986 . . . . 0.0 109.325 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 1.079 HG11 HG11 ' A' ' 37' ' ' VAL . 12.0 m -87.34 -25.55 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.42 -0.8 . . . . 0.0 109.489 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -72.01 -57.75 4.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.303 -0.873 . . . . 0.0 109.298 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.85 -40.79 61.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.397 -0.814 . . . . 0.0 109.243 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.698 HG21 ' CZ ' ' A' ' 73' ' ' PHE . 72.7 p -83.07 -26.15 31.38 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.325 -0.859 . . . . 0.0 109.483 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 77.51 25.02 64.02 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.628 HD12 ' CE2' ' A' ' 73' ' ' PHE . 15.9 mt -94.07 92.9 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -1.15 . . . . 0.0 109.359 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.8 mttt -105.71 -12.95 15.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.349 -0.845 . . . . 0.0 109.505 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -86.25 -19.6 29.71 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.182 -0.949 . . . . 0.0 109.428 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.1 HD11 ' CB ' ' A' ' 70' ' ' ALA . 15.1 tp -89.36 -51.58 5.49 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.307 -0.87 . . . . 0.0 109.461 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 1.079 HG11 HG11 ' A' ' 28' ' ' VAL . 7.3 p -93.83 136.58 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.52 -0.737 . . . . 0.0 109.018 179.672 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.5 -120.9 4.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.4 mtt85 -104.44 140.04 38.51 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.286 -1.126 . . . . 0.0 109.878 -179.399 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.547 HG22 ' HB ' ' A' ' 62' ' ' VAL . 12.9 pt -112.74 148.26 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.354 -0.841 . . . . 0.0 109.021 179.407 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.829 HG13 ' CH2' ' A' ' 7' ' ' TRP . 23.2 m -132.22 161.77 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.076 -1.015 . . . . 0.0 109.91 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.871 HD11 ' HD2' ' A' ' 21' ' ' LYS . 3.8 mt -135.28 130.84 19.36 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.379 -0.826 . . . . 0.0 109.333 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.492 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 43.0 Cg_endo -65.12 -3.59 7.53 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.851 2.368 . . . . 0.0 111.873 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.819 HG13 HG22 ' A' ' 42' ' ' ILE . 15.3 mt . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.146 -0.971 . . . . 0.0 109.446 179.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.656 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 7.2 mttp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.492 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 41.2 mt -68.06 -20.78 65.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.061 -1.025 . . . . 0.0 109.3 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.762 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 90.0 m-85 -143.66 98.2 5.37 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.304 -0.873 . . . . 0.0 109.044 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.3 Cg_endo -65.52 132.88 32.5 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.784 2.322 . . . . 0.0 112.216 -179.3 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.496 ' HA2' HG23 ' A' ' 12' ' ' THR . . . 77.02 -15.41 6.47 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.571 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 2.9 m-85 -97.83 129.59 44.8 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.624 -1.515 . . . . 0.0 110.38 -179.159 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.533 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 79.2 t -137.19 149.19 25.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.41 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.57 ' HB2' ' CG2' ' A' ' 41' ' ' VAL . 63.5 m-85 -109.67 124.39 51.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.025 -1.047 . . . . 0.0 110.23 -179.416 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.547 ' HB ' HG22 ' A' ' 40' ' ' ILE . 1.3 m -123.44 135.43 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.452 -0.78 . . . . 0.0 109.604 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.619 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 19.5 tt0 -104.87 122.91 46.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.222 -0.923 . . . . 0.0 109.402 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.544 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 22.3 mtm -157.96 179.47 9.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.085 -1.009 . . . . 0.0 110.344 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 1.046 ' CG1' HD12 ' A' ' 36' ' ' LEU . 8.4 pt -94.72 129.01 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.454 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 37.0 ttm -77.83 146.22 35.85 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.255 -0.903 . . . . 0.0 110.131 -178.581 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.454 ' HB2' ' O ' ' A' ' 66' ' ' MET . 20.8 t-20 176.58 177.72 0.25 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.596 -0.69 . . . . 0.0 109.258 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -73.38 -42.5 62.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.159 -0.963 . . . . 0.0 109.284 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -76.48 -28.18 56.37 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.23 -0.919 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.1 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -74.55 -48.15 28.53 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.262 -0.899 . . . . 0.0 109.569 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.568 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 84.0 t80 -60.52 -45.66 93.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.227 -0.921 . . . . 0.0 109.57 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -67.4 -27.3 66.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.986 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.698 ' CZ ' HG21 ' A' ' 31' ' ' THR . 10.6 t80 -81.18 -41.59 22.12 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.078 -1.014 . . . . 0.0 109.897 -179.711 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.683 HG13 ' N ' ' A' ' 75' ' ' ARG . 14.6 p -69.57 -53.77 22.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.426 -0.796 . . . . 0.0 109.585 -179.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.683 ' N ' HG13 ' A' ' 74' ' ' VAL . 14.4 tpt85 -61.15 -11.15 7.89 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.128 -0.983 . . . . 0.0 109.825 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 91.4 p -92.77 4.5 53.67 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.169 -0.957 . . . . 0.0 109.963 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.917 ' O ' HG12 ' A' ' 80' ' ' VAL . 5.2 p -76.82 135.17 67.92 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.037 -1.039 . . . . 0.0 109.344 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.622 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 42.8 Cg_endo -65.18 140.66 65.92 Favored 'Trans proline' 0 C--O 1.214 -0.72 0 C-N-CA 122.672 2.248 . . . . 0.0 112.109 -179.532 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.622 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 38.5 m-85 89.55 -9.48 0.4 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.918 -0.489 . . . . 0.0 109.744 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.917 HG12 ' O ' ' A' ' 77' ' ' VAL . 7.8 p -88.2 125.01 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.049 -1.032 . . . . 0.0 109.496 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 95.9 mmm -85.09 -26.42 26.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.108 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.531 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.23 -157.52 28.15 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.634 ' CE1' HG23 ' A' ' 10' ' ' VAL . 14.5 m-85 -132.79 149.28 52.29 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -1.138 . . . . 0.0 109.459 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.675 HG13 ' O ' ' A' ' 84' ' ' VAL . 10.9 p -74.33 115.75 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.427 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.528 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.1 p -152.83 166.58 31.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.263 -0.898 . . . . 0.0 109.403 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.2 t -96.01 -29.96 13.84 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.282 -0.886 . . . . 0.0 109.393 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -130.59 -80.24 0.22 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.533 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -110.18 -136.25 7.3 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.568 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -31.81 150.37 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.526 -0.985 . . . . 0.0 110.245 -179.619 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.528 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.5 Cg_endo -69.36 159.05 55.19 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.967 2.445 . . . . 0.0 111.884 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 28.5 m -88.9 151.69 47.61 Favored Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.207 -0.933 . . . . 0.0 109.279 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.541 ' CB ' ' HE2' ' A' ' 6' ' ' LYS . 50.6 Cg_endo -70.45 145.75 54.01 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.686 2.258 . . . . 0.0 111.789 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.903 HG23 ' O ' ' A' ' 7' ' ' TRP . 3.6 t -79.74 129.71 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.182 -0.949 . . . . 0.0 109.169 179.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . 0.442 ' O ' ' C ' ' A' ' 95' ' ' ASP . 32.4 mttp -73.92 134.0 43.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.441 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.442 ' C ' ' O ' ' A' ' 94' ' ' LYS . 69.2 m-20 -42.63 -41.65 3.16 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -0.883 . . . . 0.0 109.463 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 56.6 ttt180 -54.6 -28.64 47.87 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.235 -0.915 . . . . 0.0 109.362 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.44 ' N ' ' O ' ' A' ' 94' ' ' LYS . 23.2 mm-40 -89.38 -28.39 19.81 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.558 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.558 ' CB ' HD11 ' A' ' 102' ' ' LEU . 33.6 mmm -84.14 -28.55 27.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.254 -0.904 . . . . 0.0 109.427 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.593 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.88 -53.89 1.42 Allowed Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.465 -0.772 . . . . 0.0 109.903 -179.913 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -69.65 -28.2 26.05 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.496 2.13 . . . . 0.0 111.707 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.484 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 29.2 mm -80.69 -42.63 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.262 -0.898 . . . . 0.0 109.317 179.667 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.696 HD23 ' CD2' ' A' ' 107' ' ' LEU . 0.9 OUTLIER -67.73 -40.13 84.23 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.311 -0.868 . . . . 0.0 109.214 179.76 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -63.77 -50.72 67.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.337 -0.852 . . . . 0.0 109.096 179.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.82 -36.46 70.23 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.387 -0.821 . . . . 0.0 109.366 179.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.56 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -70.29 -0.41 8.0 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.277 -0.889 . . . . 0.0 109.995 -179.838 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 77.38 8.75 87.07 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.696 ' CD2' HD23 ' A' ' 102' ' ' LEU . 9.9 mp -74.94 -19.17 60.23 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -1.177 . . . . 0.0 109.509 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.937 . . . . 0.0 109.544 -179.934 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.614 ' CE2' ' HB3' ' A' ' 175' ' ' LYS . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.435 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 40.0 mttm -97.22 156.34 16.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.95 -1.094 . . . . 0.0 109.531 -179.652 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 11.0 p -58.39 138.6 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.469 -0.77 . . . . 0.0 109.938 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.99 -31.89 4.84 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.561 ' HB3' ' CD2' ' A' ' 123' ' ' PHE . 45.3 m-20 -48.92 160.33 0.2 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.3 -1.118 . . . . 0.0 109.552 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 2.3 ttp -97.25 127.29 43.08 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.33 -0.857 . . . . 0.0 109.026 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.587 HG13 HG12 ' A' ' 143' ' ' ILE . 33.9 m -128.84 146.25 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.115 -0.99 . . . . 0.0 109.834 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 140' ' ' ALA . 28.4 tttt -110.29 140.28 44.62 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.592 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 1.007 ' O ' HD13 ' A' ' 132' ' ' ILE . 74.6 mt -79.61 157.76 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.049 -1.032 . . . . 0.0 108.641 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 1.007 HD13 ' O ' ' A' ' 131' ' ' ILE . 0.6 OUTLIER -149.51 1.96 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.03 -1.043 . . . . 0.0 109.526 179.786 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.479 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 58.5 m -149.65 146.16 27.13 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.011 -1.055 . . . . 0.0 110.232 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.99 -167.05 16.78 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.346 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.08 -21.9 42.11 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 123.135 2.557 . . . . 0.0 112.524 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.561 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 97.2 m-85 -110.29 16.31 21.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.006 -1.059 . . . . 0.0 109.578 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.581 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.3 tt0 -43.29 143.94 0.78 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.235 -0.915 . . . . 0.0 109.641 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 26.9 m-20 72.73 28.12 2.14 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.459 -0.776 . . . . 0.0 110.234 179.406 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.994 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.3 t80 -117.82 128.77 55.18 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.115 -0.991 . . . . 0.0 109.444 179.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.489 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -76.53 131.54 39.03 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.157 -0.965 . . . . 0.0 109.746 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -139.53 165.77 25.72 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.649 ' C ' HG23 ' A' ' 155' ' ' VAL . 37.5 t -113.34 137.53 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -1.088 . . . . 0.0 109.063 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.869 HD12 ' CD2' ' A' ' 153' ' ' LEU . 14.7 mm -68.67 113.86 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.214 -0.929 . . . . 0.0 109.611 -179.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.91 -35.46 8.99 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.056 -1.027 . . . . 0.0 109.421 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.401 ' HG2' ' N ' ' A' ' 146' ' ' ILE . 81.9 tt0 -154.17 149.29 26.89 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.967 -1.083 . . . . 0.0 109.924 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.82 HG23 ' CD1' ' A' ' 153' ' ' LEU . 11.3 mt -126.16 128.46 71.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.418 -0.802 . . . . 0.0 109.332 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -110.4 101.73 49.31 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.533 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.586 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.47 172.81 13.5 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.621 2.214 . . . . 0.0 111.801 179.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.586 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.6 tt0 82.4 -20.48 0.35 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.405 -0.809 . . . . 0.0 109.795 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.481 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 96.6 mtt180 -129.99 -11.54 4.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.129 -0.982 . . . . 0.0 109.684 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.481 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 19.8 mt-30 70.12 48.53 0.52 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.222 -0.924 . . . . 0.0 109.438 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.706 ' OE2' HG23 ' A' ' 167' ' ' VAL . 53.9 tt0 -121.35 144.24 48.76 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.156 -0.965 . . . . 0.0 109.319 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.869 ' CD2' HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -138.1 112.47 8.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.235 -0.916 . . . . 0.0 109.884 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.493 ' NZ ' ' OE2' ' A' ' 152' ' ' GLU . 10.2 mttm -78.54 131.73 36.9 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.309 -0.869 . . . . 0.0 108.677 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.839 HG12 HD21 ' A' ' 168' ' ' LEU . 9.2 p -123.2 151.98 27.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.235 -0.915 . . . . 0.0 109.517 -179.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.476 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 17.9 t-20 -98.18 112.3 24.32 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.357 -0.839 . . . . 0.0 109.648 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.668 HG22 ' O ' ' A' ' 164' ' ' THR . 3.2 m -93.15 139.88 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.254 -0.904 . . . . 0.0 109.291 179.701 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 53.1 m -98.46 88.65 4.18 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.08 -1.013 . . . . 0.0 109.701 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.762 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 2.0 mt -114.24 145.55 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.276 -0.89 . . . . 0.0 109.309 179.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.431 ' HD2' ' CE1' ' A' ' 56' ' ' PHE . 9.9 m-85 62.23 38.31 13.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.418 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.64 18.06 29.59 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 42.4 mtt-85 -130.1 156.49 44.45 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.171 -1.194 . . . . 0.0 109.553 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -96.68 130.09 43.97 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.364 -0.835 . . . . 0.0 109.55 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . 0.668 ' O ' HG22 ' A' ' 157' ' ' VAL . 97.8 m -137.07 120.1 11.7 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.937 . . . . 0.0 109.76 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -71.1 137.28 31.26 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.712 2.275 . . . . 0.0 111.549 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.822 HG13 ' CD2' ' A' ' 168' ' ' LEU . 2.6 p -128.41 147.24 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.168 -0.958 . . . . 0.0 109.878 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.706 HG23 ' OE2' ' A' ' 152' ' ' GLU . 2.4 p -93.12 120.15 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.419 -0.801 . . . . 0.0 109.457 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.898 ' CD1' HG11 ' A' ' 173' ' ' VAL . 0.1 OUTLIER -141.84 167.14 22.86 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.322 -0.861 . . . . 0.0 110.585 -179.25 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.511 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 40.4 m170 -79.82 142.22 35.49 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.407 HG12 ' O ' ' A' ' 151' ' ' GLN . 3.4 p -58.72 -36.82 62.39 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 O-C-N 121.256 -0.902 . . . . 0.0 109.048 179.71 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 19.8 m -75.34 -7.61 54.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.42 -0.8 . . . . 0.0 109.415 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.511 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 65.5 mt-10 -90.33 5.39 47.52 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.33 -0.856 . . . . 0.0 109.307 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . 0.898 HG11 ' CD1' ' A' ' 168' ' ' LEU . 18.1 m -146.6 173.06 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.344 -0.848 . . . . 0.0 109.582 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.514 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 78.1 tt0 -142.08 168.56 19.45 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.3 -0.875 . . . . 0.0 109.132 179.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.614 ' HB3' ' CE2' ' A' ' 123' ' ' PHE . 42.0 mttt . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.766 -179.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.49 ' HG2' ' CG2' ' A' ' 65' ' ' ILE . 19.4 mttt . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 121.324 0.583 . . . . 0.0 109.491 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.552 ' CE ' ' HB3' ' A' ' 92' ' ' PRO . 28.0 mtpp -128.32 175.19 8.67 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.249 -0.907 . . . . 0.0 109.065 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.958 ' CH2' HG23 ' A' ' 41' ' ' VAL . 63.7 m95 -112.91 124.19 52.05 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.19 -0.943 . . . . 0.0 109.149 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 67.3 m-85 -117.06 168.43 10.27 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.348 -0.845 . . . . 0.0 109.346 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.735 HD11 ' CE1' ' A' ' 160' ' ' PHE . 75.1 mt -110.5 109.72 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.193 -0.942 . . . . 0.0 109.017 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.544 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 12.8 p -86.35 143.96 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.21 -0.931 . . . . 0.0 109.547 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.538 HD11 ' HE1' ' A' ' 59' ' ' TYR . 0.5 OUTLIER -90.28 143.09 27.08 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.441 -0.787 . . . . 0.0 109.395 -179.932 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.454 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 2.4 p -154.19 174.92 14.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.405 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.447 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 93.4 mtp -91.89 120.32 32.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.23 -0.919 . . . . 0.0 109.329 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 13' ' ' MET . 52.0 p -41.68 126.97 3.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.365 -0.835 . . . . 0.0 109.504 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.63 -19.98 35.22 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.447 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.0 m-85 -107.4 -13.9 14.99 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.266 -1.137 . . . . 0.0 109.632 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.453 ' HG2' ' CG2' ' A' ' 60' ' ' VAL . 95.1 mt-10 -43.08 -60.42 1.65 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.245 -0.909 . . . . 0.0 109.603 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 73.9 mm-40 -48.17 -34.35 9.87 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.13 -0.981 . . . . 0.0 109.523 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.468 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 56.9 mttp -76.32 -46.74 26.27 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.27 -0.894 . . . . 0.0 109.346 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.583 HG13 HG23 ' A' ' 80' ' ' VAL . 24.9 t -54.92 -47.58 75.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.308 -0.87 . . . . 0.0 109.472 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.539 ' HG3' HG21 ' A' ' 40' ' ' ILE . 79.0 tttt -59.42 -47.78 84.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.427 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -64.28 -34.89 79.16 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.303 -0.873 . . . . 0.0 109.448 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.581 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 32.6 m120 -66.53 -47.47 72.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.367 -0.833 . . . . 0.0 109.745 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.556 HG12 HG21 ' A' ' 77' ' ' VAL . 76.5 mt -55.71 -43.86 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.187 -0.946 . . . . 0.0 109.745 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -58.15 -44.8 88.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.156 -0.965 . . . . 0.0 109.901 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.3 mttt -74.92 -36.87 62.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.13 -0.981 . . . . 0.0 109.686 -179.788 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.707 ' HD2' HG23 ' A' ' 77' ' ' VAL . 17.6 tttt -59.28 -30.62 68.44 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -0.929 . . . . 0.0 109.393 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.674 HG13 ' O ' ' A' ' 33' ' ' ILE . 93.9 t -79.21 -30.15 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.195 -0.941 . . . . 0.0 109.413 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -65.82 -48.16 72.61 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.23 -0.919 . . . . 0.0 109.563 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.97 -34.63 75.07 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 109.859 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.636 HG23 ' H ' ' A' ' 33' ' ' ILE . 9.6 t -92.56 -21.73 19.92 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 68.27 33.1 77.15 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.686 ' CG2' HD23 ' A' ' 36' ' ' LEU . 47.9 mm -100.43 91.49 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.245 -1.15 . . . . 0.0 109.598 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -98.54 2.91 47.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.318 -0.864 . . . . 0.0 109.5 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.693 ' C ' HD22 ' A' ' 36' ' ' LEU . 89.8 m-20 -105.39 9.97 33.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.22 -0.925 . . . . 0.0 109.477 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.986 HD12 ' HB2' ' A' ' 70' ' ' ALA . 4.1 mm? -114.24 -46.69 2.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.936 . . . . 0.0 109.473 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 58.7 t -105.34 134.24 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.247 -0.908 . . . . 0.0 109.41 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -98.93 -131.27 7.22 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 46.3 mtt85 -91.93 142.02 28.01 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.265 -1.138 . . . . 0.0 109.522 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.91 HG23 HG12 ' A' ' 62' ' ' VAL . 53.6 mt -98.66 133.88 39.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.267 -0.896 . . . . 0.0 109.305 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 1.05 ' CG2' HD11 ' A' ' 107' ' ' LEU . 40.1 t -115.97 155.38 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.253 -0.904 . . . . 0.0 109.495 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.809 HG22 ' H ' ' A' ' 44' ' ' ILE . 18.2 mt -133.01 126.84 19.85 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.22 -0.925 . . . . 0.0 109.525 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.884 ' O ' HD12 ' A' ' 55' ' ' LEU . 46.9 Cg_endo -68.18 -4.75 13.27 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.725 2.284 . . . . 0.0 111.722 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.809 ' H ' HG22 ' A' ' 42' ' ' ILE . 20.7 mt . . . . . 0 N--CA 1.489 1.52 0 O-C-N 121.209 -0.932 . . . . 0.0 109.459 179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.654 ' HG2' HD13 ' A' ' 44' ' ' ILE . 37.5 mttp . . . . . 0 N--CA 1.491 1.617 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.884 HD12 ' O ' ' A' ' 43' ' ' PRO . 8.6 mt -61.31 -23.37 65.66 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.117 -0.99 . . . . 0.0 109.563 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.553 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 42.6 m-85 -151.06 100.18 3.05 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.167 -0.958 . . . . 0.0 109.069 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.7 Cg_endo -66.17 141.91 65.16 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.672 2.248 . . . . 0.0 111.906 -179.639 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.402 ' N ' ' OE2' ' A' ' 17' ' ' GLU . . . 75.26 -12.26 7.43 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.538 ' HE1' HD11 ' A' ' 11' ' ' LEU . 3.5 m-30 -103.38 130.9 50.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.789 -1.418 . . . . 0.0 109.942 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.544 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 3.0 t -132.49 146.24 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.694 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 14.9 m-85 -107.04 122.9 47.37 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.892 -1.13 . . . . 0.0 109.952 -179.391 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.91 HG12 HG23 ' A' ' 40' ' ' ILE . 30.0 m -129.77 139.94 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.43 -0.794 . . . . 0.0 109.48 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.505 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 48.3 tt0 -88.63 124.47 34.1 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.235 -0.916 . . . . 0.0 108.676 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.669 ' SD ' HG21 ' A' ' 74' ' ' VAL . 3.9 mtm -147.0 160.68 42.07 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.013 -1.054 . . . . 0.0 110.784 -178.78 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.525 HD11 HD13 ' A' ' 36' ' ' LEU . 26.9 pt -104.28 139.67 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . . . . . . . . . 38.3 mtp -74.33 136.45 42.55 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.971 -1.081 . . . . 0.0 110.16 -178.432 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -178.47 155.3 0.85 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -61.78 -42.46 99.02 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.183 -0.948 . . . . 0.0 109.807 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 54.6 mt-10 -75.76 -25.23 56.29 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.852 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.986 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -78.05 -47.19 18.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.122 -0.987 . . . . 0.0 109.578 -179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.575 ' CE1' ' OE1' ' A' ' 89' ' ' GLN . 65.1 t80 -61.93 -45.35 94.09 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.289 -0.882 . . . . 0.0 109.926 -179.674 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 48.2 t-20 -70.25 -29.3 66.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.096 -1.002 . . . . 0.0 110.381 -179.348 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.52 ' O ' ' NZ ' ' A' ' 27' ' ' LYS . 83.8 t80 -76.84 -39.51 50.96 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.966 -1.084 . . . . 0.0 109.55 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.669 HG21 ' SD ' ' A' ' 64' ' ' MET . 2.4 p -75.48 -48.66 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.352 -0.843 . . . . 0.0 109.516 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.593 ' N ' ' CG1' ' A' ' 74' ' ' VAL . 0.0 OUTLIER -58.64 -21.09 52.91 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.212 -0.93 . . . . 0.0 109.86 -179.689 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.6 m -95.9 5.53 51.03 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.116 -0.99 . . . . 0.0 109.837 -179.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.707 HG23 ' HD2' ' A' ' 27' ' ' LYS . 3.6 p -68.26 132.93 91.48 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.05 -1.031 . . . . 0.0 109.301 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.734 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 44.3 Cg_endo -65.87 136.07 43.75 Favored 'Trans proline' 0 C--O 1.213 -0.763 0 C-N-CA 122.821 2.347 . . . . 0.0 112.369 -179.294 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.734 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 76.3 m-85 91.17 -6.89 0.26 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.95 -0.469 . . . . 0.0 109.844 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.687 HG21 HG11 ' A' ' 77' ' ' VAL . 3.1 t -98.0 135.93 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.928 -1.107 . . . . 0.0 109.309 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 88.9 mmm -96.6 -24.6 15.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.294 -0.879 . . . . 0.0 109.704 -179.772 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.55 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 159.89 -159.88 31.05 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.573 ' HZ ' HG22 ' A' ' 74' ' ' VAL . 9.4 m-85 -137.44 148.22 45.95 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.322 -1.105 . . . . 0.0 109.519 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.52 HG13 ' O ' ' A' ' 84' ' ' VAL . 9.2 p -72.58 128.12 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.232 -0.918 . . . . 0.0 109.387 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.545 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 5.0 p -160.66 166.09 29.45 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.55 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 m -91.27 -30.27 16.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.296 -0.877 . . . . 0.0 109.164 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -134.17 -83.47 0.2 Allowed Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.531 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -102.88 -137.7 9.65 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.575 ' OE1' ' CE1' ' A' ' 71' ' ' TYR . 0.3 OUTLIER -32.79 154.66 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.566 -0.961 . . . . 0.0 110.15 -179.53 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.545 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 46.6 Cg_endo -67.58 151.05 80.03 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.83 2.353 . . . . 0.0 111.946 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.3 m -83.26 151.68 63.28 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.552 ' HB3' ' CE ' ' A' ' 6' ' ' LYS . 51.2 Cg_endo -70.24 144.5 51.63 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.632 2.221 . . . . 0.0 111.796 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.565 HG12 ' HG3' ' A' ' 98' ' ' MET . 21.4 t -82.0 127.21 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.191 -0.943 . . . . 0.0 109.301 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -67.78 140.37 56.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.242 -0.911 . . . . 0.0 109.417 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -49.76 -40.83 42.39 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.47 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 39.2 ttm180 -57.4 -30.47 64.94 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.309 -0.87 . . . . 0.0 109.569 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 52.7 mt-10 -85.8 -27.79 24.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.156 -0.965 . . . . 0.0 109.493 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.591 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 93.2 mtp -82.33 -25.82 33.54 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.286 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.612 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 2.4 mtt180 -37.11 -52.65 2.14 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.434 -0.791 . . . . 0.0 109.935 -179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.612 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.1 Cg_endo -69.78 -28.79 24.7 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.499 2.133 . . . . 0.0 111.897 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.558 HG21 ' CD2' ' A' ' 61' ' ' PHE . 38.2 mm -81.47 -43.08 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.206 -0.934 . . . . 0.0 109.56 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.627 HD23 HD12 ' A' ' 107' ' ' LEU . 0.9 OUTLIER -66.76 -39.91 88.04 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 0.0 109.264 179.819 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 48.2 mtt-85 -64.06 -49.95 70.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.341 -0.849 . . . . 0.0 109.104 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.465 HD22 ' CD1' ' A' ' 55' ' ' LEU . 1.1 tt -72.09 -35.81 69.31 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.268 -0.895 . . . . 0.0 109.231 179.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.443 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.53 -2.01 12.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.352 -0.842 . . . . 0.0 109.897 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.83 10.43 84.98 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.706 -1.358 . . . . 0.0 109.706 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 1.05 HD11 ' CG2' ' A' ' 41' ' ' VAL . 18.5 mt -78.18 -21.51 50.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.212 -1.17 . . . . 0.0 109.542 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . 0.401 ' HG3' ' CB ' ' A' ' 102' ' ' LEU . 84.5 mt-10 . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.654 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 22.9 mttt -141.5 162.62 35.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.318 -0.864 . . . . 0.0 109.534 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 15.2 m -61.4 141.62 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.747 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 86.85 -33.81 3.68 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -47.96 158.74 0.21 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.351 -1.088 . . . . 0.0 109.198 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.3 ttm -100.94 128.5 46.95 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.084 -1.01 . . . . 0.0 108.752 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.652 HG13 HG12 ' A' ' 143' ' ' ILE . 16.0 m -129.22 144.8 37.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.337 -0.852 . . . . 0.0 109.878 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.471 ' O ' HG13 ' A' ' 173' ' ' VAL . 10.6 tttp -97.93 140.64 31.98 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.406 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.65 HG22 ' HA ' ' A' ' 137' ' ' GLU . 1.2 mp -80.72 153.55 4.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.353 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.532 ' CD1' ' HB2' ' A' ' 174' ' ' GLU . 0.9 OUTLIER -149.3 2.45 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 120.793 -1.192 . . . . 0.0 109.841 -179.791 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.547 ' CB ' ' HG3' ' A' ' 172' ' ' GLU . 61.1 m -149.25 145.35 27.05 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.004 -1.06 . . . . 0.0 110.212 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 103.46 -166.74 16.18 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.511 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 48.3 Cg_endo -68.41 -21.12 41.17 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.199 2.599 . . . . 0.0 112.53 -179.614 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.521 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 92.3 m-85 -108.35 18.72 20.7 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.907 -1.121 . . . . 0.0 109.377 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.65 ' HA ' HG22 ' A' ' 131' ' ' ILE . 3.7 tt0 -42.61 140.61 1.23 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.261 -0.899 . . . . 0.0 109.711 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 22.4 m-20 72.67 29.79 1.93 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.406 -0.809 . . . . 0.0 110.727 179.147 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.612 ' CE1' HG23 ' A' ' 157' ' ' VAL . 1.2 t80 -117.85 133.27 56.09 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.838 -1.164 . . . . 0.0 109.399 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.92 134.75 36.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.213 -0.93 . . . . 0.0 109.724 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.47 169.68 26.98 Favored Glycine 0 N--CA 1.491 2.306 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.329 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.796 ' C ' HG23 ' A' ' 155' ' ' VAL . 43.6 t -119.43 136.4 56.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.567 -0.96 . . . . 0.0 109.281 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.652 HG12 HG13 ' A' ' 129' ' ' VAL . 31.7 mm -68.82 119.58 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.63 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.479 ' HD2' ' OD1' ' A' ' 156' ' ' ASN . 63.9 tttt -99.81 -33.26 10.63 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.054 -1.029 . . . . 0.0 109.527 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -154.32 149.48 26.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.123 -0.986 . . . . 0.0 109.656 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 1.029 HG23 HD22 ' A' ' 153' ' ' LEU . 3.6 mt -123.9 126.55 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.321 -0.862 . . . . 0.0 109.575 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.22 102.39 46.25 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.239 -0.913 . . . . 0.0 109.589 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.0 Cg_endo -71.99 170.96 17.66 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.749 2.299 . . . . 0.0 111.866 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.3 mt-10 79.44 -21.23 0.34 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.395 -0.815 . . . . 0.0 110.057 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.446 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 75.6 mtt-85 -125.74 -14.99 6.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.063 -1.023 . . . . 0.0 109.478 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.446 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 50.8 mt-30 69.56 48.64 0.6 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.187 -0.946 . . . . 0.0 109.67 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.816 ' O ' HD23 ' A' ' 153' ' ' LEU . 82.5 tt0 -119.07 143.25 47.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.174 -0.954 . . . . 0.0 108.968 179.626 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 1.029 HD22 HG23 ' A' ' 146' ' ' ILE . 32.3 mt -128.77 127.55 42.22 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.1 -1.0 . . . . 0.0 110.291 -179.469 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -92.03 128.67 37.96 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.077 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.796 HG23 ' C ' ' A' ' 142' ' ' VAL . 12.9 p -131.39 147.93 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.084 -1.01 . . . . 0.0 109.834 -179.496 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.588 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.8 m120 -100.85 125.09 47.35 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.413 -0.804 . . . . 0.0 109.552 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.653 HG22 HG13 ' A' ' 159' ' ' ILE . 3.3 p -105.74 144.8 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.921 . . . . 0.0 109.476 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 55.7 m -97.33 92.48 6.0 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.895 . . . . 0.0 109.928 -179.664 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.653 HG13 HG22 ' A' ' 157' ' ' VAL . 7.4 mt -116.03 142.96 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.258 -0.901 . . . . 0.0 109.237 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.735 ' CE1' HD11 ' A' ' 9' ' ' ILE . 91.0 m-85 61.88 37.15 15.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.185 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.6 17.92 35.79 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 26.2 mtp180 -126.88 157.39 39.48 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.067 -1.254 . . . . 0.0 109.555 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -100.91 132.03 46.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.277 -0.889 . . . . 0.0 109.728 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.2 m -142.47 127.06 10.02 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.37 -0.831 . . . . 0.0 109.743 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.588 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.1 Cg_endo -70.91 136.67 30.48 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.748 2.299 . . . . 0.0 111.616 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.743 HG12 HG13 ' A' ' 155' ' ' VAL . 11.7 p -119.64 164.65 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.087 -1.008 . . . . 0.0 109.706 -179.817 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.533 ' O ' HD23 ' A' ' 168' ' ' LEU . 6.7 m -117.53 117.65 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.459 -0.776 . . . . 0.0 109.66 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.641 HD21 ' CG2' ' A' ' 166' ' ' VAL . 0.2 OUTLIER -142.24 167.33 22.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.241 -0.912 . . . . 0.0 110.207 -179.779 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.504 ' HB2' ' CD ' ' A' ' 172' ' ' GLU . 19.2 m170 -82.7 146.37 29.08 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.576 HG23 HD11 ' A' ' 153' ' ' LEU . 7.1 p -56.32 -32.73 36.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 121.422 -0.798 . . . . 0.0 109.314 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 73.5 p -76.86 -7.06 54.79 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.275 -0.891 . . . . 0.0 109.762 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.547 ' HG3' ' CB ' ' A' ' 133' ' ' SER . 0.8 OUTLIER -95.53 2.8 54.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.067 -1.021 . . . . 0.0 109.376 -179.991 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . 0.516 HG12 ' N ' ' A' ' 174' ' ' GLU . 43.5 t -139.78 164.84 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 109.281 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.539 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 54.8 tt0 -141.22 167.16 22.85 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.087 -1.008 . . . . 0.0 108.928 179.73 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.539 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 32.7 tttp . . . . . 0 N--CA 1.49 1.564 0 O-C-N 121.058 -1.027 . . . . 0.0 109.476 -179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.467 ' O ' ' HD3' ' A' ' 6' ' ' LYS . 27.5 mttt . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.331 0.586 . . . . 0.0 109.61 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 36.0 mmtm -132.07 169.26 16.62 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.355 -0.841 . . . . 0.0 109.339 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.954 ' CZ3' HG22 ' A' ' 41' ' ' VAL . 68.1 m95 -103.39 129.21 50.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.255 -0.903 . . . . 0.0 109.235 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -118.47 170.33 9.02 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.22 -0.925 . . . . 0.0 109.143 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.756 HD11 ' CE1' ' A' ' 160' ' ' PHE . 22.7 mt -103.85 112.78 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.122 -0.986 . . . . 0.0 109.268 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.489 HG23 HG22 ' A' ' 62' ' ' VAL . 73.5 t -86.18 142.31 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.228 -0.92 . . . . 0.0 109.343 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.532 HD21 HG22 ' A' ' 84' ' ' VAL . 0.6 OUTLIER -93.45 142.04 27.78 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.363 -0.836 . . . . 0.0 109.416 179.904 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.726 HG21 ' HG2' ' A' ' 17' ' ' GLU . 7.0 t -160.44 -173.33 3.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.431 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.426 ' O ' ' C ' ' A' ' 14' ' ' SER . 89.1 mtp -109.18 122.46 47.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.213 -0.93 . . . . 0.0 109.47 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.426 ' C ' ' O ' ' A' ' 13' ' ' MET . 2.2 m -44.3 133.87 5.26 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.259 -0.901 . . . . 0.0 109.443 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.0 -21.37 36.09 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -113.01 -7.99 13.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.25 -1.147 . . . . 0.0 109.355 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.862 ' OE1' HD11 ' A' ' 44' ' ' ILE . 57.3 mt-10 -48.12 -59.96 2.99 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.212 -0.93 . . . . 0.0 109.442 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -45.7 -34.57 3.64 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.187 -0.946 . . . . 0.0 109.37 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.46 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 25.1 mttt -73.68 -43.72 58.58 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.276 -0.89 . . . . 0.0 109.377 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.425 HG22 ' HB2' ' A' ' 79' ' ' TYR . 92.4 t -56.76 -50.0 76.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.317 -0.864 . . . . 0.0 109.535 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . 0.666 ' HD2' HD11 ' A' ' 42' ' ' ILE . 24.8 tttt -56.24 -46.95 79.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.911 . . . . 0.0 109.145 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 69.7 tt0 -65.27 -38.81 91.44 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.341 -0.849 . . . . 0.0 109.433 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.529 ' O ' ' CB ' ' A' ' 27' ' ' LYS . 32.6 m120 -62.29 -43.12 99.56 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.241 -0.912 . . . . 0.0 110.045 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.793 HD11 HG11 ' A' ' 77' ' ' VAL . 49.4 mm -64.69 -44.99 96.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.127 -0.983 . . . . 0.0 109.738 -179.537 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.566 ' O ' HG12 ' A' ' 28' ' ' VAL . 77.8 tt0 -58.7 -46.91 86.24 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.164 -0.96 . . . . 0.0 109.96 -179.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -82.27 -37.35 26.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.993 -1.067 . . . . 0.0 109.712 -179.724 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.529 ' CB ' ' O ' ' A' ' 23' ' ' ASN . 28.2 tttm -57.22 -30.36 64.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.283 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.697 HG21 HG12 ' A' ' 37' ' ' VAL . 12.3 p -85.43 -26.38 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.296 -0.878 . . . . 0.0 109.555 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 -67.31 -47.45 70.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.324 -0.86 . . . . 0.0 109.716 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.67 -31.24 66.13 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.176 -0.952 . . . . 0.0 109.548 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 58.8 p -90.06 -21.66 22.21 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.916 . . . . 0.0 109.575 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 78.03 -2.92 63.2 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.871 HG23 HD23 ' A' ' 36' ' ' LEU . 31.2 mm -72.71 71.33 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -1.123 . . . . 0.0 109.268 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 32.5 pttt -85.87 13.79 6.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.279 -0.888 . . . . 0.0 109.453 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.633 ' O ' HD13 ' A' ' 65' ' ' ILE . 29.7 m120 -110.37 -9.57 14.62 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.22 -0.925 . . . . 0.0 109.414 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 1.098 HD12 ' HB2' ' A' ' 70' ' ' ALA . 3.8 mm? -92.1 -51.5 5.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.309 -0.869 . . . . 0.0 109.297 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.697 HG12 HG21 ' A' ' 28' ' ' VAL . 13.7 p -92.03 141.89 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 108.956 179.672 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.96 -119.01 2.91 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 56.3 mtt180 -97.52 139.54 33.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.33 -1.1 . . . . 0.0 110.142 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 1.026 HG23 HG12 ' A' ' 62' ' ' VAL . 75.4 mt -111.55 134.34 54.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.427 -0.796 . . . . 0.0 109.088 179.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 1.03 HG23 ' HB2' ' A' ' 61' ' ' PHE . 29.8 m -123.8 148.77 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.005 -1.059 . . . . 0.0 109.311 179.803 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.666 HD11 ' HD2' ' A' ' 21' ' ' LYS . 1.8 mt -129.69 131.77 23.77 Favored Pre-proline 0 C--N 1.302 -1.486 0 O-C-N 121.346 -0.846 . . . . 0.0 109.703 -179.405 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.626 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 42.3 Cg_endo -64.61 -4.5 8.47 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.856 2.371 . . . . 0.0 111.285 179.7 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.868 HG23 ' HG2' ' A' ' 54' ' ' LYS . 39.5 mt . . . . . 0 N--CA 1.49 1.543 0 O-C-N 121.459 -0.776 . . . . 0.0 109.519 179.589 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.868 ' HG2' HG23 ' A' ' 44' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.626 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 14.3 tp -55.4 -47.69 75.5 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.007 -1.058 . . . . 0.0 109.152 179.723 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.747 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 75.3 m-85 -130.56 106.08 15.76 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.35 -0.844 . . . . 0.0 108.79 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 40.6 Cg_endo -64.11 144.46 87.22 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.627 2.218 . . . . 0.0 112.022 -179.152 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.15 -20.21 2.62 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 110.56 -1.016 . . . . 0.0 110.56 179.516 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.5 m-30 -98.05 129.71 44.89 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.569 -1.548 . . . . 0.0 110.626 -178.789 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 59.8 t -131.61 143.34 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 1.03 ' HB2' HG23 ' A' ' 41' ' ' VAL . 27.2 m-85 -104.58 129.27 52.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.879 -1.138 . . . . 0.0 110.137 -179.041 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 1.026 HG12 HG23 ' A' ' 40' ' ' ILE . 34.5 m -138.99 149.44 23.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.329 -0.857 . . . . 0.0 109.849 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.644 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 83.9 tt0 -113.79 130.14 56.49 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.319 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.508 ' HE1' HG11 ' A' ' 74' ' ' VAL . 61.4 mtm -151.32 160.83 43.58 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.858 -1.151 . . . . 0.0 111.184 -178.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.753 ' CG1' HD13 ' A' ' 36' ' ' LEU . 1.4 pt -80.87 125.61 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.44 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.415 ' O ' ' CG ' ' A' ' 67' ' ' ASN . 50.5 ttm -77.24 142.7 39.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.191 -0.943 . . . . 0.0 110.115 -178.533 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.415 ' CG ' ' O ' ' A' ' 66' ' ' MET . 7.6 m-20 176.2 168.47 0.44 Allowed 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -65.85 -40.52 91.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.069 -1.019 . . . . 0.0 109.578 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -75.97 -34.31 59.8 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.93 . . . . 0.0 109.858 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 1.098 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -71.76 -48.36 47.34 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.209 -0.932 . . . . 0.0 109.733 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.587 ' CG ' ' OE1' ' A' ' 89' ' ' GLN . 83.4 t80 -60.79 -44.44 96.82 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.946 -179.574 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -69.97 -26.14 63.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -0.942 . . . . 0.0 110.037 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -80.11 -36.07 35.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.074 -1.016 . . . . 0.0 109.849 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 1.046 HG23 ' O ' ' A' ' 70' ' ' ALA . 3.3 t -67.58 -56.28 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.224 -0.923 . . . . 0.0 109.976 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -47.46 -37.02 10.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.063 -1.023 . . . . 0.0 110.211 -179.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 m -70.95 2.99 3.67 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.015 -1.053 . . . . 0.0 110.419 -179.37 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.793 HG11 HD11 ' A' ' 24' ' ' ILE . 38.8 t -64.12 134.6 96.0 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 120.941 -1.099 . . . . 0.0 109.237 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.521 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 47.5 Cg_endo -67.85 135.55 35.72 Favored 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 122.715 2.277 . . . . 0.0 111.987 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.521 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 17.3 m-85 78.45 -5.05 2.1 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.432 -0.792 . . . . 0.0 109.712 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.604 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.7 t -85.11 123.96 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.054 -1.029 . . . . 0.0 109.296 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . 0.494 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 66.0 mtp -82.4 -30.68 30.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.335 -0.853 . . . . 0.0 109.343 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.411 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.11 -157.34 27.97 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 0.487 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 7.9 m-85 -133.64 137.42 45.39 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.258 -1.143 . . . . 0.0 109.5 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.532 HG22 HD21 ' A' ' 11' ' ' LEU . 38.2 t -60.11 131.69 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.894 . . . . 0.0 109.48 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.542 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.7 OUTLIER -168.98 159.81 9.6 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.191 -0.943 . . . . 0.0 109.562 179.995 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.58 -35.46 16.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.307 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.58 -85.16 0.58 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.576 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -108.78 -134.08 7.05 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.303 -1.519 . . . . 0.0 109.303 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.587 ' OE1' ' CG ' ' A' ' 71' ' ' TYR . 0.3 OUTLIER -26.55 145.01 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.593 -0.945 . . . . 0.0 110.551 -179.533 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.542 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.4 Cg_endo -69.31 146.45 63.01 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.896 2.398 . . . . 0.0 111.991 -179.746 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.3 m -80.83 149.2 66.82 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.391 -0.818 . . . . 0.0 109.277 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.71 145.71 58.28 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.666 2.244 . . . . 0.0 111.78 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.921 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.9 t -65.4 144.62 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.196 -0.94 . . . . 0.0 109.382 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . 0.419 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.4 mttm -82.29 133.16 35.23 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.177 -0.952 . . . . 0.0 109.411 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.403 ' C ' ' O ' ' A' ' 94' ' ' LYS . 90.8 m-20 -45.99 -44.76 15.29 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.201 -0.937 . . . . 0.0 109.314 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.494 ' O ' ' HG2' ' A' ' 96' ' ' ARG . 34.4 ttm180 -58.51 -18.24 27.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.574 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.419 ' N ' ' O ' ' A' ' 94' ' ' LYS . 26.5 mt-10 -100.65 -26.45 13.81 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.24 -0.912 . . . . 0.0 109.571 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.527 ' SD ' HG11 ' A' ' 93' ' ' VAL . 50.1 mmm -78.37 -34.61 48.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.939 . . . . 0.0 109.334 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.581 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 2.5 mtt180 -33.45 -54.58 0.71 Allowed Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.588 -0.695 . . . . 0.0 110.228 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.581 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.1 Cg_endo -69.8 -29.46 23.63 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.55 2.167 . . . . 0.0 112.219 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.537 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 19.9 mm -78.7 -44.83 25.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.098 -1.001 . . . . 0.0 109.886 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.61 ' HA ' HD12 ' A' ' 107' ' ' LEU . 1.0 OUTLIER -62.83 -43.02 99.9 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.111 -0.993 . . . . 0.0 109.705 -179.877 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.406 ' NH2' ' NH2' ' A' ' 99' ' ' ARG . 46.3 mtt180 -62.3 -52.73 62.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -71.46 -37.59 71.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.393 -0.817 . . . . 0.0 109.279 179.736 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -67.87 -3.97 11.33 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.358 -0.838 . . . . 0.0 109.952 -179.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 78.09 5.24 87.01 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.957 HD11 HG11 ' A' ' 41' ' ' VAL . 61.6 mt -71.46 -19.69 62.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -1.148 . . . . 0.0 109.657 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . 0.422 ' HG3' ' HB3' ' A' ' 102' ' ' LEU . 83.9 mt-10 . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.223 -0.923 . . . . 0.0 109.517 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.607 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 22.0 m-30 . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 39.5 mttm -130.16 157.35 42.68 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 0.0 109.688 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 13.6 p -62.13 148.94 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.329 -0.857 . . . . 0.0 109.494 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.48 -30.37 3.1 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.666 -1.373 . . . . 0.0 109.666 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.589 ' HB2' HD12 ' A' ' 143' ' ' ILE . 68.6 m-20 -50.57 164.22 0.14 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.189 -1.183 . . . . 0.0 109.217 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.0 ttm -99.6 129.58 45.76 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.15 -0.969 . . . . 0.0 109.011 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.696 ' CG1' HD11 ' A' ' 143' ' ' ILE . 25.1 m -128.67 145.67 35.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.302 -0.874 . . . . 0.0 109.948 -179.836 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.465 ' HG3' ' O ' ' A' ' 139' ' ' PHE . 26.3 tttp -110.47 145.05 38.34 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.588 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.999 ' O ' HD13 ' A' ' 132' ' ' ILE . 64.7 mt -78.75 156.5 4.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.035 -1.041 . . . . 0.0 108.544 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.999 HD13 ' O ' ' A' ' 131' ' ' ILE . 0.7 OUTLIER -148.57 -3.98 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.131 -0.98 . . . . 0.0 108.966 179.54 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.4 m -148.67 146.42 28.15 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.339 -0.851 . . . . 0.0 110.11 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 104.55 -170.58 18.44 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.55 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 49.0 Cg_endo -68.97 -19.66 39.62 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 123.276 2.651 . . . . 0.0 112.508 -179.617 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.55 ' CD1' ' HG2' ' A' ' 135' ' ' PRO . 88.6 m-85 -109.09 9.41 26.25 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.975 -1.078 . . . . 0.0 109.747 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.843 ' HA ' HG22 ' A' ' 131' ' ' ILE . 0.7 OUTLIER -44.19 145.01 0.84 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 0.0 109.462 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.545 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 14.6 m-20 81.62 20.54 0.35 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.489 -0.757 . . . . 0.0 110.042 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.784 ' CB ' HD12 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -115.42 160.66 19.59 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.11 -0.993 . . . . 0.0 109.315 179.803 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.427 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -114.31 135.83 53.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.145 -0.972 . . . . 0.0 109.383 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.478 ' C ' ' CG2' ' A' ' 155' ' ' VAL . . . -147.98 169.88 28.69 Favored Glycine 0 N--CA 1.49 2.267 0 C-N-CA 119.655 -1.26 . . . . 0.0 110.181 -179.47 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.983 ' C ' HG23 ' A' ' 155' ' ' VAL . 94.8 t -109.89 134.46 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.62 -0.93 . . . . 0.0 109.319 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.696 HD11 ' CG1' ' A' ' 129' ' ' VAL . 67.8 mt -62.69 117.16 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.134 -0.979 . . . . 0.0 109.353 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.424 ' HG2' ' HG2' ' A' ' 145' ' ' GLU . 16.8 tttp -97.99 -35.86 10.31 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.164 -0.96 . . . . 0.0 109.422 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . 0.424 ' HG2' ' HG2' ' A' ' 144' ' ' LYS . 72.3 mm-40 -151.59 146.63 25.98 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.095 -1.003 . . . . 0.0 109.462 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.903 HG23 ' CG ' ' A' ' 153' ' ' LEU . 1.8 mt -122.44 125.34 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.576 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.68 102.35 44.47 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.203 -0.935 . . . . 0.0 109.603 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.546 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.6 Cg_endo -73.5 171.94 16.72 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.752 2.301 . . . . 0.0 111.846 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.546 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.0 tt0 80.57 -21.45 0.32 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.423 -0.798 . . . . 0.0 110.074 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.417 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 44.0 mtt85 -126.17 -12.48 6.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.053 -1.029 . . . . 0.0 109.323 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.417 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 42.2 mt-30 68.47 49.8 0.75 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.325 -0.86 . . . . 0.0 109.676 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.682 ' OE2' HG13 ' A' ' 167' ' ' VAL . 69.0 tt0 -123.01 146.35 47.71 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.048 -1.032 . . . . 0.0 108.747 179.515 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.903 ' CG ' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -142.51 113.93 7.83 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.119 -0.988 . . . . 0.0 110.511 -179.276 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . 0.691 ' HG2' HG22 ' A' ' 167' ' ' VAL . 27.1 mtmt -85.08 137.21 33.19 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.983 HG23 ' C ' ' A' ' 142' ' ' VAL . 1.8 p -136.72 133.19 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.007 -1.058 . . . . 0.0 110.034 -179.222 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.598 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.2 t-20 -67.02 125.95 27.62 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.396 -0.815 . . . . 0.0 109.689 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.564 HG12 HG13 ' A' ' 159' ' ' ILE . 43.7 t -107.59 147.46 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.275 -0.891 . . . . 0.0 109.057 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.683 HG23 ' O ' ' A' ' 158' ' ' THR . 9.4 t -97.4 112.18 24.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.343 -0.848 . . . . 0.0 109.986 -179.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.965 HG22 ' CD2' ' A' ' 160' ' ' PHE . 26.6 mt -138.17 137.29 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.357 -0.84 . . . . 0.0 109.183 179.298 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.965 ' CD2' HG22 ' A' ' 159' ' ' ILE . 99.7 m-85 60.86 42.34 13.29 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 108.963 -179.533 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.37 17.03 17.17 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.472 ' NH1' ' O ' ' A' ' 160' ' ' PHE . 22.5 mtt85 -126.49 147.55 49.81 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -1.184 . . . . 0.0 109.637 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 64.1 mm-40 -97.89 136.64 37.9 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 109.373 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . 0.503 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 4.3 m -143.68 132.55 11.34 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.673 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.598 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 48.0 Cg_endo -68.88 131.21 21.98 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.792 2.328 . . . . 0.0 111.366 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.915 HG23 HD11 ' A' ' 168' ' ' LEU . 24.3 m -115.55 162.89 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.052 -1.03 . . . . 0.0 109.581 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.691 HG22 ' HG2' ' A' ' 154' ' ' LYS . 41.3 t -117.77 119.14 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.411 -0.806 . . . . 0.0 109.61 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.915 HD11 HG23 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -144.38 168.73 19.4 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.956 0.884 . . . . 0.0 110.503 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -80.65 139.41 36.22 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 7.9 p -53.7 -34.18 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.156 -0.965 . . . . 0.0 109.008 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 54.0 p -75.54 -4.33 39.26 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.394 -0.816 . . . . 0.0 109.539 -179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -103.97 1.85 31.66 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.072 -1.017 . . . . 0.0 109.644 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . 0.538 HG12 ' N ' ' A' ' 174' ' ' GLU . 49.5 t -131.35 162.99 38.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.146 -0.971 . . . . 0.0 109.626 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . 0.538 ' N ' HG12 ' A' ' 173' ' ' VAL . 76.3 tt0 -139.3 159.62 41.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -0.9 . . . . 0.0 109.344 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.607 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 21.7 tttm . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.146 -0.971 . . . . 0.0 109.283 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.5 mttt . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 21.6 mtpp -130.45 176.18 8.36 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.229 -0.92 . . . . 0.0 109.256 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' TRP . . . . . 0.702 ' CH2' HG23 ' A' ' 41' ' ' VAL . 39.7 m95 -109.67 124.11 50.63 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.236 -0.915 . . . . 0.0 109.126 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' TYR . . . . . 0.462 ' CE1' ' CE ' ' A' ' 66' ' ' MET . 95.4 m-85 -113.75 170.9 7.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.245 -0.909 . . . . 0.0 109.353 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.459 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 25.9 mt -119.2 106.84 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.232 -0.918 . . . . 0.0 109.417 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.487 ' CG2' HG23 ' A' ' 80' ' ' VAL . 0.2 OUTLIER -94.45 148.16 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.183 -0.948 . . . . 0.0 109.292 179.746 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.758 HD22 ' N ' ' A' ' 11' ' ' LEU . 3.2 mm? -95.37 145.93 24.76 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.382 -0.824 . . . . 0.0 109.817 -179.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.9 p -147.78 -177.96 6.01 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.415 -0.803 . . . . 0.0 109.264 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' MET . . . . . 0.569 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 54.8 mtm -89.9 116.92 28.33 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.157 -0.964 . . . . 0.0 109.489 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 13' ' ' MET . 18.1 t -42.89 125.57 3.51 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.248 -0.908 . . . . 0.0 109.296 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.47 -19.09 40.28 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.129 -1.588 . . . . 0.0 109.129 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' TYR . . . . . 0.569 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.7 m-85 -107.33 -10.14 15.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.446 -1.031 . . . . 0.0 109.465 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . 0.487 ' O ' ' N ' ' A' ' 20' ' ' VAL . 93.9 mt-10 -45.47 -66.66 0.37 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.201 -0.937 . . . . 0.0 109.37 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . 0.409 ' C ' ' O ' ' A' ' 17' ' ' GLU . 94.8 mt-10 -44.05 -35.79 2.26 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 109.302 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.43 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 22.9 mttm -71.58 -31.35 66.86 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.214 -0.929 . . . . 0.0 109.344 179.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.73 HG22 ' HB2' ' A' ' 79' ' ' TYR . 98.2 t -72.55 -45.47 58.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.224 -0.923 . . . . 0.0 109.356 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 28.8 tttm -55.82 -50.53 70.28 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.341 -0.849 . . . . 0.0 109.303 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -62.3 -37.33 85.12 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -0.895 . . . . 0.0 109.163 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.832 ' OD1' HG22 ' A' ' 77' ' ' VAL . 13.8 t-20 -62.23 -44.58 96.23 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.322 -0.861 . . . . 0.0 109.362 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.949 ' CD1' HG21 ' A' ' 77' ' ' VAL . 29.5 mm -56.11 -45.2 80.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 109.335 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -55.13 -45.46 75.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.229 -0.92 . . . . 0.0 109.657 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 46.7 mttp -76.17 -35.73 59.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.069 -1.02 . . . . 0.0 109.61 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 1.029 ' HD3' HG23 ' A' ' 77' ' ' VAL . 18.1 ttpt -55.07 -33.89 63.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.334 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.865 HG21 HG11 ' A' ' 37' ' ' VAL . 89.4 t -82.27 -24.44 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.288 -0.882 . . . . 0.0 109.601 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -67.85 -52.31 38.18 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.654 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.39 -27.12 65.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.249 -0.907 . . . . 0.0 109.933 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 47.4 p -97.58 -32.19 11.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.205 -0.934 . . . . 0.0 109.696 -179.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 79.44 24.01 61.7 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.643 ' O ' HG13 ' A' ' 28' ' ' VAL . 62.8 mt -94.65 87.32 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.217 -1.166 . . . . 0.0 109.444 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -87.4 -5.37 58.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.215 -0.928 . . . . 0.0 109.455 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -102.14 16.46 26.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.269 -0.895 . . . . 0.0 109.628 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.929 HD11 ' CB ' ' A' ' 70' ' ' ALA . 7.2 tp -112.17 -58.12 2.18 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.263 -0.898 . . . . 0.0 109.4 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.865 HG11 HG21 ' A' ' 28' ' ' VAL . 9.0 p -95.87 134.35 33.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.427 -0.796 . . . . 0.0 109.423 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.21 -123.71 5.32 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 93.4 mtt180 -95.11 143.98 26.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.308 -1.113 . . . . 0.0 109.89 -179.473 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 1.01 HG23 HG22 ' A' ' 62' ' ' VAL . 18.9 mt -107.7 140.39 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.408 -0.807 . . . . 0.0 109.158 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 1.038 HG21 HD11 ' A' ' 107' ' ' LEU . 55.0 t -128.51 156.86 41.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.024 -1.048 . . . . 0.0 109.462 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.791 HG22 HG23 ' A' ' 44' ' ' ILE . 6.5 mt -136.72 127.19 16.23 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.367 -0.833 . . . . 0.0 109.469 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.517 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 46.3 Cg_endo -67.4 -4.71 12.37 Favored 'Trans proline' 0 C--O 1.216 -0.583 0 C-N-CA 122.824 2.349 . . . . 0.0 111.547 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.791 HG23 HG22 ' A' ' 42' ' ' ILE . 11.8 pt . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.248 -0.907 . . . . 0.0 109.474 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.71 ' HA ' HG22 ' A' ' 44' ' ' ILE . 24.5 mttt . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.635 HD23 ' HE2' ' A' ' 56' ' ' PHE . 14.5 tp -64.26 -23.73 67.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.161 -0.962 . . . . 0.0 109.132 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' PHE . . . . . 0.89 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 97.2 m-85 -149.96 99.0 3.31 Favored Pre-proline 0 N--CA 1.49 1.532 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -65.42 139.57 59.89 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.614 2.209 . . . . 0.0 111.979 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.07 -15.84 4.98 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.386 -1.085 . . . . 0.0 110.386 179.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.444 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.2 m-85 -95.73 129.87 42.81 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.759 -1.436 . . . . 0.0 110.205 -179.331 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 41.1 t -133.84 146.02 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.335 -0.853 . . . . 0.0 108.905 179.453 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.418 ' CE2' HG12 ' A' ' 9' ' ' ILE . 24.1 m-85 -110.31 122.47 47.76 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.955 -1.09 . . . . 0.0 109.521 -179.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 1.01 HG22 HG23 ' A' ' 40' ' ' ILE . 96.1 t -128.48 140.97 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.427 -0.795 . . . . 0.0 109.936 -179.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.596 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 67.6 tt0 -103.5 123.49 46.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.315 -0.865 . . . . 0.0 108.864 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.576 ' CG ' HG12 ' A' ' 62' ' ' VAL . 1.1 mtp -162.66 -174.61 4.04 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.102 -0.999 . . . . 0.0 109.778 -179.545 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.902 HG12 HD12 ' A' ' 36' ' ' LEU . 17.2 pt -97.26 122.95 49.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.236 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' MET . . . . . 0.462 ' CE ' ' CE1' ' A' ' 8' ' ' TYR . 11.1 ttm -88.16 100.31 12.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -0.885 . . . . 0.0 109.736 -179.406 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.438 ' H ' ' HB3' ' A' ' 70' ' ' ALA . 9.6 t30 -137.92 -165.75 1.84 Allowed 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.195 -0.941 . . . . 0.0 108.821 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -71.41 -48.72 47.96 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.14 -0.975 . . . . 0.0 109.681 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.403 ' O ' ' C ' ' A' ' 70' ' ' ALA . 73.9 mm-40 -66.64 -58.63 4.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.188 -0.945 . . . . 0.0 109.5 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.929 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -43.85 -41.51 5.14 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.293 -0.879 . . . . 0.0 109.718 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.541 ' CD1' ' CD ' ' A' ' 89' ' ' GLN . 72.2 t80 -61.05 -57.14 13.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.163 -0.961 . . . . 0.0 109.627 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' HB3' ' A' ' 76' ' ' SER . 38.2 t30 -52.87 -31.2 38.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.929 . . . . 0.0 110.0 -179.582 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -82.08 -44.15 16.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.96 -1.088 . . . . 0.0 109.923 -179.626 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 1.081 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 47.6 t -68.49 -56.91 10.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.357 -0.84 . . . . 0.0 109.625 -179.64 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ARG . . . . . 0.457 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 15.6 tpt180 -62.5 -11.92 19.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.165 -0.959 . . . . 0.0 109.966 -179.718 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.485 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 89.6 p -102.28 3.53 38.23 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.081 -1.012 . . . . 0.0 110.167 -179.645 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 1.033 ' O ' HG12 ' A' ' 80' ' ' VAL . 0.4 OUTLIER -69.05 142.27 92.92 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.031 -1.043 . . . . 0.0 109.273 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.664 ' HD2' HG22 ' A' ' 77' ' ' VAL . 45.2 Cg_endo -67.75 134.51 32.75 Favored 'Trans proline' 0 C--O 1.213 -0.768 0 C-N-CA 122.454 2.103 . . . . 0.0 111.876 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.73 ' HB2' HG22 ' A' ' 20' ' ' VAL . 13.1 m-85 89.32 -6.55 0.42 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.799 -0.563 . . . . 0.0 110.255 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 1.033 HG12 ' O ' ' A' ' 77' ' ' VAL . 12.4 p -88.33 126.98 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.752 -1.218 . . . . 0.0 109.643 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.4 mmm -90.78 -26.36 19.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.32 -0.863 . . . . 0.0 109.335 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . 0.57 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 161.47 -160.34 32.14 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . 1.081 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 10.8 m-85 -134.76 156.38 48.94 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.191 -1.182 . . . . 0.0 109.562 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.547 HG13 ' O ' ' A' ' 84' ' ' VAL . 12.5 p -91.71 125.35 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.248 -0.908 . . . . 0.0 109.385 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.574 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.6 OUTLIER -168.87 166.79 11.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.13 -0.981 . . . . 0.0 109.568 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 25.5 t -86.18 -32.97 20.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.238 -0.914 . . . . 0.0 109.427 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -117.42 -106.82 2.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.516 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -96.67 -122.09 4.16 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' GLN . . . . . 0.541 ' CD ' ' CD1' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -34.55 156.11 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.533 -0.981 . . . . 0.0 110.044 -179.659 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.574 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.0 Cg_endo -68.75 149.21 72.91 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.839 2.359 . . . . 0.0 111.994 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.0 m -83.89 154.97 64.74 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 109.436 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.525 ' HB3' ' CE ' ' A' ' 6' ' ' LYS . 49.9 Cg_endo -70.16 142.94 47.46 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.677 2.251 . . . . 0.0 111.673 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.512 HG12 ' HB2' ' A' ' 97' ' ' GLU . 18.6 t -82.3 139.07 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.304 -0.873 . . . . 0.0 109.433 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' LYS . . . . . 0.467 ' O ' ' N ' ' A' ' 97' ' ' GLU . 7.3 tptt -70.74 131.78 44.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.182 -0.949 . . . . 0.0 109.289 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . 0.402 ' C ' ' O ' ' A' ' 94' ' ' LYS . 87.3 m-20 -45.22 -39.52 6.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.178 -0.952 . . . . 0.0 109.436 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.4 mtp180 -61.03 -23.45 65.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.308 -0.87 . . . . 0.0 109.475 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.512 ' HB2' HG12 ' A' ' 93' ' ' VAL . 62.9 mt-10 -85.83 -28.38 24.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.913 . . . . 0.0 109.422 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' MET . . . . . 0.612 ' HE3' ' CB ' ' A' ' 7' ' ' TRP . 59.0 mtp -84.14 -24.8 30.07 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.365 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.593 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -37.46 -53.53 2.31 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.425 -0.797 . . . . 0.0 109.866 -179.952 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.4 Cg_endo -69.83 -27.55 25.98 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 122.525 2.15 . . . . 0.0 111.878 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.418 ' N ' ' O ' ' A' ' 98' ' ' MET . 37.4 mm -81.19 -42.94 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.178 -0.951 . . . . 0.0 109.304 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' LEU . . . . . 0.868 HD12 HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -65.8 -38.97 90.41 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.275 -0.891 . . . . 0.0 109.297 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.482 ' HD3' ' HB3' ' A' ' 135' ' ' PRO . 16.1 ttt-85 -65.66 -47.7 74.63 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.334 -0.854 . . . . 0.0 109.279 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.429 HD23 ' C ' ' A' ' 104' ' ' LEU . 3.0 tt -72.12 -36.31 69.38 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.215 -0.928 . . . . 0.0 109.227 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -75.25 -2.22 27.08 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.44 -0.788 . . . . 0.0 109.81 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.9 15.79 81.34 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 1.038 HD11 HG21 ' A' ' 41' ' ' VAL . 23.5 mt -81.84 -23.27 36.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.16 -1.2 . . . . 0.0 109.666 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' GLU . . . . . 0.466 ' HG2' ' HB3' ' A' ' 102' ' ' LEU . 68.2 mm-40 . . . . . 0 N--CA 1.491 1.581 0 O-C-N 121.158 -0.964 . . . . 0.0 109.327 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' PHE . . . . . 0.561 ' CD2' ' O ' ' A' ' 123' ' ' PHE . 42.5 p90 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.02 -0.734 . . . . 0.0 109.02 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' LYS . . . . . 0.686 ' C ' HD11 ' A' ' 146' ' ' ILE . 14.7 mttp -141.14 175.12 9.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.181 -0.949 . . . . 0.0 109.918 -179.58 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . 0.584 HG23 ' O ' ' A' ' 144' ' ' LYS . 10.8 p -62.51 139.62 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.529 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.13 -34.8 3.68 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . 0.452 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 9.5 m-20 -45.92 158.97 0.08 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.336 -1.096 . . . . 0.0 109.209 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.8 ttm -99.77 127.49 45.92 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.075 -1.016 . . . . 0.0 108.799 179.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.609 HG13 HG12 ' A' ' 143' ' ' ILE . 15.4 m -128.51 144.87 36.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.32 -0.862 . . . . 0.0 109.735 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' LYS . . . . . 0.412 ' HE3' ' CG2' ' A' ' 132' ' ' ILE . 32.5 ttpt -98.78 141.06 32.05 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.618 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.931 HD12 ' HB3' ' A' ' 139' ' ' PHE . 78.5 mt -82.84 151.09 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.209 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' ILE . . . . . 0.498 HG12 ' HA ' ' A' ' 173' ' ' VAL . 1.1 pt -149.66 3.64 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 120.923 -1.111 . . . . 0.0 109.957 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 69.9 m -148.26 143.52 27.02 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.846 -1.159 . . . . 0.0 109.983 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.67 -163.9 18.7 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' PRO . . . . . 0.482 ' HB3' ' HD3' ' A' ' 103' ' ' ARG . 46.4 Cg_endo -67.38 -23.18 44.58 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 123.167 2.578 . . . . 0.0 112.952 -179.28 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.528 ' CE1' ' CB ' ' A' ' 100' ' ' PRO . 97.1 m-85 -109.14 19.38 19.55 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.787 -1.196 . . . . 0.0 109.713 -179.765 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' GLU . . . . . 0.621 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.3 tt0 -45.51 139.09 3.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.15 -0.969 . . . . 0.0 109.506 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.511 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 17.7 m-20 74.41 28.23 1.34 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.459 -0.776 . . . . 0.0 110.437 179.41 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' PHE . . . . . 0.931 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.8 t80 -117.08 140.01 50.02 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.96 -1.087 . . . . 0.0 109.45 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.74 132.94 34.04 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.116 -0.99 . . . . 0.0 109.664 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.57 168.91 27.23 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.775 -1.203 . . . . 0.0 110.304 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.916 ' C ' HG23 ' A' ' 155' ' ' VAL . 41.0 t -117.9 137.07 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.634 -0.921 . . . . 0.0 109.348 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' ILE . . . . . 0.609 HG12 HG13 ' A' ' 129' ' ' VAL . 25.0 mm -69.85 119.23 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.873 . . . . 0.0 109.532 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' LYS . . . . . 0.584 ' O ' HG23 ' A' ' 125' ' ' VAL . 0.2 OUTLIER -97.76 -31.69 12.12 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.026 -1.046 . . . . 0.0 109.04 179.546 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -151.11 146.17 25.97 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.266 -0.896 . . . . 0.0 109.283 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 1.051 HG23 HD22 ' A' ' 153' ' ' LEU . 4.0 mt -121.58 126.21 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.141 -0.974 . . . . 0.0 109.545 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.92 100.08 38.13 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.449 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.4 Cg_endo -71.14 173.28 12.42 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.706 2.271 . . . . 0.0 111.821 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.2 tt0 79.52 -21.58 0.32 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.325 -0.86 . . . . 0.0 110.184 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' ARG . . . . . 0.44 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 83.9 mtt-85 -127.5 -12.77 5.53 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.045 -1.035 . . . . 0.0 109.6 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' GLN . . . . . 0.882 ' O ' HG23 ' A' ' 170' ' ' VAL . 49.8 mt-30 69.52 47.04 0.69 Allowed 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.348 -0.845 . . . . 0.0 109.704 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' GLU . . . . . 0.742 ' O ' HD23 ' A' ' 153' ' ' LEU . 40.8 tt0 -118.21 143.85 46.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.08 -1.012 . . . . 0.0 108.659 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 1.051 HD22 HG23 ' A' ' 146' ' ' ILE . 35.3 mt -133.56 122.82 24.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.996 -1.065 . . . . 0.0 110.616 -179.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 9.5 mttt -86.55 130.93 34.31 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 178.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.916 HG23 ' C ' ' A' ' 142' ' ' VAL . 7.3 p -133.65 149.77 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.087 -1.008 . . . . 0.0 109.8 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.565 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 43.3 t-20 -98.75 123.61 43.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.29 -0.881 . . . . 0.0 109.329 179.857 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' VAL . . . . . 0.557 HG13 ' CE1' ' A' ' 139' ' ' PHE . 63.9 t -105.39 146.86 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.198 -0.939 . . . . 0.0 109.663 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 25.9 m -94.9 104.05 15.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.245 -0.91 . . . . 0.0 109.633 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' ILE . . . . . 0.89 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 7.0 pt -139.65 149.12 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -0.896 . . . . 0.0 109.38 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' PHE . . . . . 0.658 ' CE2' HD12 ' A' ' 159' ' ' ILE . 11.1 m-30 61.35 36.99 17.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.261 -0.899 . . . . 0.0 109.141 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.52 13.7 17.99 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' ARG . . . . . 0.424 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 3.3 mtp-105 -134.11 159.01 42.14 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.059 -1.259 . . . . 0.0 109.601 -179.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' GLU . . . . . 0.478 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 81.7 mt-10 -99.73 140.12 34.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.253 -0.905 . . . . 0.0 109.399 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' THR . . . . . 0.553 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 22.6 m -146.55 129.93 8.23 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.785 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' PRO . . . . . 0.565 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.7 Cg_endo -71.14 139.29 35.22 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.736 2.29 . . . . 0.0 111.437 179.676 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' VAL . . . . . 0.966 HG13 HD11 ' A' ' 168' ' ' LEU . 2.9 p -124.93 143.86 36.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.088 -1.007 . . . . 0.0 109.627 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.576 HG13 ' O ' ' A' ' 167' ' ' VAL . 14.6 p -96.13 120.75 45.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.408 -0.807 . . . . 0.0 109.533 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' LEU . . . . . 0.966 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -141.4 168.71 19.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.113 -0.992 . . . . 0.0 110.54 -179.52 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' HIS . . . . . 0.468 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 72.1 m80 -83.19 143.26 30.59 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.891 HG22 ' HG ' ' A' ' 153' ' ' LEU . 71.9 t -52.82 -38.39 27.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 84.6 p -75.23 -6.97 52.51 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.492 -0.755 . . . . 0.0 110.06 -179.466 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' GLU . . . . . 0.468 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 80.4 mt-10 -91.12 -5.46 55.06 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.828 -1.17 . . . . 0.0 109.822 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' VAL . . . . . 0.498 ' HA ' HG12 ' A' ' 132' ' ' ILE . 2.8 m -139.48 175.36 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.152 -0.967 . . . . 0.0 109.439 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' GLU . . . . . . . . . . . . . 57.5 tt0 -138.17 163.03 32.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.196 -0.94 . . . . 0.0 109.045 179.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' LYS . . . . . 0.483 ' CE ' ' CB ' ' A' ' 123' ' ' PHE . 25.2 mmtm . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.088 -1.007 . . . . 0.0 109.246 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -57.23 -40.19 77.05 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.204 -1.174 . . . . 0.0 109.484 -180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 76.4 mtm -51.37 -44.04 62.02 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.17 -0.956 . . . . 0.0 109.522 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 15.0 mmtt -92.43 144.01 25.8 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.22 -0.925 . . . . 0.0 109.461 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.664 ' HG2' HG22 ' A' ' 65' ' ' ILE . 56.5 mttt -103.43 141.71 35.5 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.269 -0.894 . . . . 0.0 109.507 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.61 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.2 mttp -125.82 174.51 8.3 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.222 -0.924 . . . . 0.0 109.126 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.683 ' CH2' HG23 ' A' ' 41' ' ' VAL . 60.0 m95 -109.9 126.66 54.11 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.132 -0.98 . . . . 0.0 109.346 179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -118.74 167.39 11.72 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.211 -0.931 . . . . 0.0 109.415 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.53 HD11 ' CE1' ' A' ' 160' ' ' PHE . 95.1 mt -103.25 118.77 50.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.195 -0.94 . . . . 0.0 109.314 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.464 HG23 HG12 ' A' ' 62' ' ' VAL . 85.3 t -90.46 137.32 21.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.276 -0.89 . . . . 0.0 109.466 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.486 ' CD2' ' CG2' ' A' ' 84' ' ' VAL . 0.1 OUTLIER -89.62 141.75 28.31 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.276 -0.89 . . . . 0.0 109.245 179.875 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.527 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.2 t -157.15 -172.48 4.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.23 -0.918 . . . . 0.0 109.358 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.496 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 90.9 mtp -105.56 123.62 48.2 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.2 -0.937 . . . . 0.0 109.516 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.422 ' C ' ' O ' ' A' ' 13' ' ' MET . 9.2 t -43.07 127.07 4.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.299 -0.875 . . . . 0.0 109.397 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.74 -19.85 40.5 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.414 -1.474 . . . . 0.0 109.414 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.496 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.2 m-85 -108.47 3.54 23.28 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.239 -1.153 . . . . 0.0 109.64 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.527 ' HG2' HG21 ' A' ' 12' ' ' THR . 98.4 mt-10 -57.92 -59.33 5.41 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.259 -0.901 . . . . 0.0 109.528 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -47.71 -38.11 14.53 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.218 -0.926 . . . . 0.0 109.403 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 24.7 mttt -68.8 -43.66 75.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.282 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 16' ' ' TYR . 89.6 t -58.96 -46.53 91.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.344 -0.848 . . . . 0.0 109.566 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.819 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.4 tttm -56.94 -49.8 74.55 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.219 -0.925 . . . . 0.0 109.548 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -64.83 -43.19 93.86 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.196 -0.94 . . . . 0.0 109.407 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.486 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 89.3 m-20 -54.92 -39.77 69.18 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.222 -0.924 . . . . 0.0 109.391 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.813 HG21 HD11 ' A' ' 40' ' ' ILE . 95.1 mt -65.62 -44.04 93.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.3 -0.875 . . . . 0.0 109.624 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -55.84 -48.22 75.86 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.07 -1.019 . . . . 0.0 109.947 -179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 42.9 mttm -78.41 -35.34 47.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.093 -1.004 . . . . 0.0 109.612 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.579 ' HG3' ' CE1' ' A' ' 73' ' ' PHE . 10.7 tptt -53.25 -33.0 51.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.247 -0.908 . . . . 0.0 109.13 179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.756 HG13 ' C ' ' A' ' 33' ' ' ILE . 22.3 t -89.52 -19.89 7.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.342 -0.849 . . . . 0.0 109.287 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -72.64 -57.64 3.97 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.564 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.69 -29.9 66.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.269 -0.895 . . . . 0.0 109.437 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.419 ' HB ' HG13 ' A' ' 33' ' ' ILE . 80.7 p -96.6 -3.02 43.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.237 -0.915 . . . . 0.0 109.477 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 50.02 30.17 15.82 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.045 HG21 HD12 ' A' ' 36' ' ' LEU . 21.6 mt -98.3 72.04 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.248 -1.148 . . . . 0.0 109.519 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 37.9 mttp -90.49 20.36 4.62 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.266 -0.896 . . . . 0.0 109.505 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.755 ' O ' HD13 ' A' ' 65' ' ' ILE . 81.4 m-20 -111.27 -23.04 11.06 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.189 -0.944 . . . . 0.0 109.525 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.045 HD12 HG21 ' A' ' 33' ' ' ILE . 18.9 mt -88.36 -31.23 19.0 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.29 -0.882 . . . . 0.0 109.76 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.414 ' HB ' HG21 ' A' ' 28' ' ' VAL . 93.4 t -108.19 142.87 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.179 -0.951 . . . . 0.0 109.376 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.86 -121.88 3.17 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -92.91 140.92 28.99 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.28 -1.13 . . . . 0.0 109.838 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.881 HG12 HG23 ' A' ' 62' ' ' VAL . 85.2 mt -108.91 134.64 50.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.336 -0.853 . . . . 0.0 109.084 179.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 1.059 ' CG2' HD11 ' A' ' 107' ' ' LEU . 28.7 t -121.68 159.34 24.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.074 -1.016 . . . . 0.0 109.412 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.953 HG22 HG23 ' A' ' 44' ' ' ILE . 2.9 mt -140.44 127.62 12.28 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.292 -0.88 . . . . 0.0 109.479 -179.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.635 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 45.2 Cg_endo -66.72 -5.93 14.32 Favored 'Trans proline' 0 C--O 1.215 -0.664 0 C-N-CA 122.799 2.333 . . . . 0.0 111.391 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.953 HG23 HG22 ' A' ' 42' ' ' ILE . 6.1 pt -73.18 -46.01 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.398 -0.814 . . . . 0.0 109.374 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.849 ' O ' HD21 ' A' ' 104' ' ' LEU . 93.3 mtt-85 -49.86 134.33 21.1 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.414 -0.804 . . . . 0.0 109.57 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -137.75 -175.39 13.84 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.73 150.08 50.06 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 62.9 tt0 -61.33 -31.89 71.77 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -1.134 . . . . 0.0 109.4 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 42.5 mtp180 -61.47 -38.38 87.03 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.256 -0.903 . . . . 0.0 109.463 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 80.9 mtt85 -147.41 138.37 23.61 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.224 -0.923 . . . . 0.0 109.44 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 19.8 tttp -103.22 124.49 48.72 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.297 -0.877 . . . . 0.0 109.483 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.409 ' O ' ' HB3' ' A' ' 53' ' ' GLU . 91.5 p -62.87 -17.88 62.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.271 -0.893 . . . . 0.0 109.484 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.51 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 80.5 tt0 64.35 52.93 1.78 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.226 -0.921 . . . . 0.0 109.474 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.715 ' HA ' HG22 ' A' ' 44' ' ' ILE . 5.3 mttp 75.72 88.25 0.08 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.31 -0.869 . . . . 0.0 109.5 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 1.025 HD12 ' CE2' ' A' ' 56' ' ' PHE . 0.6 OUTLIER -56.88 -45.82 82.28 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.161 -0.962 . . . . 0.0 109.235 179.983 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 1.025 ' CE2' HD12 ' A' ' 55' ' ' LEU . 85.2 m-85 -125.25 111.94 26.29 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.2 -0.937 . . . . 0.0 109.08 179.635 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.6 Cg_endo -66.28 133.77 33.92 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.573 2.182 . . . . 0.0 111.985 -179.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.419 ' HA2' HG23 ' A' ' 12' ' ' THR . . . 74.46 -11.97 6.31 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.2 m-30 -99.82 131.29 45.89 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.649 -1.501 . . . . 0.0 110.258 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 42.5 t -134.25 148.77 29.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.671 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 17.0 m-85 -108.38 124.44 50.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.887 -1.133 . . . . 0.0 109.733 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.881 HG23 HG12 ' A' ' 40' ' ' ILE . 14.3 p -134.13 145.54 32.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.353 -0.842 . . . . 0.0 109.804 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.61 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 18.4 tt0 -108.51 127.3 53.81 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.632 ' CE ' HG11 ' A' ' 74' ' ' VAL . 58.7 mtm -151.93 163.68 38.73 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 118.954 -1.098 . . . . 0.0 111.022 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.755 HD13 ' O ' ' A' ' 35' ' ' ASN . 3.3 pt -85.87 126.9 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.485 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 47.7 ttm -75.34 141.48 43.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.203 -0.936 . . . . 0.0 109.83 -178.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.485 ' HB2' ' O ' ' A' ' 66' ' ' MET . 47.0 t30 176.4 175.36 0.32 Allowed 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 -179.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -72.12 -40.85 67.84 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.168 -0.957 . . . . 0.0 109.593 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -72.46 -32.06 65.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.234 -0.916 . . . . 0.0 109.75 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.912 ' HB2' HD22 ' A' ' 36' ' ' LEU . . . -71.71 -47.3 54.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.193 -0.942 . . . . 0.0 109.818 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 67.9 t80 -60.36 -49.33 78.01 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.154 -0.966 . . . . 0.0 109.682 -179.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 95.6 m-20 -63.14 -28.89 70.37 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.088 -1.007 . . . . 0.0 110.314 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CE1' ' HG3' ' A' ' 27' ' ' LYS . 46.3 t80 -80.72 -41.42 23.62 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.007 -1.058 . . . . 0.0 109.819 -179.642 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.716 HG22 ' O ' ' A' ' 70' ' ' ALA . 20.1 m -70.68 -53.24 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.242 -0.911 . . . . 0.0 109.405 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.61 ' N ' HG23 ' A' ' 74' ' ' VAL . 33.0 tpt85 -52.14 -32.46 35.71 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.208 -0.932 . . . . 0.0 109.577 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 51.7 p -79.64 7.05 9.12 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.366 -0.834 . . . . 0.0 109.917 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.66 HG23 ' O ' ' A' ' 74' ' ' VAL . 47.0 t -64.25 133.82 95.76 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.103 -0.998 . . . . 0.0 109.484 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.556 ' HB2' ' CD2' ' A' ' 79' ' ' TYR . 46.9 Cg_endo -68.2 136.9 38.88 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.68 2.253 . . . . 0.0 111.845 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.556 ' CD2' ' HB2' ' A' ' 78' ' ' PRO . 47.2 m-85 76.05 -1.94 2.85 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.418 -0.801 . . . . 0.0 109.623 -179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.603 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 2.8 t -87.86 127.76 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.129 -0.982 . . . . 0.0 109.273 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.1 mmm -89.02 -5.8 57.66 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.281 -0.887 . . . . 0.0 109.643 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 135.09 -152.8 20.9 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -143.14 141.7 31.27 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.138 -1.213 . . . . 0.0 109.48 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.486 ' CG2' ' CD2' ' A' ' 11' ' ' LEU . 38.8 t -63.55 128.5 25.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.249 -0.907 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.515 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 6.9 p -162.84 161.77 26.14 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.257 -0.902 . . . . 0.0 109.507 -179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 m -88.74 -35.61 16.61 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -123.58 -87.71 0.81 Allowed Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.524 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -105.32 -128.38 6.17 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.524 ' O ' ' O ' ' A' ' 88' ' ' GLY . 6.8 pm0 -34.26 155.98 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.586 -0.949 . . . . 0.0 110.115 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.515 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.4 Cg_endo -69.62 160.12 50.92 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.578 2.185 . . . . 0.0 112.081 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 20.6 m -98.84 154.0 37.59 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.349 -0.844 . . . . 0.0 109.455 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.457 ' CB ' ' HD3' ' A' ' 6' ' ' LYS . 49.6 Cg_endo -70.35 147.64 59.53 Favored 'Trans proline' 0 C--O 1.216 -0.622 0 C-N-CA 122.693 2.262 . . . . 0.0 111.809 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 7' ' ' TRP . 21.3 t -85.4 142.44 13.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.219 -0.926 . . . . 0.0 109.455 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . 0.467 ' HB3' ' HG3' ' A' ' 97' ' ' GLU . 81.1 tttt -67.66 126.24 28.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -0.9 . . . . 0.0 109.453 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 94' ' ' LYS . 47.3 t0 -43.67 -45.35 6.91 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.408 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.432 ' HD2' ' NZ ' ' A' ' 94' ' ' LYS . 57.4 mtt180 -55.42 -31.28 61.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.237 -0.914 . . . . 0.0 109.51 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.467 ' HG3' ' HB3' ' A' ' 94' ' ' LYS . 57.3 mt-10 -79.22 -24.45 43.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.262 -0.899 . . . . 0.0 109.662 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.628 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 75.7 mtp -84.53 -23.71 29.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.157 -0.964 . . . . 0.0 109.352 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.609 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 57.3 mtt180 -37.53 -52.55 2.52 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.351 -0.843 . . . . 0.0 109.919 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.609 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -69.39 -28.25 27.27 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.546 2.164 . . . . 0.0 111.989 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.54 HG21 ' CD2' ' A' ' 61' ' ' PHE . 24.4 mm -81.95 -41.18 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 109.361 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 1.022 HD12 HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -68.95 -41.44 78.0 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.198 -0.938 . . . . 0.0 109.136 179.816 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.449 ' HD3' ' CD2' ' A' ' 110' ' ' TYR . 21.4 tpt85 -63.25 -49.49 73.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -0.861 . . . . 0.0 108.989 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.849 HD21 ' O ' ' A' ' 45' ' ' ARG . 0.5 OUTLIER -72.66 -36.29 67.92 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.369 -0.832 . . . . 0.0 109.208 179.703 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.524 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.85 -0.47 9.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.436 -0.79 . . . . 0.0 109.94 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.34 7.79 85.21 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 1.059 HD11 ' CG2' ' A' ' 41' ' ' VAL . 53.5 mt -77.28 -19.97 55.74 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.28 -1.13 . . . . 0.0 109.446 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 36.1 tp10 -144.23 131.51 20.76 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.217 -0.927 . . . . 0.0 109.557 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -119.55 113.9 21.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.362 -0.836 . . . . 0.0 109.428 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.449 ' CD2' ' HD3' ' A' ' 103' ' ' ARG . 42.0 p90 -125.55 171.13 10.78 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.223 -0.923 . . . . 0.0 109.545 -179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 112' ' ' GLU . 94.2 mt-10 -100.33 -92.9 0.28 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.491 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.406 ' C ' ' O ' ' A' ' 111' ' ' GLU . 58.2 tt0 44.45 74.51 0.12 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.191 -0.943 . . . . 0.0 109.512 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 16.2 pttp -163.03 39.04 0.1 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.29 -0.881 . . . . 0.0 109.503 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.458 ' O ' ' HG3' ' A' ' 114' ' ' LYS . 7.1 pttp -101.73 33.29 3.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.235 -0.916 . . . . 0.0 109.338 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.87 57.57 30.49 Favored Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.279 -0.888 . . . . 0.0 109.493 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -70.2 82.44 0.85 Allowed 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.681 2.254 . . . . 0.0 111.759 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 28.1 t -127.49 128.68 70.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.168 -0.958 . . . . 0.0 109.566 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.571 ' HA ' ' CB ' ' A' ' 171' ' ' SER . 12.3 mttp -85.33 137.09 33.18 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.293 -0.879 . . . . 0.0 109.499 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 82.5 t -107.78 139.57 29.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.261 -0.899 . . . . 0.0 109.444 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.569 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 95.0 mt-10 -150.41 170.47 18.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.301 -0.874 . . . . 0.0 109.465 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.569 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 0.3 OUTLIER 79.92 161.48 0.18 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.391 -0.818 . . . . 0.0 109.613 179.966 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . 42.97 31.06 1.12 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.583 ' HB3' ' CD ' ' A' ' 175' ' ' LYS . 45.6 p90 -110.64 124.01 51.08 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.276 -1.132 . . . . 0.0 109.175 179.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.461 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 37.6 mttt -150.64 156.98 42.43 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.072 -1.018 . . . . 0.0 109.972 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.467 HG23 ' O ' ' A' ' 144' ' ' LYS . 14.1 p -62.93 143.99 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.389 -0.819 . . . . 0.0 109.556 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 84.49 -32.21 3.41 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.437 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 7.5 m-20 -48.67 163.82 0.07 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.359 -1.083 . . . . 0.0 109.144 -179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.0 ttm -95.57 126.4 40.83 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.182 -0.949 . . . . 0.0 109.066 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.615 HG11 ' CD1' ' A' ' 143' ' ' ILE . 5.1 p -124.21 141.93 42.71 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.192 -0.943 . . . . 0.0 109.215 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.408 ' N ' ' O ' ' A' ' 174' ' ' GLU . 12.6 ttpp -107.57 143.34 36.13 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.113 -0.992 . . . . 0.0 109.049 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 1.002 HD12 ' HB3' ' A' ' 139' ' ' PHE . 96.5 mt -83.96 152.46 3.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.127 -0.983 . . . . 0.0 108.798 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.473 ' C ' ' HG2' ' A' ' 137' ' ' GLU . 27.4 pt -150.8 2.26 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.056 -1.028 . . . . 0.0 109.606 179.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.515 ' HA ' ' HG2' ' A' ' 137' ' ' GLU . 2.5 m -145.42 141.35 28.33 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.146 -0.972 . . . . 0.0 109.665 -179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.443 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 107.5 -170.75 15.77 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.436 ' HA ' ' HG2' ' A' ' 103' ' ' ARG . 49.7 Cg_endo -69.03 -18.66 40.31 Favored 'Trans proline' 0 C--O 1.215 -0.675 0 C-N-CA 123.338 2.692 . . . . 0.0 112.57 -179.606 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.608 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 97.8 m-85 -107.53 15.31 24.93 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.969 -1.082 . . . . 0.0 109.561 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.515 ' HG2' ' HA ' ' A' ' 133' ' ' SER . 35.1 mt-10 -38.45 142.24 0.2 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.417 -0.802 . . . . 0.0 110.148 -179.716 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 138' ' ' ASP . 0.3 OUTLIER 76.53 20.34 1.47 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.333 -0.854 . . . . 0.0 110.743 178.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 1.002 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.0 OUTLIER -108.37 131.17 55.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.831 -1.168 . . . . 0.0 109.623 179.901 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -84.97 134.3 34.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.155 -0.966 . . . . 0.0 109.508 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.59 167.89 26.48 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.8 -1.19 . . . . 0.0 110.269 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.524 ' C ' HG13 ' A' ' 155' ' ' VAL . 40.9 t -108.89 136.3 45.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.452 -1.028 . . . . 0.0 109.226 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.615 ' CD1' HG11 ' A' ' 129' ' ' VAL . 18.4 mm -67.38 114.85 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 109.259 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.467 ' O ' HG23 ' A' ' 125' ' ' VAL . 64.4 tttm -97.25 -34.37 11.12 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.088 -1.007 . . . . 0.0 109.482 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -151.75 146.75 25.97 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.14 -0.975 . . . . 0.0 109.613 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.837 HG23 ' CD2' ' A' ' 153' ' ' LEU . 1.5 mt -120.06 123.7 71.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.333 -0.854 . . . . 0.0 109.304 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 15.6 t0 -107.3 98.14 21.78 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.246 -0.909 . . . . 0.0 109.655 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.553 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.8 Cg_endo -71.66 173.86 11.93 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 122.721 2.281 . . . . 0.0 111.779 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.553 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.0 tt0 80.53 -21.07 0.34 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.345 -0.847 . . . . 0.0 109.879 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.445 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 47.5 mtt85 -128.75 -11.88 4.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.111 -0.993 . . . . 0.0 109.45 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.786 ' O ' HG23 ' A' ' 170' ' ' VAL . 31.9 mt-30 69.26 48.25 0.67 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.277 -0.89 . . . . 0.0 109.774 179.82 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -122.34 146.08 47.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.132 -0.98 . . . . 0.0 108.87 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.837 ' CD2' HG23 ' A' ' 146' ' ' ILE . 0.4 OUTLIER -135.62 122.47 21.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.101 -1.0 . . . . 0.0 110.565 -179.398 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 5.8 mtmm -81.91 130.97 35.24 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.605 HG11 ' CG1' ' A' ' 129' ' ' VAL . 4.2 t -128.46 147.93 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.961 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.548 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 4.4 t30 -97.14 113.02 24.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.392 -0.817 . . . . 0.0 109.26 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.757 HG13 ' CE1' ' A' ' 139' ' ' PHE . 67.7 t -94.39 141.62 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.241 -0.912 . . . . 0.0 109.642 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 60.1 m -94.2 95.71 9.13 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.383 -0.823 . . . . 0.0 109.63 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.561 HG22 ' CD2' ' A' ' 160' ' ' PHE . 5.4 mt -121.72 141.37 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.253 -0.905 . . . . 0.0 109.581 179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.671 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 96.6 m-85 61.26 41.26 13.5 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.344 -0.847 . . . . 0.0 109.523 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.33 16.81 22.31 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 18.5 mtp85 -129.71 151.71 50.0 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.154 -1.203 . . . . 0.0 109.575 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.486 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 73.4 mt-10 -95.97 136.73 36.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.249 -0.907 . . . . 0.0 109.506 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 16.3 m -145.44 128.33 8.22 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.618 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.548 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.2 Cg_endo -70.24 136.67 32.28 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.757 2.304 . . . . 0.0 111.618 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.713 HG13 HD11 ' A' ' 168' ' ' LEU . 3.7 p -123.23 142.86 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.14 -0.975 . . . . 0.0 109.559 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.457 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 6.3 m -92.83 119.19 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.413 -0.805 . . . . 0.0 109.485 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.713 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -142.12 167.9 21.02 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.238 -0.914 . . . . 0.0 110.384 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.506 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 47.8 m170 -82.27 141.01 33.3 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.786 HG23 ' O ' ' A' ' 151' ' ' GLN . 59.5 t -53.94 -36.78 31.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.185 -0.947 . . . . 0.0 108.893 179.697 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.571 ' CB ' ' HA ' ' A' ' 118' ' ' LYS . 7.1 p -75.16 -6.77 51.36 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.561 -0.712 . . . . 0.0 109.812 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.506 ' CG ' ' HB2' ' A' ' 169' ' ' HIS . 92.7 mt-10 -96.17 -3.39 44.5 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.083 -1.011 . . . . 0.0 109.866 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.7 m -133.45 170.68 19.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.106 -0.997 . . . . 0.0 109.993 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.568 ' O ' ' CG2' ' A' ' 129' ' ' VAL . 25.6 tp10 -127.56 144.01 51.11 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.583 ' CD ' ' HB3' ' A' ' 123' ' ' PHE . 9.7 mttp -98.78 30.06 3.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.069 -1.019 . . . . 0.0 109.567 -179.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.444 ' C ' ' O ' ' A' ' 175' ' ' LYS . 27.4 mt 41.85 -95.35 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.328 -0.857 . . . . 0.0 109.636 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.512 ' N ' ' O ' ' A' ' 175' ' ' LYS . 85.4 tt0 . . . . . 0 N--CA 1.488 1.47 0 CA-C-O 117.98 -1.009 . . . . 0.0 109.493 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -61.94 -28.85 69.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -1.156 . . . . 0.0 109.43 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 44.6 ttm -61.55 -23.05 65.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.314 -0.866 . . . . 0.0 109.443 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.1 tttt -95.26 120.22 35.12 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.359 -0.838 . . . . 0.0 109.464 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.7 mttt -133.88 151.96 51.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.261 -0.899 . . . . 0.0 109.506 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.592 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 41.7 mmtt -130.65 171.11 13.43 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.356 -0.84 . . . . 0.0 109.126 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.767 ' CH2' HG23 ' A' ' 41' ' ' VAL . 60.1 m95 -104.55 126.5 51.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.202 -0.936 . . . . 0.0 109.329 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -116.94 168.03 10.6 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.154 -0.966 . . . . 0.0 109.145 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.535 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 65.1 mt -104.37 115.94 47.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.156 -0.965 . . . . 0.0 109.379 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.646 HG22 ' CD2' ' A' ' 83' ' ' PHE . 65.5 t -92.09 138.21 20.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.216 -0.927 . . . . 0.0 109.248 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.535 ' CD2' ' N ' ' A' ' 11' ' ' LEU . 3.5 mm? -88.12 141.9 28.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.312 -0.867 . . . . 0.0 109.338 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.451 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 1.3 p -153.44 174.85 13.84 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.235 -0.916 . . . . 0.0 109.375 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.436 ' O ' ' C ' ' A' ' 14' ' ' SER . 98.1 mtp -95.63 121.02 36.9 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.165 -0.959 . . . . 0.0 109.439 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.436 ' C ' ' O ' ' A' ' 13' ' ' MET . 22.4 t -42.03 126.76 3.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.291 -0.88 . . . . 0.0 109.51 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.23 -19.98 33.69 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.527 ' O ' HG23 ' A' ' 20' ' ' VAL . 89.0 m-85 -108.77 -18.79 13.62 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.233 -1.157 . . . . 0.0 109.629 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.736 ' OE1' HD11 ' A' ' 44' ' ' ILE . 43.4 mt-10 -41.48 -67.09 0.28 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.311 -0.868 . . . . 0.0 109.596 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -46.76 -38.59 10.29 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.193 -0.942 . . . . 0.0 109.415 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.444 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 24.0 tttp -69.22 -34.87 75.52 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.242 -0.911 . . . . 0.0 109.179 179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.653 HG22 ' HB2' ' A' ' 79' ' ' TYR . 43.8 t -68.78 -41.35 82.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.333 -0.854 . . . . 0.0 109.279 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.55 ' HB2' HD11 ' A' ' 42' ' ' ILE . 16.7 tttm -57.06 -50.82 71.56 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.277 -0.89 . . . . 0.0 109.487 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -62.31 -33.82 75.42 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.177 -0.952 . . . . 0.0 109.151 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.506 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 23.4 m120 -65.62 -33.65 76.4 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.302 -0.874 . . . . 0.0 109.284 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.82 HD12 HD13 ' A' ' 40' ' ' ILE . 79.2 mt -67.66 -45.37 84.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.271 -0.893 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -55.6 -46.19 77.35 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.269 -0.895 . . . . 0.0 109.576 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 41.9 mttt -75.41 -36.04 60.9 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.605 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.58 ' HE3' ' CE1' ' A' ' 73' ' ' PHE . 28.6 tttp -54.72 -32.42 59.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.21 -0.931 . . . . 0.0 109.27 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 33' ' ' ILE . 99.2 t -88.5 -22.89 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.296 -0.878 . . . . 0.0 109.504 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -72.24 -57.0 4.59 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.237 -0.914 . . . . 0.0 109.609 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -61.22 -24.17 66.15 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.536 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 48.1 p -98.43 -17.37 18.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.244 -0.91 . . . . 0.0 109.418 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 62.74 26.14 68.28 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.037 HG21 HD12 ' A' ' 36' ' ' LEU . 76.7 mt -97.38 77.48 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.176 -1.191 . . . . 0.0 109.438 179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.411 ' O ' ' HG2' ' A' ' 34' ' ' LYS . 17.8 tttp -89.72 22.85 2.89 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.29 -0.881 . . . . 0.0 109.129 179.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 1.071 ' O ' HD13 ' A' ' 65' ' ' ILE . 92.0 m-20 -118.27 -9.46 10.42 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.37 -0.831 . . . . 0.0 109.572 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.037 HD12 HG21 ' A' ' 33' ' ' ILE . 96.9 mt -97.47 -51.74 4.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.253 -0.905 . . . . 0.0 109.387 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.569 HG11 ' CG2' ' A' ' 24' ' ' ILE . 59.3 t -94.73 136.12 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.258 -0.902 . . . . 0.0 109.245 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.89 -119.99 3.84 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 86.4 mtt180 -91.76 139.97 30.15 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.295 -1.12 . . . . 0.0 109.825 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 1.164 HG23 HG22 ' A' ' 62' ' ' VAL . 29.4 mt -107.91 133.39 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.397 -0.815 . . . . 0.0 109.115 179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.767 HG23 ' CH2' ' A' ' 7' ' ' TRP . 25.8 t -121.99 132.56 70.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.175 -0.953 . . . . 0.0 109.25 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.581 HG22 HG13 ' A' ' 44' ' ' ILE . 4.5 mt -124.67 125.81 25.46 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.267 -0.896 . . . . 0.0 109.577 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.614 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 49.1 Cg_endo -68.4 -2.75 9.66 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.858 2.372 . . . . 0.0 111.422 179.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.878 HG23 ' HG2' ' A' ' 54' ' ' LYS . 87.7 mt -67.07 -28.88 44.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.35 -0.843 . . . . 0.0 109.602 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.45 ' C ' ' O ' ' A' ' 44' ' ' ILE . 9.2 tpt85 -42.32 -45.1 4.13 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.305 -0.872 . . . . 0.0 109.543 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 47.4 -111.19 0.72 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 164.97 169.17 28.23 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.434 ' O ' ' C ' ' A' ' 49' ' ' ARG . 71.3 mt-30 -60.64 -19.81 59.13 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.26 -1.141 . . . . 0.0 109.34 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.47 ' HD2' ' HB ' ' A' ' 167' ' ' VAL . 6.5 ttp180 -43.7 -48.68 7.93 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.271 -0.893 . . . . 0.0 109.435 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.881 ' CZ ' HG23 ' A' ' 167' ' ' VAL . 63.2 mtt-85 -116.19 136.59 52.87 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.286 -0.884 . . . . 0.0 109.573 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 58.1 mttm -65.23 -40.89 94.68 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.208 -0.933 . . . . 0.0 109.193 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.526 ' O ' ' CG ' ' A' ' 53' ' ' GLU . 60.0 p -60.58 -169.17 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.227 -0.92 . . . . 0.0 109.18 179.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 52' ' ' SER . 89.9 mt-10 -160.33 175.51 12.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.195 -0.941 . . . . 0.0 109.55 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.878 ' HG2' HG23 ' A' ' 44' ' ' ILE . 1.3 mttp 76.24 83.51 0.09 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.371 -0.831 . . . . 0.0 109.75 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.614 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 35.0 mt -59.7 -41.83 91.65 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.112 -0.993 . . . . 0.0 108.654 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.496 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 88.1 m-85 -129.19 105.1 17.93 Favored Pre-proline 0 N--CA 1.489 1.48 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -64.7 136.13 48.22 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.484 2.122 . . . . 0.0 112.093 -179.046 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.34 -18.47 4.36 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.6 m-30 -95.77 129.24 43.05 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.666 -1.49 . . . . 0.0 110.51 -178.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 36.1 t -133.23 147.07 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.683 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 9.6 m-85 -108.79 124.67 50.95 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.856 -1.153 . . . . 0.0 109.861 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 1.164 HG22 HG23 ' A' ' 40' ' ' ILE . 61.9 t -135.62 146.76 29.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.331 -0.856 . . . . 0.0 109.904 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.592 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 26.4 tt0 -110.88 127.41 55.43 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.739 ' HE1' HG11 ' A' ' 74' ' ' VAL . 40.4 mtm -152.16 163.65 38.95 Favored 'General case' 0 N--CA 1.491 1.587 0 C-N-CA 118.757 -1.177 . . . . 0.0 111.304 -178.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 1.071 HD13 ' O ' ' A' ' 35' ' ' ASN . 2.3 pt -82.64 124.81 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.488 ' CE ' ' HG2' ' A' ' 89' ' ' GLN . 94.9 mmm -76.23 142.72 41.35 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.146 -0.971 . . . . 0.0 109.885 -178.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 6.3 m-20 177.31 170.18 0.58 Allowed 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -68.79 -41.6 78.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.128 -0.982 . . . . 0.0 109.454 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -78.08 -29.61 49.22 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.173 -0.954 . . . . 0.0 109.85 -179.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.028 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -72.86 -48.92 33.45 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.12 -0.987 . . . . 0.0 109.479 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.442 ' CE1' ' HG3' ' A' ' 89' ' ' GLN . 75.1 t80 -61.22 -48.1 83.06 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.258 -0.901 . . . . 0.0 109.564 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -61.46 -29.32 69.88 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.209 -0.932 . . . . 0.0 109.777 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.58 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 48.7 t80 -80.78 -41.74 22.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.121 -0.987 . . . . 0.0 109.472 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 1.028 HG23 ' O ' ' A' ' 70' ' ' ALA . 4.2 t -68.76 -56.23 12.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.33 -0.856 . . . . 0.0 109.511 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 42.1 tpt85 -54.59 -17.34 3.18 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.358 -0.838 . . . . 0.0 109.735 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 26.2 p -91.3 6.91 43.41 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.26 -0.9 . . . . 0.0 109.872 -179.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.598 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 25.1 t -64.43 137.85 97.26 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.052 -1.03 . . . . 0.0 109.542 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.585 ' HB2' ' CE2' ' A' ' 79' ' ' TYR . 47.7 Cg_endo -68.47 137.63 40.01 Favored 'Trans proline' 0 C--O 1.216 -0.599 0 C-N-CA 122.718 2.278 . . . . 0.0 111.778 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.653 ' HB2' HG22 ' A' ' 20' ' ' VAL . 17.5 m-85 76.17 -4.64 2.32 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.388 -0.82 . . . . 0.0 109.712 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.598 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 5.4 t -87.02 129.66 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.055 -1.028 . . . . 0.0 109.101 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 98.9 mmm -88.14 -7.17 57.31 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.517 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 124.07 -145.23 15.84 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.646 ' CD2' HG22 ' A' ' 10' ' ' VAL . 1.4 m-85 -140.49 148.6 41.35 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.189 -1.183 . . . . 0.0 109.708 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.535 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 3.4 p -75.78 134.61 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.246 -0.909 . . . . 0.0 109.344 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.465 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.3 p -162.94 163.74 26.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.204 -0.935 . . . . 0.0 109.664 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.0 m -91.43 -33.34 15.27 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.37 -0.831 . . . . 0.0 109.421 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -124.98 -84.32 0.58 Allowed Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.554 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -110.31 -135.24 6.97 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.554 ' C ' ' O ' ' A' ' 88' ' ' GLY . 1.0 OUTLIER -29.49 150.45 0.03 OUTLIER Pre-proline 0 N--CA 1.496 1.852 0 O-C-N 121.584 -0.951 . . . . 0.0 110.302 -179.484 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.577 ' HG3' ' CB ' ' A' ' 83' ' ' PHE . 50.1 Cg_endo -68.22 142.05 54.14 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.899 2.399 . . . . 0.0 112.153 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.754 HG23 ' HD2' ' A' ' 92' ' ' PRO . 3.7 p -75.69 144.67 77.28 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 109.26 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.754 ' HD2' HG23 ' A' ' 91' ' ' VAL . 46.0 Cg_endo -68.34 150.28 76.0 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.61 2.207 . . . . 0.0 111.806 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.4 t -76.53 137.95 21.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.291 -0.881 . . . . 0.0 109.533 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.1 tttp -74.19 132.99 42.71 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.313 -0.867 . . . . 0.0 109.415 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.405 ' C ' ' O ' ' A' ' 94' ' ' LYS . 79.3 m-20 -44.11 -41.7 5.79 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.24 -0.912 . . . . 0.0 109.448 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.424 ' HB2' ' HD3' ' A' ' 94' ' ' LYS . 53.1 mtp180 -60.85 -27.03 67.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.278 -0.889 . . . . 0.0 109.497 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.516 ' N ' ' O ' ' A' ' 94' ' ' LYS . 45.1 mt-10 -86.6 -26.06 24.62 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.241 -0.912 . . . . 0.0 109.398 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.505 ' O ' HD12 ' A' ' 102' ' ' LEU . 27.9 mmm -85.59 -22.97 27.79 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.219 -0.926 . . . . 0.0 109.5 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.616 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.1 OUTLIER -42.61 -49.09 13.23 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.29 -0.881 . . . . 0.0 109.887 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.616 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 51.9 Cg_endo -74.2 -27.32 11.75 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.435 2.09 . . . . 0.0 111.672 -179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.578 HG21 ' CD2' ' A' ' 61' ' ' PHE . 33.8 mm -80.87 -38.75 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.333 -0.855 . . . . 0.0 109.344 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -69.27 -40.07 78.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 109.313 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.582 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 19.5 ttm180 -64.36 -50.42 67.78 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.254 -0.904 . . . . 0.0 109.308 179.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.549 HD23 ' C ' ' A' ' 104' ' ' LEU . 6.8 tt -72.29 -36.19 68.88 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.296 -0.877 . . . . 0.0 109.216 179.713 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -69.76 -2.93 13.36 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.308 -0.87 . . . . 0.0 109.908 -179.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.86 8.98 86.74 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.445 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 1.0 OUTLIER -72.53 -17.05 61.77 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.211 -1.17 . . . . 0.0 109.416 -179.948 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -104.33 159.28 15.85 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.241 -0.912 . . . . 0.0 109.517 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -107.72 101.44 10.75 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.235 -0.916 . . . . 0.0 109.379 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -146.09 158.05 43.86 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.197 -0.939 . . . . 0.0 109.427 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -97.17 -90.77 0.26 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.426 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.483 ' O ' ' C ' ' A' ' 113' ' ' LYS . 82.7 tt0 -146.06 152.72 39.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.199 -0.938 . . . . 0.0 109.458 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.483 ' C ' ' O ' ' A' ' 112' ' ' GLU . 54.3 pttt -38.5 144.82 0.1 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.387 -0.821 . . . . 0.0 109.758 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.18 -58.33 3.32 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.309 -0.869 . . . . 0.0 109.557 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.45 ' HB2' ' HD2' ' A' ' 116' ' ' PRO . 0.0 OUTLIER -170.3 162.42 6.29 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.233 -0.917 . . . . 0.0 109.476 -179.889 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.45 ' HD2' ' HB2' ' A' ' 115' ' ' LYS . 50.2 Cg_endo -70.2 142.04 44.97 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.763 2.309 . . . . 0.0 111.725 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 33.9 m -121.64 162.03 21.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.289 -0.882 . . . . 0.0 109.528 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.846 ' O ' HG13 ' A' ' 119' ' ' VAL . 30.9 mtpp -100.31 124.63 46.02 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.271 -0.893 . . . . 0.0 109.419 179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.846 HG13 ' O ' ' A' ' 118' ' ' LYS . 0.1 OUTLIER -169.3 57.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.282 -0.887 . . . . 0.0 109.425 -179.931 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.534 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 94.6 mt-10 -62.24 -83.68 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.216 -0.928 . . . . 0.0 109.531 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.632 ' O ' ' C ' ' A' ' 122' ' ' GLY . 9.4 mt 77.93 105.93 0.07 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.332 -0.855 . . . . 0.0 109.247 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.632 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -20.24 93.55 0.01 OUTLIER Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.446 -1.061 . . . . 0.0 110.446 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.487 ' N ' ' O ' ' A' ' 121' ' ' LEU . 8.9 p90 -103.03 143.12 32.99 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.29 -1.124 . . . . 0.0 109.281 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.428 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 13.9 mmtt -137.77 165.22 26.97 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.22 -0.925 . . . . 0.0 109.758 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.614 HG23 ' O ' ' A' ' 144' ' ' LYS . 14.2 p -62.42 143.13 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.316 -0.865 . . . . 0.0 109.536 -179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.68 -33.11 3.54 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.428 ' HB2' ' O ' ' A' ' 124' ' ' LYS . 31.8 m-20 -49.67 159.19 0.39 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.532 -0.981 . . . . 0.0 109.247 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . 0.661 ' CE ' HD12 ' A' ' 176' ' ' ILE . 2.0 ttp -94.19 127.62 40.14 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.136 -0.978 . . . . 0.0 109.008 179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.794 HG21 HD11 ' A' ' 143' ' ' ILE . 5.9 t -125.99 142.49 42.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.361 -0.837 . . . . 0.0 109.28 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.494 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 22.2 tttp -105.41 142.13 35.7 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.405 -0.809 . . . . 0.0 108.875 179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 1.029 HD12 ' HB3' ' A' ' 139' ' ' PHE . 66.9 mt -83.3 155.1 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.186 -0.946 . . . . 0.0 108.618 179.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.496 HG12 ' HA ' ' A' ' 173' ' ' VAL . 29.1 pt -150.62 2.8 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.076 -1.015 . . . . 0.0 109.549 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 72.3 m -148.19 144.44 27.72 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.071 -1.018 . . . . 0.0 109.992 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 104.29 -167.99 16.23 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.582 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 48.3 Cg_endo -68.97 -20.74 38.21 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 123.124 2.549 . . . . 0.0 112.408 -179.544 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.534 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.3 m-85 -110.31 15.95 21.97 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.829 -1.169 . . . . 0.0 109.435 -179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.642 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.7 tt0 -43.8 143.26 1.09 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.232 -0.917 . . . . 0.0 109.486 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.521 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 16.4 m-20 75.85 27.65 0.94 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.374 -0.829 . . . . 0.0 110.258 179.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 1.029 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.3 t80 -117.68 133.58 55.8 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.021 -1.049 . . . . 0.0 109.493 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -82.96 133.75 35.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.127 -0.983 . . . . 0.0 109.653 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.412 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.15 167.34 27.36 Favored Glycine 0 N--CA 1.49 2.279 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.098 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.743 ' C ' HG23 ' A' ' 155' ' ' VAL . 58.4 t -110.38 136.92 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.442 -1.034 . . . . 0.0 109.404 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 1.068 HG21 HD11 ' A' ' 146' ' ' ILE . 43.2 mm -69.36 118.69 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.297 -0.877 . . . . 0.0 109.448 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.614 ' O ' HG23 ' A' ' 125' ' ' VAL . 47.3 tttp -98.17 -32.35 11.63 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.041 -1.037 . . . . 0.0 109.557 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.518 ' CG ' ' O ' ' A' ' 144' ' ' LYS . 85.7 mt-10 -157.68 153.33 26.52 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.058 -1.026 . . . . 0.0 110.073 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 1.082 HG23 HD22 ' A' ' 153' ' ' LEU . 6.1 mm -123.65 126.49 72.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.406 -0.809 . . . . 0.0 109.591 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -108.85 99.37 34.37 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.349 -0.845 . . . . 0.0 109.476 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.549 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.2 Cg_endo -71.21 173.77 11.74 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.739 2.293 . . . . 0.0 111.764 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.549 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.5 mt-10 79.97 -20.98 0.35 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.358 -0.839 . . . . 0.0 109.865 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.402 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 32.6 mtp180 -128.78 -13.4 4.69 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.079 -1.013 . . . . 0.0 109.476 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.425 ' O ' HG12 ' A' ' 170' ' ' VAL . 37.8 mt-30 69.58 48.22 0.62 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.283 -0.886 . . . . 0.0 109.685 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.864 ' O ' HD23 ' A' ' 153' ' ' LEU . 59.5 tt0 -120.41 144.25 48.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.158 -0.964 . . . . 0.0 108.936 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 1.082 HD22 HG23 ' A' ' 146' ' ' ILE . 29.4 mt -130.12 131.01 45.53 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.078 -1.014 . . . . 0.0 110.083 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 13.6 mttt -93.07 130.9 38.53 Favored 'General case' 0 N--CA 1.488 1.451 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 179.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.758 HG12 HD11 ' A' ' 168' ' ' LEU . 13.9 p -132.7 147.48 31.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.096 -1.003 . . . . 0.0 110.057 -179.521 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.562 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.6 m-20 -96.7 117.0 30.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.464 -0.773 . . . . 0.0 109.265 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.415 HG13 ' CE1' ' A' ' 139' ' ' PHE . 44.9 t -96.79 141.38 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 109.501 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.408 ' HA ' ' O ' ' A' ' 162' ' ' ARG . 73.5 m -96.07 94.91 7.83 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.273 -0.892 . . . . 0.0 109.929 -179.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.561 HG22 ' CD2' ' A' ' 160' ' ' PHE . 6.2 mt -118.22 140.78 40.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.25 -0.906 . . . . 0.0 109.422 179.483 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.683 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 97.3 m-85 62.25 40.16 11.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.331 -0.855 . . . . 0.0 109.337 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.48 17.9 34.87 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.412 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 36.9 mtt-85 -128.29 156.12 43.52 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.179 -1.189 . . . . 0.0 109.618 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 -99.84 134.23 43.04 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.283 -0.886 . . . . 0.0 109.558 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 37.3 m -143.11 127.44 9.59 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.303 -0.873 . . . . 0.0 109.554 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.562 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.3 Cg_endo -69.63 135.18 30.09 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.76 2.307 . . . . 0.0 111.544 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 34.5 t -123.49 142.59 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.986 . . . . 0.0 109.861 -179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.881 HG23 ' CZ ' ' A' ' 50' ' ' ARG . 29.4 t -93.78 119.35 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.403 -0.81 . . . . 0.0 109.485 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.758 HD11 HG12 ' A' ' 155' ' ' VAL . 0.0 OUTLIER -141.91 168.65 19.25 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.209 -0.932 . . . . 0.0 110.413 -179.651 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.501 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 42.3 m170 -83.51 140.6 32.2 Favored 'General case' 0 N--CA 1.489 1.522 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.932 HG23 HD11 ' A' ' 153' ' ' LEU . 7.5 p -54.91 -36.33 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.26 -0.9 . . . . 0.0 109.183 179.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.412 ' N ' HG13 ' A' ' 170' ' ' VAL . 84.4 p -75.84 -7.26 54.06 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -0.868 . . . . 0.0 109.707 -179.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.501 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 84.3 mt-10 -87.61 -2.44 58.61 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.069 -1.019 . . . . 0.0 109.647 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.496 ' HA ' HG12 ' A' ' 132' ' ' ILE . 3.7 m -142.05 175.91 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.191 -0.943 . . . . 0.0 109.446 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.546 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 76.2 tt0 -140.57 167.26 22.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.281 -0.887 . . . . 0.0 108.932 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.546 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.1 tttp -86.27 15.12 5.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.03 -1.044 . . . . 0.0 109.6 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.661 HD12 ' CE ' ' A' ' 128' ' ' MET . 10.8 mt 65.74 -70.4 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.306 -0.871 . . . . 0.0 109.477 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.483 ' N ' ' O ' ' A' ' 175' ' ' LYS . 86.3 tt0 . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 117.947 -1.025 . . . . 0.0 109.506 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.452 ' O ' ' HB ' ' A' ' 65' ' ' ILE . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.452 ' HA ' HG21 ' A' ' 65' ' ' ILE . . . -61.96 -16.14 48.94 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.219 -1.166 . . . . 0.0 109.509 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . 0.438 ' O ' ' HB2' ' A' ' 4' ' ' LYS . 71.3 mtm -106.6 174.83 5.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.28 -0.887 . . . . 0.0 109.423 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.438 ' HB2' ' O ' ' A' ' 3' ' ' MET . 67.8 mttt 63.23 41.69 7.69 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.247 -0.908 . . . . 0.0 109.383 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.491 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 74.8 mttt -69.11 148.97 49.2 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.201 -0.937 . . . . 0.0 109.658 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.566 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 10.9 mttp -129.17 175.63 8.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.291 -0.881 . . . . 0.0 109.259 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.876 ' O ' HG23 ' A' ' 93' ' ' VAL . 56.7 m95 -112.38 124.69 53.05 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.262 -0.899 . . . . 0.0 109.233 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.45 ' CD1' ' HA ' ' A' ' 92' ' ' PRO . 62.6 m-85 -117.36 171.81 7.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.189 -0.944 . . . . 0.0 109.335 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.565 HG12 ' CZ ' ' A' ' 61' ' ' PHE . 40.9 mt -112.49 107.83 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.174 -0.954 . . . . 0.0 108.995 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.881 ' CG1' HG13 ' A' ' 60' ' ' VAL . 10.8 p -83.5 146.05 7.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.208 -0.932 . . . . 0.0 109.465 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.526 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.0 OUTLIER -90.77 142.25 27.95 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.525 -0.734 . . . . 0.0 109.67 -179.667 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.764 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.1 t -154.97 -176.07 5.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.243 -0.911 . . . . 0.0 109.299 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.423 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 58.2 mtm -102.23 125.66 48.99 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.187 -0.946 . . . . 0.0 109.445 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.4 m -45.59 128.02 8.03 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.203 -0.936 . . . . 0.0 109.536 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.21 -19.46 37.38 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.797 ' O ' HG23 ' A' ' 20' ' ' VAL . 94.1 m-85 -108.19 -7.91 15.89 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.313 -1.11 . . . . 0.0 109.436 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.832 ' OE1' HD11 ' A' ' 44' ' ' ILE . 47.9 mt-10 -47.93 -53.91 14.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.264 -0.898 . . . . 0.0 109.474 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -55.62 -37.05 67.66 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.239 -0.913 . . . . 0.0 109.346 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.516 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 88.5 mttt -73.25 -34.86 66.07 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.305 -0.872 . . . . 0.0 109.372 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.797 HG23 ' O ' ' A' ' 16' ' ' TYR . 13.4 t -66.69 -46.6 85.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.211 -0.931 . . . . 0.0 109.414 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 23.2 tttt -58.92 -48.44 81.48 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.278 -0.889 . . . . 0.0 109.666 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.9 mt-10 -65.71 -40.26 92.06 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.219 -0.926 . . . . 0.0 109.507 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.53 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 92.7 m-20 -60.45 -42.06 95.35 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.218 -0.926 . . . . 0.0 109.379 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.62 ' O ' HG23 ' A' ' 28' ' ' VAL . 96.7 mt -64.38 -44.64 97.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.307 -0.871 . . . . 0.0 109.552 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.459 ' O ' ' HG3' ' A' ' 29' ' ' GLU . 87.9 mt-10 -59.23 -47.02 86.91 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.172 -0.955 . . . . 0.0 110.036 -179.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.2 ttpt -80.19 -38.39 31.36 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.049 -1.032 . . . . 0.0 109.731 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.585 ' HG2' ' CE1' ' A' ' 73' ' ' PHE . 19.3 tttt -57.16 -25.64 59.26 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.331 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.856 HG21 HG11 ' A' ' 37' ' ' VAL . 89.4 t -88.07 -26.98 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.301 -0.875 . . . . 0.0 109.482 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.459 ' HG3' ' O ' ' A' ' 25' ' ' GLU . 93.1 mt-10 -66.92 -47.65 71.07 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.23 -0.919 . . . . 0.0 109.504 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.12 -28.91 69.96 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.28 -0.888 . . . . 0.0 109.365 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 71.9 p -89.03 -12.02 42.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.286 -0.884 . . . . 0.0 109.322 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 61.07 24.04 62.53 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.844 ' CG2' HD23 ' A' ' 36' ' ' LEU . 54.7 mt -101.35 74.43 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.263 -1.139 . . . . 0.0 109.552 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 55.6 mttp -85.26 -3.8 58.94 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.336 -0.853 . . . . 0.0 109.597 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.435 ' O ' HD13 ' A' ' 65' ' ' ILE . 90.5 m-20 -93.12 -7.01 46.68 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.209 -0.932 . . . . 0.0 109.4 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.019 HD12 ' HB2' ' A' ' 70' ' ' ALA . 4.4 mm? -95.66 -50.83 4.77 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.267 -0.895 . . . . 0.0 109.34 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.856 HG11 HG21 ' A' ' 28' ' ' VAL . 8.7 p -95.35 139.16 19.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.381 -0.824 . . . . 0.0 109.554 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.1 -122.16 4.07 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 88.6 mtt-85 -95.34 142.7 27.43 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.223 -1.163 . . . . 0.0 109.706 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.954 HG23 HG22 ' A' ' 62' ' ' VAL . 75.4 mt -109.73 137.5 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.222 -0.924 . . . . 0.0 109.196 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.632 HG13 ' HB2' ' A' ' 61' ' ' PHE . 7.7 p -127.93 162.08 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.169 -0.957 . . . . 0.0 109.36 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.632 HG21 HD12 ' A' ' 44' ' ' ILE . 5.9 mt -144.2 130.13 9.87 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.167 -0.958 . . . . 0.0 109.902 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.515 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.1 Cg_endo -66.36 -3.71 9.33 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.861 2.374 . . . . 0.0 111.478 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.832 HD11 ' OE1' ' A' ' 17' ' ' GLU . 61.0 mt -72.21 -28.51 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.275 -0.89 . . . . 0.0 109.508 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.421 ' C ' ' O ' ' A' ' 44' ' ' ILE . 32.4 mmt-85 -43.92 143.42 1.1 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.242 -0.911 . . . . 0.0 109.594 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 152.86 125.47 1.1 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 64.27 -123.72 28.31 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 56.1 tp60 -94.31 133.41 37.89 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.348 -1.09 . . . . 0.0 109.524 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 84.0 mtt-85 -53.53 -44.58 69.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.203 -0.936 . . . . 0.0 109.42 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 46.2 mtm105 -64.84 148.89 50.46 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.184 -0.948 . . . . 0.0 109.184 179.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . 0.417 ' O ' ' O ' ' A' ' 52' ' ' SER . 58.4 mttp 46.63 36.32 3.61 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.171 -0.956 . . . . 0.0 109.22 -179.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.695 ' HB3' HG22 ' A' ' 44' ' ' ILE . 29.1 m -50.66 179.68 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.331 -0.855 . . . . 0.0 109.535 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.496 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 92.3 mt-10 -101.22 -36.5 8.9 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.327 -0.858 . . . . 0.0 109.583 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.804 ' HG2' HG23 ' A' ' 44' ' ' ILE . 3.6 mttp 75.16 89.99 0.08 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.188 -0.945 . . . . 0.0 109.215 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.593 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 16.9 tp -65.25 -22.3 66.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.863 -1.148 . . . . 0.0 109.775 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.593 ' CE2' ' HG ' ' A' ' 55' ' ' LEU . 95.8 m-85 -148.37 98.17 3.73 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.21 -0.931 . . . . 0.0 108.818 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -65.86 140.56 61.53 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.723 2.282 . . . . 0.0 112.205 -179.243 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.4 -10.89 10.21 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -107.25 132.6 52.9 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.749 -1.442 . . . . 0.0 110.291 -179.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.881 HG13 ' CG1' ' A' ' 10' ' ' VAL . 0.2 OUTLIER -135.22 151.4 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 179.001 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.632 ' HB2' HG13 ' A' ' 41' ' ' VAL . 14.0 m-85 -111.73 126.56 55.18 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.948 -1.095 . . . . 0.0 110.258 -179.14 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.954 HG22 HG23 ' A' ' 40' ' ' ILE . 67.1 t -130.22 141.88 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.547 -0.721 . . . . 0.0 109.66 179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.601 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 10.8 tt0 -104.16 125.92 50.86 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 108.766 179.538 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.495 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 30.7 mtm -156.18 172.92 17.61 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.019 -1.051 . . . . 0.0 110.783 -179.073 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.628 ' CG1' HD13 ' A' ' 36' ' ' LEU . 4.8 pt -95.17 130.48 43.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.477 ' SD ' ' NE2' ' A' ' 89' ' ' GLN . 4.1 tpp -76.04 143.34 41.46 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.3 -0.875 . . . . 0.0 110.037 -178.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.468 ' HB2' ' O ' ' A' ' 66' ' ' MET . 42.6 t30 176.69 175.78 0.33 Allowed 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' A' ' 69' ' ' GLU . 28.6 p-10 -71.6 -40.45 69.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.145 -0.972 . . . . 0.0 109.406 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.473 ' N ' ' OD1' ' A' ' 68' ' ' ASP . 71.0 mm-40 -73.23 -35.5 66.28 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.362 -0.836 . . . . 0.0 109.716 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.019 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -67.63 -47.87 68.37 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 109.589 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.546 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 84.0 t80 -59.77 -51.57 69.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.212 -0.93 . . . . 0.0 109.676 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -57.48 -29.03 63.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.239 -0.913 . . . . 0.0 109.876 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.696 ' CE2' HG22 ' A' ' 28' ' ' VAL . 65.9 t80 -80.4 -40.79 25.78 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.113 -0.992 . . . . 0.0 109.929 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 1.008 HG23 ' O ' ' A' ' 70' ' ' ALA . 2.6 t -64.63 -60.33 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.185 -0.947 . . . . 0.0 109.92 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.463 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 10.8 tpt180 -51.58 -42.92 62.26 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.097 -1.002 . . . . 0.0 109.736 -179.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.423 ' HB3' ' HZ1' ' A' ' 27' ' ' LYS . 22.8 t -67.58 1.24 2.5 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.11 -0.994 . . . . 0.0 110.244 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.616 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 30.7 t -62.29 133.98 94.59 Favored Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 120.928 -1.107 . . . . 0.0 109.317 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.571 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 46.0 Cg_endo -68.0 136.08 36.95 Favored 'Trans proline' 0 C--O 1.213 -0.738 0 C-N-CA 122.727 2.285 . . . . 0.0 111.866 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.571 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 54.3 m-85 77.61 -2.26 2.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.528 -0.733 . . . . 0.0 109.65 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.616 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.0 t -87.45 126.96 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.102 -0.999 . . . . 0.0 109.162 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 66.1 mtp -90.02 -24.65 21.15 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.228 -0.92 . . . . 0.0 109.73 -179.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.422 ' O ' ' N ' ' A' ' 11' ' ' LEU . . . 158.25 -158.04 28.85 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.59 ' HB2' ' HB3' ' A' ' 90' ' ' PRO . 15.3 p90 -140.56 154.13 46.4 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.243 -1.151 . . . . 0.0 109.506 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.493 ' CG2' ' CD2' ' A' ' 11' ' ' LEU . 47.5 t -81.73 113.45 21.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.137 -0.977 . . . . 0.0 109.466 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.533 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 5.3 p -145.2 164.66 30.66 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.226 -0.921 . . . . 0.0 109.498 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 23.9 m -86.47 -33.17 20.46 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.2 -0.938 . . . . 0.0 109.287 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -135.58 -76.91 0.09 OUTLIER Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.55 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -109.61 -133.56 6.7 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.55 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.4 OUTLIER -29.49 150.31 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.63 -0.924 . . . . 0.0 110.315 -179.636 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.59 ' HB3' ' HB2' ' A' ' 83' ' ' PHE . 44.5 Cg_endo -67.81 147.45 75.1 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.833 2.355 . . . . 0.0 111.973 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.766 HG23 ' HD2' ' A' ' 92' ' ' PRO . 3.4 p -80.81 144.69 56.22 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.317 -0.864 . . . . 0.0 109.369 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.766 ' HD2' HG23 ' A' ' 91' ' ' VAL . 47.3 Cg_endo -68.6 151.39 75.16 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.66 2.24 . . . . 0.0 111.715 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.876 HG23 ' O ' ' A' ' 7' ' ' TRP . 11.9 t -83.64 131.76 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.232 -0.918 . . . . 0.0 109.583 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 54.9 mttm -69.87 143.17 52.89 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.31 -0.868 . . . . 0.0 109.446 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -53.3 -39.97 64.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.25 -0.907 . . . . 0.0 109.596 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -57.98 -34.34 69.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.274 -0.891 . . . . 0.0 109.558 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.7 mt-10 -81.34 -25.41 36.41 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.266 -0.896 . . . . 0.0 109.525 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.696 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 98.6 mtp -84.1 -26.42 28.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.899 . . . . 0.0 109.58 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.58 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.4 OUTLIER -36.24 -54.24 1.53 Allowed Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.448 -0.783 . . . . 0.0 109.927 -179.838 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.58 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.5 Cg_endo -70.1 -28.2 23.93 Favored 'Trans proline' 0 C--O 1.216 -0.613 0 C-N-CA 122.481 2.121 . . . . 0.0 111.748 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.495 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 33.1 mm -80.57 -41.12 19.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.305 -0.872 . . . . 0.0 109.567 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.575 ' CB ' ' HB2' ' A' ' 108' ' ' GLU . 1.0 OUTLIER -67.85 -40.65 83.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.226 -0.921 . . . . 0.0 109.505 179.995 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.491 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 1.3 ttt85 -63.91 -49.52 72.33 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.153 -0.967 . . . . 0.0 109.212 179.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.407 HD21 ' O ' ' A' ' 45' ' ' ARG . 0.4 OUTLIER -72.21 -36.42 69.17 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.264 -0.898 . . . . 0.0 108.961 179.467 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.526 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -75.62 -4.11 38.23 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.436 -0.79 . . . . 0.0 109.641 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.66 11.47 83.06 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.506 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 7.1 mt -87.3 -28.09 22.48 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.158 -1.201 . . . . 0.0 109.724 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.575 ' HB2' ' CB ' ' A' ' 102' ' ' LEU . 87.9 tt0 -123.71 131.43 53.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.247 -0.908 . . . . 0.0 109.469 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -119.61 110.78 17.26 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.257 -0.902 . . . . 0.0 109.492 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.587 ' CE2' ' O ' ' A' ' 111' ' ' GLU . 47.7 p90 -126.09 -161.52 1.06 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.923 . . . . 0.0 109.308 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.587 ' O ' ' CE2' ' A' ' 110' ' ' TYR . 61.3 mt-10 -81.17 -150.89 0.08 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.264 -0.898 . . . . 0.0 109.663 -179.722 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.484 ' HB2' ' O ' ' A' ' 111' ' ' GLU . 35.4 tt0 175.8 171.21 0.36 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.424 -0.797 . . . . 0.0 109.126 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.405 ' C ' ' O ' ' A' ' 112' ' ' GLU . 3.2 mttp 43.96 62.18 2.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.065 -1.022 . . . . 0.0 109.495 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.466 ' HD2' ' OE2' ' A' ' 137' ' ' GLU . 3.8 mttt -82.09 -30.54 31.21 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.175 -0.953 . . . . 0.0 109.29 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.658 ' HG2' HG12 ' A' ' 117' ' ' VAL . 2.5 tptp -103.51 102.8 32.07 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.31 -0.869 . . . . 0.0 109.505 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -73.02 7.95 1.88 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.745 2.296 . . . . 0.0 112.065 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.658 HG12 ' HG2' ' A' ' 115' ' ' LYS . 8.1 p -82.91 126.26 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.03 -1.044 . . . . 0.0 109.62 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 21.9 tttt -74.13 145.29 44.43 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.281 -0.887 . . . . 0.0 109.257 179.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 1.025 HG11 ' HA ' ' A' ' 174' ' ' GLU . 77.1 t -117.91 139.49 44.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.251 -0.906 . . . . 0.0 109.773 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.537 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 80.1 tt0 176.49 168.48 0.48 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.278 -0.889 . . . . 0.0 109.206 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.537 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 0.5 OUTLIER 79.94 163.36 0.18 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.385 -0.822 . . . . 0.0 109.559 179.926 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 45.39 33.52 4.32 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.482 ' HB3' ' HE2' ' A' ' 175' ' ' LYS . 50.7 p90 -109.13 129.17 55.48 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.234 -1.157 . . . . 0.0 109.219 179.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.446 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 20.8 mttm -146.48 155.65 42.69 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.131 -0.98 . . . . 0.0 109.869 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 144' ' ' LYS . 14.2 p -60.98 143.96 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.301 -0.875 . . . . 0.0 109.584 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.09 -33.45 3.13 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.446 ' OD2' ' HB2' ' A' ' 124' ' ' LYS . 32.7 m-20 -48.78 163.13 0.08 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.38 -1.07 . . . . 0.0 109.207 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.8 ttm -96.3 126.72 41.7 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.051 -1.031 . . . . 0.0 108.807 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.907 HG23 ' O ' ' A' ' 174' ' ' GLU . 5.6 p -124.3 141.28 45.01 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.108 -0.995 . . . . 0.0 109.262 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.608 ' HB2' HD11 ' A' ' 176' ' ' ILE . 35.9 tttp -104.34 144.21 31.94 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.206 -0.934 . . . . 0.0 108.956 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.997 HD12 ' HB3' ' A' ' 139' ' ' PHE . 95.7 mt -85.69 152.01 3.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.116 -0.99 . . . . 0.0 108.623 179.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . . . . . . . . . 42.1 pt -150.32 2.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.162 -0.961 . . . . 0.0 109.434 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.478 ' HB2' ' CB ' ' A' ' 172' ' ' GLU . 75.4 m -148.26 144.48 27.66 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.145 -0.972 . . . . 0.0 109.912 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.75 -165.28 18.89 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 179.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.491 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 46.9 Cg_endo -68.03 -21.82 42.51 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 123.202 2.602 . . . . 0.0 112.811 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.555 ' HB2' HD13 ' A' ' 131' ' ' ILE . 97.5 m-85 -108.29 15.78 23.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.834 -1.166 . . . . 0.0 109.604 -179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.597 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.4 tt0 -42.96 139.94 1.56 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.176 -0.953 . . . . 0.0 109.384 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.522 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 18.6 m-20 75.21 24.95 1.37 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.368 -0.832 . . . . 0.0 110.335 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.997 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.5 t80 -115.71 135.8 53.68 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.961 -1.087 . . . . 0.0 109.421 179.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.34 133.5 34.14 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.177 -0.952 . . . . 0.0 109.692 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.495 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.02 170.89 25.74 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.294 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.716 ' C ' HG13 ' A' ' 155' ' ' VAL . 40.8 t -116.12 135.72 55.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.447 -1.031 . . . . 0.0 109.357 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.874 HD11 ' HD2' ' A' ' 175' ' ' LYS . 70.8 mt -67.56 115.87 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.257 -0.902 . . . . 0.0 109.192 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.516 ' O ' HG23 ' A' ' 125' ' ' VAL . 2.0 tttp -98.08 -33.74 11.04 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.036 -1.04 . . . . 0.0 109.502 -179.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.412 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 75.3 mm-40 -151.01 146.03 25.94 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.114 -0.991 . . . . 0.0 109.536 179.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 1.044 HG22 HD22 ' A' ' 153' ' ' LEU . 23.8 pt -122.25 125.88 73.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.135 -0.978 . . . . 0.0 109.488 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.37 100.6 34.53 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.268 -0.895 . . . . 0.0 109.5 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.56 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.2 Cg_endo -71.18 171.12 16.61 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.704 2.269 . . . . 0.0 111.779 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.56 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.8 mt-10 80.95 -20.48 0.37 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.399 -0.813 . . . . 0.0 109.899 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.433 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 88.6 mtt180 -127.75 -12.01 5.44 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.086 -1.009 . . . . 0.0 109.526 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.433 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 31.5 mt-30 69.23 48.91 0.64 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.25 -0.906 . . . . 0.0 109.665 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -122.22 145.81 47.86 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.09 -1.006 . . . . 0.0 109.097 179.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 1.044 HD22 HG22 ' A' ' 146' ' ' ILE . 60.6 mt -138.42 115.29 10.78 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.075 -1.016 . . . . 0.0 110.147 -179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 27.3 mttm -78.85 133.56 37.0 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.3 -0.875 . . . . 0.0 108.643 179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.716 HG13 ' C ' ' A' ' 142' ' ' VAL . 53.9 t -127.44 151.17 33.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.182 -0.949 . . . . 0.0 109.762 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 26.2 t-20 -98.0 117.6 32.7 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.237 -0.914 . . . . 0.0 109.352 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.506 HG13 ' CE1' ' A' ' 139' ' ' PHE . 39.7 t -101.03 143.41 14.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.252 -0.905 . . . . 0.0 109.708 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 93.1 m -94.74 91.26 6.42 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.383 -0.823 . . . . 0.0 109.724 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.502 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 8.6 mt -115.78 140.54 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.248 -0.907 . . . . 0.0 109.424 179.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.411 ' CZ ' ' HZ ' ' A' ' 61' ' ' PHE . 8.4 m-85 60.54 41.21 15.93 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.376 -0.827 . . . . 0.0 109.334 -179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.05 16.28 12.9 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 92.4 mtt-85 -126.26 148.3 49.52 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.201 -1.176 . . . . 0.0 109.39 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.504 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 94.3 mt-10 -94.81 135.77 35.91 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.278 -0.889 . . . . 0.0 109.679 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . 0.51 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 49.7 m -147.2 128.18 7.1 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.274 -0.891 . . . . 0.0 109.735 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.538 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.49 139.69 38.26 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.746 2.297 . . . . 0.0 111.46 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 7.4 p -126.61 145.79 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.089 -1.007 . . . . 0.0 109.869 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.434 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 5.3 t -92.54 118.86 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.459 -0.775 . . . . 0.0 109.505 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.434 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 19.3 mt -141.52 167.23 22.66 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.184 -0.947 . . . . 0.0 110.495 -179.302 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 72.5 m80 -83.97 141.34 31.29 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.71 -0.619 . . . . 0.0 109.5 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 4.1 p -56.42 -36.28 46.63 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.287 -0.883 . . . . 0.0 109.319 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 53.8 p -75.96 -7.18 54.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.287 -0.883 . . . . 0.0 109.828 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.478 ' CB ' ' HB2' ' A' ' 133' ' ' SER . 64.5 mt-10 -99.75 -2.23 35.73 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.086 -1.009 . . . . 0.0 109.404 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.403 ' O ' HG11 ' A' ' 119' ' ' VAL . 12.7 m -132.48 170.1 20.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.23 -0.919 . . . . 0.0 109.627 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 1.025 ' HA ' HG11 ' A' ' 119' ' ' VAL . 53.5 tt0 -129.87 145.14 51.6 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.293 -0.88 . . . . 0.0 109.343 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.874 ' HD2' HD11 ' A' ' 143' ' ' ILE . 34.4 mmtm -87.83 14.82 7.97 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.024 -1.048 . . . . 0.0 109.514 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.608 HD11 ' HB2' ' A' ' 130' ' ' LYS . 81.2 mt 43.81 -94.04 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.346 -0.846 . . . . 0.0 109.618 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.524 ' N ' HG22 ' A' ' 176' ' ' ILE . 96.6 mt-10 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 117.972 -1.013 . . . . 0.0 109.489 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.294 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.61 -11.52 35.85 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.268 -1.136 . . . . 0.0 109.455 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 93.9 mtp -71.42 -8.52 54.37 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.2 -0.938 . . . . 0.0 109.457 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.438 ' O ' ' HG3' ' A' ' 4' ' ' LYS . 18.8 pttm -160.76 132.83 5.96 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.252 -0.905 . . . . 0.0 109.463 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.476 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 20.0 mttm -114.95 156.82 24.32 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.177 -0.952 . . . . 0.0 109.625 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 16.8 mmtp -127.47 172.07 11.02 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.329 -0.857 . . . . 0.0 109.39 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.959 ' O ' HG23 ' A' ' 93' ' ' VAL . 46.3 m95 -106.34 128.24 53.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.335 -0.853 . . . . 0.0 109.142 179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.541 ' CE1' ' CE ' ' A' ' 66' ' ' MET . 74.8 m-85 -120.35 160.96 22.0 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.214 -0.929 . . . . 0.0 109.359 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.524 ' HB ' HG12 ' A' ' 84' ' ' VAL . 97.1 mt -102.66 115.35 44.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.233 -0.917 . . . . 0.0 109.252 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.508 HG11 HG22 ' A' ' 80' ' ' VAL . 84.2 t -91.35 141.28 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.224 -0.923 . . . . 0.0 109.452 -179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.512 HD13 ' HA ' ' A' ' 11' ' ' LEU . 3.2 mm? -84.74 144.23 28.64 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.28 -0.888 . . . . 0.0 109.308 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.693 HG21 ' HG2' ' A' ' 17' ' ' GLU . 11.9 t -155.86 -176.56 6.02 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.167 -0.958 . . . . 0.0 109.271 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.417 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 56.8 mtm -104.71 123.73 48.13 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.25 -0.906 . . . . 0.0 109.568 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.455 ' OG ' ' HB2' ' A' ' 57' ' ' PRO . 2.6 m -45.32 128.32 7.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.271 -0.893 . . . . 0.0 109.408 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.3 -19.98 33.52 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.501 ' O ' ' N ' ' A' ' 19' ' ' LYS . 77.1 m-85 -111.64 -9.3 14.16 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.297 -1.119 . . . . 0.0 109.441 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.693 ' HG2' HG21 ' A' ' 12' ' ' THR . 92.6 mt-10 -43.3 -41.54 4.06 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.23 -0.919 . . . . 0.0 109.543 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -63.57 -31.3 72.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 109.302 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.501 ' N ' ' O ' ' A' ' 16' ' ' TYR . 27.7 mttm -76.94 -56.43 4.6 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.276 -0.89 . . . . 0.0 109.352 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.565 ' CG1' ' HA ' ' A' ' 17' ' ' GLU . 2.0 p -44.72 -49.73 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.217 -0.927 . . . . 0.0 109.415 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.751 ' HD2' HD11 ' A' ' 42' ' ' ILE . 10.5 tttm -61.03 -48.32 82.32 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.207 -0.933 . . . . 0.0 109.874 -179.711 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -62.96 -35.48 80.29 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.07 -1.019 . . . . 0.0 109.504 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.497 ' HB3' ' HG2' ' A' ' 78' ' ' PRO . 33.9 m120 -64.92 -37.54 87.99 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.308 -0.87 . . . . 0.0 109.22 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.5 HG21 HD11 ' A' ' 40' ' ' ILE . 89.0 mt -63.19 -45.62 98.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.3 -0.875 . . . . 0.0 109.478 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 88.0 mt-10 -55.41 -46.77 76.6 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.214 -0.929 . . . . 0.0 109.715 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 27.7 ttmt -76.06 -35.63 59.34 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.261 -0.899 . . . . 0.0 109.456 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.608 ' O ' HG23 ' A' ' 31' ' ' THR . 44.2 tptt -54.93 -32.33 61.16 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.918 . . . . 0.0 109.242 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.851 HG13 ' O ' ' A' ' 33' ' ' ILE . 77.5 t -87.13 -22.91 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.329 -0.857 . . . . 0.0 109.406 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -71.32 -55.4 8.09 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.669 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.39 -31.16 71.8 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.186 -0.946 . . . . 0.0 109.684 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.608 HG23 ' O ' ' A' ' 27' ' ' LYS . 29.5 p -87.32 -20.92 26.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.118 -0.989 . . . . 0.0 109.491 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 68.21 22.07 74.26 Favored Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.851 ' O ' HG13 ' A' ' 28' ' ' VAL . 63.4 mt -98.89 79.45 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.258 -1.142 . . . . 0.0 109.449 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -85.09 -17.23 38.02 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.236 -0.915 . . . . 0.0 109.24 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 22.7 m120 -84.24 5.01 28.25 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.317 -0.865 . . . . 0.0 109.482 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.043 HD12 ' CG1' ' A' ' 65' ' ' ILE . 12.5 tp -105.98 -54.26 2.51 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.176 -0.953 . . . . 0.0 109.37 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.715 ' HB ' HG21 ' A' ' 28' ' ' VAL . 86.4 t -96.5 133.32 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.403 -0.81 . . . . 0.0 109.297 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.85 -123.4 5.26 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 89.7 mtt180 -93.52 147.49 22.93 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -1.125 . . . . 0.0 109.845 -179.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.865 HG23 HG22 ' A' ' 62' ' ' VAL . 70.2 mt -110.32 135.55 49.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.291 -0.88 . . . . 0.0 109.344 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.822 HG23 ' CH2' ' A' ' 7' ' ' TRP . 32.8 t -119.72 151.7 22.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.951 . . . . 0.0 109.39 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.751 HD11 ' HD2' ' A' ' 21' ' ' LYS . 10.5 mt -131.9 127.53 21.23 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.264 -0.897 . . . . 0.0 109.442 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.527 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 46.2 Cg_endo -66.78 -4.46 11.21 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.862 2.375 . . . . 0.0 111.867 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.728 HG23 HG22 ' A' ' 42' ' ' ILE . 8.4 pt -80.7 133.23 29.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.12 -0.987 . . . . 0.0 109.387 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.423 ' O ' ' OG ' ' A' ' 52' ' ' SER . 44.6 ttp180 -67.75 150.0 49.23 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.257 -0.902 . . . . 0.0 109.574 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -96.18 179.64 35.14 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 167.71 -179.33 41.15 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 90.0 mt-30 -62.45 -33.13 74.22 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.27 -1.135 . . . . 0.0 109.384 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 79.0 mtt-85 -80.23 131.29 35.66 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.276 -0.89 . . . . 0.0 109.38 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 74.8 mtp85 -60.19 -35.33 75.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.258 -0.901 . . . . 0.0 109.556 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 53.5 mttm -84.96 138.49 32.45 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.232 -0.917 . . . . 0.0 109.448 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.423 ' OG ' ' O ' ' A' ' 45' ' ' ARG . 34.7 t -128.96 172.14 11.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 109.458 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.525 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 65.7 mm-40 -67.61 -36.71 81.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.604 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 7.6 mttp 75.72 105.47 0.07 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.228 -0.92 . . . . 0.0 109.53 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.527 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 24.7 mt -55.61 -45.43 77.47 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.105 -0.997 . . . . 0.0 109.269 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.455 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 89.3 m-85 -131.7 110.34 14.65 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.183 -0.948 . . . . 0.0 109.125 179.681 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.455 ' HB2' ' OG ' ' A' ' 14' ' ' SER . 43.1 Cg_endo -66.22 139.35 54.85 Favored 'Trans proline' 0 C--O 1.216 -0.586 0 C-N-CA 122.746 2.297 . . . . 0.0 112.184 -179.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.5 ' O ' HG22 ' A' ' 12' ' ' THR . . . 73.96 -9.83 8.43 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.5 m-30 -94.17 129.07 40.91 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.669 -1.489 . . . . 0.0 110.395 -179.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 44.8 t -130.22 137.75 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.419 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.503 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 8.0 m-85 -110.15 125.95 53.57 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.902 -1.124 . . . . 0.0 110.051 -179.462 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.865 HG22 HG23 ' A' ' 40' ' ' ILE . 55.8 t -138.51 149.92 24.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.418 -0.801 . . . . 0.0 109.805 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.635 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 61.6 tt0 -110.66 129.04 55.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 108.888 179.536 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.578 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 9.2 mtm -161.79 -176.06 5.04 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.137 -0.977 . . . . 0.0 109.804 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 1.043 ' CG1' HD12 ' A' ' 36' ' ' LEU . 18.9 pt -94.94 119.76 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.541 ' CE ' ' CE1' ' A' ' 8' ' ' TYR . 16.2 ttm -87.36 101.04 13.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.382 -0.824 . . . . 0.0 109.676 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' A' ' 66' ' ' MET . 84.8 m-20 -138.7 -166.54 2.03 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.303 -0.873 . . . . 0.0 108.895 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -71.17 -47.34 58.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.098 -1.001 . . . . 0.0 109.799 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.42 ' O ' ' C ' ' A' ' 70' ' ' ALA . 93.7 mt-10 -70.84 -57.14 4.92 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.055 -1.028 . . . . 0.0 109.612 -179.736 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.007 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -44.51 -42.99 7.62 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.22 -0.925 . . . . 0.0 109.573 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.551 ' CD1' ' OE1' ' A' ' 89' ' ' GLN . 71.1 t80 -61.39 -54.84 38.4 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.267 -0.896 . . . . 0.0 109.696 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -51.58 -31.0 23.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.18 -0.95 . . . . 0.0 110.049 -179.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -81.01 -41.95 21.9 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.144 -0.972 . . . . 0.0 109.766 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.976 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 47.4 t -70.96 -54.58 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.249 -0.907 . . . . 0.0 109.443 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.428 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 25.0 tpt85 -51.45 -18.62 1.11 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.182 -0.949 . . . . 0.0 109.211 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 66.3 p -101.65 5.89 41.73 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.41 -0.806 . . . . 0.0 109.925 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.713 HG23 ' HA ' ' A' ' 74' ' ' VAL . 17.2 t -60.86 135.57 92.89 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.013 -1.055 . . . . 0.0 109.39 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.592 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 48.4 Cg_endo -69.14 129.39 18.16 Favored 'Trans proline' 0 C--O 1.213 -0.74 0 C-N-CA 122.776 2.318 . . . . 0.0 112.002 -179.768 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.592 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 40.7 m-85 84.45 -10.13 0.88 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.665 -0.647 . . . . 0.0 109.56 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.593 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 4.9 t -84.92 127.3 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.177 -0.952 . . . . 0.0 109.257 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.484 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 78.4 mtp -87.0 -23.99 24.82 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.296 -0.877 . . . . 0.0 109.379 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.544 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 153.07 -155.58 26.21 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.976 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 1.6 m-85 -137.42 140.13 41.11 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.322 -1.105 . . . . 0.0 109.402 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.543 HG13 ' O ' ' A' ' 84' ' ' VAL . 11.5 p -64.85 125.41 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.209 -0.932 . . . . 0.0 109.519 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.545 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.7 p -159.35 161.69 35.79 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.241 -0.912 . . . . 0.0 109.516 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 85.8 p -92.01 -36.66 13.27 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.249 -0.907 . . . . 0.0 109.391 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -120.47 -88.19 1.04 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.515 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -104.25 -133.93 7.98 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.551 ' OE1' ' CD1' ' A' ' 71' ' ' TYR . 0.9 OUTLIER -34.25 155.06 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.547 -0.972 . . . . 0.0 110.134 -179.599 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.545 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.3 Cg_endo -68.47 163.72 35.55 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.824 2.349 . . . . 0.0 111.855 -179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.7 m -93.97 154.08 40.78 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.294 -0.879 . . . . 0.0 109.31 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -70.38 142.45 45.23 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.605 2.203 . . . . 0.0 111.796 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.959 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.3 t -73.04 131.49 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.262 -0.899 . . . . 0.0 109.306 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . 0.484 ' O ' ' N ' ' A' ' 97' ' ' GLU . 42.2 mttm -71.6 132.75 45.09 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.193 -0.942 . . . . 0.0 109.264 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 94' ' ' LYS . 82.1 m-20 -44.46 -41.28 6.18 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.226 -0.921 . . . . 0.0 109.459 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -61.04 -24.91 66.55 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.265 -0.897 . . . . 0.0 109.502 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.484 ' N ' ' O ' ' A' ' 94' ' ' LYS . 54.2 mt-10 -87.14 -27.0 23.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.162 -0.961 . . . . 0.0 109.511 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.644 ' SD ' HG11 ' A' ' 93' ' ' VAL . 37.4 mmm -84.63 -26.87 27.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.166 -0.959 . . . . 0.0 109.42 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.576 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 5.1 ttp180 -37.06 -54.98 1.75 Allowed Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.47 -0.769 . . . . 0.0 109.994 -179.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.576 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.1 Cg_endo -69.05 -27.21 30.13 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.535 2.157 . . . . 0.0 111.79 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.59 HG22 HG11 ' A' ' 41' ' ' VAL . 51.1 mm -81.44 -41.94 19.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.226 -0.921 . . . . 0.0 109.284 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.574 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -68.27 -40.13 81.95 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.219 -0.926 . . . . 0.0 109.231 179.754 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.52 ' HD3' ' CE1' ' A' ' 110' ' ' TYR . 21.2 mtt180 -62.77 -50.57 70.53 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.333 -0.854 . . . . 0.0 108.978 179.587 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -73.35 -35.34 65.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.459 -0.776 . . . . 0.0 109.11 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -71.99 -2.73 19.26 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.385 -0.822 . . . . 0.0 109.633 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.48 9.68 84.56 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.703 HD22 HG21 ' A' ' 41' ' ' VAL . 8.0 mp -80.9 -21.95 40.16 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.164 -1.198 . . . . 0.0 109.429 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -120.85 141.26 50.73 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.381 -0.824 . . . . 0.0 109.501 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -114.67 114.28 25.45 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.231 -0.918 . . . . 0.0 109.354 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.52 ' CE1' ' HD3' ' A' ' 103' ' ' ARG . 37.7 p90 -137.25 163.48 30.82 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.288 -0.882 . . . . 0.0 109.47 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.443 ' O ' ' C ' ' A' ' 112' ' ' GLU . 94.0 mt-10 -100.05 -100.67 0.24 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.274 -0.891 . . . . 0.0 109.507 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.443 ' C ' ' O ' ' A' ' 111' ' ' GLU . 33.2 tt0 42.03 82.26 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.23 -0.919 . . . . 0.0 109.49 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.534 ' O ' ' CG ' ' A' ' 114' ' ' LYS . 53.3 pttt -171.53 -158.54 0.14 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.287 -0.883 . . . . 0.0 109.471 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.534 ' CG ' ' O ' ' A' ' 113' ' ' LYS . 6.0 pttt 40.12 30.44 0.07 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.263 -0.898 . . . . 0.0 109.594 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.45 ' N ' ' O ' ' A' ' 113' ' ' LYS . 0.0 OUTLIER -128.16 82.15 69.06 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.293 -0.879 . . . . 0.0 109.406 -179.944 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -71.38 127.68 13.63 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.742 2.294 . . . . 0.0 111.766 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 4.3 p -135.21 129.57 50.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.222 -0.924 . . . . 0.0 109.483 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 23.8 mttt -86.79 145.65 26.54 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.273 -0.892 . . . . 0.0 109.442 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.423 HG12 ' N ' ' A' ' 120' ' ' GLU . 94.1 t -126.03 155.94 35.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.149 -0.97 . . . . 0.0 109.448 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.703 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 78.5 tt0 -130.62 153.22 49.14 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.228 -0.92 . . . . 0.0 109.496 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.732 HD23 ' HB2' ' A' ' 175' ' ' LYS . 13.7 tp 143.71 99.03 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.599 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.76 79.81 0.0 OUTLIER Glycine 0 N--CA 1.496 2.669 0 N-CA-C 111.011 -0.835 . . . . 0.0 111.011 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.716 ' N ' ' O ' ' A' ' 121' ' ' LEU . 31.4 p90 -95.7 130.95 42.44 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.251 -1.147 . . . . 0.0 109.094 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.642 ' HA ' HD11 ' A' ' 146' ' ' ILE . 14.1 mttt -140.35 -174.52 3.97 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.034 -1.041 . . . . 0.0 110.076 -179.615 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 144' ' ' LYS . 13.8 p -61.78 141.94 16.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.451 -0.781 . . . . 0.0 109.677 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 86.72 -34.31 3.55 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.549 ' HB2' HD12 ' A' ' 143' ' ' ILE . 24.0 m-20 -49.29 158.73 0.36 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.316 -1.108 . . . . 0.0 109.633 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . 0.71 ' HG3' HD11 ' A' ' 176' ' ' ILE . 2.7 tpp -95.53 127.91 41.96 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.336 -0.853 . . . . 0.0 108.871 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.683 HG22 ' CG1' ' A' ' 173' ' ' VAL . 2.0 p -127.72 143.83 39.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.264 -0.898 . . . . 0.0 109.816 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.451 ' O ' HG13 ' A' ' 173' ' ' VAL . 21.0 tttt -108.55 142.29 39.21 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.266 -0.896 . . . . 0.0 109.319 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 1.0 ' O ' HD13 ' A' ' 132' ' ' ILE . 96.6 mt -80.14 152.22 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.139 -0.976 . . . . 0.0 108.971 179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 1.0 HD13 ' O ' ' A' ' 131' ' ' ILE . 1.1 mm -146.67 2.27 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.088 -1.007 . . . . 0.0 109.391 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.577 ' CA ' ' HG2' ' A' ' 137' ' ' GLU . 50.6 m -148.64 143.12 26.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.259 -0.9 . . . . 0.0 109.758 -179.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.462 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 105.77 -169.23 15.8 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.479 ' HA ' ' OH ' ' A' ' 110' ' ' TYR . 48.5 Cg_endo -68.56 -19.98 41.73 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 123.317 2.678 . . . . 0.0 112.679 -179.414 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.521 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.6 m-85 -106.77 16.71 24.11 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.933 -1.104 . . . . 0.0 109.605 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.577 ' HG2' ' CA ' ' A' ' 133' ' ' SER . 62.9 mt-10 -41.58 139.01 1.22 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.163 -0.961 . . . . 0.0 110.073 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.568 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.8 OUTLIER 80.37 19.41 0.56 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.277 -0.89 . . . . 0.0 110.788 178.775 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.761 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.0 OUTLIER -108.18 141.67 39.57 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.794 -1.191 . . . . 0.0 109.565 179.798 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -94.53 135.95 35.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.225 -0.922 . . . . 0.0 109.22 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.494 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.83 168.99 27.38 Favored Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.571 -1.299 . . . . 0.0 110.5 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.682 ' C ' HG23 ' A' ' 155' ' ' VAL . 39.5 t -111.14 137.49 43.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.593 -0.945 . . . . 0.0 109.369 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.549 HD12 ' HB2' ' A' ' 127' ' ' ASP . 69.8 mt -68.71 118.26 12.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.244 -0.91 . . . . 0.0 109.303 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.661 ' O ' HG23 ' A' ' 125' ' ' VAL . 47.7 tttp -100.39 -33.29 10.43 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.975 -1.078 . . . . 0.0 109.561 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.435 ' HG2' ' O ' ' A' ' 144' ' ' LYS . 64.2 mt-10 -153.85 149.12 27.02 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.132 -0.98 . . . . 0.0 109.812 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 1.065 HG23 HD22 ' A' ' 153' ' ' LEU . 1.7 mt -124.33 127.59 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.354 -0.841 . . . . 0.0 109.379 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -112.13 104.1 55.77 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.628 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.528 ' O ' ' HB2' ' A' ' 149' ' ' GLU . 52.4 Cg_endo -72.35 173.21 13.47 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 122.72 2.28 . . . . 0.0 111.661 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.528 ' HB2' ' O ' ' A' ' 148' ' ' PRO . 39.5 mm-40 78.25 -22.0 0.31 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.397 -0.814 . . . . 0.0 110.062 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.437 ' NH1' ' HG3' ' A' ' 150' ' ' ARG . 0.6 OUTLIER -124.15 -15.5 6.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.1 -1.0 . . . . 0.0 109.119 179.776 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.456 ' HB3' HG11 ' A' ' 170' ' ' VAL . 30.9 mt-30 69.58 47.98 0.63 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.461 -0.774 . . . . 0.0 109.439 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.993 ' O ' HD23 ' A' ' 153' ' ' LEU . 97.8 mt-10 -119.76 143.56 47.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.215 -0.928 . . . . 0.0 109.081 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 1.065 HD22 HG23 ' A' ' 146' ' ' ILE . 14.4 mt -130.95 122.85 27.64 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.16 -0.963 . . . . 0.0 110.231 -179.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 13.9 mttt -85.57 129.78 34.74 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.682 HG23 ' C ' ' A' ' 142' ' ' VAL . 10.9 p -129.36 146.94 33.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.222 -0.923 . . . . 0.0 109.951 -179.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.543 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 3.7 m-20 -98.02 108.89 21.71 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.218 -0.926 . . . . 0.0 109.537 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.577 HG13 ' CE1' ' A' ' 139' ' ' PHE . 82.2 t -88.14 140.72 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.18 -0.95 . . . . 0.0 109.376 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 47.7 m -96.62 89.23 4.9 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.332 -0.855 . . . . 0.0 109.617 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.506 HG13 HG12 ' A' ' 157' ' ' VAL . 2.6 mt -115.74 144.87 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.192 -0.942 . . . . 0.0 109.395 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.503 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 18.7 m-85 61.93 37.41 15.16 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.276 -0.89 . . . . 0.0 109.226 -179.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.03 17.95 31.85 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.426 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 89.5 mtt-85 -127.66 157.49 40.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.216 -1.167 . . . . 0.0 109.481 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.44 ' OE2' ' ND2' ' A' ' 156' ' ' ASN . 83.6 tt0 -100.82 133.35 45.42 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.327 -0.858 . . . . 0.0 109.591 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 79.7 m -144.04 127.3 8.83 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.253 -0.905 . . . . 0.0 109.684 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.543 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.4 Cg_endo -70.98 137.16 31.33 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.723 2.282 . . . . 0.0 111.598 179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 46.1 t -125.66 144.48 35.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.229 -0.92 . . . . 0.0 109.862 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.413 ' O ' ' HG ' ' A' ' 168' ' ' LEU . 44.4 t -92.68 119.35 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.438 -0.789 . . . . 0.0 109.485 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.413 ' HG ' ' O ' ' A' ' 167' ' ' VAL . 1.4 mt -138.71 164.69 28.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.229 -0.92 . . . . 0.0 110.48 -179.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.495 ' HB2' ' HB2' ' A' ' 172' ' ' GLU . 88.6 m-70 -81.57 145.64 30.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.632 -0.668 . . . . 0.0 109.291 179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.702 HG23 HD11 ' A' ' 153' ' ' LEU . 6.2 p -62.11 -35.73 70.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.305 -0.872 . . . . 0.0 108.982 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 82.9 p -78.59 -9.66 59.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.254 -0.904 . . . . 0.0 109.362 179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.505 ' CB ' ' HB2' ' A' ' 133' ' ' SER . 46.8 mt-10 -97.69 -1.14 44.19 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.405 -0.809 . . . . 0.0 109.022 179.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.683 ' CG1' HG22 ' A' ' 129' ' ' VAL . 97.9 t -126.14 163.25 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.297 -0.877 . . . . 0.0 109.412 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.548 ' N ' HG12 ' A' ' 173' ' ' VAL . 55.8 tt0 -137.26 154.95 50.02 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.24 -0.912 . . . . 0.0 109.314 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.732 ' HB2' HD23 ' A' ' 121' ' ' LEU . 19.8 mttt -97.57 37.91 1.33 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.206 -0.934 . . . . 0.0 109.395 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.71 HD11 ' HG3' ' A' ' 128' ' ' MET . 7.1 mt 56.72 83.63 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.264 -0.897 . . . . 0.0 109.468 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 72.2 mm-40 . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.557 -179.923 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.468 ' HB1' ' HB ' ' A' ' 65' ' ' ILE . . . -98.26 27.52 4.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.235 -1.156 . . . . 0.0 109.518 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 60.4 ttp -62.57 -22.16 66.14 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.261 -0.9 . . . . 0.0 109.642 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 56.1 mttm -99.62 134.55 42.35 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.259 -0.901 . . . . 0.0 109.431 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.638 ' HG2' HG22 ' A' ' 65' ' ' ILE . 21.8 mttm -100.41 148.74 24.4 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.186 -0.946 . . . . 0.0 109.575 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.6 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 9.6 mttt -131.53 173.1 11.45 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.16 -0.962 . . . . 0.0 109.407 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.794 ' HZ3' HG22 ' A' ' 41' ' ' VAL . 51.9 m95 -108.82 126.74 53.36 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.415 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.502 ' CZ ' ' SD ' ' A' ' 66' ' ' MET . 91.3 m-85 -116.2 168.55 10.01 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.329 -0.857 . . . . 0.0 109.492 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.506 HG12 ' CE1' ' A' ' 61' ' ' PHE . 36.5 mt -106.49 116.51 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.282 -0.886 . . . . 0.0 109.197 179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.588 ' CG1' HG23 ' A' ' 80' ' ' VAL . 72.5 t -91.56 136.52 24.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.282 -0.886 . . . . 0.0 109.294 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.829 HD21 HG22 ' A' ' 84' ' ' VAL . 3.8 mm? -89.18 146.89 24.49 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.374 -0.829 . . . . 0.0 109.496 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.421 ' OG1' HG21 ' A' ' 20' ' ' VAL . 9.6 t -161.83 -168.03 1.84 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.302 -0.874 . . . . 0.0 109.362 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 67.3 mtp -107.38 134.5 50.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.242 -0.911 . . . . 0.0 109.492 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 11.0 t -54.74 130.25 39.98 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.291 -0.881 . . . . 0.0 109.393 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.46 -20.22 37.75 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -109.87 -3.23 16.75 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.285 -1.127 . . . . 0.0 109.717 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -47.48 -64.56 0.75 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.254 -0.903 . . . . 0.0 109.594 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.511 ' OE2' HD11 ' A' ' 44' ' ' ILE . 75.8 mm-40 -48.73 -38.87 22.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.183 -0.948 . . . . 0.0 109.435 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.466 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 54.1 tttp -66.77 -45.9 77.03 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.304 -0.872 . . . . 0.0 109.278 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.675 HG22 ' CB ' ' A' ' 79' ' ' TYR . 50.7 t -61.65 -44.5 98.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.244 -0.91 . . . . 0.0 109.501 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.562 ' HG3' HG21 ' A' ' 40' ' ' ILE . 48.1 tttt -60.51 -45.62 93.13 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.169 -0.957 . . . . 0.0 109.219 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -65.72 -40.42 92.19 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.315 -0.866 . . . . 0.0 109.347 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.575 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 31.2 m120 -60.59 -46.15 91.3 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.337 -0.852 . . . . 0.0 109.431 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.406 HG21 HD11 ' A' ' 40' ' ' ILE . 95.0 mt -56.01 -42.87 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.215 -0.928 . . . . 0.0 109.268 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -56.17 -43.56 78.5 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.193 -0.942 . . . . 0.0 109.594 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.428 ' HB3' ' HE2' ' A' ' 26' ' ' LYS . 47.9 mtpt -80.14 -35.62 36.39 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.208 -0.933 . . . . 0.0 109.434 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.427 ' HG2' HG23 ' A' ' 77' ' ' VAL . 11.5 tptt -54.69 -31.52 58.05 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.286 -0.883 . . . . 0.0 109.334 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.78 HG13 ' O ' ' A' ' 33' ' ' ILE . 39.2 t -89.75 -23.3 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.301 -0.874 . . . . 0.0 109.392 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 46.3 tp10 -69.2 -52.63 25.94 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.288 -0.883 . . . . 0.0 109.543 -179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.37 -32.48 73.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.196 -0.94 . . . . 0.0 109.44 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 59.4 p -84.87 -25.29 28.1 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.442 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 79.48 -3.42 67.93 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.825 HG23 HD23 ' A' ' 36' ' ' LEU . 84.8 mt -76.16 74.38 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.193 -1.18 . . . . 0.0 109.553 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.485 ' HA ' HG11 ' A' ' 28' ' ' VAL . 23.6 mttt -88.49 1.12 55.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.192 -0.942 . . . . 0.0 109.657 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -97.06 -13.09 22.46 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.181 -0.949 . . . . 0.0 109.492 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.088 HD12 ' HB2' ' A' ' 70' ' ' ALA . 2.5 mm? -88.32 -49.05 7.21 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.291 -0.881 . . . . 0.0 109.467 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.507 ' HB ' HG21 ' A' ' 28' ' ' VAL . 78.5 t -91.12 139.49 17.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.244 -0.91 . . . . 0.0 109.256 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -127.09 5.44 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 88.2 mtt180 -92.16 146.97 23.3 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.255 -1.144 . . . . 0.0 109.755 -179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.605 HG12 HG13 ' A' ' 62' ' ' VAL . 67.1 mt -112.55 134.16 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.913 . . . . 0.0 109.336 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.794 HG22 ' HZ3' ' A' ' 7' ' ' TRP . 33.3 m -128.08 155.77 39.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.235 -0.916 . . . . 0.0 109.45 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.781 HG22 HG23 ' A' ' 44' ' ' ILE . 11.5 mt -133.63 128.63 20.09 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.268 -0.895 . . . . 0.0 109.63 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.508 ' O ' HD13 ' A' ' 55' ' ' LEU . 43.8 Cg_endo -66.45 -3.89 9.77 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.928 2.418 . . . . 0.0 111.744 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.781 HG23 HG22 ' A' ' 42' ' ' ILE . 11.4 pt -80.98 -19.32 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.145 -0.972 . . . . 0.0 109.464 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 39.0 mtm180 -58.65 143.69 45.69 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.287 -0.883 . . . . 0.0 109.472 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 85.15 -6.39 79.61 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.507 ' HA3' ' HA ' ' A' ' 53' ' ' GLU . . . -66.75 -37.23 92.22 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -54.4 -36.95 64.5 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.233 -1.157 . . . . 0.0 109.477 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 5.9 mmt85 -60.16 -27.9 67.47 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.294 -0.879 . . . . 0.0 109.525 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 65.8 mtm180 -109.19 167.09 10.36 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.27 -0.894 . . . . 0.0 109.559 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 67.7 mttt -67.72 -17.83 64.7 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.293 -0.879 . . . . 0.0 109.527 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 82.5 p -112.74 145.86 39.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.2 -0.938 . . . . 0.0 109.421 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.507 ' HA ' ' HA3' ' A' ' 47' ' ' GLY . 82.5 mt-10 -124.68 155.76 38.69 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.284 -0.885 . . . . 0.0 109.418 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.693 ' HA ' HG22 ' A' ' 44' ' ' ILE . 4.7 mttp 76.22 87.48 0.08 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.246 -0.909 . . . . 0.0 109.425 -179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.545 ' CD1' ' N ' ' A' ' 55' ' ' LEU . 5.2 mp -62.29 -24.68 67.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.171 -0.956 . . . . 0.0 109.465 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 1.153 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 97.4 m-85 -148.79 100.59 3.47 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.316 -0.865 . . . . 0.0 109.056 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -66.08 139.75 57.13 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.733 2.288 . . . . 0.0 111.855 -179.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.17 -12.5 6.88 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.589 ' CE1' HD11 ' A' ' 11' ' ' LEU . 2.5 m-30 -100.03 131.3 46.07 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.704 -1.468 . . . . 0.0 110.128 -179.317 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 45.6 t -134.62 144.77 33.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.361 -0.837 . . . . 0.0 108.887 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.775 ' HB2' HG23 ' A' ' 41' ' ' VAL . 74.2 m-85 -106.55 122.98 47.4 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.978 -1.077 . . . . 0.0 109.779 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.605 HG13 HG12 ' A' ' 40' ' ' ILE . 59.7 t -131.37 143.78 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 109.796 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.632 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 18.0 tt0 -108.2 127.29 53.7 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.328 -0.857 . . . . 0.0 109.166 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.462 ' HB3' ' O ' ' A' ' 36' ' ' LEU . 32.8 mtm -153.98 170.88 20.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.072 -1.018 . . . . 0.0 110.653 -179.261 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.813 ' CG1' HD13 ' A' ' 36' ' ' LEU . 5.3 pt -95.14 131.34 42.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.536 ' CE ' ' NE2' ' A' ' 89' ' ' GLN . 59.3 mmm -75.95 143.26 41.7 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.272 -0.893 . . . . 0.0 109.897 -178.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.434 ' HB2' ' O ' ' A' ' 66' ' ' MET . 37.6 t30 178.23 158.06 0.46 Allowed 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -59.61 -42.06 91.79 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.216 -0.927 . . . . 0.0 109.594 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.573 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 69.3 mm-40 -74.85 -34.1 62.22 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.228 -0.92 . . . . 0.0 109.891 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.088 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -69.13 -46.36 67.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.149 -0.97 . . . . 0.0 109.756 -179.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.55 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 91.1 t80 -61.06 -47.03 88.25 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.156 -0.965 . . . . 0.0 109.782 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.444 ' O ' ' HB2' ' A' ' 76' ' ' SER . 27.5 m120 -62.07 -28.36 69.55 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 109.861 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.573 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 13.7 m-85 -84.54 -42.55 15.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.15 -0.969 . . . . 0.0 109.756 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.735 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 25.9 t -69.76 -57.58 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.161 -0.962 . . . . 0.0 109.697 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.453 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 0.6 OUTLIER -59.26 -13.89 9.27 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.189 -0.944 . . . . 0.0 109.311 179.823 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.444 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 15.4 m -95.86 5.38 51.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.304 -0.873 . . . . 0.0 109.93 -179.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.814 ' O ' HG12 ' A' ' 80' ' ' VAL . 2.3 p -75.46 134.29 73.31 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 120.965 -1.085 . . . . 0.0 109.457 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.627 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 43.8 Cg_endo -65.17 138.82 57.9 Favored 'Trans proline' 0 C--O 1.214 -0.72 0 C-N-CA 122.88 2.387 . . . . 0.0 112.287 -179.277 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.675 ' CB ' HG22 ' A' ' 20' ' ' VAL . 24.3 m-85 90.79 -9.32 0.3 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.857 -0.527 . . . . 0.0 109.662 -179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.814 HG12 ' O ' ' A' ' 77' ' ' VAL . 5.7 p -90.88 127.08 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.979 -1.076 . . . . 0.0 109.332 179.506 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 82.8 mtp -86.24 -29.5 23.08 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.249 -0.907 . . . . 0.0 109.375 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.524 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 167.4 -164.22 37.74 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 -179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.735 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 21.3 m-85 -134.33 141.39 46.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.207 -1.173 . . . . 0.0 109.499 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.829 HG22 HD21 ' A' ' 11' ' ' LEU . 19.9 t -64.29 123.82 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.25 -0.906 . . . . 0.0 109.409 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.551 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.6 p -162.76 162.26 26.61 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.28 -0.887 . . . . 0.0 109.522 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.1 t -91.55 -33.33 15.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.276 -0.89 . . . . 0.0 109.343 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -129.66 -82.32 0.29 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.519 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -106.66 -131.57 6.82 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.55 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 1.4 mt-30 -33.31 152.08 0.05 OUTLIER Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.522 -0.987 . . . . 0.0 110.109 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.551 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.7 Cg_endo -69.1 159.25 54.64 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.841 2.361 . . . . 0.0 111.803 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 3.7 m -98.1 154.19 37.81 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.167 -0.958 . . . . 0.0 109.378 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.443 ' CB ' ' HD2' ' A' ' 6' ' ' LYS . 49.0 Cg_endo -70.19 150.99 66.41 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.612 2.208 . . . . 0.0 111.701 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.633 HG12 ' HG3' ' A' ' 98' ' ' MET . 31.2 t -85.46 142.38 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.249 -0.907 . . . . 0.0 109.33 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 46.0 mttp -78.37 139.2 38.81 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.203 -0.936 . . . . 0.0 109.446 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.421 ' O ' ' N ' ' A' ' 99' ' ' ARG . 52.9 t0 -50.36 -39.14 45.62 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.497 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.5 mtm180 -52.06 -41.26 62.2 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.219 -0.926 . . . . 0.0 109.475 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.433 ' C ' ' HD2' ' A' ' 100' ' ' PRO . 63.0 mt-10 -85.38 -23.61 27.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.244 -0.91 . . . . 0.0 109.458 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.633 ' HG3' HG12 ' A' ' 93' ' ' VAL . 97.7 mtp -84.24 -23.64 30.35 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -0.927 . . . . 0.0 109.644 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.646 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 6.0 mmm180 -46.54 -48.04 48.13 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.256 -0.902 . . . . 0.0 109.788 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.646 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 50.6 Cg_endo -72.14 -27.3 17.03 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.394 2.063 . . . . 0.0 111.822 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.537 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 27.3 mm -81.49 -42.27 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.185 -0.947 . . . . 0.0 109.435 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.569 HD11 ' HB3' ' A' ' 98' ' ' MET . 1.2 mt -69.15 -39.9 78.54 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.237 -0.915 . . . . 0.0 109.339 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.557 ' CZ ' ' NH1' ' A' ' 99' ' ' ARG . 23.5 mtt180 -64.27 -51.17 64.86 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.3 -0.875 . . . . 0.0 109.148 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.5 tt -71.44 -36.17 71.17 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.346 -0.846 . . . . 0.0 109.247 179.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.56 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -70.86 -0.26 8.72 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.328 -0.857 . . . . 0.0 109.989 -179.729 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.19 9.12 84.1 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.719 HD21 HG11 ' A' ' 41' ' ' VAL . 10.1 mp -80.72 -22.67 40.1 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.194 -1.18 . . . . 0.0 109.456 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.42 ' HG3' ' CB ' ' A' ' 102' ' ' LEU . 53.7 mt-10 -112.05 144.72 40.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.302 -0.874 . . . . 0.0 109.497 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -98.91 121.99 41.58 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.266 -0.896 . . . . 0.0 109.471 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 24.6 p90 -150.28 154.08 37.27 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.204 -0.935 . . . . 0.0 109.52 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -91.05 -149.42 0.22 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.235 -0.916 . . . . 0.0 109.415 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.444 ' HG2' ' N ' ' A' ' 113' ' ' LYS . 67.7 tt0 -113.15 154.46 26.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.248 -0.908 . . . . 0.0 109.428 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.505 ' O ' ' CG ' ' A' ' 113' ' ' LYS . 12.1 pttt -44.3 113.8 0.59 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.185 -0.947 . . . . 0.0 109.401 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 6.2 pttt -91.91 3.54 54.96 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.217 -0.927 . . . . 0.0 109.535 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.7 80.96 71.12 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.243 -0.911 . . . . 0.0 109.462 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -70.85 121.53 7.98 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.694 2.263 . . . . 0.0 111.82 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 5.0 p -125.41 135.03 65.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.235 -0.916 . . . . 0.0 109.311 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 36.3 mtmm -98.49 128.76 44.97 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.93 . . . . 0.0 109.611 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.477 HG12 ' N ' ' A' ' 120' ' ' GLU . 22.6 t -96.99 162.75 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.353 -0.842 . . . . 0.0 109.279 179.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.655 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 88.4 mt-10 -145.16 139.42 27.25 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.143 -0.973 . . . . 0.0 109.658 -179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.655 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 2.5 mt 146.2 98.29 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.866 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.596 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -23.13 94.01 0.01 OUTLIER Glycine 0 N--CA 1.495 2.601 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.58 ' CD1' ' O ' ' A' ' 121' ' ' LEU . 19.1 m-85 -67.41 155.25 39.44 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.131 -1.217 . . . . 0.0 109.096 179.759 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.484 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 77.1 mttt -134.51 151.84 51.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.122 -0.986 . . . . 0.0 109.95 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 22.5 t -65.32 141.58 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.451 -0.781 . . . . 0.0 109.23 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.518 ' O ' HG13 ' A' ' 142' ' ' VAL . . . 89.19 -30.63 5.46 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.032 -1.627 . . . . 0.0 109.032 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.553 ' HB2' HD12 ' A' ' 143' ' ' ILE . 63.4 m-20 -47.8 161.89 0.09 Allowed 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.309 -1.112 . . . . 0.0 108.989 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . 0.565 ' HG2' HD12 ' A' ' 176' ' ' ILE . 6.1 ttm -102.09 128.23 48.65 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.025 -1.047 . . . . 0.0 109.096 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.735 HG11 HD11 ' A' ' 143' ' ' ILE . 11.6 m -128.67 143.88 39.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.387 -0.821 . . . . 0.0 109.715 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.75 ' HB2' HD11 ' A' ' 176' ' ' ILE . 44.4 tttt -100.84 140.56 34.96 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.913 HD12 ' HB3' ' A' ' 139' ' ' PHE . 86.1 mt -79.39 154.62 4.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.024 -1.048 . . . . 0.0 108.371 179.375 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.857 HD13 ' HG3' ' A' ' 174' ' ' GLU . 1.1 pt -149.12 0.46 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.015 -1.053 . . . . 0.0 109.505 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.601 ' CB ' ' HG2' ' A' ' 172' ' ' GLU . 3.1 m -148.68 147.54 29.03 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.058 -1.027 . . . . 0.0 110.372 -179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.77 -170.29 19.92 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.465 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 45.9 Cg_endo -68.24 -21.46 41.76 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.199 2.599 . . . . 0.0 112.487 -179.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.496 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 91.5 m-85 -108.81 16.33 22.84 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.002 -1.061 . . . . 0.0 109.284 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.718 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.5 tt0 -48.09 142.69 4.99 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.316 -0.865 . . . . 0.0 109.788 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.575 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 14.5 t0 81.44 23.17 0.29 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.424 -0.797 . . . . 0.0 110.242 179.36 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.913 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.0 OUTLIER -116.13 141.75 47.72 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.984 -1.073 . . . . 0.0 109.463 179.813 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -90.12 136.18 33.2 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.191 -0.943 . . . . 0.0 109.516 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.404 ' C ' ' CG1' ' A' ' 155' ' ' VAL . . . -148.02 171.18 28.56 Favored Glycine 0 N--CA 1.49 2.268 0 C-N-CA 119.636 -1.269 . . . . 0.0 110.538 -179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.908 ' C ' HG13 ' A' ' 155' ' ' VAL . 89.4 t -118.05 136.41 55.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.678 -0.895 . . . . 0.0 109.237 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.735 HD11 HG11 ' A' ' 129' ' ' VAL . 79.4 mt -66.78 115.8 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.43 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 33.2 tttt -97.63 -34.56 10.9 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.03 -1.044 . . . . 0.0 109.231 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -149.78 144.62 26.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.201 -0.937 . . . . 0.0 109.329 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 1.01 HG22 HD22 ' A' ' 153' ' ' LEU . 31.9 pt -123.98 127.66 73.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 109.573 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 28.5 t0 -111.81 100.19 47.72 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.484 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.568 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.3 Cg_endo -71.27 176.01 8.5 Favored 'Trans proline' 0 C--O 1.215 -0.654 0 C-N-CA 122.778 2.319 . . . . 0.0 111.71 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.568 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.4 mt-10 81.48 -21.05 0.33 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.434 -0.791 . . . . 0.0 109.84 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.431 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 82.1 mtt180 -131.15 -10.46 3.74 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.15 -0.969 . . . . 0.0 109.495 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.431 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 43.3 mt-30 69.97 48.54 0.54 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.252 -0.905 . . . . 0.0 109.967 179.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.541 ' OE2' HG13 ' A' ' 167' ' ' VAL . 81.3 tt0 -120.44 144.99 47.67 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.981 -1.075 . . . . 0.0 108.852 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 1.01 HD22 HG22 ' A' ' 146' ' ' ILE . 70.6 mt -139.91 127.69 21.9 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.102 -0.999 . . . . 0.0 110.441 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 36.2 mtpt -91.74 132.77 36.16 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.908 HG13 ' C ' ' A' ' 142' ' ' VAL . 92.9 t -133.99 126.96 51.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.116 -0.99 . . . . 0.0 109.914 -179.358 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.577 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 51.9 t-20 -76.1 137.12 39.93 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.341 -0.85 . . . . 0.0 109.862 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.621 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 59.8 t -114.46 147.53 17.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.329 -0.857 . . . . 0.0 109.069 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 18.2 m -99.41 91.88 5.14 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.999 -1.063 . . . . 0.0 109.913 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 1.153 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 2.5 pt -124.58 151.53 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.235 -0.916 . . . . 0.0 108.991 179.311 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.724 ' CE2' HD12 ' A' ' 159' ' ' ILE . 16.7 m-30 60.53 35.45 20.16 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -0.926 . . . . 0.0 108.969 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.03 15.37 9.99 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 21.0 mtp180 -128.22 158.22 38.71 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.179 -1.189 . . . . 0.0 109.595 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.452 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 90.7 mt-10 -100.97 132.76 46.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.268 -0.895 . . . . 0.0 109.551 -179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . 0.536 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 47.4 m -139.78 127.31 12.85 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.311 -0.868 . . . . 0.0 109.943 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.577 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.59 134.1 25.49 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.741 2.294 . . . . 0.0 111.175 179.608 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.684 ' HB ' HD21 ' A' ' 168' ' ' LEU . 2.2 t -120.03 164.09 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 120.962 -1.086 . . . . 0.0 110.153 -179.527 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 1.143 ' O ' HD13 ' A' ' 168' ' ' LEU . 43.0 t -117.03 115.94 50.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 N-CA-C 109.119 -0.696 . . . . 0.0 109.119 179.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 1.143 HD13 ' O ' ' A' ' 167' ' ' VAL . 0.3 OUTLIER -139.49 167.55 21.84 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-O 121.878 0.847 . . . . 0.0 110.249 -179.52 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.415 ' O ' ' HB2' ' A' ' 172' ' ' GLU . 96.1 m-70 -78.94 141.01 37.92 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.584 HG23 HD12 ' A' ' 153' ' ' LEU . 7.2 p -55.01 -36.43 38.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 O-C-N 121.056 -1.028 . . . . 0.0 108.88 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.406 ' N ' HG13 ' A' ' 170' ' ' VAL . 33.6 p -75.07 -5.23 43.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.455 -0.778 . . . . 0.0 109.553 179.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.601 ' HG2' ' CB ' ' A' ' 133' ' ' SER . 2.4 mt-10 -87.17 -1.82 58.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.225 -0.922 . . . . 0.0 109.707 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.52 ' HB ' ' O ' ' A' ' 130' ' ' LYS . 1.3 m -150.91 -178.31 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.138 -0.976 . . . . 0.0 109.465 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.857 ' HG3' HD13 ' A' ' 132' ' ' ILE . 3.5 mt-10 -138.01 170.2 16.45 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.082 -1.011 . . . . 0.0 109.1 179.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.519 ' HE2' ' OD2' ' A' ' 127' ' ' ASP . 52.0 tttm -86.14 5.77 32.34 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.0 -1.062 . . . . 0.0 109.553 179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.75 HD11 ' HB2' ' A' ' 130' ' ' LYS . 46.4 mt 55.1 -88.88 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.958 . . . . 0.0 109.459 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.485 ' N ' ' O ' ' A' ' 175' ' ' LYS . 85.5 tt0 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.016 -0.993 . . . . 0.0 109.483 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.21 -27.77 69.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.218 -1.166 . . . . 0.0 109.412 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 83.4 mtp -52.45 -44.26 65.4 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.252 -0.905 . . . . 0.0 109.462 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 31.4 tttt -70.08 144.52 52.11 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.29 -0.881 . . . . 0.0 109.573 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.505 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 27.4 mttm -144.43 150.07 37.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.228 -0.92 . . . . 0.0 109.488 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 1.3 mtpp -125.93 -179.78 4.85 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.196 -0.94 . . . . 0.0 109.321 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.787 ' CZ3' HG22 ' A' ' 41' ' ' VAL . 69.2 m95 -117.72 122.21 42.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.135 -0.978 . . . . 0.0 109.178 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -115.33 170.94 8.01 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.18 -0.95 . . . . 0.0 109.376 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.439 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 33.0 mt -112.89 110.74 33.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.296 -0.877 . . . . 0.0 109.065 179.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.541 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 10.3 p -88.66 142.48 12.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.215 -0.928 . . . . 0.0 109.512 -179.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.548 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.2 OUTLIER -89.04 145.68 25.32 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.294 -0.879 . . . . 0.0 109.625 -179.893 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.704 ' CG2' HG21 ' A' ' 20' ' ' VAL . 96.0 m -156.84 160.78 39.51 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.285 -0.884 . . . . 0.0 109.52 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.591 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 94.9 mmm -76.98 124.19 27.42 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.216 -0.928 . . . . 0.0 109.469 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 13' ' ' MET . 70.2 m -44.59 125.44 4.83 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.179 -0.95 . . . . 0.0 109.301 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.0 -19.98 34.26 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.591 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 92.0 m-85 -107.14 -5.64 17.86 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.22 -1.165 . . . . 0.0 109.505 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.684 ' OE1' HD11 ' A' ' 44' ' ' ILE . 68.2 mt-10 -51.52 -54.62 25.37 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 109.486 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -51.48 -34.49 35.95 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.219 -0.926 . . . . 0.0 109.368 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.46 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 64.1 mttm -76.35 -49.54 16.6 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.178 179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.704 HG21 ' CG2' ' A' ' 12' ' ' THR . 42.0 t -52.22 -49.92 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.337 -0.852 . . . . 0.0 109.365 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.681 ' HG3' HG21 ' A' ' 40' ' ' ILE . 29.9 tttt -56.83 -50.33 72.72 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.276 -0.89 . . . . 0.0 109.512 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.65 -34.55 77.29 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.191 -0.943 . . . . 0.0 109.332 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.527 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 32.8 m120 -65.32 -48.14 74.07 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.404 -0.81 . . . . 0.0 109.586 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 77.4 mt -54.02 -44.52 62.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.133 -0.98 . . . . 0.0 109.437 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.535 ' O ' HG22 ' A' ' 28' ' ' VAL . 75.1 tt0 -56.21 -46.14 79.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.246 -0.909 . . . . 0.0 109.721 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 7.7 mmtp -78.35 -36.13 46.58 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.16 -0.962 . . . . 0.0 109.509 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.465 ' O ' HG23 ' A' ' 31' ' ' THR . 8.9 tptt -53.9 -30.72 47.31 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.282 -0.886 . . . . 0.0 109.358 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.957 HG11 ' CG1' ' A' ' 37' ' ' VAL . 35.5 m -89.3 -22.04 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.3 -0.875 . . . . 0.0 109.41 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.422 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 44.6 mm-40 -70.71 -54.52 11.49 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.248 -0.908 . . . . 0.0 109.611 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.72 -31.09 71.95 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.185 -0.947 . . . . 0.0 109.451 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.465 HG23 ' O ' ' A' ' 27' ' ' LYS . 37.8 p -87.54 -8.23 56.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.217 -0.927 . . . . 0.0 109.413 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 60.58 28.54 67.89 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.719 HG23 HD23 ' A' ' 36' ' ' LEU . 46.7 mt -107.48 73.22 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -1.149 . . . . 0.0 109.515 -179.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.6 mtmt -87.68 -2.36 58.56 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.225 -0.922 . . . . 0.0 109.573 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -94.08 -12.8 27.73 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.214 -0.929 . . . . 0.0 109.473 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.769 HD12 ' HB2' ' A' ' 70' ' ' ALA . 1.8 mm? -86.92 -47.82 8.67 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 109.311 179.835 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.957 ' CG1' HG11 ' A' ' 28' ' ' VAL . 11.6 p -94.16 142.65 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.388 -0.82 . . . . 0.0 109.518 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -113.45 -123.97 4.08 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 82.0 mtt180 -94.43 140.07 30.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.253 -1.145 . . . . 0.0 109.619 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.681 HG21 ' HG3' ' A' ' 21' ' ' LYS . 58.8 mt -106.33 136.06 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 109.361 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.93 HG23 ' HB2' ' A' ' 61' ' ' PHE . 31.5 m -127.16 161.98 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.223 -0.923 . . . . 0.0 109.06 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.65 HD11 ' HD2' ' A' ' 21' ' ' LYS . 9.7 mt -144.02 126.99 8.72 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.142 -0.974 . . . . 0.0 110.034 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.69 -2.28 9.08 Favored 'Trans proline' 0 C--O 1.217 -0.533 0 C-N-CA 122.917 2.411 . . . . 0.0 111.381 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.833 ' HA ' ' HA ' ' A' ' 54' ' ' LYS . 76.8 mt -57.02 -50.31 76.7 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.185 -0.947 . . . . 0.0 109.491 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.468 ' HB3' ' O ' ' A' ' 44' ' ' ILE . 20.6 ttt85 61.37 139.47 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.296 -0.878 . . . . 0.0 109.498 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 95.59 16.73 38.55 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -59.91 -25.5 61.78 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 95.3 mt-30 -55.13 -31.61 61.42 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.307 -1.113 . . . . 0.0 109.558 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -100.91 145.72 28.26 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.25 -0.906 . . . . 0.0 109.534 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 57.1 ttm-85 -53.27 -41.4 65.5 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.243 -0.911 . . . . 0.0 109.292 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 3.2 mtpm? -93.91 115.45 27.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.313 -0.867 . . . . 0.0 109.406 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.507 ' HB2' ' CG2' ' A' ' 44' ' ' ILE . 79.1 p -104.89 156.7 17.79 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.185 -0.947 . . . . 0.0 109.421 -179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.491 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 27.5 mp0 -76.23 -45.16 34.22 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.256 -0.902 . . . . 0.0 109.433 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.833 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 8.4 mttt 75.13 88.78 0.09 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.179 -0.951 . . . . 0.0 109.238 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.581 ' HG ' ' CE2' ' A' ' 56' ' ' PHE . 61.3 tp -67.04 -23.13 65.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.8 -1.188 . . . . 0.0 109.666 -179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.741 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 57.1 m-85 -145.46 97.13 4.73 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 108.836 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -66.01 136.48 44.89 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 122.59 2.193 . . . . 0.0 112.247 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 12' ' ' THR . . . 76.74 -13.17 8.91 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.454 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.544 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 2.4 m-30 -100.84 130.47 46.86 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.688 -1.478 . . . . 0.0 110.23 -179.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.541 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 79.2 t -134.38 147.44 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.373 -0.829 . . . . 0.0 108.809 179.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.93 ' HB2' HG23 ' A' ' 41' ' ' VAL . 15.7 m-85 -107.58 122.12 46.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.005 -1.06 . . . . 0.0 109.956 -179.532 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.441 HG12 HG23 ' A' ' 40' ' ' ILE . 7.9 m -125.81 136.77 59.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.405 -0.809 . . . . 0.0 109.642 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.572 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 7.8 tt0 -101.01 123.96 45.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.228 -0.92 . . . . 0.0 108.974 179.553 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.529 ' HB3' ' O ' ' A' ' 36' ' ' LEU . 14.0 mtm -156.06 176.45 12.65 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.999 -1.063 . . . . 0.0 110.36 -179.266 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.621 ' CG1' HD13 ' A' ' 36' ' ' LEU . 7.9 pt -99.38 132.28 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.479 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 47.4 ttm -76.66 144.17 39.63 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.347 -0.846 . . . . 0.0 109.992 -178.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.479 ' HB2' ' O ' ' A' ' 66' ' ' MET . 50.6 t30 176.2 171.53 0.4 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -67.25 -41.64 85.24 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.1 -1.0 . . . . 0.0 109.446 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.579 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 97.4 mt-10 -71.72 -38.1 70.53 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.295 -0.878 . . . . 0.0 109.872 -179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.769 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -64.93 -44.9 87.97 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.19 -0.944 . . . . 0.0 109.466 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.493 ' CD2' ' OE1' ' A' ' 89' ' ' GLN . 27.9 t80 -60.0 -52.02 67.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.284 -0.885 . . . . 0.0 109.641 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.523 ' O ' ' HB3' ' A' ' 76' ' ' SER . 96.1 m-20 -59.34 -28.32 66.72 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.204 -0.935 . . . . 0.0 110.164 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 21.9 m-85 -85.45 -43.53 13.52 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.957 -1.089 . . . . 0.0 109.95 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.407 ' O ' HG12 ' A' ' 77' ' ' VAL . 71.6 t -70.06 -57.84 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.288 -0.883 . . . . 0.0 110.025 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.513 ' HD2' ' O ' ' A' ' 75' ' ' ARG . 29.3 tpt85 -60.83 -22.58 64.34 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.171 -0.956 . . . . 0.0 109.826 -179.669 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.523 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 35.4 p -93.71 5.89 50.13 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.127 -0.983 . . . . 0.0 109.88 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.718 HG11 HG21 ' A' ' 80' ' ' VAL . 5.1 p -70.15 129.42 90.66 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.125 -0.985 . . . . 0.0 109.331 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.671 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 43.5 Cg_endo -65.48 138.92 56.81 Favored 'Trans proline' 0 C--O 1.213 -0.732 0 C-N-CA 122.782 2.322 . . . . 0.0 112.177 -179.382 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.671 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 59.9 m-85 91.54 -11.98 0.23 Allowed 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.718 HG21 HG11 ' A' ' 77' ' ' VAL . 4.7 t -93.96 134.12 32.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.994 -1.066 . . . . 0.0 109.171 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 85.6 mmm -87.95 -27.4 22.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.205 -0.934 . . . . 0.0 109.492 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.9 -160.24 32.24 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.617 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 1.6 p90 -139.61 153.92 47.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -1.094 . . . . 0.0 109.314 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.669 HG13 ' O ' ' A' ' 84' ' ' VAL . 10.6 p -84.71 113.7 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.188 -0.945 . . . . 0.0 109.615 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.557 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.4 p -148.47 163.24 37.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.267 -0.895 . . . . 0.0 109.438 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 80.6 p -86.5 -34.55 19.98 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.419 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -127.32 -91.11 0.74 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.557 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -102.59 -126.95 5.97 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.557 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -30.27 152.39 0.03 OUTLIER Pre-proline 0 N--CA 1.494 1.738 0 O-C-N 121.61 -0.935 . . . . 0.0 110.375 -179.606 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.565 ' HD3' ' CD2' ' A' ' 83' ' ' PHE . 47.1 Cg_endo -68.13 137.69 41.39 Favored 'Trans proline' 0 C--O 1.215 -0.656 0 C-N-CA 122.917 2.411 . . . . 0.0 112.014 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 18.8 m -73.54 144.92 84.25 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.351 -0.843 . . . . 0.0 109.336 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -70.31 153.81 66.08 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.645 2.23 . . . . 0.0 111.702 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 7' ' ' TRP . 18.6 t -93.9 129.45 44.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.379 -0.826 . . . . 0.0 109.36 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 25.4 mttm -64.29 141.38 58.79 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.227 -0.921 . . . . 0.0 109.512 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -51.37 -38.64 54.36 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.228 -0.92 . . . . 0.0 109.415 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 62.3 mtt85 -58.2 -38.26 76.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.347 -0.846 . . . . 0.0 109.557 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -77.61 -25.93 50.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.196 -0.94 . . . . 0.0 109.454 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.608 ' CB ' HD11 ' A' ' 102' ' ' LEU . 95.4 mtp -86.03 -22.27 27.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.256 -0.903 . . . . 0.0 109.388 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.609 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 1.1 mtm180 -36.27 -52.8 1.7 Allowed Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.525 -0.734 . . . . 0.0 109.861 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.612 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 49.7 Cg_endo -70.01 -27.98 24.62 Favored 'Trans proline' 0 C--O 1.214 -0.718 0 C-N-CA 122.469 2.113 . . . . 0.0 111.908 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.526 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 29.8 mm -81.98 -43.41 19.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.176 -0.952 . . . . 0.0 109.451 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.608 HD11 ' CB ' ' A' ' 98' ' ' MET . 1.2 mt -68.94 -40.0 79.26 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.23 -0.919 . . . . 0.0 109.445 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.547 ' NH2' ' NH1' ' A' ' 99' ' ' ARG . 24.1 mtt180 -64.36 -50.59 67.14 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -0.894 . . . . 0.0 109.124 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.62 -36.07 70.66 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.382 -0.824 . . . . 0.0 109.3 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.618 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -71.27 1.47 6.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.323 -0.861 . . . . 0.0 110.035 -179.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.07 8.25 82.88 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.633 HD21 HG11 ' A' ' 41' ' ' VAL . 9.4 mp -80.91 -22.07 40.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.248 -1.148 . . . . 0.0 109.368 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.491 ' HB3' ' HA ' ' A' ' 103' ' ' ARG . 47.6 tp10 -115.95 142.95 46.11 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.333 -0.854 . . . . 0.0 109.487 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -115.89 120.74 40.19 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.228 -0.92 . . . . 0.0 109.487 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.473 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 35.8 p90 -138.96 160.12 40.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.243 -0.911 . . . . 0.0 109.414 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.473 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 47.6 mt-10 -77.44 -144.97 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.197 -0.939 . . . . 0.0 109.492 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.522 ' HG2' ' N ' ' A' ' 113' ' ' LYS . 76.7 tt0 -129.86 155.33 46.19 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.248 -0.908 . . . . 0.0 109.435 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.522 ' N ' ' HG2' ' A' ' 112' ' ' GLU . 5.6 tttp -34.51 146.0 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.484 -0.76 . . . . 0.0 109.892 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.63 -43.33 85.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 109.55 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -149.09 158.37 38.84 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 121.257 -0.902 . . . . 0.0 109.626 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -70.53 121.9 8.4 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.763 2.309 . . . . 0.0 111.798 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.452 HG21 ' OE2' ' A' ' 174' ' ' GLU . 4.1 p -98.51 147.39 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.197 -0.94 . . . . 0.0 109.518 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 35.9 mttt -86.63 169.97 12.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.238 -0.914 . . . . 0.0 109.446 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.471 HG11 HG22 ' A' ' 170' ' ' VAL . 32.8 m -113.53 177.28 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.223 -0.923 . . . . 0.0 109.51 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.554 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 6.9 mt-10 -67.99 -24.16 65.11 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.311 -0.868 . . . . 0.0 109.533 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.554 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 3.4 tp 79.67 161.41 0.18 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.358 -0.839 . . . . 0.0 109.625 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 43.19 46.07 6.44 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.746 ' CE1' HG21 ' A' ' 146' ' ' ILE . 0.3 OUTLIER -64.19 178.26 0.71 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.188 -1.184 . . . . 0.0 109.208 179.679 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.452 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 7.1 mttp -141.13 145.42 35.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.076 -1.015 . . . . 0.0 109.868 -179.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.52 HG12 HG12 ' A' ' 146' ' ' ILE . 22.4 m -63.98 141.99 17.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.38 -0.825 . . . . 0.0 109.397 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 87.44 -31.69 4.42 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.017 -1.633 . . . . 0.0 109.017 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.496 ' CG ' ' CE ' ' A' ' 175' ' ' LYS . 13.0 t70 -48.5 164.04 0.06 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.513 -0.992 . . . . 0.0 109.055 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . 0.588 ' HG2' HD12 ' A' ' 176' ' ' ILE . 4.2 ttm -100.29 127.47 46.57 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.086 -1.009 . . . . 0.0 109.241 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.585 ' CG1' HG12 ' A' ' 143' ' ' ILE . 35.0 m -125.89 142.35 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.34 -0.85 . . . . 0.0 109.26 179.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.768 ' HB2' HD11 ' A' ' 176' ' ' ILE . 7.8 tttt -102.79 141.83 34.94 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.357 -0.839 . . . . 0.0 108.858 179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 1.041 HD12 ' HB3' ' A' ' 139' ' ' PHE . 89.8 mt -81.73 152.35 4.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.102 -0.999 . . . . 0.0 108.557 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.586 HD11 ' CA ' ' A' ' 173' ' ' VAL . 0.5 OUTLIER -150.45 1.64 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.024 -1.048 . . . . 0.0 109.382 179.647 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.521 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 2.9 m -147.27 143.49 28.15 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.128 -0.982 . . . . 0.0 109.896 -179.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.17 -166.92 17.76 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 110.299 -1.12 . . . . 0.0 110.299 179.391 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.603 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 45.7 Cg_endo -68.49 -22.51 38.65 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 123.179 2.586 . . . . 0.0 112.594 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.612 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 70.7 m-85 -106.46 17.3 23.54 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.786 -1.196 . . . . 0.0 109.533 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.689 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.5 tt0 -48.18 137.57 10.56 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.168 -0.957 . . . . 0.0 109.599 -179.773 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.555 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 10.8 m-20 81.62 22.34 0.3 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.479 -0.763 . . . . 0.0 110.323 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 1.041 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.5 t80 -115.03 143.04 45.81 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.966 -1.084 . . . . 0.0 109.566 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -92.0 134.7 34.57 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.146 -0.971 . . . . 0.0 109.493 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.41 167.24 27.52 Favored Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.739 -1.22 . . . . 0.0 110.212 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.662 ' C ' HG13 ' A' ' 155' ' ' VAL . 37.6 t -115.07 137.14 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.54 -0.976 . . . . 0.0 109.139 179.651 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 1.067 ' CG2' HD11 ' A' ' 146' ' ' ILE . 28.1 mm -69.13 122.4 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.262 -0.899 . . . . 0.0 109.423 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.456 ' C ' ' HG2' ' A' ' 145' ' ' GLU . 0.2 OUTLIER -106.53 -33.3 7.73 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.04 -1.038 . . . . 0.0 109.627 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.761 ' O ' HD13 ' A' ' 146' ' ' ILE . 70.0 mm-40 -151.38 146.58 26.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.014 -1.054 . . . . 0.0 109.874 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 1.149 HG23 ' CD2' ' A' ' 153' ' ' LEU . 6.0 mm -120.86 122.76 68.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.091 -1.006 . . . . 0.0 109.491 179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 14.7 t0 -107.08 99.21 25.38 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.307 -0.87 . . . . 0.0 109.349 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.565 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.6 Cg_endo -71.45 172.26 14.57 Favored 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 122.801 2.334 . . . . 0.0 111.841 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.565 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 4.6 mt-10 80.62 -20.16 0.39 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.377 -0.827 . . . . 0.0 109.786 179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 94.8 mtt-85 -128.04 -13.66 5.08 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.142 -0.974 . . . . 0.0 109.49 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.432 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 35.9 mt-30 70.33 48.47 0.49 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.245 -0.909 . . . . 0.0 109.38 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -120.01 143.13 48.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.085 -1.01 . . . . 0.0 109.245 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 1.149 ' CD2' HG23 ' A' ' 146' ' ' ILE . 98.8 mt -128.64 130.73 47.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.219 -0.926 . . . . 0.0 110.103 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.469 ' HD3' ' HB2' ' A' ' 145' ' ' GLU . 22.7 mtpp -92.93 126.17 37.89 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.892 HG22 HD13 ' A' ' 143' ' ' ILE . 4.0 t -126.31 145.86 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.252 -0.905 . . . . 0.0 110.086 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 27.7 t-20 -98.87 114.9 27.7 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.451 -0.781 . . . . 0.0 109.326 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.621 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 41.7 t -97.54 142.59 14.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.373 -0.829 . . . . 0.0 109.665 -179.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 13.3 m -96.57 95.61 8.1 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.275 -0.891 . . . . 0.0 109.784 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.753 HD12 ' CE2' ' A' ' 160' ' ' PHE . 19.0 pt -125.94 146.72 31.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.319 -0.863 . . . . 0.0 109.301 179.76 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.753 ' CE2' HD12 ' A' ' 159' ' ' ILE . 11.5 m-85 63.24 36.26 12.0 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.219 -0.926 . . . . 0.0 109.321 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.05 16.64 19.53 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.41 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 17.8 mtt-85 -130.15 158.69 38.98 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.291 -1.123 . . . . 0.0 109.548 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.405 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 94.7 mt-10 -99.42 132.99 44.37 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.202 -0.936 . . . . 0.0 109.375 179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . 0.433 HG21 ' CZ ' ' A' ' 56' ' ' PHE . 27.9 m -144.13 124.84 7.74 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.188 -0.945 . . . . 0.0 109.647 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.538 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -70.81 139.47 36.67 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 122.738 2.292 . . . . 0.0 111.763 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.653 HG13 HD23 ' A' ' 168' ' ' LEU . 5.6 p -124.48 143.58 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.155 -0.965 . . . . 0.0 109.646 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.59 HG13 ' O ' ' A' ' 167' ' ' VAL . 10.7 p -92.31 119.36 39.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.414 -0.804 . . . . 0.0 109.33 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.653 HD23 HG13 ' A' ' 166' ' ' VAL . 0.7 OUTLIER -140.48 165.91 26.14 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.22 -0.925 . . . . 0.0 110.621 -179.054 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.451 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 98.2 m-70 -80.32 145.54 32.05 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 179.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.726 HG23 HD11 ' A' ' 153' ' ' LEU . 11.0 p -60.14 -34.58 57.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.19 -0.944 . . . . 0.0 108.975 179.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 54.3 p -76.82 -6.73 53.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.322 -0.861 . . . . 0.0 109.321 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.521 ' HA ' ' HB2' ' A' ' 133' ' ' SER . 74.4 mt-10 -96.33 5.94 49.85 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.299 -0.876 . . . . 0.0 109.25 179.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.607 HG11 HD11 ' A' ' 168' ' ' LEU . 1.5 p -148.07 169.01 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.279 -0.888 . . . . 0.0 108.723 179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.603 ' N ' HG22 ' A' ' 173' ' ' VAL . 57.0 mt-10 -138.51 167.79 21.16 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.011 -1.056 . . . . 0.0 109.202 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.535 ' O ' ' N ' ' A' ' 177' ' ' GLU . 63.0 tttt -92.55 22.57 4.57 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.077 -1.015 . . . . 0.0 109.485 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.768 HD11 ' HB2' ' A' ' 130' ' ' LYS . 84.5 mt 42.01 -94.25 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.869 . . . . 0.0 109.606 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.535 ' N ' ' O ' ' A' ' 175' ' ' LYS . 61.7 tt0 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.531 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.33 -24.15 67.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.293 -1.122 . . . . 0.0 109.451 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 57.4 mtm -63.84 -17.39 63.08 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -0.92 . . . . 0.0 109.497 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 52.0 mttp -110.13 119.0 37.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.23 -0.919 . . . . 0.0 109.452 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.6 mttt -106.83 174.31 5.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.166 -0.959 . . . . 0.0 109.498 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 24.6 mmtp -128.75 175.5 8.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -0.93 . . . . 0.0 109.307 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.908 ' CH2' HG23 ' A' ' 41' ' ' VAL . 64.6 m95 -112.17 124.59 52.77 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -0.895 . . . . 0.0 109.247 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.612 ' CZ ' ' HG3' ' A' ' 66' ' ' MET . 81.3 m-85 -117.0 170.98 8.21 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.212 -0.93 . . . . 0.0 109.422 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.612 HG12 ' CE1' ' A' ' 61' ' ' PHE . 42.1 mt -107.45 116.33 50.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.251 -0.905 . . . . 0.0 109.379 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.621 ' CG1' HG23 ' A' ' 80' ' ' VAL . 50.0 t -93.43 139.14 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.241 -0.912 . . . . 0.0 109.362 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.567 HD11 ' HE1' ' A' ' 59' ' ' TYR . 4.2 mm? -86.78 146.28 26.3 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.316 -0.865 . . . . 0.0 109.33 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.561 ' OG1' HG21 ' A' ' 20' ' ' VAL . 11.2 t -158.24 -176.21 5.78 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.263 -0.898 . . . . 0.0 109.501 -179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.507 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 64.0 mtm -101.2 120.01 39.6 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.175 -0.953 . . . . 0.0 109.533 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.435 ' OG ' ' HB2' ' A' ' 57' ' ' PRO . 43.0 m -43.39 128.3 4.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 109.385 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.08 -19.88 47.43 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.507 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 87.2 m-85 -109.54 9.59 25.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.346 -1.091 . . . . 0.0 109.511 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.531 ' HG2' HG21 ' A' ' 12' ' ' THR . 95.6 mt-10 -60.03 -45.1 93.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.203 -0.936 . . . . 0.0 109.493 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.475 ' OE2' ' HG2' ' A' ' 49' ' ' ARG . 78.3 mt-10 -58.82 -35.31 72.67 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.183 -0.948 . . . . 0.0 109.329 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.401 ' O ' ' HB2' ' A' ' 23' ' ' ASN . 83.7 mttt -72.73 -34.0 66.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.214 -0.929 . . . . 0.0 109.355 179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.561 HG21 ' OG1' ' A' ' 12' ' ' THR . 87.0 t -72.39 -53.05 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.24 -0.912 . . . . 0.0 109.461 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.507 ' HG3' HG21 ' A' ' 40' ' ' ILE . 46.2 tttm -57.62 -49.91 74.9 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.301 -0.874 . . . . 0.0 109.372 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -63.4 -35.86 81.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.196 -0.94 . . . . 0.0 109.165 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.744 ' OD1' HG22 ' A' ' 77' ' ' VAL . 13.8 t-20 -62.72 -47.59 82.94 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.345 -0.847 . . . . 0.0 109.48 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.415 ' CG2' HG11 ' A' ' 37' ' ' VAL . 89.7 mt -55.75 -43.58 74.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.278 -0.889 . . . . 0.0 109.501 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -57.64 -46.87 83.62 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.943 . . . . 0.0 110.11 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 76.4 mttt -75.63 -37.31 59.83 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.984 -1.073 . . . . 0.0 109.824 -179.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.93 ' CD ' HG23 ' A' ' 77' ' ' VAL . 42.2 tttp -55.95 -29.68 60.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.133 -0.98 . . . . 0.0 109.204 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.818 HG13 ' O ' ' A' ' 33' ' ' ILE . 37.8 t -82.98 -26.42 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.866 . . . . 0.0 109.508 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.416 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 66.8 mm-40 -67.68 -51.65 47.16 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.247 -0.908 . . . . 0.0 109.474 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.07 -43.91 51.54 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.246 -0.909 . . . . 0.0 109.444 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.401 HG21 ' CZ ' ' A' ' 73' ' ' PHE . 62.6 p -88.88 -7.95 55.16 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.187 -0.946 . . . . 0.0 109.624 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 54.95 22.58 28.12 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.073 HG21 ' CD1' ' A' ' 36' ' ' LEU . 74.8 mt -84.69 100.91 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.252 -1.146 . . . . 0.0 109.512 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 75.5 mttt -103.54 35.33 2.63 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.264 -0.897 . . . . 0.0 109.357 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.566 ' OD1' HG23 ' A' ' 33' ' ' ILE . 18.6 p-10 -136.41 8.45 3.13 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.204 -0.935 . . . . 0.0 109.784 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.073 ' CD1' HG21 ' A' ' 33' ' ' ILE . 82.1 mt -113.09 -42.88 3.46 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.22 -0.925 . . . . 0.0 109.34 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.48 ' HA ' ' HB3' ' A' ' 64' ' ' MET . 52.5 t -106.93 138.68 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.226 179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -109.37 -124.65 4.93 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.409 ' O ' ' CH2' ' A' ' 7' ' ' TRP . 64.8 mtt85 -95.13 140.12 30.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.243 -1.151 . . . . 0.0 109.789 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.548 HG23 HG12 ' A' ' 62' ' ' VAL . 67.9 mt -102.13 135.94 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.307 -0.87 . . . . 0.0 109.032 179.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.908 HG23 ' CH2' ' A' ' 7' ' ' TRP . 53.5 t -118.51 147.21 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.066 -1.021 . . . . 0.0 109.678 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.9 HG22 HG23 ' A' ' 44' ' ' ILE . 2.5 mt -119.74 125.72 27.28 Favored Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.254 -0.904 . . . . 0.0 109.411 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.501 ' CB ' ' CD2' ' A' ' 56' ' ' PHE . 49.6 Cg_endo -70.33 -5.33 16.3 Favored 'Trans proline' 0 C--O 1.216 -0.616 0 C-N-CA 122.735 2.29 . . . . 0.0 111.814 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.9 HG23 HG22 ' A' ' 42' ' ' ILE . 14.6 pt -66.09 130.43 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.258 -0.901 . . . . 0.0 109.569 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.617 ' HD2' HD11 ' A' ' 104' ' ' LEU . 34.0 tpt85 -62.61 -48.73 78.11 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.356 -0.84 . . . . 0.0 109.513 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -77.0 118.97 5.27 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -84.78 11.76 58.74 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -107.02 165.14 11.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.317 -1.107 . . . . 0.0 109.453 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.475 ' HG2' ' OE2' ' A' ' 18' ' ' GLU . 64.2 mtt85 -62.63 -30.58 71.47 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.277 -0.889 . . . . 0.0 109.463 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 65.8 mtt85 -114.36 174.98 5.68 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.253 -0.904 . . . . 0.0 109.415 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 69.7 mttt 56.05 28.64 13.15 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.215 -0.928 . . . . 0.0 109.277 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.38 137.69 32.15 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.326 -0.859 . . . . 0.0 109.462 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.502 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 82.9 tt0 -91.83 -48.99 6.49 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.269 -0.894 . . . . 0.0 109.479 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.571 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 37.8 mttt 75.33 87.54 0.09 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.302 -0.874 . . . . 0.0 109.494 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.618 ' O ' ' CD1' ' A' ' 56' ' ' PHE . 49.4 mt -60.72 -24.77 65.93 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.091 -1.006 . . . . 0.0 109.462 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 1.058 ' CE1' HD11 ' A' ' 159' ' ' ILE . 1.0 OUTLIER -151.59 104.58 2.89 Favored Pre-proline 0 N--CA 1.491 1.609 0 O-C-N 121.298 -0.876 . . . . 0.0 108.78 179.655 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.435 ' HB2' ' OG ' ' A' ' 14' ' ' SER . 43.7 Cg_endo -66.93 142.17 61.39 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.541 2.161 . . . . 0.0 111.845 -179.442 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.48 -9.48 10.31 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.567 ' HE1' HD11 ' A' ' 11' ' ' LEU . 2.9 m-30 -102.52 132.08 48.81 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.8 -1.412 . . . . 0.0 110.046 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 45.8 t -134.74 147.75 29.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.859 . . . . 0.0 108.818 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.612 ' CE1' HG12 ' A' ' 9' ' ' ILE . 93.2 m-85 -110.34 123.19 49.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.937 -1.102 . . . . 0.0 109.902 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.548 HG12 HG23 ' A' ' 40' ' ' ILE . 4.9 m -130.66 143.34 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.302 -0.874 . . . . 0.0 109.767 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.608 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 8.1 tt0 -101.46 125.35 48.09 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 109.04 179.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.523 ' CE ' HG11 ' A' ' 74' ' ' VAL . 14.6 ptt? -163.38 -177.37 5.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.984 -1.072 . . . . 0.0 110.457 -179.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.843 HD11 ' CD2' ' A' ' 36' ' ' LEU . 7.5 pt -100.9 125.04 54.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.539 -0.726 . . . . 0.0 109.578 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.612 ' HG3' ' CZ ' ' A' ' 8' ' ' TYR . 73.5 mmm -89.56 99.64 12.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.34 -0.85 . . . . 0.0 109.398 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.446 ' OD1' HG13 ' A' ' 65' ' ' ILE . 21.3 m120 -139.04 -164.29 1.63 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.062 -1.024 . . . . 0.0 109.174 179.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -73.04 -51.92 16.34 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.249 -0.907 . . . . 0.0 110.005 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -72.82 -58.34 3.41 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.096 -1.003 . . . . 0.0 109.743 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.007 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -47.3 -44.19 23.13 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.271 -0.893 . . . . 0.0 109.456 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.587 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 88.0 t80 -61.65 -51.6 67.79 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.164 -0.96 . . . . 0.0 109.586 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.492 ' O ' ' HB3' ' A' ' 76' ' ' SER . 83.6 m-20 -59.16 -29.28 67.32 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.228 -0.92 . . . . 0.0 109.888 -179.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.604 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 15.8 t80 -82.61 -43.21 17.28 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.091 -1.006 . . . . 0.0 109.636 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 1.007 HG23 ' O ' ' A' ' 70' ' ' ALA . 16.4 t -65.22 -58.1 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.41 -0.806 . . . . 0.0 109.505 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.511 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 15.1 tpt180 -58.23 -11.02 2.28 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.324 -0.86 . . . . 0.0 110.095 -179.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.492 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 29.0 p -95.41 5.38 51.79 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.927 -1.108 . . . . 0.0 109.898 -179.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.93 HG23 ' CD ' ' A' ' 27' ' ' LYS . 0.3 OUTLIER -71.85 128.72 89.11 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.094 -1.004 . . . . 0.0 109.086 179.871 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.644 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 42.0 Cg_endo -64.97 140.45 66.26 Favored 'Trans proline' 0 C--O 1.214 -0.677 0 C-N-CA 122.566 2.177 . . . . 0.0 111.891 -179.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.644 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 8.2 m-85 91.7 -10.02 0.24 Allowed 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.89 -0.506 . . . . 0.0 109.817 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.72 HG12 ' O ' ' A' ' 77' ' ' VAL . 4.3 p -93.57 134.47 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.879 -1.138 . . . . 0.0 109.85 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 88.6 mtp -86.91 -23.98 24.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.379 -0.825 . . . . 0.0 109.258 179.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.572 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 155.19 -156.38 26.91 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.572 ' CD1' ' O ' ' A' ' 82' ' ' GLY . 15.3 m-85 -135.19 143.22 46.3 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.266 -1.137 . . . . 0.0 109.474 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.461 ' CG1' ' HB ' ' A' ' 9' ' ' ILE . 9.5 p -69.46 131.81 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.286 -0.884 . . . . 0.0 109.512 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.56 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.3 p -166.92 158.65 12.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.271 -0.893 . . . . 0.0 109.616 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.2 m -86.05 -31.79 21.78 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.282 -0.886 . . . . 0.0 109.269 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -131.03 -85.37 0.34 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.542 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -104.17 -134.24 8.09 Favored Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.587 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.6 OUTLIER -30.91 150.79 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.819 0 O-C-N 121.557 -0.967 . . . . 0.0 110.317 -179.622 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.56 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.5 Cg_endo -68.38 141.3 50.92 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 122.819 2.346 . . . . 0.0 112.087 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.758 HG23 ' HD2' ' A' ' 92' ' ' PRO . 4.0 p -77.14 144.35 71.4 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.344 -0.847 . . . . 0.0 109.364 179.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.758 ' HD2' HG23 ' A' ' 91' ' ' VAL . 47.4 Cg_endo -68.39 153.52 73.92 Favored 'Trans proline' 0 C--O 1.216 -0.575 0 C-N-CA 122.66 2.24 . . . . 0.0 111.743 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.52 ' CG1' ' HB2' ' A' ' 97' ' ' GLU . 86.2 t -89.38 133.66 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.268 -0.895 . . . . 0.0 109.649 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 26.4 mtmt -61.49 138.4 58.28 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.331 -0.856 . . . . 0.0 109.449 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 78.2 m-20 -49.4 -35.81 20.15 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.216 -0.928 . . . . 0.0 109.464 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 76.5 mtt180 -61.57 -28.95 69.71 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.222 -0.924 . . . . 0.0 109.504 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.52 ' HB2' ' CG1' ' A' ' 93' ' ' VAL . 77.1 mt-10 -82.41 -25.22 33.9 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -0.92 . . . . 0.0 109.599 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.509 ' HE3' HD11 ' A' ' 102' ' ' LEU . 30.9 mmm -85.37 -28.92 24.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.208 -0.932 . . . . 0.0 109.385 179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.597 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -36.33 -54.26 1.56 Allowed Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.413 -0.804 . . . . 0.0 109.844 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.639 ' HB2' ' CE1' ' A' ' 136' ' ' PHE . 48.6 Cg_endo -69.28 -26.91 29.39 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.581 2.188 . . . . 0.0 111.938 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.456 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 22.3 mm -82.67 -39.42 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.255 -0.903 . . . . 0.0 109.352 179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.688 ' N ' HD13 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -72.05 -40.53 68.27 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.097 179.823 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.496 ' HA ' ' HB2' ' A' ' 108' ' ' GLU . 9.3 ttt180 -64.54 -48.5 74.84 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.309 -0.869 . . . . 0.0 109.158 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.617 HD11 ' HD2' ' A' ' 45' ' ' ARG . 1.2 tt -71.72 -35.12 70.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.271 -0.893 . . . . 0.0 109.184 179.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.46 ' CB ' HG13 ' A' ' 41' ' ' VAL . . . -71.83 2.15 5.92 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.335 -0.853 . . . . 0.0 110.178 -179.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.0 9.4 83.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.455 ' HB3' ' HB3' ' A' ' 102' ' ' LEU . 0.4 OUTLIER -76.56 -18.68 58.54 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.073 -1.251 . . . . 0.0 109.314 179.85 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.496 ' HB2' ' HA ' ' A' ' 103' ' ' ARG . 91.2 mt-10 -109.65 152.87 25.03 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.278 -0.889 . . . . 0.0 109.555 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 93.0 mt-10 -108.27 112.68 25.27 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.27 -0.894 . . . . 0.0 109.468 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.448 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 25.8 p90 -149.53 158.27 44.02 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.297 -0.877 . . . . 0.0 109.327 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.448 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 18.6 mt-10 -89.12 -149.96 0.19 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.23 -0.919 . . . . 0.0 109.5 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.471 ' HG2' ' N ' ' A' ' 113' ' ' LYS . 74.4 tt0 -103.87 153.49 20.7 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.226 -0.921 . . . . 0.0 109.469 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.539 ' HG3' ' N ' ' A' ' 114' ' ' LYS . 15.0 pttm -45.56 -43.71 12.25 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.204 -0.935 . . . . 0.0 109.524 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.539 ' N ' ' HG3' ' A' ' 113' ' ' LYS . 0.3 OUTLIER 68.63 52.81 0.56 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.263 -0.898 . . . . 0.0 109.365 -179.967 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.57 ' HG3' HG12 ' A' ' 117' ' ' VAL . 0.1 OUTLIER -138.64 80.23 26.72 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.31 -0.869 . . . . 0.0 109.362 -179.973 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -71.13 -6.09 18.44 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.732 2.288 . . . . 0.0 111.933 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.57 HG12 ' HG3' ' A' ' 115' ' ' LYS . 14.4 p -67.47 134.87 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.908 . . . . 0.0 109.51 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 58.6 mttp -83.92 151.92 24.81 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.296 -0.877 . . . . 0.0 109.38 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.56 HG12 ' HA ' ' A' ' 171' ' ' SER . 7.6 p -114.83 144.88 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.249 -0.907 . . . . 0.0 109.523 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.654 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 86.3 mt-10 -126.81 170.85 11.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.25 -0.906 . . . . 0.0 109.438 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.654 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 3.8 mt 146.14 100.91 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.616 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.22 92.05 0.01 OUTLIER Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.508 ' N ' ' O ' ' A' ' 121' ' ' LEU . 45.7 p90 -104.29 141.76 35.73 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.168 -1.195 . . . . 0.0 109.097 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.405 ' HG2' ' C ' ' A' ' 123' ' ' PHE . 12.5 mmtt -138.12 163.75 30.87 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.094 -1.004 . . . . 0.0 110.063 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 11.0 p -62.9 141.95 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.443 -0.785 . . . . 0.0 109.548 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.461 ' O ' HG23 ' A' ' 142' ' ' VAL . . . 86.98 -33.21 3.83 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.531 ' HB2' HD12 ' A' ' 143' ' ' ILE . 71.4 m-20 -46.51 161.76 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.378 -1.072 . . . . 0.0 109.102 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 15.4 ttm -99.82 127.88 45.96 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.138 -0.976 . . . . 0.0 108.959 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.679 HG11 HD11 ' A' ' 143' ' ' ILE . 33.4 m -127.78 143.21 41.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.193 -0.942 . . . . 0.0 109.612 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.5 ' HG3' ' O ' ' A' ' 139' ' ' PHE . 12.1 ttpt -101.69 143.02 32.16 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.45 -0.781 . . . . 0.0 109.046 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.776 HD12 ' HB3' ' A' ' 139' ' ' PHE . 93.1 mt -80.39 147.0 6.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.132 -0.98 . . . . 0.0 108.421 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.547 HG13 ' C ' ' A' ' 131' ' ' ILE . 18.7 mt -145.03 1.22 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.018 -1.051 . . . . 0.0 109.337 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.524 ' OG ' ' CD ' ' A' ' 113' ' ' LYS . 16.7 t -148.48 142.37 25.77 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.188 -0.945 . . . . 0.0 109.689 -179.608 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.449 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 105.38 -166.5 14.44 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 110.162 -1.175 . . . . 0.0 110.162 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.472 ' HA ' ' HD3' ' A' ' 103' ' ' ARG . 47.7 Cg_endo -68.09 -19.88 44.7 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 123.23 2.62 . . . . 0.0 112.714 -179.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.655 ' HB2' HD13 ' A' ' 131' ' ' ILE . 96.4 m-85 -107.28 19.74 19.92 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.816 -1.177 . . . . 0.0 109.626 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.525 ' O ' ' CB ' ' A' ' 138' ' ' ASP . 36.7 mt-10 -43.85 137.51 3.13 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.206 -0.934 . . . . 0.0 109.991 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.525 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.6 OUTLIER 77.87 26.47 0.62 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.259 -0.901 . . . . 0.0 110.675 178.87 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.805 ' CE1' HG13 ' A' ' 157' ' ' VAL . 2.0 t80 -114.62 159.79 20.05 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.774 -1.204 . . . . 0.0 109.556 179.696 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -108.63 135.22 50.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.245 -0.909 . . . . 0.0 109.399 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -146.86 170.23 27.84 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.52 -179.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.733 ' C ' HG23 ' A' ' 155' ' ' VAL . 8.5 p -119.19 136.94 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.627 -0.926 . . . . 0.0 109.222 179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.679 HD11 HG11 ' A' ' 129' ' ' VAL . 88.7 mt -67.22 115.14 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.302 -0.874 . . . . 0.0 109.445 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 68.9 tttt -98.33 -34.77 10.55 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.099 -1.001 . . . . 0.0 109.223 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -149.39 144.47 26.41 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.273 -0.892 . . . . 0.0 109.105 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 1.001 HG22 HD22 ' A' ' 153' ' ' LEU . 26.7 pt -126.27 129.32 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.101 -0.999 . . . . 0.0 109.695 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.85 103.13 48.5 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.345 -0.847 . . . . 0.0 109.38 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.549 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.3 Cg_endo -71.08 169.37 20.73 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.711 2.274 . . . . 0.0 111.898 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.549 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.2 tt0 80.81 -21.23 0.33 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.433 -0.792 . . . . 0.0 110.044 179.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.443 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 24.0 mtp85 -124.91 -11.73 7.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.063 -1.023 . . . . 0.0 109.515 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.443 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 42.8 mt-30 69.07 48.13 0.7 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.316 -0.865 . . . . 0.0 109.499 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.72 ' OE2' HG13 ' A' ' 167' ' ' VAL . 56.3 tt0 -121.13 144.93 48.31 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.104 179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 1.001 HD22 HG22 ' A' ' 146' ' ' ILE . 58.1 mt -139.54 121.89 16.02 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.16 -0.963 . . . . 0.0 110.226 -179.701 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.448 ' HE3' ' CB ' ' A' ' 165' ' ' PRO . 18.5 ttpt -83.18 132.04 35.09 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.242 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.733 HG23 ' C ' ' A' ' 142' ' ' VAL . 9.0 p -125.92 149.76 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.781 -179.612 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.531 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 3.5 t30 -99.19 116.21 30.87 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.396 -0.815 . . . . 0.0 109.205 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.805 HG13 ' CE1' ' A' ' 139' ' ' PHE . 65.7 t -102.59 146.09 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.212 -0.93 . . . . 0.0 109.581 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 25.8 m -93.75 113.02 24.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.356 -0.84 . . . . 0.0 109.533 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 1.058 HD11 ' CE1' ' A' ' 56' ' ' PHE . 15.0 pt -145.35 144.6 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.292 -0.88 . . . . 0.0 109.256 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.567 ' CE2' HD12 ' A' ' 159' ' ' ILE . 46.5 m-85 60.18 35.78 21.04 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.242 -0.911 . . . . 0.0 109.133 -179.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.91 15.41 13.09 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 67.7 mtp180 -127.37 154.28 45.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.063 -1.257 . . . . 0.0 109.637 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.436 ' OE1' ' N ' ' A' ' 163' ' ' GLU . 58.0 mp0 -97.73 134.9 40.28 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.151 -0.968 . . . . 0.0 109.427 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 24.5 m -147.9 126.12 5.99 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.257 -0.902 . . . . 0.0 109.764 -179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.531 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.8 Cg_endo -70.83 142.8 44.06 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.702 2.268 . . . . 0.0 111.545 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 41.8 t -125.72 144.08 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.058 -1.026 . . . . 0.0 109.788 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.72 HG13 ' OE2' ' A' ' 152' ' ' GLU . 55.4 t -91.48 118.4 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.414 -0.804 . . . . 0.0 109.194 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.407 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 27.0 mt -140.71 166.31 25.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.12 -0.987 . . . . 0.0 110.543 -179.014 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.438 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 79.7 m80 -81.54 144.44 31.3 Favored 'General case' 0 N--CA 1.491 1.584 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.845 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.6 HG23 ' CD1' ' A' ' 153' ' ' LEU . 11.6 p -59.22 -35.39 57.55 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.346 -0.846 . . . . 0.0 109.025 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.56 ' HA ' HG12 ' A' ' 119' ' ' VAL . 19.4 m -76.96 -8.16 56.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.249 -0.907 . . . . 0.0 109.508 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.467 ' HG2' ' HB3' ' A' ' 133' ' ' SER . 18.6 mt-10 -92.22 2.22 56.74 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.301 -0.874 . . . . 0.0 109.195 179.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 4.1 m -145.06 173.07 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.313 -0.867 . . . . 0.0 109.242 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.533 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 84.2 tt0 -136.94 164.0 29.38 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.165 -0.959 . . . . 0.0 108.985 179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.533 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 36.7 tttm -96.35 33.23 1.81 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.084 -1.01 . . . . 0.0 109.521 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . . . . . . . . . 75.0 mt 54.41 -86.74 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.237 -0.914 . . . . 0.0 109.403 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.528 ' N ' ' O ' ' A' ' 175' ' ' LYS . 28.3 tt0 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.397 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.56 -20.15 65.4 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.238 -1.154 . . . . 0.0 109.486 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 44.0 mtm -76.92 -6.95 54.54 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.24 -0.913 . . . . 0.0 109.488 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 10.8 tptt -98.14 113.81 25.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.709 ' HG2' HG22 ' A' ' 65' ' ' ILE . 20.5 mttt -125.92 168.72 13.5 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.179 -0.951 . . . . 0.0 109.536 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.595 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.4 mmtp -129.99 172.11 12.07 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.277 -0.89 . . . . 0.0 109.419 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.938 ' O ' HG23 ' A' ' 93' ' ' VAL . 61.3 m95 -107.44 127.17 53.36 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.286 -0.884 . . . . 0.0 109.215 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.428 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 54.0 m-85 -117.86 167.88 11.0 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.179 -0.951 . . . . 0.0 109.288 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.555 ' HB ' HG12 ' A' ' 84' ' ' VAL . 22.7 mt -101.98 118.32 48.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.903 . . . . 0.0 109.29 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.539 HG23 HG22 ' A' ' 62' ' ' VAL . 84.3 t -93.88 136.79 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.273 -0.892 . . . . 0.0 109.337 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.489 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.2 OUTLIER -89.2 141.13 28.78 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.202 -0.936 . . . . 0.0 109.419 -179.901 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.533 ' OG1' HG21 ' A' ' 20' ' ' VAL . 11.3 t -154.48 -170.91 3.68 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.282 -0.886 . . . . 0.0 109.442 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . . . . . . . . . 59.2 mtm -105.07 122.93 46.91 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.203 -0.935 . . . . 0.0 109.496 -179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 21.0 m -45.75 128.87 8.99 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.223 -0.923 . . . . 0.0 109.278 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.74 -20.18 44.8 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -111.01 10.23 22.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.278 -1.131 . . . . 0.0 109.57 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.594 ' OE1' HD13 ' A' ' 44' ' ' ILE . 94.8 mt-10 -61.8 -46.59 88.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.204 -0.935 . . . . 0.0 109.456 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -56.73 -34.02 67.11 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.19 -0.943 . . . . 0.0 109.524 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -75.31 -44.72 43.95 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.241 -0.912 . . . . 0.0 109.456 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.533 HG21 ' OG1' ' A' ' 12' ' ' THR . 48.4 t -59.0 -50.98 77.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.318 -0.863 . . . . 0.0 109.385 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 49.5 tttm -59.79 -47.83 84.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.305 -0.872 . . . . 0.0 109.437 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -62.38 -34.81 77.43 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.259 -0.9 . . . . 0.0 109.245 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.478 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 5.7 m120 -64.77 -38.03 89.6 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.251 -0.906 . . . . 0.0 109.517 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.886 HG21 HD11 ' A' ' 40' ' ' ILE . 92.6 mt -63.52 -45.26 98.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.226 -0.921 . . . . 0.0 109.755 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -57.32 -46.04 83.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.146 -0.971 . . . . 0.0 109.992 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 90.5 mttt -81.6 -37.11 28.14 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.03 -1.044 . . . . 0.0 109.825 -179.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.566 ' HG3' ' CZ ' ' A' ' 73' ' ' PHE . 13.3 tptp -55.86 -29.63 60.2 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.114 -0.991 . . . . 0.0 109.283 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.051 HG21 HG11 ' A' ' 37' ' ' VAL . 70.4 t -87.56 -25.21 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.296 -0.877 . . . . 0.0 109.43 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 48.2 tp10 -66.47 -49.09 67.8 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.324 -0.86 . . . . 0.0 109.32 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.02 -27.49 65.5 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.379 -0.826 . . . . 0.0 109.313 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 73.0 p -94.25 -25.55 17.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.234 -0.916 . . . . 0.0 109.388 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 73.26 25.49 72.96 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.535 ' CG2' ' HB2' ' A' ' 36' ' ' LEU . 76.4 mt -98.09 82.27 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -1.109 . . . . 0.0 109.447 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.424 ' O ' ' HG3' ' A' ' 34' ' ' LYS . 14.8 tptm -89.63 -6.07 56.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.227 -0.921 . . . . 0.0 109.714 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.508 ' O ' HD13 ' A' ' 65' ' ' ILE . 33.1 m120 -94.34 -4.58 48.34 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.249 -0.907 . . . . 0.0 109.561 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.136 HD11 ' CB ' ' A' ' 70' ' ' ALA . 8.3 tp -97.85 -54.39 3.11 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.305 -0.872 . . . . 0.0 109.664 -179.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 1.051 HG11 HG21 ' A' ' 28' ' ' VAL . 3.7 p -92.65 135.2 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.228 -0.92 . . . . 0.0 109.104 179.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -106.8 -123.14 5.04 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 59.6 mtt85 -94.11 139.7 30.66 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.34 -1.094 . . . . 0.0 110.006 -179.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 1.081 HG23 HG12 ' A' ' 62' ' ' VAL . 91.8 mt -108.39 136.56 43.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.931 HG23 ' HB2' ' A' ' 61' ' ' PHE . 33.9 m -130.59 155.09 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.071 -1.018 . . . . 0.0 109.616 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.54 HG22 HG23 ' A' ' 44' ' ' ILE . 11.8 mt -128.48 133.91 25.69 Favored Pre-proline 0 N--CA 1.489 1.482 0 O-C-N 121.371 -0.831 . . . . 0.0 109.353 -179.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.58 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 40.9 Cg_endo -63.33 -6.57 10.32 Favored 'Trans proline' 0 C--O 1.214 -0.676 0 C-N-CA 122.715 2.276 . . . . 0.0 111.502 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.598 ' CB ' ' HA ' ' A' ' 54' ' ' LYS . 3.7 pt -92.43 117.77 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.329 -0.857 . . . . 0.0 109.09 179.324 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.493 ' O ' ' CB ' ' A' ' 52' ' ' SER . 40.9 mtm-85 -45.87 123.79 4.76 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.167 -0.958 . . . . 0.0 109.367 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -131.92 -172.94 13.19 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 70.95 20.63 77.91 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 88.9 mt-30 -122.4 155.67 35.58 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.32 -1.106 . . . . 0.0 109.492 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 97.8 mtt180 -61.97 -31.37 71.72 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 109.448 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 53.0 mtp85 -101.78 153.68 19.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.261 -0.899 . . . . 0.0 109.47 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 54.4 mttt -72.04 168.08 18.84 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.388 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.493 ' CB ' ' O ' ' A' ' 45' ' ' ARG . 12.5 t -110.72 167.97 9.83 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.27 -0.894 . . . . 0.0 109.459 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.501 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 97.1 mt-10 -76.85 -19.01 58.0 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 109.439 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.598 ' HA ' ' CB ' ' A' ' 44' ' ' ILE . 11.3 mttp 75.78 103.85 0.07 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.257 -0.902 . . . . 0.0 109.291 -179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.58 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 9.9 tp -53.64 -47.93 69.86 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.1 -1.0 . . . . 0.0 109.423 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 1.029 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 95.9 m-85 -135.57 111.95 10.7 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.121 -0.987 . . . . 0.0 109.121 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -66.7 142.48 64.05 Favored 'Trans proline' 0 C--O 1.214 -0.709 0 C-N-CA 122.584 2.189 . . . . 0.0 111.879 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.37 -8.18 7.34 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.4 m-30 -100.27 131.94 45.92 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.793 -1.416 . . . . 0.0 110.122 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.457 HG13 HG12 ' A' ' 42' ' ' ILE . 46.5 t -134.28 144.69 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.325 -0.859 . . . . 0.0 109.03 179.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.931 ' HB2' HG23 ' A' ' 41' ' ' VAL . 59.6 m-85 -107.03 123.38 48.13 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.114 -0.991 . . . . 0.0 109.821 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 1.081 HG12 HG23 ' A' ' 40' ' ' ILE . 29.6 m -132.94 144.46 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.344 -0.848 . . . . 0.0 109.653 179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.622 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 37.3 tt0 -110.62 128.95 55.9 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.228 -0.92 . . . . 0.0 109.051 179.652 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.493 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 35.1 mtm -156.01 174.3 15.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.011 -1.056 . . . . 0.0 110.66 -179.35 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 1.02 ' CG1' HD12 ' A' ' 36' ' ' LEU . 10.2 pt -93.92 128.23 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 CA-C-O 121.323 0.583 . . . . 0.0 109.577 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.569 ' HE3' ' HG2' ' A' ' 89' ' ' GLN . 91.3 mtp -76.82 145.29 38.53 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.372 -0.83 . . . . 0.0 110.046 -178.834 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.482 ' HB2' ' O ' ' A' ' 66' ' ' MET . 45.1 t-20 176.48 173.63 0.38 Allowed 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -70.44 -42.06 72.03 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.056 -1.028 . . . . 0.0 109.292 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -75.92 -30.86 58.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.269 -0.894 . . . . 0.0 109.59 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.136 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -69.58 -48.08 61.39 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.192 -0.942 . . . . 0.0 109.37 -179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.4 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 74.5 t80 -60.21 -48.55 81.24 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.237 -0.914 . . . . 0.0 109.555 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -59.66 -29.4 68.02 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.193 -0.942 . . . . 0.0 109.987 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.566 ' CZ ' ' HG3' ' A' ' 27' ' ' LYS . 72.4 t80 -82.0 -43.43 18.0 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.112 -0.992 . . . . 0.0 109.578 -179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 1.028 HG23 ' O ' ' A' ' 70' ' ' ALA . 2.7 t -66.26 -57.01 12.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.321 -0.862 . . . . 0.0 109.247 179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 13.2 tpt180 -50.34 -32.75 18.08 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.427 -0.796 . . . . 0.0 109.612 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 9.4 t -78.33 6.25 8.72 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.331 -0.856 . . . . 0.0 110.199 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 74' ' ' VAL . 54.8 t -63.27 131.48 94.79 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 120.957 -1.09 . . . . 0.0 109.408 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.578 ' HB2' ' CD2' ' A' ' 79' ' ' TYR . 47.2 Cg_endo -67.89 137.73 42.37 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.66 2.24 . . . . 0.0 111.983 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.578 ' CD2' ' HB2' ' A' ' 78' ' ' PRO . 58.9 m-85 76.15 -4.41 2.37 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.503 -0.748 . . . . 0.0 109.797 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.593 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.8 t -87.57 129.94 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.108 -0.995 . . . . 0.0 109.162 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.431 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 95.5 mmm -88.31 -7.2 57.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.153 -0.967 . . . . 0.0 109.49 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.403 ' H ' ' CG1' ' A' ' 80' ' ' VAL . . . 132.44 -150.83 19.75 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.65 ' CE2' HG12 ' A' ' 74' ' ' VAL . 4.6 m-85 -140.01 145.79 38.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.228 -1.16 . . . . 0.0 109.542 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.657 HG13 ' O ' ' A' ' 84' ' ' VAL . 10.0 p -68.06 119.1 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.385 -0.822 . . . . 0.0 109.469 -179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.541 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 6.1 p -153.81 165.65 35.36 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.195 -0.941 . . . . 0.0 109.452 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 t -91.11 -30.43 16.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.259 -0.901 . . . . 0.0 109.399 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -134.57 -73.9 0.08 OUTLIER Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -115.4 -133.05 5.3 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.569 ' HG2' ' HE3' ' A' ' 66' ' ' MET . 0.5 OUTLIER -31.07 146.48 0.06 OUTLIER Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.588 -0.948 . . . . 0.0 110.135 -179.634 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.541 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.3 Cg_endo -69.12 141.35 47.59 Favored 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 122.957 2.438 . . . . 0.0 112.096 -179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.743 HG13 ' HD2' ' A' ' 92' ' ' PRO . 68.9 t -67.48 143.9 97.45 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.323 -0.861 . . . . 0.0 109.434 179.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.743 ' HD2' HG13 ' A' ' 91' ' ' VAL . 48.0 Cg_endo -69.43 148.14 66.55 Favored 'Trans proline' 0 C--O 1.216 -0.606 0 C-N-CA 122.622 2.215 . . . . 0.0 111.701 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.938 HG23 ' O ' ' A' ' 7' ' ' TRP . 3.0 t -81.87 127.49 39.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.19 -0.944 . . . . 0.0 109.54 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -69.99 139.87 52.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.317 -0.864 . . . . 0.0 109.47 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -48.83 -40.41 29.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.212 -0.93 . . . . 0.0 109.37 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 59.9 mtt180 -59.01 -34.48 71.92 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.235 -0.916 . . . . 0.0 109.418 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -80.2 -25.96 39.42 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.276 -0.89 . . . . 0.0 109.417 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.542 ' CB ' HD11 ' A' ' 102' ' ' LEU . 93.2 mtp -84.26 -24.73 29.83 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.261 -0.9 . . . . 0.0 109.556 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.599 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 3.2 tpt85 -36.43 -53.15 1.74 Allowed Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.39 -0.819 . . . . 0.0 109.829 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.599 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 50.2 Cg_endo -70.49 -28.07 22.23 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.574 2.183 . . . . 0.0 111.724 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.495 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 35.8 mm -80.62 -42.26 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.245 -0.909 . . . . 0.0 109.486 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.542 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.7 OUTLIER -67.06 -40.03 87.0 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.184 -0.948 . . . . 0.0 109.236 179.772 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.626 ' CZ ' ' CE2' ' A' ' 110' ' ' TYR . 39.8 ttt-85 -63.06 -50.57 70.1 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.155 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.628 HD23 ' C ' ' A' ' 104' ' ' LEU . 5.5 tt -72.58 -35.26 67.89 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.267 -0.896 . . . . 0.0 109.078 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.564 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -71.18 -3.12 18.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.425 -0.797 . . . . 0.0 109.778 -179.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.46 11.63 82.5 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.898 HD21 HG11 ' A' ' 41' ' ' VAL . 9.9 mp -79.46 -19.38 49.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.308 -1.113 . . . . 0.0 109.698 -179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.431 ' OE2' HD13 ' A' ' 102' ' ' LEU . 96.5 mt-10 -123.62 159.34 29.48 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.236 -0.915 . . . . 0.0 109.608 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 62.9 mt-10 -109.59 118.81 37.58 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.309 -0.869 . . . . 0.0 109.412 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.626 ' CE2' ' CZ ' ' A' ' 103' ' ' ARG . 42.4 p90 -127.8 -162.93 1.21 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.302 -0.874 . . . . 0.0 109.564 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.574 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 64.3 mm-40 -101.25 -135.81 0.31 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.335 -0.853 . . . . 0.0 109.342 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 68.0 tt0 -113.22 -43.21 3.39 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.06 -1.025 . . . . 0.0 109.632 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.564 ' NZ ' ' HA ' ' A' ' 116' ' ' PRO . 0.0 OUTLIER -173.05 107.74 0.16 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.186 -0.946 . . . . 0.0 109.647 -179.772 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.549 ' O ' ' HD3' ' A' ' 116' ' ' PRO . 13.1 tptm -45.9 -35.86 4.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.328 -0.857 . . . . 0.0 109.384 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.52 79.08 0.38 Allowed Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.167 -0.958 . . . . 0.0 109.53 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.564 ' HA ' ' NZ ' ' A' ' 113' ' ' LYS . 51.3 Cg_endo -71.31 3.52 3.49 Favored 'Trans proline' 0 C--O 1.216 -0.597 0 C-N-CA 122.728 2.285 . . . . 0.0 111.837 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.469 ' O ' ' HB2' ' A' ' 171' ' ' SER . 26.9 m -120.21 147.98 23.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.112 -0.993 . . . . 0.0 109.843 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.583 ' HA ' ' CB ' ' A' ' 171' ' ' SER . 24.7 mttt -74.38 154.46 38.81 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.332 -0.855 . . . . 0.0 109.301 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.451 HG12 ' N ' ' A' ' 120' ' ' GLU . 40.7 t -131.01 159.19 43.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.229 -0.92 . . . . 0.0 109.491 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.662 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 58.5 mp0 -115.1 -179.17 3.55 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.249 -0.907 . . . . 0.0 109.373 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.662 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 4.7 mt 145.56 100.77 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.904 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.63 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.19 93.54 0.01 OUTLIER Glycine 0 N--CA 1.496 2.69 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.504 ' N ' ' O ' ' A' ' 121' ' ' LEU . 13.3 p90 -107.87 148.42 29.61 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.212 -1.169 . . . . 0.0 109.531 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.412 ' HG2' ' O ' ' A' ' 123' ' ' PHE . 14.7 mttp -150.95 161.43 42.73 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.238 -0.913 . . . . 0.0 109.397 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.484 HG13 ' O ' ' A' ' 144' ' ' LYS . 40.2 t -60.15 141.33 16.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.258 -0.901 . . . . 0.0 109.525 -179.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 86.06 -33.29 3.6 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 70.3 m-20 -47.74 162.22 0.08 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.374 -1.074 . . . . 0.0 109.132 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 9.4 ttm -96.67 126.66 42.0 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.157 -0.964 . . . . 0.0 109.082 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.552 ' CG2' HD11 ' A' ' 143' ' ' ILE . 2.7 t -125.37 141.27 45.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.23 -0.919 . . . . 0.0 109.214 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.514 ' HB2' HG12 ' A' ' 176' ' ' ILE . 15.8 tttt -102.55 143.02 32.78 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.245 -0.909 . . . . 0.0 108.98 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.956 HD12 ' HB3' ' A' ' 139' ' ' PHE . 66.8 mt -83.71 151.78 3.9 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.434 ' C ' ' HG2' ' A' ' 137' ' ' GLU . 2.2 pt -149.67 2.69 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.038 -1.038 . . . . 0.0 109.382 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.587 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 71.9 m -148.7 143.33 26.38 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.185 -0.947 . . . . 0.0 109.884 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.488 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 101.57 -164.07 17.69 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.531 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 47.4 Cg_endo -68.16 -22.01 41.47 Favored 'Trans proline' 0 C--O 1.216 -0.587 0 C-N-CA 123.215 2.61 . . . . 0.0 112.913 -179.187 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.556 ' HB2' HD13 ' A' ' 131' ' ' ILE . 94.0 m-85 -106.21 19.59 20.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.743 -1.223 . . . . 0.0 109.418 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.543 ' HG2' ' HA ' ' A' ' 133' ' ' SER . 44.4 mt-10 -40.75 137.04 1.26 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.871 . . . . 0.0 109.988 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.445 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 4.4 m-20 71.08 29.77 2.85 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.389 -0.82 . . . . 0.0 110.656 179.05 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.956 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.9 t80 -116.7 128.06 54.98 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.912 -1.117 . . . . 0.0 109.579 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -76.34 133.3 40.01 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.285 -0.884 . . . . 0.0 109.797 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.525 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -142.66 169.66 25.46 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 155' ' ' VAL . 41.1 t -115.31 136.61 51.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.314 -1.109 . . . . 0.0 109.506 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.606 HG23 HD23 ' A' ' 153' ' ' LEU . 49.6 mt -67.28 113.82 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.221 -0.924 . . . . 0.0 108.898 179.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.484 ' O ' HG13 ' A' ' 125' ' ' VAL . 18.1 tptm -98.56 -35.45 10.22 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.926 -1.109 . . . . 0.0 109.768 -179.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.46 ' HB2' ' HB2' ' A' ' 154' ' ' LYS . 38.6 mt-10 -153.29 148.31 26.65 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.133 -0.979 . . . . 0.0 109.754 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.719 HG23 ' HG ' ' A' ' 153' ' ' LEU . 3.4 mt -125.15 127.85 72.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.277 -0.889 . . . . 0.0 109.434 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -110.61 102.3 51.54 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.192 -0.942 . . . . 0.0 109.525 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.538 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.9 Cg_endo -71.54 173.07 13.05 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.607 2.204 . . . . 0.0 111.881 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.538 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 45.2 mm-40 79.86 -21.1 0.35 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.473 -0.767 . . . . 0.0 109.906 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.443 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 46.6 mtt180 -127.63 -13.98 5.26 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.058 -1.026 . . . . 0.0 109.509 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.825 ' O ' HG13 ' A' ' 170' ' ' VAL . 66.9 mm-40 70.82 47.99 0.43 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.32 -0.863 . . . . 0.0 109.802 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -118.43 142.21 47.78 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.116 -0.99 . . . . 0.0 108.852 179.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.719 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -129.76 113.06 14.25 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.137 -0.977 . . . . 0.0 110.16 -179.535 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.46 ' HB2' ' HB2' ' A' ' 145' ' ' GLU . 13.7 mttm -78.18 127.66 32.61 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 179.083 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.679 HG13 ' O ' ' A' ' 142' ' ' VAL . 40.4 t -126.17 147.05 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.088 -1.007 . . . . 0.0 109.908 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.54 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 70.1 m-20 -95.81 113.72 25.38 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.431 -0.793 . . . . 0.0 109.035 179.376 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.722 HG12 HG23 ' A' ' 159' ' ' ILE . 89.3 t -97.72 142.8 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.205 -0.935 . . . . 0.0 109.613 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 28.2 m -100.32 94.25 6.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.341 -0.85 . . . . 0.0 109.876 -179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 1.029 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 2.2 pt -125.85 152.3 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.281 -0.887 . . . . 0.0 109.143 179.586 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.572 ' CD2' HD12 ' A' ' 159' ' ' ILE . 18.8 m-30 60.47 38.68 19.02 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.143 -0.973 . . . . 0.0 109.111 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 55.05 14.47 5.75 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.419 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 52.3 mtt85 -128.99 156.32 43.98 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.129 -1.218 . . . . 0.0 109.668 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -99.39 134.52 42.13 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.32 -0.862 . . . . 0.0 109.255 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 21.7 m -147.51 127.45 6.66 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.271 -0.893 . . . . 0.0 109.674 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.54 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.8 Cg_endo -70.5 139.94 38.8 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.725 2.283 . . . . 0.0 111.701 179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.762 HG13 HD11 ' A' ' 168' ' ' LEU . 5.3 p -125.13 144.35 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.18 -0.95 . . . . 0.0 109.515 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.435 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 14.1 m -93.76 119.23 41.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.386 -0.821 . . . . 0.0 109.534 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.762 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -142.07 168.78 18.93 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -0.909 . . . . 0.0 110.576 -179.492 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.417 ' HB2' ' OE1' ' A' ' 172' ' ' GLU . 99.1 m-70 -83.98 142.39 30.53 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.825 HG13 ' O ' ' A' ' 151' ' ' GLN . 3.1 m -53.58 -34.85 24.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.295 -0.878 . . . . 0.0 109.151 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.583 ' CB ' ' HA ' ' A' ' 118' ' ' LYS . 60.2 p -73.81 -6.05 44.65 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.335 -0.853 . . . . 0.0 109.982 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.587 ' CG ' ' HB2' ' A' ' 133' ' ' SER . 2.4 mt-10 -95.6 3.88 53.63 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.015 -1.053 . . . . 0.0 110.02 -179.54 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 11.2 m -144.0 169.36 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.057 -1.027 . . . . 0.0 109.601 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.537 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 80.3 tt0 -140.56 166.15 25.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.223 -0.923 . . . . 0.0 108.893 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.537 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 38.9 tttm -89.38 14.95 10.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.019 -1.05 . . . . 0.0 109.51 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.542 HG22 ' HG3' ' A' ' 177' ' ' GLU . 64.1 mt 63.1 -73.57 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.326 -0.858 . . . . 0.0 109.705 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.542 ' HG3' HG22 ' A' ' 176' ' ' ILE . 95.7 mt-10 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.001 -1.0 . . . . 0.0 109.496 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 N-CA-C 109.489 -1.445 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.8 -13.16 58.94 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.264 -1.139 . . . . 0.0 109.505 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 91.2 mtp -59.12 -24.8 63.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.424 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 11.9 mtpp -126.18 123.91 39.28 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.199 -0.938 . . . . 0.0 109.327 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.79 ' HG2' HG22 ' A' ' 65' ' ' ILE . 55.4 mttt -77.3 164.43 25.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.249 -0.907 . . . . 0.0 109.699 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.9 mmtp -128.0 175.26 8.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.289 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.949 ' CZ3' HG22 ' A' ' 41' ' ' VAL . 80.9 m95 -110.33 127.0 54.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.137 -0.977 . . . . 0.0 109.576 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.453 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 60.7 m-85 -121.78 167.07 13.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.229 -0.919 . . . . 0.0 109.488 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.964 HD11 ' CE1' ' A' ' 160' ' ' PHE . 76.2 mt -106.61 117.1 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.158 -0.964 . . . . 0.0 109.301 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.417 ' CG1' HG22 ' A' ' 80' ' ' VAL . 85.3 t -88.56 141.98 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.28 -0.888 . . . . 0.0 109.569 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.49 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -93.74 138.84 31.51 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.325 -0.86 . . . . 0.0 109.387 179.905 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.589 HG21 ' HG2' ' A' ' 17' ' ' GLU . 14.9 t -155.58 -169.54 3.15 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.23 -0.919 . . . . 0.0 109.457 -179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.44 ' O ' ' C ' ' A' ' 14' ' ' SER . 90.8 mmm -104.01 119.55 39.18 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.233 -0.917 . . . . 0.0 109.387 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.44 ' C ' ' O ' ' A' ' 13' ' ' MET . 17.8 p -42.46 128.52 3.92 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.232 -0.918 . . . . 0.0 109.475 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.34 -20.31 35.35 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.429 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 90.3 m-85 -110.67 -1.4 16.78 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.274 -1.133 . . . . 0.0 109.557 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.646 ' OE1' HD11 ' A' ' 44' ' ' ILE . 49.4 mt-10 -53.34 -55.24 26.39 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.241 -0.912 . . . . 0.0 109.404 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -49.13 -32.22 9.62 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.166 -0.958 . . . . 0.0 109.418 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.47 ' O ' ' HB2' ' A' ' 23' ' ' ASN . 62.3 mttm -76.83 -36.75 56.66 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.286 -0.883 . . . . 0.0 109.311 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.666 HG22 ' HB2' ' A' ' 79' ' ' TYR . 98.4 t -66.73 -52.01 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.33 -0.856 . . . . 0.0 109.523 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.44 ' HB2' HD11 ' A' ' 42' ' ' ILE . 63.1 tttm -56.89 -50.87 71.19 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.231 -0.918 . . . . 0.0 109.484 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -64.68 -34.82 79.19 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.153 -0.967 . . . . 0.0 109.38 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.479 ' CG ' ' HG2' ' A' ' 78' ' ' PRO . 2.1 t30 -66.0 -44.32 85.14 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.252 -0.905 . . . . 0.0 109.408 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.659 ' O ' HG23 ' A' ' 28' ' ' VAL . 81.7 mt -57.39 -43.37 82.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.272 -0.892 . . . . 0.0 109.443 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -58.38 -44.44 88.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.205 -0.934 . . . . 0.0 109.789 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 31.9 mtmt -77.88 -37.48 48.05 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.112 -0.992 . . . . 0.0 109.798 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.759 ' CD ' HG23 ' A' ' 77' ' ' VAL . 42.1 tttp -57.04 -28.94 62.98 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.246 -0.908 . . . . 0.0 109.313 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 24' ' ' ILE . 42.4 t -83.86 -27.43 7.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.314 -0.866 . . . . 0.0 109.464 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.454 ' OE1' ' HA ' ' A' ' 29' ' ' GLU . 54.9 mm-40 -66.8 -49.25 66.45 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.271 -0.893 . . . . 0.0 109.444 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.2 -35.12 66.91 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.241 -0.912 . . . . 0.0 109.482 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.3 p -92.86 -22.71 19.12 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.271 -0.893 . . . . 0.0 109.591 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 74.3 1.59 60.87 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.038 HG21 HD12 ' A' ' 36' ' ' LEU . 48.1 mm -69.39 80.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.318 -1.107 . . . . 0.0 109.429 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 91.0 mttt -90.89 14.54 13.45 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.24 -0.912 . . . . 0.0 109.458 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.877 ' O ' HD13 ' A' ' 65' ' ' ILE . 24.7 m120 -113.39 -3.07 13.81 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.235 -0.916 . . . . 0.0 109.601 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.038 HD12 HG21 ' A' ' 33' ' ' ILE . 11.8 mt -98.59 -51.2 4.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.946 . . . . 0.0 109.599 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 99.1 t -95.55 144.58 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -0.892 . . . . 0.0 109.313 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.87 -124.75 3.92 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 18.6 mtt85 -91.56 142.18 27.91 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.309 -1.112 . . . . 0.0 109.885 -179.497 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 1.016 HG23 HG22 ' A' ' 62' ' ' VAL . 65.4 mt -109.94 134.42 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.318 -0.864 . . . . 0.0 109.152 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.963 HG23 ' HB2' ' A' ' 61' ' ' PHE . 30.4 m -127.5 144.54 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.208 -0.932 . . . . 0.0 109.263 179.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.92 HG21 HD12 ' A' ' 44' ' ' ILE . 67.6 mt -129.94 129.14 22.98 Favored Pre-proline 0 N--CA 1.489 1.487 0 O-C-N 121.294 -0.879 . . . . 0.0 109.623 -179.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.565 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.3 Cg_endo -66.71 -2.65 7.93 Favored 'Trans proline' 0 C--O 1.217 -0.544 0 C-N-CA 122.879 2.386 . . . . 0.0 111.348 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.92 HD12 HG21 ' A' ' 42' ' ' ILE . 85.6 mt -66.15 -39.26 83.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.144 -0.972 . . . . 0.0 109.554 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 38.4 ttt85 -45.58 -34.97 3.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.229 -0.92 . . . . 0.0 109.494 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.639 ' HA3' HD11 ' A' ' 104' ' ' LEU . . . -72.51 154.55 50.43 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 100.69 15.4 29.32 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 52.6 mt-30 -71.03 -31.38 67.84 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.296 -1.12 . . . . 0.0 109.429 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 20.2 mtp180 -61.31 -32.31 72.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 109.532 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.735 ' HD2' HG11 ' A' ' 167' ' ' VAL . 57.4 mtp85 -112.97 151.0 31.09 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.213 -0.93 . . . . 0.0 109.572 179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 71.2 mttt -53.72 -33.65 56.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.241 -0.912 . . . . 0.0 109.331 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 21.0 t -52.97 136.53 34.68 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.34 -0.85 . . . . 0.0 109.421 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.53 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 84.5 tt0 -125.76 159.39 32.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.253 -0.905 . . . . 0.0 109.462 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.751 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 1.9 mttp 77.21 89.56 0.07 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.245 -0.91 . . . . 0.0 109.629 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.565 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 9.2 tp -59.71 -42.14 92.36 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.904 -1.123 . . . . 0.0 108.909 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.922 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 19.4 m-85 -126.3 101.15 28.51 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.217 -0.927 . . . . 0.0 108.789 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.431 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 41.7 Cg_endo -65.63 137.09 48.75 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.681 2.254 . . . . 0.0 112.26 -179.087 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 74.36 -12.61 5.5 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.574 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 1.7 m-30 -100.47 132.15 46.01 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.748 -1.442 . . . . 0.0 110.32 -179.199 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.847 HG13 HG12 ' A' ' 42' ' ' ILE . 40.0 t -132.99 143.07 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.349 -0.844 . . . . 0.0 108.926 179.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.963 ' HB2' HG23 ' A' ' 41' ' ' VAL . 18.8 m-30 -106.68 123.86 48.75 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.003 -1.061 . . . . 0.0 109.805 -179.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 1.016 HG22 HG23 ' A' ' 40' ' ' ILE . 93.0 t -131.16 142.13 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.339 -0.851 . . . . 0.0 109.653 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.591 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 39.1 tt0 -105.9 128.77 53.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.262 -0.899 . . . . 0.0 108.981 179.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.494 ' CG ' ' C ' ' A' ' 63' ' ' GLU . 16.5 mtm -155.96 178.65 10.03 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.169 -0.957 . . . . 0.0 110.05 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.879 ' CG1' HD23 ' A' ' 36' ' ' LEU . 6.1 pt -101.01 133.89 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.59 -0.694 . . . . 0.0 109.321 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.473 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 53.9 ttm -77.24 144.33 38.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.224 -0.922 . . . . 0.0 110.1 -178.654 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.473 ' HB2' ' O ' ' A' ' 66' ' ' MET . 29.0 t-20 176.46 175.56 0.32 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -72.6 -43.06 63.83 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.249 -0.907 . . . . 0.0 109.323 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -75.64 -28.01 58.63 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.233 -0.917 . . . . 0.0 109.686 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.058 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -70.58 -47.56 59.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.131 -0.981 . . . . 0.0 109.302 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.536 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 89.0 t80 -60.88 -54.94 38.9 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.289 -0.882 . . . . 0.0 109.275 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.447 ' O ' ' OG ' ' A' ' 76' ' ' SER . 42.2 t-20 -52.85 -31.81 41.21 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.221 -0.924 . . . . 0.0 109.975 -179.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CE1' ' HE3' ' A' ' 27' ' ' LYS . 81.9 t80 -80.08 -43.27 22.09 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.035 -1.04 . . . . 0.0 109.567 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 1.058 HG23 ' O ' ' A' ' 70' ' ' ALA . 3.2 t -68.26 -55.48 16.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.295 -0.878 . . . . 0.0 109.414 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.473 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 16.5 tpt180 -61.56 -9.58 6.23 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.338 -0.851 . . . . 0.0 109.837 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 72' ' ' ASN . 42.7 p -101.67 2.09 38.32 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.148 -0.97 . . . . 0.0 109.983 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.759 HG23 ' CD ' ' A' ' 27' ' ' LYS . 0.5 OUTLIER -68.75 135.29 90.15 Favored Pre-proline 0 N--CA 1.488 1.468 0 O-C-N 121.057 -1.027 . . . . 0.0 108.954 179.901 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.629 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 43.9 Cg_endo -66.21 138.96 53.43 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.394 2.063 . . . . 0.0 111.99 -179.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.666 ' HB2' HG22 ' A' ' 20' ' ' VAL . 5.5 m-85 89.09 -8.08 0.44 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.801 -0.562 . . . . 0.0 109.829 -179.838 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.713 ' CG2' HG12 ' A' ' 77' ' ' VAL . 2.4 t -89.34 129.5 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.966 -1.084 . . . . 0.0 109.661 179.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.428 ' HE1' ' SD ' ' A' ' 13' ' ' MET . 18.7 mtt -93.53 -25.06 17.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.459 -0.776 . . . . 0.0 109.246 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 164.54 -162.61 35.59 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.479 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 48.6 m-85 -136.21 151.74 50.02 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.187 -1.184 . . . . 0.0 109.559 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.8 t -67.01 101.42 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.282 -0.886 . . . . 0.0 109.438 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.538 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.0 OUTLIER -143.98 162.85 35.12 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -0.918 . . . . 0.0 109.505 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.0 m -95.18 -34.52 12.22 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.349 -0.845 . . . . 0.0 109.278 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -129.39 -72.78 0.14 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.541 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -113.91 -137.89 6.75 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.541 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.3 OUTLIER -31.03 148.45 0.04 OUTLIER Pre-proline 0 N--CA 1.493 1.704 0 O-C-N 121.506 -0.997 . . . . 0.0 110.274 -179.718 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.538 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.3 Cg_endo -69.54 149.61 68.53 Favored 'Trans proline' 0 C--O 1.214 -0.693 0 C-N-CA 122.82 2.347 . . . . 0.0 111.887 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 36.0 m -80.73 152.31 72.13 Favored Pre-proline 0 N--CA 1.489 1.485 0 O-C-N 121.323 -0.861 . . . . 0.0 109.403 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.07 143.36 49.12 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 122.693 2.262 . . . . 0.0 111.81 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.659 HG11 ' SD ' ' A' ' 98' ' ' MET . 29.3 t -69.48 142.16 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.192 -0.942 . . . . 0.0 109.414 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . 0.434 ' HB2' ' HG3' ' A' ' 97' ' ' GLU . 32.0 mttt -70.67 134.12 47.25 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.246 -0.909 . . . . 0.0 109.537 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -50.27 -41.46 50.55 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.863 . . . . 0.0 109.419 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -63.14 -24.07 67.72 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.438 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.434 ' HG3' ' HB2' ' A' ' 94' ' ' LYS . 40.9 mt-10 -84.95 -23.66 28.68 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -0.913 . . . . 0.0 109.456 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.659 ' SD ' HG11 ' A' ' 93' ' ' VAL . 52.5 mmm -85.19 -33.18 22.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.265 -0.897 . . . . 0.0 109.384 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.6 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -36.1 -53.41 1.57 Allowed Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.459 -0.776 . . . . 0.0 109.795 -179.987 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.615 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 47.4 Cg_endo -69.79 -26.57 27.3 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.494 2.129 . . . . 0.0 111.616 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.531 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 32.3 mm -81.09 -38.51 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.234 -0.916 . . . . 0.0 109.236 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.715 ' N ' HD13 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -71.36 -40.35 70.69 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.328 -0.858 . . . . 0.0 109.16 179.733 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 58.0 mtt-85 -63.15 -50.06 71.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.403 -0.81 . . . . 0.0 109.028 179.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.639 HD11 ' HA3' ' A' ' 46' ' ' GLY . 1.4 tt -72.35 -35.55 68.58 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.385 -0.822 . . . . 0.0 109.079 179.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -69.33 -1.62 8.71 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.393 -0.817 . . . . 0.0 110.023 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.12 8.25 82.97 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.639 -1.385 . . . . 0.0 109.639 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.406 ' HB3' ' HB3' ' A' ' 102' ' ' LEU . 0.7 OUTLIER -74.37 -17.55 60.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.16 -1.2 . . . . 0.0 109.431 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.447 ' HG3' ' HB3' ' A' ' 102' ' ' LEU . 88.9 mt-10 -117.12 157.56 25.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.264 -0.898 . . . . 0.0 109.479 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -106.65 112.64 25.72 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.273 -0.892 . . . . 0.0 109.513 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.446 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 28.3 p90 -144.63 150.56 37.6 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.237 -0.914 . . . . 0.0 109.342 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.446 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 37.0 mm-40 -86.47 -147.72 0.13 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.238 -0.914 . . . . 0.0 109.48 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.408 ' HG2' ' N ' ' A' ' 113' ' ' LYS . 81.0 tt0 -113.59 163.83 14.45 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.283 -0.886 . . . . 0.0 109.579 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.408 ' N ' ' HG2' ' A' ' 112' ' ' GLU . 3.4 pttm -45.32 126.65 6.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.203 -0.936 . . . . 0.0 109.508 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 6.0 mtpt -105.28 5.22 31.81 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.313 -0.867 . . . . 0.0 109.383 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.424 ' HD2' HG22 ' A' ' 117' ' ' VAL . 4.0 ttmt -109.75 75.28 0.8 Allowed Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.213 -0.929 . . . . 0.0 109.564 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -70.25 75.16 1.44 Allowed 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.702 2.268 . . . . 0.0 111.753 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.424 HG22 ' HD2' ' A' ' 115' ' ' LYS . 32.4 m -126.47 154.61 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.289 -0.882 . . . . 0.0 109.469 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -104.0 151.55 23.08 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.169 -0.957 . . . . 0.0 109.458 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.598 HG12 ' N ' ' A' ' 120' ' ' GLU . 39.7 t -129.77 168.28 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.286 -0.884 . . . . 0.0 109.464 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.598 ' N ' HG12 ' A' ' 119' ' ' VAL . 88.8 mt-10 -135.83 -120.07 0.16 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.304 -0.872 . . . . 0.0 109.425 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.595 ' O ' ' C ' ' A' ' 122' ' ' GLY . 6.2 mt 78.53 114.03 0.07 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.196 -0.94 . . . . 0.0 109.368 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.595 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -20.63 90.63 0.01 OUTLIER Glycine 0 N--CA 1.496 2.642 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.615 ' CB ' ' HD3' ' A' ' 175' ' ' LYS . 38.3 p90 -96.81 126.46 41.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.182 -1.187 . . . . 0.0 109.156 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 17.4 mttt -144.27 162.75 35.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.135 -0.978 . . . . 0.0 109.922 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.457 HG13 ' O ' ' A' ' 144' ' ' LYS . 12.1 t -64.04 141.79 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.472 -0.768 . . . . 0.0 109.297 179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 87.47 -31.23 4.58 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.263 -1.535 . . . . 0.0 109.263 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -49.71 162.92 0.14 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.299 -1.118 . . . . 0.0 109.27 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.9 ttp -94.72 125.35 39.31 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.13 -0.982 . . . . 0.0 109.073 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.544 HG11 ' CD1' ' A' ' 143' ' ' ILE . 2.0 p -124.31 140.77 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.173 -0.954 . . . . 0.0 109.02 179.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 174' ' ' GLU . 59.9 tttt -106.2 142.72 35.41 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.153 -0.967 . . . . 0.0 109.361 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.927 ' O ' HD13 ' A' ' 132' ' ' ILE . 88.2 mt -82.75 152.91 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.161 -0.962 . . . . 0.0 108.581 179.421 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.927 HD13 ' O ' ' A' ' 131' ' ' ILE . 2.6 mm -148.94 1.66 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.103 -0.998 . . . . 0.0 109.463 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.566 ' CB ' ' HG2' ' A' ' 172' ' ' GLU . 28.3 m -150.82 147.64 27.51 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.13 -0.981 . . . . 0.0 110.331 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.84 -164.12 18.56 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 179.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.483 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 46.2 Cg_endo -67.93 -23.52 40.79 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 123.026 2.484 . . . . 0.0 112.535 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.615 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 93.4 m-85 -108.86 18.76 20.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.962 -1.086 . . . . 0.0 109.456 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.629 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.8 tt0 -48.35 140.69 7.39 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.289 -0.882 . . . . 0.0 109.687 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 12.8 m-20 76.93 28.73 0.64 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.468 -0.77 . . . . 0.0 110.243 179.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.91 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.9 t80 -118.42 153.52 33.95 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.08 -1.012 . . . . 0.0 109.485 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -101.2 133.34 45.91 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.246 -0.909 . . . . 0.0 109.197 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.499 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -145.25 170.38 26.65 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 119.535 -1.317 . . . . 0.0 110.604 -179.413 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.646 ' C ' HG23 ' A' ' 155' ' ' VAL . 44.9 t -115.11 137.71 47.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.602 -0.94 . . . . 0.0 109.348 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.94 HD12 HD23 ' A' ' 153' ' ' LEU . 14.9 mm -68.74 115.27 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.226 -0.921 . . . . 0.0 109.502 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.457 ' O ' HG13 ' A' ' 125' ' ' VAL . 21.2 tttp -99.0 -34.46 10.41 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.039 -1.038 . . . . 0.0 109.321 179.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.43 ' HG3' ' HG2' ' A' ' 144' ' ' LYS . 89.5 mt-10 -152.57 147.6 26.37 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.133 -0.98 . . . . 0.0 109.444 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.838 HG23 ' HG ' ' A' ' 153' ' ' LEU . 6.6 mt -126.56 130.05 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.216 -0.928 . . . . 0.0 109.622 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -110.33 103.39 53.87 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.286 -0.884 . . . . 0.0 109.528 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.557 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.55 171.83 15.52 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 122.747 2.298 . . . . 0.0 111.631 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.557 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.3 mt-10 80.68 -20.34 0.38 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.319 -0.863 . . . . 0.0 109.876 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.434 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 43.3 mtt85 -128.21 -12.18 5.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.05 -1.031 . . . . 0.0 109.582 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.539 ' O ' HG12 ' A' ' 170' ' ' VAL . 37.1 mt-30 69.68 48.97 0.56 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.281 -0.887 . . . . 0.0 109.907 179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 15.6 tp10 -120.12 144.54 47.58 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.081 -1.012 . . . . 0.0 109.116 179.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.94 HD23 HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -133.92 115.73 14.76 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.097 -1.002 . . . . 0.0 110.115 -179.381 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 7.1 mttt -78.04 132.42 37.76 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.328 -0.857 . . . . 0.0 108.786 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.646 HG23 ' C ' ' A' ' 142' ' ' VAL . 13.2 p -130.21 147.01 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.119 -0.988 . . . . 0.0 110.008 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.488 ' OD1' ' CA ' ' A' ' 165' ' ' PRO . 0.9 OUTLIER -97.53 115.96 28.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.435 -0.791 . . . . 0.0 109.183 179.66 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.579 HG13 ' CE1' ' A' ' 139' ' ' PHE . 87.1 t -97.64 143.22 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.163 -0.961 . . . . 0.0 109.747 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.3 m -91.88 111.88 23.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.314 -0.867 . . . . 0.0 109.643 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.922 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 13.6 pt -144.56 143.92 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.295 -0.878 . . . . 0.0 109.486 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.964 ' CE1' HD11 ' A' ' 9' ' ' ILE . 78.2 m-85 62.1 34.36 16.45 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.282 -0.886 . . . . 0.0 109.396 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.28 16.47 20.42 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 73.6 mtt-85 -128.91 151.14 49.97 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 69.1 mm-40 -93.7 135.05 35.38 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.233 -0.917 . . . . 0.0 109.392 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 60.8 m -144.64 126.31 7.96 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.242 -0.911 . . . . 0.0 109.67 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.488 ' CA ' ' OD1' ' A' ' 156' ' ' ASN . 50.0 Cg_endo -70.8 139.58 36.93 Favored 'Trans proline' 0 C--O 1.216 -0.598 0 C-N-CA 122.624 2.216 . . . . 0.0 111.39 179.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.563 ' HB ' HD21 ' A' ' 168' ' ' LEU . 1.9 m -125.75 144.54 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.059 -1.026 . . . . 0.0 109.988 -179.682 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 1.018 ' C ' HD22 ' A' ' 168' ' ' LEU . 14.7 m -92.05 117.48 35.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 179.29 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 1.018 HD22 ' C ' ' A' ' 167' ' ' VAL . 3.2 mm? -139.78 166.24 25.14 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.156 -0.965 . . . . 0.0 110.289 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.493 ' HB2' ' HB2' ' A' ' 172' ' ' GLU . 82.2 m-70 -83.95 141.15 31.45 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 151' ' ' GLN . 9.1 p -56.78 -36.58 49.85 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 121.293 -0.879 . . . . 0.0 109.296 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.424 ' N ' HG13 ' A' ' 170' ' ' VAL . 32.1 p -77.29 -8.47 57.67 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.094 -1.004 . . . . 0.0 109.722 -179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.566 ' HG2' ' CB ' ' A' ' 133' ' ' SER . 1.3 mt-10 -88.67 -4.79 58.47 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.194 -0.941 . . . . 0.0 109.275 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.9 m -137.22 176.51 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.192 -0.942 . . . . 0.0 109.799 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.544 ' O ' HG22 ' A' ' 129' ' ' VAL . 72.9 tt0 -132.15 155.43 48.18 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.615 ' HD3' ' CB ' ' A' ' 123' ' ' PHE . 16.2 mttm -108.42 35.8 3.05 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.965 -1.084 . . . . 0.0 109.712 -179.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.481 ' C ' ' O ' ' A' ' 175' ' ' LYS . 6.6 mt 39.22 -133.84 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.472 -0.767 . . . . 0.0 109.632 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.442 ' H ' HG22 ' A' ' 176' ' ' ILE . 57.0 tt0 . . . . . 0 N--CA 1.488 1.471 0 CA-C-O 117.961 -1.018 . . . . 0.0 109.526 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.24 -27.55 69.12 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.23 -1.159 . . . . 0.0 109.497 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 91.0 mtp -66.74 -27.32 67.52 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.287 -0.883 . . . . 0.0 109.454 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 34.5 tttt -147.18 131.26 17.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.269 -0.894 . . . . 0.0 109.417 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 33.4 mttm -96.71 146.98 24.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.183 -0.948 . . . . 0.0 109.51 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.593 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 11.6 mttt -130.47 173.76 10.54 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.905 . . . . 0.0 109.192 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 1.063 ' O ' HG23 ' A' ' 93' ' ' VAL . 61.5 m95 -108.59 127.51 54.01 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -0.901 . . . . 0.0 109.3 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.447 ' OH ' ' SD ' ' A' ' 66' ' ' MET . 91.6 m-85 -115.61 169.15 9.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.211 -0.93 . . . . 0.0 109.33 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.597 HD11 ' CE1' ' A' ' 160' ' ' PHE . 27.3 mt -109.89 113.57 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 109.192 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 82.4 t -88.51 140.58 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.221 -0.925 . . . . 0.0 109.369 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 59' ' ' TYR . 2.9 mm? -95.36 146.36 24.45 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.357 -0.839 . . . . 0.0 109.414 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.5 t -161.17 -164.26 1.14 Allowed 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.265 -0.897 . . . . 0.0 109.114 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.518 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 94.0 mtp -105.32 124.71 50.0 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.186 -0.946 . . . . 0.0 109.516 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.0 t -45.78 131.1 9.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.247 -0.908 . . . . 0.0 109.294 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.94 -19.33 47.08 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.249 -1.54 . . . . 0.0 109.249 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.518 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 95.6 m-85 -108.96 6.34 25.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.284 -1.127 . . . . 0.0 109.564 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -62.79 -52.82 61.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.261 -0.899 . . . . 0.0 109.507 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -50.7 -35.78 32.84 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.187 -0.945 . . . . 0.0 109.61 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.48 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 58.4 mttt -73.9 -47.81 35.32 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.247 -0.908 . . . . 0.0 109.556 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.963 HG22 ' HB2' ' A' ' 79' ' ' TYR . 74.8 t -54.32 -48.41 67.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.226 -0.922 . . . . 0.0 109.579 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.604 ' HD2' HD11 ' A' ' 42' ' ' ILE . 40.8 tttm -57.56 -49.66 75.66 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.224 -0.923 . . . . 0.0 109.615 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -65.42 -39.18 91.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.244 -0.91 . . . . 0.0 109.497 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.48 ' ND2' ' O ' ' A' ' 19' ' ' LYS . 70.2 m-20 -62.16 -44.62 96.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.309 -0.869 . . . . 0.0 109.622 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.404 HG21 HD11 ' A' ' 40' ' ' ILE . 96.7 mt -57.76 -43.83 84.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.247 -0.908 . . . . 0.0 109.522 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -56.42 -44.55 80.48 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.206 -0.934 . . . . 0.0 109.823 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 32.0 mttt -75.55 -35.33 60.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.06 -1.025 . . . . 0.0 109.437 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.88 ' HD3' HG23 ' A' ' 77' ' ' VAL . 10.1 tttm -56.44 -34.16 66.57 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.229 -0.92 . . . . 0.0 109.331 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.691 HG13 ' O ' ' A' ' 33' ' ' ILE . 43.4 t -83.99 -25.42 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.334 -0.854 . . . . 0.0 109.593 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 46.7 tp10 -70.32 -53.95 14.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.264 -0.897 . . . . 0.0 109.656 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.92 -33.6 72.11 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -0.92 . . . . 0.0 109.693 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.5 HG23 ' O ' ' A' ' 27' ' ' LYS . 50.7 p -83.35 -35.91 24.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.182 -0.949 . . . . 0.0 109.488 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 84.75 17.8 62.91 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.691 ' O ' HG13 ' A' ' 28' ' ' VAL . 78.8 mt -95.74 78.31 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.218 -1.166 . . . . 0.0 109.414 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 45.0 mttm -85.68 6.1 29.12 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.478 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 24.5 m120 -102.3 -6.94 22.52 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.224 -0.923 . . . . 0.0 109.547 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.101 HD11 ' HB2' ' A' ' 70' ' ' ALA . 10.5 tp -97.68 -54.05 3.24 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.302 -0.874 . . . . 0.0 109.681 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.878 HG22 ' CE ' ' A' ' 64' ' ' MET . 87.4 t -90.38 133.66 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.284 -0.885 . . . . 0.0 109.324 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.65 -126.87 5.88 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 44.5 mtt180 -93.58 140.65 29.37 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.237 -1.155 . . . . 0.0 109.887 -179.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.682 HG23 HG12 ' A' ' 62' ' ' VAL . 63.2 mt -103.76 134.0 46.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.308 -0.87 . . . . 0.0 109.09 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.863 HG23 ' HB2' ' A' ' 61' ' ' PHE . 34.7 m -124.7 146.7 29.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.132 -0.98 . . . . 0.0 109.692 -179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.811 HG22 HG23 ' A' ' 44' ' ' ILE . 1.2 mt -117.75 128.9 25.7 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.423 -0.798 . . . . 0.0 109.465 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.696 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 44.6 Cg_endo -66.43 -6.22 14.59 Favored 'Trans proline' 0 C--O 1.214 -0.715 0 C-N-CA 122.903 2.402 . . . . 0.0 111.857 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.994 ' O ' HD21 ' A' ' 104' ' ' LEU . 13.1 pt -56.55 137.23 18.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.178 -0.951 . . . . 0.0 109.413 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.977 ' HA ' HD11 ' A' ' 104' ' ' LEU . 20.5 ttt-85 -53.1 -47.72 68.36 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.239 -0.913 . . . . 0.0 109.457 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 75.68 156.59 6.12 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.429 ' O ' ' C ' ' A' ' 48' ' ' GLN . . . 91.14 3.93 69.36 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.429 ' C ' ' O ' ' A' ' 47' ' ' GLY . 16.3 tt0 43.33 27.17 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.317 -1.108 . . . . 0.0 109.549 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.483 ' HB2' ' NH1' ' A' ' 45' ' ' ARG . 4.2 tpt180 -59.49 -38.13 80.08 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.246 -0.909 . . . . 0.0 109.541 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 76.7 mtp85 -134.56 151.43 51.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.266 -0.896 . . . . 0.0 109.472 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 53.4 tttp -51.98 -39.33 59.17 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 41.3 m -68.86 144.23 54.3 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.299 -0.876 . . . . 0.0 109.527 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.533 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 88.0 mt-10 -151.38 162.52 40.78 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.199 -0.938 . . . . 0.0 109.415 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.776 ' HA ' HG22 ' A' ' 44' ' ' ILE . 1.9 mttt 76.96 94.42 0.07 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.267 -0.896 . . . . 0.0 109.348 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.889 HD12 ' CZ ' ' A' ' 56' ' ' PHE . 0.7 OUTLIER -54.16 -45.84 72.15 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.036 -1.04 . . . . 0.0 108.85 179.756 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.889 ' CZ ' HD12 ' A' ' 55' ' ' LEU . 16.5 m-85 -123.97 110.32 29.41 Favored Pre-proline 0 N--CA 1.487 1.422 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.368 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 44.2 Cg_endo -66.92 137.89 46.37 Favored 'Trans proline' 0 C--O 1.214 -0.694 0 C-N-CA 122.645 2.23 . . . . 0.0 111.942 -179.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.19 -7.71 10.28 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.972 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.7 m-85 -107.54 134.37 50.65 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.896 -1.355 . . . . 0.0 110.082 -179.351 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 43.3 t -134.52 150.42 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.863 ' HB2' HG23 ' A' ' 41' ' ' VAL . 72.9 m-85 -108.67 123.64 49.28 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.988 -1.07 . . . . 0.0 109.711 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.682 HG12 HG23 ' A' ' 40' ' ' ILE . 19.0 m -131.86 144.24 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.382 -0.824 . . . . 0.0 109.569 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.62 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 22.7 tt0 -105.27 126.7 52.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.364 -0.835 . . . . 0.0 109.038 179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.878 ' CE ' HG22 ' A' ' 37' ' ' VAL . 4.9 mtp -156.47 175.0 14.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.107 -0.996 . . . . 0.0 110.293 -179.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.96 HG12 HD12 ' A' ' 36' ' ' LEU . 10.6 pt -97.39 129.13 47.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.608 -0.683 . . . . 0.0 109.236 179.7 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.479 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 0.0 OUTLIER -76.36 145.87 39.16 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.229 -0.919 . . . . 0.0 109.621 -179.026 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.582 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 44.1 t30 175.78 163.61 0.34 Allowed 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -59.56 -40.47 87.39 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.058 -1.027 . . . . 0.0 109.581 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.544 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 99.1 mt-10 -72.19 -43.74 64.07 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.217 -0.927 . . . . 0.0 109.895 -179.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.101 ' HB2' HD11 ' A' ' 36' ' ' LEU . . . -56.4 -44.88 80.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.087 -1.008 . . . . 0.0 109.572 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.582 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 36.2 m-85 -60.32 -62.39 1.9 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.22 -0.925 . . . . 0.0 109.269 179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.479 ' O ' ' HB2' ' A' ' 76' ' ' SER . 95.8 m-20 -43.52 -30.86 0.62 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.388 -0.82 . . . . 0.0 109.82 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.544 ' CD2' ' O ' ' A' ' 69' ' ' GLU . 24.4 m-85 -82.94 -42.41 17.69 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.167 -0.958 . . . . 0.0 109.898 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.955 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 61.2 t -69.99 -55.33 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.217 -0.927 . . . . 0.0 109.498 -179.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.493 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 6.1 tpt180 -57.77 -14.32 5.65 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.292 -0.88 . . . . 0.0 109.307 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.479 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 3.8 m -105.61 2.5 28.28 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.208 -0.933 . . . . 0.0 109.691 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 1.015 ' O ' HG12 ' A' ' 80' ' ' VAL . 0.4 OUTLIER -68.37 150.65 97.63 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.048 -1.033 . . . . 0.0 109.087 179.911 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.904 ' HD2' HG22 ' A' ' 77' ' ' VAL . 47.7 Cg_endo -68.83 124.75 11.79 Favored 'Trans proline' 0 C--O 1.214 -0.714 0 C-N-CA 122.569 2.179 . . . . 0.0 112.429 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.963 ' HB2' HG22 ' A' ' 20' ' ' VAL . 53.5 m-85 88.59 0.02 0.38 Allowed 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.776 -0.577 . . . . 0.0 110.773 179.164 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 1.015 HG12 ' O ' ' A' ' 77' ' ' VAL . 7.4 p -84.16 112.9 22.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.738 -1.226 . . . . 0.0 109.523 179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 86.0 mmm -87.43 -30.1 20.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.274 -0.891 . . . . 0.0 109.232 179.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 11' ' ' LEU . . . 174.26 -169.03 41.99 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.955 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 15.7 m-85 -127.66 147.62 50.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.248 -1.148 . . . . 0.0 109.514 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.719 ' CG2' HD21 ' A' ' 11' ' ' LEU . 59.2 t -67.3 77.1 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.32 -0.862 . . . . 0.0 109.254 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.529 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 3.1 p -127.71 162.78 25.76 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.332 -0.855 . . . . 0.0 109.634 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 87.8 p -95.91 -33.33 12.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.42 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.98 -77.09 0.19 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 -179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.508 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -106.58 -145.19 12.41 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.508 ' C ' ' O ' ' A' ' 88' ' ' GLY . 2.5 pm0 -33.31 154.01 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.582 -0.952 . . . . 0.0 110.188 -179.458 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.529 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 51.7 Cg_endo -70.68 168.55 22.42 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.513 2.142 . . . . 0.0 112.032 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.914 HG12 ' HD2' ' A' ' 92' ' ' PRO . 0.1 OUTLIER -98.7 148.98 35.29 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.33 -0.856 . . . . 0.0 109.199 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.914 ' HD2' HG12 ' A' ' 91' ' ' VAL . 48.7 Cg_endo -69.31 150.8 71.4 Favored 'Trans proline' 0 C--O 1.215 -0.638 0 C-N-CA 122.616 2.21 . . . . 0.0 111.705 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 1.063 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.5 t -80.06 126.65 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.24 -0.912 . . . . 0.0 109.528 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . 0.487 ' O ' ' N ' ' A' ' 97' ' ' GLU . 51.0 mttt -71.9 136.62 46.96 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.267 -0.895 . . . . 0.0 109.271 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.485 ' O ' ' HG3' ' A' ' 99' ' ' ARG . 82.8 m-20 -43.25 -41.65 3.99 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.232 -0.918 . . . . 0.0 109.346 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 21.8 mtm180 -56.75 -30.38 63.53 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.336 -0.852 . . . . 0.0 109.692 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.487 ' N ' ' O ' ' A' ' 94' ' ' LYS . 53.6 mt-10 -87.01 -27.75 23.03 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.212 -0.93 . . . . 0.0 109.599 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.593 ' SD ' HG11 ' A' ' 93' ' ' VAL . 75.2 mmm -80.08 -24.72 40.43 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.223 -0.923 . . . . 0.0 109.359 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.603 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 25.6 mtp85 -37.37 -53.71 2.2 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.482 -0.761 . . . . 0.0 109.786 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.603 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.9 Cg_endo -69.28 -30.74 24.02 Favored 'Trans proline' 0 C--O 1.216 -0.577 0 C-N-CA 122.587 2.191 . . . . 0.0 111.749 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.42 HD13 ' HA ' ' A' ' 101' ' ' ILE . 16.3 mm -77.52 -43.69 29.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.139 -0.976 . . . . 0.0 109.238 179.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.529 ' CB ' ' HB2' ' A' ' 108' ' ' GLU . 1.1 mt -63.19 -40.77 98.46 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.275 -0.891 . . . . 0.0 109.031 179.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.577 ' HG3' ' CE1' ' A' ' 110' ' ' TYR . 24.7 ttt-85 -60.11 -45.85 91.59 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.212 -0.93 . . . . 0.0 108.783 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.994 HD21 ' O ' ' A' ' 44' ' ' ILE . 0.6 OUTLIER -68.45 -34.31 75.74 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.391 -0.818 . . . . 0.0 108.912 179.397 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.514 ' O ' ' HG ' ' A' ' 107' ' ' LEU . . . -90.47 17.88 6.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.32 -0.863 . . . . 0.0 109.033 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 43.76 28.89 1.22 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.723 HD11 ' CG1' ' A' ' 41' ' ' VAL . 88.3 mt -90.12 -26.64 20.1 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -1.158 . . . . 0.0 109.535 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.529 ' HB2' ' CB ' ' A' ' 102' ' ' LEU . 87.2 tt0 -107.78 145.07 34.06 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.238 -0.914 . . . . 0.0 109.63 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -111.11 119.32 38.59 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.305 -0.872 . . . . 0.0 109.354 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.577 ' CE1' ' HG3' ' A' ' 103' ' ' ARG . 29.8 p90 -126.22 -167.4 1.7 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.254 -0.904 . . . . 0.0 109.517 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.575 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 50.7 mt-10 -90.82 -145.64 0.19 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.286 -0.884 . . . . 0.0 109.464 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -106.71 -59.56 1.78 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.211 -0.931 . . . . 0.0 109.414 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -158.41 124.84 4.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.356 -0.84 . . . . 0.0 109.519 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.42 ' HG2' ' HB2' ' A' ' 115' ' ' LYS . 0.0 OUTLIER -58.59 -48.48 80.8 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.305 -0.872 . . . . 0.0 109.458 -179.952 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.42 ' HB2' ' HG2' ' A' ' 114' ' ' LYS . 1.7 ttpt -147.22 112.68 4.1 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.136 -0.978 . . . . 0.0 109.58 -179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -73.44 86.55 1.16 Allowed 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 122.692 2.261 . . . . 0.0 112.128 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.59 HG12 ' CD1' ' A' ' 132' ' ' ILE . 8.1 p -99.68 165.02 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.122 -0.986 . . . . 0.0 109.253 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.482 ' N ' HG22 ' A' ' 117' ' ' VAL . 33.3 mttm -124.25 134.53 53.22 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.22 -0.925 . . . . 0.0 109.759 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.578 HG22 ' N ' ' A' ' 120' ' ' GLU . 11.3 p -49.06 169.71 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.312 -0.867 . . . . 0.0 109.372 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.649 ' C ' HD12 ' A' ' 121' ' ' LEU . 14.5 mt-10 -156.68 127.53 6.78 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -0.908 . . . . 0.0 109.921 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.7 ' N ' HD12 ' A' ' 121' ' ' LEU . 6.0 mp 76.64 94.45 0.07 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.721 -0.612 . . . . 0.0 110.165 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.549 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -29.52 95.48 0.01 OUTLIER Glycine 0 N--CA 1.494 2.561 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.652 ' CE2' ' HB3' ' A' ' 127' ' ' ASP . 0.0 OUTLIER -55.94 178.05 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.929 -1.336 . . . . 0.0 109.188 179.758 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.475 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 12.2 mttt -113.91 157.22 22.67 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.11 -0.994 . . . . 0.0 110.146 -179.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 22.0 t -64.43 144.99 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.512 -0.742 . . . . 0.0 109.469 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.423 ' O ' HG13 ' A' ' 142' ' ' VAL . . . 84.68 -28.23 4.5 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.652 ' HB3' ' CE2' ' A' ' 123' ' ' PHE . 8.3 m-20 -50.48 167.52 0.06 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.466 -1.02 . . . . 0.0 108.898 179.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . 0.485 ' HG2' HD12 ' A' ' 176' ' ' ILE . 0.1 OUTLIER -99.05 126.36 44.75 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.026 -1.047 . . . . 0.0 109.112 179.838 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.547 HG22 ' O ' ' A' ' 174' ' ' GLU . 2.3 p -124.93 142.8 40.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.373 -0.829 . . . . 0.0 109.08 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.466 ' N ' ' O ' ' A' ' 174' ' ' GLU . 21.1 tttt -104.9 142.91 33.92 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.293 -0.879 . . . . 0.0 109.236 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.932 HD12 ' HB3' ' A' ' 139' ' ' PHE . 74.3 mt -83.01 152.99 3.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 O-C-N 121.152 -0.967 . . . . 0.0 108.629 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.59 ' CD1' HG12 ' A' ' 117' ' ' VAL . 34.2 pt -150.1 2.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 120.926 -1.109 . . . . 0.0 109.494 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.578 ' CA ' ' HG2' ' A' ' 137' ' ' GLU . 5.9 t -147.11 142.09 26.99 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.048 -1.032 . . . . 0.0 109.634 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.464 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 102.22 -166.0 17.33 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.426 -1.069 . . . . 0.0 110.426 179.266 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.527 ' CA ' ' HD3' ' A' ' 103' ' ' ARG . 48.4 Cg_endo -68.28 -20.61 42.69 Favored 'Trans proline' 0 C--O 1.214 -0.701 0 C-N-CA 123.382 2.721 . . . . 0.0 113.104 -179.157 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.525 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.1 m-85 -105.77 15.86 26.13 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.836 -1.165 . . . . 0.0 109.54 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.578 ' HG2' ' CA ' ' A' ' 133' ' ' SER . 73.0 mt-10 -41.5 137.35 1.56 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.196 -0.94 . . . . 0.0 109.95 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.491 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 0.6 OUTLIER 75.48 25.18 1.26 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.303 -0.873 . . . . 0.0 110.656 178.954 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.932 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.1 t80 -115.96 134.25 55.17 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.876 -1.14 . . . . 0.0 109.579 179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -83.79 134.29 34.73 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.196 -0.94 . . . . 0.0 109.551 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.17 169.38 25.78 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 126' ' ' GLY . 71.2 t -115.25 136.3 52.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.404 -1.057 . . . . 0.0 109.42 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.945 HD13 HD21 ' A' ' 153' ' ' LEU . 39.4 mt -67.61 117.92 10.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.162 -0.961 . . . . 0.0 109.505 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 24.5 tttm -99.79 -34.5 10.13 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.152 -0.967 . . . . 0.0 109.407 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.478 ' HB3' ' HD2' ' A' ' 154' ' ' LYS . 85.1 tt0 -153.85 148.99 26.89 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.11 -0.994 . . . . 0.0 109.66 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.703 HG23 ' CD1' ' A' ' 153' ' ' LEU . 3.3 mt -124.07 126.79 72.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.287 -0.883 . . . . 0.0 109.425 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -107.55 101.75 41.14 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.219 -0.925 . . . . 0.0 109.495 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.563 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 49.9 Cg_endo -71.6 170.54 18.34 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.653 2.235 . . . . 0.0 111.665 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.563 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.1 mt-10 80.48 -20.39 0.38 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.441 -0.787 . . . . 0.0 109.952 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.405 ' O ' ' CB ' ' A' ' 151' ' ' GLN . 70.8 mtp180 -127.55 -13.58 5.38 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.12 -0.987 . . . . 0.0 109.67 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.405 ' CB ' ' O ' ' A' ' 150' ' ' ARG . 29.0 mt-30 69.44 48.16 0.64 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.28 -0.887 . . . . 0.0 109.499 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.765 ' OE2' HG13 ' A' ' 167' ' ' VAL . 82.9 tt0 -118.75 143.05 47.14 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.099 -1.001 . . . . 0.0 108.803 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.945 HD21 HD13 ' A' ' 143' ' ' ILE . 0.1 OUTLIER -130.77 117.67 19.73 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.048 -1.032 . . . . 0.0 110.321 -179.174 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.478 ' HD2' ' HB3' ' A' ' 145' ' ' GLU . 11.2 mttt -79.82 129.65 34.66 Favored 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.677 ' O ' HG22 ' A' ' 166' ' ' VAL . 14.3 m -131.19 148.02 32.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.157 -0.965 . . . . 0.0 109.724 -179.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.564 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.7 m-20 -100.48 119.04 37.89 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.37 -0.832 . . . . 0.0 109.437 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.581 HG23 ' CE1' ' A' ' 139' ' ' PHE . 3.4 p -100.35 144.05 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.309 -0.869 . . . . 0.0 109.501 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 28.0 m -96.89 97.05 8.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.391 -0.818 . . . . 0.0 109.984 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.644 HG22 ' CD2' ' A' ' 160' ' ' PHE . 13.0 mt -118.21 139.27 46.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.238 -0.914 . . . . 0.0 109.332 179.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.644 ' CD2' HG22 ' A' ' 159' ' ' ILE . 40.0 m-85 59.67 41.74 18.14 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.402 -0.811 . . . . 0.0 109.32 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 54.14 16.61 6.55 Favored Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 4.3 mtp-105 -119.21 147.07 44.64 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.089 -1.242 . . . . 0.0 109.628 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -95.66 129.73 42.77 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.28 -0.887 . . . . 0.0 109.573 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.2 m -145.94 128.22 7.87 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.263 -0.898 . . . . 0.0 109.908 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.564 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.5 Cg_endo -70.52 138.72 36.0 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.686 2.257 . . . . 0.0 111.369 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.677 HG22 ' O ' ' A' ' 155' ' ' VAL . 2.9 m -122.4 168.09 15.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.005 -1.059 . . . . 0.0 110.01 -179.703 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.765 HG13 ' OE2' ' A' ' 152' ' ' GLU . 42.8 t -116.44 117.95 57.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.541 -0.724 . . . . 0.0 109.309 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.749 HD12 ' N ' ' A' ' 168' ' ' LEU . 2.4 mp -141.21 165.75 26.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.258 -0.901 . . . . 0.0 110.519 -179.227 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -80.2 143.38 33.83 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.526 HG23 HD13 ' A' ' 153' ' ' LEU . 4.3 p -57.96 -36.86 57.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.269 -0.895 . . . . 0.0 108.789 179.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.431 ' N ' ' CG1' ' A' ' 170' ' ' VAL . 49.8 m -77.17 -7.47 55.89 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.482 -0.761 . . . . 0.0 109.417 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.434 ' CG ' ' HB3' ' A' ' 133' ' ' SER . 5.5 mt-10 -95.8 -2.66 47.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.263 -0.898 . . . . 0.0 109.291 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 11.3 m -127.51 164.72 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.225 -0.922 . . . . 0.0 109.392 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.547 ' O ' HG22 ' A' ' 129' ' ' VAL . 58.3 tt0 -134.64 153.81 51.81 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.259 -0.901 . . . . 0.0 109.07 179.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.643 ' HB2' ' CZ ' ' A' ' 123' ' ' PHE . 33.1 pttt -92.91 20.99 6.03 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.182 -0.949 . . . . 0.0 109.493 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.485 HD12 ' HG2' ' A' ' 128' ' ' MET . 64.2 mt 61.8 -76.98 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.3 -0.875 . . . . 0.0 109.39 -179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.522 ' N ' ' O ' ' A' ' 175' ' ' LYS . 95.5 mt-10 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.374 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.5 -30.57 71.37 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.217 -1.166 . . . . 0.0 109.483 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 96.1 mmm -55.22 -41.36 71.95 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.459 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -92.68 143.89 25.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.354 -0.841 . . . . 0.0 109.52 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.487 ' HB2' ' OE2' ' A' ' 63' ' ' GLU . 82.9 mttt -95.41 144.48 25.9 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.203 -0.936 . . . . 0.0 109.496 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.521 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 18.7 mttp -130.65 176.45 8.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.294 -0.879 . . . . 0.0 109.579 -179.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 1.055 ' CZ3' HG23 ' A' ' 41' ' ' VAL . 76.1 m95 -113.16 125.06 53.93 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.279 -0.888 . . . . 0.0 109.179 179.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -115.37 170.4 8.42 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.164 -0.96 . . . . 0.0 109.139 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.562 HG12 ' CE1' ' A' ' 61' ' ' PHE . 21.5 mt -113.88 97.77 6.12 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.101 -1.0 . . . . 0.0 108.818 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.802 HG13 ' CG1' ' A' ' 60' ' ' VAL . 3.9 p -81.83 151.09 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.254 -0.903 . . . . 0.0 109.264 -179.771 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.874 HD21 ' CE1' ' A' ' 59' ' ' TYR . 0.2 OUTLIER -94.34 142.96 26.82 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.388 -0.82 . . . . 0.0 110.013 -179.312 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.4 p -144.59 -171.59 3.64 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.372 -0.83 . . . . 0.0 109.01 179.671 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.504 ' CG ' ' SD ' ' A' ' 81' ' ' MET . 44.4 mtm -102.38 118.98 38.04 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.165 -0.959 . . . . 0.0 109.596 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.445 ' C ' ' O ' ' A' ' 13' ' ' MET . 43.7 m -42.14 121.74 1.94 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.29 -0.881 . . . . 0.0 109.22 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.53 -18.3 32.69 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.069 -1.613 . . . . 0.0 109.069 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.43 ' O ' ' C ' ' A' ' 17' ' ' GLU . 92.9 m-85 -108.91 -13.25 14.78 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.397 -1.061 . . . . 0.0 109.61 -179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.43 ' C ' ' O ' ' A' ' 16' ' ' TYR . 95.1 mt-10 -42.71 -55.27 3.67 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.279 -0.888 . . . . 0.0 109.372 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -54.16 -36.46 63.36 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.215 -0.928 . . . . 0.0 109.141 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.421 ' N ' ' O ' ' A' ' 16' ' ' TYR . 28.0 mttp -70.3 -37.41 74.78 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.275 -0.891 . . . . 0.0 109.131 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 61.2 t -64.07 -47.13 91.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.431 -0.793 . . . . 0.0 109.411 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 52.6 tttm -55.1 -50.93 67.96 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.224 -0.923 . . . . 0.0 109.331 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -64.55 -41.92 96.01 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.281 -0.887 . . . . 0.0 109.311 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.489 ' ND2' ' HG2' ' A' ' 78' ' ' PRO . 24.1 t-20 -57.62 -39.75 77.62 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.186 -0.946 . . . . 0.0 109.452 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.798 HG21 HD11 ' A' ' 40' ' ' ILE . 96.4 mt -62.89 -44.73 99.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -0.927 . . . . 0.0 109.648 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 74.9 mm-40 -53.81 -45.29 70.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.15 -0.969 . . . . 0.0 109.64 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.9 mttt -79.99 -32.37 39.73 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.212 -0.93 . . . . 0.0 109.485 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.748 ' HG2' HG23 ' A' ' 77' ' ' VAL . 48.7 tptt -56.77 -38.3 72.3 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.215 -0.928 . . . . 0.0 109.308 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.788 HG13 ' O ' ' A' ' 33' ' ' ILE . 40.7 t -83.81 -22.93 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.338 -0.851 . . . . 0.0 109.399 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -69.16 -53.27 20.97 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.266 -0.896 . . . . 0.0 109.571 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.77 -33.47 64.36 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.161 -0.962 . . . . 0.0 109.619 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 23.1 p -91.42 -19.92 22.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.229 -0.92 . . . . 0.0 109.612 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 68.83 9.97 60.37 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.788 ' O ' HG13 ' A' ' 28' ' ' VAL . 54.3 mt -80.16 88.5 1.49 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.292 -1.122 . . . . 0.0 109.414 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 38.3 mttt -91.74 9.18 33.6 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.155 -0.966 . . . . 0.0 109.438 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.47 ' O ' HD13 ' A' ' 65' ' ' ILE . 38.0 p30 -110.93 9.13 22.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.289 -0.882 . . . . 0.0 109.59 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.988 HD21 ' HB2' ' A' ' 70' ' ' ALA . 0.2 OUTLIER -109.71 -55.22 2.46 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.182 -0.948 . . . . 0.0 109.172 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.805 HG22 ' HE3' ' A' ' 64' ' ' MET . 68.9 t -94.15 130.98 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.317 -0.864 . . . . 0.0 109.31 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.75 -122.84 5.16 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 74.2 mtt180 -89.74 148.56 23.19 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.275 -1.132 . . . . 0.0 109.822 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.798 HD11 HG21 ' A' ' 24' ' ' ILE . 72.2 mt -116.21 132.93 64.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.4 -0.812 . . . . 0.0 108.909 179.641 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 1.055 HG23 ' CZ3' ' A' ' 7' ' ' TRP . 34.3 t -125.87 161.81 30.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 O-C-N 121.049 -1.032 . . . . 0.0 109.346 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.659 HG22 HG23 ' A' ' 44' ' ' ILE . 2.3 mt -140.92 127.61 11.74 Favored Pre-proline 0 N--CA 1.487 1.402 0 O-C-N 121.208 -0.933 . . . . 0.0 109.83 -179.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.562 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 45.8 Cg_endo -67.16 -2.64 8.39 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.841 2.36 . . . . 0.0 111.305 179.569 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.769 HG22 ' HB3' ' A' ' 54' ' ' LYS . 19.0 pt -81.14 -9.59 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.312 -0.868 . . . . 0.0 109.615 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.568 ' HB2' HD21 ' A' ' 104' ' ' LEU . 22.5 mtp85 -50.16 -23.64 2.3 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.081 -1.012 . . . . 0.0 109.345 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.472 ' HA3' HD11 ' A' ' 104' ' ' LEU . . . -101.77 -168.19 27.39 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 60.15 43.41 98.4 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 96.7 mt-30 -67.9 -29.32 68.39 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.242 -1.152 . . . . 0.0 109.459 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.414 ' O ' ' O ' ' A' ' 52' ' ' SER . 99.2 mtt180 -53.66 140.49 29.01 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.248 -0.907 . . . . 0.0 109.455 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 58.3 mtt-85 -61.98 -24.88 67.3 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.16 -0.963 . . . . 0.0 109.444 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 28.5 mttm -59.05 -27.74 65.78 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.196 -0.94 . . . . 0.0 109.5 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.414 ' O ' ' O ' ' A' ' 49' ' ' ARG . 48.8 p -146.43 144.84 29.97 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.934 . . . . 0.0 109.591 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.489 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 75.5 mm-40 -139.77 128.12 22.69 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 109.479 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.769 ' HB3' HG22 ' A' ' 44' ' ' ILE . 13.6 mttp 74.83 115.8 0.06 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.258 -0.901 . . . . 0.0 109.646 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.656 HD23 ' HE2' ' A' ' 56' ' ' PHE . 18.2 tp -57.48 -45.85 84.38 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.039 -1.038 . . . . 0.0 109.291 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.656 ' HE2' HD23 ' A' ' 55' ' ' LEU . 57.9 m-85 -131.44 109.4 14.83 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.141 -0.974 . . . . 0.0 108.864 179.482 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -65.45 138.9 56.89 Favored 'Trans proline' 0 C--O 1.214 -0.692 0 C-N-CA 122.579 2.186 . . . . 0.0 111.974 -179.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.59 ' O ' HD13 ' A' ' 11' ' ' LEU . . . 76.84 -16.7 5.11 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 179.605 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.874 ' CE1' HD21 ' A' ' 11' ' ' LEU . 3.3 m-30 -98.63 129.08 45.13 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.788 -1.419 . . . . 0.0 110.406 -179.207 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.802 ' CG1' HG13 ' A' ' 10' ' ' VAL . 7.7 p -136.92 151.58 27.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.562 ' CE1' HG12 ' A' ' 9' ' ' ILE . 7.7 m-85 -110.0 127.07 54.58 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.914 -1.116 . . . . 0.0 110.756 -178.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.783 HG13 HG12 ' A' ' 40' ' ' ILE . 90.3 t -129.51 139.82 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.649 -0.657 . . . . 0.0 109.318 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.604 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 9.7 tt0 -101.83 126.94 48.81 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.114 -0.991 . . . . 0.0 109.104 179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.805 ' HE3' HG22 ' A' ' 37' ' ' VAL . 1.8 mtp -157.28 178.02 10.8 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.043 -1.036 . . . . 0.0 110.071 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.616 ' CG1' HD22 ' A' ' 36' ' ' LEU . 12.2 pt -99.95 131.92 46.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.593 -0.692 . . . . 0.0 109.286 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.47 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 42.1 ttm -77.65 145.76 36.5 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.202 -0.936 . . . . 0.0 110.086 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.508 ' OD1' ' N ' ' A' ' 68' ' ' ASP . 49.8 t-20 176.74 172.37 0.45 Allowed 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 -179.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.508 ' N ' ' OD1' ' A' ' 67' ' ' ASN . 90.2 m-20 -69.47 -42.81 74.35 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.163 -0.961 . . . . 0.0 109.275 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.504 ' HG2' ' CD2' ' A' ' 73' ' ' PHE . 69.7 tt0 -73.82 -31.54 63.28 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.327 -0.858 . . . . 0.0 109.55 179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.988 ' HB2' HD21 ' A' ' 36' ' ' LEU . . . -70.92 -45.07 64.92 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.146 -0.971 . . . . 0.0 109.356 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.495 ' HA ' ' CG1' ' A' ' 74' ' ' VAL . 71.8 t80 -60.99 -47.0 88.48 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.265 -0.897 . . . . 0.0 109.72 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' HB2' ' A' ' 76' ' ' SER . 96.4 m-20 -64.72 -27.65 69.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.106 -0.996 . . . . 0.0 110.035 -179.518 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.504 ' CD2' ' HG2' ' A' ' 69' ' ' GLU . 3.6 m-85 -84.19 -42.98 15.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.045 -1.034 . . . . 0.0 109.917 -179.618 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.848 HG12 ' O ' ' A' ' 70' ' ' ALA . 2.9 p -67.12 -57.87 8.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.264 -0.898 . . . . 0.0 109.803 -179.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.696 ' H ' HG13 ' A' ' 74' ' ' VAL . 28.5 tpt85 -62.84 -10.27 12.58 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.103 -0.998 . . . . 0.0 109.676 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.481 ' HB2' ' O ' ' A' ' 72' ' ' ASN . 19.4 m -99.25 1.49 44.74 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.147 -0.971 . . . . 0.0 109.953 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.787 HG12 ' CG2' ' A' ' 80' ' ' VAL . 0.4 OUTLIER -70.43 140.71 87.57 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.023 -1.048 . . . . 0.0 109.229 -179.976 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.648 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 45.6 Cg_endo -66.73 134.9 36.58 Favored 'Trans proline' 0 C--O 1.213 -0.765 0 C-N-CA 122.706 2.271 . . . . 0.0 111.849 -179.791 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.648 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 10.0 m-85 92.62 -10.77 0.18 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.816 -0.552 . . . . 0.0 109.52 -179.708 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.787 ' CG2' HG12 ' A' ' 77' ' ' VAL . 2.3 t -85.7 121.06 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.116 -0.99 . . . . 0.0 109.144 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.504 ' SD ' ' CG ' ' A' ' 13' ' ' MET . 82.8 mtp -88.4 -33.69 17.82 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.241 -0.912 . . . . 0.0 109.565 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 11' ' ' LEU . . . 172.01 -168.98 42.12 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.631 ' N ' ' CD1' ' A' ' 83' ' ' PHE . 0.8 OUTLIER -134.21 146.65 50.33 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.189 -1.183 . . . . 0.0 109.524 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.675 HG13 ' O ' ' A' ' 84' ' ' VAL . 14.2 p -81.23 114.38 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.212 -0.93 . . . . 0.0 109.368 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.598 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.9 OUTLIER -154.04 164.88 37.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.256 -0.902 . . . . 0.0 109.639 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 77.0 p -84.5 -30.63 25.02 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.167 -0.958 . . . . 0.0 109.267 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -130.96 -102.54 0.93 Allowed Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.548 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -93.16 -129.15 5.08 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.548 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -29.5 150.47 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.824 0 O-C-N 121.675 -0.897 . . . . 0.0 110.315 -179.56 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.598 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 46.2 Cg_endo -67.66 143.03 60.52 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 122.753 2.302 . . . . 0.0 112.002 -179.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 6.2 m -74.07 147.56 85.96 Favored Pre-proline 0 N--CA 1.49 1.535 0 O-C-N 121.325 -0.86 . . . . 0.0 109.293 179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.506 ' CB ' ' HD3' ' A' ' 6' ' ' LYS . 49.2 Cg_endo -69.82 145.39 56.63 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 122.708 2.272 . . . . 0.0 111.7 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.529 ' CG1' ' HG2' ' A' ' 98' ' ' MET . 9.9 p -70.11 135.16 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.208 -0.932 . . . . 0.0 109.231 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . 0.487 ' HE2' ' HD2' ' A' ' 96' ' ' ARG . 15.4 tttp -70.95 136.48 48.52 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.179 -0.95 . . . . 0.0 109.592 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -46.58 -52.05 14.34 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.221 -0.924 . . . . 0.0 109.355 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.487 ' HD2' ' HE2' ' A' ' 94' ' ' LYS . 72.0 mtt85 -60.84 -16.47 41.63 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.292 -0.88 . . . . 0.0 109.425 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.489 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 6.7 mt-10 -88.59 -28.5 20.67 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.233 -0.917 . . . . 0.0 109.274 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.651 ' HE3' ' CD1' ' A' ' 7' ' ' TRP . 31.4 mtp -75.85 -28.69 58.3 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.302 -0.874 . . . . 0.0 109.61 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.59 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.46 -53.37 1.3 Allowed Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.485 -0.76 . . . . 0.0 109.979 -179.609 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.59 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.7 Cg_endo -69.01 -34.96 15.85 Favored 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 122.538 2.158 . . . . 0.0 112.111 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.489 HD13 ' HA ' ' A' ' 101' ' ' ILE . 8.7 mm -78.57 -44.51 26.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.118 -0.989 . . . . 0.0 109.444 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.908 ' HA ' HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -62.19 -41.35 98.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.106 -0.996 . . . . 0.0 108.873 179.725 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.478 ' HD2' ' O ' ' A' ' 135' ' ' PRO . 36.3 mtt180 -61.03 -43.21 99.23 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.467 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.568 HD21 ' HB2' ' A' ' 45' ' ' ARG . 0.7 OUTLIER -70.01 -35.76 74.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 109.134 179.667 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.508 ' HA ' ' HD3' ' A' ' 45' ' ' ARG . . . -88.13 20.96 2.94 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.21 179.681 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 46.92 28.4 3.88 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.908 HD12 ' HA ' ' A' ' 102' ' ' LEU . 35.9 mt -80.04 -22.84 41.91 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.196 -1.179 . . . . 0.0 109.146 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -112.85 149.51 33.01 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.345 -0.847 . . . . 0.0 109.314 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -93.93 124.09 37.71 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.235 -0.916 . . . . 0.0 109.585 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.473 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 48.1 p90 -144.27 160.36 41.13 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.27 -0.894 . . . . 0.0 109.477 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.473 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 6.4 mt-10 -68.73 -147.76 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.241 -0.912 . . . . 0.0 109.49 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.458 ' O ' ' HB3' ' A' ' 113' ' ' LYS . 81.8 tt0 -100.61 -48.57 4.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.215 -0.928 . . . . 0.0 109.488 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.458 ' HB3' ' O ' ' A' ' 112' ' ' GLU . 16.6 pttt 173.72 177.83 0.11 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.252 -0.905 . . . . 0.0 109.298 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.504 ' O ' ' CB ' ' A' ' 115' ' ' LYS . 6.6 mttt -70.44 -64.65 0.85 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.176 -0.953 . . . . 0.0 109.238 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.504 ' CB ' ' O ' ' A' ' 114' ' ' LYS . 2.8 mtpt 164.71 148.72 0.05 OUTLIER Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.297 -0.877 . . . . 0.0 109.259 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -68.82 53.83 0.81 Allowed 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 122.673 2.249 . . . . 0.0 111.7 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.516 HG22 ' O ' ' A' ' 117' ' ' VAL . 7.6 p -71.28 -5.3 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.287 -0.883 . . . . 0.0 109.58 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.493 ' HA ' ' HB3' ' A' ' 171' ' ' SER . 26.5 tttt 68.4 125.81 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.282 -0.886 . . . . 0.0 109.464 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.65 HG11 ' HA ' ' A' ' 174' ' ' GLU . 74.3 t -128.08 123.83 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.188 -0.945 . . . . 0.0 109.403 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.663 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 89.4 mt-10 -153.81 170.53 20.75 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.936 . . . . 0.0 109.515 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.663 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 4.1 mt 145.33 112.77 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.857 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . 42.08 57.67 3.51 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.525 ' CD2' ' O ' ' A' ' 123' ' ' PHE . 51.7 p90 -103.18 121.9 43.62 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.294 -1.121 . . . . 0.0 109.498 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.463 ' N ' ' OD2' ' A' ' 127' ' ' ASP . 27.5 mttp -141.81 164.48 30.07 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.247 -0.908 . . . . 0.0 109.558 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.55 HG23 ' O ' ' A' ' 144' ' ' LYS . 7.9 p -66.5 126.11 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.318 -0.864 . . . . 0.0 109.659 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 103.68 -33.32 6.67 Favored Glycine 0 N--CA 1.488 2.14 0 N-CA-C 108.973 -1.651 . . . . 0.0 108.973 -179.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.751 ' HB2' HD12 ' A' ' 143' ' ' ILE . 73.2 m-20 -48.15 165.33 0.04 OUTLIER 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.385 -1.068 . . . . 0.0 108.922 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.4 ttm -97.26 126.91 42.78 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.044 -1.035 . . . . 0.0 108.97 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.707 ' CG2' HD11 ' A' ' 143' ' ' ILE . 12.7 t -125.36 141.91 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.248 -0.908 . . . . 0.0 109.535 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.484 ' O ' ' HB ' ' A' ' 173' ' ' VAL . 42.8 tttp -106.61 143.91 34.04 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.357 -0.839 . . . . 0.0 108.946 179.495 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 1.009 HD12 ' HB3' ' A' ' 139' ' ' PHE . 65.8 mt -84.76 155.31 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.129 -0.982 . . . . 0.0 108.817 179.636 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.459 ' O ' ' HE3' ' A' ' 114' ' ' LYS . 27.2 pt -150.59 2.95 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.126 -0.984 . . . . 0.0 109.488 179.775 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 72.7 m -148.66 145.08 27.57 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.151 -0.968 . . . . 0.0 110.107 -179.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.15 -170.55 16.8 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.478 ' O ' ' HD2' ' A' ' 103' ' ' ARG . 48.2 Cg_endo -68.66 -19.8 41.31 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 123.275 2.65 . . . . 0.0 112.467 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.534 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 98.1 m-85 -112.96 13.22 19.48 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.05 -1.031 . . . . 0.0 109.487 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.727 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.6 tt0 -42.73 151.74 0.12 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.332 -0.855 . . . . 0.0 109.663 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.515 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 25.3 m-20 72.99 28.1 1.98 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.455 -0.778 . . . . 0.0 110.091 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 1.009 ' HB3' HD12 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -120.43 136.99 54.57 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.99 -1.069 . . . . 0.0 109.539 179.877 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.08 133.94 34.21 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.225 -0.922 . . . . 0.0 109.579 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.92 170.05 25.95 Favored Glycine 0 N--CA 1.492 2.374 0 C-N-CA 119.836 -1.173 . . . . 0.0 110.171 -179.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.887 ' C ' HG23 ' A' ' 155' ' ' VAL . 47.9 t -115.76 136.03 53.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.387 -1.066 . . . . 0.0 109.439 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.815 HG23 HD23 ' A' ' 153' ' ' LEU . 87.7 mt -65.12 115.22 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.275 -0.89 . . . . 0.0 109.386 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.55 ' O ' HG23 ' A' ' 125' ' ' VAL . 36.6 tttp -100.26 -36.38 9.3 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.062 -1.024 . . . . 0.0 109.377 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.441 ' HG2' ' C ' ' A' ' 144' ' ' LYS . 67.2 mm-40 -149.57 144.26 26.11 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.967 . . . . 0.0 109.351 -179.9 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 1.084 HG23 ' HG ' ' A' ' 153' ' ' LEU . 2.4 mt -123.04 125.85 72.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.183 -0.948 . . . . 0.0 109.406 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -108.18 101.46 41.9 Favored Pre-proline 0 N--CA 1.491 1.594 0 O-C-N 121.236 -0.915 . . . . 0.0 109.63 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.552 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.7 171.4 16.49 Favored 'Trans proline' 0 C--O 1.215 -0.653 0 C-N-CA 122.72 2.28 . . . . 0.0 111.781 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.552 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 10.8 tt0 80.55 -20.97 0.35 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.3 -0.875 . . . . 0.0 109.791 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.452 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 93.1 mtt-85 -126.59 -12.99 6.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.235 -0.916 . . . . 0.0 109.437 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.452 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 29.9 mt-30 69.83 48.6 0.56 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.204 -0.935 . . . . 0.0 109.61 179.823 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -120.06 143.62 48.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.138 -0.976 . . . . 0.0 109.08 179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 1.084 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -136.99 112.38 9.24 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.15 -0.969 . . . . 0.0 110.12 -179.599 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.429 ' HD2' ' HB2' ' A' ' 145' ' ' GLU . 30.8 mttm -79.85 130.94 35.72 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.06 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.887 HG23 ' C ' ' A' ' 142' ' ' VAL . 7.3 p -133.39 127.48 53.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.121 -0.987 . . . . 0.0 109.752 -179.469 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.56 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 50.2 m-20 -73.18 135.4 44.61 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.362 -0.836 . . . . 0.0 109.709 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.553 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 53.9 t -116.8 149.96 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.466 -0.772 . . . . 0.0 109.195 179.756 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 57.2 m -96.34 103.01 14.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.107 -0.996 . . . . 0.0 109.711 -179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.509 HG22 ' CD2' ' A' ' 160' ' ' PHE . 20.5 mt -129.98 140.77 48.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.285 -0.884 . . . . 0.0 109.311 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.509 ' CD2' HG22 ' A' ' 159' ' ' ILE . 52.8 m-85 60.3 40.4 17.76 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.186 -0.946 . . . . 0.0 108.97 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.64 16.31 15.88 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 46.1 mtp180 -128.43 156.13 43.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.111 -1.229 . . . . 0.0 109.57 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -100.24 133.75 44.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.289 -0.882 . . . . 0.0 109.443 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.7 m -141.33 127.77 11.41 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.342 -0.849 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.56 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.9 Cg_endo -70.35 133.68 25.03 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 122.658 2.238 . . . . 0.0 111.44 179.697 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.635 HG12 ' O ' ' A' ' 155' ' ' VAL . 2.8 p -122.67 141.87 41.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.204 -0.935 . . . . 0.0 109.675 -179.837 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.588 ' O ' HG23 ' A' ' 167' ' ' VAL . 18.0 m -93.17 120.11 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.458 -0.776 . . . . 0.0 109.458 -179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.867 HD11 HG12 ' A' ' 155' ' ' VAL . 0.0 OUTLIER -142.3 167.81 21.22 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.33 -0.857 . . . . 0.0 110.487 -179.471 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.482 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 98.0 m-70 -81.6 142.0 33.19 Favored 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.622 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.533 HG22 ' O ' ' A' ' 119' ' ' VAL . 10.8 p -55.92 -35.98 42.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.177 -0.952 . . . . 0.0 109.025 179.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.493 ' HB3' ' HA ' ' A' ' 118' ' ' LYS . 74.6 p -75.71 -6.61 51.39 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.403 -0.811 . . . . 0.0 109.626 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.482 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 41.8 mt-10 -90.99 -0.68 57.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.135 -0.978 . . . . 0.0 109.572 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.484 ' HB ' ' O ' ' A' ' 130' ' ' LYS . 2.8 m -147.13 177.74 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.176 -0.953 . . . . 0.0 109.452 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.65 ' HA ' HG11 ' A' ' 119' ' ' VAL . 83.5 tt0 -136.55 163.75 29.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.149 -0.969 . . . . 0.0 109.263 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.538 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.3 mmtt -94.77 18.0 12.53 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.47 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.452 HG22 ' HG3' ' A' ' 177' ' ' GLU . 63.5 mt 59.8 -79.08 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.29 -0.881 . . . . 0.0 109.684 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.528 ' N ' ' O ' ' A' ' 175' ' ' LYS . 94.1 mt-10 . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 117.905 -1.045 . . . . 0.0 109.515 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.51 -22.92 65.42 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.219 -1.166 . . . . 0.0 109.491 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 91.3 mtp -66.97 -24.76 66.08 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.288 -0.882 . . . . 0.0 109.479 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 30.1 mttt -112.16 132.51 54.84 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.283 -0.886 . . . . 0.0 109.476 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 47.0 mttt -89.12 146.73 24.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.246 -0.909 . . . . 0.0 109.493 179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.561 ' HB2' ' CZ ' ' A' ' 8' ' ' TYR . 26.5 mmtp -128.6 175.47 8.54 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.354 -0.841 . . . . 0.0 109.613 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.932 ' O ' HG23 ' A' ' 93' ' ' VAL . 47.2 m95 -111.65 124.26 51.94 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.39 -0.819 . . . . 0.0 108.968 179.657 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.561 ' CZ ' ' HB2' ' A' ' 6' ' ' LYS . 59.3 m-85 -117.94 168.65 10.31 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.141 -0.975 . . . . 0.0 109.478 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.537 HG12 ' CE1' ' A' ' 61' ' ' PHE . 33.9 mt -107.5 114.63 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.208 -0.932 . . . . 0.0 109.367 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.604 HG12 ' HB ' ' A' ' 60' ' ' VAL . 8.5 p -92.65 141.17 15.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.234 -0.916 . . . . 0.0 109.222 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.674 HD11 ' CE1' ' A' ' 59' ' ' TYR . 3.7 mm? -89.62 143.28 26.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.408 -0.807 . . . . 0.0 109.739 -179.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.731 HG21 ' OE1' ' A' ' 17' ' ' GLU . 9.0 t -152.99 -166.03 2.34 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.325 -0.859 . . . . 0.0 109.408 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.441 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 46.2 mtt -108.14 130.83 55.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.252 -0.905 . . . . 0.0 109.532 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.0 t -54.26 128.27 30.54 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.196 -0.94 . . . . 0.0 109.391 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 102.55 -20.31 44.8 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 -179.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.441 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 79.4 m-85 -104.47 5.94 34.48 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.38 -1.071 . . . . 0.0 109.557 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.731 ' OE1' HG21 ' A' ' 12' ' ' THR . 41.1 mm-40 -53.36 -62.32 1.73 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.219 -0.926 . . . . 0.0 109.62 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.419 ' C ' ' O ' ' A' ' 17' ' ' GLU . 60.7 mt-10 -42.68 -35.64 1.18 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -0.889 . . . . 0.0 109.583 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.528 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 27.3 mttt -74.18 -44.61 52.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.263 -0.898 . . . . 0.0 109.472 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.688 HG21 ' OG1' ' A' ' 12' ' ' THR . 70.6 t -58.44 -53.11 51.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.48 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.417 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.5 tttm -58.4 -47.07 85.08 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.348 179.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 92.8 mt-10 -63.13 -41.17 99.26 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.199 -0.938 . . . . 0.0 109.329 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.54 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 87.7 m-20 -59.29 -42.78 92.09 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.253 -0.904 . . . . 0.0 109.503 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.911 HG21 HD11 ' A' ' 40' ' ' ILE . 69.7 mt -61.5 -46.46 96.53 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.229 -0.919 . . . . 0.0 109.715 -179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -54.83 -46.22 74.56 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.145 -0.972 . . . . 0.0 109.56 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 93.4 mttt -75.78 -35.57 60.07 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.132 -0.98 . . . . 0.0 109.459 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.604 ' O ' HG23 ' A' ' 31' ' ' THR . 7.8 ttpt -56.14 -34.26 65.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.253 -0.905 . . . . 0.0 109.314 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.793 HG13 ' O ' ' A' ' 33' ' ' ILE . 44.2 t -85.52 -25.15 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.304 -0.873 . . . . 0.0 109.377 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 73.9 mt-10 -69.77 -54.17 14.91 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.186 -0.946 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.22 -24.76 67.79 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.197 -0.94 . . . . 0.0 109.526 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.604 HG23 ' O ' ' A' ' 27' ' ' LYS . 40.2 p -94.96 -21.75 18.41 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.165 -0.959 . . . . 0.0 109.531 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 63.68 22.01 65.66 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.014 HG21 HD12 ' A' ' 36' ' ' LEU . 42.7 mm -95.07 91.79 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.271 -1.134 . . . . 0.0 109.465 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 22.9 mtpt -98.81 10.03 42.15 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.27 -0.894 . . . . 0.0 109.52 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -108.24 5.44 25.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.19 -0.944 . . . . 0.0 109.492 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.014 HD12 HG21 ' A' ' 33' ' ' ILE . 88.3 mt -117.78 -30.94 5.29 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.276 -0.89 . . . . 0.0 109.39 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.499 ' HA ' ' HG2' ' A' ' 64' ' ' MET . 73.0 t -114.68 129.35 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.309 -0.869 . . . . 0.0 109.305 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.73 -129.89 6.84 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 23.4 mtt-85 -90.44 147.89 23.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.274 -1.133 . . . . 0.0 109.777 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 1.061 HG23 HG22 ' A' ' 62' ' ' VAL . 59.9 mt -113.32 136.61 49.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.337 -0.852 . . . . 0.0 109.383 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.575 ' CG1' ' HB2' ' A' ' 61' ' ' PHE . 9.3 p -130.4 158.29 42.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.199 -0.938 . . . . 0.0 109.54 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.773 HG22 HG23 ' A' ' 44' ' ' ILE . 3.3 mt -131.78 129.05 21.86 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.28 -0.887 . . . . 0.0 109.559 -179.825 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.533 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 46.1 Cg_endo -67.2 -4.73 12.19 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.788 2.325 . . . . 0.0 111.587 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.773 HG23 HG22 ' A' ' 42' ' ' ILE . 12.7 pt -78.08 -17.81 13.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.299 -0.876 . . . . 0.0 109.451 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.98 ' O ' HD21 ' A' ' 104' ' ' LEU . 60.0 mtt-85 -54.21 150.16 8.79 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.249 -0.907 . . . . 0.0 109.485 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 150.94 160.91 9.67 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 53.7 -119.7 11.88 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 16.3 mt-30 -103.65 146.66 28.25 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.266 -1.138 . . . . 0.0 109.446 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -57.32 -33.12 67.38 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.217 -0.927 . . . . 0.0 109.544 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -66.81 -33.05 74.75 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.236 -0.915 . . . . 0.0 109.292 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 8.4 mmtp -100.98 148.64 24.79 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.316 -0.865 . . . . 0.0 109.384 179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 6.1 p -146.18 115.83 7.22 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.313 -0.867 . . . . 0.0 109.396 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.505 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 55.4 mm-40 -77.92 -31.3 51.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.305 -0.872 . . . . 0.0 109.545 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.703 ' HA ' HG22 ' A' ' 44' ' ' ILE . 47.6 mttt 74.86 85.71 0.1 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.3 -0.875 . . . . 0.0 109.42 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.533 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 6.7 mp -61.55 -26.8 68.18 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.097 -1.002 . . . . 0.0 109.527 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.616 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 97.2 m-85 -145.83 103.8 4.2 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.272 -0.893 . . . . 0.0 109.31 179.778 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 43.5 Cg_endo -67.17 137.75 44.96 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.666 2.244 . . . . 0.0 111.865 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.91 -9.28 6.68 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.674 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.2 m-85 -103.49 132.65 49.56 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.795 -1.415 . . . . 0.0 109.82 -179.511 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.604 ' HB ' HG12 ' A' ' 10' ' ' VAL . 4.9 t -135.58 148.65 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.354 -0.841 . . . . 0.0 108.923 179.41 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.575 ' HB2' ' CG1' ' A' ' 41' ' ' VAL . 63.3 m-85 -107.87 121.65 45.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.073 -1.017 . . . . 0.0 109.764 -179.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 1.061 HG22 HG23 ' A' ' 40' ' ' ILE . 57.6 t -129.06 141.14 47.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.357 -0.839 . . . . 0.0 109.699 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.618 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 52.4 tt0 -97.03 124.73 41.09 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.339 -0.851 . . . . 0.0 108.862 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.512 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 37.3 mtm -158.4 -179.82 8.45 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.147 -0.971 . . . . 0.0 109.777 -179.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.851 HD11 ' CD2' ' A' ' 36' ' ' LEU . 8.5 pt -102.64 129.0 54.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.2 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.501 ' O ' ' HG3' ' A' ' 66' ' ' MET . 5.2 ptp -85.58 96.2 9.57 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.129 -0.982 . . . . 0.0 109.668 -179.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.598 ' O ' ' CD2' ' A' ' 71' ' ' TYR . 23.0 t-20 -140.04 170.48 15.78 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 80.3 m-20 -52.81 -47.58 67.53 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.038 -1.039 . . . . 0.0 109.987 -179.507 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.458 ' O ' ' C ' ' A' ' 70' ' ' ALA . 64.6 mm-40 -64.87 -64.34 0.89 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.095 -1.003 . . . . 0.0 110.132 -179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.854 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -39.77 -38.8 0.69 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.263 -0.898 . . . . 0.0 109.926 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.598 ' CD2' ' O ' ' A' ' 67' ' ' ASN . 15.4 m-85 -61.11 -62.16 2.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.226 -0.921 . . . . 0.0 109.362 179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -45.76 -34.9 3.93 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.503 -0.748 . . . . 0.0 110.412 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 45.0 m-85 -81.39 -43.85 18.39 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.888 -1.133 . . . . 0.0 110.136 -179.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.995 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 45.4 t -64.43 -58.67 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.25 -0.906 . . . . 0.0 109.643 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -35.05 19.23 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.366 -0.834 . . . . 0.0 110.034 -179.589 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 53.6 p -78.16 4.89 11.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.083 -1.01 . . . . 0.0 110.37 -179.279 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.611 ' CG1' ' CG2' ' A' ' 80' ' ' VAL . 41.1 t -64.32 133.62 95.71 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 120.872 -1.143 . . . . 0.0 109.286 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.569 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 46.1 Cg_endo -68.27 134.83 32.43 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.702 2.268 . . . . 0.0 112.02 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.569 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 60.2 m-85 77.61 -1.54 2.66 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.525 -0.734 . . . . 0.0 109.855 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.611 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.4 t -88.6 127.32 41.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.173 -0.955 . . . . 0.0 109.147 179.609 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 82.5 mmm -90.77 -17.97 25.74 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.21 -0.931 . . . . 0.0 109.645 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.592 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 151.71 -155.61 26.23 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.995 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 3.6 m-85 -140.04 152.67 46.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.228 -1.16 . . . . 0.0 109.5 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.571 HG22 HD21 ' A' ' 11' ' ' LEU . 4.6 t -77.27 119.58 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.291 -0.881 . . . . 0.0 109.275 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.556 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.9 p -156.49 162.17 39.98 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.227 -0.92 . . . . 0.0 109.596 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -91.78 -34.8 14.45 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.282 -0.887 . . . . 0.0 109.393 179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -122.09 -86.33 0.83 Allowed Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.545 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -107.04 -130.37 6.43 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.545 ' O ' ' O ' ' A' ' 88' ' ' GLY . 0.1 OUTLIER -33.82 156.4 0.04 OUTLIER Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 121.43 -1.041 . . . . 0.0 110.056 -179.693 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.556 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.9 Cg_endo -69.71 157.74 59.44 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 122.492 2.128 . . . . 0.0 112.109 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.402 ' H ' HG22 ' A' ' 91' ' ' VAL . 10.9 m -90.15 153.64 46.83 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.351 -0.843 . . . . 0.0 109.452 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.453 ' HB3' ' HB3' ' A' ' 6' ' ' LYS . 49.1 Cg_endo -69.81 145.48 56.99 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.658 2.239 . . . . 0.0 111.812 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.932 HG23 ' O ' ' A' ' 7' ' ' TRP . 7.6 t -84.22 129.69 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.235 -0.915 . . . . 0.0 109.194 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . 0.414 ' O ' ' C ' ' A' ' 95' ' ' ASP . 23.6 tttt -70.56 132.77 46.0 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.191 -0.943 . . . . 0.0 109.578 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 94' ' ' LYS . 80.5 m-20 -44.48 -39.86 5.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.205 -0.934 . . . . 0.0 109.356 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.5 ' CZ ' ' HB3' ' A' ' 96' ' ' ARG . 13.4 mtp-105 -53.79 -35.51 61.44 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.272 -0.893 . . . . 0.0 109.374 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.446 ' O ' ' HD2' ' A' ' 100' ' ' PRO . 65.2 mt-10 -84.73 -27.48 26.94 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.269 -0.894 . . . . 0.0 109.372 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.628 ' CE ' ' CG ' ' A' ' 7' ' ' TRP . 94.4 mtp -84.98 -12.31 53.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.295 -0.878 . . . . 0.0 109.505 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.667 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -51.18 -48.42 85.46 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.171 -0.956 . . . . 0.0 109.853 179.864 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.667 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.5 Cg_endo -70.82 -27.6 21.22 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 122.485 2.123 . . . . 0.0 111.861 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.439 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 35.8 mm -81.52 -44.4 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.144 -0.972 . . . . 0.0 109.565 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.601 HD12 ' O ' ' A' ' 98' ' ' MET . 0.7 OUTLIER -66.46 -38.76 88.06 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.232 -0.917 . . . . 0.0 109.256 -179.926 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.524 ' CZ ' ' NH1' ' A' ' 99' ' ' ARG . 67.7 mtt180 -65.47 -50.16 66.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.429 -0.794 . . . . 0.0 109.322 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.98 HD21 ' O ' ' A' ' 45' ' ' ARG . 0.6 OUTLIER -72.64 -36.24 67.96 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.273 -0.892 . . . . 0.0 109.364 179.762 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.535 ' HB1' ' CG2' ' A' ' 41' ' ' VAL . . . -73.44 -0.99 16.52 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.371 -0.831 . . . . 0.0 109.687 -179.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 74.03 11.6 81.44 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.452 ' HB2' ' HA ' ' A' ' 102' ' ' LEU . 61.3 mt -85.51 -24.11 27.45 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.128 -1.219 . . . . 0.0 109.428 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.46 ' HB2' ' HB2' ' A' ' 102' ' ' LEU . 73.5 tt0 -116.9 160.92 20.16 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.283 -0.886 . . . . 0.0 109.591 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -100.05 120.32 39.65 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.274 -0.891 . . . . 0.0 109.405 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.582 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 46.9 p90 -133.77 168.07 19.38 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.236 -0.915 . . . . 0.0 109.505 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.582 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 41.4 mt-10 -79.23 -147.56 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.258 -0.901 . . . . 0.0 109.592 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -111.77 -49.48 2.98 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.19 -0.944 . . . . 0.0 109.316 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.457 ' HE3' ' HB3' ' A' ' 116' ' ' PRO . 31.0 pttt -151.9 140.94 21.2 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.326 -0.859 . . . . 0.0 109.325 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.49 ' CB ' ' O ' ' A' ' 132' ' ' ILE . 5.3 tttt -74.79 -54.14 7.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.181 -0.949 . . . . 0.0 109.593 -179.787 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.626 ' HG3' HD12 ' A' ' 132' ' ' ILE . 10.5 mttt -103.57 96.96 9.55 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.243 -0.911 . . . . 0.0 109.545 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . 0.482 ' HD3' ' O ' ' A' ' 114' ' ' LYS . 52.2 Cg_endo -73.49 -4.72 15.9 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.911 2.408 . . . . 0.0 111.651 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.34 142.15 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.225 -0.922 . . . . 0.0 109.366 -179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.461 ' HG2' ' N ' ' A' ' 119' ' ' VAL . 50.3 tttp -50.51 157.17 0.77 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.118 -0.989 . . . . 0.0 109.487 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.461 ' N ' ' HG2' ' A' ' 118' ' ' LYS . 60.8 t -121.31 144.4 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.289 -0.882 . . . . 0.0 109.48 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.659 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 83.6 mt-10 -129.81 168.6 16.33 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.235 -0.916 . . . . 0.0 109.365 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.659 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 2.0 mt 145.82 100.58 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.973 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.617 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.53 93.17 0.01 OUTLIER Glycine 0 N--CA 1.496 2.662 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.496 ' N ' ' O ' ' A' ' 121' ' ' LEU . 3.6 p90 -96.71 149.71 21.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.2 -1.177 . . . . 0.0 109.489 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 22.4 mttt -149.02 157.29 43.3 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.221 -0.925 . . . . 0.0 109.52 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.613 HG13 ' O ' ' A' ' 144' ' ' LYS . 44.7 t -60.33 140.04 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 87.85 -34.12 3.81 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.768 ' HB3' HD12 ' A' ' 143' ' ' ILE . 43.0 t0 -48.51 157.68 0.34 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.431 -1.041 . . . . 0.0 109.465 -179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . 0.442 ' HG2' HD12 ' A' ' 176' ' ' ILE . 4.8 ttm -96.07 127.5 42.13 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.244 -0.91 . . . . 0.0 108.861 179.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 1.021 HG13 ' O ' ' A' ' 174' ' ' GLU . 51.3 t -126.44 142.08 44.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 O-C-N 121.256 -0.903 . . . . 0.0 109.42 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . . . . . . . . . 5.8 ttpp -101.95 142.85 32.6 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.376 -0.828 . . . . 0.0 109.065 179.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.86 HD12 ' HB3' ' A' ' 139' ' ' PHE . 70.8 mt -82.9 151.35 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.042 -1.036 . . . . 0.0 108.761 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.669 HD13 ' CD ' ' A' ' 174' ' ' GLU . 33.2 pt -148.99 2.95 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.95 -1.093 . . . . 0.0 109.503 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.559 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 68.8 m -146.35 141.76 27.57 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.11 -0.994 . . . . 0.0 109.712 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.423 ' N ' ' HG3' ' A' ' 137' ' ' GLU . . . 107.04 -170.85 16.16 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.581 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.52 -18.91 43.23 Favored 'Trans proline' 0 C--O 1.216 -0.607 0 C-N-CA 123.213 2.609 . . . . 0.0 112.797 -179.445 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.529 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 97.9 m-85 -108.94 19.11 19.97 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.964 -1.085 . . . . 0.0 109.487 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.559 ' HA ' HG22 ' A' ' 131' ' ' ILE . 43.8 mt-10 -41.31 141.85 0.64 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 110.22 -179.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 138' ' ' ASP . 0.5 OUTLIER 76.03 24.39 1.19 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.299 -0.875 . . . . 0.0 110.757 179.002 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.86 ' HB3' HD12 ' A' ' 131' ' ' ILE . 0.5 OUTLIER -111.73 129.32 56.15 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.828 -1.17 . . . . 0.0 109.729 179.912 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.401 ' N ' ' HD1' ' A' ' 139' ' ' PHE . . . -76.46 134.8 39.44 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.905 . . . . 0.0 109.392 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -143.79 166.62 26.94 Favored Glycine 0 N--CA 1.489 2.221 0 C-N-CA 119.718 -1.23 . . . . 0.0 110.164 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.814 ' C ' HG23 ' A' ' 155' ' ' VAL . 47.0 t -116.16 137.34 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.591 -0.946 . . . . 0.0 109.256 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.768 HD12 ' HB3' ' A' ' 127' ' ' ASP . 88.6 mt -70.39 120.49 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.305 -0.872 . . . . 0.0 109.268 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.613 ' O ' HG13 ' A' ' 125' ' ' VAL . 75.0 tttt -103.65 -33.07 9.1 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.964 -1.085 . . . . 0.0 109.711 -179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.519 ' HG2' ' O ' ' A' ' 144' ' ' LYS . 15.5 mt-10 -150.5 145.66 26.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.058 -1.027 . . . . 0.0 109.845 -179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 1.032 HG23 HD11 ' A' ' 153' ' ' LEU . 0.9 OUTLIER -115.44 117.91 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.218 -0.926 . . . . 0.0 108.973 179.542 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -106.64 98.13 19.46 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.156 -0.965 . . . . 0.0 109.785 -179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.55 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.5 Cg_endo -72.33 173.65 12.76 Favored 'Trans proline' 0 C--O 1.216 -0.588 0 C-N-CA 122.675 2.25 . . . . 0.0 111.734 179.754 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.55 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 4.5 mt-10 78.98 -22.06 0.3 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.26 -0.9 . . . . 0.0 109.876 179.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.441 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 40.8 mtm180 -126.33 -16.78 5.34 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.039 -1.038 . . . . 0.0 109.3 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.441 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 6.0 mt-30 71.04 47.54 0.41 Allowed 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.3 -0.875 . . . . 0.0 109.511 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.704 ' OE2' HG13 ' A' ' 167' ' ' VAL . 64.9 tt0 -116.44 139.83 50.01 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.124 -0.985 . . . . 0.0 108.885 179.651 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 1.032 HD11 HG23 ' A' ' 146' ' ' ILE . 2.7 mm? -124.88 111.79 15.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.153 -0.967 . . . . 0.0 110.108 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.441 ' HD3' ' HB2' ' A' ' 145' ' ' GLU . 17.2 mtpp -78.02 122.68 25.88 Favored 'General case' 0 N--CA 1.489 1.486 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.814 HG23 ' C ' ' A' ' 142' ' ' VAL . 10.4 p -126.92 149.27 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.039 -1.038 . . . . 0.0 109.904 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 1.9 t-20 -97.99 110.54 23.09 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.439 -0.788 . . . . 0.0 109.488 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.577 HG13 ' CD1' ' A' ' 139' ' ' PHE . 87.1 t -96.38 144.64 10.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.2 -0.938 . . . . 0.0 109.268 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 96.1 m -102.92 111.93 24.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.157 -0.965 . . . . 0.0 109.995 -179.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.616 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 2.9 mt -133.22 143.24 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.276 -0.89 . . . . 0.0 109.036 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.431 ' O ' ' HG3' ' A' ' 162' ' ' ARG . 11.9 m-85 62.18 43.37 8.65 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.241 -0.912 . . . . 0.0 109.152 -179.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 54.35 16.15 6.45 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 179.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.431 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 15.8 mtt-85 -126.59 160.05 31.79 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.036 -1.273 . . . . 0.0 109.54 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -100.93 127.88 47.22 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.25 -0.907 . . . . 0.0 109.687 -179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 43.3 m -136.91 121.22 12.39 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 0.0 109.606 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.538 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -70.34 136.57 31.75 Favored 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 122.755 2.304 . . . . 0.0 111.541 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.982 HG13 HD11 ' A' ' 168' ' ' LEU . 3.6 p -125.74 144.24 36.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.035 -1.041 . . . . 0.0 110.165 -179.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.704 HG13 ' OE2' ' A' ' 152' ' ' GLU . 51.1 t -95.51 120.15 44.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.554 -0.716 . . . . 0.0 109.465 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.982 HD11 HG13 ' A' ' 166' ' ' VAL . 0.1 OUTLIER -141.01 168.38 19.93 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.204 -0.935 . . . . 0.0 110.518 -179.44 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.442 ' CD2' ' OE1' ' A' ' 172' ' ' GLU . 90.7 m-70 -79.45 144.59 33.9 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.829 ' HB ' HD23 ' A' ' 153' ' ' LEU . 9.6 p -58.68 -35.49 55.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.121 -0.987 . . . . 0.0 108.822 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.411 ' N ' HG13 ' A' ' 170' ' ' VAL . 53.0 p -75.69 -6.67 51.64 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.43 -0.794 . . . . 0.0 109.115 179.541 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.559 ' CG ' ' HB2' ' A' ' 133' ' ' SER . 1.2 mt-10 -88.65 2.85 52.48 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.289 -0.882 . . . . 0.0 109.44 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.453 ' CG2' HG11 ' A' ' 129' ' ' VAL . 2.9 m -152.03 176.54 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.218 -0.926 . . . . 0.0 109.293 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 1.021 ' O ' HG13 ' A' ' 129' ' ' VAL . 5.5 mt-10 -141.54 172.73 12.28 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.141 -0.974 . . . . 0.0 109.01 179.82 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.498 ' CE ' ' OD2' ' A' ' 127' ' ' ASP . 24.4 tttt -89.83 3.24 53.52 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.091 -1.006 . . . . 0.0 109.37 179.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.452 ' HB ' ' O ' ' A' ' 175' ' ' LYS . 22.1 mt 67.92 -65.66 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.291 -0.881 . . . . 0.0 109.387 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 175' ' ' LYS . 96.5 mt-10 . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.446 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.248 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.99 -25.16 65.28 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.233 -1.157 . . . . 0.0 109.455 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 90.7 mmm -62.66 -20.41 64.79 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.258 -0.902 . . . . 0.0 109.463 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 73.8 mttt -95.35 124.23 39.28 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.241 -0.912 . . . . 0.0 109.43 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.627 ' HG2' HG22 ' A' ' 65' ' ' ILE . 33.0 mttt -94.31 137.46 33.44 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.228 -0.92 . . . . 0.0 109.546 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.585 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 15.7 mtpp -126.41 175.82 7.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.361 -0.837 . . . . 0.0 109.52 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.792 ' CZ3' HG23 ' A' ' 41' ' ' VAL . 46.6 m95 -110.47 126.72 54.64 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.225 -0.922 . . . . 0.0 109.278 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -115.53 164.46 14.27 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.232 -0.918 . . . . 0.0 109.472 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.542 HG12 ' CE1' ' A' ' 61' ' ' PHE . 62.0 mt -106.03 115.29 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.16 -0.962 . . . . 0.0 109.021 179.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.493 HG13 ' CE1' ' A' ' 83' ' ' PHE . 92.2 t -92.09 138.25 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.237 -0.914 . . . . 0.0 109.626 -179.719 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.518 HD22 ' N ' ' A' ' 11' ' ' LEU . 4.0 mm? -92.78 146.5 23.6 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.321 -0.862 . . . . 0.0 109.209 179.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.574 ' OG1' HG21 ' A' ' 20' ' ' VAL . 12.6 t -157.22 -177.97 7.01 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.187 -0.945 . . . . 0.0 109.376 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.515 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 49.0 mtm -96.72 130.39 43.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.182 -0.949 . . . . 0.0 109.504 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.5 p -50.87 129.37 23.17 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.912 . . . . 0.0 109.544 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.84 -20.27 36.67 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.515 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 80.3 m-85 -108.83 -5.2 16.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.214 -1.168 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.733 ' OE1' HD11 ' A' ' 44' ' ' ILE . 88.9 mt-10 -46.72 -52.48 13.82 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.253 -0.904 . . . . 0.0 109.554 -179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 85.8 mt-10 -55.11 -36.19 65.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.221 -0.925 . . . . 0.0 109.465 179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 60.7 mttp -74.55 -31.37 62.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.256 -0.903 . . . . 0.0 109.291 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.574 HG21 ' OG1' ' A' ' 12' ' ' THR . 51.6 t -67.64 -48.78 75.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.34 -0.85 . . . . 0.0 109.353 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.582 ' HB2' HD11 ' A' ' 42' ' ' ILE . 29.9 tttm -59.05 -44.48 91.82 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.273 -0.892 . . . . 0.0 109.302 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -65.13 -45.08 86.51 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.906 . . . . 0.0 109.275 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.954 ' OD1' HG22 ' A' ' 77' ' ' VAL . 1.1 t-20 -51.78 -38.82 57.11 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.315 -0.866 . . . . 0.0 109.402 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.586 HG21 HD11 ' A' ' 40' ' ' ILE . 65.9 mt -68.89 -44.29 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.252 -0.905 . . . . 0.0 109.764 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 41.9 tp10 -55.18 -49.13 72.66 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.047 -1.033 . . . . 0.0 109.858 -179.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 23.6 mttm -75.22 -34.42 61.47 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.105 -0.997 . . . . 0.0 109.456 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.926 ' CD ' HG23 ' A' ' 77' ' ' VAL . 33.1 tttm -55.62 -36.2 66.72 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.325 -0.86 . . . . 0.0 109.205 179.774 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.739 HG13 ' O ' ' A' ' 33' ' ' ILE . 84.0 t -83.07 -24.0 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.294 -0.879 . . . . 0.0 109.601 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 -69.9 -55.12 10.53 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.279 -0.888 . . . . 0.0 109.485 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.74 -38.92 50.43 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.291 -0.881 . . . . 0.0 109.412 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.403 ' CB ' HG13 ' A' ' 33' ' ' ILE . 82.6 p -98.54 0.1 44.34 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.271 -0.893 . . . . 0.0 109.513 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 46.82 34.42 7.13 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.069 HG21 HD12 ' A' ' 36' ' ' LEU . 37.4 mt -92.6 75.34 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.331 -1.099 . . . . 0.0 109.498 -179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -90.19 24.92 2.34 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.211 -0.931 . . . . 0.0 109.049 179.69 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 85.9 m-20 -117.25 -24.29 7.52 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.346 -0.846 . . . . 0.0 109.456 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.091 HD23 HD11 ' A' ' 65' ' ' ILE . 22.9 mt -92.11 -29.29 16.6 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.282 -0.886 . . . . 0.0 109.419 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.433 ' HA ' ' HG2' ' A' ' 64' ' ' MET . 38.9 t -110.43 129.35 65.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.368 -0.833 . . . . 0.0 109.04 179.728 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.51 -124.37 5.42 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 77.5 mtt180 -92.23 146.85 23.39 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.273 -1.133 . . . . 0.0 109.859 -179.431 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.901 HG12 HG23 ' A' ' 62' ' ' VAL . 55.7 mt -113.64 135.27 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.397 -0.815 . . . . 0.0 109.15 179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.884 HG21 HD11 ' A' ' 107' ' ' LEU . 17.3 t -128.76 159.31 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.116 -0.99 . . . . 0.0 109.643 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.582 HD11 ' HB2' ' A' ' 21' ' ' LYS . 12.3 mt -144.36 128.67 9.13 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.471 -0.768 . . . . 0.0 109.359 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.544 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 44.0 Cg_endo -66.32 -6.19 14.34 Favored 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 122.713 2.275 . . . . 0.0 111.43 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.733 HD11 ' OE1' ' A' ' 17' ' ' GLU . 14.5 mt -45.58 -47.45 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.406 -0.808 . . . . 0.0 109.397 179.749 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.436 ' C ' ' O ' ' A' ' 44' ' ' ILE . 24.8 mtt-85 -42.6 160.21 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.259 -0.901 . . . . 0.0 109.561 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 113.66 133.36 5.72 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.92 -150.24 19.4 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -95.68 149.94 20.92 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.174 -1.192 . . . . 0.0 109.505 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 55.3 ttt-85 -62.81 -37.14 85.56 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.471 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 50.7 mtt180 -55.3 -43.0 74.43 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.909 . . . . 0.0 109.432 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 17.1 tttm -140.01 113.88 8.83 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.327 -0.858 . . . . 0.0 109.441 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 1.7 t -85.25 151.68 23.88 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.31 -0.869 . . . . 0.0 109.476 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.531 ' C ' ' HG3' ' A' ' 54' ' ' LYS . 81.5 mt-10 -100.03 -39.39 8.14 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.198 -0.939 . . . . 0.0 109.471 -179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.58 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 69.2 mttt 74.06 114.17 0.06 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.18 -0.95 . . . . 0.0 109.388 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.548 ' HB3' ' CE2' ' A' ' 56' ' ' PHE . 6.7 mp -52.7 -47.3 67.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.226 -0.921 . . . . 0.0 109.379 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.632 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 3.2 m-85 -139.23 113.0 8.08 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.14 -0.975 . . . . 0.0 109.374 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -65.67 146.26 83.66 Favored 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 122.546 2.164 . . . . 0.0 111.471 -179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 73.04 -13.56 3.26 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.533 ' HB2' ' HB2' ' A' ' 56' ' ' PHE . 1.9 m-85 -93.69 129.28 40.07 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.883 -1.363 . . . . 0.0 110.044 -179.422 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.502 HG13 HG12 ' A' ' 42' ' ' ILE . 41.9 t -134.69 142.82 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.202 179.703 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.688 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 76.7 m-85 -108.05 124.97 51.0 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.127 -0.983 . . . . 0.0 109.826 -179.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.901 HG23 HG12 ' A' ' 40' ' ' ILE . 3.6 p -130.33 142.2 44.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.345 -0.847 . . . . 0.0 109.868 -179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.613 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 37.7 tt0 -103.4 124.62 49.05 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.215 -0.928 . . . . 0.0 108.844 179.434 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.505 ' HE1' HG21 ' A' ' 74' ' ' VAL . 41.8 mtm -153.47 169.09 24.03 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.92 -1.113 . . . . 0.0 110.648 -179.259 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 1.091 HD11 HD23 ' A' ' 36' ' ' LEU . 5.4 pt -94.49 130.07 43.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.47 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 36.8 ttm -77.15 144.54 38.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.318 -0.864 . . . . 0.0 109.973 -178.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.47 ' HB2' ' O ' ' A' ' 66' ' ' MET . 35.3 t30 176.81 171.6 0.47 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.677 -0.639 . . . . 0.0 109.289 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -69.27 -42.53 75.41 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.228 -0.92 . . . . 0.0 109.402 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -75.85 -29.17 58.47 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.309 -0.869 . . . . 0.0 109.71 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.733 ' HB2' HD22 ' A' ' 36' ' ' LEU . . . -75.27 -47.54 27.51 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.121 -0.987 . . . . 0.0 109.418 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 56.3 t80 -59.97 -46.49 89.26 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.291 -0.88 . . . . 0.0 109.504 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.451 ' O ' ' HB3' ' A' ' 76' ' ' SER . 23.4 m120 -68.18 -26.22 65.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.327 -0.858 . . . . 0.0 109.962 -179.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.476 ' CE1' ' NZ ' ' A' ' 27' ' ' LYS . 22.6 t80 -83.42 -42.76 16.61 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.03 -1.044 . . . . 0.0 109.915 -179.675 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.76 HG22 ' CZ ' ' A' ' 83' ' ' PHE . 7.4 p -67.89 -55.71 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.405 -0.81 . . . . 0.0 109.605 -179.503 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.674 ' N ' HG13 ' A' ' 74' ' ' VAL . 0.2 OUTLIER -57.99 -10.72 1.95 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.145 -0.972 . . . . 0.0 109.747 -179.934 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.451 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 25.6 p -93.24 4.89 53.23 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.073 -1.017 . . . . 0.0 109.98 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.954 HG22 ' OD1' ' A' ' 23' ' ' ASN . 0.4 OUTLIER -73.81 126.8 89.25 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.085 -1.009 . . . . 0.0 109.327 -179.978 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.629 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 42.7 Cg_endo -65.1 142.86 76.09 Favored 'Trans proline' 0 C--O 1.213 -0.752 0 C-N-CA 122.65 2.234 . . . . 0.0 111.898 -179.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.629 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 17.9 m-85 89.37 -12.79 0.37 Allowed 'General case' 0 N--CA 1.492 1.673 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.63 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 1.7 t -89.51 130.12 39.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.077 -1.014 . . . . 0.0 109.361 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 90.9 mmm -84.38 -27.33 27.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.32 -0.862 . . . . 0.0 109.311 179.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 161.35 -160.58 32.31 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.875 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.76 ' CZ ' HG22 ' A' ' 74' ' ' VAL . 14.9 m-85 -136.23 140.24 43.35 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.272 -1.134 . . . . 0.0 109.341 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.536 HG13 ' O ' ' A' ' 84' ' ' VAL . 7.7 p -66.35 125.09 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.122 -0.986 . . . . 0.0 109.405 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.547 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.6 p -163.72 159.08 21.05 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.211 -0.931 . . . . 0.0 109.573 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -86.23 -33.85 20.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.272 -0.893 . . . . 0.0 109.314 179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.23 -87.59 0.71 Allowed Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.547 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -108.85 -125.86 5.24 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.547 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.1 OUTLIER -31.17 147.27 0.05 OUTLIER Pre-proline 0 N--CA 1.495 1.776 0 O-C-N 121.614 -0.933 . . . . 0.0 110.015 -179.819 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.547 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.3 Cg_endo -69.2 154.29 70.19 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.8 2.334 . . . . 0.0 112.081 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . 0.905 HG12 ' HD2' ' A' ' 92' ' ' PRO . 0.2 OUTLIER -86.97 147.7 43.6 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.308 -0.87 . . . . 0.0 109.25 179.849 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.905 ' HD2' HG12 ' A' ' 91' ' ' VAL . 48.7 Cg_endo -69.24 150.6 71.58 Favored 'Trans proline' 0 C--O 1.215 -0.655 0 C-N-CA 122.626 2.217 . . . . 0.0 111.82 -179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 7' ' ' TRP . 5.3 t -83.57 135.66 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.911 . . . . 0.0 109.621 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 19.1 mttt -72.86 136.05 45.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.346 -0.846 . . . . 0.0 109.393 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -47.94 -36.91 13.24 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.21 -0.931 . . . . 0.0 109.578 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 73.4 mtt85 -56.59 -37.14 70.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.571 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 62.7 mt-10 -83.36 -24.24 32.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.25 -0.906 . . . . 0.0 109.608 -179.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.49 ' O ' ' C ' ' A' ' 99' ' ' ARG . 56.5 mtp -84.39 -29.6 26.07 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.142 -0.974 . . . . 0.0 109.495 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.597 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 31.6 ttt85 -37.01 -53.81 1.9 Allowed Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.344 -0.848 . . . . 0.0 109.931 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.597 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -68.82 -27.8 30.82 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.497 2.132 . . . . 0.0 111.777 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.509 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 19.5 mm -80.66 -41.7 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.24 -0.912 . . . . 0.0 109.248 179.71 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.59 ' CD1' ' N ' ' A' ' 102' ' ' LEU . 3.7 mp -68.52 -40.71 80.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.304 -0.872 . . . . 0.0 109.193 179.775 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.614 ' HG3' ' CD1' ' A' ' 110' ' ' TYR . 34.0 ttt180 -64.25 -50.34 68.35 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.278 -0.889 . . . . 0.0 109.347 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.86 -36.88 70.25 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.35 -0.844 . . . . 0.0 109.272 179.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.509 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -72.21 0.6 9.39 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.854 -179.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 77.26 8.32 86.98 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.884 HD11 HG21 ' A' ' 41' ' ' VAL . 19.2 mt -79.88 -22.53 42.74 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.134 -1.215 . . . . 0.0 109.511 179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.485 ' HB2' ' HA ' ' A' ' 103' ' ' ARG . 10.3 mt-10 -107.51 143.91 35.24 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.228 -0.92 . . . . 0.0 109.459 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -96.84 120.1 36.54 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.24 -0.913 . . . . 0.0 109.451 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.614 ' CD1' ' HG3' ' A' ' 103' ' ' ARG . 43.6 p90 -150.21 174.62 12.6 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.241 -0.912 . . . . 0.0 109.567 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.521 ' O ' ' CB ' ' A' ' 112' ' ' GLU . 92.4 mt-10 -101.55 -91.74 0.32 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.269 -0.894 . . . . 0.0 109.418 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.521 ' CB ' ' O ' ' A' ' 111' ' ' GLU . 30.9 tt0 163.76 161.72 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.291 -0.881 . . . . 0.0 109.245 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.542 ' HB3' ' CB ' ' A' ' 133' ' ' SER . 0.0 OUTLIER -119.81 134.15 55.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.202 -0.936 . . . . 0.0 109.394 -179.941 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 18.0 tttm -159.81 103.51 1.52 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.194 -0.941 . . . . 0.0 109.466 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -85.29 143.75 39.73 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.192 -0.943 . . . . 0.0 109.437 179.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.81 -2.18 9.77 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 122.643 2.228 . . . . 0.0 111.847 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 1.9 t -107.08 124.61 62.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -0.924 . . . . 0.0 109.39 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.435 ' HA ' ' OG ' ' A' ' 171' ' ' SER . 27.3 mttm -68.19 128.82 37.97 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.245 -0.909 . . . . 0.0 109.336 179.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.56 ' O ' HG12 ' A' ' 170' ' ' VAL . 30.3 t -100.93 128.97 52.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.22 -0.925 . . . . 0.0 109.581 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.582 ' HA ' ' CE2' ' A' ' 123' ' ' PHE . 82.3 mt-10 -159.44 -167.48 2.05 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.33 -0.857 . . . . 0.0 109.095 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.547 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 0.2 OUTLIER 78.47 162.57 0.21 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.362 -0.837 . . . . 0.0 109.912 179.61 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.406 ' H ' HD13 ' A' ' 121' ' ' LEU . . . 44.59 26.46 1.07 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 110.301 -1.119 . . . . 0.0 110.301 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.582 ' CE2' ' HA ' ' A' ' 120' ' ' GLU . 22.8 m-30 -115.17 116.51 28.49 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.083 -1.245 . . . . 0.0 108.879 178.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 50.9 mttt -130.89 153.83 48.72 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.155 -0.966 . . . . 0.0 109.863 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.512 HG23 ' O ' ' A' ' 144' ' ' LYS . 7.1 p -61.51 144.43 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.359 -0.838 . . . . 0.0 109.501 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 84.32 -33.38 3.19 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.587 ' HB3' HD12 ' A' ' 143' ' ' ILE . 34.3 t0 -50.16 161.27 0.29 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.368 -1.078 . . . . 0.0 109.397 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . 0.481 ' SD ' HD12 ' A' ' 176' ' ' ILE . 4.6 ttm -95.76 126.88 41.33 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.28 -0.887 . . . . 0.0 108.669 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.761 HG11 HG11 ' A' ' 155' ' ' VAL . 6.7 p -125.64 141.58 45.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.193 -0.942 . . . . 0.0 109.388 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.524 ' N ' ' O ' ' A' ' 174' ' ' GLU . 24.1 tttt -104.41 142.78 33.98 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.225 -0.922 . . . . 0.0 108.988 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.952 HD12 ' HB3' ' A' ' 139' ' ' PHE . 81.5 mt -82.3 153.62 4.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.448 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.848 HD13 ' CD ' ' A' ' 174' ' ' GLU . 17.9 pt -149.08 1.25 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 120.967 -1.083 . . . . 0.0 109.499 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.542 ' CB ' ' HB3' ' A' ' 113' ' ' LYS . 31.2 t -145.85 143.23 29.49 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.124 -0.985 . . . . 0.0 110.039 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.03 -168.91 15.3 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 179.318 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.58 ' HG2' ' CD2' ' A' ' 136' ' ' PHE . 47.5 Cg_endo -68.63 -18.15 42.77 Favored 'Trans proline' 0 C--O 1.215 -0.642 0 C-N-CA 123.365 2.71 . . . . 0.0 112.563 -179.565 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.58 ' CD2' ' HG2' ' A' ' 135' ' ' PRO . 73.1 m-85 -111.84 13.92 20.98 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.878 -1.139 . . . . 0.0 109.636 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.519 ' HG2' ' OD2' ' A' ' 138' ' ' ASP . 1.2 tt0 -41.56 148.09 0.16 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.277 -0.889 . . . . 0.0 109.55 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.519 ' OD2' ' HG2' ' A' ' 137' ' ' GLU . 17.0 m-20 72.54 28.14 2.26 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.34 -0.85 . . . . 0.0 110.268 179.505 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.952 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.1 t80 -117.74 131.51 56.59 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.029 -1.044 . . . . 0.0 109.414 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -82.24 134.15 35.28 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.123 -0.986 . . . . 0.0 109.6 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.513 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.9 172.93 25.59 Favored Glycine 0 N--CA 1.49 2.269 0 C-N-CA 119.78 -1.2 . . . . 0.0 110.305 -179.567 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 128' ' ' MET . 23.2 t -117.56 136.24 55.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.469 -1.018 . . . . 0.0 109.363 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.587 HD12 ' HB3' ' A' ' 127' ' ' ASP . 67.3 mt -66.33 115.25 4.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.299 -0.876 . . . . 0.0 109.184 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.512 ' O ' HG23 ' A' ' 125' ' ' VAL . 2.4 tttt -100.02 -35.53 9.67 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.04 -1.037 . . . . 0.0 109.615 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -152.8 147.66 26.3 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.142 -0.974 . . . . 0.0 109.622 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.816 HG23 ' CD1' ' A' ' 153' ' ' LEU . 3.1 mt -124.96 126.83 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.304 -0.872 . . . . 0.0 109.352 179.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -107.94 99.43 30.53 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.217 -0.927 . . . . 0.0 109.647 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.562 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 50.1 Cg_endo -70.3 171.93 14.12 Favored 'Trans proline' 0 C--O 1.216 -0.59 0 C-N-CA 122.681 2.254 . . . . 0.0 111.747 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.562 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.8 mt-10 81.06 -20.87 0.35 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.35 -0.844 . . . . 0.0 109.887 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.43 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 16.1 mtt-85 -128.83 -12.96 4.72 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.619 -179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.995 ' O ' HG23 ' A' ' 170' ' ' VAL . 29.4 mt-30 70.72 48.49 0.42 Allowed 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.271 -0.893 . . . . 0.0 109.636 179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -118.6 141.66 48.38 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.138 -0.976 . . . . 0.0 108.745 179.297 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.816 ' CD1' HG23 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -133.4 111.82 11.07 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.101 -0.999 . . . . 0.0 109.937 -179.537 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 21.1 mttt -80.61 129.5 34.55 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.761 HG11 HG11 ' A' ' 129' ' ' VAL . 35.4 m -123.61 152.54 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.059 -1.026 . . . . 0.0 109.715 -179.641 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.507 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 47.2 t-20 -96.53 108.56 21.16 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.385 -0.822 . . . . 0.0 109.431 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.73 HG12 ' O ' ' A' ' 164' ' ' THR . 2.2 p -92.02 140.19 16.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.282 -0.886 . . . . 0.0 109.162 179.888 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 84.9 m -99.79 99.16 9.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.271 -0.893 . . . . 0.0 109.952 -179.612 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.692 HG13 HG22 ' A' ' 157' ' ' VAL . 2.0 mt -122.45 143.66 34.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.296 -0.878 . . . . 0.0 109.092 179.548 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.688 ' CZ ' ' CZ ' ' A' ' 61' ' ' PHE . 85.0 m-85 61.72 39.38 14.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.241 -179.733 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.77 17.89 29.81 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.531 ' CZ ' ' OH ' ' A' ' 59' ' ' TYR . 25.2 mtt85 -127.26 156.72 41.45 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.106 -1.232 . . . . 0.0 109.568 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.431 ' HB3' ' OD1' ' A' ' 156' ' ' ASN . 91.3 mt-10 -99.92 130.72 46.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.219 -0.925 . . . . 0.0 109.471 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . 0.73 ' O ' HG12 ' A' ' 157' ' ' VAL . 16.1 m -140.52 121.64 9.21 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.285 -0.884 . . . . 0.0 109.732 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.523 ' HA ' ' O ' ' A' ' 155' ' ' VAL . 49.8 Cg_endo -70.02 138.21 36.48 Favored 'Trans proline' 0 C--O 1.215 -0.668 0 C-N-CA 122.697 2.264 . . . . 0.0 111.536 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . . . . . . . . . 4.4 p -126.89 145.65 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.117 -0.989 . . . . 0.0 109.815 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.591 HG13 ' O ' ' A' ' 167' ' ' VAL . 11.4 p -91.87 119.73 39.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.416 -0.802 . . . . 0.0 109.326 179.813 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.427 ' HG ' ' C ' ' A' ' 167' ' ' VAL . 12.3 mt -140.28 165.29 27.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 110.582 -179.16 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.628 ' O ' HG13 ' A' ' 173' ' ' VAL . 91.6 m-70 -79.07 147.0 32.95 Favored 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 121.345 0.593 . . . . 0.0 109.576 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.995 HG23 ' O ' ' A' ' 151' ' ' GLN . 4.4 t -63.16 -35.17 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.533 ' HA ' ' HB ' ' A' ' 119' ' ' VAL . 37.7 m -77.05 -7.12 55.13 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.467 -0.77 . . . . 0.0 109.295 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.517 ' CB ' ' HB3' ' A' ' 133' ' ' SER . 91.6 mt-10 -103.05 5.41 38.09 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.284 -0.885 . . . . 0.0 109.385 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.628 HG13 ' O ' ' A' ' 169' ' ' HIS . 2.7 m -129.69 160.29 40.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.19 -0.944 . . . . 0.0 109.58 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.848 ' CD ' HD13 ' A' ' 132' ' ' ILE . 28.8 mt-10 -133.16 150.8 52.0 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.295 -0.878 . . . . 0.0 109.048 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 129' ' ' VAL . 4.2 pttm -93.13 21.42 5.89 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.094 -1.004 . . . . 0.0 109.514 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.591 HG22 ' N ' ' A' ' 177' ' ' GLU . 27.4 mt 54.64 170.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.192 -0.943 . . . . 0.0 109.547 179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.591 ' N ' HG22 ' A' ' 176' ' ' ILE . 85.8 tt0 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.462 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.235 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 47.32 34.92 3.46 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.287 -1.125 . . . . 0.0 109.466 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 60.4 mtm -73.91 -9.67 58.87 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.174 -0.954 . . . . 0.0 109.458 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 25.7 mttt -107.79 122.26 46.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.275 -0.891 . . . . 0.0 109.465 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.808 ' HG2' HG22 ' A' ' 65' ' ' ILE . 83.5 mttt -100.93 143.42 31.1 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.222 -0.924 . . . . 0.0 109.495 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.574 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 41.2 mmtm -130.24 174.52 9.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.399 -0.813 . . . . 0.0 109.539 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.782 ' CH2' HG23 ' A' ' 41' ' ' VAL . 40.3 m95 -105.56 125.4 50.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.293 -0.879 . . . . 0.0 109.011 179.664 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 52.0 m-85 -115.48 166.35 11.99 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.11 -0.994 . . . . 0.0 109.343 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.568 HG12 ' CD1' ' A' ' 61' ' ' PHE . 55.8 mt -110.87 112.15 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.194 -0.941 . . . . 0.0 109.087 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.632 HG12 ' CD2' ' A' ' 83' ' ' PHE . 20.3 m -90.51 141.1 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.171 -0.956 . . . . 0.0 109.496 -179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.534 HD13 ' HA ' ' A' ' 11' ' ' LEU . 0.1 OUTLIER -85.98 145.07 27.28 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.424 -0.797 . . . . 0.0 109.401 -179.926 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.7 p -149.63 -173.74 4.49 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.182 -0.949 . . . . 0.0 109.507 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.49 ' HB2' ' CD1' ' A' ' 16' ' ' TYR . 70.9 mtp -107.81 128.89 55.0 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.21 -0.931 . . . . 0.0 109.738 -179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 7.5 m -47.65 119.82 2.98 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.261 -0.899 . . . . 0.0 109.279 179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.59 -20.26 27.63 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.49 ' CD1' ' HB2' ' A' ' 13' ' ' MET . 94.5 m-85 -105.58 -16.36 14.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.198 -1.177 . . . . 0.0 109.496 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.429 ' C ' ' O ' ' A' ' 16' ' ' TYR . 49.7 mt-10 -44.0 -62.04 1.26 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.193 -0.942 . . . . 0.0 109.345 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -49.54 -38.83 32.37 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.215 -0.928 . . . . 0.0 109.206 179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 83.9 mttt -66.73 -33.0 74.66 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.346 -0.846 . . . . 0.0 109.076 179.651 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.672 HG22 ' HB2' ' A' ' 79' ' ' TYR . 91.8 t -72.01 -45.94 61.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.323 -0.861 . . . . 0.0 109.369 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.624 ' HB2' HD11 ' A' ' 42' ' ' ILE . 19.0 tttm -51.85 -56.09 16.09 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.23 -0.919 . . . . 0.0 109.246 179.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -62.04 -34.93 77.16 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.319 -0.863 . . . . 0.0 109.256 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.503 ' O ' ' HB2' ' A' ' 27' ' ' LYS . 23.2 t-20 -65.28 -36.67 84.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.315 -0.866 . . . . 0.0 109.411 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.401 HG13 ' O ' ' A' ' 20' ' ' VAL . 90.4 mt -66.3 -46.47 87.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.145 -0.972 . . . . 0.0 109.782 -179.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.461 ' O ' ' HG2' ' A' ' 29' ' ' GLU . 65.8 mm-40 -56.88 -46.68 81.72 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.099 -1.0 . . . . 0.0 109.874 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 29.0 mttt -77.3 -36.72 53.91 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.104 -0.998 . . . . 0.0 109.576 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.89 ' HG2' HG23 ' A' ' 77' ' ' VAL . 5.3 tptt -56.12 -31.05 62.94 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 109.095 179.774 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.806 HG13 ' O ' ' A' ' 33' ' ' ILE . 11.6 t -84.76 -26.31 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.347 -0.845 . . . . 0.0 109.264 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.461 ' HG2' ' O ' ' A' ' 25' ' ' GLU . 61.7 mm-40 -67.87 -51.48 47.72 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.298 -0.876 . . . . 0.0 109.375 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.42 -32.3 66.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.921 . . . . 0.0 109.386 179.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.701 HG21 ' CE1' ' A' ' 73' ' ' PHE . 63.1 p -94.71 -11.31 29.36 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.354 -0.842 . . . . 0.0 109.447 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 54.83 24.51 33.84 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.991 HG21 HD22 ' A' ' 36' ' ' LEU . 69.8 mt -85.96 116.62 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.198 -1.178 . . . . 0.0 109.352 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.459 ' HG2' ' O ' ' A' ' 34' ' ' LYS . 86.0 tttt -121.98 -10.44 8.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.179 -0.95 . . . . 0.0 109.395 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 1.057 ' O ' HD13 ' A' ' 65' ' ' ILE . 87.5 m-20 -98.67 13.81 30.8 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.207 -0.933 . . . . 0.0 109.426 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.991 HD22 HG21 ' A' ' 33' ' ' ILE . 6.0 mp -120.69 -53.38 2.09 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.336 -0.853 . . . . 0.0 109.111 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.544 HG22 ' SD ' ' A' ' 64' ' ' MET . 90.3 t -100.66 129.55 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.426 -0.796 . . . . 0.0 109.034 179.53 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.25 -121.76 4.62 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 95.9 mtt180 -98.03 148.4 23.54 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.277 -1.131 . . . . 0.0 109.991 -179.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 1.058 HG22 HG13 ' A' ' 62' ' ' VAL . 44.5 pt -119.8 143.21 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.42 -0.8 . . . . 0.0 108.857 179.495 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.82 HG21 HD22 ' A' ' 107' ' ' LEU . 25.1 t -129.52 154.6 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.127 -0.983 . . . . 0.0 109.871 -179.527 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.913 HG22 ' H ' ' A' ' 44' ' ' ILE . 18.4 mt -127.86 128.62 23.83 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.366 -0.834 . . . . 0.0 109.212 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.489 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 45.1 Cg_endo -66.82 -4.27 10.92 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 122.836 2.357 . . . . 0.0 111.692 -179.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.913 ' H ' HG22 ' A' ' 42' ' ' ILE . 54.8 mt -70.66 -49.89 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.336 -0.853 . . . . 0.0 109.551 179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.47 ' HB3' ' O ' ' A' ' 44' ' ' ILE . 30.5 ttt85 61.81 144.46 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.225 -0.922 . . . . 0.0 109.502 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.418 ' N ' ' HG2' ' A' ' 45' ' ' ARG . . . -71.28 152.83 50.24 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 178.0 -178.71 48.53 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 93.8 mt-30 -80.87 147.83 30.19 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -1.141 . . . . 0.0 109.47 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.497 ' HB3' ' CZ ' ' A' ' 49' ' ' ARG . 12.3 mtp-105 -59.9 -36.12 76.3 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.243 -0.91 . . . . 0.0 109.44 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 19.8 ttp180 -54.01 -37.96 64.61 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.248 -0.907 . . . . 0.0 109.453 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 30.4 mmtp -80.66 156.89 26.13 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.235 -0.915 . . . . 0.0 109.456 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 23.6 t -68.53 139.86 55.64 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.266 -0.896 . . . . 0.0 109.381 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.469 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 95.2 mt-10 -124.79 153.62 42.2 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.204 -0.935 . . . . 0.0 109.458 -179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.693 ' HG2' HG23 ' A' ' 44' ' ' ILE . 63.6 mttt 74.53 86.85 0.1 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.293 -0.879 . . . . 0.0 109.479 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.5 ' O ' ' CD1' ' A' ' 56' ' ' PHE . 44.2 mt -64.13 -21.54 66.59 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -1.0 . . . . 0.0 109.181 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 1.054 ' CE1' HD11 ' A' ' 159' ' ' ILE . 8.8 m-85 -148.97 101.88 3.39 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.323 -0.861 . . . . 0.0 108.986 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -65.47 136.31 46.12 Favored 'Trans proline' 0 C--O 1.215 -0.635 0 C-N-CA 122.7 2.267 . . . . 0.0 112.176 -179.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.472 ' O ' HD13 ' A' ' 11' ' ' LEU . . . 77.44 -15.22 7.55 Favored Glycine 0 N--CA 1.489 2.2 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 179.576 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.0 m-30 -99.31 129.53 45.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.799 -1.412 . . . . 0.0 110.292 -179.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.546 ' HB ' ' CG2' ' A' ' 10' ' ' VAL . 88.2 t -133.23 148.88 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.131 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.599 ' CE1' ' CZ ' ' A' ' 160' ' ' PHE . 84.2 m-85 -109.71 124.62 51.55 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.773 -1.205 . . . . 0.0 110.248 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 1.058 HG13 HG22 ' A' ' 40' ' ' ILE . 91.8 t -133.58 145.16 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.382 -0.824 . . . . 0.0 109.635 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.626 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 28.2 tt0 -112.08 128.01 56.08 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.24 -0.913 . . . . 0.0 108.976 179.575 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.832 ' HE1' HG11 ' A' ' 74' ' ' VAL . 15.4 mtm -153.9 168.69 25.51 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 120.867 -1.146 . . . . 0.0 110.805 -179.113 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 1.057 HD13 ' O ' ' A' ' 35' ' ' ASN . 0.5 OUTLIER -89.11 130.39 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.653 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.417 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 56.6 ttm -75.85 141.8 42.34 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.89 . . . . 0.0 110.191 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.417 ' HB2' ' O ' ' A' ' 66' ' ' MET . 46.0 t30 179.11 166.15 0.96 Allowed 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -66.14 -41.13 90.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.154 -0.966 . . . . 0.0 109.505 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 64.2 tt0 -76.46 -31.5 57.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.295 -0.878 . . . . 0.0 109.844 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.023 ' O ' HG23 ' A' ' 74' ' ' VAL . . . -68.78 -49.36 59.31 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.972 -1.08 . . . . 0.0 109.621 -179.763 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.579 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 71.8 t80 -60.62 -50.98 71.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.215 -0.928 . . . . 0.0 109.751 -179.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 29.2 t30 -57.09 -29.69 63.71 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.201 -0.937 . . . . 0.0 110.059 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.701 ' CE1' HG21 ' A' ' 31' ' ' THR . 77.4 t80 -80.51 -41.88 23.47 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.098 -1.001 . . . . 0.0 109.776 -179.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 1.023 HG23 ' O ' ' A' ' 70' ' ' ALA . 2.8 t -70.08 -55.07 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.466 -0.771 . . . . 0.0 109.602 -179.618 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.437 ' O ' ' HG3' ' A' ' 75' ' ' ARG . 32.0 tpt85 -61.43 -13.33 19.52 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.329 -0.857 . . . . 0.0 110.013 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 78.1 p -97.31 4.57 50.79 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.115 -0.99 . . . . 0.0 109.923 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.912 ' O ' HG12 ' A' ' 80' ' ' VAL . 0.4 OUTLIER -74.85 137.21 73.32 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 120.965 -1.084 . . . . 0.0 109.315 -179.992 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.63 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 44.2 Cg_endo -66.34 137.36 46.95 Favored 'Trans proline' 0 C--O 1.213 -0.75 0 C-N-CA 122.676 2.251 . . . . 0.0 111.893 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.672 ' HB2' HG22 ' A' ' 20' ' ' VAL . 19.1 m-85 92.45 -13.54 0.18 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.934 -0.479 . . . . 0.0 109.759 -179.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.912 HG12 ' O ' ' A' ' 77' ' ' VAL . 8.6 p -82.43 122.91 37.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.891 -1.131 . . . . 0.0 109.365 179.765 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 95.5 mmm -87.94 -30.71 19.86 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.294 -0.879 . . . . 0.0 109.362 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.545 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 168.05 -165.85 39.04 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.632 ' CD2' HG12 ' A' ' 10' ' ' VAL . 4.6 m-85 -137.52 139.61 40.62 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.332 -1.099 . . . . 0.0 109.46 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.412 HG22 ' CD2' ' A' ' 11' ' ' LEU . 21.0 t -66.08 125.01 22.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.258 -0.901 . . . . 0.0 109.331 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.568 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 4.8 p -160.18 158.97 31.06 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.15 -0.969 . . . . 0.0 109.667 -179.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 59.5 p -82.84 -36.47 25.45 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.329 -0.857 . . . . 0.0 109.234 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.07 -86.56 0.52 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -103.13 -127.87 6.21 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.579 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.1 OUTLIER -33.98 151.93 0.05 OUTLIER Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.512 -0.993 . . . . 0.0 110.046 -179.668 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.568 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 49.1 Cg_endo -69.38 158.66 56.64 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.807 2.338 . . . . 0.0 112.01 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 27.8 m -93.38 154.14 41.38 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.307 -0.871 . . . . 0.0 109.423 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -70.06 146.96 59.86 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 122.654 2.236 . . . . 0.0 111.735 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 7' ' ' TRP . 45.1 t -83.62 140.18 16.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.297 -0.877 . . . . 0.0 109.417 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . 0.492 ' HE2' ' NH2' ' A' ' 96' ' ' ARG . 79.8 tttt -73.21 130.69 40.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.202 -0.936 . . . . 0.0 109.491 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 45.7 t0 -46.53 -39.07 10.26 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.278 -0.889 . . . . 0.0 109.425 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.492 ' NH2' ' HE2' ' A' ' 94' ' ' LYS . 15.5 mtt85 -60.56 -30.77 70.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.344 -0.847 . . . . 0.0 109.417 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.427 ' N ' ' O ' ' A' ' 94' ' ' LYS . 52.7 mt-10 -80.08 -26.8 39.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.272 -0.892 . . . . 0.0 109.528 -179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.686 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 55.3 mtp -86.12 -21.77 27.44 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.271 -0.893 . . . . 0.0 109.226 179.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.581 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.47 -53.23 1.31 Allowed Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.482 -0.761 . . . . 0.0 109.807 179.981 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.624 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 50.4 Cg_endo -71.41 -26.69 20.11 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.463 2.109 . . . . 0.0 111.878 -179.936 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.479 ' N ' ' O ' ' A' ' 98' ' ' MET . 35.2 mm -82.42 -42.96 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.206 -0.934 . . . . 0.0 109.607 -179.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.654 ' N ' HD13 ' A' ' 102' ' ' LEU . 0.0 OUTLIER -67.83 -40.82 83.74 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.183 -0.948 . . . . 0.0 109.417 179.923 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.42 ' HG2' ' HA ' ' A' ' 135' ' ' PRO . 19.7 tpt180 -65.86 -49.1 69.32 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.253 -0.904 . . . . 0.0 109.315 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -71.71 -37.03 70.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.358 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.557 ' CB ' HG11 ' A' ' 41' ' ' VAL . . . -74.35 1.3 11.95 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.315 -0.866 . . . . 0.0 109.773 -179.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.47 11.07 85.44 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.82 HD22 HG21 ' A' ' 41' ' ' VAL . 3.2 tp -82.05 -24.86 35.07 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.219 -1.166 . . . . 0.0 109.525 179.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -125.19 132.92 52.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.214 -0.929 . . . . 0.0 109.584 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -119.98 123.66 44.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.205 -0.934 . . . . 0.0 109.354 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.572 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 33.0 p90 -140.45 177.5 7.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.229 -0.919 . . . . 0.0 109.615 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.572 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 61.3 mt-10 -67.6 -148.83 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.221 -0.925 . . . . 0.0 109.405 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.481 ' HG2' ' N ' ' A' ' 113' ' ' LYS . 85.2 tt0 -156.29 164.72 37.98 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.307 -0.871 . . . . 0.0 109.341 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.481 ' N ' ' HG2' ' A' ' 112' ' ' GLU . 5.6 pttt -44.16 144.31 0.99 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.18 -0.95 . . . . 0.0 109.423 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 5.0 tttp -105.0 10.19 34.2 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.226 -0.921 . . . . 0.0 109.513 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 8.6 mtmm -129.12 73.4 81.74 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.203 -0.935 . . . . 0.0 109.459 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -72.51 80.5 1.67 Allowed 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 122.689 2.259 . . . . 0.0 111.583 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.467 ' O ' ' HB2' ' A' ' 171' ' ' SER . 12.8 m -133.11 145.8 33.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.35 -0.844 . . . . 0.0 109.546 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.536 ' HA ' ' HB3' ' A' ' 171' ' ' SER . 3.5 ttpm? -62.66 140.22 58.69 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.323 -0.861 . . . . 0.0 109.37 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.609 ' O ' HG12 ' A' ' 170' ' ' VAL . 53.5 t -128.98 118.45 46.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.213 -0.929 . . . . 0.0 109.638 -179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.758 ' O ' HD23 ' A' ' 121' ' ' LEU . 98.3 mt-10 -147.07 147.71 30.9 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.318 -0.864 . . . . 0.0 109.342 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.758 HD23 ' O ' ' A' ' 120' ' ' GLU . 1.4 pp 145.71 145.41 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.846 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.425 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . 42.43 33.6 1.46 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.974 -1.251 . . . . 0.0 109.974 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.573 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 14.1 m-85 -107.84 115.53 30.3 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.142 -1.21 . . . . 0.0 109.159 179.554 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.419 ' HD3' ' O ' ' A' ' 123' ' ' PHE . 62.1 mmtt -139.35 156.37 47.05 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.25 -0.906 . . . . 0.0 109.536 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.439 HG13 ' O ' ' A' ' 144' ' ' LYS . 10.1 t -57.37 137.46 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.258 -0.901 . . . . 0.0 109.606 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.81 -34.55 3.86 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.432 ' O ' HG23 ' A' ' 142' ' ' VAL . 37.2 m-20 -47.8 160.8 0.12 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.341 -1.094 . . . . 0.0 109.405 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 3.4 ttm -100.87 127.93 47.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.193 -0.942 . . . . 0.0 109.059 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.616 HG13 HG13 ' A' ' 143' ' ' ILE . 25.7 m -128.72 145.31 35.82 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.358 -0.839 . . . . 0.0 109.667 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.521 ' CB ' HG12 ' A' ' 176' ' ' ILE . 57.7 tttt -103.22 139.39 38.76 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.787 -0.819 . . . . 0.0 108.787 179.609 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 1.031 HD12 ' HB3' ' A' ' 139' ' ' PHE . 80.9 mt -78.41 153.71 5.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -149.17 1.26 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 120.946 -1.096 . . . . 0.0 109.465 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.51 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 70.1 m -148.27 144.3 27.53 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.114 -0.991 . . . . 0.0 110.06 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.59 -164.88 17.73 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.506 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 46.2 Cg_endo -68.35 -21.84 40.53 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 123.071 2.514 . . . . 0.0 112.643 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.624 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 86.9 m-85 -107.67 18.21 21.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.84 -1.163 . . . . 0.0 109.442 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.518 ' O ' ' HB2' ' A' ' 138' ' ' ASP . 3.1 tt0 -45.53 139.05 4.03 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.255 -0.903 . . . . 0.0 109.617 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 28.9 m-20 73.74 28.54 1.6 Allowed 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.385 -0.822 . . . . 0.0 110.423 179.526 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 1.031 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.7 t80 -117.4 131.87 56.68 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.041 -1.037 . . . . 0.0 109.445 179.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.409 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -78.53 132.26 37.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.19 -0.944 . . . . 0.0 109.647 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -142.98 167.46 26.33 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.537 ' CG1' ' HB2' ' A' ' 156' ' ' ASN . 11.1 p -117.42 138.33 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.353 -1.086 . . . . 0.0 109.393 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.735 ' HA ' HG12 ' A' ' 155' ' ' VAL . 60.6 mt -68.81 117.11 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.152 -0.968 . . . . 0.0 109.676 -179.832 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.439 ' O ' HG13 ' A' ' 125' ' ' VAL . 15.6 tttt -102.43 -35.52 8.75 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.142 -0.973 . . . . 0.0 109.253 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.464 ' HB2' ' HB2' ' A' ' 154' ' ' LYS . 62.8 mt-10 -152.95 148.19 26.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.241 -0.912 . . . . 0.0 109.526 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.653 HG23 ' HG ' ' A' ' 153' ' ' LEU . 2.1 mt -123.8 125.65 71.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.257 -0.902 . . . . 0.0 109.412 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -106.74 99.61 26.42 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.192 -0.943 . . . . 0.0 109.674 -179.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.583 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.8 Cg_endo -70.74 170.96 16.49 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.704 2.27 . . . . 0.0 111.677 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.583 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 2.4 mt-10 81.64 -20.5 0.36 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.362 -0.836 . . . . 0.0 109.868 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.47 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 42.1 mtt180 -128.89 -12.47 4.74 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.997 -1.065 . . . . 0.0 109.694 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.876 ' O ' HG23 ' A' ' 170' ' ' VAL . 48.1 mt-30 70.69 48.8 0.42 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.26 -0.9 . . . . 0.0 109.604 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 90.3 mt-10 -119.59 142.18 48.62 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.175 -0.953 . . . . 0.0 109.02 179.583 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.653 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.1 OUTLIER -129.34 112.36 13.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.237 -0.914 . . . . 0.0 110.083 -179.514 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.464 ' HB2' ' HB2' ' A' ' 145' ' ' GLU . 17.6 mttt -79.9 126.41 30.97 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 179.071 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.735 HG12 ' HA ' ' A' ' 143' ' ' ILE . 16.1 m -128.32 152.98 37.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.035 -1.041 . . . . 0.0 110.05 -179.458 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.537 ' HB2' ' CG1' ' A' ' 142' ' ' VAL . 86.8 m-20 -98.88 112.9 24.87 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.313 -0.867 . . . . 0.0 109.376 179.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.792 HG13 ' CE1' ' A' ' 139' ' ' PHE . 38.8 t -99.97 147.69 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.273 -0.892 . . . . 0.0 109.553 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 163' ' ' GLU . 29.2 m -94.08 117.76 30.56 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.415 -0.803 . . . . 0.0 109.802 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 1.054 HD11 ' CE1' ' A' ' 56' ' ' PHE . 18.8 pt -145.9 138.62 20.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.348 -0.845 . . . . 0.0 109.387 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.599 ' CZ ' ' CE1' ' A' ' 61' ' ' PHE . 72.2 m-85 62.57 39.36 11.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.245 -0.909 . . . . 0.0 109.379 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 62.26 16.96 55.19 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 48.9 mtp180 -137.73 142.21 41.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.092 -1.24 . . . . 0.0 109.501 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.553 ' HA ' ' HA ' ' A' ' 158' ' ' THR . 84.8 mt-10 -98.45 110.2 22.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.184 -0.948 . . . . 0.0 109.465 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . 0.579 HG23 ' HD2' ' A' ' 165' ' ' PRO . 16.6 m -112.8 139.9 23.38 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.211 -0.93 . . . . 0.0 109.341 -179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.579 ' HD2' HG23 ' A' ' 164' ' ' THR . 48.7 Cg_endo -69.21 137.3 36.72 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 122.711 2.274 . . . . 0.0 111.778 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 1.02 HG13 HD11 ' A' ' 168' ' ' LEU . 2.1 p -123.41 142.06 41.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.157 -0.964 . . . . 0.0 109.743 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.501 ' C ' ' HG ' ' A' ' 168' ' ' LEU . 72.8 t -92.89 119.13 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.383 -0.823 . . . . 0.0 109.552 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 1.02 HD11 HG13 ' A' ' 166' ' ' VAL . 0.3 OUTLIER -141.27 167.96 20.92 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.313 -0.867 . . . . 0.0 110.567 -179.719 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.531 ' HB2' ' CG ' ' A' ' 172' ' ' GLU . 61.8 m80 -78.59 145.58 34.67 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.876 HG23 ' O ' ' A' ' 151' ' ' GLN . 24.0 t -59.67 -35.84 62.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.457 0 O-C-N 121.274 -0.891 . . . . 0.0 108.702 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.536 ' HB3' ' HA ' ' A' ' 118' ' ' LYS . 87.9 p -75.27 -7.06 52.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.494 -0.754 . . . . 0.0 109.324 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.531 ' CG ' ' HB2' ' A' ' 169' ' ' HIS . 82.5 mt-10 -90.62 4.07 52.37 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.34 -0.85 . . . . 0.0 109.832 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.578 ' CG2' ' N ' ' A' ' 174' ' ' GLU . 1.4 p -141.7 167.74 15.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.024 -1.048 . . . . 0.0 109.484 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.578 ' N ' ' CG2' ' A' ' 173' ' ' VAL . 52.4 tt0 -142.78 168.77 18.94 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.341 -0.849 . . . . 0.0 108.857 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.573 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 33.1 tttm -91.74 33.18 1.04 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.021 -1.05 . . . . 0.0 109.289 179.829 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.521 HG12 ' CB ' ' A' ' 130' ' ' LYS . 40.4 mt 43.95 74.47 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.19 -0.944 . . . . 0.0 109.394 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 117.957 -1.02 . . . . 0.0 109.477 -179.954 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.48 -24.12 66.37 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.299 -1.118 . . . . 0.0 109.475 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 89.6 mtp -64.93 -30.99 72.01 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.231 -0.918 . . . . 0.0 109.519 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 50.5 mttm -118.92 137.08 53.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.422 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.4 mttm -110.08 156.8 20.07 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.177 -0.952 . . . . 0.0 109.667 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 12.7 mttt -135.49 176.03 9.05 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 110.009 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.837 ' CH2' HG23 ' A' ' 41' ' ' VAL . 60.3 m95 -109.83 125.71 53.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.362 -0.836 . . . . 0.0 109.211 179.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.58 ' CE2' ' HG3' ' A' ' 66' ' ' MET . 66.1 m-85 -116.64 171.76 7.66 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.186 -0.946 . . . . 0.0 109.383 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.657 HD11 ' CE1' ' A' ' 160' ' ' PHE . 56.2 mt -110.9 109.95 30.37 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.242 -0.911 . . . . 0.0 109.069 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.608 HG23 ' CE1' ' A' ' 83' ' ' PHE . 8.9 p -88.6 143.47 11.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.186 -0.946 . . . . 0.0 109.477 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.51 HD13 ' HA ' ' A' ' 11' ' ' LEU . 4.6 mm? -88.83 141.83 28.17 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.389 -0.819 . . . . 0.0 109.545 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.69 ' OG1' HG21 ' A' ' 20' ' ' VAL . 15.1 t -154.69 -169.35 3.18 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.281 -0.887 . . . . 0.0 109.393 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.502 ' SD ' ' CE2' ' A' ' 16' ' ' TYR . 36.2 ttm -107.68 119.6 39.88 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.3 -0.875 . . . . 0.0 109.48 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 13' ' ' MET . 54.0 p -42.82 128.19 4.15 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.332 -0.855 . . . . 0.0 109.279 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.65 -19.69 33.13 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.523 ' O ' HG23 ' A' ' 20' ' ' VAL . 19.6 m-30 -110.31 -5.84 15.15 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.301 -1.117 . . . . 0.0 109.75 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.486 ' HG2' HG21 ' A' ' 12' ' ' THR . 87.0 mt-10 -44.58 -65.49 0.51 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.148 -0.97 . . . . 0.0 109.547 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.44 ' O ' ' HG3' ' A' ' 22' ' ' GLU . 95.7 mt-10 -43.2 -33.41 0.92 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.199 -0.938 . . . . 0.0 109.271 179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.524 ' O ' ' ND2' ' A' ' 23' ' ' ASN . 46.7 mttm -77.19 -41.12 42.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.3 -0.875 . . . . 0.0 109.324 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.69 HG21 ' OG1' ' A' ' 12' ' ' THR . 18.4 t -59.7 -48.17 88.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.327 -0.858 . . . . 0.0 109.33 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.58 ' HG3' HG21 ' A' ' 40' ' ' ILE . 28.1 tttm -60.53 -43.12 97.49 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.264 -0.897 . . . . 0.0 109.067 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.44 ' HG3' ' O ' ' A' ' 18' ' ' GLU . 93.7 mt-10 -63.87 -42.07 97.61 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.406 -0.809 . . . . 0.0 109.045 179.716 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.629 ' ND2' ' CD2' ' A' ' 79' ' ' TYR . 54.9 m-80 -56.91 -52.22 66.01 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.335 -0.853 . . . . 0.0 109.508 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.925 ' CD1' HG21 ' A' ' 77' ' ' VAL . 21.0 mm -50.33 -44.21 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.051 -1.031 . . . . 0.0 109.408 179.809 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -54.61 -44.27 72.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.272 -0.893 . . . . 0.0 109.832 -179.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.8 mttp -79.86 -35.09 38.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.09 -1.006 . . . . 0.0 109.905 -179.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.91 ' HD3' HG23 ' A' ' 77' ' ' VAL . 12.6 ttpp -56.65 -35.16 68.06 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.114 -0.991 . . . . 0.0 109.282 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.828 HG13 ' O ' ' A' ' 33' ' ' ILE . 15.6 t -82.47 -27.05 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.355 -0.841 . . . . 0.0 109.575 -179.794 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 69.8 mt-10 -66.35 -49.84 65.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.214 -0.929 . . . . 0.0 109.68 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.38 -27.74 69.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.207 -0.933 . . . . 0.0 109.741 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.454 HG23 ' O ' ' A' ' 27' ' ' LYS . 60.9 p -88.83 -12.76 41.01 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.041 -1.037 . . . . 0.0 109.517 -179.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 63.72 15.43 57.67 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.356 -1.498 . . . . 0.0 109.356 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.828 ' O ' HG13 ' A' ' 28' ' ' VAL . 13.7 mt -94.84 85.6 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.314 -1.11 . . . . 0.0 109.481 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 49.9 mttt -85.59 7.64 22.41 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.149 -0.97 . . . . 0.0 109.074 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -111.77 18.52 18.86 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.339 -0.85 . . . . 0.0 109.433 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.845 ' CD2' HD11 ' A' ' 65' ' ' ILE . 0.1 OUTLIER -111.6 -52.95 2.75 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.144 -0.972 . . . . 0.0 109.344 -179.959 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.464 ' HA ' ' HB3' ' A' ' 64' ' ' MET . 87.7 t -97.01 137.06 25.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.295 -0.878 . . . . 0.0 109.462 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 63' ' ' GLU . . . -107.81 -125.28 5.27 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.426 ' O ' ' CH2' ' A' ' 7' ' ' TRP . 95.2 mtt180 -91.72 138.69 31.35 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.309 -1.112 . . . . 0.0 109.694 -179.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.876 HG12 HG13 ' A' ' 62' ' ' VAL . 46.1 mt -105.78 136.96 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.374 -0.829 . . . . 0.0 109.042 179.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 1.113 ' CG2' HD11 ' A' ' 107' ' ' LEU . 98.4 t -124.26 150.51 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.212 -0.93 . . . . 0.0 109.527 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.747 HG22 HG23 ' A' ' 44' ' ' ILE . 5.7 mt -128.38 126.05 23.43 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.341 -0.849 . . . . 0.0 109.413 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.462 ' O ' HD13 ' A' ' 55' ' ' LEU . 47.8 Cg_endo -68.5 -2.99 10.18 Favored 'Trans proline' 0 C--O 1.216 -0.621 0 C-N-CA 122.86 2.374 . . . . 0.0 111.814 179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.747 HG23 HG22 ' A' ' 42' ' ' ILE . 11.3 pt -76.44 132.88 32.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.07 -1.019 . . . . 0.0 109.649 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 43.6 ttp-105 -71.28 -28.49 64.18 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.389 -0.819 . . . . 0.0 109.466 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 70.1 36.46 72.12 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -140.27 139.55 9.89 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 83.3 mt-30 -88.63 11.64 16.85 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.19 -1.182 . . . . 0.0 109.453 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 12.1 ttt-85 -54.94 -38.67 67.99 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.234 -0.916 . . . . 0.0 109.445 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 65.8 ttt-85 -104.66 153.28 21.44 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.28 -0.887 . . . . 0.0 109.431 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 16.8 mtmt -62.55 -24.37 67.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.924 . . . . 0.0 109.54 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . . . . . . . . . 68.0 p -96.83 157.04 16.09 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.273 -0.892 . . . . 0.0 109.566 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.497 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 81.0 tt0 -136.62 145.92 45.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.344 -0.847 . . . . 0.0 109.324 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.692 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 22.6 mttm 74.85 111.27 0.07 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.249 -0.907 . . . . 0.0 109.195 -179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.54 ' N ' HD12 ' A' ' 55' ' ' LEU . 6.8 mp -65.91 -25.57 67.21 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.835 -1.165 . . . . 0.0 109.47 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.533 ' HB3' ' HB2' ' A' ' 59' ' ' TYR . 84.3 m-85 -142.08 98.23 6.22 Favored Pre-proline 0 N--CA 1.489 1.513 0 O-C-N 121.283 -0.886 . . . . 0.0 108.86 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 43.2 Cg_endo -66.7 134.39 34.94 Favored 'Trans proline' 0 C--O 1.214 -0.698 0 C-N-CA 122.755 2.303 . . . . 0.0 112.23 -179.082 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 75.56 -12.87 7.17 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.533 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 2.9 m-85 -100.67 131.23 46.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.693 -1.475 . . . . 0.0 110.183 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.569 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 76.8 t -135.32 148.6 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.377 -0.827 . . . . 0.0 108.809 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.634 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 16.8 m-85 -110.7 123.87 50.85 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.874 -1.141 . . . . 0.0 109.926 -179.395 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.876 HG13 HG12 ' A' ' 40' ' ' ILE . 90.0 t -129.62 142.77 43.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.405 -0.809 . . . . 0.0 109.793 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.612 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 9.8 tt0 -99.86 125.52 45.83 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.335 -0.853 . . . . 0.0 109.175 179.671 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.464 ' HB3' ' HA ' ' A' ' 37' ' ' VAL . 12.5 ptt? -164.96 -175.39 3.71 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.025 -1.047 . . . . 0.0 110.174 -179.665 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.845 HD11 ' CD2' ' A' ' 36' ' ' LEU . 38.6 pt -103.35 128.36 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.479 -0.763 . . . . 0.0 109.165 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.58 ' HG3' ' CE2' ' A' ' 8' ' ' TYR . 33.6 mtm -90.75 101.64 14.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.196 -0.94 . . . . 0.0 109.898 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.543 ' OD1' ' N ' ' A' ' 69' ' ' GLU . 10.3 p30 -137.91 -163.09 1.39 Allowed 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.123 -0.986 . . . . 0.0 109.077 179.591 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -74.98 -50.15 17.56 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.135 -0.978 . . . . 0.0 110.105 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.543 ' N ' ' OD1' ' A' ' 67' ' ' ASN . 98.0 mt-10 -64.85 -54.64 27.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.05 -1.031 . . . . 0.0 109.585 -179.747 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.011 ' O ' HG22 ' A' ' 74' ' ' VAL . . . -52.34 -38.75 59.48 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.265 -0.897 . . . . 0.0 109.727 -179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.433 ' CD1' ' CD ' ' A' ' 89' ' ' GLN . 72.3 t80 -60.02 -50.51 73.46 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 109.853 -179.818 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -65.59 -28.46 69.15 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.156 -0.965 . . . . 0.0 110.436 -179.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -82.52 -42.63 18.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.865 -1.147 . . . . 0.0 110.035 -179.443 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 1.011 HG22 ' O ' ' A' ' 70' ' ' ALA . 6.8 m -65.92 -57.37 10.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.186 -0.947 . . . . 0.0 109.562 -179.78 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.681 ' H ' HG23 ' A' ' 74' ' ' VAL . 12.6 mmt180 -53.87 -40.95 66.99 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.226 -0.922 . . . . 0.0 109.751 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 25.7 p -75.42 3.07 9.86 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.204 -0.935 . . . . 0.0 110.149 -179.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.925 HG21 ' CD1' ' A' ' 24' ' ' ILE . 1.8 p -71.8 130.0 87.52 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 120.875 -1.141 . . . . 0.0 109.136 179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.765 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 44.0 Cg_endo -66.14 132.32 29.49 Favored 'Trans proline' 0 C--O 1.212 -0.797 0 C-N-CA 122.83 2.353 . . . . 0.0 112.627 -178.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.765 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 70.8 m-85 95.43 -8.63 0.1 Allowed 'General case' 0 N--CA 1.496 1.862 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.683 HG21 HG11 ' A' ' 77' ' ' VAL . 16.0 t -99.15 133.72 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.973 -1.079 . . . . 0.0 109.494 179.726 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 64.2 mtt -92.79 -19.23 21.96 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.337 -0.852 . . . . 0.0 109.399 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.575 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 150.48 -154.38 25.6 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.608 ' CE1' HG23 ' A' ' 10' ' ' VAL . 5.3 m-85 -137.14 149.22 47.15 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.258 -1.142 . . . . 0.0 109.602 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.524 HG12 ' HB ' ' A' ' 9' ' ' ILE . 13.8 p -74.86 129.39 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.283 -0.886 . . . . 0.0 109.37 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.553 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 2.2 p -163.06 165.6 24.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.732 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.4 t -92.89 -30.87 15.19 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.396 -0.815 . . . . 0.0 109.24 179.742 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -128.77 -87.7 0.54 Allowed Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.527 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -103.19 -135.5 8.7 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.527 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -32.59 153.99 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.568 -0.96 . . . . 0.0 110.259 -179.624 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.553 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 47.8 Cg_endo -67.86 151.2 78.56 Favored 'Trans proline' 0 C--O 1.216 -0.61 0 C-N-CA 122.891 2.394 . . . . 0.0 112.013 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 33.4 m -84.22 155.07 63.64 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.318 -0.864 . . . . 0.0 109.336 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.41 ' HB3' ' HD3' ' A' ' 6' ' ' LYS . 49.0 Cg_endo -69.81 141.27 44.59 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 122.676 2.251 . . . . 0.0 111.753 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 7' ' ' TRP . 41.4 t -71.73 141.4 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.209 -0.932 . . . . 0.0 109.367 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 97' ' ' GLU . 93.8 mttt -75.53 130.02 38.17 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.257 -0.902 . . . . 0.0 109.444 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 78.5 m-20 -45.25 -39.4 6.42 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.288 -0.883 . . . . 0.0 109.354 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 77.6 mtt180 -60.69 -24.74 65.87 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.483 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.464 ' N ' ' O ' ' A' ' 94' ' ' LYS . 87.6 mt-10 -89.42 -26.06 21.19 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.556 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.594 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 89.5 mtp -82.54 -30.93 29.41 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.401 -0.812 . . . . 0.0 109.448 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.623 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 1.2 tpt180 -38.7 -51.95 3.67 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.402 -0.811 . . . . 0.0 109.857 -179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.623 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.3 Cg_endo -68.78 -28.1 30.69 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.483 2.122 . . . . 0.0 111.801 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.459 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 23.4 mm -81.58 -42.13 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.243 -0.91 . . . . 0.0 109.402 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 1.021 HD12 HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -67.46 -39.88 85.35 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.207 -0.933 . . . . 0.0 109.051 179.715 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.568 ' CD ' ' HA ' ' A' ' 135' ' ' PRO . 26.1 ttm180 -63.62 -49.27 73.96 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.375 -0.828 . . . . 0.0 108.981 179.768 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -72.99 -35.24 66.83 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.329 -0.857 . . . . 0.0 109.048 179.532 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.517 ' HB1' HG13 ' A' ' 41' ' ' VAL . . . -74.38 -2.8 26.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.356 -0.84 . . . . 0.0 109.654 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.42 14.4 82.43 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 1.113 HD11 ' CG2' ' A' ' 41' ' ' VAL . 66.0 mt -81.65 -24.17 36.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.202 -1.176 . . . . 0.0 109.646 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 37.9 tp10 -102.37 138.9 38.69 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -0.999 . . . . 0.0 109.627 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -93.05 106.96 18.85 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.301 -0.875 . . . . 0.0 109.35 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.459 ' CE1' ' HG2' ' A' ' 103' ' ' ARG . 22.8 p90 -144.13 153.64 42.35 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.227 -0.921 . . . . 0.0 109.493 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.442 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 18.4 mt-10 -93.03 -148.91 0.25 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.278 -0.889 . . . . 0.0 109.384 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.488 ' O ' ' C ' ' A' ' 113' ' ' LYS . 30.4 tt0 -98.45 148.18 23.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.172 -0.955 . . . . 0.0 109.482 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.488 ' C ' ' O ' ' A' ' 112' ' ' GLU . 11.3 pttm -36.74 126.55 0.87 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.385 -0.822 . . . . 0.0 109.784 -179.838 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -79.49 -43.04 23.94 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.313 -0.867 . . . . 0.0 109.413 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.79 108.12 60.19 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.23 -0.919 . . . . 0.0 109.425 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -70.08 133.02 24.0 Favored 'Trans proline' 0 C--O 1.215 -0.671 0 C-N-CA 122.645 2.23 . . . . 0.0 111.817 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 17.8 t -107.03 136.56 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.269 -0.894 . . . . 0.0 109.511 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 48.4 mttt -90.89 138.81 31.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.268 -0.895 . . . . 0.0 109.439 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.842 HG22 ' H ' ' A' ' 121' ' ' LEU . 13.3 p -47.71 148.18 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.203 -0.936 . . . . 0.0 109.589 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.549 ' O ' ' HB2' ' A' ' 121' ' ' LEU . 2.1 mt-10 -71.25 -13.28 61.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.282 -0.886 . . . . 0.0 109.389 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.842 ' H ' HG22 ' A' ' 119' ' ' VAL . 29.5 mt 79.66 163.83 0.19 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.495 -0.753 . . . . 0.0 109.992 179.786 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 47.77 65.78 2.27 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 179.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.588 ' CE1' ' HB2' ' A' ' 175' ' ' LYS . 3.6 m-30 -100.75 142.49 32.15 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.199 -1.177 . . . . 0.0 108.61 178.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.409 ' HB2' ' CG ' ' A' ' 127' ' ' ASP . 74.8 mttt -124.87 154.32 41.25 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.013 -1.054 . . . . 0.0 110.124 -179.462 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 9.8 m -64.66 141.89 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.856 . . . . 0.0 109.331 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 143' ' ' ILE . . . 88.22 -31.75 4.65 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 -179.666 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.506 ' HB2' HD12 ' A' ' 143' ' ' ILE . 28.9 m-20 -49.66 158.74 0.43 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.433 -1.039 . . . . 0.0 109.26 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . 0.592 ' HG2' HD12 ' A' ' 176' ' ' ILE . 4.4 ttm -98.13 127.86 44.31 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.205 -0.934 . . . . 0.0 109.052 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.672 HG11 HD11 ' A' ' 143' ' ' ILE . 27.4 m -128.11 143.41 40.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.276 -0.89 . . . . 0.0 109.604 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.571 ' HB2' HD11 ' A' ' 176' ' ' ILE . 75.8 tttt -100.31 139.42 36.01 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 179.485 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.989 ' O ' HD13 ' A' ' 132' ' ' ILE . 1.2 mp -79.86 152.77 4.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.989 HD13 ' O ' ' A' ' 131' ' ' ILE . 1.1 mm -148.79 2.4 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 120.956 -1.09 . . . . 0.0 109.809 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.526 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 41.7 m -147.5 144.66 28.73 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.971 -1.08 . . . . 0.0 110.198 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 103.22 -166.44 16.29 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.568 ' HA ' ' CD ' ' A' ' 103' ' ' ARG . 47.5 Cg_endo -68.52 -20.85 40.84 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 123.111 2.541 . . . . 0.0 112.315 -179.663 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.535 ' O ' ' HB2' ' A' ' 139' ' ' PHE . 98.8 m-85 -107.86 19.09 20.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.954 -1.091 . . . . 0.0 109.3 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.614 ' HA ' HG22 ' A' ' 131' ' ' ILE . 4.0 tt0 -43.17 139.9 1.7 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.268 -0.895 . . . . 0.0 109.797 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.537 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 44.3 m-20 72.62 30.74 1.81 Allowed 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.463 -0.773 . . . . 0.0 110.871 179.191 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.535 ' HB2' ' O ' ' A' ' 136' ' ' PHE . 0.7 OUTLIER -116.66 128.46 55.39 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.76 -1.212 . . . . 0.0 109.573 179.654 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -74.14 133.49 42.8 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.28 -0.887 . . . . 0.0 109.455 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -144.05 168.96 26.37 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.432 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.616 ' C ' HG13 ' A' ' 155' ' ' VAL . 53.5 t -118.19 137.47 52.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.578 -0.954 . . . . 0.0 109.311 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.672 HD11 HG11 ' A' ' 129' ' ' VAL . 98.7 mt -70.05 115.47 9.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.177 -0.952 . . . . 0.0 109.42 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -99.03 -33.85 10.65 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.085 -1.009 . . . . 0.0 109.479 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.454 ' HB2' ' HE2' ' A' ' 154' ' ' LYS . 93.7 mt-10 -154.39 149.48 26.88 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.211 -0.931 . . . . 0.0 109.702 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.642 HG23 ' HG ' ' A' ' 153' ' ' LEU . 2.8 mt -125.91 128.46 72.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.431 -0.793 . . . . 0.0 109.394 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -110.91 102.17 51.79 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.234 -0.916 . . . . 0.0 109.534 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.557 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.0 Cg_endo -70.94 172.54 13.58 Favored 'Trans proline' 0 C--O 1.214 -0.724 0 C-N-CA 122.692 2.261 . . . . 0.0 111.699 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.557 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.6 mt-10 80.37 -20.74 0.36 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.348 -0.845 . . . . 0.0 109.848 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.427 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 74.6 mtt180 -128.53 -14.02 4.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.1 -1.0 . . . . 0.0 109.567 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.427 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 35.9 mt-30 70.51 48.64 0.45 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.216 -0.927 . . . . 0.0 109.851 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.576 ' OE2' HG23 ' A' ' 167' ' ' VAL . 84.6 tt0 -117.76 141.83 47.96 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.075 -1.015 . . . . 0.0 109.038 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.642 ' HG ' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -130.77 113.27 13.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.013 -1.054 . . . . 0.0 110.158 -179.512 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.454 ' HE2' ' HB2' ' A' ' 145' ' ' GLU . 2.5 ttpt -78.61 128.58 33.7 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.242 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.72 ' O ' HG12 ' A' ' 166' ' ' VAL . 47.0 t -124.54 145.82 31.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.168 -0.958 . . . . 0.0 109.985 -179.41 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.534 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 27.0 t-20 -98.32 110.96 23.45 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.377 -0.827 . . . . 0.0 109.37 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.492 ' CG1' ' CE1' ' A' ' 139' ' ' PHE . 60.4 t -95.22 142.33 13.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.282 -0.886 . . . . 0.0 109.453 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 41.2 m -100.55 100.03 10.7 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.255 -0.903 . . . . 0.0 109.728 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.497 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 4.1 mt -123.81 146.98 28.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.217 -0.927 . . . . 0.0 109.178 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.657 ' CE1' HD11 ' A' ' 9' ' ' ILE . 97.9 m-85 61.84 38.66 14.52 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.238 -0.914 . . . . 0.0 109.205 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 55.24 17.19 10.63 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.463 ' CZ ' ' OH ' ' A' ' 59' ' ' TYR . 90.7 mtt-85 -125.58 158.71 33.94 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.094 -1.239 . . . . 0.0 109.563 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -100.73 128.37 46.8 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.194 -0.941 . . . . 0.0 109.687 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 48.8 m -139.2 125.78 12.58 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.313 -0.867 . . . . 0.0 109.792 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.2 Cg_endo -71.51 135.28 26.08 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 122.7 2.267 . . . . 0.0 111.429 179.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 1.008 HG13 HD11 ' A' ' 168' ' ' LEU . 7.1 p -118.47 163.39 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.167 -0.958 . . . . 0.0 109.966 -179.524 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 167' ' ' VAL . 14.4 p -116.61 117.01 54.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.296 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 1.008 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -143.21 168.85 18.8 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.243 -0.911 . . . . 0.0 110.91 -179.264 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -78.96 144.0 35.21 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.572 HG23 HD13 ' A' ' 153' ' ' LEU . 10.8 p -57.78 -36.23 54.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.215 -0.928 . . . . 0.0 108.83 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.432 ' N ' HG13 ' A' ' 170' ' ' VAL . 42.5 p -76.39 -6.64 52.52 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.45 -0.782 . . . . 0.0 109.401 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.526 ' HA ' ' HB2' ' A' ' 133' ' ' SER . 2.8 mt-10 -89.72 -0.29 57.44 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.239 -0.913 . . . . 0.0 109.394 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . . . . . . . . . 3.2 m -144.06 174.35 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.253 -0.905 . . . . 0.0 109.21 179.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.491 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 53.9 tt0 -139.49 168.16 20.46 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.113 -0.992 . . . . 0.0 108.975 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.588 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 73.1 tttt -89.31 15.11 9.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.028 -1.045 . . . . 0.0 109.358 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.592 HD12 ' HG2' ' A' ' 128' ' ' MET . 79.8 mt 53.58 -88.42 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.241 -0.912 . . . . 0.0 109.615 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.511 ' N ' ' O ' ' A' ' 175' ' ' LYS . 74.0 mm-40 . . . . . 0 N--CA 1.489 1.49 0 O-C-N 121.114 -0.991 . . . . 0.0 109.459 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.63 -30.06 71.22 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.146 -1.208 . . . . 0.0 109.449 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 91.0 mtp -64.63 -21.6 66.76 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.205 -0.935 . . . . 0.0 109.469 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 17.1 tttp -106.17 120.08 40.9 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.252 -0.905 . . . . 0.0 109.415 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.557 ' HG2' HG22 ' A' ' 65' ' ' ILE . 36.8 mttt -105.89 159.65 15.86 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 109.55 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.533 ' HB3' ' HB3' ' A' ' 92' ' ' PRO . 9.4 mttt -132.36 176.29 8.54 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.298 -0.876 . . . . 0.0 109.337 179.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.864 ' O ' HG23 ' A' ' 93' ' ' VAL . 64.8 m95 -112.67 124.04 51.66 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.924 . . . . 0.0 109.386 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.494 ' OH ' ' HG3' ' A' ' 66' ' ' MET . 78.4 m-85 -113.35 179.79 3.86 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.18 -0.95 . . . . 0.0 109.266 179.785 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.542 HG12 ' CE1' ' A' ' 61' ' ' PHE . 66.8 mt -119.7 107.38 21.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.186 -0.946 . . . . 0.0 109.384 -179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.555 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 13.1 p -86.01 144.6 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.271 -0.893 . . . . 0.0 109.518 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.797 HD11 ' HE1' ' A' ' 59' ' ' TYR . 2.8 mm? -94.8 143.83 26.14 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.336 -0.853 . . . . 0.0 109.601 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.405 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 1.3 p -151.3 -168.59 3.14 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.307 -0.87 . . . . 0.0 109.317 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.437 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 95.4 mtp -106.2 136.15 46.42 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.181 -0.949 . . . . 0.0 109.294 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.8 t -55.8 123.38 14.0 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.246 -0.908 . . . . 0.0 109.424 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.08 -19.67 32.11 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.342 -1.503 . . . . 0.0 109.342 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.437 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.8 m-85 -108.15 -11.26 15.29 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.323 -1.104 . . . . 0.0 109.561 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.473 ' OE2' ' N ' ' A' ' 58' ' ' GLY . 77.5 mt-10 -46.52 -61.5 1.79 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.187 -0.945 . . . . 0.0 109.408 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.891 ' OE2' HD11 ' A' ' 44' ' ' ILE . 67.4 mm-40 -47.98 -36.55 12.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.288 -0.883 . . . . 0.0 109.339 179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -71.69 -45.96 60.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.346 -0.847 . . . . 0.0 109.436 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.852 HG22 ' CB ' ' A' ' 79' ' ' TYR . 78.8 t -57.31 -47.14 85.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.186 -0.946 . . . . 0.0 109.444 179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.738 ' HD2' HD11 ' A' ' 42' ' ' ILE . 21.7 tttt -56.09 -51.54 67.5 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.234 -0.916 . . . . 0.0 109.532 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 61.1 tt0 -63.06 -33.67 75.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.166 -0.959 . . . . 0.0 109.398 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.581 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 23.6 m120 -66.18 -41.26 90.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.318 -0.864 . . . . 0.0 109.501 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.453 HG13 ' O ' ' A' ' 20' ' ' VAL . 92.2 mt -60.52 -44.98 97.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.217 -0.927 . . . . 0.0 109.43 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -55.77 -47.09 77.63 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.201 -0.937 . . . . 0.0 109.672 -179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 71.5 mttt -70.19 -34.71 73.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.136 -0.977 . . . . 0.0 109.316 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.562 ' HD2' HG23 ' A' ' 77' ' ' VAL . 34.4 tttp -57.14 -35.9 70.05 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.379 -0.826 . . . . 0.0 109.478 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.816 HG13 ' O ' ' A' ' 33' ' ' ILE . 33.8 t -81.32 -25.51 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.241 -0.912 . . . . 0.0 109.529 -179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -71.6 -56.56 5.63 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.248 -0.908 . . . . 0.0 109.562 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.86 -26.2 45.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.223 -0.923 . . . . 0.0 109.553 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.476 ' OG1' HG12 ' A' ' 33' ' ' ILE . 41.8 p -98.05 -28.66 13.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.192 -0.942 . . . . 0.0 109.57 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 76.88 21.1 75.06 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.816 ' O ' HG13 ' A' ' 28' ' ' VAL . 34.1 mm -90.02 94.87 5.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -1.154 . . . . 0.0 109.495 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 16.0 mttp -97.74 5.13 49.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.183 -0.948 . . . . 0.0 109.49 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -110.22 13.45 23.07 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.203 -0.936 . . . . 0.0 109.341 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.052 HD21 ' HB2' ' A' ' 70' ' ' ALA . 1.2 tm? -115.73 -54.28 2.52 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.329 -0.857 . . . . 0.0 109.187 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.572 ' HB ' HG21 ' A' ' 28' ' ' VAL . 42.9 t -99.21 130.01 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.443 -0.786 . . . . 0.0 109.219 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.82 -124.33 5.22 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 90.7 mtt180 -96.51 141.94 29.19 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.266 -1.138 . . . . 0.0 109.589 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.409 HD13 HD12 ' A' ' 24' ' ' ILE . 63.3 mt -101.43 138.1 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.297 -0.877 . . . . 0.0 109.251 179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 1.13 HG21 HD11 ' A' ' 107' ' ' LEU . 44.4 t -126.42 137.51 57.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.236 -0.915 . . . . 0.0 109.285 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.807 HG22 HG23 ' A' ' 44' ' ' ILE . 12.2 mt -128.08 127.84 23.79 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.187 -0.946 . . . . 0.0 109.692 -179.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.53 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 45.6 Cg_endo -68.05 -3.86 11.45 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.895 2.396 . . . . 0.0 111.461 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.891 HD11 ' OE2' ' A' ' 18' ' ' GLU . 18.8 pt -76.36 -6.11 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.307 -0.87 . . . . 0.0 109.561 -179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.439 ' NH1' ' HG3' ' A' ' 45' ' ' ARG . 5.6 ttt85 -44.48 -33.53 1.75 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.212 -0.93 . . . . 0.0 109.428 -179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 74.6 -156.62 49.85 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -164.58 -158.01 9.98 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 48.8 tt0 -52.24 -29.53 23.26 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.275 -1.132 . . . . 0.0 109.469 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.792 ' HD3' HG21 ' A' ' 167' ' ' VAL . 66.0 mtm180 -52.04 154.26 2.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.244 -0.91 . . . . 0.0 109.346 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.442 ' O ' ' HB2' ' A' ' 51' ' ' LYS . 44.6 mtp180 -127.15 160.67 30.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.214 -0.928 . . . . 0.0 109.521 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . 0.442 ' HB2' ' O ' ' A' ' 50' ' ' ARG . 21.8 mttm 62.31 28.72 17.1 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.258 -0.901 . . . . 0.0 109.529 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.425 ' C ' ' HG3' ' A' ' 53' ' ' GLU . 48.2 t -161.81 126.09 3.31 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.222 -0.923 . . . . 0.0 109.502 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.495 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 82.1 mt-10 -151.67 169.38 22.3 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.161 -0.962 . . . . 0.0 109.578 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.727 ' HA ' HG22 ' A' ' 44' ' ' ILE . 6.2 mttt 75.1 82.72 0.1 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.642 179.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.53 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 16.7 mt -71.83 -21.47 61.68 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.136 -0.978 . . . . 0.0 109.407 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.968 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 37.2 m-85 -143.95 93.09 6.17 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.285 -0.885 . . . . 0.0 108.826 179.688 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -64.34 135.91 48.61 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 122.628 2.219 . . . . 0.0 112.267 -179.193 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.473 ' N ' ' OE2' ' A' ' 17' ' ' GLU . . . 78.81 -20.52 4.42 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 179.541 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.797 ' HE1' HD11 ' A' ' 11' ' ' LEU . 3.9 m-30 -96.34 127.81 42.68 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.707 -1.467 . . . . 0.0 110.47 -179.085 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.555 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 94.3 t -135.59 150.41 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.111 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.542 ' CE1' HG12 ' A' ' 9' ' ' ILE . 86.8 m-85 -108.46 122.97 48.14 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.858 -1.151 . . . . 0.0 110.227 -179.248 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 87.9 t -121.98 127.8 75.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.322 -0.861 . . . . 0.0 109.873 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.587 ' HG3' ' CD1' ' A' ' 7' ' ' TRP . 7.6 tt0 -89.68 121.76 32.16 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.282 -0.886 . . . . 0.0 109.278 179.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . . . . . . . . . 14.8 ptt? -154.04 174.08 15.17 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.03 -1.044 . . . . 0.0 110.538 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.662 HG12 HD22 ' A' ' 36' ' ' LEU . 39.0 pt -100.35 134.99 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.755 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.551 ' O ' ' HB3' ' A' ' 67' ' ' ASN . 84.9 mtp -79.55 142.87 35.34 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.096 -1.003 . . . . 0.0 110.799 -178.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.551 ' HB3' ' O ' ' A' ' 66' ' ' MET . 16.4 p30 171.67 -174.31 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 93.0 m-20 -76.51 -42.89 41.67 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.147 -0.971 . . . . 0.0 110.006 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.621 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 85.1 tt0 -66.54 -31.42 72.13 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.216 -0.927 . . . . 0.0 110.383 -179.299 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.052 ' HB2' HD21 ' A' ' 36' ' ' LEU . . . -77.11 -40.78 44.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.848 -1.157 . . . . 0.0 109.791 -179.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.468 ' CD1' ' OE1' ' A' ' 89' ' ' GLN . 87.3 t80 -58.79 -51.41 70.1 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.11 -0.994 . . . . 0.0 109.586 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.471 ' O ' ' HB3' ' A' ' 76' ' ' SER . 38.1 t-20 -69.89 -27.27 64.67 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.201 -0.937 . . . . 0.0 110.581 -179.196 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.621 ' CD1' ' O ' ' A' ' 69' ' ' GLU . 5.1 m-85 -78.19 -41.21 35.26 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.693 -1.254 . . . . 0.0 110.073 -179.447 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.848 HG22 ' CZ ' ' A' ' 83' ' ' PHE . 7.7 p -66.48 -52.11 50.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.22 -0.925 . . . . 0.0 109.232 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.662 ' N ' HG13 ' A' ' 74' ' ' VAL . 7.5 mmm-85 -67.59 -1.22 4.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.313 -0.867 . . . . 0.0 109.904 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 89.3 p -101.0 -4.94 26.53 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.031 -1.043 . . . . 0.0 110.167 -179.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.873 ' O ' HG12 ' A' ' 80' ' ' VAL . 5.6 p -80.13 137.9 52.95 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 120.994 -1.066 . . . . 0.0 109.377 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.624 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 43.5 Cg_endo -65.77 140.53 61.97 Favored 'Trans proline' 0 C--O 1.213 -0.737 0 C-N-CA 122.763 2.308 . . . . 0.0 112.119 -179.367 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.852 ' CB ' HG22 ' A' ' 20' ' ' VAL . 42.0 m-85 89.0 -11.89 0.41 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.831 -0.543 . . . . 0.0 109.675 -179.691 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.873 HG12 ' O ' ' A' ' 77' ' ' VAL . 7.9 p -81.84 119.03 30.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.957 -1.089 . . . . 0.0 109.299 179.772 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.8 mmm -88.44 -27.16 21.71 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.196 -0.94 . . . . 0.0 109.41 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.588 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.27 -158.03 28.58 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.848 ' CZ ' HG22 ' A' ' 74' ' ' VAL . 7.4 m-85 -139.61 156.95 46.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -1.124 . . . . 0.0 109.573 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 84' ' ' VAL . 7.7 p -88.74 118.69 34.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.232 -0.918 . . . . 0.0 109.339 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.596 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.8 OUTLIER -157.0 166.78 32.38 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -0.915 . . . . 0.0 109.627 -179.944 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 m -87.06 -29.93 21.54 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.405 -0.809 . . . . 0.0 109.432 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.44 -103.18 1.4 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -99.5 -124.34 5.19 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.559 ' C ' ' O ' ' A' ' 88' ' ' GLY . 0.0 OUTLIER -29.24 146.09 0.05 OUTLIER Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.524 -0.986 . . . . 0.0 110.142 -179.751 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.596 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 48.2 Cg_endo -68.66 153.92 72.41 Favored 'Trans proline' 0 C--O 1.216 -0.601 0 C-N-CA 122.827 2.352 . . . . 0.0 112.001 -179.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.2 m -89.9 149.75 42.43 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.301 -0.874 . . . . 0.0 109.253 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.533 ' HB3' ' HB3' ' A' ' 6' ' ' LYS . 49.5 Cg_endo -69.62 152.37 70.01 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.682 2.255 . . . . 0.0 111.664 -179.925 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.864 HG23 ' O ' ' A' ' 7' ' ' TRP . 15.5 t -79.93 141.21 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -0.885 . . . . 0.0 109.322 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . 0.5 ' O ' ' N ' ' A' ' 97' ' ' GLU . 69.6 tttt -78.9 130.14 35.3 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.086 -1.009 . . . . 0.0 109.357 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.442 ' C ' ' O ' ' A' ' 94' ' ' LYS . 81.3 m-20 -42.78 -41.96 3.4 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.189 -0.944 . . . . 0.0 109.367 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.462 ' CD ' ' HE2' ' A' ' 94' ' ' LYS . 75.1 mtt180 -56.36 -29.91 62.0 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.271 -0.893 . . . . 0.0 109.433 179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.5 ' N ' ' O ' ' A' ' 94' ' ' LYS . 47.5 mt-10 -88.07 -28.26 21.44 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.221 -0.924 . . . . 0.0 109.589 -179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.599 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 94.6 mtp -82.91 -25.51 32.37 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.148 -0.97 . . . . 0.0 109.431 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.567 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.14 -54.62 1.08 Allowed Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.524 -0.735 . . . . 0.0 109.995 -179.845 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.614 ' HB2' ' CE2' ' A' ' 136' ' ' PHE . 49.4 Cg_endo -70.17 -27.75 24.14 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 122.591 2.194 . . . . 0.0 112.132 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.525 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 18.9 mm -80.21 -42.74 21.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.156 -0.965 . . . . 0.0 109.546 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.557 HD11 ' CB ' ' A' ' 98' ' ' MET . 0.8 OUTLIER -67.36 -40.63 85.79 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.207 -0.933 . . . . 0.0 109.494 -179.884 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.54 ' CG ' ' HB3' ' A' ' 135' ' ' PRO . 22.2 tpt180 -65.13 -49.73 68.78 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.326 -0.859 . . . . 0.0 109.162 179.722 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 1.4 tt -72.05 -37.86 69.61 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.208 -0.932 . . . . 0.0 109.2 179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.52 -1.04 9.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.398 -0.814 . . . . 0.0 109.829 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.75 8.57 86.42 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 1.13 HD11 HG21 ' A' ' 41' ' ' VAL . 29.3 mt -78.38 -21.4 49.44 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.19 -1.182 . . . . 0.0 109.613 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 42.6 tp10 -124.81 134.37 52.78 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.15 -0.969 . . . . 0.0 109.365 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 64.9 mt-10 -120.4 108.33 14.0 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.918 . . . . 0.0 109.557 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.578 ' CD1' ' O ' ' A' ' 111' ' ' GLU . 35.0 p90 -138.47 164.86 28.3 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.313 -0.867 . . . . 0.0 109.455 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.578 ' O ' ' CD1' ' A' ' 110' ' ' TYR . 61.9 mm-40 -62.5 -142.05 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.891 . . . . 0.0 109.636 -179.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -161.29 172.21 17.02 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.289 -0.882 . . . . 0.0 109.425 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.615 ' CG ' ' HA ' ' A' ' 133' ' ' SER . 7.3 mmtp -68.3 -56.04 9.97 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.215 -0.928 . . . . 0.0 109.623 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.424 ' HG3' ' C ' ' A' ' 113' ' ' LYS . 8.7 mttt 50.36 23.59 1.28 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.347 -0.846 . . . . 0.0 109.475 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.52 ' HG2' ' HB3' ' A' ' 113' ' ' LYS . 0.4 OUTLIER -101.25 104.66 34.56 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.289 -0.882 . . . . 0.0 109.48 -179.948 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -70.77 117.98 5.44 Favored 'Trans proline' 0 C--O 1.216 -0.589 0 C-N-CA 122.661 2.24 . . . . 0.0 111.707 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 21.9 t -129.83 129.68 66.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.18 -0.95 . . . . 0.0 109.44 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 23.4 mttt -65.31 147.63 53.1 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 109.482 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 29.5 m -114.54 167.88 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.308 -0.87 . . . . 0.0 109.405 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.663 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 84.4 mt-10 -60.49 -35.28 75.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 109.497 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.663 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 5.1 mt 145.0 155.16 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.844 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.626 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -21.95 93.82 0.01 OUTLIER Glycine 0 N--CA 1.494 2.564 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.533 ' O ' ' CD1' ' A' ' 146' ' ' ILE . 18.0 m-85 -47.59 178.56 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.294 -1.121 . . . . 0.0 109.528 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.443 ' O ' ' HB2' ' A' ' 127' ' ' ASP . 80.9 mttt -102.08 148.72 25.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.166 -0.958 . . . . 0.0 109.915 -179.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 20.5 m -64.14 144.26 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.433 -0.792 . . . . 0.0 109.375 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 85.72 -29.92 4.38 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.348 -1.501 . . . . 0.0 109.348 -179.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.553 ' HB2' HD12 ' A' ' 143' ' ' ILE . 26.2 m-20 -48.01 165.71 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.306 -1.114 . . . . 0.0 109.127 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . 0.481 ' HG3' HG12 ' A' ' 142' ' ' VAL . 2.9 ttm -103.54 127.8 50.88 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.136 -0.978 . . . . 0.0 109.153 179.775 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.674 HG11 HD11 ' A' ' 143' ' ' ILE . 26.8 m -129.06 145.88 35.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.855 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.443 ' HA ' ' HA ' ' A' ' 140' ' ' ALA . 42.2 tttt -102.81 142.41 33.99 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.87 HD12 ' HB3' ' A' ' 139' ' ' PHE . 60.5 mt -83.14 154.34 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.488 HG12 ' HA ' ' A' ' 173' ' ' VAL . 0.2 OUTLIER -152.02 2.78 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 120.948 -1.095 . . . . 0.0 109.65 179.828 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.615 ' HA ' ' CG ' ' A' ' 113' ' ' LYS . 47.3 t -148.03 144.1 27.69 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.07 -1.019 . . . . 0.0 110.252 -179.66 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 99.62 -163.18 19.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.54 ' HB3' ' CG ' ' A' ' 103' ' ' ARG . 46.8 Cg_endo -67.89 -23.46 41.14 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 123.312 2.675 . . . . 0.0 112.541 -179.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.649 ' HB2' HD13 ' A' ' 131' ' ' ILE . 93.2 m-85 -104.22 17.61 23.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.957 -1.09 . . . . 0.0 109.562 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.553 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.9 tt0 -43.83 133.61 4.76 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.251 -0.906 . . . . 0.0 109.649 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.545 ' CB ' ' O ' ' A' ' 137' ' ' GLU . 16.8 t0 78.92 19.26 0.82 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.262 -0.899 . . . . 0.0 110.36 179.161 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.87 ' HB3' HD12 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -109.24 130.4 55.49 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.912 -1.117 . . . . 0.0 109.47 179.825 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -83.7 136.9 34.01 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.16 -0.963 . . . . 0.0 109.597 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -146.55 175.6 25.89 Favored Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.67 -1.252 . . . . 0.0 110.612 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.828 ' C ' HG13 ' A' ' 155' ' ' VAL . 19.4 m -118.42 137.01 53.76 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.702 -0.881 . . . . 0.0 109.659 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.674 HD11 HG11 ' A' ' 129' ' ' VAL . 93.3 mt -67.48 114.6 4.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.321 -0.862 . . . . 0.0 109.407 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -98.15 -34.51 10.72 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.976 -1.077 . . . . 0.0 109.331 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -150.8 145.58 25.81 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.153 -0.967 . . . . 0.0 109.367 179.771 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.686 HG23 ' CD1' ' A' ' 153' ' ' LEU . 2.2 mt -122.74 126.28 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.202 -0.936 . . . . 0.0 109.678 -179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -107.41 101.68 40.32 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.314 -0.867 . . . . 0.0 109.447 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.528 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.1 Cg_endo -71.96 170.92 17.73 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 122.734 2.29 . . . . 0.0 111.899 179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.7 tt0 79.85 -20.92 0.36 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.336 -0.852 . . . . 0.0 109.862 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.412 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 66.6 mtp85 -125.35 -13.18 6.7 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.155 -0.965 . . . . 0.0 109.43 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.412 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 36.2 mt-30 68.98 49.08 0.67 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.204 -0.935 . . . . 0.0 109.678 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -121.1 145.25 48.0 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.111 -0.993 . . . . 0.0 108.896 179.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.686 ' CD1' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -135.82 113.13 10.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.035 -1.041 . . . . 0.0 110.262 -179.498 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 10.4 mttt -79.59 133.25 36.43 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.102 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.828 HG13 ' C ' ' A' ' 142' ' ' VAL . 21.5 t -126.34 150.49 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.077 -1.014 . . . . 0.0 110.01 -179.27 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.51 ' OD1' ' N ' ' A' ' 164' ' ' THR . 20.9 t-20 -97.26 114.5 26.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.446 -0.784 . . . . 0.0 109.293 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.709 HG12 HG23 ' A' ' 159' ' ' ILE . 50.0 t -95.98 139.77 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.159 -0.963 . . . . 0.0 109.712 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 20.6 m -92.55 95.24 9.5 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.409 -0.807 . . . . 0.0 109.514 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.968 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 5.5 pt -130.9 150.2 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.269 -0.895 . . . . 0.0 109.488 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.601 ' CE2' HD12 ' A' ' 159' ' ' ILE . 13.7 m-30 62.95 33.13 15.18 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.271 -0.893 . . . . 0.0 109.313 -179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 60.64 16.35 44.64 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 60.0 mtt-85 -135.63 159.27 42.16 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.188 -1.183 . . . . 0.0 109.455 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.449 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 95.6 mt-10 -100.46 140.85 34.14 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.244 -0.91 . . . . 0.0 109.516 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . 0.51 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 16.4 m -148.0 127.86 6.59 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.325 -0.859 . . . . 0.0 109.46 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 49.5 Cg_endo -69.86 140.0 41.23 Favored 'Trans proline' 0 C--O 1.216 -0.619 0 C-N-CA 122.751 2.301 . . . . 0.0 111.583 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 1.024 HG23 HD21 ' A' ' 168' ' ' LEU . 35.2 m -121.28 168.19 13.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.056 -1.028 . . . . 0.0 109.598 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 1.136 ' O ' HD13 ' A' ' 168' ' ' LEU . 8.4 m -118.2 115.66 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.442 -0.786 . . . . 0.0 109.492 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 1.136 HD13 ' O ' ' A' ' 167' ' ' VAL . 0.0 OUTLIER -139.56 166.28 25.0 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-O 121.797 0.808 . . . . 0.0 109.937 179.959 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.452 ' O ' ' HB2' ' A' ' 172' ' ' GLU . 40.5 m80 -79.04 139.72 38.09 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.175 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.484 HG13 ' N ' ' A' ' 171' ' ' SER . 11.4 p -51.43 -37.91 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.067 -1.021 . . . . 0.0 108.521 179.598 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.484 ' N ' HG13 ' A' ' 170' ' ' VAL . 53.3 p -74.86 -4.83 40.16 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.615 -0.678 . . . . 0.0 109.798 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.479 ' HG2' ' HB3' ' A' ' 133' ' ' SER . 23.8 mt-10 -92.7 -6.44 49.19 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.077 -1.014 . . . . 0.0 109.874 -179.712 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.488 ' HA ' HG12 ' A' ' 132' ' ' ILE . 4.1 m -137.29 175.15 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.057 -1.027 . . . . 0.0 109.488 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.543 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 84.4 tt0 -140.02 164.53 29.77 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.263 -0.898 . . . . 0.0 109.132 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.543 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 51.8 tttt -90.18 19.03 5.32 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.055 -1.028 . . . . 0.0 109.347 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.563 HG22 ' N ' ' A' ' 177' ' ' GLU . 71.1 mt 54.89 164.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.293 -0.879 . . . . 0.0 109.571 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.563 ' N ' HG22 ' A' ' 176' ' ' ILE . 90.5 mt-10 . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 118.007 -0.997 . . . . 0.0 109.471 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.05 -25.01 67.43 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.262 -1.14 . . . . 0.0 109.601 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 90.0 mtp -72.6 -10.92 60.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.221 -0.925 . . . . 0.0 109.535 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 89.2 mttt -112.42 121.08 43.81 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.186 -0.946 . . . . 0.0 109.528 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.514 ' HG2' HG22 ' A' ' 65' ' ' ILE . 72.1 mttt -115.74 143.58 45.18 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.293 -0.879 . . . . 0.0 109.496 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.591 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 26.0 mtpp -130.56 174.72 9.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.282 -0.886 . . . . 0.0 109.28 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.903 ' O ' HG23 ' A' ' 93' ' ' VAL . 61.9 m95 -108.84 124.43 50.61 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.232 -0.917 . . . . 0.0 109.031 179.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.487 ' O ' ' HA ' ' A' ' 61' ' ' PHE . 79.5 m-85 -110.92 174.07 6.03 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.163 -0.961 . . . . 0.0 109.569 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.535 HG12 ' CD1' ' A' ' 61' ' ' PHE . 61.7 mt -116.76 109.05 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.316 -0.865 . . . . 0.0 109.141 179.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.716 ' CG2' HG23 ' A' ' 80' ' ' VAL . 9.7 p -90.88 142.98 12.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.178 -0.951 . . . . 0.0 109.65 -179.682 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.55 HD22 ' N ' ' A' ' 11' ' ' LEU . 3.5 mm? -89.5 153.86 20.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.353 -0.842 . . . . 0.0 109.615 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.499 HG21 ' HG2' ' A' ' 17' ' ' GLU . 9.2 t -162.84 -172.87 3.24 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.251 -0.906 . . . . 0.0 109.349 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.519 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 67.5 mtm -103.54 133.45 48.56 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.227 -0.92 . . . . 0.0 109.658 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 32.4 m -54.43 127.4 27.36 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.285 -0.884 . . . . 0.0 109.383 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.23 -20.18 38.43 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.519 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 85.6 m-85 -107.51 -1.56 21.24 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.34 -1.094 . . . . 0.0 109.429 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.499 ' HG2' HG21 ' A' ' 12' ' ' THR . 46.3 mt-10 -55.21 -59.4 4.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.233 -0.917 . . . . 0.0 109.388 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -47.48 -36.38 10.1 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.345 -0.847 . . . . 0.0 109.402 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 12.9 mttp -72.44 -46.46 54.89 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.201 -0.937 . . . . 0.0 109.388 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.527 HG22 ' HB2' ' A' ' 79' ' ' TYR . 73.4 t -55.09 -47.17 77.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.281 -0.887 . . . . 0.0 109.307 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.871 ' HD2' HD11 ' A' ' 42' ' ' ILE . 17.8 tttm -56.23 -50.92 69.92 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.225 -0.922 . . . . 0.0 109.413 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -63.25 -37.39 87.05 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.189 -0.944 . . . . 0.0 109.522 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.583 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 31.5 m120 -61.89 -49.04 77.82 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.203 -0.935 . . . . 0.0 109.565 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.465 ' O ' HG13 ' A' ' 28' ' ' VAL . 81.2 mt -53.93 -44.22 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.08 -1.013 . . . . 0.0 109.354 179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.636 ' O ' HG22 ' A' ' 28' ' ' VAL . 83.1 tt0 -56.56 -47.95 78.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.188 -0.945 . . . . 0.0 110.035 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 40.4 mttp -73.41 -36.95 66.06 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.145 -0.972 . . . . 0.0 109.939 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.482 ' HD3' HG23 ' A' ' 77' ' ' VAL . 23.7 ttpp -56.31 -34.12 66.21 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.122 -0.986 . . . . 0.0 109.325 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 1.079 HG11 HG11 ' A' ' 37' ' ' VAL . 12.0 m -87.34 -25.55 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.42 -0.8 . . . . 0.0 109.489 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -72.01 -57.75 4.03 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.303 -0.873 . . . . 0.0 109.298 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.85 -40.79 61.12 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.397 -0.814 . . . . 0.0 109.243 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.698 HG21 ' CZ ' ' A' ' 73' ' ' PHE . 72.7 p -83.07 -26.15 31.38 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.325 -0.859 . . . . 0.0 109.483 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 77.51 25.02 64.02 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.628 HD12 ' CE2' ' A' ' 73' ' ' PHE . 15.9 mt -94.07 92.9 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.244 -1.15 . . . . 0.0 109.359 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 41.8 mttt -105.71 -12.95 15.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.349 -0.845 . . . . 0.0 109.505 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.1 t-20 -86.25 -19.6 29.71 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.182 -0.949 . . . . 0.0 109.428 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.1 HD11 ' CB ' ' A' ' 70' ' ' ALA . 15.1 tp -89.36 -51.58 5.49 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.307 -0.87 . . . . 0.0 109.461 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 1.079 HG11 HG11 ' A' ' 28' ' ' VAL . 7.3 p -93.83 136.58 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.52 -0.737 . . . . 0.0 109.018 179.672 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.5 -120.9 4.59 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.4 mtt85 -104.44 140.04 38.51 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.286 -1.126 . . . . 0.0 109.878 -179.399 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.547 HG22 ' HB ' ' A' ' 62' ' ' VAL . 12.9 pt -112.74 148.26 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.354 -0.841 . . . . 0.0 109.021 179.407 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.829 HG13 ' CH2' ' A' ' 7' ' ' TRP . 23.2 m -132.22 161.77 40.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.076 -1.015 . . . . 0.0 109.91 -179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.871 HD11 ' HD2' ' A' ' 21' ' ' LYS . 3.8 mt -135.28 130.84 19.36 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.379 -0.826 . . . . 0.0 109.333 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.492 ' HB2' ' HB2' ' A' ' 55' ' ' LEU . 43.0 Cg_endo -65.12 -3.59 7.53 Favored 'Trans proline' 0 C--O 1.215 -0.663 0 C-N-CA 122.851 2.368 . . . . 0.0 111.873 -179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.819 HG13 HG22 ' A' ' 42' ' ' ILE . 15.3 mt -65.11 -44.09 95.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.146 -0.971 . . . . 0.0 109.446 179.701 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.935 ' O ' HD21 ' A' ' 104' ' ' LEU . 18.6 ttt180 -47.03 146.16 1.83 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.213 -0.93 . . . . 0.0 109.486 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.666 ' HA3' HD11 ' A' ' 104' ' ' LEU . . . 113.98 97.22 2.22 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.92 24.7 52.0 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.494 ' O ' ' OE2' ' A' ' 53' ' ' GLU . 50.8 tt0 -51.5 -40.78 60.23 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -1.142 . . . . 0.0 109.486 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 46.1 ttt180 -56.61 -36.61 69.63 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.068 -1.02 . . . . 0.0 109.379 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.72 HH11 HG11 ' A' ' 167' ' ' VAL . 39.1 mtp-105 -66.76 154.34 41.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.236 -0.915 . . . . 0.0 109.519 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 24.1 mttm -65.76 -32.8 74.55 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.247 -0.908 . . . . 0.0 109.538 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.42 ' C ' ' HG3' ' A' ' 53' ' ' GLU . 45.5 p -80.81 138.59 36.25 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.261 -0.899 . . . . 0.0 109.72 -179.702 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.494 ' OE2' ' O ' ' A' ' 48' ' ' GLN . 69.3 mt-10 -155.55 173.12 17.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.48 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.656 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 7.2 mttp 74.33 87.03 0.1 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.351 -0.843 . . . . 0.0 109.504 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.492 ' HB2' ' HB2' ' A' ' 43' ' ' PRO . 41.2 mt -68.06 -20.78 65.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.061 -1.025 . . . . 0.0 109.3 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.762 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 90.0 m-85 -143.66 98.2 5.37 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.304 -0.873 . . . . 0.0 109.044 179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.3 Cg_endo -65.52 132.88 32.5 Favored 'Trans proline' 0 C--O 1.215 -0.65 0 C-N-CA 122.784 2.322 . . . . 0.0 112.216 -179.3 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.496 ' HA2' HG23 ' A' ' 12' ' ' THR . . . 77.02 -15.41 6.47 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.571 ' HB2' ' HB3' ' A' ' 56' ' ' PHE . 2.9 m-85 -97.83 129.59 44.8 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.624 -1.515 . . . . 0.0 110.38 -179.159 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.533 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 79.2 t -137.19 149.19 25.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 179.41 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.57 ' HB2' ' CG2' ' A' ' 41' ' ' VAL . 63.5 m-85 -109.67 124.39 51.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.025 -1.047 . . . . 0.0 110.23 -179.416 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.547 ' HB ' HG22 ' A' ' 40' ' ' ILE . 1.3 m -123.44 135.43 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.452 -0.78 . . . . 0.0 109.604 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.619 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 19.5 tt0 -104.87 122.91 46.76 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.222 -0.923 . . . . 0.0 109.402 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.544 ' HG2' ' O ' ' A' ' 63' ' ' GLU . 22.3 mtm -157.96 179.47 9.15 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.085 -1.009 . . . . 0.0 110.344 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 1.046 ' CG1' HD12 ' A' ' 36' ' ' LEU . 8.4 pt -94.72 129.01 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.454 ' O ' ' HB2' ' A' ' 67' ' ' ASN . 37.0 ttm -77.83 146.22 35.85 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.255 -0.903 . . . . 0.0 110.131 -178.581 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.454 ' HB2' ' O ' ' A' ' 66' ' ' MET . 20.8 t-20 176.58 177.72 0.25 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.596 -0.69 . . . . 0.0 109.258 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -73.38 -42.5 62.09 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.159 -0.963 . . . . 0.0 109.284 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 87.9 mt-10 -76.48 -28.18 56.37 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.23 -0.919 . . . . 0.0 109.559 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.1 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -74.55 -48.15 28.53 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.262 -0.899 . . . . 0.0 109.569 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.568 ' CD1' ' HG3' ' A' ' 89' ' ' GLN . 84.0 t80 -60.52 -45.66 93.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.227 -0.921 . . . . 0.0 109.57 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -67.4 -27.3 66.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.986 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.698 ' CZ ' HG21 ' A' ' 31' ' ' THR . 10.6 t80 -81.18 -41.59 22.12 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.078 -1.014 . . . . 0.0 109.897 -179.711 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.683 HG13 ' N ' ' A' ' 75' ' ' ARG . 14.6 p -69.57 -53.77 22.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.426 -0.796 . . . . 0.0 109.585 -179.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.683 ' N ' HG13 ' A' ' 74' ' ' VAL . 14.4 tpt85 -61.15 -11.15 7.89 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.128 -0.983 . . . . 0.0 109.825 -179.724 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 91.4 p -92.77 4.5 53.67 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.169 -0.957 . . . . 0.0 109.963 -179.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.917 ' O ' HG12 ' A' ' 80' ' ' VAL . 5.2 p -76.82 135.17 67.92 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.037 -1.039 . . . . 0.0 109.344 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.622 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 42.8 Cg_endo -65.18 140.66 65.92 Favored 'Trans proline' 0 C--O 1.214 -0.72 0 C-N-CA 122.672 2.248 . . . . 0.0 112.109 -179.532 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.622 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 38.5 m-85 89.55 -9.48 0.4 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.918 -0.489 . . . . 0.0 109.744 -179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.917 HG12 ' O ' ' A' ' 77' ' ' VAL . 7.8 p -88.2 125.01 41.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.049 -1.032 . . . . 0.0 109.496 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 95.9 mmm -85.09 -26.42 26.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.108 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.531 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.23 -157.52 28.15 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.634 ' CE1' HG23 ' A' ' 10' ' ' VAL . 14.5 m-85 -132.79 149.28 52.29 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.265 -1.138 . . . . 0.0 109.459 179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.675 HG13 ' O ' ' A' ' 84' ' ' VAL . 10.9 p -74.33 115.75 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.2 -0.938 . . . . 0.0 109.427 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.528 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 1.1 p -152.83 166.58 31.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.263 -0.898 . . . . 0.0 109.403 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 33.2 t -96.01 -29.96 13.84 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.282 -0.886 . . . . 0.0 109.393 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -130.59 -80.24 0.22 Allowed Glycine 0 N--CA 1.489 2.19 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.533 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -110.18 -136.25 7.3 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.568 ' HG3' ' CD1' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -31.81 150.37 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.526 -0.985 . . . . 0.0 110.245 -179.619 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.528 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.5 Cg_endo -69.36 159.05 55.19 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.967 2.445 . . . . 0.0 111.884 -179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 28.5 m -88.9 151.69 47.61 Favored Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.207 -0.933 . . . . 0.0 109.279 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.541 ' CB ' ' HE2' ' A' ' 6' ' ' LYS . 50.6 Cg_endo -70.45 145.75 54.01 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 122.686 2.258 . . . . 0.0 111.789 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.903 HG23 ' O ' ' A' ' 7' ' ' TRP . 3.6 t -79.74 129.71 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.182 -0.949 . . . . 0.0 109.169 179.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . 0.442 ' O ' ' C ' ' A' ' 95' ' ' ASP . 32.4 mttp -73.92 134.0 43.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.441 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.442 ' C ' ' O ' ' A' ' 94' ' ' LYS . 69.2 m-20 -42.63 -41.65 3.16 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.286 -0.883 . . . . 0.0 109.463 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 56.6 ttt180 -54.6 -28.64 47.87 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.235 -0.915 . . . . 0.0 109.362 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.44 ' N ' ' O ' ' A' ' 94' ' ' LYS . 23.2 mm-40 -89.38 -28.39 19.81 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.266 -0.896 . . . . 0.0 109.558 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.558 ' CB ' HD11 ' A' ' 102' ' ' LEU . 33.6 mmm -84.14 -28.55 27.35 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.254 -0.904 . . . . 0.0 109.427 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.593 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -35.88 -53.89 1.42 Allowed Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.465 -0.772 . . . . 0.0 109.903 -179.913 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.5 Cg_endo -69.65 -28.2 26.05 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 122.496 2.13 . . . . 0.0 111.707 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.484 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 29.2 mm -80.69 -42.63 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.262 -0.898 . . . . 0.0 109.317 179.667 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.696 HD23 ' CD2' ' A' ' 107' ' ' LEU . 0.9 OUTLIER -67.73 -40.13 84.23 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.311 -0.868 . . . . 0.0 109.214 179.76 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -63.77 -50.72 67.92 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.337 -0.852 . . . . 0.0 109.096 179.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.935 HD21 ' O ' ' A' ' 45' ' ' ARG . 0.4 OUTLIER -71.82 -36.46 70.23 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.387 -0.821 . . . . 0.0 109.366 179.598 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.56 ' CB ' HD13 ' A' ' 107' ' ' LEU . . . -70.29 -0.41 8.0 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.277 -0.889 . . . . 0.0 109.995 -179.838 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 77.38 8.75 87.07 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.696 ' CD2' HD23 ' A' ' 102' ' ' LEU . 9.9 mp -74.94 -19.17 60.23 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -1.177 . . . . 0.0 109.509 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -130.73 142.53 50.42 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.2 -0.937 . . . . 0.0 109.544 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -114.19 122.52 47.04 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.224 -0.923 . . . . 0.0 109.621 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.483 ' OH ' ' HA ' ' A' ' 135' ' ' PRO . 28.2 p90 -150.78 162.28 41.03 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.344 -0.847 . . . . 0.0 109.441 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 79.8 mt-10 -101.81 -94.35 0.29 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.252 -0.905 . . . . 0.0 109.496 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.412 ' O ' ' CB ' ' A' ' 113' ' ' LYS . 8.3 mt-10 45.57 85.77 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.263 -0.898 . . . . 0.0 109.634 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.412 ' CB ' ' O ' ' A' ' 112' ' ' GLU . 2.9 tttt 170.21 -29.05 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.348 -0.845 . . . . 0.0 109.516 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 8.0 mttm -65.85 -19.47 65.89 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.205 -0.934 . . . . 0.0 109.377 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.94 112.72 27.1 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.171 -0.956 . . . . 0.0 109.571 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -70.31 133.8 25.39 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 122.712 2.275 . . . . 0.0 111.649 179.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 2.5 p -143.38 128.46 15.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.172 -0.955 . . . . 0.0 109.825 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 41.1 mttm -120.53 131.61 54.78 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.337 -0.852 . . . . 0.0 109.307 179.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.515 ' O ' ' HG ' ' A' ' 121' ' ' LEU . 6.0 m -138.31 -162.27 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.295 -0.878 . . . . 0.0 109.283 -179.741 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.649 ' O ' ' HB2' ' A' ' 121' ' ' LEU . 16.2 tt0 -44.66 -74.48 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.106 -0.996 . . . . 0.0 108.813 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.774 HD22 HG22 ' A' ' 170' ' ' VAL . 43.6 mt 76.34 168.41 0.26 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.372 -0.83 . . . . 0.0 110.36 179.134 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 50.64 62.38 5.26 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.614 ' CE2' ' HB3' ' A' ' 175' ' ' LYS . 0.2 OUTLIER -77.13 -174.9 3.38 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.318 -1.107 . . . . 0.0 108.431 178.63 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.435 ' HB2' ' OD2' ' A' ' 127' ' ' ASP . 40.0 mttm -97.22 156.34 16.46 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.95 -1.094 . . . . 0.0 109.531 -179.652 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 11.0 p -58.39 138.6 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.469 -0.77 . . . . 0.0 109.938 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.99 -31.89 4.84 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.705 -1.358 . . . . 0.0 109.705 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.561 ' HB3' ' CD2' ' A' ' 123' ' ' PHE . 45.3 m-20 -48.92 160.33 0.2 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.3 -1.118 . . . . 0.0 109.552 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 2.3 ttp -97.25 127.29 43.08 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.33 -0.857 . . . . 0.0 109.026 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.587 HG13 HG12 ' A' ' 143' ' ' ILE . 33.9 m -128.84 146.25 34.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.115 -0.99 . . . . 0.0 109.834 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.545 ' CB ' HG12 ' A' ' 176' ' ' ILE . 28.4 tttt -110.29 140.28 44.62 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.592 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 1.007 ' O ' HD13 ' A' ' 132' ' ' ILE . 74.6 mt -79.61 157.76 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.049 -1.032 . . . . 0.0 108.641 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 1.007 HD13 ' O ' ' A' ' 131' ' ' ILE . 0.6 OUTLIER -149.51 1.96 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.03 -1.043 . . . . 0.0 109.526 179.786 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.479 ' HB2' ' HA ' ' A' ' 172' ' ' GLU . 58.5 m -149.65 146.16 27.13 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.011 -1.055 . . . . 0.0 110.232 -179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.447 ' C ' ' HH ' ' A' ' 110' ' ' TYR . . . 102.99 -167.05 16.78 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.346 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.483 ' HA ' ' OH ' ' A' ' 110' ' ' TYR . 46.0 Cg_endo -68.08 -21.9 42.11 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 123.135 2.557 . . . . 0.0 112.524 -179.555 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.561 ' CE1' ' HB2' ' A' ' 100' ' ' PRO . 97.2 m-85 -110.29 16.31 21.77 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.006 -1.059 . . . . 0.0 109.578 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.581 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.3 tt0 -43.29 143.94 0.78 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.235 -0.915 . . . . 0.0 109.641 -179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 26.9 m-20 72.73 28.12 2.14 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.459 -0.776 . . . . 0.0 110.234 179.406 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.994 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.3 t80 -117.82 128.77 55.18 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.115 -0.991 . . . . 0.0 109.444 179.739 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.489 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -76.53 131.54 39.03 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.157 -0.965 . . . . 0.0 109.746 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 129' ' ' VAL . . . -139.53 165.77 25.72 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 -179.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.649 ' C ' HG23 ' A' ' 155' ' ' VAL . 37.5 t -113.34 137.53 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.351 -1.088 . . . . 0.0 109.063 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.869 HD12 ' CD2' ' A' ' 153' ' ' LEU . 14.7 mm -68.67 113.86 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.214 -0.929 . . . . 0.0 109.611 -179.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.91 -35.46 8.99 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.056 -1.027 . . . . 0.0 109.421 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.401 ' HG2' ' N ' ' A' ' 146' ' ' ILE . 81.9 tt0 -154.17 149.29 26.89 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.967 -1.083 . . . . 0.0 109.924 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.82 HG23 ' CD1' ' A' ' 153' ' ' LEU . 11.3 mt -126.16 128.46 71.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.418 -0.802 . . . . 0.0 109.332 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 12.2 t0 -110.4 101.73 49.31 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.533 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.586 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 51.7 Cg_endo -71.47 172.81 13.5 Favored 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 122.621 2.214 . . . . 0.0 111.801 179.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.586 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 3.6 tt0 82.4 -20.48 0.35 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.405 -0.809 . . . . 0.0 109.795 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.481 ' C ' ' HG3' ' A' ' 151' ' ' GLN . 96.6 mtt180 -129.99 -11.54 4.25 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.129 -0.982 . . . . 0.0 109.684 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.481 ' HG3' ' C ' ' A' ' 150' ' ' ARG . 19.8 mt-30 70.12 48.53 0.52 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.222 -0.924 . . . . 0.0 109.438 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.706 ' OE2' HG23 ' A' ' 167' ' ' VAL . 53.9 tt0 -121.35 144.24 48.76 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.156 -0.965 . . . . 0.0 109.319 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.869 ' CD2' HD12 ' A' ' 143' ' ' ILE . 0.0 OUTLIER -138.1 112.47 8.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.235 -0.916 . . . . 0.0 109.884 -179.874 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.493 ' NZ ' ' OE2' ' A' ' 152' ' ' GLU . 10.2 mttm -78.54 131.73 36.9 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.309 -0.869 . . . . 0.0 108.677 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.839 HG12 HD21 ' A' ' 168' ' ' LEU . 9.2 p -123.2 151.98 27.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.235 -0.915 . . . . 0.0 109.517 -179.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.476 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 17.9 t-20 -98.18 112.3 24.32 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.357 -0.839 . . . . 0.0 109.648 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.668 HG22 ' O ' ' A' ' 164' ' ' THR . 3.2 m -93.15 139.88 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.254 -0.904 . . . . 0.0 109.291 179.701 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 53.1 m -98.46 88.65 4.18 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.08 -1.013 . . . . 0.0 109.701 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.762 HD12 ' HZ ' ' A' ' 56' ' ' PHE . 2.0 mt -114.24 145.55 19.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.276 -0.89 . . . . 0.0 109.309 179.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.431 ' HD2' ' CE1' ' A' ' 56' ' ' PHE . 9.9 m-85 62.23 38.31 13.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.418 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 57.64 18.06 29.59 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 42.4 mtt-85 -130.1 156.49 44.45 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.171 -1.194 . . . . 0.0 109.553 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -96.68 130.09 43.97 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.364 -0.835 . . . . 0.0 109.55 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . 0.668 ' O ' HG22 ' A' ' 157' ' ' VAL . 97.8 m -137.07 120.1 11.7 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.937 . . . . 0.0 109.76 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.5 Cg_endo -71.1 137.28 31.26 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 122.712 2.275 . . . . 0.0 111.549 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.822 HG13 ' CD2' ' A' ' 168' ' ' LEU . 2.6 p -128.41 147.24 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.168 -0.958 . . . . 0.0 109.878 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.72 HG11 HH11 ' A' ' 50' ' ' ARG . 2.4 p -93.12 120.15 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.419 -0.801 . . . . 0.0 109.457 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.898 ' CD1' HG11 ' A' ' 173' ' ' VAL . 0.1 OUTLIER -141.84 167.14 22.86 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.322 -0.861 . . . . 0.0 110.585 -179.25 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.511 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 40.4 m170 -79.82 142.22 35.49 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 179.731 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.774 HG22 HD22 ' A' ' 121' ' ' LEU . 3.4 p -58.72 -36.82 62.39 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 O-C-N 121.256 -0.902 . . . . 0.0 109.048 179.71 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 19.8 m -75.34 -7.61 54.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.42 -0.8 . . . . 0.0 109.415 179.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.511 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 65.5 mt-10 -90.33 5.39 47.52 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.33 -0.856 . . . . 0.0 109.307 179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.898 HG11 ' CD1' ' A' ' 168' ' ' LEU . 18.1 m -146.6 173.06 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.344 -0.848 . . . . 0.0 109.582 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.514 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 78.1 tt0 -142.08 168.56 19.45 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.3 -0.875 . . . . 0.0 109.132 179.767 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.614 ' HB3' ' CE2' ' A' ' 123' ' ' PHE . 42.0 mttt -87.24 21.16 2.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.177 -0.952 . . . . 0.0 109.766 -179.689 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.558 HG22 ' HG3' ' A' ' 177' ' ' GLU . 50.2 mt 60.38 146.81 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.164 -0.96 . . . . 0.0 109.565 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.558 ' HG3' HG22 ' A' ' 176' ' ' ILE . 96.2 mt-10 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.997 -1.001 . . . . 0.0 109.556 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -60.37 -29.52 68.98 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.246 -1.149 . . . . 0.0 109.487 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 64.9 mtt -60.48 -29.26 68.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.225 -0.922 . . . . 0.0 109.53 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 83.5 tttt -140.92 120.25 13.05 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.328 -0.857 . . . . 0.0 109.42 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.49 ' HG2' ' CG2' ' A' ' 65' ' ' ILE . 19.4 mttt -87.38 167.06 14.36 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.141 -0.975 . . . . 0.0 109.491 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.552 ' CE ' ' HB3' ' A' ' 92' ' ' PRO . 28.0 mtpp -128.32 175.19 8.67 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.249 -0.907 . . . . 0.0 109.065 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.958 ' CH2' HG23 ' A' ' 41' ' ' VAL . 63.7 m95 -112.91 124.19 52.05 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.19 -0.943 . . . . 0.0 109.149 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 67.3 m-85 -117.06 168.43 10.27 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.348 -0.845 . . . . 0.0 109.346 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.735 HD11 ' CE1' ' A' ' 160' ' ' PHE . 75.1 mt -110.5 109.72 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.193 -0.942 . . . . 0.0 109.017 179.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.544 ' CG1' ' HB ' ' A' ' 60' ' ' VAL . 12.8 p -86.35 143.96 10.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.21 -0.931 . . . . 0.0 109.547 -179.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.538 HD11 ' HE1' ' A' ' 59' ' ' TYR . 0.5 OUTLIER -90.28 143.09 27.08 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.441 -0.787 . . . . 0.0 109.395 -179.932 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.454 ' CG2' ' C ' ' A' ' 11' ' ' LEU . 2.4 p -154.19 174.92 14.11 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.278 -0.889 . . . . 0.0 109.405 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.447 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 93.4 mtp -91.89 120.32 32.46 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.23 -0.919 . . . . 0.0 109.329 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 13' ' ' MET . 52.0 p -41.68 126.97 3.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.365 -0.835 . . . . 0.0 109.504 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 106.63 -19.98 35.22 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.447 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.0 m-85 -107.4 -13.9 14.99 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.266 -1.137 . . . . 0.0 109.632 -179.814 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.453 ' HG2' ' CG2' ' A' ' 60' ' ' VAL . 95.1 mt-10 -43.08 -60.42 1.65 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.245 -0.909 . . . . 0.0 109.603 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 73.9 mm-40 -48.17 -34.35 9.87 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.13 -0.981 . . . . 0.0 109.523 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.468 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 56.9 mttp -76.32 -46.74 26.27 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.27 -0.894 . . . . 0.0 109.346 179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.583 HG13 HG23 ' A' ' 80' ' ' VAL . 24.9 t -54.92 -47.58 75.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.308 -0.87 . . . . 0.0 109.472 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.539 ' HG3' HG21 ' A' ' 40' ' ' ILE . 79.0 tttt -59.42 -47.78 84.16 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.231 -0.918 . . . . 0.0 109.427 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -64.28 -34.89 79.16 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.303 -0.873 . . . . 0.0 109.448 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.581 ' OD1' ' CD2' ' A' ' 79' ' ' TYR . 32.6 m120 -66.53 -47.47 72.81 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.367 -0.833 . . . . 0.0 109.745 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.556 HG12 HG21 ' A' ' 77' ' ' VAL . 76.5 mt -55.71 -43.86 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.187 -0.946 . . . . 0.0 109.745 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -58.15 -44.8 88.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.156 -0.965 . . . . 0.0 109.901 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.3 mttt -74.92 -36.87 62.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.13 -0.981 . . . . 0.0 109.686 -179.788 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.707 ' HD2' HG23 ' A' ' 77' ' ' VAL . 17.6 tttt -59.28 -30.62 68.44 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.213 -0.929 . . . . 0.0 109.393 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.674 HG13 ' O ' ' A' ' 33' ' ' ILE . 93.9 t -79.21 -30.15 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.195 -0.941 . . . . 0.0 109.413 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -65.82 -48.16 72.61 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.23 -0.919 . . . . 0.0 109.563 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.97 -34.63 75.07 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.212 -0.93 . . . . 0.0 109.859 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.636 HG23 ' H ' ' A' ' 33' ' ' ILE . 9.6 t -92.56 -21.73 19.92 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.159 -0.963 . . . . 0.0 109.541 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 68.27 33.1 77.15 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.686 ' CG2' HD23 ' A' ' 36' ' ' LEU . 47.9 mm -100.43 91.49 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.245 -1.15 . . . . 0.0 109.598 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 57.1 mttm -98.54 2.91 47.96 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.318 -0.864 . . . . 0.0 109.5 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.693 ' C ' HD22 ' A' ' 36' ' ' LEU . 89.8 m-20 -105.39 9.97 33.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.22 -0.925 . . . . 0.0 109.477 -179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.986 HD12 ' HB2' ' A' ' 70' ' ' ALA . 4.1 mm? -114.24 -46.69 2.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.936 . . . . 0.0 109.473 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 58.7 t -105.34 134.24 47.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.247 -0.908 . . . . 0.0 109.41 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -98.93 -131.27 7.22 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 46.3 mtt85 -91.93 142.02 28.01 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.265 -1.138 . . . . 0.0 109.522 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.91 HG23 HG12 ' A' ' 62' ' ' VAL . 53.6 mt -98.66 133.88 39.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.267 -0.896 . . . . 0.0 109.305 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 1.05 ' CG2' HD11 ' A' ' 107' ' ' LEU . 40.1 t -115.97 155.38 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.253 -0.904 . . . . 0.0 109.495 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.809 HG22 ' H ' ' A' ' 44' ' ' ILE . 18.2 mt -133.01 126.84 19.85 Favored Pre-proline 0 N--CA 1.489 1.483 0 O-C-N 121.22 -0.925 . . . . 0.0 109.525 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.884 ' O ' HD12 ' A' ' 55' ' ' LEU . 46.9 Cg_endo -68.18 -4.75 13.27 Favored 'Trans proline' 0 C--O 1.216 -0.624 0 C-N-CA 122.725 2.284 . . . . 0.0 111.722 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.809 ' H ' HG22 ' A' ' 42' ' ' ILE . 20.7 mt -79.34 135.22 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.209 -0.932 . . . . 0.0 109.459 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.421 ' NH2' ' OG ' ' A' ' 52' ' ' SER . 14.3 ptt180 -112.56 -2.39 14.62 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.278 -0.889 . . . . 0.0 109.539 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 72.54 33.32 61.08 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -45.1 135.17 7.31 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 95.5 mt-30 -61.22 -32.11 71.89 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.208 -1.172 . . . . 0.0 109.467 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.405 ' NE ' ' HB2' ' A' ' 51' ' ' LYS . 77.5 ttt180 -71.74 118.71 14.92 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.259 -0.9 . . . . 0.0 109.513 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 41.0 ttp180 -60.56 -31.49 70.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.274 -0.891 . . . . 0.0 109.441 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . 0.405 ' HB2' ' NE ' ' A' ' 49' ' ' ARG . 30.9 mttm -68.84 -17.44 64.0 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.191 -0.943 . . . . 0.0 109.475 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.421 ' OG ' ' NH2' ' A' ' 45' ' ' ARG . 14.2 t -123.31 89.18 3.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.233 -0.917 . . . . 0.0 109.582 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.489 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 32.8 tt0 -139.96 128.53 22.95 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.242 -0.911 . . . . 0.0 109.452 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.654 ' HG2' HD13 ' A' ' 44' ' ' ILE . 37.5 mttp 74.25 106.4 0.07 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.232 -0.917 . . . . 0.0 109.337 -179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.884 HD12 ' O ' ' A' ' 43' ' ' PRO . 8.6 mt -61.31 -23.37 65.66 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.117 -0.99 . . . . 0.0 109.563 -179.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.553 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 42.6 m-85 -151.06 100.18 3.05 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.167 -0.958 . . . . 0.0 109.069 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 42.7 Cg_endo -66.17 141.91 65.16 Favored 'Trans proline' 0 C--O 1.214 -0.686 0 C-N-CA 122.672 2.248 . . . . 0.0 111.906 -179.639 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.402 ' N ' ' OE2' ' A' ' 17' ' ' GLU . . . 75.26 -12.26 7.43 Favored Glycine 0 N--CA 1.488 2.167 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.538 ' HE1' HD11 ' A' ' 11' ' ' LEU . 3.5 m-30 -103.38 130.9 50.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.789 -1.418 . . . . 0.0 109.942 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.544 ' HB ' ' CG1' ' A' ' 10' ' ' VAL . 3.0 t -132.49 146.24 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 108.55 -0.908 . . . . 0.0 108.55 179.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.694 ' CZ ' ' CZ ' ' A' ' 160' ' ' PHE . 14.9 m-85 -107.04 122.9 47.37 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.892 -1.13 . . . . 0.0 109.952 -179.391 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.91 HG12 HG23 ' A' ' 40' ' ' ILE . 30.0 m -129.77 139.94 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.43 -0.794 . . . . 0.0 109.48 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.505 ' HA ' ' O ' ' A' ' 6' ' ' LYS . 48.3 tt0 -88.63 124.47 34.1 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.235 -0.916 . . . . 0.0 108.676 179.38 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.669 ' SD ' HG21 ' A' ' 74' ' ' VAL . 3.9 mtm -147.0 160.68 42.07 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.013 -1.054 . . . . 0.0 110.784 -178.78 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.525 HD11 HD13 ' A' ' 36' ' ' LEU . 26.9 pt -104.28 139.67 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . . . . . . . . . 38.3 mtp -74.33 136.45 42.55 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.971 -1.081 . . . . 0.0 110.16 -178.432 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -178.47 155.3 0.85 Allowed 'General case' 0 N--CA 1.489 1.524 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -61.78 -42.46 99.02 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.183 -0.948 . . . . 0.0 109.807 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 54.6 mt-10 -75.76 -25.23 56.29 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.852 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.986 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -78.05 -47.19 18.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.122 -0.987 . . . . 0.0 109.578 -179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.575 ' CE1' ' OE1' ' A' ' 89' ' ' GLN . 65.1 t80 -61.93 -45.35 94.09 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.289 -0.882 . . . . 0.0 109.926 -179.674 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 48.2 t-20 -70.25 -29.3 66.06 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.096 -1.002 . . . . 0.0 110.381 -179.348 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.52 ' O ' ' NZ ' ' A' ' 27' ' ' LYS . 83.8 t80 -76.84 -39.51 50.96 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.966 -1.084 . . . . 0.0 109.55 -179.759 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.669 HG21 ' SD ' ' A' ' 64' ' ' MET . 2.4 p -75.48 -48.66 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.352 -0.843 . . . . 0.0 109.516 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.593 ' N ' ' CG1' ' A' ' 74' ' ' VAL . 0.0 OUTLIER -58.64 -21.09 52.91 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.212 -0.93 . . . . 0.0 109.86 -179.689 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.6 m -95.9 5.53 51.03 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.116 -0.99 . . . . 0.0 109.837 -179.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.707 HG23 ' HD2' ' A' ' 27' ' ' LYS . 3.6 p -68.26 132.93 91.48 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.05 -1.031 . . . . 0.0 109.301 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.734 ' O ' ' HB2' ' A' ' 79' ' ' TYR . 44.3 Cg_endo -65.87 136.07 43.75 Favored 'Trans proline' 0 C--O 1.213 -0.763 0 C-N-CA 122.821 2.347 . . . . 0.0 112.369 -179.294 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.734 ' HB2' ' O ' ' A' ' 78' ' ' PRO . 76.3 m-85 91.17 -6.89 0.26 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.95 -0.469 . . . . 0.0 109.844 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.687 HG21 HG11 ' A' ' 77' ' ' VAL . 3.1 t -98.0 135.93 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.928 -1.107 . . . . 0.0 109.309 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 88.9 mmm -96.6 -24.6 15.95 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.294 -0.879 . . . . 0.0 109.704 -179.772 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.55 ' C ' ' CD1' ' A' ' 83' ' ' PHE . . . 159.89 -159.88 31.05 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.573 ' HZ ' HG22 ' A' ' 74' ' ' VAL . 9.4 m-85 -137.44 148.22 45.95 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.322 -1.105 . . . . 0.0 109.519 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.52 HG13 ' O ' ' A' ' 84' ' ' VAL . 9.2 p -72.58 128.12 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.232 -0.918 . . . . 0.0 109.387 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.545 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 5.0 p -160.66 166.09 29.45 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.55 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 2.1 m -91.27 -30.27 16.7 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.296 -0.877 . . . . 0.0 109.164 179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -134.17 -83.47 0.2 Allowed Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.531 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -102.88 -137.7 9.65 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.575 ' OE1' ' CE1' ' A' ' 71' ' ' TYR . 0.3 OUTLIER -32.79 154.66 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.566 -0.961 . . . . 0.0 110.15 -179.53 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.545 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 46.6 Cg_endo -67.58 151.05 80.03 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.83 2.353 . . . . 0.0 111.946 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.3 m -83.26 151.68 63.28 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 121.284 -0.885 . . . . 0.0 109.366 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.552 ' HB3' ' CE ' ' A' ' 6' ' ' LYS . 51.2 Cg_endo -70.24 144.5 51.63 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 122.632 2.221 . . . . 0.0 111.796 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.565 HG12 ' HG3' ' A' ' 98' ' ' MET . 21.4 t -82.0 127.21 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.191 -0.943 . . . . 0.0 109.301 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -67.78 140.37 56.65 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.242 -0.911 . . . . 0.0 109.417 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -49.76 -40.83 42.39 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.246 -0.909 . . . . 0.0 109.47 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 39.2 ttm180 -57.4 -30.47 64.94 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.309 -0.87 . . . . 0.0 109.569 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 52.7 mt-10 -85.8 -27.79 24.93 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.156 -0.965 . . . . 0.0 109.493 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.591 ' HE3' ' CG ' ' A' ' 7' ' ' TRP . 93.2 mtp -82.33 -25.82 33.54 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.25 -0.906 . . . . 0.0 109.286 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.612 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 2.4 mtt180 -37.11 -52.65 2.14 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 121.434 -0.791 . . . . 0.0 109.935 -179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.612 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.1 Cg_endo -69.78 -28.79 24.7 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 122.499 2.133 . . . . 0.0 111.897 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.558 HG21 ' CD2' ' A' ' 61' ' ' PHE . 38.2 mm -81.47 -43.08 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.206 -0.934 . . . . 0.0 109.56 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.627 HD23 HD12 ' A' ' 107' ' ' LEU . 0.9 OUTLIER -66.76 -39.91 88.04 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.223 -0.923 . . . . 0.0 109.264 179.819 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 48.2 mtt-85 -64.06 -49.95 70.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.341 -0.849 . . . . 0.0 109.104 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.465 HD22 ' CD1' ' A' ' 55' ' ' LEU . 1.1 tt -72.09 -35.81 69.31 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.268 -0.895 . . . . 0.0 109.231 179.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.443 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -70.53 -2.01 12.78 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.352 -0.842 . . . . 0.0 109.897 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 75.83 10.43 84.98 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.706 -1.358 . . . . 0.0 109.706 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 1.05 HD11 ' CG2' ' A' ' 41' ' ' VAL . 18.5 mt -78.18 -21.51 50.06 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.212 -1.17 . . . . 0.0 109.542 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.401 ' HG3' ' CB ' ' A' ' 102' ' ' LEU . 84.5 mt-10 -115.53 158.23 22.91 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.196 -0.94 . . . . 0.0 109.654 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -102.81 120.25 40.27 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.294 -0.879 . . . . 0.0 109.43 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.43 ' CD2' ' O ' ' A' ' 111' ' ' GLU . 23.5 p90 -148.95 162.81 39.14 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.233 -0.917 . . . . 0.0 109.515 179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.43 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 51.0 mm-40 -101.03 -148.01 0.36 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.326 -0.859 . . . . 0.0 109.447 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.619 ' O ' ' C ' ' A' ' 113' ' ' LYS . 62.7 tt0 -125.48 153.52 43.41 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.2 -0.937 . . . . 0.0 109.373 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.619 ' C ' ' O ' ' A' ' 112' ' ' GLU . 0.0 OUTLIER 20.91 93.58 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.669 -0.644 . . . . 0.0 110.522 179.768 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.418 ' O ' ' HD2' ' A' ' 115' ' ' LYS . 0.3 OUTLIER -54.41 -31.77 55.83 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.227 -0.92 . . . . 0.0 109.211 179.704 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.419 ' HB3' ' HE2' ' A' ' 115' ' ' LYS . 12.1 mmmm -114.68 115.24 44.17 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.241 -0.912 . . . . 0.0 109.401 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.95 -5.2 15.77 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.715 2.277 . . . . 0.0 111.829 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 9.2 t -72.99 133.65 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.875 . . . . 0.0 109.513 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -71.06 160.59 32.62 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.272 -0.892 . . . . 0.0 109.452 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 55.5 t -132.87 150.15 32.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.127 -0.983 . . . . 0.0 109.556 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.667 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 92.5 mt-10 -142.85 -172.69 3.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.304 -0.872 . . . . 0.0 109.442 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.667 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 2.3 mt 145.82 108.84 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.622 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -20.97 94.61 0.01 OUTLIER Glycine 0 N--CA 1.496 2.681 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.481 ' N ' ' O ' ' A' ' 121' ' ' LEU . 0.7 OUTLIER -107.32 145.87 32.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.228 -1.16 . . . . 0.0 109.581 179.995 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 22.9 mttt -141.5 162.62 35.05 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.318 -0.864 . . . . 0.0 109.534 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 15.2 m -61.4 141.62 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.747 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 86.85 -33.81 3.68 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -47.96 158.74 0.21 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.351 -1.088 . . . . 0.0 109.198 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.3 ttm -100.94 128.5 46.95 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.084 -1.01 . . . . 0.0 108.752 179.581 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.652 HG13 HG12 ' A' ' 143' ' ' ILE . 16.0 m -129.22 144.8 37.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.337 -0.852 . . . . 0.0 109.878 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.55 ' CB ' HG12 ' A' ' 176' ' ' ILE . 10.6 tttp -97.93 140.64 31.98 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.406 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.65 HG22 ' HA ' ' A' ' 137' ' ' GLU . 1.2 mp -80.72 153.55 4.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.353 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.532 ' CD1' ' HB2' ' A' ' 174' ' ' GLU . 0.9 OUTLIER -149.3 2.45 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 120.793 -1.192 . . . . 0.0 109.841 -179.791 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.547 ' CB ' ' HG3' ' A' ' 172' ' ' GLU . 61.1 m -149.25 145.35 27.05 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.004 -1.06 . . . . 0.0 110.212 -179.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 103.46 -166.74 16.18 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 179.503 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.511 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 48.3 Cg_endo -68.41 -21.12 41.17 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 C-N-CA 123.199 2.599 . . . . 0.0 112.53 -179.614 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.521 ' CE2' ' HB2' ' A' ' 100' ' ' PRO . 92.3 m-85 -108.35 18.72 20.7 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.907 -1.121 . . . . 0.0 109.377 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.65 ' HA ' HG22 ' A' ' 131' ' ' ILE . 3.7 tt0 -42.61 140.61 1.23 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.261 -0.899 . . . . 0.0 109.711 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.518 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 22.4 m-20 72.67 29.79 1.93 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.406 -0.809 . . . . 0.0 110.727 179.147 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.612 ' CE1' HG23 ' A' ' 157' ' ' VAL . 1.2 t80 -117.85 133.27 56.09 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.838 -1.164 . . . . 0.0 109.399 179.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -78.92 134.75 36.86 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.213 -0.93 . . . . 0.0 109.724 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.47 169.68 26.98 Favored Glycine 0 N--CA 1.491 2.306 0 C-N-CA 119.79 -1.195 . . . . 0.0 110.329 -179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.796 ' C ' HG23 ' A' ' 155' ' ' VAL . 43.6 t -119.43 136.4 56.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.567 -0.96 . . . . 0.0 109.281 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.652 HG12 HG13 ' A' ' 129' ' ' VAL . 31.7 mm -68.82 119.58 14.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.324 -0.86 . . . . 0.0 109.63 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.479 ' HD2' ' OD1' ' A' ' 156' ' ' ASN . 63.9 tttt -99.81 -33.26 10.63 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.054 -1.029 . . . . 0.0 109.527 179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 93.4 mt-10 -154.32 149.48 26.96 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.123 -0.986 . . . . 0.0 109.656 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 1.029 HG23 HD22 ' A' ' 153' ' ' LEU . 3.6 mt -123.9 126.55 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.321 -0.862 . . . . 0.0 109.575 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.22 102.39 46.25 Favored Pre-proline 0 N--CA 1.489 1.49 0 O-C-N 121.239 -0.913 . . . . 0.0 109.589 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.0 Cg_endo -71.99 170.96 17.66 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 122.749 2.299 . . . . 0.0 111.866 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.3 mt-10 79.44 -21.23 0.34 Allowed 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.395 -0.815 . . . . 0.0 110.057 179.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.446 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 75.6 mtt-85 -125.74 -14.99 6.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.063 -1.023 . . . . 0.0 109.478 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.446 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 50.8 mt-30 69.56 48.64 0.6 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.187 -0.946 . . . . 0.0 109.67 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.816 ' O ' HD23 ' A' ' 153' ' ' LEU . 82.5 tt0 -119.07 143.25 47.24 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.174 -0.954 . . . . 0.0 108.968 179.626 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 1.029 HD22 HG23 ' A' ' 146' ' ' ILE . 32.3 mt -128.77 127.55 42.22 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.1 -1.0 . . . . 0.0 110.291 -179.469 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -92.03 128.67 37.96 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.077 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.796 HG23 ' C ' ' A' ' 142' ' ' VAL . 12.9 p -131.39 147.93 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.084 -1.01 . . . . 0.0 109.834 -179.496 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.588 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.8 m120 -100.85 125.09 47.35 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.413 -0.804 . . . . 0.0 109.552 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.653 HG22 HG13 ' A' ' 159' ' ' ILE . 3.3 p -105.74 144.8 14.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.921 . . . . 0.0 109.476 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 55.7 m -97.33 92.48 6.0 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.269 -0.895 . . . . 0.0 109.928 -179.664 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.653 HG13 HG22 ' A' ' 157' ' ' VAL . 7.4 mt -116.03 142.96 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.258 -0.901 . . . . 0.0 109.237 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.735 ' CE1' HD11 ' A' ' 9' ' ' ILE . 91.0 m-85 61.88 37.15 15.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.287 -0.883 . . . . 0.0 109.185 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.6 17.92 35.79 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . . . . . . . . . 26.2 mtp180 -126.88 157.39 39.48 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.067 -1.254 . . . . 0.0 109.555 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 80.3 tt0 -100.91 132.03 46.51 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.277 -0.889 . . . . 0.0 109.728 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . . . . . . . . . 17.2 m -142.47 127.06 10.02 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 121.37 -0.831 . . . . 0.0 109.743 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.588 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 51.1 Cg_endo -70.91 136.67 30.48 Favored 'Trans proline' 0 C--O 1.214 -0.7 0 C-N-CA 122.748 2.299 . . . . 0.0 111.616 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.743 HG12 HG13 ' A' ' 155' ' ' VAL . 11.7 p -119.64 164.65 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 O-C-N 121.087 -1.008 . . . . 0.0 109.706 -179.817 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.533 ' O ' HD23 ' A' ' 168' ' ' LEU . 6.7 m -117.53 117.65 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.459 -0.776 . . . . 0.0 109.66 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.641 HD21 ' CG2' ' A' ' 166' ' ' VAL . 0.2 OUTLIER -142.24 167.33 22.36 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.241 -0.912 . . . . 0.0 110.207 -179.779 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.504 ' HB2' ' CD ' ' A' ' 172' ' ' GLU . 19.2 m170 -82.7 146.37 29.08 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 179.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.576 HG23 HD11 ' A' ' 153' ' ' LEU . 7.1 p -56.32 -32.73 36.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.566 0 O-C-N 121.422 -0.798 . . . . 0.0 109.314 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 73.5 p -76.86 -7.06 54.79 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.275 -0.891 . . . . 0.0 109.762 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.547 ' HG3' ' CB ' ' A' ' 133' ' ' SER . 0.8 OUTLIER -95.53 2.8 54.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.067 -1.021 . . . . 0.0 109.376 -179.991 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.516 HG12 ' N ' ' A' ' 174' ' ' GLU . 43.5 t -139.78 164.84 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.212 -0.93 . . . . 0.0 109.281 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.539 ' HG2' ' N ' ' A' ' 175' ' ' LYS . 54.8 tt0 -141.22 167.16 22.85 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.087 -1.008 . . . . 0.0 108.928 179.73 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.539 ' N ' ' HG2' ' A' ' 174' ' ' GLU . 32.7 tttp -93.9 28.83 2.27 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.058 -1.027 . . . . 0.0 109.476 -179.855 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.55 HG12 ' CB ' ' A' ' 130' ' ' LYS . 53.2 mt 48.27 96.61 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.284 -0.885 . . . . 0.0 109.52 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.476 -179.982 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -58.95 -35.12 72.6 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.252 -1.146 . . . . 0.0 109.413 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 88.8 mtp -59.56 -26.37 65.33 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.282 -0.886 . . . . 0.0 109.387 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 18.4 mttt -110.72 128.72 55.84 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.282 -0.886 . . . . 0.0 109.292 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.467 ' O ' ' HD3' ' A' ' 6' ' ' LYS . 27.5 mttt -111.61 163.01 14.56 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.192 -0.942 . . . . 0.0 109.61 -179.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.578 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 36.0 mmtm -132.07 169.26 16.62 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.355 -0.841 . . . . 0.0 109.339 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.954 ' CZ3' HG22 ' A' ' 41' ' ' VAL . 68.1 m95 -103.39 129.21 50.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.255 -0.903 . . . . 0.0 109.235 179.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . . . . . . . . . 73.7 m-85 -118.47 170.33 9.02 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.22 -0.925 . . . . 0.0 109.143 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.756 HD11 ' CE1' ' A' ' 160' ' ' PHE . 22.7 mt -103.85 112.78 38.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.122 -0.986 . . . . 0.0 109.268 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.489 HG23 HG22 ' A' ' 62' ' ' VAL . 73.5 t -86.18 142.31 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.228 -0.92 . . . . 0.0 109.343 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.532 HD21 HG22 ' A' ' 84' ' ' VAL . 0.6 OUTLIER -93.45 142.04 27.78 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.363 -0.836 . . . . 0.0 109.416 179.904 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.726 HG21 ' HG2' ' A' ' 17' ' ' GLU . 7.0 t -160.44 -173.33 3.94 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.279 -0.888 . . . . 0.0 109.431 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.426 ' O ' ' C ' ' A' ' 14' ' ' SER . 89.1 mtp -109.18 122.46 47.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.213 -0.93 . . . . 0.0 109.47 179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.426 ' C ' ' O ' ' A' ' 13' ' ' MET . 2.2 m -44.3 133.87 5.26 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.259 -0.901 . . . . 0.0 109.443 179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.0 -21.37 36.09 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . . . . . . . . . 78.0 m-85 -113.01 -7.99 13.67 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.25 -1.147 . . . . 0.0 109.355 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.862 ' OE1' HD11 ' A' ' 44' ' ' ILE . 57.3 mt-10 -48.12 -59.96 2.99 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.212 -0.93 . . . . 0.0 109.442 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -45.7 -34.57 3.64 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.187 -0.946 . . . . 0.0 109.37 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.46 ' O ' ' OD1' ' A' ' 23' ' ' ASN . 25.1 mttt -73.68 -43.72 58.58 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.276 -0.89 . . . . 0.0 109.377 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.425 HG22 ' HB2' ' A' ' 79' ' ' TYR . 92.4 t -56.76 -50.0 76.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.317 -0.864 . . . . 0.0 109.535 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . 0.666 ' HD2' HD11 ' A' ' 42' ' ' ILE . 24.8 tttt -56.24 -46.95 79.38 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.243 -0.911 . . . . 0.0 109.145 179.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 69.7 tt0 -65.27 -38.81 91.44 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.341 -0.849 . . . . 0.0 109.433 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.529 ' O ' ' CB ' ' A' ' 27' ' ' LYS . 32.6 m120 -62.29 -43.12 99.56 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.241 -0.912 . . . . 0.0 110.045 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.793 HD11 HG11 ' A' ' 77' ' ' VAL . 49.4 mm -64.69 -44.99 96.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.127 -0.983 . . . . 0.0 109.738 -179.537 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.566 ' O ' HG12 ' A' ' 28' ' ' VAL . 77.8 tt0 -58.7 -46.91 86.24 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.164 -0.96 . . . . 0.0 109.96 -179.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -82.27 -37.35 26.01 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.993 -1.067 . . . . 0.0 109.712 -179.724 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.529 ' CB ' ' O ' ' A' ' 23' ' ' ASN . 28.2 tttm -57.22 -30.36 64.51 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.283 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.697 HG21 HG12 ' A' ' 37' ' ' VAL . 12.3 p -85.43 -26.38 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.296 -0.878 . . . . 0.0 109.555 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 -67.31 -47.45 70.53 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.324 -0.86 . . . . 0.0 109.716 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.67 -31.24 66.13 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.176 -0.952 . . . . 0.0 109.548 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 58.8 p -90.06 -21.66 22.21 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -0.916 . . . . 0.0 109.575 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 78.03 -2.92 63.2 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.871 HG23 HD23 ' A' ' 36' ' ' LEU . 31.2 mm -72.71 71.33 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.291 -1.123 . . . . 0.0 109.268 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 32.5 pttt -85.87 13.79 6.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.279 -0.888 . . . . 0.0 109.453 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.633 ' O ' HD13 ' A' ' 65' ' ' ILE . 29.7 m120 -110.37 -9.57 14.62 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.22 -0.925 . . . . 0.0 109.414 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 1.098 HD12 ' HB2' ' A' ' 70' ' ' ALA . 3.8 mm? -92.1 -51.5 5.16 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.309 -0.869 . . . . 0.0 109.297 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.697 HG12 HG21 ' A' ' 28' ' ' VAL . 13.7 p -92.03 141.89 13.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.278 -0.889 . . . . 0.0 108.956 179.672 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.96 -119.01 2.91 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 56.3 mtt180 -97.52 139.54 33.29 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.33 -1.1 . . . . 0.0 110.142 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 1.026 HG23 HG12 ' A' ' 62' ' ' VAL . 75.4 mt -111.55 134.34 54.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.427 -0.796 . . . . 0.0 109.088 179.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 1.03 HG23 ' HB2' ' A' ' 61' ' ' PHE . 29.8 m -123.8 148.77 27.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.005 -1.059 . . . . 0.0 109.311 179.803 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.666 HD11 ' HD2' ' A' ' 21' ' ' LYS . 1.8 mt -129.69 131.77 23.77 Favored Pre-proline 0 C--N 1.302 -1.486 0 O-C-N 121.346 -0.846 . . . . 0.0 109.703 -179.405 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.626 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 42.3 Cg_endo -64.61 -4.5 8.47 Favored 'Trans proline' 0 C--O 1.216 -0.604 0 C-N-CA 122.856 2.371 . . . . 0.0 111.285 179.7 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.868 HG23 ' HG2' ' A' ' 54' ' ' LYS . 39.5 mt -68.11 -42.04 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.459 -0.776 . . . . 0.0 109.519 179.589 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.433 ' C ' ' O ' ' A' ' 44' ' ' ILE . 84.0 mtt-85 -42.88 149.34 0.2 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.341 -0.849 . . . . 0.0 109.601 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -171.87 -159.48 18.26 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.25 131.05 41.83 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -58.32 -22.2 52.21 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.295 -1.121 . . . . 0.0 109.449 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 18.8 mtp180 -59.83 -24.52 64.25 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.126 -0.983 . . . . 0.0 109.322 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 66.7 mtm-85 -122.07 136.27 54.9 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.296 -0.877 . . . . 0.0 109.323 179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . . . . . . . . . 10.2 tttt -59.56 168.89 1.45 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.276 -0.89 . . . . 0.0 109.458 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.51 ' HB3' ' CG2' ' A' ' 44' ' ' ILE . 0.9 OUTLIER -48.64 107.2 0.12 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.193 -0.942 . . . . 0.0 109.428 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.543 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 80.5 tt0 -86.22 -29.21 23.34 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.364 -0.835 . . . . 0.0 109.619 -179.889 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.868 ' HG2' HG23 ' A' ' 44' ' ' ILE . 0.2 OUTLIER 78.41 89.0 0.06 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.875 . . . . 0.0 109.389 -179.95 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.626 ' HB3' ' HB2' ' A' ' 43' ' ' PRO . 14.3 tp -55.4 -47.69 75.5 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.007 -1.058 . . . . 0.0 109.152 179.723 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.747 ' HZ ' HD12 ' A' ' 159' ' ' ILE . 75.3 m-85 -130.56 106.08 15.76 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.35 -0.844 . . . . 0.0 108.79 179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 56' ' ' PHE . 40.6 Cg_endo -64.11 144.46 87.22 Favored 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 122.627 2.218 . . . . 0.0 112.022 -179.152 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.15 -20.21 2.62 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 110.56 -1.016 . . . . 0.0 110.56 179.516 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 3.5 m-30 -98.05 129.71 44.89 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.569 -1.548 . . . . 0.0 110.626 -178.789 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 59.8 t -131.61 143.34 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 179.163 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 1.03 ' HB2' HG23 ' A' ' 41' ' ' VAL . 27.2 m-85 -104.58 129.27 52.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.879 -1.138 . . . . 0.0 110.137 -179.041 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 1.026 HG12 HG23 ' A' ' 40' ' ' ILE . 34.5 m -138.99 149.44 23.44 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.329 -0.857 . . . . 0.0 109.849 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.644 ' HB2' ' CD2' ' A' ' 7' ' ' TRP . 83.9 tt0 -113.79 130.14 56.49 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.319 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.508 ' HE1' HG11 ' A' ' 74' ' ' VAL . 61.4 mtm -151.32 160.83 43.58 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.858 -1.151 . . . . 0.0 111.184 -178.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.753 ' CG1' HD13 ' A' ' 36' ' ' LEU . 1.4 pt -80.87 125.61 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 179.44 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.415 ' O ' ' CG ' ' A' ' 67' ' ' ASN . 50.5 ttm -77.24 142.7 39.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.191 -0.943 . . . . 0.0 110.115 -178.533 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.415 ' CG ' ' O ' ' A' ' 66' ' ' MET . 7.6 m-20 176.2 168.47 0.44 Allowed 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 88.4 m-20 -65.85 -40.52 91.81 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.069 -1.019 . . . . 0.0 109.578 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -75.97 -34.31 59.8 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.93 . . . . 0.0 109.858 -179.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 1.098 ' HB2' HD12 ' A' ' 36' ' ' LEU . . . -71.76 -48.36 47.34 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.209 -0.932 . . . . 0.0 109.733 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.587 ' CG ' ' OE1' ' A' ' 89' ' ' GLN . 83.4 t80 -60.79 -44.44 96.82 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.946 -179.574 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -69.97 -26.14 63.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.192 -0.942 . . . . 0.0 110.037 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 63.9 t80 -80.11 -36.07 35.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.074 -1.016 . . . . 0.0 109.849 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 1.046 HG23 ' O ' ' A' ' 70' ' ' ALA . 3.3 t -67.58 -56.28 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.224 -0.923 . . . . 0.0 109.976 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -47.46 -37.02 10.9 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.063 -1.023 . . . . 0.0 110.211 -179.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 m -70.95 2.99 3.67 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.015 -1.053 . . . . 0.0 110.419 -179.37 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.793 HG11 HD11 ' A' ' 24' ' ' ILE . 38.8 t -64.12 134.6 96.0 Favored Pre-proline 0 N--CA 1.49 1.571 0 O-C-N 120.941 -1.099 . . . . 0.0 109.237 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.521 ' O ' ' CB ' ' A' ' 79' ' ' TYR . 47.5 Cg_endo -67.85 135.55 35.72 Favored 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 122.715 2.277 . . . . 0.0 111.987 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.521 ' CB ' ' O ' ' A' ' 78' ' ' PRO . 17.3 m-85 78.45 -5.05 2.1 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.432 -0.792 . . . . 0.0 109.712 179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.604 ' CG2' ' CG1' ' A' ' 77' ' ' VAL . 3.7 t -85.11 123.96 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.054 -1.029 . . . . 0.0 109.296 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . 0.494 ' HB2' ' HB3' ' A' ' 11' ' ' LEU . 66.0 mtp -82.4 -30.68 30.05 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.335 -0.853 . . . . 0.0 109.343 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.411 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 157.11 -157.34 27.97 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 0.487 ' HB3' ' HG3' ' A' ' 90' ' ' PRO . 7.9 m-85 -133.64 137.42 45.39 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.258 -1.143 . . . . 0.0 109.5 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.532 HG22 HD21 ' A' ' 11' ' ' LEU . 38.2 t -60.11 131.69 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.894 . . . . 0.0 109.48 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.542 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.7 OUTLIER -168.98 159.81 9.6 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.191 -0.943 . . . . 0.0 109.562 179.995 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -88.58 -35.46 16.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.307 179.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -125.58 -85.16 0.58 Allowed Glycine 0 N--CA 1.49 2.253 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.576 ' O ' ' C ' ' A' ' 89' ' ' GLN . . . -108.78 -134.08 7.05 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.303 -1.519 . . . . 0.0 109.303 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.587 ' OE1' ' CG ' ' A' ' 71' ' ' TYR . 0.3 OUTLIER -26.55 145.01 0.04 OUTLIER Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.593 -0.945 . . . . 0.0 110.551 -179.533 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.542 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.4 Cg_endo -69.31 146.45 63.01 Favored 'Trans proline' 0 C--O 1.215 -0.661 0 C-N-CA 122.896 2.398 . . . . 0.0 111.991 -179.746 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 16.3 m -80.83 149.2 66.82 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.391 -0.818 . . . . 0.0 109.277 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.71 145.71 58.28 Favored 'Trans proline' 0 C--O 1.215 -0.627 0 C-N-CA 122.666 2.244 . . . . 0.0 111.78 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.921 HG23 ' O ' ' A' ' 7' ' ' TRP . 2.9 t -65.4 144.62 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.196 -0.94 . . . . 0.0 109.382 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . 0.419 ' O ' ' N ' ' A' ' 97' ' ' GLU . 32.4 mttm -82.29 133.16 35.23 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.177 -0.952 . . . . 0.0 109.411 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.403 ' C ' ' O ' ' A' ' 94' ' ' LYS . 90.8 m-20 -45.99 -44.76 15.29 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.201 -0.937 . . . . 0.0 109.314 -179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.494 ' O ' ' HG2' ' A' ' 96' ' ' ARG . 34.4 ttm180 -58.51 -18.24 27.67 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.239 -0.913 . . . . 0.0 109.574 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.419 ' N ' ' O ' ' A' ' 94' ' ' LYS . 26.5 mt-10 -100.65 -26.45 13.81 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.24 -0.912 . . . . 0.0 109.571 -179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.527 ' SD ' HG11 ' A' ' 93' ' ' VAL . 50.1 mmm -78.37 -34.61 48.17 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.939 . . . . 0.0 109.334 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.581 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 2.5 mtt180 -33.45 -54.58 0.71 Allowed Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.588 -0.695 . . . . 0.0 110.228 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.581 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 49.1 Cg_endo -69.8 -29.46 23.63 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 122.55 2.167 . . . . 0.0 112.219 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.537 ' O ' ' CB ' ' A' ' 105' ' ' ALA . 19.9 mm -78.7 -44.83 25.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.098 -1.001 . . . . 0.0 109.886 -179.688 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.61 ' HA ' HD12 ' A' ' 107' ' ' LEU . 1.0 OUTLIER -62.83 -43.02 99.9 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.111 -0.993 . . . . 0.0 109.705 -179.877 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.406 ' NH2' ' NH2' ' A' ' 99' ' ' ARG . 46.3 mtt180 -62.3 -52.73 62.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.225 -0.922 . . . . 0.0 109.431 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -71.46 -37.59 71.34 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.393 -0.817 . . . . 0.0 109.279 179.736 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 101' ' ' ILE . . . -67.87 -3.97 11.33 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.358 -0.838 . . . . 0.0 109.952 -179.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 78.09 5.24 87.01 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.957 HD11 HG11 ' A' ' 41' ' ' VAL . 61.6 mt -71.46 -19.69 62.19 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.248 -1.148 . . . . 0.0 109.657 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.422 ' HG3' ' HB3' ' A' ' 102' ' ' LEU . 83.9 mt-10 -128.63 154.73 45.95 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.223 -0.923 . . . . 0.0 109.517 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -112.2 115.86 29.51 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.204 -0.935 . . . . 0.0 109.545 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.474 ' OH ' ' HB3' ' A' ' 135' ' ' PRO . 15.3 p90 -137.12 160.27 39.48 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.261 -0.899 . . . . 0.0 109.372 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.402 ' O ' ' CD2' ' A' ' 110' ' ' TYR . 44.6 mt-10 -99.33 -148.7 0.35 Allowed 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.129 -0.982 . . . . 0.0 109.354 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 72.6 tt0 -121.6 145.45 47.97 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.142 -0.974 . . . . 0.0 109.478 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . 0.446 ' CD ' ' O ' ' A' ' 132' ' ' ILE . 0.8 OUTLIER -66.49 141.63 57.82 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.476 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 13.5 mttt -65.97 -35.05 79.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.213 -0.929 . . . . 0.0 109.357 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . 0.416 ' HD2' ' HA ' ' A' ' 115' ' ' LYS . 7.1 tptt 63.94 69.19 0.78 Allowed Pre-proline 0 N--CA 1.489 1.509 0 O-C-N 121.288 -0.882 . . . . 0.0 109.457 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -71.16 -5.51 17.17 Favored 'Trans proline' 0 C--O 1.216 -0.623 0 C-N-CA 122.719 2.279 . . . . 0.0 111.79 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 19.2 m -125.27 148.62 29.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.212 -0.93 . . . . 0.0 109.603 -179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.479 ' O ' ' O ' ' A' ' 119' ' ' VAL . 60.0 mttp -101.81 139.8 36.96 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.314 -0.866 . . . . 0.0 109.296 179.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.61 ' HB ' ' CE2' ' A' ' 123' ' ' PHE . 3.1 m -43.65 168.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.285 -0.884 . . . . 0.0 109.677 -179.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.554 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 85.6 mt-10 -158.57 161.45 37.28 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.262 -0.899 . . . . 0.0 109.666 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.572 ' O ' ' C ' ' A' ' 122' ' ' GLY . 0.7 OUTLIER 80.21 95.93 0.05 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.369 -0.832 . . . . 0.0 109.678 179.834 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.572 ' C ' ' O ' ' A' ' 121' ' ' LEU . . . -26.42 94.34 0.01 OUTLIER Glycine 0 N--CA 1.494 2.563 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 179.632 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.61 ' CE2' ' HB ' ' A' ' 119' ' ' VAL . 22.0 m-30 -60.74 145.8 48.24 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.022 -1.281 . . . . 0.0 109.151 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . . . . . . . . . 39.5 mttm -130.16 157.35 42.68 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.233 -0.917 . . . . 0.0 109.688 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 13.6 p -62.13 148.94 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.329 -0.857 . . . . 0.0 109.494 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 82.48 -30.37 3.1 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.666 -1.373 . . . . 0.0 109.666 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.589 ' HB2' HD12 ' A' ' 143' ' ' ILE . 68.6 m-20 -50.57 164.22 0.14 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.189 -1.183 . . . . 0.0 109.217 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 4.0 ttm -99.6 129.58 45.76 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.15 -0.969 . . . . 0.0 109.011 179.717 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.696 ' CG1' HD11 ' A' ' 143' ' ' ILE . 25.1 m -128.67 145.67 35.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.302 -0.874 . . . . 0.0 109.948 -179.836 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.551 ' HB2' ' CG1' ' A' ' 176' ' ' ILE . 26.3 tttp -110.47 145.05 38.34 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 179.588 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.999 ' O ' HD13 ' A' ' 132' ' ' ILE . 64.7 mt -78.75 156.5 4.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.035 -1.041 . . . . 0.0 108.544 179.479 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.999 HD13 ' O ' ' A' ' 131' ' ' ILE . 0.7 OUTLIER -148.57 -3.98 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.131 -0.98 . . . . 0.0 108.966 179.54 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.4 m -148.67 146.42 28.15 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.339 -0.851 . . . . 0.0 110.11 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 104.55 -170.58 18.44 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.55 ' HG2' ' CD1' ' A' ' 136' ' ' PHE . 49.0 Cg_endo -68.97 -19.66 39.62 Favored 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 123.276 2.651 . . . . 0.0 112.508 -179.617 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.55 ' CD1' ' HG2' ' A' ' 135' ' ' PRO . 88.6 m-85 -109.09 9.41 26.25 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.975 -1.078 . . . . 0.0 109.747 -179.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.843 ' HA ' HG22 ' A' ' 131' ' ' ILE . 0.7 OUTLIER -44.19 145.01 0.84 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.09 -1.006 . . . . 0.0 109.462 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.545 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 14.6 m-20 81.62 20.54 0.35 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.489 -0.757 . . . . 0.0 110.042 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.784 ' CB ' HD12 ' A' ' 131' ' ' ILE . 0.9 OUTLIER -115.42 160.66 19.59 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.11 -0.993 . . . . 0.0 109.315 179.803 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.427 ' HA ' ' HA ' ' A' ' 130' ' ' LYS . . . -114.31 135.83 53.64 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.145 -0.972 . . . . 0.0 109.383 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.478 ' C ' ' CG2' ' A' ' 155' ' ' VAL . . . -147.98 169.88 28.69 Favored Glycine 0 N--CA 1.49 2.267 0 C-N-CA 119.655 -1.26 . . . . 0.0 110.181 -179.47 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.983 ' C ' HG23 ' A' ' 155' ' ' VAL . 94.8 t -109.89 134.46 51.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.62 -0.93 . . . . 0.0 109.319 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.696 HD11 ' CG1' ' A' ' 129' ' ' VAL . 67.8 mt -62.69 117.16 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.134 -0.979 . . . . 0.0 109.353 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.424 ' HG2' ' HG2' ' A' ' 145' ' ' GLU . 16.8 tttp -97.99 -35.86 10.31 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.164 -0.96 . . . . 0.0 109.422 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . 0.424 ' HG2' ' HG2' ' A' ' 144' ' ' LYS . 72.3 mm-40 -151.59 146.63 25.98 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.095 -1.003 . . . . 0.0 109.462 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.903 HG23 ' CG ' ' A' ' 153' ' ' LEU . 1.8 mt -122.44 125.34 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.576 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -107.68 102.35 44.47 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.203 -0.935 . . . . 0.0 109.603 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.546 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 53.6 Cg_endo -73.5 171.94 16.72 Favored 'Trans proline' 0 C--O 1.215 -0.643 0 C-N-CA 122.752 2.301 . . . . 0.0 111.846 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.546 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 5.0 tt0 80.57 -21.45 0.32 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.423 -0.798 . . . . 0.0 110.074 179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.417 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 44.0 mtt85 -126.17 -12.48 6.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.053 -1.029 . . . . 0.0 109.323 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.417 ' HB2' ' O ' ' A' ' 150' ' ' ARG . 42.2 mt-30 68.47 49.8 0.75 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.325 -0.86 . . . . 0.0 109.676 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.682 ' OE2' HG13 ' A' ' 167' ' ' VAL . 69.0 tt0 -123.01 146.35 47.71 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.048 -1.032 . . . . 0.0 108.747 179.515 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.903 ' CG ' HG23 ' A' ' 146' ' ' ILE . 0.0 OUTLIER -142.51 113.93 7.83 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.119 -0.988 . . . . 0.0 110.511 -179.276 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . 0.691 ' HG2' HG22 ' A' ' 167' ' ' VAL . 27.1 mtmt -85.08 137.21 33.19 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.983 HG23 ' C ' ' A' ' 142' ' ' VAL . 1.8 p -136.72 133.19 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.007 -1.058 . . . . 0.0 110.034 -179.222 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.598 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 2.2 t-20 -67.02 125.95 27.62 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.396 -0.815 . . . . 0.0 109.689 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.564 HG12 HG13 ' A' ' 159' ' ' ILE . 43.7 t -107.59 147.46 12.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.275 -0.891 . . . . 0.0 109.057 179.535 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.683 HG23 ' O ' ' A' ' 158' ' ' THR . 9.4 t -97.4 112.18 24.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.343 -0.848 . . . . 0.0 109.986 -179.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.965 HG22 ' CD2' ' A' ' 160' ' ' PHE . 26.6 mt -138.17 137.29 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.357 -0.84 . . . . 0.0 109.183 179.298 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.965 ' CD2' HG22 ' A' ' 159' ' ' ILE . 99.7 m-85 60.86 42.34 13.29 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.295 -0.878 . . . . 0.0 108.963 -179.533 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 56.37 17.03 17.17 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.466 -1.453 . . . . 0.0 109.466 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.472 ' NH1' ' O ' ' A' ' 160' ' ' PHE . 22.5 mtt85 -126.49 147.55 49.81 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -1.184 . . . . 0.0 109.637 -179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . . . . . . . . . 64.1 mm-40 -97.89 136.64 37.9 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.286 -0.884 . . . . 0.0 109.373 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . 0.503 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 4.3 m -143.68 132.55 11.34 Favored Pre-proline 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.673 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.598 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 48.0 Cg_endo -68.88 131.21 21.98 Favored 'Trans proline' 0 C--O 1.215 -0.659 0 C-N-CA 122.792 2.328 . . . . 0.0 111.366 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.915 HG23 HD11 ' A' ' 168' ' ' LEU . 24.3 m -115.55 162.89 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.052 -1.03 . . . . 0.0 109.581 -179.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.691 HG22 ' HG2' ' A' ' 154' ' ' LYS . 41.3 t -117.77 119.14 60.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.411 -0.806 . . . . 0.0 109.61 179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.915 HD11 HG23 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -144.38 168.73 19.4 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.956 0.884 . . . . 0.0 110.503 -179.957 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -80.65 139.41 36.22 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.044 -0.725 . . . . 0.0 109.044 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.416 HG22 HG21 ' A' ' 119' ' ' VAL . 7.9 p -53.7 -34.18 24.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.156 -0.965 . . . . 0.0 109.008 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.4 ' O ' ' HG2' ' A' ' 115' ' ' LYS . 54.0 p -75.54 -4.33 39.26 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.394 -0.816 . . . . 0.0 109.539 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -103.97 1.85 31.66 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.072 -1.017 . . . . 0.0 109.644 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.538 HG12 ' N ' ' A' ' 174' ' ' GLU . 49.5 t -131.35 162.99 38.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.146 -0.971 . . . . 0.0 109.626 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.538 ' N ' HG12 ' A' ' 173' ' ' VAL . 76.3 tt0 -139.3 159.62 41.73 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -0.9 . . . . 0.0 109.344 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.607 ' HB2' ' CE1' ' A' ' 123' ' ' PHE . 21.7 tttm -91.82 34.82 0.98 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.146 -0.971 . . . . 0.0 109.283 179.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.551 ' CG1' ' HB2' ' A' ' 130' ' ' LYS . 87.4 mt 43.05 78.05 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.306 -0.871 . . . . 0.0 109.537 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 117.992 -1.004 . . . . 0.0 109.505 -179.979 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.218 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.496 ' HA ' HG21 ' A' ' 65' ' ' ILE . . . -61.43 -34.65 75.76 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.281 -1.129 . . . . 0.0 109.475 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . 21.9 ttp -53.94 -38.13 64.59 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.514 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -115.31 130.49 56.92 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.252 -0.905 . . . . 0.0 109.549 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 22.5 mttt -122.24 161.36 23.41 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.29 -0.881 . . . . 0.0 109.488 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 63' ' ' GLU . 21.6 mtpp -130.45 176.18 8.36 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.229 -0.92 . . . . 0.0 109.256 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.702 ' CH2' HG23 ' A' ' 41' ' ' VAL . 39.7 m95 -109.67 124.11 50.63 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.236 -0.915 . . . . 0.0 109.126 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' TYR . . . . . 0.462 ' CE1' ' CE ' ' A' ' 66' ' ' MET . 95.4 m-85 -113.75 170.9 7.92 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.245 -0.909 . . . . 0.0 109.353 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.459 ' HB ' ' CG1' ' A' ' 84' ' ' VAL . 25.9 mt -119.2 106.84 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.232 -0.918 . . . . 0.0 109.417 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.487 ' CG2' HG23 ' A' ' 80' ' ' VAL . 0.2 OUTLIER -94.45 148.16 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.183 -0.948 . . . . 0.0 109.292 179.746 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.758 HD22 ' N ' ' A' ' 11' ' ' LEU . 3.2 mm? -95.37 145.93 24.76 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.382 -0.824 . . . . 0.0 109.817 -179.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.9 p -147.78 -177.96 6.01 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.415 -0.803 . . . . 0.0 109.264 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' MET . . . . . 0.569 ' HB2' ' CD2' ' A' ' 16' ' ' TYR . 54.8 mtm -89.9 116.92 28.33 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.157 -0.964 . . . . 0.0 109.489 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 13' ' ' MET . 18.1 t -42.89 125.57 3.51 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.248 -0.908 . . . . 0.0 109.296 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 105.47 -19.09 40.28 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.129 -1.588 . . . . 0.0 109.129 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' TYR . . . . . 0.569 ' CD2' ' HB2' ' A' ' 13' ' ' MET . 97.7 m-85 -107.33 -10.14 15.86 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.446 -1.031 . . . . 0.0 109.465 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.487 ' O ' ' N ' ' A' ' 20' ' ' VAL . 93.9 mt-10 -45.47 -66.66 0.37 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.201 -0.937 . . . . 0.0 109.37 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.409 ' C ' ' O ' ' A' ' 17' ' ' GLU . 94.8 mt-10 -44.05 -35.79 2.26 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 109.302 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.43 ' HB2' ' O ' ' A' ' 16' ' ' TYR . 22.9 mttm -71.58 -31.35 66.86 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.214 -0.929 . . . . 0.0 109.344 179.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.73 HG22 ' HB2' ' A' ' 79' ' ' TYR . 98.2 t -72.55 -45.47 58.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.224 -0.923 . . . . 0.0 109.356 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' LYS . . . . . . . . . . . . . 28.8 tttm -55.82 -50.53 70.28 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.341 -0.849 . . . . 0.0 109.303 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 94.0 mt-10 -62.3 -37.33 85.12 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.268 -0.895 . . . . 0.0 109.163 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.832 ' OD1' HG22 ' A' ' 77' ' ' VAL . 13.8 t-20 -62.23 -44.58 96.23 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.322 -0.861 . . . . 0.0 109.362 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.949 ' CD1' HG21 ' A' ' 77' ' ' VAL . 29.5 mm -56.11 -45.2 80.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 109.335 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 91.6 mt-10 -55.13 -45.46 75.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.229 -0.92 . . . . 0.0 109.657 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 46.7 mttp -76.17 -35.73 59.03 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.069 -1.02 . . . . 0.0 109.61 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 1.029 ' HD3' HG23 ' A' ' 77' ' ' VAL . 18.1 ttpt -55.07 -33.89 63.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.334 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.865 HG21 HG11 ' A' ' 37' ' ' VAL . 89.4 t -82.27 -24.44 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.288 -0.882 . . . . 0.0 109.601 -179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -67.85 -52.31 38.18 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.259 -0.901 . . . . 0.0 109.654 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.39 -27.12 65.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.249 -0.907 . . . . 0.0 109.933 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 47.4 p -97.58 -32.19 11.92 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.205 -0.934 . . . . 0.0 109.696 -179.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.493 ' N ' ' O ' ' A' ' 28' ' ' VAL . . . 79.44 24.01 61.7 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.508 -1.437 . . . . 0.0 109.508 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.643 ' O ' HG13 ' A' ' 28' ' ' VAL . 62.8 mt -94.65 87.32 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.217 -1.166 . . . . 0.0 109.444 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -87.4 -5.37 58.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.215 -0.928 . . . . 0.0 109.455 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -102.14 16.46 26.03 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.269 -0.895 . . . . 0.0 109.628 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.929 HD11 ' CB ' ' A' ' 70' ' ' ALA . 7.2 tp -112.17 -58.12 2.18 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.263 -0.898 . . . . 0.0 109.4 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.865 HG11 HG21 ' A' ' 28' ' ' VAL . 9.0 p -95.87 134.35 33.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.427 -0.796 . . . . 0.0 109.423 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.21 -123.71 5.32 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 93.4 mtt180 -95.11 143.98 26.12 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.308 -1.113 . . . . 0.0 109.89 -179.473 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 1.01 HG23 HG22 ' A' ' 62' ' ' VAL . 18.9 mt -107.7 140.39 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.408 -0.807 . . . . 0.0 109.158 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 1.038 HG21 HD11 ' A' ' 107' ' ' LEU . 55.0 t -128.51 156.86 41.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.024 -1.048 . . . . 0.0 109.462 179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.791 HG22 HG23 ' A' ' 44' ' ' ILE . 6.5 mt -136.72 127.19 16.23 Favored Pre-proline 0 N--CA 1.488 1.463 0 O-C-N 121.367 -0.833 . . . . 0.0 109.469 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.517 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . 46.3 Cg_endo -67.4 -4.71 12.37 Favored 'Trans proline' 0 C--O 1.216 -0.583 0 C-N-CA 122.824 2.349 . . . . 0.0 111.547 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.791 HG23 HG22 ' A' ' 42' ' ' ILE . 11.8 pt -76.76 -22.63 14.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.248 -0.907 . . . . 0.0 109.474 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.444 ' O ' HD21 ' A' ' 104' ' ' LEU . 35.2 mtp180 -64.74 163.65 13.64 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.334 -0.854 . . . . 0.0 109.45 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.42 0.97 59.31 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -111.65 60.73 0.32 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 -60.77 -27.41 67.96 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.247 -1.149 . . . . 0.0 109.575 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 20.5 mtm180 -62.86 -26.43 68.76 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.223 -0.923 . . . . 0.0 109.498 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 34.1 mtt-85 -127.83 164.43 22.23 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.184 -0.948 . . . . 0.0 109.515 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' LYS . . . . . 0.407 ' C ' ' OG ' ' A' ' 52' ' ' SER . 49.2 mttt -59.62 -33.97 72.18 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.31 -0.869 . . . . 0.0 109.54 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' SER . . . . . 0.455 ' O ' ' HG3' ' A' ' 54' ' ' LYS . 0.3 OUTLIER -171.78 98.13 0.18 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.272 -0.892 . . . . 0.0 109.462 -179.895 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.498 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 94.6 mt-10 -64.48 -48.7 74.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.174 -0.954 . . . . 0.0 109.381 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.71 ' HA ' HG22 ' A' ' 44' ' ' ILE . 24.5 mttt 75.44 86.73 0.09 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.238 -0.914 . . . . 0.0 109.577 179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.635 HD23 ' HE2' ' A' ' 56' ' ' PHE . 14.5 tp -64.26 -23.73 67.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.161 -0.962 . . . . 0.0 109.132 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.89 ' CZ ' HD11 ' A' ' 159' ' ' ILE . 97.2 m-85 -149.96 99.0 3.31 Favored Pre-proline 0 N--CA 1.49 1.532 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -65.42 139.57 59.89 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 122.614 2.209 . . . . 0.0 111.979 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.07 -15.84 4.98 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.386 -1.085 . . . . 0.0 110.386 179.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.444 ' CE1' HD11 ' A' ' 11' ' ' LEU . 3.2 m-85 -95.73 129.87 42.81 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.759 -1.436 . . . . 0.0 110.205 -179.331 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 41.1 t -133.84 146.02 32.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.335 -0.853 . . . . 0.0 108.905 179.453 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.418 ' CE2' HG12 ' A' ' 9' ' ' ILE . 24.1 m-85 -110.31 122.47 47.76 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.955 -1.09 . . . . 0.0 109.521 -179.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 1.01 HG22 HG23 ' A' ' 40' ' ' ILE . 96.1 t -128.48 140.97 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.427 -0.795 . . . . 0.0 109.936 -179.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.596 ' HB2' ' CE2' ' A' ' 7' ' ' TRP . 67.6 tt0 -103.5 123.49 46.99 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.315 -0.865 . . . . 0.0 108.864 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.576 ' CG ' HG12 ' A' ' 62' ' ' VAL . 1.1 mtp -162.66 -174.61 4.04 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.102 -0.999 . . . . 0.0 109.778 -179.545 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.902 HG12 HD12 ' A' ' 36' ' ' LEU . 17.2 pt -97.26 122.95 49.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.236 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' MET . . . . . 0.462 ' CE ' ' CE1' ' A' ' 8' ' ' TYR . 11.1 ttm -88.16 100.31 12.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.284 -0.885 . . . . 0.0 109.736 -179.406 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.438 ' H ' ' HB3' ' A' ' 70' ' ' ALA . 9.6 t30 -137.92 -165.75 1.84 Allowed 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.195 -0.941 . . . . 0.0 108.821 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -71.41 -48.72 47.96 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.14 -0.975 . . . . 0.0 109.681 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.403 ' O ' ' C ' ' A' ' 70' ' ' ALA . 73.9 mm-40 -66.64 -58.63 4.76 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.188 -0.945 . . . . 0.0 109.5 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.929 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -43.85 -41.51 5.14 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.293 -0.879 . . . . 0.0 109.718 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.541 ' CD1' ' CD ' ' A' ' 89' ' ' GLN . 72.2 t80 -61.05 -57.14 13.8 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.163 -0.961 . . . . 0.0 109.627 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' HB3' ' A' ' 76' ' ' SER . 38.2 t30 -52.87 -31.2 38.22 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.214 -0.929 . . . . 0.0 110.0 -179.582 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -82.08 -44.15 16.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.96 -1.088 . . . . 0.0 109.923 -179.626 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 1.081 HG12 ' CZ ' ' A' ' 83' ' ' PHE . 47.6 t -68.49 -56.91 10.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.357 -0.84 . . . . 0.0 109.625 -179.64 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ARG . . . . . 0.457 ' HA ' ' CZ ' ' A' ' 83' ' ' PHE . 15.6 tpt180 -62.5 -11.92 19.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.165 -0.959 . . . . 0.0 109.966 -179.718 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.485 ' HB3' ' O ' ' A' ' 72' ' ' ASN . 89.6 p -102.28 3.53 38.23 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.081 -1.012 . . . . 0.0 110.167 -179.645 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 1.033 ' O ' HG12 ' A' ' 80' ' ' VAL . 0.4 OUTLIER -69.05 142.27 92.92 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.031 -1.043 . . . . 0.0 109.273 -179.969 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.664 ' HD2' HG22 ' A' ' 77' ' ' VAL . 45.2 Cg_endo -67.75 134.51 32.75 Favored 'Trans proline' 0 C--O 1.213 -0.768 0 C-N-CA 122.454 2.103 . . . . 0.0 111.876 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.73 ' HB2' HG22 ' A' ' 20' ' ' VAL . 13.1 m-85 89.32 -6.55 0.42 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.799 -0.563 . . . . 0.0 110.255 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 1.033 HG12 ' O ' ' A' ' 77' ' ' VAL . 12.4 p -88.33 126.98 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 120.752 -1.218 . . . . 0.0 109.643 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 92.4 mmm -90.78 -26.36 19.5 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.32 -0.863 . . . . 0.0 109.335 179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.57 ' O ' ' CD1' ' A' ' 83' ' ' PHE . . . 161.47 -160.34 32.14 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . 1.081 ' CZ ' HG12 ' A' ' 74' ' ' VAL . 10.8 m-85 -134.76 156.38 48.94 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.191 -1.182 . . . . 0.0 109.562 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.547 HG13 ' O ' ' A' ' 84' ' ' VAL . 12.5 p -91.71 125.35 44.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.248 -0.908 . . . . 0.0 109.385 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.574 ' CB ' ' HA ' ' A' ' 90' ' ' PRO . 0.6 OUTLIER -168.87 166.79 11.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.13 -0.981 . . . . 0.0 109.568 -179.955 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 25.5 t -86.18 -32.97 20.94 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.238 -0.914 . . . . 0.0 109.427 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -117.42 -106.82 2.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.516 ' O ' ' O ' ' A' ' 89' ' ' GLN . . . -96.67 -122.09 4.16 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.541 ' CD ' ' CD1' ' A' ' 71' ' ' TYR . 0.0 OUTLIER -34.55 156.11 0.04 OUTLIER Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.533 -0.981 . . . . 0.0 110.044 -179.659 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.574 ' HA ' ' CB ' ' A' ' 85' ' ' SER . 50.0 Cg_endo -68.75 149.21 72.91 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 122.839 2.359 . . . . 0.0 111.994 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' VAL . . . . . . . . . . . . . 25.0 m -83.89 154.97 64.74 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 109.436 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.525 ' HB3' ' CE ' ' A' ' 6' ' ' LYS . 49.9 Cg_endo -70.16 142.94 47.46 Favored 'Trans proline' 0 C--O 1.215 -0.662 0 C-N-CA 122.677 2.251 . . . . 0.0 111.673 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.512 HG12 ' HB2' ' A' ' 97' ' ' GLU . 18.6 t -82.3 139.07 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.304 -0.873 . . . . 0.0 109.433 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' LYS . . . . . 0.467 ' O ' ' N ' ' A' ' 97' ' ' GLU . 7.3 tptt -70.74 131.78 44.38 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.182 -0.949 . . . . 0.0 109.289 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . 0.402 ' C ' ' O ' ' A' ' 94' ' ' LYS . 87.3 m-20 -45.22 -39.52 6.41 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.178 -0.952 . . . . 0.0 109.436 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.4 mtp180 -61.03 -23.45 65.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.308 -0.87 . . . . 0.0 109.475 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.512 ' HB2' HG12 ' A' ' 93' ' ' VAL . 62.9 mt-10 -85.83 -28.38 24.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.24 -0.913 . . . . 0.0 109.422 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' MET . . . . . 0.612 ' HE3' ' CB ' ' A' ' 7' ' ' TRP . 59.0 mtp -84.14 -24.8 30.07 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.212 -0.93 . . . . 0.0 109.365 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.593 ' N ' ' HD2' ' A' ' 100' ' ' PRO . 0.0 OUTLIER -37.46 -53.53 2.31 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.425 -0.797 . . . . 0.0 109.866 -179.952 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.593 ' HD2' ' N ' ' A' ' 99' ' ' ARG . 48.4 Cg_endo -69.83 -27.55 25.98 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 122.525 2.15 . . . . 0.0 111.878 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.418 ' N ' ' O ' ' A' ' 98' ' ' MET . 37.4 mm -81.19 -42.94 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.178 -0.951 . . . . 0.0 109.304 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' LEU . . . . . 0.868 HD12 HD12 ' A' ' 107' ' ' LEU . 0.0 OUTLIER -65.8 -38.97 90.41 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.275 -0.891 . . . . 0.0 109.297 179.89 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.5 ' HG3' ' CE2' ' A' ' 110' ' ' TYR . 16.1 ttt-85 -65.66 -47.7 74.63 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.334 -0.854 . . . . 0.0 109.279 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.444 HD21 ' O ' ' A' ' 45' ' ' ARG . 3.0 tt -72.12 -36.31 69.38 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.215 -0.928 . . . . 0.0 109.227 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -75.25 -2.22 27.08 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.44 -0.788 . . . . 0.0 109.81 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 76.9 15.79 81.34 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 1.038 HD11 HG21 ' A' ' 41' ' ' VAL . 23.5 mt -81.84 -23.27 36.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.16 -1.2 . . . . 0.0 109.666 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' GLU . . . . . 0.466 ' HG2' ' HB3' ' A' ' 102' ' ' LEU . 68.2 mm-40 -133.22 138.59 46.58 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.158 -0.964 . . . . 0.0 109.327 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' GLU . . . . . . . . . . . . . 35.4 mp0 -120.7 121.83 39.11 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.281 -0.887 . . . . 0.0 109.72 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.527 ' CD1' ' C ' ' A' ' 110' ' ' TYR . 13.6 p90 -145.16 174.33 11.16 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.253 -0.905 . . . . 0.0 109.219 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.412 ' O ' ' C ' ' A' ' 112' ' ' GLU . 90.3 mt-10 -96.18 -102.69 0.17 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.21 -0.931 . . . . 0.0 109.85 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.479 ' HG3' ' OE1' ' A' ' 137' ' ' GLU . 0.2 OUTLIER 44.9 68.12 0.6 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.136 -0.978 . . . . 0.0 109.543 -179.913 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 176.74 -40.99 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.345 -0.847 . . . . 0.0 109.523 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 12.0 pttm -47.49 -23.55 0.65 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.214 -0.929 . . . . 0.0 109.432 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -121.68 83.25 41.97 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.178 -0.951 . . . . 0.0 109.562 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_endo -71.15 163.1 40.35 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 122.683 2.255 . . . . 0.0 111.696 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.436 ' C ' ' HB2' ' A' ' 171' ' ' SER . 41.6 t -138.01 120.88 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.185 -0.947 . . . . 0.0 109.622 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 53.3 tttt -68.57 156.76 37.44 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.242 -0.911 . . . . 0.0 109.501 179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.995 HG21 ' O ' ' A' ' 173' ' ' VAL . 27.5 m -150.8 148.38 15.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.21 -0.931 . . . . 0.0 109.54 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' GLU . . . . . 0.712 ' O ' ' CB ' ' A' ' 121' ' ' LEU . 76.7 mt-10 -158.38 167.0 30.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.205 179.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' LEU . . . . . 0.712 ' CB ' ' O ' ' A' ' 120' ' ' GLU . 19.3 tp 144.26 99.37 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.716 -0.615 . . . . 0.0 109.459 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . 0.47 ' O ' ' OD2' ' A' ' 127' ' ' ASP . . . 37.72 36.12 0.27 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' PHE . . . . . 0.561 ' CD2' ' O ' ' A' ' 123' ' ' PHE . 42.5 p90 -76.75 116.65 17.61 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.973 -1.31 . . . . 0.0 109.02 179.607 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' LYS . . . . . 0.686 ' C ' HD11 ' A' ' 146' ' ' ILE . 14.7 mttp -141.14 175.12 9.89 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.181 -0.949 . . . . 0.0 109.918 -179.58 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . 0.584 HG23 ' O ' ' A' ' 144' ' ' LYS . 10.8 p -62.51 139.62 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.324 -0.86 . . . . 0.0 109.529 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 88.13 -34.8 3.68 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . 0.47 ' OD2' ' O ' ' A' ' 122' ' ' GLY . 9.5 m-20 -45.92 158.97 0.08 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.336 -1.096 . . . . 0.0 109.209 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . 0.576 ' HG2' HD12 ' A' ' 176' ' ' ILE . 3.8 ttm -99.77 127.49 45.92 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.075 -1.016 . . . . 0.0 108.799 179.553 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.609 HG13 HG12 ' A' ' 143' ' ' ILE . 15.4 m -128.51 144.87 36.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.32 -0.862 . . . . 0.0 109.735 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' LYS . . . . . 0.412 ' HE3' ' CG2' ' A' ' 132' ' ' ILE . 32.5 ttpt -98.78 141.06 32.05 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.618 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.931 HD12 ' HB3' ' A' ' 139' ' ' PHE . 78.5 mt -82.84 151.09 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.209 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' ILE . . . . . 0.498 HG12 ' HA ' ' A' ' 173' ' ' VAL . 1.1 pt -149.66 3.64 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 120.923 -1.111 . . . . 0.0 109.957 -179.657 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 69.9 m -148.26 143.52 27.02 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 120.846 -1.159 . . . . 0.0 109.983 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 100.67 -163.9 18.7 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.482 ' HB3' ' HD3' ' A' ' 103' ' ' ARG . 46.4 Cg_endo -67.38 -23.18 44.58 Favored 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 123.167 2.578 . . . . 0.0 112.952 -179.28 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.528 ' CE1' ' CB ' ' A' ' 100' ' ' PRO . 97.1 m-85 -109.14 19.38 19.55 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.787 -1.196 . . . . 0.0 109.713 -179.765 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . 0.621 ' HA ' HG22 ' A' ' 131' ' ' ILE . 2.3 tt0 -45.51 139.09 3.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.15 -0.969 . . . . 0.0 109.506 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.511 ' HB2' ' O ' ' A' ' 137' ' ' GLU . 17.7 m-20 74.41 28.23 1.34 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.459 -0.776 . . . . 0.0 110.437 179.41 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' PHE . . . . . 0.931 ' HB3' HD12 ' A' ' 131' ' ' ILE . 1.8 t80 -117.08 140.01 50.02 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.96 -1.087 . . . . 0.0 109.45 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -85.74 132.94 34.04 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.116 -0.99 . . . . 0.0 109.664 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -145.57 168.91 27.23 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.775 -1.203 . . . . 0.0 110.304 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.916 ' C ' HG23 ' A' ' 155' ' ' VAL . 41.0 t -117.9 137.07 53.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.634 -0.921 . . . . 0.0 109.348 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' ILE . . . . . 0.609 HG12 HG13 ' A' ' 129' ' ' VAL . 25.0 mm -69.85 119.23 15.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.302 -0.873 . . . . 0.0 109.532 -179.835 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' LYS . . . . . 0.584 ' O ' HG23 ' A' ' 125' ' ' VAL . 0.2 OUTLIER -97.76 -31.69 12.12 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.026 -1.046 . . . . 0.0 109.04 179.546 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -151.11 146.17 25.97 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.266 -0.896 . . . . 0.0 109.283 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 1.051 HG23 HD22 ' A' ' 153' ' ' LEU . 4.0 mt -121.58 126.21 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.141 -0.974 . . . . 0.0 109.545 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.92 100.08 38.13 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.247 -0.908 . . . . 0.0 109.449 -179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . 0.544 ' O ' ' CB ' ' A' ' 149' ' ' GLU . 52.4 Cg_endo -71.14 173.28 12.42 Favored 'Trans proline' 0 C--O 1.215 -0.66 0 C-N-CA 122.706 2.271 . . . . 0.0 111.821 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.544 ' CB ' ' O ' ' A' ' 148' ' ' PRO . 6.2 tt0 79.52 -21.58 0.32 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.325 -0.86 . . . . 0.0 110.184 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' ARG . . . . . 0.44 ' O ' ' HB2' ' A' ' 151' ' ' GLN . 83.9 mtt-85 -127.5 -12.77 5.53 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.045 -1.035 . . . . 0.0 109.6 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' GLN . . . . . 0.882 ' O ' HG23 ' A' ' 170' ' ' VAL . 49.8 mt-30 69.52 47.04 0.69 Allowed 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.348 -0.845 . . . . 0.0 109.704 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' GLU . . . . . 0.742 ' O ' HD23 ' A' ' 153' ' ' LEU . 40.8 tt0 -118.21 143.85 46.21 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.08 -1.012 . . . . 0.0 108.659 179.632 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 1.051 HD22 HG23 ' A' ' 146' ' ' ILE . 35.3 mt -133.56 122.82 24.11 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.996 -1.065 . . . . 0.0 110.616 -179.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' LYS . . . . . . . . . . . . . 9.5 mttt -86.55 130.93 34.31 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 178.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.916 HG23 ' C ' ' A' ' 142' ' ' VAL . 7.3 p -133.65 149.77 31.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.087 -1.008 . . . . 0.0 109.8 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.565 ' HA ' ' HA ' ' A' ' 165' ' ' PRO . 43.3 t-20 -98.75 123.61 43.08 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.29 -0.881 . . . . 0.0 109.329 179.857 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' VAL . . . . . 0.557 HG13 ' CE1' ' A' ' 139' ' ' PHE . 63.9 t -105.39 146.86 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.198 -0.939 . . . . 0.0 109.663 -179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 25.9 m -94.9 104.05 15.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.245 -0.91 . . . . 0.0 109.633 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' ILE . . . . . 0.89 HD11 ' CZ ' ' A' ' 56' ' ' PHE . 7.0 pt -139.65 149.12 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.267 -0.896 . . . . 0.0 109.38 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' PHE . . . . . 0.658 ' CE2' HD12 ' A' ' 159' ' ' ILE . 11.1 m-30 61.35 36.99 17.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.261 -0.899 . . . . 0.0 109.141 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' GLY . . . . . . . . . . . . . . . 58.52 13.7 17.99 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' ARG . . . . . 0.424 ' HG3' ' O ' ' A' ' 160' ' ' PHE . 3.3 mtp-105 -134.11 159.01 42.14 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.059 -1.259 . . . . 0.0 109.601 -179.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' GLU . . . . . 0.478 ' HB3' ' ND2' ' A' ' 156' ' ' ASN . 81.7 mt-10 -99.73 140.12 34.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.253 -0.905 . . . . 0.0 109.399 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' THR . . . . . 0.553 ' N ' ' OD1' ' A' ' 156' ' ' ASN . 22.6 m -146.55 129.93 8.23 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 109.785 -179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' PRO . . . . . 0.565 ' HA ' ' HA ' ' A' ' 156' ' ' ASN . 50.7 Cg_endo -71.14 139.29 35.22 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 122.736 2.29 . . . . 0.0 111.437 179.676 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' VAL . . . . . 0.966 HG13 HD11 ' A' ' 168' ' ' LEU . 2.9 p -124.93 143.86 36.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.088 -1.007 . . . . 0.0 109.627 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.576 HG13 ' O ' ' A' ' 167' ' ' VAL . 14.6 p -96.13 120.75 45.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.408 -0.807 . . . . 0.0 109.533 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' LEU . . . . . 0.966 HD11 HG13 ' A' ' 166' ' ' VAL . 0.0 OUTLIER -141.4 168.71 19.13 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.113 -0.992 . . . . 0.0 110.54 -179.52 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' HIS . . . . . 0.468 ' HB2' ' HG3' ' A' ' 172' ' ' GLU . 72.1 m80 -83.19 143.26 30.59 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.891 HG22 ' HG ' ' A' ' 153' ' ' LEU . 71.9 t -52.82 -38.39 27.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.436 ' HB2' ' C ' ' A' ' 117' ' ' VAL . 84.6 p -75.23 -6.97 52.51 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.492 -0.755 . . . . 0.0 110.06 -179.466 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' GLU . . . . . 0.468 ' HG3' ' HB2' ' A' ' 169' ' ' HIS . 80.4 mt-10 -91.12 -5.46 55.06 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.828 -1.17 . . . . 0.0 109.822 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' VAL . . . . . 0.995 ' O ' HG21 ' A' ' 119' ' ' VAL . 2.8 m -139.48 175.36 7.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.152 -0.967 . . . . 0.0 109.439 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' GLU . . . . . 0.407 ' HA ' HG21 ' A' ' 119' ' ' VAL . 57.5 tt0 -138.17 163.03 32.73 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.196 -0.94 . . . . 0.0 109.045 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' LYS . . . . . 0.523 ' O ' ' N ' ' A' ' 177' ' ' GLU . 25.2 mmtm -91.04 12.37 20.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.088 -1.007 . . . . 0.0 109.246 179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' ILE . . . . . 0.576 HD12 ' HG2' ' A' ' 128' ' ' MET . 75.8 mt 58.28 -81.06 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.411 -0.806 . . . . 0.0 109.561 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' GLU . . . . . 0.578 ' O ' HD23 ' A' ' 121' ' ' LEU . 94.6 mt-10 . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 117.954 -1.022 . . . . 0.0 109.431 179.953 . . . . . . . . 1 1 . 1 stop_ save_